
<html lang="en"     class="pb-page"  data-request-id="e695c072-e060-4c26-a57d-0502cb5ec524"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2008.51.issue-5;wgroup:string:ACHS website Group;article:article:10.1021/jm701094q;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era" /></meta><meta name="dc.Creator" content="Michael J.  Marino" /></meta><meta name="dc.Creator" content="Lars J. S.  Knutsen" /></meta><meta name="dc.Creator" content="Michael  Williams" /></meta><meta name="dc.Publisher" content=" American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 17, 2008" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm701094q" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2008 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm701094q" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm701094q" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm701094q" /></link>
        
    
    

<title>Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm701094q" /></meta><meta property="og:title" content="Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm701094q"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm701094q">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm701094q&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm701094q&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm701094q&amp;href=/doi/10.1021/jm701094q" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2008</span><span class="cit-fg-volume">, 51</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1077-1107</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/51/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm070694n" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Marino">Michael J. Marino</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lars+J.+S.++Knutsen">Lars J. S. Knutsen</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Williams">Michael Williams</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">Worldwide Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380</span></div><div class="corresp-info"><strong>*</strong> To whom correspondence should be addressed. Phone: 610-738-6658 . Fax: 610-738-6630. E-mail: <a href="/cdn-cgi/l/email-protection#2b465c424747424a466b484e5b434a47444505484446"><span class="__cf_email__" data-cfemail="a8c5dfc1c4c4c1c9c5e8cbcdd8c0c9c4c7c686cbc7c5">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm701094q&amp;href=/doi/10.1021%2Fjm701094q" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2008</span></span><span class="cit-volume">, 51</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1077–1107</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 17, 2008</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 September 2007</li><li><span class="item_label"><b>Published</b> online</span>17 January 2008</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 March 2008</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm701094q" title="DOI URL">https://doi.org/10.1021/jm701094q</a></div><div class="article_header-article-copyright"><strong>Copyright © 2008 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1077%26pageCount%3D31%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMichael%2BJ.%2BMarino%252C%2BLars%2BJ.%2BS.%2BKnutsen%252C%2BMichael%2BWilliams%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D51%26issueNum%3D5%26contentID%3Djm701094q%26title%3DEmerging%2BOpportunities%2Bfor%2BAntipsychotic%2BDrug%2BDiscovery%2Bin%2Bthe%2BPostgenomic%2BEra%26numPages%3D31%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1107%26publicationDate%3DMarch%2B2008">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm701094q"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2253</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">43</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm701094q" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Marino&quot;},{&quot;first_name&quot;:&quot;Lars&quot;,&quot;last_name&quot;:&quot;J. S. Knutsen&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Williams&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2008&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;51&quot;,&quot;pages&quot;:&quot;1077-1107&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm701094q&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm701094q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm701094q" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm701094q&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm701094q" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm701094q&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm701094q" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm701094q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm701094q&amp;href=/doi/10.1021/jm701094q" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm701094q" /></input><a href="/doi/pdf/10.1021/jm701094q" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (562 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm701094q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm701094q%26sid%3Dliteratum%253Aachs%26pmid%3D18198826%26genre%3Darticle%26aulast%3DMarino%26date%3D2008%26atitle%3DEmerging%2BOpportunities%2Bfor%2BAntipsychotic%2BDrug%2BDiscovery%2Bin%2Bthe%2BPostgenomic%2BEra%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D51%26issue%3D5%26spage%3D1077%26epage%3D1107%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291363" title="Schizophrenia">Schizophrenia</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/51/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Schizophrenia is a chronic, debilitating mental disorder<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> affecting 1−2% of the global population. It has a median lifetime prevalence of 0.7−0.8%,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> shows no accepted gender, ethnic, or social boundaries,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and is associated with mortality rates 2−3 times higher than those in the general population.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">After nearly a century of research, the etiology and pathophysiology of schizophrenia remain largely unresolved. Its existence as a discrete disease state, as contrasted to a spectrum of related psychiatric disorders,<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5-8)</a> remains unclear despite a relatively well defined set of symptoms.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Current treatment for schizophrenia involves psychotherapy,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> electroconvulsive therapy, and drug treatment, the latter reflecting almost exclusively the dopamine (DA) hyperfunction hypothesis of disease causality<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9, 11)</a> Proactive efforts for the early detection of schizophrenia, e.g., the Portland Identification and Early Referral (PIER) Program Prodromal/UHR (ultrahigh risk), involving early drug intervention are also being explored for the potential to reduce the development of psychosis in adolescents.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a></div><div class="NLM_p">Currently prescribed drugs for the treatment of schizophrenia are the <i>typical</i> and <i>atypical</i> antipsychotics also known as first generation (FGA<a class="ref internalNav" href="#fn1" aria-label="a">a</a>) <div class="NLM_fn" id="fn1"><i>a</i><p class="last"> Abbreviations: CATIE, Clinical Antipsychotic Trials of Intervention Effectiveness; CDS, cognitive deficits of schizophrenia; CUtLASS, Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study; DLB, dementia with Lewy bodies; EAAT, excitatory amino acid transporters; FGAs, first generation antipsychotics; RTK, receptor tyrosine kinase; MATRICS, measurement and treatment research to improve cognition in schizophrenia; MCCB, measurement and treatment research to improve cognition in schizophrenia consensus cognitive battery; SGA, second generation antipsychotics.</p></div>  and second (SGA) generation antipsychotics, respectively.<a onclick="showRef(event, 'ref3 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref11">(3, 11)</a> These drugs have combined sales in excess of $18 billion per year and effectively treat the core “positive” psychotic symptoms of the disorder, e.g., auditory and visual delusions and hallucinations. However even with active drug treatment, approximately 15% of schizophrenics have residual, moderate-to-severe positive symptoms and remain treatment resistant with only 20−30% of schizophrenics under treatment being capable of leading independent lives.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">A considerable body of genetic, molecular, and chemical research on the causality, pathophysiology, and treatment of schizophrenia has appeared since the last Perspective on this topic some 7 years ago,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> much of it controversial with few new insights into disease causality, novel drug treatments, or novel targets that address the limitations in the current generations of antipsychotic medications. Nonetheless, the mapping of the human genome has allowed the identification of a number of potential new drug “targets” through the use of gene association studies in affected schizophrenic populations<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16-19)</a> that reinforce (a) the neurodevelopmental nature of the disease, (b) the impact of the environment on disease progress,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and (c) the potential role of glutamate in the etiology of schizophrenia.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Many of these novel targets appear unique, lacking a clear role in neurotransmission or cellular signal transduction processes.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> These targets thus remain largely unvalidated from a drug discovery perspective or in the context of an improved/expanded understanding of disease genesis.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p last">Concomitant with these newer findings, increasing concerns have emerged with (i) the life threatening class effects of current antipsychotic agents that include QT prolongation<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and their potential to cause metabolic syndrome, e.g.,weight gain and diabetes<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> and (ii) the highly controversial<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24-26)</a> NIMH-sponsored CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) and NHS-sponsored CUtLASS (Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study) clinical trials that have reported no major differences in the clinical effectiveness of FGAs and SGAs.<a onclick="showRef(event, 'ref7 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref7 ref27 ref28 ref29">(7, 27-29)</a></div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Disease State/Diagnosis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While behavioral phenotypes similar to schizophrenia were known before the 18th century,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> the description of the disorder as schizophrenia (from the Greek “schizo”, to tear or split, and from “phren”, the intellect or mind) was not coined until 1911 by Bleuler. The current DSM-IV-TR category for schizophrenia, 295.<i>xx</i>, “Schizophrenia and Other Psychotic Disorders”,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> has evolved over the past century and can be divided into several major subclasses: paranoid type (295.30), disorganized type (295.10), catatonic type (295.10), undifferentiated type (295.90), residual type (295.6), schizophreniform disorder (295.40), schizoaffective disorder (295.70, including bipolar and depressive types), delusional disorder (297.1), brief psychotic disorder (298.8), and shared psychotic disorder (297.3).</div><div class="NLM_p">Six diagnostic criteria have been developed for schizophrenia.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> These include (i) characteristic symptoms of the disorder including delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms (affective flattening, alogia (poverty or absence of speech), avolition (lack of interest and drive)) (two or more of which must be present for a significant duration over a one month period), (ii) social/occupational dysfunction, (iii) duration of the disturbance for at least 6 months (unless successfully treated after early diagnosis), (iv) schizoaffective and mood disorder exclusion, (v) substance/general medical condition exclusion, and (vi) relationship to a pervasive developmental disorder, e.g., autistic disorder. Schizophrenia is frequently present before actual diagnosis, the various symptoms being expressed in a sufficiently subtle manner that fails to reflect the severity of the clinical disorder or distinguish it from various aspects of the normal developmental process.<a onclick="showRef(event, 'ref8 ref12'); return false;" href="javascript:void(0);" class="ref ref8 ref12">(8, 12)</a></div><div class="NLM_p">Schizophrenia can be divided into three main domains: positive and negative symptoms and cognitive dysfunction.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Positive symptoms involve an excess or distortion of normal function. These include bizarre behavior, auditory, and more rarely, visual hallucinations, paranoia, and other delusional states together with disorganized thought.</div><div class="NLM_p">Negative symptoms involve a decrease or loss of normal function and include affective flattening, anhedonia, social withdrawal, lack of motivation and spontaneity, and alogia and avolition (poverty of thought and speech, respectively).</div><div class="NLM_p">Cognitive impairment begins before the presentation of any psychotic symptoms and remains severe, with some progression, throughout the course of the disease. While the precise domains of schizophrenia-associated cognitive dysfunction have yet to be elucidated, these are generally widespread and multifaceted involving executive function, attention, processing, vigilance, verbal learning and memory, verbal and spatial working memory, semantic memory and social cognition.<a onclick="showRef(event, 'ref9 ref31'); return false;" href="javascript:void(0);" class="ref ref9 ref31">(9, 31)</a> Cognitive impairment is currently thought to be of equal or greater importance than either the positive or negative symptoms in predicting the functional consequences of schizophrenia, such as work status, quality of life, and social problem solving.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> This issue has been highlighted by a U.S. federal initiative, Measurement and Treatment Research To Improve Cognition in Schizophrenia (MATRICS),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> to define the guidelines for the approval of new drugs to treat the cognitive aspects of schizophrenia. A consortium headed by the NIMH, including academic groups and representatives from the FDA and the pharmaceutical industry, is currently validating the MATRICS consensus cognitive battery (MCCB) for evaluating therapeutic effects on cognitive function in schizophrenics.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> An additional facet of the MATRICS initiative is the matching of domains of clinical efficacy, e.g., working memory, attention/vigilance, speed of processing, social cognition, etc., with appropriately predictive animal models to facilitate the transition of compounds from the research bench to the clinic.</div><div class="NLM_p">Schizophrenia has a high comorbidity with mood disorders, bipolar disorder, autism, and depression, the last being a key factor in increasing the risk for suicide in schizophrenics compared to the general population, especially in young adult males. While these comorbidities have been considered as an additional phenotypic domain for the disease, it is currently unclear as to whether they share a common etiology with schizophrenia or represent an epiphenomenon associated with either the disease state or its treatment.</div><div class="NLM_p last">Schizophrenia is usually diagnosed early in life with the symptoms following a characteristic developmental pattern.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Cognitive symptoms first occur during adolescence, accompanied by changes in social behavior that are reflected in peer group interactions, declining academic performance, and increased irritability. Because many of these symptoms occur, albeit to a lesser degree, in normal adolescents, diagnosis is not commonly made until the emergence of positive symptoms. Positive symptoms usually develop in males in their late teens and early 20s and in females in their mid-20s to early 30s.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">3 Disease Causality</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58631" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58631" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Schizophrenia is currently viewed as a neurodevelopmental<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> disease involving both epigenetic and genetic factors.<a onclick="showRef(event, 'ref2 ref3 ref17 ref18 ref36'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref17 ref18 ref36">(2, 3, 17, 18, 36)</a> Epigenetic risk factors for the disease include<a onclick="showRef(event, 'ref3 ref18 ref37'); return false;" href="javascript:void(0);" class="ref ref3 ref18 ref37">(3, 18, 37)</a> place and time of birth including winter birth and city living,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> prenatal and obstetric influences,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> e.g., maternal depression, obstetric complications including maternal nutrition,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> hypoxia, low birth weight, pre-eclampsia, infection (e.g., influenza,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> rubella, intrauterine/viral infections related to birth), parasitic infections,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> autoimmune disorders,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> miscellaneous factors including low IQ,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> immigration, low socioeconomic status, cannabis use,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> as well as a family history of the disorder.<a onclick="showRef(event, 'ref17 ref18 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref36 ref37">(17, 18, 36, 37)</a></div><div class="NLM_p">While evidence for a genetic component for schizophrenia was summarized some 60 years ago<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and multiple family, twin, and adoption studies have reliably demonstrated the inheritability of schizophrenia, there is considerable debate as to the validity of many of these findings<a onclick="showRef(event, 'ref19 ref36'); return false;" href="javascript:void(0);" class="ref ref19 ref36">(19, 36)</a> in light of the current somewhat confusing/misleading outcomes from gene association studies.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> The debate is focused on requirements for precision in the replication of genetic association studies,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> concerns regarding the inherent usefulness of genome wide scans,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> newer insights into the complexity of genome function,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and concerns regarding the value of the data accumulated to date. As an example, a reassessment<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> of 432 human gene association studies reporting gender-related differences in gene-related effects concluded that “most claims were insufficiently documented or spurious, and claims with documented good internal and external validity were uncommon”.</div><div class="NLM_p last">Thus, despite the identification of a large number of candidate genes associated with the diagnosis of schizophrenia,<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref36'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref36">(16-19, 36)</a> the number of which has regularly increased without any resolution of previously identified gene-based targets, no single genetic defect has (a) yet been identified that is specifically associated with schizophrenia and (b) been unequivocally found in different populations of schizophrenics.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Furthermore, no genetic alterations have been identified that account for more than a small proportion of the risk of inheriting the disease. Schizophrenia is therefore considered genetically heterogeneous with several discrete genes contributing to disease causality—the <i>schizophrenia spectrum</i>.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Twin studies have, however, further emphasized the major contribution of epigenetic factors to schizophrenia causality.<a onclick="showRef(event, 'ref17 ref18 ref36'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref36">(17, 18, 36)</a> A first degree relative of a schizophrenic patient has a 10% increase in the probability of developing schizophrenia, while in the case of an identical twin, this probability is increased to 40−65%.</div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">4 Molecular Lesions in Schizophrenia</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68848" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68848" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Like the majority of CNS disorders,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> the initial understanding of the molecular targets involved in schizophrenia was based on clinical serendipity. Compound <b>1</b> (chlorpromazine, Chart <a class="ref internalNav" href="#chart1" aria-label="1">1</a>), initially developed for use as an analeptic, was found serendipitously to be effective in the treatment of schizophrenics in the 1950s and subsequently found to be a dopamine (DA) receptor antagonsist.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><figure id="chart1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As previously noted, the antipsychotic drugs currently used to treat schizophrenia can be divided into two distinct classes, <i>typical</i> or first generation antipsychotics (FGAs) and <i>atypical</i> or second generation antipsychotics (SGAs).<a onclick="showRef(event, 'ref3 ref6 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref6 ref11">(3, 6, 11)</a> The distinction between these two drug classes is based on the time of introduction to the market, FGAs preceding SGAs, and their receptor binding profiles. FGAs block DA D2 receptors,<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a> while SGAs have antagonist activity at both D2 and 5HT<sub>2</sub> receptors.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a> Of greatest importance, however, is the ability, albeit limited, of SGAs to treat the negative symptoms of schizophrenia that is coupled with a lower risk of developing the tardive dyskinesias associated with FGA use.<a onclick="showRef(event, 'ref3 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref11">(3, 11)</a></div><div id="sec1_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">4.1 The Dopamine (DA) Hyperfunction Hypothesis</h3><div class="NLM_p">The seminal hypothesis regarding the pathophysiology of schizophrenia is that excessive dopaminergic transmission in the forebrain is causal to the disease. This hypothesis<a onclick="showRef(event, 'ref3 ref6 ref51 ref56'); return false;" href="javascript:void(0);" class="ref ref3 ref6 ref51 ref56">(3, 6, 51, 56)</a> was based on the observation that all clinically effective antipsychotics have potent antagonist/inverse agonist activity at DA D2 receptors and that the therapeutic efficacy of these drugs could be correlated with their affinity for striatal D2 receptors.<a onclick="showRef(event, 'ref52 ref53 ref55'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref55">(52, 53, 55)</a> Similarly, the psychotomimetic properties of the indirect DA agonists <b>2</b> (amphetamine) and <b>3</b> (cocaine) and alterations in striatal DA release in schizophrenics have provided additional support for the involvement of DA in aspects of the pathophysiology of schizophrenia.</div><div class="NLM_p last">The DA hypothesis has accordingly dominated antipsychotic drug discovery efforts for the better part of 60 years<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> but is limited in that it recapitulates, not illogically, the discovery of known antipsychotic agents in a circular manner; e.g., since DA D2 antagonists are effective in treating schizophrenia, schizophrenia is a dysfunction of DA D2 receptor signaling. Moreover, DA hyperfunction does not represent the sole molecular cause of schizophrenia because current antipsychotics, all of which block DA D2 receptors with varying degrees of potency and efficacy, are generally ineffective in treating the negative and/or cognitive symptoms of schizophrenia. Additionally, the clinical efficacy of currently used antipsychotics has a slower time to onset than would be expected from drugs that simply bind to the DA D2 receptor. This suggests that the clinical efficacy of D2 antagonists is not an immediate consequence of acute D2 receptor blockade but may depend on additional effects (e.g., gene expression, neurogenesis) that only occur with chronic treatment.<a onclick="showRef(event, 'ref45 ref58'); return false;" href="javascript:void(0);" class="ref ref45 ref58">(45, 58)</a></div></div><div id="sec1_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">4.2 The Serotonin (5HT) Hypothesis</h3><div class="NLM_p">The serotonin hypothesis of schizophrenia predated the DA hypothesis and was based on similarities between schizophrenic psychosis and LSD-induced hallucinations. The finding that <b>4</b> (LSD) antagonized the actions of 5HT on smooth muscle led to the hypothesis<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59, 60)</a> that schizophrenia resulted from a decrease in central 5HT function. While many antipsychotics interact with 5HT receptors,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> this hypothesis was modified when <b>4</b> was found to be a 5HT agonist in some tissue systems. Interest in 5HT receptor-mediated signaling dysfunction as causal in schizophrenia waned with the discovery of <b>1</b> with DA D2 receptor antagonists becoming the primary target of interest for medicinal chemistry efforts. Research on the role of the 5HT axis in schizophrenia has increased<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> because many of the newer SGAs have been found to have 5HT<sub>2A</sub> antagonist properties<a onclick="showRef(event, 'ref11 ref54'); return false;" href="javascript:void(0);" class="ref ref11 ref54">(11, 54)</a> that can modulate DA neurotransmission.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Additionally, most of the effective antipsychotic drugs are 5HT<sub>2A</sub> inverse agonists.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div class="NLM_p">Several studies<a onclick="showRef(event, 'ref54 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref54 ref64 ref65">(54, 64, 65)</a> have attempted to differentiate the efficacy and safety of novel antipsychotics based on their receptor binding profiles in order to provide a potentially predictive in vitro phenotype for the assessment of newer compounds. These studies have ranged from relatively simple radar plot relationships<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> to more sophisticated principal component analysis.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Building on the DA and 5HT receptor interactions of antipsychotics in defining their intrinsic efficacy/side effect profiles,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> in vitro binding data from the NIMH Psychoactive Drug Screening Program at cloned D1, D2, and 5HT receptors for 22 clinically effective antipsychotics were compared with their efficacy on the positive symptoms of schizophrenia.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The authors concluded that clinically effective doses of FGAs were only modestly correlated with D2 receptor binding affinity (<i>r</i> = 0.54) with a stronger correlation existing for 5HT<sub>2C</sub> receptor binding (<i>r</i> = 0.68). The strongest correlation for FGAs was the 5HT<sub>2C</sub>/D2 receptor binding ratio (<i>r</i> = −0.81). For SGAs, there was no correlation between clinical efficacy with D2, 5HT<sub>2A</sub>, or 5HT<sub>2C</sub> receptor binding, but correlations were observed with the more complex D2 (5HT<sub>2A</sub>/5HT<sub>1A</sub>; <i>r</i> = 0.80) and D2 (5HT<sub>2C</sub>/5HT<sub>1A</sub>; <i>r</i> = 0.78) binding ratios. These findings further suggested that modulation of 5HT<sub>2C</sub> receptor signaling improved the clinical response to D2 receptor blockade by antipsychotics. For FGAs, increased affinity at D2, 5HT<sub>2A</sub>, and 5HT<sub>2C</sub> receptors was associated with enhanced antipsychotic efficacy while increased 5HT<sub>1A</sub> receptor affinity was associated with reduced antipsychotic efficacy.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> These obtained results, while somewhat complex, did not, as the authors noted, take into account the limitations inherent in in vitro binding studies using cloned receptors. These limitations include (i) the lack of consideration/knowledge of information on the intrinsic efficacy, ADME properties, protein binding, and active metabolite formation of the antipsychotics studied and (ii) the relationship of native receptors in the brain limbic regions in vivo compared to cloned receptors. Given the ongoing debate on the contribution of the degree of receptor occupancy and “on” and “off” rates to the efficacy and side effect liability of antipsychotics, this study is more archival than a useful tool on which to base a drug discovery program.</div><div class="NLM_p last">Use of principal component analysis to analyze the binding profiles of a series of new antipsychotics, <b>5</b> (SLV310), <b>6</b> (SLV313), and <b>7</b> (SLV314) at 15 G-protein-coupled receptors and the serotonin transporter (SERT) in comparison to nine approved antipyschotics identified three domains for activity. The first, accounting for 35% variance, had positive contributions from D2 receptors with negative contributions from muscarinic M<sub>1</sub>/M<sub>4</sub>, histamine H<sub>1</sub>, and 5HT<sub>6</sub>, 5HT<sub>3</sub>, 5HT<sub>2A</sub>, and 5HT<sub>2c</sub> receptor interactions. The second, accounting for 15% variance, had positive contributions from 5HT<sub>1A</sub>, 5HT<sub>2B</sub>, 5HT3, 5HT<sub>6</sub>, and SERT interactions and negative contributions from α<sub>1</sub>/α<sub>2</sub> and 5HT<sub>7</sub> receptor interactions. The third domain, accounting for 13% variance, involved positive contributions from 5HT<sub>7</sub>, 5HT<sub>1A</sub>, and 5HT<sub>2B</sub> receptor interactions and negative contributions from D2 and α<sub>1</sub> adrenergic receptors.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Compounds <b>5</b>−<b>7</b> and the SGA <b>8</b> (aripiprazole) clustered positively into the first and second domains with the former compounds having binding profiles most similar, of the antipsychotics studied, to that of <b>8</b>. Compounds <b>5</b> and <b>7</b> are D2 antagonists with SERT inhibitory activity, while <b>6</b> is a D2 antagonist/5HT<sub>1A</sub> antagonist. Antipsychotics associated with weight gain scored strongly negative for domain 1, while those associated with hyperprolactinemia clustered with negative scores for domain 2.</div></div><div id="sec1_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">4.3 The Clozapine Hypothesis</h3><div class="NLM_p">The dibenzodiazepine <b>9</b> (clozapine) was introduced into human use as an antipsychotic in the 1960s<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> and is considered to be the prototypic SGA.<a onclick="showRef(event, 'ref3 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref11">(3, 11)</a> It was identified as a D2 receptor antagonist with broad spectrum efficacy in schizophrenia, being effective in the treatment of refractory schizophrenics, with additional efficacy in treating cognitive deficits, having a lower EPS liability<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68, 69)</a> and a longer average length of therapy prior to discontinuation compared with other antipsychotics. These positive attributes were limited by a high incidence of potentially fatal agranulocytosis that led to <b>9</b> being withdrawn in 1975 for unrestricted use. A subsequent large multicenter trial in treatment-resistant schizophrenics showed <b>9</b> to be superior to FGAs<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> and led to its reintroduction in 1990 with continuous monitoring for blood dyscrasias in patients with nonresponsive positive symptoms. Compound <b>9</b> is the only SGA with unambiguously demonstrated superiority to other compounds in its therapeutic class.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><div class="NLM_p">Given the superior therapeutic profile of <b>9</b>, a search, now over 30 years old, has been ongoing to identify “clozapine-like” new chemical entities (NCEs) that have the superior antipsychotic efficacy of clozapine with a reduced risk of agranulocyotosis. While many SGAs have been identified,<a onclick="showRef(event, 'ref3 ref11 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref3 ref11 ref54 ref55">(3, 11, 54, 55)</a> none of them have demonstrated the efficacy profile of <b>9</b>.</div><div class="NLM_p">Considerable effort has also been expended in searching for “the” mechanism of action of <b>9</b> in the anticipation that the interaction of this drug with some known/unknown receptor/ion channel will provide a complete insight into its efficacy and side effect profile and perhaps for that of the SGAs as a class. Instead, the receptor binding profile of <b>9</b> has expanded with each new receptor that is discovered, only serving to emphasize the polypharmic profile of the drug making it truly deserving of the designation “magic shotgun”<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and as such difficult to mimic in an SAR-focused medicinal chemistry effort even with the use of “chemometric” computational approaches.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p">On the basis of the reduction in EPS liability and hyperprolactinemia, it had also been hypothesized that the primary difference between FGAs and SGAs involved the degree to which these drugs occupied DA receptors. In particular, it was suggested that the FGAs occupy the D2 receptor to a greater degree and more persistently at efficacious doses than do SGAs.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> However, even at very low doses, FGAs induce very different neurochemical outcomes than those seen with SGAs.<a onclick="showRef(event, 'ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref73 ref74 ref75">(73-75)</a> In fact, most SGAs other than <b>9</b> and <b>10</b> (quetiapine), when used at low doses to treat psychotic symptoms in Parkinson’s patients, can elicit EPS and, in rare cases, tardive dyskinesia and neuropleptic malignant syndrome. This suggests that even the SGAs produce too much and too persistent a D2 receptor occupancy that is revealed in DA-compromised Parkinson’s patients. Interestingly, the lack of EPS associated with <b>9</b> and <b>10</b> use may result from their low affinity and rapid dissociation from the D2 DA receptor.<a onclick="showRef(event, 'ref72 ref76'); return false;" href="javascript:void(0);" class="ref ref72 ref76">(72, 76)</a> Since D2 receptor occupancy does not account for the uniqueness of the SGAs, other activities must add to or counteract some of the influences of D2 receptor blockade. Nearly all antipsychotics are potent and efficacious 5HT<sub>2A</sub> inverse agonists;<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> however, the SGAs are unique in having higher potency as 5HT<sub>2A</sub> inverse agonists than as DA antagonists,<a onclick="showRef(event, 'ref59 ref66'); return false;" href="javascript:void(0);" class="ref ref59 ref66">(59, 66)</a> suggesting that the “atypical” nature of these drugs can be predicted by 5HT<sub>2A</sub> inverse agonism. SGAs can occupy greater than 80% of cortical 5HT<sub>2A</sub> receptors at therapeutic doses, while occupancy of striatal D2 receptors is much less.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> There are also differences between striatal and extrastriatal D2 receptor occupancy observed between FGAs and SGAs. PET studies<a onclick="showRef(event, 'ref77 ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref77 ref78 ref79">(77-79)</a> have suggested that FGAs preferentially interact with striatal D2 receptors while SGAs have a complex pattern of interactions with extrastriatal D2 receptors. Consistent with this, SGAs appear to preferentially increase DA release in rat prefrontal cortex relative to the nucleus accumbens, while FGAs exhibit a reverse pattern of activity.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><div class="NLM_p">If the primary difference between FGAs and SGAs involves the ability of the 5-HT<sub>2A</sub> antagonism to counteract the adverse effects of D2 antagonism, then the combination of a relatively “clean” D2 antagonist and 5HT<sub>2A</sub> antagonist should produce an SGA profile in the clinic. In fact, <b>11</b> (mirtazapine), a 5HT<sub>2A</sub> antagonist, given at low doses significantly reduced the acute akathisia produced by high doses of FGAs,<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> suggesting that 5-HT<sub>2A</sub> antagonism/inverse agonism can alleviate the adverse effects of D2 antagonism.</div><div class="NLM_p last">Most recently, the <i>N</i>-desmethyl metabolite <b>12</b> (NDMC, ACP-104) of <b>9</b>, a potent partial agonist at the muscarinic M<sub>1</sub> receptor that also has 5HT<sub>2A</sub> receptor antagonist activity, has been proposed as the missing link to understanding the unique efficacy of the parent drug.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81, 82)</a> In animals, <b>12</b> blocked MK-801-induced hyperactivity and enhanced cognition in an eight-arm radial maze<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> supportive of an activity profile as an SGA. However, additional preclinical studies with <b>12</b> showed a limited antipsychotic profile except at high doses,<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> leading to the suggestion that this compound would only be useful as an adjunctive therapy with existing antipsychotic agents.</div></div><div id="sec1_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">4.4 The Glutamate Hypofunction Hypothesis</h3><div class="NLM_p">Glutamate is the major excitatory neurotransmitter in the CNS. Antagonists of the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) glutamate receptor subtype, the psychotomimetics, <b>13</b> (phencyclidine, PCP, Chart <a class="ref internalNav" href="#chart1" aria-label="1">1</a>), and <b>14</b> (ketamine, Chart <a class="ref internalNav" href="#chart2" aria-label="2">2</a>), mimic the positive, negative, and cognitive symptoms of schizophrenia.<a onclick="showRef(event, 'ref20 ref84 ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref20 ref84 ref85 ref86">(20, 84-86)</a> In both recreational abusers of <b>13</b> and controlled human studies of psychosis induced by <b>13</b> or <b>14</b>, major similarities exist between psychosis induced by NMDA receptor blockade and schizophrenia. NMDA receptor antagonists exacerbate symptoms in schizophrenics and can trigger the re-emergence of symptoms in stable patients. First generation amino acid based NMDA receptor glycine transporter type 1 (GlyT1) inhibitors, e.g., <b>15</b> (sarcosine), and NMDA receptor coagonists, e.g., <b>16</b> (glycine), <b>17</b> (<span class="smallcaps smallerCapital">d</span>-serine), and <b>18</b> (<span class="smallcaps smallerCapital">d</span>-cycloserine), have produced modest beneficial effects in schizophrenics,<a onclick="showRef(event, 'ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref87 ref88 ref89">(87-89)</a> further implicating NMDA receptor hypofunction in the disorder.<a onclick="showRef(event, 'ref20 ref86'); return false;" href="javascript:void(0);" class="ref ref20 ref86">(20, 86)</a> While these findings suggest that schizophrenia involves a decreased activation of forebrain NMDA receptors, acute NMDA antagonist treatment can increase cortical glutamate levels in freely behaving rats, increasing non-NMDA-mediated glutamatergic transmission and a subsequent increase in DA efflux.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The importance of this observed increase is further supported by the finding that activation of group II metabotropic glutamate receptors by agonists such as <b>19</b> (LY379268) can decrease presynaptic glutamate release, attenuating both PCP-induced increases in glutamate release and the behavioral effects of this psychostimulant.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Together with studies demonstrating a dissociation between cortical DA levels and the behavioral effects of <b>13</b>,<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> this finding suggests that NMDA antagonist-induced increases in cortical glutamate are a key event in the psychotomimetic effects of PCP and ketamine. The glutamate/NMDA hypofunction hypothesis of schizophrenia remains consistent with both the DA and 5HT hypotheses representing a unifying link between the two neurochemical systems. The observation that cortical DA efflux increases after NMDA antagonist treatment<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> is also consistent with NMDA hypofunction being causal in inducing a hyperdopaminergic state and may, in part, explain the efficacy of FGAs and SGAs in reversing the psychotomimetic actions of NMDA antagonists in both animal models and the clinic.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> 5HT<sub>2A</sub> receptor activation increases the frequency of excitatory postsynaptic potentials at thalamocortical synapses in neocortical pyramidal neurons inducing an asynchronous release of glutamate that evokes a slow, late excitatory postsynaptic potential.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Both NMDA antagonists and 5HT<sub>2A</sub> agonists could thus share a common path of psychotomimetic action through effects on cortical glutamate release.</div><figure id="chart2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0002.jpeg" id="gr13" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">4.5 The GABA Hypothesis</h3><div class="NLM_p last">GABA, the major inhibitory transmitter in the CNS, has many effects that are opposite those of glutamate, some involving direct GABAergic inhibition of glutamate function. A role of GABA in the etiology of schizophrenia was first proposed in the early 1970s based on the GABAergic regulation of DA neuronal function, specifically in the context of the role of GABA in working memory.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94, 95)</a> Furthermore, GABA uptake sites were found to be decreased in the hippocampus, amygdala, and left temporal cortex in schizophrenics with evidence of GABA<sub>A</sub> receptor up-regulation<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> and decreases in GABA interneurons.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Clinical trials with benzodiazepines,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> GABA<sub>A</sub> agonists, the GABA<sub>B</sub> agonist <b>20</b> (baclofen), and the anticonvulsant <b>21</b> (valproic acid, the last used as a putative GABAergic agent) used alone and in combination with antipsychotics have led to mixed outcomes.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> However, a prototypic GABA uptake inhibitor, <b>22</b> (CI-966) produced psychotic episodes in a small phase I trial<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> producing symptoms similar to that of psychotomimetics. More recently, genetic evidence has implicated alterations in GABAergic function in the etiology of schzophrenia.<a onclick="showRef(event, 'ref99 ref100 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref99 ref100 ref101 ref102">(99-102)</a></div></div></div><div id="sec1_4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">5 Neurodevelopmental Aspects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74466" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74466" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Schizophrenia is widely viewed as a neurodevelopmental disorder,<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> the occurrence of which is correlated with reductions in the neuropil, the nonmyelinated neuronal processes in the gray matter<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> and white matter.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Evidence for a neurodevelopmental contribution has also come from human imaging studies that have documented schizophrenia-associated decreases in cortical volume.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> By use of diffusion tensor imaging, a disorganization of the white matter was found in the brains of schizophrenics that was associated with myelin abnormalities.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> This finding led to the concept of a “myelin model” systems biology/connectivity-based approach to the etiology of the disease<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> that is in marked contrast with the more traditional, neurotransmitter-based approaches to schizophrenia therapy and causality.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Schizophrenia-associated genetic signatures have also been found in multiple myelination-related genes that are associated with oligodendrocytes.<a onclick="showRef(event, 'ref108 ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref108 ref109 ref110">(108-110)</a> These are indicative of a potential dysfunction in frontal lobe myelination that can lead to alterations in white-matter tracts,<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> focusing attention on myelination as a possible target for drug discovery.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112, 113)</a> The use of <b>23</b> (ethyl eicosapentanoic acid, EPA, LAX-101) to alleviate the synaptic membrane phospholipid dysfunction thought to be associated with schzophrenia<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> as add-on therapy in clinical trials has resulted in both positive<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> and negative<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> effects. These have been critiqued on the basis of trial design and dose selection.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Treatment of schizophrenics with the SGA <b>24</b> (risperidone) has been associated with increases in myelination as assessed by MRI.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></div></div><div id="sec1_5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">6 Genetic Associations with Schizophrenia</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Genome scans, linkage disequilibrium and association studies in brain tissues from schizophrenic populations, have resulted in the identification of a number of vulnerability genes associated with schizophrenia.<a onclick="showRef(event, 'ref5 ref16 ref17 ref18 ref19 ref20 ref36 ref49 ref69 ref97 ref98 ref99 ref100 ref101 ref107 ref108 ref119 ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref5 ref16 ref17 ref18 ref19 ref20 ref36 ref49 ref69 ref97 ref98 ref99 ref100 ref101 ref107 ref108 ref119 ref120 ref121">(5, 16-20, 36, 49, 69, 97-101, 107, 108, 119-121)</a> These associations encompass many neurotransmitter systems in the brain including the enzymes involved in their synthesis and degradation, their receptors and uptake transporters, and a number of novel targets.</div><div class="NLM_p">There has, however, been considerable debate as to the viability/relevance of many of these genes,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> the design methodologies used to identify them,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and their replication,<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> with frequent “failures to replicate” the initial finding occurring in subsequent studies.<a onclick="showRef(event, 'ref19 ref36'); return false;" href="javascript:void(0);" class="ref ref19 ref36">(19, 36)</a> Additionally, considerable caution is required in ensuring that “schizophrenia-associated” gene associations are not the result of clinical misdiagnosis (one key patient cohort reportedly included brain tissue from a 3-year-old “schizophrenic”), the effects of the drugs used to treat the condition on gene function, or the potential identification of putative targets involved in the side effects of the drug class. Additionally, some of the putative genetic associations with schizophrenia, such as the allelic variations in the enzyme catechol-<i>O</i>-methyl transferase (COMT),<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> have been implicated in a broad range of other disease states. These include gender-related pain sensitivity,<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> obsessive-compulsive disorder,<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> myofacial pain syndrome,<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> breast cancer,<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> blood pressure dysfunction,<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> anorexia nervosa,<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> anxiety,<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> panic disorder,<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> depression,<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> and Alzheimer’s disease associated psychosis.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><div class="NLM_p">Given the expectation that the human genome map would be a facile source for a multitude of new targets for drug discovery<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> representing the lifespring for the future of the pharmaceutical industry, the following sections highlight the progress (or lack thereof) in the identification of new gene-based targets for antipsychotic drug discovery, schizophrenia being perhaps the most actively explored in terms of gene associations in neuropsychiatry research.</div><div id="sec1_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">6.1 Catechol-<i>O</i>-methyl Transferase (COMT)<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></h3><div class="NLM_p last">A microdeletion in the COMT gene localized to Chr22q11 produces velocardiofacial syndrome (22qDS, DiGeorge or Shprintzen syndrome), a genetic subtype of schizophrenia.<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135, 136)</a> COMT exists in two forms, Met<sup>158</sup> and Val<sup>158</sup>, with the former coding for a form of COMT that is thermally unstable and thus has lower activity than the Val<sup>158</sup> form. COMT is an enzyme important in regulating DA but not NE levels in the prefrontal cortex.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Val<sup>158</sup> Met heterozygotic mice have higher COMT activity and, correspondingly, lower prefrontal cortex DA levels and show greater tyrosine hydroxylase expression in the midbrain, indicating increased DA synthetic capability.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Neuroimaging studies have shown greater midbrain F-DOPA uptake in human Val<sup>158</sup> than Met<sup>158</sup> carriers, consistent with increased DA biosynthesis. Similarly, individuals with 22q11 deletion syndrome have higher urine DA levels and lower plasma levels of the DA metabolite homovanillic acid (HVA) compared to controls supporting a disruption of dopaminergic neurotransmission in this syndrome.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> DA levels in prefrontal cortex are key to cognitive function and high activity Val<sup>158</sup>COMT is associated with poorer performance and “inefficient” prefrontal cortex function.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Despite the large number of studies extending the effects of the Val<sup>158</sup>Met polymorphism to altered P50 sensory gating,<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> the relationship of COMT dysfunction to schizophrenia is controversial. Val<sup>158</sup> is thus considered a “weak risk factor” that may reflect COMT variation providing “a weak general predisposition to neuropsychiatric disease”.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Similarly, the relationship of allelic forms of COMT to the incidence of schizophrenia in velocardiofacial syndrome has been questioned.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Despite this, in normal subjects and in Val<sup>158</sup> carriers, CNS-penetrant COMT inhibitors such as <b>25</b> (tolcapone) can improve aspects of working memory and executive function in schizophrenics.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div></div><div id="sec1_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">6.2 Neuregulin (NRG1)</h3><div class="NLM_p last">The <i>NRG1</i> (neuregulin 1 growth factor) gene on chr8p13 has been associated with schizophrenia susceptibility.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> It contains a core EGF domain, and its product can activate the ErbB4 receptor tyrosine kinase (RTK) and the non-RTKs Fyn and PyK2 in hippocampus. These phosphorylate the NR2B subunit of the NMDA receptor, linking NRG1 to the glutamate hypothesis of schizophrenia.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a><i>NRG1</i> is functionally involved in interneuron migration, myelination, receptor recruitment, synaptic plasticity, and signaling between axons and Schwann cells. <i>NRG1+/−</i> gene knockout mice show phenotypic symptoms of schizophrenia that can be reversed by <b>9</b><a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> as can the NRG1/ErbB4-mediated phosphorylation of NR2B.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> In a Finnish cohort of schizophrenics, the NRG1 genotype was shown to be overrepresented in nonresponders to FGAs treated with <b>9</b>.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> NRG1 is also involved in interactions between NMDA receptors and PSD-95.<a onclick="showRef(event, 'ref142 ref145'); return false;" href="javascript:void(0);" class="ref ref142 ref145">(142, 145)</a> Blockade of NRG1/ErbB4 signaling in oligodendrocytes results in a defect in myelination that may contribute to the white matter defects associated with schizophrenia.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> This relationship has been further strengthened by genetic associations between oligodendrocyte lineage transcription factor 2 (<i>OLIG2</i>), ErbB4, CNP (2′,3′-cyclic nucleotide 3′-phosphodiesterase), and schizophrenia.<a onclick="showRef(event, 'ref110 ref135'); return false;" href="javascript:void(0);" class="ref ref110 ref135">(110, 135)</a><i>OLIG2</i> encodes a transcription factor that is key to oligodendrocyte development,<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> while CNP, a marker of myelinating oligodendrocytes, is reduced in schizophrenia<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> and has been genetically linked with the disorder.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Interaction studies between <i>OLIG2, CNP, NRG1</i>, and <i>ErbB4</i> showed that brain <i>OLIG2</i> expression was highly correlated with that of <i>CNP</i> and <i>ErbB4</i> but not <i>NRG1</i>, supporting a role for this gene in schizophrenia susceptibility via a genetic network linking myelination to glutamate receptor function,<a onclick="showRef(event, 'ref110 ref142'); return false;" href="javascript:void(0);" class="ref ref110 ref142">(110, 142)</a> further reinforcing the neurodevelopmental aspects of the disorder. These findings were further supported by in situ hybridization measurements of a number of gene transcripts involved in myelination, including CNP and ErbB4.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Despite the considerable body of evidence implicating NRG1, <i>OLIG2, ErbB4</i>, and <i>CNP</i> in the pathophysiology of schizophrenia, evidence that has led to new perspectives<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> on the genetic origins of schizophrenia and its neurodevelopmental nature,<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> the role of NRG1 in schizophrenia has been described as “substantial but not incontrovertible”.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Other studies have also failed to replicate the initial findings regarding the various genes involved in the NRG-1 axis.<a onclick="showRef(event, 'ref149 ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref149 ref150 ref151">(149-151)</a></div></div><div id="sec1_5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">6.3 Glutamate Receptors</h3><div class="NLM_p last">In addition to the NRG1 linkage to NMDA receptor hypofunction, polymorphisms in <i>GRM3</i> (metabotropic glutamate receptor-3) on chr7q21.1-q21.2,<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> GRIN1 (NMDA subunit gene) on chr9q34 that encodes for the NMDA receptor subunit NR-1,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> and GRIN2<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> have been associated with schizophrenia. The C2664T GRIN2 genotype shows an association with <b>9</b> treatment.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> A reduction in GRIN1 expression in mice produces a schizophrenia-like phenotype.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div></div><div id="sec1_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">6.4 Dysbindin-1 (DTNBP1, Dystrobrevin Binding Protein 1)</h3><div class="NLM_p last">Dysbindin-1 at chr6p22.2 is another schizophrenia susceptibility gene identified in several patient cohorts.<a onclick="showRef(event, 'ref156 ref157 ref158 ref159'); return false;" href="javascript:void(0);" class="ref ref156 ref157 ref158 ref159">(156-159)</a> Dysbindin-1 is a part of the dystrophin/dystrobrevin glycoprotein complex, located in synaptic densities, where it may play a role in the reductions in neuropil and neuronal size in the hippocampal formation that are associated with schizophrenia. Dysbindin-1 occurs in high levels in the cells providing the intrinsic glutamatergic input to the hippocampal formation. Cultured neurons with reduced <i>DTNBP1</i> expression have reduced glutamate release. Reduced levels of <i>DTNBP1</i> mRNA and protein expression have been recorded in brain samples from schizophrenics.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div></div><div id="sec1_5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">6.5 Regulator of G Protein Signaling 4 (RGS4)</h3><div class="NLM_p last">RGS4 on chr1q23.3 is another schizophrenia susceptibility locus.<a onclick="showRef(event, 'ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref160 ref161">(160, 161)</a> Patients with alleles containing the rs951436 SNP of <i>RGS4</i> show differences in the volume of the dorsolateral prefrontal cortex<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> and also differences in brain activation in a working memory task.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> The gene product of <i>RGS4</i>, one of the family of 23 RGS proteins that control the duration and timing of GPCR-associated intracellular signaling events, down-regulates signaling at DA and 5HT receptors. Its expression can be modulated by stress. A review of replicate studies<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> led to the conclusion that the RGS association with schizophrenia was “enticing but not conclusive”. However, subsequent studies<a onclick="showRef(event, 'ref164 ref165'); return false;" href="javascript:void(0);" class="ref ref164 ref165">(164, 165)</a> have provided additional evidence for a role of <i>RGS4</i> polymorphisms as a factor in schizophrenia causality and in antipsychotic responsiveness.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div></div><div id="sec1_5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">6.6 <span class="smallcaps smallerCapital">d</span>-Amino Acid Oxidase Activator (DAOA)/G72</h3><div class="NLM_p last">DAOA/G72 present on chr13q32-22 is a brain-expressed protein genetically associated with schizophrenia.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> It binds to the enzyme <span class="smallcaps smallerCapital">d</span>-amino acid oxidase (DAAO). DAAO, which occurs in neuronal and glial forms,<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> oxidizes <span class="smallcaps smallerCapital">d</span>-serine, a potent activator of the NMDA receptor, leading to an indirect modulation of glutamate receptor function. DAOA/G72 can activate DAAO in vitro.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> While this effect has not been demonstrated in vivo, DAAO<sup>−/−</sup> mice have high levels of <span class="smallcaps smallerCapital">d</span>-serine and show reduced stereotype and rotational activity in response to NMDA receptor antagonists compared to wild-type mice.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Increased transcript levels of DAOA/G72 but not the complementary gene <i>G30</i> were identified in the dorsolateral prefrontal cortex of schizophrenics.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> In addition to the association of DAOA/G72 with schizophrenia,<a onclick="showRef(event, 'ref169 ref170 ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref169 ref170 ref171 ref172">(169-172)</a> there is also evidence of an association with bipolar disorder,<a onclick="showRef(event, 'ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref172 ref173">(172, 173)</a> part of the schizophrenia spectrum,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and with analgesia.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The several instances of a failure to replicate the schizophrenia association of DAOA/G72<a onclick="showRef(event, 'ref175 ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref175 ref176 ref177">(175-177)</a> may be colored by the associated prevalence of mood disorders with schizophrenia and differences in allelic variants.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a>While the DAOA/G72 gene association with schizophrenia has been described as “among the most compelling in psychiatry”,<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> a lack of evidence for a brain-expressed gene for DAOA/G72, the absence of a functional native protein for the gene, and the overlap of the association with bipolar disorder and analgesia<a onclick="showRef(event, 'ref172 ref173 ref178 ref179'); return false;" href="javascript:void(0);" class="ref ref172 ref173 ref178 ref179">(172, 173, 178, 179)</a> have led to this “compelling” gene being described as having a “weak” role in the etiology of schizophrenia.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></div></div><div id="sec1_5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">6.7 Disrupted-in-Schizophrenia 1 (DISC1)</h3><div class="NLM_p last">DISC1 on chr1q is a component of the microtubule-associated dynein motor complex associated with schizophrenia in Scottish,<a onclick="showRef(event, 'ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref181 ref182">(181, 182)</a> Finnish,<a onclick="showRef(event, 'ref183 ref184'); return false;" href="javascript:void(0);" class="ref ref183 ref184">(183, 184)</a> and Taiwanese<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> patient cohorts. A weaker, gender-linked effect has also been described in a Chinese patient cohort.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a><i>DISC1</i> is involved in maintaining the centrosome complex and microtubular function.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Depletion of endogenous DISC1 or mutated DISC1 results in neurite dysfunction in vitro and impairment of cerebral cortex function in vivo, reflected in effects on working memory in mice,<a onclick="showRef(event, 'ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref188 ref189">(188, 189)</a> altered cortical development,<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> and asymmetrical increases in lateral ventricle size in dominant-negative DISC-1 mice.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> DISC-1 interacts with the UCR2 domain of the phosphodiesterase, PDE4B, suggesting a possible role in cAMP signaling processes involving CREB elements.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> The association of DISC-1 with schizophrenia has, however, been disputed<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> on the basis of a lack of evidence of linkage to the disease from a cohort of over 1000 sibling pairs.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec1_5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">6.8 GABA</h3><div class="NLM_p last">A number of genes involved in GABA neurotransmission have been linked to schizophrenia.<a onclick="showRef(event, 'ref99 ref100 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref99 ref100 ref101 ref102">(99-102)</a> Genes for the β2 subunit of the GABA<sub>A</sub> receptor (GABRB2) on chr5q34 and the GABA<sub>B</sub> receptor 1 (GABBR1) on 6p21.3 have been identified as susceptibility loci in schizophrenia.<a onclick="showRef(event, 'ref193 ref194'); return false;" href="javascript:void(0);" class="ref ref193 ref194">(193, 194)</a> Decreases in the mRNA for the 67 kDa isoform of glutamic decarboxylase (GAD, GAD67) were observed in brains from schizophrenics and individuals with related disorders including autism and bipolar disorder.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Additional studies in schizophrenics with dysfunction of the dorsolateral prefrontal cortex showed expression deficits in transcripts for GAD, the GABA transporter, and the α1, α4, β3, γ2 and δ subunits of the GABA<sub>A</sub> receptor.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Network association analysis for hippocampal GAD67 in brains from schizophrenics identified 25 GAD-associated genes. These included those involved in the regulation of kainate receptors, TGF-β, and <i>wnt</i> signaling and were consistent with a decreased expression of GAD67 that was epigenetic in origin.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Interactions between polymorphisms in the genes for GABRB2, GAD1 (the gene expressing GAD67), and GAD2 have also been associated with schizophrenia.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div></div><div id="sec1_5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">6.9 α7 Neuronal Nicotinic Receptor (CHRNA7)</h3><div class="NLM_p">The association of <i>CHRNA7</i> with schizophrenia is of interest in the context of the widely reported phenomenon that schizophrenics self medicate to treat their symptoms by using cigarettes as a nicotine source.<a onclick="showRef(event, 'ref195 ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref195 ref196 ref197">(195-197)</a> Schizophrenics show a high degree of comorbid abuse of a variety of substances in addition to nicotine, including alcohol, cannabis, cocaine, and amphetamine, their rate of substance abuse being higher than that seen in the general population. This behavior can exacerbate positive symptoms, increase hospitalization, and increase the frequency of homelessness. This propensity for abuse, regardless of the consequences, suggests that the reward systems of schizophrenics may be dysregulated. Alternatively, high levels of D2 receptor occupancy by SGAs may blunt DA-mediated reward and lead to an enhanced abuse drive. In support of this, a correlation exists between D2 receptor occupancy by antipsychotic drugs and the number of cigarettes smoked by schizophrenics.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a></div><div class="NLM_p last">Alternative phenotypes of <i>CHRNA7</i> on chr15q14 are associated with deficits in the P50 auditory response, a key phenotype in schizophrenia.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> This finding has been replicated in additional studies<a onclick="showRef(event, 'ref200 ref201 ref202'); return false;" href="javascript:void(0);" class="ref ref200 ref201 ref202">(200-202)</a> but not in others.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> Additional nicotinic receptor genes including CHRNA1, CHRNA2, and CHRNB2 have also been associated with smoking in schizophrenics.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> On the basis of the strength of the epidemiological and genetic studies, a number of α7 receptor agonists, e.g., <b>26</b> (GTS-21/DXMBA), <b>27</b> (PHA-5436130), <b>28</b> (SSR180711), and <b>29</b> (AZD0328), have shown benefit in animal models of sensory gating (prepulse inhibition, PPI) deficit.</div></div><div id="sec1_5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">6.10 Dopamine Receptors</h3><div class="NLM_p last">Despite the unequivocal evidence resulting from the efficacy of known antipsychotics<a onclick="showRef(event, 'ref51 ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54 ref55">(51-55)</a> that reducing DA neurotransmission is beneficial in treating schizophrenia, there are few robust studies that have implicated DA-related genes in the etiology of the disorder.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Polymorphisms of the DA D2 receptor gene DRD2 show limited evidence for an association with schizophrenia.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> For the DA D3 receptor, a Ser<sup>9</sup>Gly polymorphism on <i>rs6280</i> showed a modest, “marginal” association with schizophrenia,<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> with other studies being equivocal.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Association of the DA D4 receptor with schizophrenia has also been equivocal.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> The association of the COMT polymorphism Met<sup>158</sup>Val to schizophrenia<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> and multiple other diseases has already been discussed. Initial studies showing a positive association of the DA transporter (DAT, <i>SLC6A3</i>) with schizophrenia<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> were not supported by meta-analysis.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> Inconsistent associations have also been reported for the DA-interacting proteins NURR (<i>NR4A21</i>, orphan nuclear receptor subunit 4), CALCYON (<i>DRD11P</i>, D1 receptor interacting protein), DARPP-32 (PPP1R1B, protein phosphatase 1, regulatory (inhibitory) subunit 1B), syntaxin1A (<i>STX1A</i>), protein interacting with PRKCA1 (<i>PICK1</i>), synaptosomal-associated protein, 25kDa (SNAP 25), and β-adrenoceptor kinase 3(GRK3).<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> In aggregate, most of the studies implicating DA receptors and their associated proteins (COMT, DAT, NURR, etc.) with schizophrenia have been inconclusive.</div></div><div id="sec1_5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">6.11 Miscellaneous Associations</h3><div class="NLM_p">Additional genetic and nongenetic associations with schizophrenia include V-AKT murine thyoma viral oncogene homolog 1(AKT), proline dehydrogenase (<i>PRODH</i>), the 5HT transporter, SERT (<i>SLC6A4</i>), the 5HT<sub>2A</sub> receptor (<i>HTR2A</i>),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> calcineurin,<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> and reelin.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> Negative symptoms have been associated with methylenetetrahydrofolate reductase (MTHFR).<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> Other associations include Dickkopf receptor 4(DKK4), a negative regulator of the <i>Wnt</i> signaling pathway,<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> the tumor suppressor gene TGFBR2 located at chromosome 3p22,<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> netrins,<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> TRPs (transient receptor potential channels),<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> IL-1β, TGF-B2, HDAC1, DAXX (death associated protein), and cyclin D2 (CCND2).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Equivocal data exist for the involvement of the putative σ1 receptor in schizophrenia.<a onclick="showRef(event, 'ref217 ref218 ref219'); return false;" href="javascript:void(0);" class="ref ref217 ref218 ref219">(217-219)</a> Negative associations have been reported for carboxy-terminal PDZ ligand of neuronal nitric oxide synthase (CAPON)<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> and the α<sub>2A</sub> adrenoceptor.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a></div><div class="NLM_p">In an approach termed “convergent functional genomics”,<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> data from mice separately treated with <b>9</b> and <b>13</b> were used together with human genetic linkage and post-mortem brain data from schizophrenics to associate genes involved with GABA (<i>GABAR1</i>, <i>GABBR1</i>, <i>GAD2</i>), glutamate (<i>GRIA2</i>), and neuropeptide (<i>TAC1</i>) signaling, synaptic (<i>SYN2, KCNJ4</i>) and myelin/glial (<i>CNP</i>, <i>MAL</i>, <i>PLP1</i>, <i>MBP</i>, <i>MOBP</i>, <i>GFAP</i>) function, and lipid metabolism (<i>LPL</i>) to the disorder. Additional associations identified with this “Bayesian” approach included genes involved in neurite outgrowth and circadian rhythm, adding further to the complexity of the schizophrenia genome (the “schizome”?).</div><div class="NLM_p">The increasingly large and still evoling number of studies focused on elucidating the genetic basis of schizophrenia, and the multiple genetic foci thus far identified appear to be inversely proportional to the useful knowledge gained in understanding disease causality and treatment and in using viable new targets to drive drug discovery efforts. The genetic and clinical data to date clearly support schizophrenia as having a neurodevelopmental component<a onclick="showRef(event, 'ref34 ref120'); return false;" href="javascript:void(0);" class="ref ref34 ref120">(34, 120)</a> with multiple risk genes of small effect adding to a complex genetic framework that is made additionally complex because of allelic heterogenicity and major epistatic influences.<a onclick="showRef(event, 'ref17 ref36'); return false;" href="javascript:void(0);" class="ref ref17 ref36">(17, 36)</a></div><div class="NLM_p">Despite initial promising findings, the lack of reproducibility (the failure to replicate) of many of the schizophrenia gene associations reported has led to ambiguous outcomes. Associations described as having a “compelling rationale” are also described as “weak”.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The ultimate validation of the several novel gene-associated targets will thus need to be driven by traditional drug discovery efforts using defined molecular targets to develop small molecules that can be used to drive the “proof of concept” in the clinic in the appropriate patient population.</div><div class="NLM_p">The identification of each new gene putatively associated with schizophrenia, based on the progress to date, appears to lead to at least an additional 5 years of research in order to replicate and extend the original finding. This makes it likely that at least another decade will be required to develop a better understanding of how the various gene associations reported and their expressed proteins (if known) contribute to disease causality, thus providing an appropriate context for a focused drug discovery effort. At what point a gene association for a neuropsychiatric disorder such as schizophrenia can be considered as validated and useful as a novel target is unclear because “there is no obvious criterion for distinguishing signal from noise”.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The failure of many meta-analyses to identify consistent sites of linkage together with the lack of replication of candidate genes like COMT, RGS4, DISC1, DAOA, neuregulin, COMT, etc. has led to the consideration<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> that “multiple genes of small effect” together with “<i>the speciation event</i>” account for the predisposition to schizophrenia. The latter refers to the chromosomal rearrangement occurring in the brain during evolution that separated humans from nonhuman primates. This has been used as the basis for the hypothesis that psychosis is uniquely species-associated and is primarily manifested through epigenetic variation involving DNA methylation or histone phosphorylation, acetylation, and methylation. The last is then superimposable on the DNA transcription process, adding considerable additional complexity to simple alterations in DNA base content.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> This is in marked contrast to the “common-disease−rare allele” hypothesis<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> and remains the subject of active debate.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">Several of the gene associations identified (NRG1, GRM-3, GRIA2, GRIN1, dysbindin-1, DAOA/G72, and GAD67) provide additional support for the glutamate hypothesis of schizophrenia. In addition to the effects of glutamate receptor modulators, the first mGlu2/3 receptor agonist <b>30</b> (LY2140023),<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> an orally active prodrug of <b>31</b> (LY404039, Chart <a class="ref internalNav" href="#chart3" aria-label="3">3</a>), showed improvements in both positive and negative symptoms at week 4 in a randomized, double-blind, placebo controlled clinical trial. Compound <b>30</b> had efficacy equivalent to that of the SGA <b>32</b> (olanzapine) but did not differ from placebo in terms of prolactin production, extrapyramidal symptoms, or weight, providing clinical proof of concept that mGlu2/3 receptor agonists may represent a viable alternative approach for the treatment of schizophrenia. While a major advance in the area, issues with proconvulsant activity<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> may still confound the path forward with this compound class in the treatment of schizophrenia.</div><figure id="chart3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0003.jpeg" id="_i23" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In realistically assessing of the role of the gene-based approach to disease causality and novel drug discovery in schizophrenia, this is weakened by (i) the genetic association of COMT with multiple diseases/disorders in addition to schizophrenia and (ii) the minimal genetic evidence to support the concept that the targets of the currently used antipsychotics, the DA receptor blocking FGAs and SGAs, are involved in the etiology of the disease. Indeed, the use of a gene-based approach to target identification and drug discovery would not have resulted in the discovery of any of the currently used antipsychotics. It is also of interest that the only new drug approved for the treatment of schizophrenia in the past 5 years, <b>8</b>, was developed on a purely empirical basis deliberately eschewing a dependence on molecular target or disease-associated genetic approaches. Rather, the intuition of a medicinal chemist and pharmacologist, the latter using animal models, working in proximity led to the identification of this partial DA agonist, the mechanism(s) of which was established after the compound entered the clinic.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> An additional, and somewhat disturbing, point is the finding that the “magic bullet” of schizophrenia, <b>9</b>, is effective in reversing both the phenotypic symptoms of schizophrenia<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> and alterations in ErbB4-mediated phosphorylation of the NMDA receptor subunit NR2B<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> that were observed in NRG−/− mice. This either argues that <b>9</b> has additional and as yet unidentified molecular interactions with components of the ErbB4/Fyn/Pyk2 signaling axis<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> or that the signaling dysfunction in this transgenic model can be rectified by modulation of the existing receptor galaxy with which <b>9</b> interacts.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div></div></div><div id="sec1_6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">7 Animal Models of Schizophrenia</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Key in the validation of putative new targets and the identification and iterative development of new drugs for the treatment of schizophrenia are the animal models of efficacy used to advance new chemical entities (NCEs) through the discovery process to the clinic. Given that schizophrenia is a neurodevelopmental disease<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> involving aspects of higher cognitive function that are unique to humans,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> the modeling of the disorder in less cognitively developed species represents a significant challenge.<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> Currently used animal models have historically been back-validated using clinical benchmarks to provide a basis for arguing for future predictive validity. While this reasoning seems to hold for recent SGAs in that they produce the predicted preclinical effects, the fact that many of these newer compounds are largely subtle variations on the clozapine theme discussed above raises questions regarding the validity of the back-validation approach. The MATRICS initiative<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> emphasizes the critical translational importance of correlating animal models with predictive value for planning human trials to evaluate novel antipsychotic NCEs.</div><div id="sec1_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">7.1 Behavioral Assays</h3><div id="sec1_6_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">7.1.1 Conditioned Avoidance</h4><div class="NLM_p last">The ability of an NCE to inhibit the conditioned avoidance response (CAR) to an aversive stimulus is a classical predictor of antipsychotic efficacy. Rats are trained to respond to an audible cue (the conditioned stimulus) in order to avoid a foot shock (the unconditioned stimulus). Both FGAs and SGAs are effective in decreasing the CAR to the conditioned stimulus without altering the escape response elicited by the unconditioned stimulus. Inhibition of CAR is a facile in vivo method of measuring DA receptor blockade, as demonstrated by the findings that the inhibition of the CAR is mediated by a decreased dopaminergic function in the striatum and nucleus accumbens.<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> Inhibition of the unconditioned response is suggestive of sedation or catalepsy, providing a convenient method to determine a therapeutic index for the adverse effects of an NCE.</div></div><div id="sec1_6_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27">7.1.2 Locomotor Activity</h4><div class="NLM_p last">The majority of antipsychotic drugs decrease either drug-induced or spontaneous locomotor activity. As in the case of the CAR, decreased locomotor activity can be interpreted as an in vivo readout of DA antagonism. However, the ability of novel, nondopaminergic agents to reduce the hyperlocomotion elicited by <b>2</b> or <b>13</b><a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> suggests that this particular model involves more complex circuitry and may hold greater clinical relevance.</div></div><div id="sec1_6_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">7.1.3 Latent Inhibition</h4><div class="NLM_p last">The ability of a pre-exposed nonreinforced stimulus to inhibit later stimulus-response learning<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> can be disrupted by amphetamine in rodents and humans. This behavior has been suggested as a valid model of the positive symptoms of schizophrenia. However, there is still disagreement on several aspects including the prevalence of disrupted latent inhibition in schizophrenic patients, the ability of SGAs to rescue amphetamine-disrupted latent inhibition, and differences in the protocols used in human and animal studies. While latent inhibition holds considerable interest, results from these studies need to be interpreted with caution until there is better agreement as to the validity and interpretation of results.</div></div><div id="sec1_6_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">7.1.4 Prepulse Inhibition</h4><div class="NLM_p last">Many of the symptoms of schizophrenia are hypothesized to be the result of disrupted sensory and cognitive gating. Prepulse inhibition (PPI) describes the ability of a low-intensity stimulus, or prepulse, to diminish the startle response elicited by a higher intensity stimulus. The findings that schizophrenic patients exhibit deficits in sensory and cognitive gating have led to an increased focus on PPI as a preclinical model. One of the interesting aspects of PPI is the possible path forward for performing translational medicine. This is particularly evident in studies of event-related potentials (ERPs) in the electroencephalogram in which the latency and amplitude of P300 is assessed in response to an unpredictable change in a stimulus series—the “oddball” paradigm. Schizophrenics exhibit a reduction in <i>P</i><sub>300</sub> amplitude in response to novelty.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> The <i>P</i><sub>50</sub> ERP in response to pairs of brief auditory stimuli provides a direct clinical analog of the preclinical PPI model because schizophrenic patients do not show a decreased <i>P</i><sub>50</sub> response to the second stimulus of a pair.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> ERP abnormalities have been interpreted as suggestive of a deficit in the gating or processing of sensory information. Consistent with this, schizophrenics show impaired PPI relative to normal control subjects.<a onclick="showRef(event, 'ref231 ref232'); return false;" href="javascript:void(0);" class="ref ref231 ref232">(231, 232)</a> In animals, PPI can be disrupted by various psychotomimetics and restored by antipsychotic drugs<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> and as such is the current gold-standard assay based on the high degree of face and apparent predictive validity.</div></div></div><div id="sec1_6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">7.2 Pharmacological Models</h3><div class="NLM_p last">Compounds that are psychotomimetic in humans can induce phenotypes in laboratory animals that are presumed to model some of the underlying pathophysiology of schizophrenia. These compounds encompass three of the mechanistic categories already discussed: DA releasing agents, 5HT<sub>2</sub> agonists, and NMDA receptor antagonists. Compounds <b>2</b>, <b>3</b>, and <b>33</b> (methylphenidate), all of which increase DA release, are psychotomimetic, a property not shared by directly acting DA agonists, suggesting that enhanced dopaminergic transmission produces circuit-level changes in neuronal function. The hallucinogenic effects of <b>4</b>, <b>34</b> (psilocybin), and the phenethylamines <b>35</b> (dimethoxymethylamphetamine) and <b>36</b> (mescaline) and the relatively high affinity of these agents for the 5HT<sub>2A</sub> receptor have supported the use of 5HT<sub>2A</sub> agonists as preclinical psychotomimetics. The noncompetitive NMDA receptor antagonists <b>13</b>, <b>14</b>, and <b>37</b> (dizocilpine, MK-801) induce a psychotic state in humans that is very similar to that observed in schizophrenics. The disruption in PPI produced by these three compound classes is responsive to SGAs.<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> As discussed above, DA, 5HT, and NMDA receptor systems are dysregulated in schizophrenia, providing a level of construct validity to these models. However, the pharmacological nature of these models raises an important caveat. Given the incomplete understanding of the pathophysiology of schizophrenia, a purely pharmacological disruption of the model cannot be ruled out even with a truly novel NCE. Care is therefore required in interpreting data from this type of model.</div></div><div id="sec1_6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">7.3 Lesion Models</h3><div class="NLM_p">Increases in ventricle size, decreases in cortical and hippocampal volume, and a selective decrease in subpopulations of GABAergic interneurons in brains from schizophrenics all indicate that neuronal loss is a key part of the pathophysiology of the disease. In the absence of robust indications of gross neurodevelopmental abnormalities, attention has focused on pathological changes that may occur during the pre- or perinatal period. Several rodent models have been developed including the modeling of perinatal hypoxia and anoxia to mimic obstetric complications<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(235)</a> and the modeling of aspiration, electrolytic, or excitotoxic lesioning of the prefrontal cortex or hippocampus.<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(236)</a></div><div class="NLM_p last">Symptom onset is delayed in a number of neonatal lesion models, a finding that has been suggested to mirror the clinical presentation of symptoms in schizophrenic humans. For example, the increased sensitivity to amphetamine, a reduced sensitivity to <b>38</b> (haloperidol), disrupted latent inhibition, and deficits in PPI observed after postnatal excitotoxic lesion of the ventral hippocampus do not become apparent until postnatal day 53.<a onclick="showRef(event, 'ref237 ref238'); return false;" href="javascript:void(0);" class="ref ref237 ref238">(237, 238)</a> While these models have several attractive features, the extent and nature of the lesions are distinct from those observed in brains from schizophrenics.</div></div><div id="sec1_6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">7.4 Genetic Models</h3><div class="NLM_p last">Several transgenic mouse models have been developed that involve the selective knockout or knockdown of neurotransmitter receptors thought to be relevant to schizophrenia, e.g., D1-D5 and NMDA.<a onclick="showRef(event, 'ref239 ref240'); return false;" href="javascript:void(0);" class="ref ref239 ref240">(239, 240)</a> Knockdown of the obligatory NR1 subunit of the NMDA receptor to approximately 5% of normal expression levels resulted in mice that exhibited increased spontaneous hyperlocomotion and social deficits that respond to an antipsychotic drug.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Other genetically modified mouse models for schizophrenia include knockout of <span class="smallcaps smallerCapital">d</span>-amino acid oxidase,<a onclick="showRef(event, 'ref168 ref241'); return false;" href="javascript:void(0);" class="ref ref168 ref241">(168, 241)</a> neuregulin 1,<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a> and DISC-1.<a onclick="showRef(event, 'ref190 ref243'); return false;" href="javascript:void(0);" class="ref ref190 ref243">(190, 243)</a> The number of largely inconclusive human genetic studies<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> indicates schizophrenia as being a nonhomogeneous multifactorial disorder. Thus, the generation of a “schizophrenic mouse” model appears unlikely because any selective alteration of implicated genes will likely result in an incomplete model of the disorder requiring caution in their use.<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a> An interesting genetic knockout is the Df1/+ mouse generated by engineering a chromosomal deletion spanning the same region as the human 22q11 deletion responsible for velocardiofacial syndrome<a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a> resulting in a mouse that exhibits a number of pathologies consistent with the human deletion including deficits in PPI and learning and memory.</div></div><div id="sec1_6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">7.5 Spontaneous Models</h3><div class="NLM_p last">Animal models of schizophrenia that do not rely on genetic or pharmacological manipulation involve rodents that appear to have a naturally occurring behavioral deficit relevant to the disorder. These include the PPI deficits evident in the spontaneously hypertensive rat,<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> the Brattleboro rat,<a onclick="showRef(event, 'ref247 ref248'); return false;" href="javascript:void(0);" class="ref ref247 ref248">(247, 248)</a> and the DBA/2 mouse.<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a> Of these, the DBA/2 mouse has been the most extensively characterized and has become a valuable tool for drug discovery research. However, care must be exercised with this type of model because subtle differences in variables such as the source and choice of vehicle can dramatically affect the experimental outcome.<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a></div></div><div id="sec1_6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">7.6 Models of Cognitive and Negative Symptom Domains</h3><div class="NLM_p last">Most of the models discussed above focus on the positive symptoms of schizophrenia. This has been useful in developing clozapine-like molecules but does not address the debilitating negative or cognitive symptoms of the disease. Enhanced cognitive function can be assessed through a variety of classical behavioral pharmacology tests including the Morris water maze, passive avoidance, and operant tasks, e.g., delayed alternation.<a onclick="showRef(event, 'ref251 ref252 ref253'); return false;" href="javascript:void(0);" class="ref ref251 ref252 ref253">(251-253)</a> While these assays measure cognitive enhancement in normal, aged, or pharmacologically impaired animals, it is not yet known if these models are predictive for efficacy against the cognitive symptoms of schizophrenia. Available antipsychotics produce only modest improvement in the negative symptoms of schizophrenia.<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> With the realization that the negative symptoms of schizophrenia constitute a distinct therapeutic domain and with the understanding that the negative symptoms are a significant contributor to poor quality of life,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> there has been increased interest in the development of preclinical models of this symptom domain. These models are primarily focused on anhedonia and social withdrawal. Anhedonia can be measured in both rats and nonhuman primates by a variety of methods including sucrose preference and intracranial self stimulation. While there is conflicting data on the ability of amphetamine to induce anhedonia,<a onclick="showRef(event, 'ref255 ref256'); return false;" href="javascript:void(0);" class="ref ref255 ref256">(255, 256)</a><b>13</b> can decrease voluntary sucrose consumption in rats,<a onclick="showRef(event, 'ref257'); return false;" href="javascript:void(0);" class="ref ref257">(257)</a> an effect reversed by subcronic treatment with <b>9</b> but not by acute <b>9</b> or <b>38</b>.<a onclick="showRef(event, 'ref258'); return false;" href="javascript:void(0);" class="ref ref258">(258)</a> Social withdrawal can be assessed in both rodents and nonhuman primates and can be induced by both <b>2</b> and <b>13</b>.<a onclick="showRef(event, 'ref259 ref260 ref261 ref262'); return false;" href="javascript:void(0);" class="ref ref259 ref260 ref261 ref262">(259-262)</a> While these models are of considerable interest, it is not possible to estimate their predictive validity without the availability of clinically efficacious comparators, the “derived knowledge” that results from the development of effective therapeutics.<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a></div></div></div><div id="sec1_7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">8 Current Treatment Options</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">8.1 First Generation “Typical” Antipsychotic Drugs (FGAs)</h3><div class="NLM_p">The discovery of the DA receptor antagonist properties of <b>1</b><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> led to the discovery of numerous drugs with a similar mechanism of action, e.g., D2 receptor antagonism. These included the phenothiazines (e.g., <b>39</b> (fluphenazine), <b>40</b> (mesoridazine), <b>41</b> (methotrimeprazine), <b>42</b> (perphenazine), <b>43 (</b>prochlorperazine), <b>44</b> (thioproperazine), <b>45</b> (thioridazine), and <b>46</b> (trifluoperazine)), the thioxanthenes (e.g., <b>47</b> (chlorprothixene), <b>48</b> (flupenthixol), and <b>49</b> (thiothixene)), the butyrophenones (e.g., phenylbutylpiperadines that include <b>38</b>, <b>50</b> (melperone), <b>51</b> (bromperidol), and <b>52</b> (pimozide)), the substituted benzamides (e.g., <b>53</b> (sulpiride) and <b>54</b> (amisulpride)), the dihydroindolone (<b>55</b> (molindone)), and the dibenzoxazepine (<b>56</b> (loxapine)) (Chart <a class="ref internalNav" href="#chart4" aria-label="4">4</a>). Treatment with FGAs, including <b>38</b>, was associated with the development of extrapyramidal side effects (EPS) (e.g., dystonias, akathisias)<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and tardive dyskinesia in about 20% of patients, the latter characterized by abnormal involuntary movements of the tongue, facial muscles, or limb muscles. Additional adverse effects with FGAs were increased prolactin secretion (leading to gynecomastia, galactorrhea, menstrual irregularities, sexual dysfunction, sedation), hypotension, weight gain, Parkinsonism, and the sometimes fatal neuroleptic malignant syndrome. While all FGAs effectively control the positive symptoms of schizophrenia, they do not treat, and in some cases may worsen, the negative and cognitive dysfunction aspects of the disease. Because of their limited efficacy, narrow therapeutic window, and the development of more effective and tolerable agents, FGAs generally do not represent the preferred treatment option for schizophrenia.</div><figure id="chart4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0004.jpeg" id="_i37" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">8.2 Second Generation “Atypical” Antipsychotic Drugs (SGAs)</h3><div class="NLM_p">On the basis of the improved efficacy and therapeutic index of clozapine, the prototypic SGA, a number of analogues of <b>9</b>, e.g., <b>32</b>, <b>56</b>, and <b>57</b> (asenapine), the benzisoxidils <b>24</b>, <b>58</b> (iloperidone), and <b>59</b> (ziprasidone), and the phenylindole <b>60</b> (sertindole) were identified. While the SGAs have clearly exhibited a unique therapeutic profile that prompted their discovery and introduction to the clinic, 60 years of research in academia and industry have failed to identify a convincing mechanistic theory to explain this “atypicality”, a topic that has been discussed in detail above. Compound <b>58</b>, which has been in clinical trials for over a decade, has been reported to have less propensity to produce metabolic syndrome but still produces QT prolongation.<a onclick="showRef(event, 'ref263'); return false;" href="javascript:void(0);" class="ref ref263">(263)</a></div><div class="NLM_p last">The outcomes of CATIE and CUtLASS trials<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28 ref29">(24-29)</a> provide a dilemma for those involved in the drug discovery process to identify new antipsychotics. These trials have indicated that the older and less expensive FGAs can offer equivalent or better efficacy than the SGAs, a conclusion that has been considered as flawed on the basis of issues with study design and data interpretation.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24-26)</a> Furthermore, considerable preclinical data exist that differentiate FGAs from SGAs and many clinical studies conducted prior to the CATIE and CUtLASS trials similarly differentiate individual SGAs from FGAs.<a onclick="showRef(event, 'ref3 ref6 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref6 ref11">(3, 6, 11)</a> An interesting outcome from this debate has been data<a onclick="showRef(event, 'ref263'); return false;" href="javascript:void(0);" class="ref ref263">(263)</a> suggesting that the prototypic heterocycle <b>61</b> (cyproheptadine) resembles <b>9</b> in animal models.</div></div><div id="sec1_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">8.3 Dopamine Receptor Modulators/Dopamine Partial Agonists</h3><div class="NLM_p">The introduction of <b>8</b> in 2002<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> was heralded as the first breakthrough in antipsychotic treatment since the discovery of <b>9</b>. As noted above, <b>8</b> was discovered through the same serendipitous process that led to the identification of <b>1</b> and <b>9</b>, observation of the effects of NCEs by experienced pharmacologists using carefully designed in vivo pharmacological studies. Compound <b>8</b> is structurally unique with a mechanism of action that appears to reflect its partial agonist properties at DA D2 receptors.<a onclick="showRef(event, 'ref264'); return false;" href="javascript:void(0);" class="ref ref264">(264)</a> This latter functional profile depends on a number of factors including receptor reserve and endogenous agonist tone.<a onclick="showRef(event, 'ref265'); return false;" href="javascript:void(0);" class="ref ref265">(265)</a> A partial agonist will thus function as a full agonist in a tissue with high receptor reserve. In contrast, in a tissue with low receptor reserve in the absence of endogenous agonist, a partial agonist will function as a partial agonist. However, if the tissue has low receptor reserve with significant endogenous DA tone, a partial agonist will function as an antagonist by occupying receptors that would have otherwise been occupied by the endogenous agonist. Differences in receptor reserve occur in the various DA D2 receptor systems in the brain; presynaptic D2 autoreceptors have a high receptor reserve, while postsynaptic D2 receptors have very low receptor reserve.<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> A partial agonist can thus act as an antagonist at postsynaptic DA receptors in the mesolimbic system where overactivity is thought to elicit positive symptoms and as a presynaptic agonist at DA autoreceptors eliciting a decrease in postsynaptic DA tone. Theoretically, a partial agonist can dynamically modulate DA neurotransmission as a direct function of dopaminergic tone. The first partial DA agonist to be tested clinically was the <i>S</i>-(−)-isomer of <b>62</b> (<i>S</i>-(−)-3-PPP, preclamol; Chart <a class="ref internalNav" href="#chart5" aria-label="5">5</a>).<a onclick="showRef(event, 'ref267'); return false;" href="javascript:void(0);" class="ref ref267">(267)</a> In the clinic, <b>62</b> produced initial improvements in schizophrenics relative to placebo during the first week of therapy; however, efficacy decreased with continued treatment. Other partial DA agonists, including <b>63</b>(terguride),<a onclick="showRef(event, 'ref268'); return false;" href="javascript:void(0);" class="ref ref268">(268)</a> have antipsychotic efficacy, albeit in limited clinical trials. As expected with a partial agonist,<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a><b>8</b> appears to stabilize dopaminergic neurotransmission by acting as an antagonist at functionally hyperdopaminergic D2 receptors and as a D2 agonist in hypodopaminergic states. The additional interactions of <b>8</b> at 5HT<sub>1A</sub>, 5HT<sub>2A</sub>, D<sub>4</sub>, 5HT<sub>2c</sub>, 5HT<sub>7</sub>, α1-adrenergic, and histamine H<sub>1</sub> receptors<a onclick="showRef(event, 'ref270'); return false;" href="javascript:void(0);" class="ref ref270">(270)</a> may also contribute to the efficacy of this novel SGA. In vivo studies indicate, however, that <b>8</b> has low levels of 5HT<sub>1A</sub> and 5HT<sub>2A</sub> receptor occupancy when administered at clinically relevant doses, suggesting that its efficacy is DA rather than 5HT mediated.<a onclick="showRef(event, 'ref271'); return false;" href="javascript:void(0);" class="ref ref271">(271)</a> Compound <b>8</b> effectively treats the symptoms of acutely exacerbated schizophrenics, improving both positive and negative symptoms without eliciting EPS, hyperprolactinemia, weight gain, or QTc interval prolongation.<a onclick="showRef(event, 'ref272'); return false;" href="javascript:void(0);" class="ref ref272">(272)</a></div><figure id="chart5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0005.jpeg" id="_i40" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compounds <b>6</b><a onclick="showRef(event, 'ref273'); return false;" href="javascript:void(0);" class="ref ref273">(273)</a> and <b>64</b> (bifeprunox, DU-127090)<a onclick="showRef(event, 'ref274 ref275 ref276'); return false;" href="javascript:void(0);" class="ref ref274 ref275 ref276">(274-276)</a> are other compounds with partial D2/5HT<sub>1A</sub> agonist−antagonist activity that have minimal interactions at 5HT<sub>2A</sub>, 5HT<sub>2c</sub>, α1-adrenergic, and histamine H<sub>1</sub> receptors.<a onclick="showRef(event, 'ref65 ref273 ref275'); return false;" href="javascript:void(0);" class="ref ref65 ref273 ref275">(65, 273, 275)</a> These NCEs, like <b>8</b>, may represent a new generation of potential antipsychotics that will allow the further evaluation of the hypothesis that 5HT<sub>2A</sub> antagonism is critical for SGA efficacy.<a onclick="showRef(event, 'ref59 ref271 ref275 ref277 ref278'); return false;" href="javascript:void(0);" class="ref ref59 ref271 ref275 ref277 ref278">(59, 271, 275, 277, 278)</a> Early clinical reports with <b>64</b> indicated that this NCE could stabilize schizophrenic symptoms without prolonging QTc or altering metabolic parameters (lipid profile, glucose dysregulation) and with EPS symptoms similar to placebo.<a onclick="showRef(event, 'ref274'); return false;" href="javascript:void(0);" class="ref ref274">(274)</a> Compound <b>64</b> was, however, not approved by the FDA in August 2007 because of a lack of demonstrated efficacy. Compounds <b>65</b> (SSR-181507),<a onclick="showRef(event, 'ref279'); return false;" href="javascript:void(0);" class="ref ref279">(279)</a><b>66</b> (RGH-188), and <b>67</b> (F-15603)<a onclick="showRef(event, 'ref275'); return false;" href="javascript:void(0);" class="ref ref275">(275)</a> are other D2 receptor partial agonists. It remains to be demonstrated in a large clinical study that partial DA receptor agonism alone is sufficient to reliably elicit antipsychotic efficacy because it is unclear as to what degree of partial D2 agonism is required for efficacy.<a onclick="showRef(event, 'ref275'); return false;" href="javascript:void(0);" class="ref ref275">(275)</a></div></div></div><div id="sec1_8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">9 Unmet Medical Needs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nearly all SGAs have significant side effects with a limited therapeutic index that can limit efficacy and compliance.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Compounds <b>24</b> and <b>32</b> have a lower risk of inducing EPS when compared to FGAs, but this risk is still present. As a class, the SGAs are sedating and increase the risk of metabolic syndrome (obesity, high diabetes, stroke) and neuroleptic malignant syndrome, a rare but potentially fatal reaction characterized by fever, altered mental status, muscular rigidity, and autonomic dysfunction. Many of these effects appear to be linked to an extension of the D2 receptor antagonist pharmacology, while metabolic syndrome is associated with histamine H<sub>1</sub> receptor activity.<a onclick="showRef(event, 'ref280'); return false;" href="javascript:void(0);" class="ref ref280">(280)</a></div><div id="sec1_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">9.1 QTc Liability</h3><div class="NLM_p last">As a class, antipsychotics are associated with the potential for prolongation of the cardiac QTc interval, torsade de pointes, and sudden cardiac death.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The last occurs nearly twice as often in antipsychotic treated patients as in the general population with 10–15 such events in 10 000 person-years of observation.<a onclick="showRef(event, 'ref281'); return false;" href="javascript:void(0);" class="ref ref281">(281)</a> Compounds <b>38</b>, <b>45</b>, <b>52</b>, <b>59</b>, and <b>60</b> are associated with torsade and sudden death. In a population-based case-control study of 554 cases of sudden cardiac death, currently used antipsychotics were associated with a 3-fold increase in risk of sudden cardiac death.<a onclick="showRef(event, 'ref282'); return false;" href="javascript:void(0);" class="ref ref282">(282)</a></div></div><div id="sec1_8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">9.2 Metabolic Syndrome</h3><div class="NLM_p last">SGA use is associated with marked weight gain progressing, in some instances, to diabetes,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> the prevalence of which is 2-fold greater among schizophrenics than in the general population.<a onclick="showRef(event, 'ref283'); return false;" href="javascript:void(0);" class="ref ref283">(283)</a> Metabolic syndrome includes abdominal obesity, dyslipidemia, hypertension, and insulin resistance and has an increased prevalence in schizophrenics. Mechanistically, metabolic syndrome is thought to be associated with histamine H<sub>1</sub> receptor activity.<a onclick="showRef(event, 'ref280'); return false;" href="javascript:void(0);" class="ref ref280">(280)</a> While the role of the histamine H<sub>1</sub> receptor activity as the molecular mediator of antipsychotic-induced weight gain has been questioned,<a onclick="showRef(event, 'ref284'); return false;" href="javascript:void(0);" class="ref ref284">(284)</a> H<sub>1</sub> receptor activation has been linked to modulation of hypothalamic AMP kinase.<a onclick="showRef(event, 'ref285'); return false;" href="javascript:void(0);" class="ref ref285">(285)</a> NCEs with antipsychotic potential and decreased H<sub>1</sub> receptor activity, e.g., <b>68</b> (FMPD), are under investigation.<a onclick="showRef(event, 'ref286'); return false;" href="javascript:void(0);" class="ref ref286">(286)</a> The CATIE study<a onclick="showRef(event, 'ref287'); return false;" href="javascript:void(0);" class="ref ref287">(287)</a> reported that <b>32</b>, of four atypical antipsychotics studied, had the greatest incidence of weight gain (0.9 kg/month) with greater increases in glycosylated hemoglobin, total cholesterol, and triglycerides, effects consistent with the development of metabolic syndrome.</div></div><div id="sec1_8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44">9.3 Efficacy</h3><div class="NLM_p">While current antipsychotics are, to a major extent, effective at treating the positive symptoms of schizophrenia, the negative and cognitive symptoms along with comorbid mood disorders are not improved and remain a major outstanding challenge to finding new drugs.</div><div class="NLM_p">The FDAʼs <a href="http://clinicaltrials.gov" class="extLink">clinicaltrials.gov</a> Web site<a onclick="showRef(event, 'ref288'); return false;" href="javascript:void(0);" class="ref ref288">(288)</a> lists 345 clinical trials ongoing in schizophrenia with a number of novel SGAs being evaluated as monotherapy or adjunct therapy. Those not covered in the new research areas section below include several new SGAs, <b>7</b>, <b>17</b>, <b>18</b>, <b>21</b>, <b>23</b>, <b>57</b>, <b>58</b>, <b>69</b> (zotepine), <b>70</b> (ocaperidone), <b>71</b> (lurasidone), <b>72</b> (vabicaserin, SCA-136), <b>73</b> (nemonapride), <b>74</b> (perospirone), <b>75</b> (blonaserin), <b>76</b> (eplivanserin), <b>77</b> (abaperidone), <b>78</b> (ADX-10061), <b>79</b> (BL-1020, the 4-aminobutyrate salt of <b>42</b>), the adenosine uptake inhibitor <b>80 (</b>dipyridamole), the monoamine uptake inhibitor <b>81</b> (atomoxetine), <b>82</b> (MK-0557), an NPY5 receptor antagonist AL-108 (activity-dependent neuroprotective protein), the selective estrogen receptor modulator (SERM) <b>83</b> (raloxifene), and <b>84</b> (estradiol) for use in female schizophrenics, <b>85</b> (lamotrigine), <b>86</b> (buproprion), the COMT inhibitors <b>25</b> and <b>87</b> (entacapone), the retinoid <b>88</b> (bexarotene), the MAO-B inhibitor <b>89</b> (rasagiline), <b>90</b> (guanfacine), <b>91</b>(<span class="smallcaps smallerCapital">l</span>-theanine), RG1068, a form of recombinant human secretin, the wake promoting agent <b>92</b> (modafinil), and its <i>R</i>-enantiomer and a series of compounds with unknown structure and unspecified mechanisms of action that include ABT-925, MK-249, LX6171, and PF02545920. Additionally, transcranial magnetic and direct current stimulation and shiatsu, the latter a form of psychotherapy,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> are also being evaluated for efficacy in schizophrenia as a further indication of the unmet medical need in this area.</div><figure id="chart6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0006.jpeg" id="_i45" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="chart7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0007.jpeg" id="_i46" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec1_9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">10 New and Emerging Research Areas</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05704" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05704" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48">10.1 Muscarinic Cholinergic Agonists</h3><div class="NLM_p last">The cholinergic deficits that occur in patients with dementia with Lewy bodies (DLB)<a onclick="showRef(event, 'ref289'); return false;" href="javascript:void(0);" class="ref ref289">(289)</a> lead to visual hallucinations, delusions, apathy, agitation, dementia, and mild-Parkinsonism, all aspects of the schizophrenia phenotype.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Treatment of DLB patients with cholinesterase inhibitors such as <b>93</b> (rivastigmine) and <b>94</b> (donepezil) can diminish these symptoms, thus leading to antipsychotic-like activity.<a onclick="showRef(event, 'ref290 ref291'); return false;" href="javascript:void(0);" class="ref ref290 ref291">(290, 291)</a> However, the peripheral cholinergic side effects of these drugs preclude their broader use outside of DLB and Alzheimer’s disease (AD). Compound <b>95</b> (xanomeline) and other selective muscarinic agonists (e.g., <b>96</b>, NGX267) have an antipsychotic-like profile in animal models of psychosis similar to that seen with D2 antagonists with the exception that muscarinic agonists do not elicit catalepsy.<a onclick="showRef(event, 'ref292'); return false;" href="javascript:void(0);" class="ref ref292">(292)</a> A small study suggested that <b>95</b> had antipsychotic-like activity in AD patients.<a onclick="showRef(event, 'ref293'); return false;" href="javascript:void(0);" class="ref ref293">(293)</a> Compound <b>12</b>, the demethylated metabolite of <b>9</b>, occurs in serum at concentrations comparable to those of the parent.<a onclick="showRef(event, 'ref294'); return false;" href="javascript:void(0);" class="ref ref294">(294)</a> Like other SGAs, <b>12</b> has weak partial agonist activity at DA D2 receptors and is a potent inverse agonist at 5HT<sub>2A</sub> receptors.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> It also has partial agonist/allosteric activity at muscarinic M<sub>1</sub> and M<sub>5</sub> receptors and is a competitive antagonist of M<sub>3</sub> muscarinic receptors. Compound <b>12</b> can potentiate NMDA receptor currents in CA1 pyramidal cells via activation of muscarinic receptors<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> and is active in animal models predictive of antipsychotic activity. This supports the hypothesis that the muscarinic agonist properties of <b>12</b> may contribute to the unique therapeutic properties of <b>9</b>. The <b>12</b>/<b>9</b> plasma ratio is apparently a better predictor of the clinical response to <b>9</b> than <b>9</b> levels particularly for negative symptoms and cognitive enhancement.<a onclick="showRef(event, 'ref295'); return false;" href="javascript:void(0);" class="ref ref295">(295)</a></div></div><div id="sec1_9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49">10.2 Neuronal Nicotinic Receptor Agonists and Positive Modulators</h3><div class="NLM_p">Smoking, a form of nicotine self-administration, is high in schizophrenics, at a rate at least 3 times higher than that in the general population.<a onclick="showRef(event, 'ref195 ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref195 ref196 ref197">(195-197)</a> Nicotine can produce modest transient improvements in cognitive and sensory deficits in these patients, while <b>9</b>, but not <b>38</b>, can improve sensory gating deficits in mice via a nicotinic α7 receptor mechanism.<a onclick="showRef(event, 'ref296'); return false;" href="javascript:void(0);" class="ref ref296">(296)</a> A number of selective α7 nicotinic receptor agonists including <b>26</b>, <b>28</b>, <b>29</b>, <b>97</b> (W-56203), ABT-107, TC-2216, PH399733, and SEN12333/WAY-317538 are being assessed for the treatment of cognition deficits in schizophrenia (CDS).<a onclick="showRef(event, 'ref297'); return false;" href="javascript:void(0);" class="ref ref297">(297)</a> Compound <b>28</b> can improve PCP-induced cognitive deficits in mice<a onclick="showRef(event, 'ref298'); return false;" href="javascript:void(0);" class="ref ref298">(298)</a> and is currently in phase II clinical trials. The α7 nicotinic agonist, <b>98</b> (A-582941), which on its own has no effect on PPI responses, can enhance the efficacy of <b>24</b> and <b>38</b> when the latter two are given at suboptimal doses. This suggests that α7 agonists might be useful in combination with FGAs and SGAs to reduce their clinical dose and, as a consequence, to reduce their side effects. The selective α7 nicotinic agonists <b>99</b> (PHA-543613) and <b>100</b> (PHA-709829) showed efficacy in animal cognition models and in phase I trials. Their clinical development was discontinued because of a low (5%) incidence of cardiac arrythmias (nonsustainable ventricular tachycardia). It is unclear whether these were target or compound related. The nicotinic receptor antagonist <b>101</b> (mecamylamine) and the α4β2 agonist <b>102</b> (varenicline) are also being evaluated clinically for their positive effects on cognitive performance. In addition to being a partial agonist acting at α4β2 nicotinic receptors, <b>103</b> (TC-1734/AZD3480, ispronicline) is also a full agonist at α7 receptors.<a onclick="showRef(event, 'ref299'); return false;" href="javascript:void(0);" class="ref ref299">(299)</a> Compound <b>103</b> improved episodic memory, power of attention, and speed of response and is currently in CDS (cognitive domain of schizophrenia) trials to study the cognitive domain of schizophrenia.<a onclick="showRef(event, 'ref300'); return false;" href="javascript:void(0);" class="ref ref300">(300)</a> Allosteric modulators of nicotinic receptor function such as <b>104</b> (PNU-120596, Chart <a class="ref internalNav" href="#chart8" aria-label="8">8</a>) may also have potential in the treatment of the cognitive domains of schizophrenia.<a onclick="showRef(event, 'ref301'); return false;" href="javascript:void(0);" class="ref ref301">(301)</a></div><figure id="chart8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Chart 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0008.jpeg" id="_i50" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51">10.3 Histamine H<sub>3</sub> Receptor Antagonists</h3><div class="NLM_p last">Examination of the therapeutic utility of histamine for the treament of schizophrenia dates back to the 1930s<a onclick="showRef(event, 'ref302'); return false;" href="javascript:void(0);" class="ref ref302">(302)</a> with inconclusive results. With the discovery of the histamine H<sub>3</sub> receptor<a onclick="showRef(event, 'ref303 ref304'); return false;" href="javascript:void(0);" class="ref ref303 ref304">(303, 304)</a> and the development of selective druglike antagonists for this GPCR,<a onclick="showRef(event, 'ref305 ref306'); return false;" href="javascript:void(0);" class="ref ref305 ref306">(305, 306)</a> it has been well established in animal models that NCEs like <b>105</b> (JNJ-10181457),<a onclick="showRef(event, 'ref307'); return false;" href="javascript:void(0);" class="ref ref307">(307)</a><b>106</b> (GSK189254),<a onclick="showRef(event, 'ref308'); return false;" href="javascript:void(0);" class="ref ref308">(308)</a> and <b>107</b> (BF2.649)<a onclick="showRef(event, 'ref309'); return false;" href="javascript:void(0);" class="ref ref309">(309)</a> and analogues of <b>108</b><a onclick="showRef(event, 'ref310'); return false;" href="javascript:void(0);" class="ref ref310">(310)</a> like <b>109</b> (A-688057)<a onclick="showRef(event, 'ref311'); return false;" href="javascript:void(0);" class="ref ref311">(311)</a> may have potential in the treatment of the cognitive dysfunction associated with schizophrenia.<a onclick="showRef(event, 'ref309'); return false;" href="javascript:void(0);" class="ref ref309">(309)</a> There has been no proof of concept in clinical trials for this approach to date.</div></div><div id="sec1_9_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52">10.4 Glutamatergic Agents</h3><div class="NLM_p">The glutamate hypofunction hypothesis of schizophrenia has been discussed in the context of both clinical and genetic data. In rodents, NMDA antagonists increase locomotor activity and enhance amphetamine-induced DA release. However, 5HT<sub>2A</sub> antagonists are more effective than D2 antagonists in blocking increases in locomotor activity, consistent with the concept that SGAs that are both 5HT<sub>2A</sub> and D2 receptor antagonists, e.g., <b>9</b> and <b>24</b>, and are more effective in treating the disorder and that dysregulation of the DA function associated with schizophrenia is secondary to NMDA hypofunction. The balance between D2 antagonism and NMDA receptor modulation may thus be pivotal for the improvement of both positive and negative symptoms in schizophrenia. While NCEs that directly activate NMDA receptors may be useful in treating schizophrenics, these are usually proconvulsant and neurotoxic, leading to a strategy of indirect activation of glutamate receptors. Compound <b>16</b> is the prototypic obligatory positive allosteric modulator of the NDMA receptor that, like <b>17</b> and <b>18</b> and the glycine transporter (GlyT) inhibitor <b>15</b>, can treat the negative symptoms and cognitive impairment of schizophrenia when used adjunctively with existing antipsychotics.<a onclick="showRef(event, 'ref312'); return false;" href="javascript:void(0);" class="ref ref312">(312)</a> Newer GlyT inhibitors include <b>110</b> (ALX-5407/JNJ-17305660),<a onclick="showRef(event, 'ref313'); return false;" href="javascript:void(0);" class="ref ref313">(313)</a><b>111</b> (SSR504734),<a onclick="showRef(event, 'ref314'); return false;" href="javascript:void(0);" class="ref ref314">(314)</a><b>112</b>,<a onclick="showRef(event, 'ref315'); return false;" href="javascript:void(0);" class="ref ref315">(315)</a><b>113</b> (PF-3311945), and <b>114</b>. Of these NMDA receptor modulators, <b>17</b> is currently the most promising on the basis of druglike characteristics and clinical outcomes. In combination with <b>24</b> and <b>32</b>, <b>17</b> improves both positive and negative symptoms in treatment-resistant patients.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> However, the efficacy of <b>17</b> appears to be modest and is not useful in patients receiving <b>9</b>.<a onclick="showRef(event, 'ref316 ref317'); return false;" href="javascript:void(0);" class="ref ref316 ref317">(316, 317)</a> Despite the lack of agreement regarding the strength of the genetic association of DAOA/G72 with schizophrenia,<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> inhibitors of DAAO, <b>115</b> and <b>116</b>, have been reported.<a onclick="showRef(event, 'ref318 ref319'); return false;" href="javascript:void(0);" class="ref ref318 ref319">(318, 319)</a></div><div id="sec1_9_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53">10.4.1 Metabotropic Glutamate Receptors</h4><div class="NLM_p">Metabotropic glutamate receptors comprise eight receptor subtypes grouped into three families, group I (mGluR1, mGluR5), group II (mGluR2, mGluR3), and group III (mGluR4, mGluR6−8), that are also viable targets for the treatment of schizophrenia.<a onclick="showRef(event, 'ref320'); return false;" href="javascript:void(0);" class="ref ref320">(320)</a> Groups II and III receptors are located presynaptically and modulate glutamate release. Group II agonists, e.g., <b>31</b>, <b>117</b> (LY354740), and <b>118</b> (MGS 0039) (Chart <a class="ref internalNav" href="#chart9" aria-label="9">9</a>), can block <b>2</b>- and <b>13</b>-induced behavioral activation in rats,<a onclick="showRef(event, 'ref321 ref322'); return false;" href="javascript:void(0);" class="ref ref321 ref322">(321, 322)</a> and both orthosteric and allosteric modulators have antipsychotic-like activity in animal models.<a onclick="showRef(event, 'ref321 ref323'); return false;" href="javascript:void(0);" class="ref ref321 ref323">(321, 323)</a> Allosteric modulators may not induce rapid tachyphylaxis<a onclick="showRef(event, 'ref321 ref324'); return false;" href="javascript:void(0);" class="ref ref321 ref324">(321, 324)</a> and may thus have utility as a novel approach as a maintenance therapy for the treatment of schizophrenia.</div><figure id="chart9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0009.jpeg" id="_i54" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As already noted, the orally active mGlu2/3 receptor agonist <b>30</b><a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> improved both positive and negative symptoms at week 4 in a randomized, double-blind, placebo controlled clinical trial with efficacy equivalent to that of the SGA <b>32</b> without increasing prolactin production, extrapyramidal symptoms, or weight. The group I mGluR, mGluR5, is also a potential novel target for schizophrenia. Pharmacological blockade<a onclick="showRef(event, 'ref325 ref326'); return false;" href="javascript:void(0);" class="ref ref325 ref326">(325, 326)</a> and genetic ablation of mGluR5<a onclick="showRef(event, 'ref325 ref327'); return false;" href="javascript:void(0);" class="ref ref325 ref327">(325, 327)</a> decreased PPI in rodents with <b>119</b> (CDPPB), a selective positive allosteric modulator of the mGluR5 receptor reversing the psychotomimetic effects of amphetamine in rats.<a onclick="showRef(event, 'ref328'); return false;" href="javascript:void(0);" class="ref ref328">(328)</a> Additional mGluR5 potentiators include <b>120</b> (DFB), <b>121</b> (CPPHA), and <b>122</b> (ADX47273).</div></div><div id="sec1_9_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55">10.4.2 Ampakines, e.g., <b>123</b> (CX516), Allosterically Enhance AMPA Receptor Activity<a onclick="showRef(event, 'ref329'); return false;" href="javascript:void(0);" class="ref ref329">(329)</a></h4><div class="NLM_p last">In combination with <b>9</b>, <b>123</b> improved some symptoms associated with schizophrenia but was ineffective as monotherapy in improving positive symptoms or cognition in schizophrenics. It has, however, not faired well in clinical trials because of animal toxicity issues. Another ampakine, <b>124</b> (ORG 24448/CX-691), is under evaluation as adjunctive therapy as part of the NIMH MATRICS effort to facilitate the development of medications to enhance cognition in patients with schizophrenia.<a onclick="showRef(event, 'ref288'); return false;" href="javascript:void(0);" class="ref ref288">(288)</a> Compounds <b>125</b> (IDRA-21) and <b>126</b> (LY404187) are other AMPA allosteric modulators currently in clinical trials.</div></div><div id="sec1_9_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56">10.4.3 Glutamate Transport Inhibitors</h4><div class="NLM_p last">Blockade of excitatory amino acid transporters (EAATs), specifically the EAAT3 neuronal subtype, may also have potential in physiologically manipulating endogenous glutamate tone.<a onclick="showRef(event, 'ref330'); return false;" href="javascript:void(0);" class="ref ref330">(330)</a> This represents a relatively unexploited area in drug discovery. However, EAAT3 expression is altered in schizophrenia<a onclick="showRef(event, 'ref331'); return false;" href="javascript:void(0);" class="ref ref331">(331)</a> and epilepsy<a onclick="showRef(event, 'ref332'); return false;" href="javascript:void(0);" class="ref ref332">(332)</a> and a prototypic EAAT3 inhibitor, <b>127</b> (NBI-59159), can dose-dependently attenuate amphetamine-stimulated motor activity.<a onclick="showRef(event, 'ref330'); return false;" href="javascript:void(0);" class="ref ref330">(330)</a></div></div><div id="sec1_9_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57">10.4.4 <i>N</i>-Acetyl-<span class="smallcaps smallerCapital">l</span>-aspartyl-<span class="smallcaps smallerCapital">l</span>-glutamate (NAAG)</h4><div class="NLM_p last">NAGG is a peptide with putative neurotransmitter function<a onclick="showRef(event, 'ref333'); return false;" href="javascript:void(0);" class="ref ref333">(333)</a> that acts as an endogenous agonist at group II mGluR receptors.<a onclick="showRef(event, 'ref334'); return false;" href="javascript:void(0);" class="ref ref334">(334)</a> It is catabolized to <i>N</i>-acetylaspartate and glutamate by the NAAG peptidases, glutamate carboxypeptidase II and III, present on the cell surface of astrocytes. Therefore, NAAG peptidase inhibitors, by increasing NAAG levels, could provide antipsychotic efficacy via activation of group II mGluRs. Compounds <b>128</b> (2-PMPA), <b>129</b> (GPI5693), and <b>130</b> (ZJ38) represent first generation NAAG peptidase inhibitors.<a onclick="showRef(event, 'ref335'); return false;" href="javascript:void(0);" class="ref ref335">(335)</a></div></div></div><div id="sec1_9_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58">10.5 DA Receptor Modulators</h3><div class="NLM_p">DA D1 receptor agonists such as <b>131</b> (dihydrexidine) and <b>132</b> (SKF-81297) have procognitive effects in animal models (Chart <a class="ref internalNav" href="#chart10" aria-label="10">10</a>).<a onclick="showRef(event, 'ref336'); return false;" href="javascript:void(0);" class="ref ref336">(336)</a> The D1/D5 agonist <b>133</b> (adrogolide, ABT-431, DAS-431) had cognition enhancing activity in a rat model of antipsychotic-induced working memory deficit<a onclick="showRef(event, 'ref337'); return false;" href="javascript:void(0);" class="ref ref337">(337)</a> that was not replicated in more traditional animal models of cognitive performance, e.g., Morris water maze (M. W. Decker, unpublished data). D1/D5 agonists also have limited potential as drugs because of the inherent tolerance of their mechanism. Nonetheless, there still appears to be to continuing interest in D1/D5 agonists for the treatment of cognitive deficits.<a onclick="showRef(event, 'ref338'); return false;" href="javascript:void(0);" class="ref ref338">(338)</a> There is also an ongoing effort to identify improved D2 receptor antagonists with the current focus being on selective D3 receptor antagonists. These are anticipated to have reduced EPS liability compared to D2 receptor antagonists.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Recent examples include the tetrahydrobenzazepine, <b>134</b> (SB-414796), the arylalkylpiperazine <b>135</b> (ST-280), the benzazepinone, <b>136</b> (A-706149), <b>137</b> (S-33138),<a onclick="showRef(event, 'ref339'); return false;" href="javascript:void(0);" class="ref ref339">(339)</a> and <b>138</b> (PNU-177864) (Charts <a class="ref internalNav" href="#chart10" aria-label="10">10</a> and <a class="ref internalNav" href="#chart11" aria-label="11">11</a>).</div><figure id="chart10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Chart 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0010.jpeg" id="_i59" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="chart11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0011.jpeg" id="_i60" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Past interest in selective D4 receptor antagonists as antipsychotics was driven by the higher affinity of clozapine for the dopamine D4 receptor relative to the D2 receptor.<a onclick="showRef(event, 'ref340'); return false;" href="javascript:void(0);" class="ref ref340">(340)</a> D4 receptors appear to be involved in working memory<a onclick="showRef(event, 'ref341'); return false;" href="javascript:void(0);" class="ref ref341">(341)</a> and can prevent stress-induced cognitive deficits in monkeys.<a onclick="showRef(event, 'ref342'); return false;" href="javascript:void(0);" class="ref ref342">(342)</a> A number of selective D4 antagonists have been identified including <b>139</b> (L-745,870), <b>140</b> (fananserin, RP62203), <b>141</b> (NGD 94-1), <b>142</b> (PNU-101,387), <b>143</b> (CP-293019), and <b>144</b> (PD-172938). In both preclinical<a onclick="showRef(event, 'ref343'); return false;" href="javascript:void(0);" class="ref ref343">(343)</a> and clinical studies,<a onclick="showRef(event, 'ref344'); return false;" href="javascript:void(0);" class="ref ref344">(344)</a><b>139</b> failed to show an antipsychotic profile, a result that may reflect partial D4 agonist activity similar to that reported for <b>141</b>.<a onclick="showRef(event, 'ref345'); return false;" href="javascript:void(0);" class="ref ref345">(345)</a></div></div><div id="sec1_9_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61">10.6 5HT Receptor Ligands</h3><div class="NLM_p">Research has also continued on the 5HT receptor axis of schizophrenia. Newer targets/ligands include the 5-HT<sub>2A</sub> receptor inverse agonist <b>145</b> (ACP-103)<a onclick="showRef(event, 'ref346'); return false;" href="javascript:void(0);" class="ref ref346">(346)</a> and the 5HT<sub>2C</sub> receptor agonists <b>146</b> (WAY-163909), <b>147</b> (VER-2692), and <b>148</b> (Ro 60-0175). Activation of the 5HT<sub>2C</sub> receptor reduces mesolimbic DA neurotransmission.<a onclick="showRef(event, 'ref347'); return false;" href="javascript:void(0);" class="ref ref347">(347)</a> Interest in 5HT<sub>6</sub> receptor antagonists, like that for D4 receptor antagonists, was driven by the high-affinity binding of <b>9</b> to this receptor<a onclick="showRef(event, 'ref348'); return false;" href="javascript:void(0);" class="ref ref348">(348)</a> and also the ability of <b>9</b> to down-regulate the 5HT<sub>6</sub> receptor.<a onclick="showRef(event, 'ref349'); return false;" href="javascript:void(0);" class="ref ref349">(349)</a> This has resulted in considerable patent activity in the area of 5HT<sub>6</sub> antagonists.<a onclick="showRef(event, 'ref350'); return false;" href="javascript:void(0);" class="ref ref350">(350)</a> While these antagonists have been implicated in enhancing cognition with potential utility in Alzheimer’s disease and schizophrenia,<a onclick="showRef(event, 'ref349'); return false;" href="javascript:void(0);" class="ref ref349">(349)</a> NCEs including <b>149</b> (SB-271046) and <b>150</b> (Ro 04-6790, Chart <a class="ref internalNav" href="#chart12" aria-label="12">12</a>) have been reported to have cognition enhancing activity, an effect sensitive to NMDA receptor antagonists.<a onclick="showRef(event, 'ref351'); return false;" href="javascript:void(0);" class="ref ref351">(351)</a> The utility of 5HT<sub>6</sub> antagonists as cognition enhancers has, however, been questioned.<a onclick="showRef(event, 'ref352 ref353'); return false;" href="javascript:void(0);" class="ref ref352 ref353">(352, 353)</a> Newer compounds active at this 5HT receptor include <b>151</b> (SGS-518), <b>152</b> (ALX-0440), <b>153</b> (BGC-20-761), <b>154</b> (E-6801), <b>155</b> (PRX-07034), and <b>156</b> (WAY181187).</div><figure id="chart12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Chart 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0012.jpeg" id="_i62" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_9_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63">10.7 PDE Inhibitors</h3><div class="NLM_p">Members of the PDE (phosphodiesterase) family of enzymes including PDE1B, PDE4, and PDE10A have been targeted as new approaches for the treatment of CNS disorders including cognitive dysfunction.<a onclick="showRef(event, 'ref354 ref355 ref356'); return false;" href="javascript:void(0);" class="ref ref354 ref355 ref356">(354-356)</a> The PDEs, comprising a superfamily of some 11 enzymes,<a onclick="showRef(event, 'ref354'); return false;" href="javascript:void(0);" class="ref ref354">(354)</a> are responsible for the breakdown of the intracellular messenger cAMP. PDE inhibitors were first shown to have therapeutic potential with the serendipitous development of the erectile dysfunction drug sildenafil.<a onclick="showRef(event, 'ref357'); return false;" href="javascript:void(0);" class="ref ref357">(357)</a></div><div class="NLM_p">Mice with disrupted PDE1B function are hyperactive and show altered responses to <b>2</b> and <b>38</b>.<a onclick="showRef(event, 'ref358'); return false;" href="javascript:void(0);" class="ref ref358">(358)</a> Compound <b>157</b> (vinpocetine) represents the first generation of PDE1B inhibitors. The PDE4 inhibitor <b>158</b> (rolipram) has antidepressant-like<a onclick="showRef(event, 'ref359'); return false;" href="javascript:void(0);" class="ref ref359">(359)</a> and cognition-enhancing properties<a onclick="showRef(event, 'ref360'); return false;" href="javascript:void(0);" class="ref ref360">(360)</a> and may thus have potential in the treatment of schizophrenia.<a onclick="showRef(event, 'ref361'); return false;" href="javascript:void(0);" class="ref ref361">(361)</a> PDE4B, a member of the PDE4 family, has been linked with DISC1 in the genetic aspects of schizophrenia.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Prototypic PDE4 inhibitors had pronounced emetic activity that has been reduced in second generation compounds such as <b>159</b> (cilomilast) and <b>160</b> (AWD 12-281).<a onclick="showRef(event, 'ref362'); return false;" href="javascript:void(0);" class="ref ref362">(362)</a></div><div class="NLM_p">PDE10A is highly expressed in the striatum and has been implicated in psychotic disorders like schizophrenia.<a onclick="showRef(event, 'ref354 ref363'); return false;" href="javascript:void(0);" class="ref ref354 ref363">(354, 363)</a> Animals treated with the prototypic PDE10A inhibitor <b>161</b> (papaverine)<a onclick="showRef(event, 'ref354'); return false;" href="javascript:void(0);" class="ref ref354">(354)</a> and <i>PDE10A</i><sup>−/−</sup> mice<a onclick="showRef(event, 'ref364'); return false;" href="javascript:void(0);" class="ref ref364">(364)</a> exhibited reduced conditioned avoidance behavior (CAR), reductions in spontaneous locomotor activity, and deficits in locomotor or visual acuity tests.<a onclick="showRef(event, 'ref365'); return false;" href="javascript:void(0);" class="ref ref365">(365)</a> While there is considerable medicinal chemistry activity in this area as evidenced by patent applications, only <b>161</b>, <b>162</b> (PQ-10), and <b>163</b> (MP-10) have been identified as selective PDE10A inhibitors (Chart <a class="ref internalNav" href="#chart13" aria-label="13">13</a>).<a onclick="showRef(event, 'ref354 ref366'); return false;" href="javascript:void(0);" class="ref ref354 ref366">(354, 366)</a></div><figure id="chart13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Chart 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0013.jpeg" id="_i64" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_9_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65">10.8 Neurokinin<sub>3</sub> (NK<sub>3</sub>) Receptor Antagonists</h3><div class="NLM_p last">NK<sub>3</sub> receptors are present on DA neurons in the A9 and A10 groups and modulate DA release and cholinergic tone.<a onclick="showRef(event, 'ref367'); return false;" href="javascript:void(0);" class="ref ref367">(367)</a> In animal models, the NK<sub>3</sub> receptor antagonist <b>164</b> (SSR146977) prevented NK<sub>3</sub> agonist-induced release of ACh, 5HT, and DA. In the clinic, <b>165</b> (osanetant) showed similar efficacy compared to haloperidol on positive symptoms in schizophrenia with reduced EPS and weight gain liabilities but failed to show dose-dependent related efficacy. Compound <b>166</b> (talnetant) is currently in phase II trials in schizophrenics.<a onclick="showRef(event, 'ref367'); return false;" href="javascript:void(0);" class="ref ref367">(367)</a></div></div><div id="sec1_9_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66">10.9 Cannabinoids</h3><div class="NLM_p last">An emerging literature has suggested that endocannabinoids including <b>167</b> (anandamide) may be involved in aspects of the pathophysiology of schizophrenia<a onclick="showRef(event, 'ref368'); return false;" href="javascript:void(0);" class="ref ref368">(368)</a> with conflicting reports<a onclick="showRef(event, 'ref369 ref370'); return false;" href="javascript:void(0);" class="ref ref369 ref370">(369, 370)</a> of changes in cannabinoid (CB) receptors in schizophrenics. Individuals with Δ-9-tetrahydrocannibinol intoxication have a perceptual dysfunction similar to that seen in schizophrenics.<a onclick="showRef(event, 'ref42 ref371'); return false;" href="javascript:void(0);" class="ref ref42 ref371">(42, 371)</a> Compound <b>168</b> (rimonabant/ SR141716), a selective CB<sub>1</sub> receptor antagonist, can reduce stimulant-induced hyperactivity.<a onclick="showRef(event, 'ref372'); return false;" href="javascript:void(0);" class="ref ref372">(372)</a> CB ligands including <b>168</b>, <b>169</b> (AVE-1625), and <b>170</b> (SLV-319) are under investigation for the treatment of schizophrenia.<a onclick="showRef(event, 'ref288'); return false;" href="javascript:void(0);" class="ref ref288">(288)</a></div></div></div><div id="sec1_10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">11 Future Directions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Improved treatments for schizophrenia are, not surprisingly, most likely to come from a better understanding of disease origin, pathophysiology, and newer, disease-related, drug tractable targets. Existing antipsychotic drugs, both FGAs and SGAs, and the many compounds currently in clinical development represent modest clinical and chemical improvements on earlier drugs (variations on a theme (<b>32</b> versus <b>9</b>), metabolites of existing drugs (<b>171</b> (9-hydroxyrisperidone/paliperidone) versus <b>24</b>; <b>12</b> versus <b>9</b>)) or attempts to mimic a limited set of molecular attributes (<b>8</b> (partial dopamine agonism) and <b>57</b> (5-HT<sub>2A</sub>/D2 antagonism). In this context, the controversial CATIE/CUtLASS clinical studies<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28 ref29">(24-29)</a> have confounded the basic premise that has driven DA receptor-based antipsychotic drug discovery research for the past 30 years, namely, that SGAs have an improved efficacy and safety profile compared to FGAs. The objective resolution of the CATIE controversy and the integration of the CATIE/CUtLASS trials with the many previous clinical trials that have shown superiority for individual SGAs over FGAs will be crucial in helping to define continuing medicinal chemistry efforts around the traditional DA/5HT approaches to antipsychotic drug research. Given the CATIE/CUtLASS studies, it is likely that the regulatory hurdles to the approval of yet another SGA acting primarily through a “conventional” 5HT<sub>2</sub>/D2 receptor antagonist mechanism will probably be insurmountable. Nonetheless, the NDA for <b>58</b> was recently accepted by the FDA.<a onclick="showRef(event, 'ref373'); return false;" href="javascript:void(0);" class="ref ref373">(373)</a> It remains to be seen whether the CATIE/CUtLASS studies represent the death knell for the advancement of “classical” SGAs like <b>58</b>.</div><div class="NLM_p">The decades-old interest in the superior efficacy of the prototypic SGA <b>9</b> represents a major theme in drug discovery efforts. Efforts continue to find “a” mechanism of action for <b>9</b> beyond its current multitude of receptor interactions (GPCRs and LGICs (ligand gated ion channels)) that could more clearly define unique clinical profile of the compound. The search for selective “magic bullets” to treat schizophrenia has been debated in the context of “magic shotguns”<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> or “selectively” nonselective agents,<a onclick="showRef(event, 'ref374'); return false;" href="javascript:void(0);" class="ref ref374">(374)</a> neither concepts of which make the task of the medicinal chemist any less empirical. The anticipation that the deconvolution and prioritization of the many genetic associations with schizophrenia may lead to tractable new targets has, as has been discussed in detail above, been less than productive. Indeed, to the casual reader, the efforts focused on the many novel targets identified is, in many ways, reminiscent of Horrobin’s contrary but insightful view<a onclick="showRef(event, 'ref375'); return false;" href="javascript:void(0);" class="ref ref375">(375)</a> of the “Castalian” nature of modern biomedical research: intellectually compelling, eminently fundable, self-contained, and ultimately tangential to any real life situation.</div><div class="NLM_p">Continuing evidence supports a major neurodevelopmental aspect of the genesis of schizophrenia that may argue that unless drug treatment is initiated before, or concomitant with, birth (assuming a reliable diagnostic test<a onclick="showRef(event, 'ref376'); return false;" href="javascript:void(0);" class="ref ref376">(376)</a>), then it will inevitably be palliative, its effect being superimposed on aberrant neuronal circuitry, the genesis of which is probably long gone by the time of adolesence.</div><div class="NLM_p">It has also been proposed<a onclick="showRef(event, 'ref377'); return false;" href="javascript:void(0);" class="ref ref377">(377)</a> that disrupted cortical circuitry resulting from neuronal apoptosis represents a key event in the pathophysiology of schizophrenia. Changes in key enzymes involved in the apoptotic cascade, e.g., Bax/Bcl2, have been observed in brains from schizophrenics<a onclick="showRef(event, 'ref378'); return false;" href="javascript:void(0);" class="ref ref378">(378)</a> and have been viewed in terms of proapoptotic stress in schizophrenia. Stress-related dysfunction of neuronal plasticity mechanism and neurogenesis in psychiatric disorders has evolved in the context of a consideration of a “failure to recover”.<a onclick="showRef(event, 'ref379'); return false;" href="javascript:void(0);" class="ref ref379">(379)</a> Neurogenesis is a key event in the delayed onset of antidepressants<a onclick="showRef(event, 'ref380'); return false;" href="javascript:void(0);" class="ref ref380">(380)</a> and may also be involved in the delayed onset of action of antipsychotics.<a onclick="showRef(event, 'ref381'); return false;" href="javascript:void(0);" class="ref ref381">(381)</a></div><div class="NLM_p last">Whether the contributions from the various genomic studies and an improved understanding of the neurocircuitry and plasticity of the brain will provide new insights into the molecular targeting for the next generation of antipsychotic drugs remains to be seen. In the meantime, there is considerable work to be done to advance the various molecular targets related to the glutamate hypofunction hypothesis (e.g., mGluRs, GlyT, EAAT<sub>3</sub>, AMPA) and newer targets with a compelling rationale (5HT<sub>6</sub>, PDE10A, α7 nicotinic agonists/partial agonists/modulators) to the level of optimized druglike leads using the proven approach of iterative medicinal chemistry in conjunction with in vivo and in vitro functional pharmacological assays.</div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25882" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25882" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Marino</span> - <span class="hlFld-Affiliation affiliation">Worldwide Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380</span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lars J. S. Knutsen</span> - <span class="hlFld-Affiliation affiliation">Worldwide Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Williams</span> - <span class="hlFld-Affiliation affiliation">Worldwide Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b4d9c3ddd8d8ddd5d9f4d7d1c4dcd5d8dbda9ad7dbd9"><span class="__cf_email__" data-cfemail="f9948e909595909894b99a9c899198959697d79a9694">[email protected]</span></a></span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm701094q" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65104" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65104" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Michael J. Marino</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p><b>Biographies</b></p><p class="last"><b>Michael J. Marino</b> received his Ph.D. in Neuroscience in 1995 from the University of Pittsburgh. After working as a postdoctoral fellow with Jeff Conn at Emory University studying the role of metabotropic glutamate receptors in regulating the circuitry of the basal ganglia, he joined Merck Research Laboratories in West Point, PA, in 2001 where he worked on projects in schizophrenia, Parkinson’s disease, and related movement disorders. He joined Cephalon, Inc. in 2005 where he is Associate Director of CNS Biology.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Lars J. S. Knutsen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lars J. S. Knutsen</b> completed his Ph.D. in Nucleoside Chemistry in 1983 while working at Glaxo in the U.K. On joining Novo Nordisk in Denmark in 1986, he led the project that identified the marketed GABA uptake inhibitor tiagabine. In 1997, he joined Cerebrus (now Vernalis) in the U.K. where he was involved in projects in the areas of Parkinsonʼs disease and obesity. From 2002 to 2005 he was Director of Chemistry at Ionix Pharmaceuticals in Cambridge, U.K. He joined the CNS Medicinal Chemistry group at Cephalon, Inc. in 2006 where he is a Distinguished Scientist.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Michael Williams</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Michael Williams</b> received his Ph.D. in Neurochemistry from the Institute of Psychiatry, University of London, in 1974 and his D.Sc. in Pharmacology also from the University of London in 1987. He has worked in the U.S. based pharmaceutical industry for 30 years at Merck, Sharp and Dohme Research Laboratories, Nova Pharmaceutical, CIBA-Geigy, and Abbott Laboratories. Following retirement in 2000, he worked as a consultant/manager with various biotechnology/pharmaceutical/venture capital companies in the U.S. and Europe including Genset and Molecumetics. He joined Cephalon, Inc. in 2003 where he is Vice President, Worldwide Discovery Research.</p></figure></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Daniel Cohen, Joe Coyle, Bob Davis, and Herb Meltzer for helpful discussions during the genesis of this Perspective.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 381 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Falkai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wobrock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenthoj, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattaz, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, H. J.</span><span> </span><span class="NLM_article-title">World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: acute treatment of schizophrenia</span> <span class="citation_source-journal">World J. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1080%2F15622970510030090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16173147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MrgtFaiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=132-191&author=P.+Falkaiauthor=T.+Wobrockauthor=J.+Liebermanauthor=B.+Glenthojauthor=W.+F.+Gattazauthor=H.+J.+Moller&title=World+Federation+of+Societies+of+Biological+Psychiatry+%28WFSBP%29+guidelines+for+biological+treatment+of+schizophrenia.+Part+1%3A+acute+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia</span></div><div class="casAuthors">Falkai Peter; Wobrock Thomas; Lieberman Jeffrey; Glenthoj Birte; Gattaz Wagner F; Moller Hans-Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">132-91</span>
        ISSN:<span class="NLM_cas:issn">1562-2975</span>.
    </div><div class="casAbstract">These guide lines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBO).  The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence.  These guidelines are intended for use by all physicians seeing and treating people with schizophrenia.  The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library.  The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D).  This first part of the guidelines covers disease definition, classification, epidemiology and course of schizophrenia, as well as the management of the acute phase treatment.  These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5l8JKjExhwW52AMpI4GK2fW6udTcc2eakyc6h9OEtNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrgtFaiuw%253D%253D&md5=d47b1cbd5e6979a085a179cf1e5e2bba</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1080%2F15622970510030090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15622970510030090%26sid%3Dliteratum%253Aachs%26aulast%3DFalkai%26aufirst%3DP.%26aulast%3DWobrock%26aufirst%3DT.%26aulast%3DLieberman%26aufirst%3DJ.%26aulast%3DGlenthoj%26aufirst%3DB.%26aulast%3DGattaz%26aufirst%3DW.%2BF.%26aulast%3DMoller%26aufirst%3DH.%2BJ.%26atitle%3DWorld%2520Federation%2520of%2520Societies%2520of%2520Biological%2520Psychiatry%2520%2528WFSBP%2529%2520guidelines%2520for%2520biological%2520treatment%2520of%2520schizophrenia.%2520Part%25201%253A%2520acute%2520treatment%2520of%2520schizophrenia%26jtitle%3DWorld%2520J.%2520Biol.%2520Psychiatry%26date%3D2005%26volume%3D6%26spage%3D132%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Saha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, J.</span><span> </span><span class="NLM_article-title">A systematic review of the prevalence of schizophrenia</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e141</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e141&author=S.+Sahaauthor=D.+Chantauthor=J.+Welhamauthor=J.+McGrath&title=A+systematic+review+of+the+prevalence+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DChant%26aufirst%3DD.%26aulast%3DWelham%26aufirst%3DJ.%26aulast%3DMcGrath%26aufirst%3DJ.%26atitle%3DA%2520systematic%2520review%2520of%2520the%2520prevalence%2520of%2520schizophrenia%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Carpenter, W. T.,  Jr.; Conley, R. R.; Buchanan, R. W.</span><span> </span><span class="NLM_article-title">Schizophrenia</span>. In  <span class="citation_source-book">Pharmacological Management of Neurological and Psychiatric Disorders</span>; <span class="NLM_contrib-group">Enna, S. J.; Coyle, J. T.</span>, Eds.; <span class="NLM_publisher-name">McGraw-Hill</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1998</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=27-51&author=W.+T.+Carpenter&author=R.+R.+Conley&author=R.+W.+Buchananauthor=S.+J.+Enna&author=J.+T.+Coyle&title=Pharmacological+Management+of+Neurological+and+Psychiatric+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DW.%2BT.%26atitle%3DSchizophrenia%26btitle%3DPharmacological%2520Management%2520of%2520Neurological%2520and%2520Psychiatric%2520Disorders%26aulast%3DEnna%26aufirst%3DS.%2BJ.%26pub%3DMcGraw-Hill%26date%3D1998%26spage%3D27%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Auquier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouillon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lader, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, C.</span><span> </span><span class="NLM_article-title">Mortality in schizophrenia</span> <span class="citation_source-journal">Pharmacoepidemiol. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2Fpds.1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17058327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28npvVCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=873-879&author=P.+Auquierauthor=C.+Lanconauthor=F.+Rouillonauthor=M.+Laderauthor=C.+Holmes&title=Mortality+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mortality in schizophrenia</span></div><div class="casAuthors">Auquier Pascal; Lancon Christophe; Rouillon Frederic; Lader Malcolm; Holmes Catriona</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and drug safety</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">873-9</span>
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    </div><div class="casAbstract">PURPOSE:  The purpose of this article is to describe the current status of knowledge on excess mortality in schizophrenia and its causative factors, and to expand upon previous work evaluating approaches that may reduce mortality rates.  METHODS:  Literature available since 1995 was identified in a computerized search of the bibliographical databases Medline and Embase, using the topics 'mortality' and 'schizophrenia', and in a cross-reference search for articles that were particularly relevant.  RESULTS:  Schizophrenia is associated with mortality rates that are two to three times higher than those expected or observed in the general population.  This excess of mortality is accounted for by a combination of an increased risk of suicide, in particular in young male patients soon after diagnosis, and more importantly, a higher number of natural deaths.  In order to diminish the level of suicide among people with schizophrenia, the majority of research has focused on the identification of risk factors that predispose patients to attempt or commit suicide, while unhealthy styles, polypharmacy and inadequate healthcare have been shown to contribute to the high natural mortality.  The link between the use of antipychotics and mortality has not been yet clarified.  CONCLUSION:  Dramatically increased mortality of schizophrenia patients is well established.  It is time to move beyond this topic, and work towards interventions that aim at reducing the mortality risk in such patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRikot9EnR3I7YtC3U5jeOifW6udTcc2eYR7tZlix82FLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28npvVCgtg%253D%253D&md5=0cba5ddf026bd80e8468247f6dcb7e42</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fpds.1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1325%26sid%3Dliteratum%253Aachs%26aulast%3DAuquier%26aufirst%3DP.%26aulast%3DLancon%26aufirst%3DC.%26aulast%3DRouillon%26aufirst%3DF.%26aulast%3DLader%26aufirst%3DM.%26aulast%3DHolmes%26aufirst%3DC.%26atitle%3DMortality%2520in%2520schizophrenia%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2006%26volume%3D15%26spage%3D873%26epage%3D879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Crow, T. J.</span><span> </span><span class="NLM_article-title">Molecular pathology of schizophrenia: more than one disease process</span> <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1136%2Fbmj.280.6207.66" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=6101544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL3cXhs1Wmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=1980&pages=66-68&author=T.+J.+Crow&title=Molecular+pathology+of+schizophrenia%3A+more+than+one+disease+process"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pathology of schizophrenia: more than one disease process?</span></div><div class="casAuthors">Crow, T. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Medical Journal</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">6207</span>),
    <span class="NLM_cas:pages">66-8</span>CODEN:
                <span class="NLM_cas:coden">BMJOAE</span>;
        ISSN:<span class="NLM_cas:issn">0007-1447</span>.
    </div><div class="casAbstract">A review with 40 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXd8uOWmWptrVg90H21EOLACvtfcHk0lj61ICegQo7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhs1Wmu7g%253D&md5=2afcd7dff055669622339a82f49e56da</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1136%2Fbmj.280.6207.66&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.280.6207.66%26sid%3Dliteratum%253Aachs%26aulast%3DCrow%26aufirst%3DT.%2BJ.%26atitle%3DMolecular%2520pathology%2520of%2520schizophrenia%253A%2520more%2520than%2520one%2520disease%2520process%26jtitle%3DBr.%2520Med.%2520J.%26date%3D1980%26volume%3D280%26spage%3D66%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Sawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Schizophrenia: diverse approaches to a complex disease</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">692</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1126%2Fscience.1070532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11976442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtlOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=692-695&author=A.+Sawaauthor=S.+H.+Snyder&title=Schizophrenia%3A+diverse+approaches+to+a+complex+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Review: Schizophrenia: diverse approaches to a complex disease</span></div><div class="casAuthors">Sawa, Akira; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5568</span>),
    <span class="NLM_cas:pages">692-695</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is a debilitating mental illness that affects 1% of the. population.  Despite intensive study, its mol. etiol. remains enigmatic.  Like many common diseases, schizophrenia is multifactorial in origin, with both genetic and environmental contributions likely playing an important role in the manifestation of symptoms.  Recent advances based on pharmacol. studies, brain imaging analyses, and genetic research are now converging on tantalizing leads that point to a central role for several neurotransmitters, including dopamine, glutamate, and serotonin, that may interface with neurodevelopmental defects reflecting disease-related genetic aberrations.  Here, we provide a brief overview of the parallel approaches being used to identify the mol. causes of schizophrenia and discuss possible directions for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHr6I_om8RjLVg90H21EOLACvtfcHk0lj61ICegQo7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtlOhtbs%253D&md5=49ca9e400ba12ac906f7284ae72d9e9f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070532%26sid%3Dliteratum%253Aachs%26aulast%3DSawa%26aufirst%3DA.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DSchizophrenia%253A%2520diverse%2520approaches%2520to%2520a%2520complex%2520disease%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D692%26epage%3D695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Tamminga, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span> </span><span class="NLM_article-title">The neuropharmacology of psychosis</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbm063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17562697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2szoslylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=937-946&author=C.+A.+Tammingaauthor=J.+M.+Davis&title=The+neuropharmacology+of+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The neuropharmacology of psychosis</span></div><div class="casAuthors">Tamminga Carol A; Davis John M</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">937-46</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">Antipsychotic drugs (APDs) are therapeutic in psychotic disorders.  They are not specific treatments for schizophrenia (SZ) but useful in bipolar disorder (BD), psychotic depression, Alzheimers disease, and other psychotic diagnoses.  In this perspective, we discuss the actions of APDs for the treatment of both SZ and bipolar-1 disorder (BD-1) with a specific focus on the implications of these data for the whole group of psychotic diagnoses.  Both schizophrenic and BD-1 are characterized by several symptom dimensions, some overlapping and some distinctive.  We discuss a dimensional approach to the diagnosis of BD and SZ and suggest that psychosis is an important dimension of each.  In order to define the dimension of psychosis more carefully would require additional research to fill in the gaps in our knowledge.  We propose that psychosis is a dimension that cuts through many psychiatric disorders, and the use of this dimension may be useful for clinical and research progress.  We discuss the kinds of data necessary to further support the dimensional aspects of psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHzG4u3UWGajAyhZbj3lKdfW6udTcc2eYR7tZlix82FLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szoslylsg%253D%253D&md5=da092e5611c6067de61b8777b41ee19e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbm063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbm063%26sid%3Dliteratum%253Aachs%26aulast%3DTamminga%26aufirst%3DC.%2BA.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520neuropharmacology%2520of%2520psychosis%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D937%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Walker, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kestler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochman, K. M.</span><span> </span><span class="NLM_article-title">Schizophrenia: etiology and course</span> <span class="citation_source-journal">Annu. Rev. Psychol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1146%2Fannurev.psych.55.090902.141950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14744221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FktlOmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=401-430&author=E.+Walkerauthor=L.+Kestlerauthor=A.+Bolliniauthor=K.+M.+Hochman&title=Schizophrenia%3A+etiology+and+course"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia: etiology and course</span></div><div class="casAuthors">Walker Elaine; Kestler Lisa; Bollini Annie; Hochman Karen M</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of psychology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">401-30</span>
        ISSN:<span class="NLM_cas:issn">0066-4308</span>.
    </div><div class="casAbstract">Decades of research on schizophrenia have not produced major breakthroughs, but gradual progress has been made in identifying risk factors and clarifying the nature of the etiologic process.  This article provides an overview of trends in research findings as well as current assumptions about the interplay between environmental and genetic factors in the etiology of schizophrenia.  Based on the cumulative findings, it appears that both genetic and prenatal factors can give rise to constitutional vulnerability.  Subsequent neuromaturational processes, especially those that occur during adolescence, and exposure to stressful events can trigger the behavioral expression of this vulnerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-6gep1jH3Hxgd2Wuil24tfW6udTcc2eaQ4y0Fft9Hbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FktlOmsQ%253D%253D&md5=02d0f2cbb26628636dd659d1a74c93ac</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.psych.55.090902.141950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.psych.55.090902.141950%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%26aulast%3DKestler%26aufirst%3DL.%26aulast%3DBollini%26aufirst%3DA.%26aulast%3DHochman%26aufirst%3DK.%2BM.%26atitle%3DSchizophrenia%253A%2520etiology%2520and%2520course%26jtitle%3DAnnu.%2520Rev.%2520Psychol.%26date%3D2004%26volume%3D55%26spage%3D401%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">First, M. B.; Tasman, A. Ct.</span> In  <span class="citation_source-book">DSM-IV-TR Mental Disorders: Diagnosis, Etiology and Treatment</span>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Chichester, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=639-701&author=M.+B.+First&author=A.+Ct.+Tasman&title=DSM-IV-TR+Mental+Disorders%3A+Diagnosis%2C+Etiology+and+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFirst%26aufirst%3DM.%2BB.%26btitle%3DDSM-IV-TR%2520Mental%2520Disorders%253A%2520Diagnosis%252C%2520Etiology%2520and%2520Treatment%26pub%3DWiley%26date%3D2004%26spage%3D639%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Dickerson, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehman, A. F.</span><span> </span><span class="NLM_article-title">Evidence-based psychotherapy for schizophrenia</span> <span class="citation_source-journal">J. Nerv. Ment. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F01.nmd.0000195316.86036.8a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16462548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28%252Fns1arsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2006&pages=3-9&author=F.+B.+Dickersonauthor=A.+F.+Lehman&title=Evidence-based+psychotherapy+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence-based psychotherapy for schizophrenia</span></div><div class="casAuthors">Dickerson Faith B; Lehman Anthony F</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of nervous and mental disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-9</span>
        ISSN:<span class="NLM_cas:issn">0022-3018</span>.
    </div><div class="casAbstract">Many patients with schizophrenia have psychological distress and receive some form of psychotherapy.  Several different psychotherapeutic approaches for schizophrenia have been developed and studied.  Of these approaches, cognitive behavior therapy has the strongest evidence base and has shown benefit for symptom reduction in outpatients with residual symptoms.  In addition to cognitive behavior therapy, other approaches include compliance therapy, personal therapy, acceptance and commitment therapy, and supportive therapy.  Although usually studied as distinct approaches, the therapies overlap with each other in their therapeutic elements.  As psychotherapy for schizophrenia further evolves, it will likely be informed by other psychosocial interventions used with this clinical population.  In particular, techniques of remediating cognitive deficits, teaching behavioral skills, and educating about schizophrenia may be incorporated with psychotherapy.  Future research may also consider three different goals of psychotherapy with this population: to provide emotional support, to enhance skills for functional recovery, and to alter the underlying illness process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbzkHLtnHpO0cLvDNbOD4DfW6udTcc2eaQ4y0Fft9Hbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252Fns1arsg%253D%253D&md5=3b2fd0fde526cd65466b037ebb07a263</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1097%2F01.nmd.0000195316.86036.8a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.nmd.0000195316.86036.8a%26sid%3Dliteratum%253Aachs%26aulast%3DDickerson%26aufirst%3DF.%2BB.%26aulast%3DLehman%26aufirst%3DA.%2BF.%26atitle%3DEvidence-based%2520psychotherapy%2520for%2520schizophrenia%26jtitle%3DJ.%2520Nerv.%2520Ment.%2520Dis.%26date%3D2006%26volume%3D194%26spage%3D3%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span> </span><span class="NLM_article-title">Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15289815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=79-104&author=S.+Miyamotoauthor=G.+E.+Duncanauthor=C.+E.+Marxauthor=J.+A.+Lieberman&title=Treatments+for+schizophrenia%3A+a+critical+review+of+pharmacology+and+mechanisms+of+action+of+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs</span></div><div class="casAuthors">Miyamoto, S.; Duncan, G. E.; Marx, C. E.; Lieberman, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-104</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development.  Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems.  Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia.  However, the pharmacol. properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life.  Moreover, the efficacy of antipsychotic drugs is limited prompting the clin. use of adjunctive pharmacy to augment the effects of treatment.  In addn., the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiol. hypotheses.  This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5K7PMOCd2ubVg90H21EOLACvtfcHk0ljPMn4-u52zMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3M&md5=f81c985a28797f02b7a1213c604433e4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001556%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DDuncan%26aufirst%3DG.%2BE.%26aulast%3DMarx%26aufirst%3DC.%2BE.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DTreatments%2520for%2520schizophrenia%253A%2520a%2520critical%2520review%2520of%2520pharmacology%2520and%2520mechanisms%2520of%2520action%2520of%2520antipsychotic%2520drugs%26jtitle%3DMol.%2520Psychiatry%26date%3D2005%26volume%3D10%26spage%3D79%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Klosterkotter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmeyer, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze-Lutter, F.</span><span> </span><span class="NLM_article-title">Diagnosing schizophrenia in the initial prodromal phase</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.58.2.158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11177117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3M7kvFGntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2001&pages=158-164&author=J.+Klosterkotterauthor=M.+Hellmichauthor=E.+M.+Steinmeyerauthor=F.+Schultze-Lutter&title=Diagnosing+schizophrenia+in+the+initial+prodromal+phase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing schizophrenia in the initial prodromal phase</span></div><div class="casAuthors">Klosterkotter J; Hellmich M; Steinmeyer E M; Schultze-Lutter F</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-64</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">BACKGROUND:  In schizophrenia research, early detection in the initial prodrome before first psychotic episodes is a major topic.  Therefore, the prognostic accuracy of initial prodromal symptoms was examined prospectively.  METHODS:  The study sample was composed of patients referred to outpatient departments of German psychiatric university departments, because of diagnostic problems, between 1987 and 1991.  They were examined with the Bonn Scale for the Assessment of Basic Symptoms and the Ninth Version of the Present State Examination to detect an incipient schizophrenic disorder.  Of 385 patients showing no schizophrenia-characteristic symptoms, between 1995 and 1998, 110 with and 50 without initial prodromal symptoms were followed up and reexamined with the same instruments for a transition to schizophrenia.  RESULTS:  During a mean follow-up period of 9.6 years, 79 (49.4%) of the 160 patients had transited to schizophrenia.  The absence of prodromal symptoms excluded a subsequent schizophrenia with a probability of 96% (sensitivity: 0.98; false-negative predictions: 1.3%), whereas their presence predicted schizophrenia with a probability of 70% (specificity: 0.59; false-positive predictions: 20%).  Certain disturbances, such as thought interference, disturbances of receptive language, or visual distortions, predicted schizophrenia, even with a probability up to 91% (specificity: 0.85-0.91; false-positive predictions: 1.9%-7.5%).  CONCLUSIONS:  The Bonn Scale for the Assessment of Basic Symptoms operationalization of prodromal symptoms performed well in the early detection of schizophrenia.  It therefore might be useful for the prediction of the disorder, especially if it is further refined to select those items with particularly high prognostic accuracy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVN8ekeLthwsK3uFsUIZtkfW6udTcc2ebcajCY0-2wWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7kvFGntQ%253D%253D&md5=1c3953ebd1eabbadb51c75e2067b29ae</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.58.2.158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.58.2.158%26sid%3Dliteratum%253Aachs%26aulast%3DKlosterkotter%26aufirst%3DJ.%26aulast%3DHellmich%26aufirst%3DM.%26aulast%3DSteinmeyer%26aufirst%3DE.%2BM.%26aulast%3DSchultze-Lutter%26aufirst%3DF.%26atitle%3DDiagnosing%2520schizophrenia%2520in%2520the%2520initial%2520prodromal%2520phase%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2001%26volume%3D58%26spage%3D158%26epage%3D164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Schmidt, C.</span><span> </span><span class="NLM_article-title">Psychiatric research. Putting the brakes on psychosis</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">976</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=976-977&author=C.+Schmidt&title=Psychiatric+research.+Putting+the+brakes+on+psychosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%26atitle%3DPsychiatric%2520research.%2520Putting%2520the%2520brakes%2520on%2520psychosis%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D976%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Cancro, R.</span><span> </span><span class="NLM_article-title">Schizophrenia</span>. In  <span class="citation_source-book">Treatments of Psychiatric Disorders: A Task Force Report of the American Psychiatric Association</span>; <span class="NLM_publisher-name">American Psychiatric Association</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">1989</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1485</span><span class="NLM_x">–</span> <span class="NLM_lpage">1606</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&pages=1485-1606&author=R.+Cancro&title=Treatments+of+Psychiatric+Disorders%3A+A+Task+Force+Report+of+the+American+Psychiatric+Association"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCancro%26aufirst%3DR.%26atitle%3DSchizophrenia%26btitle%3DTreatments%2520of%2520Psychiatric%2520Disorders%253A%2520A%2520Task%2520Force%2520Report%2520of%2520the%2520American%2520Psychiatric%2520Association%26pub%3DAmerican%2520Psychiatric%2520Association%26date%3D1989%26spage%3D1485%26epage%3D1606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, P. H.</span><span> </span><span class="NLM_article-title">Current and novel approaches to the drug treatment of schizophrenia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0002432" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=477-501&author=M.+Rowleyauthor=L.+J.+Bristowauthor=P.+H.+Hutson&title=Current+and+novel+approaches+to+the+drug+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Current and novel approaches to the drug treatment of schizophrenia</span></div><div class="casAuthors">Rowley, Michael; Bristow, Linda J.; Hutson, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 283 refs. on neurochem. hypotheses of schizophrenia, animal models developed for novel antipsychotic detection, and novel approaches to the drug treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh5OOZYcroI7Vg90H21EOLACvtfcHk0liSLIy0zGhysw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFKiug%253D%253D&md5=b30ff1715d5499955938fdbf236291f9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm0002432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0002432%26sid%3Dliteratum%253Aachs%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DHutson%26aufirst%3DP.%2BH.%26atitle%3DCurrent%2520and%2520novel%2520approaches%2520to%2520the%2520drug%2520treatment%2520of%2520schizophrenia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D477%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Harrison, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15263907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=40-68&author=P.+J.+Harrisonauthor=D.+R.+Weinberger&title=Schizophrenia+genes%2C+gene+expression%2C+and+neuropathology%3A+on+the+matter+of+their+convergence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence</span></div><div class="casAuthors">Harrison, P. J.; Weinberger, D. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-68</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This review critically summarizes the neuropathol. and genetics of schizophrenia, the relationship between them, and speculates on their functional convergence.  The morphol. correlates of schizophrenia are subtle, and range from a slight redn. in brain size to localized alterations in the morphol. and mol. compn. of specific neuronal, synaptic, and glial populations in the hippocampus, dorsolateral prefrontal cortex, and dorsal thalamus.  These findings have fostered the view of schizophrenia as a disorder of connectivity and of the synapse.  Although attractive, such concepts are vague, and differentiating primary events from epiphenomena has been difficult.  A way forward is provided by the recent identification of several putative susceptibility genes (including neuregulin, dysbindin, COMT, DISC1, RGS4, GRM3, and G72).  We discuss the evidence for these and other genes, along with what is known of their expression profiles and biol. roles in brain and how these may be altered in schizophrenia.  The evidence for several of the genes is now strong.  However, for none, with the likely exception of COMT, has a causative allele or the mechanism by which it predisposes to schizophrenia been identified.  Nevertheless, we speculate that the genes may all converge functionally upon schizophrenia risk via an influence upon synaptic plasticity and the development and stabilization of cortical microcircuitry.  NMDA receptor-mediated glutamate transmission may be esp. implicated, though there are also direct and indirect links to dopamine and GABA signaling.  Hence, there is a correspondence between the putative roles of the genes at the mol. and synaptic levels and the existing understanding of the disorder at the neural systems level.  Characterization of a core mol. pathway and a genetic cytoarchitecture' would be a profound advance in understanding schizophrenia, and may have equally significant therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEeG0dw3pqdbVg90H21EOLACvtfcHk0liSLIy0zGhysw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3N&md5=6e69aab6f45644278ca29a89ea03724a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001558%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DP.%2BJ.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DSchizophrenia%2520genes%252C%2520gene%2520expression%252C%2520and%2520neuropathology%253A%2520on%2520the%2520matter%2520of%2520their%2520convergence%26jtitle%3DMol.%2520Psychiatry%26date%3D2005%26volume%3D10%26spage%3D40%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Petronis, A.</span><span> </span><span class="NLM_article-title">The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">965</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2004.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15121478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Gisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=965-970&author=A.+Petronis&title=The+origin+of+schizophrenia%3A+genetic+thesis%2C+epigenetic+antithesis%2C+and+resolving+synthesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis</span></div><div class="casAuthors">Petronis, Arturas</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">965-970</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Traditionally, it has been thought that schizophrenia results from the interaction of predisposing genes and hazardous environmental factors.  In this article, the paradigm of "genes plus environment" is challenged, and a new interpretation is presented, in which the emphasis on DNA sequence variation is shared with epigenetic misregulation as a crit. etiopathogenic factor.  Partial epigenetic stability (metastability) of gene regulation is consistent with various nonmendelian irregularities of schizophrenia, such as the presence of clin. indistinguishable sporadic and familial cases, discordance of monozygotic twins, coincidence of peaks of susceptibility with major endocrine rearrangements, and fluctuating course of disease severity, among others.  It is also suggested that stochastic epigenetic events might account for a substantial portion of phenotypic variance, which traditionally has been ascribed to environmental effects.  This theoretic essay is constructed according to the principle of Hegelian dialectic reasoning (thesis-antithesis-synthesis), which serves the goal of showing that the best outcome of mol. genetic studies in schizophrenia (and perhaps other complex diseases) can be expected when components that effect chromatin structure and gene regulation are taken into account and investigated comprehensively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGLbFTxl9rV7Vg90H21EOLACvtfcHk0lh_K2HZnxLUjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Gisr0%253D&md5=6c85564a1a2cd5be8451412ae8aa7263</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2004.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2004.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DPetronis%26aufirst%3DA.%26atitle%3DThe%2520origin%2520of%2520schizophrenia%253A%2520genetic%2520thesis%252C%2520epigenetic%2520antithesis%252C%2520and%2520resolving%2520synthesis%26jtitle%3DBiol.%2520Psychiatry%26date%3D2004%26volume%3D55%26spage%3D965%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sullivan, P. F.</span><span> </span><span class="NLM_article-title">The genetics of schizophrenia</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=614-618&author=P.+F.+Sullivan&title=The+genetics+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DP.%2BF.%26atitle%3DThe%2520genetics%2520of%2520schizophrenia%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D614%26epage%3D618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=31-36&author=M.+Williams&title=Genome-based+drug+discovery%3A+prioritizing+disease-susceptibility%2Fdisease-associated+genes+as+novel+drug+targets+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DGenome-based%2520drug%2520discovery%253A%2520prioritizing%2520disease-susceptibility%252Fdisease-associated%2520genes%2520as%2520novel%2520drug%2520targets%2520for%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2003%26volume%3D4%26spage%3D31%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Coyle, J. T.</span><span> </span><span class="NLM_article-title">Glutamate and schizophrenia: beyond the dopamine hypothesis</span> <span class="citation_source-journal">Cell. Mol. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs10571-006-9062-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16773445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtleksb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=365-384&author=J.+T.+Coyle&title=Glutamate+and+schizophrenia%3A+beyond+the+dopamine+hypothesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis</span></div><div class="casAuthors">Coyle, Joseph T.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4-6</span>),
    <span class="NLM_cas:pages">365-384</span>CODEN:
                <span class="NLM_cas:coden">CMNEDI</span>;
        ISSN:<span class="NLM_cas:issn">0272-4340</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals.  2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the neg. symptoms, cognitive impairments and physiol. disturbances obsd. in schizophrenia.  3. Furthermore, a no. of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission.  4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown redn. in neg. symptoms, improvement in cognition and in some cases redn. in pos. symptoms in schizophrenic patients receiving concurrent antipsychotic medications.  5. Thus, hypofunction of the NMDA receptor, possibly on crit. GABAergic inter-neurons, may contribute to the pathophysiol. of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7x2DRLp7eO7Vg90H21EOLACvtfcHk0lh_K2HZnxLUjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtleksb3O&md5=f8410001e05e630ff19333692790857e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs10571-006-9062-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10571-006-9062-8%26sid%3Dliteratum%253Aachs%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3DGlutamate%2520and%2520schizophrenia%253A%2520beyond%2520the%2520dopamine%2520hypothesis%26jtitle%3DCell.%2520Mol.%2520Neurobiol.%26date%3D2006%26volume%3D26%26spage%3D365%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Taylor, D. M.</span><span> </span><span class="NLM_article-title">Antipsychotics and QT prolongation</span> <span class="citation_source-journal">Acta Psychiatr. Scand.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1034%2Fj.1600-0447.2003.02078.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12534433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1Wrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2003&pages=85-95&author=D.+M.+Taylor&title=Antipsychotics+and+QT+prolongation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotics and QT prolongation</span></div><div class="casAuthors">Taylor, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Psychiatrica Scandinavica</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-95</span>CODEN:
                <span class="NLM_cas:coden">APYSA9</span>;
        ISSN:<span class="NLM_cas:issn">0001-690X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Munksgaard</span>)
        </div><div class="casAbstract">A review.  The aim of this study was to evaluate literature relating to cardiac QT prolongation and the use of antipsychotic drugs.  Literature searches of EMBASE, Medline, PsychLIT were performed in Dec. 2001 and ref. sections of retrieved papers scrutinized for further relevant reports.  The Cardiac QTc interval is difficult to measure precisely or accurately but appears to be a useful predictor of risk of dysrhythmia (specifically torsade de pointes) and sudden death.  It is less clear that drug-induced QTc prolongation gives rise to similar risks but data are emerging, linking antipsychotic use to increased cardiac mortality.  Many antipsychotics have been clearly assocd. with QTc prolongation.  Methodol. considerations arguably preclude assuming that any antipsychotic is free of the risk of QTc prolongation and dysrhythmia.  Available data do not allow assessment of relative or abs. risk of dysrhythmia or sudden death engendered by antipsychotics but caution is advised.  Risk of dysrhythmia can very probably be reduced by careful prescribing of antipsychotics in low doses in simple drug regimens which avoid metabolic interactions.  Electrocardiog. monitoring may also help to reduce risk but review by specialist cardiologist may be necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolhHdJSE2ivrVg90H21EOLACvtfcHk0lgknBp-TWpuoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1Wrt70%253D&md5=2cfd6ebd65ac7d059841c834fdfe4901</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-0447.2003.02078.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-0447.2003.02078.x%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DD.%2BM.%26atitle%3DAntipsychotics%2520and%2520QT%2520prolongation%26jtitle%3DActa%2520Psychiatr.%2520Scand.%26date%3D2003%26volume%3D107%26spage%3D85%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Casey, D. E.</span><span> </span><span class="NLM_article-title">Metabolic issues and cardiovascular disease in patients with psychiatric disorders</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">15S</span><span class="NLM_x">–</span> <span class="NLM_lpage">22S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=15S-22S&issue=Suppl.+2&author=D.+E.+Casey&title=Metabolic+issues+and+cardiovascular+disease+in+patients+with+psychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasey%26aufirst%3DD.%2BE.%26atitle%3DMetabolic%2520issues%2520and%2520cardiovascular%2520disease%2520in%2520patients%2520with%2520psychiatric%2520disorders%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2005%26volume%3D118%26issue%3DSuppl.%25202%26spage%3D15S%26epage%3D22S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Newcomer, J. W.</span><span> </span><span class="NLM_article-title">Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1-93&issue=Suppl.+1&author=J.+W.+Newcomer&title=Second-generation+%28atypical%29+antipsychotics+and+metabolic+effects%3A+a+comprehensive+literature+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewcomer%26aufirst%3DJ.%2BW.%26atitle%3DSecond-generation%2520%2528atypical%2529%2520antipsychotics%2520and%2520metabolic%2520effects%253A%2520a%2520comprehensive%2520literature%2520review%26jtitle%3DCNS%2520Drugs%26date%3D2005%26volume%3D19%26issue%3DSuppl.%25201%26spage%3D1%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Dettling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anghelescu, I. G.</span><span> </span><span class="NLM_article-title">Antipsychotic drugs and schizophrenia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">354</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1056%2FNEJMc052822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16421374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xls1Krtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=298-300&author=M.+Dettlingauthor=I.+G.+Anghelescu&title=Antipsychotic+drugs+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drugs and schizophrenia</span></div><div class="casAuthors">Dettling, Michael; Anghelescu, Ion-George</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">298</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW-YdH_-MBorVg90H21EOLACvtfcHk0lgknBp-TWpuoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xls1Krtg%253D%253D&md5=de51e94af1a375e2760ba734f4eadffe</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1056%2FNEJMc052822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc052822%26sid%3Dliteratum%253Aachs%26aulast%3DDettling%26aufirst%3DM.%26aulast%3DAnghelescu%26aufirst%3DI.%2BG.%26atitle%3DAntipsychotic%2520drugs%2520and%2520schizophrenia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D298%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Leucht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauml, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span> </span><span class="NLM_article-title">Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbl025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16905632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28jksVyqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=183-191&author=S.+Leuchtauthor=R.+R.+Engelauthor=J.+Baumlauthor=J.+M.+Davis&title=Is+the+superior+efficacy+of+new+generation+antipsychotics+an+artifact+of+LOCF%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</span></div><div class="casAuthors">Leucht Stefan; Engel Rolf R; Bauml Josef; Davis John M</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-91</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">It has been argued that the efficacy superiority found in meta-analyses for some of the atypical antipsychotics is an artifact of higher dropout rates due to side effects in the haloperidol group combined with last-observation-carried-forward (LOCF) analyses.  We therefore reanalyzed a number of pivotal studies comparing new generation antipsychotics (NGAs) and conventional antipsychotics (CAs).  A total of 5 studies (n = 1271) comparing amisulpride and 3 studies (n = 2454) comparing olanzapine with CAs were reanalyzed using original patient data.  We applied 4 different models: LOCF, completer analysis, LOCF but excluding dropouts due to adverse events, and LOCF but excluding all dropouts with the exception of dropouts related to efficacy.  Effect sizes expressed as standardized mean differences between NGAs and CAs based on the 4 different analysis models were compared.  The overall results were not different irrespective of the model used.  Single studies, however, showed higher effect sizes when LOCF instead of other models was used.  Overall, it does not seem that higher dropout rates due to side effects in the haloperidol groups together with LOCF analyses consistently biased the results in favor of amisulpride and olanzapine.  Because the results of the single studies, however, showed that this may occasionally be the case, future studies should look at the data from different angles applying sensitivity analyses, and they may use alternative statistics such as mixed models, which need to be developed further.  Ultimately, strategies to reduce dropout rates are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6rFzFzFcpL3T4ugvCDgnZfW6udTcc2eZhPLm_TMmb3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jksVyqtw%253D%253D&md5=9cfd2c40c460c429141467c419cee239</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbl025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbl025%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DR.%2BR.%26aulast%3DBauml%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DIs%2520the%2520superior%2520efficacy%2520of%2520new%2520generation%2520antipsychotics%2520an%2520artifact%2520of%2520LOCF%253F%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D183%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobo, W. V.</span><span> </span><span class="NLM_article-title">Interpreting the efficacy findings in the CATIE study: what clinicians should know</span> <span class="citation_source-journal">CNS Spectrums</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=14-24&author=H.+Y.+Meltzerauthor=W.+V.+Bobo&title=Interpreting+the+efficacy+findings+in+the+CATIE+study%3A+what+clinicians+should+know"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DBobo%26aufirst%3DW.%2BV.%26atitle%3DInterpreting%2520the%2520efficacy%2520findings%2520in%2520the%2520CATIE%2520study%253A%2520what%2520clinicians%2520should%2520know%26jtitle%3DCNS%2520Spectrums%26date%3D2006%26volume%3D11%26spage%3D14%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Jones, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayhurst, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markwick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, S. W.</span><span> </span><span class="NLM_article-title">Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.63.10.1079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17015810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKhtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=1079-1087&author=P.+B.+Jonesauthor=T.+R.+Barnesauthor=L.+Daviesauthor=G.+Dunnauthor=H.+Lloydauthor=K.+P.+Hayhurstauthor=R.+M.+Murrayauthor=A.+Markwickauthor=S.+W.+Lewis&title=Randomized+controlled+trial+of+the+effect+on+quality+of+life+of+second-+vs+first-generation+antipsychotic+drugs+in+schizophrenia%3A+Cost+Utility+of+the+Latest+Antipsychotic+Drugs+in+Schizophrenia+Study+%28CUtLASS+1%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)</span></div><div class="casAuthors">Jones, Peter B.; Barnes, Thomas R. E.; Davies, Linda; Dunn, Graham; Lloyd, Helen; Hayhurst, Karen P.; Murray, Robin M.; Markwick, Alison; Lewis, Shon W.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1079-1087</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Second-generation (atypical) antipsychotics (SGAs) are more expensive than first-generation (typical) antipsychotics (FGAs) but are perceived to be more effective, with fewer adverse effects, and preferable to patients.  Most evidence comes from short-term efficacy trials of symptoms.  Objective: To test the hypothesis that in people with schizophrenia requiring a change in treatment, SGAs other than clozapine are assocd. with improved quality of life across 1 yr compared with FGAs.  Design: A noncommercially funded, pragmatic, multisite, randomized controlled trial of antipsychotic drug classes, with blind assessments at 12, 26, and 56 wk using intention-to-treat anal.  Setting: Fourteen community psychiatric services in the English National Health Service.  Participants: Two hundred twenty-seven people aged 18 to 65 years with DSM-IV schizophrenia and related disorders assessed for medication review because of inadequate response or adverse effects.  Interventions: Randomized prescription of either FGAs or SGAs (other than clozapine), with the choice of individual drug made by the managing psychiatrist.  Main Outcome Measures: Quality of Life Scale scores, symptoms, adverse effects, participant satisfaction, and costs of care.  Results: The primary hypothesis of significant improvement in Quality of Life Scale scores during the year after commencement of SGAs vs FGAs was excluded.  Participants in the FGA arm showed a trend toward greater improvements in Quality of Life Scale and symptom scores.  Participants reported no clear preference for either drug group; costs were similar.  Conclusions: In people with schizophrenia whose medication is changed for clin. reasons, there is no disadvantage across 1 yr in terms of quality of life, symptoms, or assocd. costs of care in using FGAs rather than nonclozapine SGAs.  Neither inadequate power nor patterns of drug discontinuation accounted for the result.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnqG682dYJM7Vg90H21EOLACvtfcHk0lhjNFgiTy7MMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKhtrzP&md5=b5027b469da573212342107d56543b1e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.63.10.1079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.63.10.1079%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BB.%26aulast%3DBarnes%26aufirst%3DT.%2BR.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DDunn%26aufirst%3DG.%26aulast%3DLloyd%26aufirst%3DH.%26aulast%3DHayhurst%26aufirst%3DK.%2BP.%26aulast%3DMurray%26aufirst%3DR.%2BM.%26aulast%3DMarkwick%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DS.%2BW.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520the%2520effect%2520on%2520quality%2520of%2520life%2520of%2520second-%2520vs%2520first-generation%2520antipsychotic%2520drugs%2520in%2520schizophrenia%253A%2520Cost%2520Utility%2520of%2520the%2520Latest%2520Antipsychotic%2520Drugs%2520in%2520Schizophrenia%2520Study%2520%2528CUtLASS%25201%2529%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2006%26volume%3D63%26spage%3D1079%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Stroup, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvoy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swartz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenheck, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefe, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao, J. K.</span><span> </span><span class="NLM_article-title">Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.163.4.611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16585435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287os1Kgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2006&pages=611-622&author=T.+S.+Stroupauthor=J.+A.+Liebermanauthor=J.+P.+McEvoyauthor=M.+S.+Swartzauthor=S.+M.+Davisauthor=R.+A.+Rosenheckauthor=D.+O.+Perkinsauthor=R.+S.+Keefeauthor=C.+E.+Davisauthor=J.+Severeauthor=J.+K.+Hsiao&title=Effectiveness+of+olanzapine%2C+quetiapine%2C+risperidone%2C+and+ziprasidone+in+patients+with+chronic+schizophrenia+following+discontinuation+of+a+previous+atypical+antipsychotic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</span></div><div class="casAuthors">Stroup T Scott; Lieberman Jeffrey A; McEvoy Joseph P; Swartz Marvin S; Davis Sonia M; Rosenheck Robert A; Perkins Diana O; Keefe Richard S E; Davis Clarence E; Severe Joanne; Hsiao John K</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">611-22</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">BACKGROUND:  In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown.  This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic.  METHOD:  Subjects with schizophrenia (N=444) who had discontinued the atypical antipsychotic randomly assigned during phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigation were randomly reassigned to double-blind treatment with a different antipsychotic (olanzapine, 7.5-30 mg/day [N=66]; quetiapine, 200-800 mg/day [N=63]; risperidone, 1.5-6.0 mg/day [N=69]; or ziprasidone, 40-160 mg/day [N=135]).  The primary aim was to determine if there were differences between these four treatments in effectiveness measured by time until discontinuation for any reason.  RESULTS:  The time to treatment discontinuation was longer for patients treated with risperidone (median: 7.0 months) and olanzapine (6.3 months) than with quetiapine (4.0 months) and ziprasidone (2.8 months).  Among patients who discontinued their previous antipsychotic because of inefficacy (N=184), olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine.  There were no significant differences between antipsychotics among those who discontinued their previous treatment because of intolerability (N=168).  CONCLUSIONS:  Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyaiGBE8WJGu98rul4nhSdfW6udTcc2eZhPLm_TMmb3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287os1Kgug%253D%253D&md5=7b0efddd9623cf4122c1ee69e77ec94a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.163.4.611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.163.4.611%26sid%3Dliteratum%253Aachs%26aulast%3DStroup%26aufirst%3DT.%2BS.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DMcEvoy%26aufirst%3DJ.%2BP.%26aulast%3DSwartz%26aufirst%3DM.%2BS.%26aulast%3DDavis%26aufirst%3DS.%2BM.%26aulast%3DRosenheck%26aufirst%3DR.%2BA.%26aulast%3DPerkins%26aufirst%3DD.%2BO.%26aulast%3DKeefe%26aufirst%3DR.%2BS.%26aulast%3DDavis%26aufirst%3DC.%2BE.%26aulast%3DSevere%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DJ.%2BK.%26atitle%3DEffectiveness%2520of%2520olanzapine%252C%2520quetiapine%252C%2520risperidone%252C%2520and%2520ziprasidone%2520in%2520patients%2520with%2520chronic%2520schizophrenia%2520following%2520discontinuation%2520of%2520a%2520previous%2520atypical%2520antipsychotic%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D163%26spage%3D611%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">McEvoy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroup, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenheck, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swartz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefe, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao, J. K.</span><span> </span><span class="NLM_article-title">Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">610</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.163.4.600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16585434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287os1KgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2006&pages=600-610&author=J.+P.+McEvoyauthor=J.+A.+Liebermanauthor=T.+S.+Stroupauthor=S.+M.+Davisauthor=H.+Y.+Meltzerauthor=R.+A.+Rosenheckauthor=M.+S.+Swartzauthor=D.+O.+Perkinsauthor=R.+S.+Keefeauthor=C.+E.+Davisauthor=J.+Severeauthor=J.+K.+Hsiao&title=Effectiveness+of+clozapine+versus+olanzapine%2C+quetiapine%2C+and+risperidone+in+patients+with+chronic+schizophrenia+who+did+not+respond+to+prior+atypical+antipsychotic+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</span></div><div class="casAuthors">McEvoy Joseph P; Lieberman Jeffrey A; Stroup T Scott; Davis Sonia M; Meltzer Herbert Y; Rosenheck Robert A; Swartz Marvin S; Perkins Diana O; Keefe Richard S E; Davis Clarence E; Severe Joanne; Hsiao John K</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">600-10</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine.  In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation.  METHOD:  Ninety-nine patients who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily because of inadequate efficacy, were randomly assigned to open-label treatment with clozapine (N=49) or blinded treatment with another newer atypical antipsychotic not previously received in the trial (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16]).  RESULTS:  Time until treatment discontinuation for any reason was significantly longer for clozapine (median=10.5 months) than for quetiapine (median=3.3), or risperidone (median=2.8), but not for olanzapine (median=2.7).  Time to discontinuation because of inadequate therapeutic effect was significantly longer for clozapine than for olanzapine, quetiapine, or risperidone.  At 3-month assessments, Positive and Negative Syndrome Scale total scores had decreased more in patients treated with clozapine than in patients treated with quetiapine or risperidone but not olanzapine.  One patient treated with clozapine developed agranulocytosis, and another developed eosinophilia; both required treatment discontinuation.  CONCLUSIONS:  For these patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypical antipsychotic.  Safety monitoring is necessary to detect and manage clozapine's serious side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyaiGBE8WJGoJKJbLTgsvCfW6udTcc2eaVht3C9CBqfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287os1KgtQ%253D%253D&md5=5a4fed46f9e5be5d2af7a90782b52523</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.163.4.600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.163.4.600%26sid%3Dliteratum%253Aachs%26aulast%3DMcEvoy%26aufirst%3DJ.%2BP.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DStroup%26aufirst%3DT.%2BS.%26aulast%3DDavis%26aufirst%3DS.%2BM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRosenheck%26aufirst%3DR.%2BA.%26aulast%3DSwartz%26aufirst%3DM.%2BS.%26aulast%3DPerkins%26aufirst%3DD.%2BO.%26aulast%3DKeefe%26aufirst%3DR.%2BS.%26aulast%3DDavis%26aufirst%3DC.%2BE.%26aulast%3DSevere%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DJ.%2BK.%26atitle%3DEffectiveness%2520of%2520clozapine%2520versus%2520olanzapine%252C%2520quetiapine%252C%2520and%2520risperidone%2520in%2520patients%2520with%2520chronic%2520schizophrenia%2520who%2520did%2520not%2520respond%2520to%2520prior%2520atypical%2520antipsychotic%2520treatment%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D163%26spage%3D600%26epage%3D610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Jeste, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Carmen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohr, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, R. J.</span><span> </span><span class="NLM_article-title">Did schizophrenia exist before the eighteenth century</span> <span class="citation_source-journal">Compr. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0010-440X%2885%2990016-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=3905241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaL28%252FlsVOhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1985&pages=493-503&author=D.+V.+Jesteauthor=R.+del+Carmenauthor=J.+B.+Lohrauthor=R.+J.+Wyatt&title=Did+schizophrenia+exist+before+the+eighteenth+century"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Did schizophrenia exist before the eighteenth century?</span></div><div class="casAuthors">Jeste D V; del Carmen R; Lohr J B; Wyatt R J</div><div class="citationInfo"><span class="NLM_cas:title">Comprehensive psychiatry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">493-503</span>
        ISSN:<span class="NLM_cas:issn">0010-440X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-3QKU6NoKce2mnZh2OgS0fW6udTcc2eaVht3C9CBqfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FlsVOhtA%253D%253D&md5=fb89750721575debe32e4e05ec10518c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0010-440X%2885%2990016-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0010-440X%252885%252990016-1%26sid%3Dliteratum%253Aachs%26aulast%3DJeste%26aufirst%3DD.%2BV.%26aulast%3Ddel%2BCarmen%26aufirst%3DR.%26aulast%3DLohr%26aufirst%3DJ.%2BB.%26aulast%3DWyatt%26aufirst%3DR.%2BJ.%26atitle%3DDid%2520schizophrenia%2520exist%2520before%2520the%2520eighteenth%2520century%26jtitle%3DCompr.%2520Psychiatry%26date%3D1985%26volume%3D26%26spage%3D493%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Green, M. F.</span><span> </span><span class="NLM_article-title">Stimulating the development of drug treatments to improve cognition in schizophrenia</span> <span class="citation_source-journal">Ann. Rev. Clin. Psychol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1146%2Fannurev.clinpsy.3.022806.091529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17716052" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=159-180&author=M.+F.+Green&title=Stimulating+the+development+of+drug+treatments+to+improve+cognition+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1146%2Fannurev.clinpsy.3.022806.091529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.clinpsy.3.022806.091529%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DM.%2BF.%26atitle%3DStimulating%2520the%2520development%2520of%2520drug%2520treatments%2520to%2520improve%2520cognition%2520in%2520schizophrenia%26jtitle%3DAnn.%2520Rev.%2520Clin.%2520Psychol.%26date%3D2007%26volume%3D3%26spage%3D159%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Nuechterlein, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barch, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, R. K.</span><span> </span><span class="NLM_article-title">Identification of separable cognitive factors in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15531405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crlvFKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2004&pages=29-39&author=K.+H.+Nuechterleinauthor=D.+M.+Barchauthor=J.+M.+Goldauthor=T.+E.+Goldbergauthor=M.+F.+Greenauthor=R.+K.+Heaton&title=Identification+of+separable+cognitive+factors+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of separable cognitive factors in schizophrenia</span></div><div class="casAuthors">Nuechterlein Keith H; Barch Deanna M; Gold James M; Goldberg Terry E; Green Michael F; Heaton Robert K</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">One of the primary goals in the NIMH initiative to encourage development of new interventions for cognitive deficits in schizophrenia, Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS), has been to develop a reliable and valid consensus cognitive battery for use in clinical trials.  Absence of such a battery has hampered standardized evaluation of new treatments and, in the case of pharmacological agents, has been an obstacle to FDA approval of medications targeting cognitive deficits in schizophrenia.  A fundamental step in developing such a battery was to identify the major separable cognitive impairments in schizophrenia.  As part of this effort, we evaluated the empirical evidence for cognitive performance dimensions in schizophrenia, emphasizing factor analytic studies.  We concluded that seven separable cognitive factors were replicable across studies and represent fundamental dimensions of cognitive deficit in schizophrenia: Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning and Memory, Visual Learning and Memory, Reasoning and Problem Solving, and Verbal Comprehension.  An eighth domain, Social Cognition, was added due to recent increased interest in this area and other evidence of its relevance for clinical trials aiming to evaluate the impact of potential cognitive enhancers on cognitive performance and functional outcome.  Verbal Comprehension was not considered appropriate for a cognitive battery intended to be sensitive to cognitive change, due to its resistance to change.  The remaining seven domains were recommended for inclusion in the MATRICS-NIMH consensus cognitive battery and will serve as the basic structure for that battery.  These separable cognitive dimensions also have broader relevance to future research aimed at understanding the nature and structure of core cognitive deficits in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjOcc4H71WSkEksK8CslK8fW6udTcc2eaVht3C9CBqfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crlvFKrsA%253D%253D&md5=bb3fcc504206b4d2936ee995694d8f59</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DNuechterlein%26aufirst%3DK.%2BH.%26aulast%3DBarch%26aufirst%3DD.%2BM.%26aulast%3DGold%26aufirst%3DJ.%2BM.%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DGreen%26aufirst%3DM.%2BF.%26aulast%3DHeaton%26aufirst%3DR.%2BK.%26atitle%3DIdentification%2520of%2520separable%2520cognitive%2520factors%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2004%26volume%3D72%26spage%3D29%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Marder, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenton, W.</span><span> </span><span class="NLM_article-title">Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15531402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crlvFKkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2004&pages=5-9&author=S.+R.+Marderauthor=W.+Fenton&title=Measurement+and+treatment+research+to+improve+cognition+in+schizophrenia%3A+NIMH+MATRICS+initiative+to+support+the+development+of+agents+for+improving+cognition+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia</span></div><div class="casAuthors">Marder Stephen R; Fenton Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-9</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The impairments in social and vocational outcome that are common in schizophrenia are strongly related to the severity of impaired neurocognition.  This observation led to the initiation of The NIMH's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, which supports the development of pharmacological agents to improve cognition in schizophrenia.  MATRICS addresses barriers to drug development through a number of activities, including the development of a consensus battery for measuring cognition in schizophrenia; the development of a consensus regarding the most promising molecular targets that should be the focus of drug development; the use of a joint meeting with representatives from the industry, academia, NIMH, and the U.S.  Food and Drug Administration (FDA) to clarify guidelines for the design of clinical trials for cognition enhancing agents; and finally, to assist NIMH in developing its research agenda in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjOcc4H71WSnT4ugvCDgnZfW6udTcc2ebRI54wdf5dArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crlvFKkuw%253D%253D&md5=f778dc43a12f8bd4526c411368b738d6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DMarder%26aufirst%3DS.%2BR.%26aulast%3DFenton%26aufirst%3DW.%26atitle%3DMeasurement%2520and%2520treatment%2520research%2520to%2520improve%2520cognition%2520in%2520schizophrenia%253A%2520NIMH%2520MATRICS%2520initiative%2520to%2520support%2520the%2520development%2520of%2520agents%2520for%2520improving%2520cognition%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2004%26volume%3D72%26spage%3D5%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitt, P.</span><span> </span><span class="NLM_article-title">Schizophrenia as a disorder of neurodevelopment</span> <span class="citation_source-journal">Annu. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1146%2Fannurev.neuro.25.112701.142754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12052915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtF2hsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2002&pages=409-432&author=D.+A.+Lewisauthor=P.+Levitt&title=Schizophrenia+as+a+disorder+of+neurodevelopment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia as a disorder of neurodevelopment</span></div><div class="casAuthors">Lewis, David A.; Levitt, Pat</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">409-432</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A combination of genetic susceptibility and environmental perturbations appear to be necessary for the expression of schizophrenia.  In addn., the pathogenesis of the disease is hypothesized to be neurodevelopmental in nature based on reports of an excess of adverse events during the pre- and perinatal periods, the presence of cognitive and behavioral signs during childhood and adolescence, and the lack of evidence of a neurodegenerative process in most individuals with schizophrenia.  Recent studies of neurodevelopmental mechanisms strongly suggest that no single gene or factor is responsible for driving a highly complex biol. process.  Together, these findings suggest that combinatorial genetic and environmental factors, which disturb a normal developmental course early in life, result in mol. and histogenic responses that cumulatively lead to different developmental trajectories and the clin. phenotype recognized as schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokBRthEqD1WbVg90H21EOLACvtfcHk0lhpnvB883RTAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtF2hsbw%253D&md5=bab0de349e55e799fc9bf15938d93958</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.25.112701.142754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.25.112701.142754%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DLevitt%26aufirst%3DP.%26atitle%3DSchizophrenia%2520as%2520a%2520disorder%2520of%2520neurodevelopment%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2002%26volume%3D25%26spage%3D409%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Raine, A.</span><span> </span><span class="NLM_article-title">Schizotypal personality: neurodevelopmental and psychosocial trajectories</span> <span class="citation_source-journal">Ann. Rev. Clin. Psychol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1146%2Fannurev.clinpsy.2.022305.095318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17716072" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=291-326&author=A.+Raine&title=Schizotypal+personality%3A+neurodevelopmental+and+psychosocial+trajectories"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1146%2Fannurev.clinpsy.2.022305.095318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.clinpsy.2.022305.095318%26sid%3Dliteratum%253Aachs%26aulast%3DRaine%26aufirst%3DA.%26atitle%3DSchizotypal%2520personality%253A%2520neurodevelopmental%2520and%2520psychosocial%2520trajectories%26jtitle%3DAnn.%2520Rev.%2520Clin.%2520Psychol.%26date%3D2006%26volume%3D2%26spage%3D291%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Crow, T. J.</span><span> </span><span class="NLM_article-title">How and why genetic linkage has not solved the problem of psychosis: review and hypothesis</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.164.1.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17202538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgs1WgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2007&pages=13-21&author=T.+J.+Crow&title=How+and+why+genetic+linkage+has+not+solved+the+problem+of+psychosis%3A+review+and+hypothesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">How and why genetic linkage has not solved the problem of psychosis: review and hypothesis</span></div><div class="casAuthors">Crow Timothy J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-21</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The author examined the chromosomal linkage method as an approach to the genetic basis of schizophrenia and bipolar disorder.  METHOD:  Comparisons were conducted of recent meta-analyses of genome scans of schizophrenia and bipolar disorder and of the three largest (N>300) sibling pair studies of schizophrenia and schizoaffective disorder and a comparable study of bipolar illness.  RESULTS:  Recent meta-analyses have not identified consistent sites of linkage.  The three largest studies of schizophrenia fail to agree on a single locus, no commonality with bipolar illness has been demonstrated, and there is no replicable support for any of the current candidate genes.  DISCUSSION:  An alternative to the concept that DNA sequence variation lies in "multiple genes of small effect" is the hypothesis that the variation is epigenetic but related to the genetic transition ("the speciation event") that separated Homo sapiens from a prior hominid species.  This hypothesis draws attention to the chromosomal rearrangement (the Xq21.3/Yp translocation) that occurred some 6 million years ago in the hominid lineage and subsequent rearrangements, including a paracentric inversion, that have taken place within the translocated segment.  Here it is argued that the most recent of these events is relevant to specifically human characteristics, including language.  The gene pair protocadherin X and Y within this region is under new selective pressure and is in a novel (epigenetic) situation with respect to X inactivation.  CONCLUSIONS:  Epigenetic variation associated with chromosomal rearrangements that occurred in the hominid lineage and that relates to the evolution of language could account for predisposition to schizophrenia and schizoaffective and bipolar disorder and failure to detect such variation by standard linkage approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-UbtLFI4-l5HZzFRCXxVKfW6udTcc2ebRI54wdf5dArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgs1WgtA%253D%253D&md5=957bc6018ec0c5a0a1134bb84ee2465b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.164.1.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.164.1.13%26sid%3Dliteratum%253Aachs%26aulast%3DCrow%26aufirst%3DT.%2BJ.%26atitle%3DHow%2520and%2520why%2520genetic%2520linkage%2520has%2520not%2520solved%2520the%2520problem%2520of%2520psychosis%253A%2520review%2520and%2520hypothesis%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D164%26spage%3D13%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Morgan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, H.</span><span> </span><span class="NLM_article-title">Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma—a critical review</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbl053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17105965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28jksV2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=3-10&author=C.+Morganauthor=H.+Fisher&title=Environment+and+schizophrenia%3A+environmental+factors+in+schizophrenia%3A+childhood+trauma%E2%80%94a+critical+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma--a critical review</span></div><div class="casAuthors">Morgan Craig; Fisher Helen</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">There is renewed interest in the relationship between early childhood trauma and risk of psychosis in adulthood.  There are a large number of studies of psychiatric inpatients, and of outpatients in which a majority have a psychotic disorder, that suggest the prevalence of childhood trauma in these populations is high.  However, these are generally small studies of diagnostically heterogeneous and chronic samples and, as such, can tell us very little about whether childhood trauma is of etiological importance in psychosis.  A small number of recent population-based studies provide more robust evidence of an association, and there are now plausible biological mechanisms linking childhood trauma and psychosis.  However, there remain a number of conceptual and methodological issues, which mean much more research is needed before firm conclusions can be drawn about whether childhood trauma is a cause of psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6rFzFzFcpL_tos8R3JUhXfW6udTcc2eZG0hyo2j6LHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jksV2jtw%253D%253D&md5=b41b038e68957a173ec1a421400548ce</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbl053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbl053%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DFisher%26aufirst%3DH.%26atitle%3DEnvironment%2520and%2520schizophrenia%253A%2520environmental%2520factors%2520in%2520schizophrenia%253A%2520childhood%2520trauma%25E2%2580%2594a%2520critical%2520review%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D3%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Krabbendam, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van, O. J.</span><span> </span><span class="NLM_article-title">Schizophrenia and urbanicity: a major environmental influence—conditional on genetic risk</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">799</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbi060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16150958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2Mrjtlelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2005&pages=795-799&author=L.+Krabbendamauthor=O.+J.+Van&title=Schizophrenia+and+urbanicity%3A+a+major+environmental+influence%E2%80%94conditional+on+genetic+risk"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk</span></div><div class="casAuthors">Krabbendam Lydia; van Os Jim</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">795-9</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">More than 10 studies have consistently shown that around one-third of all schizophrenia incidence may be related to unknown but likely unconfounded environmental factors operating in the urban environment that have an impact on developing children and adolescents to increase, relatively specifically, the later expression of psychosis-like at-risk mental states and overt psychotic disorders.  The available evidence suggests that causation (urban environment causes psychosis) is more important than selection (high-risk individuals move into urban areas) and that the effect of the environmental factors in the urban environment is conditional on genetic risk (i.e., there may be gene-environment interaction).  The effect associated with urbanicity has grown in more recent birth cohorts, while studies focusing on within-city contrasts have found important within-city variation in the incidence of schizophrenia associated with neighborhood social characteristics.  Future approaches may focus on the complex interactions between neighborhood cognitive social capital and genetic risk as the substrate for the increased incidence of schizophrenia in the increasingly urbanized areas that children are growing up in.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHRmsFg_e25Eg6wdEZmT2rfW6udTcc2eZG0hyo2j6LHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mrjtlelsg%253D%253D&md5=b196e34e2bf2dd6237c1c9dd369b8419</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbi060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbi060%26sid%3Dliteratum%253Aachs%26aulast%3DKrabbendam%26aufirst%3DL.%26aulast%3DVan%26aufirst%3DO.%2BJ.%26atitle%3DSchizophrenia%2520and%2520urbanicity%253A%2520a%2520major%2520environmental%2520influence%25E2%2580%2594conditional%2520on%2520genetic%2520risk%26jtitle%3DSchizophr.%2520Bull.%26date%3D2005%26volume%3D31%26spage%3D795%26epage%3D799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Gershon, E. S.</span><span> </span><span class="NLM_article-title">Pregnancy, chromosomes and receptors</span>.  <span class="citation_source-journal">Scientist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span><span class="NLM_issue">December Suppl. (Schizophrenia)</span><span class="NLM_x">) </span> <span class="NLM_fpage">45</span>− <span class="NLM_lpage">47</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=45-47&issue=December+Suppl.+%28Schizophrenia%29&author=E.+S.+Gershon&title=Pregnancy%2C+chromosomes+and+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGershon%26aufirst%3DE.%2BS.%26atitle%3DPregnancy%252C%2520chromosomes%2520and%2520receptors%26jtitle%3DScientist%26date%3D2007%26issue%3DDecember%2520Suppl.%2520%2528Schizophrenia%2529%26spage%3D45%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Torrey, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartko, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lun, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yolken, R. H.</span><span> </span><span class="NLM_article-title">Antibodies to <i>Toxoplasma gondii</i> in patients with schizophrenia: a meta-analysis</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">736</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbl050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17085743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s3ps1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=729-736&author=E.+F.+Torreyauthor=J.+J.+Bartkoauthor=Z.+R.+Lunauthor=R.+H.+Yolken&title=Antibodies+to+Toxoplasma+gondii+in+patients+with+schizophrenia%3A+a+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis</span></div><div class="casAuthors">Torrey E Fuller; Bartko John J; Lun Zhao-Rong; Yolken Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">729-36</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">Recent studies have linked infectious agents to schizophrenia.  The largest number of studies has involved the analysis of Toxoplasma gondii; these studies were subjected to a meta-analysis.  Published articles and abstracts were identified by searches of MEDLINE, Ovid, and Google Scholar; by a search of Chinese publications; through letters to researchers; and by visiting China.  Published and unpublished controlled studies that used serological methods for measuring T. gondii antibodies to assess inpatients and/or outpatients diagnosed with schizophrenia were selected for analysis, and source documents were translated as needed.  Forty-two studies carried out in 17 countries over 5 decades were identified; 23 of these (6 unpublished) met selection criteria.  The combined odds ratio (OR) was 2.73 (95% confidence interval, 2.10 to 3.60; chi-square with 1 df 263; P < .000001).  Seven studies that included only patients with first-episode schizophrenia (OR 2.54) did not differ significantly from 16 studies that included patients in all clinical phases (OR 2.79).  The results suggest that individuals with schizophrenia have an increased prevalence of antibodies to T. gondii.  This association is consistent with other epidemiological studies as well as with animal studies.  Although the OR of 2.73 is modest, it exceeds that for genetic or other environmental factors identified to date and suggests that Toxoplasma is in some way associated with a large number of cases of schizophrenia.  If an etiological association can be proven, it would have implications for the design of measures for the prevention and treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5GCvKt2-s4nqj_yg7twvpfW6udTcc2eZG0hyo2j6LHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3ps1Kktg%253D%253D&md5=4bf9691aeb7a4c6f9066ea3ab32079c7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbl050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbl050%26sid%3Dliteratum%253Aachs%26aulast%3DTorrey%26aufirst%3DE.%2BF.%26aulast%3DBartko%26aufirst%3DJ.%2BJ.%26aulast%3DLun%26aufirst%3DZ.%2BR.%26aulast%3DYolken%26aufirst%3DR.%2BH.%26atitle%3DAntibodies%2520to%2520Toxoplasma%2520gondii%2520in%2520patients%2520with%2520schizophrenia%253A%2520a%2520meta-analysis%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D729%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Eaton, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mors, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agerbo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortensen, P. B.</span><span> </span><span class="NLM_article-title">Association of schizophrenia and autoimmune diseases: linkage of Danish national registers</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.163.3.521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16513876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287isFyrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2006&pages=521-528&author=W.+W.+Eatonauthor=M.+Byrneauthor=H.+Ewaldauthor=O.+Morsauthor=C.+Y.+Chenauthor=E.+Agerboauthor=P.+B.+Mortensen&title=Association+of+schizophrenia+and+autoimmune+diseases%3A+linkage+of+Danish+national+registers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Association of schizophrenia and autoimmune diseases: linkage of Danish national registers</span></div><div class="casAuthors">Eaton William W; Byrne Majella; Ewald Henrik; Mors Ole; Chen Chuan-Yu; Agerbo Esben; Mortensen Preben Bo</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-8</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Individuals with schizophrenia and their relatives tend to have either higher or lower than expected prevalences of autoimmune disorders, especially rheumatoid arthritis, celiac disease, autoimmune thyroid diseases, and type 1 diabetes.  The purpose of the study was to estimate the association of schizophrenia with these disorders as well as a range of other autoimmune diseases in a single large epidemiologic study.  METHOD:  The Danish Psychiatric Register, the National Patient Register, and a register with socioeconomic information were linked to form a data file that included all 7,704 persons in Denmark diagnosed with schizophrenia from 1981 to 1998 and their parents along with a sample of matched comparison subjects and their parents.  The data linkage required that the autoimmune disease occur before the diagnosis of schizophrenia.  RESULTS:  A history of any autoimmune disease was associated with a 45% increase in risk for schizophrenia.  Nine autoimmune disorders had higher prevalence rates among patients with schizophrenia than among comparison subjects (crude incidence rate ratios ranging from 1.9 to 12.5), and 12 autoimmune diseases had higher prevalence rates among parents of schizophrenia patients than among parents of comparison subjects (adjusted incidence rate ratios ranging from 1.3 to 3.8).  Thyrotoxicosis, celiac disease, acquired hemolytic anemia, interstitial cystitis, and Sjogren's syndrome had higher prevalence rates among patients with schizophrenia than among comparison subjects and also among family members of schizophrenia patients than among family members of comparison subjects.  CONCLUSIONS:  Schizophrenia is associated with a larger range of autoimmune diseases than heretofore suspected.  Future research on comorbidity has the potential to advance understanding of pathogenesis of both psychiatric and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl-ee7fCyRFjjk2McQZ6XmfW6udTcc2eb6wosnDKr_77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287isFyrtA%253D%253D&md5=51e712a23f4b7af86f581eece98dfdb2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.163.3.521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.163.3.521%26sid%3Dliteratum%253Aachs%26aulast%3DEaton%26aufirst%3DW.%2BW.%26aulast%3DByrne%26aufirst%3DM.%26aulast%3DEwald%26aufirst%3DH.%26aulast%3DMors%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DAgerbo%26aufirst%3DE.%26aulast%3DMortensen%26aufirst%3DP.%2BB.%26atitle%3DAssociation%2520of%2520schizophrenia%2520and%2520autoimmune%2520diseases%253A%2520linkage%2520of%2520Danish%2520national%2520registers%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D163%26spage%3D521%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Moore, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingford-Hughes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, G.</span><span> </span><span class="NLM_article-title">Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=319-328&author=T.+H.+Mooreauthor=S.+Zammitauthor=A.+Lingford-Hughesauthor=T.+R.+Barnesauthor=P.+B.+Jonesauthor=M.+Burkeauthor=G.+Lewis&title=Cannabis+use+and+risk+of+psychotic+or+affective+mental+health+outcomes%3A+a+systematic+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DT.%2BH.%26aulast%3DZammit%26aufirst%3DS.%26aulast%3DLingford-Hughes%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DT.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BB.%26aulast%3DBurke%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DG.%26atitle%3DCannabis%2520use%2520and%2520risk%2520of%2520psychotic%2520or%2520affective%2520mental%2520health%2520outcomes%253A%2520a%2520systematic%2520review%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D319%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Huxley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffer, A.</span><span> </span><span class="NLM_article-title">Schizophrenia as a genetic morphism</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=1964&pages=220-221&author=J.+Huxleyauthor=E.+Mayreauthor=A.+Hoffer&title=Schizophrenia+as+a+genetic+morphism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuxley%26aufirst%3DJ.%26aulast%3DMayre%26aufirst%3DE.%26aulast%3DHoffer%26aufirst%3DA.%26atitle%3DSchizophrenia%2520as%2520a%2520genetic%2520morphism%26jtitle%3DNature%26date%3D1964%26volume%3D204%26spage%3D220%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Patsopoulos, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatsioni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, J. P.</span><span> </span><span class="NLM_article-title">Claims of sex differences: an empirical assessment in genetic associations</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">880</span><span class="NLM_x">–</span> <span class="NLM_lpage">893</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2007&pages=880-893&author=N.+A.+Patsopoulosauthor=A.+Tatsioniauthor=J.+P.+Ioannidis&title=Claims+of+sex+differences%3A+an+empirical+assessment+in+genetic+associations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatsopoulos%26aufirst%3DN.%2BA.%26aulast%3DTatsioni%26aufirst%3DA.%26aulast%3DIoannidis%26aufirst%3DJ.%2BP.%26atitle%3DClaims%2520of%2520sex%2520differences%253A%2520an%2520empirical%2520assessment%2520in%2520genetic%2520associations%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2007%26volume%3D298%26spage%3D880%26epage%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Newton, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duman, R. S.</span><span> </span><span class="NLM_article-title">Neurogenic actions of atypical antipsychotic drugs and therapeutic implications</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=715-725&author=S.+S.+Newtonauthor=R.+S.+Duman&title=Neurogenic+actions+of+atypical+antipsychotic+drugs+and+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewton%26aufirst%3DS.%2BS.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DNeurogenic%2520actions%2520of%2520atypical%2520antipsychotic%2520drugs%2520and%2520therapeutic%2520implications%26jtitle%3DCNS%2520Drugs%26date%3D2007%26volume%3D21%26spage%3D715%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Sullivan, P. F.</span><span> </span><span class="NLM_article-title">Spurious genetic associations</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1121</span><span class="NLM_x">–</span> <span class="NLM_lpage">1126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2006.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17346679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFOrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=1121-1126&author=P.+F.+Sullivan&title=Spurious+genetic+associations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Spurious Genetic Associations</span></div><div class="casAuthors">Sullivan, Patrick F.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1121-1126</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Genetic assocn. studies are widely used in biomedical research and yet only a minority of pos. findings stand the test of replication.  I explored the capacity of assocn. studies to produce false pos. findings and the impact of various definitions of replication.  Methods: Genetically realistic simulation data of a typical genotyping/analytic approach for 10 single nucleotide polymorphisms (SNPs) in COMT, a commonly studied candidate gene.  Results: Candidate gene studies like those simulated here are highly likely to produce one or more false pos. findings at α ≤ .05, the pattern of findings can often be "compelling" or "intriguing," and false pos. findings propagate and confuse the literature unless the definition of replication is precise.  Conclusions: Findings from single assocn. studies constitute "tentative knowledge" and must be interpreted with exceptional caution.  For the assocn. method to function as intended, every statistical comparison must be tracked and reported, and integrated replication is essential.  Precise replication (the same SNPs, phenotype, and direction of assocn.) is required in the interpretation of multiple assocn. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvZbUahrMbrVg90H21EOLACvtfcHk0lg4tO-3xqHSGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFOrur0%253D&md5=825ffc077fd4f45f4d2c83badb1dca69</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DP.%2BF.%26atitle%3DSpurious%2520genetic%2520associations%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D61%26spage%3D1121%26epage%3D1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Williams, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canter, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, J. L.</span><span> </span><span class="NLM_article-title">Problems with genome-wide association studies</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1840</span><span class="NLM_x">–</span> <span class="NLM_lpage">1842</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1840-1842&author=S.+M.+Williamsauthor=J.+A.+Canterauthor=D.+C.+Crawfordauthor=J.+H.+Mooreauthor=M.+D.+Ritchieauthor=J.+L.+Haines&title=Problems+with+genome-wide+association+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DS.%2BM.%26aulast%3DCanter%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DD.%2BC.%26aulast%3DMoore%26aufirst%3DJ.%2BH.%26aulast%3DRitchie%26aufirst%3DM.%2BD.%26aulast%3DHaines%26aufirst%3DJ.%2BL.%26atitle%3DProblems%2520with%2520genome-wide%2520association%2520studies%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1840%26epage%3D1842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">ENCODE Project Consortium</span><span> </span><span class="NLM_article-title">Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">447</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnature05874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17571346" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2007&pages=799-816&author=+ENCODE+Project+Consortium&title=Identification+and+analysis+of+functional+elements+in+1%25+of+the+human+genome+by+the+ENCODE+pilot+project"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature05874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05874%26sid%3Dliteratum%253Aachs%26aulast%3DENCODE%2BProject%2BConsortium%26atitle%3DIdentification%2520and%2520analysis%2520of%2520functional%2520elements%2520in%25201%2525%2520of%2520the%2520human%2520genome%2520by%2520the%2520ENCODE%2520pilot%2520project%26jtitle%3DNature%26date%3D2007%26volume%3D447%26spage%3D799%26epage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Kendler, K. S.</span><span> </span><span class="NLM_article-title">The genetics of schizophrenia: chromosomal deletions, attentional disturbances, and spectrum boundaries</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1549</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.160.9.1549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12944326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3svgsFWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2003&pages=1549-1553&author=K.+S.+Kendler&title=The+genetics+of+schizophrenia%3A+chromosomal+deletions%2C+attentional+disturbances%2C+and+spectrum+boundaries"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The genetics of schizophrenia: chromosomal deletions, attentional disturbances, and spectrum boundaries</span></div><div class="casAuthors">Kendler Kenneth S</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1549-53</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREF4-5Nt9cPkkUaC_kzhvyfW6udTcc2ebqbJjq0XV2crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgsFWmsg%253D%253D&md5=cb468e86aaaaeb4a87ec99cf39d64af6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.160.9.1549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.160.9.1549%26sid%3Dliteratum%253Aachs%26aulast%3DKendler%26aufirst%3DK.%2BS.%26atitle%3DThe%2520genetics%2520of%2520schizophrenia%253A%2520chromosomal%2520deletions%252C%2520attentional%2520disturbances%252C%2520and%2520spectrum%2520boundaries%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2003%26volume%3D160%26spage%3D1549%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaikh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, M. W.</span><span> </span><span class="NLM_article-title">Same brain, new decade. Challenges in CNS drug discovery in the postgenomic, proteomic era</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2001&pages=1-10&author=M.+Williamsauthor=J.+T.+Coyleauthor=S.+Shaikhauthor=M.+W.+Decker&title=Same+brain%2C+new+decade.+Challenges+in+CNS+drug+discovery+in+the+postgenomic%2C+proteomic+era"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26aulast%3DShaikh%26aufirst%3DS.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26atitle%3DSame%2520brain%252C%2520new%2520decade.%2520Challenges%2520in%2520CNS%2520drug%2520discovery%2520in%2520the%2520postgenomic%252C%2520proteomic%2520era%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2001%26volume%3D36%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Carlsson, A.</span><span> </span><span class="NLM_article-title">The Suppression of Psychotic Behavior. Part 3. Antipsychotic Agents: Elucidation of Their Mechanism of Action</span>. In  <span class="citation_source-book">Psycho- and Neuro-Pharmacology</span>; <span class="NLM_contrib-group">Parnham, M. J.; Bruinvels, J.</span>, Eds.; <span class="NLM_series">Discoveries in Pharmacology</span>; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>,<span class="NLM_x"> </span><span class="NLM_year">1983</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1</span>, pp  <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1983&pages=197-206&author=A.+Carlsson&title=Psycho-+and+Neuro-Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DA.%26atitle%3DThe%2520Suppression%2520of%2520Psychotic%2520Behavior.%2520Part%25203.%2520Antipsychotic%2520Agents%253A%2520Elucidation%2520of%2520Their%2520Mechanism%2520of%2520Action%26btitle%3DPsycho-%2520and%2520Neuro-Pharmacology%26aulast%3DParnham%26aufirst%3DM.%2BJ.%26pub%3DElsevier%26date%3D1983%26volume%3D1%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Creese, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burt, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=1976&pages=481-483&author=I.+Creeseauthor=D.+R.+Burtauthor=S.+H.+Snyder&title=Dopamine+receptor+binding+predicts+clinical+and+pharmacological+potencies+of+antischizophrenic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCreese%26aufirst%3DI.%26aulast%3DBurt%26aufirst%3DD.%2BR.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DDopamine%2520receptor%2520binding%2520predicts%2520clinical%2520and%2520pharmacological%2520potencies%2520of%2520antischizophrenic%2520drugs%26jtitle%3DScience%26date%3D1976%26volume%3D192%26spage%3D481%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Seeman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau-Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span> </span><span class="NLM_article-title">Antipsychotic drug doses and neuroleptic/dopamine receptors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">261</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2F261717a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=945467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaE28XlsFCisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1976&pages=717-719&author=P.+Seemanauthor=T.+Leeauthor=M.+Chau-Wongauthor=K.+Wong&title=Antipsychotic+drug+doses+and+neuroleptic%2Fdopamine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drug doses and neuroleptic/dopamine receptors</span></div><div class="casAuthors">Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">5562</span>),
    <span class="NLM_cas:pages">717-19</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Clin. effective antipsychotic drugs, e.g., chlorpromazine [50-53-3], blocked the stereospecific binding of 3H-labeled haloperidol [52-86-8] at concns. which correlated directly with their clin. potencies.  In addn., the antipsychotics blocked binding of dopamine [51-61-6], the IC50 values (concns. producing 50% blockade) for this effect correlated quant. with the clin. antipsychotic potencies.  The neuroleptic receptor assay can thus be used to screen potentially useful antipsychotic drugs.  The IC50 values for blockade of haloperidol binding were almost identical to the concns. of drugs in the patients plasma; e.g., 29 and 30nM, resp., for chlorpromazine.  These IC50 values may therefore be of therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXIuatc5GaFrVg90H21EOLACvtfcHk0lhlPdZVjYiPig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XlsFCisbk%253D&md5=2800e926625d767c976dbf4181fc6ad2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2F261717a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F261717a0%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DChau-Wong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%26atitle%3DAntipsychotic%2520drug%2520doses%2520and%2520neuroleptic%252Fdopamine%2520receptors%26jtitle%3DNature%26date%3D1976%26volume%3D261%26spage%3D717%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Richtand, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logue, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keck, P. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strakowski, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, R. K.</span><span> </span><span class="NLM_article-title">Dopamine and serotonin receptor binding and antipsychotic efficacy</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1726</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1715-1726&author=N.+M.+Richtandauthor=J.+A.+Welgeauthor=A.+D.+Logueauthor=P.+E.+Keckauthor=S.+M.+Strakowskiauthor=R.+K.+McNamara&title=Dopamine+and+serotonin+receptor+binding+and+antipsychotic+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichtand%26aufirst%3DN.%2BM.%26aulast%3DWelge%26aufirst%3DJ.%2BA.%26aulast%3DLogue%26aufirst%3DA.%2BD.%26aulast%3DKeck%26aufirst%3DP.%2BE.%26aulast%3DStrakowski%26aufirst%3DS.%2BM.%26aulast%3DMcNamara%26aufirst%3DR.%2BK.%26atitle%3DDopamine%2520and%2520serotonin%2520receptor%2520binding%2520and%2520antipsychotic%2520efficacy%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D1715%26epage%3D1726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0ljIdJim7dPQeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">The dopamine hypothesis of schizophrenia: focus on the dopamine receptor</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1251927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaE28XhsF2gtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=1976&pages=197-202&author=S.+H.+Snyder&title=The+dopamine+hypothesis+of+schizophrenia%3A+focus+on+the+dopamine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The dopamine hypothesis of schizophrenia:  focus on the dopamine receptor</span></div><div class="casAuthors">Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Psychiatry</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-202</span>CODEN:
                <span class="NLM_cas:coden">AJPSAO</span>;
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">A review with 31 refs. on the role of dopamine (I) [51-61-6] in schizophrenia and on the pharmacol. of drugs wich affect I receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIUxX7v_hIOrVg90H21EOLACvtfcHk0ljIdJim7dPQeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XhsF2gtbw%253D&md5=2222fa0ca087bd0655f3edfe06c5066b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DThe%2520dopamine%2520hypothesis%2520of%2520schizophrenia%253A%2520focus%2520on%2520the%2520dopamine%2520receptor%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1976%26volume%3D133%26spage%3D197%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Rogers, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. H.</span><span> </span><span class="NLM_article-title">Novel approaches for the treatment of schizophrenia</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2006&pages=1-21&author=B.+N.+Rogersauthor=C.+H.+Schmidt&title=Novel+approaches+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DSchmidt%26aufirst%3DC.%2BH.%26atitle%3DNovel%2520approaches%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2006%26volume%3D41%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span> </span><span class="NLM_article-title">Catching up on schizophrenia: natural history and neurobiology</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=325-334&author=D.+A.+Lewisauthor=J.+A.+Lieberman&title=Catching+up+on+schizophrenia%3A+natural+history+and+neurobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DCatching%2520up%2520on%2520schizophrenia%253A%2520natural%2520history%2520and%2520neurobiology%26jtitle%3DNeuron%26date%3D2000%26volume%3D28%26spage%3D325%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">The role of serotonin in antipsychotic drug action</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">106S</span><span class="NLM_x">–</span> <span class="NLM_lpage">115S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=106S-115S&author=H.+Y.+Meltzer&title=The+role+of+serotonin+in+antipsychotic+drug+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DThe%2520role%2520of%2520serotonin%2520in%2520antipsychotic%2520drug%2520action%26jtitle%3DNeuropsychopharmacology%26date%3D1999%26volume%3D21%26spage%3D106S%26epage%3D115S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Gaddum, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammeed, K. A.</span><span> </span><span class="NLM_article-title">Drugs which antagonize 5-hydroxytryptamine</span> <span class="citation_source-journal">Br. J. Pharmacol. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=13172437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaG2cXmsFGmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1954&pages=240-248&author=J.+H.+Gaddumauthor=K.+A.+Hammeed&title=Drugs+which+antagonize+5-hydroxytryptamine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs which antagonize 5-hydroxytryptamine</span></div><div class="casAuthors">Gaddum, J. H.; Hameed, Khan A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology and Chemotherapy</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">240-8</span>CODEN:
                <span class="NLM_cas:coden">BJPCAL</span>;
        ISSN:<span class="NLM_cas:issn">0366-0826</span>.
    </div><div class="casAbstract">With suitable concns. of mepyramine, piperoxan, and atropine it was possible to inhibit the effects of histamine, adrenaline, and acetylcholine without altering the effects of 5-hydroxytryptamine (I) on pharmacol. test prepns., supporting the view that I acts on a specific receptor.  One type of receptor to I was present in smooth muscle of the rat uterus and rabbit's perfused ear and was inhibited by low concns. of lysergic acid diethylamide (II).  The 2nd type, present in nervous tissue of guinea-pig ileum, was not inhibited by II.  The effect of I on ileum was inhibited by atropine or cocaine in the same way nicotine is inhibited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz0Fm5NQMiSrVg90H21EOLACvtfcHk0ljIdJim7dPQeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2cXmsFGmtQ%253D%253D&md5=ef08f60a262dfbeec028e743379f6de2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaddum%26aufirst%3DJ.%2BH.%26aulast%3DHammeed%26aufirst%3DK.%2BA.%26atitle%3DDrugs%2520which%2520antagonize%25205-hydroxytryptamine%26jtitle%3DBr.%2520J.%2520Pharmacol.%2520Chemother.%26date%3D1954%26volume%3D9%26spage%3D240%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Leysen, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemegeers, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tollenaere, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laduron, P. M.</span><span> </span><span class="NLM_article-title">Serotonergic component of neuroleptic receptors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1978&pages=168-171&author=J.+E.+Leysenauthor=C.+J.+Niemegeersauthor=J.+P.+Tollenaereauthor=P.+M.+Laduron&title=Serotonergic+component+of+neuroleptic+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeysen%26aufirst%3DJ.%2BE.%26aulast%3DNiemegeers%26aufirst%3DC.%2BJ.%26aulast%3DTollenaere%26aufirst%3DJ.%2BP.%26aulast%3DLaduron%26aufirst%3DP.%2BM.%26atitle%3DSerotonergic%2520component%2520of%2520neuroleptic%2520receptors%26jtitle%3DNature%26date%3D1978%26volume%3D272%26spage%3D168%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikich, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, J. E.</span><span> </span><span class="NLM_article-title">Serotonergic basis of antipsychotic drug effects in schizophrenia</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1099</span><span class="NLM_x">–</span> <span class="NLM_lpage">1117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0006-3223%2898%2900187-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9836014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFKqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1998&pages=1099-1117&author=J.+A.+Liebermanauthor=R.+B.+Mailmanauthor=G.+Duncanauthor=L.+Sikichauthor=M.+Chakosauthor=D.+E.+Nicholsauthor=J.+E.+Kraus&title=Serotonergic+basis+of+antipsychotic+drug+effects+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A decade of serotonin research: Role of serotonin in treatment of psychosis. Serotonergic basis of antipsychotic drug effects in schizophrenia</span></div><div class="casAuthors">Lieberman, Jeffrey A.; Mailman, Richard B.; Duncan, Gary; Sikich, Lin; Chakos, Miranda; Nichols, David E.; Kraus, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1099-1117</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review and discussion with many refs.  Recent attention has been focused on the involvement of serotonin (5-HT) in the pathophysiol. of schizophrenia and its role in mediating antipsychotic drug effects.  There are 2 reasons for the new emphasis: the tremendous success of the so-called atypical antipsychotic drugs (a common feature of which is their high affinity for specific 5-HT receptor subtypes); and the elucidation of a complex family of 5-HT receptors whose function and pharmacol. is only beginning to be understood.  This paper will review the evidence that pertains to the role of 5-HT in mediating antipsychotic drug effects.  The interaction of dopamine and 5-HT systems will be reviewed, and the mechanisms of action of atypical antipsychotic drugs will be evaluated in this context.  The impact of serotonin on neurodevelopment, and the involvement of serotonin in the psychotomimetic and psychotogenic properties of hallucinogens, is discussed.  Together, these facts are placed into the context of changes in serotonergic function in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNtFkClCY2_7Vg90H21EOLACvtfcHk0lg8oFqOEe5WYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFKqurk%253D&md5=2f37716bd875d593d1593fd93d4db466</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2898%2900187-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252898%252900187-5%26sid%3Dliteratum%253Aachs%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26aulast%3DDuncan%26aufirst%3DG.%26aulast%3DSikich%26aufirst%3DL.%26aulast%3DChakos%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKraus%26aufirst%3DJ.%2BE.%26atitle%3DSerotonergic%2520basis%2520of%2520antipsychotic%2520drug%2520effects%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D1998%26volume%3D44%26spage%3D1099%26epage%3D1117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Alex, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pehek, E. A.</span><span> </span><span class="NLM_article-title">Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pharmthera.2006.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17049611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2007&pages=296-320&author=K.+D.+Alexauthor=E.+A.+Pehek&title=Pharmacologic+mechanisms+of+serotonergic+regulation+of+dopamine+neurotransmission"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission</span></div><div class="casAuthors">Alex, K. D.; Pehek, E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-320</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The neurotransmitter dopamine (DA) has a long assocn. with normal functions such as motor control, cognition, and reward, as well as a no. of syndromes including drug abuse, schizophrenia, and Parkinson's disease.  Studies show that serotonin (5-HT) acts through several 5-HT receptors in the brain to modulate DA neurons in all 3 major dopaminergic pathways.  There are at least fourteen 5-HT receptor subtypes, many of which have been shown to play some role in mediating 5-HT/DA interactions.  Several subtypes, including the 5-HT1A, 5-HT1B, 5-HT2A, 5-HT3 and 5-HT4 receptors, act to facilitate DA release, while the 5-HT2C receptor mediates an inhibitory effect of 5-HT on DA release.  Most 5-HT receptor subtypes only modulate DA release when 5-HT and/or DA neurons are stimulated, but the 5-HT2C receptor, characterized by high levels of constitutive activity, inhibits tonic as well as evoked DA release.  This review summarizes the anatomical evidence for the presence of each 5-HT receptor subtype in dopaminergic regions of the brain and the neuropharmacol. evidence demonstrating regulation of each DA pathway.  The relevance of 5-HT receptor modulation of DA systems to the development of therapeutics used to treat schizophrenia, depression, and drug abuse is discussed.  Lastly, areas are highlighted in which future research would be maximally beneficial to the treatment of these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodrXef3tT1c7Vg90H21EOLACvtfcHk0lg8oFqOEe5WYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgt7Y%253D&md5=df3ad8cc3cad32d3a3f04e93d99ffc71</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2006.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2006.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DAlex%26aufirst%3DK.%2BD.%26aulast%3DPehek%26aufirst%3DE.%2BA.%26atitle%3DPharmacologic%2520mechanisms%2520of%2520serotonergic%2520regulation%2520of%2520dopamine%2520neurotransmission%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D113%26spage%3D296%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Millan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lejeune, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cussac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivet, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audinot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adhumeau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brocco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Despaux, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peglion, J. L.</span><span> </span><span class="NLM_article-title">S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10604930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslGntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2000&pages=38-53&author=M.+J.+Millanauthor=A.+Gobertauthor=A.+Newman-Tancrediauthor=F.+Lejeuneauthor=D.+Cussacauthor=J.+M.+Rivetauthor=V.+Audinotauthor=A.+Adhumeauauthor=M.+Broccoauthor=J.+P.+Nicolasauthor=J.+A.+Boutinauthor=N.+Despauxauthor=J.+L.+Peglion&title=S18327+%281-%5B2-%5B4-%286-fluoro-1%2C+2-benzisoxazol-3-yl%29piperid-1-yl%5Dethyl%5D3-phenyl+imidazolin-2-one%29%2C+a+novel%2C+potential+antipsychotic+displaying+marked+antagonist+properties+at+alpha%281%29-+and+alpha%282%29-adrenergic+receptors%3A+I.+Receptorial%2C+neurochemical%2C+and+electrophysiological+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at α1- and α2-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile</span></div><div class="casAuthors">Millan, Mark J.; Gobert, Alain; Newman-Tancredi, Adrian; Lejeune, Francoise; Cussac, Didier; Rivet, Jean-Michel; Audinot, Valerie; Adhumeau, Agnes; Brocco, Mauricette; Nicolas, Jean-Paul; Boutin, Jean A.; Despaux, Nicole; Peglion, Jean-Louis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-53</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">S18327 displayed modest affinity for human (h)D2 and hD3 receptors and high affinity for hD4 receptors.  At each, S18327 antagonized stimulation of [35S]guanosine-5'-O-(3-thio)triphosphate binding by dopamine (DA).  It also blocked activation of mitogen-activated protein kinase at hD3 receptors.  The affinity of S18327 at hD1 and hD5 sites was modest.  S18327 showed pronounced affinity for human serotonin (h5-HT)2A receptors and human α1A-adrenergic receptors (hARs), at which it antagonized increases in intracellular Ca2+ concn. levels elicited by 5-HT and norepinephrine (NE), resp.  S18327 presented significant affinity for hα2A-ARs and antagonized NE-induced[35S]guanosine-5'-O-(3-thio)triphosphate binding both at these sites and at α2-ARs in rat amygdala.  Reflecting blockade of α2-autoreceptors, S18327 enhanced firing of adrenergic neurons in locus ceruleus, accelerated hippocampal synthesis of NE, and increased dialyzate levels of NE in hippocampus, accumbens, and frontal cortex.  S18327 abolished inhibition of ventrotegmental area-localized dopaminergic neurons by apomorphine.  However, S18327 alone did not affect their activity and only modestly enhanced cerebral turnover of DA and dialyzate levels of DA in striatum and accumbens.  In contrast, S18327 markedly increased dialyzate levels of DA in frontal cortex, an action abolished by the selective α2-AR agonist, S18616.  Finally, S18327 reduced synthesis and dialyzate levels of 5-HT in striatum and suppressed firing of dorsal raphe-localized serotonergic neurons, an action attenuated by the α1-AR agonist cirazoline.  In conclusion, S18327 possesses marked antagonist activity at α1-ARs and D4 and 5-HT2A receptors and less potent antagonist activity at α2-ARs and D1 and D2 receptors.  Antagonism by S18327 of α2-ARs enhances adrenergic transmission and reinforces frontocortical dopaminergic transmission, whereas blockade of α1-ARs inhibits dorsal raphe-derived serotonergic pathways.  As further described in the accompanying paper, this profile of activity may contribute to the potential antipsychotic properties of S18327.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf_-9Df2xyXLVg90H21EOLACvtfcHk0lg8oFqOEe5WYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslGntg%253D%253D&md5=f80b12e01145760f2725e868fe8e634a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DLejeune%26aufirst%3DF.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DRivet%26aufirst%3DJ.%2BM.%26aulast%3DAudinot%26aufirst%3DV.%26aulast%3DAdhumeau%26aufirst%3DA.%26aulast%3DBrocco%26aufirst%3DM.%26aulast%3DNicolas%26aufirst%3DJ.%2BP.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26aulast%3DDespaux%26aufirst%3DN.%26aulast%3DPeglion%26aufirst%3DJ.%2BL.%26atitle%3DS18327%2520%25281-%255B2-%255B4-%25286-fluoro-1%252C%25202-benzisoxazol-3-yl%2529piperid-1-yl%255Dethyl%255D3-phenyl%2520imidazolin-2-one%2529%252C%2520a%2520novel%252C%2520potential%2520antipsychotic%2520displaying%2520marked%2520antagonist%2520properties%2520at%2520alpha%25281%2529-%2520and%2520alpha%25282%2529-adrenergic%2520receptors%253A%2520I.%2520Receptorial%252C%2520neurochemical%252C%2520and%2520electrophysiological%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D292%26spage%3D38%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Lange, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinders, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolboom, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coolen, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">5103</span><span class="NLM_x">–</span> <span class="NLM_lpage">5108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070516u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5103-5108&author=J.+H.+Langeauthor=J.+H.+Reindersauthor=J.+T.+Tolboomauthor=J.+C.+Glennonauthor=H.+K.+Coolenauthor=C.+G.+Kruse&title=Principal+component+analysis+differentiates+the+receptor+binding+profiles+of+three+antipsychotic+drug+candidates+from+current+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm070516u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070516u%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%26aulast%3DReinders%26aufirst%3DJ.%2BH.%26aulast%3DTolboom%26aufirst%3DJ.%2BT.%26aulast%3DGlennon%26aufirst%3DJ.%2BC.%26aulast%3DCoolen%26aufirst%3DH.%2BK.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DPrincipal%2520component%2520analysis%2520differentiates%2520the%2520receptor%2520binding%2520profiles%2520of%2520three%2520antipsychotic%2520drug%2520candidates%2520from%2520current%2520antipsychotic%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5103%26epage%3D5108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsubara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">The ratios of serotonin<sub>2</sub> and dopamine<sub>2</sub> affinities differentiate atypical and typical antipsychotic drugs</span> <span class="citation_source-journal">Psychopharmacol. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=2576319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFWmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1989&pages=390-392&author=H.+Y.+Meltzerauthor=S.+Matsubaraauthor=J.+C.+Lee&title=The+ratios+of+serotonin2+and+dopamine2+affinities+differentiate+atypical+and+typical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, Herbert Y.; Matsubara, Shigehiro; Lee, Jar Chi</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology Bulletin</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">390-2</span>CODEN:
                <span class="NLM_cas:coden">PSYBB9</span>;
        ISSN:<span class="NLM_cas:issn">0048-5764</span>.
    </div><div class="casAbstract">Atypical antipsychotic drugs such as clozapine, fluperlapine, and melperone produce weak catalepsy in rodents, and minimal extrapyramidal symptoms and serum prolactin elevations in humans, compared to typical antipsychotic drugs such as haloperidol.  The biol. basis for these differences has been attributed to relatively weak blockade at D2 dopamine (DA) receptors, various effects at D1 receptors, or potent serotonin2 (5-HT2) antagonism, although other possibilities exist.  To clarify the relative importance of actions of D1, D2, and 5-HT2 receptors for identification of candidate typical and atypical drugs, the authors detd. the neg. log of the Ki (pKi) value of 21 typical and 17 atypical antipsychotic drugs for the striatal D1 and D2 and frontal cortex 5-HT2 receptors of rodent brain.  Cluster anal. identified that the 5-HT2/D2 ratio was the most successful means of utilizing this data to classify typical and atypical antipsychotic drugs correctly.  A 92% accuracy was achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0Xqr2TSGcLVg90H21EOLACvtfcHk0lgyQT5v-AuJtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFWmu7Y%253D&md5=3f5c199f61ada18f6210532b086b0e13</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMatsubara%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520ratios%2520of%2520serotonin2%2520and%2520dopamine2%2520affinities%2520differentiate%2520atypical%2520and%2520typical%2520antipsychotic%2520drugs%26jtitle%3DPsychopharmacol.%2520Bull.%26date%3D1989%26volume%3D25%26spage%3D390%26epage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Hippius, H.</span><span> </span><span class="NLM_article-title">The history of clozapine</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">S5</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1989&pages=S3-S5&issue=Suppl.&author=H.+Hippius&title=The+history+of+clozapine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHippius%26aufirst%3DH.%26atitle%3DThe%2520history%2520of%2520clozapine%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D1989%26volume%3D99%26issue%3DSuppl%26spage%3DS3%26epage%3DS5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Wahlbeck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essali, M. A.</span><span> </span><span class="NLM_article-title">Clozapine versus typical neuroleptic medication for schizophrenia</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD000059</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=CD000059&author=K.+Wahlbeckauthor=M.+Cheineauthor=M.+A.+Essali&title=Clozapine+versus+typical+neuroleptic+medication+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWahlbeck%26aufirst%3DK.%26aulast%3DCheine%26aufirst%3DM.%26aulast%3DEssali%26aufirst%3DM.%2BA.%26atitle%3DClozapine%2520versus%2520typical%2520neuroleptic%2520medication%2520for%2520schizophrenia%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2000%26spage%3DCD000059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Bagnall, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginnelly, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glanville, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbody, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgerson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleijnen, J.</span><span> </span><span class="NLM_article-title">A systematic review of atypical antipsychotic drugs in schizophrenia</span> <span class="citation_source-journal">Health Technol. Assess.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12925268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3szovVCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=1-193&author=A.+M.+Bagnallauthor=L.+Jonesauthor=L.+Ginnellyauthor=R.+Lewisauthor=J.+Glanvilleauthor=S.+Gilbodyauthor=L.+Daviesauthor=D.+Torgersonauthor=J.+Kleijnen&title=A+systematic+review+of+atypical+antipsychotic+drugs+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic review of atypical antipsychotic drugs in schizophrenia</span></div><div class="casAuthors">Bagnall A-M; Jones L; Ginnelly L; Lewis R; Glanville J; Gilbody S; Davies L; Torgerson D; Kleijnen J</div><div class="citationInfo"><span class="NLM_cas:title">Health technology assessment (Winchester, England)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1-193</span>
        ISSN:<span class="NLM_cas:issn">1366-5278</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCnB-pOEKCvJQHPYJuLg8TfW6udTcc2eb9jNY2A36Lvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3szovVCmug%253D%253D&md5=e511ad4857d7459fafd895cf636ffddd</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBagnall%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DGinnelly%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DGlanville%26aufirst%3DJ.%26aulast%3DGilbody%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DTorgerson%26aufirst%3DD.%26aulast%3DKleijnen%26aufirst%3DJ.%26atitle%3DA%2520systematic%2520review%2520of%2520atypical%2520antipsychotic%2520drugs%2520in%2520schizophrenia%26jtitle%3DHealth%2520Technol.%2520Assess.%26date%3D2003%26volume%3D7%26spage%3D1%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Kane, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigfeld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H.</span><span> </span><span class="NLM_article-title">Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.1988.01800330013001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=3046553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaL1czisFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1988&pages=789-796&author=J.+Kaneauthor=G.+Honigfeldauthor=J.+Singerauthor=H.+Meltzer&title=Clozapine+for+the+treatment-resistant+schizophrenic.+A+double-blind+comparison+with+chlorpromazine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine</span></div><div class="casAuthors">Kane J; Honigfeld G; Singer J; Meltzer H</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">789-96</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">The treatment of schizophrenic patients who fail to respond to adequate trials of neuroleptics is a major challenge.  Clozapine, an atypical antipsychotic drug, has long been of scientific interest, but its clinical development has been delayed because of an associated risk of agranulocytosis.  This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refractory to neuroleptics.  DSM-III schizophrenics who had failed to respond to at least three different neuroleptics underwent a prospective, single-blind trial of haloperidol (mean dosage, 61 +/- 14 mg/d) for six weeks.  Patients whose condition remained unimproved were then randomly assigned, in a double-blind manner, to clozapine (up to 900 mg/d) or chlorpromazine (up to 1800 mg/d) for six weeks.  Two hundred sixty-eight patients were entered in the double-blind comparison.  When a priori criteria were used, 30% of the clozapine-treated patients were categorized as responders compared with 4% of chlorpromazine-treated patients.  Clozapine produced significantly greater improvement on the Brief Psychiatric Rating Scale, Clinical Global Impression Scale, and Nurses' Observation Scale for Inpatient Evaluation; this improvement included "negative" as well as positive symptom areas.  Although no cases of agranulocytosis occurred during this relatively brief study, in our view, the apparently increased comparative risk requires that the use of clozapine be limited to selected treatment-resistant patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl1_q6E__kp8KL0FlyGHDofW6udTcc2eb9jNY2A36Lvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1czisFyisQ%253D%253D&md5=f3cba6c60391f3f227e206ab985e4b8c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.1988.01800330013001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.1988.01800330013001%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DJ.%26aulast%3DHonigfeld%26aufirst%3DG.%26aulast%3DSinger%26aufirst%3DJ.%26aulast%3DMeltzer%26aufirst%3DH.%26atitle%3DClozapine%2520for%2520the%2520treatment-resistant%2520schizophrenic.%2520A%2520double-blind%2520comparison%2520with%2520chlorpromazine%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1988%26volume%3D45%26spage%3D789%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Barnes, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvedy, C. J.</span><span> </span><span class="NLM_article-title">Pharmacological treatment strategies in the non-responsive schizophrenic patient</span> <span class="citation_source-journal">Int. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F00004850-199605002-00011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8803663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK28zps1GnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1996&pages=67-71&issue=Suppl.+2&author=T.+R.+Barnesauthor=C.+J.+McEvedy&title=Pharmacological+treatment+strategies+in+the+non-responsive+schizophrenic+patient"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment strategies in the non-responsive schizophrenic patient</span></div><div class="casAuthors">Barnes T R; McEvedy C J</div><div class="citationInfo"><span class="NLM_cas:title">International clinical psychopharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">11 Suppl 2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-71</span>
        ISSN:<span class="NLM_cas:issn">0268-1315</span>.
    </div><div class="casAbstract">The care of people with schizophrenia that has failed to respond to conventional antipsychotic medication remains a formidable challenge.  However, the introduction of clozapine heralded a new optimism in this area, and prompted an increase in research interest in the pharmacotherapeutic options for such patients.  This brief review covers some of the more recent studies with clozapine that are relevant to the use of the drug in clinical practice, and also summarises the potential indications, benefits and limitations of various adjuncts to antipsychotic drug treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8rigev3TehtbHMBt0mMIXfW6udTcc2eYU8z7prq2K1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zps1GnsQ%253D%253D&md5=3f206d5a797032a4e81080e9104f4ca0</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1097%2F00004850-199605002-00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004850-199605002-00011%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DT.%2BR.%26aulast%3DMcEvedy%26aufirst%3DC.%2BJ.%26atitle%3DPharmacological%2520treatment%2520strategies%2520in%2520the%2520non-responsive%2520schizophrenic%2520patient%26jtitle%3DInt.%2520Clin.%2520Psychopharmacol.%26date%3D1996%26volume%3D11%26issue%3DSuppl.%25202%26spage%3D67%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeman, P.</span><span> </span><span class="NLM_article-title">Does fast dissociation from the dopamine D<sub>2</sub> receptor explain the action of atypical antipsychotics? A new hypothesis</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.158.3.360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11229973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3M7pslSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=360-369&author=S.+Kapurauthor=P.+Seeman&title=Does+fast+dissociation+from+the+dopamine+D2+receptor+explain+the+action+of+atypical+antipsychotics%3F+A+new+hypothesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis</span></div><div class="casAuthors">Kapur S; Seeman P</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">360-9</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Although atypical antipsychotics are becoming the treatment of choice for schizophrenia, what makes an antipsychotic "atypical" is not clear.  This article provides a new hypothesis about the mechanism of action of atypical antipsychotics.  METHOD:  Published data regarding the molecular, animal model, neuroimaging, and clinical aspects of typical and atypical antipsychotics were reviewed to develop this hypothesis.  Particular attention was paid to data regarding the role of the serotonin 5-HT(2) and dopamine D(4) receptors in atypicality.  RESULTS:  Neuroimaging data show that optimal dopamine D(2) occupancy is sufficient to produce the atypical antipsychotic effect.  Freedom from motor side effects results from low D(2) occupancy, not from high 5-HT(2) occupancy.  If D(2) occupancy is excessive, atypicality is lost even in the presence of high 5-HT(2) occupancy.  Animal data show that a rapid dissociation from the D(2) receptor at a molecular level produces the atypical antipsychotic effect.  In vitro data show that the single most powerful predictor of atypicality for the current generation of atypical antipsychotics is fast dissociation from the D(2) receptor, not its high affinity at 5-HT(2), D(4), or another receptor.  CONCLUSIONS:  The authors propose that fast dissociation from the D(2) receptor makes an antipsychotic more accommodating of physiological dopamine transmission, permitting an antipsychotic effect without motor side effects, prolactin elevation, or secondary negative symptoms.  In contrast to the multireceptor hypotheses, the authors predict that the atypical antipsychotic effect can be produced by appropriate modulation of the D(2) receptor alone; the blockade of other receptors is neither necessary nor sufficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1OTyBcviHdd0Q2ypr7jHkfW6udTcc2eYU8z7prq2K1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7pslSltg%253D%253D&md5=dae2a684b208e0fc09688835b0975c00</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.3.360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.3.360%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DDoes%2520fast%2520dissociation%2520from%2520the%2520dopamine%2520D2%2520receptor%2520explain%2520the%2520action%2520of%2520atypical%2520antipsychotics%253F%2520A%2520new%2520hypothesis%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D360%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Ichikawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Laughlin, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=325-339&author=J.+Ichikawaauthor=J.+Daiauthor=I.+A.+O%E2%80%99Laughlinauthor=W.+L.+Fowlerauthor=H.+Y.+Meltzer&title=Atypical%2C+but+not+typical%2C+antipsychotic+drugs+increase+cortical+acetylcholine+release+without+an+effect+in+the+nucleus+accumbens+or+striatum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIchikawa%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Laughlin%26aufirst%3DI.%2BA.%26aulast%3DFowler%26aufirst%3DW.%2BL.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DAtypical%252C%2520but%2520not%2520typical%252C%2520antipsychotic%2520drugs%2520increase%2520cortical%2520acetylcholine%2520release%2520without%2520an%2520effect%2520in%2520the%2520nucleus%2520accumbens%2520or%2520striatum%26jtitle%3DNeuropsychopharmacology%26date%3D2002%26volume%3D26%26spage%3D325%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Kuroki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, J.</span><span> </span><span class="NLM_article-title">Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">774</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9918588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1MXpvFOmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=1999&pages=774-781&author=T.+Kurokiauthor=H.+Y.+Meltzerauthor=J.+Ichikawa&title=Effects+of+antipsychotic+drugs+on+extracellular+dopamine+levels+in+rat+medial+prefrontal+cortex+and+nucleus+accumbens"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens</span></div><div class="casAuthors">Kuroki, Toshihide; Meltzer, Herbert Y.; Ichikawa, Junji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">774-781</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present study was designed to compare the effects of typical and atypical antipsychotic drugs on extracellular dopamine (DA) levels in the medial prefrontal cortex (mPFC) and the nucleus accumbens (NAC), using in vivo microdialysis with dual probe implantation in awake, freely moving rats.  Amperozide (2 and 10 mg/kg), clozapine (5 and 20 mg/kg), and olanzapine (10 mg/kg), all of which are atypical antipsychotics, produced greater increases in extracellular DA levels in the mPFC than in the NAC.  Olanzapine (1 mg/kg), risperidone (0.1 and 1 mg/kg), also an atypical antipsychotic, and S-(-)-sulpiride (25 mg/kg), a typical antipsychotic, produced comparable increases in extra-cellular DA levels in the mPFC and the NAC.  S-(-)-sulpiride (10 mg/kg) and haloperidol (0.1 and 1 mg/kg), another typical antipsychotic, significantly increased extracellular DA levels in the NAC but not in the mPFC.  The effects of the six antipsychotic drugs to increase extracellular DA levels in the mPFC relative to those in the NAC was pos. correlated with the difference between their pKi values for serotonin (5-hydroxytryptamine, 5-HT2A) and DA-D2 receptors and was inversely correlated to their pKi values for D2 or D3 receptors, but was not for 5-HT2A receptors alone.  These results are consistent with the hypothesis that the ability of antipsychotic drugs to produce a greater increase in prefrontal compared with NAC extracellular DA levels may be related, in part, to weak D2 and D3 receptor affinity relative to 5-HT2A receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAWlyAnjsaprVg90H21EOLACvtfcHk0lhH1YoOHDkXBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXpvFOmuw%253D%253D&md5=aca5e902a20d6edeefaacf3419c3d07d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuroki%26aufirst%3DT.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DIchikawa%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520antipsychotic%2520drugs%2520on%2520extracellular%2520dopamine%2520levels%2520in%2520rat%2520medial%2520prefrontal%2520cortex%2520and%2520nucleus%2520accumbens%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D288%26spage%3D774%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Moghaddam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunney, B. S.</span><span> </span><span class="NLM_article-title">Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1755</span><span class="NLM_x">–</span> <span class="NLM_lpage">1760</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1111%2Fj.1471-4159.1990.tb01230.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1969939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK3cXktVSntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1990&pages=1755-1760&author=B.+Moghaddamauthor=B.+S.+Bunney&title=Acute+effects+of+typical+and+atypical+antipsychotic+drugs+on+the+release+of+dopamine+from+prefrontal+cortex%2C+nucleus+accumbens%2C+and+striatum+of+the+rat%3A+an+in+vivo+microdialysis+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat:  an in vivo microdialysis study</span></div><div class="casAuthors">Moghaddam, Bita; Bunney, Benjamin S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1755-60</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">In vivo microdialysis has been used to study the acute effects of antipsychotic drugs on the extracellular level of dopamine from the nucleus accumbens, striatum, and prefrontal cortex of the rat.  (-)-Sulpiride (20, 50, and 100 mg/kg i.v.) and haloperidol (0.1 and 0.5 mg/kg i.v.) enhanced the outflow of dopamine in the striatum and nucleus accumbens.  In the medial prefrontal cortex, (-)-sulpiride at all doses tested did not affect the extracellular level of dopamine.  The effect of haloperidol was also attenuated in the medial prefrontal cortex; 0.1 mg/kg did not increase the outflow of dopamine and the effect of 0.5 mg/kg haloperidol was of shorter duration in the prefrontal cortex than that obsd. in striatum and nucleus accumbens.  The atypical antipsychotic drug clozapine (5 and 10 mg/kg) increased the extracellular concn. of dopamine in all three regions.  In contrast to the effects of sulpiride and haloperidol, that of clozapine in the medial prefrontal cortex was profound.  These data suggest that different classes of antipsychotic drugs may have distinct effects on the release of dopamine from the nigrostriatal, mesolimbic, and mesocortical terminals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXh61lbtJPCrVg90H21EOLACvtfcHk0lhJzkg5HVxsfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktVSntr0%253D&md5=d8485270d0b53822ab5aaa5fb960ee3b</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1990.tb01230.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1990.tb01230.x%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DB.%26aulast%3DBunney%26aufirst%3DB.%2BS.%26atitle%3DAcute%2520effects%2520of%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%2520on%2520the%2520release%2520of%2520dopamine%2520from%2520prefrontal%2520cortex%252C%2520nucleus%2520accumbens%252C%2520and%2520striatum%2520of%2520the%2520rat%253A%2520an%2520in%2520vivo%2520microdialysis%2520study%26jtitle%3DJ.%2520Neurochem.%26date%3D1990%26volume%3D54%26spage%3D1755%26epage%3D1760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeman, P.</span><span> </span><span class="NLM_article-title">Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action</span> <span class="citation_source-journal">J. Psychiatry Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10740989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3c3gsFWlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2000&pages=161-166&author=S.+Kapurauthor=P.+Seeman&title=Antipsychotic+agents+differ+in+how+fast+they+come+off+the+dopamine+D2+receptors.+Implications+for+atypical+antipsychotic+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action</span></div><div class="casAuthors">Kapur S; Seeman P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-6</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">RATIONALE AND OBJECTIVE:  While the blockade of dopamine D2 receptors are necessary for antipsychotic action, antipsychotic agents differ nearly a thousand-fold in their affinity for the D2 receptor.  This affinity is determined by the rate at which the antipsychotic agent binds to (kon) and the rate at which it dissociates from (koff) the D2 receptors.  The objective of this study was to determine the relationship between kon, koff and the affinity (Ki) of antipsychotic agents for the D2 receptors, with particular reference to typical and atypical antipsychotic agents.  DESIGN:  The koff of several typical as well as atypical antipsychotic agents (nemonapride, spiperone, haloperidol, chlorpromazine, raclopride, olanzapine, sertindole, clozapine and quetiapine) was measured in vitro using the 3H-radiolabelled analogues of these drugs.  The affinity of these drugs for the D2 receptor was determined by competition with 3H-raclopride in vitro.  The kon was derived from values of affinity and ++koff.  MAIN OUTCOME MEASURES:  kon, koff, and the Ki of antipsychotic drugs.  RESULTS:  The range of affinity values was similar to that conventionally accepted (0.025-155 nmol/L).  The koff values varied a thousand-fold from 0.002 to 3.013 min-1, with relatively little variation in kon.  The rate at which antipsychotic agents come off the receptor (koff) accounted for 99% of the variation in their affinity for the D2 receptor; differences in kon did not account for differences in affinity.  CONCLUSIONS:  The differences in the affinity of antipsychotic agents are entirely determined by how fast they come off the D2 receptor.  These differences in koff may lead to functionally different kinds of dopamine blockade.  Drugs with a higher koff will be faster in blocking receptors, and once blocked, will provide more access to surges in dopamine transmission.  Since atypical drugs show a lower affinity and a faster dissociation, a higher koff for the D2 receptor is proposed as a mechanism for "atypical" antipsychotic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiFVfZJOQ7_1UIs6wFK5xJfW6udTcc2eaXB1lMPOVU17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3gsFWlsA%253D%253D&md5=bde1272de3b90ba1fd77b61805c3a39d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DAntipsychotic%2520agents%2520differ%2520in%2520how%2520fast%2520they%2520come%2520off%2520the%2520dopamine%2520D2%2520receptors.%2520Implications%2520for%2520atypical%2520antipsychotic%2520action%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2000%26volume%3D25%26spage%3D161%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Kessler, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansari, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2283</span><span class="NLM_x">–</span> <span class="NLM_lpage">2289</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=2283-2289&author=R.+M.+Kesslerauthor=M.+S.+Ansariauthor=P.+Riccardiauthor=R.+Liauthor=K.+Jayathilakeauthor=B.+Dawantauthor=H.+Y.+Meltzer&title=Occupancy+of+striatal+and+extrastriatal+dopamine+D2%2FD3+receptors+by+olanzapine+and+haloperidol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DR.%2BM.%26aulast%3DAnsari%26aufirst%3DM.%2BS.%26aulast%3DRiccardi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DDawant%26aufirst%3DB.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DOccupancy%2520of%2520striatal%2520and%2520extrastriatal%2520dopamine%2520D2%252FD3%2520receptors%2520by%2520olanzapine%2520and%2520haloperidol%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D2283%26epage%3D2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Agid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginovart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitcu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zipursky, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, S.</span><span> </span><span class="NLM_article-title">Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response—a double-blind PET study in schizophrenia</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1209</span><span class="NLM_x">–</span> <span class="NLM_lpage">1215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1209-1215&author=O.+Agidauthor=D.+Mamoauthor=N.+Ginovartauthor=I.+Vitcuauthor=A.+A.+Wilsonauthor=R.+B.+Zipurskyauthor=S.+Kapur&title=Striatal+vs+extrastriatal+dopamine+D2+receptors+in+antipsychotic+response%E2%80%94a+double-blind+PET+study+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAgid%26aufirst%3DO.%26aulast%3DMamo%26aufirst%3DD.%26aulast%3DGinovart%26aufirst%3DN.%26aulast%3DVitcu%26aufirst%3DI.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DZipursky%26aufirst%3DR.%2BB.%26aulast%3DKapur%26aufirst%3DS.%26atitle%3DStriatal%2520vs%2520extrastriatal%2520dopamine%2520D2%2520receptors%2520in%2520antipsychotic%2520response%25E2%2580%2594a%2520double-blind%2520PET%2520study%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D1209%26epage%3D1215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Kessler, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansari, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1991</span><span class="NLM_x">–</span> <span class="NLM_lpage">2001</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=1991-2001&author=R.+M.+Kesslerauthor=M.+S.+Ansariauthor=P.+Riccardiauthor=R.+Liauthor=K.+Jayathilakeauthor=B.+Dawantauthor=H.+Y.+Meltzer&title=Occupancy+of+striatal+and+extrastriatal+dopamine+D2+receptors+by+clozapine+and+quetiapine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DR.%2BM.%26aulast%3DAnsari%26aufirst%3DM.%2BS.%26aulast%3DRiccardi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DDawant%26aufirst%3DB.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DOccupancy%2520of%2520striatal%2520and%2520extrastriatal%2520dopamine%2520D2%2520receptors%2520by%2520clozapine%2520and%2520quetiapine%26jtitle%3DNeuropsychopharmacology%26date%3D2006%26volume%3D31%26spage%3D1991%26epage%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Poyurovsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epshtein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneidman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizman, A.</span><span> </span><span class="NLM_article-title">Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F00004714-200306000-00011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12826992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltFKjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=305-308&author=M.+Poyurovskyauthor=S.+Epshteinauthor=C.+Fuchsauthor=M.+Schneidmanauthor=R.+Weizmanauthor=A.+Weizman&title=Efficacy+of+low-dose+mirtazapine+in+neuroleptic-induced+akathisia%3A+a+double-blind+randomized+placebo-controlled+pilot+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Low-Dose Mirtazapine in Neuroleptic-Induced Akathisia: A Double-Blind Randomized Placebo-Controlled Pilot Study</span></div><div class="casAuthors">Poyurovsky, Michael; Epshtein, Svetlana; Fuchs, Camil; Schneidman, Michael; Weizman, Ronit; Weizman, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-308</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The nonselective serotonin (5-HT)-2A antagonists ritanserin, mianserin, and cyproheptadine were found efficacious in neuroleptic-induced akathisia (NIA).  Mirtazapine is structurally and pharmacol. similar to mianserin, and the authors sought to det. its anti-NIA activity.  Twenty-six neuroleptic-treated schizophrenic patients with DSM-IV diagnosis of NIA received add-on mirtazapine (15 mg/day) or placebo for 5 days in a double-blind design.  Patients were assessed at baseline and days 3 and 5 with the Barnes Akathisia Scale (BAS), Pos. and Neg. Symptom Scale, Hamilton Rating Scale for Depression, and Simpson-Angus Scale for parkinsonism.  Anal. of covariance with repeated measurements revealed significant group × time effects in favor of the mirtazapine group in both completers (n = 10 in each group) and intent-to-treat anal. (n = 13 in each group) for the BAS global subscale (F [1, 17] = 14.87, p = 0.001, and F [1, 23] = 13.24, p = 0.01, resp.) and objective subscale (F [1, 17] = 8.25, p = 0.011, and F [1, 23] = 7.35, p = 0.012, resp.) and borderline significant superiority for the BAS subjective subscale (F [1, 17] = 4.39, p = 0.051, and F [1, 23] = 4.12, p = 0.054, resp.) and distress subscale (F [1, 17] = 4.21, p = 0.056, and F [1, 23] = 3.80, p = 0.064, resp.).  Significantly more mirtazapine-than placebo-treated patients (53.8% [7/13] vs. 7.7% [1/13], resp.; χ2=8.3, p = 0.004) met operational response criterion, a redn. of at least two points on the BAS global subscale.  Mirtazapine treatment was assocd. with modest improvement of psychotic and parkinsonian symptoms.  Mild sedation was the only side effect.  Our study demonstrated that mirtazapine (15 mg/day) is an efficacious and well-tolerated therapeutic option in NIA.  Marked 5HT2A/2C antagonistic activity of mirtazapine apparently accounts for its anti-NIA activity.  The role of mirtazapine in the treatment of akathisia induced by atypical antipsychotic agents merits further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpepcVf6AevgbVg90H21EOLACvtfcHk0lhFgjV2QZq3xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltFKjtLk%253D&md5=ad345d3ee27e50384b179f1821fbf0a0</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1097%2F00004714-200306000-00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004714-200306000-00011%26sid%3Dliteratum%253Aachs%26aulast%3DPoyurovsky%26aufirst%3DM.%26aulast%3DEpshtein%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DC.%26aulast%3DSchneidman%26aufirst%3DM.%26aulast%3DWeizman%26aufirst%3DR.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DEfficacy%2520of%2520low-dose%2520mirtazapine%2520in%2520neuroleptic-induced%2520akathisia%253A%2520a%2520double-blind%2520randomized%2520placebo-controlled%2520pilot%2520study%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2003%26volume%3D23%26spage%3D305%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Sur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallorga, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascarella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandish, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolnick, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title"><i>N</i>-Desmethylclozapine, an allosteric agonist at muscarinic<sub>1</sub> receptor, potentiates <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">13674</span><span class="NLM_x">–</span> <span class="NLM_lpage">13679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=13674-13679&author=C.+Surauthor=P.+J.+Mallorgaauthor=M.+Wittmannauthor=M.+A.+Jacobsonauthor=D.+Pascarellaauthor=J.+B.+Williamsauthor=P.+E.+Brandishauthor=D.+J.+Pettiboneauthor=E.+M.+Scolnickauthor=P.+J.+Conn&title=N-Desmethylclozapine%2C+an+allosteric+agonist+at+muscarinic1+receptor%2C+potentiates+N-methyl-d-aspartate+receptor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMallorga%26aufirst%3DP.%2BJ.%26aulast%3DWittmann%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DPascarella%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BB.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DScolnick%26aufirst%3DE.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DN-Desmethylclozapine%252C%2520an%2520allosteric%2520agonist%2520at%2520muscarinic1%2520receptor%252C%2520potentiates%2520N-methyl-d-aspartate%2520receptor%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D13674%26epage%3D13679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Lameh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonhaus, D. W.</span><span> </span><span class="NLM_article-title">Pharmacology of <i>N</i>-desmethylclozapine</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pharmthera.2007.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17583355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXns1yrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2007&pages=223-231&author=J.+Lamehauthor=E.+S.+Bursteinauthor=E.+Taylorauthor=D.+M.+Weinerauthor=K.+E.+Vanoverauthor=D.+W.+Bonhaus&title=Pharmacology+of+N-desmethylclozapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of N-desmethylclozapine</span></div><div class="casAuthors">Lameh, Jelveh; Burstein, Ethan S.; Taylor, Eve; Weiner, David M.; Vanover, Kimberly E.; Bonhaus, Douglas W.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-231</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Currently available treatments for schizophrenia have limited efficacy and are generally poorly tolerated.  However, among these antipsychotic agents, clozapine stands apart in having generally superior motoric tolerability and efficacy.  One intriguing possibility, based on clin. correlations, receptor activity profiles and studies with animal models predictive of antipsychotic or cognitive action is that the activity of N-desmethylclozapine (NDMC), a major metabolite of clozapine, may, at least in part, underlie the unique efficacy of clozapine.  In this review we compare the pharmacol. properties of NDMC to those of clozapine and consider how they may contribute to the overall clin. properties of clozapine.  We also consider whether NDMC, in its own right, might be a superior antipsychotic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBphY-h1xi2LVg90H21EOLACvtfcHk0lhFgjV2QZq3xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXns1yrsro%253D&md5=6606ac8c9da24c82e08700976934d79b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2007.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2007.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DLameh%26aufirst%3DJ.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DBonhaus%26aufirst%3DD.%2BW.%26atitle%3DPharmacology%2520of%2520N-desmethylclozapine%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D115%26spage%3D223%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Natesan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckless, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nobrega, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, S.</span><span> </span><span class="NLM_article-title">Evaluation of <i>N</i>-desmethylclozapine as a potential antipsychotic═preclinical studies</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1540</span><span class="NLM_x">–</span> <span class="NLM_lpage">1549</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1540-1549&author=S.+Natesanauthor=G.+E.+Recklessauthor=K.+B.+Barlowauthor=J.+N.+Nobregaauthor=S.+Kapur&title=Evaluation+of+N-desmethylclozapine+as+a+potential+antipsychotic%E2%95%90preclinical+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNatesan%26aufirst%3DS.%26aulast%3DReckless%26aufirst%3DG.%2BE.%26aulast%3DBarlow%26aufirst%3DK.%2BB.%26aulast%3DNobrega%26aufirst%3DJ.%2BN.%26aulast%3DKapur%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520N-desmethylclozapine%2520as%2520a%2520potential%2520antipsychotic%25E2%2595%2590preclinical%2520studies%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D1540%26epage%3D1549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Coyle, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D.</span><span> </span><span class="NLM_article-title">Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1003</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1196%2Fannals.1300.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14684455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlGqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1003&publication_year=2003&pages=318-327&author=J.+T.+Coyleauthor=G.+Tsaiauthor=D.+Goff&title=Converging+evidence+of+NMDA+receptor+hypofunction+in+the+pathophysiology+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia</span></div><div class="casAuthors">Coyle, Joseph T.; Tsai, Guochuan; Goff, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1003</span>
        (<span class="NLM_cas:issue">Glutamate and Disorders of Cognition and Motivation</span>),
    <span class="NLM_cas:pages">318-327</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Numerous clin. studies demonstrate that subanesthetic doses of dissociative anesthetics, which are noncompetitive antagonists at the NMDA receptor, replicate in normal subjects the cognitive impairments, neg. symptoms, and brain functional abnormalities of schizophrenia.  Postmortem and genetic studies have identified several abnormalities assocd. with schizophrenia that would interfere with the activation of the glycine modulatory site on the NMDA receptor.  Placebo-controlled clin. trials with agents that directly or indirectly activate the glycine modulatory site consistently reduce neg. symptoms and frequently improve cognition in patients with chronic schizophrenia who are receiving concurrent typical antipsychotics.  Thus, there is convincing evidence that hypofunction of a subset of NMDA receptors may contribute to the symptomatic features of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQixZ_xxPHLVg90H21EOLACvtfcHk0lhFgjV2QZq3xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlGqtQ%253D%253D&md5=0688464460facbf01a7b2ecd701bc87d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1196%2Fannals.1300.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1196%252Fannals.1300.020%26sid%3Dliteratum%253Aachs%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26aulast%3DTsai%26aufirst%3DG.%26aulast%3DGoff%26aufirst%3DD.%26atitle%3DConverging%2520evidence%2520of%2520NMDA%2520receptor%2520hypofunction%2520in%2520the%2520pathophysiology%2520of%2520schizophrenia%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2003%26volume%3D1003%26spage%3D318%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Collier, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span> </span><span class="NLM_article-title">The genetics of schizophrenia: glutamate not dopamine</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">480</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ejphar.2003.08.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14623361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGmsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2003&pages=177-184&author=D.+A.+Collierauthor=T.+Li&title=The+genetics+of+schizophrenia%3A+glutamate+not+dopamine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The genetics of schizophrenia: glutamate not dopamine?</span></div><div class="casAuthors">Collier, David A.; Li, Tao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">177-184</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The major targets of current drugs used in mental health, such as neurotransmitter receptors and transporters, are based on serendipitous findings from several decades ago, and there is currently a severe drought of new drug targets.  There is a pressing need for novel drugs, and much hope has been placed on the use of mol. genetics to help define them.  However, despite evidence for a genetic basis to schizophrenia stretching back for over a century, and a heritability of about 80%, the identification of susceptibility genes has been an uphill struggle.  Candidate gene studies, which have generally focussed on obvious candidates from the dopamine and serotonin systems, as well as genes involved in brain development, have not generally been successful, although meta-anal. indicates that the dopamine D3 receptor gene (DRD3) and the serotonin receptor gene type 2A (HTR2A) may have a very small influence on risk.  Linkage anal. has provided robust evidence of genetic loci, for example, on chromosomes 8p, 13q and 22q, and also implies shared genetic etiol. with bipolar disorder.  The identification of these loci together with advances in genetic technol., esp. the characterization of polymorphisms, the understanding of haplotypes and the development of statistical methods, has lead to the identification of several plausible susceptibility genes, including neuregulin 1, proline dehydrogenase and dysbindin.  Interestingly, these genes point more towards a role for the glutamate pathway rather than the dopamine pathway in schizophrenia.  We have attempted to replicate some of these findings in schizophrenic patients from SW China, and we find significant assocn. with a novel neuregulin 1 haplotype, with proline dehydrogenase polymorphisms, but not with catechol-O-methyltransferase (COMT).  The replication of neuregulin 1 assocn. on chromosome 8p by several investigators is the most convincing to date, and the presence of a syndrome similar to dementia praecox of 8p linked families, and the lack of linkage of bipolar disorder to this region is a testament to the ideas of Kraepelin more than 100 yr ago.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGtod_Hv_OrVg90H21EOLACvtfcHk0lga5PzAlxAlJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGmsrs%253D&md5=8f544e0ddf190c4203ef54b0a54c6780</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2003.08.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2003.08.105%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DT.%26atitle%3DThe%2520genetics%2520of%2520schizophrenia%253A%2520glutamate%2520not%2520dopamine%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D480%26spage%3D177%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Millan, M. J.</span><span> </span><span class="NLM_article-title"><i>N</i>-Methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-005-2199-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15761697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtV2iur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2005&pages=30-53&author=M.+J.+Millan&title=N-Methyl-d-aspartate+receptors+as+a+target+for+improved+antipsychotic+agents%3A+novel+insights+and+clinical+perspectives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-53</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Activation of "co-agonist" N-methyl-d-aspartate (NMDA) and GlycineB sites is mandatory for the operation of NMDA receptors, which play an important role in the control of mood, cognition, and motor function.  This article outlines the complex regulation of activity at GlycineB/NMDA receptors by multiple classes of endogenous ligand.  It also summarizes the evidence that a hypoactivity of GlycineB/NMDA receptors contributes to the pathogenesis of psychotic states, and that drugs which enhance activity at these sites may possess antipsychotic properties.  Polymorphisms in several genes known to interact with NMDA receptors are related to an altered risk for schizophrenia, and psychotic patients display changes in levels of mRNA encoding NMDA receptors, including the NR1 subunit on which GlycineB sites are located.  Schizophrenia is also assocd. with an overall decrease in activity of endogenous agonists at GlycineB/NMDA sites, whereas levels of endogenous antagonists are elevated.  NMDA receptor "open channel blockers," such as phencyclidine, are psychotomimetic in man and in rodents, and antipsychotic agents attenuate certain of their effects.  Moreover, mice with genetically invalidated GlycineB/NMDA receptors reveal similar changes in behavior.  Finally, in initial clin. studies, GlycineB agonists and inhibitors of Gly reuptake were found to potentiate the ability of "conventional" antipsychotics to improve neg. and, albeit modestly, cognitive and pos. symptoms.  In contrast, therapeutic effects of clozapine are not reinforced, likely since clozapine itself enhances activity at NMDA receptors.  Reduced activity at NMDA receptors is implicated in the etiol. of schizophrenia.  Correspondingly, drugs that (directly or indirectly) increase activity at GlycineB sites may be of use as adjuncts to other classes of antipsychotic agent.  However, there is an urgent need for broader clin. evaluation of this possibility, and, to date, there is no evidence that stimulation of GlycineB sites alone improves psychotic states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrik4YrYY-zS7Vg90H21EOLACvtfcHk0lga5PzAlxAlJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtV2iur0%253D&md5=08bfcddb54b062d8ec9c0f1294984608</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-2199-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-2199-1%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DN-Methyl-d-aspartate%2520receptors%2520as%2520a%2520target%2520for%2520improved%2520antipsychotic%2520agents%253A%2520novel%2520insights%2520and%2520clinical%2520perspectives%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2005%26volume%3D179%26spage%3D30%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Heresco-Levy, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitt, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vass, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catinari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ermilov, M.</span><span> </span><span class="NLM_article-title"><span class="smallcaps smallerCapital">d</span>-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2004.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15780844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVWqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=577-585&author=U.+Heresco-Levyauthor=D.+C.+Javittauthor=R.+Ebsteinauthor=A.+Vassauthor=P.+Lichtenbergauthor=G.+Barauthor=S.+Catinariauthor=M.+Ermilov&title=d-Serine+efficacy+as+add-on+pharmacotherapy+to+risperidone+and+olanzapine+for+treatment-refractory+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia</span></div><div class="casAuthors">Heresco-Levy, Uriel; Javitt, Daniel C.; Ebstein, Richard; Vass, Agnes; Lichtenberg, Pesach; Bar, Gali; Catinari, Sara; Ermilov, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">577-585</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: D-serine, a selective full agonist at the glycine site of N-methyl--aspartate glutamate receptor, might presently be the compd. of choice for counteracting the hypothesized dysfunction of this receptor class in schizophrenia.  Studies performed with Taiwanese patients indicate that D-serine significantly improves schizophrenia symptoms when used as adjuvant to conventional neuroleptics but not to clozapine.  We assessed the efficacy and safety of D-serine adjuvant treatment for Occidental schizophrenia patients treated with newer atypical antipsychotics.  Methods: Thirty-nine risperidone- or olanzapine-treated schizophrenia patients participated in a double-blind, placebo-controlled, 6-wk crossover trial with 30 mg/kg/day D-serine added to their antipsychotic medication.  Measures of clin. efficacy and side effects were detd. biweekly throughout the study.  Clin. lab. parameters and amino acid serum levels were monitored.  Results: D-serine administration induced increased serine serum levels (p < .001) and resulted in significant (p < .001) improvements in neg., pos., cognitive, and depression symptoms, as measured by the Pos. and Neg. Syndrome Scale.  For approx. one third of the sample, D-serine treatment resulted in significant (>20%) redns. in Brief Psychiatric Rating Scale total scores.  D-serine was well tolerated, and no detrimental changes in clin. lab. parameters were noted.  Conclusions: These findings (1) indicate that risperidone and olanzapine efficacy might be augmented with D-serine adjuvant treatment; (2) confirm D-serine efficacy against main schizophrenia symptom domains; and (3) warrant the assessment of D-serine antipsychotic monotherapy for this illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3antEVGoMtrVg90H21EOLACvtfcHk0lga5PzAlxAlJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVWqs70%253D&md5=f713584af1ab98f77b66020d1fbbd638</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2004.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2004.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DHeresco-Levy%26aufirst%3DU.%26aulast%3DJavitt%26aufirst%3DD.%2BC.%26aulast%3DEbstein%26aufirst%3DR.%26aulast%3DVass%26aufirst%3DA.%26aulast%3DLichtenberg%26aufirst%3DP.%26aulast%3DBar%26aufirst%3DG.%26aulast%3DCatinari%26aufirst%3DS.%26aulast%3DErmilov%26aufirst%3DM.%26atitle%3Dd-Serine%2520efficacy%2520as%2520add-on%2520pharmacotherapy%2520to%2520risperidone%2520and%2520olanzapine%2520for%2520treatment-refractory%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D2005%26volume%3D57%26spage%3D577%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Lane, H. Y.; Liu, H.-C.; Huang, C.-L.; Chang, Y. C.; Liau, C.-H.; Perng, C.-H.; Tsai, G.</span><span> </span><span class="NLM_article-title">Sarcosine (<i>N</i>-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study</span>.  <span class="citation_source-journal">Biol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lane%2C+H.+Y.%3B+Liu%2C+H.-C.%3B+Huang%2C+C.-L.%3B+Chang%2C+Y.+C.%3B+Liau%2C+C.-H.%3B+Perng%2C+C.-H.%3B+Tsai%2C+G.+Sarcosine+%28N-methylglycine%29+treatment+for+acute+schizophrenia%3A+a+randomized%2C+double-blind+study.+Biol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DH.%2BY.%26atitle%3DSarcosine%2520%2528N-methylglycine%2529%2520treatment%2520for%2520acute%2520schizophrenia%253A%2520a%2520randomized%252C%2520double-blind%2520study%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Lane, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, G. E.</span><span> </span><span class="NLM_article-title">Sarcosine or <span class="smallcaps smallerCapital">d</span>-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1196</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.62.11.1196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16275807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1CgsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2005&pages=1196-1204&author=H.+Y.+Laneauthor=Y.+C.+Changauthor=Y.+C.+Liuauthor=C.+C.+Chiuauthor=G.+E.+Tsai&title=Sarcosine+or+d-serine+add-on+treatment+for+acute+exacerbation+of+schizophrenia%3A+a+randomized%2C+double-blind%2C+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study</span></div><div class="casAuthors">Lane, Hsien-Yuan; Chang, Yue-Cune; Liu, Yi-Ching; Chiu, Chih-Chiang; Tsai, Guochuan E.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1196-1204</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia.  To det. whether NMDA-glycine site agonists or glycine transporter-1 inhibitors have better efficacy and whether NMDA receptor-enhancing agents have beneficial effects for acute exacerbation of schizophrenia.  Randomized, double-blind, placebo-controlled trial.  Inpatient units of 2 major medical centers in Taiwan.  Sixty-five schizophrenic inpatients with acute exacerbation.  Six weeks of treatment with sarcosine (2 g/d), D-serine (2 g/d), or placebo and concomitant optimal risperidone therapy.  Pos. and Neg. Syndrome Scale (PANSS) and Scale for the Assessment of Neg. Symptoms (SANS) (20 and 17 items) total scores.  The sarcosine group revealed more redns. in PANSS total scores than the placebo (P = .04) and D-serine (P < .001) groups.  Sarcosine adjunctive treatment was also superior to placebo in reducing SANS-20 (P = .007) and SANS-17 (P = .003) scores and to D-serine in decreasing SANS-20 (P = .006) and SANS-17 (P = .002) scores.  The PANSS-general, PANSS-cognitive, and PANSS-depressive symptoms scores and SANS-alogia and SANS-blunted affect scores improved significantly more in sarcosine-cotreated patients than in risperidone monotherapy patients (P ≤ .02 for all).  Sarcosine adjunctive therapy also surpassed D-serine in terms of PANSS-general, PANSS-pos., PANSS-neg., and PANSS-depressive symptoms scores (P ≤ .04 for all).  D-Serine and risperidone cotreatment did not differ significantly from risperidone monotherapy in all efficacy domains.  This first short-term treatment study on NMDA receptor-enhancing agents suggests that sarcosine, superior to D-serine, can benefit not only patients with long-term stable disease but also acutely ill persons with schizophrenia.  This finding indicates that a glycine transporter 1 inhibitor may be more efficacious than NMDA-glycine site agonists for adjuvant treatment of schizophrenia, at least during the acute phase.  Further studies are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyLHlPPnkgV7Vg90H21EOLACvtfcHk0ljn33-qe5FR2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1CgsLzK&md5=8d2aa013405ff2f7b4dc531b40497d3e</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.62.11.1196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.62.11.1196%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DH.%2BY.%26aulast%3DChang%26aufirst%3DY.%2BC.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DChiu%26aufirst%3DC.%2BC.%26aulast%3DTsai%26aufirst%3DG.%2BE.%26atitle%3DSarcosine%2520or%2520d-serine%2520add-on%2520treatment%2520for%2520acute%2520exacerbation%2520of%2520schizophrenia%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2005%26volume%3D62%26spage%3D1196%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Moghaddam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, D.</span><span> </span><span class="NLM_article-title">Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2921</span><span class="NLM_x">–</span> <span class="NLM_lpage">2927</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1523%2FJNEUROSCI.17-08-02921.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9092613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2sXisValurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=2921-2927&author=B.+Moghaddamauthor=B.+Adamsauthor=A.+Vermaauthor=D.+Daly&title=Activation+of+glutamatergic+neurotransmission+by+ketamine%3A+a+novel+step+in+the+pathway+from+NMDA+receptor+blockade+to+dopaminergic+and+cognitive+disruptions+associated+with+the+prefrontal+cortex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</span></div><div class="casAuthors">Moghaddam, Bita; Adams, Barbara; Verma, Anita; Daly, Darron</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2921-2927</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Subanesthetic doses of ketamine, a noncompetitive NMDA receptor antagonist, impair prefrontal cortex (PFC) function in the rat and produce symptoms in humans similar to those obsd. in schizophrenia and dissociative states, including impaired performance of frontal lobe-sensitive tests.  Several lines of evidence suggest that ketamine may impair PFC function in part by interacting with dopamine neurotransmission in this region.  This study sought to det. the mechanism by which ketamine may disrupt dopaminergic neurotransmission in, and cognitive functions assocd. with, the PFC.  A thorough dose-response study using microdialysis in conscious rats indicated that low doses of ketamine (10, 20, and 30 mg/kg) increase glutamate outflow in the PFC, suggesting that at these doses ketamine may increase glutamatergic neurotransmission in the PFC at non-NMDA glutamate receptors.  An anesthetic dose of ketamine (200 mg/kg) decreased, and an intermediate dose of 50 mg/kg did not affect, glutamate levels.  Ketamine, at 30 mg/kg, also increased the release of dopamine in the PFC.  This increase was blocked by intra-PFC application of the AMPA/kainate receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione CNQX.  Furthermore, ketamine-induced activation of dopamine release and impairment of spatial delayed alternation in the rodent, a PFC-sensitive cognitive task, was ameliorated by systemic pretreatment with AMPA/kainate receptor antagonist LY293558.  These findings suggest that ketamine may disrupt dopaminergic neurotransmission in the PFC as well as cognitive functions assocd. with this region, in part, by increasing the release of glutamate, thereby stimulating postsynaptic non-NMDA glutamate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKNWCBwx_sLVg90H21EOLACvtfcHk0ljn33-qe5FR2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisValurk%253D&md5=74f7a1696b2c30f0a38e34963334eb0b</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.17-08-02921.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.17-08-02921.1997%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DB.%26aulast%3DAdams%26aufirst%3DB.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DDaly%26aufirst%3DD.%26atitle%3DActivation%2520of%2520glutamatergic%2520neurotransmission%2520by%2520ketamine%253A%2520a%2520novel%2520step%2520in%2520the%2520pathway%2520from%2520NMDA%2520receptor%2520blockade%2520to%2520dopaminergic%2520and%2520cognitive%2520disruptions%2520associated%2520with%2520the%2520prefrontal%2520cortex%26jtitle%3DJ.%2520Neurosci.%26date%3D1997%26volume%3D17%26spage%3D2921%26epage%3D2927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Lorrain, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varney, M. A.</span><span> </span><span class="NLM_article-title">Effects of ketamine and <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">–</span> <span class="NLM_lpage">706</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2003&pages=697-706&author=D.+S.+Lorrainauthor=C.+S.+Bacceiauthor=L.+J.+Bristowauthor=J.+J.+Andersonauthor=M.+A.+Varney&title=Effects+of+ketamine+and+N-methyl-d-aspartate+on+glutamate+and+dopamine+release+in+the+rat+prefrontal+cortex%3A+modulation+by+a+group+II+selective+metabotropic+glutamate+receptor+agonist+LY379268"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BJ.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26atitle%3DEffects%2520of%2520ketamine%2520and%2520N-methyl-d-aspartate%2520on%2520glutamate%2520and%2520dopamine%2520release%2520in%2520the%2520rat%2520prefrontal%2520cortex%253A%2520modulation%2520by%2520a%2520group%2520II%2520selective%2520metabotropic%2520glutamate%2520receptor%2520agonist%2520LY379268%26jtitle%3DNeuroscience%26date%3D2003%26volume%3D117%26spage%3D697%26epage%3D706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Adams, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, B.</span><span> </span><span class="NLM_article-title">Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5545</span><span class="NLM_x">–</span> <span class="NLM_lpage">5554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9651235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1cXksFartLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=5545-5554&author=B.+Adamsauthor=B.+Moghaddam&title=Corticolimbic+dopamine+neurotransmission+is+temporally+dissociated+from+the+cognitive+and+locomotor+effects+of+phencyclidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine</span></div><div class="casAuthors">Adams, Barbara; Moghaddam, Bita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5545-5554</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The behavioral syndrome produced by phencyclidine (PCP) and its analog ketamine represents a pharmacol. model for some aspects of schizophrenia.  Despite the multifaceted properties of these drugs, the main mechanism for their psychotomimetic and cognitive-impairing effects has been thought heretofore to involve the corticolimbic dopamine system.  The present study examd. the temporal relation between alterations in corticolimbic dopamine and glutamate neurotransmission and two dopamine-dependent behavioral effects of PCP in the rodent that have relevance to the clin. phenomenol., namely, impairment of working memory, which is used to model the frontal lobe deficits assocd. with schizophrenia, and hyperlocomotion, which is used as a predictor of the propensity of a drug to elicit or exacerbate psychosis.  PCP increased dopamine and glutamate efflux in the prefrontal cortex and nucleus accumbens, as measured by microdialysis.  The increase in dopamine in both regions remained elevated well above baseline 2.5 h after the injection, at which time the expt. was terminated.  However, locomotor activity returned to baseline in <2 h after injection.  Furthermore, impaired performance in a discrete trial delayed alternation task, a rodent working memory task, was only evident ≤60 min after PCP injection; animals tested 80 min after injection, when cortical dopamine release was elevated at 300% of baseline, did not exhibit impaired performance.  These findings indicate that activation of dopamine neurotransmission is not sufficient to sustain PCP-induced locomotion and impairment of working memory.  Thus, effects of PCP, including a glutamatergic hyperstimulation, may be necessary to account for the psychotomimetic and cognitive-impairing effects of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZhIAn_TccKLVg90H21EOLACvtfcHk0ljHLOCZC9csNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFartLY%253D&md5=238f891f884d0ba6ac9e98bef1dd1670</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DB.%26aulast%3DMoghaddam%26aufirst%3DB.%26atitle%3DCorticolimbic%2520dopamine%2520neurotransmission%2520is%2520temporally%2520dissociated%2520from%2520the%2520cognitive%2520and%2520locomotor%2520effects%2520of%2520phencyclidine%26jtitle%3DJ.%2520Neurosci.%26date%3D1998%26volume%3D18%26spage%3D5545%26epage%3D5554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Aghajanian, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span> </span><span class="NLM_article-title">Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">825</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0006-8993%2899%2901224-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10216183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1MXisV2hu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=825&publication_year=1999&pages=161-171&author=G.+K.+Aghajanianauthor=G.+J.+Marek&title=Serotonin%2C+via+5-HT2A+receptors%2C+increases+EPSCs+in+layer+V+pyramidal+cells+of+prefrontal+cortex+by+an+asynchronous+mode+of+glutamate+release"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release</span></div><div class="casAuthors">Aghajanian, George K.; Marek, Gerard J.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">825</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">161-171</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Previously, serotonin (5-HT) was found to induce a marked increase in glutamatergic spontaneous excitatory postsynaptic currents (EPSCs) in apical dendrites of layer V pyramidal cells of prefrontal cortex; this effect was mediated by 5-HT2A receptors, a proposed site of action of hallucinogenic and atypical antipsychotic drugs.  Unexpectedly, although the effect of 5-HT was Ca2+-dependent and tetrodotoxin-sensitive, it did not appear to involve the activation of excitatory afferent impulse flow.  This paradox prompted us to investigate (in rat brain slices) whether 5-HT was acting through an atypical mode of excitatory transmitter release.  We found that the frequency of 5-HT-induced spontaneous EPSCs was fully supported by Sr2+ in the absence of added Ca2+, implicating the mechanism of asynchronous transmitter release which has been linked to the high-affinity Ca2+-sensor synaptotagmin III.  Although the early, synchronous component of elec. evoked EPSCs was reduced while 5-HT was being applied, late, nonsynchronous components were enhanced during 5-HT washout and also by the 5-HT2 partial agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI); the effect of DOI was blocked by a selective 5-HT2A antagonist (MDL 100907).  This late, nonsynchronous component was distinct from conventional polysynaptic EPSCs evoked in the presence of the GABAA antagonist bicuculline, but resembled asynchronous glutamatergic excitatory postsynaptic potentials (EPSPs) evoked in the presence of Sr2+.  An enhancement of asynchronous EPSCs by a specific neurotransmitter receptor has not been reported previously.  The possible role of excessive asynchronous transmission in the cerebral cortex in mediating the hallucinogenic effects of 5-HT2A agonists such as DOI is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOcZBhsnFz7Vg90H21EOLACvtfcHk0ljHLOCZC9csNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisV2hu7c%253D&md5=1db5c5a4c5a80bc3ee08298229e4bdff</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2899%2901224-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252899%252901224-X%26sid%3Dliteratum%253Aachs%26aulast%3DAghajanian%26aufirst%3DG.%2BK.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26atitle%3DSerotonin%252C%2520via%25205-HT2A%2520receptors%252C%2520increases%2520EPSCs%2520in%2520layer%2520V%2520pyramidal%2520cells%2520of%2520prefrontal%2520cortex%2520by%2520an%2520asynchronous%2520mode%2520of%2520glutamate%2520release%26jtitle%3DBrain%2520Res.%26date%3D1999%26volume%3D825%26spage%3D161%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Van Kammen, D. P.</span><span> </span><span class="NLM_article-title">γ-Aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=835733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaE2sXoslWhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=1977&pages=138-143&author=D.+P.+Van+Kammen&title=%CE%B3-Aminobutyric+acid+%28GABA%29+and+the+dopamine+hypothesis+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">γ-Aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia</span></div><div class="casAuthors">Van Kammen, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Psychiatry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-43</span>CODEN:
                <span class="NLM_cas:coden">AJPSAO</span>;
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">A review with 47 refs. including pharmacol. interventions that may raise GABA-mediated function in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBO82PpQSc4LVg90H21EOLACvtfcHk0ljHLOCZC9csNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXoslWhtA%253D%253D&md5=c1a957f58055dc01f836822ee6c61c11</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BKammen%26aufirst%3DD.%2BP.%26atitle%3D%25CE%25B3-Aminobutyric%2520acid%2520%2528GABA%2529%2520and%2520the%2520dopamine%2520hypothesis%2520of%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1977%26volume%3D134%26spage%3D138%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Wassef, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kochan, L. D.</span><span> </span><span class="NLM_article-title">GABA and schizophrenia: a review of basic science and clinical studies</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F01.jcp.0000095349.32154.a5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14624191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVCntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=601-640&author=A.+Wassefauthor=J.+Bakerauthor=L.+D.+Kochan&title=GABA+and+schizophrenia%3A+a+review+of+basic+science+and+clinical+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">GABA and schizophrenia: A review of basic science and clinical studies</span></div><div class="casAuthors">Wassef, Adel; Baker, Jeffrey; Kochan, Lisa D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-640</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  A converging body of evidence implicates the γ-aminobutyric acid (GABA) neurotransmitter system in the pathogenesis of schizophrenia.  The authors review neuroscience literature and clin. studies investigating the role of the GABA system in the pathophysiol. of schizophrenia.  First, a background on the GABA system is provided, including GABA pharmacol. and neuroanatomy of GABAergic neurons.  Results from basic science schizophrenia animal models and human studies are reviewed.  The role of GABA in cognitive dysfunction in schizophrenia is then presented, followed by a discussion of GABAergic compds. used in monotherapy or adjunctively in clin. schizophrenia studies.  In basic studies, redns. in GABAergic neuronal d. and abnormalities in receptors and reuptake sites have been identified in several cortical and subcortical GABA systems.  A model has been developed suggesting GABA's role (including GABA-dopamine interactions) in schizophrenia.  In several clin. studies, the use of adjunctive GABA agonists was assocd. with greater improvement in core schizophrenia symptoms.  Conclusions: Alterations in the GABA neurotransmitter system are found in clin. and basic neuroscience schizophrenia studies as well as animal models and may be involved in the pathophysiol. of schizophrenia.  The interaction of GABA with other well-characterized neurotransmitter abnormalities remains to be understood.  Future studies should elucidate the potential therapeutic role for GABA ligands in schizophrenia treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUFAE0s-24rVg90H21EOLACvtfcHk0lha-M4amtXVHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVCntbw%253D&md5=69cda8f117fda03030986ca0dc548a10</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1097%2F01.jcp.0000095349.32154.a5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.jcp.0000095349.32154.a5%26sid%3Dliteratum%253Aachs%26aulast%3DWassef%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DKochan%26aufirst%3DL.%2BD.%26atitle%3DGABA%2520and%2520schizophrenia%253A%2520a%2520review%2520of%2520basic%2520science%2520and%2520clinical%2520studies%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2003%26volume%3D23%26spage%3D601%26epage%3D640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Benes, F. M.</span><span> </span><span class="NLM_article-title">Emerging principles of altered neural circuitry in schizophrenia</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">269</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0165-0173%2899%2900041-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10719152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3c7osFCquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2000&pages=251-269&author=F.+M.+Benes&title=Emerging+principles+of+altered+neural+circuitry+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging principles of altered neural circuitry in schizophrenia</span></div><div class="casAuthors">Benes F M</div><div class="citationInfo"><span class="NLM_cas:title">Brain research. Brain research reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">251-69</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This paper presents an overview of recent microscopic studies that have sought to define how limbic circuitry may be altered in postmortem schizophrenic brain.  The discussion is organized around several basic questions regarding the manner in which interconnections within and between the anterior cingulate cortex and hippocampal formation and involving the glutamate, GABA and dopamine systems may contribute to the pathophysiology of this disorder.  The answers to these questions are used to derive several conclusions regarding circuitry changes in schizophrenia: 1) Schizophrenia is not a 'typical' degenerative disorder, but rather it is one in which excitotoxicity may contribute to neuronal pathology, whether or not cell death occurs; 2) Three or more neurotransmitter systems may be simultaneously altered within a single microcircuit; 3) Each transmitter system may show circuitry changes in more than one region, but such changes may vary on a region-by-region basis; 4) The pathophysiology of schizophrenia may involve 'mis-wirings' in intrinsic circuits (microcircuitry) within a given region, but significant changes are probably also present at the level of interconnections between two or more regions within a network (macrocircuitry); 5) While some microscopic findings appear to be selectively present in schizophrenia and be related to a susceptibility gene for this disorder, others may also be present in patients with bipolar disorder; 6) Although some of the circuitry changes seen in schizophrenia and bipolar disorder seem to be associated with neuroleptic exposure, most are not and may reflect the influence of non-specific environmental factors such as pre- and/or postnatal stress; 7) Normal postnatal changes at the level of both macro- and microcircuitry within the limbic system may serve as 'triggers' for the onset of schizophrenia during adolescence.  Taken together, these emerging principles can provide a framework for future postmortem studies of schizophrenic brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStXyTLo7wGZP6AExegM5LLfW6udTcc2eaKR8H5WmGtb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7osFCquw%253D%253D&md5=0979c3a0bea53bba782138c1fd934d21</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS0165-0173%2899%2900041-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-0173%252899%252900041-7%26sid%3Dliteratum%253Aachs%26aulast%3DBenes%26aufirst%3DF.%2BM.%26atitle%3DEmerging%2520principles%2520of%2520altered%2520neural%2520circuitry%2520in%2520schizophrenia%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2000%26volume%3D31%26spage%3D251%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Lingjaerde, O.</span><span> </span><span class="NLM_article-title">Benzodiazepines in the treatment of schizophrenia: an updated survey</span> <span class="citation_source-journal">Acta Psychiatr. Scand.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">459</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1111%2Fj.1600-0447.1991.tb03177.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1685616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK387jtlensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1991&pages=453-459&author=O.+Lingjaerde&title=Benzodiazepines+in+the+treatment+of+schizophrenia%3A+an+updated+survey"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Benzodiazepines in the treatment of schizophrenia: an updated survey</span></div><div class="casAuthors">Lingjaerde O</div><div class="citationInfo"><span class="NLM_cas:title">Acta psychiatrica Scandinavica</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">453-9</span>
        ISSN:<span class="NLM_cas:issn">0001-690X</span>.
    </div><div class="casAbstract">Reports on the effects of benzodiazepines in schizophrenia have appeared since the early 1960s.  Conclusions drawn from these studies, most of which have been uncontrolled, have ranged from worse than placebo to better than neuroleptics.  A critical appraisal of the literature seems to warrant the following main conclusions.  Benzodiazepines alone, in conventional doses, have no convincing antipsychotic effect in schizophrenia, although they may reduce anxiety, tension and insomnia.  However, very high doses of diazepam, and possibly other benzodiazepines, may have a symptomatic antipsychotic effect, especially in paranoid-hallucinatory schizophrenics, also when given alone.  Benzodiazepines, in conventional doses, can enhance the antipsychotic effect of neuroleptics in schizophrenics who have not responded satisfactorily to neuroleptics alone.  This effect may be most conspicuous against hallucinations, but improvement may also be obtained from delusions, thought disturbances, some negative symptoms, anxiety and tension.  Some benzodiazepines may be more effective than others in schizophrenia, but this has been insufficiently elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_Fv5sszlCB3thwrmtH4OBfW6udTcc2eaKR8H5WmGtb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387jtlensQ%253D%253D&md5=79e0096ea98b723d78b24808655a7ff1</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0447.1991.tb03177.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0447.1991.tb03177.x%26sid%3Dliteratum%253Aachs%26aulast%3DLingjaerde%26aufirst%3DO.%26atitle%3DBenzodiazepines%2520in%2520the%2520treatment%2520of%2520schizophrenia%253A%2520an%2520updated%2520survey%26jtitle%3DActa%2520Psychiatr.%2520Scand.%26date%3D1991%26volume%3D84%26spage%3D453%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Taylor, C. P.</span><span> </span><span class="NLM_article-title">GABA receptors and GABAergic synapses as targets for drug development</span> <span class="citation_source-journal">Drug Dev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1990&pages=151-160&author=C.+P.+Taylor&title=GABA+receptors+and+GABAergic+synapses+as+targets+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DC.%2BP.%26atitle%3DGABA%2520receptors%2520and%2520GABAergic%2520synapses%2520as%2520targets%2520for%2520drug%2520development%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D1990%26volume%3D21%26spage%3D151%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Hashimoto, T.; Arion, D.; Unger, T.; Maldonado-Aviles, J. G.; Morris, H. M.; Volk, D. W.; Mirnics, K.; Lewis, D. A.</span><span> </span><span class="NLM_article-title">Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia</span>.  <span class="citation_source-journal">Mol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hashimoto%2C+T.%3B+Arion%2C+D.%3B+Unger%2C+T.%3B+Maldonado-Aviles%2C+J.+G.%3B+Morris%2C+H.+M.%3B+Volk%2C+D.+W.%3B+Mirnics%2C+K.%3B+Lewis%2C+D.+A.+Alterations+in+GABA-related+transcriptome+in+the+dorsolateral+prefrontal+cortex+of+subjects+with+schizophrenia.+Mol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DT.%26atitle%3DAlterations%2520in%2520GABA-related%2520transcriptome%2520in%2520the%2520dorsolateral%2520prefrontal%2520cortex%2520of%2520subjects%2520with%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Akbarian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. S.</span><span> </span><span class="NLM_article-title">Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.brainresrev.2006.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16759710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFCitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2006&pages=293-304&author=S.+Akbarianauthor=H.+S.+Huang&title=Molecular+and+cellular+mechanisms+of+altered+GAD1%2FGAD67+expression+in+schizophrenia+and+related+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders</span></div><div class="casAuthors">Akbarian, Schahram; Huang, Hsien-Sung</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-304</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The 67 and 65 kDa isoforms of glutamic acid decarboxylase, the key enzymes for GABA biosynthesis, are expressed at altered levels in postmortem brain of subjects diagnosed with schizophrenia and related disorders, including autism and bipolar illness.  The predominant finding is a decrease in GAD67 mRNA levels, affecting multiple brain regions, including prefrontal and temporal cortex.  Postmortem studies, in conjunction with animal models, identified several mechanisms that contribute to the dysregulation of GAD67 in cerebral cortex.  These include disordered connectivity formation during development, abnormal expression of Reelin and neural cell adhesion mol. (NCAM) glycoproteins, defects in neurotrophin signaling and alterations in dopaminergic and glutamatergic neurotransmission.  These mechanisms are likely to operate in conjunction with genetic risk factors for psychosis, including sequence polymorphisms residing in the promoter of GAD1 (2q31), the gene encoding GAD67.  We propose an integrative model, with multiple mol. and cellular mechanisms contributing to transcriptional dysregulation of GAD67 and cortical dysfunction in psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohPNNWoo19rbVg90H21EOLACvtfcHk0ljibot6U_i3bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFCitL8%253D&md5=9c0a8a5e8e505d46c03ded47f99fd3d8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2006.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2006.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DAkbarian%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DH.%2BS.%26atitle%3DMolecular%2520and%2520cellular%2520mechanisms%2520of%2520altered%2520GAD1%252FGAD67%2520expression%2520in%2520schizophrenia%2520and%2520related%2520disorders%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2006%26volume%3D52%26spage%3D293%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Benes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzilevich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subburaju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minns, M.</span><span> </span><span class="NLM_article-title">Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">10164</span><span class="NLM_x">–</span> <span class="NLM_lpage">10169</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=10164-10169&author=F.+M.+Benesauthor=B.+Limauthor=D.+Matzilevichauthor=J.+P.+Walshauthor=S.+Subburajuauthor=M.+Minns&title=Regulation+of+the+GABA+cell+phenotype+in+hippocampus+of+schizophrenics+and+bipolars"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenes%26aufirst%3DF.%2BM.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DMatzilevich%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DJ.%2BP.%26aulast%3DSubburaju%26aufirst%3DS.%26aulast%3DMinns%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520the%2520GABA%2520cell%2520phenotype%2520in%2520hippocampus%2520of%2520schizophrenics%2520and%2520bipolars%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D10164%26epage%3D10169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span> </span><span class="NLM_article-title">Systematic study of association of four GABAergic genes: glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABA<sub>B</sub> receptor 1 gene and GABA<sub>A</sub> receptor subunit β2 gene, with schizophrenia using a universal DNA microarray</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2007.02.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17412563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2szivF2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2007&pages=374-384&author=X.+Zhaoauthor=S.+Qinauthor=Y.+Shiauthor=A.+Zhangauthor=J.+Zhangauthor=L.+Bianauthor=C.+Wanauthor=G.+Fengauthor=N.+Guauthor=G.+Zhangauthor=G.+Heauthor=L.+He&title=Systematic+study+of+association+of+four+GABAergic+genes%3A+glutamic+acid+decarboxylase+1+gene%2C+glutamic+acid+decarboxylase+2+gene%2C+GABAB+receptor+1+gene+and+GABAA+receptor+subunit+%CE%B22+gene%2C+with+schizophrenia+using+a+universal+DNA+microarray"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic study of association of four GABAergic genes: glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABA(B) receptor 1 gene and GABA(A) receptor subunit beta2 gene, with schizophrenia using a universal DNA microarray</span></div><div class="casAuthors">Zhao Xu; Qin Shengying; Shi Yongyong; Zhang Aiping; Zhang Jing; Bian Li; Wan Chunling; Feng Guoyin; Gu Niufan; Zhang Guangqi; He Guang; He Lin</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">374-84</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Several studies have suggested the dysfunction of the GABAergic system as a risk factor in the pathogenesis of schizophrenia.  In the present study, case-control association analysis was conducted in four GABAergic genes: two glutamic acid decarboxylase genes (GAD1 and GAD2), a GABA(A) receptor subunit beta2 gene (GABRB2) and a GABA(B) receptor 1 gene (GABBR1).  Using a universal DNA microarray procedure we genotyped a total of 20 SNPs on the above four genes in a study involving 292 patients and 286 controls of Chinese descent.  Statistically significant differences were observed in the allelic frequencies of the rs187269C/T polymorphism in the GABRB2 gene (P=0.0450, chi(2)=12.40, OR=1.65) and the -292A/C polymorphism in the GAD1 gene (P=0.0450, chi(2)=14.64 OR=1.77).  In addition, using an electrophoretic mobility shift assay (EMSA), we discovered differences in the U251 nuclear protein binding to oligonucleotides representing the -292 SNP on the GAD1 gene, which suggests that the -292C allele has reduced transcription factor binding efficiency compared with the 292A allele.  Using the multifactor-dimensionality reduction method (MDR), we found that the interactions among the rs187269C/T polymorphism in the GABRB2 gene, the -243A/G polymorphism in the GAD2 gene and the 27379C/T and 661C/T polymorphisms in the GAD1 gene revealed a significant association with schizophrenia (P<0.001).  These findings suggest that the GABRB2 and GAD1 genes alone and the combined effects of the polymorphisms in the four GABAergic system genes may confer susceptibility to the development of schizophrenia in the Chinese population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1CQap_ZwngOkdrW1FkXG-fW6udTcc2eYvLOp15-Otxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szivF2nug%253D%253D&md5=73e87b75b3e702e565e05247e5584949</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2007.02.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2007.02.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBian%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DGu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DSystematic%2520study%2520of%2520association%2520of%2520four%2520GABAergic%2520genes%253A%2520glutamic%2520acid%2520decarboxylase%25201%2520gene%252C%2520glutamic%2520acid%2520decarboxylase%25202%2520gene%252C%2520GABAB%2520receptor%25201%2520gene%2520and%2520GABAA%2520receptor%2520subunit%2520%25CE%25B22%2520gene%252C%2520with%2520schizophrenia%2520using%2520a%2520universal%2520DNA%2520microarray%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D93%26spage%3D374%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Selemon, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman-Rakic, P. S.</span><span> </span><span class="NLM_article-title">The reduced neuropil hypothesis: a circuit based model of schizophrenia</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0006-3223%2898%2900281-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9894571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1M7htF2nsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1999&pages=17-25&author=L.+D.+Selemonauthor=P.+S.+Goldman-Rakic&title=The+reduced+neuropil+hypothesis%3A+a+circuit+based+model+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">The reduced neuropil hypothesis: a circuit based model of schizophrenia</span></div><div class="casAuthors">Selemon L D; Goldman-Rakic P S</div><div class="citationInfo"><span class="NLM_cas:title">Biological psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-25</span>
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    </div><div class="casAbstract">In recent years, quantitative studies of the neuropathology of schizophrenia have reignited interest in the cerebral cortex and focused attention on the cellular and subcellular constituents that may be altered in this disease.  Findings have ranged from compromised circuitry in prefrontal areas to outright neuronal loss in temporal and cingulate cortices.  Herein, we propose that a reduction in interneuronal neuropil in the prefrontal cortex is a prominent feature of cortical pathology in schizophrenia and review the growing evidence for this view from reports of altered neuronal density and immunohistochemical markers in various cortical regions.  The emerging picture of neuropathology in schizophrenia is one of subtle changes in cellular architecture and brain circuity that nonetheless have a devastating impact on cortical function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtejfReLEhZZWtyewyzkyLfW6udTcc2eYvLOp15-Otxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7htF2nsA%253D%253D&md5=ef0b99beb1d632843d3b9ca2492cd636</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2898%2900281-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252898%252900281-9%26sid%3Dliteratum%253Aachs%26aulast%3DSelemon%26aufirst%3DL.%2BD.%26aulast%3DGoldman-Rakic%26aufirst%3DP.%2BS.%26atitle%3DThe%2520reduced%2520neuropil%2520hypothesis%253A%2520a%2520circuit%2520based%2520model%2520of%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D1999%26volume%3D45%26spage%3D17%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Dwork, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancevski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosoklija, G.</span><span> </span><span class="NLM_article-title">White matter and cognitive function in schizophrenia</span> <span class="citation_source-journal">Int. J. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS1461145707007638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17313699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=513-536&author=A.+J.+Dworkauthor=B.+Mancevskiauthor=G.+Rosoklija&title=White+matter+and+cognitive+function+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">White matter and cognitive function in schizophrenia</span></div><div class="casAuthors">Dwork, Andrew J.; Mancevski, Branislav; Rosoklija, Gorazd</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">513-536</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  Abnormalities of cerebral white matter, oligodendrocytes, and myelin have been obsd. in schizophrenia with in-vivo imaging and post-mortem biochem.  White-matter abnormalities are also frequently assocd. with cognitive impairment in both healthy and diseased individuals, and cognitive dysfunction is an important component of schizophrenia.  While many studies have documented these assocns., only a handful have examd. the role of white matter in cognitive function in schizophrenia.  In this paper, we explore what is known about white-matter deficits in relation to schizophrenia, cognitive deficits, or both together, in order to generate a theor. model for the role that compromise of white matter might play in producing cognitive impairment in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ5o5vWvkxVbVg90H21EOLACvtfcHk0lhynqmGjP9Etg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt7k%253D&md5=58a11b74de917da1f3271144db27e333</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1017%2FS1461145707007638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145707007638%26sid%3Dliteratum%253Aachs%26aulast%3DDwork%26aufirst%3DA.%2BJ.%26aulast%3DMancevski%26aufirst%3DB.%26aulast%3DRosoklija%26aufirst%3DG.%26atitle%3DWhite%2520matter%2520and%2520cognitive%2520function%2520in%2520schizophrenia%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D10%26spage%3D513%26epage%3D536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Hulshoff Pol, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnack, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertens, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Haren, N. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Tweel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baare, W. F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R. S.</span><span> </span><span class="NLM_article-title">Volume changes in gray matter in patients with schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.159.2.244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11823266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD387gs1yltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=244-250&author=H.+E.+Hulshoff+Polauthor=H.+G.+Schnackauthor=M.+G.+Bertensauthor=N.+E.+M.+van+Harenauthor=I.+van+der+Tweelauthor=W.+G.+Staalauthor=W.+F.+C.+Baareauthor=R.+S.+Kahn&title=Volume+changes+in+gray+matter+in+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Volume changes in gray matter in patients with schizophrenia</span></div><div class="casAuthors">Hulshoff Pol Hilleke E; Schnack Hugo G; Bertens Madelief G B C; van Haren Neeltje E M; van der Tweel Ingeborg; Staal Wouter G; Baare Wim F C; Kahn Rene S</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">244-50</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Schizophrenia is generally characterized by a progressive decline in functioning.  Although structural brain abnormalities, particularly decrements in gray matter volume, are considered important to the pathology of schizophrenia, it is not resolved whether the brain abnormalities become more prominent over time.  METHOD:  Magnetic resonance brain images from 159 patients with schizophrenia and 158 healthy comparison subjects between 16 and 70 years of age were compared.  Using linear regression analysis, the authors analyzed the relationship between the volumes of the total brain, gray and white matter, cerebellum, and lateral and third ventricles with patient age.  RESULTS:  Total brain (-2.2%), cerebral gray matter (-3.3%), prefrontal gray matter (-4.4%), and prefrontal white matter (-3.5%) volumes were smaller, and lateral (27%) and third (30%) ventricle and peripheral CSF (11%) volumes were larger in schizophrenia patients.  A significant group-by-age interaction for gray matter volume was found, as shown by a steeper regression slope between age and gray matter volume in patients (-3.43 ml/year) than in healthy comparison subjects (-2.74 ml/year).  CONCLUSIONS:  The smaller brains of the patients with schizophrenia can be explained by decreases in gray matter volume.  Moreover, the finding that the smaller gray matter volume was more pronounced in older patients with schizophrenia may suggest progressive loss of cerebral gray matter in schizophrenia patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEEl3bXaKI7rxanA7vODO6fW6udTcc2eYX07QihHLuQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387gs1yltg%253D%253D&md5=e325c662a644ae22ff521ba15e0054fc</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.2.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.2.244%26sid%3Dliteratum%253Aachs%26aulast%3DHulshoff%2BPol%26aufirst%3DH.%2BE.%26aulast%3DSchnack%26aufirst%3DH.%2BG.%26aulast%3DBertens%26aufirst%3DM.%2BG.%26aulast%3Dvan%2BHaren%26aufirst%3DN.%2BE.%2BM.%26aulast%3Dvan%2Bder%2BTweel%26aufirst%3DI.%26aulast%3DStaal%26aufirst%3DW.%2BG.%26aulast%3DBaare%26aufirst%3DW.%2BF.%2BC.%26aulast%3DKahn%26aufirst%3DR.%2BS.%26atitle%3DVolume%2520changes%2520in%2520gray%2520matter%2520in%2520patients%2520with%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D244%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Buchsbaum, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peled, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudbjartsson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazlett, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downhill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fallon, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atlas, S. W.</span><span> </span><span class="NLM_article-title">MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia</span> <span class="citation_source-journal">NeuroReport</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1998&pages=425-430&author=M.+S.+Buchsbaumauthor=C.+Y.+Tangauthor=S.+Peledauthor=H.+Gudbjartssonauthor=D.+Luauthor=E.+A.+Hazlettauthor=J.+Downhillauthor=M.+Haznedarauthor=J.+H.+Fallonauthor=S.+W.+Atlas&title=MRI+white+matter+diffusion+anisotropy+and+PET+metabolic+rate+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuchsbaum%26aufirst%3DM.%2BS.%26aulast%3DTang%26aufirst%3DC.%2BY.%26aulast%3DPeled%26aufirst%3DS.%26aulast%3DGudbjartsson%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DHazlett%26aufirst%3DE.%2BA.%26aulast%3DDownhill%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DM.%26aulast%3DFallon%26aufirst%3DJ.%2BH.%26aulast%3DAtlas%26aufirst%3DS.%2BW.%26atitle%3DMRI%2520white%2520matter%2520diffusion%2520anisotropy%2520and%2520PET%2520metabolic%2520rate%2520in%2520schizophrenia%26jtitle%3DNeuroReport%26date%3D1998%26volume%3D9%26spage%3D425%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, K. L.</span><span> </span><span class="NLM_article-title">Introduction to the special section: myelin and oligodendrocyte abnormalities in schizophrenia</span> <span class="citation_source-journal">Int. J. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS1461145706007449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17583597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=499-502&author=V.+Haroutunianauthor=K.+L.+Davis&title=Introduction+to+the+special+section%3A+myelin+and+oligodendrocyte+abnormalities+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Introduction to the Special Section: Myelin and oligodendrocyte abnormalities in schizophrenia</span></div><div class="casAuthors">Haroutunian, Vahram; Davis, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">499-502</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  A central tenet of modern views of the neurobiol. of schizophrenia is that the symptoms of schizophrenia arise from a failure of adequate communication between different brain regions and disruption of the circuitry that underlies behavior and perception.  Historically this disconnectivity syndrome has been approached from a neurotransmitter-based perspective.  However, efficient communication between brain circuits is also contingent on saltatory signal propagation and salubrious myelination of axons.  The papers in this Special Section examine the neuroanatomical and mol. biol. evidence for abnormal myelination and oligodendroglial function in schizophrenia through studies of post-mortem brain tissue and animal model systems.  The picture that emerges from the studies described suggests that although schizophrenia is not characterized by gross abnormalities of white matter such as those evident in multiple sclerosis, it does involve a profound dysregulation of myelin-assocd. gene expression, redns. in oligodendrocyte nos., and marked abnormalities in the ultrastructure of myelin sheaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Rm-kShoCTrVg90H21EOLACvtfcHk0lhynqmGjP9Etg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt7s%253D&md5=239f5456e309bde3aabb6f61e5d1566d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1017%2FS1461145706007449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145706007449%26sid%3Dliteratum%253Aachs%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DK.%2BL.%26atitle%3DIntroduction%2520to%2520the%2520special%2520section%253A%2520myelin%2520and%2520oligodendrocyte%2520abnormalities%2520in%2520schizophrenia%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D10%26spage%3D499%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Hakak, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxbaum, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fienberg, A. A.</span><span> </span><span class="NLM_article-title">Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">4746</span><span class="NLM_x">–</span> <span class="NLM_lpage">4751</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=4746-4751&author=Y.+Hakakauthor=J.+R.+Walkerauthor=C.+Liauthor=W.+H.+Wongauthor=K.+L.+Davisauthor=J.+D.+Buxbaumauthor=V.+Haroutunianauthor=A.+A.+Fienberg&title=Genome-wide+expression+analysis+reveals+dysregulation+of+myelination-related+genes+in+chronic+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHakak%26aufirst%3DY.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DW.%2BH.%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DBuxbaum%26aufirst%3DJ.%2BD.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DFienberg%26aufirst%3DA.%2BA.%26atitle%3DGenome-wide%2520expression%2520analysis%2520reveals%2520dysregulation%2520of%2520myelination-related%2520genes%2520in%2520chronic%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D4746%26epage%3D4751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Georgieva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskvina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peirce, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmans, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macgregor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxbaum, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. C.</span><span> </span><span class="NLM_article-title">Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">12469</span><span class="NLM_x">–</span> <span class="NLM_lpage">12474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=12469-12474&author=L.+Georgievaauthor=V.+Moskvinaauthor=T.+Peirceauthor=N.+Nortonauthor=N.+J.+Brayauthor=L.+Jonesauthor=P.+Holmansauthor=S.+Macgregorauthor=S.+Zammitauthor=J.+Wilkinsonauthor=H.+Williamsauthor=I.+Nikolovauthor=N.+Williamsauthor=D.+Ivanovauthor=K.+L.+Davisauthor=V.+Haroutunianauthor=J.+D.+Buxbaumauthor=N.+Craddockauthor=G.+Kirovauthor=M.+J.+Owenauthor=M.+C.+O%E2%80%99Donovan&title=Convergent+evidence+that+oligodendrocyte+lineage+transcription+factor+2+%28OLIG2%29+and+interacting+genes+influence+susceptibility+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgieva%26aufirst%3DL.%26aulast%3DMoskvina%26aufirst%3DV.%26aulast%3DPeirce%26aufirst%3DT.%26aulast%3DNorton%26aufirst%3DN.%26aulast%3DBray%26aufirst%3DN.%2BJ.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DHolmans%26aufirst%3DP.%26aulast%3DMacgregor%26aufirst%3DS.%26aulast%3DZammit%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DH.%26aulast%3DNikolov%26aufirst%3DI.%26aulast%3DWilliams%26aufirst%3DN.%26aulast%3DIvanov%26aufirst%3DD.%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DBuxbaum%26aufirst%3DJ.%2BD.%26aulast%3DCraddock%26aufirst%3DN.%26aulast%3DKirov%26aufirst%3DG.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26atitle%3DConvergent%2520evidence%2520that%2520oligodendrocyte%2520lineage%2520transcription%2520factor%25202%2520%2528OLIG2%2529%2520and%2520interacting%2520genes%2520influence%2520susceptibility%2520to%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D12469%26epage%3D12474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Roy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtie, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Khodor, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sardi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooks, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benoit-Marand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corfas, G.</span><span> </span><span class="NLM_article-title">Loss of <i>erbB</i> signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">8131</span><span class="NLM_x">–</span> <span class="NLM_lpage">8136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=8131-8136&author=K.+Royauthor=J.+C.+Murtieauthor=B.+F.+El+Khodorauthor=N.+Edgarauthor=S.+P.+Sardiauthor=B.+M.+Hooksauthor=M.+Benoit-Marandauthor=C.+Chenauthor=H.+Mooreauthor=P.+O%E2%80%99Donnellauthor=D.+Brunnerauthor=G.+Corfas&title=Loss+of+erbB+signaling+in+oligodendrocytes+alters+myelin+and+dopaminergic+function%2C+a+potential+mechanism+for+neuropsychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DK.%26aulast%3DMurtie%26aufirst%3DJ.%2BC.%26aulast%3DEl%2BKhodor%26aufirst%3DB.%2BF.%26aulast%3DEdgar%26aufirst%3DN.%26aulast%3DSardi%26aufirst%3DS.%2BP.%26aulast%3DHooks%26aufirst%3DB.%2BM.%26aulast%3DBenoit-Marand%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DCorfas%26aufirst%3DG.%26atitle%3DLoss%2520of%2520erbB%2520signaling%2520in%2520oligodendrocytes%2520alters%2520myelin%2520and%2520dopaminergic%2520function%252C%2520a%2520potential%2520mechanism%2520for%2520neuropsychiatric%2520disorders%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D8131%26epage%3D8136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Segal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koschnick, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slegers, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hof, P. R.</span><span> </span><span class="NLM_article-title">Oligodendrocyte pathophysiology: a new view of schizophrenia</span> <span class="citation_source-journal">Int. J. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS146114570600722X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17291369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=503-511&author=D.+Segalauthor=J.+R.+Koschnickauthor=L.+H.+Slegersauthor=P.+R.+Hof&title=Oligodendrocyte+pathophysiology%3A+a+new+view+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Oligodendrocyte pathophysiology: a new view of schizophrenia</span></div><div class="casAuthors">Segal, Devorah; Koschnick, Jessica R.; Slegers, Linda H. A.; Hof, Patrick R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">503-511</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  A recent focus of schizophrenia research is disruption of white-matter integrity as a key facet of this complex disorder.  This was spurred, partly, by new imaging modalities, magnetic transfer imaging and diffusion tensor imaging, which showed differences in white-matter integrity and tract coherence in persons with schizophrenia compared to controls.  Oligodendrocytes, in particular, have been the subject of increased study after gene microarray analyses revealed that six myelin-related genes specific to oligodendrocytes have decreased expression levels in schizophrenia.  Oligodendrocytes have also been shown to be decreased in no. in the superior frontal gyrus of subjects with schizophrenia.  The MAG knockout mouse, missing a myelin-related gene linked to schizophrenia, may prove to be a useful animal model for the dysmyelination obsd. in the human disease.  Studies currently ongoing on this model have found changes in dendritic branching patterns of pyramidal cells in layer III of the prefrontal cortex.  Further characterization of the pathol. in these mice is underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA8cDI-BEjQbVg90H21EOLACvtfcHk0libplINwz_SyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt78%253D&md5=b580af644fe5d5e6802430e786c36bb2</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1017%2FS146114570600722X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS146114570600722X%26sid%3Dliteratum%253Aachs%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DKoschnick%26aufirst%3DJ.%2BR.%26aulast%3DSlegers%26aufirst%3DL.%2BH.%26aulast%3DHof%26aufirst%3DP.%2BR.%26atitle%3DOligodendrocyte%2520pathophysiology%253A%2520a%2520new%2520view%2520of%2520schizophrenia%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D10%26spage%3D503%26epage%3D511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Woo, T. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowell, A. L.</span><span> </span><span class="NLM_article-title">Targeting synapses and myelin in the prevention of schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15653262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FosleksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2005&pages=193-207&author=T.+U.+Wooauthor=A.+L.+Crowell&title=Targeting+synapses+and+myelin+in+the+prevention+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting synapses and myelin in the prevention of schizophrenia</span></div><div class="casAuthors">Woo T-U W; Crowell A L</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">193-207</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Many of the functions that are mediated by the prefrontal cortex (PFC) are severely impaired in schizophrenia.  The maturation of these functions takes place during late adolescence and early adulthood, which coincides with the period of time when overt symptomatology of schizophrenia most commonly emerges.  Two developmental processes occurring during the periadolescence period appear to mediate the functional maturation of the PFC: pruning of exuberant synapses and myelination of axons.  It has long been speculated in the literature that disturbances of these processes may result in dysfunction of the PFC and thereby trigger the emergence of symptoms and deficits of schizophrenia.  Alternatively, but not mutually exclusively, it has also been suggested that these late developmental processes may not be aberrant but they "unmask" preexisting deficits in the PFC, resulting in the onset of symptoms.  The important implication of both of these scenarios is that in either case the emergence of PFC functional disturbances and the onset of symptoms and deficits of schizophrenia would in theory be preventable by pharmacologic manipulation of the synaptic pruning and/or axonal myelination processes.  Thus, better understanding of the cellular and molecular mechanisms that mediate these processes will provide truly novel insight into the therapeutics and prevention of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREMCZWEFaJroJKJbLTgsvCfW6udTcc2eZ2PM6jkQTcR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FosleksQ%253D%253D&md5=8a2d803364cd381723dd2774e269ac1a</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DT.%2BU.%26aulast%3DCrowell%26aufirst%3DA.%2BL.%26atitle%3DTargeting%2520synapses%2520and%2520myelin%2520in%2520the%2520prevention%2520of%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2005%26volume%3D73%26spage%3D193%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Lim, K. O.</span><span> </span><span class="NLM_article-title">Connections in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">998</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.164.7.995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17606646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2szovFakuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2007&pages=995-998&author=K.+O.+Lim&title=Connections+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Connections in schizophrenia</span></div><div class="casAuthors">Lim Kelvin O</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">995-8</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRadZisR7EXCsve_zCu79I8fW6udTcc2eaNmoGf-SHxKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szovFakuw%253D%253D&md5=615d297011490d095520eca6c47073c1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.164.7.995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.164.7.995%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DK.%2BO.%26atitle%3DConnections%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D164%26spage%3D995%26epage%3D998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Horrobin, D. F.</span><span> </span><span class="NLM_article-title">The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0920-9964%2897%2900151-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9589514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1c3ltFCiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1998&pages=193-208&author=D.+F.+Horrobin&title=The+membrane+phospholipid+hypothesis+as+a+biochemical+basis+for+the+neurodevelopmental+concept+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia</span></div><div class="casAuthors">Horrobin D F</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-208</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The neurodevelopmental hypothesis of schizophrenia is becoming an important feature of research in the field.  However, its major drawback is that it lacks any biochemical basis which might draw the diverse observations together.  It is suggested that the membrane phospholipid hypothesis can provide such a biochemical basis and that the neurodevelopmental phospholipid concept offers a powerful paradigm to guide future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0-oAsfqF7Xf6AExegM5LLfW6udTcc2eaNmoGf-SHxKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3ltFCiuw%253D%253D&md5=8b0f1760bbd4043e9f23982bde9a242a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2897%2900151-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252897%252900151-5%26sid%3Dliteratum%253Aachs%26aulast%3DHorrobin%26aufirst%3DD.%2BF.%26atitle%3DThe%2520membrane%2520phospholipid%2520hypothesis%2520as%2520a%2520biochemical%2520basis%2520for%2520the%2520neurodevelopmental%2520concept%2520of%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D1998%26volume%3D30%26spage%3D193%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Emsley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myburgh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oosthuizen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Rensburg, S. J.</span><span> </span><span class="NLM_article-title">Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1596</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.159.9.1596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12202284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD38vktlOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=1596-1598&author=R.+Emsleyauthor=C.+Myburghauthor=P.+Oosthuizenauthor=S.+J.+van+Rensburg&title=Randomized%2C+placebo-controlled+study+of+ethyl-eicosapentaenoic+acid+as+supplemental+treatment+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia</span></div><div class="casAuthors">Emsley Robin; Myburgh Christo; Oosthuizen Pieter; van Rensburg Susan J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1596-8</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The study investigated the efficacy and tolerability of ethyl-eicosapentaenoic acid (E-EPA) as add-on treatment in chronic, severe schizophrenia.  METHOD:  A randomized, parallel-group, double-blind, placebo-controlled, fixed-dose, add-on study was conducted over 12 weeks.  Forty patients with persistent symptoms after at least 6 months of stable antipsychotic treatment received E-EPA or placebo, in addition to their existing treatment.  RESULTS:  At 12 weeks, the E-EPA group had significantly greater reduction of Positive and Negative Syndrome Scale total scores and of dyskinesia scores than the placebo group.  CONCLUSIONS:  EPA may be an effective and well-tolerated add-on treatment in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmduL8oJpJeRjv2lLSLOxFfW6udTcc2eaNmoGf-SHxKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vktlOqtA%253D%253D&md5=a2c344322c0afdd5333115a654e639b6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.9.1596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.9.1596%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DR.%26aulast%3DMyburgh%26aufirst%3DC.%26aulast%3DOosthuizen%26aufirst%3DP.%26aulast%3Dvan%2BRensburg%26aufirst%3DS.%2BJ.%26atitle%3DRandomized%252C%2520placebo-controlled%2520study%2520of%2520ethyl-eicosapentaenoic%2520acid%2520as%2520supplemental%2520treatment%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D1596%26epage%3D1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Fenton, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boronow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hibbeln, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knable, M.</span><span> </span><span class="NLM_article-title">A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">–</span> <span class="NLM_lpage">2074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.158.12.2071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11729030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3Mnot1akug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=2071-2074&author=W.+S.+Fentonauthor=F.+Dickersonauthor=J.+Boronowauthor=J.+R.+Hibbelnauthor=M.+Knable&title=A+placebo-controlled+trial+of+omega-3+fatty+acid+%28ethyl+eicosapentaenoic+acid%29+supplementation+for+residual+symptoms+and+cognitive+impairment+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia</span></div><div class="casAuthors">Fenton W S; Dickerson F; Boronow J; Hibbeln J R; Knable M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2071-4</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder.  METHOD:  Eighty-seven patients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despite neuroleptic treatment were randomly assigned to receive either 3 g/day of ethyl EPA (N=43) or placebo (N=44) in a 16-week, double-blind supplementation trial.  Assessments were performed at baseline and at weeks 1, 2, 4, 8, 12, and 16; a cognitive battery was administered at baseline and at week 16.  RESULTS:  No differences were found between groups in positive or negative symptoms, mood, cognition, or global impression ratings.  Results were similar for the intention-to-treat (N=87) and completer (N=75) groups.  CONCLUSIONS:  For schizophrenia patients treated with 3 g/day of ethyl EPA, improvement in residual symptoms and cognitive impairment was no greater than for schizophrenia patients treated with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpjrX2QIQDJr9KldV63DuefW6udTcc2eaNmoGf-SHxKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mnot1akug%253D%253D&md5=d42ff74cb752a7a1966294dbe196e843</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.12.2071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.12.2071%26sid%3Dliteratum%253Aachs%26aulast%3DFenton%26aufirst%3DW.%2BS.%26aulast%3DDickerson%26aufirst%3DF.%26aulast%3DBoronow%26aufirst%3DJ.%26aulast%3DHibbeln%26aufirst%3DJ.%2BR.%26aulast%3DKnable%26aufirst%3DM.%26atitle%3DA%2520placebo-controlled%2520trial%2520of%2520omega-3%2520fatty%2520acid%2520%2528ethyl%2520eicosapentaenoic%2520acid%2529%2520supplementation%2520for%2520residual%2520symptoms%2520and%2520cognitive%2520impairment%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D2071%26epage%3D2074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Horrobin, D. F.</span><span> </span><span class="NLM_article-title">Omega-3 fatty acid for schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.160.1.188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12505833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FhtVWhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2003&pages=188-189&author=D.+F.+Horrobin&title=Omega-3+fatty+acid+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">omega-3 Fatty acid for schizophrenia</span></div><div class="casAuthors">Horrobin David F</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">188-9; author reply 189</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsO5OOVwADCMvLc4ARHEmzfW6udTcc2eZW_au0DwRUa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FhtVWhtA%253D%253D&md5=703fdda4b3394cdc41095d658485b671</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.160.1.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.160.1.188%26sid%3Dliteratum%253Aachs%26aulast%3DHorrobin%26aufirst%3DD.%2BF.%26atitle%3DOmega-3%2520fatty%2520acid%2520for%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2003%26volume%3D160%26spage%3D188%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Bartzokis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuechterlein, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altshuler, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mintz, J.</span><span> </span><span class="NLM_article-title">Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2007.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17407804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2svgtFSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2007&pages=13-22&author=G.+Bartzokisauthor=P.+H.+Luauthor=K.+H.+Nuechterleinauthor=M.+Gitlinauthor=C.+Doiauthor=N.+Edwardsauthor=C.+Lieuauthor=L.+L.+Altshulerauthor=J.+Mintz&title=Differential+effects+of+typical+and+atypical+antipsychotics+on+brain+myelination+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia</span></div><div class="casAuthors">Bartzokis George; Lu Po H; Nuechterlein Keith H; Gitlin Michael; Doi Clarissa; Edwards Nancy; Lieu Christopher; Altshuler Lori L; Mintz Jim</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">13-22</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">CONTEXT:  Imaging and post-mortem studies provide converging evidence that patients with schizophrenia have a dysregulated developmental trajectory of frontal lobe myelination even in adulthood.  Atypical antipsychotics have been shown to have a wide spectrum of efficacy across multiple psychiatric diseases and to be particularly efficacious in treatment resistant cases of disorders such as schizophrenia.  OBJECTIVE:  To test the a priori hypothesis that antipsychotic medications may differentially impact frontal lobe myelination in patients with schizophrenia.  DESIGN, SETTING, AND PARTICIPANTS:  Participants ranged in age from 18-35 years, were all male, and were recruited by a single group of investigators using the same criteria.  Two cohorts of subjects with schizophrenia early in their disease who were treated either with oral risperidone (Ris) or fluphenazine decanoate (Fd) were imaged in conjunction with cohorts of healthy controls.  Each cohort was imaged using a different MRI instrument using identical imaging sequences.  MAIN OUTCOME MEASURE:  MRI measures of frontal lobe white matter volume.  RESULTS:  We estimated differences due to differences in the MRI instruments used in the two studies in the two healthy control groups matched to the patient samples, adjusting for age and other covariates.  We then statistically removed those differences (which we assumed were due to instrument effects) from the data in the schizophrenia samples by subtraction.  Relative to the differences seen in controls, the two groups of schizophrenic patients differed in their pattern of frontal lobe structure with the Ris-treated group having significantly larger white matter volume than the Fd group.  CONCLUSIONS:  The results suggest that the choice of antipsychotic treatment may differentially impact brain myelination in adults with schizophrenia.  Prospective studies are needed to confirm this finding.  MRI can be used to dissect subtle differences in brain tissue characteristics and thus could help clarify the effect of pharmacologic treatments on neurodevelopmental and pathologic processes in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZ4Oqj7RRORXO4gDb7JggCfW6udTcc2eZW_au0DwRUa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svgtFSrsQ%253D%253D&md5=6cee317df9bd90db873f7d5603249ead</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2007.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2007.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DBartzokis%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DP.%2BH.%26aulast%3DNuechterlein%26aufirst%3DK.%2BH.%26aulast%3DGitlin%26aufirst%3DM.%26aulast%3DDoi%26aufirst%3DC.%26aulast%3DEdwards%26aufirst%3DN.%26aulast%3DLieu%26aufirst%3DC.%26aulast%3DAltshuler%26aufirst%3DL.%2BL.%26aulast%3DMintz%26aufirst%3DJ.%26atitle%3DDifferential%2520effects%2520of%2520typical%2520and%2520atypical%2520antipsychotics%2520on%2520brain%2520myelination%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D93%26spage%3D13%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Owen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. C.</span><span> </span><span class="NLM_article-title">Schizophrenia: genes at last</span> <span class="citation_source-journal">Trends Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">518</span><span class="NLM_x">–</span> <span class="NLM_lpage">525</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.tig.2005.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16009449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Squ7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2005&pages=518-525&author=M.+J.+Owenauthor=N.+Craddockauthor=M.+C.+O%E2%80%99Donovan&title=Schizophrenia%3A+genes+at+last"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia: genes at last?</span></div><div class="casAuthors">Owen, M. J.; Craddock, N.; O'Donovan, M. C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">518-525</span>CODEN:
                <span class="NLM_cas:coden">TRGEE2</span>;
        ISSN:<span class="NLM_cas:issn">0168-9525</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Genetic epidemiol. studies suggest that individual variation in susceptibility to schizophrenia is largely genetic, reflecting alleles of moderate to small effect in multiple genes.  Mol. genetic studies have identified several potential regions of linkage and two assocd. chromosomal abnormalities, and evidence is accumulating in favor of several positional candidate genes.  Currently, the positional candidate genes for which we consider the evidence to be strong are those encoding dysbindin (DTNBP1) and neuregulin 1 (NRG1).  For other genes, disrupted in schizophrenia 1 (DISC1), D-amino-acid oxidase (DAO), D-amino-acid oxidase activator (DAOA, formerly known as G72) and regulator of G-protein signaling 4 (RGS4), the data are promising but not yet compelling.  The identification of these, and other susceptibility genes, will open up new avenues for research aimed at understanding the pathogenesis of schizophrenia, and will catalyze a re-appraisal of the classification of psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgdd8Y2a-2H7Vg90H21EOLACvtfcHk0lhDUATWsLo25A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Squ7o%253D&md5=19a3170e0a9a413f94d8f6d3fe6058cd</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.tig.2005.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tig.2005.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DCraddock%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26atitle%3DSchizophrenia%253A%2520genes%2520at%2520last%26jtitle%3DTrends%2520Genet.%26date%3D2005%26volume%3D21%26spage%3D518%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Harrison, P. J.</span><span> </span><span class="NLM_article-title">Schizophrenia susceptibility genes and neurodevelopment</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2007.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17481418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s3ntlShuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=1119-1120&author=P.+J.+Harrison&title=Schizophrenia+susceptibility+genes+and+neurodevelopment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia susceptibility genes and neurodevelopment</span></div><div class="casAuthors">Harrison Paul J</div><div class="citationInfo"><span class="NLM_cas:title">Biological psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-20</span>
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsatmfAEXXwFWTCLT8lX9SfW6udTcc2ebJmhanuaJIY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3ntlShuw%253D%253D&md5=0298cb28512bf0631b7ce968b633c8bc</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2007.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2007.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DP.%2BJ.%26atitle%3DSchizophrenia%2520susceptibility%2520genes%2520and%2520neurodevelopment%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D61%26spage%3D1119%26epage%3D1120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Arranz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Leon, J.</span><span> </span><span class="NLM_article-title">Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4002009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17549063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1Crurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=707-747&author=M.+J.+Arranzauthor=J.+de+Leon&title=Pharmacogenetics+and+pharmacogenomics+of+schizophrenia%3A+a+review+of+last+decade+of+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research</span></div><div class="casAuthors">Arranz, M. J.; de Leon, J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">707-747</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The last decade of research into the pharmacogenetics of antipsychotics has seen the development of genetic tests to det. the patients' metabolic status and the first attempts at personalization of antipsychotic treatment.  The most significant results are the assocn. between drug metabolic polymorphisms, mainly in cytochrome P 450 genes, with variations in drug metabolic rates and side effects.  Patients with genetically detd. CYP2D6 poor metabolizer (PMs) status may require lower doses of antipsychotic.  Alternatively, CYP2D6 ultrarapid metabolizers (UMs) will need increased drug dosage to obtain therapeutic response.  Addnl., polymorphisms in dopamine and serotonin receptor genes are repeatedly found assocd. with response phenotypes, probably reflecting the strong affinities that most antipsychotics display for these receptors.  In particular, there is important evidence suggesting assocn. between dopamine 2 receptor (D2) polymorphisms (Taq I and -141-C Ins/Del) and a dopamine 3 receptor (D3) polymorphism (Ser9Gly) with antipsychotic response and drug-induced tardive dyskinesia.  Addnl., there is accumulating evidence indicating the influence of a 5-HT2C polymorphism (-759-T/C) in antipsychotic-induced wt. gain.  Application of this knowledge to clin. practice is slowly gathering pace, with pretreatment detn. of individual's drug metabolic rates, via CYP genotyping, leading the field.  Genetic detn. of patients' metabolic status is expected to bring clin. benefits by helping to adjust therapeutic doses and reduce adverse reactions.  Genetic tests for the pretreatment prediction of antipsychotic response, although still in its infancy, have obvious implications for the selection and improvement of antipsychotic treatment.  These developments can be considered as successes, but the objectives of bringing pharmacogenetic and pharmacogenomic research in psychiatric clin. practice are far from being realized.  Further development of genetic tests is required before the concept of tailored treatment can be applied to psychopharmatherapy.  This review aims to summarize the key findings from the last decade of research in the field.  Current knowledge on genetic prediction of drug metabolic status, general response and drug-induced side effects will be reviewed and future pharmacogenomic and epigenetic research will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMc1xH6xQVzbVg90H21EOLACvtfcHk0ljU-iDxStJE-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1Crurc%253D&md5=abadb4851c30ba3856ec52dd5ee8bac3</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4002009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4002009%26sid%3Dliteratum%253Aachs%26aulast%3DArranz%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BLeon%26aufirst%3DJ.%26atitle%3DPharmacogenetics%2520and%2520pharmacogenomics%2520of%2520schizophrenia%253A%2520a%2520review%2520of%2520last%2520decade%2520of%2520research%26jtitle%3DMol.%2520Psychiatry%26date%3D2007%26volume%3D12%26spage%3D707%26epage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Ioannidis, J. P.</span><span> </span><span class="NLM_article-title">Commentary: grading the credibility of molecular evidence for complex diseases</span> <span class="citation_source-journal">Int. J. Epidemiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">572</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fije%2Fdyl003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16540537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28zjtVyitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2006&pages=572-578&author=J.+P.+Ioannidis&title=Commentary%3A+grading+the+credibility+of+molecular+evidence+for+complex+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Commentary: grading the credibility of molecular evidence for complex diseases</span></div><div class="casAuthors">Ioannidis John P A</div><div class="citationInfo"><span class="NLM_cas:title">International journal of epidemiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">572-8; discussion 593-6</span>
        ISSN:<span class="NLM_cas:issn">0300-5771</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyqotWrLt9_AvupmecNw_lfW6udTcc2ebJmhanuaJIY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zjtVyitg%253D%253D&md5=6587a7ef2d542e8e87c05c352b437008</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1093%2Fije%2Fdyl003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fije%252Fdyl003%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DJ.%2BP.%26atitle%3DCommentary%253A%2520grading%2520the%2520credibility%2520of%2520molecular%2520evidence%2520for%2520complex%2520diseases%26jtitle%3DInt.%2520J.%2520Epidemiol.%26date%3D2006%26volume%3D35%26spage%3D572%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Tunbridge, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Catechol-<i>o</i>-methyltransferase, cognition, and psychosis: Val158Met and beyond</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2005.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16476412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmsl2jurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=141-151&author=E.+M.+Tunbridgeauthor=P.+J.+Harrisonauthor=D.+R.+Weinberger&title=Catechol-o-methyltransferase%2C+cognition%2C+and+psychosis%3A+Val158Met+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond</span></div><div class="casAuthors">Tunbridge, Elizabeth M.; Harrison, Paul J.; Weinberger, Daniel R.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">This review summarizes our current understanding of catechol-o-methyltransferase (COMT) and how it relates to brain function and schizophrenia.  We begin by considering the COMT gene, its transcripts and proteins, and its relevance for central catecholamine function.  We then describe how variation in COMT activity affects the function of the prefrontal cortex (PFC) and assocd. areas, reviewing evidence that COMT modulates executive function and working memory and highlighting recent data that also implicate it in emotional processing.  Finally, we discuss briefly the genetic assocn. between COMT and schizophrenia, focusing in particular on the complex interaction of functional loci within the gene that may underlie the mixed results of studies to date.  We conclude by outlining preliminary data indicating that COMT is a promising therapeutic target for ameliorating the cognitive deficits assocd. with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp242swF50Jc7Vg90H21EOLACvtfcHk0ljU-iDxStJE-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmsl2jurw%253D&md5=18505f5bdbdaa84a38b47ca604e873fb</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DTunbridge%26aufirst%3DE.%2BM.%26aulast%3DHarrison%26aufirst%3DP.%2BJ.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DCatechol-o-methyltransferase%252C%2520cognition%252C%2520and%2520psychosis%253A%2520Val158Met%2520and%2520beyond%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D60%26spage%3D141%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Diatchenko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slade, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nackley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigurdsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabalina, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shagin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Max, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makarov, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maixner, W.</span><span> </span><span class="NLM_article-title">Genetic basis for individual variations in pain perception and the development of a chronic pain condition</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fhmg%2Fddi013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15537663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFGlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2005&pages=135-143&author=L.+Diatchenkoauthor=G.+D.+Sladeauthor=A.+G.+Nackleyauthor=K.+Bhalangauthor=A.+Sigurdssonauthor=I.+Belferauthor=D.+Goldmanauthor=K.+Xuauthor=S.+A.+Shabalinaauthor=D.+Shaginauthor=M.+B.+Maxauthor=S.+S.+Makarovauthor=W.+Maixner&title=Genetic+basis+for+individual+variations+in+pain+perception+and+the+development+of+a+chronic+pain+condition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic basis for individual variations in pain perception and the development of a chronic pain condition</span></div><div class="casAuthors">Diatchenko, Luda; Slade, Gary D.; Nackley, Andrea G.; Bhalang, Konakporn; Sigurdsson, Asgeir; Belfer, Inna; Goldman, David; Xu, Ke; Shabalina, Svetlana A.; Shagin, Dmitry; Max, Mitchell B.; Makarov, Sergei S.; Maixner, William</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-143</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Pain sensitivity varies substantially among humans.  A significant part of the human population develops chronic pain conditions that are characterized by heightened pain sensitivity.  We identified three genetic variants (haplotypes) of the gene encoding catecholamine-O-methyltransferase (COMT) that we designated as low pain sensitivity (LPS), av. pain sensitivity (APS) and high pain sensitivity (HPS).  We show that these haplotypes encompass 96% of the human population, and five combinations of these haplotypes are strongly assocd. (P=0.0004) with variation in the sensitivity to exptl. pain.  The presence of even a single LPS haplotype diminishes, by as much as 2.3 times, the risk of developing myogenous temporomandibular joint disorder (TMD), a common musculoskeletal pain condition.  The LPS haplotype produces much higher levels of COMT enzymic activity when compared with the APS or HPS haplotypes.  Inhibition of COMT in the rat results in a profound increase in pain sensitivity.  Thus, COMT activity substantially influences pain sensitivity, and the three major haplotypes det. COMT activity in humans that inversely correlates with pain sensitivity and the risk of developing TMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogws27k2gPu7Vg90H21EOLACvtfcHk0lhyTFYfTxjyog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFGlsA%253D%253D&md5=475889479a249d6ac898612693d97182</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddi013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddi013%26sid%3Dliteratum%253Aachs%26aulast%3DDiatchenko%26aufirst%3DL.%26aulast%3DSlade%26aufirst%3DG.%2BD.%26aulast%3DNackley%26aufirst%3DA.%2BG.%26aulast%3DBhalang%26aufirst%3DK.%26aulast%3DSigurdsson%26aufirst%3DA.%26aulast%3DBelfer%26aufirst%3DI.%26aulast%3DGoldman%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DShabalina%26aufirst%3DS.%2BA.%26aulast%3DShagin%26aufirst%3DD.%26aulast%3DMax%26aufirst%3DM.%2BB.%26aulast%3DMakarov%26aufirst%3DS.%2BS.%26aulast%3DMaixner%26aufirst%3DW.%26atitle%3DGenetic%2520basis%2520for%2520individual%2520variations%2520in%2520pain%2520perception%2520and%2520the%2520development%2520of%2520a%2520chronic%2520pain%2520condition%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2005%26volume%3D14%26spage%3D135%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Alsobrook, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zohar, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leboyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabane, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebstein, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, D. L.</span><span> </span><span class="NLM_article-title">Association between the COMT locus and obsessive-compulsive disorder in females but not males</span> <span class="citation_source-journal">Am. J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2Fajmg.10040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11840516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD387hvVahsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2002&pages=116-120&author=J.+P.+Alsobrookauthor=A.+H.+Zoharauthor=M.+Leboyerauthor=N.+Chabaneauthor=R.+P.+Ebsteinauthor=D.+L.+Pauls&title=Association+between+the+COMT+locus+and+obsessive-compulsive+disorder+in+females+but+not+males"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Association between the COMT locus and obsessive-compulsive disorder in females but not males</span></div><div class="casAuthors">Alsobrook John P 2nd; Zohar Ada H; Leboyer Marion; Chabane Nadia; Ebstein Richard P; Pauls David L</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-20</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">A polymorphism in the coding region of catechol-O-methyltransferase gene (COMT) was previously reported to be associated with obsessive-compulsive disorder (OCD), particularly in male probands.  We attempted to replicate the previous finding using a family-based genetic design in haplotype relative risk (HRR) and transmission disequilibrium (TDT) analyses.  Fifty-six OCD probands and their parents were genotyped for the COMT locus using established methods.  Analysis of allele and genotype frequencies between the proband genotypes and the control (parental nontransmitted) genotypes failed to replicate the previous finding of gender divergence, gave no evidence of overall association, nor was linkage detected by TDT.  However, further analysis of the COMT allele frequencies by proband gender gave evidence of a mildly significant association with the low-activity COMT allele in female probands (P=0.049), but not in male probands.  These findings indicate that COMT may be etiologically relevant to OCD in a gender-specific manner opposite to that shown in previous studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXMeBCgq3LydFxYDaSSP8XfW6udTcc2ea87MuwXJ9yKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387hvVahsg%253D%253D&md5=d1f9d8e2235629763465b7532c009151</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1002%2Fajmg.10040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajmg.10040%26sid%3Dliteratum%253Aachs%26aulast%3DAlsobrook%26aufirst%3DJ.%2BP.%26aulast%3DZohar%26aufirst%3DA.%2BH.%26aulast%3DLeboyer%26aufirst%3DM.%26aulast%3DChabane%26aufirst%3DN.%26aulast%3DEbstein%26aufirst%3DR.%2BP.%26aulast%3DPauls%26aufirst%3DD.%2BL.%26atitle%3DAssociation%2520between%2520the%2520COMT%2520locus%2520and%2520obsessive-compulsive%2520disorder%2520in%2520females%2520but%2520not%2520males%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%26date%3D2002%26volume%3D114%26spage%3D116%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Erdal, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herken, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlu, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayazit, Y. A.</span><span> </span><span class="NLM_article-title">Significance of catechol-<i>O</i>-methyltransferase gene polymorphism in myofacial pain syndrome</span> <span class="citation_source-journal">Pain Clinic</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1163%2F156856903767650844" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=309-313&author=M.+E.+Erdalauthor=H.+Herkenauthor=M.+N.+Mutluauthor=Y.+A.+Bayazit&title=Significance+of+catechol-O-methyltransferase+gene+polymorphism+in+myofacial+pain+syndrome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1163%2F156856903767650844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1163%252F156856903767650844%26sid%3Dliteratum%253Aachs%26aulast%3DErdal%26aufirst%3DM.%2BE.%26aulast%3DHerken%26aufirst%3DH.%26aulast%3DMutlu%26aufirst%3DM.%2BN.%26aulast%3DBayazit%26aufirst%3DY.%2BA.%26atitle%3DSignificance%2520of%2520catechol-O-methyltransferase%2520gene%2520polymorphism%2520in%2520myofacial%2520pain%2520syndrome%26jtitle%3DPain%2520Clinic%26date%3D2003%26volume%3D15%26spage%3D309%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Goodman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavigne, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helzlsouer, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selhub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yager, J. D.</span><span> </span><span class="NLM_article-title">COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1661</span><span class="NLM_x">–</span> <span class="NLM_lpage">1665</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=1661-1665&author=J.+E.+Goodmanauthor=J.+A.+Lavigneauthor=K.+Wuauthor=K.+J.+Helzlsouerauthor=P.+T.+Stricklandauthor=J.+Selhubauthor=J.+D.+Yager&title=COMT+genotype%2C+micronutrients+in+the+folate+metabolic+pathway+and+breast+cancer+risk"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DJ.%2BE.%26aulast%3DLavigne%26aufirst%3DJ.%2BA.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DHelzlsouer%26aufirst%3DK.%2BJ.%26aulast%3DStrickland%26aufirst%3DP.%2BT.%26aulast%3DSelhub%26aufirst%3DJ.%26aulast%3DYager%26aufirst%3DJ.%2BD.%26atitle%3DCOMT%2520genotype%252C%2520micronutrients%2520in%2520the%2520folate%2520metabolic%2520pathway%2520and%2520breast%2520cancer%2520risk%26jtitle%3DCarcinogenesis%26date%3D2001%26volume%3D22%26spage%3D1661%26epage%3D1665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Voutilainen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuomainen, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korhonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mursu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virtanen, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Happonen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfthan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlund, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">North, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosher, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauhanen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiihonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salonen, J. T.</span><span> </span><span class="NLM_article-title">Functional COMT Val158Met polymorphism, risk of acute coronary events and serum homocysteine: the kuopio ischaemic heart disease risk factor study</span> <span class="citation_source-journal">PLoS ONE</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e181</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=e181&author=S.+Voutilainenauthor=T.+P.+Tuomainenauthor=M.+Korhonenauthor=J.+Mursuauthor=J.+K.+Virtanenauthor=P.+Happonenauthor=G.+Alfthanauthor=I.+Erlundauthor=K.+E.+Northauthor=M.+J.+Mosherauthor=J.+Kauhanenauthor=J.+Tiihonenauthor=G.+A.+Kaplanauthor=J.+T.+Salonen&title=Functional+COMT+Val158Met+polymorphism%2C+risk+of+acute+coronary+events+and+serum+homocysteine%3A+the+kuopio+ischaemic+heart+disease+risk+factor+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVoutilainen%26aufirst%3DS.%26aulast%3DTuomainen%26aufirst%3DT.%2BP.%26aulast%3DKorhonen%26aufirst%3DM.%26aulast%3DMursu%26aufirst%3DJ.%26aulast%3DVirtanen%26aufirst%3DJ.%2BK.%26aulast%3DHapponen%26aufirst%3DP.%26aulast%3DAlfthan%26aufirst%3DG.%26aulast%3DErlund%26aufirst%3DI.%26aulast%3DNorth%26aufirst%3DK.%2BE.%26aulast%3DMosher%26aufirst%3DM.%2BJ.%26aulast%3DKauhanen%26aufirst%3DJ.%26aulast%3DTiihonen%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DG.%2BA.%26aulast%3DSalonen%26aufirst%3DJ.%2BT.%26atitle%3DFunctional%2520COMT%2520Val158Met%2520polymorphism%252C%2520risk%2520of%2520acute%2520coronary%2520events%2520and%2520serum%2520homocysteine%253A%2520the%2520kuopio%2520ischaemic%2520heart%2520disease%2520risk%2520factor%2520study%26jtitle%3DPLoS%2520ONE%26date%3D2007%26volume%3D2%26spage%3De181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Frisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danziger, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelovsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenig, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mimouni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizman, A.</span><span> </span><span class="NLM_article-title">Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4000830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11317231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFGlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=243-245&author=A.+Frischauthor=N.+Lauferauthor=Y.+Danzigerauthor=E.+Michaelovskyauthor=S.+Leorauthor=C.+Carelauthor=D.+Steinauthor=S.+Fenigauthor=M.+Mimouniauthor=A.+Apterauthor=A.+Weizman&title=Association+of+anorexia+nervosa+with+the+high+activity+allele+of+the+COMT+gene%3A+a+family-based+study+in+Israeli+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients</span></div><div class="casAuthors">Frisch, A.; Laufer, N.; Danziger, Y.; Michaelovsky, E.; Leor, S.; Carel, C.; Stein, D.; Fenig, S.; Mimouni, M.; Apter, A.; Weizman, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-245</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Anorexia nervosa (AN) is a common, severe and disabling psychiatric disorder, characterized by profound wt. loss and body image disturbance.  Family and twin studies indicate a significant genetic contribution and pharmacol. data suggest possible dysfunction of the serotonergic and dopaminergic pathways.  Catechol-O-methyltransferase (COMT) is a candidate gene for mediating susceptibility to AN since it is involved in the dopamine catabolism and because its functional polymorphism (Val/Met 158) dets. high (H) and low (L) enzymic activity alleles.  51 Israeli AN patients and their parents were genotyped with the COMT polymorphism.  Using the haplotype relative risk (HRR) method it was found that the frequency of the H allele among alleles transmitted to AN patients from their parents was significantly higher than in those not transmitted (68% vs 51% X2 = 5.20, df = 1, P = 0.023, odds ratio: 2.01).  Transmission disequil. test (TDT) revealed that out of 49 heterozygote parents the H allele was transmitted to AN patients 33 times while the L allele was transmitted only 16 (McNemar's X2 = 5.90, df = 1, P = 0.015).  The study suggests that the COMT gene is assocd. with genetic susceptibility to AN, and that individuals homozygous for the high activity allele (HH) have a 2-fold increased risk for development of the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfFok5w6jlcrVg90H21EOLACvtfcHk0liQH_a8gnHSyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFGlu7Y%253D&md5=2a2e9b029bf90be11a858602bf7a3039</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4000830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4000830%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DA.%26aulast%3DLaufer%26aufirst%3DN.%26aulast%3DDanziger%26aufirst%3DY.%26aulast%3DMichaelovsky%26aufirst%3DE.%26aulast%3DLeor%26aufirst%3DS.%26aulast%3DCarel%26aufirst%3DC.%26aulast%3DStein%26aufirst%3DD.%26aulast%3DFenig%26aufirst%3DS.%26aulast%3DMimouni%26aufirst%3DM.%26aulast%3DApter%26aufirst%3DA.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DAssociation%2520of%2520anorexia%2520nervosa%2520with%2520the%2520high%2520activity%2520allele%2520of%2520the%2520COMT%2520gene%253A%2520a%2520family-based%2520study%2520in%2520Israeli%2520patients%26jtitle%3DMol.%2520Psychiatry%26date%3D2001%26volume%3D6%26spage%3D243%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">McGrath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawachi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascherio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colditz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, I.</span><span> </span><span class="NLM_article-title">Association between catechol-<i>O</i>-methyltransferase and phobic anxiety</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">1703</span><span class="NLM_x">–</span> <span class="NLM_lpage">1705</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.161.9.1703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15337664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2cvjtVSitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2004&pages=1703-1705&author=M.+McGrathauthor=I.+Kawachiauthor=A.+Ascherioauthor=G.+A.+Colditzauthor=D.+J.+Hunterauthor=I.+De+Vivo&title=Association+between+catechol-O-methyltransferase+and+phobic+anxiety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Association between catechol-O-methyltransferase and phobic anxiety</span></div><div class="casAuthors">McGrath Monica; Kawachi Ichiro; Ascherio Alberto; Colditz Graham A; Hunter David J; De Vivo Immaculata</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1703-5</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The authors assessed the association between the catechol-O-methyltransferase (COMT) Val158Met polymorphism and scores on the phobic anxiety scale of the Crown-Crisp Experimental Index.  METHOD:  A total of 1,234 women completed the Crown-Crisp Experimental Index phobic anxiety scale and were genotyped for the COMT polymorphism.  The authors used unconditional logistic regression to compute odds ratios and 95% confidence intervals (CIs) to evaluate the association between the COMT genotype and phobic anxiety.  RESULTS:  The mean scores for the three genotypes were statistically significantly different.  Compared to the COMT Met/Met genotype, the age-adjusted odds ratio for scoring >/=6 compared to scoring 0 or 1 were 1.15 (95% CI=0.71-1.85) and 1.99 (95% CI=1.17-3.40) for the COMT Val/Met and COMT Val/Val genotypes, respectively; a significant gene dosage effect was observed.  CONCLUSIONS:  Our results suggest that the functional COMT polymorphism is associated with the development of phobic anxiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQADwu3Vrlx25dYoSR9eyvsfW6udTcc2eZvbjCQx29KK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvjtVSitQ%253D%253D&md5=7d56b7ee71482410f9f43b343aad47e7</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.161.9.1703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.161.9.1703%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DM.%26aulast%3DKawachi%26aufirst%3DI.%26aulast%3DAscherio%26aufirst%3DA.%26aulast%3DColditz%26aufirst%3DG.%2BA.%26aulast%3DHunter%26aufirst%3DD.%2BJ.%26aulast%3DDe%2BVivo%26aufirst%3DI.%26atitle%3DAssociation%2520between%2520catechol-O-methyltransferase%2520and%2520phobic%2520anxiety%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2004%26volume%3D161%26spage%3D1703%26epage%3D1705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Woo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, B. H.</span><span> </span><span class="NLM_article-title">The association between panic disorder and the L/L genotype of catechol-<i>O</i>-methyltransferase</span> <span class="citation_source-journal">J. Psychiatr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.jpsychires.2004.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15203287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2czgtlemsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2004&pages=365-370&author=J.+M.+Wooauthor=K.+S.+Yoonauthor=Y.+H.+Choiauthor=K.+S.+Ohauthor=Y.+S.+Leeauthor=B.+H.+Yu&title=The+association+between+panic+disorder+and+the+L%2FL+genotype+of+catechol-O-methyltransferase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The association between panic disorder and the L/L genotype of catechol-O-methyltransferase</span></div><div class="casAuthors">Woo Jong-Min; Yoon Kyung-Sik; Choi Young-Hee; Oh Kang-Sub; Lee Young-Sik; Yu Bum-Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">365-70</span>
        ISSN:<span class="NLM_cas:issn">0022-3956</span>.
    </div><div class="casAbstract">To clarify the role of catechol-O-methyltransferase (COMT) polymorphism in panic disorder (PD), we investigated a large group of Korean PD patients (N = 178) and controls (N = 182) using a case-control study.  We also assessed the response to paroxetine treatment and other clinical variables in the PD patients.  The increase in the COMT(L) allele was not statistically significant in PD (p = 0.104).  However, compared with the sum of the other genotypes, the frequency of the L/L genotype was significantly higher in PD (p = 0.042).  The odd ratios (ORs) also indicated a significant effect of the homozygosity for the COMT(L) allele on an increased risk for PD (OR=2.38; 95% CI 1.03-5.51).  In addition, patients with L/L genotype had higher trait-anxiety levels (p = 0.030) and poorer treatment response to paroxetine than those with other genotypes (p = 0.002).  Our results suggest that the COMT L/L genotype is associated with PD and the genetic variant of the COMT enzyme may be related to the clinical severity and treatment response to paroxetine in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuwYbRV842iBe4jJGKT5N0fW6udTcc2eZvbjCQx29KK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czgtlemsw%253D%253D&md5=1b37515d2059c988175fef918f5bcaa9</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2004.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2004.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DJ.%2BM.%26aulast%3DYoon%26aufirst%3DK.%2BS.%26aulast%3DChoi%26aufirst%3DY.%2BH.%26aulast%3DOh%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DYu%26aufirst%3DB.%2BH.%26atitle%3DThe%2520association%2520between%2520panic%2520disorder%2520and%2520the%2520L%252FL%2520genotype%2520of%2520catechol-O-methyltransferase%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2004%26volume%3D38%26spage%3D365%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Baune, B. T.; Hohoff, C.; Berger, K.; Neumann, A.; Mortensen, S.; Roehrs, T.; Deckert, J.; Arolt, V.; Domschke, K.</span><span> </span><span class="NLM_article-title">Association of the COMT val158met variant with antidepressant treatment response in major depression</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Baune%2C+B.+T.%3B+Hohoff%2C+C.%3B+Berger%2C+K.%3B+Neumann%2C+A.%3B+Mortensen%2C+S.%3B+Roehrs%2C+T.%3B+Deckert%2C+J.%3B+Arolt%2C+V.%3B+Domschke%2C+K.+Association+of+the+COMT+val158met+variant+with+antidepressant+treatment+response+in+major+depression.+Neuropsychopharmacology%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaune%26aufirst%3DB.%2BT.%26atitle%3DAssociation%2520of%2520the%2520COMT%2520val158met%2520variant%2520with%2520antidepressant%2520treatment%2520response%2520in%2520major%2520depression%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Borroni, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agosti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghianda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenzi, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caimi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Luca, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padovani, A.</span><span> </span><span class="NLM_article-title">Catechol-<i>O</i>-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer disease</span> <span class="citation_source-journal">Neurosci. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2004&pages=127-129&author=B.+Borroniauthor=C.+Agostiauthor=S.+Archettiauthor=C.+Costanziauthor=S.+Bonomiauthor=D.+Ghiandaauthor=G.+L.+Lenziauthor=L.+Caimiauthor=M.+Di+Lucaauthor=A.+Padovani&title=Catechol-O-methyltransferase+gene+polymorphism+is+associated+with+risk+of+psychosis+in+Alzheimer+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBorroni%26aufirst%3DB.%26aulast%3DAgosti%26aufirst%3DC.%26aulast%3DArchetti%26aufirst%3DS.%26aulast%3DCostanzi%26aufirst%3DC.%26aulast%3DBonomi%26aufirst%3DS.%26aulast%3DGhianda%26aufirst%3DD.%26aulast%3DLenzi%26aufirst%3DG.%2BL.%26aulast%3DCaimi%26aufirst%3DL.%26aulast%3DDi%2BLuca%26aufirst%3DM.%26aulast%3DPadovani%26aufirst%3DA.%26atitle%3DCatechol-O-methyltransferase%2520gene%2520polymorphism%2520is%2520associated%2520with%2520risk%2520of%2520psychosis%2520in%2520Alzheimer%2520disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D2004%26volume%3D370%26spage%3D127%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">The genome: five years on</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16425665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28%252Fjsl2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=14-17&author=M.+Williams&title=The+genome%3A+five+years+on"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The genome: five years on</span></div><div class="casAuthors">Williams Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in investigational drugs (London, England : 2000)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-7</span>
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3trd7SzcHM_6BottYdIAWfW6udTcc2ebm1N5RS15bn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252Fjsl2qtw%253D%253D&md5=cb4a4715130c6633f904daed207f65a8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DThe%2520genome%253A%2520five%2520years%2520on%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2006%26volume%3D7%26spage%3D14%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Bassett, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">AbdelMalik, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheorghiu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husted, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weksberg, R.</span><span> </span><span class="NLM_article-title">The schizophrenia phenotype in 22q11 deletion syndrome</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1580</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.160.9.1580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12944331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3svgsFWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2003&pages=1580-1586&author=A.+S.+Bassettauthor=E.+W.+Chowauthor=P.+AbdelMalikauthor=M.+Gheorghiuauthor=J.+Hustedauthor=R.+Weksberg&title=The+schizophrenia+phenotype+in+22q11+deletion+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">The schizophrenia phenotype in 22q11 deletion syndrome</span></div><div class="casAuthors">Bassett Anne S; Chow Eva W C; AbdelMalik Philip; Gheorghiu Mirona; Husted Janice; Weksberg Rosanna</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1580-6</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  This study investigated the schizophrenia phenotype in 24 subjects with 22q11 deletion syndrome (22qDS) and schizophrenia (22qDS-schizophrenia), a rare but relatively homogenous genetic subtype of schizophrenia associated with a microdeletion on chromosome 22.  Individuals with 22qDS are at genetically high risk for schizophrenia.  METHOD:  Standard measures of signs, symptoms, and course of schizophrenia were assessed in 16 adults with 22qDS-schizophrenia who did not meet criteria for mental retardation and in 46 adults with schizophrenia without evidence of 22qDS from a community familial sample.  RESULTS:  There were no significant differences in age at onset, lifetime or cross-sectional core positive and negative schizophrenic symptoms, or global functioning between the two groups of patients with schizophrenia.  Patients with 22qDS-schizophrenia had higher excitement subscale scores and less lifetime substance use than the comparison patients with schizophrenia, but no significant differences in anxiety-depression symptom severity were found between the groups.  CONCLUSIONS:  These findings indicate that the core clinical schizophrenia phenotype would not distinguish individuals with a 22qDS subtype from those with schizophrenia who did not have the 22qDS subtype.  The results provide further support for the utility of 22qDS-schizophrenia as a neurodevelopmental model of schizophrenia as well as support for prospective studies of individuals with 22qDS to help identify precursors of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREF4-5Nt9cPuIHSmpohpd0fW6udTcc2ebm1N5RS15bn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgsFWmtw%253D%253D&md5=23337cc52c5e8ca653c7a68958f0f52c</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.160.9.1580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.160.9.1580%26sid%3Dliteratum%253Aachs%26aulast%3DBassett%26aufirst%3DA.%2BS.%26aulast%3DChow%26aufirst%3DE.%2BW.%26aulast%3DAbdelMalik%26aufirst%3DP.%26aulast%3DGheorghiu%26aufirst%3DM.%26aulast%3DHusted%26aufirst%3DJ.%26aulast%3DWeksberg%26aufirst%3DR.%26atitle%3DThe%2520schizophrenia%2520phenotype%2520in%252022q11%2520deletion%2520syndrome%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2003%26volume%3D160%26spage%3D1580%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Bassett, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caluseriu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weksberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, E. W.</span><span> </span><span class="NLM_article-title">Catechol-<i>O</i>-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1135</span><span class="NLM_x">–</span> <span class="NLM_lpage">1140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2006.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17217925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFOrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=1135-1140&author=A.+S.+Bassettauthor=O.+Caluseriuauthor=R.+Weksbergauthor=D.+A.+Youngauthor=E.+W.+Chow&title=Catechol-O-methyl+transferase+and+expression+of+schizophrenia+in+73+adults+with+22q11+deletion+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Catechol-O-methyl Transferase and Expression of Schizophrenia in 73 Adults with 22q11 Deletion Syndrome</span></div><div class="casAuthors">Bassett, Anne S.; Caluseriu, Oana; Weksberg, Rosanna; Young, Donald A.; Chow, Eva W. C.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1135-1140</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Catechol-O-Me transferase (COMT) is a candidate gene for schizophrenia with a role in dopamine metab., particularly in frontal cortex.  COMT is within the region commonly deleted in 22q11 deletion syndrome (22q11DS), a syndrome with high prevalence of schizophrenia.  We examd. the role of COMT in schizophrenia-related expression in 22q11DS.  Methods: We genotyped the COMT functional Val158/108Met allele in 73 Caucasian adults with 22q11DS (36 men, 37 women; aged 33.8, SD 10.1 years; 37 Met, 36 Val hemizygosity) blind to clin. data and assessed effects on symptoms and frontal functioning.  Results: The lower activity Met allele was not significantly more prevalent than the Val allele in 33 subjects with schizophrenia.  Excitement symptoms were more severe, however, and three frontal cognitive tests (theory of mind, Trails B, and olfactory identification), communication, and social functioning measures showed significantly worse performance with Met allele hemizygosity, even after accounting for effects of schizophrenia.  Conclusions: The results suggest that hemizygosity of the COMT functional allele exerts an effect on some measures of frontal functioning in 22q11DS.  Elevated levels of tonic dopamine activation assocd. with the COMT Met allele may underlie these aspects of expression.  We must look elsewhere for causes of the high prevalence of schizophrenia in 22q11DS, however.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeokUayaUXdLVg90H21EOLACvtfcHk0lgV3WDMlz6W1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFOrurs%253D&md5=3a3493e6406da8bd13f819a34698e61d</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DBassett%26aufirst%3DA.%2BS.%26aulast%3DCaluseriu%26aufirst%3DO.%26aulast%3DWeksberg%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DD.%2BA.%26aulast%3DChow%26aufirst%3DE.%2BW.%26atitle%3DCatechol-O-methyl%2520transferase%2520and%2520expression%2520of%2520schizophrenia%2520in%252073%2520adults%2520with%252022q11%2520deletion%2520syndrome%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D61%26spage%3D1135%26epage%3D1140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Egan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolachana, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callicott, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzanti, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">6917</span><span class="NLM_x">–</span> <span class="NLM_lpage">6922</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=6917-6922&author=M.+F.+Eganauthor=T.+E.+Goldbergauthor=B.+S.+Kolachanaauthor=J.+H.+Callicottauthor=C.+M.+Mazzantiauthor=R.+E.+Straubauthor=D.+Goldmanauthor=D.+R.+Weinberger&title=Effect+of+COMT+Val108%2F158+Met+genotype+on+frontal+lobe+function+and+risk+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DKolachana%26aufirst%3DB.%2BS.%26aulast%3DCallicott%26aufirst%3DJ.%2BH.%26aulast%3DMazzanti%26aufirst%3DC.%2BM.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DGoldman%26aufirst%3DD.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DEffect%2520of%2520COMT%2520Val108%252F158%2520Met%2520genotype%2520on%2520frontal%2520lobe%2520function%2520and%2520risk%2520for%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D6917%26epage%3D6922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Boot, E.; Booij, J.; Zinkstok, J.; Abeling, N.; de Haan, L.; Baas, F.; Linszen, D.; van Amelsvoort, T.</span><span> </span><span class="NLM_article-title">Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Boot%2C+E.%3B+Booij%2C+J.%3B+Zinkstok%2C+J.%3B+Abeling%2C+N.%3B+de+Haan%2C+L.%3B+Baas%2C+F.%3B+Linszen%2C+D.%3B+van+Amelsvoort%2C+T.+Disrupted+dopaminergic+neurotransmission+in+22q11+deletion+syndrome.+Neuropsychopharmacology%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoot%26aufirst%3DE.%26atitle%3DDisrupted%2520dopaminergic%2520neurotransmission%2520in%252022q11%2520deletion%2520syndrome%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Lu, B. Y.; Martin, K. E.; Edgar, J. C.; Smith, A. K.; Lewis, S. F.; Escamilla, M. A.; Miller, G. A.; Canive, J. M.</span><span> </span><span class="NLM_article-title">Effect of catechol <i>O</i>-methyltransferase Val(158)Met polymorphism on the P50 gating endophenotype in schizophrenia</span>.  <span class="citation_source-journal">Biol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lu%2C+B.+Y.%3B+Martin%2C+K.+E.%3B+Edgar%2C+J.+C.%3B+Smith%2C+A.+K.%3B+Lewis%2C+S.+F.%3B+Escamilla%2C+M.+A.%3B+Miller%2C+G.+A.%3B+Canive%2C+J.+M.+Effect+of+catechol+O-methyltransferase+Val%28158%29Met+polymorphism+on+the+P50+gating+endophenotype+in+schizophrenia.+Biol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DB.%2BY.%26atitle%3DEffect%2520of%2520catechol%2520O-methyltransferase%2520Val%2528158%2529Met%2520polymorphism%2520on%2520the%2520P50%2520gating%2520endophenotype%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Funke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malhotra, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plocik, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lencz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRosse, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucherlapati, R.</span><span> </span><span class="NLM_article-title">COMT genetic variation confers risk for psychotic and affective disorders: a case control study</span> <span class="citation_source-journal">Behav. Brain Funct.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1186%2F1744-9081-1-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16232322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MngsVSjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=19&author=B.+Funkeauthor=A.+K.+Malhotraauthor=C.+T.+Finnauthor=A.+M.+Plocikauthor=S.+L.+Lakeauthor=T.+Lenczauthor=P.+DeRosseauthor=J.+M.+Kaneauthor=R.+Kucherlapati&title=COMT+genetic+variation+confers+risk+for+psychotic+and+affective+disorders%3A+a+case+control+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">COMT genetic variation confers risk for psychotic and affective disorders: a case control study</span></div><div class="casAuthors">Funke Birgit; Malhotra Anil K; Finn Christine T; Plocik Alex M; Lake Stephen L; Lencz Todd; DeRosse Pamela; Kane John M; Kucherlapati Raju</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral and brain functions : BBF</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Variation in the COMT gene has been implicated in a number of psychiatric disorders, including psychotic, affective and anxiety disorders.  The majority of these studies have focused on the functional Val108/158Met polymorphism and yielded conflicting results, with limited studies examining the relationship between other polymorphisms, or haplotypes, and psychiatric illness.  We hypothesized that COMT variation may confer a general risk for psychiatric disorders and have genotyped four COMT variants (Val158Met, rs737865, rs165599, and a SNP in the P2 promoter [-278A/G; rs2097603]) in 394 Caucasian cases and 467 controls.  Cases included patients with schizophrenia (n = 196), schizoaffective disorder (n = 62), bipolar disorder (n = 82), major depression (n = 30), and patients diagnosed with either psychotic disorder NOS or depressive disorder NOS (n = 24).  RESULTS:  SNP rs2097603, the Val/Met variant and SNP rs165599 were significantly associated (p = 0.004; p = 0.05; p = 0.035) with a broad "all affected" diagnosis.  Haplotype analysis revealed a potentially protective G-A-A-A haplotype haplotype (-278A/G; rs737865; Val108/158Met; rs165599), which was significantly underrepresented in this group (p = 0.0033) and contained the opposite alleles of the risk haplotype previously described by Shifman et al.  Analysis of diagnostic subgroups within the "all affecteds group" showed an association of COMT in patients with psychotic disorders as well as in cases with affective illness although the associated variants differed.  The protective haplotype remained significantly underrepresented in most of these subgroups.  CONCLUSION:  Our results support the view that COMT variation provides a weak general predisposition to neuropsychiatric disease including psychotic and affective disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSep6d9yAzxFoNpW7w2tapOfW6udTcc2ebJKTqokjyf27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MngsVSjsg%253D%253D&md5=2c981c5931addff99ecb4e267b8bb157</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1186%2F1744-9081-1-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1744-9081-1-19%26sid%3Dliteratum%253Aachs%26aulast%3DFunke%26aufirst%3DB.%26aulast%3DMalhotra%26aufirst%3DA.%2BK.%26aulast%3DFinn%26aufirst%3DC.%2BT.%26aulast%3DPlocik%26aufirst%3DA.%2BM.%26aulast%3DLake%26aufirst%3DS.%2BL.%26aulast%3DLencz%26aufirst%3DT.%26aulast%3DDeRosse%26aufirst%3DP.%26aulast%3DKane%26aufirst%3DJ.%2BM.%26aulast%3DKucherlapati%26aufirst%3DR.%26atitle%3DCOMT%2520genetic%2520variation%2520confers%2520risk%2520for%2520psychotic%2520and%2520affective%2520disorders%253A%2520a%2520case%2520control%2520study%26jtitle%3DBehav.%2520Brain%2520Funct.%26date%3D2005%26volume%3D1%26spage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Apud, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-<i>o</i>-methyltransferase inhibitors</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2165%2F00023210-200721070-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17579498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFCis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=535-557&author=J.+A.+Apudauthor=D.+R.+Weinberger&title=Treatment+of+cognitive+deficits+associated+with+schizophrenia%3A+potential+role+of+catechol-o-methyltransferase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of cognitive deficits associated with schizophrenia. Potential role of catechol-O-methyltransferase inhibitors</span></div><div class="casAuthors">Apud, Jose A.; Weinberger, Daniel R.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">535-557</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  In the last two decades, understanding of the dynamics of dopamine function in the prefrontal cortex and its role in prefrontal cortex physiol. has opened up new avenues for therapeutic interventions in conditions in which prefrontal cortex function is compromised.  Neuropsychol. and imaging studies of prefrontal information processing have confirmed specific cognitive and neurophysiol. abnormalities in individuals with schizophrenia.  Because such findings are also obsd. in the healthy siblings of patients with schizophrenia, they may represent intermediate phenotypes related to schizophrenia susceptibility genes.  Catechol-O-methyltransferase (COMT) represents an important candidate as a susceptibility gene for cognitive dysfunction in schizophrenia because of the unique role this enzyme plays in regulating prefrontal dopaminergic function.  A functional COMT polymorphism (Val158Met) predicts performance in tasks of prefrontal executive function and the neurophysiol. response measured with electroencephalog. and functional magnetic resonance imaging in tasks assessing working memory.  In fact, individuals with the Val/Val genotype, which encodes for the high-activity enzyme resulting in lower dopamine concns. in the prefrontal cortex, perform less well and are less efficient physiol. than Met/Met individuals.  These findings raise the possibility of new pharmacol. interventions for the treatment of prefrontal cortex dysfunction and of predicting outcome based on COMT genotype.  One strategy consists of the use of CNS-penetrant COMT inhibitors such as tolcapone.  A second strategy is to increase extracellular dopamine concns. in the frontal cortex by blocking the noradrenaline (norepinephrine) reuptake system, a secondary mechanism responsible for the disposal of dopamine from synaptic clefts in the prefrontal cortex.  A third possibility involves the use of modafinil, a drug with an unclear mechanism of action but with pos. effects on working memory in rodents.  The potential of these drugs to improve executive cognitive function by selectively increasing dopamine load in the frontal cortex but not in subcortical territories, and the possibility that response to them may be modified by a COMT polymorphism, provides a novel genotype-based targeted pharmacol. approach without abuse potential for the treatment of cognitive disorder in schizophrenia and in other conditions involving prefrontal cortex dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZmnS6TUnyZ7Vg90H21EOLACvtfcHk0lhYTRF33eiUpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFCis7s%253D&md5=380a19dbe5725aee9c41c264bee848ac</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.2165%2F00023210-200721070-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00023210-200721070-00002%26sid%3Dliteratum%253Aachs%26aulast%3DApud%26aufirst%3DJ.%2BA.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DTreatment%2520of%2520cognitive%2520deficits%2520associated%2520with%2520schizophrenia%253A%2520potential%2520role%2520of%2520catechol-o-methyltransferase%2520inhibitors%26jtitle%3DCNS%2520Drugs%26date%3D2007%26volume%3D21%26spage%3D535%26epage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Stefansson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigurdsson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinthorsdottir, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjornsdottir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigmundsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brynjolfsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunnarsdottir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivarsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjaltason, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birgisdottir, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonsson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudnadottir, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudmundsdottir, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjornsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingvarsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingason, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigfusson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardardottir, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sainz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johannesson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andresson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudbjartsson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manolescu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frigge, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulcher, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petursson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, K.</span><span> </span><span class="NLM_article-title">Neuregulin 1 and susceptibility to schizophrenia</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">877</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F342734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12145742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD38vos1CjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=877-892&author=H.+Stefanssonauthor=E.+Sigurdssonauthor=V.+Steinthorsdottirauthor=S.+Bjornsdottirauthor=T.+Sigmundssonauthor=S.+Ghoshauthor=J.+Brynjolfssonauthor=S.+Gunnarsdottirauthor=O.+Ivarssonauthor=T.+T.+Chouauthor=O.+Hjaltasonauthor=B.+Birgisdottirauthor=H.+Jonssonauthor=V.+G.+Gudnadottirauthor=E.+Gudmundsdottirauthor=A.+Bjornssonauthor=B.+Ingvarssonauthor=A.+Ingasonauthor=S.+Sigfussonauthor=H.+Hardardottirauthor=R.+P.+Harveyauthor=D.+Laiauthor=M.+Zhouauthor=D.+Brunnerauthor=V.+Mutelauthor=A.+Gonzaloauthor=G.+Lemkeauthor=J.+Sainzauthor=G.+Johannessonauthor=T.+Andressonauthor=D.+Gudbjartssonauthor=A.+Manolescuauthor=M.+L.+Friggeauthor=M.+E.+Gurneyauthor=A.+Kongauthor=J.+R.+Gulcherauthor=H.+Peturssonauthor=K.+Stefansson&title=Neuregulin+1+and+susceptibility+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin 1 and susceptibility to schizophrenia</span></div><div class="casAuthors">Stefansson Hreinn; Sigurdsson Engilbert; Steinthorsdottir Valgerdur; Bjornsdottir Soley; Sigmundsson Thordur; Ghosh Shyamali; Brynjolfsson Jon; Gunnarsdottir Steinunn; Ivarsson Omar; Chou Thomas T; Hjaltason Omar; Birgisdottir Birgitta; Jonsson Helgi; Gudnadottir Vala G; Gudmundsdottir Elsa; Bjornsson Asgeir; Ingvarsson Brynjolfur; Ingason Andres; Sigfusson Sigmundur; Hardardottir Hronn; Harvey Richard P; Lai Donna; Zhou Mingdong; Brunner Daniela; Mutel Vincent; Gonzalo Acuna; Lemke Greg; Sainz Jesus; Johannesson Gardar; Andresson Thorkell; Gudbjartsson Daniel; Manolescu Andrei; Frigge Michael L; Gurney Mark E; Kong Augustine; Gulcher Jeffrey R; Petursson Hannes; Stefansson Kari</div><div class="citationInfo"><span class="NLM_cas:title">American journal of human genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">877-92</span>
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    </div><div class="casAbstract">The cause of schizophrenia is unknown, but it has a significant genetic component.  Pharmacologic studies, studies of gene expression in man, and studies of mouse mutants suggest involvement of glutamate and dopamine neurotransmitter systems.  However, so far, strong association has not been found between schizophrenia and variants of the genes encoding components of these systems.  Here, we report the results of a genomewide scan of schizophrenia families in Iceland; these results support previous work, done in five populations, showing that schizophrenia maps to chromosome 8p.  Extensive fine-mapping of the 8p locus and haplotype-association analysis, supplemented by a transmission/disequilibrium test, identifies neuregulin 1 (NRG1) as a candidate gene for schizophrenia.  NRG1 is expressed at central nervous system synapses and has a clear role in the expression and activation of neurotransmitter receptors, including glutamate receptors.  Mutant mice heterozygous for either NRG1 or its receptor, ErbB4, show a behavioral phenotype that overlaps with mouse models for schizophrenia.  Furthermore, NRG1 hypomorphs have fewer functional NMDA receptors than wild-type mice.  We also demonstrate that the behavioral phenotypes of the NRG1 hypomorphs are partially reversible with clozapine, an atypical antipsychotic drug used to treat schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNlYdlXyBdeWhHGZei4OW9fW6udTcc2ebJKTqokjyf27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vos1CjtA%253D%253D&md5=416dbb13b7bb87c296f1fcfbadcfb64a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1086%2F342734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F342734%26sid%3Dliteratum%253Aachs%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSigurdsson%26aufirst%3DE.%26aulast%3DSteinthorsdottir%26aufirst%3DV.%26aulast%3DBjornsdottir%26aufirst%3DS.%26aulast%3DSigmundsson%26aufirst%3DT.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DBrynjolfsson%26aufirst%3DJ.%26aulast%3DGunnarsdottir%26aufirst%3DS.%26aulast%3DIvarsson%26aufirst%3DO.%26aulast%3DChou%26aufirst%3DT.%2BT.%26aulast%3DHjaltason%26aufirst%3DO.%26aulast%3DBirgisdottir%26aufirst%3DB.%26aulast%3DJonsson%26aufirst%3DH.%26aulast%3DGudnadottir%26aufirst%3DV.%2BG.%26aulast%3DGudmundsdottir%26aufirst%3DE.%26aulast%3DBjornsson%26aufirst%3DA.%26aulast%3DIngvarsson%26aufirst%3DB.%26aulast%3DIngason%26aufirst%3DA.%26aulast%3DSigfusson%26aufirst%3DS.%26aulast%3DHardardottir%26aufirst%3DH.%26aulast%3DHarvey%26aufirst%3DR.%2BP.%26aulast%3DLai%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DMutel%26aufirst%3DV.%26aulast%3DGonzalo%26aufirst%3DA.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DSainz%26aufirst%3DJ.%26aulast%3DJohannesson%26aufirst%3DG.%26aulast%3DAndresson%26aufirst%3DT.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DManolescu%26aufirst%3DA.%26aulast%3DFrigge%26aufirst%3DM.%2BL.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DGulcher%26aufirst%3DJ.%2BR.%26aulast%3DPetursson%26aufirst%3DH.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DNeuregulin%25201%2520and%2520susceptibility%2520to%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2002%26volume%3D71%26spage%3D877%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Bjarnadottir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haverfield-Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helgason, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigmundsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firth, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansdottir, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novak, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andresson, T.</span><span> </span><span class="NLM_article-title">Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/− knock-outs compared with wild-type mice</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4519</span><span class="NLM_x">–</span> <span class="NLM_lpage">4529</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1523%2FJNEUROSCI.4314-06.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17460065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltF2jtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=4519-4529&author=M.+Bjarnadottirauthor=D.+L.+Misnerauthor=S.+Haverfield-Grossauthor=S.+Bruunauthor=V.+G.+Helgasonauthor=H.+Stefanssonauthor=A.+Sigmundssonauthor=D.+R.+Firthauthor=B.+Nielsenauthor=R.+Stefansdottirauthor=T.+J.+Novakauthor=K.+Stefanssonauthor=M.+E.+Gurneyauthor=T.+Andresson&title=Neuregulin1+%28NRG1%29+signaling+through+Fyn+modulates+NMDA+receptor+phosphorylation%3A+differential+synaptic+function+in+NRG1%2B%2F%E2%88%92+knock-outs+compared+with+wild-type+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice</span></div><div class="casAuthors">Bjarnadottir, Maria; Misner, Dinah L.; Haverfield-Gross, Sascha; Bruun, Silas; Helgason, Vignir G.; Stefansson, Hreinn; Sigmundsson, Arnar; Firth, David R.; Nielsen, Berit; Stefansdottir, Ragnheidur; Novak, Thomas J.; Stefansson, Kari; Gurney, Mark E.; Andresson, Thorkell</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4519-4529</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">We previously identified Neuregulin 1 (NRG1) as a gene contributing to the risk of developing schizophrenia.  Furthermore, we showed that NRG1+/- mutant mice display behavioral abnormalities that are reversed by clozapine, an atypical antipsychotic drug used for the treatment of schizophrenia.  We now present evidence that ErbB4 (v-erb-a erythroblastic leukemia viral oncogene homolog 4), the tyrosine kinase receptor for NRG1 in hippocampal neurons, interacts with two nonreceptor tyrosine kinases, Fyn and Pyk2 (proline-rich tyrosine kinase 2).  NRG1 stimulation of cells expressing ErbB4 and Fyn leads to the assocn. of Fyn with ErbB4 and consequent activation.  Furthermore, we show that NRG1 signaling, through activation of Fyn and Pyk2 kinases, stimulates phosphorylation of Y1472 on the NR2B subunit of the NMDA receptor (NMDAR), a key regulatory site that modulates channel properties.  NR2B Y1472 is hypophosphorylated in NRG1+/- mutant mice, and this defect can be reversed by clozapine at a dose that reverses their behavioral abnormalities.  We also demonstrate that short-term synaptic plasticity is altered and theta-burst long-term potentiation is impaired in NRG1+/- mutant mice, and incubation of hippocampal slices from these mice with NRG1 reversed those effects.  Attenuated NRG1 signaling through ErbB4 may contribute to the pathophysiol. of schizophrenia through dysfunction of NMDAR modulation.  Thus, our data support the glutamate hypothesis of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXxhBS-u92bbVg90H21EOLACvtfcHk0li6ofmFPheEJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltF2jtbs%253D&md5=687aca3a32f7a2fa0ccc69abd4557984</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4314-06.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4314-06.2007%26sid%3Dliteratum%253Aachs%26aulast%3DBjarnadottir%26aufirst%3DM.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DHaverfield-Gross%26aufirst%3DS.%26aulast%3DBruun%26aufirst%3DS.%26aulast%3DHelgason%26aufirst%3DV.%2BG.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSigmundsson%26aufirst%3DA.%26aulast%3DFirth%26aufirst%3DD.%2BR.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DStefansdottir%26aufirst%3DR.%26aulast%3DNovak%26aufirst%3DT.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DAndresson%26aufirst%3DT.%26atitle%3DNeuregulin1%2520%2528NRG1%2529%2520signaling%2520through%2520Fyn%2520modulates%2520NMDA%2520receptor%2520phosphorylation%253A%2520differential%2520synaptic%2520function%2520in%2520NRG1%252B%252F%25E2%2588%2592%2520knock-outs%2520compared%2520with%2520wild-type%2520mice%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D4519%26epage%3D4529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Kampman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anttila, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saarela, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rontu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattila, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leinonen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehtimaki, T.</span><span> </span><span class="NLM_article-title">Neuregulin genotype and medication response in Finnish patients with schizophrenia</span> <span class="citation_source-journal">NeuroReport</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2517</span><span class="NLM_x">–</span> <span class="NLM_lpage">2520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=2517-2520&author=O.+Kampmanauthor=S.+Anttilaauthor=A.+Illiauthor=M.+Saarelaauthor=R.+Rontuauthor=K.+M.+Mattilaauthor=E.+Leinonenauthor=T.+Lehtimaki&title=Neuregulin+genotype+and+medication+response+in+Finnish+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKampman%26aufirst%3DO.%26aulast%3DAnttila%26aufirst%3DS.%26aulast%3DIlli%26aufirst%3DA.%26aulast%3DSaarela%26aufirst%3DM.%26aulast%3DRontu%26aufirst%3DR.%26aulast%3DMattila%26aufirst%3DK.%2BM.%26aulast%3DLeinonen%26aufirst%3DE.%26aulast%3DLehtimaki%26aufirst%3DT.%26atitle%3DNeuregulin%2520genotype%2520and%2520medication%2520response%2520in%2520Finnish%2520patients%2520with%2520schizophrenia%26jtitle%3DNeuroReport%26date%3D2004%26volume%3D15%26spage%3D2517%26epage%3D2520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Harrison, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, A. J.</span><span> </span><span class="NLM_article-title">Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2005.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16442083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmsl2jur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=132-140&author=P.+J.+Harrisonauthor=A.+J.+Law&title=Neuregulin+1+and+schizophrenia%3A+genetics%2C+gene+expression%2C+and+neurobiology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology</span></div><div class="casAuthors">Harrison, Paul J.; Law, Amanda J.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">132-140</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Neuregulin 1 (NRG1) is a leading schizophrenia susceptibility gene.  The NRG1 locus on chromosome 8p shows linkage to the disorder, and genetic assocn. has been found between schizophrenia and various non-coding polymorphisms and haplotypes, esp. at the 5' end of the NRG1 gene, in many but not all case-control and family studies.  NRG1 is a pleiotropic growth factor, important in nervous system development and functioning; roles include the modulation of neuronal migration, synaptogenesis, gliogenesis, neuron-glia communication, myelination, and neurotransmission.  Understanding the neurobiol. of NRG1 and its involvement in schizophrenia is challenged by the complexity of the gene, which gives rise to multiple functionally distinct isoforms, including six "types" of NRG1 defined by 5' exon usage.  Type IV and type I NRG1 may be particularly relevant to schizophrenia, with initial data showing altered expression of these isoforms in the disorder or in assocn. with NRG1 risk alleles.  We review the structure and functions of NRG1, consider the evidence for and against it being a schizophrenia susceptibility gene, and discuss mechanisms that might underlie the contribution of NRG1 to disease pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouJG1lix4yCLVg90H21EOLACvtfcHk0li6ofmFPheEJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmsl2jur8%253D&md5=139f04d4b824662e43d8daa96abd6c17</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DP.%2BJ.%26aulast%3DLaw%26aufirst%3DA.%2BJ.%26atitle%3DNeuregulin%25201%2520and%2520schizophrenia%253A%2520genetics%252C%2520gene%2520expression%252C%2520and%2520neurobiology%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D60%26spage%3D132%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Peirce, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskvina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preece, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxbaum, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. C.</span><span> </span><span class="NLM_article-title">Convergent evidence for 2′,3′-cyclic nucleotide 3′-phosphodiesterase as a possible susceptibility gene for schizophrenia</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.63.1.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16389193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1Cruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=18-24&author=T.+R.+Peirceauthor=N.+J.+Brayauthor=N.+M.+Williamsauthor=N.+Nortonauthor=V.+Moskvinaauthor=A.+Preeceauthor=V.+Haroutunianauthor=J.+D.+Buxbaumauthor=M.+J.+Owenauthor=M.+C.+O%E2%80%99Donovan&title=Convergent+evidence+for+2%E2%80%B2%2C3%E2%80%B2-cyclic+nucleotide+3%E2%80%B2-phosphodiesterase+as+a+possible+susceptibility+gene+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Convergent evidence for 2'3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia</span></div><div class="casAuthors">Peirce, Timothy R.; Bray, Nicholas J.; Williams, Nigel M.; Norton, Nadine; Moskvina, Valentina; Preece, Anna; Haroutunian, Vahram; Buxbaum, Joseph D.; Owen, Michael J.; O'Donovan, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-24</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Convergent data make 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) a candidate gene for schizophrenia.  Reduced expression has been reported in the schizophrenic brain.  The CNP gene maps to a region to which we have reported linkage to schizophrenia.  Mice in which the CNP gene has been knocked out display central nervous system pathol. characteristics reminiscent of some features obsd. in schizophrenia.  2',3'-Cyclic nucleotide 3'-phosphodiesterase is used as a marker of myelin-forming cells and is detectable in cells of oligodendrocyte lineage throughout life.  Because CNP is thought to be important for oligodendrocyte function, altered expression has been interpreted as supportive of the hypothesis that altered oligodendrocyte function may be an etiol. factor in schizophrenia.  However, it is unclear whether the obsd. changes in the schizophrenic brain are primary or secondary.  Objectives: To det. if CNP expression is influenced by DNA polymorphisms and to verify if these polymorphisms are assocd. with schizophrenia.  Design: Allele-specific mRNA expression assay and genetic assocn. studies.  Setting: Unrelated subjects were ascertained from secondary psychiatric inpatient and outpatient services.  Participants: We used brain tissue from 60 anonymous individuals with no known psychiatric disorder; a case-control sample of 708 white individuals from the United Kingdom meeting DSM-IV criteria for schizophrenia matched for age, sex, and ethnicity to 711 blood donor controls; and a pedigree with DNA from 6 affected siblings and 1 parent, showing evidence for linkage to CNP.  Main Outcome Measures: Assocn. between allele and gene expression.  Assocn. between allele and schizophrenia.  Results: The exonic single nucleotide polymorphism rs2070106 was assocd. with CNP expression (P<.001).  Compatible with underexpression of CNP mRNA in schizophrenia, the lower-expressing A allele was significantly assocd. with schizophrenia (P=.04) in die case-control sample.  All affected individuals in the linked pedigree were homozygous for the lower-expression allele, providing independent support for the assocn. (P=.03).  Conclusions: Our data support the hypothesis that reduced CNP expression in the schizophrenic brain is relevant to disease etiol. and therefore provide support for the general hypothesis that altered oligodendrocyte function is an etiol. factor in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovrELRdAwkxLVg90H21EOLACvtfcHk0liChy5BWM4EWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1Cruw%253D%253D&md5=8c93e92b773ac0e48dbd837895ca0f57</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.63.1.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.63.1.18%26sid%3Dliteratum%253Aachs%26aulast%3DPeirce%26aufirst%3DT.%2BR.%26aulast%3DBray%26aufirst%3DN.%2BJ.%26aulast%3DWilliams%26aufirst%3DN.%2BM.%26aulast%3DNorton%26aufirst%3DN.%26aulast%3DMoskvina%26aufirst%3DV.%26aulast%3DPreece%26aufirst%3DA.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DBuxbaum%26aufirst%3DJ.%2BD.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26atitle%3DConvergent%2520evidence%2520for%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-cyclic%2520nucleotide%25203%25E2%2580%25B2-phosphodiesterase%2520as%2520a%2520possible%2520susceptibility%2520gene%2520for%2520schizophrenia%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2006%26volume%3D63%26spage%3D18%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Corfas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxbaum, J. D.</span><span> </span><span class="NLM_article-title">Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia</span> <span class="citation_source-journal">Nat. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnn1258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15162166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1GgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=575-580&author=G.+Corfasauthor=K.+Royauthor=J.+D.+Buxbaum&title=Neuregulin+1-erbB+signaling+and+the+molecular%2Fcellular+basis+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia</span></div><div class="casAuthors">Corfas, Gabriel; Roy, Kristine; Buxbaum, Joseph D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">575-580</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is a devastating psychiatric disease that affects 0.5-1% of the world's adult population.  The hypothesis that this disease is a developmental disorder of the nervous system with late onset of its characteristic symptoms has been gaining acceptance in past years.  However, the anatomical, cellular and mol. bases of schizophrenia remain unclear.  Numerous studies point to alterations in different aspects of brain development as possible causes of schizophrenia, including defects in neuronal migration, neurotransmitter receptor expression and myelination.  Recently, the gene that encodes neuregulin-1 (NRG1) has been identified as a potential susceptibility gene for schizophrenia, and defects in the expression of erbB3, one of the NRG1 receptors, have been shown to occur in the prefrontal cortex of schizophrenic patients, suggesting that NRG1-erbB signaling is involved in the pathogenesis of schizophrenia.  These findings open new approaches to defining the mol. and cellular basis of schizophrenia in more mechanistic terms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdq9uN8qygebVg90H21EOLACvtfcHk0liChy5BWM4EWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1GgsLo%253D&md5=30a6191ac013370d8566f014b9440547</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnn1258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1258%26sid%3Dliteratum%253Aachs%26aulast%3DCorfas%26aufirst%3DG.%26aulast%3DRoy%26aufirst%3DK.%26aulast%3DBuxbaum%26aufirst%3DJ.%2BD.%26atitle%3DNeuregulin%25201-erbB%2520signaling%2520and%2520the%2520molecular%252Fcellular%2520basis%2520of%2520schizophrenia%26jtitle%3DNat.%2520Neurosci.%26date%3D2004%26volume%3D7%26spage%3D575%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Flynn, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goghari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vavasour, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittall, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwork, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falkai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honer, W. G.</span><span> </span><span class="NLM_article-title">Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">820</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12931208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsFWhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=811-820&author=S.+W.+Flynnauthor=D.+J.+Langauthor=A.+L.+Mackayauthor=V.+Goghariauthor=I.+M.+Vavasourauthor=K.+P.+Whittallauthor=G.+N.+Smithauthor=V.+Arangoauthor=J.+J.+Mannauthor=A.+J.+Dworkauthor=P.+Falkaiauthor=W.+G.+Honer&title=Abnormalities+of+myelination+in+schizophrenia+detected+in+vivo+with+MRI%2C+and+post-mortem+with+analysis+of+oligodendrocyte+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins</span></div><div class="casAuthors">Flynn, S. W.; Lang, D. J.; Mackay, A. L.; Goghari, V.; Vavasour, I. M.; Whittall, K. P.; Smith, G. N.; Arango, V.; Mann, J. J.; Dwork, A. J.; Falkai, P.; Honer, W. G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">811-820</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Schizophrenia unfolds during the late period of brain maturation, while myelination is still continuing.  In the present study, the authors used MRI and T2 relaxation anal. to measure the myelin water fraction in schizophrenia.  In schizophrenia (n=30) compared with healthy subjects (n=27), overall white matter showed 12% lower myelin water fraction (P=0.031), with the most prominent effects on the left genu of the corpus callosum (36% lower, P=0.002).  The left anterior genu was affected in both first-episode (P=0.035) and chronic patients (P=0.011).  In healthy subjects, myelin water fraction in total white matter and in frontal white matter increased with age, and with years of education, indicating ongoing maturation.  In patients with schizophrenia, neither relation was statistically significant.  Post-mortem studies of anterior frontal cortex demonstrated less immunoreactivity of 2 oligodendrocyte-assocd. proteins in schizophrenia (2',3'-cyclic nucleotide 3'-phosphodiesterase by 33%, P=0.05; myelin-assocd. glycoprotein by 27%, P=0.14).  Impaired myelination in schizophrenia could contribute to abnormalities of neural connectivity and persistent functional impairment in the illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtKIMDeH25E7Vg90H21EOLACvtfcHk0liChy5BWM4EWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsFWhtrY%253D&md5=bcc7ced371935d122b5a174e3d0d2b9b</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001337%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DS.%2BW.%26aulast%3DLang%26aufirst%3DD.%2BJ.%26aulast%3DMackay%26aufirst%3DA.%2BL.%26aulast%3DGoghari%26aufirst%3DV.%26aulast%3DVavasour%26aufirst%3DI.%2BM.%26aulast%3DWhittall%26aufirst%3DK.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BN.%26aulast%3DArango%26aufirst%3DV.%26aulast%3DMann%26aufirst%3DJ.%2BJ.%26aulast%3DDwork%26aufirst%3DA.%2BJ.%26aulast%3DFalkai%26aufirst%3DP.%26aulast%3DHoner%26aufirst%3DW.%2BG.%26atitle%3DAbnormalities%2520of%2520myelination%2520in%2520schizophrenia%2520detected%2520in%2520vivo%2520with%2520MRI%252C%2520and%2520post-mortem%2520with%2520analysis%2520of%2520oligodendrocyte%2520proteins%26jtitle%3DMol.%2520Psychiatry%26date%3D2003%26volume%3D8%26spage%3D811%26epage%3D820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">McCullumsmith, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beneyto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meador-Woodruff, J. H.</span><span> </span><span class="NLM_article-title">Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17223013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FnsFOrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2007&pages=15-27&author=R.+E.+McCullumsmithauthor=D.+Guptaauthor=M.+Beneytoauthor=E.+Kregerauthor=V.+Haroutunianauthor=K.+L.+Davisauthor=J.+H.+Meador-Woodruff&title=Expression+of+transcripts+for+myelination-related+genes+in+the+anterior+cingulate+cortex+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia</span></div><div class="casAuthors">McCullumsmith Robert E; Gupta Daya; Beneyto Monica; Kreger Emily; Haroutunian Vahram; Davis Kenneth L; Meador-Woodruff James H</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">15-27</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Several recent studies have found changes in the expression of genes functionally related to myelination and oligodendrocyte homeostasis in schizophrenia.  These studies utilized microarrays and quantitative PCR (QPCR), methodologies which do not permit direct, unamplified examination of mRNA expression.  In addition, these studies generally only examined transcript expression in homogenates of gray matter.  In the present study, we examined the expression of myelination-related genes previously implicated in schizophrenia by microarray or QPCR.  Using in situ hybridization, we measured transcript expression of 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), myelin-associated glycoprotein (MAG), transferrin (TF), quaking (QKI), gelsolin, myelin oligodendrocyte glycoprotein, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3, erbb2 interacting protein, motility-related protein-1, SRY-box containing gene 10, oligodendrocyte transcription factor 2, peripheral myelin protein 22, and claudin-11 in both gray and white matter of the anterior cingulate cortex (ACC) in subjects with schizophrenia (n=41) and a comparison group (n=34).  We found decreased expression of MAG, QKI, TF, and CNP transcripts in white matter.  We did not find any differences in expression of these transcripts between medicated (n=31) and unmedicated (n=10) schizophrenics, suggesting that these changes are not secondary to treatment with antipsychotics.  Finally, we found significant positive correlations between QKI and MAG or CNP mRNA expression, suggesting that the transcription factor QKI regulates MAG and CNP expression.  Our results support the hypothesis that myelination and oligodendrocyte function are impaired in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKRlaq_gfxtJcXNb62YGmbfW6udTcc2eaPwANzHDnqBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FnsFOrtA%253D%253D&md5=85b17364d13957f8bd0bf3c1af66d6f4</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DMcCullumsmith%26aufirst%3DR.%2BE.%26aulast%3DGupta%26aufirst%3DD.%26aulast%3DBeneyto%26aufirst%3DM.%26aulast%3DKreger%26aufirst%3DE.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DMeador-Woodruff%26aufirst%3DJ.%2BH.%26atitle%3DExpression%2520of%2520transcripts%2520for%2520myelination-related%2520genes%2520in%2520the%2520anterior%2520cingulate%2520cortex%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D90%26spage%3D15%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gejman, P. V.</span><span> </span><span class="NLM_article-title">Neuregulin 1 (NRG1 ) and schizophrenia: analysis of a U.S. family sample and the evidence in the balance</span> <span class="citation_source-journal">Psychol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1610</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS0033291705005428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16219118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MrksVWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2005&pages=1599-1610&author=J.+Duanauthor=M.+Martinezauthor=A.+R.+Sandersauthor=C.+Houauthor=A.+J.+Krasnerauthor=D.+B.+Schwartzauthor=P.+V.+Gejman&title=Neuregulin+1+%28NRG1+%29+and+schizophrenia%3A+analysis+of+a+U.S.+family+sample+and+the+evidence+in+the+balance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin 1 (NRG1 ) and schizophrenia: analysis of a US family sample and the evidence in the balance</span></div><div class="casAuthors">Duan Jubao; Martinez Maria; Sanders Alan R; Hou Cuiping; Krasner Aaron J; Schwartz Daniel B; Gejman Pablo V</div><div class="citationInfo"><span class="NLM_cas:title">Psychological medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1599-610</span>
        ISSN:<span class="NLM_cas:issn">0033-2917</span>.
    </div><div class="casAbstract">BACKGROUND:  Individual genome-wide linkage scans and meta-analyses support that one or more susceptibility genes for schizophrenia are located in chromosome 8p.  A gene from this region, neuregulin 1 (NRG1 ), known to be involved with glutamatergic function, has been found to be associated in some studied samples.  METHOD:  We have examined a new combined schizophrenia sample with 136 schizophrenia families largely of European ancestry (EA) and 646 subjects with DNA.  We genotyped 14 single nucleotide polymorphisms (SNPs) in NRG1 including those reported to comprise schizophrenia-associated haplotypes in Icelandic, Scottish, Irish, and Chinese Han populations.  RESULTS:  We found no evidence of association at a single-marker or a haplotypic level.  We review methodological aspects of previous studies to enable us to put our findings into context.  CONCLUSIONS:  Our failure to find an association between NRG1 and schizophrenia might reflect different linkage disequilibrium (LD) patterns found in different populations, disease allelic heterogeneity, clinical heterogeneity of schizophrenia, or inadequate statistical power deriving from moderate sample size.  NRG1, if a true gene for schizophrenia, accounts for a small fraction of the disease in most populations.  The confirmation of NRG1 as a schizophrenia susceptibility gene will require studies with a comprehensive set of markers and in larger samples.  The possibility remains that reports of NRG1 association might reflect false positives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3Sr3EzPuVblHFYivNCdPRfW6udTcc2eaPwANzHDnqBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrksVWksA%253D%253D&md5=9e34bacf48b1de296b963b80a39203d5</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1017%2FS0033291705005428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033291705005428%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DM.%26aulast%3DSanders%26aufirst%3DA.%2BR.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DKrasner%26aufirst%3DA.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BB.%26aulast%3DGejman%26aufirst%3DP.%2BV.%26atitle%3DNeuregulin%25201%2520%2528NRG1%2520%2529%2520and%2520schizophrenia%253A%2520analysis%2520of%2520a%2520U.S.%2520family%2520sample%2520and%2520the%2520evidence%2520in%2520the%2520balance%26jtitle%3DPsychol.%2520Med.%26date%3D2005%26volume%3D35%26spage%3D1599%26epage%3D1610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Ingason, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soeby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakobsen, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink-Jensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmingsen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werge, T.</span><span> </span><span class="NLM_article-title">No significant association of the 5′ end of neuregulin 1 and schizophrenia in a large Danish sample</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2005.12.850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16483744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287otV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2006&pages=1-5&author=A.+Ingasonauthor=K.+Soebyauthor=S.+Timmauthor=A.+G.+Wangauthor=K.+D.+Jakobsenauthor=A.+Fink-Jensenauthor=R.+Hemmingsenauthor=R.+H.+Bergauthor=T.+Werge&title=No+significant+association+of+the+5%E2%80%B2+end+of+neuregulin+1+and+schizophrenia+in+a+large+Danish+sample"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">No significant association of the 5' end of neuregulin 1 and schizophrenia in a large Danish sample</span></div><div class="casAuthors">Ingason Andres; Soeby Karen; Timm Sally; Wang August G; Jakobsen Klaus D; Fink-Jensen Anders; Hemmingsen Ralf; Berg Rasmussen Henrik; Werge Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Neuregulin 1 has been implicated as a susceptibility gene in schizophrenia.  Several research groups have reported association with the 5' end of the gene although no causative variant has been reported.  We have investigated whether there is association with the 5' end of the gene in Danish schizophrenia patients.  We found that the at-risk haplotype initially reported in the Icelandic population was not found in significant excess (or = 1.4, p = 0.12).  The haplotype structure in the Danish sample was similar to that of other reported in other Caucasian populations and highly different from that of Chinese.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXmqk5iGCx74qdXsLcGTEUfW6udTcc2eaPwANzHDnqBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287otV2ktg%253D%253D&md5=398f7f29e668234271ba264059d3314d</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2005.12.850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2005.12.850%26sid%3Dliteratum%253Aachs%26aulast%3DIngason%26aufirst%3DA.%26aulast%3DSoeby%26aufirst%3DK.%26aulast%3DTimm%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.%2BG.%26aulast%3DJakobsen%26aufirst%3DK.%2BD.%26aulast%3DFink-Jensen%26aufirst%3DA.%26aulast%3DHemmingsen%26aufirst%3DR.%26aulast%3DBerg%26aufirst%3DR.%2BH.%26aulast%3DWerge%26aufirst%3DT.%26atitle%3DNo%2520significant%2520association%2520of%2520the%25205%25E2%2580%25B2%2520end%2520of%2520neuregulin%25201%2520and%2520schizophrenia%2520in%2520a%2520large%2520Danish%2520sample%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D83%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Egan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakub, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callicott, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hariri, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattay, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertolino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon-Weickert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakkalanka, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">12604</span><span class="NLM_x">–</span> <span class="NLM_lpage">12609</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=12604-12609&author=M.+F.+Eganauthor=R.+E.+Straubauthor=T.+E.+Goldbergauthor=I.+Yakubauthor=J.+H.+Callicottauthor=A.+R.+Haririauthor=V.+S.+Mattayauthor=A.+Bertolinoauthor=T.+M.+Hydeauthor=C.+Shannon-Weickertauthor=M.+Akilauthor=J.+Crookauthor=R.+K.+Vakkalankaauthor=R.+Balkissoonauthor=R.+A.+Gibbsauthor=J.+E.+Kleinmanauthor=D.+R.+Weinberger&title=Variation+in+GRM3+affects+cognition%2C+prefrontal+glutamate%2C+and+risk+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DYakub%26aufirst%3DI.%26aulast%3DCallicott%26aufirst%3DJ.%2BH.%26aulast%3DHariri%26aufirst%3DA.%2BR.%26aulast%3DMattay%26aufirst%3DV.%2BS.%26aulast%3DBertolino%26aufirst%3DA.%26aulast%3DHyde%26aufirst%3DT.%2BM.%26aulast%3DShannon-Weickert%26aufirst%3DC.%26aulast%3DAkil%26aufirst%3DM.%26aulast%3DCrook%26aufirst%3DJ.%26aulast%3DVakkalanka%26aufirst%3DR.%2BK.%26aulast%3DBalkissoon%26aufirst%3DR.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DKleinman%26aufirst%3DJ.%2BE.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DVariation%2520in%2520GRM3%2520affects%2520cognition%252C%2520prefrontal%2520glutamate%252C%2520and%2520risk%2520for%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D12604%26epage%3D12609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span> </span><span class="NLM_article-title">Significant association between the genetic variations in the 5′ end of the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor subunit gene GRIN1 and schizophrenia</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2005.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16476413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFaisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=747-753&author=X.+Zhaoauthor=H.+Liauthor=Y.+Shiauthor=R.+Tangauthor=W.+Chenauthor=J.+Liuauthor=G.+Fengauthor=J.+Shiauthor=L.+Yanauthor=H.+Liuauthor=L.+He&title=Significant+association+between+the+genetic+variations+in+the+5%E2%80%B2+end+of+the+N-methyl-d-aspartate+receptor+subunit+gene+GRIN1+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Significant Association Between the Genetic Variations in the 5' End of the N-Methyl-D-Aspartate Receptor Subunit Gene GRIN1 and Schizophrenia</span></div><div class="casAuthors">Zhao, Xinzhi; Li, Huafang; Shi, Yongyong; Tang, Ruqi; Chen, Wuyan; Liu, Jixia; Feng, Guoyin; Shi, Jianguo; Yan, Lijuan; Liu, Huijun; He, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">747-753</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: N-methyl-D-aspartate (NMDA) receptors play important roles in many neurophysiol. processes.  Evidence from previous studies indicate that NMDA receptors contribute to the pathophysiol. of schizophrenia.  Two NMDA receptor subunit genes, GRIN1 and GRIN2A, are both good candidate genes for schizophrenia.  Method: We genotyped five single nucleotide polymorphisms (SNPs) in GRIN1 and two in GRIN2A in 2455 Han Chinese subjects, including population- and family-based samples, and performed case-control and transmission disequil. test (TDT) analyses.  A microsatellite in GRIN2A was genotyped in population-based samples and a Mann-Whitney U test was performed.  Results: A highly significant assocn. was detected at the 5' end of GRIN1.  Analyses of single variants and multiple-locus haplotypes indicate that the assocn. is mainly generated by rs11146020 (case-control study: p = .0000013, odds ratio = .61, 95% confidence interval .50-.74; TDT: p = .0019, T/NT = 79/123).  No assocn. was found in the GRIN2A polymorphisms.  Conclusions: Our results provide support for the hypothesis that NMDA receptors are an important factor in schizophrenia.  Moreover, rs11146020 is located in 5' untranslated region where several functional elements have been found.  Hence, the SNP is a potential candidate in altering risk for schizophrenia and worthy of further replication and functional study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOsUTnWuF3_rVg90H21EOLACvtfcHk0lg3JG61q_6N4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFaisr4%253D&md5=4c3e72e6f870e41591cc162e8789384b</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DSignificant%2520association%2520between%2520the%2520genetic%2520variations%2520in%2520the%25205%25E2%2580%25B2%2520end%2520of%2520the%2520N-methyl-d-aspartate%2520receptor%2520subunit%2520gene%2520GRIN1%2520and%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D747%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Hong, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. J.</span><span> </span><span class="NLM_article-title">Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia</span> <span class="citation_source-journal">Psychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F00041444-200112000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11807413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD387hs1aqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=219-222&author=C.+J.+Hongauthor=Y.+W.+Yuauthor=C.+H.+Linauthor=C.+Y.+Chengauthor=S.+J.+Tsai&title=Association+analysis+for+NMDA+receptor+subunit+2B+%28GRIN2B%29+genetic+variants+and+psychopathology+and+clozapine+response+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia</span></div><div class="casAuthors">Hong C J; Yu Y W; Lin C H; Cheng C Y; Tsai S J</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatric genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-22</span>
        ISSN:<span class="NLM_cas:issn">0955-8829</span>.
    </div><div class="casAbstract">It is known that a syndrome resembling schizophrenia is produced by the N-methyl-d-aspartate receptor antagonists.  It has also been demonstrated that the level of an ionotropic N-methyl-d-aspartate 2B subunit (GRIN2B) of the glutamate receptor tends to increase after subchronic administration of clozapine, suggesting that GRIN2B may play an active role in the pathogenesis of schizophrenia and the function of clozapine medication.  We studied 100 schizophrenic patients, investigating the associations for the GRIN2B genetic variants, and psychiatric symptoms and clozapine response.  No significant differences were demonstrated comparing these three groups in terms of the baseline Brief Psychiatric Rating Scale (BPRS) score (P = 0.441).  The percentage of patients scoring within 20% of baseline BPRS after clozapine treatment was similar for the three genotype groups (P = 0.132).  A marginally higher mean clozapine dosage was revealed, however, for patients bearing the 2664C/C genotype (P = 0.013).  Although replication of this research is required to confirm the results, an association for the GRIN2B C2664T polymorphism and clozapine treatment is suggested from our findings, which may assist in the prediction of optimal dosage for schizophrenic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7dU054vF8aXy-c-E1v-fmfW6udTcc2eY55QKRYN5CILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387hs1aqsA%253D%253D&md5=73c5bc493612928ff8060bdfd00f248a</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1097%2F00041444-200112000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00041444-200112000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DC.%2BJ.%26aulast%3DYu%26aufirst%3DY.%2BW.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DCheng%26aufirst%3DC.%2BY.%26aulast%3DTsai%26aufirst%3DS.%2BJ.%26atitle%3DAssociation%2520analysis%2520for%2520NMDA%2520receptor%2520subunit%25202B%2520%2528GRIN2B%2529%2520genetic%2520variants%2520and%2520psychopathology%2520and%2520clozapine%2520response%2520in%2520schizophrenia%26jtitle%3DPsychiatr.%2520Genet.%26date%3D2001%26volume%3D11%26spage%3D219%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Mohn, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, B. H.</span><span> </span><span class="NLM_article-title">Mice with reduced NMDA receptor expression display behaviors related to schizophrenia</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1999&pages=427-436&author=A.+R.+Mohnauthor=R.+R.+Gainetdinovauthor=M.+G.+Caronauthor=B.+H.+Koller&title=Mice+with+reduced+NMDA+receptor+expression+display+behaviors+related+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMohn%26aufirst%3DA.%2BR.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DKoller%26aufirst%3DB.%2BH.%26atitle%3DMice%2520with%2520reduced%2520NMDA%2520receptor%2520expression%2520display%2520behaviors%2520related%2520to%2520schizophrenia%26jtitle%3DCell%26date%3D1999%26volume%3D98%26spage%3D427%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLean, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myakishev, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris-Kerr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wormley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadek, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadambi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesare, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibberman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendler, K. S.</span><span> </span><span class="NLM_article-title">Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F341750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12098102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvV2qtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=337-348&author=R.+E.+Straubauthor=Y.+Jiangauthor=C.+J.+MacLeanauthor=Y.+Maauthor=B.+T.+Webbauthor=M.+V.+Myakishevauthor=C.+Harris-Kerrauthor=B.+Wormleyauthor=H.+Sadekauthor=B.+Kadambiauthor=A.+J.+Cesareauthor=A.+Gibbermanauthor=X.+Wangauthor=F.+A.+O%E2%80%99Neillauthor=D.+Walshauthor=K.+S.+Kendler&title=Genetic+variation+in+the+6p22.3+gene+DTNBP1%2C+the+human+ortholog+of+the+mouse+dysbindin+gene%2C+is+associated+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia</span></div><div class="casAuthors">Straub, Richard E.; Jiang, Yuxin; MacLean, Charles J.; Ma, Yunlong; Webb, Bradley T.; Myakishev, Maxim V.; Harris-Kerr, Carole; Wormley, Brandon; Sadek, Hannah; Kadambi, Bharat; Cesare, Anthony J.; Gibberman, Avi; Wang, Xu; O'Neill, F. Anthony; Walsh, Dermot; Kendler, Kenneth S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-348</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Prior evidence has supported the existence of multiple susceptibility genes for schizophrenia.  Multipoint linkage anal. of the 270 Irish high-d. pedigrees that we have studied, as well as results from several other samples, suggest that at least one such gene is located in region 6p24-21.  In the present study, family-based assocn. anal. of 36 simple sequence-length-polymorphism markers and of 17 SNP markers implicated two regions, sepd. by ∼7 Mb.  The first region, and the focus of this report, is 6p22.3.  In this region, single-nucleotide polymorphisms within the 140-kb gene DTNBP1 (dystrobrevin-binding protein 1, or dysbindin) are strongly assocd. with schizophrenia.  Uncorrected, empirical P values produced by the program TRANSMIT were significant (P <.01) for a no. of individual SNP markers, and most remained significant when the data were restricted to include only one affected offspring per nuclear family per extended pedigree; multiple three-marker haplotypes were highly significant (P =.008-.0001) under the restricted conditions.  The pattern of linkage disequil. is consistent with the presence of more than one susceptibility allele, but this important issue is unresolved.  The no. of markers tested in the adjacent genes, all of which are neg., is not sufficient to rule out the possibility that the dysbindin gene is not the actual susceptibility gene, but this possibility appears to be very unlikely.  We conclude that further investigation of dysbindin is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3luPjEDmn0bVg90H21EOLACvtfcHk0lg3JG61q_6N4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvV2qtb4%253D&md5=999f50788656c9d7995c2a1f5a887369</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1086%2F341750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F341750%26sid%3Dliteratum%253Aachs%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMacLean%26aufirst%3DC.%2BJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DWebb%26aufirst%3DB.%2BT.%26aulast%3DMyakishev%26aufirst%3DM.%2BV.%26aulast%3DHarris-Kerr%26aufirst%3DC.%26aulast%3DWormley%26aufirst%3DB.%26aulast%3DSadek%26aufirst%3DH.%26aulast%3DKadambi%26aufirst%3DB.%26aulast%3DCesare%26aufirst%3DA.%2BJ.%26aulast%3DGibberman%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DF.%2BA.%26aulast%3DWalsh%26aufirst%3DD.%26aulast%3DKendler%26aufirst%3DK.%2BS.%26atitle%3DGenetic%2520variation%2520in%2520the%25206p22.3%2520gene%2520DTNBP1%252C%2520the%2520human%2520ortholog%2520of%2520the%2520mouse%2520dysbindin%2520gene%252C%2520is%2520associated%2520with%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2002%26volume%3D71%26spage%3D337%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrell, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gejman, P. V.</span><span> </span><span class="NLM_article-title">DTNBP1 (dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3′ end of the gene</span> <span class="citation_source-journal">Hum. Hered.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1159%2F000101961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17476109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlaku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=97-106&author=J.+Duanauthor=M.+Martinezauthor=A.+R.+Sandersauthor=C.+Houauthor=G.+J.+Burrellauthor=A.+J.+Krasnerauthor=D.+B.+Schwartzauthor=P.+V.+Gejman&title=DTNBP1+%28dystrobrevin+binding+protein+1%29+and+schizophrenia%3A+association+evidence+in+the+3%E2%80%B2+end+of+the+gene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">DTNBP1 (dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3' end of the gene</span></div><div class="casAuthors">Duan, Jubao; Martinez, Maria; Sanders, Alan R.; Hou, Cuiping; Burrell, Gregory J.; Krasner, Aaron J.; Schwartz, Daniel B.; Gejman, Pablo V.</div><div class="citationInfo"><span class="NLM_cas:title">Human Heredity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-106</span>CODEN:
                <span class="NLM_cas:coden">HUHEAS</span>;
        ISSN:<span class="NLM_cas:issn">0001-5652</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">(DTNBP1) has been identified as a susceptibility gene for schizophrenia (SZ) through a positional approach.  However, a variety of single nucleotide polymorphisms (SNPs) and haplotypes, in different parts of the gene, have been reported to be assocd. in different samples, and a precise mol. mechanism of disease remains to be defined.  We have performed an assocn. study with two well-characterized family samples not previously investigated at the DTNBP1 locus.  We examd. 646 subjects in 136 families with SZ, largely of European ancestry (EA), genotyping 26 SNPs in DTNBP1.  Three correlated markers (rs875462, rs760666, and rs7758659) at the 3' region of DTNBP1showed evidence for assocn. to SZ (p = 0.004), obsd. in both the EA (p = 0.031) and the African American (AA) subset (p = 0.045) with the same over-transmitted allele.  The most significant haplotype in our study was rs7758659-rs3213207 (global p = 0.0015), with rs3213207 being the most frequently reported assocd. marker in previous studies.  A non-conservative missense variant (Pro272Ser) in the 3' region of DTNBP1 that may impair DTNBP1 function was more common in SZ probands (8.2%) than in founders (5%) and in dbSNP (2.1%), but did not reach statistical significance.  These results provide evidence for an assocn. of SZ with SNPs at the 3' end of DTNBP1 in the samples studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9nOu1FcvqorVg90H21EOLACvtfcHk0liGsQsxz0tHhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlaku7c%253D&md5=3e54d2c424c6e0397367e060cc4f8acb</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1159%2F000101961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000101961%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DM.%26aulast%3DSanders%26aufirst%3DA.%2BR.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DBurrell%26aufirst%3DG.%2BJ.%26aulast%3DKrasner%26aufirst%3DA.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BB.%26aulast%3DGejman%26aufirst%3DP.%2BV.%26atitle%3DDTNBP1%2520%2528dystrobrevin%2520binding%2520protein%25201%2529%2520and%2520schizophrenia%253A%2520association%2520evidence%2520in%2520the%25203%25E2%2580%25B2%2520end%2520of%2520the%2520gene%26jtitle%3DHum.%2520Hered.%26date%3D2007%26volume%3D64%26spage%3D97%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Van Den, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlraun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovalenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freudenberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonsson, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattila-Evenden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedvall, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapelski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rietschel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Propping, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nothen, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichon, S.</span><span> </span><span class="NLM_article-title">The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1438</span><span class="NLM_x">–</span> <span class="NLM_lpage">1443</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F379928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14618545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitlWn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2003&pages=1438-1443&author=B.+A.+Van+Denauthor=J.+Schumacherauthor=T.+G.+Schulzeauthor=A.+C.+Otteauthor=S.+Ohlraunauthor=S.+Kovalenkoauthor=T.+Beckerauthor=J.+Freudenbergauthor=E.+G.+Jonssonauthor=M.+Mattila-Evendenauthor=G.+C.+Sedvallauthor=P.+M.+Czerskiauthor=P.+Kapelskiauthor=J.+Hauserauthor=W.+Maierauthor=M.+Rietschelauthor=P.+Proppingauthor=M.+M.+Nothenauthor=S.+Cichon&title=The+DTNBP1+%28dysbindin%29+gene+contributes+to+schizophrenia%2C+depending+on+family+history+of+the+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease</span></div><div class="casAuthors">Van Den Bogaert, Ann; Schumacher, Johannes; Schulze, Thomas G.; Otte, Andreas C.; Ohlraun, Stephanie; Kovalenko, Svetlana; Becker, Tim; Freudenberg, Jan; Joensson, Erik G.; Mattila-evenden, Marja; Sedvall, Goeran C.; Czerski, Piotr M.; Kapelski, Pawel; Hauser, Joanna; Maier, Wolfgang; Rietschel, Marcella; Propping, Peter; Noethen, Markus M.; Cichon, Sven</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1438-1443</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">The authors have investigated the gene for dystrobrevin-binding protein 1 (DTNBP1), or dysbindin, which has been strongly suggested as a positional candidate gene for schizophrenia, in three samples of subjects with schizophrenia and unaffected control subjects of German (418 cases, 285 controls), Polish (294 cases, 113 controls), and Swedish (142 cases, 272 controls) descent.  The authors analyzed five single-nucleotide polymorphisms (P1635, P1325, P1320, P1757, and P1578) and identified significant evidence of assocn. in the Swedish sample but not in those from Germany or Poland.  The results in the Swedish sample became even more significant after a sep. anal. of those cases with a pos. family history of schizophrenia, in whom the five-marker haplotype A-C-A-T-T showed a P value of .00009 (3.1% in controls, 17.8% in cases; OR 6.75; P = .00153 after Bonferroni correction).  These results suggest that genetic variation in the dysbindin gene is particularly involved in the development of schizophrenia in cases with a familial loading of the disease.  This would also explain the difficulty of replicating this assocn. in consecutively ascertained case-control samples, which usually comprise only a small proportion of subjects with a family history of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEh3jhy6kFbVg90H21EOLACvtfcHk0liGsQsxz0tHhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitlWn&md5=0abbdf8979feefe4f90ae1bea3650914</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1086%2F379928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F379928%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDen%26aufirst%3DB.%2BA.%26aulast%3DSchumacher%26aufirst%3DJ.%26aulast%3DSchulze%26aufirst%3DT.%2BG.%26aulast%3DOtte%26aufirst%3DA.%2BC.%26aulast%3DOhlraun%26aufirst%3DS.%26aulast%3DKovalenko%26aufirst%3DS.%26aulast%3DBecker%26aufirst%3DT.%26aulast%3DFreudenberg%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DE.%2BG.%26aulast%3DMattila-Evenden%26aufirst%3DM.%26aulast%3DSedvall%26aufirst%3DG.%2BC.%26aulast%3DCzerski%26aufirst%3DP.%2BM.%26aulast%3DKapelski%26aufirst%3DP.%26aulast%3DHauser%26aufirst%3DJ.%26aulast%3DMaier%26aufirst%3DW.%26aulast%3DRietschel%26aufirst%3DM.%26aulast%3DPropping%26aufirst%3DP.%26aulast%3DNothen%26aufirst%3DM.%2BM.%26aulast%3DCichon%26aufirst%3DS.%26atitle%3DThe%2520DTNBP1%2520%2528dysbindin%2529%2520gene%2520contributes%2520to%2520schizophrenia%252C%2520depending%2520on%2520family%2520history%2520of%2520the%2520disease%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2003%26volume%3D73%26spage%3D1438%26epage%3D1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Talbot, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eidem, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinsley, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gur, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, S. E.</span><span> </span><span class="NLM_article-title">Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">1353</span><span class="NLM_x">–</span> <span class="NLM_lpage">1363</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=1353-1363&author=K.+Talbotauthor=W.+L.+Eidemauthor=C.+L.+Tinsleyauthor=M.+A.+Bensonauthor=E.+W.+Thompsonauthor=R.+J.+Smithauthor=C.+G.+Hahnauthor=S.+J.+Siegelauthor=J.+Q.+Trojanowskiauthor=R.+E.+Gurauthor=D.+J.+Blakeauthor=S.+E.+Arnold&title=Dysbindin-1+is+reduced+in+intrinsic%2C+glutamatergic+terminals+of+the+hippocampal+formation+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTalbot%26aufirst%3DK.%26aulast%3DEidem%26aufirst%3DW.%2BL.%26aulast%3DTinsley%26aufirst%3DC.%2BL.%26aulast%3DBenson%26aufirst%3DM.%2BA.%26aulast%3DThompson%26aufirst%3DE.%2BW.%26aulast%3DSmith%26aufirst%3DR.%2BJ.%26aulast%3DHahn%26aufirst%3DC.%2BG.%26aulast%3DSiegel%26aufirst%3DS.%2BJ.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DGur%26aufirst%3DR.%2BE.%26aulast%3DBlake%26aufirst%3DD.%2BJ.%26aulast%3DArnold%26aufirst%3DS.%2BE.%26atitle%3DDysbindin-1%2520is%2520reduced%2520in%2520intrinsic%252C%2520glutamatergic%2520terminals%2520of%2520the%2520hippocampal%2520formation%2520in%2520schizophrenia%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D113%26spage%3D1353%26epage%3D1363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Chowdari, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirnics, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semwal, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">B. K., T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devlin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimgaonkar, V. L.</span><span> </span><span class="NLM_article-title">Association and linkage analyses of RGS4 polymorphisms in schizophrenia</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1373</span><span class="NLM_x">–</span> <span class="NLM_lpage">1380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fhmg%2F11.12.1373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12023979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XksFWms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=1373-1380&author=K.+V.+Chowdariauthor=K.+Mirnicsauthor=P.+Semwalauthor=J.+Woodauthor=E.+Lawrenceauthor=T.+Bhatiaauthor=S.+N.+Deshpandeauthor=T.+B.+K.author=R.+E.+Ferrellauthor=F.+A.+Middletonauthor=B.+Devlinauthor=P.+Levittauthor=D.+A.+Lewisauthor=V.+L.+Nimgaonkar&title=Association+and+linkage+analyses+of+RGS4+polymorphisms+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Association and linkage analyses of RGS4 polymorphisms in schizophrenia</span></div><div class="casAuthors">Chowdari, Kodavali V.; Mirnics, Karoly; Semwal, Prachi; Wood, Joel; Lawrence, Elizabeth; Bhatia, Triptish; Deshpande, Smita N.; Thelma, B. K.; Ferrell, Robert E.; Middleton, Frank A.; Devlin, Bernie; Levitt, Pat; Lewis, David A.; Nimgaonkar, Vishwajit L.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1373-1380</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Gene expression analyses of postmortem cerebral cortex suggest that transcription of the regulator of G-protein signaling 4 (RGS4) is decreased in a diagnosis-specific manner in subjects with schizophrenia.  To evaluate the possible role of RGS4 in the pathogenesis of schizophrenia, we conducted genetic assocn. and linkage studies using samples ascertained independently in Pittsburgh and New Delhi and by the NIMH Collaborative Genetics Initiative.  Using the transmission disequil. test, significant transmission distortion was obsd. in the Pittsburgh and NIMH samples.  Among single-nucleotide polymorphisms (SNPs) spanning approx. 300 kb, significant assocns. involved four SNPs localized to a 10 kb region at RGS4, but the assocd. haplotypes differed.  A trend for transmission distortion was also present in the Indian sample for haplotypes incorporating the same SNPs.  Consistent with the linkage/assocn. obsd. from the family-based tests, samples with affected siblings (NIMH, India) showed higher levels of allele sharing, identical by descent, at RGS4.  When the US patients were contrasted to two population-based control samples, however, no significant differences were obsd.  To check the specificity of the transmission bias, we therefore examd. US families with bipolar I disorder (BD1) probands.  This sample also showed a trend for transmission distortion, and differed significantly from the population-based controls for the four-SNP haplotypes tested in the other samples.  The transmission distortion is unlikely to be due to chance, but its mechanism and specificity require further study.  Our results illustrate the potential power of combining gene expression profiling and genomic analyses to identify susceptibility genes for genetically complex disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg-xKE593UwrVg90H21EOLACvtfcHk0lj2TQru1PjCtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksFWms7Y%253D&md5=76b28246787987d38909b96f08f32d90</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F11.12.1373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F11.12.1373%26sid%3Dliteratum%253Aachs%26aulast%3DChowdari%26aufirst%3DK.%2BV.%26aulast%3DMirnics%26aufirst%3DK.%26aulast%3DSemwal%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DE.%26aulast%3DBhatia%26aufirst%3DT.%26aulast%3DDeshpande%26aufirst%3DS.%2BN.%26aulast%3DB.%2BK.%26aufirst%3DT.%26aulast%3DFerrell%26aufirst%3DR.%2BE.%26aulast%3DMiddleton%26aufirst%3DF.%2BA.%26aulast%3DDevlin%26aufirst%3DB.%26aulast%3DLevitt%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26atitle%3DAssociation%2520and%2520linkage%2520analyses%2520of%2520RGS4%2520polymorphisms%2520in%2520schizophrenia%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2002%26volume%3D11%26spage%3D1373%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Talkowski, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdari, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimgaonkar, V. L.</span><span> </span><span class="NLM_article-title">Can RGS4 polymorphisms be viewed as credible risk factors for schizophrenia? A critical review of the evidence</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbj058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16469939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD283ktFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2006&pages=203-208&author=M.+E.+Talkowskiauthor=K.+Chowdariauthor=D.+A.+Lewisauthor=V.+L.+Nimgaonkar&title=Can+RGS4+polymorphisms+be+viewed+as+credible+risk+factors+for+schizophrenia%3F+A+critical+review+of+the+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Can RGS4 polymorphisms be viewed as credible risk factors for schizophrenia? A critical review of the evidence</span></div><div class="casAuthors">Talkowski Michael E; Chowdari Kv; Lewis David A; Nimgaonkar Vishwajit L</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-8</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">There has been a recent explosion in the list of putative susceptibility genes for schizophrenia (SZ).  These genes have been identified on the basis of presumed pathogenesis, linkage, and genetic association studies.  While several promising candidates have arisen, identification of a conclusive genetic risk factor has remained elusive.  The proof would be most compelling if it stemmed from all three of these domains.  In this review, we consider such evidence in relation to the regulator of G-protein signaling 4 (RGS4), a gene localized to chromosome 1q23.  Disorder-specific changes in RGS4 mRNA levels have been observed in post-mortem brain samples; linkage has been reported at chromosome 1q23; and several association studies have concluded that significant associations exist.  The latter are supported by a recently conducted meta-analysis.  Thus, there is suggestive evidence in each of these domains implicating a role for RGS4 in SZ susceptibility.  However, analogous to other promising susceptibility candidates, the nature of the genetic association, the precise polymorphism(s) conferring risk, and the functional implications of sequence variation at this gene are unclear.  We review the published data and place them in the context of suggested criteria for establishing a candidate gene as a credible susceptibility factor for disorders with non-Mendelian patterns of inheritance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHQtI9xFsUKpcXNb62YGmbfW6udTcc2ebrZGH2SeeaOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283ktFOgug%253D%253D&md5=4f5d81c025460dfd525aeac4da8e087f</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbj058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbj058%26sid%3Dliteratum%253Aachs%26aulast%3DTalkowski%26aufirst%3DM.%2BE.%26aulast%3DChowdari%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26atitle%3DCan%2520RGS4%2520polymorphisms%2520be%2520viewed%2520as%2520credible%2520risk%2520factors%2520for%2520schizophrenia%253F%2520A%2520critical%2520review%2520of%2520the%2520evidence%26jtitle%3DSchizophr.%2520Bull.%26date%3D2006%26volume%3D32%26spage%3D203%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Prasad, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdari, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimgaonkar, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talkowski, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshavan, M. S.</span><span> </span><span class="NLM_article-title">Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15381923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnt1Slsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=213-219&author=K.+M.+Prasadauthor=K.+V.+Chowdariauthor=V.+L.+Nimgaonkarauthor=M.+E.+Talkowskiauthor=D.+A.+Lewisauthor=M.+S.+Keshavan&title=Genetic+polymorphisms+of+the+RGS4+and+dorsolateral+prefrontal+cortex+morphometry+among+first+episode+schizophrenia+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients</span></div><div class="casAuthors">Prasad, K. M. R.; Chowdari, K. V.; Nimgaonkar, V. L.; Talkowski, M. E.; Lewis, D. A.; Keshavan, M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-219</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polymorphisms of the gene encoding the regulator of G-protein signaling subtype 4 (RGS4) may confer risk for schizophrenia.1.  DNA microarray studies of postmortem brain samples have shown RGS4 underexpression in the dorsolateral prefrontal cortex (DLPFC, area 9), motor and visual cortices in schizophrenia patients relative to control subjects.2.  Underexpression of RGS4 in DLPFC is pathophysiol. significant because DLPFC pathol. in schizophrenia has been supported by neurocognitive,3,4 structural5 and functional6,7 imaging, postmortem,8 cellular9,10 and mol.11 pathol. studies.  For these reasons, we examd. the assocn. of DLPFC gray matter vol. with RGS4 polymorphisms in a series of antipsychotic-naive first-episode schizophrenia patients and control subjects.  We hypothesized that volumetric alterations of the DLPFC would be assocd. with RGS4 polymorphisms and that these differences would be more pronounced in patients than in controls.  We obsd. robust volumetric differences across the genotypes in the pooled sample of patients and control subjects; when sep. analyzed, we obsd. differences within the patient group (n=30) but not in control subject (n=27) group.  The findings suggest that RGS4 polymorphisms may contribute to structural alterations in the DLPFC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIyqOWbAdkc7Vg90H21EOLACvtfcHk0lj2TQru1PjCtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnt1Slsw%253D%253D&md5=5cdb32e9d00b00606bedec20ca903d8b</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001562%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad%26aufirst%3DK.%2BM.%26aulast%3DChowdari%26aufirst%3DK.%2BV.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26aulast%3DTalkowski%26aufirst%3DM.%2BE.%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DKeshavan%26aufirst%3DM.%2BS.%26atitle%3DGenetic%2520polymorphisms%2520of%2520the%2520RGS4%2520and%2520dorsolateral%2520prefrontal%2520cortex%2520morphometry%2520among%2520first%2520episode%2520schizophrenia%2520patients%26jtitle%3DMol.%2520Psychiatry%26date%3D2005%26volume%3D10%26spage%3D213%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Buckholtz, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer-Lindenberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honea, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezawas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakkalanka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolachana, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verchinski, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sust, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattay, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callicott, J. H.</span><span> </span><span class="NLM_article-title">Allelic variation in RGS4 impacts functional and structural connectivity in the human brain</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1593</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1523%2FJNEUROSCI.5112-06.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17301167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitl2gu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1584-1593&author=J.+W.+Buckholtzauthor=A.+Meyer-Lindenbergauthor=R.+A.+Honeaauthor=R.+E.+Straubauthor=L.+Pezawasauthor=M.+F.+Eganauthor=R.+Vakkalankaauthor=B.+Kolachanaauthor=B.+A.+Verchinskiauthor=S.+Sustauthor=V.+S.+Mattayauthor=D.+R.+Weinbergerauthor=J.+H.+Callicott&title=Allelic+variation+in+RGS4+impacts+functional+and+structural+connectivity+in+the+human+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Allelic variation in RGS4 impacts functional and structural connectivity in the human brain</span></div><div class="casAuthors">Buckholtz, Joshua W.; Meyer-Lindenberg, Andreas; Honea, Robyn A.; Straub, Richard E.; Pezawas, Lukas; Egan, Michael F.; Vakkalanka, Radhakrishna; Kolachana, Bhaskar; Verchinski, Beth A.; Sust, Steven; Mattay, Venkata S.; Weinberger, Daniel R.; Callicott, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1584-1593</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Regulator of G-protein signaling 4 (RGS4) modulates postsynaptic signal transduction by affecting the kinetics of Gα-GTP binding.  Linkage, assocn., and postmortem studies have implicated the gene encoding RGS4 (RGS4) as a schizophrenia susceptibility factor.  Using a multimodal neuroimaging approach, we demonstrate that genetic variation in RGS4 is assocd. with functional activation and connectivity during working memory in the absence of overt behavioral differences, with regional gray and white matter vol. and with gray matter structural connectivity in healthy human subjects.  Specifically, variation at one RGS4 single nucleotide polymorphism that has been assocd. previously with psychosis (rs951436) impacts frontoparietal and frontotemporal blood oxygenation level-dependent response and network coupling during working memory and results in regionally specific redns. in gray and white matter structural vol. in individuals carrying the A allele.  These findings suggest mechanisms in brain for the assocn. of RGS4 with risk for psychiatric illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosqVnUstnVZ7Vg90H21EOLACvtfcHk0lgS6YVVGG8r6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitl2gu7s%253D&md5=541c1912095ca35c530dbbdfbde1c5b9</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5112-06.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5112-06.2007%26sid%3Dliteratum%253Aachs%26aulast%3DBuckholtz%26aufirst%3DJ.%2BW.%26aulast%3DMeyer-Lindenberg%26aufirst%3DA.%26aulast%3DHonea%26aufirst%3DR.%2BA.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DPezawas%26aufirst%3DL.%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DVakkalanka%26aufirst%3DR.%26aulast%3DKolachana%26aufirst%3DB.%26aulast%3DVerchinski%26aufirst%3DB.%2BA.%26aulast%3DSust%26aufirst%3DS.%26aulast%3DMattay%26aufirst%3DV.%2BS.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26aulast%3DCallicott%26aufirst%3DJ.%2BH.%26atitle%3DAllelic%2520variation%2520in%2520RGS4%2520impacts%2520functional%2520and%2520structural%2520connectivity%2520in%2520the%2520human%2520brain%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D1584%26epage%3D1593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Bowden, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tooney, P. A.</span><span> </span><span class="NLM_article-title">Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17071056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FmtlKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2007&pages=165-168&author=N.+A.+Bowdenauthor=R.+J.+Scottauthor=P.+A.+Tooney&title=Altered+expression+of+regulator+of+G-protein+signalling+4+%28RGS4%29+mRNA+in+the+superior+temporal+gyrus+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia</span></div><div class="casAuthors">Bowden Nikola A; Scott Rodney J; Tooney Paul A</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">165-8</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">To identify altered mRNA expression of regulator of G-protein signalling 4 (RGS4) in the superior temporal gyrus (STG) in schizophrenia mRNA expression of RGS4 was measured from post-mortem STG tissue from 13 individuals with schizophrenia and 13 matched non-psychiatric controls using relative real-time PCR.  Significantly decreased expression of RGS4 mRNA in the STG in schizophrenia was identified in 10 of the 13 matched pairs.  Altered expression of RGS4 in cortical regions previously implicated in schizophrenia, such as the STG further supports the notion of RGS4 as a potential genetic and functional biological marker of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC8bASUGlThX6CEoQgWY10fW6udTcc2eanJXJQtCH-nrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FmtlKkug%253D%253D&md5=f057e40f301553b2064aa3f6b71fa5bb</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DBowden%26aufirst%3DN.%2BA.%26aulast%3DScott%26aufirst%3DR.%2BJ.%26aulast%3DTooney%26aufirst%3DP.%2BA.%26atitle%3DAltered%2520expression%2520of%2520regulator%2520of%2520G-protein%2520signalling%25204%2520%2528RGS4%2529%2520mRNA%2520in%2520the%2520superior%2520temporal%2520gyrus%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D89%26spage%3D165%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Campbell, D. B.; Ebert, P. J.; Skelly, T.; Stroup, T. S.; Lieberman, J.; Levitt, P.; Sullivan, P. F.</span><span> </span><span class="NLM_article-title">Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia</span>.  <span class="citation_source-journal">Biol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Campbell%2C+D.+B.%3B+Ebert%2C+P.+J.%3B+Skelly%2C+T.%3B+Stroup%2C+T.+S.%3B+Lieberman%2C+J.%3B+Levitt%2C+P.%3B+Sullivan%2C+P.+F.+Ethnic+stratification+of+the+association+of+RGS4+variants+with+antipsychotic+treatment+response+in+schizophrenia.+Biol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DD.%2BB.%26atitle%3DEthnic%2520stratification%2520of%2520the%2520association%2520of%2520RGS4%2520variants%2520with%2520antipsychotic%2520treatment%2520response%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Chumakov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenfeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerassimenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavarec, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palicio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abderrahim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bougueleret, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puech, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen-Akenine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabrosse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lissarrague, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essioux, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millasseau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debailleul, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caterina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufaure, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malekzadeh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouillot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambucy, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Primas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saumier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boubkiri, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Saumier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasroune, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peixoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaye, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinchot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastucci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevillon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sainz-Fuertes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meguenni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aurich-Costa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherif, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimalac, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Duijn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauvreau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellette, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raelson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherbatich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riazanskaia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogaev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeymaekers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aerssens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konings, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luyten, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macciardi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sham, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span> </span><span class="NLM_article-title">Genetic and physiological data implicating the new human gene G72 and the gene for <span class="smallcaps smallerCapital">d</span>-amino acid oxidase in schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">13675</span><span class="NLM_x">–</span> <span class="NLM_lpage">13680</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=13675-13680&author=I.+Chumakovauthor=M.+Blumenfeldauthor=O.+Guerassimenkoauthor=L.+Cavarecauthor=M.+Palicioauthor=H.+Abderrahimauthor=L.+Bougueleretauthor=C.+Barryauthor=H.+Tanakaauthor=P.+La+Rosaauthor=A.+Puechauthor=N.+Tahriauthor=A.+Cohen-Akenineauthor=S.+Delabrosseauthor=S.+Lissarragueauthor=F.+P.+Picardauthor=K.+Mauriceauthor=L.+Essiouxauthor=P.+Millasseauauthor=P.+Grelauthor=V.+Debailleulauthor=A.+M.+Simonauthor=D.+Caterinaauthor=I.+Dufaureauthor=K.+Malekzadehauthor=M.+Belovaauthor=J.+J.+Luanauthor=M.+Bouillotauthor=J.+L.+Sambucyauthor=G.+Primasauthor=M.+Saumierauthor=N.+Boubkiriauthor=S.+Martin-Saumierauthor=M.+Nasrouneauthor=H.+Peixotoauthor=A.+Delayeauthor=V.+Pinchotauthor=M.+Bastucciauthor=S.+Guillouauthor=M.+Chevillonauthor=R.+Sainz-Fuertesauthor=S.+Meguenniauthor=J.+Aurich-Costaauthor=D.+Cherifauthor=A.+Gimalacauthor=C.+Van+Duijnauthor=D.+Gauvreauauthor=G.+Ouelletteauthor=I.+Fortierauthor=J.+Raelsonauthor=T.+Sherbatichauthor=N.+Riazanskaiaauthor=E.+Rogaevauthor=P.+Raeymaekersauthor=J.+Aerssensauthor=F.+Koningsauthor=W.+Luytenauthor=F.+Macciardiauthor=P.+C.+Shamauthor=R.+E.+Straubauthor=D.+R.+Weinbergerauthor=N.+Cohenauthor=D.+Cohen&title=Genetic+and+physiological+data+implicating+the+new+human+gene+G72+and+the+gene+for+d-amino+acid+oxidase+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChumakov%26aufirst%3DI.%26aulast%3DBlumenfeld%26aufirst%3DM.%26aulast%3DGuerassimenko%26aufirst%3DO.%26aulast%3DCavarec%26aufirst%3DL.%26aulast%3DPalicio%26aufirst%3DM.%26aulast%3DAbderrahim%26aufirst%3DH.%26aulast%3DBougueleret%26aufirst%3DL.%26aulast%3DBarry%26aufirst%3DC.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DLa%2BRosa%26aufirst%3DP.%26aulast%3DPuech%26aufirst%3DA.%26aulast%3DTahri%26aufirst%3DN.%26aulast%3DCohen-Akenine%26aufirst%3DA.%26aulast%3DDelabrosse%26aufirst%3DS.%26aulast%3DLissarrague%26aufirst%3DS.%26aulast%3DPicard%26aufirst%3DF.%2BP.%26aulast%3DMaurice%26aufirst%3DK.%26aulast%3DEssioux%26aufirst%3DL.%26aulast%3DMillasseau%26aufirst%3DP.%26aulast%3DGrel%26aufirst%3DP.%26aulast%3DDebailleul%26aufirst%3DV.%26aulast%3DSimon%26aufirst%3DA.%2BM.%26aulast%3DCaterina%26aufirst%3DD.%26aulast%3DDufaure%26aufirst%3DI.%26aulast%3DMalekzadeh%26aufirst%3DK.%26aulast%3DBelova%26aufirst%3DM.%26aulast%3DLuan%26aufirst%3DJ.%2BJ.%26aulast%3DBouillot%26aufirst%3DM.%26aulast%3DSambucy%26aufirst%3DJ.%2BL.%26aulast%3DPrimas%26aufirst%3DG.%26aulast%3DSaumier%26aufirst%3DM.%26aulast%3DBoubkiri%26aufirst%3DN.%26aulast%3DMartin-Saumier%26aufirst%3DS.%26aulast%3DNasroune%26aufirst%3DM.%26aulast%3DPeixoto%26aufirst%3DH.%26aulast%3DDelaye%26aufirst%3DA.%26aulast%3DPinchot%26aufirst%3DV.%26aulast%3DBastucci%26aufirst%3DM.%26aulast%3DGuillou%26aufirst%3DS.%26aulast%3DChevillon%26aufirst%3DM.%26aulast%3DSainz-Fuertes%26aufirst%3DR.%26aulast%3DMeguenni%26aufirst%3DS.%26aulast%3DAurich-Costa%26aufirst%3DJ.%26aulast%3DCherif%26aufirst%3DD.%26aulast%3DGimalac%26aufirst%3DA.%26aulast%3DVan%2BDuijn%26aufirst%3DC.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DOuellette%26aufirst%3DG.%26aulast%3DFortier%26aufirst%3DI.%26aulast%3DRaelson%26aufirst%3DJ.%26aulast%3DSherbatich%26aufirst%3DT.%26aulast%3DRiazanskaia%26aufirst%3DN.%26aulast%3DRogaev%26aufirst%3DE.%26aulast%3DRaeymaekers%26aufirst%3DP.%26aulast%3DAerssens%26aufirst%3DJ.%26aulast%3DKonings%26aufirst%3DF.%26aulast%3DLuyten%26aufirst%3DW.%26aulast%3DMacciardi%26aufirst%3DF.%26aulast%3DSham%26aufirst%3DP.%2BC.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26aulast%3DCohen%26aufirst%3DN.%26aulast%3DCohen%26aufirst%3DD.%26atitle%3DGenetic%2520and%2520physiological%2520data%2520implicating%2520the%2520new%2520human%2520gene%2520G72%2520and%2520the%2520gene%2520for%2520d-amino%2520acid%2520oxidase%2520in%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26spage%3D13675%26epage%3D13680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Boks, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rietkerk, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Beek, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommer, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Koning, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R. S.</span><span> </span><span class="NLM_article-title">Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.euroneuro.2006.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17250995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVWktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=567-572&author=M.+P.+Boksauthor=T.+Rietkerkauthor=M.+H.+van+de+Beekauthor=I.+E.+Sommerauthor=T.+J.+de+Koningauthor=R.+S.+Kahn&title=Reviewing+the+role+of+the+genes+G72+and+DAAO+in+glutamate+neurotransmission+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia</span></div><div class="casAuthors">Boks, M. P. M.; Rietkerk, T.; van de Beek, M. H.; Sommer, I. E.; de Koning, T. J.; Kahn, R. S.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">567-572</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  We review the role of two susceptibility genes; G72 and DAAO in glutamate neurotransmission and the etiol. of schizophrenia.  The gene product of G72 is an activator of DAAO (D-amino acid oxidase), which is the only enzyme oxidising D-serine.  D-Serine is an important co-agonist for the NMDA glutamate receptor and plays a role in neuronal migration and cell death.  Studies of -serine revealed lower serum levels in schizophrenia patients as compared to healthy controls.  Furthermore, administration of -serine as add-on medication reduced the symptoms of schizophrenia.  The underlying mechanism of the involvement of G72 and DAAO in schizophrenia is probably based on decreased levels of -serine and decreased NMDA receptor functioning in patients.  The involvement of this gene is therefore indirect support for the glutamate dysfunction hypothesis in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsQd-NGf4uCrVg90H21EOLACvtfcHk0lgt35zXp6cq8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVWktL0%253D&md5=458daf1d2510c701029ed6aa97148744</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2006.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2006.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DBoks%26aufirst%3DM.%2BP.%26aulast%3DRietkerk%26aufirst%3DT.%26aulast%3Dvan%2Bde%2BBeek%26aufirst%3DM.%2BH.%26aulast%3DSommer%26aufirst%3DI.%2BE.%26aulast%3Dde%2BKoning%26aufirst%3DT.%2BJ.%26aulast%3DKahn%26aufirst%3DR.%2BS.%26atitle%3DReviewing%2520the%2520role%2520of%2520the%2520genes%2520G72%2520and%2520DAAO%2520in%2520glutamate%2520neurotransmission%2520in%2520schizophrenia%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D17%26spage%3D567%26epage%3D572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Hashimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, R.</span><span> </span><span class="NLM_article-title">Mice lacking <span class="smallcaps smallerCapital">d</span>-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1033</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.brainres.2004.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15694926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1033&publication_year=2005&pages=210-215&author=A.+Hashimotoauthor=M.+Yoshikawaauthor=A.+Niwaauthor=R.+Konno&title=Mice+lacking+d-amino+acid+oxidase+activity+display+marked+attenuation+of+stereotypy+and+ataxia+induced+by+MK-801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Mice lacking D-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801</span></div><div class="casAuthors">Hashimoto, Atsushi; Yoshikawa, Masanobu; Niwa, Akira; Konno, Ryuichi</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1033</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The behavioral effects produced by MK-801 (0.4 mg/kg) were compared in mutant DAO-/- mice lacking -amino acid oxidase activity and normal DAO+/+ mice.  Mutant mice display marked diminution of stereotypy and ataxia induced by MK-801 compared to normal mice.  Because the -serine level in the brain of mutant mice is significantly higher than that of normal mice, the elevated -serine in the brain of mutant mice could antagonize MK-801-induced stereotypy and ataxia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmWfbRNOZnM7Vg90H21EOLACvtfcHk0lgt35zXp6cq8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOru74%253D&md5=eccfcf188c174fb98bc9f02e7b5d89da</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2004.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2004.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DNiwa%26aufirst%3DA.%26aulast%3DKonno%26aufirst%3DR.%26atitle%3DMice%2520lacking%2520d-amino%2520acid%2520oxidase%2520activity%2520display%2520marked%2520attenuation%2520of%2520stereotypy%2520and%2520ataxia%2520induced%2520by%2520MK-801%26jtitle%3DBrain%2520Res.%26date%3D2005%26volume%3D1033%26spage%3D210%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Korostishevsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaganovich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cholostoy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashkenazi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratner, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bening-Abu-Shach, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben Asher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritsner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navon, R.</span><span> </span><span class="NLM_article-title">Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2004.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15271585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFyksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=169-176&author=M.+Korostishevskyauthor=M.+Kaganovichauthor=A.+Cholostoyauthor=M.+Ashkenaziauthor=Y.+Ratnerauthor=D.+Daharyauthor=J.+Bernsteinauthor=U.+Bening-Abu-Shachauthor=E.+Ben+Asherauthor=D.+Lancetauthor=M.+Ritsnerauthor=R.+Navon&title=Is+the+G72%2FG30+locus+associated+with+schizophrenia%3F+Single+nucleotide+polymorphisms%2C+haplotypes%2C+and+gene+expression+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis</span></div><div class="casAuthors">Korostishevsky, Michael; Kaganovich, Miryam; Cholostoy, Alina; Ashkenazi, Maya; Ratner, Yael; Dahary, Dvir; Bernstein, Jeanne; Bening-Abu-Shach, Ullrike; Ben-Asher, Edna; Lancet, Doron; Ritsner, Michael; Navon, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-176</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The genes G72/G30 were recently implicated in schizophrenia in both Canadian and Russian populations.  The authors hypothesized that 1) polymorphic changes in this gene region might be assocd. with schizophrenia in the Ashkenazi Jewish population and that 2) changes in G72/G30 gene expression might be expected in schizophrenic patients compared with control subjects.  Eleven single nucleotide polymorphisms (SNPs) encompassing the G72/G30 genes were typed in the genomic DNA from 60 schizophrenic patients and 130 matched control subjects of Ashkenazi ethnic origin.  Case-control comparisons were based on linkage disequil. (LD) and haplotype frequency estns.  Gene expression anal. of G72 and G30 was performed on 88 postmortem dorsolateral prefrontal cortex samples.  Linkage disequil. anal. revealed two main SNP blocks.  Haplotype anal. on block II, contg. three SNPs external to the genes, demonstrated an assocn. with schizophrenia.  Gene expression anal. exhibited correlations between expression levels of the G72 and G30 genes, as well as a tendency toward overexpression of the G72 gene in schizophrenic brain samples of 44 schizophrenic patients compared with 44 control subjects.  It is likely that the G72/G30 region is involved in susceptibility to schizophrenia in the Ashkenazi population.  The elevation in expression of the G72 gene coincides with the glutamatergic theory of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPaJ1RTu5n_rVg90H21EOLACvtfcHk0lgt35zXp6cq8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFyksLk%253D&md5=39867b825d0abe084b75d49fed4f69c6</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2004.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2004.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DKorostishevsky%26aufirst%3DM.%26aulast%3DKaganovich%26aufirst%3DM.%26aulast%3DCholostoy%26aufirst%3DA.%26aulast%3DAshkenazi%26aufirst%3DM.%26aulast%3DRatner%26aufirst%3DY.%26aulast%3DDahary%26aufirst%3DD.%26aulast%3DBernstein%26aufirst%3DJ.%26aulast%3DBening-Abu-Shach%26aufirst%3DU.%26aulast%3DBen%2BAsher%26aufirst%3DE.%26aulast%3DLancet%26aufirst%3DD.%26aulast%3DRitsner%26aufirst%3DM.%26aulast%3DNavon%26aufirst%3DR.%26atitle%3DIs%2520the%2520G72%252FG30%2520locus%2520associated%2520with%2520schizophrenia%253F%2520Single%2520nucleotide%2520polymorphisms%252C%2520haplotypes%252C%2520and%2520gene%2520expression%2520analysis%26jtitle%3DBiol.%2520Psychiatry%26date%3D2004%26volume%3D56%26spage%3D169%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Schumacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamra, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freudenberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlraun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tullius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovalenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogaert, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rietschel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Propping, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nothen, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichon, S.</span><span> </span><span class="NLM_article-title">Examination of G72 and <span class="smallcaps smallerCapital">d</span>-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14966479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXht1Sjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=203-207&author=J.+Schumacherauthor=R.+A.+Jamraauthor=J.+Freudenbergauthor=T.+Beckerauthor=S.+Ohlraunauthor=A.+C.+Otteauthor=M.+Tulliusauthor=S.+Kovalenkoauthor=A.+V.+Bogaertauthor=W.+Maierauthor=M.+Rietschelauthor=P.+Proppingauthor=M.+M.+Nothenauthor=S.+Cichon&title=Examination+of+G72+and+d-amino-acid+oxidase+as+genetic+risk+factors+for+schizophrenia+and+bipolar+affective+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder</span></div><div class="casAuthors">Schumacher, J.; Jamra, R. Abon; Freudenberg, J.; Becker, T.; Ohlraun, S.; Otte, A. C. J.; Tullius, M.; Kovalenko, S.; Van Den Bogaert, A.; Maier, W.; Rietschel, M.; Propping, P.; Noethen, M. M.; Cichon, S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-207</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A recent study has suggested that the brain-expressed genes for G72 and D-amino-acid oxidase (DAAO) exert an influence on susceptibility to schizophrenia.  Our aim was to replicate this finding in German schizophrenic patients and to assess whether G72 and DAAO might also contribute to the development of bipolar affective disorder.  We genotyped 7 single-nucleotide polymorphisms (SNPs) in the G72 gene and 3 in the DAAO gene in 599 patients (299 schizophrenic, 300 bipolar) and 300 controls.  At G72, individual SNPs and a 4-marker haplotype were assocd. with schizophrenia.  The most significant SNP as well as the haplotype were also assocd. with bipolar affective disorder (BPAD).  DAAO was assocd. with schizophrenia, but not with BPAD.  The assocn. of variation at G72 with schizophrenia as well as BPAD provides mol. support for the hypothesis that these 2 major psychiatric disorders share some of their etiol. background.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf7hdjcbTClbVg90H21EOLACvtfcHk0lhLUILdnPKFsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXht1Sjtbs%253D&md5=dc0c63f88f3ca42247626902fbc32b61</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001421%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DJ.%26aulast%3DJamra%26aufirst%3DR.%2BA.%26aulast%3DFreudenberg%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DT.%26aulast%3DOhlraun%26aufirst%3DS.%26aulast%3DOtte%26aufirst%3DA.%2BC.%26aulast%3DTullius%26aufirst%3DM.%26aulast%3DKovalenko%26aufirst%3DS.%26aulast%3DBogaert%26aufirst%3DA.%2BV.%26aulast%3DMaier%26aufirst%3DW.%26aulast%3DRietschel%26aufirst%3DM.%26aulast%3DPropping%26aufirst%3DP.%26aulast%3DNothen%26aufirst%3DM.%2BM.%26aulast%3DCichon%26aufirst%3DS.%26atitle%3DExamination%2520of%2520G72%2520and%2520d-amino-acid%2520oxidase%2520as%2520genetic%2520risk%2520factors%2520for%2520schizophrenia%2520and%2520bipolar%2520affective%2520disorder%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D203%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callicott, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hariri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattay, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigelow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppola, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">The G72/G30 gene complex and cognitive abnormalities in schizophrenia</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=2022-2032&author=T.+E.+Goldbergauthor=R.+E.+Straubauthor=J.+H.+Callicottauthor=A.+Haririauthor=V.+S.+Mattayauthor=L.+Bigelowauthor=R.+Coppolaauthor=M.+F.+Eganauthor=D.+R.+Weinberger&title=The+G72%2FG30+gene+complex+and+cognitive+abnormalities+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DCallicott%26aufirst%3DJ.%2BH.%26aulast%3DHariri%26aufirst%3DA.%26aulast%3DMattay%26aufirst%3DV.%2BS.%26aulast%3DBigelow%26aufirst%3DL.%26aulast%3DCoppola%26aufirst%3DR.%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DThe%2520G72%252FG30%2520gene%2520complex%2520and%2520cognitive%2520abnormalities%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D2006%26volume%3D31%26spage%3D2022%26epage%3D2032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Hattori, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christian, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheshwari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detera-Wadleigh, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershon, E. S.</span><span> </span><span class="NLM_article-title">Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1131</span><span class="NLM_x">–</span> <span class="NLM_lpage">1140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F374822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12647258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslagtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2003&pages=1131-1140&author=E.+Hattoriauthor=C.+Liuauthor=J.+A.+Badnerauthor=T.+I.+Bonnerauthor=S.+L.+Christianauthor=M.+Maheshwariauthor=S.+D.+Detera-Wadleighauthor=R.+A.+Gibbsauthor=E.+S.+Gershon&title=Polymorphisms+at+the+G72%2FG30+gene+locus%2C+on+13q33%2C+are+associated+with+bipolar+disorder+in+two+independent+pedigree+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series</span></div><div class="casAuthors">Hattori, Eiji; Liu, Chunyu; Badner, Judith A.; Bonner, Tom I.; Christian, Susan L.; Maheshwari, Manjula; Detera-Wadleigh, Sevilla D.; Gibbs, Richard A.; Gershon, Elliot S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1131-1140</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Linkage evidence suggests that chromosome 13 (13q32-33) contains susceptibility genes for both bipolar disorder and schizophrenia.  Recently, genes called "G72" and "G30" were identified, and polymorphisms of these overlapping genes were reported to be assocd. with schizophrenia.  We studied two series of pedigrees with bipolar disorder: the Clin. Neurogenetics (CNG) pedigrees (in which linkage to illness had been previously reported at 13q32-33), with 83 samples from 22 multiplex families, and the National Institute of Mental Health (NIMH) Genetics Initiative pedigrees, with 474 samples from 152 families.  Sixteen single-nucleotide polymorphisms (SNPs) were genotyped at and around the G72/G30 locus, which covered a 157-kb region encompassing the entire complementary DNA sequences of G72 and G30.  We performed transmission/disequil. testing (TDT) and haplotype anal., since a linkage-disequil. block was present at this gene locus.  In the CNG and NIMH data sets, the results of global TDT of the entire haplotype set were significant and consistent (P =.0004 and P =.008, resp.).  In the CNG series, the assocd. genotypes divided the families into those with linkage and those without linkage (partitioned by the linkage evidence).  Anal. of the decay of haplotype sharing gave a location est. that included G72/G30 in its 95% confidence interval.  Although statistically significant assocn. was not detected for individual SNPs in the NIMH data set, the same haplotype was consistently over-transmitted in both series.  These data suggest that a susceptibility variant for bipolar illness exists in the vicinity of the G72/G30 genes.  Taken together with the earlier report, this is the first demonstration of a novel gene(s), discovered through a positional approach, independently assocd. with both bipolar illness and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAaxhb-qcG77Vg90H21EOLACvtfcHk0lhLUILdnPKFsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslagtbk%253D&md5=c02b757f9a22b1827260aa5700238586</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1086%2F374822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F374822%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DBadner%26aufirst%3DJ.%2BA.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DChristian%26aufirst%3DS.%2BL.%26aulast%3DMaheshwari%26aufirst%3DM.%26aulast%3DDetera-Wadleigh%26aufirst%3DS.%2BD.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DGershon%26aufirst%3DE.%2BS.%26atitle%3DPolymorphisms%2520at%2520the%2520G72%252FG30%2520gene%2520locus%252C%2520on%252013q33%252C%2520are%2520associated%2520with%2520bipolar%2520disorder%2520in%2520two%2520independent%2520pedigree%2520series%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2003%26volume%3D72%26spage%3D1131%26epage%3D1140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Chen, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akula, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detera-Wadleigh, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potash, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePaulo, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnis, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, F. J.</span><span> </span><span class="NLM_article-title">Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14699445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=87-92&author=Y.+S.+Chenauthor=N.+Akulaauthor=S.+D.+Detera-Wadleighauthor=T.+G.+Schulzeauthor=J.+Thomasauthor=J.+B.+Potashauthor=J.+R.+DePauloauthor=M.+G.+McInnisauthor=N.+J.+Coxauthor=F.+J.+McMahon&title=Findings+in+an+independent+sample+support+an+association+between+bipolar+affective+disorder+and+the+G72%2FG30+locus+on+chromosome+13q33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33</span></div><div class="casAuthors">Chen, Y-S.; Akula, N.; Detera-Wadleigh, S. D.; Schulze, T. G.; Thomas, J.; Potash, J. B.; DePaulo, J. R.; McInnis, M. G.; Cox, N. J.; McMahon, F. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Markers near the nested genes G72 and G30 on chromosome 13q33 have been implicated in the etiol. of schizophrenia and, recently, bipolar affective disorder (BPAD).  Hattori, E.; et al (2003) reported that single-nucleotide polymorphisms (SNPs) near the G72/G30 locus were assocd. with BPAD in a sample of 22 pedigrees, and that SNP haplotypes were assocd. in a second, larger sample of triads.  The present study attempts to replicate this finding in an independent case-control sample.  Six SNPs near the G72/G30 locus, including the most strongly assocd. markers in the previous study, were tested in 139 cases and 113 ethnically matched controls.  Significant assocn. was detected between BPAD and two adjacent SNPs (smallest P=0.007; global P=0.024).  Haplotype anal. produced addnl. support for assocn. (smallest P=0.004; global P=0.004).  Anal. of 31 unlinked microsatellite markers detected no population stratification in the cases or controls studied.  Although the assocd. alleles and haplotypes differ from those previously reported, these new results provide further evidence, in an independent sample, for an assocn. between BPAD and genetic variation in the vicinity of the genes G72 and G30.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGproFFRzgLhCLVg90H21EOLACvtfcHk0lhLUILdnPKFsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtr%252FM&md5=f3c8767bf3425afa51521b700ba4b904</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001453%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DAkula%26aufirst%3DN.%26aulast%3DDetera-Wadleigh%26aufirst%3DS.%2BD.%26aulast%3DSchulze%26aufirst%3DT.%2BG.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DPotash%26aufirst%3DJ.%2BB.%26aulast%3DDePaulo%26aufirst%3DJ.%2BR.%26aulast%3DMcInnis%26aufirst%3DM.%2BG.%26aulast%3DCox%26aufirst%3DN.%2BJ.%26aulast%3DMcMahon%26aufirst%3DF.%2BJ.%26atitle%3DFindings%2520in%2520an%2520independent%2520sample%2520support%2520an%2520association%2520between%2520bipolar%2520affective%2520disorder%2520and%2520the%2520G72%252FG30%2520locus%2520on%2520chromosome%252013q33%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D87%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Yoshikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, A.</span><span> </span><span class="NLM_article-title">Acute treatment with morphine augments the expression of serine racemase and <span class="smallcaps smallerCapital">d</span>-amino acid oxidase mRNAs in rat brain</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">525</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16256980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gnt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=525&publication_year=2005&pages=94-97&author=M.+Yoshikawaauthor=H.+Andohauthor=K.+Itoauthor=T.+Suzukiauthor=M.+Kawaguchiauthor=H.+Kobayashiauthor=T.+Okaauthor=A.+Hashimoto&title=Acute+treatment+with+morphine+augments+the+expression+of+serine+racemase+and+d-amino+acid+oxidase+mRNAs+in+rat+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Acute treatment with morphine augments the expression of serine racemase and D-amino acid oxidase mRNAs in rat brain</span></div><div class="casAuthors">Yoshikawa, Masanobu; Andoh, Hidehiro; Ito, Kenji; Suzuki, Toshiyasu; Kawaguchi, Mitsuru; Kobayashi, Hiroyuki; Oka, Tetsuo; Hashimoto, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">525</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">94-97</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To obtain further insight into the interactions between the N-methyl-D-aspartate receptor and opioid receptor systems, we have investigated the effects of the acute treatment of morphine on the expression of serine racemase and D-amino acid oxidase mRNAs in several brain areas of rats.  The morphine administration produced a dose-dependent and transient elevation in the levels of serine racemase and D-amino acid oxidase mRNAs in all the brain areas.  The present results are the first to suggest an interaction between the expression of the mRNAs for the D-serine-related enzymes and the opioid receptor activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcpgUcyMlLPrVg90H21EOLACvtfcHk0lgyLIFdfw-4bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gnt7fK&md5=0f682f0343642ae8b04dab4e426588fb</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DAndoh%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DKawaguchi%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DA.%26atitle%3DAcute%2520treatment%2520with%2520morphine%2520augments%2520the%2520expression%2520of%2520serine%2520racemase%2520and%2520d-amino%2520acid%2520oxidase%2520mRNAs%2520in%2520rat%2520brain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D525%26spage%3D94%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Yue, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span> </span><span class="NLM_article-title">Association of G72/G30 polymorphisms with early-onset and male schizophrenia</span> <span class="citation_source-journal">NeuroReport</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1899</span><span class="NLM_x">–</span> <span class="NLM_lpage">1902</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=1899-1902&author=W.+Yueauthor=Z.+Liuauthor=G.+Kangauthor=J.+Yanauthor=F.+Tangauthor=Y.+Ruanauthor=J.+Zhangauthor=D.+Zhang&title=Association+of+G72%2FG30+polymorphisms+with+early-onset+and+male+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DKang%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DRuan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DAssociation%2520of%2520G72%252FG30%2520polymorphisms%2520with%2520early-onset%2520and%2520male%2520schizophrenia%26jtitle%3DNeuroReport%26date%3D2006%26volume%3D17%26spage%3D1899%26epage%3D1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Liu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, H. G.</span><span> </span><span class="NLM_article-title">No association of G72 and <span class="smallcaps smallerCapital">d</span>-amino acid oxidase genes with schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16842973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28rnvFalsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2006&pages=15-20&author=Y.+L.+Liuauthor=C.+S.+Fannauthor=C.+M.+Liuauthor=C.+C.+Changauthor=J.+Y.+Wuauthor=S.+I.+Hungauthor=S.+K.+Liuauthor=M.+H.+Hsiehauthor=T.+J.+Hwangauthor=H.+Y.+Chanauthor=J.+J.+Chenauthor=S.+V.+Faraoneauthor=M.+T.+Tsuangauthor=W.+J.+Chenauthor=H.+G.+Hwu&title=No+association+of+G72+and+d-amino+acid+oxidase+genes+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">No association of G72 and D-amino acid oxidase genes with schizophrenia</span></div><div class="casAuthors">Liu Yu-Li; Fann Cathy Shen-Jang; Liu Chih-Min; Chang Chien Ching; Wu Jer-Yuarn; Hung Shuen-Iu; Liu Shih-Kai; Hsieh Ming H; Hwang Tzung-Jeng; Chan Hung-Yu; Chen Jiahn-Jyh; Faraone Stephen V; Tsuang Ming T; Chen Wei J; Hwu Hai-Gwo</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">15-20</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The genes of D-amino acid oxidase (DAAO) activator (DAOA or G72; 13q34) and DAAO (12q24) have been suggested as candidate genes and involved in the N-methyl-D-aspartate receptor regulation pathway for schizophrenia.  In order to evaluate the potential association of these two genes with schizophrenia in a Taiwanese sample, three single nucleotide polymorphisms (SNPs) for DAAO (rs2111902, rs3918346, rs3741775) and eleven SNPs for G72 (rs3916965, rs3916966, rs3916967, rs2391191, rs3916968, rs947267, rs778294, rs3916970, rs3916971, rs778293, rs3918342) were genotyped by the MALDI-TOF mass spectrometry method in 218 families (864 individuals) containing at least two siblings affected with schizophrenia.  In SNP-based single locus association analyses, neither G72 nor DAAO showed significant association with schizophrenia.  Additionally, a three-SNP haplotype in DAAO, and a four-SNP as well as a two-SNP haplotype in G72, showed no significant associations with schizophrenia.  These results suggest that the DAAO and G72 genes are not susceptibility genes for schizophrenia in a Taiwanese sample.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2IzNCcYz_Vq91pGlMMoT5fW6udTcc2eZV16R2RK79Ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rnvFalsw%253D%253D&md5=fb14d4eda9f5ddd61ad4b712e5ce8e5e</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DFann%26aufirst%3DC.%2BS.%26aulast%3DLiu%26aufirst%3DC.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DWu%26aufirst%3DJ.%2BY.%26aulast%3DHung%26aufirst%3DS.%2BI.%26aulast%3DLiu%26aufirst%3DS.%2BK.%26aulast%3DHsieh%26aufirst%3DM.%2BH.%26aulast%3DHwang%26aufirst%3DT.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DTsuang%26aufirst%3DM.%2BT.%26aulast%3DChen%26aufirst%3DW.%2BJ.%26aulast%3DHwu%26aufirst%3DH.%2BG.%26atitle%3DNo%2520association%2520of%2520G72%2520and%2520d-amino%2520acid%2520oxidase%2520genes%2520with%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D87%26spage%3D15%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Williams, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macgregor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raybould, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grozeva, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamshere, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, N.</span><span> </span><span class="NLM_article-title">Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">366</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.63.4.366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16585465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xktlekt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=366-373&author=N.+M.+Williamsauthor=E.+K.+Greenauthor=S.+Macgregorauthor=S.+Dwyerauthor=N.+Nortonauthor=H.+Williamsauthor=R.+Raybouldauthor=D.+Grozevaauthor=M.+Hamshereauthor=S.+Zammitauthor=L.+Jonesauthor=A.+Cardnoauthor=G.+Kirovauthor=I.+Jonesauthor=M.+C.+O%E2%80%99Donovanauthor=M.+J.+Owenauthor=N.+Craddock&title=Variation+at+the+DAOA%2FG30+locus+influences+susceptibility+to+major+mood+episodes+but+not+psychosis+in+schizophrenia+and+bipolar+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Variation at the DAOA/G30 locus influences susceptibility to major mood episode but not psychosis in schizophrenia and bipolar disorder</span></div><div class="casAuthors">Williams, Nigel M.; Green, Elaine K.; Macgregor, Stuart; Dwyer, Sarah; Norton, Nadine; Williams, Hywel; Raybould, Rachel; Grozeva, Detelina; Hamshere, Marian; Zammit, Stanley; Jones, Lisa; Cardno, Alastair; Kirov, George; Jones, Ian; O'Donovan, Michael C.; Owen, Michael J.; Craddock, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">366-373</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Variation at the DAOA/G30 locus has been described to be assocd. with both schizophrenia and bipolar disorder, but there is little consistency between studies of the tested polymorphisms or variants showing assocn.  Objectives: To obtain a stringent replication of assocn. in large samples of both disorders using consistent clin. and lab. methods, and to test the hypothesis that assocn. at DAOA/G30 identifies an underlying domain of psychopathol. abnormalities that cuts across traditional diagnostic categories.  Design: A systematic study of polymorphisms at DAOA/G30 using genetic case-control assocn. anal.  Setting: Subjects were unrelated and ascertained from general psychiatric inpatient and outpatient services.  Participants: White persons from the United Kingdom meeting criteria for DSM-IV schizophrenia (n = 709) or bipolar I disorder (n = 706) and 1416 ethnically matched controls.  Methods: Nine polymorphisms that tag common genetic variations at DAOA/G30 were genotyped in all of the individuals, and comparisons were made between affected and unaffected individuals.  Results: We identified significant assocn. (P = .01-.047) between 3 single-nucleotide polymorphisms and bipolar disorder but failed to find assocn. with schizophrenia.  Analyses across the traditional diagnostic categories revealed significant evidence (P = .002-.02) for assocn. with 4 single-nucleotide polymorphisms in the subset of cases (n = 818) in which episodes of major mood disorder had occurred (gene-wide P = .009).  We found a similar pattern of assocn. in bipolar cases and in schizophrenia cases in which individuals had experienced major mood disorder.  In contrast, we found no evidence for assocn. in the subset of cases (n = 1153) in which psychotic features occurred (all P > .08).  Conclusions: Despite being originally described as a schizophrenia susceptibility locus, our data suggest that variation at the DAOA/G30 locus does not primarily increase susceptibility for prototypical schizophrenia or psychosis.  Instead, our results imply that variation at the DAOA/G30 locus influences susceptibility to episodes of mood disorder across the traditional bipolar and schizophrenia categories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0VRETMHHdgbVg90H21EOLACvtfcHk0lgyLIFdfw-4bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xktlekt7w%253D&md5=b984dd0e1bf6f7c7edd24fd25672f01a</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.63.4.366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.63.4.366%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BM.%26aulast%3DGreen%26aufirst%3DE.%2BK.%26aulast%3DMacgregor%26aufirst%3DS.%26aulast%3DDwyer%26aufirst%3DS.%26aulast%3DNorton%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DH.%26aulast%3DRaybould%26aufirst%3DR.%26aulast%3DGrozeva%26aufirst%3DD.%26aulast%3DHamshere%26aufirst%3DM.%26aulast%3DZammit%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DCardno%26aufirst%3DA.%26aulast%3DKirov%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DI.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DCraddock%26aufirst%3DN.%26atitle%3DVariation%2520at%2520the%2520DAOA%252FG30%2520locus%2520influences%2520susceptibility%2520to%2520major%2520mood%2520episodes%2520but%2520not%2520psychosis%2520in%2520schizophrenia%2520and%2520bipolar%2520disorder%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2006%26volume%3D63%26spage%3D366%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Detera-Wadleigh, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, F. J.</span><span> </span><span class="NLM_article-title">G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2006.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16581030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmsl2jtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=106-114&author=S.+D.+Detera-Wadleighauthor=F.+J.+McMahon&title=G72%2FG30+in+schizophrenia+and+bipolar+disorder%3A+review+and+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">G72/G30 in Schizophrenia and Bipolar Disorder: Review and Meta-analysis</span></div><div class="casAuthors">Detera-Wadleigh, Sevilla D.; McMahon, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106-114</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Assocn. of the G72/G30 locus with schizophrenia and bipolar disorder has now been reported in several studies.  The G72/G30 locus may be one of several that account for the evidence of linkage that spans a broad region of chromosome 13q.  However, the story of G72/G30 is complex.  Our meta-anal. of published assocn. studies shows highly significant evidence of assocn. between nucleotide variations in the G72/G30 region and schizophrenia, along with compelling evidence of assocn. with bipolar disorder.  But the assocd. alleles and haplotypes are not identical across studies, and some strongly assocd. variants are located ∼50 kb telomeric of G72.  Interestingly, G72 and G30 are transcribed in opposite directions; hence, their transcripts could cross-regulate translation.  A functional native protein and functional motifs for G72 or G30 remain to be demonstrated.  The interaction of G72 with D-amino acid oxidase, itself of interest as a modulator of N-methyl-D-aspartate receptors through regulation of D-serine levels, has been reported in one study and could be a key functional link that deserves further investigation.  The assocn. findings in the G72/G30 region, among the most compelling in psychiatry, may expose an important mol. pathway involved in susceptibility to schizophrenia and bipolar disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0GWVDNGt_FrVg90H21EOLACvtfcHk0lhuHhh8JOQD9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmsl2jtbY%253D&md5=2c61b1975d113bce05f691a2dc6964d5</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DDetera-Wadleigh%26aufirst%3DS.%2BD.%26aulast%3DMcMahon%26aufirst%3DF.%2BJ.%26atitle%3DG72%252FG30%2520in%2520schizophrenia%2520and%2520bipolar%2520disorder%253A%2520review%2520and%2520meta-analysis%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D60%26spage%3D106%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Abou, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmael, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rietschel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nothen, M. M.</span><span> </span><span class="NLM_article-title">The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbl028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16914640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28rjtV2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2006&pages=599-608&author=J.+R.+Abouauthor=C.+Schmaelauthor=S.+Cichonauthor=M.+Rietschelauthor=J.+Schumacherauthor=M.+M.+Nothen&title=The+G72%2FG30+gene+locus+in+psychiatric+disorders%3A+a+challenge+to+diagnostic+boundaries"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries?</span></div><div class="casAuthors">Abou Jamra Rami; Schmael Christine; Cichon Sven; Rietschel Marcella; Schumacher Johannes; Nothen Markus M</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">599-608</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">In follow-up from evidence obtained in linkage studies, systematic linkage disequilibrium mapping within chromosomal region 13q33 has led to the identification of a schizophrenia susceptibility locus which harbors the genes G72 and G30.  These association findings have been replicated in several independent schizophrenia samples.  Association has also been found between genetic variants at the G72/G30 locus and bipolar affective disorder (BPAD), with replication in independent studies.  Results from studies of more detailed psychiatric phenotypes show that association exists with symptom clusters that are common to several disorders as well as with specific psychiatric diagnoses.  These findings may indicate that the association lies not with the diagnostic categories per se but with more specific aspects of the phenotype, such as affective symptoms and cognitive effects, which cross traditional psychiatric diagnostic boundaries.  At the molecular level, the picture remains far from clear.  No putative functional variants have been identified in the coding regions of G72 or G30, and it is therefore likely that disease susceptibility is caused by as yet unidentified variants which alter gene expression or splicing.  A further complication is the fact that inconsistencies are evident in the risk alleles and haplotypes observed to be associated across different samples and studies, which may suggest the presence of multiple susceptibility variants at this locus.  Functional analyses indicate that the G72 gene product plays a role in the activation of N-methyl-D-aspartate receptors, a molecular pathway implicated in both schizophrenia and BPAD, making it the most plausible candidate gene at this locus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgkQuoRCrl6kbxh97K6Vt6fW6udTcc2ebVhcRQwz4Babntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rjtV2qtw%253D%253D&md5=8a50265ab8bf1f7b88ea67d568109533</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbl028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbl028%26sid%3Dliteratum%253Aachs%26aulast%3DAbou%26aufirst%3DJ.%2BR.%26aulast%3DSchmael%26aufirst%3DC.%26aulast%3DCichon%26aufirst%3DS.%26aulast%3DRietschel%26aufirst%3DM.%26aulast%3DSchumacher%26aufirst%3DJ.%26aulast%3DNothen%26aufirst%3DM.%2BM.%26atitle%3DThe%2520G72%252FG30%2520gene%2520locus%2520in%2520psychiatric%2520disorders%253A%2520a%2520challenge%2520to%2520diagnostic%2520boundaries%26jtitle%3DSchizophr.%2520Bull.%26date%3D2006%26volume%3D32%26spage%3D599%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span> </span><span class="NLM_article-title">G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies</span> <span class="citation_source-journal">Genetics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2007&pages=917-922&author=D.+Liauthor=L.+He&title=G72%2FG30+genes+and+schizophrenia%3A+a+systematic+meta-analysis+of+association+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DG72%252FG30%2520genes%2520and%2520schizophrenia%253A%2520a%2520systematic%2520meta-analysis%2520of%2520association%2520studies%26jtitle%3DGenetics%26date%3D2007%26volume%3D175%26spage%3D917%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Millar, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao-Wei, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devon, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arveiler, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, D. J.</span><span> </span><span class="NLM_article-title">Genomic structure and localisation within a linkage hotspot of disrupted in schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4000784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11317219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFGlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=173-178&author=J.+K.+Millarauthor=S.+Christieauthor=S.+Andersonauthor=D.+Lawsonauthor=L.+D.+Hsiao-Weiauthor=R.+S.+Devonauthor=B.+Arveilerauthor=W.+J.+Muirauthor=D.+H.+Blackwoodauthor=D.+J.+Porteous&title=Genomic+structure+and+localisation+within+a+linkage+hotspot+of+disrupted+in+schizophrenia+1%2C+a+gene+disrupted+by+a+translocation+segregating+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic structure and localization within a linkage hotspot of Disrupted in Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia</span></div><div class="casAuthors">Millar, J. K.; Christie, S.; Anderson, S.; Lawson, D.; Loh, D. Hsiao-Wei; Devon, R. S.; Arveiler, B.; Muir, W. J.; Blackwood, D. H. R.; Porteous, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Two overlapping and antiparallel genes on chromosome 1, Disrupted In Schizophrenia 1 and 2 (DISC1 and DISC2), are disrupted by a (1;11)(q42.1;q14.3) translocation which segregates with schizophrenia through at least four generations of a large Scottish family.  Consequently, these genes are worthy of further investigation as candidate genes potentially involved in the etiol. of major psychiatric illness.  We have constructed a contiguous clone map of PACs and cosmids extending across at least 400 kb of the chromosome 1 translocation breakpoint region and this has provided the basis for examn. of the genomic structure of DISC1.  The gene consists of thirteen exons, estd. to extend across at least 300 kb of DNA.  The antisense gene DISC2 overlaps with exon 9.  Exon 11 contains an alternative splice site that removes 66 nucleotides from the open reading frame.  The final intron of DISC1 belongs to the rare AT-AC class of introns.  We have also mapped marker DIS251 in close proximity to DISC1, localising the gene within a crit. region identified by several independent studies.  Information regarding the structure of the DISC1 gene will facilitate assessment of its involvement in the etiol. of major mental illness in psychotic individuals unrelated to carriers of the translocation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsuW3XVZfay7Vg90H21EOLACvtfcHk0lgnlbId6z3BUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFGlurg%253D&md5=1b2d0c548b3020064408f7c32d2e59c6</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4000784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4000784%26sid%3Dliteratum%253Aachs%26aulast%3DMillar%26aufirst%3DJ.%2BK.%26aulast%3DChristie%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DD.%26aulast%3DHsiao-Wei%26aufirst%3DL.%2BD.%26aulast%3DDevon%26aufirst%3DR.%2BS.%26aulast%3DArveiler%26aufirst%3DB.%26aulast%3DMuir%26aufirst%3DW.%2BJ.%26aulast%3DBlackwood%26aufirst%3DD.%2BH.%26aulast%3DPorteous%26aufirst%3DD.%2BJ.%26atitle%3DGenomic%2520structure%2520and%2520localisation%2520within%2520a%2520linkage%2520hotspot%2520of%2520disrupted%2520in%2520schizophrenia%25201%252C%2520a%2520gene%2520disrupted%2520by%2520a%2520translocation%2520segregating%2520with%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry%26date%3D2001%26volume%3D6%26spage%3D173%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarginson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crombie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Clair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span> </span><span class="NLM_article-title">Genetic association between schizophrenia and the DISC1 gene in the Scottish population</span> <span class="citation_source-journal">Am. J. Med. Genet. B: Neuropsychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1SrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2006&pages=155-159&author=F.+Zhangauthor=J.+Sarginsonauthor=C.+Crombieauthor=N.+Walkerauthor=D.+St+Clairauthor=D.+Shaw&title=Genetic+association+between+schizophrenia+and+the+DISC1+gene+in+the+Scottish+population"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic association between schizophrenia and the DISC1 gene in the Scottish population</span></div><div class="casAuthors">Zhang, Feng; Sarginson, Jane; Crombie, Caroline; Walker, Nick; St. Clair, David; Shaw, Duncan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">141B</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">AJMGC9</span>;
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Several lines of evidence support the involvement of the disrupted in schizophrenia 1 (DISC1) gene in schizophrenia susceptibility, including its original identification in a schizophrenia family with a chromosome translocation, several genetic assocn. studies, and functional characterization of the gene product.  In the present study, we have genotyped multiple SNP and microsatellite markers in a large Scottish case-control sample.  We identified two SNPs and one microsatellite that show significant assocn. with schizophrenia.  The strongest assocn. is with a haplotype of SNPs rs751229 and rs3738401, located at the 5' end of the gene; the C-A haplotype of these SNPs is assocd. with a relative risk of schizophrenia of 5 in our population.  We also observe assocn. with a microsatellite in intron 7, but no assocn. with markers toward the 3' end of the gene.  The results are in broad agreement with those of other genetic studies, but there are differences in terms of the precise patterns of assocn.  This anal. further strengthens the candidacy of DISC1 as a risk factor for schizophrenia in the general population, and suggests that more intensive searching for causative variants is justified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqD59QkGi9B7Vg90H21EOLACvtfcHk0lgnlbId6z3BUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1SrtLs%253D&md5=6806dbc61cb83863225f04514a7d4ba3</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DSarginson%26aufirst%3DJ.%26aulast%3DCrombie%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DSt%2BClair%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DD.%26atitle%3DGenetic%2520association%2520between%2520schizophrenia%2520and%2520the%2520DISC1%2520gene%2520in%2520the%2520Scottish%2520population%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%2520B%253A%2520Neuropsychiatr.%2520Genet.%26date%3D2006%26volume%3D141%26spage%3D155%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Ekelund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hovatta, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paunio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varilo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suhonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellonen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinsheimer, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juvonen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arajarvi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partonen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suvisaari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonnqvist, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltonen, L.</span><span> </span><span class="NLM_article-title">Chromosome 1 loci in Finnish schizophrenia families</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1611</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fhmg%2F10.15.1611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11468279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFOiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2001&pages=1611-1617&author=J.+Ekelundauthor=I.+Hovattaauthor=A.+Parkerauthor=T.+Paunioauthor=T.+Variloauthor=R.+Martinauthor=J.+Suhonenauthor=P.+Ellonenauthor=G.+Chanauthor=J.+S.+Sinsheimerauthor=E.+Sobelauthor=H.+Juvonenauthor=R.+Arajarviauthor=T.+Partonenauthor=J.+Suvisaariauthor=J.+Lonnqvistauthor=J.+Meyerauthor=L.+Peltonen&title=Chromosome+1+loci+in+Finnish+schizophrenia+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Chromosome 1 loci in Finnish schizophrenia families</span></div><div class="casAuthors">Ekelund, Jesper; Hovatta, Iiris; Parker, Alex; Paunio, Tiina; Varilo, Teppo; Martin, Rory; Suhonen, Johanna; Ellonen, Pekka; Chan, Gayun; Sinsheimer, Janet S.; Sobel, Eric; Juvonen, Hannu; Arajarvi, Ritva; Partonen, Timo; Suvisaari, Jaana; Lonnqvist, Jouko; Meyer, Joanne; Peltonen, Leena</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1611-1617</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">We have earlier reported evidence for linkage to two regions on chromosome 1q32-q42 in schizophrenia families collected for two sep. studies in Finland.  Here we report the results of a fine mapping effort aimed at further definition of the chromosomal region of interest using a large, population-based study sample (221 families, 557 affected individuals).  Most affecteds (78%) had a DSM-IV schizophrenia diagnosis and the remaining had schizophrenia spectrum disorders.  We genotyped a total of 147 microsatellite markers on a wide 45 cM region of chromosome 1q.  The results were analyzed sep. for families originating from an internal isolate of Finland and for families from the rest of Finland, as well as for all families jointly.  We used traditional two-point linkage anal., SimWalk2 multipoint anal. and a novel gamete-competition assocn./linkage method.  Evidence for linkage was obtained for one locus in the combined sample (Zmax = 2.71, D1S2709) and in the nuclear families from outside the internal isolate (Zmax = 3.21, D1S2709).  In the families from the internal isolate the strongest evidence for linkage was obtained with markers located 22 cM centromeric from this marker (Zmax = 2.30, D1S245).  Multipoint anal. also indicated these loci.  Some evidence for assocn. with several markers was obsd. using the gamete-competition method.  Interestingly, the strongest evidence for linkage in the combined study sample was obtained for marker D1S2709, which is an intragenic marker of the DISC1 gene, previously suggested as a susceptibility gene for schizophrenia.  These results are consistent with the presence of susceptibility gene(s) in this chromosomal region, a result also implied in other recent family studies of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmp9KYBQRL0rVg90H21EOLACvtfcHk0lgnlbId6z3BUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFOiurw%253D&md5=72221ff2dddd22fbb1999459558c1b79</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F10.15.1611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F10.15.1611%26sid%3Dliteratum%253Aachs%26aulast%3DEkelund%26aufirst%3DJ.%26aulast%3DHovatta%26aufirst%3DI.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DPaunio%26aufirst%3DT.%26aulast%3DVarilo%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DSuhonen%26aufirst%3DJ.%26aulast%3DEllonen%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DSinsheimer%26aufirst%3DJ.%2BS.%26aulast%3DSobel%26aufirst%3DE.%26aulast%3DJuvonen%26aufirst%3DH.%26aulast%3DArajarvi%26aufirst%3DR.%26aulast%3DPartonen%26aufirst%3DT.%26aulast%3DSuvisaari%26aufirst%3DJ.%26aulast%3DLonnqvist%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DPeltonen%26aufirst%3DL.%26atitle%3DChromosome%25201%2520loci%2520in%2520Finnish%2520schizophrenia%2520families%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2001%26volume%3D10%26spage%3D1611%26epage%3D1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Ekelund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennah, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiekkalinna, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonnqvist, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltonen, L.</span><span> </span><span class="NLM_article-title">Replication of 1q42 linkage in Finnish schizophrenia pedigrees</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1037</span><span class="NLM_x">–</span> <span class="NLM_lpage">1041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15197400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVGit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=1037-1041&author=J.+Ekelundauthor=W.+Hennahauthor=T.+Hiekkalinnaauthor=A.+Parkerauthor=J.+Meyerauthor=J.+Lonnqvistauthor=L.+Peltonen&title=Replication+of+1q42+linkage+in+Finnish+schizophrenia+pedigrees"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of 1q42 linkage in Finnish schizophrenia pedigrees</span></div><div class="casAuthors">Ekelund, J.; Hennah, W.; Hiekkalinna, T.; Parker, A.; Meyer, J.; Loennqvist, J.; Peltonen, L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1037-1041</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chromosome 1q has been implicated in the etiol. of schizophrenia in several independent studies.  However, the peak linkage findings have been dispersed over a large chromosomal region, with neg. findings in this region also being reported.  The authors' group has previously obsd. linkage on chromosome 1q42, maximizing within the DISC1 gene, which has also been implied in the etiol. of schizophrenia based on functional studies.  In the study presented here, the authors genotyped 300 polymorphic markers on chromosome 1 using a study sample of 70 families with multiple individuals affected with schizophrenia or related conditions, independent of the study samples in our previous reports.  The authors again found evidence for linkage on 1q42 maximizing within the DISC1 gene (rs1000731, lod=2.70).  Further, a haplotype contg. the most strongly linked markers showed some evidence of assocn. with the disease.  This replicates the previous linkage finding in the same region and constitutes supportive evidence for a susceptibility gene in this region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqelJAmTHzFxbVg90H21EOLACvtfcHk0lgevBgMiHE1QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVGit70%253D&md5=68c523f5c1c94ae6313e04d3cf5e8310</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001536%26sid%3Dliteratum%253Aachs%26aulast%3DEkelund%26aufirst%3DJ.%26aulast%3DHennah%26aufirst%3DW.%26aulast%3DHiekkalinna%26aufirst%3DT.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DLonnqvist%26aufirst%3DJ.%26aulast%3DPeltonen%26aufirst%3DL.%26atitle%3DReplication%2520of%25201q42%2520linkage%2520in%2520Finnish%2520schizophrenia%2520pedigrees%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D1037%26epage%3D1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Hwu, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou-Yang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. F.</span><span> </span><span class="NLM_article-title">Linkage of schizophrenia with chromosome 1q loci in Taiwanese families</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12740602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFOjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=445-452&author=H.+G.+Hwuauthor=C.+M.+Liuauthor=C.+S.+Fannauthor=W.+C.+Ou-Yangauthor=S.+F.+Lee&title=Linkage+of+schizophrenia+with+chromosome+1q+loci+in+Taiwanese+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Linkage of schizophrenia with chromosome 1q loci in Taiwanese families</span></div><div class="casAuthors">Hwu, H-G.; Liu, C-M.; Fann, C. S-J.; Ou-Yang, W-C.; Lee, S. F-C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">445-452</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A pos. linkage of schizophrenia with chromosome 1q loci has been reported in Caucasian patients.  This study was designed to evaluate the linkage of schizophrenia with markers of the 1q22-44 region in 52 Taiwanese families with at least two affected siblings.  In the region 1q22-31 (17.8 cM), marker D1S1679 had a maximal proportion (0.57, P=0.03) of shared identity by descent (IBD) under a narrow phenotype (DSM-IV schizophrenia only).  In the region 1q42-44 (26.8 cM), the marker D1S251, located near the breakpoint of a balanced translocation t (1;11) (q42.1;q14.3) segregated with schizophrenia, and also near the neurodevelopment-related Disrupted in Schizophrenia 1' gene, had a max. NPL score of 1.73 (P=0.03) under the narrow phenotype model and 2.18 (P=0.01) under the broad phenotype model comprised of schizophrenia, schizoaffective disorder, and other nonaffective psychotic disorders as defined by DSM-IV criteria.  The marker D1S2836 also had a maximal proportion (0.57, P=0.05) of shared IBD under the broad model.  These findings may provide guidance for positional cloning studies on candidate genes in the 1q22-31 and 1q41-44 regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkh7wFc9XDbbVg90H21EOLACvtfcHk0lgevBgMiHE1QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFOjtbk%253D&md5=24320d16ddcf618d6a9797405457326e</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001235%26sid%3Dliteratum%253Aachs%26aulast%3DHwu%26aufirst%3DH.%2BG.%26aulast%3DLiu%26aufirst%3DC.%2BM.%26aulast%3DFann%26aufirst%3DC.%2BS.%26aulast%3DOu-Yang%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DS.%2BF.%26atitle%3DLinkage%2520of%2520schizophrenia%2520with%2520chromosome%25201q%2520loci%2520in%2520Taiwanese%2520families%26jtitle%3DMol.%2520Psychiatry%26date%3D2003%26volume%3D8%26spage%3D445%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Chen, Q. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindpaintner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span> </span><span class="NLM_article-title">Case-control association study of disrupted-in-schizophrenia-1 (DISC1) gene and schizophrenia in the Chinese population</span> <span class="citation_source-journal">J. Psychiatr Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.jpsychires.2006.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16524593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s7jslegtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2007&pages=428-434&author=Q.+Y.+Chenauthor=Q.+Chenauthor=G.+Y.+Fengauthor=K.+Lindpaintnerauthor=L.+J.+Wangauthor=Z.+X.+Chenauthor=Z.+S.+Gaoauthor=J.+S.+Tangauthor=G.+Huangauthor=L.+He&title=Case-control+association+study+of+disrupted-in-schizophrenia-1+%28DISC1%29+gene+and+schizophrenia+in+the+Chinese+population"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Case-control association study of Disrupted-in-Schizophrenia-1 (DISC1) gene and schizophrenia in the Chinese population</span></div><div class="casAuthors">Chen Qing-Ying; Chen Qi; Feng Guo-Yin; Lindpaintner Klaus; Wang Li-Jun; Chen Zheng-Xiong; Gao Zhen-Song; Tang Ji-Sheng; Huang Gang; He Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">428-34</span>
        ISSN:<span class="NLM_cas:issn">0022-3956</span>.
    </div><div class="casAbstract">Disrupted-in-Schizophrenia-1 (DISC1) has first been identified as a candidate gene for schizophrenia through study of a Scottish family with a balanced (1; 11) (q42.1; q14.3) translocation.  Lots of linkage and association studies supported DISC1 as a risk factor for schizophrenia.  In this study, we genotyped three SNPs in DISC1 using a set of Han Chinese samples of 560 schizophrenics and 576 controls.  No positive association was detected in the whole samples but analysis of allele frequencies in female samples showed weak association between SNP rs2295959 and the disease (chi(2)=6.188, P=0.0135, OR=0.728, 95% CI=0.567-0.935).  Our results provide further evidence for sex difference for the effect of the gene on the aetiology of schizophrenia.  Our findings also would encourage further studies, particularly family-based association studies with larger samples, to analyze the association between DISC1 and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSw-M-59aPeCUHdcurJClFcfW6udTcc2ebGswKCGiTGv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7jslegtA%253D%253D&md5=80b36866cdc6db22cfd9b7c2acf8baad</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2006.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2006.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%2BY.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DG.%2BY.%26aulast%3DLindpaintner%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DZ.%2BX.%26aulast%3DGao%26aufirst%3DZ.%2BS.%26aulast%3DTang%26aufirst%3DJ.%2BS.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DCase-control%2520association%2520study%2520of%2520disrupted-in-schizophrenia-1%2520%2528DISC1%2529%2520gene%2520and%2520schizophrenia%2520in%2520the%2520Chinese%2520population%26jtitle%3DJ.%2520Psychiatr%2520Res.%26date%3D2007%26volume%3D41%26spage%3D428%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">Porteous, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millar, J. K.</span><span> </span><span class="NLM_article-title">Disrupted in schizophrenia 1: building brains and memories</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=255-261&author=D.+J.+Porteousauthor=J.+K.+Millar&title=Disrupted+in+schizophrenia+1%3A+building+brains+and+memories"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPorteous%26aufirst%3DD.%2BJ.%26aulast%3DMillar%26aufirst%3DJ.%2BK.%26atitle%3DDisrupted%2520in%2520schizophrenia%25201%253A%2520building%2520brains%2520and%2520memories%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D255%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Koike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arguello, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kvajo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karayiorgou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogos, J. A.</span><span> </span><span class="NLM_article-title">Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3693</span><span class="NLM_x">–</span> <span class="NLM_lpage">3697</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=3693-3697&author=H.+Koikeauthor=P.+A.+Arguelloauthor=M.+Kvajoauthor=M.+Karayiorgouauthor=J.+A.+Gogos&title=Disc1+is+mutated+in+the+129S6%2FSvEv+strain+and+modulates+working+memory+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoike%26aufirst%3DH.%26aulast%3DArguello%26aufirst%3DP.%2BA.%26aulast%3DKvajo%26aufirst%3DM.%26aulast%3DKarayiorgou%26aufirst%3DM.%26aulast%3DGogos%26aufirst%3DJ.%2BA.%26atitle%3DDisc1%2520is%2520mutated%2520in%2520the%2520129S6%252FSvEv%2520strain%2520and%2520modulates%2520working%2520memory%2520in%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D3693%26epage%3D3697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Kamiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomoda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatten, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawa, A.</span><span> </span><span class="NLM_article-title">A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1067</span><span class="NLM_x">–</span> <span class="NLM_lpage">1078</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fncb1328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Kntr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=1067-1078&author=A.+Kamiyaauthor=K.+Kuboauthor=T.+Tomodaauthor=M.+Takakiauthor=R.+Younauthor=Y.+Ozekiauthor=N.+Sawamuraauthor=U.+Parkauthor=C.+Kudoauthor=M.+Okawaauthor=C.+A.+Rossauthor=M.+E.+Hattenauthor=K.+Nakajimaauthor=A.+Sawa&title=A+schizophrenia-associated+mutation+of+DISC1+perturbs+cerebral+cortex+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development</span></div><div class="casAuthors">Kamiya, Atsushi; Kubo, Ken-ichiro; Tomoda, Toshifumi; Takaki, Manabu; Youn, Richard; Ozeki, Yuji; Sawamura, Naoya; Park, Una; Kudo, Chikako; Okawa, Masako; Ross, Christopher A.; Hatten, Mary E.; Nakajima, Kazunori; Sawa, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1067-1078</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Disrupted-In-Schizophrenia-1 (DISC1), originally identified at the breakpoint of a chromosomal translocation that is linked to a rare familial schizophrenia, has been genetically implicated in schizophrenia in other populations.  Schizophrenia involves subtle cyto-architectural abnormalities that arise during neuro-development, but the underlying mol. mechanisms are unclear.  Here, we demonstrate that DISC1 is a component of the microtubule-assocd. dynein motor complex and is essential for maintaining the complex at the centrosome, hence contributing to normal microtubular dynamics.  Carboxy-terminal-truncated mutant DISC1 (mutDISC1), which results from a chromosomal translocation, functions in a dominant-neg. manner by redistributing wild-type DISC1 through self-assocn. and by dissocg. the DISC1-dynein complex from the centrosome.  Consequently, either depletion of endogenous DISC1 or expression of mutDISC1 impairs neurite outgrowth in vitro and proper development of the cerebral cortex in vivo.  These results indicate that DISC1 is involved in cerebral cortex development, and suggest that loss of DISC1 function may underlie neurodevelopmental dysfunction in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkrUfkjhqs8rVg90H21EOLACvtfcHk0lgA-WspW8eKQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Kntr%252FL&md5=e8c1589b520226705e5651d464aa1247</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fncb1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1328%26sid%3Dliteratum%253Aachs%26aulast%3DKamiya%26aufirst%3DA.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DTomoda%26aufirst%3DT.%26aulast%3DTakaki%26aufirst%3DM.%26aulast%3DYoun%26aufirst%3DR.%26aulast%3DOzeki%26aufirst%3DY.%26aulast%3DSawamura%26aufirst%3DN.%26aulast%3DPark%26aufirst%3DU.%26aulast%3DKudo%26aufirst%3DC.%26aulast%3DOkawa%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DC.%2BA.%26aulast%3DHatten%26aufirst%3DM.%2BE.%26aulast%3DNakajima%26aufirst%3DK.%26aulast%3DSawa%26aufirst%3DA.%26atitle%3DA%2520schizophrenia-associated%2520mutation%2520of%2520DISC1%2520perturbs%2520cerebral%2520cortex%2520development%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2005%26volume%3D7%26spage%3D1067%26epage%3D1078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Hikida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaaro-Peled, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshadri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hookway, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tankou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pletnikov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawa, A.</span><span> </span><span class="NLM_article-title">Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">14501</span><span class="NLM_x">–</span> <span class="NLM_lpage">14506</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=14501-14506&author=T.+Hikidaauthor=H.+Jaaro-Peledauthor=S.+Seshadriauthor=K.+Oishiauthor=C.+Hookwayauthor=S.+Kongauthor=D.+Wuauthor=R.+Xueauthor=M.+Andradeauthor=S.+Tankouauthor=S.+Moriauthor=M.+Gallagherauthor=K.+Ishizukaauthor=M.+Pletnikovauthor=S.+Kidaauthor=A.+Sawa&title=Dominant-negative+DISC1+transgenic+mice+display+schizophrenia-associated+phenotypes+detected+by+measures+translatable+to+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHikida%26aufirst%3DT.%26aulast%3DJaaro-Peled%26aufirst%3DH.%26aulast%3DSeshadri%26aufirst%3DS.%26aulast%3DOishi%26aufirst%3DK.%26aulast%3DHookway%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DXue%26aufirst%3DR.%26aulast%3DAndrade%26aufirst%3DM.%26aulast%3DTankou%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DGallagher%26aufirst%3DM.%26aulast%3DIshizuka%26aufirst%3DK.%26aulast%3DPletnikov%26aufirst%3DM.%26aulast%3DKida%26aufirst%3DS.%26aulast%3DSawa%26aufirst%3DA.%26atitle%3DDominant-negative%2520DISC1%2520transgenic%2520mice%2520display%2520schizophrenia-associated%2520phenotypes%2520detected%2520by%2520measures%2520translatable%2520to%2520humans%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D14501%26epage%3D14506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group">Millar, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malloy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chubb, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huston, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandon, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camargo, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiting, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, D. J.</span><span> </span><span class="NLM_article-title">DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">310</span><span class="NLM_x">, </span> <span class="NLM_fpage">1187</span><span class="NLM_x">–</span> <span class="NLM_lpage">1191</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2005&pages=1187-1191&author=J.+K.+Millarauthor=B.+S.+Pickardauthor=S.+Mackieauthor=R.+Jamesauthor=S.+Christieauthor=S.+R.+Buchananauthor=M.+P.+Malloyauthor=J.+E.+Chubbauthor=E.+Hustonauthor=G.+S.+Baillieauthor=P.+A.+Thomsonauthor=E.+V.+Hillauthor=N.+J.+Brandonauthor=J.+C.+Rainauthor=L.+M.+Camargoauthor=P.+J.+Whitingauthor=M.+D.+Houslayauthor=D.+H.+Blackwoodauthor=W.+J.+Muirauthor=D.+J.+Porteous&title=DISC1+and+PDE4B+are+interacting+genetic+factors+in+schizophrenia+that+regulate+cAMP+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillar%26aufirst%3DJ.%2BK.%26aulast%3DPickard%26aufirst%3DB.%2BS.%26aulast%3DMackie%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DS.%2BR.%26aulast%3DMalloy%26aufirst%3DM.%2BP.%26aulast%3DChubb%26aufirst%3DJ.%2BE.%26aulast%3DHuston%26aufirst%3DE.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DThomson%26aufirst%3DP.%2BA.%26aulast%3DHill%26aufirst%3DE.%2BV.%26aulast%3DBrandon%26aufirst%3DN.%2BJ.%26aulast%3DRain%26aufirst%3DJ.%2BC.%26aulast%3DCamargo%26aufirst%3DL.%2BM.%26aulast%3DWhiting%26aufirst%3DP.%2BJ.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DBlackwood%26aufirst%3DD.%2BH.%26aulast%3DMuir%26aufirst%3DW.%2BJ.%26aulast%3DPorteous%26aufirst%3DD.%2BJ.%26atitle%3DDISC1%2520and%2520PDE4B%2520are%2520interacting%2520genetic%2520factors%2520in%2520schizophrenia%2520that%2520regulate%2520cAMP%2520signaling%26jtitle%3DScience%26date%3D2005%26volume%3D310%26spage%3D1187%26epage%3D1191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group">Crow, T. J.</span><span> </span><span class="NLM_article-title">Is DISC1 really a gene predisposing to psychosis</span> <span class="citation_source-journal">Br. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">190</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1192%2Fbjp.190.3.270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17329752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s7ivFykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2007&pages=270-271&author=T.+J.+Crow&title=Is+DISC1+really+a+gene+predisposing+to+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Is DISC1 really a gene predisposing to psychosis?</span></div><div class="casAuthors">Crow T J</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270; author reply 270-1</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnlSZlU-r1f5PlX7E30qdzfW6udTcc2eYY_v_WeaiJjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7ivFykuw%253D%253D&md5=f7b11ab919b2ed599e63429bd5e022c2</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1192%2Fbjp.190.3.270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.190.3.270%26sid%3Dliteratum%253Aachs%26aulast%3DCrow%26aufirst%3DT.%2BJ.%26atitle%3DIs%2520DISC1%2520really%2520a%2520gene%2520predisposing%2520to%2520psychosis%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D190%26spage%3D270%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group">Lo, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luan, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, H.</span><span> </span><span class="NLM_article-title">Association of SNPs and haplotypes in GABAA receptor beta2 gene with schizophrenia</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14699426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Gnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=603-608&author=W.+S.+Loauthor=C.+F.+Lauauthor=Z.+Xuanauthor=C.+F.+Chanauthor=G.+Y.+Fengauthor=L.+Heauthor=Z.+C.+Caoauthor=H.+Liuauthor=Q.+M.+Luanauthor=H.+Xue&title=Association+of+SNPs+and+haplotypes+in+GABAA+receptor+beta2+gene+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Association of SNPs and haplotypes in GABAA receptor β2 gene with schizophrenia</span></div><div class="casAuthors">Lo, W-S.; Lau, C-F.; Xuan, Z.; Chan, C-F.; Feng, G-Y.; He, L.; Cao, Z-C.; Liu, H.; Luan, Q-M.; Xue, H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-608</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Disturbances in GABAergic system have been obsd. in schizophrenics.  In the present study, population assocn. anal. was performed on 19 SNPs in the α1, β2, γ2, ε and π subunit genes of GABAA receptor.  Five SNPs in GABRB2, namely B2I7G1584T, rs1816071, rs194072, rs252944 and rs187269, were found to be significantly assocd., and their haplotypes in linkage disequil., with schizophrenia.  This represents the first report on any disease assocn. of SNPs in the human GABAA receptor genes, and focuses attention on the GABAergic hypothesis of schizophrenia etiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj9FZnnGG_GrVg90H21EOLACvtfcHk0li659AwaCwWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Gnt74%253D&md5=b59b14a4570fa123bfd70e950724a576</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001461%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DW.%2BS.%26aulast%3DLau%26aufirst%3DC.%2BF.%26aulast%3DXuan%26aufirst%3DZ.%26aulast%3DChan%26aufirst%3DC.%2BF.%26aulast%3DFeng%26aufirst%3DG.%2BY.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DZ.%2BC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DQ.%2BM.%26aulast%3DXue%26aufirst%3DH.%26atitle%3DAssociation%2520of%2520SNPs%2520and%2520haplotypes%2520in%2520GABAA%2520receptor%2520beta2%2520gene%2520with%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D603%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group">Zai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, J. L.</span><span> </span><span class="NLM_article-title">Possible association between the γ-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophrenia</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.euroneuro.2004.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15820424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFKksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=347-352&author=G.+Zaiauthor=N.+Kingauthor=G.+W.+Wongauthor=C.+L.+Barrauthor=J.+L.+Kennedy&title=Possible+association+between+the+%CE%B3-aminobutyric+acid+type+B+receptor+1+%28GABBR1%29+gene+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Possible association between the gamma-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophrenia</span></div><div class="casAuthors">Zai, Gwyneth; King, Nicole; Wong, Gregory W. H.; Barr, Cathy L.; Kennedy, James L.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-352</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Schizophrenia (SCZ) is a severe neuropsychiatric disorder with a genetic component.  The major inhibitory GABA-(gamma-aminobutyric acid) ergic system may be involved.  The GABA type B receptor 1 (GABBR1) gene was localized to 6p21.3, a region linked to SCZ.  The authors therefore investigated 5 polymorphisms (A-7265G, C10497G, Ser-491-Ser-T1473C, Phe-659-Phe-T1977C, and 3'-UTR A33795G substitutions) in the GABBR1 gene in a sample of 101 DSM-IV SCZ probands and their families, 150 unrelated affected individuals matched with 150 healthy controls, using the transmission disequil. test (TDT) and case-control anal.  The authors did not observe biased transmission of alleles in any of the polymorphisms individually and haplotypes within the gene to SCZ probands.  However, a weak significant difference was obsd. in the A-7265G polymorphism between the allelic frequency (χ2 = 4.310, P = 0.038) and a trend was obsd. between the genotype frequency (χ2 = 4.970, 2 df, P = 0.083) of SCZ individuals and controls.  Further investigations of the role of GABBR1 in SCZ are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpnikTSakLgrVg90H21EOLACvtfcHk0li659AwaCwWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFKksL0%253D&md5=e6abff2d5a56349992aa5d5b83b38252</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2004.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2004.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DZai%26aufirst%3DG.%26aulast%3DKing%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DG.%2BW.%26aulast%3DBarr%26aufirst%3DC.%2BL.%26aulast%3DKennedy%26aufirst%3DJ.%2BL.%26atitle%3DPossible%2520association%2520between%2520the%2520%25CE%25B3-aminobutyric%2520acid%2520type%2520B%2520receptor%25201%2520%2528GABBR1%2529%2520gene%2520and%2520schizophrenia%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2005%26volume%3D15%26spage%3D347%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group">Adler, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffer, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, R.</span><span> </span><span class="NLM_article-title">Normalization of auditory physiology by cigarette smoking in schizophrenic patients</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">1856</span><span class="NLM_x">–</span> <span class="NLM_lpage">1861</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8238642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK2c%252FlslWitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=1993&pages=1856-1861&author=L.+E.+Adlerauthor=L.+D.+Hofferauthor=A.+Wiserauthor=R.+Freedman&title=Normalization+of+auditory+physiology+by+cigarette+smoking+in+schizophrenic+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Normalization of auditory physiology by cigarette smoking in schizophrenic patients</span></div><div class="casAuthors">Adler L E; Hoffer L D; Wiser A; Freedman R</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1856-61</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Because many schizophrenic patients are heavy smokers, it has been suggested that nicotine normalizes some neuronal deficit involved in their illness.  Schizophrenic subjects have various difficulties with maintenance of attention and selective processing of sensory information.  One defect in sensory gating in schizophrenia has been characterized by recording auditory evoked potentials.  Most normal subjects have a decrease in the evoked response to the second of two closely paired stimuli, whereas most schizophrenic subjects do not.  The aim of this study was to determine whether smoking normalizes this deficit in auditory sensory gating in schizophrenia.  METHOD:  Changes in auditory sensory gating in response to smoking cigarettes were studied in 10 smokers without psychiatric illness and 10 schizophrenic smokers.  Both groups were asked to abstain from smoking from 11:00 p.m. until 8:00 a.m. the next morning, when their auditory evoked responses to pairs of clicks were recorded.  The ability to gate sensory information is reflected in a decrease in the P50 wave amplitude in response to the second of the two stimuli.  After baseline recordings, the subjects smoked as much as they wished, and then two postsmoking recordings were performed.  RESULTS:  The schizophrenic patients had a marked but brief improvement in P50 auditory gating immediately after smoking, whereas P50 gating for the normal smokers was slightly impaired.  CONCLUSIONS:  This study suggests that cigarette smoking can transiently normalize the impairment of auditory sensory gating in schizophrenic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5QavxFsthtekdrW1FkXG-fW6udTcc2ebSDzv4JX1u07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252FlslWitA%253D%253D&md5=5a095d3f2e6a46a68f9f9383919f1606</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdler%26aufirst%3DL.%2BE.%26aulast%3DHoffer%26aufirst%3DL.%2BD.%26aulast%3DWiser%26aufirst%3DA.%26aulast%3DFreedman%26aufirst%3DR.%26atitle%3DNormalization%2520of%2520auditory%2520physiology%2520by%2520cigarette%2520smoking%2520in%2520schizophrenic%2520patients%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1993%26volume%3D150%26spage%3D1856%26epage%3D1861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group">Kelly, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreadie, R.</span><span> </span><span class="NLM_article-title">Cigarette smoking and schizophrenia</span> <span class="citation_source-journal">Adv. Psychiatr. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">331</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1192%2Fapt.6.5.327" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=327-331&author=C.+Kellyauthor=R.+McCreadie&title=Cigarette+smoking+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1192%2Fapt.6.5.327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fapt.6.5.327%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DC.%26aulast%3DMcCreadie%26aufirst%3DR.%26atitle%3DCigarette%2520smoking%2520and%2520schizophrenia%26jtitle%3DAdv.%2520Psychiatr.%2520Treat.%26date%3D2000%26volume%3D6%26spage%3D327%26epage%3D331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group">Sacco, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seyal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudas, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vessicchio, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan-Sarin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jatlow, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, T. P.</span><span> </span><span class="NLM_article-title">Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.62.6.649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15939842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ptlWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2005&pages=649-659&author=K.+A.+Saccoauthor=A.+Termineauthor=A.+Seyalauthor=M.+M.+Dudasauthor=J.+C.+Vessicchioauthor=S.+Krishnan-Sarinauthor=P.+I.+Jatlowauthor=B.+E.+Wexlerauthor=T.+P.+George&title=Effects+of+cigarette+smoking+on+spatial+working+memory+and+attentional+deficits+in+schizophrenia%3A+involvement+of+nicotinic+receptor+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms</span></div><div class="casAuthors">Sacco Kristi A; Termine Angelo; Seyal Aisha; Dudas Melissa M; Vessicchio Jennifer C; Krishnan-Sarin Suchitra; Jatlow Peter I; Wexler Bruce E; George Tony P</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">649-59</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">BACKGROUND:  Cigarette smoking rates in schizophrenia are higher than in the general population.  OBJECTIVES:  To determine whether cigarette smoking modifies cognitive deficits in schizophrenia and to establish the role of nicotinic acetylcholine receptors (nAChRs) in mediating cigarette smoking-related cognitive enhancement.  DESIGN:  Neuropsychological assessments were performed at smoking baseline, after overnight abstinence, and after smoking reinstatement across 3 separate test weeks during which subjects were pretreated in a counterbalanced manner with the nonselective nAChR antagonist mecamylamine hydrochloride (0, 5, or 10 mg/d).  PARTICIPANTS:  Twenty-five smokers with schizophrenia and 25 control smokers.  SETTING:  Outpatient mental health center.  MAIN OUTCOME MEASURES:  Visuospatial working memory (VSWM) and Continuous Performance Test (CPT) scores.  RESULTS:  In smokers with schizophrenia and control smokers, overnight abstinence led to undetectable plasma nicotine levels and an increase in tobacco craving.  While abstinence reduced CPT hit rate in both groups, VSWM was only impaired in smokers with schizophrenia.  Smoking reinstatement reversed abstinence-induced cognitive impairment.  Enhancement of VSWM and CPT performance by smoking reinstatement in smokers with schizophrenia, but not the subjective effects of smoking, was blocked by mecamylamine treatment.  CONCLUSIONS:  Cigarette smoking may selectively enhance VSWM and attentional deficits in smokers with schizophrenia, which may depend on nAChR stimulation.  These findings may have implications for understanding the high rates of smoking in schizophrenia and for developing pharmacotherapies for cognitive deficits and nicotine dependence in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG4lFrjFq_mWBAiYWy6n3SfW6udTcc2ebSDzv4JX1u07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ptlWjsg%253D%253D&md5=29fbb9d5a50174b7db25eaba77cbc35c</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.62.6.649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.62.6.649%26sid%3Dliteratum%253Aachs%26aulast%3DSacco%26aufirst%3DK.%2BA.%26aulast%3DTermine%26aufirst%3DA.%26aulast%3DSeyal%26aufirst%3DA.%26aulast%3DDudas%26aufirst%3DM.%2BM.%26aulast%3DVessicchio%26aufirst%3DJ.%2BC.%26aulast%3DKrishnan-Sarin%26aufirst%3DS.%26aulast%3DJatlow%26aufirst%3DP.%2BI.%26aulast%3DWexler%26aufirst%3DB.%2BE.%26aulast%3DGeorge%26aufirst%3DT.%2BP.%26atitle%3DEffects%2520of%2520cigarette%2520smoking%2520on%2520spatial%2520working%2520memory%2520and%2520attentional%2520deficits%2520in%2520schizophrenia%253A%2520involvement%2520of%2520nicotinic%2520receptor%2520mechanisms%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2005%26volume%3D62%26spage%3D649%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group">deHaan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavalaye, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linszen, D.</span><span> </span><span class="NLM_article-title">Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">505</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-005-0218-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2006&pages=500-505&author=L.+deHaanauthor=J.+Booijauthor=J.+Lavalayeauthor=A.+T.+vanauthor=D.+Linszen&title=Occupancy+of+dopamine+D2+receptors+by+antipsychotic+drugs+is+related+to+nicotine+addiction+in+young+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-0218-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-0218-x%26sid%3Dliteratum%253Aachs%26aulast%3DdeHaan%26aufirst%3DL.%26aulast%3DBooij%26aufirst%3DJ.%26aulast%3DLavalaye%26aufirst%3DJ.%26aulast%3Dvan%26aufirst%3DA.%2BT.%26aulast%3DLinszen%26aufirst%3DD.%26atitle%3DOccupancy%2520of%2520dopamine%2520D2%2520receptors%2520by%2520antipsychotic%2520drugs%2520is%2520related%2520to%2520nicotine%2520addiction%2520in%2520young%2520patients%2520with%2520schizophrenia%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2006%26volume%3D183%26spage%3D500%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group">Freedman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myles-Worsley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr-Urtreger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olincy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polymeropoulos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimherr, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wender, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruglyak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byerley, W.</span><span> </span><span class="NLM_article-title">Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=587-592&author=R.+Freedmanauthor=H.+Coonauthor=M.+Myles-Worsleyauthor=A.+Orr-Urtregerauthor=A.+Olincyauthor=A.+Davisauthor=M.+Polymeropoulosauthor=J.+Holikauthor=J.+Hopkinsauthor=M.+Hoffauthor=J.+Rosenthalauthor=M.+C.+Waldoauthor=F.+Reimherrauthor=P.+Wenderauthor=J.+Yawauthor=D.+A.+Youngauthor=C.+R.+Breeseauthor=C.+Adamsauthor=D.+Pattersonauthor=L.+E.+Adlerauthor=L.+Kruglyakauthor=S.+Leonardauthor=W.+Byerley&title=Linkage+of+a+neurophysiological+deficit+in+schizophrenia+to+a+chromosome+15+locus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFreedman%26aufirst%3DR.%26aulast%3DCoon%26aufirst%3DH.%26aulast%3DMyles-Worsley%26aufirst%3DM.%26aulast%3DOrr-Urtreger%26aufirst%3DA.%26aulast%3DOlincy%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DPolymeropoulos%26aufirst%3DM.%26aulast%3DHolik%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DJ.%26aulast%3DHoff%26aufirst%3DM.%26aulast%3DRosenthal%26aufirst%3DJ.%26aulast%3DWaldo%26aufirst%3DM.%2BC.%26aulast%3DReimherr%26aufirst%3DF.%26aulast%3DWender%26aufirst%3DP.%26aulast%3DYaw%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DD.%2BA.%26aulast%3DBreese%26aufirst%3DC.%2BR.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DPatterson%26aufirst%3DD.%26aulast%3DAdler%26aufirst%3DL.%2BE.%26aulast%3DKruglyak%26aufirst%3DL.%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DByerley%26aufirst%3DW.%26atitle%3DLinkage%2520of%2520a%2520neurophysiological%2520deficit%2520in%2520schizophrenia%2520to%2520a%2520chromosome%252015%2520locus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D587%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group">Leonard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olincy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloninger, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malaspina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svrakic, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, R.</span><span> </span><span class="NLM_article-title">Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative</span> <span class="citation_source-journal">Am. J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">312</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2F%28SICI%291096-8628%2819980710%2981%3A4%3C308%3A%3AAID-AJMG6%3E3.0.CO%3B2-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9674976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1czjslOgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1998&pages=308-312&author=S.+Leonardauthor=J.+Gaultauthor=T.+Mooreauthor=J.+Hopkinsauthor=M.+Robinsonauthor=A.+Olincyauthor=L.+E.+Adlerauthor=C.+R.+Cloningerauthor=C.+A.+Kaufmannauthor=M.+T.+Tsuangauthor=S.+V.+Faraoneauthor=D.+Malaspinaauthor=D.+M.+Svrakicauthor=R.+Freedman&title=Further+investigation+of+a+chromosome+15+locus+in+schizophrenia%3A+analysis+of+affected+sibpairs+from+the+NIMH+Genetics+Initiative"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative</span></div><div class="casAuthors">Leonard S; Gault J; Moore T; Hopkins J; Robinson M; Olincy A; Adler L E; Cloninger C R; Kaufmann C A; Tsuang M T; Faraone S V; Malaspina D; Svrakic D M; Freedman R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-12</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">Linkage of a neurophysiological deficit associated with schizophrenia, i.e., the failure to inhibit the auditory P50 response, was previously reported at chromosome 15q14.  The marker with the highest pairwise lod score, D15S1360, was isolated from a yeast artificial chromosome containing a candidate gene, the alpha7-nicotinic acetylcholine receptor gene.  In the present study, this linkage was further investigated in a subset of the NIMH Genetics Initiative schizophrenia families.  These families have not been studied neurophysiologically, as were the families in the original report.  Therefore, the DSMIII-R diagnosis of schizophrenia was used as the affected phenotype.  Twenty families fulfilled the criteria of at least one sibpair concordant for schizophrenia, along with their two parents or another affected relative outside the nuclear family, available for genotyping.  Sibpair analysis showed a significant proportion of D15S1360 alleles shared identical-by-descent (0.58; P < 0.0024).  The results further support the involvement of this chromosomal locus in the genetic transmission of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRn60l4znupf1w2ofyr07jXfW6udTcc2ea6axoesWO5Gbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1czjslOgsQ%253D%253D&md5=c35bd47bbb0f78641152c4034bb0cd6a</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-8628%2819980710%2981%3A4%3C308%3A%3AAID-AJMG6%3E3.0.CO%3B2-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-8628%252819980710%252981%253A4%253C308%253A%253AAID-AJMG6%253E3.0.CO%253B2-P%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DGault%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DT.%26aulast%3DHopkins%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DM.%26aulast%3DOlincy%26aufirst%3DA.%26aulast%3DAdler%26aufirst%3DL.%2BE.%26aulast%3DCloninger%26aufirst%3DC.%2BR.%26aulast%3DKaufmann%26aufirst%3DC.%2BA.%26aulast%3DTsuang%26aufirst%3DM.%2BT.%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DMalaspina%26aufirst%3DD.%26aulast%3DSvrakic%26aufirst%3DD.%2BM.%26aulast%3DFreedman%26aufirst%3DR.%26atitle%3DFurther%2520investigation%2520of%2520a%2520chromosome%252015%2520locus%2520in%2520schizophrenia%253A%2520analysis%2520of%2520affected%2520sibpairs%2520from%2520the%2520NIMH%2520Genetics%2520Initiative%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%26date%3D1998%26volume%3D81%26spage%3D308%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Eerdewegh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T.</span><span> </span><span class="NLM_article-title">A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families</span> <span class="citation_source-journal">Hum. Hered.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1159%2F000077543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15192278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksl2gurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2004&pages=59-68&author=S.+V.+Faraoneauthor=J.+Suauthor=L.+Taylorauthor=M.+Wilcoxauthor=P.+Van+Eerdeweghauthor=M.+T.+Tsuang&title=A+novel+permutation+testing+method+implicates+sixteen+nicotinic+acetylcholine+receptor+genes+as+risk+factors+for+smoking+in+schizophrenia+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Permutation Testing Method Implicates Sixteen Nicotinic Acetylcholine Receptor Genes as Risk Factors for Smoking in Schizophrenia Families</span></div><div class="casAuthors">Faraone, Stephen V.; Su, Jessica; Taylor, Levi; Wilcox, Marsha; Van Eerdewegh, Paul; Tsuang, Ming T.</div><div class="citationInfo"><span class="NLM_cas:title">Human Heredity</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">HUHEAS</span>;
        ISSN:<span class="NLM_cas:issn">0001-5652</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Smoking is a common correlate of schizophrenia, which leads to medical morbidity.  Although twin and adoption studies have consistently implicated genes in the etiol. of both smoking and schizophrenia, finding genes has been difficult.  Several authors have suggested that clin. or neurobiol. features assocd. with schizophrenia, such as smoking, might improve the ability to detect schizophrenia susceptibility genes by identifying genes related to the etiol. of that feature.  The objective of this study is to assess evidence for linkage of sixteen nicotinic acetylcholine receptor genes and smoking in schizophrenia families, using data from the NIMH Genetics Initiative for schizophrenia.  Sixteen nicotinic acetylcholine receptor genes were selected prior to anal.  We used a multipoint sibling pair linkage anal. program, SIBPAL2, with a smoking trait in schizophrenia families.  The significance of the group of candidate genes, in addn. to each individual candidate gene, was assessed using permutation testing, which adjusted for multiple comparisons.  The group of genes showed significant linkage to the smoking trait after adjusting for multiple comparisons through permutation testing (p = 0.039).  In addn., two of the individual candidate genes were significant (CHRNA2, p = 0.044) and (CHRNB2, p = 0.015) and two genes were marginally significant (CHRNA7, p = 0.095; CHRNA1, p = 0.076).  The significance of the complex hypothesis, involving sixteen genes, implicates the nicotinic system in smoking for schizophrenic families.  Individual gene anal. suggests that CHRNA2 and CHRNB2 may play a particular role in this involvement.  Such findings help prioritize genes for future case control studies.  In addn., we provide a novel permutation method that is useful in future analyses involving a single hypothesis, with multiple candidate genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEqVFPSQTvyLVg90H21EOLACvtfcHk0lgd_8eLvYakEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksl2gurY%253D&md5=9b9dc0d6562250c3295440a8b2201402</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1159%2F000077543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000077543%26sid%3Dliteratum%253Aachs%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DWilcox%26aufirst%3DM.%26aulast%3DVan%2BEerdewegh%26aufirst%3DP.%26aulast%3DTsuang%26aufirst%3DM.%2BT.%26atitle%3DA%2520novel%2520permutation%2520testing%2520method%2520implicates%2520sixteen%2520nicotinic%2520acetylcholine%2520receptor%2520genes%2520as%2520risk%2520factors%2520for%2520smoking%2520in%2520schizophrenia%2520families%26jtitle%3DHum.%2520Hered.%26date%3D2004%26volume%3D57%26spage%3D59%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group">Leonard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianzon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drebing, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirota, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olincy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, R.</span><span> </span><span class="NLM_article-title">Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">–</span> <span class="NLM_lpage">1096</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.59.12.1085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12470124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslejsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2002&pages=1085-1096&author=S.+Leonardauthor=J.+Gaultauthor=J.+Hopkinsauthor=J.+Logelauthor=R.+Vianzonauthor=M.+Shortauthor=C.+Drebingauthor=R.+Bergerauthor=D.+Vennauthor=P.+Sirotaauthor=G.+Zerbeauthor=A.+Olincyauthor=R.+G.+Rossauthor=L.+E.+Adlerauthor=R.+Freedman&title=Association+of+promoter+variants+in+the+%CE%B17+nicotinic+acetylcholine+receptor+subunit+gene+with+an+inhibitory+deficit+found+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia</span></div><div class="casAuthors">Leonard, Sherry; Gault, Judith; Hopkins, Jan; Logel, Judith; Vianzon, Ruby; Short, Margaret; Drebing, Carla; Berger, Ralph; Venn, Diana; Sirota, Pinkhas; Zerbe, Gary; Olincy, Ann; Ross, Randal G.; Adler, Lawrence E.; Freedman, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1085-1096</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Background: The α7 neuronal nicotinic acetylcholine receptor subunit gene (CHRNA7) was implicated as a candidate gene for schizophrenia, and for an auditory sensory processing deficit found in the disease, by both genetic linkage at 15q14 and biochem. data.  The expression of CHRNA7 is reduced in several brain regions in schizophrenic subjects compared with control subjects.  This study presents DNA sequence anal. of the core promoter region for CHRNA7 in schizophrenic and control subjects.  Methods: Single-strand conformation polymorphism anal. and DNA sequencing were used for mutation screening of the core promoter in the CHRNA7 gene.  The sample included subjects from 166 schizophrenic families and 165 controls.  Controls had no evidence of current or past psychosis and had auditory evoked potentials recorded.  Results: Multiple polymorphic patterns were identified in the CHRNA7 core promoter in both schizophrenic and control subjects.  Functional anal. of polymorphisms indicated that transcription was reduced.  The prevalence of functional promoter variants was statistically greater in schizophrenic subjects than in the controls.  Presence of an α7 promoter polymorphism in controls was assocd. with failure to inhibit the P50 auditory evoked potential response.  Conclusions: Although linkage disequil. with other genetic alterations cannot be excluded, the CHRNA7 core promoter variants, found in this study, may contribute to a common pathophysiol. feature of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA0UwLDMqkjLVg90H21EOLACvtfcHk0li8br38J0KW2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslejsL4%253D&md5=2b0174e9ab18427a2d0fa215300c4c77</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.59.12.1085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.59.12.1085%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DGault%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DJ.%26aulast%3DLogel%26aufirst%3DJ.%26aulast%3DVianzon%26aufirst%3DR.%26aulast%3DShort%26aufirst%3DM.%26aulast%3DDrebing%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DVenn%26aufirst%3DD.%26aulast%3DSirota%26aufirst%3DP.%26aulast%3DZerbe%26aufirst%3DG.%26aulast%3DOlincy%26aufirst%3DA.%26aulast%3DRoss%26aufirst%3DR.%2BG.%26aulast%3DAdler%26aufirst%3DL.%2BE.%26aulast%3DFreedman%26aufirst%3DR.%26atitle%3DAssociation%2520of%2520promoter%2520variants%2520in%2520the%2520%25CE%25B17%2520nicotinic%2520acetylcholine%2520receptor%2520subunit%2520gene%2520with%2520an%2520inhibitory%2520deficit%2520found%2520in%2520schizophrenia%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2002%26volume%3D59%26spage%3D1085%26epage%3D1096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group">Curtis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blouin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radhakrishna, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehrig, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasseter, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolyniec, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestadt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombroski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazazian, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulver, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Housman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonarakis, S. E.</span><span> </span><span class="NLM_article-title">No evidence for linkage between schizophrenia and markers at chromosome 15q13-14</span> <span class="citation_source-journal">Am. J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2F%28SICI%291096-8628%2819990416%2988%3A2%3C109%3A%3AAID-AJMG1%3E3.0.CO%3B2-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10206225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1M3itFSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1999&pages=109-112&author=L.+Curtisauthor=J.+L.+Blouinauthor=U.+Radhakrishnaauthor=C.+Gehrigauthor=V.+K.+Lasseterauthor=P.+Wolyniecauthor=G.+Nestadtauthor=B.+Dombroskiauthor=H.+H.+Kazazianauthor=A.+E.+Pulverauthor=D.+Housmanauthor=D.+Bertrandauthor=S.+E.+Antonarakis&title=No+evidence+for+linkage+between+schizophrenia+and+markers+at+chromosome+15q13-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">No evidence for linkage between schizophrenia and markers at chromosome 15q13-14</span></div><div class="casAuthors">Curtis L; Blouin J L; Radhakrishna U; Gehrig C; Lasseter V K; Wolyniec P; Nestadt G; Dombroski B; Kazazian H H; Pulver A E; Housman D; Bertrand D; Antonarakis S E</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-12</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">Freedman et al. [1997: Proc Natl Acad Sci USA 94:587-592] reported linkage in nine multiplex schizophrenia families to markers on chromosome 15, using impaired neuronal inhibition to repeated auditory stimuli (P50), a neurophysiological deficit associated with schizophrenia, as the phenotype.  The highest LOD score obtained (5.3 at theta = 0) was for marker D15S1360 mapped to chromosome 15q13-14, less than 120 kb from the alpha7-nicotinic receptor (CHRNA7) gene.  The study also reported a small positive LOD score for D15S1360 when examined for linkage to the schizophrenia phenotype.  Following these findings, we examined three polymorphic markers (D15S1360, L76630, and ACTC) on chromosome 15q13-14 near the CHRNA7 gene for linkage to schizophrenia, using 54 pedigrees from an independent study.  Alleles for these three markers were genotyped and analyzed using parametric and nonparametric methods.  No LOD score above 1.00 was obtained for any marker, and affected sib-pair analysis likewise showed no evidence for linkage.  We conclude that in our families the region around the CHRNA7 locus does not contain a major locus for susceptibility to schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk3N8ZO0OrzEmhnSqMnvzDfW6udTcc2ebbbC8Y0iv52bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3itFSltA%253D%253D&md5=49ff25dc0bce7919544a81aa618a309e</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-8628%2819990416%2988%3A2%3C109%3A%3AAID-AJMG1%3E3.0.CO%3B2-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-8628%252819990416%252988%253A2%253C109%253A%253AAID-AJMG1%253E3.0.CO%253B2-3%26sid%3Dliteratum%253Aachs%26aulast%3DCurtis%26aufirst%3DL.%26aulast%3DBlouin%26aufirst%3DJ.%2BL.%26aulast%3DRadhakrishna%26aufirst%3DU.%26aulast%3DGehrig%26aufirst%3DC.%26aulast%3DLasseter%26aufirst%3DV.%2BK.%26aulast%3DWolyniec%26aufirst%3DP.%26aulast%3DNestadt%26aufirst%3DG.%26aulast%3DDombroski%26aufirst%3DB.%26aulast%3DKazazian%26aufirst%3DH.%2BH.%26aulast%3DPulver%26aufirst%3DA.%2BE.%26aulast%3DHousman%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DAntonarakis%26aufirst%3DS.%2BE.%26atitle%3DNo%2520evidence%2520for%2520linkage%2520between%2520schizophrenia%2520and%2520markers%2520at%2520chromosome%252015q13-14%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%26date%3D1999%26volume%3D88%26spage%3D109%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group">Talkowski, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimgaonkar, V. L.</span><span> </span><span class="NLM_article-title">Dopamine genes and schizophrenia: case closed or evidence pending</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">–</span> <span class="NLM_lpage">1081</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbm076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17630406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2srgvFyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=1071-1081&author=M.+E.+Talkowskiauthor=M.+Bamneauthor=H.+Mansourauthor=V.+L.+Nimgaonkar&title=Dopamine+genes+and+schizophrenia%3A+case+closed+or+evidence+pending"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine genes and schizophrenia: case closed or evidence pending?</span></div><div class="casAuthors">Talkowski Michael E; Bamne Mikhil; Mansour Hader; Nimgaonkar Vishwajit L</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1071-81</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">The dopamine hypothesis of schizophrenia (SZ) has motivated a large number of genetic association studies but few if any dopaminergic (DA) polymorphisms are accepted as credible risk factors at present.  To evaluate whether dopamine-related genes have been investigated adequately, we surveyed public genetic databases and published SZ association studies with regard to 14 conventional DA genes and 7 selected dopamine-interacting proteins.  We estimate that 325 polymorphisms would be required to evaluate the impact of common variation on SZ risk among Caucasian samples.  To date, 98 polymorphisms have been analyzed in published association studies.  We estimate that only 19 of these variations have been evaluated in samples with at least 50% power to detect an association of the effect size commonly found in genetically complex disorders.  While it is possible that DA genes do not harbor genetic risk factors for SZ, our review suggests that satisfactory conclusions for most genes cannot be drawn at present.  Whole-genome association studies have begun to fill this void, but additional analyses are likely to be needed.  Recommendations for future association studies include analysis of adequately powered samples, judiciously selected polymorphisms, multiple ethnic groups, and concurrent evaluation of function at associated single-nucleotide polymorphisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnh99bDRxYg8RAV4D_Ins_fW6udTcc2ebbbC8Y0iv52bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srgvFyrtg%253D%253D&md5=8e8a7a7f5218fed20ab7f173fa474cac</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbm076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbm076%26sid%3Dliteratum%253Aachs%26aulast%3DTalkowski%26aufirst%3DM.%2BE.%26aulast%3DBamne%26aufirst%3DM.%26aulast%3DMansour%26aufirst%3DH.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26atitle%3DDopamine%2520genes%2520and%2520schizophrenia%253A%2520case%2520closed%2520or%2520evidence%2520pending%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D1071%26epage%3D1081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group">Fallin, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasseter, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avramopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicodemus, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolyniec, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestadt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huganir, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulver, A. E.</span><span> </span><span class="NLM_article-title">Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F497703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16380905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ygtLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=918-936&author=M.+D.+Fallinauthor=V.+K.+Lasseterauthor=D.+Avramopoulosauthor=K.+K.+Nicodemusauthor=P.+S.+Wolyniecauthor=J.+A.+McGrathauthor=G.+Steelauthor=G.+Nestadtauthor=K.+Y.+Liangauthor=R.+L.+Huganirauthor=D.+Valleauthor=A.+E.+Pulver&title=Bipolar+I+disorder+and+schizophrenia%3A+a+440-single-nucleotide+polymorphism+screen+of+64+candidate+genes+among+Ashkenazi+Jewish+case-parent+trios"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Bipolar I disorder and schizophrenia: A 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios</span></div><div class="casAuthors">Fallin, M. Daniele; Lasseter, Virginia K.; Avramopoulos, Dimitrios; Nicodemus, Kristin K.; Wolyniec, Paula S.; McGrath, John A.; Steel, Gary; Nestadt, Gerald; Liang, Kung-Yee; Huganir, Richard L.; Valle, David; Pulver, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">918-936</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Bipolar, schizophrenia, and schizoaffective disorders are common, highly heritable psychiatric disorders, for which familial coaggregation, as well as epidemiol. and genetic evidence, suggests overlapping etiologies.  No definitive susceptibility genes have yet been identified for any of these disorders.  Genetic heterogeneity, combined with phenotypic imprecision and poor marker coverage, has contributed to the difficulty in defining risk variants.  We focused on families of Ashkenazi Jewish descent, to reduce genetic heterogeneity, and, as a precursor to genomewide assocn. studies, we undertook a single-nucleotide polymorphism (SNP) genotyping screen of 64 candidate genes (440 SNPs) chosen on the basis of previous linkage or of assocn. and/or biol. relevance.  We genotyped an av. of 6.9 SNPs per gene, with an av. d. of 1 SNP per 11.9 kb in 323 bipolar I disorder and 274 schizophrenia or schizoaffective Ashkenazi case-parent trios.  Using single-SNP and haplotype-based transmission/disequil. tests, we ranked genes on the basis of strength of assocn.  Six genes (DAO, GRM3, GRM4, GRIN2B, IL2RB, and TUBA8) met this criterion for bipolar I disorder; only DAO has been previously assocd. with bipolar disorder.  Six genes (RGS4, SCA1, GRM4, DPYSL2, NOS1, and GRID1) met this criterion for schizophrenia or schizoaffective disorder; five replicate previous assocns., and one, GRID1, shows a novel assocn. with schizophrenia.  In addn., six genes (DPYSL2, DTNBP1, G30/G72, GRID1, GRM4, and NOS1) showed overlapping suggestive evidence of assocn. in both disorders.  These results may help to prioritize candidate genes for future study from among the many suspected/proposed for schizophrenia and bipolar disorders.  They provide further support for shared genetic susceptibility between these two disorders that involve glutamate-signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzKkGnZnTIObVg90H21EOLACvtfcHk0lgeiRdEuXCKAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ygtLbL&md5=6608559e392030ac38c84d4efc9393a6</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1086%2F497703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F497703%26sid%3Dliteratum%253Aachs%26aulast%3DFallin%26aufirst%3DM.%2BD.%26aulast%3DLasseter%26aufirst%3DV.%2BK.%26aulast%3DAvramopoulos%26aufirst%3DD.%26aulast%3DNicodemus%26aufirst%3DK.%2BK.%26aulast%3DWolyniec%26aufirst%3DP.%2BS.%26aulast%3DMcGrath%26aufirst%3DJ.%2BA.%26aulast%3DSteel%26aufirst%3DG.%26aulast%3DNestadt%26aufirst%3DG.%26aulast%3DLiang%26aufirst%3DK.%2BY.%26aulast%3DHuganir%26aufirst%3DR.%2BL.%26aulast%3DValle%26aufirst%3DD.%26aulast%3DPulver%26aufirst%3DA.%2BE.%26atitle%3DBipolar%2520I%2520disorder%2520and%2520schizophrenia%253A%2520a%2520440-single-nucleotide%2520polymorphism%2520screen%2520of%252064%2520candidate%2520genes%2520among%2520Ashkenazi%2520Jewish%2520case-parent%2520trios%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2005%26volume%3D77%26spage%3D918%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group">Staddon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arranz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancama, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Nievas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrizabalaga, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckland, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mata, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, R. W.</span><span> </span><span class="NLM_article-title">Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population</span> <span class="citation_source-journal">Schizophr. Res</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15567076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crpsVCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2005&pages=49-54&author=S.+Staddonauthor=M.+J.+Arranzauthor=D.+Mancamaauthor=F.+Perez-Nievasauthor=I.+Arrizabalagaauthor=R.+Anneyauthor=P.+Bucklandauthor=A.+Elkinauthor=S.+Osborneauthor=J.+Munroauthor=I.+Mataauthor=R.+W.+Kerwin&title=Association+between+dopamine+D3+receptor+gene+polymorphisms+and+schizophrenia+in+an+isolate+population"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population</span></div><div class="casAuthors">Staddon Susan; Arranz Maria J; Mancama Dalu; Perez-Nievas Fernando; Arrizabalaga Inaki; Anney Richard; Buckland Paul; Elkin Amanda; Osborne Sarah; Munro Janet; Mata Ignacio; Kerwin Robert W</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-54</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">There are several lines of evidence implicating the dopamine D3 receptor in the pathophysiology of schizophrenia.  The Ser9Gly polymorphism of the dopamine D3 receptor gene (DRD3) has been the most extensively investigated DRD3 variant in connection with the disease but results have been inconclusive.  Recent reports indicate that the Ser9Gly polymorphism is in linkage disequilibrium with other markers, but association studies between DRD3 haplotypes and schizophrenia have had mixed results.  Genetic heterogeneity may be one of the causes of contradicting results.  In order to clarify the role of DRD3 alterations in the aetiology of disease, we have investigated three D3 genetic variants (Ser9Gly, -205-G/A, -7685-G/C) in a sample of patients with schizophrenia or schizoaffective disorder (N=118) and controls (N=162) recruited from a human isolate from Navarra (Northern Spain) of Basque origin.  Although no association was found between the Ser9Gly or the -205-A/G polymorphisms and disease, an excess of allele -7685-C was observed in patients (p=0.002 after correction for multiple analyses).  Haplotype analysis shows the three markers to be in strong linkage disequilibrium (p<0.0001) and strongly associated with disease (p<1x 10(-5)).  These results may suggest that these polymorphisms exert a combined or synergistic effect on susceptibility to schizophrenia, or are in linkage with an unknown causative factor.  However, further replication in independent samples is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSF_qcmKJg1blQKX3ooHxWjfW6udTcc2eaxdpcEAQVuzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpsVCmtQ%253D%253D&md5=ef591a077cfba433b49594bcc0459476</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DStaddon%26aufirst%3DS.%26aulast%3DArranz%26aufirst%3DM.%2BJ.%26aulast%3DMancama%26aufirst%3DD.%26aulast%3DPerez-Nievas%26aufirst%3DF.%26aulast%3DArrizabalaga%26aufirst%3DI.%26aulast%3DAnney%26aufirst%3DR.%26aulast%3DBuckland%26aufirst%3DP.%26aulast%3DElkin%26aufirst%3DA.%26aulast%3DOsborne%26aufirst%3DS.%26aulast%3DMunro%26aufirst%3DJ.%26aulast%3DMata%26aufirst%3DI.%26aulast%3DKerwin%26aufirst%3DR.%2BW.%26atitle%3DAssociation%2520between%2520dopamine%2520D3%2520receptor%2520gene%2520polymorphisms%2520and%2520schizophrenia%2520in%2520an%2520isolate%2520population%26jtitle%3DSchizophr.%2520Res%26date%3D2005%26volume%3D73%26spage%3D49%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group">Mitsuyasu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ninomiya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinukawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahira, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, V. P.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springett, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashiro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanba, S.</span><span> </span><span class="NLM_article-title">Genetic structure of the dopamine receptor D4 gene (DRD4) and lack of association with schizophrenia in Japanese patients</span> <span class="citation_source-journal">J. Psychiatr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.jpsychires.2006.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16887146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s3mtFyktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2007&pages=763-775&author=H.+Mitsuyasuauthor=H.+Kawasakiauthor=H.+Ninomiyaauthor=N.+Kinukawaauthor=T.+Yamanakaauthor=T.+Tahiraauthor=V.+P.+Stantonauthor=G.+M.+Springettauthor=K.+Hayashiauthor=N.+Tashiroauthor=S.+Kanba&title=Genetic+structure+of+the+dopamine+receptor+D4+gene+%28DRD4%29+and+lack+of+association+with+schizophrenia+in+Japanese+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic structure of the dopamine receptor D4 gene (DRD4) and lack of association with schizophrenia in Japanese patients</span></div><div class="casAuthors">Mitsuyasu Hiroshi; Kawasaki Hiroaki; Ninomiya Hideaki; Kinukawa Naoko; Yamanaka Takeharu; Tahira Tomoko; Stanton Vincent P Jr; Springett Gregory M; Hayashi Kenshi; Tashiro Nobutada; Kanba Shigenobu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">763-75</span>
        ISSN:<span class="NLM_cas:issn">0022-3956</span>.
    </div><div class="casAbstract">In order to investigate the contribution of genetic variation in the human dopamine receptor D4 gene (DRD4) to the risk of developing schizophrenia, we carried out a genetic analysis of 27 polymorphisms in 216 schizophrenic patients and 243 healthy controls from the Kyushu region of Japan.  Twenty-two single nucleotide polymorphisms (SNPs) and five insertion/deletion polymorphisms were analyzed in this study, including four novel SNPs and a novel mononucleotide repeat.  Linkage disequilibrium (LD) and haplotype analyses reveal weak LD across the DRD4 gene.  In univariate analysis female individuals with allele -521C had a higher risk for schizophrenia.  However, this finding was not significant after correction for multiple hypothesis testing.  No other polymorphisms or haplotypes differed between schizophrenic patients and controls.  Likewise, multivariate analyses did not reveal any statistically significant associations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLiZw_gc8v50bxh97K6Vt6fW6udTcc2eaxdpcEAQVuzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3mtFyktw%253D%253D&md5=d28f2ed06d54ca3b0dd549c7c302a7c9</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2006.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2006.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuyasu%26aufirst%3DH.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DNinomiya%26aufirst%3DH.%26aulast%3DKinukawa%26aufirst%3DN.%26aulast%3DYamanaka%26aufirst%3DT.%26aulast%3DTahira%26aufirst%3DT.%26aulast%3DStanton%26aufirst%3DV.%2BP.%26aulast%3DSpringett%26aufirst%3DG.%2BM.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DTashiro%26aufirst%3DN.%26aulast%3DKanba%26aufirst%3DS.%26atitle%3DGenetic%2520structure%2520of%2520the%2520dopamine%2520receptor%2520D4%2520gene%2520%2528DRD4%2529%2520and%2520lack%2520of%2520association%2520with%2520schizophrenia%2520in%2520Japanese%2520patients%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2007%26volume%3D41%26spage%3D763%26epage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group">Khodayari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garshasbi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahimi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafizi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebrahimi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najmabadi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohadi, M.</span><span> </span><span class="NLM_article-title">Association of the dopamine transporter gene (DAT1) core promoter polymorphism-67T variant with schizophrenia</span> <span class="citation_source-journal">Am. J. Med. Genet. B: Neuropsychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2Fajmg.b.30067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2czntVahtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2004&pages=10-12&author=N.+Khodayariauthor=M.+Garshasbiauthor=F.+Fadaiauthor=A.+Rahimiauthor=L.+Hafiziauthor=A.+Ebrahimiauthor=H.+Najmabadiauthor=M.+Ohadi&title=Association+of+the+dopamine+transporter+gene+%28DAT1%29+core+promoter+polymorphism-67T+variant+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Association of the dopamine transporter gene (DAT1) core promoter polymorphism -67T variant with schizophrenia</span></div><div class="casAuthors">Khodayari N; Garshasbi M; Fadai F; Rahimi A; Hafizi L; Ebrahimi A; Najmabadi H; Ohadi Mina</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">129B</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-2</span>
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    </div><div class="casAbstract">Dysfunction of the central dopaminergic neurotransmission has been suggested to play an important role in the etiology of schizophrenia.  The dopamine transporter (DAT1) mediates the active reuptake of dopamine from the synapses and thereby plays a key role in the regulation of the dopaminergic neurotransmission.  In this study, we sought to determine the possible association of the DAT1 gene core promoter polymorphism -67A/T with schizophrenia in a case/control study.  The allele and genotype frequencies of the polymorphism were studied in 100 patients and 100 controls, which were matched on the basis of sex, age, and ethnicity.  The genotype frequencies in the patients group were as follows: AA 29%; AT 59%; TT 12% versus the genotype frequencies in the control group: AA 57%; AT 38%; TT 5% [chi2 = 16.54, df = 2, OR = 2.25 (95% CI 1.46-3.45, P < or = 0.0003].  For the first time, these findings provide tentative evidence for the contribution of the DAT1 gene core promoter polymorphism to the etiopathophysiology of schizophrenia at least in the Iranian male population that we studied.  Replication studies of independent samples and family-based association studies are necessary to further evaluate the significance of our findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWuOT5Fj1SKWPgL4LrC-0VfW6udTcc2eYd15nVJ4-sSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czntVahtQ%253D%253D&md5=70c70e057762c690813985dde7af9656</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1002%2Fajmg.b.30067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajmg.b.30067%26sid%3Dliteratum%253Aachs%26aulast%3DKhodayari%26aufirst%3DN.%26aulast%3DGarshasbi%26aufirst%3DM.%26aulast%3DFadai%26aufirst%3DF.%26aulast%3DRahimi%26aufirst%3DA.%26aulast%3DHafizi%26aufirst%3DL.%26aulast%3DEbrahimi%26aufirst%3DA.%26aulast%3DNajmabadi%26aufirst%3DH.%26aulast%3DOhadi%26aufirst%3DM.%26atitle%3DAssociation%2520of%2520the%2520dopamine%2520transporter%2520gene%2520%2528DAT1%2529%2520core%2520promoter%2520polymorphism-67T%2520variant%2520with%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%2520B%253A%2520Neuropsychiatr.%2520Genet.%26date%3D2004%26volume%3D129%26spage%3D10%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group">Gamma, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glatt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T.</span><span> </span><span class="NLM_article-title">Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.09.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15567077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crpsVCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2005&pages=55-58&author=F.+Gammaauthor=S.+V.+Faraoneauthor=S.+J.+Glattauthor=Y.+C.+Yehauthor=M.+T.+Tsuang&title=Meta-analysis+shows+schizophrenia+is+not+associated+with+the+40-base-pair+repeat+polymorphism+of+the+dopamine+transporter+gene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene</span></div><div class="casAuthors">Gamma F; Faraone Stephen V; Glatt Stephen J; Yeh Yu-Chi; Tsuang Ming T</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-8</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">OBJECTIVE:  Several case-control studies examined an association between schizophrenia and the 40-bp variable number tandem repeat (VTNR) polymorphism in the 3'-UTR of the dopamine transporter gene (SLC6A3).  The results of these studies have been equivocal due to small sample size and low power.  This meta-analysis has the aim to evaluate the collective evidence for an association between the VTNR polymorphism and schizophrenia.  METHOD:  Different meta-analyses were performed, sequentially considering the 9- and 10-repeat alleles and different genotypes (genotypes 9/9, 9/10, 10/10) as risk factors for schizophrenia.  Analyses of the alleles included 659 cases and 563 controls from six case-control studies.  RESULTS:  The pooled OR from each analysis approximated 1.0, and none were significant.  Lack of significance attributable to the negative effects of single large studies or to heterogeneity between the studies was excluded.  CONCLUSION:  Despite over 90% power to detect a significant odds ratio as small as 1.3, no association was observed.  Considering the cumulative evidence from six case-control studies and results from additional family-based studies, it seems unlikely that the 40-base-pair VTNR polymorphism of the SLC6A3 gene influences risk for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSF_qcmKJg1bl1C8OJBvdfbfW6udTcc2eYd15nVJ4-sSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpsVCmug%253D%253D&md5=bcadfcd81802e7661ec3edecd11169d2</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DGamma%26aufirst%3DF.%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DGlatt%26aufirst%3DS.%2BJ.%26aulast%3DYeh%26aufirst%3DY.%2BC.%26aulast%3DTsuang%26aufirst%3DM.%2BT.%26atitle%3DMeta-analysis%2520shows%2520schizophrenia%2520is%2520not%2520associated%2520with%2520the%252040-base-pair%2520repeat%2520polymorphism%2520of%2520the%2520dopamine%2520transporter%2520gene%26jtitle%3DSchizophr.%2520Res.%26date%3D2005%26volume%3D73%26spage%3D55%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group">Miyakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotnikova, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonegawa, S.</span><span> </span><span class="NLM_article-title">Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">8987</span><span class="NLM_x">–</span> <span class="NLM_lpage">8992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=8987-8992&author=T.+Miyakawaauthor=L.+M.+Leiterauthor=D.+J.+Gerberauthor=R.+R.+Gainetdinovauthor=T.+D.+Sotnikovaauthor=H.+Zengauthor=M.+G.+Caronauthor=S.+Tonegawa&title=Conditional+calcineurin+knockout+mice+exhibit+multiple+abnormal+behaviors+related+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyakawa%26aufirst%3DT.%26aulast%3DLeiter%26aufirst%3DL.%2BM.%26aulast%3DGerber%26aufirst%3DD.%2BJ.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DSotnikova%26aufirst%3DT.%2BD.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DTonegawa%26aufirst%3DS.%26atitle%3DConditional%2520calcineurin%2520knockout%2520mice%2520exhibit%2520multiple%2520abnormal%2520behaviors%2520related%2520to%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D8987%26epage%3D8992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group">Impagnatiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guidotti, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwivedi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruncho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisu, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzunov, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalheiser, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappas, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tueting, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, E.</span><span> </span><span class="NLM_article-title">A decrease of reelin expression as a putative vulnerability factor in schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">15718</span><span class="NLM_x">–</span> <span class="NLM_lpage">15723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=15718-15723&author=F.+Impagnatielloauthor=A.+R.+Guidottiauthor=C.+Pesoldauthor=Y.+Dwivediauthor=H.+Carunchoauthor=M.+G.+Pisuauthor=D.+P.+Uzunovauthor=N.+R.+Smalheiserauthor=J.+M.+Davisauthor=G.+N.+Pandeyauthor=G.+D.+Pappasauthor=P.+Tuetingauthor=R.+P.+Sharmaauthor=E.+Costa&title=A+decrease+of+reelin+expression+as+a+putative+vulnerability+factor+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DGuidotti%26aufirst%3DA.%2BR.%26aulast%3DPesold%26aufirst%3DC.%26aulast%3DDwivedi%26aufirst%3DY.%26aulast%3DCaruncho%26aufirst%3DH.%26aulast%3DPisu%26aufirst%3DM.%2BG.%26aulast%3DUzunov%26aufirst%3DD.%2BP.%26aulast%3DSmalheiser%26aufirst%3DN.%2BR.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26aulast%3DPandey%26aufirst%3DG.%2BN.%26aulast%3DPappas%26aufirst%3DG.%2BD.%26aulast%3DTueting%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DR.%2BP.%26aulast%3DCosta%26aufirst%3DE.%26atitle%3DA%2520decrease%2520of%2520reelin%2520expression%2520as%2520a%2520putative%2520vulnerability%2520factor%2520in%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D15718%26epage%3D15723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group">Roffman, J. L.; Weiss, A. P.; Purcell, S.; Caffalette, C. A.; Freudenreich, O.; Henderson, D. C.; Bottiglieri, T.; Wong, D. H.; Halsted, C. H.; Goff, D. C.</span><span> </span><span class="NLM_article-title">Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia</span>.  <span class="citation_source-journal">Biol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Roffman%2C+J.+L.%3B+Weiss%2C+A.+P.%3B+Purcell%2C+S.%3B+Caffalette%2C+C.+A.%3B+Freudenreich%2C+O.%3B+Henderson%2C+D.+C.%3B+Bottiglieri%2C+T.%3B+Wong%2C+D.+H.%3B+Halsted%2C+C.+H.%3B+Goff%2C+D.+C.+Contribution+of+methylenetetrahydrofolate+reductase+%28MTHFR%29+polymorphisms+to+negative+symptoms+in+schizophrenia.+Biol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoffman%26aufirst%3DJ.%2BL.%26atitle%3DContribution%2520of%2520methylenetetrahydrofolate%2520reductase%2520%2528MTHFR%2529%2520polymorphisms%2520to%2520negative%2520symptoms%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group">Proitsi, P.; Li, T.; Hamilton, G.; Di Forti, M.; Collier, D.; Killick, R.; Chen, R.; Sham, P.; Murray, R.; Powell, J.; Lovestone, S.</span><span> </span><span class="NLM_article-title">Positional pathway screen of wnt signaling genes in schizophrenia: association with DKK4</span>.  <span class="citation_source-journal">Biol. Psychiatry</span><div class="note"><p class="first last"><b>2007,</b><i>62,</i> 275–278.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Proitsi%2C+P.%3B+Li%2C+T.%3B+Hamilton%2C+G.%3B+Di+Forti%2C+M.%3B+Collier%2C+D.%3B+Killick%2C+R.%3B+Chen%2C+R.%3B+Sham%2C+P.%3B+Murray%2C+R.%3B+Powell%2C+J.%3B+Lovestone%2C+S.+Positional+pathway+screen+of+wnt+signaling+genes+in+schizophrenia%3A+association+with+DKK4.+Biol.+Psychiatry2007%2C62%2C+275%E2%80%93278."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DProitsi%26aufirst%3DP.%26atitle%3DPositional%2520pathway%2520screen%2520of%2520wnt%2520signaling%2520genes%2520in%2520schizophrenia%253A%2520association%2520with%2520DKK4%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group">Numata, S.; Ueno, S. I.; Iga, J. I.; Yamauchi, K.; Hongwei, S.; Hashimoto, R.; Takeda, M.; Kunugi, H.; Itakura, M.; Ohmori, T.</span><span> </span><span class="NLM_article-title">TGFBR2 gene expression and genetic association with schizophrenia</span>.  <span class="citation_source-journal">J. Psychiatr. Res.</span>, in press.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Numata%2C+S.%3B+Ueno%2C+S.+I.%3B+Iga%2C+J.+I.%3B+Yamauchi%2C+K.%3B+Hongwei%2C+S.%3B+Hashimoto%2C+R.%3B+Takeda%2C+M.%3B+Kunugi%2C+H.%3B+Itakura%2C+M.%3B+Ohmori%2C+T.+TGFBR2+gene+expression+and+genetic+association+with+schizophrenia.+J.+Psychiatr.+Res.%2C+in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNumata%26aufirst%3DS.%26atitle%3DTGFBR2%2520gene%2520expression%2520and%2520genetic%2520association%2520with%2520schizophrenia%26jtitle%3DJ.%2520Psychiatr.%2520Res." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group">Eastwood, S. L.; Harrison, P. J.</span><span> </span><span class="NLM_article-title">Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Eastwood%2C+S.+L.%3B+Harrison%2C+P.+J.+Decreased+mRNA+expression+of+netrin-G1+and+netrin-G2+in+the+temporal+lobe+in+schizophrenia+and+bipolar+disorder.+Neuropsychopharmacology%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEastwood%26aufirst%3DS.%2BL.%26atitle%3DDecreased%2520mRNA%2520expression%2520of%2520netrin-G1%2520and%2520netrin-G2%2520in%2520the%2520temporal%2520lobe%2520in%2520schizophrenia%2520and%2520bipolar%2520disorder%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group">Chahl, L. A.</span><span> </span><span class="NLM_article-title">TRP’s: links to schizophrenia?</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><div class="note"><p class="first last"><b>2007,</b><i>1772,</i> 968–977.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chahl%2C+L.+A.+TRP%E2%80%99s%3A+links+to+schizophrenia%3FBiochim.+Biophys.+Acta2007%2C1772%2C+968%E2%80%93977."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChahl%26aufirst%3DL.%2BA.%26atitle%3DTRP%25E2%2580%2599s%253A%2520links%2520to%2520schizophrenia%253F%26jtitle%3DBiochim.%2520Biophys.%2520Acta" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group">Ishiguro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toru, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itokawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumaji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okubo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwawaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arinami, T.</span><span> </span><span class="NLM_article-title">Association between polymorphisms in the type 1 σ receptor gene and schizophrenia</span> <span class="citation_source-journal">Neurosci. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1998&pages=45-48&author=H.+Ishiguroauthor=T.+Ohtsukiauthor=M.+Toruauthor=M.+Itokawaauthor=J.+Aokiauthor=H.+Shibuyaauthor=A.+Kurumajiauthor=Y.+Okuboauthor=A.+Iwawakiauthor=K.+Otaauthor=H.+Shimizuauthor=H.+Hamaguchiauthor=T.+Arinami&title=Association+between+polymorphisms+in+the+type+1+%CF%83+receptor+gene+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshiguro%26aufirst%3DH.%26aulast%3DOhtsuki%26aufirst%3DT.%26aulast%3DToru%26aufirst%3DM.%26aulast%3DItokawa%26aufirst%3DM.%26aulast%3DAoki%26aufirst%3DJ.%26aulast%3DShibuya%26aufirst%3DH.%26aulast%3DKurumaji%26aufirst%3DA.%26aulast%3DOkubo%26aufirst%3DY.%26aulast%3DIwawaki%26aufirst%3DA.%26aulast%3DOta%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DH.%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DArinami%26aufirst%3DT.%26atitle%3DAssociation%2520between%2520polymorphisms%2520in%2520the%2520type%25201%2520%25CF%2583%2520receptor%2520gene%2520and%2520schizophrenia%26jtitle%3DNeurosci.%2520Lett.%26date%3D1998%26volume%3D257%26spage%3D45%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group">Ohmori, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinkai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span> </span><span class="NLM_article-title">Polymorphisms of the σ<sub>1</sub> receptor gene in schizophrenia: an association study</span> <span class="citation_source-journal">Am. J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2F%28SICI%291096-8628%2820000207%2996%3A1%3C118%3A%3AAID-AJMG23%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10686564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3cvitlyitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=118-122&author=O.+Ohmoriauthor=T.+Shinkaiauthor=T.+Suzukiauthor=C.+Okanoauthor=H.+Kojimaauthor=T.+Teraoauthor=J.+Nakamura&title=Polymorphisms+of+the+%CF%831+receptor+gene+in+schizophrenia%3A+an+association+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Polymorphisms of the sigma(1) receptor gene in schizophrenia: An association study</span></div><div class="casAuthors">Ohmori O; Shinkai T; Suzuki T; Okano C; Kojima H; Terao T; Nakamura J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-22</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">Possible involvement of sigma receptors in the pathogenesis of schizophrenia has been suggested.  In this study we searched systematically for polymorphisms in the 5'-franking region of the sigma(1) receptor.  Genetic variation in this region could reduce the expression of the gene, and this suggestion is compatible with findings of reduced sigma binding sites in several cortical regions of schizophrenia.  We confirmed G-241T and G-240T polymorphisms; these two consecutive polymorphisms were resolved to be in complete linkage disequilibrium with each other by single-strand conformation polymorphism (SSCP) analysis.  We also identified the A61C (Gln2Pro) polymorphism, which was in almost complete linkage disequilibrium with G-241T/G-240T.  There was no significant difference in the distribution of alleles or overall genotypes of the polymorphisms between schizophrenic patients (n = 129) and controls (n = 140).  We found slight increased homozygosity for T-241/T-240 and C61 in patients compared with controls using multiple comparison (p = 0. 045).  However, the significance did not remain when a Bonferroni correction was made (p = 0.135).  These results do not support that the sigma(1) receptor gene plays a major role in the pathogenesis of schizophrenia.  Am.  J.  Med.  Genet. (Neuropsychiatr.  Genet.) 96:118-122, 2000.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPXt4iirRsYmhHGZei4OW9fW6udTcc2ea6q8WCRhL3k7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvitlyitg%253D%253D&md5=73d2a0faa1d580cf3b7c4cccf4485801</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-8628%2820000207%2996%3A1%3C118%3A%3AAID-AJMG23%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-8628%252820000207%252996%253A1%253C118%253A%253AAID-AJMG23%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DShinkai%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DOkano%26aufirst%3DC.%26aulast%3DKojima%26aufirst%3DH.%26aulast%3DTerao%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DJ.%26atitle%3DPolymorphisms%2520of%2520the%2520%25CF%25831%2520receptor%2520gene%2520in%2520schizophrenia%253A%2520an%2520association%2520study%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%26date%3D2000%26volume%3D96%26spage%3D118%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group">Uchida, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ujike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, S.</span><span> </span><span class="NLM_article-title">No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies</span> <span class="citation_source-journal">BMC Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=13&author=N.+Uchidaauthor=H.+Ujikeauthor=K.+Nakataauthor=M.+Takakiauthor=A.+Nomuraauthor=T.+Katsuauthor=Y.+Tanakaauthor=T.+Imamuraauthor=A.+Sakaiauthor=S.+Kuroda&title=No+association+between+the+sigma+receptor+type+1+gene+and+schizophrenia%3A+results+of+analysis+and+meta-analysis+of+case-control+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DN.%26aulast%3DUjike%26aufirst%3DH.%26aulast%3DNakata%26aufirst%3DK.%26aulast%3DTakaki%26aufirst%3DM.%26aulast%3DNomura%26aufirst%3DA.%26aulast%3DKatsu%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DA.%26aulast%3DKuroda%26aufirst%3DS.%26atitle%3DNo%2520association%2520between%2520the%2520sigma%2520receptor%2520type%25201%2520gene%2520and%2520schizophrenia%253A%2520results%2520of%2520analysis%2520and%2520meta-analysis%2520of%2520case-control%2520studies%26jtitle%3DBMC%2520Psychiatry%26date%3D2003%26volume%3D3%26spage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group">Puri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuillin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thirumalai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasucki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quested, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pimm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorey, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandasami, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badacsonyi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punukollu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadeem, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurling, H. M.</span><span> </span><span class="NLM_article-title">Failure to confirm allelic association between markers at the CAPON gene locus and schizophrenia in a British sample</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2005.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16202394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=195-197&author=V.+Puriauthor=A.+McQuillinauthor=S.+Thirumalaiauthor=J.+Lawrenceauthor=R.+Krasuckiauthor=K.+Choudhuryauthor=S.+Dattaauthor=S.+Kerwinauthor=D.+Questedauthor=N.+Bassauthor=J.+Pimmauthor=G.+Lambauthor=H.+Mooreyauthor=G.+Kandasamiauthor=A.+Badacsonyiauthor=K.+Kellyauthor=J.+Morganauthor=B.+Punukolluauthor=H.+Nadeemauthor=D.+Curtisauthor=H.+M.+Gurling&title=Failure+to+confirm+allelic+association+between+markers+at+the+CAPON+gene+locus+and+schizophrenia+in+a+British+sample"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Failure to Confirm Allelic Association Between Markers at the CAPON Gene Locus and Schizophrenia in a British Sample</span></div><div class="casAuthors">Puri, Vinay; McQuillin, Andrew; Thirumalai, Srinivasa; Lawrence, Jacob; Krasucki, Robert; Choudhury, Khalid; Datta, Susmita; Kerwin, Simon; Quested, Digby; Bass, Nicholas; Pimm, Jonathan; Lamb, Graham; Moorey, Helen; Kandasami, Gomathinayagam; Badacsonyi, Allison; Kelly, Katie; Morgan, Jenny; Punukollu, Bhaskar; Nadeem, Haitham; Curtis, David; Gurling, Hugh M. D.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-197</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Linkage studies have confirmed that chromosome 1q23.3 is a susceptibility locus for schizophrenia.  It was then claimed that markers at the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase (CAPON) gene showed allelic assocn. with schizophrenia in Canadian families.  A second Chinese study found a base pair polymorphism at the CAPON gene also assocd. with schizophrenia.  Methods: We attempted replication using eight markers from the Canadian study in a UK based sample of 450 cases and 450 supernormal controls.  Results: We found no evidence for allelic or haplotypic assocn. with schizophrenia for any of the markers found to be assocd. in the Canadian sample.  Conclusions: The neg. results might reflect genetic heterogeneity between the Canadian, Chinese and UK samples or be due to methodol. problems.  The present finding weakens the evidence that mutations or variation in the CAPON gene are causing genetic susceptibility to schizophrenia in European populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrki7QPC6Zsb7Vg90H21EOLACvtfcHk0ljRMQsc4UhSCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVGkug%253D%253D&md5=650a99e7c442b2d6e4e6123007827cfc</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DV.%26aulast%3DMcQuillin%26aufirst%3DA.%26aulast%3DThirumalai%26aufirst%3DS.%26aulast%3DLawrence%26aufirst%3DJ.%26aulast%3DKrasucki%26aufirst%3DR.%26aulast%3DChoudhury%26aufirst%3DK.%26aulast%3DDatta%26aufirst%3DS.%26aulast%3DKerwin%26aufirst%3DS.%26aulast%3DQuested%26aufirst%3DD.%26aulast%3DBass%26aufirst%3DN.%26aulast%3DPimm%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DG.%26aulast%3DMoorey%26aufirst%3DH.%26aulast%3DKandasami%26aufirst%3DG.%26aulast%3DBadacsonyi%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DMorgan%26aufirst%3DJ.%26aulast%3DPunukollu%26aufirst%3DB.%26aulast%3DNadeem%26aufirst%3DH.%26aulast%3DCurtis%26aufirst%3DD.%26aulast%3DGurling%26aufirst%3DH.%2BM.%26atitle%3DFailure%2520to%2520confirm%2520allelic%2520association%2520between%2520markers%2520at%2520the%2520CAPON%2520gene%2520locus%2520and%2520schizophrenia%2520in%2520a%2520British%2520sample%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D195%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group">Clark, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mata, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arranz, M. J.</span><span> </span><span class="NLM_article-title">No association between ADRA2A polymorphisms and schizophrenia</span> <span class="citation_source-journal">Am. J. Med. Genet. B: Neuropsychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFalu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2007&pages=341-343&author=D.+A.+Clarkauthor=I.+Mataauthor=R.+W.+Kerwinauthor=J.+Munroauthor=M.+J.+Arranz&title=No+association+between+ADRA2A+polymorphisms+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">No association between ADRA2A polymorphisms and schizophrenia</span></div><div class="casAuthors">Clark, D. A.; Mata, I.; Kerwin, R. W.; Munro, J.; Arranz, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">144B</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-343</span>CODEN:
                <span class="NLM_cas:coden">AJMGC9</span>;
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">There is evidence to suggest that the α2A-adrenergic receptor may be involved in schizophrenia.  With attention directed at the upstream regulatory region of the gene which codes for this receptor (ADRA2A), we proposed that single nucleotide polymorphisms (SNPs) within this region influences susceptibility to schizophrenia by altering the expression of this receptor.  We opted to test for an influence on susceptibility by assocn. study using 112 schizophrenic/schizoaffective disorder patients and 159 controls.  The region of interest was screened for SNPs using a combination of bioinformatic searches and sequencing.  A total of nine SNPs were discovered, of which four (-5972-G/A, -2211-A/T, -1291-C/G and -261-G/A) were genotyped in the entire clin. sample.  No assocns. were evident, suggesting no influence for these SNPs in susceptibility to schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgn0fy6z3yybVg90H21EOLACvtfcHk0ljRMQsc4UhSCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFalu74%253D&md5=72538fb0b206f382360d871153043b62</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DD.%2BA.%26aulast%3DMata%26aufirst%3DI.%26aulast%3DKerwin%26aufirst%3DR.%2BW.%26aulast%3DMunro%26aufirst%3DJ.%26aulast%3DArranz%26aufirst%3DM.%2BJ.%26atitle%3DNo%2520association%2520between%2520ADRA2A%2520polymorphisms%2520and%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%2520B%253A%2520Neuropsychiatr.%2520Genet.%26date%3D2007%26volume%3D144%26spage%3D341%26epage%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group">Le Niculescu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balaraman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidhu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerome, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edenberg, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuczenski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurnberger, J. I.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu, A. B.</span><span> </span><span class="NLM_article-title">Towards understanding the schizophrenia code: an expanded convergent functional genomics approach</span> <span class="citation_source-journal">Am. J. Med. Genet. B: Neuropsychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Sru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2007&pages=129-158&author=H.+Le+Niculescuauthor=Y.+Balaramanauthor=S.+Patelauthor=J.+Tanauthor=K.+Sidhuauthor=R.+E.+Jeromeauthor=H.+J.+Edenbergauthor=R.+Kuczenskiauthor=M.+A.+Geyerauthor=J.+I.+Nurnbergerauthor=S.+V.+Faraoneauthor=M.+T+Tsuangauthor=A.+B.+Niculescu&title=Towards+understanding+the+schizophrenia+code%3A+an+expanded+convergent+functional+genomics+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Towards understanding the schizophrenia code: an expanded convergent functional genomics approach</span></div><div class="casAuthors">Le-Niculescu, H.; Balaraman, Y.; Patel, S.; Tan, J.; Sidhu, K.; Jerome, R. E.; Edenberg, H. J.; Kuczenski, R.; Geyer, M. A.; Nurnberger, J. I., Jr.; Faraone, S. V.; Tsuang, M. T.; Niculescu, A. B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">144B</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-158</span>CODEN:
                <span class="NLM_cas:coden">AJMGC9</span>;
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Identifying genes for schizophrenia through classical genetic approaches has proven arduous.  Here, we present a comprehensive convergent anal. that translationally integrates brain gene expression data from a relevant pharmacogenomic mouse model (involving treatments with a psychomimetic agent-phencyclidine (PCP), and an anti-psychotic-clozapine), with human genetic linkage data and human postmortem brain data, as a Bayesian strategy of cross validating findings.  Topping the list of candidate genes, we have three genes involved in GABA neurotransmission (GABRA1, GABBR1, and GAD2), one gene involved in glutamate neurotransmission (GRIA2), one gene involved in neuropeptide signaling (TAC1), two genes involved in synaptic function (SYN2 and KCNJ4), six genes involved in myelin/glial function (CNP, MAL, MBP, PLP1, MOBP and GFAP), and one gene involved in lipid metab. (LPL).  These data suggest that schizophrenia is primarily a disorder of brain functional and structural connectivity, with GABA neurotransmission playing a prominent role.  These findings may explain the EEG gamma band abnormalities detected in schizophrenia.  The anal. also revealed other high probability candidates genes (neurotransmitter signaling, other structural proteins, ion channels, signal transduction, regulatory enzymes, neuronal migration/neurite outgrowth, clock genes, transcription factors, RNA regulatory genes), pathways and mechanisms of likely importance in pathophysiol.  Some of the pathways identified suggest possible avenues for augmentation pharmacotherapy of schizophrenia with other existing agents, such as benzodiazepines, anticonvulsants and lipid modulating agents.  Other pathways are new potential targets for drug development.  Lastly, a comparison with our earlier work on bipolar disorder illuminates the significant mol. overlap between schizophrenia and bipolar disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAlLjMQxkpnLVg90H21EOLACvtfcHk0ljRMQsc4UhSCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Sru7s%253D&md5=3ccb7736f7fb1969d8bdd39060354d0b</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BNiculescu%26aufirst%3DH.%26aulast%3DBalaraman%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DSidhu%26aufirst%3DK.%26aulast%3DJerome%26aufirst%3DR.%2BE.%26aulast%3DEdenberg%26aufirst%3DH.%2BJ.%26aulast%3DKuczenski%26aufirst%3DR.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DNurnberger%26aufirst%3DJ.%2BI.%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DTsuang%26aufirst%3DM.%2BT%26aulast%3DNiculescu%26aufirst%3DA.%2BB.%26atitle%3DTowards%2520understanding%2520the%2520schizophrenia%2520code%253A%2520an%2520expanded%2520convergent%2520functional%2520genomics%2520approach%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%2520B%253A%2520Neuropsychiatr.%2520Genet.%26date%3D2007%26volume%3D144%26spage%3D129%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group">McClellan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Susser, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M. C.</span><span> </span><span class="NLM_article-title">Schizophrenia: a common disease caused by multiple rare alleles</span> <span class="citation_source-journal">Br. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">190</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1192%2Fbjp.bp.106.025585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17329737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s7ivFyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2007&pages=194-199&author=J.+M.+McClellanauthor=E.+Susserauthor=M.+C.+King&title=Schizophrenia%3A+a+common+disease+caused+by+multiple+rare+alleles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia: a common disease caused by multiple rare alleles</span></div><div class="casAuthors">McClellan Jon M; Susser Ezra; King Mary-Claire</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">194-9</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">Schizophrenia is widely held to stem from the combined effects of multiple common polymorphisms, each with a small impact on disease risk.  We suggest an alternative view: that schizophrenia is highly heterogeneous genetically and that many predisposing mutations are highly penetrant and individually rare, even specific to single cases or families.  This "common disease--rare alleles" hypothesis is supported by recent findings in human genomics and by allelic and locus heterogeneity for other complex traits.  We review the implications of this model for gene discovery research in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnlSZlU-r1f90Q2ypr7jHkfW6udTcc2ebrbmZzs2H7Prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7ivFyltg%253D%253D&md5=dab7809d16aadb88add52ef7d937e1ef</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1192%2Fbjp.bp.106.025585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.bp.106.025585%26sid%3Dliteratum%253Aachs%26aulast%3DMcClellan%26aufirst%3DJ.%2BM.%26aulast%3DSusser%26aufirst%3DE.%26aulast%3DKing%26aufirst%3DM.%2BC.%26atitle%3DSchizophrenia%253A%2520a%2520common%2520disease%2520caused%2520by%2520multiple%2520rare%2520alleles%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D190%26spage%3D194%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group">Patil, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martenyi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreev, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avedisova, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardenstein, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurovich, I. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morozova, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosolov, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neznanov, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reznik, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smulevich, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tochilov, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1102</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnm1632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17767166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSgtrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1102-1107&author=S.+T.+Patilauthor=L.+Zhangauthor=F.+Martenyiauthor=S.+L.+Loweauthor=K.+A.+Jacksonauthor=B.+V.+Andreevauthor=A.+S.+Avedisovaauthor=L.+M.+Bardensteinauthor=I.+Y.+Gurovichauthor=M.+A.+Morozovaauthor=S.+N.+Mosolovauthor=N.+G.+Neznanovauthor=A.+M.+Reznikauthor=A.+B.+Smulevichauthor=V.+A.+Tochilovauthor=B.+G.+Johnsonauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=Activation+of+mGlu2%2F3+receptors+as+a+new+approach+to+treat+schizophrenia%3A+a+randomized+phase+2+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial</span></div><div class="casAuthors">Patil, Sandeep T.; Zhang, Lu; Martenyi, Ferenc; Lowe, Stephen L.; Jackson, Kimberley A.; Andreev, Boris V.; Avedisova, Alla S.; Bardenstein, Leonid M.; Gurovich, Issak Y.; Morozova, Margarita A.; Mosolov, Sergey N.; Neznanov, Nikolai G.; Reznik, Alexander M.; Smulevich, Anatoly B.; Tochilov, Vladimir A.; Johnson, Bryan G.; Monn, James A.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1102-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathol. features of disrupted neuronal excitability and plasticity within limbic structures of the brain.  These pathol. features manifest behaviorally as pos. symptoms (including hallucinations, delusions and thought disorder), neg. symptoms (such as social withdrawal, apathy and emotional blunting) and other psychopathol. symptoms (such as psychomotor retardation, lack of insight, poor attention and impulse control).  Altered glutamate neurotransmission has for decades been linked to schizophrenia, but all commonly prescribed antipsychotics act on dopamine receptors.  LY404039 is a selective agonist for metabotropic glutamate 2/3 (mGlu2/3) receptors and has shown antipsychotic potential in animal studies.  With data from rodents, we provide new evidence that mGlu2/3 receptor agonists work by a distinct mechanism different from that of olanzapine.  To clin. test this mechanism, an oral prodrug of LY404039 (LY2140023) was evaluated in schizophrenic patients with olanzapine as an active control in a randomized, three-armed, double-blind, placebo-controlled study.  Treatment with LY2140023, like treatment with olanzapine, was safe and well-tolerated; treated patients showed statistically significant improvements in both pos. and neg. symptoms of schizophrenia compared to placebo (P < 0.001 at week 4).  Notably, patients treated with LY2140023 did not differ from placebo-treated patients with respect to prolactin elevation, extrapyramidal symptoms or wt. gain.  These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtB0jdSzAQrVg90H21EOLACvtfcHk0lgxNqDD0UFScA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSgtrvF&md5=afab88e888cba7e72e14c4e949f894d7</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1038%2Fnm1632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1632%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DS.%2BT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DJackson%26aufirst%3DK.%2BA.%26aulast%3DAndreev%26aufirst%3DB.%2BV.%26aulast%3DAvedisova%26aufirst%3DA.%2BS.%26aulast%3DBardenstein%26aufirst%3DL.%2BM.%26aulast%3DGurovich%26aufirst%3DI.%2BY.%26aulast%3DMorozova%26aufirst%3DM.%2BA.%26aulast%3DMosolov%26aufirst%3DS.%2BN.%26aulast%3DNeznanov%26aufirst%3DN.%2BG.%26aulast%3DReznik%26aufirst%3DA.%2BM.%26aulast%3DSmulevich%26aufirst%3DA.%2BB.%26aulast%3DTochilov%26aufirst%3DV.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DActivation%2520of%2520mGlu2%252F3%2520receptors%2520as%2520a%2520new%2520approach%2520to%2520treat%2520schizophrenia%253A%2520a%2520randomized%2520phase%25202%2520clinical%2520trial%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D1102%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group">Dunayevich, E.; Erickson, J.; Levine, L.; Landbloom, R.; Schoepp, D. D.; Tollefson, G. D.</span><span> </span><span class="NLM_article-title">Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, in press.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Dunayevich%2C+E.%3B+Erickson%2C+J.%3B+Levine%2C+L.%3B+Landbloom%2C+R.%3B+Schoepp%2C+D.+D.%3B+Tollefson%2C+G.+D.+Efficacy+and+tolerability+of+an+mGlu2%2F3+agonist+in+the+treatment+of+generalized+anxiety+disorder.+Neuropsychopharmacology%2C+in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunayevich%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520an%2520mGlu2%252F3%2520agonist%2520in%2520the%2520treatment%2520of%2520generalized%2520anxiety%2520disorder%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">A return to the fundamentals of drug discovery</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14983970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FpsVejsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=29-33&author=M.+Williams&title=A+return+to+the+fundamentals+of+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">A return to the fundamentals of drug discovery?</span></div><div class="casAuthors">Williams Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in investigational drugs (London, England : 2000)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-33</span>
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFI00P36ra3KqcneEtCi92fW6udTcc2ebrbmZzs2H7Prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FpsVejsg%253D%253D&md5=90a01e280254d52e31ba8df7c619ac9b</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DA%2520return%2520to%2520the%2520fundamentals%2520of%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2004%26volume%3D5%26spage%3D29%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group">Marcotte, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, L. K.</span><span> </span><span class="NLM_article-title">Animal models of schizophrenia: a critical review</span> <span class="citation_source-journal">J. Psychiatry Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11762207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD38%252Fjs1Sjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2001&pages=395-410&author=E.+R.+Marcotteauthor=D.+M.+Pearsonauthor=L.+K.+Srivastava&title=Animal+models+of+schizophrenia%3A+a+critical+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of schizophrenia: a critical review</span></div><div class="casAuthors">Marcotte E R; Pearson D M; Srivastava L K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">395-410</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">Current research into schizophrenia has remained highly fragmented, much like the clinical presentation of the disease itself.  Differing theories as to the cause and progression of schizophrenia, as well as the heterogeneity of clinical symptoms, have made it difficult to develop a coherent framework suitable for animal modelling.  However, a number of limited animal models have been developed to explore various causative theories and to test specific mechanistic hypotheses.  Historically, these models have been based on the manipulation of neurotransmitter systems believed to be involved in schizophrenia.  In recent years, the emphasis has shifted to targeting relevant brain regions in an attempt to explore potential etiologic hypotheses.  The specific animal models developed within these frameworks are described in this review.  Emphasis is placed on the critical evaluation of currently available models because these models help to shape the direction of future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKcAfzhfkiXzdblLE_E9PWfW6udTcc2eYXqrqB2s-gGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252Fjs1Sjuw%253D%253D&md5=c90ea93a6490d940ece1a2eeb0339bb6</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DE.%2BR.%26aulast%3DPearson%26aufirst%3DD.%2BM.%26aulast%3DSrivastava%26aufirst%3DL.%2BK.%26atitle%3DAnimal%2520models%2520of%2520schizophrenia%253A%2520a%2520critical%2520review%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2001%26volume%3D26%26spage%3D395%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group">Sams-Dodd, F.</span><span> </span><span class="NLM_article-title">A test of the predictive validity of animal models of schizophrenia based on phencyclidine and <span class="smallcaps smallerCapital">d</span>-amphetamine</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=293-304&author=F.+Sams-Dodd&title=A+test+of+the+predictive+validity+of+animal+models+of+schizophrenia+based+on+phencyclidine+and+d-amphetamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSams-Dodd%26aufirst%3DF.%26atitle%3DA%2520test%2520of%2520the%2520predictive%2520validity%2520of%2520animal%2520models%2520of%2520schizophrenia%2520based%2520on%2520phencyclidine%2520and%2520d-amphetamine%26jtitle%3DNeuropsychopharmacology%26date%3D1998%26volume%3D18%26spage%3D293%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group">Weiner, I.</span><span> </span><span class="NLM_article-title">The “two-headed” latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-002-1313-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12601500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVCgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2003&pages=257-297&author=I.+Weiner&title=The+%E2%80%9Ctwo-headed%E2%80%9D+latent+inhibition+model+of+schizophrenia%3A+modeling+positive+and+negative+symptoms+and+their+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment</span></div><div class="casAuthors">Weiner, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">257-297</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Rationale. Latent inhibition (LI), namely, poorer performance on a learning task involving a previously pre-exposed non-reinforced stimulus, is disrupted in the rat by the dopamine (DA) releaser amphetamine which produces and exacerbates psychotic (pos.) symptoms, and this is reversed by treatment with typical and atypical antipsychotic drugs (APDs) which on their own potentiate LI.  These phenomena are paralleled by disrupted LI in normal amphetamine-treated humans, in high schizotypal humans, and in schizophrenia patients in the acute stages of the disorder, as well as by potentiated LI in normal humans treated with APDs.  Consequently, disrupted LI is considered to provide an animal model of pos. symptoms of schizophrenia with face, construct and predictive validity.  Objectives.  To review most of the rodent data on the neural substrates of LI as well as on the effects of APDs on this phenomenon with an attempt to interpret and integrate these data within the framework of the switching model of LI; to show that there are two distinct LI models, disrupted and abnormally persistent LI; to relate these findings to the clin. condition.  The nucleus accumbens (NAC) and its DA innervation form a crucial component of the neural circuitry of LI, and are involved at the conditioning stage.  There is a clear functional differentiation between the NAC shell and core subregions whereby damage to the shell disrupts LI and damage to the core renders LI abnormally persistent under conditions that disrupt LI in normal rats.  The effects of shell and core lesions parallel those produced by lesions to the major sources of input to the NAC: entorhinal cortex lesion, like shell lesion, disrupts LI, whereas hippocampal lesion, like core lesion, produces persistent LI with changes in context, and basolateral amygdala (BLA) lesion, like core lesion, produces persistent LI with extended conditioning.  Systemically induced blockade of glutamatergic as well as DA transmission produce persistent LI via effects exerted at the conditioning stage, whereas enhancement of DA transmission disrupts LI via effects at the conditioning stage.  Serotonergic manipulations can disrupt or potentiate LI via effects at the pre-exposure stage.  Both typical and atypical APDs potentiate LI via effects at conditioning whereas atypical APDs in addn. disrupt LI via effects at pre-exposure.  Schizophrenia patients can exhibit disrupted or normal LI as a function of the state of the disorder (acute vs. chronic), as well as persistent LI.  Conclusions.  Different drug and lesion manipulations produce two poles of abnormality in LI, namely, disrupted LI under conditions which lead to LI in normal rats, and abnormally persistent LI under conditions which disrupt it in normal rats.  Disrupted and persistent LI are differentially responsive to APDs, with the former reversed by both typical and atypical APDs and the latter selectively reversed by atypical APDs.  It is suggested that this "two-headed LI model" mimics two extremes of deficient cognitive switching seen in schizophrenia, excessive and retarded switching between assocns., mediated by dysfunction of different brain circuitries, and can serve to model pos. symptoms of schizophrenia and typical antipsychotic action, as well as neg. symptoms of schizophrenia and atypical antipsychotic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCPGkGeIm5lLVg90H21EOLACvtfcHk0liXbefH6E9VTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVCgsbk%253D&md5=bd3898d17b46c9fdf8a1172f2b6f3728</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1007%2Fs00213-002-1313-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-002-1313-x%26sid%3Dliteratum%253Aachs%26aulast%3DWeiner%26aufirst%3DI.%26atitle%3DThe%2520%25E2%2580%259Ctwo-headed%25E2%2580%259D%2520latent%2520inhibition%2520model%2520of%2520schizophrenia%253A%2520modeling%2520positive%2520and%2520negative%2520symptoms%2520and%2520their%2520treatment%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2003%26volume%3D169%26spage%3D257%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group">Ford, J. M.</span><span> </span><span class="NLM_article-title">Schizophrenia: the broken P300 and beyond</span> <span class="citation_source-journal">Psychophysiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">682</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1999&pages=667-682&author=J.+M.+Ford&title=Schizophrenia%3A+the+broken+P300+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFord%26aufirst%3DJ.%2BM.%26atitle%3DSchizophrenia%253A%2520the%2520broken%2520P300%2520and%2520beyond%26jtitle%3DPsychophysiology%26date%3D1999%26volume%3D36%26spage%3D667%26epage%3D682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group">Louchart-de la Chapelle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levillain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Elst, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haouzir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dollfus, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campion, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibaut, F.</span><span> </span><span class="NLM_article-title">P50 inhibitory gating deficit is correlated with the negative symptomatology of schizophrenia</span> <span class="citation_source-journal">Psychiatry Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.psychres.2003.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16014313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MzptlGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2005&pages=27-34&author=S.+Louchart-de+la+Chapelleauthor=D.+Levillainauthor=J.+F.+Menardauthor=A.+Van+der+Elstauthor=G.+Allioauthor=S.+Haouzirauthor=S.+Dollfusauthor=D.+Campionauthor=F.+Thibaut&title=P50+inhibitory+gating+deficit+is+correlated+with+the+negative+symptomatology+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">P50 inhibitory gating deficit is correlated with the negative symptomatology of schizophrenia</span></div><div class="casAuthors">Louchart-de la Chapelle Sandrine; Levillain Daniel; Menard Jean-Francois; Van der Elst Alexis; Allio Gabrielle; Haouzir Sadeq; Dollfus Sonia; Campion Dominique; Thibaut Florence</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-34</span>
        ISSN:<span class="NLM_cas:issn">0165-1781</span>.
    </div><div class="casAbstract">Abnormal sensory gating in schizophrenia has frequently been reported.  The strength of central inhibitory pathways was measured using the P50 component of the auditory evoked potential in a conditioning-testing paradigm.  The relationships between a relative decrease in P50 amplitude to repeated auditory stimuli and clinical symptoms remain controversial.  Using the Positive and Negative Syndrome Scale, we studied the P50 auditory conditioning-testing paradigm in 81 schizophrenic subjects, categorized into subgroups with and without prominent negative symptoms, in comparison with 88 control subjects.  We found increased ratios of testing stimuli to conditioning stimuli in both schizophrenic subgroups relative to findings in the control group.  In addition, we found significantly increased mean latencies of the P50 responses to conditioning (C) and testing (T) stimuli and significantly increased T/C ratios in the subgroup with negative symptoms compared with the subgroup with non-negative symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgBYDANNTKUpagfuraLLzSfW6udTcc2eYXqrqB2s-gGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzptlGntw%253D%253D&md5=62d86441942fbbf49fc1f12a468ba70a</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.psychres.2003.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psychres.2003.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DLouchart-de%2Bla%2BChapelle%26aufirst%3DS.%26aulast%3DLevillain%26aufirst%3DD.%26aulast%3DMenard%26aufirst%3DJ.%2BF.%26aulast%3DVan%2Bder%2BElst%26aufirst%3DA.%26aulast%3DAllio%26aufirst%3DG.%26aulast%3DHaouzir%26aufirst%3DS.%26aulast%3DDollfus%26aufirst%3DS.%26aulast%3DCampion%26aufirst%3DD.%26aulast%3DThibaut%26aufirst%3DF.%26atitle%3DP50%2520inhibitory%2520gating%2520deficit%2520is%2520correlated%2520with%2520the%2520negative%2520symptomatology%2520of%2520schizophrenia%26jtitle%3DPsychiatry%2520Res.%26date%3D2005%26volume%3D136%26spage%3D27%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group">Braff, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span> </span><span class="NLM_article-title">Gating and habituation of the startle reflex in schizophrenic patients</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1567275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK383jtFKktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1992&pages=206-215&author=D.+L.+Braffauthor=C.+Grillonauthor=M.+A.+Geyer&title=Gating+and+habituation+of+the+startle+reflex+in+schizophrenic+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Gating and habituation of the startle reflex in schizophrenic patients</span></div><div class="casAuthors">Braff D L; Grillon C; Geyer M A</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-15</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">Schizophrenic patients exhibit impairments in both sensorimotor gating and habituation in a number of paradigms.  Through human and animal model research, these fundamental cognitive deficits have well-described neurobiologic bases and offer insights into the neuroanatomic and neurotransmitter abnormalities that characterize patients with schizophrenic spectrum disorders.  In this context, the startle response is particularly interesting, because it is a cross-species response to strong stimuli that is plastic or alterable using experimental and neurobiologic manipulations.  Thirty-nine medicated schizophrenic patients and 37 normal control subjects were studied in a new electromyography based startle response paradigm in which both prepulse inhibition (an operational measure of sensorimotor gating) and habituation (the normal decrease in response magnitude to repeated stimuli over time) can be separated and assessed in one test session.  The results indicate that schizophrenic patients have extensive deficits in both intramodal and cross-modal sensorimotor gating and a trend to show acoustic startle habituation deficits.  The deficit in prepulse inhibition of startle amplitude exhibited by schizophrenic patients was evident when an acoustic prepulse stimulus preceded either an acoustic or a tactile startle stimulus.  No deficit was observed in the prepulse-induced facilitation of startle latencies, indicating that the failure of gating was not due to a failure of stimulus detection.  These findings suggest centrally mediated deficits in sensorimotor gating in schizophrenic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmgyi6ciJduI2y4bB4mnvYfW6udTcc2eZ-I2SIASVtZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK383jtFKktA%253D%253D&md5=5d17032b7a6addae27cc31e198ac4675</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBraff%26aufirst%3DD.%2BL.%26aulast%3DGrillon%26aufirst%3DC.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26atitle%3DGating%2520and%2520habituation%2520of%2520the%2520startle%2520reflex%2520in%2520schizophrenic%2520patients%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1992%26volume%3D49%26spage%3D206%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group">Grillon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ameli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charney, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braff, D.</span><span> </span><span class="NLM_article-title">Startle gating deficits occur across prepulse intensities in schizophrenic patients</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0006-3223%2892%2990183-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1467378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK3s7gsVehtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1992&pages=939-943&author=C.+Grillonauthor=R.+Ameliauthor=D.+S.+Charneyauthor=J.+Krystalauthor=D.+Braff&title=Startle+gating+deficits+occur+across+prepulse+intensities+in+schizophrenic+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Startle gating deficits occur across prepulse intensities in schizophrenic patients</span></div><div class="casAuthors">Grillon C; Ameli R; Charney D S; Krystal J; Braff D</div><div class="citationInfo"><span class="NLM_cas:title">Biological psychiatry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">939-43</span>
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    </div><div class="casAbstract">The effects of prepulse stimuli of different intensities in inhibiting the startle reflex was assessed in 14 age-matched and gender-matched schizophrenic patients and 14 normal controls.  The subjects were presented with startling stimuli consisting of bursts of white noise (106 dBA) with or without prepulse stimuli.  Four intensities of prepulse stimuli were utilized: 75, 80, 85, and 90 dBA.  Throughout the testing, the background noise was maintained at 70 dBA.  The prepulse stimuli more effectively inhibited the startle reflex in the control group compared to the schizophrenic patients who showed deficient prepulse inhibition (gating) of the startle reflex.  These results suggest that schizophrenics have impaired central inhibitory mechanisms over a fairly broad range of background noise to prepulse ratios.  Further studies are needed to clarify exactly which ratios are optimal in eliciting prepulse inhibition (PPI) and in differentiating between schizophrenic and control groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAyGtpcdk70Kx48Rj5GnGofW6udTcc2eZ-I2SIASVtZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s7gsVehtQ%253D%253D&md5=3fa2fcdc1daaa605af185753a9646c39</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1016%2F0006-3223%2892%2990183-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-3223%252892%252990183-Z%26sid%3Dliteratum%253Aachs%26aulast%3DGrillon%26aufirst%3DC.%26aulast%3DAmeli%26aufirst%3DR.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DKrystal%26aufirst%3DJ.%26aulast%3DBraff%26aufirst%3DD.%26atitle%3DStartle%2520gating%2520deficits%2520occur%2520across%2520prepulse%2520intensities%2520in%2520schizophrenic%2520patients%26jtitle%3DBiol.%2520Psychiatry%26date%3D1992%26volume%3D32%26spage%3D939%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs-Thomson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braff, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swerdlow, N. R.</span><span> </span><span class="NLM_article-title">Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs002130100811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11549216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtlCqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2001&pages=117-154&author=M.+A.+Geyerauthor=K.+Krebs-Thomsonauthor=D.+L.+Braffauthor=N.+R.+Swerdlow&title=Pharmacological+studies+of+prepulse+inhibition+models+of+sensorimotor+gating+deficits+in+schizophrenia%3A+a+decade+in+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review</span></div><div class="casAuthors">Geyer, Mark A.; Krebs-Thomson, Kirsten; Braff, David L.; Swerdlow, Neal R.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">117-154</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with refs. is given.  Patients with schizophrenia exhibit deficits in an operational measure of sensorimotor gating: prepulse inhibition (PPI) of startle.  Similar deficits in PPI are produced in rats by pharmacol. or developmental manipulations.  These exptl. induced PPI deficits in rats are clearly not animal models of schizophrenia per se, but appear to provide models of sensorimotor gating deficits in schizophrenia patients that have face, predictive, and construct validity.  In rodents, disruptions in PPI of startle are produced by: stimulation of D2 dopamine (DA) receptors, produced by amphetamine or apomorphine; activation of serotonergic systems, produced by serotonin (5-HT) releasers or direct agonists at multiple serotonin receptors; and blockade of N-methyl-D-aspartate (NMDA) receptors, produced by drugs such as phencyclidine (PCP).  Accordingly, dopaminergic, serotonergic, and glutamatergic models of disrupted PPI have evolved and were applied to the identification of potential antipsychotic treatments.  In addn., some developmental manipulations, such as isolation rearing, have provided non-pharmacol. animal models of the PPI deficits seen in schizophrenia.  This review summarizes and evaluates studies assessing the effects of systemic drug administrations on PPI in rats.  Studies examg. systemic drug effects on PPI in rats prior to Jan. 15, 2001 were compiled and organized into 6 annotated appendices.  Based on this catalog of studies, the specific advantages and disadvantages of each of the 4 main PPI models used in the study of antipsychotic drugs were critically evaluated.  Despite some notable inconsistencies, the literature provides strong support for disruptions in PPI in rats produced by DA agonists, 5-HT2 agonists, NMDA antagonists, and isolation rearing.  Each of these models exhibits sensitivity to at least some antipsychotic medications.  While the PPI model based on the effects of direct DA agonists is the most well-validated for the identification of known antipsychotics, the isolation rearing model also appears to be sensitive to both typical and atypical antipsychotics.  The 5-HT PPI model is less generally sensitive to antipsychotic medications, but can provide insight into the contribution of serotonergic systems to the actions of newer antipsychotics that act upon multiple receptors.  The deficits in PPI produced by NMDA antagonists appear to be more sensitive to clozapine-like atypical antipsychotics than to typical antipsychotics.  Hence, despite some exceptions to this generalization, the NMDA PPI model might aid in the identification of novel or atypical antipsychotic medications.  Studies of drug effects on PPI in rats have generated 4 distinctive models that have utility in the identification of antipsychotic medications.  Because each of these models has specific advantages and disadvantages, the choice of model to be used depends upon the question being addressed.  This review should help to guide such decisions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMUgR_yJM15bVg90H21EOLACvtfcHk0lgMCRmuuTKOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtlCqtLY%253D&md5=dcf9c549a4a0063d55478351c784be31</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1007%2Fs002130100811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002130100811%26sid%3Dliteratum%253Aachs%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DKrebs-Thomson%26aufirst%3DK.%26aulast%3DBraff%26aufirst%3DD.%2BL.%26aulast%3DSwerdlow%26aufirst%3DN.%2BR.%26atitle%3DPharmacological%2520studies%2520of%2520prepulse%2520inhibition%2520models%2520of%2520sensorimotor%2520gating%2520deficits%2520in%2520schizophrenia%253A%2520a%2520decade%2520in%2520review%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2001%26volume%3D156%26spage%3D117%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group">Boksa, P.</span><span> </span><span class="NLM_article-title">Animal models of obstetric complications in relation to schizophrenia</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.brainresrev.2004.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15063096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2c7mvVGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=1-17&author=P.+Boksa&title=Animal+models+of+obstetric+complications+in+relation+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of obstetric complications in relation to schizophrenia</span></div><div class="casAuthors">Boksa Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Brain research. Brain research reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidemiological studies have provided strong evidence that exposure to obstetric complications is associated with an increased risk for later development of schizophrenia.  These human studies have now begun to tease out which specific pregnancy, labor/delivery or neonatal complications might confer greatest risk for schizophrenia.  Animal modeling can be a useful tool to directly ask if a particular obstetric complication can actually cause changes in brain function or behavior resembling changes in schizophrenia.  This review describes currently available animal models for some of the obstetric complications with greatest effect size for schizophrenia, including maternal diabetes, preeclampsia, infection and stress during pregnancy, intrauterine growth retardation and fetal/neonatal hypoxia.  Where available, evidence that these types of obstetric complications in animals produce alterations in CNS function or behavior, related to features of schizophrenic pathology, is presented.  Animal models might provide insights into the mechanisms by which specific obstetric complications have long-term influence on brain development leading to increased risk for schizophrenia.  Factors common to several obstetric complications associated with schizophrenia may also be discerned.  In this way, animal modeling may provide the framework for human studies to ask further more refined questions concerning the role of specific obstetric factors contributing to schizophrenia, and may provide clues to prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0XbAlyVeJhTToTC3aBaesfW6udTcc2eaZEk4LvptWv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7mvVGmtA%253D%253D&md5=9ccac532a2767c31b679f736ecd31634</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2004.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2004.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DBoksa%26aufirst%3DP.%26atitle%3DAnimal%2520models%2520of%2520obstetric%2520complications%2520in%2520relation%2520to%2520schizophrenia%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2004%26volume%3D45%26spage%3D1%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group">Lipska, B. K.</span><span> </span><span class="NLM_article-title">Using animal models to test a neurodevelopmental hypothesis of schizophrenia</span> <span class="citation_source-journal">J. Psychiatry Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15309044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2cvgsV2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=282-286&author=B.+K.+Lipska&title=Using+animal+models+to+test+a+neurodevelopmental+hypothesis+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Using animal models to test a neurodevelopmental hypothesis of schizophrenia</span></div><div class="casAuthors">Lipska Barbara K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">282-6</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">A series of studies has shown that neonatal excitotoxic disconnection of the rat ventral hippocampus may serve as a heuristic model of schizophrenia.  The model mimics a spectrum of neurobiologic and behavioural features of schizophrenia.  It produces functional pathology in critical brain regions implicated in schizophrenia and connected with the hippocampal formation, namely, the striatum, nucleus accumbens and the prefrontal cortex.  These brain regions are also targeted by antipsychotic drugs.  Neonatal insult leads in young adulthood to the emergence of abnormalities in a number of dopamine-related behaviours.  It also models some of the negative aspects of schizophrenia, such as social impairments and working memory deficits.  Moreover, our data show that even transient inactivation of the ventral hippocampus during a critical period of development that produces subtle anatomical changes in the hippocampus may be sufficient to trigger behavioural changes similar to those observed in animals with the permanent excitotoxic lesion.  The results of bromodeoxyuridine (BrdU) incorporation studies show that this transient disconnection in the CA1 and CA2 area of the hippocampus may have long-lasting consequences for neurogenesis in the dentate gyrus.  Our data suggest that neonatal disconnection of the ventral hippocampus alters development and plasticity of prefrontal cortical circuitry and produces a constellation of behavioural and cellular changes that mimic many aspects of schizophrenia.  The neonatal hippocampal disconnection model represents a potential new model of schizophrenia without a gross anatomical lesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZfG1UEEH_MmmbXvSEQle5fW6udTcc2eaZEk4LvptWv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvgsV2jtw%253D%253D&md5=e76bb25fc2e87911ff27b338ef3f5719</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipska%26aufirst%3DB.%2BK.%26atitle%3DUsing%2520animal%2520models%2520to%2520test%2520a%2520neurodevelopmental%2520hypothesis%2520of%2520schizophrenia%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2004%26volume%3D29%26spage%3D282%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group">Lipska, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaskiw, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1993&pages=67-75&author=B.+K.+Lipskaauthor=G.+E.+Jaskiwauthor=D.+R.+Weinberger&title=Postpubertal+emergence+of+hyperresponsiveness+to+stress+and+to+amphetamine+after+neonatal+excitotoxic+hippocampal+damage%3A+a+potential+animal+model+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipska%26aufirst%3DB.%2BK.%26aulast%3DJaskiw%26aufirst%3DG.%2BE.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DPostpubertal%2520emergence%2520of%2520hyperresponsiveness%2520to%2520stress%2520and%2520to%2520amphetamine%2520after%2520neonatal%2520excitotoxic%2520hippocampal%2520damage%253A%2520a%2520potential%2520animal%2520model%2520of%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D1993%26volume%3D9%26spage%3D67%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group">Daenen, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolterink, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerrits, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Ree, J. M.</span><span> </span><span class="NLM_article-title">Amygdala or ventral hippocampal lesions at two early stages of life differentially affect open field behaviour later in life; an animal model of neurodevelopmental psychopathological disorders</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0166-4328%2801%2900350-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11844573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD387ht1CmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2002&pages=67-78&author=E.+W.+Daenenauthor=G.+Wolterinkauthor=M.+A.+Gerritsauthor=J.+M.+van+Ree&title=Amygdala+or+ventral+hippocampal+lesions+at+two+early+stages+of+life+differentially+affect+open+field+behaviour+later+in+life%3B+an+animal+model+of+neurodevelopmental+psychopathological+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Amygdala or ventral hippocampal lesions at two early stages of life differentially affect open field behaviour later in life; an animal model of neurodevelopmental psychopathological disorders</span></div><div class="casAuthors">Daenen Elisabeth W P M; Wolterink Gerrit; Gerrits Mirjam A F M; Van Ree Jan M</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural brain research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">67-78</span>
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    </div><div class="casAbstract">Psychiatric disorders like schizophrenia or autism are thought to result from disruption of the normal pattern of brain development.  Abnormalities in the amygdaloid complex and hippocampus have been reported in these disorders.  In the present study rats were lesioned in the amygdala or ventral hippocampus on day 7 of life (immature brain) or day 21 of life (almost mature brain) and open field behaviour was determined later in life before and after puberty.  Lesioning on day 7 resulted in behavioural changes, interpreted as locomotor stereotypy and decreased anxiety in case of amygdala or hippocampus, respectively.  These effects were more profoundly present after puberty.  Lesioning on day 21 did not result in these behavioural changes, which subscribes to the importance of the stage of brain maturation on functional development.  The results suggest that the behavioural changes in rats lesioned on day 7 may due to a malfunctioning of structures connected to the amygdala or ventral hippocampus.  Brain lesions made on day 7 of life may serve as a potential model of psychopathological neurodevelopmental disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSV2jl0mqc5tO3MPKNEWB5RfW6udTcc2eaZEk4LvptWv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387ht1CmtQ%253D%253D&md5=ed5b0663464c51490e1e5a6032b2abfc</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1016%2FS0166-4328%2801%2900350-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-4328%252801%252900350-3%26sid%3Dliteratum%253Aachs%26aulast%3DDaenen%26aufirst%3DE.%2BW.%26aulast%3DWolterink%26aufirst%3DG.%26aulast%3DGerrits%26aufirst%3DM.%2BA.%26aulast%3Dvan%2BRee%26aufirst%3DJ.%2BM.%26atitle%3DAmygdala%2520or%2520ventral%2520hippocampal%2520lesions%2520at%2520two%2520early%2520stages%2520of%2520life%2520differentially%2520affect%2520open%2520field%2520behaviour%2520later%2520in%2520life%253B%2520an%2520animal%2520model%2520of%2520neurodevelopmental%2520psychopathological%2520disorders%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2002%26volume%3D131%26spage%3D67%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group">Joober, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boksa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benkelfat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouleau, G.</span><span> </span><span class="NLM_article-title">Genetics of schizophrenia: from animal models to clinical studies</span> <span class="citation_source-journal">J. Psychiatry Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">336</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12271789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD38vosFOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=336-347&author=R.+Jooberauthor=P.+Boksaauthor=C.+Benkelfatauthor=G.+Rouleau&title=Genetics+of+schizophrenia%3A+from+animal+models+to+clinical+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics of schizophrenia: from animal models to clinical studies</span></div><div class="casAuthors">Joober Ridha; Boksa Patricia; Benkelfat Chawki; Rouleau Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">336-47</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">Genetic epidemiological studies strongly suggest that additive and interactive genes, each with small effects, mediate the genetic vulnerability for schizophrenia.  With the human genome working draft at hand, candidate gene (and ultimately large-scale genome-wide) association studies are gaining renewed interest in the effort to unravel the complex genetics of schizophrenia.  In the absence of an unequivocally established biological theory for schizophrenia, identifying candidate genes to be tested in an association paradigm remains a challenging task.  We maintain that it is possible to use animal models to map genes or loci involved in behavioural traits that are relevant to schizophrenia.  The human genes (or syntenic loci) homologous to those identified in mice can subsequently be tested in patients with schizophrenia who have been carefully phenotyped for traits "isomorphic" to the ones modelled in mice.  If confirmed in humans, these genes may be further analyzed in the animal model to identify their role and the biological network they are involved in.  To tackle the complex and intimidating problem of the genetics of schizophrenia, it may be necessary to go from animal models to human studies and vice versa; this strategy has been proven to be efficient in less complicated, though complex, human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWW2loxrEJSZVVjGoY74BafW6udTcc2eaZEk4LvptWv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vosFOqtA%253D%253D&md5=e4f057d81ed404a0f541250761b86d95</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJoober%26aufirst%3DR.%26aulast%3DBoksa%26aufirst%3DP.%26aulast%3DBenkelfat%26aufirst%3DC.%26aulast%3DRouleau%26aufirst%3DG.%26atitle%3DGenetics%2520of%2520schizophrenia%253A%2520from%2520animal%2520models%2520to%2520clinical%2520studies%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2002%26volume%3D27%26spage%3D336%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group">Kellendonk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polan, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malleret, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vronskaya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winiger, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandel, E. R.</span><span> </span><span class="NLM_article-title">Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.neuron.2006.01.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16476668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFyjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=603-615&author=C.+Kellendonkauthor=E.+H.+Simpsonauthor=H.+J.+Polanauthor=G.+Malleretauthor=S.+Vronskayaauthor=V.+Winigerauthor=H.+Mooreauthor=E.+R.+Kandel&title=Transient+and+selective+overexpression+of+dopamine+D2+receptors+in+the+striatum+causes+persistent+abnormalities+in+prefrontal+cortex+functioning"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning</span></div><div class="casAuthors">Kellendonk, Christoph; Simpson, Eleanor H.; Polan, H. Jonathan; Malleret, Gael; Vronskaya, Svetlana; Winiger, Vanessa; Moore, Holly; Kandel, Eric R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">603-615</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Increased activity of D2 receptors (D2Rs) in the striatum has been linked to the pathophysiol. of schizophrenia.  To det. directly the behavioral and physiol. consequences of increased D2R function in the striatum, we generated mice with reversibly increased levels of D2Rs restricted to the striatum.  D2 transgenic mice exhibit selective cognitive impairments in working memory tasks and behavioral flexibility without more general cognitive deficits.  The deficit in the working memory task persists even after the transgene has been switched off, indicating that it results not from continued overexpression of D2Rs but from excess expression during development.  To det. the effects that may mediate the obsd. cognitive deficits, we analyzed the prefrontal cortex, the brain structure mainly assocd. with working memory.  We found that D2R overexpression in the striatum impacts dopamine levels, rates of dopamine turnover, and activation of D1 receptors in the prefrontal cortex, measures that are crit. for working memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBx2c7jWNhS7Vg90H21EOLACvtfcHk0licZbRnG3t6HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFyjtr0%253D&md5=1f974c993ee1b8f3b3fc126aad4ce721</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2006.01.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2006.01.023%26sid%3Dliteratum%253Aachs%26aulast%3DKellendonk%26aufirst%3DC.%26aulast%3DSimpson%26aufirst%3DE.%2BH.%26aulast%3DPolan%26aufirst%3DH.%2BJ.%26aulast%3DMalleret%26aufirst%3DG.%26aulast%3DVronskaya%26aufirst%3DS.%26aulast%3DWiniger%26aufirst%3DV.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DKandel%26aufirst%3DE.%2BR.%26atitle%3DTransient%2520and%2520selective%2520overexpression%2520of%2520dopamine%2520D2%2520receptors%2520in%2520the%2520striatum%2520causes%2520persistent%2520abnormalities%2520in%2520prefrontal%2520cortex%2520functioning%26jtitle%3DNeuron%26date%3D2006%26volume%3D49%26spage%3D603%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group">Almond, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fradley, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutter, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandon, N. J.</span><span> </span><span class="NLM_article-title">Behavioral and biochemical characterization of a mutant mouse strain lacking <span class="smallcaps smallerCapital">d</span>-amino acid oxidase activity and its implications for schizophrenia</span> <span class="citation_source-journal">Mol. Cell. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">324</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.mcn.2006.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16843004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2006&pages=324-334&author=S.+L.+Almondauthor=R.+L.+Fradleyauthor=E.+J.+Armstrongauthor=R.+B.+Heavensauthor=A.+R.+Rutterauthor=R.+J.+Newmanauthor=C.+S.+Chiuauthor=R.+Konnoauthor=P.+H.+Hutsonauthor=N.+J.+Brandon&title=Behavioral+and+biochemical+characterization+of+a+mutant+mouse+strain+lacking+d-amino+acid+oxidase+activity+and+its+implications+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia</span></div><div class="casAuthors">Almond, S. L.; Fradley, R. L.; Armstrong, E. J.; Heavens, R. B.; Rutter, A. R.; Newman, R. J.; Chiu, C. S.; Konno, R.; Hutson, P. H.; Brandon, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">324-334</span>CODEN:
                <span class="NLM_cas:coden">MOCNED</span>;
        ISSN:<span class="NLM_cas:issn">1044-7431</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Amino acid oxidase (DAO) degrades -serine, a co-agonist at the NMDA receptor (NMDAR).  Hypofunction of the NMDAR has been suggested to contribute to the pathophysiol. of schizophrenia.  Intriguingly, DAO has been recently identified as a risk factor for schizophrenia through genetic assocn. studies.  A naturally occurring mouse strain (ddY/DAO-) has been identified which lacks DAO activity.  We have characterized this strain both behaviorally and biochem. to evaluate DAO as a target for schizophrenia.  We have confirmed that this strain lacks DAO activity and shown for the first time it has increased occupancy of the NMDAR glycine site due to elevated extracellular D-serine levels and has enhanced NMDAR function in vivo.  Furthermore, the ddY/DAO- strain displays behaviors which suggest that it will be a useful tool for evaluation of the clin. benefit of DAO inhibition in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe3jOi1kOw0rVg90H21EOLACvtfcHk0licZbRnG3t6HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWrsr4%253D&md5=2b4ba43b50f49d5b035ba22042518c3e</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2Fj.mcn.2006.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mcn.2006.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DAlmond%26aufirst%3DS.%2BL.%26aulast%3DFradley%26aufirst%3DR.%2BL.%26aulast%3DArmstrong%26aufirst%3DE.%2BJ.%26aulast%3DHeavens%26aufirst%3DR.%2BB.%26aulast%3DRutter%26aufirst%3DA.%2BR.%26aulast%3DNewman%26aufirst%3DR.%2BJ.%26aulast%3DChiu%26aufirst%3DC.%2BS.%26aulast%3DKonno%26aufirst%3DR.%26aulast%3DHutson%26aufirst%3DP.%2BH.%26aulast%3DBrandon%26aufirst%3DN.%2BJ.%26atitle%3DBehavioral%2520and%2520biochemical%2520characterization%2520of%2520a%2520mutant%2520mouse%2520strain%2520lacking%2520d-amino%2520acid%2520oxidase%2520activity%2520and%2520its%2520implications%2520for%2520schizophrenia%26jtitle%3DMol.%2520Cell.%2520Neurosci.%26date%3D2006%26volume%3D32%26spage%3D324%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group">O’Tuathaigh, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babovic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Sullivan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clifford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tighe, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croke, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waddington, J. L.</span><span> </span><span class="NLM_article-title">Phenotypic characterization of spatial cognition and social behavior in mice with “knockout” of the schizophrenia risk gene neuregulin 1</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2007&pages=18-27&author=C.+M.+O%E2%80%99Tuathaighauthor=D.+Babovicauthor=G.+J.+O%E2%80%99Sullivanauthor=J.+J.+Cliffordauthor=O.+Tigheauthor=D.+T.+Crokeauthor=R.+Harveyauthor=J.+L.+Waddington&title=Phenotypic+characterization+of+spatial+cognition+and+social+behavior+in+mice+with+%E2%80%9Cknockout%E2%80%9D+of+the+schizophrenia+risk+gene+neuregulin+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Tuathaigh%26aufirst%3DC.%2BM.%26aulast%3DBabovic%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DG.%2BJ.%26aulast%3DClifford%26aufirst%3DJ.%2BJ.%26aulast%3DTighe%26aufirst%3DO.%26aulast%3DCroke%26aufirst%3DD.%2BT.%26aulast%3DHarvey%26aufirst%3DR.%26aulast%3DWaddington%26aufirst%3DJ.%2BL.%26atitle%3DPhenotypic%2520characterization%2520of%2520spatial%2520cognition%2520and%2520social%2520behavior%2520in%2520mice%2520with%2520%25E2%2580%259Cknockout%25E2%2580%259D%2520of%2520the%2520schizophrenia%2520risk%2520gene%2520neuregulin%25201%26jtitle%3DNeuroscience%26date%3D2007%26volume%3D147%26spage%3D18%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group">Clapcote, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipina, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millar, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerch, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trimble, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuraba, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiroishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkelman, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sled, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gondo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roder, J. C.</span><span> </span><span class="NLM_article-title">Behavioral phenotypes of Disc1 missense mutations in mice</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2007&pages=387-402&author=S.+J.+Clapcoteauthor=T.+V.+Lipinaauthor=J.+K.+Millarauthor=S.+Mackieauthor=S.+Christieauthor=F.+Ogawaauthor=J.+P.+Lerchauthor=K.+Trimbleauthor=M.+Uchiyamaauthor=Y.+Sakurabaauthor=H.+Kanedaauthor=T.+Shiroishiauthor=M.+D.+Houslayauthor=R.+M.+Henkelmanauthor=J.+G.+Sledauthor=Y.+Gondoauthor=D.+J.+Porteousauthor=J.+C.+Roder&title=Behavioral+phenotypes+of+Disc1+missense+mutations+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClapcote%26aufirst%3DS.%2BJ.%26aulast%3DLipina%26aufirst%3DT.%2BV.%26aulast%3DMillar%26aufirst%3DJ.%2BK.%26aulast%3DMackie%26aufirst%3DS.%26aulast%3DChristie%26aufirst%3DS.%26aulast%3DOgawa%26aufirst%3DF.%26aulast%3DLerch%26aufirst%3DJ.%2BP.%26aulast%3DTrimble%26aufirst%3DK.%26aulast%3DUchiyama%26aufirst%3DM.%26aulast%3DSakuraba%26aufirst%3DY.%26aulast%3DKaneda%26aufirst%3DH.%26aulast%3DShiroishi%26aufirst%3DT.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DHenkelman%26aufirst%3DR.%2BM.%26aulast%3DSled%26aufirst%3DJ.%2BG.%26aulast%3DGondo%26aufirst%3DY.%26aulast%3DPorteous%26aufirst%3DD.%2BJ.%26aulast%3DRoder%26aufirst%3DJ.%2BC.%26atitle%3DBehavioral%2520phenotypes%2520of%2520Disc1%2520missense%2520mutations%2520in%2520mice%26jtitle%3DNeuron%26date%3D2007%26volume%3D54%26spage%3D387%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group">Low, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, J.</span><span> </span><span class="NLM_article-title">What is a schizophrenic mouse?</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">348</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2007&pages=348-349&author=N.+C.+Lowauthor=J.+Hardy&title=What+is+a+schizophrenic+mouse%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DN.%2BC.%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DWhat%2520is%2520a%2520schizophrenic%2520mouse%253F%26jtitle%3DNeuron%26date%3D2007%26volume%3D54%26spage%3D348%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group">Sivagnanasundaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubank, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illingworth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skuse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scambler, P.</span><span> </span><span class="NLM_article-title">Differential gene expression in the hippocampus of the Df1/+ mice: a model for 22q11.2 deletion syndrome and schizophrenia</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1139</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.brainres.2007.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17292336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVWgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1139&publication_year=2007&pages=48-59&author=S.+Sivagnanasundaramauthor=D.+Fletcherauthor=M.+Hubankauthor=E.+Illingworthauthor=D.+Skuseauthor=P.+Scambler&title=Differential+gene+expression+in+the+hippocampus+of+the+Df1%2F%2B+mice%3A+a+model+for+22q11.2+deletion+syndrome+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Differential gene expression in the hippocampus of the Df1/+ mice: A model for 22q11.2 deletion syndrome and schizophrenia</span></div><div class="casAuthors">Sivagnanasundaram, Sinthuja; Fletcher, Danielle; Hubank, Mike; Illingworth, Elizabeth; Skuse, David; Scambler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-59</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Genes and a 3-Mb deletion mapping to human chromosome 22q11.2 have been implicated in 22q11.2 deletion syndrome (22q11.2DS) and schizophrenia.  The Df1 heterozygous (Df1/+) mice, a model for 22q11.2DS, display specific deficits in hippocampus-dependent learning and memory and impaired sensorimotor gating, abnormalities obsd. in patients with schizophrenia and 22q11.2DS.  In light of the analogous behavioral abnormalities obsd. between the Df1/+ mice and 22q11.2DS and schizophrenia resp., particularly in assocn. with the 22q11.2 deletion, the Df1/+ mice are suitable for investigating the mol. changes that may underlie the cognitive deficits and behavioral abnormalities arising as a result of this deletion.  Hence we applied microarray technol. to identify such mol. changes in the hippocampus at the transcript level.  Twelve genes mapping to the deleted region were reliably identified as expressed in the hippocampus by microarray anal. 159 other differentially expressed genes/ESTs were also identified.  Thus far differential expression of fifteen of these genes involved in signal transduction, synaptic plasticity, neuronal differentiation, microtubule assembly and ubiquitin pathway relevant to hippocampus mediated function have been confirmed by real-time PCR.  Of particular interest is the decreased expression (32%) of calmodulin 1, encoding a calcium-dependent protein involved in the calmodulin-calcineurin regulated pathway implicated in learning and memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqVsuRJ6JzF7Vg90H21EOLACvtfcHk0lgRBVwwqSdvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVWgsr4%253D&md5=4a0d2977527dd0c840ce4e1050192359</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2007.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2007.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DSivagnanasundaram%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DD.%26aulast%3DHubank%26aufirst%3DM.%26aulast%3DIllingworth%26aufirst%3DE.%26aulast%3DSkuse%26aufirst%3DD.%26aulast%3DScambler%26aufirst%3DP.%26atitle%3DDifferential%2520gene%2520expression%2520in%2520the%2520hippocampus%2520of%2520the%2520Df1%252F%252B%2520mice%253A%2520a%2520model%2520for%252022q11.2%2520deletion%2520syndrome%2520and%2520schizophrenia%26jtitle%3DBrain%2520Res.%26date%3D2007%26volume%3D1139%26spage%3D48%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group">Van den Buuse, M.</span><span> </span><span class="NLM_article-title">Prepulse inhibition of acoustic startle in spontaneously hypertensive rats</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.bbr.2004.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15313020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2cvgslyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2004&pages=331-337&author=M.+Van+den+Buuse&title=Prepulse+inhibition+of+acoustic+startle+in+spontaneously+hypertensive+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Prepulse inhibition of acoustic startle in spontaneously hypertensive rats</span></div><div class="casAuthors">van den Buuse Maarten</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural brain research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-7</span>
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    </div><div class="casAbstract">Prepulse inhibition is modulated by dopaminergic drugs and is disrupted in attention-deficit hyperactivity disorder, as well as mental illnesses such as schizophrenia.  Spontaneously hypertensive rats (SHR) have been proposed as an animal model of attention-deficit hyperactivity disorder and show marked alterations of dopaminergic regulation of behaviour.  SHR showed significantly lower startle amplitude than Wistar-Kyoto (WKY) rats and Sprague-Dawley (SD) rats, but no difference in startle habituation.  Baseline percentage prepulse inhibition was higher in SHR and WKY rats than in SD rats.  Treatment with amphetamine caused significant disruption of prepulse inhibition in SHR and WKY rats, but not SD rats.  In contrast, treatment with apomorphine caused prepulse-dependent disruption of prepulse inhibition in SD rats only.  Both MK-801 and 8-OH-DPAT treatment caused disruption of prepulse inhibition in all three rat strains.  This study shows differential changes in startle level and prepulse inhibition in SHR, however these rats are not uniformly different from either WKY rats or SD rats and WKY rats differ in a number of respects from SD rats.  In conclusion, these data further reveal altered dopaminergic regulation of behaviour in SHR, but also shows that caution is needed about the control strain used to compare these animals with.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZ6QQNnkMStJotVjB3IRIyfW6udTcc2ea1xNwxorz3Rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvgslyltQ%253D%253D&md5=15fc9f1552478284ac1923689eec67fb</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2004.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2004.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BBuuse%26aufirst%3DM.%26atitle%3DPrepulse%2520inhibition%2520of%2520acoustic%2520startle%2520in%2520spontaneously%2520hypertensive%2520rats%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2004%26volume%3D154%26spage%3D331%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group">Feifel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melendez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shilling, P. D.</span><span> </span><span class="NLM_article-title">Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=731-738&author=D.+Feifelauthor=G.+Melendezauthor=P.+D.+Shilling&title=Reversal+of+sensorimotor+gating+deficits+in+Brattleboro+rats+by+acute+administration+of+clozapine+and+a+neurotensin+agonist%2C+but+not+haloperidol%3A+a+potential+predictive+model+for+novel+antipsychotic+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeifel%26aufirst%3DD.%26aulast%3DMelendez%26aufirst%3DG.%26aulast%3DShilling%26aufirst%3DP.%2BD.%26atitle%3DReversal%2520of%2520sensorimotor%2520gating%2520deficits%2520in%2520Brattleboro%2520rats%2520by%2520acute%2520administration%2520of%2520clozapine%2520and%2520a%2520neurotensin%2520agonist%252C%2520but%2520not%2520haloperidol%253A%2520a%2520potential%2520predictive%2520model%2520for%2520novel%2520antipsychotic%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2004%26volume%3D29%26spage%3D731%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group">Feifel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melendez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shilling, P. D.</span><span> </span><span class="NLM_article-title">The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.bbr.2007.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17559953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2007&pages=278-286&author=D.+Feifelauthor=G.+Melendezauthor=K.+Priebeauthor=P.+D.+Shilling&title=The+effects+of+chronic+administration+of+established+and+putative+antipsychotics+on+natural+prepulse+inhibition+deficits+in+Brattleboro+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats</span></div><div class="casAuthors">Feifel, David; Melendez, Gilia; Priebe, Kristianne; Shilling, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-286</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We previously reported that vasopressin deficient Brattleboro (BRAT) rats exhibit deficits in prepulse inhibition (PPI) of the startle reflex that are consistent with PPI deficits exhibited by patients with schizophrenia and other neuropsychiatric disorders.  Preliminary evidence indicates that this may be the basis of a predictive model for antipsychotic drug efficacy.  Here we report the effects of acute and chronic administration of established and putative antipsychotics on these PPI deficits.  BRAT rats, compared to their deriv. strain, Long Evans rats, exhibited significantly decreased PPI and startle habituation consistent with patients with schizophrenia and other neuropsychiatric disorders.  The second generation antipsychotics, risperidone and clozapine as well as a neurotensin agonist (PD149163) increased BRAT rat PPI, whereas saline, the typical antipsychotic, haloperidol, and a vasopressin analog (1-desamino--arginine vasopressin) did not.  Similar to their effects in humans, chronic administration of antipsychotic drugs produced stronger effects than acute administration.  These results further support the BRAT rat as a model of sensorimotor gating deficits with predictive validity for antipsychotics.  The model appears to be able to differentiate first generation from second generation antipsychotics, identify putative antipsychotics with novel mechanisms (i.e., peptides) and reasonably model the therapeutic time course of antipsychotic drugs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzIur8GgxCSLVg90H21EOLACvtfcHk0lgRBVwwqSdvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFygtL8%253D&md5=4b6c630b4b4e3d4ed1bff491837c680f</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2007.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2007.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DFeifel%26aufirst%3DD.%26aulast%3DMelendez%26aufirst%3DG.%26aulast%3DPriebe%26aufirst%3DK.%26aulast%3DShilling%26aufirst%3DP.%2BD.%26atitle%3DThe%2520effects%2520of%2520chronic%2520administration%2520of%2520established%2520and%2520putative%2520antipsychotics%2520on%2520natural%2520prepulse%2520inhibition%2520deficits%2520in%2520Brattleboro%2520rats%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2007%26volume%3D181%26spage%3D278%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group">Olivier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groppi, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarnyai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span> </span><span class="NLM_article-title">The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs002130100828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11549230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtlCqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2001&pages=284-290&author=B.+Olivierauthor=C.+Leahyauthor=T.+Mullenauthor=R.+Paylorauthor=V.+E.+Groppiauthor=Z.+Sarnyaiauthor=D.+Brunner&title=The+DBA%2F2J+strain+and+prepulse+inhibition+of+startle%3A+a+model+system+to+test+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?</span></div><div class="casAuthors">Olivier, Berend; Leahy, Christina; Mullen, Tanner; Paylor, Richard; Groppi, Vincent E.; Sarnyai, Zoltan; Brunner, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">284-290</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Prepulse inhibition (PPI) of the startle response in mice is increasingly used as a paradigm of sensory gating with potential predictive and construct validity towards schizophrenia.  Establishment of a mouse PPI paradigm in which typical and atypical antipsychotic drugs directly improve a low performance PPI.  Three strains of mice - C57Bl/6J, 129S6/SvEvTac and DBA/2J - were tested in a startle paradigm with 3 prepulse intensities, 2, 4, and 8 dB above background.  Under these conditions, risperidone (0, 0.25, 0.5, and 1 mg/kg i.p.) and clozapine (0, 1, 3, and 9 mg/kg i.p.) improved PPI in all 3 strains, with order of effect in DBA/2J > 129S6/SvEvTac > C57Bl/6J.  The DBA/2J strain showed larger PPI-enhancing effects, without disturbing the basal startle response.  Two α7 nicotinic receptor agonists, GTS-21 (1-10 mg/kg i.p.) and AR-R17779 (1-10 mg/kg i.p.) were inactive in the PPI procedure in DBA/2J mice.  DBA/2J mice were very sensitive to the antipsychotic-like effects of atypical (clozapine) and typical (risperidone) antipsychotics, and this strain is proposed as a model to directly measure sensory gating properties of drugs.  α7 Nicotinergic receptor agonists were ineffective in this PPI paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYrWulmkGVrVg90H21EOLACvtfcHk0ljmO8QwN0R5pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtlCqurw%253D&md5=30db2d3ab455931c1dee97379da6b802</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1007%2Fs002130100828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002130100828%26sid%3Dliteratum%253Aachs%26aulast%3DOlivier%26aufirst%3DB.%26aulast%3DLeahy%26aufirst%3DC.%26aulast%3DMullen%26aufirst%3DT.%26aulast%3DPaylor%26aufirst%3DR.%26aulast%3DGroppi%26aufirst%3DV.%2BE.%26aulast%3DSarnyai%26aufirst%3DZ.%26aulast%3DBrunner%26aufirst%3DD.%26atitle%3DThe%2520DBA%252F2J%2520strain%2520and%2520prepulse%2520inhibition%2520of%2520startle%253A%2520a%2520model%2520system%2520to%2520test%2520antipsychotics%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2001%26volume%3D156%26spage%3D284%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group">Flood, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasior, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, M. J.</span><span> </span><span class="NLM_article-title">Variables affecting prepulse inhibition of the startle reflex and the response to antipsychotics in DBA/2NCrl mice</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-007-0894-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17668187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CltbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2007&pages=203-211&author=D.+G.+Floodauthor=M.+Gasiorauthor=M.+J.+Marino&title=Variables+affecting+prepulse+inhibition+of+the+startle+reflex+and+the+response+to+antipsychotics+in+DBA%2F2NCrl+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Variables affecting prepulse inhibition of the startle reflex and the response to antipsychotics in DBA/2NCrl mice</span></div><div class="casAuthors">Flood, Dorothy G.; Gasior, Maciej; Marino, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-211</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">DBA/2 mice demonstrate poor prepulse inhibition (PPI) as is also obsd. in schizophrenic patients, and their PPI is improved by antipsychotics.  Thus, the DBA/2 mouse is increasingly used for testing of novel antipsychotics in PPI; however, the strain has not been fully characterized for relevant variables affecting compd. testing.  The objectives of this study were to compare four DBA/2 substrains, evaluate light- and dark-phase testing on startle, PPI, and drug-induced improvement in PPI in DBA/2NCrl mice, test chamber lighting on startle and PPI in DBA/2NCrl mice and to evaluate vehicles on baseline PPI in DBA/2NCrl mice.  DBA/2NCrl and DBA/2J mice were acceptable for PPI testing, while DBA/2NHsd mice had diminished startle reflexes.  Startle responses to the prepulses alone were obsd. in 46% of the DBA/2NTac mice.  PPI and startle did not show diurnal variations or variations due to chamber lighting.  Olanzapine and aripiprazole showed better drug-induced improvements in PPI during the light phase.  The vehicle 25% (2-hydroxypropyl)-β-cyclodextrin variably improved PPI, an effect not obsd. with other vehicles.  DBA/2NHsd and DBA/2NTac mice were unacceptable for PPI expts.  The finding of responses to the prepulses alone by DBA/2NTac mice further indicates the advisability of routinely monitoring responses to prepulses alone.  Unlike rats, DBA/2NCrl mice did not have greater startle amplitudes during the dark phase.  Compd. efficacy was better during the light phase because of poorer PPI in the vehicle group.  Some vehicles may have unacceptable effects on PPI in DBA/2NCrl mice and may not be appropriate for studies evaluating novel compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwFwaoCxXHRrVg90H21EOLACvtfcHk0ljmO8QwN0R5pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CltbrN&md5=00ab647340a969ede579d8ed2feddb92</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1007%2Fs00213-007-0894-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-007-0894-9%26sid%3Dliteratum%253Aachs%26aulast%3DFlood%26aufirst%3DD.%2BG.%26aulast%3DGasior%26aufirst%3DM.%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26atitle%3DVariables%2520affecting%2520prepulse%2520inhibition%2520of%2520the%2520startle%2520reflex%2520and%2520the%2520response%2520to%2520antipsychotics%2520in%2520DBA%252F2NCrl%2520mice%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2007%26volume%3D195%26spage%3D203%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group">D’Hooge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Deyn, P. P.</span><span> </span><span class="NLM_article-title">Applications of the Morris water maze in the study of learning and memory</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0165-0173%2801%2900067-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11516773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3MvntFyitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2001&pages=60-90&author=R.+D%E2%80%99Hoogeauthor=P.+P.+De+Deyn&title=Applications+of+the+Morris+water+maze+in+the+study+of+learning+and+memory"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of the Morris water maze in the study of learning and memory</span></div><div class="casAuthors">D'Hooge R; De Deyn P P</div><div class="citationInfo"><span class="NLM_cas:title">Brain research. Brain research reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Morris water maze (MWM) was described 20 years ago as a device to investigate spatial learning and memory in laboratory rats.  In the meanwhile, it has become one of the most frequently used laboratory tools in behavioral neuroscience.  Many methodological variations of the MWM task have been and are being used by research groups in many different applications.  However, researchers have become increasingly aware that MWM performance is influenced by factors such as apparatus or training procedure as well as by the characteristics of the experimental animals (sex, species/strain, age, nutritional state, exposure to stress or infection).  Lesions in distinct brain regions like hippocampus, striatum, basal forebrain, cerebellum and cerebral cortex were shown to impair MWM performance, but disconnecting rather than destroying brain regions relevant for spatial learning may impair MWM performance as well.  Spatial learning in general and MWM performance in particular appear to depend upon the coordinated action of different brain regions and neurotransmitter systems constituting a functionally integrated neural network.  Finally, the MWM task has often been used in the validation of rodent models for neurocognitive disorders and the evaluation of possible neurocognitive treatments.  Through its many applications, MWM testing gained a position at the very core of contemporary neuroscience research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRf7R5RmXH7hRKDYG3bNImrfW6udTcc2eZZ6EPdOpJAjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvntFyitw%253D%253D&md5=dcf5c0168a705aae724bb4d7e0abccc4</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2FS0165-0173%2801%2900067-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-0173%252801%252900067-4%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DR.%26aulast%3DDe%2BDeyn%26aufirst%3DP.%2BP.%26atitle%3DApplications%2520of%2520the%2520Morris%2520water%2520maze%2520in%2520the%2520study%2520of%2520learning%2520and%2520memory%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2001%26volume%3D36%26spage%3D60%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group">Wilson, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. A.</span><span> </span><span class="NLM_article-title">Cholinergic manipulations and passive avoidance in the rat: effects on acquisition and recall</span> <span class="citation_source-journal">Acta Neurobiol. Exp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=7887188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK2M7ptlGntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=377-391&author=W.+J.+Wilsonauthor=J.+A.+Cook&title=Cholinergic+manipulations+and+passive+avoidance+in+the+rat%3A+effects+on+acquisition+and+recall"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinergic manipulations and passive avoidance in the rat: effects on acquisition and recall</span></div><div class="casAuthors">Wilson W J; Cook J A</div><div class="citationInfo"><span class="NLM_cas:title">Acta neurobiologiae experimentalis</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">377-91</span>
        ISSN:<span class="NLM_cas:issn">0065-1400</span>.
    </div><div class="casAbstract">A review of the literature concerning cholinergic manipulations and passive avoidance reveals that state-dependency is usually not controlled adequately, nor is acquisition of the passive avoidance task ascertained before retention is tested.  These problems make interpretation of results difficult.  We report three experiments on 129 rats, controlling both of these factors, in which scopolamine and pilocarpine impaired both acquisition and retention of a passive avoidance response.  Lesions of the nucleus basalis magnocellularis had no effect on this task.  The results suggest that an optimal level of central cholinergic activity exists for learning and memory, and that deviations from this optimal level impair acquisition and retention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNsan4zefecpcXNb62YGmbfW6udTcc2eYMcLplr690grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7ptlGntA%253D%253D&md5=d0823a052bc71795f34e1090604db0f7</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DW.%2BJ.%26aulast%3DCook%26aufirst%3DJ.%2BA.%26atitle%3DCholinergic%2520manipulations%2520and%2520passive%2520avoidance%2520in%2520the%2520rat%253A%2520effects%2520on%2520acquisition%2520and%2520recall%26jtitle%3DActa%2520Neurobiol.%2520Exp.%26date%3D1994%26volume%3D54%26spage%3D377%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubert, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenegre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milinkevitch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porsolt, R. D.</span><span> </span><span class="NLM_article-title">Effects of piracetam on indices of cognitive function in a delayed alternation task in young and aged rats</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">688</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0091-3057%2894%2990088-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=7862724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFaltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1994&pages=683-688&author=S.+Rouxauthor=I.+Hubertauthor=A.+Lenegreauthor=D.+Milinkevitchauthor=R.+D.+Porsolt&title=Effects+of+piracetam+on+indices+of+cognitive+function+in+a+delayed+alternation+task+in+young+and+aged+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of piracetam on indices of cognitive function in a delayed alteration task in young and aged rats</span></div><div class="casAuthors">Roux, Sylvain; Hubert, Isabelle; Lenegre, Antoine; Milinkevitch, Daniel; Porsolt, Roger D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">683-8</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The effects of piracetam (64, 128, and 256 mg/kg PO) on the performance of a delayed alternation in a Skinner Box were investigated.  Test sessions consisted of 36 trials during which animals were first presented with a single lever (left or right) followed 5, 10, or 20 s later by two levers.  A press on the lever opposite to that presented previously (nonmatching to sample) was rewarded.  The no. of correct responses and the reaction times to the one- and two-lever presentations were recorded.  All animals received all treatments in a balanced order.  Aged animals showed clear deficits on all three parameters.  Piracetam was without effect on the performance of young animals but dose-dependently decreased the choice reaction times (two levers) in aged animals without affecting the other two parameters.  These results suggest that piracetam does not affect short-term memory but may facilitate choice behavior in aged animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYYWvMpV-5GLVg90H21EOLACvtfcHk0liNgJLQJeWjfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFaltL8%253D&md5=5c2d497417d9026afac2c44b17878935</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1016%2F0091-3057%2894%2990088-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-3057%252894%252990088-4%26sid%3Dliteratum%253Aachs%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DHubert%26aufirst%3DI.%26aulast%3DLenegre%26aufirst%3DA.%26aulast%3DMilinkevitch%26aufirst%3DD.%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26atitle%3DEffects%2520of%2520piracetam%2520on%2520indices%2520of%2520cognitive%2520function%2520in%2520a%2520delayed%2520alternation%2520task%2520in%2520young%2520and%2520aged%2520rats%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D1994%26volume%3D49%26spage%3D683%26epage%3D688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group">Murphy, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGorry, P. D.</span><span> </span><span class="NLM_article-title">Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16930948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28nmsVeitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2006&pages=5-25&author=B.+P.+Murphyauthor=Y.+C.+Chungauthor=T.+W.+Parkauthor=P.+D.+McGorry&title=Pharmacological+treatment+of+primary+negative+symptoms+in+schizophrenia%3A+a+systematic+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review</span></div><div class="casAuthors">Murphy Brendan P; Chung Young-Chul; Park Tae-Won; McGorry Patrick D</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">5-25</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">BACKGROUND:  Optimal treatment of primary negative symptoms is important because their presence is associated with poor outcome.  AIMS:  To systematically review all studies dealing with the efficacy of pharmacological agents on primary negative symptoms.  METHOD:  A comprehensive search of the relevant literature was undertaken using electronic database, reference lists and personal contact.  RESULTS:  There is a lack of standardized research designs.  Amisulpride is the most extensively studied drug with respect to efficacy against primary negative symptoms.  At low doses it demonstrates a consistent, modest effect compared to placebo, though not to conventional antipsychotics and has yet to be tested against other atypicals.  Evidence from multiple studies that used simple statistical analyses and inclusion criteria for patients with primary negative symptoms does not support a direct effect for clozapine.  Path-analysis studies support the direct effects of risperidone, olanzapine, sertindole and aripiprazole, however, different statistical analyses of the same risperidone study produced conflicting results and the direct effects of olanzapine were not confirmed in selected patients with primary negative symptoms.  There are no studies supporting the use of ziprasidone or quetiapine.  The effects of typical antipsychotics on primary negative symptoms are inconclusive and likely to depend on drug dosages.  Selective serotonin reuptake inhibitors (SSRIs), mirtazepine and NMDA agonists show early promise but require further study.  Novel agents such as selegiline, naltrexone, dehydroepiandrosterone, galantamine, Ginkgo, nitric oxide, L-deprenyl and pergolide show positive effects on general negative symptoms but remain untested against primary negative symptoms.  CONCLUSIONS:  Further studies using standardized selective inclusion criteria and controlling for chronicity are needed.  Research guidelines are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4q2ys7r2A8sRAV4D_Ins_fW6udTcc2eYMcLplr690grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nmsVeitA%253D%253D&md5=446745a0581fea16f62f08d48b0676ac</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DB.%2BP.%26aulast%3DChung%26aufirst%3DY.%2BC.%26aulast%3DPark%26aufirst%3DT.%2BW.%26aulast%3DMcGorry%26aufirst%3DP.%2BD.%26atitle%3DPharmacological%2520treatment%2520of%2520primary%2520negative%2520symptoms%2520in%2520schizophrenia%253A%2520a%2520systematic%2520review%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D88%26spage%3D5%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group">Orthen-Gambill, N.</span><span> </span><span class="NLM_article-title">Sucrose intake unaffected by fenfluramine but suppressed by amphetamine administration</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2FBF00431772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=2997826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL2MXlsFeqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1985&pages=25-29&author=N.+Orthen-Gambill&title=Sucrose+intake+unaffected+by+fenfluramine+but+suppressed+by+amphetamine+administration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Sucrose intake unaffected by fenfluramine but suppressed by amphetamine administration</span></div><div class="casAuthors">Orthen-Gambill, Nilla</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-9</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">The acute effects of the anorectic agents, fenfluramine  [458-24-2] and amphetamine  [300-62-9], on nutrient selection were studied in male rats.  One group of animals received continuous access to both granulated sucrose  [57-50-1] and Purina chow (presented in sep. cups), while the other group received only Purina chow.  Four doses of fenfluramine (0, 1.5, 3.0, 6.0 mg/kg) and 4 doses of amphetamine (0, 0.5, 1.0, 2.0 mg/kg) were tested.  Injections were given at the beginning of the feeding period, and nutrient intakes were measured at 2, 4, and 8 h postinjection.  While both fenfluramine and amphetamine resulted in similar overall decreases in caloric intakes, the 2 drugs produced different effects on nutrient selection.  Following fenfluramine administration, sucrose intakes remained relatively unaffected, while Purina chow intakes showed pronounced suppression.  In contrast, amphetamine administration resulted in a more equal suppression of both sucrose and Purina chow intakes.  While the overall decreases in food intake seen with fenfluramine and amphetamine may be linked to changes in central neurotransmitter levels, the sparing of sucrose consumption obsd. with fenfluramine may also involve drug-induced changes in peripheral metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTms7_YGeEnbVg90H21EOLACvtfcHk0liNgJLQJeWjfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlsFeqsb0%253D&md5=f50bfd08304b105f964ff82cd880e477</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1007%2FBF00431772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00431772%26sid%3Dliteratum%253Aachs%26aulast%3DOrthen-Gambill%26aufirst%3DN.%26atitle%3DSucrose%2520intake%2520unaffected%2520by%2520fenfluramine%2520but%2520suppressed%2520by%2520amphetamine%2520administration%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D1985%26volume%3D87%26spage%3D25%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group">Wauquier, A.</span><span> </span><span class="NLM_article-title">Neuroleptics and brain self-stimulation behavior</span> <span class="citation_source-journal">Int. Rev. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0074-7742%2808%2960643-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=43847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL3cXhslCjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1979&pages=335-403&author=A.+Wauquier&title=Neuroleptics+and+brain+self-stimulation+behavior"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroleptics and brain self-stimulation behavior</span></div><div class="casAuthors">Wauquier, Albert</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">335-403</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    </div><div class="casAbstract">A review with 172 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWyPEeSbx6xbVg90H21EOLACvtfcHk0lgDWMd2OT4Lbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhslCjs70%253D&md5=8244e538245d15ffdd10f979d973b6a5</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1016%2FS0074-7742%2808%2960643-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0074-7742%252808%252960643-1%26sid%3Dliteratum%253Aachs%26aulast%3DWauquier%26aufirst%3DA.%26atitle%3DNeuroleptics%2520and%2520brain%2520self-stimulation%2520behavior%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D1979%26volume%3D21%26spage%3D335%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group">Turgeon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoge, S. G.</span><span> </span><span class="NLM_article-title">Prior exposure to phencyclidine decreases voluntary sucrose consumption and operant performance for food reward</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pbb.2003.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14643837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Cjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2003&pages=393-400&author=S.+M.+Turgeonauthor=S.+G.+Hoge&title=Prior+exposure+to+phencyclidine+decreases+voluntary+sucrose+consumption+and+operant+performance+for+food+reward"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Prior exposure to phencyclidine decreases voluntary sucrose consumption and operant performance for food reward</span></div><div class="casAuthors">Turgeon, Sarah M.; Hoge, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">393-400</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Prior exposure to the psychotomimetic drug phencyclidine (PCP) produces a no. of schizophrenia-like behaviors in animals.  The goal of the present study was to det. whether prior exposure to PCP produces decreased reward function, thereby modeling one aspect of neg. schizophrenic symptomatol.  To this aim, the consequences of prior exposure to PCP were assessed on two types of appetitive consumptive behavior.  In the first set of expts., the effects of PCP (15 mg/kg, 20 h before testing) on sucrose consumption were tested for three consecutive days under conditions of deprivation and nondeprivation.  In the deprivation condition, animals were water deprived for 4 h prior to injection of PCP or saline (SAL).  Twenty hours following the injection (24 h after the onset of water deprivation), animals were allowed access to either 5% sucrose or water for 30 min.  In the nondeprivation condition, 5% sucrose consumption was measured for 30 min, 20 h after PCP or SAL injection and water consumption was measured during the 23.5 h preceding sucrose consumption.  PCP decreased both sucrose and water consumption under deprivation conditions on the second and third day of testing but selectively decreased sucrose consumption under nondeprivation conditions on all three testing days.  LiCl (50 mg/kg, 20 h before testing) did not significantly reduce sucrose consumption in the nondeprivation paradigm, indicating that the effect of PCP was not due to conditioned taste aversion.  In the second expt., PCP (15 mg/kg, 20 h before testing) decreased operant performance when animals were switched from a continuous reinforcement schedule of food delivery to a fixed ratio (FR4) schedule.  Apomorphine (APO, 30 μg/kg, 30 min before testing), a pos. control, induced a similar performance deficit.  However, the PCP-induced deficit was not apparent until the third day of FR4 testing while the APO deficit was apparent on the first day.  The effects of PCP on sucrose consumption demonstrate PCP-induced decreases in reward function.  However, the delayed appearance of the PCP-induced decrease in operant performance suggests that these results may be better explained by a PCP-induced attentional deficit, also characteristic of schizophrenic psychopathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq38J7BfwyAsrVg90H21EOLACvtfcHk0lgDWMd2OT4Lbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Cjs7Y%253D&md5=371b9fe6b3afd4ff835bb175e7a547b8</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2003.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2003.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DTurgeon%26aufirst%3DS.%2BM.%26aulast%3DHoge%26aufirst%3DS.%2BG.%26atitle%3DPrior%2520exposure%2520to%2520phencyclidine%2520decreases%2520voluntary%2520sucrose%2520consumption%2520and%2520operant%2520performance%2520for%2520food%2520reward%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D2003%26volume%3D76%26spage%3D393%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group">Turgeon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulick, V. C.</span><span> </span><span class="NLM_article-title">Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">524</span><span class="NLM_x">–</span> <span class="NLM_lpage">530</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pbb.2007.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17320157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Ojsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2007&pages=524-530&author=S.+M.+Turgeonauthor=V.+C.+Hulick&title=Differential+effects+of+acute+and+subchronic+clozapine+and+haloperidol+on+phencyclidine-induced+decreases+in+voluntary+sucrose+consumption+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats</span></div><div class="casAuthors">Turgeon, Sarah M.; Hulick, Virginia C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">524-530</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prior exposure to the psychotomimetic drug phencyclidine (PCP) decreases voluntary sucrose consumption in rats.  This may be indicative of reduced reward function, a phenomenon assocd. with neg. schizophrenic symptomatol.  Given that atypical antipsychotics have been shown to ameliorate neg. symptoms of schizophrenia more effectively than typical neuroleptics, this effect should be reversed by clozapine but not haloperidol.  PCP (15 mg/kg) or saline was administered 20 h prior to testing for voluntary sucrose consumption in non-deprived rats.  In the acute expts., rats were treated with clozapine (5 mg/kg), haloperidol (0.2 mg/kg), or vehicle 45 min prior to testing.  In the subchronic expts., rats were treated with clozapine (3 mg/kg, bid), haloperidol (0.5 mg/kg, bid), or vehicle for 10 days prior to PCP administration.  Acute clozapine exacerbated the PCP-induced decrease in sucrose consumption without altering water consumption.  Acute haloperidol produced an overall decrease in sucrose consumption in both PCP-pretreated and control groups.  Subchronic treatment with clozapine, but not haloperidol, reversed PCP-induced decreases in sucrose consumption.  The synergistic effect of acute clozapine and PCP may reflect a PCP-induced increase in the reward-reducing properties of CLZ, normally seen only at higher doses.  The observation that subchronic clozapine, but not haloperidol, reversed PCP-induced decreases in sucrose consumption supports the hypothesis that this effect of PCP represents a plausible animal model for neg. schizophrenic symptomatol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVG1qRQG2wBrVg90H21EOLACvtfcHk0lgDWMd2OT4Lbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Ojsr0%253D&md5=820be135d6ec92fd70fb09f7c4430f07</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2007.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2007.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DTurgeon%26aufirst%3DS.%2BM.%26aulast%3DHulick%26aufirst%3DV.%2BC.%26atitle%3DDifferential%2520effects%2520of%2520acute%2520and%2520subchronic%2520clozapine%2520and%2520haloperidol%2520on%2520phencyclidine-induced%2520decreases%2520in%2520voluntary%2520sucrose%2520consumption%2520in%2520rats%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D2007%26volume%3D86%26spage%3D524%26epage%3D530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group">Gambill, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornetsky, C.</span><span> </span><span class="NLM_article-title">Effects of chronic d-amphetamine on social behavior of the rat: implications for an animal model of paranoid schizophrenia</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2FBF00426835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=826965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaE2sXjslKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1976&pages=215-223&author=J.+D.+Gambillauthor=C.+Kornetsky&title=Effects+of+chronic+d-amphetamine+on+social+behavior+of+the+rat%3A+implications+for+an+animal+model+of+paranoid+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of chronic d-amphetamine on social behavior of the rat:  implications for an animal model of paranoid schizophrenia</span></div><div class="casAuthors">Gambill, John D.; Kornetsky, Conan</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-23</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">Rats in a social colony were given increasing daily i.p. doses of d-amphetamine [51-64-9] ≤8 mg/kg.  Subordinant rats receiving d-amphetamine actively withdrew from social interactions by retreating to strategically defensible locations in the environment.  They remained hypervigilant of other rats and overreacted to their approaches by either fleeing or by defensively rearing and boxing.  On the other hand, when the dominant rat received the max. dose, it seemed totally oblivious to the other rats.  The responses to drug treatment in subordinant rats may provide a model for the social behavior of frightened paranoid schizophrenics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq70_O5gjA96rVg90H21EOLACvtfcHk0liHwhF_msPRXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXjslKmuw%253D%253D&md5=ab97ed498c7f33dfe724d5da8c84ebb5</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1007%2FBF00426835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00426835%26sid%3Dliteratum%253Aachs%26aulast%3DGambill%26aufirst%3DJ.%2BD.%26aulast%3DKornetsky%26aufirst%3DC.%26atitle%3DEffects%2520of%2520chronic%2520d-amphetamine%2520on%2520social%2520behavior%2520of%2520the%2520rat%253A%2520implications%2520for%2520an%2520animal%2520model%2520of%2520paranoid%2520schizophrenia%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D1976%26volume%3D50%26spage%3D215%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group">Knobbout, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellenbroek, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, A. R.</span><span> </span><span class="NLM_article-title">The influence of social structure on social isolation in amphetamine-treated Java monkeys (<i>Macaca fascicularis</i>)</span> <span class="citation_source-journal">Behav. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=417-429&author=D.+A.+Knobboutauthor=B.+A.+Ellenbroekauthor=A.+R.+Cools&title=The+influence+of+social+structure+on+social+isolation+in+amphetamine-treated+Java+monkeys+%28Macaca+fascicularis%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnobbout%26aufirst%3DD.%2BA.%26aulast%3DEllenbroek%26aufirst%3DB.%2BA.%26aulast%3DCools%26aufirst%3DA.%2BR.%26atitle%3DThe%2520influence%2520of%2520social%2520structure%2520on%2520social%2520isolation%2520in%2520amphetamine-treated%2520Java%2520monkeys%2520%2528Macaca%2520fascicularis%2529%26jtitle%3DBehav.%2520Pharmacol.%26date%3D1996%26volume%3D7%26spage%3D417%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group">Steinpreis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sokolowski, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papanikolaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salamone, J. D.</span><span> </span><span class="NLM_article-title">The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0091-3057%2894%2990162-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8208777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2cXitVyms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1994&pages=579-585&author=R.+E.+Steinpreisauthor=J.+D.+Sokolowskiauthor=A.+Papanikolaouauthor=J.+D.+Salamone&title=The+effects+of+haloperidol+and+clozapine+on+PCP-+and+amphetamine-induced+suppression+of+social+behavior+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of haloperidol and clozapine on PCP - and amphetamine-induced suppression of social behavior in the rat</span></div><div class="casAuthors">Steinpreis, Rhea E.; Sokolowski, Jonathan D.; Papanikolaou, Alex; Salamone, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">579-85</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    </div><div class="casAbstract">Previous work has shown that phencyclidine (PCP) and amphetamine decrease social behavior in rats.  The purpose of the present study was to det. the effects of the dopamine antagonists clozapine and haloperidol on PCP- and amphetamine-induced changes in rat social behavior.  An intruder paradigm was used, in which rats were injected with drug and placed into a stable home colony of three other rats.  Social behaviors were recorded for 30 min.  Both amphetamine (4.0 mg/kg) and PCP (4.0 mg/kg) substantially reduced social behavior.  Haloperidol and clozapine did not produce a general reversal of the effects of amphetamine or PCP on the total no. of social behaviors.  Nevertheless, 0.025 mg/kg haloperidol did reverse the effects of PCP and amphetamine on some of the specific social behaviors obsd. (side threats, mounting, crawling under).  Clozapine had no effect on reversing the actions of amphetamine on social behavior, but 2.0 mg/kg clozapine did reverse the effect of PCP on side threats and mounting.  These results indicate that DA antagonists do not restore normal social behavior in animals treated with PCP or amphetamine, but can reverse some of the effects of PCP or amphetamine on specific social behaviors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXb7eVBx_btLVg90H21EOLACvtfcHk0liHwhF_msPRXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitVyms7s%253D&md5=737454ca7d32fa30cbfdfc85eafc144c</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1016%2F0091-3057%2894%2990162-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-3057%252894%252990162-7%26sid%3Dliteratum%253Aachs%26aulast%3DSteinpreis%26aufirst%3DR.%2BE.%26aulast%3DSokolowski%26aufirst%3DJ.%2BD.%26aulast%3DPapanikolaou%26aufirst%3DA.%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520effects%2520of%2520haloperidol%2520and%2520clozapine%2520on%2520PCP-%2520and%2520amphetamine-induced%2520suppression%2520of%2520social%2520behavior%2520in%2520the%2520rat%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D1994%26volume%3D47%26spage%3D579%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group">Schlemmer, R. F.,  Jr.; Davis, J. M.</span><span> </span><span class="NLM_article-title">A Comparison of Three Psychotomimetic-Induced Models of Psychosis in Nonhuman Primate Social Colonies</span>. In  <span class="citation_source-book">Ethopharmacology: Primate Models of Neuropsychiatric Disorders</span>; <span class="NLM_contrib-group">Miczek, K. A.</span>, Ed.; <span class="NLM_publisher-name">Alan R. Liss</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1983</span><span class="NLM_x">; </span> <span class="NLM_fpage">33</span>− <span class="NLM_lpage">78</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1983&pages=33-78&author=R.+F.+Schlemmer&author=J.+M.+Davisauthor=K.+A.+Miczek&title=Ethopharmacology%3A+Primate+Models+of+Neuropsychiatric+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSchlemmer%26aufirst%3DR.%2BF.%26atitle%3DA%2520Comparison%2520of%2520Three%2520Psychotomimetic-Induced%2520Models%2520of%2520Psychosis%2520in%2520Nonhuman%2520Primate%2520Social%2520Colonies%26btitle%3DEthopharmacology%253A%2520Primate%2520Models%2520of%2520Neuropsychiatric%2520Disorders%26aulast%3DMiczek%26aufirst%3DK.%2BA.%26pub%3DAlan%2520R.%2520Liss%26date%3D1983%26spage%3D33%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span><span class="NLM_contrib-group">Goudie, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumnall, H. R.</span><span> </span><span class="NLM_article-title">Cyproheptadine resembles clozapine <i>in vivo</i> following both acute and chronic administration in rats</span> <span class="citation_source-journal">J. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1177%2F0269881107067076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17329298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Wksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=179-190&author=A.+J.+Goudieauthor=G.+D.+Cooperauthor=J.+C.+Coleauthor=H.+R.+Sumnall&title=Cyproheptadine+resembles+clozapine+in+vivo+following+both+acute+and+chronic+administration+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats</span></div><div class="casAuthors">Goudie, Andrew J.; Cooper, Gillian D.; Cole, Jon C.; Sumnall, Harry R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-190</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Cyproheptadine is a cheap, widely available anti-allergy drug with a broad receptor binding profile which resembles that of clozapine.  In rats discriminating clozapine from vehicle cyproheptadine mimicked clozapine very closely.  Acutely it induced full generalization in the absence of response suppression, as obsd. with clozapine.  Chronic administration of clozapine and cyproheptadine induced tolerance and cross-tolerance resp. to the clozapine stimulus.  This was characterized by circa 3.5-fold parallel shifts to the right in the clozapine generalization curves.  Such tolerance and cross-tolerance was spontaneously reversible, suggesting that it was pharmacodynamic, and that clozapine and cyproheptadine induce similar neuroadaptations when administered chronically.  Administration of chlordiazepoxide at a very high dose induced no cross-tolerance to the clozapine stimulus showing the pharmacol. specificity of tolerance.  The clozapine stimulus is a compd. cue involving actions at various receptors, and various clozapine-like antipsychotic (APD) drugs generalize fully to it.  These data demonstrate that in vivo cyproheptadine resembles clozapine both acutely and chronically.  The findings, in conjunction with other actions of cyproheptadine - induction of wt. gain, alleviation of clozapine withdrawal, anxiolytic actions, alleviation of 'typical' APD-induced motoric side effects, and some preliminary clin. findings - suggest that further study of cyproheptadine in conjunction with a 'typical' APD for the possible treatment of schizophrenia is merited at both pre-clin. and clin. levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokDPn1ZPQtELVg90H21EOLACvtfcHk0liHwhF_msPRXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Wksbw%253D&md5=f20cfb940640814b477f55a3f6d84345</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1177%2F0269881107067076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881107067076%26sid%3Dliteratum%253Aachs%26aulast%3DGoudie%26aufirst%3DA.%2BJ.%26aulast%3DCooper%26aufirst%3DG.%2BD.%26aulast%3DCole%26aufirst%3DJ.%2BC.%26aulast%3DSumnall%26aufirst%3DH.%2BR.%26atitle%3DCyproheptadine%2520resembles%2520clozapine%2520in%2520vivo%2520following%2520both%2520acute%2520and%2520chronic%2520administration%2520in%2520rats%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2007%26volume%3D21%26spage%3D179%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span><span class="NLM_contrib-group">Kikuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uwahodo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirose, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oshiro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, S.</span><span> </span><span class="NLM_article-title">7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1<i>H</i>)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=7616416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2MXntVWlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1995&pages=329-336&author=T.+Kikuchiauthor=K.+Tottoriauthor=Y.+Uwahodoauthor=T.+Hiroseauthor=T.+Miwaauthor=Y.+Oshiroauthor=S.+Morita&title=7-%284-%5B4-%282%2C3-Dichlorophenyl%29-1-piperazinyl%5Dbutyloxy%29-3%2C4-dihydro-2%281H%29-quinolinone+%28OPC-14597%29%2C+a+new+putative+antipsychotic+drug+with+both+presynaptic+dopamine+autoreceptor+agonistic+activity+and+postsynaptic+D2+receptor+antagonistic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">7-{4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity</span></div><div class="casAuthors">Kikuchi, Tetsuro; Tottori, Katsura; Uwahodo, Yasufumi; Hirose, Tsuyoshi; Miwa, Takashi; Oshiro, Yasuo; Morita, Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">329-36</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The effects of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a deriv. of the dopamine (DA) autoreceptor agonist 7-{3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy}-2(1H)-quinolinone (OPC-4392), on DA receptors were biochem. and behaviorally studied and compared with those of OPC-4392.  Both OPC-14597 and OPC-4392 inhibited reserpine- and gamma-butyrolactone (GBL)-induced increase in tyrosine hydroxylase activity in the mouse and rat brain.  The effects of OPC-14597 were comparable to those of OPC04392 and were completely antagonized by haloperidol.  OPC-14597, unlike apomorphine, did not evoke postsynaptic DA receptor-stimulating behavioral signs such as hyperlocomotion in the reserpinized mice and contralateral rotation in rats with unilateral striatal 6-hydroxydopamine lesions.  Both OPC-14597 and OPC-4392 inhibited such apomorphine-induced postsynaptic behavioral changes as stereotypy and hyperlocomotion in mice and rats and rotation in rats with unilateral striatal kainic acid lesions.  The anti-apomorphine effects of OPC-14597 were about 30 to 140 times greater than those of OPC-4392 and were obsd. at doses that inhibit the increases in tyrosine hydroxylase activity.  The affinities of OPC-14597 for 3H-spiperone-labeled D2 receptors in the rat frontal cortex, limbic forebrain and striatum were higher than those of OPC-4392.  These results suggest that OPC-14597 is a unique antipsychotic drug candidate, being a DA autoreceptor agonist that has a stronger postsynaptic D2 receptor antagonistic activity than that of OPC-4392.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9cUwebqVxn7Vg90H21EOLACvtfcHk0lhdql5cRmme7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntVWlt7c%253D&md5=37354f14ec4e30898ffe78848252bebc</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKikuchi%26aufirst%3DT.%26aulast%3DTottori%26aufirst%3DK.%26aulast%3DUwahodo%26aufirst%3DY.%26aulast%3DHirose%26aufirst%3DT.%26aulast%3DMiwa%26aufirst%3DT.%26aulast%3DOshiro%26aufirst%3DY.%26aulast%3DMorita%26aufirst%3DS.%26atitle%3D7-%25284-%255B4-%25282%252C3-Dichlorophenyl%2529-1-piperazinyl%255Dbutyloxy%2529-3%252C4-dihydro-2%25281H%2529-quinolinone%2520%2528OPC-14597%2529%252C%2520a%2520new%2520putative%2520antipsychotic%2520drug%2520with%2520both%2520presynaptic%2520dopamine%2520autoreceptor%2520agonistic%2520activity%2520and%2520postsynaptic%2520D2%2520receptor%2520antagonistic%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D274%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group">Hoyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boddeke, H. W.</span><span> </span><span class="NLM_article-title">Partial agonists, full agonists, antagonists: dilemmas of definition</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1993&pages=270-275&author=D.+Hoyerauthor=H.+W.+Boddeke&title=Partial+agonists%2C+full+agonists%2C+antagonists%3A+dilemmas+of+definition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoyer%26aufirst%3DD.%26aulast%3DBoddeke%26aufirst%3DH.%2BW.%26atitle%3DPartial%2520agonists%252C%2520full%2520agonists%252C%2520antagonists%253A%2520dilemmas%2520of%2520definition%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1993%26volume%3D14%26spage%3D270%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group">Meller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, M.</span><span> </span><span class="NLM_article-title">Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0014-2999%2888%2990413-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=2907486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL1cXmt1ehs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1988&pages=151-154&author=E.+Mellerauthor=A.+Enzauthor=M.+Goldstein&title=Absence+of+receptor+reserve+at+striatal+dopamine+receptors+regulating+cholinergic+neuronal+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity</span></div><div class="casAuthors">Meller, Emanuel; Enz, Albert; Goldstein, Menek</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">151-4</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">N-Propylnorapomorphine (NPA) dose dependently increased rat striatal acetylcholine levels [50% ED (ED50) = 18 μg/kg].  After irreversible dopamine (DA) receptor inactivation with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, neither the ED50 nor the slope of the dose-response curve for NPA was altered, whereas the maximal response was reduced to 56% of control.  Anal. of the results yielded a linear relationship between receptor occupancy and response (i.e. no receptor reserve).  In contrast, DA autoreceptors display a large receptor reserve for NPA.  Evidently, a differential receptor reserve at pre- vs. postsynaptic DA receptors in rat striatum accounts for the autoreceptor selectivity of DA agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQEoUNjhfV-rVg90H21EOLACvtfcHk0lhdql5cRmme7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmt1ehs78%253D&md5=22322b968d9eb9e86a4f2c96c699402e</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2888%2990413-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252888%252990413-X%26sid%3Dliteratum%253Aachs%26aulast%3DMeller%26aufirst%3DE.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DGoldstein%26aufirst%3DM.%26atitle%3DAbsence%2520of%2520receptor%2520reserve%2520at%2520striatal%2520dopamine%2520receptors%2520regulating%2520cholinergic%2520neuronal%2520activity%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1988%26volume%3D155%26spage%3D151%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group">Tamminga, C. A.</span><span> </span><span class="NLM_article-title">Partial dopamine agonists in the treatment of psychosis</span> <span class="citation_source-journal">J. Neural Transm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=411-420&author=C.+A.+Tamminga&title=Partial+dopamine+agonists+in+the+treatment+of+psychosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamminga%26aufirst%3DC.%2BA.%26atitle%3DPartial%2520dopamine%2520agonists%2520in%2520the%2520treatment%2520of%2520psychosis%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2002%26volume%3D109%26spage%3D411%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group">Benkert, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Siecheneder, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, H.</span><span> </span><span class="NLM_article-title">Dopamine agonists in schizophrenia: a review</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0924-977X%2895%2900022-H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8775758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2MXptlCms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=43-53&issue=Suppl.&author=O.+Benkertauthor=F.+Muller-Siechenederauthor=H.+Wetzel&title=Dopamine+agonists+in+schizophrenia%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonists in schizophrenia: a review</span></div><div class="casAuthors">Benkert, O.; Mueller-Siecheneder, F.; Wetzel, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">Suppl.</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with many refs.  Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochem. abnormality alone, indirect pharmacol. evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. pos. symptomatol.  Synthesis and release of dopamine as well as firing rates of dopaminergic neurons are controlled by stimulation of autoreceptors via a neg. feedback regulation.  Investigations on therapeutic effects of autoreceptor-nonselective dopamine agonists in schizophrenia have yielded inconsistent results.  Dopamine autoreceptor agonists like pramipexole, roxindole, talipexole and OPC-4392 as well as partial agonists like terguride and SDZ HDC 912 have been tested in pos. schizophrenic symptomatol. to reduce the postulated excess of central dopaminergic activity.  However, administration of autoreceptor-'selective' agonists did not result in a significant improvement of pos. symptoms.  In predominantly neg. schizophrenic symptomatol., a dopamine deficit rather than an excess has been hypothesized.  Consequently, a nonselective dopamine agonistic action could be effective in some neg. symptoms.  Current evidence from several open and one placebo-controlled clin. trial suggests that some dopamine autoreceptor agonists like pramipexole, roxindole and talipexole may produce a mild improvement of symptoms like affective flattening, depressed mood, alogia and avolition.  Nevertheless, these findings do not yet allow a reliable judgement and remain to be clarified by further double-blind placebo-controlled studies over a sufficient treatment duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpZegHtiVmUrVg90H21EOLACvtfcHk0lhdql5cRmme7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptlCms7g%253D&md5=7049529e49afc3344ef8c826d222b0c6</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=10.1016%2F0924-977X%2895%2900022-H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0924-977X%252895%252900022-H%26sid%3Dliteratum%253Aachs%26aulast%3DBenkert%26aufirst%3DO.%26aulast%3DMuller-Siecheneder%26aufirst%3DF.%26aulast%3DWetzel%26aufirst%3DH.%26atitle%3DDopamine%2520agonists%2520in%2520schizophrenia%253A%2520a%2520review%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D1995%26volume%3D5%26issue%3DSuppl%26spage%3D43%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group">Hirose, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span> </span><span class="NLM_article-title">Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist</span> <span class="citation_source-journal">J. Med. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=284-290&issue=Suppl.&author=T.+Hiroseauthor=T.+Kikuchi&title=Aripiprazole%2C+a+novel+antipsychotic+agent%3A+dopamine+D2+receptor+partial+agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirose%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DT.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520antipsychotic%2520agent%253A%2520dopamine%2520D2%2520receptor%2520partial%2520agonist%26jtitle%3DJ.%2520Med.%2520Invest.%26date%3D2005%26volume%3D52%26issue%3DSuppl%26spage%3D284%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group">Shapiro, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiodo, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R.</span><span> </span><span class="NLM_article-title">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1400</span><span class="NLM_x">–</span> <span class="NLM_lpage">1411</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1400-1411&author=D.+A.+Shapiroauthor=S.+Renockauthor=E.+Arringtonauthor=L.+A.+Chiodoauthor=L.+X.+Liuauthor=D.+R.+Sibleyauthor=B.+L.+Rothauthor=R.+Mailman&title=Aripiprazole%2C+a+novel+atypical+antipsychotic+drug+with+a+unique+and+robust+pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DD.%2BA.%26aulast%3DRenock%26aufirst%3DS.%26aulast%3DArrington%26aufirst%3DE.%26aulast%3DChiodo%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DL.%2BX.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMailman%26aufirst%3DR.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520atypical%2520antipsychotic%2520drug%2520with%2520a%2520unique%2520and%2520robust%2520pharmacology%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1400%26epage%3D1411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reavill, C.</span><span> </span><span class="NLM_article-title">Aripiprazole acts as a selective dopamine D2 receptor partial agonist</span> <span class="citation_source-journal">Expert. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1517%2F13543784.16.6.771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17501690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=771-775&author=M.+Woodauthor=C.+Reavill&title=Aripiprazole+acts+as+a+selective+dopamine+D2+receptor+partial+agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole acts as a selective dopamine D2 receptor partial agonist</span></div><div class="casAuthors">Wood, Martyn; Reavill, Charlie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">771-775</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacol. profile.  It has been claimed that partial agonism of the dopamine D2 and 5-HT1A receptors and antagonism of the 5-HT2 receptor contribute to the clin. profile of aripiprazole, a so-called dopamine- and 5-HT stabilizer.  However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole.  This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D2 receptor and does not affect 5-HT receptors at therapeutic doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWgIj2R8RUsLVg90H21EOLACvtfcHk0ljbsqJUKgVLng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOisrw%253D&md5=3fb0254fb1e67e4669e397ad3cbbc977</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.6.771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.6.771%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%26aulast%3DReavill%26aufirst%3DC.%26atitle%3DAripiprazole%2520acts%2520as%2520a%2520selective%2520dopamine%2520D2%2520receptor%2520partial%2520agonist%26jtitle%3DExpert.%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D771%26epage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group">Keck, P. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, S. L.</span><span> </span><span class="NLM_article-title">Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic</span> <span class="citation_source-journal">Expert. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=655-662&author=P.+E.+Keckauthor=S.+L.+McElroy&title=Aripiprazole%3A+a+partial+dopamine+D2+receptor+agonist+antipsychotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DP.%2BE.%26aulast%3DMcElroy%26aufirst%3DS.%2BL.%26atitle%3DAripiprazole%253A%2520a%2520partial%2520dopamine%2520D2%2520receptor%2520agonist%2520antipsychotic%26jtitle%3DExpert.%2520Opin.%2520Invest.%2520Drugs%26date%3D2003%26volume%3D12%26spage%3D655%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group">McCreary, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashby, C. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinders, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselink, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herremans, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Stuivenberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feenstra, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT<sub>1A</sub> receptor agonist potential antipsychotic drug</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=78-94&author=A.+C.+McCrearyauthor=J.+C.+Glennonauthor=C.+R.+Ashbyauthor=H.+Y.+Meltzerauthor=Z.+Liauthor=J.+H.+Reindersauthor=M.+B.+Hesselinkauthor=S.+K.+Longauthor=A.+H.+Herremansauthor=H.+van+Stuivenbergauthor=R.+W.+Feenstraauthor=C.+G.+Kruse&title=SLV313+%281-%282%2C3-dihydro-benzo%5B1%2C4%5Ddioxin-5-yl%29-4-+%5B5-%284-fluoro-phenyl%29-pyridin-3-ylmethyl%5D-piperazine+monohydrochloride%29%3A+a+novel+dopamine+D2+receptor+antagonist+and+5-HT1A+receptor+agonist+potential+antipsychotic+drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DGlennon%26aufirst%3DJ.%2BC.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DReinders%26aufirst%3DJ.%2BH.%26aulast%3DHesselink%26aufirst%3DM.%2BB.%26aulast%3DLong%26aufirst%3DS.%2BK.%26aulast%3DHerremans%26aufirst%3DA.%2BH.%26aulast%3Dvan%2BStuivenberg%26aufirst%3DH.%26aulast%3DFeenstra%26aufirst%3DR.%2BW.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DSLV313%2520%25281-%25282%252C3-dihydro-benzo%255B1%252C4%255Ddioxin-5-yl%2529-4-%2520%255B5-%25284-fluoro-phenyl%2529-pyridin-3-ylmethyl%255D-piperazine%2520monohydrochloride%2529%253A%2520a%2520novel%2520dopamine%2520D2%2520receptor%2520antagonist%2520and%25205-HT1A%2520receptor%2520agonist%2520potential%2520antipsychotic%2520drug%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D78%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbato, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heisternerg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira, N. A.</span><span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=446&author=H.+Y.+Meltzerauthor=L.+M.+Barbatoauthor=J.+Heisternergauthor=P.+P.+Yeungauthor=N.+A.+Shapira&title=A+randomized%2C+double-blind%2C+placebo-controlled+efficacy+and+safety+study+of+bifeprunox+as+treatment+for+patients+with+acutely+exacerbated+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DBarbato%26aufirst%3DL.%2BM.%26aulast%3DHeisternerg%26aufirst%3DJ.%26aulast%3DYeung%26aufirst%3DP.%2BP.%26aulast%3DShapira%26aufirst%3DN.%2BA.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520efficacy%2520and%2520safety%2520study%2520of%2520bifeprunox%2520as%2520treatment%2520for%2520patients%2520with%2520acutely%2520exacerbated%2520schizophrenia%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cussac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depoortere, R.</span><span> </span><span class="NLM_article-title">Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17659474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1Knsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=539-554&author=A.+Newman-Tancrediauthor=D.+Cussacauthor=R.+Depoortere&title=Neuropharmacological+profile+of+bifeprunox%3A+merits+and+limitations+in+comparison+with+other+third-generation+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics</span></div><div class="casAuthors">Newman-Tancredi, Adrian; Cussac, Didier; Depoortere, Ronan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (Thomson Scientific)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">539-554</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is characterized by a range of pos. and neg. symptoms, and cognitive deficits.  While pos. symptoms respond to current antipsychotic agents, neg. symptoms and cognitive deficits are often resistant to pharmacopea.  Thus research is now focused on developing third-generation antipsychotics that combine antagonism or partial agonism at dopamine D2-like receptors with agonism at serotonin 5-HT1A receptors.  Such an assocn. is anticipated to provide therapeutic benefits against a broader range of schizophrenia symptoms.  Bifeprunox is one such third-generation antipsychotic agent which acts as a partial agonist at D2-like receptors and is an efficacious agonist at 5-HT1A receptors, with little interaction at 5-HT2A/2C, muscarinic or histaminergic H1 receptors.  This review summarizes the pharmacol. profiles of the current antipsychotic agents and describes the rationale behind the development of third-generation antipsychotics.  It also evaluates current data concerning bifeprunox in comparison with currently available antipsychotics, as well as those that are still under clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojeH0wGFNm5bVg90H21EOLACvtfcHk0li3nHkvnqEy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1Knsrc%253D&md5=95f4f0b129c6127aa70477de9132db3a</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DDepoortere%26aufirst%3DR.%26atitle%3DNeuropharmacological%2520profile%2520of%2520bifeprunox%253A%2520merits%2520and%2520limitations%2520in%2520comparison%2520with%2520other%2520third-generation%2520antipsychotics%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D8%26spage%3D539%26epage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref276"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref276'); return false;" data-citation="" class="refNumLink">276</a></strong><div class="NLM_citation" id="cit276"><span><span class="NLM_contrib-group">Wadenberg, M.-L. G.</span><span> </span><span class="NLM_article-title">Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT<sub>1A</sub> receptors</span> <span class="citation_source-journal">Future Neurol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2217%2F14796708.2.2.153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2itrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=153-165&author=M.-L.+G.+Wadenberg&title=Bifeprunox%3A+a+novel+antipsychotic+agent+with+partial+agonist+properties+at+dopamine+D2+and+serotonin+5-HT1A+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors</span></div><div class="casAuthors">Wadenberg, Marie-Louise G.</div><div class="citationInfo"><span class="NLM_cas:title">Future Neurology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-165</span>CODEN:
                <span class="NLM_cas:coden">FNUEAM</span>;
        ISSN:<span class="NLM_cas:issn">1479-6708</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Most second-generation, atypical, dopamine (DA) D2/5-HT2 blocking antipsychotics still induce extrapyramidal side effects (EPS) in higher doses.  Wt. gain and metabolic disturbances are also a problem, and neg. and cognitive symptoms have not been sufficiently addressed.  The current brain DA mesolimbic hyperactive/mesocortical hypoactive hypothesis of schizophrenia suggests that DA D2/5-HT1A receptor partial agonist properties may be more efficacious with less side effects.  DA D2 receptor partial agonists may stabilize a hyperactive/hypoactive DA condition.  Addnl. 5-HT1A stimulation may enhance therapeutic efficacy and also improve EPS liability profile.  In clin. trials in schizophrenic patients, the novel DA D2/5-HT1A partial agonist bifeprunox indeed demonstrates therapeutic efficacy, a safe EPS profile and appears beneficial regarding wt. gain, prolactin, blood lipid and glucose levels and cardiac rhythm.  The data on bifeprunox are promising and suggest that combined DA D2/5-HT1A partial agonism may well be important properties for future-generation antipsychotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr-UMb2Am2ErVg90H21EOLACvtfcHk0li3nHkvnqEy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2itrw%253D&md5=4b9df0c72aeeb3cdc4a7e7b17ba55410</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.2217%2F14796708.2.2.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F14796708.2.2.153%26sid%3Dliteratum%253Aachs%26aulast%3DWadenberg%26aufirst%3DM.-L.%2BG.%26atitle%3DBifeprunox%253A%2520a%2520novel%2520antipsychotic%2520agent%2520with%2520partial%2520agonist%2520properties%2520at%2520dopamine%2520D2%2520and%2520serotonin%25205-HT1A%2520receptors%26jtitle%3DFuture%2520Neurol%26date%3D2007%26volume%3D2%26spage%3D153%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref277"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref277'); return false;" data-citation="" class="refNumLink">277</a></strong><div class="NLM_citation" id="cit277"><span><span class="NLM_contrib-group">Assie, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravailhe, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucillon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">Contrasting contribution of 5-hydroxytryptamine<sub>1A</sub> receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.105.087163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15987834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=265-272&author=M.+B.+Assieauthor=V.+Ravailheauthor=V.+Faucillonauthor=A.+Newman-Tancredi&title=Contrasting+contribution+of+5-hydroxytryptamine1A+receptor+activation+to+neurochemical+profile+of+novel+antipsychotics%3A+frontocortical+dopamine+and+hippocampal+serotonin+release+in+rat+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: Frontocortical dopamine and hippocampal serotonin release in rat brain</span></div><div class="casAuthors">Assie, Marie-Bernadette; Ravailhe, Veronique; Faucillon, Valerie; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-272</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several novel antipsychotics, such as aripiprazole, bifeprunox, SSR181507 [(3-exo)-8-benzoyl-N-(((2S)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl)methyl)-8-azabicyclo(3.2.1)octane-3-methanamine], and SLV313 [1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-piperazine], activate serotonin 5-hydroxytryptamine (5-HT)1A receptors.  Such activity is assocd. with enhanced treatment of neg. symptoms and cognitive deficits, which may be mediated by modulation of cerebral dopamine and serotonin levels.  We employed microdialysis coupled to high pressure liq. chromatog. with electrochem. detection to examine 5-HT1A receptor activation in the modulation of extracellular dopamine in medial prefrontal cortex and serotonin in hippocampus of freely moving rats.  The above compds. were compared with drugs that have less interaction with 5-HT1A receptors (clozapine, nemonapride, ziprasidone, olanzapine, risperidone, and haloperidol).  Hippocampal 5-HT was decreased by bifeprunox, SSR181507, SLV313, sarizotan, and nemonapride, effects similar to those seen with the 5-HT1A agonist, (+)-8-hydroxy-2-(di-n-propylamino)tetralin [(+)8-OH-DPAT], consistent with activation of 5-HT1A autoreceptors.  These decreases were reversed by the selective 5-HT1A antagonist, WAY100635 [N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide].  In contrast, haloperidol, risperidone, clozapine, olanzapine, ziprasidone, and aripiprazole did not significantly modify hippocampal serotonin levels.  In medial prefrontal cortex, dopamine levels were increased by SSR181507, SLV313, sarizotan, and (+)8-OH-DPAT.  These effects were reversed by WAY100635, indicating mediation by 5-HT1A receptors.  In contrast, the increases in dopamine levels induced by clozapine, risperidone, olanzapine, and ziprasidone were not blocked by WAY100635, consistent with predominant influence of other mechanisms in the actions of these drugs.  Haloperidol, nemonapride, and the D2 partial agonists, aripiprazole and bifeprunox, did not significantly alter dopamine release.  Taken together, these data demonstrate the diverse contribution of 5-HT1A receptor activation to the profile of antipsychotics and suggest that novel drugs selectively targeting D2 and 5-HT1A receptors may present distinctive therapeutic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBt7wOWcBBz7Vg90H21EOLACvtfcHk0li3nHkvnqEy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7rN&md5=02dd395718229c99a82c4e3db88dcb82</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.087163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.087163%26sid%3Dliteratum%253Aachs%26aulast%3DAssie%26aufirst%3DM.%2BB.%26aulast%3DRavailhe%26aufirst%3DV.%26aulast%3DFaucillon%26aufirst%3DV.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DContrasting%2520contribution%2520of%25205-hydroxytryptamine1A%2520receptor%2520activation%2520to%2520neurochemical%2520profile%2520of%2520novel%2520antipsychotics%253A%2520frontocortical%2520dopamine%2520and%2520hippocampal%2520serotonin%2520release%2520in%2520rat%2520brain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D265%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref278"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref278'); return false;" data-citation="" class="refNumLink">278</a></strong><div class="NLM_citation" id="cit278"><span><span class="NLM_contrib-group">Cosi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carilla-Durand, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assie, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ormiere, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maraval, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leduc, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">535</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ejphar.2006.01.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16554049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFGmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2006&pages=135-144&author=C.+Cosiauthor=E.+Carilla-Durandauthor=M.+B.+Assieauthor=A.+M.+Ormiereauthor=M.+Maravalauthor=N.+Leducauthor=A.+Newman-Tancredi&title=Partial+agonist+properties+of+the+antipsychotics+SSR181507%2C+aripiprazole+and+bifeprunox+at+dopamine+D2+receptors%3A+G+protein+activation+and+prolactin+release"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release</span></div><div class="casAuthors">Cosi, Cristina; Carilla-Durand, Elisabeth; Assie, Marie Bernadette; Ormiere, Anne Marie; Maraval, Mireille; Leduc, Nathalie; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">135-144</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dopamine D2 receptor antagonists induce hyperprolactinemia depending on the extent of D2 receptor blockade.  We compared the effects of the new antipsychotic agents SSR181507, bifeprunox, and SLV313 with those of aripiprazole, clozapine, and haloperidol, on functional measures of dopamine D2 receptor activity in vitro and in vivo: [35S]-GTPγS binding to membranes from Sf9 insect cells expressing human dopamine D2 Long (hD2 L) receptors, and serum prolactin levels in the rat.  All compds. antagonized apomorphine-induced G protein activation at dopamine hD2 L receptors.  Antagonist potencies of aripiprazole, bifeprunox and SLV313 were similar to haloperidol (pK b = 9.12), whereas SSR181507 (8.16) and clozapine (7.35) were less potent.  Haloperidol, SLV313 and clozapine were silent antagonists but SSR181507, bifeprunox and aripiprazole stimulated [35S]-GTPγS binding by 17.5%, 26.3% and 25.6%, resp., relative to 100 μM apomorphine (Emax = 100%). pEC50s were: SSR181507, 8.08; bifeprunox, 8.97; aripiprazole, 8.56.  These effects were antagonized by raclopride.  Following oral administration in vivo, the drugs increased prolactin release to different extents.  SLV313 and haloperidol potently (ED50 0.12 and 0.22 mg/kg p.o., resp.) stimulated prolactin release up to 86 and 83 ng/mL.  Aripiprazole potently (ED50 0.66 mg/kg p.o.) but partially (32 ng/mL) induced prolactin release.  SSR181507 (ED50 4.9 mg/kg p.o.) also partially (23 ng/mL) enhanced prolactin release.  Bifeprunox only weakly increased prolactin at high doses (13 ng/mL at 40 mg/kg) and clozapine only affected prolactin at the highest dose tested (41 ng/mL at 40 mg/kg).  Prolactin levels of the corresponding vehicle-treated animals were < 4.3 ng/mL.  These data show that (1) SSR181507, aripiprazole and bifeprunox, but not SLV313, are partial agonists at dopamine hD2 L receptors in vitro; (2) SSR181507, bifeprunox and aripiprazole exhibit reduced prolactin release in vivo compared with drugs that are neutral antagonists at dopamine D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrtKly85ekeLVg90H21EOLACvtfcHk0li3nHkvnqEy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFGmu74%253D&md5=f3d0bc9e55df9cfd8b48338824545c22</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.01.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.01.051%26sid%3Dliteratum%253Aachs%26aulast%3DCosi%26aufirst%3DC.%26aulast%3DCarilla-Durand%26aufirst%3DE.%26aulast%3DAssie%26aufirst%3DM.%2BB.%26aulast%3DOrmiere%26aufirst%3DA.%2BM.%26aulast%3DMaraval%26aufirst%3DM.%26aulast%3DLeduc%26aufirst%3DN.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DPartial%2520agonist%2520properties%2520of%2520the%2520antipsychotics%2520SSR181507%252C%2520aripiprazole%2520and%2520bifeprunox%2520at%2520dopamine%2520D2%2520receptors%253A%2520G%2520protein%2520activation%2520and%2520prolactin%2520release%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D535%26spage%3D135%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref279"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref279'); return false;" data-citation="" class="refNumLink">279</a></strong><div class="NLM_citation" id="cit279"><span><span class="NLM_contrib-group">Depoortere, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrault, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergis, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decobert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simiand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scatton, B.</span><span> </span><span class="NLM_article-title">SSR181507, a dopamine D2 receptor antagonist and 5-HT<sub>1A</sub> receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">–</span> <span class="NLM_lpage">1902</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1889-1902&author=R.+Depoortereauthor=D.+Boulayauthor=G.+Perraultauthor=O.+Bergisauthor=M.+Decobertauthor=D.+Franconauthor=M.+Jungauthor=J.+Simiandauthor=P.+Soubrieauthor=B.+Scatton&title=SSR181507%2C+a+dopamine+D2+receptor+antagonist+and+5-HT1A+receptor+agonist.+II%3A+Behavioral+profile+predictive+of+an+atypical+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDepoortere%26aufirst%3DR.%26aulast%3DBoulay%26aufirst%3DD.%26aulast%3DPerrault%26aufirst%3DG.%26aulast%3DBergis%26aufirst%3DO.%26aulast%3DDecobert%26aufirst%3DM.%26aulast%3DFrancon%26aufirst%3DD.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DSimiand%26aufirst%3DJ.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DScatton%26aufirst%3DB.%26atitle%3DSSR181507%252C%2520a%2520dopamine%2520D2%2520receptor%2520antagonist%2520and%25205-HT1A%2520receptor%2520agonist.%2520II%253A%2520Behavioral%2520profile%2520predictive%2520of%2520an%2520atypical%2520antipsychotic%2520activity%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1889%26epage%3D1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref280"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref280'); return false;" data-citation="" class="refNumLink">280</a></strong><div class="NLM_citation" id="cit280"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popadak, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">H<sub>1</sub>-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=519-526&author=W.+K.+Kroezeauthor=S.+J.+Hufeisenauthor=B.+A.+Popadakauthor=S.+M.+Renockauthor=S.+Steinbergauthor=P.+Ernsbergerauthor=K.+Jayathilakeauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=H1-histamine+receptor+affinity+predicts+short-term+weight+gain+for+typical+and+atypical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DPopadak%26aufirst%3DB.%2BA.%26aulast%3DRenock%26aufirst%3DS.%2BM.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DH1-histamine%2520receptor%2520affinity%2520predicts%2520short-term%2520weight%2520gain%2520for%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D519%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref281"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref281'); return false;" data-citation="" class="refNumLink">281</a></strong><div class="NLM_citation" id="cit281"><span><span class="NLM_contrib-group">Glassman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigger, J. T.,  Jr</span><span> </span><span class="NLM_article-title">Antipsychotic drugs: prolonged QTc interval, <i>torsade de pointes</i>, and sudden death</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">1774</span><span class="NLM_x">–</span> <span class="NLM_lpage">1782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.158.11.1774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11691681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3MnktVentQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=1774-1782&author=A.+H.+Glassmanauthor=J.+T.+Bigger&title=Antipsychotic+drugs%3A+prolonged+QTc+interval%2C+torsade+de+pointes%2C+and+sudden+death"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death</span></div><div class="casAuthors">Glassman A H; Bigger J T Jr</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1774-82</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The authors review the mechanisms and establish the risk of torsade de pointes and sudden death with antipsychotic drugs.  METHOD:  They present a review of original concepts, the distinction between familial and drug-induced cases of torsade de pointes, and the recognition of the role of noncardiac drugs in torsade de pointes and sudden death.  They review the evidence linking QTc interval prolongation, potassium channels, and torsade de pointes from both the long QT syndrome and drugs.  They examine the risk for torsade de pointes from antipsychotic drugs and estimate the frequency of sudden death on the basis of epidemiological data in normal and schizophrenic populations.  RESULTS:  All drugs that cause torsade de pointes prolong the QTc interval and bind to the potassium rectifier channel, but the relationships are not precise.  Prediction of torsade de pointes and sudden death can be improved by examining dose dependency, the percent of QTc intervals higher than 500 msec, and the risk of drug-drug interactions.  Although sudden unexpected death occurs almost twice as often in populations treated with antipsychotics as in normal populations, there are still only 10-15 such events in 10,000 person-years of observation.  CONCLUSIONS:  Although pimozide, sertindole, droperidol, and haloperidol have been documented to cause torsade de pointes and sudden death, the most marked risk is with thioridazine.  There is no association with olanzapine, quetiapine, or risperidone.  Ziprasidone does prolong the QT interval, but there is no evidence to suggest that this leads to torsade de pointes or sudden death.  Only widespread use will prove if ziprasidone is entirely safe.  To date, all antipsychotic drugs have the potential for serious adverse events.  Balancing these risks with the positive effects of treatment poses a challenge for psychiatry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSchHdwJKkRrP6AExegM5LLfW6udTcc2eaZRGoMOB-oULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnktVentQ%253D%253D&md5=e7ad13b4d164c94efaa27ac2052e9c3d</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.11.1774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.11.1774%26sid%3Dliteratum%253Aachs%26aulast%3DGlassman%26aufirst%3DA.%2BH.%26aulast%3DBigger%26aufirst%3DJ.%2BT.%26atitle%3DAntipsychotic%2520drugs%253A%2520prolonged%2520QTc%2520interval%252C%2520torsade%2520de%2520pointes%252C%2520and%2520sudden%2520death%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D1774%26epage%3D1782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref282"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref282'); return false;" data-citation="" class="refNumLink">282</a></strong><div class="NLM_citation" id="cit282"><span><span class="NLM_contrib-group">Straus, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleumink, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieleman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">’t Jong, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingma, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturkenboom, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stricker, B. H.</span><span> </span><span class="NLM_article-title">Antipsychotics and the risk of sudden cardiac death</span> <span class="citation_source-journal">Arch. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">1293</span><span class="NLM_x">–</span> <span class="NLM_lpage">1297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2004&pages=1293-1297&author=S.+M.+Strausauthor=G.+S.+Bleuminkauthor=J.+P.+Dielemanauthor=L.+J.+van+derauthor=G.+W.+%E2%80%99t+Jongauthor=J.+H.+Kingmaauthor=M.+C.+Sturkenboomauthor=B.+H.+Stricker&title=Antipsychotics+and+the+risk+of+sudden+cardiac+death"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStraus%26aufirst%3DS.%2BM.%26aulast%3DBleumink%26aufirst%3DG.%2BS.%26aulast%3DDieleman%26aufirst%3DJ.%2BP.%26aulast%3Dvan%2Bder%26aufirst%3DL.%2BJ.%26aulast%3D%25E2%2580%2599t%2BJong%26aufirst%3DG.%2BW.%26aulast%3DKingma%26aufirst%3DJ.%2BH.%26aulast%3DSturkenboom%26aufirst%3DM.%2BC.%26aulast%3DStricker%26aufirst%3DB.%2BH.%26atitle%3DAntipsychotics%2520and%2520the%2520risk%2520of%2520sudden%2520cardiac%2520death%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D2004%26volume%3D164%26spage%3D1293%26epage%3D1297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref283"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref283'); return false;" data-citation="" class="refNumLink">283</a></strong><div class="NLM_citation" id="cit283"><span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koro, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">L’Italien, G. J.</span><span> </span><span class="NLM_article-title">The metabolic syndrome and schizophrenia: a review</span> <span class="citation_source-journal">Int. Rev. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1080%2F09540260500071798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16194788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MritFCjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=173-180&author=J.+Meyerauthor=C.+E.+Koroauthor=G.+J.+L%E2%80%99Italien&title=The+metabolic+syndrome+and+schizophrenia%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic syndrome and schizophrenia: a review</span></div><div class="casAuthors">Meyer Jonathan; Koro Carol E; L'Italien Gilbert J</div><div class="citationInfo"><span class="NLM_cas:title">International review of psychiatry (Abingdon, England)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-80</span>
        ISSN:<span class="NLM_cas:issn">0954-0261</span>.
    </div><div class="casAbstract">The clinical phenomenon described as the metabolic syndrome has received considerable attention both in the recent medical literature and popular press.  Many of the sequelae of events attributable to newer atypical antipsychotics are consistent with the metabolic syndrome definition.  This article describes and summarizes the information available on metabolic syndrome in the mental illness disease area and the proposed mechanisms for the increased prevalence of the metabolic syndrome in this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_XZQ_6ygeS4IRAdBLKY41fW6udTcc2eaZRGoMOB-oULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MritFCjuw%253D%253D&md5=2d7f9b4d4a591f33cc4d4afb782f2eb7</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1080%2F09540260500071798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09540260500071798%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DKoro%26aufirst%3DC.%2BE.%26aulast%3DL%25E2%2580%2599Italien%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520metabolic%2520syndrome%2520and%2520schizophrenia%253A%2520a%2520review%26jtitle%3DInt.%2520Rev.%2520Psychiatry%26date%3D2005%26volume%3D17%26spage%3D173%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref284"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref284'); return false;" data-citation="" class="refNumLink">284</a></strong><div class="NLM_citation" id="cit284"><span><span class="NLM_contrib-group">Goudie, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halford, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dovey, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neill, J. C.</span><span> </span><span class="NLM_article-title">H<sub>1</sub>-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2209</span><span class="NLM_x">–</span> <span class="NLM_lpage">2211</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=2209-2211&author=A.+J.+Goudieauthor=J.+C.+Halfordauthor=T.+M.+Doveyauthor=G.+D.+Cooperauthor=J.+C.+Neill&title=H1-histamine+receptor+affinity+predicts+short-term+weight+gain+for+typical+and+atypical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoudie%26aufirst%3DA.%2BJ.%26aulast%3DHalford%26aufirst%3DJ.%2BC.%26aulast%3DDovey%26aufirst%3DT.%2BM.%26aulast%3DCooper%26aufirst%3DG.%2BD.%26aulast%3DNeill%26aufirst%3DJ.%2BC.%26atitle%3DH1-histamine%2520receptor%2520affinity%2520predicts%2520short-term%2520weight%2520gain%2520for%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D2209%26epage%3D2211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref285"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref285'); return false;" data-citation="" class="refNumLink">285</a></strong><div class="NLM_citation" id="cit285"><span><span class="NLM_contrib-group">Kim, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snowman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teuscher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">3456</span><span class="NLM_x">–</span> <span class="NLM_lpage">3459</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3456-3459&author=S.+F.+Kimauthor=A.+S.+Huangauthor=A.+M.+Snowmanauthor=C.+Teuscherauthor=S.+H.+Snyder&title=Antipsychotic+drug-induced+weight+gain+mediated+by+histamine+H1+receptor-linked+activation+of+hypothalamic+AMP-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BF.%26aulast%3DHuang%26aufirst%3DA.%2BS.%26aulast%3DSnowman%26aufirst%3DA.%2BM.%26aulast%3DTeuscher%26aufirst%3DC.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DAntipsychotic%2520drug-induced%2520weight%2520gain%2520mediated%2520by%2520histamine%2520H1%2520receptor-linked%2520activation%2520of%2520hypothalamic%2520AMP-kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D3456%26epage%3D3459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref286"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref286'); return false;" data-citation="" class="refNumLink">286</a></strong><div class="NLM_citation" id="cit286"><span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenga, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calligaro, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemrick-Luecke, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisenbaum, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaus, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundquist, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tupper, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiernicki, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. L.</span><span> </span><span class="NLM_article-title">Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4<i>H</i>-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H<sub>1</sub> receptor affinity than olanzapine</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">1265</span><span class="NLM_x">–</span> <span class="NLM_lpage">1277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.105.089326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16141369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlalurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=1265-1277&author=K.+Rasmussenauthor=M.+J.+Benvengaauthor=F.+P.+Bymasterauthor=D.+O.+Calligaroauthor=I.+R.+Cohenauthor=J.+F.+Falconeauthor=S.+K.+Hemrick-Lueckeauthor=F.+M.+Martinauthor=N.+A.+Mooreauthor=L.+K.+Nisenbaumauthor=J.+M.+Schausauthor=S.+J.+Sundquistauthor=D.+E.+Tupperauthor=T.+R.+Wiernickiauthor=D.+L.+Nelson&title=Preclinical+pharmacology+of+FMPD+%5B6-fluoro-10-%5B3-%282-methoxyethyl%29-4-methyl-piperazin-1-yl%5D-2-methyl-4H-3-thia-4%2C9-diaza-benzo%5Bf%5Dazulene%5D%3A+a+potential+novel+antipsychotic+with+lower+histamine+H1+receptor+affinity+than+olanzapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]:A potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine</span></div><div class="casAuthors">Rasmussen, Kurt; Benvenga, Mark J.; Bymaster, Frank P.; Calligaro, David O.; Cohen, Ilene R.; Falcone, Julie F.; Hemrick-Luecke, Susan K.; Martin, Fionna M.; Moore, Nicholas A.; Nisenbaum, Laura K.; Schaus, John M.; Sundquist, Sarah J.; Tupper, David E.; Wiernicki, Todd R.; Nelson, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1265-1277</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene] is a potential novel antipsychotic with high affinity for dopamine D2 (Ki = 6.3 nM), 5-HT2A (Ki = 7.3 nM), and 5-HT6 (Ki = 8.0 nM) human recombinant receptors and lower affinity for histamine H1 (Ki = 30 nM) and 5-HT2C (Ki = 102 nM) human recombinant receptors than olanzapine.  Oral administration of FMPD increased rat nucleus accumbens 3,4-dihyroxyphenylacetic acid concns. (ED200 = 6 mg/kg), blocked 5-HT2A agonist-induced increases in rat serum corticosterone levels (ED50 = 1.8 mg/kg), and inhibited the ex vivo binding of [125I]SB-258585 [4-iodo-N-[4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]- benzenesulfonamide] to striatal 5-HT6 receptors (ED50 = 10 mg/kg) but failed to inhibit ex vivo binding of [3H]pyrilamine to hypothalamic histamine H1 receptors at doses of up to 30 mg/kg.  In electrophysiol. studies, acute administration of FMPD selectively elevated the no. of spontaneously active A10 (vs. A9) dopamine neurons and chronic administration selectively decreased the no. of spontaneously active A10 (vs. A9) dopamine neurons.  FMPD did not produce catalepsy at doses lower than 25 mg/kg p.o.  In Fos-induction studies, FMPD had an atypical antipsychotic profile in the striatum and nucleus accumbens and increased Fos expression in orexin-contg. neurons of the hypothalamus.  FMPD produced only a transient elevation of prolactin levels.  These data indicate that FMPD is an orally available potent antagonist of dopamine D2, 5-HT2A, and 5-HT6 receptors and a weak antagonist of H1 and 5-HT2C receptors.  FMPD has the potential to have efficacy in treating schizophrenia and bipolar mania with a low risk of treatment-emergent extrapyramidal symptoms, prolactin elevation, and wt. gain.  Clin. trials are needed to test these hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrphTNFAvhZjLVg90H21EOLACvtfcHk0ljcxhBatPQuVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlalurnK&md5=11bb1fabd4cc6f820041ce4f0fd4e725</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.089326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.089326%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DBenvenga%26aufirst%3DM.%2BJ.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DCohen%26aufirst%3DI.%2BR.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DHemrick-Luecke%26aufirst%3DS.%2BK.%26aulast%3DMartin%26aufirst%3DF.%2BM.%26aulast%3DMoore%26aufirst%3DN.%2BA.%26aulast%3DNisenbaum%26aufirst%3DL.%2BK.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DSundquist%26aufirst%3DS.%2BJ.%26aulast%3DTupper%26aufirst%3DD.%2BE.%26aulast%3DWiernicki%26aufirst%3DT.%2BR.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26atitle%3DPreclinical%2520pharmacology%2520of%2520FMPD%2520%255B6-fluoro-10-%255B3-%25282-methoxyethyl%2529-4-methyl-piperazin-1-yl%255D-2-methyl-4H-3-thia-4%252C9-diaza-benzo%255Bf%255Dazulene%255D%253A%2520a%2520potential%2520novel%2520antipsychotic%2520with%2520lower%2520histamine%2520H1%2520receptor%2520affinity%2520than%2520olanzapine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D1265%26epage%3D1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref287"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref287'); return false;" data-citation="" class="refNumLink">287</a></strong><div class="NLM_citation" id="cit287"><span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroup, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvoy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swartz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenheck, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefe, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao, J. K.</span><span> </span><span class="NLM_article-title">Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">1209</span><span class="NLM_x">–</span> <span class="NLM_lpage">1223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1056%2FNEJMoa051688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16172203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=1209-1223&author=J.+A.+Liebermanauthor=T.+S.+Stroupauthor=J.+P.+McEvoyauthor=M.+S.+Swartzauthor=R.+A.+Rosenheckauthor=D.+O.+Perkinsauthor=R.+S.+Keefeauthor=S.+M.+Davisauthor=C.+E.+Davisauthor=B.+D.+Lebowitzauthor=J.+Severeauthor=J.+K.+Hsiao&title=Effectiveness+of+antipsychotic+drugs+in+patients+with+chronic+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</span></div><div class="casAuthors">Lieberman, Jeffrey A.; Stroup, T. Scott; McEvoy, Joseph P.; Swartz, Marvin S.; Rosenheck, Robert A.; Perkins, Diana O.; Keefe, Richard S. E.; Davis, Sonia M.; Davis, Clarence E.; Lebowitz, Barry D.; Severe, Joanne; Hsiao, John K.; Adler, L.; Bari, M.; Belz, I.; Bland, R.; Blocher, T.; Bolyard, B.; Buffenstein, A.; Burruss, J.; Byerly, M.; Canive, J.; Caroff, S.; Casat, C.; Chavez-Rice, E.; Csernansky, J.; Delgado, P.; Douyon, R.; D'Souza, C.; Glick, I.; Goff, D.; Gratz, S.; Grossberg, G. T.; Hale, M.; Hamner, M.; Jaffe, R.; Jeste, D.; Kablinger, A.; Khan, A.; Lamberti, S.; Levy, M. T.; Lieberman, J. A.; Maguire, G.; Manschreck, T.; McEvoy, J.; McGee, M.; Meltzer, H.; Miller, A.; Miller, D. D.; Nastrallah, H.; Nemeroff, C.; Olson, S.; Oxenkrug, G. F.; Patel, J.; Reimherr, F.; Riggio, S.; Risch, S.; Saltz, B.; Simpatico, T.; Simpson, G.; Smith, M.; Sommi, R.; Steinbook, R. M.; Stevens, M.; Tapp, A.; Torres, R.; Weiden, P.; Wolberg, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1209-1223</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly.  We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study.  A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 mo.  Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration.  The primary aim was to delineate differences in the overall effectiveness of these five treatments.  Overall, 74% of patients discontinued the study medication before 18 mo (1061 of the 1432 patients who received at least one dose): 64% of those assigned to olanzapine, 75% of those assigned to perphenazine, 82% of those assigned to quetiapine, 74% of those assigned to risperidone, and 79% of those assigned to ziprasidone.  The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P < 0.001) or risperidone (P = 0.002) group, but not in the perphenazine (P = 0.021) or ziprasidone (P = 0.028) group.  The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P = 0.04); olanzapine was assocd. with more discontinuation for wt. gain or metabolic effects, and perphenazine was assocd. with more discontinuation for extrapyramidal effects.  The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons.  Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional anti-psychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.  Olanzapine was assocd. with greater wt. gain and increases in measures of glucose and lipid metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod3gBNEmBl1LVg90H21EOLACvtfcHk0ljcxhBatPQuVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeltL%252FN&md5=d7fee36157ec0240ebef0813791335ec</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051688%26sid%3Dliteratum%253Aachs%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DStroup%26aufirst%3DT.%2BS.%26aulast%3DMcEvoy%26aufirst%3DJ.%2BP.%26aulast%3DSwartz%26aufirst%3DM.%2BS.%26aulast%3DRosenheck%26aufirst%3DR.%2BA.%26aulast%3DPerkins%26aufirst%3DD.%2BO.%26aulast%3DKeefe%26aufirst%3DR.%2BS.%26aulast%3DDavis%26aufirst%3DS.%2BM.%26aulast%3DDavis%26aufirst%3DC.%2BE.%26aulast%3DLebowitz%26aufirst%3DB.%2BD.%26aulast%3DSevere%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DJ.%2BK.%26atitle%3DEffectiveness%2520of%2520antipsychotic%2520drugs%2520in%2520patients%2520with%2520chronic%2520schizophrenia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D1209%26epage%3D1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref288"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref288'); return false;" data-citation="" class="refNumLink">288</a></strong><div class="NLM_citation" id="cit288"><span><a href="http://www.clinicaltrials.gov/ct/search?term=schiophrenia" class="extLink">www.clinicaltrials.gov/ct/search?term=schiophrenia</a>. <div class="note"><p class="first last">Accessed Aug 4, 2007.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=www.clinicaltrials.gov%2Fct%2Fsearch%3Fterm%3Dschiophrenia.+Accessed+Aug+4%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref289"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref289'); return false;" data-citation="" class="refNumLink">289</a></strong><div class="NLM_citation" id="cit289"><span><span class="NLM_contrib-group">Simard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Reekum, R.</span><span> </span><span class="NLM_article-title">The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies</span> <span class="citation_source-journal">J. Neuropsychiatry Clin. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15616167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVWmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=409-425&author=M.+Simardauthor=R.+van+Reekum&title=The+acetylcholinesterase+inhibitors+for+treatment+of+cognitive+and+behavioral+symptoms+in+dementia+with+Lewy+bodies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies</span></div><div class="casAuthors">Simard, Martine; van Reekum, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuropsychiatry and Clinical Neurosciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">409-425</span>CODEN:
                <span class="NLM_cas:coden">JNCNE7</span>;
        ISSN:<span class="NLM_cas:issn">0895-0172</span>.
    
            (<span class="NLM_cas:orgname">American Psychiatric Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Dementia with Lewy bodies (DLB) is a common cause of dementia with effects on cognition, mood, behavior, and function.  Changes in the acetylcholine system have been reported in brains of patients with DLB, which provides a rationale for trials of acetylcholinesterase inhibitors in DLB.  This review includes all English-language publications found via Medline and related to the efficacy and/or safety of these compds. in DLB.  Preliminary data suggest that these compds. may be efficacious in DLB and that future randomized clin. trials are strongly needed.  Methodol. limitations of the existing data include small sample sizes, and the paucity of standardized psychometric measures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwQRigQlcg1rVg90H21EOLACvtfcHk0liIHkVKix_kLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVWmtg%253D%253D&md5=3416ccfe7e2bacba9b3b6d2483b2df23</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DM.%26aulast%3Dvan%2BReekum%26aufirst%3DR.%26atitle%3DThe%2520acetylcholinesterase%2520inhibitors%2520for%2520treatment%2520of%2520cognitive%2520and%2520behavioral%2520symptoms%2520in%2520dementia%2520with%2520Lewy%2520bodies%26jtitle%3DJ.%2520Neuropsychiatry%2520Clin.%2520Neurosci.%26date%3D2004%26volume%3D16%26spage%3D409%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref290"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref290'); return false;" data-citation="" class="refNumLink">290</a></strong><div class="NLM_citation" id="cit290"><span><span class="NLM_contrib-group">McKeith, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Ser, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesnes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cicin-Sain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiegel, R.</span><span> </span><span class="NLM_article-title">Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">2031</span><span class="NLM_x">–</span> <span class="NLM_lpage">2036</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2000&pages=2031-2036&author=I.+McKeithauthor=T.+Del+Serauthor=P.+Spanoauthor=M.+Emreauthor=K.+Wesnesauthor=R.+Anandauthor=A.+Cicin-Sainauthor=R.+Ferraraauthor=R.+Spiegel&title=Efficacy+of+rivastigmine+in+dementia+with+Lewy+bodies%3A+a+randomised%2C+double-blind%2C+placebo-controlled+international+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeith%26aufirst%3DI.%26aulast%3DDel%2BSer%26aufirst%3DT.%26aulast%3DSpano%26aufirst%3DP.%26aulast%3DEmre%26aufirst%3DM.%26aulast%3DWesnes%26aufirst%3DK.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DCicin-Sain%26aufirst%3DA.%26aulast%3DFerrara%26aufirst%3DR.%26aulast%3DSpiegel%26aufirst%3DR.%26atitle%3DEfficacy%2520of%2520rivastigmine%2520in%2520dementia%2520with%2520Lewy%2520bodies%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520international%2520study%26jtitle%3DLancet%26date%3D2000%26volume%3D356%26spage%3D2031%26epage%3D2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref291"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref291'); return false;" data-citation="" class="refNumLink">291</a></strong><div class="NLM_citation" id="cit291"><span><span class="NLM_contrib-group">Shea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKnight, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockwood, K.</span><span> </span><span class="NLM_article-title">Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients</span> <span class="citation_source-journal">Int. Psychogeriatr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS1041610298005341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9785144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1M%252FgtFehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=229-238&author=C.+Sheaauthor=C.+MacKnightauthor=K.+Rockwood&title=Donepezil+for+treatment+of+dementia+with+Lewy+bodies%3A+a+case+series+of+nine+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit291R"><div class="casContent"><span class="casTitleNuber">291</span><div class="casTitle"><span class="NLM_cas:atitle">Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients</span></div><div class="casAuthors">Shea C; MacKnight C; Rockwood K</div><div class="citationInfo"><span class="NLM_cas:title">International psychogeriatrics / IPA</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-38</span>
        ISSN:<span class="NLM_cas:issn">1041-6102</span>.
    </div><div class="casAbstract">Dementia with Lewy bodies (DLB) is common.  Symptomatic treatment can be difficult.  We reviewed nine consecutive patients with DLB (mean age 77.5 [range 67 to 84] years; seven men and two women; mean duration of disease 3.7 [range 1.5 to 8.0] years) who had been treated with donepezil.  Each initially received 2.5 to 5 mg per day of donepezil, and was stabilized on 5 mg per day.  Donepezil was increased to 10 mg per day in five patients.  The mean observation period was 12 (range 8 to 24) weeks.  Target symptoms included cognition, hallucinations, parkinsonism, and functional abilities.  By both cognitive testing and family reports, cognition improved in seven of nine patients, remained the same in one of nine, and fluctuated in one of nine (mean Mini-Mental State Examination change 4.4 +/- 6.3 points).  Function was improved or maintained in six of nine patients and fluctuated in two of nine.  Hallucinations initially worsened, then fluctuated in one patient, but improvement in frequency, duration, and content was reported in eight of nine cases.  In three of nine patients, treatment with donepezil resulted in worsening of parkinsonism, which in each case responded to levodopa/carbidopa.  Treatment of DLB patients with donepezil for 12 weeks most commonly improved hallucinations, and sometimes improved cognition and overall function.  Treatment with donepezil was sometimes associated with worse parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWpYaQZZjmxf6BottYdIAWfW6udTcc2eaOegU2wlkPurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FgtFehsQ%253D%253D&md5=e7a6bceae64edaf3c2b5ee84f3857e35</span></div><a href="/servlet/linkout?suffix=cit291&amp;dbid=16384&amp;doi=10.1017%2FS1041610298005341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1041610298005341%26sid%3Dliteratum%253Aachs%26aulast%3DShea%26aufirst%3DC.%26aulast%3DMacKnight%26aufirst%3DC.%26aulast%3DRockwood%26aufirst%3DK.%26atitle%3DDonepezil%2520for%2520treatment%2520of%2520dementia%2520with%2520Lewy%2520bodies%253A%2520a%2520case%2520series%2520of%2520nine%2520patients%26jtitle%3DInt.%2520Psychogeriatr.%26date%3D1998%26volume%3D10%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref292"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref292'); return false;" data-citation="" class="refNumLink">292</a></strong><div class="NLM_citation" id="cit292"><span><span class="NLM_contrib-group">Shannon, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swedberg, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeppesen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheardown, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauerberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink-Jensen, A.</span><span> </span><span class="NLM_article-title">Xanomeline, an M<sub>1</sub>/M<sub>4</sub> preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0920-9964%2899%2900138-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10785583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3c3kvFShug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2000&pages=249-259&author=H.+E.+Shannonauthor=K.+Rasmussenauthor=F.+P.+Bymasterauthor=J.+C.+Hartauthor=S.+C.+Petersauthor=M.+D.+Swedbergauthor=L.+Jeppesenauthor=M.+J.+Sheardownauthor=P.+Sauerbergauthor=A.+Fink-Jensen&title=Xanomeline%2C+an+M1%2FM4+preferring+muscarinic+cholinergic+receptor+agonist%2C+produces+antipsychotic-like+activity+in+rats+and+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit292R"><div class="casContent"><span class="casTitleNuber">292</span><div class="casTitle"><span class="NLM_cas:atitle">Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice</span></div><div class="casAuthors">Shannon H E; Rasmussen K; Bymaster F P; Hart J C; Peters S C; Swedberg M D; Jeppesen L; Sheardown M J; Sauerberg P; Fink-Jensen A</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-59</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Xanomeline is an M(1)/M(4) preferring muscarinic receptor agonist which decreased psychotic behaviors in patients with Alzheimer's disease, suggesting that xanomeline might be useful in the treatment of psychotic symptoms in patients with schizophrenia.  The purpose of the present studies was, therefore, to compare the pharmacologic profile of xanomeline with that of known antipsychotic drugs.  Electrophysiologically, xanomeline, after both acute and chronic administration in rats, inhibited A10 but not A9 dopamine cells in a manner which was blocked by the muscarinic receptor antagonist scopolamine.  Behaviorally, xanomeline, like haloperidol, clozapine and olanzapine, blocked dopamine agonist-induced turning in unilateral 6-hydroxydopamine-lesioned rats, as well as apomorphine-induced climbing in mice.  However, unlike the dopamine antagonist antipsychotic haloperidol, xanomeline did not produce catalepsy in rats.  Moreover, xanomeline, like haloperidol, clozapine and olanzapine, inhibited conditioned avoidance responding in rats, an effect which also was blocked by scopolamine.  The present results thus demonstrate that xanomeline has a pharmacologic profile which is similar to that of the atypical antipsychotics clozapine and olanzapine, thus indicating that xanomeline has the potential to be a novel approach in the treatment of psychotic symptoms in patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTihsHSLfSgZ3y-c-E1v-fmfW6udTcc2eZFTFvzWzMfMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3kvFShug%253D%253D&md5=34ff0cecc296de723491b20f0d6f864c</span></div><a href="/servlet/linkout?suffix=cit292&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2899%2900138-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252899%252900138-3%26sid%3Dliteratum%253Aachs%26aulast%3DShannon%26aufirst%3DH.%2BE.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DHart%26aufirst%3DJ.%2BC.%26aulast%3DPeters%26aufirst%3DS.%2BC.%26aulast%3DSwedberg%26aufirst%3DM.%2BD.%26aulast%3DJeppesen%26aufirst%3DL.%26aulast%3DSheardown%26aufirst%3DM.%2BJ.%26aulast%3DSauerberg%26aufirst%3DP.%26aulast%3DFink-Jensen%26aufirst%3DA.%26atitle%3DXanomeline%252C%2520an%2520M1%252FM4%2520preferring%2520muscarinic%2520cholinergic%2520receptor%2520agonist%252C%2520produces%2520antipsychotic-like%2520activity%2520in%2520rats%2520and%2520mice%26jtitle%3DSchizophr.%2520Res.%26date%3D2000%26volume%3D42%26spage%3D249%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref293"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref293'); return false;" data-citation="" class="refNumLink">293</a></strong><div class="NLM_citation" id="cit293"><span><span class="NLM_contrib-group">Bodick, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offen, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levey, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutler, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tollefson, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, S. M.</span><span> </span><span class="NLM_article-title">Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease</span> <span class="citation_source-journal">Arch. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchneur.1997.00550160091022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9109749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK2s3mtlyktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1997&pages=465-473&author=N.+C.+Bodickauthor=W.+W.+Offenauthor=A.+I.+Leveyauthor=N.+R.+Cutlerauthor=S.+G.+Gauthierauthor=A.+Satlinauthor=H.+E.+Shannonauthor=G.+D.+Tollefsonauthor=K.+Rasmussenauthor=F.+P.+Bymasterauthor=D.+J.+Hurleyauthor=W.+Z.+Potterauthor=S.+M.+Paul&title=Effects+of+xanomeline%2C+a+selective+muscarinic+receptor+agonist%2C+on+cognitive+function+and+behavioral+symptoms+in+Alzheimer+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit293R"><div class="casContent"><span class="casTitleNuber">293</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease</span></div><div class="casAuthors">Bodick N C; Offen W W; Levey A I; Cutler N R; Gauthier S G; Satlin A; Shannon H E; Tollefson G D; Rasmussen K; Bymaster F P; Hurley D J; Potter W Z; Paul S M</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">465-73</span>
        ISSN:<span class="NLM_cas:issn">0003-9942</span>.
    </div><div class="casAbstract">OBJECTIVE:  To evaluate the therapeutic effects of selective cholinergic replacement with xanomeline tartrate, an m1 and m4 selective muscarinic receptor (mAChR) agonist in patients with probable Alzheimer disease (AD).  DESIGN:  A 6-month, randomized, double-blind, placebo-controlled, parallel-group trial followed by a 1-month, single-blind, placebo washout.  SETTING:  Outpatients at 17 centers in the United States and Canada.  PARTICIPANTS:  A total of 343 men and women at least 60 years of age with mild to moderate AD.  INTERVENTIONS:  Patients received 75, 150, or 225 mg (low, medium, and high doses) of xanomeline per day or placebo for 6 months.  OUTCOME MEASURES:  Scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog), the Clinician's Interview-Based Impression of Change (CIBIC+), the Alzheimer's Disease Symptomatology Scale (ADSS), and the Nurses' Observational Scale for Geriatric Patients (NOSGER).  RESULTS:  A significant treatment effect existed for ADAS-Cog (high dose vs placebo; P < or = .05), and CIBIC+ (high dose vs placebo; P < or = .02).  Treatment Emergent Signs and Symptoms analysis of the ADSS, which assesses behavioral symptoms in patients with AD, disclosed significant (P < or = .002) dose-dependent reductions in vocal outbursts, suspiciousness, delusions, agitation, and hallucinations.  On end-point analysis, NOSGER, which assesses memory, instrumental activities of daily living, self-care, mood, social behavior, and disturbing behavior in the elderly, also showed a significant dose-response relationship (P < or = .02).  In the high-dose arm, 52% of patients discontinued treatment because of adverse events; dose-dependent adverse events were predominantly gastrointestinal in nature.  Syncope, defined as loss of consciousness and muscle tone, occurred in 12.6% of patients in the high-dose group.  CONCLUSIONS:  The observed improvements in ADAS-Cog and CIBIC+ following treatment with xanomeline provide the first evidence, from a large-scale, placebo-controlled clinical trial, that a direct-acting muscarinic receptor agonist can improve cognitive function in patients with AD.  Furthermore, the dramatic and favorable effects on disturbing behaviors in AD suggest a novel approach for treatment of noncognitive symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5beLwC0CkxUGy1nwu7K2mfW6udTcc2eZFTFvzWzMfMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3mtlyktQ%253D%253D&md5=a1d8d3b2b495133fb37078d387136243</span></div><a href="/servlet/linkout?suffix=cit293&amp;dbid=16384&amp;doi=10.1001%2Farchneur.1997.00550160091022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneur.1997.00550160091022%26sid%3Dliteratum%253Aachs%26aulast%3DBodick%26aufirst%3DN.%2BC.%26aulast%3DOffen%26aufirst%3DW.%2BW.%26aulast%3DLevey%26aufirst%3DA.%2BI.%26aulast%3DCutler%26aufirst%3DN.%2BR.%26aulast%3DGauthier%26aufirst%3DS.%2BG.%26aulast%3DSatlin%26aufirst%3DA.%26aulast%3DShannon%26aufirst%3DH.%2BE.%26aulast%3DTollefson%26aufirst%3DG.%2BD.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DHurley%26aufirst%3DD.%2BJ.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DPaul%26aufirst%3DS.%2BM.%26atitle%3DEffects%2520of%2520xanomeline%252C%2520a%2520selective%2520muscarinic%2520receptor%2520agonist%252C%2520on%2520cognitive%2520function%2520and%2520behavioral%2520symptoms%2520in%2520Alzheimer%2520disease%26jtitle%3DArch.%2520Neurol.%26date%3D1997%26volume%3D54%26spage%3D465%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref294"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref294'); return false;" data-citation="" class="refNumLink">294</a></strong><div class="NLM_citation" id="cit294"><span><span class="NLM_contrib-group">Xiang, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Q. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C. Y.</span><span> </span><span class="NLM_article-title">Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16524698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287ovVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2006&pages=201-210&author=Y.+Q.+Xiangauthor=Z.+J.+Zhangauthor=Y.+Z.+Wengauthor=Y.+M.+Zhaiauthor=W.+B.+Liauthor=Z.+J.+Caiauthor=Q.+R.+Tanauthor=C.+Y.+Wang&title=Serum+concentrations+of+clozapine+and+norclozapine+in+the+prediction+of+relapse+of+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit294R"><div class="casContent"><span class="casTitleNuber">294</span><div class="casTitle"><span class="NLM_cas:atitle">Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia</span></div><div class="casAuthors">Xiang Ying-Qiang; Zhang Zhang-Jin; Weng Yong-Zhen; Zhai Yi-Min; Li Wen-Biao; Cai Zhuo-Ji; Tan Qing-Rong; Wang Chuan-Yue</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">201-10</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Schizophrenic outpatients (n=102) whose condition had stabilized with clozapine (CLZ) therapy and were being maintained on CLZ were followed for 1 year.  Clinical status and concentrations of serum clozapine (CLZ) and its metabolite norclozapine (NCLZ) were evaluated periodically or when relapse occurred.  Relapse was defined as a significant exacerbation of psychotic symptoms or hospitalization.  Thirty-three patients relapsed and 69 did not.  Relapse patients displayed significantly lower serum concentrations of CLZ and a sum of CLZ and NCLZ at endpoint than non-relapses (CLZ: 162 ng/ml vs. 237 ng/ml, p<0.001; CLZ+NCLZ: 225 ng/ml vs. 301 ng/ml, p<0.001).  When all subjects were pooled together, a significant inverse correlation was observed between percent increase in the total score on the Brief Psychiatric Rating Scale (BPRS) from baseline and serum levels of CLZ alone (r=0.404, p<0.001) and the sum of CLZ and NCLZ (r=0.364, p<0.001).  Relapses and non-relapses were well separated by a threshold CLZ serum concentration of 200 ng/ml with a sensitivity of 73% and a specificity of 80%.  The threshold value represented about a 40% lower serum CLZ level than concentration achieved in acute treatment.  Survival analysis showed a similarity of the relapse risk over time defined by the CLZ serum threshold and by symptomatic criteria.  These results suggest that effective relapse prevention may require maintenance of patients at CLZ serum concentrations above 200 ng/ml and above 60% of the acute-phase level during long-term maintenance treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRumTWZBORPmgRQsDqrjW_fW6udTcc2eZFTFvzWzMfMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287ovVCisQ%253D%253D&md5=14e10ca9f6728468a99d7b67f3b9dc1b</span></div><a href="/servlet/linkout?suffix=cit294&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DY.%2BQ.%26aulast%3DZhang%26aufirst%3DZ.%2BJ.%26aulast%3DWeng%26aufirst%3DY.%2BZ.%26aulast%3DZhai%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DW.%2BB.%26aulast%3DCai%26aufirst%3DZ.%2BJ.%26aulast%3DTan%26aufirst%3DQ.%2BR.%26aulast%3DWang%26aufirst%3DC.%2BY.%26atitle%3DSerum%2520concentrations%2520of%2520clozapine%2520and%2520norclozapine%2520in%2520the%2520prediction%2520of%2520relapse%2520of%2520patients%2520with%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D83%26spage%3D201%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref295"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref295'); return false;" data-citation="" class="refNumLink">295</a></strong><div class="NLM_citation" id="cit295"><span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veinbergs, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalding, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lameh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levey, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacksell, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span> </span><span class="NLM_article-title">The role of M<sub>1</sub> muscarinic receptor agonism of <i>N</i>-desmethylclozapine in the unique clinical effects of clozapine</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-004-1940-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15258717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVehtLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2004&pages=207-216&author=D.+M.+Weinerauthor=H.+Y.+Meltzerauthor=I.+Veinbergsauthor=E.+M.+Donohueauthor=T.+A.+Spaldingauthor=T.+T.+Smithauthor=N.+Mohellauthor=S.+C.+Harveyauthor=J.+Lamehauthor=N.+Nashauthor=K.+E.+Vanoverauthor=R.+Olssonauthor=K.+Jayathilakeauthor=M.+Leeauthor=A.+I.+Leveyauthor=U.+Hacksellauthor=E.+S.+Bursteinauthor=R.+E.+Davisauthor=M.+R.+Brann&title=The+role+of+M1+muscarinic+receptor+agonism+of+N-desmethylclozapine+in+the+unique+clinical+effects+of+clozapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit295R"><div class="casContent"><span class="casTitleNuber">295</span><div class="casTitle"><span class="NLM_cas:atitle">The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine</span></div><div class="casAuthors">Weiner, D. M.; Meltzer, H. Y.; Veinbergs, I.; Donohue, E. M.; Spalding, T. A.; Smith, T. T.; Mohell, N.; Harvey, S. C.; Lameh, J.; Nash, N.; Vanover, K. E.; Olsson, R.; Jayathilake, K.; Lee, M.; Levey, A. I.; Hacksell, U.; Burstein, E. S.; Davis, R. E.; Brann, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Clozapine is a unique antipsychotic, with efficacy against pos. symptoms in treatment-resistant schizophrenic patients, and the ability to improve cognition and treat the neg. symptoms characteristic of this disease.  Despite its unique clin. actions, no specific mol. mechanism responsible for these actions has yet been described.  To comprehensively profile a large library of neuropsychiatric drugs, including most antipsychotics, at human monoamine receptors using R-SAT, an in vitro functional assay.  Profiling revealed that N-desmethylclozapine (NDMC), the principal metabolite of clozapine, but not clozapine itself, is a potent and efficacious muscarinic receptor agonist, a mol. property not shared by any other antipsychotic.  To further explore the role of NDMC muscarinic receptor agonist properties in mediating the physiol. actions of clozapine, systemically administered NDMC was found to stimulate the phosphorylation of mitogen-activated protein kinase (MAP kinase) in mouse CA1 hippocampal neurons, an effect that was blocked by scopolamine, confirming central M1 muscarinic receptor agonist activity in vivo.  Lastly, an anal. of clozapine and NDMC serum levels in schizophrenic patients indicated that high NDMC/clozapine ratios better predicted improvement in cognitive functioning and quality of life than the levels of either compd. alone.  The muscarinic receptor agonist activities of NDMC are unique among antipsychotics, and provide a possible mol. basis for the superior clin. effects of clozapine pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTt5orAqq3dLVg90H21EOLACvtfcHk0lgWGh1ldULZTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVehtLvJ&md5=565a237b914964552581b11a09853f58</span></div><a href="/servlet/linkout?suffix=cit295&amp;dbid=16384&amp;doi=10.1007%2Fs00213-004-1940-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-004-1940-5%26sid%3Dliteratum%253Aachs%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DVeinbergs%26aufirst%3DI.%26aulast%3DDonohue%26aufirst%3DE.%2BM.%26aulast%3DSpalding%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DT.%2BT.%26aulast%3DMohell%26aufirst%3DN.%26aulast%3DHarvey%26aufirst%3DS.%2BC.%26aulast%3DLameh%26aufirst%3DJ.%26aulast%3DNash%26aufirst%3DN.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DOlsson%26aufirst%3DR.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DLevey%26aufirst%3DA.%2BI.%26aulast%3DHacksell%26aufirst%3DU.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26atitle%3DThe%2520role%2520of%2520M1%2520muscarinic%2520receptor%2520agonism%2520of%2520N-desmethylclozapine%2520in%2520the%2520unique%2520clinical%2520effects%2520of%2520clozapine%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2004%26volume%3D177%26spage%3D207%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref296"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref296'); return false;" data-citation="" class="refNumLink">296</a></strong><div class="NLM_citation" id="cit296"><span><span class="NLM_contrib-group">Singhal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oz, M.</span><span> </span><span class="NLM_article-title">Antipsychotic clozapine inhibits the function of α7-nicotinic acetylcholine receptors</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2007&pages=387-394&author=S.+K.+Singhalauthor=L.+Zhangauthor=M.+Moralesauthor=M.+Oz&title=Antipsychotic+clozapine+inhibits+the+function+of+%CE%B17-nicotinic+acetylcholine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit296&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSinghal%26aufirst%3DS.%2BK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMorales%26aufirst%3DM.%26aulast%3DOz%26aufirst%3DM.%26atitle%3DAntipsychotic%2520clozapine%2520inhibits%2520the%2520function%2520of%2520%25CE%25B17-nicotinic%2520acetylcholine%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2007%26volume%3D52%26spage%3D387%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref297"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref297'); return false;" data-citation="" class="refNumLink">297</a></strong><div class="NLM_citation" id="cit297"><span><span class="NLM_contrib-group">Olincy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. E.</span><span> </span><span class="NLM_article-title">Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1192</span><span class="NLM_x">–</span> <span class="NLM_lpage">1201</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2007&pages=1192-1201&author=A.+Olincyauthor=K.+E.+Stevens&title=Treating+schizophrenia+symptoms+with+an+%CE%B17+nicotinic+agonist%2C+from+mice+to+men"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit297&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOlincy%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DK.%2BE.%26atitle%3DTreating%2520schizophrenia%2520symptoms%2520with%2520an%2520%25CE%25B17%2520nicotinic%2520agonist%252C%2520from%2520mice%2520to%2520men%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D74%26spage%3D1192%26epage%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref298"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref298'); return false;" data-citation="" class="refNumLink">298</a></strong><div class="NLM_citation" id="cit298"><span><span class="NLM_contrib-group">Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M.</span><span> </span><span class="NLM_article-title">Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711</span>.  <span class="citation_source-journal">Biol. Psychiatry</span><div class="note"><p class="first last"><b>2007,</b><i>63,</i> 92–97.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hashimoto%2C+K.%3B+Ishima%2C+T.%3B+Fujita%2C+Y.%3B+Matsuo%2C+M.%3B+Kobashi%2C+T.%3B+Takahagi%2C+M.%3B+Tsukada%2C+H.%3B+Iyo%2C+M.+Phencyclidine-induced+cognitive+deficits+in+mice+are+improved+by+subsequent+subchronic+administration+of+the+novel+selective+%CE%B17+nicotinic+receptor+agonist+SSR180711.+Biol.+Psychiatry2007%2C63%2C+92%E2%80%9397."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit298&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DPhencyclidine-induced%2520cognitive%2520deficits%2520in%2520mice%2520are%2520improved%2520by%2520subsequent%2520subchronic%2520administration%2520of%2520the%2520novel%2520selective%2520%25CE%25B17%2520nicotinic%2520receptor%2520agonist%2520SSR180711%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref299"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref299'); return false;" data-citation="" class="refNumLink">299</a></strong><div class="NLM_citation" id="cit299"><span><span class="NLM_contrib-group">Mihalak, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetje, C. W.</span><span> </span><span class="NLM_article-title">Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=801-805&author=K.+B.+Mihalakauthor=F.+I.+Carrollauthor=C.+W.+Luetje&title=Varenicline+is+a+partial+agonist+at+%CE%B14%CE%B22+and+a+full+agonist+at+%CE%B17+neuronal+nicotinic+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit299&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMihalak%26aufirst%3DK.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DLuetje%26aufirst%3DC.%2BW.%26atitle%3DVarenicline%2520is%2520a%2520partial%2520agonist%2520at%2520%25CE%25B14%25CE%25B22%2520and%2520a%2520full%2520agonist%2520at%2520%25CE%25B17%2520neuronal%2520nicotinic%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D801%26epage%3D805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref300"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref300'); return false;" data-citation="" class="refNumLink">300</a></strong><div class="NLM_citation" id="cit300"><span><span class="NLM_contrib-group">Dunbar, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchibhatla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wamsley, J.</span><span> </span><span class="NLM_article-title">Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)</span> <span class="citation_source-journal">J. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1177%2F0269881107066855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17329297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Wksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=171-178&author=G.+C.+Dunbarauthor=F.+Inglisauthor=R.+Kuchibhatlaauthor=T.+Sharmaauthor=M.+Tomlinsonauthor=J.+Wamsley&title=Effect+of+ispronicline%2C+a+neuronal+nicotinic+acetylcholine+receptor+partial+agonist%2C+in+subjects+with+age+associated+memory+impairment+%28AAMI%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit300R"><div class="casContent"><span class="casTitleNuber">300</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)</span></div><div class="casAuthors">Dunbar, Geoffrey C.; Inglis, Fraser; Kuchibhatla, Ramana; Sharma, Tonmoy; Tomlinson, Mark; Wamsley, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-178</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Cognitive decline seen in the normal elderly is assocd. with selective loss of neuronal nicotinic acetylcholine receptors (nAChRs).  Nicotine given either by inhalation or transdermally helps cognition, but unacceptable side effects limit its utility.  The present study assessed the safety, tolerability and effect on cognition of ispronicline, a highly selective partial agonist at the α4β2 nAChR, in elderly subjects (n = 76) with age assocd. memory impairment (AAMI).  This double-blind, placebo-controlled cross-over study explored ascending oral doses of ispronicline in the range 50-150 mg given as a single morning dose for a period of 3 wk.  Pharmacokinetics (PK) were assessed, as well as cognitive function measured by means of the Cognitive Drug Research (CDR) computerized test battery.  Ispronicline had a favorable safety profile and was well tolerated at doses below 150 mg.  No effect of clin. importance was seen on biochem., haematol., urine anal., vital signs, ECG (ECG) or Holter monitoring.  The most frequent drug induced adverse event was light-headedness (dizziness).  A beneficial effect was seen on cognition across the dose range.  This was most marked at 50 mg on factors measuring attention and episodic memory.  PK anal. indicated a plasma Cmax range of 5-25/35 ng/mL ispronicline was assocd. with the most beneficial effect.  These early results demonstrate ispronicline was well tolerated and did not display the side effects typical of nicotine.  Ispronicline also had a beneficial effect on cognition in subjects with AAMI.  This was seen most strongly in a Cmax range that had been predicted from pre-clin. animal studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrktOwlNLoEtLVg90H21EOLACvtfcHk0lgWGh1ldULZTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Wksb8%253D&md5=e73a6f0ec5a75698571e10505a3ca9da</span></div><a href="/servlet/linkout?suffix=cit300&amp;dbid=16384&amp;doi=10.1177%2F0269881107066855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881107066855%26sid%3Dliteratum%253Aachs%26aulast%3DDunbar%26aufirst%3DG.%2BC.%26aulast%3DInglis%26aufirst%3DF.%26aulast%3DKuchibhatla%26aufirst%3DR.%26aulast%3DSharma%26aufirst%3DT.%26aulast%3DTomlinson%26aufirst%3DM.%26aulast%3DWamsley%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520ispronicline%252C%2520a%2520neuronal%2520nicotinic%2520acetylcholine%2520receptor%2520partial%2520agonist%252C%2520in%2520subjects%2520with%2520age%2520associated%2520memory%2520impairment%2520%2528AAMI%2529%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2007%26volume%3D21%26spage%3D171%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref301"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref301'); return false;" data-citation="" class="refNumLink">301</a></strong><div class="NLM_citation" id="cit301"><span><span class="NLM_contrib-group">Arneric, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holladay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">Neuronal nicotinic receptors: a perspective on two decades of drug discovery research</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1092</span><span class="NLM_x">–</span> <span class="NLM_lpage">1101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2007&pages=1092-1101&author=S.+P.+Arnericauthor=M.+Holladayauthor=M.+Williams&title=Neuronal+nicotinic+receptors%3A+a+perspective+on+two+decades+of+drug+discovery+research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit301&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArneric%26aufirst%3DS.%2BP.%26aulast%3DHolladay%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DNeuronal%2520nicotinic%2520receptors%253A%2520a%2520perspective%2520on%2520two%2520decades%2520of%2520drug%2520discovery%2520research%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D74%26spage%3D1092%26epage%3D1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref302"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref302'); return false;" data-citation="" class="refNumLink">302</a></strong><div class="NLM_citation" id="cit302"><span><span class="NLM_contrib-group">Hoffer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, S.</span><span> </span><span class="NLM_article-title">Histamine therapy for schizophrenia: a follow-up study</span> <span class="citation_source-journal">Can. Med Assoc. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1955</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">352</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14352097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaG2M%252FltlKrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1955&pages=352-355&author=A.+Hofferauthor=S.+Parsons&title=Histamine+therapy+for+schizophrenia%3A+a+follow-up+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit302R"><div class="casContent"><span class="casTitleNuber">302</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine therapy for schizophrenia: a follow-up study</span></div><div class="casAuthors">HOFFER A; PARSONS S</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Medical Association journal</span>
        (<span class="NLM_cas:date">1955</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">352-5</span>
        ISSN:<span class="NLM_cas:issn">0008-4409</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqxF1ZPkosme2qxNLjzXe8fW6udTcc2eZIOTCRf-SO2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG2M%252FltlKrtw%253D%253D&md5=4c785567b2b44192ca24b5e963804bf4</span></div><a href="/servlet/linkout?suffix=cit302&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffer%26aufirst%3DA.%26aulast%3DParsons%26aufirst%3DS.%26atitle%3DHistamine%2520therapy%2520for%2520schizophrenia%253A%2520a%2520follow-up%2520study%26jtitle%3DCan.%2520Med%2520Assoc.%2520J.%26date%3D1955%26volume%3D72%26spage%3D352%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref303"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref303'); return false;" data-citation="" class="refNumLink">303</a></strong><div class="NLM_citation" id="cit303"><span><span class="NLM_contrib-group">Arrang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbarg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, J. C.</span><span> </span><span class="NLM_article-title">Auto-inhibition of brain histamine release mediated by a novel class (H<sub>3</sub>) of histamine receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2F302832a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=6188956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL3sXitFSmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=1983&pages=832-837&author=J.+M.+Arrangauthor=M.+Garbargauthor=J.+C.+Schwartz&title=Auto-inhibition+of+brain+histamine+release+mediated+by+a+novel+class+%28H3%29+of+histamine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit303R"><div class="casContent"><span class="casTitleNuber">303</span><div class="casTitle"><span class="NLM_cas:atitle">Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor</span></div><div class="casAuthors">Arrang, Jean Michel; Garbarg, Monique; Schwartz, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5911</span>),
    <span class="NLM_cas:pages">832-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The K+-induced release of 3H-labeled histamine (I)  [51-45-6] from rat cerebral cortex slices was inhibited by exogenous I, suggesting the presence of histaminic receptors by which this compd. can control its own release.  Although Nα-methylhistamine  [673-50-7] and Nα,Nα-dimethylhistamine  [673-46-1] also inhibited [3H]-I release, a no. of compds. known to exhibit agonist activities of H1 or H2 receptors had no significant effect.  Consequently, autoinhibition of I release by the brain is apparently mediated by a type of receptor (histaminic H3) that is clearly different from H1 and H2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpu3HYACgLprVg90H21EOLACvtfcHk0ljgIyc_gI9lfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXitFSmsbc%253D&md5=891b1e95467aa9213317c930f12bf3b7</span></div><a href="/servlet/linkout?suffix=cit303&amp;dbid=16384&amp;doi=10.1038%2F302832a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F302832a0%26sid%3Dliteratum%253Aachs%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DGarbarg%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26atitle%3DAuto-inhibition%2520of%2520brain%2520histamine%2520release%2520mediated%2520by%2520a%2520novel%2520class%2520%2528H3%2529%2520of%2520histamine%2520receptor%26jtitle%3DNature%26date%3D1983%26volume%3D302%26spage%3D832%26epage%3D837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref304"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref304'); return false;" data-citation="" class="refNumLink">304</a></strong><div class="NLM_citation" id="cit304"><span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmerman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J.</span><span> </span><span class="NLM_article-title">The histamine H3 receptor: from gene cloning to H<sub>3</sub> receptor drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnrd1631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15665857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1Wlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=107-120&author=R.+Leursauthor=R.+A.+Bakkerauthor=H.+Timmermanauthor=I.+J.+de+Esch&title=The+histamine+H3+receptor%3A+from+gene+cloning+to+H3+receptor+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit304R"><div class="casContent"><span class="casTitleNuber">304</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: from gene cloning to H3 receptor drugs</span></div><div class="casAuthors">Leurs, Rob; Bakker, Remko A.; Timmerman, Henk; de Esch, Iwan J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-120</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the cloning of the histamine H3 receptor cDNA in 1999 by Lovenberg and coworkers, this histamine receptor has gained the interest of many pharmaceutical companies as a potential drug target for the treatment of various important disorders, including obesity, attention-deficit hyperactivity disorder, Alzheimer's disease, schizophrenia, as well as for myocardial ischemia, migraine and inflammatory diseases.  Here, the authors discuss relevant information on this target protein and describe the development of various H3 receptor agonists and antagonists, and their effects in preclin. animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS284dYZ2NqrVg90H21EOLACvtfcHk0ljgIyc_gI9lfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1Wlsw%253D%253D&md5=78f1127c7e8fb9abd416dae666f5bcfe</span></div><a href="/servlet/linkout?suffix=cit304&amp;dbid=16384&amp;doi=10.1038%2Fnrd1631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1631%26sid%3Dliteratum%253Aachs%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DBakker%26aufirst%3DR.%2BA.%26aulast%3DTimmerman%26aufirst%3DH.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%26atitle%3DThe%2520histamine%2520H3%2520receptor%253A%2520from%2520gene%2520cloning%2520to%2520H3%2520receptor%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D107%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref305"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref305'); return false;" data-citation="" class="refNumLink">305</a></strong><div class="NLM_citation" id="cit305"><span><span class="NLM_contrib-group">Esbenshade, T. A.; Fox, G. B.; Cowart, M. D.</span><span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> receptor antagonists: preclinical promise for treating obesity and cognitive disorders</span>.  <span class="citation_source-journal">Mol. Interventions</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span>− <span class="NLM_lpage">88</span>,  <span class="NLM_fpage">59</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=77+59-88&author=T.+A.+Esbenshade&author=G.+B.+Fox&author=M.+D.+Cowart&title=Histamine+H3+receptor+antagonists%3A+preclinical+promise+for+treating+obesity+and+cognitive+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit305&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26atitle%3DHistamine%2520H3%2520receptor%2520antagonists%253A%2520preclinical%2520promise%2520for%2520treating%2520obesity%2520and%2520cognitive%2520disorders%26jtitle%3DMol.%2520Interventions%26date%3D2006%26volume%3D6%26spage%3D77%26epage%3D88%26spage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref306"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref306'); return false;" data-citation="" class="refNumLink">306</a></strong><div class="NLM_citation" id="cit306"><span><span class="NLM_contrib-group">Hudkins, R. H.; Raddatz, R.</span><span> </span><span class="NLM_article-title">Recent advances in drug discovery of histamine H<sub>3</sub> antagonists</span>.  <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><div class="note"><p class="first last"><b>2007,</b><i>42,</i> 49–62.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hudkins%2C+R.+H.%3B+Raddatz%2C+R.+Recent+advances+in+drug+discovery+of+histamine+H3+antagonists.+Annu.+Rep.+Med.+Chem.2007%2C42%2C+49%E2%80%9362."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit306&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BH.%26atitle%3DRecent%2520advances%2520in%2520drug%2520discovery%2520of%2520histamine%2520H3%2520antagonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref307"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref307'); return false;" data-citation="" class="refNumLink">307</a></strong><div class="NLM_citation" id="cit307"><span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pudiak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamme, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T.</span><span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> receptor antagonists: from target identification to drug leads</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1084</span><span class="NLM_x">–</span> <span class="NLM_lpage">1096</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1084-1096&author=P.+Bonaventureauthor=M.+Letavicauthor=C.+Dugovicauthor=S.+Wilsonauthor=L.+Aluisioauthor=C.+Pudiakauthor=B.+Lordauthor=C.+Mazurauthor=F.+Kammeauthor=S.+Nishinoauthor=N.+Carruthersauthor=T.+Lovenberg&title=Histamine+H3+receptor+antagonists%3A+from+target+identification+to+drug+leads"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit307&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DLetavic%26aufirst%3DM.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DPudiak%26aufirst%3DC.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DMazur%26aufirst%3DC.%26aulast%3DKamme%26aufirst%3DF.%26aulast%3DNishino%26aufirst%3DS.%26aulast%3DCarruthers%26aufirst%3DN.%26aulast%3DLovenberg%26aufirst%3DT.%26atitle%3DHistamine%2520H3%2520receptor%2520antagonists%253A%2520from%2520target%2520identification%2520to%2520drug%2520leads%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D1084%26epage%3D1096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref308"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref308'); return false;" data-citation="" class="refNumLink">308</a></strong><div class="NLM_citation" id="cit308"><span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresford, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brackenborough, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briggs, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calver, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluderay, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crook, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gartlon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heslop, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martyn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ociepka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schogger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stean, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wald, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolley, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worby, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">GSK189254, a novel H<sub>3</sub> receptor antagonist that binds to histamine H<sub>3</sub> receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">1032</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref308/cit308&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.107.120311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref308/cit308&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17327487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref308/cit308&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFeqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=1032-1045&author=A.+D.+Medhurstauthor=A.+R.+Atkinsauthor=I.+J.+Beresfordauthor=K.+Brackenboroughauthor=M.+A.+Briggsauthor=A.+R.+Calverauthor=J.+Ciliaauthor=J.+E.+Cluderayauthor=B.+Crookauthor=J.+B.+Davisauthor=R.+K.+Davisauthor=R.+P.+Davisauthor=L.+A.+Dawsonauthor=A.+G.+Foleyauthor=J.+Gartlonauthor=M.+I.+Gonzalezauthor=T.+Heslopauthor=W.+D.+Hirstauthor=C.+Jenningsauthor=D.+N.+Jonesauthor=L.+P.+Lacroixauthor=A.+Martynauthor=S.+Ociepkaauthor=A.+Rayauthor=C.+M.+Reganauthor=J.+C.+Robertsauthor=J.+Schoggerauthor=E.+Southamauthor=T.+O.+Steanauthor=B.+K.+Trailauthor=N.+Uptonauthor=G.+Wadsworthauthor=J.+A.+Waldauthor=T.+Whiteauthor=J.+Witheringtonauthor=M.+L.+Woolleyauthor=A.+Worbyauthor=D.+M.+Wilson&title=GSK189254%2C+a+novel+H3+receptor+antagonist+that+binds+to+histamine+H3+receptors+in+Alzheimer%E2%80%99s+disease+brain+and+improves+cognitive+performance+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit308R"><div class="casContent"><span class="casTitleNuber">308</span><div class="casTitle"><span class="NLM_cas:atitle">GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models</span></div><div class="casAuthors">Medhurst, Andrew D.; Atkins, Alan R.; Beresford, Isabel J.; Brackenborough, Kim; Briggs, Michael A.; Calver, Andrew R.; Cilia, Jackie; Cluderay, Jane E.; Crook, Barry; Davis, John B.; Davis, Rebecca K.; Davis, Robert P.; Dawson, Lee A.; Foley, Andrew G.; Gartlon, Jane; Gonzalez, M. Isabel; Heslop, Teresa; Hirst, Warren D.; Jennings, Carol; Jones, Declan N. C.; Lacroix, Laurent P.; Martyn, Abbe; Ociepka, Sandrine; Ray, Alison; Regan, Ciaran M.; Roberts, Jennifer C.; Schogger, Joanne; Southam, Eric; Stean, Tania O.; Trail, Brenda K.; Upton, Neil; Wadsworth, Graham; Wald, Jeffrey A.; White, Trevor; Witherington, Jason; Woolley, Marie L.; Worby, Angela; Wilson, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1032-1045</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">6[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) is a novel histamine H3 receptor antagonist with high affinity for human (pKi = 9.59-9.90) and rat (pKi = 8.51-9.17) H3 receptors.  GSK189254 is >10,000-fold selective for human H3 receptors vs. other targets tested, and it exhibited potent functional antagonism (pA2 = 9.06 vs. agonist-induced changes in cAMP) and inverse agonism [pIC50 = 8.20 vs. basal guanosine 5'-O-(3-[35S]thio)triphosphate binding] at the human recombinant H3 receptor.  In vitro autoradiog. demonstrated specific [3H]GSK189254 binding in rat and human brain areas, including cortex and hippocampus.  In addn., dense H3 binding was detected in medial temporal cortex samples from severe cases of Alzheimer's disease, suggesting for the first time that H3 receptors are preserved in late-stage disease.  After oral administration, GSK189254 inhibited cortical ex vivo R-(-)-α-methyl[imidazole-2,5(n)-3H]histamine dihydrochloride ([3H]R-α-methylhistamine) binding (ED50 = 0.17 mg/kg) and increased c-Fos immunoreactivity in prefrontal and somatosensory cortex (3 mg/kg).  Microdialysis studies demonstrated that GSK189254 (0.3-3 mg/kg p.o.) increased the release of acetylcholine, noradrenaline, and dopamine in the anterior cingulate cortex and acetylcholine in the dorsal hippocampus.  Functional antagonism of central H3 receptors was demonstrated by blockade of R-α-methylhistamine-induced dipsogenia in rats (ID50 = 0.03 mg/kg p.o.).  GSK189254 significantly improved performance of rats in diverse cognition paradigms, including passive avoidance (1 and 3 mg/kg p.o.), water maze (1 and 3 mg/kg p.o.), object recognition (0.3 and 1 mg/kg p.o.), and attentional set shift (1 mg/kg p.o.).  These data suggest that GSK189254 may have therapeutic potential for the symptomatic treatment of dementia in Alzheimer's disease and other cognitive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1RSEKGEQaDbVg90H21EOLACvtfcHk0ljlZt7wLglPTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFeqs74%253D&md5=c72dfbcb1db4f56cda723eff6b0f0e85</span></div><a href="/servlet/linkout?suffix=cit308&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.120311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.120311%26sid%3Dliteratum%253Aachs%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DAtkins%26aufirst%3DA.%2BR.%26aulast%3DBeresford%26aufirst%3DI.%2BJ.%26aulast%3DBrackenborough%26aufirst%3DK.%26aulast%3DBriggs%26aufirst%3DM.%2BA.%26aulast%3DCalver%26aufirst%3DA.%2BR.%26aulast%3DCilia%26aufirst%3DJ.%26aulast%3DCluderay%26aufirst%3DJ.%2BE.%26aulast%3DCrook%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DDavis%26aufirst%3DR.%2BK.%26aulast%3DDavis%26aufirst%3DR.%2BP.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DFoley%26aufirst%3DA.%2BG.%26aulast%3DGartlon%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DM.%2BI.%26aulast%3DHeslop%26aufirst%3DT.%26aulast%3DHirst%26aufirst%3DW.%2BD.%26aulast%3DJennings%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DD.%2BN.%26aulast%3DLacroix%26aufirst%3DL.%2BP.%26aulast%3DMartyn%26aufirst%3DA.%26aulast%3DOciepka%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DRegan%26aufirst%3DC.%2BM.%26aulast%3DRoberts%26aufirst%3DJ.%2BC.%26aulast%3DSchogger%26aufirst%3DJ.%26aulast%3DSoutham%26aufirst%3DE.%26aulast%3DStean%26aufirst%3DT.%2BO.%26aulast%3DTrail%26aufirst%3DB.%2BK.%26aulast%3DUpton%26aufirst%3DN.%26aulast%3DWadsworth%26aufirst%3DG.%26aulast%3DWald%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DT.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DWoolley%26aufirst%3DM.%2BL.%26aulast%3DWorby%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DGSK189254%252C%2520a%2520novel%2520H3%2520receptor%2520antagonist%2520that%2520binds%2520to%2520histamine%2520H3%2520receptors%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brain%2520and%2520improves%2520cognitive%2520performance%2520in%2520preclinical%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D1032%26epage%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref309"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref309'); return false;" data-citation="" class="refNumLink">309</a></strong><div class="NLM_citation" id="cit309"><span><span class="NLM_contrib-group">Ligneau, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landais, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piriou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uguen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmentier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anaclet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, J. C.</span><span> </span><span class="NLM_article-title">Brain histamine and schizophrenia: potential therapeutic applications of H<sub>3</sub>-receptor inverse agonists studied with BF2.649</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1215</span><span class="NLM_x">–</span> <span class="NLM_lpage">1224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1215-1224&author=X.+Ligneauauthor=L.+Landaisauthor=D.+Perrinauthor=J.+Piriouauthor=M.+Uguenauthor=E.+Denisauthor=P.+Robertauthor=R.+Parmentierauthor=C.+Anacletauthor=J.+S.+Linauthor=A.+Burbanauthor=J.+M.+Arrangauthor=J.+C.+Schwartz&title=Brain+histamine+and+schizophrenia%3A+potential+therapeutic+applications+of+H3-receptor+inverse+agonists+studied+with+BF2.649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit309&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DLandais%26aufirst%3DL.%26aulast%3DPerrin%26aufirst%3DD.%26aulast%3DPiriou%26aufirst%3DJ.%26aulast%3DUguen%26aufirst%3DM.%26aulast%3DDenis%26aufirst%3DE.%26aulast%3DRobert%26aufirst%3DP.%26aulast%3DParmentier%26aufirst%3DR.%26aulast%3DAnaclet%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%2BS.%26aulast%3DBurban%26aufirst%3DA.%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26atitle%3DBrain%2520histamine%2520and%2520schizophrenia%253A%2520potential%2520therapeutic%2520applications%2520of%2520H3-receptor%2520inverse%2520agonists%2520studied%2520with%2520BF2.649%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D1215%26epage%3D1224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref310"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref310'); return false;" data-citation="" class="refNumLink">310</a></strong><div class="NLM_citation" id="cit310"><span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radek, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komater, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faghih, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueter, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">Pharmacological properties of ABT-239 [4-(2-{2-[(2<i>R</i>)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H<sub>3</sub> receptor antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.104.078402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15608077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=176-190&author=G.+B.+Foxauthor=T.+A.+Esbenshadeauthor=J.+B.+Panauthor=R.+J.+Radekauthor=K.+M.+Kruegerauthor=B.+B.+Yaoauthor=K.+E.+Browmanauthor=M.+J.+Buckleyauthor=M.+E.+Ballardauthor=V.+A.+Komaterauthor=H.+Minerauthor=M.+Zhangauthor=R.+Faghihauthor=L.+E.+Rueterauthor=R.+S.+Bitnerauthor=K.+U.+Drescherauthor=J.+Wetterauthor=K.+Marshauthor=M.+Lemaireauthor=R.+D.+Porsoltauthor=Y.+L.+Bennaniauthor=J.+P.+Sullivanauthor=M.+D.+Cowartauthor=M.+W.+Deckerauthor=A.+A.+Hancock&title=Pharmacological+properties+of+ABT-239+%5B4-%282-%7B2-%5B%282R%29-2-methylpyrrolidinyl%5Dethyl%7D-benzofuran-5-yl%29benzonitrile%5D%3A+II.+Neurophysiological+characterization+and+broad+preclinical+efficacy+in+cognition+and+schizophrenia+of+a+potent+and+selective+histamine+H3+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit310R"><div class="casContent"><span class="casTitleNuber">310</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist</span></div><div class="casAuthors">Fox, Gerard B.; Esbenshade, Timothy A.; Pan, Jia Bao; Radek, Richard J.; Krueger, Kathleen M.; Yao, Betty B.; Browman, Kaitlin E.; Buckley, Michael J.; Ballard, Michael E.; Komater, Victoria A.; Miner, Holly; Zhang, Min; Faghih, Ramin; Rueter, Lynne E.; Bitner, R. Scott; Drescher, Karla U.; Wetter, Jill; Marsh, Kennan; Lemaire, Martine; Porsolt, Roger D.; Bennani, Youssef L.; Sullivan, James P.; Cowart, Marlon D.; Decker, Michael W.; Hancock, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-190</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acute pharmacol. blockade of central histamine H3 receptors (H3Rs) enhances arousal/attention in rodents.  However, there is little information available for other behavioral domains or for repeated administration using selective compds.  ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] exemplifies such a selective, nonimidazole H3R antagonist with high affinity for rat (pKi = 8.9) and human (pKi = 9.5) H3Rs.  Acute functional blockade of central H3Rs was demonstrated by blocking the dipsogenia response to the selective H3R agonist (R)-α-methylhistamine in mice.  In cognition studies, acquisition of a five-trial, inhibitory avoidance test in rat pups was improved with ABT-239 (0.1-1.0 mg/kg), a 10- to 150-fold gain in potency, with similar efficacy, over previous antagonists such as thioperamide, ciproxifan, A-304121 [(4-(3-(4-((2R)-2-aminopropanoyl)-1-piperazinyl)propoxy)phenyl)(cyclopropyl) methanone], A-317920 [N-((1R)-2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide], and A-349821 [(4'-(3-((R,R)2,5-dimethyl-pyrrolidin-1-yl)-propoxy)-biphenyl-4-yl)- morpholin-4-yl-methanone].  Efficacy in this model was maintained for 3 to 6 h and following repeated dosing with ABT-239.  Social memory was also improved in adult (0.01-0.3 mg/kg) and aged (0.3-1.0 mg/kg) rats.  In schizophrenia models, ABT-239 improved gating deficits in DBA/2 mice using prepulse inhibition of startle (1.0-3.0 mg/kg) and N40 (1.0-10.0 mg/kg).  Furthermore, ABT-239 (1.0 mg/kg) attenuated methamphetamine-induced hyperactivity in mice.  In freely moving rat microdialysis studies, ABT-239 enhanced acetylcholine release (0.1-3.0 mg/kg) in adult rat frontal cortex and hippocampus and enhanced dopamine release in frontal cortex (3.0 mg/kg), but not striatum.  In summary, broad efficacy was obsd. with ABT-239 across animal models such that potential clin. efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5hD1Q0ydnubVg90H21EOLACvtfcHk0ljlZt7wLglPTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLo%253D&md5=437e154a172071e4c5d31e44134ab1b5</span></div><a href="/servlet/linkout?suffix=cit310&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.078402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.078402%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DPan%26aufirst%3DJ.%2BB.%26aulast%3DRadek%26aufirst%3DR.%2BJ.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DBuckley%26aufirst%3DM.%2BJ.%26aulast%3DBallard%26aufirst%3DM.%2BE.%26aulast%3DKomater%26aufirst%3DV.%2BA.%26aulast%3DMiner%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DFaghih%26aufirst%3DR.%26aulast%3DRueter%26aufirst%3DL.%2BE.%26aulast%3DBitner%26aufirst%3DR.%2BS.%26aulast%3DDrescher%26aufirst%3DK.%2BU.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DPharmacological%2520properties%2520of%2520ABT-239%2520%255B4-%25282-%257B2-%255B%25282R%2529-2-methylpyrrolidinyl%255Dethyl%257D-benzofuran-5-yl%2529benzonitrile%255D%253A%2520II.%2520Neurophysiological%2520characterization%2520and%2520broad%2520preclinical%2520efficacy%2520in%2520cognition%2520and%2520schizophrenia%2520of%2520a%2520potent%2520and%2520selective%2520histamine%2520H3%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D176%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref311"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref311'); return false;" data-citation="" class="refNumLink">311</a></strong><div class="NLM_citation" id="cit311"><span><span class="NLM_contrib-group">Cowart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gfesser, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faghih, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milicic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baranowski, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molesky, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komater, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagne, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">Novel heterocyclic-substituted benzofuran histamine H<sub>3</sub> receptor antagonists: in vitro properties, drug-likeness, and behavioral activity</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1243</span><span class="NLM_x">–</span> <span class="NLM_lpage">1255</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1243-1255&author=M.+Cowartauthor=G.+A.+Gfesserauthor=K.+E.+Browmanauthor=R.+Faghihauthor=T.+R.+Millerauthor=I.+Milicicauthor=J.+L.+Baranowskiauthor=K.+M.+Kruegerauthor=D.+G.+Witteauthor=A.+L.+Moleskyauthor=V.+A.+Komaterauthor=M.+J.+Buckleyauthor=G.+J.+Diazauthor=G.+D.+Gagneauthor=D.+Zhouauthor=X.+Dengauthor=L.+Panauthor=E.+M.+Robertsauthor=M.+S.+Diehlauthor=J.+M.+Wetterauthor=K.+C.+Marshauthor=G.+B.+Foxauthor=J.+D.+Brioniauthor=T.+A.+Esbenshadeauthor=A.+A.+Hancock&title=Novel+heterocyclic-substituted+benzofuran+histamine+H3+receptor+antagonists%3A+in+vitro+properties%2C+drug-likeness%2C+and+behavioral+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit311&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCowart%26aufirst%3DM.%26aulast%3DGfesser%26aufirst%3DG.%2BA.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DFaghih%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DT.%2BR.%26aulast%3DMilicic%26aufirst%3DI.%26aulast%3DBaranowski%26aufirst%3DJ.%2BL.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DWitte%26aufirst%3DD.%2BG.%26aulast%3DMolesky%26aufirst%3DA.%2BL.%26aulast%3DKomater%26aufirst%3DV.%2BA.%26aulast%3DBuckley%26aufirst%3DM.%2BJ.%26aulast%3DDiaz%26aufirst%3DG.%2BJ.%26aulast%3DGagne%26aufirst%3DG.%2BD.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DE.%2BM.%26aulast%3DDiehl%26aufirst%3DM.%2BS.%26aulast%3DWetter%26aufirst%3DJ.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DNovel%2520heterocyclic-substituted%2520benzofuran%2520histamine%2520H3%2520receptor%2520antagonists%253A%2520in%2520vitro%2520properties%252C%2520drug-likeness%252C%2520and%2520behavioral%2520activity%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D1243%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref312"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref312'); return false;" data-citation="" class="refNumLink">312</a></strong><div class="NLM_citation" id="cit312"><span><span class="NLM_contrib-group">Javitt, D. C.</span><span> </span><span class="NLM_article-title">Glycine modulators in schizophrenia</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1067</span><span class="NLM_x">–</span> <span class="NLM_lpage">1072</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12186269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFOnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=1067-1072&author=D.+C.+Javitt&title=Glycine+modulators+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit312R"><div class="casContent"><span class="casTitleNuber">312</span><div class="casTitle"><span class="NLM_cas:atitle">Glycine modulators in schizophrenia</span></div><div class="casAuthors">Javitt, Daniel C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (PharmaPress Ltd.)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1067-1072</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    
            (<span class="NLM_cas:orgname">PharmaPress Ltd.</span>)
        </div><div class="casAbstract">A review.  N-methyl-D-aspartate (NMDA) receptor dysfunction may play a key role in the pathophysiol. of schizophrenia.  Recent studies have investigated the ability of NMDA/glycine-site modulators to ameliorate persistent neg. and cognitive symptoms.  Several full or partial glycine-site agonists, including glycine, D-serine and D-cycloserine, have shown effectiveness in small-scale clin. trials.  Glycine levels in brain are regulated by GLYT1-type glycine transporters.  Recently developed glycine transport inhibitors (GTI) have preclin. behavioral effects similar to those of glycine or D-serine, and may represent a 'next generation' approach to the treatment of the persistent neg. and cognitive symptoms of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHJn9BGdsbZ7Vg90H21EOLACvtfcHk0lg7aoZjsbwVng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFOnsL4%253D&md5=96d9eed6c77e9019c84556710b6196e6</span></div><a href="/servlet/linkout?suffix=cit312&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJavitt%26aufirst%3DD.%2BC.%26atitle%3DGlycine%2520modulators%2520in%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D3%26spage%3D1067%26epage%3D1072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref313"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref313'); return false;" data-citation="" class="refNumLink">313</a></strong><div class="NLM_citation" id="cit313"><span><span class="NLM_contrib-group">Atkinson, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ognyanov, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tham, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klitenick, M. A.</span><span> </span><span class="NLM_article-title">ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1414</span><span class="NLM_x">–</span> <span class="NLM_lpage">1420</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=1414-1420&author=B.+N.+Atkinsonauthor=S.+C.+Bellauthor=M.+De+Vivoauthor=L.+R.+Kowalskiauthor=S.+M.+Lechnerauthor=V.+I.+Ognyanovauthor=C.+S.+Thamauthor=C.+Tsaiauthor=J.+Jiaauthor=D.+Ashtonauthor=M.+A.+Klitenick&title=ALX+5407%3A+a+potent%2C+selective+inhibitor+of+the+hGlyT1+glycine+transporter"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit313&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DB.%2BN.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DKowalski%26aufirst%3DL.%2BR.%26aulast%3DLechner%26aufirst%3DS.%2BM.%26aulast%3DOgnyanov%26aufirst%3DV.%2BI.%26aulast%3DTham%26aufirst%3DC.%2BS.%26aulast%3DTsai%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DAshton%26aufirst%3DD.%26aulast%3DKlitenick%26aufirst%3DM.%2BA.%26atitle%3DALX%25205407%253A%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520the%2520hGlyT1%2520glycine%2520transporter%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D1414%26epage%3D1420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref314"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref314'); return false;" data-citation="" class="refNumLink">314</a></strong><div class="NLM_citation" id="cit314"><span><span class="NLM_contrib-group">Depoortere, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dargazanli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estenne-Bouhtou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coste, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanneau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desvignes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncelet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaulme, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decobert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cudennec, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voltz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terranova, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemmelin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marabout, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sevrin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vige, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avenet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oury-Donat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrault, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griebel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scatton, B.</span><span> </span><span class="NLM_article-title">Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1963</span><span class="NLM_x">–</span> <span class="NLM_lpage">1985</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=1963-1985&author=R.+Depoortereauthor=G.+Dargazanliauthor=G.+Estenne-Bouhtouauthor=A.+Costeauthor=C.+Lanneauauthor=C.+Desvignesauthor=M.+Ponceletauthor=M.+Heaulmeauthor=V.+Santucciauthor=M.+Decobertauthor=A.+Cudennecauthor=C.+Voltzauthor=D.+Boulayauthor=J.+P.+Terranovaauthor=J.+Stemmelinauthor=P.+Rogerauthor=B.+Maraboutauthor=M.+Sevrinauthor=X.+Vigeauthor=B.+Bitonauthor=R.+Steinbergauthor=D.+Franconauthor=R.+Alonsoauthor=P.+Avenetauthor=F.+Oury-Donatauthor=G.+Perraultauthor=G.+Griebelauthor=P.+Georgeauthor=P.+Soubrieauthor=B.+Scatton&title=Neurochemical%2C+electrophysiological+and+pharmacological+profiles+of+the+selective+inhibitor+of+the+glycine+transporter-1+SSR504734%2C+a+potential+new+type+of+antipsychotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit314&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDepoortere%26aufirst%3DR.%26aulast%3DDargazanli%26aufirst%3DG.%26aulast%3DEstenne-Bouhtou%26aufirst%3DG.%26aulast%3DCoste%26aufirst%3DA.%26aulast%3DLanneau%26aufirst%3DC.%26aulast%3DDesvignes%26aufirst%3DC.%26aulast%3DPoncelet%26aufirst%3DM.%26aulast%3DHeaulme%26aufirst%3DM.%26aulast%3DSantucci%26aufirst%3DV.%26aulast%3DDecobert%26aufirst%3DM.%26aulast%3DCudennec%26aufirst%3DA.%26aulast%3DVoltz%26aufirst%3DC.%26aulast%3DBoulay%26aufirst%3DD.%26aulast%3DTerranova%26aufirst%3DJ.%2BP.%26aulast%3DStemmelin%26aufirst%3DJ.%26aulast%3DRoger%26aufirst%3DP.%26aulast%3DMarabout%26aufirst%3DB.%26aulast%3DSevrin%26aufirst%3DM.%26aulast%3DVige%26aufirst%3DX.%26aulast%3DBiton%26aufirst%3DB.%26aulast%3DSteinberg%26aufirst%3DR.%26aulast%3DFrancon%26aufirst%3DD.%26aulast%3DAlonso%26aufirst%3DR.%26aulast%3DAvenet%26aufirst%3DP.%26aulast%3DOury-Donat%26aufirst%3DF.%26aulast%3DPerrault%26aufirst%3DG.%26aulast%3DGriebel%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DScatton%26aufirst%3DB.%26atitle%3DNeurochemical%252C%2520electrophysiological%2520and%2520pharmacological%2520profiles%2520of%2520the%2520selective%2520inhibitor%2520of%2520the%2520glycine%2520transporter-1%2520SSR504734%252C%2520a%2520potential%2520new%2520type%2520of%2520antipsychotic%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D1963%26epage%3D1985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref315"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref315'); return false;" data-citation="" class="refNumLink">315</a></strong><div class="NLM_citation" id="cit315"><span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span> </span><span class="NLM_article-title">Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">807</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=807-811&author=C.+W.+Lindsleyauthor=Z.+Zhaoauthor=W.+H.+Leisterauthor=J.+O%E2%80%99Brienauthor=W.+Lemaireauthor=D.+L.+Williamsauthor=T.+B.+Chenauthor=R.+S.+Changauthor=M.+Burnoauthor=M.+A.+Jacobsonauthor=C.+Surauthor=G.+G.+Kinneyauthor=D.+J.+Pettiboneauthor=P.+R.+Tillerauthor=S.+Smithauthor=N.+N.+Tsouauthor=M.+E.+Dugganauthor=P.+J.+Connauthor=G.+D.+Hartman&title=Design%2C+synthesis%2C+and+in+vivo+efficacy+of+glycine+transporter-1+%28GlyT1%29+inhibitors+derived+from+a+series+of+%5B4-phenyl-1-%28propylsulfonyl%29piperidin-4-yl%5Dmethyl+benzamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit315&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DTiller%26aufirst%3DP.%2BR.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520glycine%2520transporter-1%2520%2528GlyT1%2529%2520inhibitors%2520derived%2520from%2520a%2520series%2520of%2520%255B4-phenyl-1-%2528propylsulfonyl%2529piperidin-4-yl%255Dmethyl%2520benzamides%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D807%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref316"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref316'); return false;" data-citation="" class="refNumLink">316</a></strong><div class="NLM_citation" id="cit316"><span><span class="NLM_contrib-group">Tsai, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. T.</span><span> </span><span class="NLM_article-title"><span class="smallcaps smallerCapital">d</span>-Serine added to clozapine for the treatment of schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">1822</span><span class="NLM_x">–</span> <span class="NLM_lpage">1825</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref316/cit316&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10553752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref316/cit316&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FhvFWrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1999&pages=1822-1825&author=G.+E.+Tsaiauthor=P.+Yangauthor=L.+C.+Chungauthor=I.+C.+Tsaiauthor=C.+W.+Tsaiauthor=J.+T.+Coyle&title=d-Serine+added+to+clozapine+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit316R"><div class="casContent"><span class="casTitleNuber">316</span><div class="casTitle"><span class="NLM_cas:atitle">D-serine added to clozapine for the treatment of schizophrenia</span></div><div class="casAuthors">Tsai G E; Yang P; Chung L C; Tsai I C; Tsai C W; Coyle J T</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1822-5</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  D-Serine is a full agonist at the glycine site on the N-methyl-D-aspartate (NMDA) receptor.  Previous administration of D-serine to schizophrenic patients taking nonclozapine antipsychotics improved positive, negative, and cognitive symptoms, whereas the partial agonist D-cycloserine improved negative symptoms of patients taking conventional antipsychotics but worsened symptoms in clozapine-treated patients.  To study the difference between full and partial agonists at the NMDA receptor glycine site, the clinical effects of adding D-serine to clozapine were assessed.  METHOD:  In a 6-week double-blind trial, 20 schizophrenic patients received placebo or D-serine (30 mg/kg per day) in addition to clozapine.  Clinical efficacy, side effects, and serum levels of D-serine were determined every other week.  RESULTS:  The patients exhibited no improvement with D-serine, nor did their symptoms worsen, as previously reported with D-cycloserine.  CONCLUSIONS:  The results suggest either that clozapine may have an agonistic effect on the NMDA system or that clozapine-treated patients do not respond to D-serine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSg_EqLFISEu1HFYivNCdPRfW6udTcc2eZ0r1EHgxU5Vrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FhvFWrsg%253D%253D&md5=c751c699c41f5056935a8d85c88e9c75</span></div><a href="/servlet/linkout?suffix=cit316&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DG.%2BE.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DChung%26aufirst%3DL.%2BC.%26aulast%3DTsai%26aufirst%3DI.%2BC.%26aulast%3DTsai%26aufirst%3DC.%2BW.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3Dd-Serine%2520added%2520to%2520clozapine%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1999%26volume%3D156%26spage%3D1822%26epage%3D1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref317"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref317'); return false;" data-citation="" class="refNumLink">317</a></strong><div class="NLM_citation" id="cit317"><span><span class="NLM_contrib-group">Tuominen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiihonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlbeck, K.</span><span> </span><span class="NLM_article-title">Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref317/cit317&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref317/cit317&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15560967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref317/cit317&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crovVyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2005&pages=225-234&author=H.+J.+Tuominenauthor=J.+Tiihonenauthor=K.+Wahlbeck&title=Glutamatergic+drugs+for+schizophrenia%3A+a+systematic+review+and+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit317R"><div class="casContent"><span class="casTitleNuber">317</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis</span></div><div class="casAuthors">Tuominen Harri J; Tiihonen Jari; Wahlbeck Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">225-34</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">OBJECTIVE:  To evaluate the efficacy of glutamatergic drugs, acting agonistically on the N-methyl-D-aspartate (NMDA) or the non-NMDA receptors, in schizophrenia.  METHOD:  All relevant randomized controlled trials of glutamatergic drugs for schizophrenia were obtained from the Cochrane Schizophrenia Group's Register of Trials without any language or year limitations.  Trials were classified according to their methodological quality.  For binary and continuous data, relative risks and weighted (WMD) or standardized mean differences (SMD) were calculated, respectively.  RESULTS:  Eighteen short-term trials with 343 randomized patients were included in the meta-analysis.  In all of these trials, glycine, D-serine, D-cycloserine or ampakine CX516 was used to augment antipsychotics.  NMDA receptor co-agonists glycine and D-serine are effective in reducing negative symptoms (N = 132, fixed effect model SMD = -0.66, 95% CI -1.02 to -0.29, p = 0.0004) of schizophrenia, the magnitude of the effect is moderate.  D-Cycloserine, a partial agonist of NMDA receptors, is less effective towards negative symptoms (N = 119, fixed effect model SMD = -0.11, 95% CI -0.48 to 0.25, p = 0.6).  Positive symptoms fail to respond to glutamatergic medication.  Available derived data on cognitive functioning do not indicate a significant effect of glycine or D-serine (N = 80, random effect model WMD = -2.79, 95% CI -6.17 to 0.60, p = 0.11).  CONCLUSIONS:  In the current limited data set, a moderate amelioration of negative symptoms of schizophrenia was found, but no other statistically significant beneficial effects on symptoms of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWMnnE49ze_fxQvRxYU81tfW6udTcc2eZ0r1EHgxU5Vrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crovVyntw%253D%253D&md5=2aacaaa0e6fba75cf152ef85a668ba77</span></div><a href="/servlet/linkout?suffix=cit317&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DTuominen%26aufirst%3DH.%2BJ.%26aulast%3DTiihonen%26aufirst%3DJ.%26aulast%3DWahlbeck%26aufirst%3DK.%26atitle%3DGlutamatergic%2520drugs%2520for%2520schizophrenia%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DSchizophr.%2520Res.%26date%3D2005%26volume%3D72%26spage%3D225%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref318"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref318'); return false;" data-citation="" class="refNumLink">318</a></strong><div class="NLM_citation" id="cit318"><span>Sepracor Inc. <span> </span><span class="NLM_article-title">Pyrrole and Pyrazole DAAO Inhibitors</span>. WO/2005/066135,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sepracor+Inc.+Pyrrole+and+Pyrazole+DAAO+Inhibitors.+WO%2F2005%2F066135%2C+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit318&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DPyrrole%2520and%2520Pyrazole%2520DAAO%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref319"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref319'); return false;" data-citation="" class="refNumLink">319</a></strong><div class="NLM_citation" id="cit319"><span>Sepracor Inc. <span> </span><span class="NLM_article-title">Benzo[<span class="smallcaps smallerCapital">d</span>]isoxazol-3-ol DAAO Inhibitors</span>. U.S. 7,166,725 B2,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sepracor+Inc.+Benzo%5Bd%5Disoxazol-3-ol+DAAO+Inhibitors.+U.S.+7%2C166%2C725+B2%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit319&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DBenzo%255Bd%255Disoxazol-3-ol%2520DAAO%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref320"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref320'); return false;" data-citation="" class="refNumLink">320</a></strong><div class="NLM_citation" id="cit320"><span><span class="NLM_contrib-group">Chavez-Noriega, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaffhauser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia</span> <span class="citation_source-journal">Curr. Drug Targets: CNS Neurol. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">281</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref320/cit320&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2174%2F1568007023339337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref320/cit320&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12769619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref320/cit320&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFKgtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=261-281&author=L.+E.+Chavez-Noriegaauthor=H.+Schaffhauserauthor=U.+C.+Campbell&title=Metabotropic+glutamate+receptors%3A+potential+drug+targets+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit320R"><div class="casContent"><span class="casTitleNuber">320</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors: Potential drug targets for the treatment of schizophrenia</span></div><div class="casAuthors">Chavez-Noriega, Laura E.; Schaffhauser, Herve; Campbell, Una C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: CNS & Neurological Disorders</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-281</span>CODEN:
                <span class="NLM_cas:coden">CDTCCC</span>;
        ISSN:<span class="NLM_cas:issn">1568-007X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is a debilitating chronic psychiatric illness affecting 1% of the population.  The cardinal features of schizophrenia are pos. symptoms (thought disorder, hallucinations, catatonic behavior), neg. symptoms (social withdrawal, anhedonia, apathy) and cognitive impairment.  Although progress in elucidating the etiol. of schizophrenia has been slow, new insights on the neurochem. and neurophysiol. mechanisms underlying the pathophysiol. of this illness are beginning to emerge.  The glutamate/N-methyl-D-aspartate (NMDA) hypofunction hypothesis of schizophrenia is supported by observations that administration of NMDA glutamate receptor antagonists such as phencyclidine (PCP) or ketamine induces psychosis in humans; moreover, decreased levels of glutamate and changes in several markers of glutamatergic function occur in schizophrenic brain.  Administration of PCP or ketamine to rodents elicits an increase in locomotion and stereotypy accompanied by an increase in glutamate efflux in several brain regions.  Systemic administration of group II metabotropic glutamate (mGlu) receptor agonists suppresses PCP-induced behavioral effects and the increase in glutamate efflux.  Activation of group II mGlu receptors (mGlu2 and mGlu3) decreases glutamate release from presynaptic nerve terminals, suggesting that group II mGlu receptor agonists may be beneficial in the treatment of schizophrenia.  In addn., pharmacol. manipulations that enhance NMDA function may be efficacious antipsychotics.  Selective activation of mGlu5 receptors significantly potentiates NMDA-induced responses, supporting this novel approach for the treatment of schizophrenia.  The glutamate hypothesis of schizophrenia predicts that agents that restore the balance in glutamatergic neurotransmission will ameliorate the symptomatol. assocd. with this illness.  Development of potent, efficacious, systemically active drugs will help to address the antipsychotic potential of these novel therapeutics.  This review will discuss recent progress in elucidating the pharmacol. and function of group II mGlu and mGlu5 receptors in the context of current hypotheses on the pathophysiol. of schizophrenia and the need for new and better antipsychotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNJSTzsZh9hbVg90H21EOLACvtfcHk0ljpL6rKOL5bvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFKgtrk%253D&md5=c58d098adfa3964101deb45511c46af2</span></div><a href="/servlet/linkout?suffix=cit320&amp;dbid=16384&amp;doi=10.2174%2F1568007023339337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568007023339337%26sid%3Dliteratum%253Aachs%26aulast%3DChavez-Noriega%26aufirst%3DL.%2BE.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26atitle%3DMetabotropic%2520glutamate%2520receptors%253A%2520potential%2520drug%2520targets%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520CNS%2520Neurol.%2520Disord.%26date%3D2002%26volume%3D1%26spage%3D261%26epage%3D281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref321"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref321'); return false;" data-citation="" class="refNumLink">321</a></strong><div class="NLM_citation" id="cit321"><span><span class="NLM_contrib-group">Cartmell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref321/cit321&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10490900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref321/cit321&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlaks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1999&pages=161-170&author=J.+Cartmellauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=The+metabotropic+glutamate+2%2F3+receptor+agonists+LY354740+and+LY379268+selectively+attenuate+phencyclidine+versus+d-amphetamine+motor+behaviors+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit321R"><div class="casContent"><span class="casTitleNuber">321</span><div class="casTitle"><span class="NLM_cas:atitle">The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats</span></div><div class="casAuthors">Cartmell, Jayne; Monn, James A.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Previous animal studies have indicated that drugs targeted at metabotropic glutamate (mGlu) receptors may be useful for treatment of psychosis.  In this article, the effects of the novel, potent, and selective mGlu2/3 receptor agonists LY354740 and LY379268, and the clin. effective agents clozapine and haloperidol, were investigated using phencyclidine (PCP; 5 mg/kg)- vs. d-amphetamine (AMP; 3 mg/kg)-evoked motor activities.  LY354740 (1-10 mg/kg s.c.), LY379268 (0.3-3 mg/kg s.c.), clozapine (1-10 mg/kg s.c.), and haloperidol (0.03-1 mg/kg s.c.) reversed the increases in ambulations, fine motor (nonambulatory) movements, and decreased time at rest evoked by PCP.  Furthermore, the inhibitions of the PCP response by the mGlu2/3 agonist LY379268, but not by clozapine, were completely reversed by the selective mGlu2/3 receptor antagonist LY341495.  Doses of LY354740 and LY379268 that blocked the effects on PCP had no effects on rotorod performance, and (with the exception of rearing behavior) had minimal effects on AMP-evoked motor activities.  Clozapine blocked AMP-induced rearing but enhanced AMP-induced ambulations and fine movements at the lower doses (1 and 3 mg/kg).  Unlike the mGlu2/3 agonists, the highest dose of clozapine tested (10 mg/kg) impaired animals on the rotorod.  Haloperidol potently blocked all PCP and AMP effects, but only at doses assocd. with motor impairment.  These data demonstrate that mGlu2/3 receptor agonists act via a unique mechanism to selectively block PCP-induced behaviors.  Moreover, the marked mGlu2/3 receptor-mediated inhibitions of PCP-evoked behaviors by LY354740 and LY379268, with minimal effects on AMP, may indicate potential antipsychotic effects in humans in the absence of dopamine mediated extrapyramidal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6C09T4kWFLVg90H21EOLACvtfcHk0ljpL6rKOL5bvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlaks7g%253D&md5=93425a0c85f8dfbea2a7cd5323e645c2</span></div><a href="/servlet/linkout?suffix=cit321&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCartmell%26aufirst%3DJ.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DThe%2520metabotropic%2520glutamate%25202%252F3%2520receptor%2520agonists%2520LY354740%2520and%2520LY379268%2520selectively%2520attenuate%2520phencyclidine%2520versus%2520d-amphetamine%2520motor%2520behaviors%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D291%26spage%3D161%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref322"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref322'); return false;" data-citation="" class="refNumLink">322</a></strong><div class="NLM_citation" id="cit322"><span><span class="NLM_contrib-group">Rorick-Kehn, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knitowski, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salhoff, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffey, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tizzano, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinzie, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref322/cit322&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-007-0758-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref322/cit322&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17384937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref322/cit322&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtlGktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2007&pages=121-136&author=L.+M.+Rorick-Kehnauthor=B.+G.+Johnsonauthor=K.+M.+Knitowskiauthor=C.+R.+Salhoffauthor=J.+M.+Witkinauthor=K.+W.+Perryauthor=K.+I.+Griffeyauthor=J.+P.+Tizzanoauthor=J.+A.+Monnauthor=D.+L.+McKinzieauthor=D.+D.+Schoepp&title=In+vivo+pharmacological+characterization+of+the+structurally+novel%2C+potent%2C+selective+mGlu2%2F3+receptor+agonist+LY404039+in+animal+models+of+psychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit322R"><div class="casContent"><span class="casTitleNuber">322</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders</span></div><div class="casAuthors">Rorick-Kehn, Linda M.; Johnson, Bryan G.; Knitowski, Karen M.; Salhoff, Craig R.; Witkin, Jeffrey M.; Perry, Kenneth W.; Griffey, Kelly I.; Tizzano, Joseph P.; Monn, James A.; McKinzie, David L.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Data from both preclin. and clin. studies have provided proof of concept that modulation of limbic and forebrain glutamate, via mGlu2/3 receptor agonists, might provide therapeutic benefits in many psychiatric disorders including schizophrenia and anxiety.  The aim of this study was to assess the efficacy of a structurally novel, potent, selective mGlu2/3 receptor agonist with improved bioavailability (LY404039) in animal models predictive of antipsychotic and anxiolytic efficacy.  LY404039 was assessed in amphetamine- and phencyclidine-induced hyperlocomotion, conditioned avoidance responding, fear-potentiated startle, marble burying, and rotarod behavioral tests.  Monoamine release and turnover were assessed using microdialysis and ex vivo tissue levels.  LY404039 attenuated amphetamine- and phencyclidine-induced hyperlocomotion (3-30 and 10 mg/kg, resp.).  LY404039 (3-10 mg/kg) inhibited conditioned avoidance responding.  LY404039 also reduced fear-potentiated startle in rats (3-30 μg/kg) and marble burying in mice (3-10 mg/kg), indicating anxiolytic-like effects.  Importantly, LY404039 did not produce sedative effects or motor impairment as measured by rotarod performance and lack of escape failures in the conditioned avoidance task (at doses up to 30 and 10 mg/kg, resp.).  LY404039 (10 mg/kg) also increased dopamine and serotonin release/turnover in the prefrontal cortex.  These results demonstrate the broad preclin. efficacy of LY404039 across multiple animal models of antipsychotic and anxiolytic efficacy.  Addnl., this compd. modulates mesocortical neurotransmission and provides a novel mechanism for the treatment of psychiatric disorders that may be assocd. with improved efficacy and reduced incidence of undesirable side effects.  As glutamatergic dysfunction has been linked to the etiol. of schizophrenia, clin. studies with more potent mGlu2/3 agonists, such as LY404039, may be useful to explore the validity of this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYlJEGsofLAbVg90H21EOLACvtfcHk0ljpL6rKOL5bvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtlGktr8%253D&md5=b829e3e415cd9bdaf44ac26ee8863edb</span></div><a href="/servlet/linkout?suffix=cit322&amp;dbid=16384&amp;doi=10.1007%2Fs00213-007-0758-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-007-0758-3%26sid%3Dliteratum%253Aachs%26aulast%3DRorick-Kehn%26aufirst%3DL.%2BM.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DKnitowski%26aufirst%3DK.%2BM.%26aulast%3DSalhoff%26aufirst%3DC.%2BR.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DPerry%26aufirst%3DK.%2BW.%26aulast%3DGriffey%26aufirst%3DK.%2BI.%26aulast%3DTizzano%26aufirst%3DJ.%2BP.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DMcKinzie%26aufirst%3DD.%2BL.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DIn%2520vivo%2520pharmacological%2520characterization%2520of%2520the%2520structurally%2520novel%252C%2520potent%252C%2520selective%2520mGlu2%252F3%2520receptor%2520agonist%2520LY404039%2520in%2520animal%2520models%2520of%2520psychiatric%2520disorders%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2007%26volume%3D193%26spage%3D121%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref323"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref323'); return false;" data-citation="" class="refNumLink">323</a></strong><div class="NLM_citation" id="cit323"><span><span class="NLM_contrib-group">Pinkerton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cube, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaffhauser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daggett, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J. M.</span><span> </span><span class="NLM_article-title">Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1565</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1565-1571&author=A.+B.+Pinkertonauthor=R.+V.+Cubeauthor=J.+H.+Hutchinsonauthor=J.+K.+Jamesauthor=M.+F.+Gardnerauthor=B.+A.+Roweauthor=H.+Schaffhauserauthor=D.+E.+Rodriguezauthor=U.+C.+Campbellauthor=L.+P.+Daggettauthor=J.+M.+Vernier&title=Allosteric+potentiators+of+the+metabotropic+glutamate+receptor+2+%28mGlu2%29.+Part+3%3A+Identification+and+biological+activity+of+indanone+containing+mGlu2+receptor+potentiators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit323&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DCube%26aufirst%3DR.%2BV.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DJames%26aufirst%3DJ.%2BK.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DRowe%26aufirst%3DB.%2BA.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DRodriguez%26aufirst%3DD.%2BE.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DDaggett%26aufirst%3DL.%2BP.%26aulast%3DVernier%26aufirst%3DJ.%2BM.%26atitle%3DAllosteric%2520potentiators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25202%2520%2528mGlu2%2529.%2520Part%25203%253A%2520Identification%2520and%2520biological%2520activity%2520of%2520indanone%2520containing%2520mGlu2%2520receptor%2520potentiators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1565%26epage%3D1571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref324"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref324'); return false;" data-citation="" class="refNumLink">324</a></strong><div class="NLM_citation" id="cit324"><span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberle, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, H. E.</span><span> </span><span class="NLM_article-title">Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=206-218&issue=Suppl.+1&author=C.+K.+Jonesauthor=E.+L.+Eberleauthor=S.+C.+Petersauthor=J.+A.+Monnauthor=H.+E.+Shannon&title=Analgesic+effects+of+the+selective+group+II+%28mGlu2%2F3%29+metabotropic+glutamate+receptor+agonists+LY379268+and+LY389795+in+persistent+and+inflammatory+pain+models+after+acute+and+repeated+dosing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit324&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DEberle%26aufirst%3DE.%2BL.%26aulast%3DPeters%26aufirst%3DS.%2BC.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DShannon%26aufirst%3DH.%2BE.%26atitle%3DAnalgesic%2520effects%2520of%2520the%2520selective%2520group%2520II%2520%2528mGlu2%252F3%2529%2520metabotropic%2520glutamate%2520receptor%2520agonists%2520LY379268%2520and%2520LY389795%2520in%2520persistent%2520and%2520inflammatory%2520pain%2520models%2520after%2520acute%2520and%2520repeated%2520dosing%26jtitle%3DNeuropharmacology%26date%3D2005%26volume%3D49%26issue%3DSuppl.%25201%26spage%3D206%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref325"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref325'); return false;" data-citation="" class="refNumLink">325</a></strong><div class="NLM_citation" id="cit325"><span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref325/cit325&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.103.048702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref325/cit325&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12660307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref325/cit325&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvF2lur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=116-123&author=G.+G.+Kinneyauthor=M.+Burnoauthor=U.+C.+Campbellauthor=L.+M.+Hernandezauthor=D.+Rodriguezauthor=L.+J.+Bristowauthor=P.+J.+Conn&title=Metabotropic+glutamate+subtype+5+receptors+modulate+locomotor+activity+and+sensorimotor+gating+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit325R"><div class="casContent"><span class="casTitleNuber">325</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents</span></div><div class="casAuthors">Kinney, Gene G.; Burno, Maryann; Campbell, Una C.; Hernandez, Lisa M.; Rodriguez, Dana; Bristow, Linda J.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-123</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Use-dependent N-methyl-D-asparate receptor (NMDAR) antagonists produce behaviors in human volunteers that resemble schizophrenia and exacerbate those behaviors in schizophrenic patients, suggesting that hypofunction of NMDAR-mediated neuronal circuitry may be involved in the etiol. of clin. schizophrenia.  Activation of the metabotropic glutamate receptor subtype 5 (mGluR5) enhances NMDAR-mediated currents in vitro.  Thus, activation of mGluR5 could potentiate hypofunctional NMDARs in neuronal circuitry relevant to schizophrenia.  To further elucidate the role of mGluR5, the present study examd. the effects of mGluR5 antagonist administration, with and without coadministration of the use-dependent NMDAR antagonist phencyclidine (PCP), on locomotor activity and prepulse inhibition (PPI) of the acoustic startle response in rodents.  We further examd. PPI in mGluR5 knockout mice.  Finally, we examd. PPI after administration of the mGluR5 agonist 2-chloro-5-hydroxyphenylglycine (CHPG) alone and in combination with amphetamine.  The data indicate that the mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine has no effect on locomotor activity or PPI by itself but does potentiate both PCP-induced locomotor activity and disruption of PPI.  We further found that mGluR5 knockout mice display consistent deficits in PPI relative to their wild-type controls.  Finally, the data indicate that CHPG has no effect on PPI by itself, but ameliorates amphetamine-induced disruption of PPI.  Collectively, these data suggest that mGluR5 receptors play a modulatory role on rodent PPI and locomotor behaviors and are consistent with the hypothesis that mGluR5 agonist/potentiator may represent a novel approach for antipsychotic drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf6hlEX7jl2LVg90H21EOLACvtfcHk0ljITJ2pgnOpgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvF2lur8%253D&md5=10d6738c19a05e1bbb2a63c04c86432f</span></div><a href="/servlet/linkout?suffix=cit325&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.048702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.048702%26sid%3Dliteratum%253Aachs%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DHernandez%26aufirst%3DL.%2BM.%26aulast%3DRodriguez%26aufirst%3DD.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DMetabotropic%2520glutamate%2520subtype%25205%2520receptors%2520modulate%2520locomotor%2520activity%2520and%2520sensorimotor%2520gating%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D116%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref326"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref326'); return false;" data-citation="" class="refNumLink">326</a></strong><div class="NLM_citation" id="cit326"><span><span class="NLM_contrib-group">Henry, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Masten, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markou, A.</span><span> </span><span class="NLM_article-title">The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1199</span><span class="NLM_x">–</span> <span class="NLM_lpage">1209</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=1199-1209&author=S.+A.+Henryauthor=V.+Lehmann-Mastenauthor=F.+Gaspariniauthor=M.+A.+Geyerauthor=A.+Markou&title=The+mGluR5+antagonist+MPEP%2C+but+not+the+mGluR2%2F3+agonist+LY314582%2C+augments+PCP+effects+on+prepulse+inhibition+and+locomotor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit326&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DS.%2BA.%26aulast%3DLehmann-Masten%26aufirst%3DV.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DMarkou%26aufirst%3DA.%26atitle%3DThe%2520mGluR5%2520antagonist%2520MPEP%252C%2520but%2520not%2520the%2520mGluR2%252F3%2520agonist%2520LY314582%252C%2520augments%2520PCP%2520effects%2520on%2520prepulse%2520inhibition%2520and%2520locomotor%2520activity%26jtitle%3DNeuropharmacology%26date%3D2002%26volume%3D43%26spage%3D1199%26epage%3D1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref327"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref327'); return false;" data-citation="" class="refNumLink">327</a></strong><div class="NLM_citation" id="cit327"><span><span class="NLM_contrib-group">Brody, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulawa, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conquet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span> </span><span class="NLM_article-title">Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref327/cit327&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref327/cit327&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14699440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref327/cit327&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=35-41&author=S.+A.+Brodyauthor=S.+C.+Dulawaauthor=F.+Conquetauthor=M.+A.+Geyer&title=Assessment+of+a+prepulse+inhibition+deficit+in+a+mutant+mouse+lacking+mGlu5+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit327R"><div class="casContent"><span class="casTitleNuber">327</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors</span></div><div class="casAuthors">Brody, S. A.; Dulawa, S. C.; Conquet, F.; Geyer, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-41</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The glutamate hypothesis of schizophrenia derived from evidence that phencyclidine, a noncompetitive N-methyl-D-aspartate (NMDA) antagonist, produces schizophrenia-like symptoms in healthy humans.  Sensorimotor gating, measured by prepulse inhibition (PPI), is a fundamental form of information processing that is deficient in schizophrenia patients and rodents treated with NMDA antagonists.  Hence, PPI is widely used to study the neurobiol. of schizophrenia.  As the use of PPI as a model of gating deficits in schizophrenia has become more widespread, it has become increasingly important to assess such deficits accurately.  Here we identify a possible role of mGluR5 in PPI by using wild type (WT) and mGluR5 knockout (KO) mice of two different background strains, 129SvPasIco and C57BL/6.  In both strains, PPI was disrupted dramatically in the mGluR5 KO mice throughout a range of interstimulus intervals and sensory modalities.  The present findings further support the glutamate hypothesis of schizophrenia and identify a functional role for mGluR5 in sensorimotor gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjaGWdVbLdtbVg90H21EOLACvtfcHk0ljITJ2pgnOpgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtr7P&md5=595be94962ebb72a7a60f93b5ad24f64</span></div><a href="/servlet/linkout?suffix=cit327&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001404%26sid%3Dliteratum%253Aachs%26aulast%3DBrody%26aufirst%3DS.%2BA.%26aulast%3DDulawa%26aufirst%3DS.%2BC.%26aulast%3DConquet%26aufirst%3DF.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26atitle%3DAssessment%2520of%2520a%2520prepulse%2520inhibition%2520deficit%2520in%2520a%2520mutant%2520mouse%2520lacking%2520mGlu5%2520receptors%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D35%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref328"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref328'); return false;" data-citation="" class="refNumLink">328</a></strong><div class="NLM_citation" id="cit328"><span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickel, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clements, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisnoski, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. L.,  Jr</span><span> </span><span class="NLM_article-title">A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref328/cit328&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.104.079244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref328/cit328&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15608073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref328/cit328&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=199-206&author=G.+G.+Kinneyauthor=J.+A.+O%E2%80%99Brienauthor=W.+Lemaireauthor=M.+Burnoauthor=D.+J.+Bickelauthor=M.+K.+Clementsauthor=T.+B.+Chenauthor=D.+D.+Wisnoskiauthor=C.+W.+Lindsleyauthor=P.+R.+Tillerauthor=S.+Smithauthor=M.+A.+Jacobsonauthor=C.+Surauthor=M.+E.+Dugganauthor=D.+J.+Pettiboneauthor=P.+J.+Connauthor=D.+L.+Williams&title=A+novel+selective+positive+allosteric+modulator+of+metabotropic+glutamate+receptor+subtype+5+has+in+vivo+activity+and+antipsychotic-like+effects+in+rat+behavioral+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit328R"><div class="casContent"><span class="casTitleNuber">328</span><div class="casTitle"><span class="NLM_cas:atitle">A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models</span></div><div class="casAuthors">Kinney, Gene G.; O'Brien, Julie A.; Lemaire, Wei; Burno, Maryann; Bickel, Denise J.; Clements, Michelle K.; Chen, Tsing-Bau; Wisnoski, David D.; Lindsley, Craig W.; Tiller, Philip R.; Smith, Sheri; Jacobson, Marlene A.; Sur, Cyrille; Duggan, Mark E.; Pettibone, Douglas J.; Conn, P. Jeffrey; Williams, David L., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">199-206</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We found that 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) is a potent and selective pos. allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5).  In Chinese hamster ovary cells expressing human mGluR5, CDPPB potentiated threshold responses to glutamate in fluorometric Ca2+ assays more than 7-fold with an EC50 value of approx. 27 nM.  At 1 μM, CDPPB shifted mGluR5 agonist concn. response curves to glutamate, quisqualate, and (R,S)-3,5-dihydroxyphenylglycine 3- to 9-fold to the left.  At higher concns., CDPPB exhibited agonist-like activity on cells expressing mGluR5.  No other activity was obsd. on any other mGluR or cell type at concns. up to 10 μM.  CDPPB had no effect on [3H]quisqualate binding to mGluR5 but did compete for binding of [3H]methoxyPEPy, an analog of the selective mGluR5 neg. allosteric modulator MPEP.  CDPPB was found to be brain penetrant and reversed amphetamine-induced locomotor activity and amphetamine-induced deficits in prepulse inhibition in rats, two models sensitive to antipsychotic drug treatment.  These results demonstrate that pos. allosteric modulation of mGluR5 produces behavioral effects, suggesting that such modulation serves as a viable approach to increasing mGluR5 activity in vivo.  These effects are consistent with the hypothesis that allosteric potentiation of mGluR5 may provide a novel approach for development of antipsychotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5MND_DZkDL7Vg90H21EOLACvtfcHk0lgYYHxrhgxdxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLg%253D&md5=371bb91ca8ac48cdf8b38c95634385da</span></div><a href="/servlet/linkout?suffix=cit328&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.079244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.079244%26sid%3Dliteratum%253Aachs%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DBickel%26aufirst%3DD.%2BJ.%26aulast%3DClements%26aufirst%3DM.%2BK.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DWisnoski%26aufirst%3DD.%2BD.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DTiller%26aufirst%3DP.%2BR.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26atitle%3DA%2520novel%2520selective%2520positive%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptor%2520subtype%25205%2520has%2520in%2520vivo%2520activity%2520and%2520antipsychotic-like%2520effects%2520in%2520rat%2520behavioral%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D199%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref329"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref329'); return false;" data-citation="" class="refNumLink">329</a></strong><div class="NLM_citation" id="cit329"><span><span class="NLM_contrib-group">Arai, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, M.</span><span> </span><span class="NLM_article-title">Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref329/cit329&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2174%2F138945007780618490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref329/cit329&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17504103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref329/cit329&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVWmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=583-602&author=A.+C.+Araiauthor=M.+Kessler&title=Pharmacology+of+ampakine+modulators%3A+from+AMPA+receptors+to+synapses+and+behavior"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit329R"><div class="casContent"><span class="casTitleNuber">329</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior</span></div><div class="casAuthors">Arai, A. C.; Kessler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">583-602</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Ampakines are drugs structurally derived from aniracetam that potentiate currents mediated by AMPA type glutamate receptors.  These drugs slow deactivation and attenuate desensitization of AMPA receptor currents, increase synaptic responses and enhance long-term potentiation.  This review focuses mainly on recent physiol. studies and on evidence for two distinct subfamilies.  Type I compds. like CX546 are very effective in prolonging synaptic responses while type II compds. like CX516 mainly increase response amplitude.  Type I and II drugs do not compete in binding assays and thus presumably act through sep. sites.  Their differences are likely to have consequences also for synaptic plasticity and behavior.  Thus, while all ampakines facilitated long-term potentiation, only CX546 enhanced long-term depression.  Further discussed are studies showing that ampakine effects vary substantially between neurons, with increases in EPSCs being larger in CA1 pyramidal cells than in thalamus and in hippocampal interneurons.  In behavioral tests, ampakines facilitate learning in many paradigms including odor discrimination, spatial mazes, and conditioning, and they improved short-term memory in a non-matching-to-sample task.  Pos. results were also obtained in various psychol. tests with human subjects.  The drugs were effective in correcting behaviors in various animal models of schizophrenia and depression.  Lastly, evidence is discussed that ampakines have few adverse effects at therapeutically relevant concns. and that they protect neurons against neurotoxic insults, in part by mobilizing growth factors like BDNF.  Type II drugs like CX516 in particular appear to be inherently safe since their ability to prolong responses is kinetically limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoUgfoEMXCALVg90H21EOLACvtfcHk0lgYYHxrhgxdxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVWmurk%253D&md5=77ecd4442f0c551eaec7a9d52c218efc</span></div><a href="/servlet/linkout?suffix=cit329&amp;dbid=16384&amp;doi=10.2174%2F138945007780618490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007780618490%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DA.%2BC.%26aulast%3DKessler%26aufirst%3DM.%26atitle%3DPharmacology%2520of%2520ampakine%2520modulators%253A%2520from%2520AMPA%2520receptors%2520to%2520synapses%2520and%2520behavior%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26spage%3D583%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref330"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref330'); return false;" data-citation="" class="refNumLink">330</a></strong><div class="NLM_citation" id="cit330"><span><span class="NLM_contrib-group">Dunlop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, K.</span><span> </span><span class="NLM_article-title">Glutamate transport inhibitors as targets for treating psychosis</span> <span class="citation_source-journal">Drug Discovery Today: Ther. Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref330/cit330&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ddstr.2006.10.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=533-537&author=J.+Dunlopauthor=K.+Marquis&title=Glutamate+transport+inhibitors+as+targets+for+treating+psychosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit330&amp;dbid=16384&amp;doi=10.1016%2Fj.ddstr.2006.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddstr.2006.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DMarquis%26aufirst%3DK.%26atitle%3DGlutamate%2520transport%2520inhibitors%2520as%2520targets%2520for%2520treating%2520psychosis%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Ther.%2520Strategies%26date%3D2006%26volume%3D3%26spage%3D533%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref331"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref331'); return false;" data-citation="" class="refNumLink">331</a></strong><div class="NLM_citation" id="cit331"><span><span class="NLM_contrib-group">McCullumsmith, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meador-Woodruff, J. H.</span><span> </span><span class="NLM_article-title">Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">368</span><span class="NLM_x">–</span> <span class="NLM_lpage">375</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=368-375&author=R.+E.+McCullumsmithauthor=J.+H.+Meador-Woodruff&title=Striatal+excitatory+amino+acid+transporter+transcript+expression+in+schizophrenia%2C+bipolar+disorder%2C+and+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit331&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCullumsmith%26aufirst%3DR.%2BE.%26aulast%3DMeador-Woodruff%26aufirst%3DJ.%2BH.%26atitle%3DStriatal%2520excitatory%2520amino%2520acid%2520transporter%2520transcript%2520expression%2520in%2520schizophrenia%252C%2520bipolar%2520disorder%252C%2520and%2520major%2520depressive%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2002%26volume%3D26%26spage%3D368%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref332"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref332'); return false;" data-citation="" class="refNumLink">332</a></strong><div class="NLM_citation" id="cit332"><span><span class="NLM_contrib-group">Crino, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shumate, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulter, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks-Kayal, A. R.</span><span> </span><span class="NLM_article-title">Increased expression of the neuronal glutamate transporter (EAAT3/EAAC1) in hippocampal and neocortical epilepsy</span> <span class="citation_source-journal">Epilepsia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=211-218&author=P.+B.+Crinoauthor=H.+Jinauthor=M.+D.+Shumateauthor=M.+B.+Robinsonauthor=D.+A.+Coulterauthor=A.+R.+Brooks-Kayal&title=Increased+expression+of+the+neuronal+glutamate+transporter+%28EAAT3%2FEAAC1%29+in+hippocampal+and+neocortical+epilepsy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit332&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrino%26aufirst%3DP.%2BB.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DShumate%26aufirst%3DM.%2BD.%26aulast%3DRobinson%26aufirst%3DM.%2BB.%26aulast%3DCoulter%26aufirst%3DD.%2BA.%26aulast%3DBrooks-Kayal%26aufirst%3DA.%2BR.%26atitle%3DIncreased%2520expression%2520of%2520the%2520neuronal%2520glutamate%2520transporter%2520%2528EAAT3%252FEAAC1%2529%2520in%2520hippocampal%2520and%2520neocortical%2520epilepsy%26jtitle%3DEpilepsia%26date%3D2002%26volume%3D43%26spage%3D211%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref333"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref333'); return false;" data-citation="" class="refNumLink">333</a></strong><div class="NLM_citation" id="cit333"><span><span class="NLM_contrib-group">Wroblewska, B.</span><span> </span><span class="NLM_article-title">NAAG as a neurotransmitter</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">576</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref333/cit333&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2F0-387-30172-0_23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref333/cit333&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16802723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref333/cit333&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFygtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=576&publication_year=2006&pages=317-325&author=B.+Wroblewska&title=NAAG+as+a+neurotransmitter"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit333R"><div class="casContent"><span class="casTitleNuber">333</span><div class="casTitle"><span class="NLM_cas:atitle">NAAG as a neurotransmitter</span></div><div class="casAuthors">Wroblewska, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">576</span>
        (<span class="NLM_cas:issue">N-Acetylaspartate</span>),
    <span class="NLM_cas:pages">317-325</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  A review on the role of N-acetylaspartylglutamate (NAAG) as a neurotransmitter.  It discusses NAAG in the context of pain models and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRSgVqaVFABLVg90H21EOLACvtfcHk0lgYYHxrhgxdxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFygtrs%253D&md5=19e8133bd82cc9e117e85bcded7f9b2d</span></div><a href="/servlet/linkout?suffix=cit333&amp;dbid=16384&amp;doi=10.1007%2F0-387-30172-0_23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F0-387-30172-0_23%26sid%3Dliteratum%253Aachs%26aulast%3DWroblewska%26aufirst%3DB.%26atitle%3DNAAG%2520as%2520a%2520neurotransmitter%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2006%26volume%3D576%26spage%3D317%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref334"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref334'); return false;" data-citation="" class="refNumLink">334</a></strong><div class="NLM_citation" id="cit334"><span><span class="NLM_contrib-group">Wroblewska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pshenichkin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neale, J. H.</span><span> </span><span class="NLM_article-title"><i>N</i>-Acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref334/cit334&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1046%2Fj.1471-4159.1997.69010174.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref334/cit334&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9202308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref334/cit334&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2sXktV2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=174-181&author=B.+Wroblewskaauthor=J.+T.+Wroblewskiauthor=S.+Pshenichkinauthor=A.+Surinauthor=S.+E.+Sullivanauthor=J.+H.+Neale&title=N-Acetylaspartylglutamate+selectively+activates+mGluR3+receptors+in+transfected+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit334R"><div class="casContent"><span class="casTitleNuber">334</span><div class="casTitle"><span class="NLM_cas:atitle">N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells</span></div><div class="casAuthors">Wroblewska, Barbara; Wroblewski, Jarda T.; Pshenichkin, Sergei; Surin, Alexander; Sullivan, Suzanne E.; Neale, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-181</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">In previous studies, we demonstrated that the neuropeptide, N-acetylaspartylglutamate (NAAG), meets the traditional criteria for a neurotransmitter and selectively activates metabotropic glutamate receptor mGluR2 or mGluR3 in cultured cerebellar granule cells and glia.  Sequence homol. and pharmacol. data suggest that these two receptors are highly related structurally and functionally.  To define more rigorously the receptor specificity of NAAG, cloned rat cDNAs for mGluR1-6 were transiently or stably transfected into Chinese hamster ovary cells and human embryonic kidney cells and assayed for their second messenger responses to the two endogenous neurotransmitters, glutamate and NAAG, as well as to metabotropic receptor agonists, trans-1-aminocyclopentane-1,3-dicarboxylate (trans-ACPD) and L-2-amino-4-phosphonobutyrate (L-AP4).  Despite the high degree of relatedness of mGluR2 and mGluR3, NAAG selectively activated the mGluR3 receptor.  NAAG activated neither mGluR2 nor mGluR1, mGluR4, mGluR5, or mGluR6.  The mGluR agonist, trans-ACPD, activated each of the transfected receptors, whereas L-AP4 activated mGluR4 and mGluR6, consistent with the published selectivity of these agonists.  Hybrid cDNA constructs of the extracellular domains of mGluR2 and mGluR3 were independently fused with the transmembrane and cytoplasmic domain of mGluR1a.  This latter receptor domain is coupled to phosphoinositol turnover, and its activation increases intracellular calcium.  The cells transfected with these chimeric receptors responded to activation by glutamate and trans-ACPD with increases in intracellular calcium.  NAAG activated the chimeric receptor that contained the extracellular domain of mGluR3 and did not activate the mGluR2 chimera.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGOi2H5RX3W7Vg90H21EOLACvtfcHk0lgX5OGEEl7ABg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktV2msrk%253D&md5=ebcceed22e3f04dfe9701804e47cb4b0</span></div><a href="/servlet/linkout?suffix=cit334&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1997.69010174.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1997.69010174.x%26sid%3Dliteratum%253Aachs%26aulast%3DWroblewska%26aufirst%3DB.%26aulast%3DWroblewski%26aufirst%3DJ.%2BT.%26aulast%3DPshenichkin%26aufirst%3DS.%26aulast%3DSurin%26aufirst%3DA.%26aulast%3DSullivan%26aufirst%3DS.%2BE.%26aulast%3DNeale%26aufirst%3DJ.%2BH.%26atitle%3DN-Acetylaspartylglutamate%2520selectively%2520activates%2520mGluR3%2520receptors%2520in%2520transfected%2520cells%26jtitle%3DJ.%2520Neurochem.%26date%3D1997%26volume%3D69%26spage%3D174%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref335"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref335'); return false;" data-citation="" class="refNumLink">335</a></strong><div class="NLM_citation" id="cit335"><span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neale, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomper, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">NAAG peptidase inhibitors and their potential for diagnosis and therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1026</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref335/cit335&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnrd1903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref335/cit335&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16341066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref335/cit335&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1015-1026&author=J.+Zhouauthor=J.+H.+Nealeauthor=M.+G.+Pomperauthor=A.+P.+Kozikowski&title=NAAG+peptidase+inhibitors+and+their+potential+for+diagnosis+and+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit335R"><div class="casContent"><span class="casTitleNuber">335</span><div class="casTitle"><span class="NLM_cas:atitle">NAAG peptidase inhibitors and their potential for diagnosis and therapy</span></div><div class="casAuthors">Zhou, Jia; Neale, Joseph H.; Pomper, Martin G.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1015-1026</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Modulation of N-acetyl-L-aspartyl-L-glutamate peptidase activity with small-mol. inhibitors holds promise for a wide variety of diseases that involve glutamatergic transmission, and has implications for the diagnosis and therapy of cancer.  This new class of compds., of which at least one has entered clin. trials and proven to be well tolerated, has demonstrated efficacy in exptl. models of pain, schizophrenia, amyotrophic lateral sclerosis, traumatic brain injury and, when appropriately functionalized, can image prostate cancer.  Further investigation of these promising drug candidates will be needed to bring them to the marketplace.  The recent publication of the x-ray crystal structure for the enzymic target of these compds. should facilitate the development of other new agents with enhanced activity that could improve both the diagnosis and treatment of neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5SLEevwkG37Vg90H21EOLACvtfcHk0lgX5OGEEl7ABg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjJ&md5=0b869a52270f951f4e03c458672e373f</span></div><a href="/servlet/linkout?suffix=cit335&amp;dbid=16384&amp;doi=10.1038%2Fnrd1903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1903%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DNeale%26aufirst%3DJ.%2BH.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DNAAG%2520peptidase%2520inhibitors%2520and%2520their%2520potential%2520for%2520diagnosis%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D1015%26epage%3D1026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref336"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref336'); return false;" data-citation="" class="refNumLink">336</a></strong><div class="NLM_citation" id="cit336"><span><span class="NLM_contrib-group">Salmi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, B.</span><span> </span><span class="NLM_article-title">Dihydrexidine. The First Full Dopamine D1 Receptor Agonist</span> <span class="citation_source-journal">CNS Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">230</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=230-242&author=P.+Salmiauthor=R.+Isacsonauthor=B.+Kull&title=Dihydrexidine.+The+First+Full+Dopamine+D1+Receptor+Agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit336&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalmi%26aufirst%3DP.%26aulast%3DIsacson%26aufirst%3DR.%26aulast%3DKull%26aufirst%3DB.%26atitle%3DDihydrexidine.%2520The%2520First%2520Full%2520Dopamine%2520D1%2520Receptor%2520Agonist%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2004%26volume%3D10%26spage%3D230%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref337"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref337'); return false;" data-citation="" class="refNumLink">337</a></strong><div class="NLM_citation" id="cit337"><span><span class="NLM_contrib-group">Castner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman-Rakic, P. S.</span><span> </span><span class="NLM_article-title">Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">2020</span><span class="NLM_x">–</span> <span class="NLM_lpage">2022</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=2020-2022&author=S.+A.+Castnerauthor=G.+V.+Williamsauthor=P.+S.+Goldman-Rakic&title=Reversal+of+antipsychotic-induced+working+memory+deficits+by+short-term+dopamine+D1+receptor+stimulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit337&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCastner%26aufirst%3DS.%2BA.%26aulast%3DWilliams%26aufirst%3DG.%2BV.%26aulast%3DGoldman-Rakic%26aufirst%3DP.%2BS.%26atitle%3DReversal%2520of%2520antipsychotic-induced%2520working%2520memory%2520deficits%2520by%2520short-term%2520dopamine%2520D1%2520receptor%2520stimulation%26jtitle%3DScience%26date%3D2000%26volume%3D287%26spage%3D2020%26epage%3D2022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref338"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref338'); return false;" data-citation="" class="refNumLink">338</a></strong><div class="NLM_citation" id="cit338"><span><span class="NLM_contrib-group">Goldman-Rakic, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siever, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G. V.</span><span> </span><span class="NLM_article-title">Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref338/cit338&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-004-1793-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref338/cit338&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15118803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref338/cit338&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVahtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2004&pages=3-16&author=P.+S.+Goldman-Rakicauthor=S.+A.+Castnerauthor=T.+H.+Svenssonauthor=L.+J.+Sieverauthor=G.+V.+Williams&title=Targeting+the+dopamine+D1+receptor+in+schizophrenia%3A+insights+for+cognitive+dysfunction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit338R"><div class="casContent"><span class="casTitleNuber">338</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D1 receptor in schizophrenia: Insights for cognitive dysfunction</span></div><div class="casAuthors">Goldman-Rakic, Patricia S.; Castner, Stacy A.; Svensson, Torgny H.; Siever, Larry J.; Williams, Graham V.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review with refs.  Background and rationale: Reinstatement of the function of working memory, the cardinal cognitive process essential for human reasoning and judgment, is potentially the most intractable problem for the treatment of schizophrenia.  Since deficits in working memory are assocd. with dopamine dysregulation and altered D1 receptor signaling within prefrontal cortex, we present the case for targeting novel drug therapies towards enhancing prefrontal D1 stimulation for the amelioration of the debilitating cognitive deficits in schizophrenia.  Objectives: This review examines the role of dopamine in regulating cellular and circuit function within prefrontal cortex in order to understand the significance of the dopamine dysregulation found in schizophrenia and related non-human primate models.  By revealing the assocns. among prefrontal neuronal function, dopamine and D1 signaling, and cognition, we seek to pinpoint the mechanisms by which dopamine modulates working memory processes and how these mechanisms may be exploited to improve cognitive function.  Results and conclusions: Dopamine deficiency within dorsolateral prefrontal cortex leads to abnormal recruitment of this region by cognitive tasks.  Both preclin. and clin. studies have demonstrated a direct relationship between prefrontal dopamine function and the integrity of working memory, suggesting that insufficient D1 receptor signaling in this region results in cognitive deficits.  Moreover, working memory deficits can be ameliorated by treatments that augment D1 receptor stimulation, indicating that this target presents a unique opportunity for the restoration of cognitive function in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp539YARYKsU7Vg90H21EOLACvtfcHk0lgX5OGEEl7ABg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVahtL0%253D&md5=814e05ee453cf0aaf6ae9b7b0fe0ef59</span></div><a href="/servlet/linkout?suffix=cit338&amp;dbid=16384&amp;doi=10.1007%2Fs00213-004-1793-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-004-1793-y%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman-Rakic%26aufirst%3DP.%2BS.%26aulast%3DCastner%26aufirst%3DS.%2BA.%26aulast%3DSvensson%26aufirst%3DT.%2BH.%26aulast%3DSiever%26aufirst%3DL.%2BJ.%26aulast%3DWilliams%26aufirst%3DG.%2BV.%26atitle%3DTargeting%2520the%2520dopamine%2520D1%2520receptor%2520in%2520schizophrenia%253A%2520insights%2520for%2520cognitive%2520dysfunction%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2004%26volume%3D174%26spage%3D3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref339"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref339'); return false;" data-citation="" class="refNumLink">339</a></strong><div class="NLM_citation" id="cit339"><span><span class="NLM_contrib-group">Millan, M. J.; Mannoury, I. C.; Novi, F.; Maggio, R.; Audinot, V.; Newman-Tancredi, A.; Cussac, D.; Pasteau, V.; Boutin, J. A.; Dubuffet, T.; Lavielle, G.</span><span> </span><span class="NLM_article-title">S33138, a preferential dopamine D<sub>3</sub> versus D<sub>2</sub> receptor antagonist and potential antipsychotic agent. I. Receptor-binding profile and functional actions at G-protein coupled receptors</span>.  <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Millan%2C+M.+J.%3B+Mannoury%2C+I.+C.%3B+Novi%2C+F.%3B+Maggio%2C+R.%3B+Audinot%2C+V.%3B+Newman-Tancredi%2C+A.%3B+Cussac%2C+D.%3B+Pasteau%2C+V.%3B+Boutin%2C+J.+A.%3B+Dubuffet%2C+T.%3B+Lavielle%2C+G.+S33138%2C+a+preferential+dopamine+D3+versus+D2+receptor+antagonist+and+potential+antipsychotic+agent.+I.+Receptor-binding+profile+and+functional+actions+at+G-protein+coupled+receptors.+J.+Pharmacol.+Exp.+Ther.%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit339&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DS33138%252C%2520a%2520preferential%2520dopamine%2520D3%2520versus%2520D2%2520receptor%2520antagonist%2520and%2520potential%2520antipsychotic%2520agent.%2520I.%2520Receptor-binding%2520profile%2520and%2520functional%2520actions%2520at%2520G-protein%2520coupled%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref340"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref340'); return false;" data-citation="" class="refNumLink">340</a></strong><div class="NLM_citation" id="cit340"><span><span class="NLM_contrib-group">Van Tol, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunzow, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niznik, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, O.</span><span> </span><span class="NLM_article-title">Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">–</span> <span class="NLM_lpage">614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref340/cit340&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2F350610a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref340/cit340&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1840645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref340/cit340&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK38XhsV2n" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1991&pages=610-614&author=H.+H.+Van+Tolauthor=J.+R.+Bunzowauthor=H.+C.+Guanauthor=R.+K.+Sunaharaauthor=P.+Seemanauthor=H.+B.+Niznikauthor=O.+Civelli&title=Cloning+of+the+gene+for+a+human+dopamine+D4+receptor+with+high+affinity+for+the+antipsychotic+clozapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit340R"><div class="casContent"><span class="casTitleNuber">340</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine</span></div><div class="casAuthors">Van Tol, Hubert H. M.; Bunzow, James R.; Guan, Hong Chang; Sunahara, Roger K.; Seeman, Philip; Niznik, Hyman B.; Civelli, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">6319</span>),
    <span class="NLM_cas:pages">610-14</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The cloning of a gene that encodes a clozapine-sensitive dopamine receptor, D4 is reported.  The D4 receptor gene has high homol. to the human dopamine D2 and D3 receptor genes.  The pharmacol. characteristics of this receptor resemble those of the D2 and D3 receptors, but its affinity for clozapine is one order of magnitude higher.  Recognition and characterization of this clozapine neuroleptic site may prove useful in the design of new types of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpneU9aH4jnoLVg90H21EOLACvtfcHk0libtuSkMUE4eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsV2n&md5=de5f7ade54d85f54181c53d15d6af169</span></div><a href="/servlet/linkout?suffix=cit340&amp;dbid=16384&amp;doi=10.1038%2F350610a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F350610a0%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BTol%26aufirst%3DH.%2BH.%26aulast%3DBunzow%26aufirst%3DJ.%2BR.%26aulast%3DGuan%26aufirst%3DH.%2BC.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DNiznik%26aufirst%3DH.%2BB.%26aulast%3DCivelli%26aufirst%3DO.%26atitle%3DCloning%2520of%2520the%2520gene%2520for%2520a%2520human%2520dopamine%2520D4%2520receptor%2520with%2520high%2520affinity%2520for%2520the%2520antipsychotic%2520clozapine%26jtitle%3DNature%26date%3D1991%26volume%3D350%26spage%3D610%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref341"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref341'); return false;" data-citation="" class="refNumLink">341</a></strong><div class="NLM_citation" id="cit341"><span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grady, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsapakis, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarazi, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldessarini, R. J.</span><span> </span><span class="NLM_article-title">Regulation of working memory by dopamine D4 receptor in rats</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1648</span><span class="NLM_x">–</span> <span class="NLM_lpage">1655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=1648-1655&author=K.+Zhangauthor=C.+J.+Gradyauthor=E.+M.+Tsapakisauthor=S.+L.+Andersenauthor=F.+I.+Taraziauthor=R.+J.+Baldessarini&title=Regulation+of+working+memory+by+dopamine+D4+receptor+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit341&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DGrady%26aufirst%3DC.%2BJ.%26aulast%3DTsapakis%26aufirst%3DE.%2BM.%26aulast%3DAndersen%26aufirst%3DS.%2BL.%26aulast%3DTarazi%26aufirst%3DF.%2BI.%26aulast%3DBaldessarini%26aufirst%3DR.%2BJ.%26atitle%3DRegulation%2520of%2520working%2520memory%2520by%2520dopamine%2520D4%2520receptor%2520in%2520rats%26jtitle%3DNeuropsychopharmacology%26date%3D2004%26volume%3D29%26spage%3D1648%26epage%3D1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref342"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref342'); return false;" data-citation="" class="refNumLink">342</a></strong><div class="NLM_citation" id="cit342"><span><span class="NLM_contrib-group">Arnsten, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, K.</span><span> </span><span class="NLM_article-title">The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2000&pages=405-410&author=A.+F.+Arnstenauthor=B.+Murphyauthor=K.+Merchant&title=The+selective+dopamine+D4+receptor+antagonist%2C+PNU-101387G%2C+prevents+stress-induced+cognitive+deficits+in+monkeys"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit342&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArnsten%26aufirst%3DA.%2BF.%26aulast%3DMurphy%26aufirst%3DB.%26aulast%3DMerchant%26aufirst%3DK.%26atitle%3DThe%2520selective%2520dopamine%2520D4%2520receptor%2520antagonist%252C%2520PNU-101387G%252C%2520prevents%2520stress-induced%2520cognitive%2520deficits%2520in%2520monkeys%26jtitle%3DNeuropsychopharmacology%26date%3D2000%26volume%3D23%26spage%3D405%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref343"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref343'); return false;" data-citation="" class="refNumLink">343</a></strong><div class="NLM_citation" id="cit343"><span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collinson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragan, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridgill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saywell, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tricklebank, M. D.</span><span> </span><span class="NLM_article-title">L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">1256</span><span class="NLM_x">–</span> <span class="NLM_lpage">1263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref343/cit343&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9400001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref343/cit343&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1cXis1Cqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=1256-1263&author=L.+J.+Bristowauthor=N.+Collinsonauthor=G.+P.+Cookauthor=N.+Curtisauthor=S.+B.+Freedmanauthor=J.+J.+Kulagowskiauthor=P.+D.+Leesonauthor=S.+Patelauthor=C.+I.+Raganauthor=M.+Ridgillauthor=K.+L.+Saywellauthor=M.+D.+Tricklebank&title=L-745%2C870%2C+a+subtype+selective+dopamine+D4+receptor+antagonist%2C+does+not+exhibit+a+neuroleptic-like+profile+in+rodent+behavioral+tests"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit343R"><div class="casContent"><span class="casTitleNuber">343</span><div class="casTitle"><span class="NLM_cas:atitle">L-745870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests</span></div><div class="casAuthors">Bristow, Linda J.; Collinson, Neil; Cook, Gina P.; Curtis, Neil; Freedman, Stephen B.; Kulagowski, Janusz J.; Leeson, Paul D.; Patel, Smita; Ragan, C. Ian; Ridgill, Mark; Saywell, Kay L.; Tricklebank, Mark D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1256-1263</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">This study examd. the high-affinity, selective dopamine D4 receptor antagonist, L-745870 (3-{[4-(4-chlorophenyl)piperazin-1-yl]methyl}-1H-pyrrolo[2,3-b]pyridine) in rodent behavioral models used to predict antipsychotic potential and side-effect liabilities in humans.  In contrast to the classical neuroleptic, haloperidol, and the atypical neuroleptic, clozapine, L-745870 failed to antagonize amphetamine-induced hyperactivity in mice or impair conditioned avoidance responding in the rat at doses selectively blocking D4 receptors.  Furthermore, L-745870 failed to reverse the deficit in prepulse inhibition of acoustic startle responding induced by the nonselective dopamine D2/3/4 receptor agonist apomorphine, an effect which was abolished in rats pretreated with the D2/3 receptor antagonist, raclopride (0.2 mg/kg s.c.).  L-745870 had no effect on apomorphine-induced stereotypy in the rat but did induce catalepsy in the mouse, albeit at a high dose of 100 mg/kg, which is likely to occupy dopamine D2 receptors in vivo.  High doses also impaired motor performance; in rats L-745870 significantly reduced spontaneous locomotor activity (min. ED = 30 mg/kg) and in mice, L-745870 reduced the time spent on a rotarod revolving at 15 rpm (min. ED = 100 mg/kg).  Altogether these results suggest that dopamine D4 receptor antagonism is not responsible for the ability of clozapine to attenuate amphetamine-induced hyperactivity and conditioned avoidance responding in rodents.  Furthermore, the lack of effect of L-745870 in these behavioral tests is consistent with the inability of the compd. to alleviate psychotic symptoms in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-i7KBCKHpxrVg90H21EOLACvtfcHk0libtuSkMUE4eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1Cqtg%253D%253D&md5=6fa87b67fd755980d2c41851e444de1b</span></div><a href="/servlet/linkout?suffix=cit343&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DCollinson%26aufirst%3DN.%26aulast%3DCook%26aufirst%3DG.%2BP.%26aulast%3DCurtis%26aufirst%3DN.%26aulast%3DFreedman%26aufirst%3DS.%2BB.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DRagan%26aufirst%3DC.%2BI.%26aulast%3DRidgill%26aufirst%3DM.%26aulast%3DSaywell%26aufirst%3DK.%2BL.%26aulast%3DTricklebank%26aufirst%3DM.%2BD.%26atitle%3DL-745%252C870%252C%2520a%2520subtype%2520selective%2520dopamine%2520D4%2520receptor%2520antagonist%252C%2520does%2520not%2520exhibit%2520a%2520neuroleptic-like%2520profile%2520in%2520rodent%2520behavioral%2520tests%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D1256%26epage%3D1263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref344"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref344'); return false;" data-citation="" class="refNumLink">344</a></strong><div class="NLM_citation" id="cit344"><span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragan, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seabrook, G. R.</span><span> </span><span class="NLM_article-title">Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1997&pages=186-188&author=L.+J.+Bristowauthor=M.+S.+Kramerauthor=J.+Kulagowskiauthor=S.+Patelauthor=C.+I.+Raganauthor=G.+R.+Seabrook&title=Schizophrenia+and+L-745%2C870%2C+a+novel+dopamine+D4+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit344&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DKramer%26aufirst%3DM.%2BS.%26aulast%3DKulagowski%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DRagan%26aufirst%3DC.%2BI.%26aulast%3DSeabrook%26aufirst%3DG.%2BR.%26atitle%3DSchizophrenia%2520and%2520L-745%252C870%252C%2520a%2520novel%2520dopamine%2520D4%2520receptor%2520antagonist%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1997%26volume%3D18%26spage%3D186%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref345"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref345'); return false;" data-citation="" class="refNumLink">345</a></strong><div class="NLM_citation" id="cit345"><span><span class="NLM_contrib-group">Gazi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nozulak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoeffter, P.</span><span> </span><span class="NLM_article-title">NGD 94-1 as an agonist at human recombinant dopamine D4.4 receptors expressed in HEK293 cells</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">R9</span><span class="NLM_x">–</span> <span class="NLM_lpage">R10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1999&pages=R9-R10&author=L.+Gaziauthor=B.+Sommerauthor=J.+Nozulakauthor=P.+Schoeffter&title=NGD+94-1+as+an+agonist+at+human+recombinant+dopamine+D4.4+receptors+expressed+in+HEK293+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit345&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGazi%26aufirst%3DL.%26aulast%3DSommer%26aufirst%3DB.%26aulast%3DNozulak%26aufirst%3DJ.%26aulast%3DSchoeffter%26aufirst%3DP.%26atitle%3DNGD%252094-1%2520as%2520an%2520agonist%2520at%2520human%2520recombinant%2520dopamine%2520D4.4%2520receptors%2520expressed%2520in%2520HEK293%2520cells%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D372%26spage%3DR9%26epage%3DR10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref346"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref346'); return false;" data-citation="" class="refNumLink">346</a></strong><div class="NLM_citation" id="cit346"><span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croston, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currier, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalding, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs-Thomson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacksell, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span> </span><span class="NLM_article-title">5-Hydroxytryptamine<sub>2a</sub> receptor inverse agonists as antipsychotics</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref346/cit346&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11561089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref346/cit346&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFWltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=268-276&author=D.+M.+Weinerauthor=E.+S.+Bursteinauthor=N.+Nashauthor=G.+E.+Crostonauthor=E.+A.+Currierauthor=K.+E.+Vanoverauthor=S.+C.+Harveyauthor=E.+Donohueauthor=H.+C.+Hansenauthor=C.+M.+Anderssonauthor=T.+A.+Spaldingauthor=D.+F.+Gibsonauthor=K.+Krebs-Thomsonauthor=S.+B.+Powellauthor=M.+A.+Geyerauthor=U.+Hacksellauthor=M.+R.+Brann&title=5-Hydroxytryptamine2a+receptor+inverse+agonists+as+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit346R"><div class="casContent"><span class="casTitleNuber">346</span><div class="casTitle"><span class="NLM_cas:atitle">5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics</span></div><div class="casAuthors">Weiner, D. M.; Burstein, E. S.; Nash, N.; Croston, G. E.; Currier, E. A.; Vanover, K. E.; Harvey, S. C.; Donohue, E.; Hansen, H. C.; Andersson, C. M.; Spalding, T. A.; Gibson, D. F. C.; Krebs-Thomson, K.; Powell, S. B.; Geyer, M. A.; Hacksell, U.; Brann, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">268-276</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have used a cell-based functional assay to define the pharmacol. profiles of a wide range of central nervous system active compds. as agonists, competitive antagonists, and inverse agonists at almost all known monoaminergic G-protein-coupled receptor (GPCR) subtypes.  Detailed profiling of 40 antipsychotics confirmed that as expected, most of these agents are potent competitive antagonists of the dopamine D2 receptor.  Surprisingly, this anal. also revealed that most are potent and fully efficacious 5-hydroxytryptamine (5-HT)2A receptor inverse agonists.  No other mol. property was shared as universally by this class of compds.  Furthermore, comparisons of receptor potencies revealed that antipsychotics with the highest extrapyramidal side effects (EPS) liability are significantly more potent at D2 receptors, the EPS-sparing atypical agents had relatively higher potencies at 5-HT2A receptors, while three were significantly more potent at 5-HT2A receptors.  Functional high-throughput screening of a diverse chem. library identified 530 ligands with inverse agonist activity at 5-HT2A receptors, including several series of compds. related to known antipsychotics, as well as a no. of novel chemistries.  An analog of one of the novel chem. series, AC-90179, was pharmacol. profiled against the remaining monoaminergic GPCRs and a highly selective 5-HT2A receptor inverse agonist.  The behavioral pharmacol. of AC-90179 is characteristic of an atypical antipsychotic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz5gySB-lx-LVg90H21EOLACvtfcHk0limZf1AsZrZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFWltb8%253D&md5=0dfb323ac371f6c494236e32eb2ce032</span></div><a href="/servlet/linkout?suffix=cit346&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26aulast%3DNash%26aufirst%3DN.%26aulast%3DCroston%26aufirst%3DG.%2BE.%26aulast%3DCurrier%26aufirst%3DE.%2BA.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DHarvey%26aufirst%3DS.%2BC.%26aulast%3DDonohue%26aufirst%3DE.%26aulast%3DHansen%26aufirst%3DH.%2BC.%26aulast%3DAndersson%26aufirst%3DC.%2BM.%26aulast%3DSpalding%26aufirst%3DT.%2BA.%26aulast%3DGibson%26aufirst%3DD.%2BF.%26aulast%3DKrebs-Thomson%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DS.%2BB.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DHacksell%26aufirst%3DU.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26atitle%3D5-Hydroxytryptamine2a%2520receptor%2520inverse%2520agonists%2520as%2520antipsychotics%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D299%26spage%3D268%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref347"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref347'); return false;" data-citation="" class="refNumLink">347</a></strong><div class="NLM_citation" id="cit347"><span><span class="NLM_contrib-group">Navailles, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spampinato, U.</span><span> </span><span class="NLM_article-title">Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin<sub>2C</sub> receptors</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1311</span><span class="NLM_x">–</span> <span class="NLM_lpage">1319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref347/cit347&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1111%2Fj.1471-4159.2006.04188.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref347/cit347&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17018023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref347/cit347&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yks7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=1311-1319&author=S.+Navaillesauthor=D.+Moisonauthor=D.+Ryczkoauthor=U.+Spampinato&title=Region-dependent+regulation+of+mesoaccumbens+dopamine+neurons+in+vivo+by+the+constitutive+activity+of+central+serotonin2C+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit347R"><div class="casContent"><span class="casTitleNuber">347</span><div class="casTitle"><span class="NLM_cas:atitle">Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin 2C receptors</span></div><div class="casAuthors">Navailles, Sylvia; Moison, Delphine; Ryczko, Dimitri; Spampinato, Umberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1311-1319</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Central serotonin 2C receptors (5-HT2CRs) control the mesoaccumbens dopamine (DA) pathway.  This control involves the constitutive activity (CA) of 5-HT2CRs, and is thought to engage regionally distinct populations of 5-HT2CRs, leading to opposite functional effects.  Here, using in vivo microdialysis in halothane-anesthetized rats, we investigated the relative contribution of ventral tegmental area (VTA) and nucleus accumbens shell (NAc) 5-HT2CRs in the phasic/tonic control of accumbal DA release, to specifically identify the nature (inhibition/excitation) of the control, and the role of the 5-HT2CR CA.  Intra-VTA injections of the selective 5-HT2CR antagonists SB 242084 and/or SB 243213 (0.1-0.5 μg/0.2 μL) prevented the decrease in accumbal DA outflow induced by the 5-HT2CR agonist Ro 60-0175 (3 mg/kg, i.p), but did not affect the increase in DA outflow induced by the 5-HT2CR inverse agonist SB 206553 (5 mg/kg, i.p).  Intra-NAc infusions of SB 242084 (0.1-1 μM) blocked Ro 60-0175- and SB 206553-induced changes of DA outflow.  Intra-NAc, but not intra-VTA administration of SB 206553 increased basal DA outflow.  These findings demonstrate that both VTA and NAc 5-HT2CRs participate in the inhibitory control exerted by 5-HT2CRs on accumbal DA release, and that the NAc shell may represent a primary action site for the CA of 5-HT2CRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPNwO4upWLArVg90H21EOLACvtfcHk0limZf1AsZrZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yks7nN&md5=8e67ee3560b9e43c3b2f7add6f0cc388</span></div><a href="/servlet/linkout?suffix=cit347&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04188.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04188.x%26sid%3Dliteratum%253Aachs%26aulast%3DNavailles%26aufirst%3DS.%26aulast%3DMoison%26aufirst%3DD.%26aulast%3DRyczko%26aufirst%3DD.%26aulast%3DSpampinato%26aufirst%3DU.%26atitle%3DRegion-dependent%2520regulation%2520of%2520mesoaccumbens%2520dopamine%2520neurons%2520in%2520vivo%2520by%2520the%2520constitutive%2520activity%2520of%2520central%2520serotonin2C%2520receptors%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D99%26spage%3D1311%26epage%3D1319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref348"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref348'); return false;" data-citation="" class="refNumLink">348</a></strong><div class="NLM_citation" id="cit348"><span><span class="NLM_contrib-group">Glatt, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snowman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Clozapine: selective labeling of sites resembling 5HT<sub>6</sub> serotonin receptors may reflect psychoactive profile</span> <span class="citation_source-journal">Mol. Med</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref348/cit348&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8521297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref348/cit348&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2MXmsVGgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=398-406&author=C.+E.+Glattauthor=A.+M.+Snowmanauthor=D.+R.+Sibleyauthor=S.+H.+Snyder&title=Clozapine%3A+selective+labeling+of+sites+resembling+5HT6+serotonin+receptors+may+reflect+psychoactive+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit348R"><div class="casContent"><span class="casTitleNuber">348</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine: selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile</span></div><div class="casAuthors">Glatt, Charles E.; Snowman, Adele M.; Sibley, David R.; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Baltimore, MD, United States)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-406</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    </div><div class="casAbstract">Clozapine, the classic atypical neuroleptic, exerts therapeutic actions in schizophrenic patients unresponsive to most neuroleptics.  Clozapine interacts with numerous neurotransmitter receptors, and selective actions at novel subtypes of dopamine and serotonin receptors have been proposed to explain clozapine's unique psychotropic effects.  To identify sites with which clozapine preferentially interacts in a therapeutic setting, we have characterized clozapine binding to brain membranes.  [3H]Clozapine binding was examd. in rat brain membranes as well as cloned-expressed 5-HT6 serotonin receptors.  [3H]Clozapine binds with low nanomolar affinity to two distinct sites.  One reflects muscarinic receptors consistent with the drug's anticholinergic actions.  The drug competition profile of the second site most closely resembles 5HT6 serotonin receptors, though serotonin itself displays low affinity.  [3H]Clozapine binding levels are similar in all brain regions examd. with no concn. in the corpus striatum.  Besides muscarinic receptors, clozapine primarily labels sites with properties resembling 5HT6 serotonin receptors.  If this is also the site with which clozapine principally interacts in intact human brain, it may account for the unique beneficial actions of clozapine and other atypical neuroleptics, and provide a mol. target for developing new, safer, and more effective agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSPrW-DMBTRbVg90H21EOLACvtfcHk0limZf1AsZrZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsVGgtbc%253D&md5=1b08638cfcf1f7262c25647425b98f5a</span></div><a href="/servlet/linkout?suffix=cit348&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlatt%26aufirst%3DC.%2BE.%26aulast%3DSnowman%26aufirst%3DA.%2BM.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DClozapine%253A%2520selective%2520labeling%2520of%2520sites%2520resembling%25205HT6%2520serotonin%2520receptors%2520may%2520reflect%2520psychoactive%2520profile%26jtitle%3DMol.%2520Med%26date%3D1995%26volume%3D1%26spage%3D398%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref349"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref349'); return false;" data-citation="" class="refNumLink">349</a></strong><div class="NLM_citation" id="cit349"><span><span class="NLM_contrib-group">Mitchell, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumaier, J. F.</span><span> </span><span class="NLM_article-title">5-HT<sub>6</sub> receptors: a novel target for cognitive enhancement</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref349/cit349&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pharmthera.2005.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref349/cit349&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16005519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref349/cit349&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Olsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2005&pages=320-333&author=E.+S.+Mitchellauthor=J.+F.+Neumaier&title=5-HT6+receptors%3A+a+novel+target+for+cognitive+enhancement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit349R"><div class="casContent"><span class="casTitleNuber">349</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT6 receptors: a novel target for cognitive enhancement</span></div><div class="casAuthors">Mitchell, Ellen S.; Neumaier, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">320-333</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Over the past decade, there has been increasing interest in the role of serotonin 6 (5-HT6) receptors in higher cognitive processes such as memory.  Polymorphisms of the 5-HT6 receptor have been implicated in syndromes that affect cognition, such as schizophrenia and dementia.  Manipulation of 5-HT6 receptor activity alters the transmission of several neurotransmitters important in memory: acetylcholine and glutamate, as well as dopamine, gamma -aminobutyric acid (GABA), epinephrine (E), and norepinephrine (NE).  Several 5-HT6 antagonists have been developed, advancing the understanding of the relationship between 5-HT6 blockade and memory consolidation in diverse learning paradigms.  There is also evidence that 5-HT6 receptor activity affects anxiety behaviors and may be involved in the pathophysiol. of schizophrenia.  Several clin. useful atypical antipsychotics and antidepressants have 5-HT6 affinity, but recently developed selective 5-HT6 receptor antagonists may present attractive, new therapeutic options for several types of disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVJqq1oagMarVg90H21EOLACvtfcHk0lhfrtt7IF_nXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Olsr%252FO&md5=a3b24549c7ffbee5d9ae0f119ea258b7</span></div><a href="/servlet/linkout?suffix=cit349&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DE.%2BS.%26aulast%3DNeumaier%26aufirst%3DJ.%2BF.%26atitle%3D5-HT6%2520receptors%253A%2520a%2520novel%2520target%2520for%2520cognitive%2520enhancement%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D108%26spage%3D320%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref350"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref350'); return false;" data-citation="" class="refNumLink">350</a></strong><div class="NLM_citation" id="cit350"><span><span class="NLM_contrib-group">Holenz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merce, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codony, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buschmann, H.</span><span> </span><span class="NLM_article-title">Medicinal chemistry strategies to 5-HT<sub>6</sub> receptor ligands as potential cognitive enhancers and antiobesity agents</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=283-299&author=J.+Holenzauthor=P.+J.+Pauwelsauthor=J.+L.+Diazauthor=R.+Merceauthor=X.+Codonyauthor=H.+Buschmann&title=Medicinal+chemistry+strategies+to+5-HT6+receptor+ligands+as+potential+cognitive+enhancers+and+antiobesity+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit350&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DPauwels%26aufirst%3DP.%2BJ.%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DMerce%26aufirst%3DR.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DBuschmann%26aufirst%3DH.%26atitle%3DMedicinal%2520chemistry%2520strategies%2520to%25205-HT6%2520receptor%2520ligands%2520as%2520potential%2520cognitive%2520enhancers%2520and%2520antiobesity%2520agents%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2006%26volume%3D11%26spage%3D283%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref351"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref351'); return false;" data-citation="" class="refNumLink">351</a></strong><div class="NLM_citation" id="cit351"><span><span class="NLM_contrib-group">King, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleight, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolley, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsden, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fone, K. C.</span><span> </span><span class="NLM_article-title">5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=195-204&author=M.+V.+Kingauthor=A.+J.+Sleightauthor=M.+L.+Woolleyauthor=I.+A.+Tophamauthor=C.+A.+Marsdenauthor=K.+C.+Fone&title=5-HT6+receptor+antagonists+reverse+delay-dependent+deficits+in+novel+object+discrimination+by+enhancing+consolidation%E2%80%94an+effect+sensitive+to+NMDA+receptor+antagonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit351&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DM.%2BV.%26aulast%3DSleight%26aufirst%3DA.%2BJ.%26aulast%3DWoolley%26aufirst%3DM.%2BL.%26aulast%3DTopham%26aufirst%3DI.%2BA.%26aulast%3DMarsden%26aufirst%3DC.%2BA.%26aulast%3DFone%26aufirst%3DK.%2BC.%26atitle%3D5-HT6%2520receptor%2520antagonists%2520reverse%2520delay-dependent%2520deficits%2520in%2520novel%2520object%2520discrimination%2520by%2520enhancing%2520consolidation%25E2%2580%2594an%2520effect%2520sensitive%2520to%2520NMDA%2520receptor%2520antagonism%26jtitle%3DNeuropharmacology%26date%3D2004%26volume%3D47%26spage%3D195%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref352"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref352'); return false;" data-citation="" class="refNumLink">352</a></strong><div class="NLM_citation" id="cit352"><span><span class="NLM_contrib-group">Lindner, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodges, D. B.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orie, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsa, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barten, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guss, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillman, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starrett, J. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribkoff, V. K.</span><span> </span><span class="NLM_article-title">An assessment of the effects of serotonin 6 (5-HT<sub>6</sub>) receptor antagonists in rodent models of learning</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref352/cit352&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.103.056002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref352/cit352&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12975483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref352/cit352&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Shsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=682-691&author=M.+D.+Lindnerauthor=D.+B.+Hodgesauthor=J.+B.+Hoganauthor=A.+F.+Orieauthor=J.+A.+Corsaauthor=D.+M.+Bartenauthor=C.+Polsonauthor=B.+J.+Robertsonauthor=V.+L.+Gussauthor=K.+W.+Gillmanauthor=J.+E.+Starrettauthor=V.+K.+Gribkoff&title=An+assessment+of+the+effects+of+serotonin+6+%285-HT6%29+receptor+antagonists+in+rodent+models+of+learning"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit352R"><div class="casContent"><span class="casTitleNuber">352</span><div class="casTitle"><span class="NLM_cas:atitle">An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning</span></div><div class="casAuthors">Lindner, Mark D.; Hodges, Donald B., Jr.; Hogan, John B.; Orie, Anitra F.; Corsa, Jason A.; Barten, Donna M.; Polson, Craig; Robertson, Barbara J.; Guss, Valerie L.; Gillman, Kevin W.; Starrett, John E., Jr.; Gribkoff, Valentin K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">682-691</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Antagonists of serotonin 6 (5-HT6) receptors have been reported to enhance cognition in animal models of learning, although this finding has not been universal.  We have assessed the therapeutic potential of the specific 5-HT6 receptor antagonists 4-amino-N-(2,6-bis-methylamino-pyrimidin-4-yl)-benzenesulfonamide (Ro 04-6790) and 5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2- benzothiophenesulfonamide (SB-271046) in rodent models of cognitive function.  Although mice express the 5-HT6 receptor and the function of this receptor has been investigated in mice, all reports of activity with 5-HT6 receptor antagonists have used rat models.  In the present study, receptor binding revealed that the pharmacol. properties of the mouse receptor are different from the rat and human receptor: Ro 04-6790 does not bind to the mouse 5-HT6 receptor, so all in vivo testing included in the present report was conducted in rats.  We replicated previous reports that 5-HT6 receptor antagonists produce a stretching syndrome previously shown to be mediated through cholinergic mechanisms, but Ro 04-6790 and SB-271046 failed to attenuate scopolamine-induced deficits in a test of contextual fear conditioning.  We also failed to replicate the significant effects reported previously in both an autoshaping task and in a version of the Morris water maze.  The results of our expts. are not consistent with previous reports that suggested that 5-HT6 antagonists might have therapeutic potential for cognitive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1aBFn1xz7d7Vg90H21EOLACvtfcHk0lhfrtt7IF_nXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Shsrg%253D&md5=43eec6e55d870801aca53ebdcf11e987</span></div><a href="/servlet/linkout?suffix=cit352&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.056002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.056002%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DM.%2BD.%26aulast%3DHodges%26aufirst%3DD.%2BB.%26aulast%3DHogan%26aufirst%3DJ.%2BB.%26aulast%3DOrie%26aufirst%3DA.%2BF.%26aulast%3DCorsa%26aufirst%3DJ.%2BA.%26aulast%3DBarten%26aufirst%3DD.%2BM.%26aulast%3DPolson%26aufirst%3DC.%26aulast%3DRobertson%26aufirst%3DB.%2BJ.%26aulast%3DGuss%26aufirst%3DV.%2BL.%26aulast%3DGillman%26aufirst%3DK.%2BW.%26aulast%3DStarrett%26aufirst%3DJ.%2BE.%26aulast%3DGribkoff%26aufirst%3DV.%2BK.%26atitle%3DAn%2520assessment%2520of%2520the%2520effects%2520of%2520serotonin%25206%2520%25285-HT6%2529%2520receptor%2520antagonists%2520in%2520rodent%2520models%2520of%2520learning%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D307%26spage%3D682%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref353"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref353'); return false;" data-citation="" class="refNumLink">353</a></strong><div class="NLM_citation" id="cit353"><span><span class="NLM_contrib-group">Pouzet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didriksen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnt, J.</span><span> </span><span class="NLM_article-title">Effects of the 5-HT<sub>6</sub> receptor antagonist, SB-271046, in animal models for schizophrenia</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref353/cit353&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0091-3057%2801%2900743-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref353/cit353&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11888555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref353/cit353&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVChur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=635-643&author=B.+Pouzetauthor=M.+Didriksenauthor=J.+Arnt&title=Effects+of+the+5-HT6+receptor+antagonist%2C+SB-271046%2C+in+animal+models+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit353R"><div class="casContent"><span class="casTitleNuber">353</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the 5-HT6 receptor antagonist, SB-271046, in animal models for schizophrenia</span></div><div class="casAuthors">Pouzet, B.; Didriksen, M.; Arnt, J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">635-643</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The 5-HT6 receptor is targeted by several new antipsychotics such as clozapine, olanzapine, and sertindole.  We studied the effect of SB-271046 [5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide], a specific 5-HT6 receptor antagonist, in three models for the pos. symptoms of schizophrenia-d-amphetamine-induced hyperactivity, and d-amphetamine- or phencyclidine (PCP)-disrupted prepulse inhibition (PPI).  We also tested this compd. in a model for the neg. symptoms of schizophrenia, PCP-disrupted social interaction (SIT) in rats.  Induction of side effects by this compd. was evaluated by testing its potency to reduce spontaneous motility, and to induce catalepsy in rats.  The effect of SB-271046 was compared to clozapine in all models tested.  This study showed that SB-271046 had no beneficial effect in PCP-disrupted SIT.  However, SB-271046 dose-dependently normalized d-amphetamine-disrupted PPI, but did not reverse PCP-disrupted PPI.  In addn., SB-271046 did not antagonize d-amphetamine-induced hyperactivity.  Thus, this specific 5-HT6 receptor antagonist was assocd. with a clear pos. outcome in only one model for the pos. symptoms of schizophrenia, and had no beneficial effect in the model for neg. symptoms.  Consequently, it is clear that SB-271046 is not expected to have an antipsychotic efficacy, at least when given as monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ4ROm5ZpVPLVg90H21EOLACvtfcHk0lhfrtt7IF_nXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVChur4%253D&md5=32c4a1f8b85b72e5e54af4f05dad3f67</span></div><a href="/servlet/linkout?suffix=cit353&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2801%2900743-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252801%252900743-2%26sid%3Dliteratum%253Aachs%26aulast%3DPouzet%26aufirst%3DB.%26aulast%3DDidriksen%26aufirst%3DM.%26aulast%3DArnt%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520the%25205-HT6%2520receptor%2520antagonist%252C%2520SB-271046%252C%2520in%2520animal%2520models%2520for%2520schizophrenia%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D2002%26volume%3D71%26spage%3D635%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref354"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref354'); return false;" data-citation="" class="refNumLink">354</a></strong><div class="NLM_citation" id="cit354"><span><span class="NLM_contrib-group">Siuciak, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strick, C. A.</span><span> </span><span class="NLM_article-title">Treating neuropsychiatric disorders with PDE10A inhibitors</span> <span class="citation_source-journal">Drug Discovery Today: Ther. Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref354/cit354&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ddstr.2006.10.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=527-532&author=J.+A.+Siuciakauthor=C.+A.+Strick&title=Treating+neuropsychiatric+disorders+with+PDE10A+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit354&amp;dbid=16384&amp;doi=10.1016%2Fj.ddstr.2006.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddstr.2006.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26aulast%3DStrick%26aufirst%3DC.%2BA.%26atitle%3DTreating%2520neuropsychiatric%2520disorders%2520with%2520PDE10A%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Ther.%2520Strategies%26date%3D2006%26volume%3D3%26spage%3D527%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref355"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref355'); return false;" data-citation="" class="refNumLink">355</a></strong><div class="NLM_citation" id="cit355"><span><span class="NLM_contrib-group">Halene, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, S. J.</span><span> </span><span class="NLM_article-title">PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">870</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=870-878&author=T.+B.+Haleneauthor=S.+J.+Siegel&title=PDE+inhibitors+in+psychiatry-future+options+for+dementia%2C+depression+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit355&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalene%26aufirst%3DT.%2BB.%26aulast%3DSiegel%26aufirst%3DS.%2BJ.%26atitle%3DPDE%2520inhibitors%2520in%2520psychiatry-future%2520options%2520for%2520dementia%252C%2520depression%2520and%2520schizophrenia%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D870%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref356"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref356'); return false;" data-citation="" class="refNumLink">356</a></strong><div class="NLM_citation" id="cit356"><span><span class="NLM_contrib-group">Hebb, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, H. A.</span><span> </span><span class="NLM_article-title">Role of phosphodiesterases in neurological and psychiatric disease</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref356/cit356&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.coph.2006.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref356/cit356&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17113826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref356/cit356&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntlGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=86-92&author=A.+L.+Hebbauthor=H.+A.+Robertson&title=Role+of+phosphodiesterases+in+neurological+and+psychiatric+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit356R"><div class="casContent"><span class="casTitleNuber">356</span><div class="casTitle"><span class="NLM_cas:atitle">Role of phosphodiesterases in neurological and psychiatric disease</span></div><div class="casAuthors">Hebb, Andrea L. O.; Robertson, Harold A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-92</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotides such as cAMP and cGMP play a central role in neuronal cell function and are regulated by changes in synthesis and/or degrdn.  Degrdn. is regulated by phosphodiesterases (PDEs), a group of enzymes consisting of at least 11 families, several of which have multiple isoforms.  As inhibition of PDEs can have profound effects on cell function, there is considerable interest in selective antagonists of these enzymes.  Recent work has also revealed that PDEs are heterogeneously distributed, thus making them interesting targets for drug development.  In particular, PDE10A may play a role in disorders that involve striatal neurons, such as Huntington's disease and psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot53Y0Vz3VFbVg90H21EOLACvtfcHk0lgkRI-y1x04Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntlGhtg%253D%253D&md5=364fce31458b6e8ff62ea473da63621e</span></div><a href="/servlet/linkout?suffix=cit356&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2006.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2006.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DHebb%26aufirst%3DA.%2BL.%26aulast%3DRobertson%26aufirst%3DH.%2BA.%26atitle%3DRole%2520of%2520phosphodiesterases%2520in%2520neurological%2520and%2520psychiatric%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2007%26volume%3D7%26spage%3D86%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref357"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref357'); return false;" data-citation="" class="refNumLink">357</a></strong><div class="NLM_citation" id="cit357"><span><span class="NLM_contrib-group">Boolell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gepi-Attee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muirhead, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterloh, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, C.</span><span> </span><span class="NLM_article-title">Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction</span> <span class="citation_source-journal">Int. J. Impotence Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref357/cit357&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8858389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref357/cit357&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK2s%252FhtFekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1996&pages=47-52&author=M.+Boolellauthor=M.+J.+Allenauthor=S.+A.+Ballardauthor=S.+Gepi-Atteeauthor=G.+J.+Muirheadauthor=A.+M.+Naylorauthor=I.+H.+Osterlohauthor=C.+Gingell&title=Sildenafil%3A+an+orally+active+type+5+cyclic+GMP-specific+phosphodiesterase+inhibitor+for+the+treatment+of+penile+erectile+dysfunction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit357R"><div class="casContent"><span class="casTitleNuber">357</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction</span></div><div class="casAuthors">Boolell M; Allen M J; Ballard S A; Gepi-Attee S; Muirhead G J; Naylor A M; Osterloh I H; Gingell C</div><div class="citationInfo"><span class="NLM_cas:title">International journal of impotence research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">47-52</span>
        ISSN:<span class="NLM_cas:issn">0955-9930</span>.
    </div><div class="casAbstract">Sildenafil (Viagra, UK-92,480) is a novel oral agent under development for the treatment of penile erectile dysfunction.  Erection is dependent on nitric oxide and its second messenger, cyclic guanosine monophosphate (cGMP).  However, the relative importance of phosphodiesterase (PDE) isozymes is not clear.  We have identified both cGMP- and cyclic adenosine monophosphate-specific phosphodiesterases (PDEs) in human corpora cavernosa in vitro.  The main PDE activity in this tissue was due to PDE5, with PDE2 and 3 also identified.  Sildenafil is a selective inhibitor of PDE5 with a mean IC50 of 0.0039 microM.  In human volunteers, we have shown sildenafil to have suitable pharmacokinetic and pharmacodynamic properties (rapid absorption, relatively short half-life, no significant effect on heart rate and blood pressure) for an oral agent to be taken, as required, prior to sexual activity.  Moreover, in a clinical study of 12 patients with erectile dysfunction without an established organic cause, we have shown sildenafil to enhance the erectile response (duration and rigidity of erection) to visual sexual stimulation, thus highlighting the important role of PDE5 in human penile erection.  Sildenafil holds promise as a new effective oral treatment for penile erectile dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHiUn0Ryiem0bxh97K6Vt6fW6udTcc2ebdidkeXZ6p27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FhtFekuw%253D%253D&md5=35783bf8f6ff593b0a67e7e302392cd5</span></div><a href="/servlet/linkout?suffix=cit357&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoolell%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DM.%2BJ.%26aulast%3DBallard%26aufirst%3DS.%2BA.%26aulast%3DGepi-Attee%26aufirst%3DS.%26aulast%3DMuirhead%26aufirst%3DG.%2BJ.%26aulast%3DNaylor%26aufirst%3DA.%2BM.%26aulast%3DOsterloh%26aufirst%3DI.%2BH.%26aulast%3DGingell%26aufirst%3DC.%26atitle%3DSildenafil%253A%2520an%2520orally%2520active%2520type%25205%2520cyclic%2520GMP-specific%2520phosphodiesterase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520penile%2520erectile%2520dysfunction%26jtitle%3DInt.%2520J.%2520Impotence%2520Res.%26date%3D1996%26volume%3D8%26spage%3D47%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref358"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref358'); return false;" data-citation="" class="refNumLink">358</a></strong><div class="NLM_citation" id="cit358"><span><span class="NLM_contrib-group">Siuciak, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorhees, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repaske, D. R.</span><span> </span><span class="NLM_article-title">Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2007&pages=113-124&author=J.+A.+Siuciakauthor=S.+A.+McCarthyauthor=D.+S.+Chapinauthor=T.+M.+Reedauthor=C.+V.+Vorheesauthor=D.+R.+Repaske&title=Behavioral+and+neurochemical+characterization+of+mice+deficient+in+the+phosphodiesterase-1B+%28PDE1B%29+enzyme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit358&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26aulast%3DMcCarthy%26aufirst%3DS.%2BA.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DReed%26aufirst%3DT.%2BM.%26aulast%3DVorhees%26aufirst%3DC.%2BV.%26aulast%3DRepaske%26aufirst%3DD.%2BR.%26atitle%3DBehavioral%2520and%2520neurochemical%2520characterization%2520of%2520mice%2520deficient%2520in%2520the%2520phosphodiesterase-1B%2520%2528PDE1B%2529%2520enzyme%26jtitle%3DNeuropharmacology%26date%3D2007%26volume%3D53%26spage%3D113%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref359"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref359'); return false;" data-citation="" class="refNumLink">359</a></strong><div class="NLM_citation" id="cit359"><span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mix, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winblad, B.</span><span> </span><span class="NLM_article-title">The antidepressant and antiinflammatory effects of rolipram in the central nervous system</span> <span class="citation_source-journal">CNS Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">398</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=387-398&author=J.+Zhuauthor=E.+Mixauthor=B.+Winblad&title=The+antidepressant+and+antiinflammatory+effects+of+rolipram+in+the+central+nervous+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit359&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMix%26aufirst%3DE.%26aulast%3DWinblad%26aufirst%3DB.%26atitle%3DThe%2520antidepressant%2520and%2520antiinflammatory%2520effects%2520of%2520rolipram%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2001%26volume%3D7%26spage%3D387%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref360"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref360'); return false;" data-citation="" class="refNumLink">360</a></strong><div class="NLM_citation" id="cit360"><span><span class="NLM_contrib-group">Rose, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tehim, A.</span><span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors for cognitive enhancement</span> <span class="citation_source-journal">Curr. Pharm. Des</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3329</span><span class="NLM_x">–</span> <span class="NLM_lpage">3334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref360/cit360&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2174%2F138161205774370799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref360/cit360&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16250839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref360/cit360&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3329-3334&author=G.+M.+Roseauthor=A.+Hopperauthor=M.+De+Vivoauthor=A.+Tehim&title=Phosphodiesterase+inhibitors+for+cognitive+enhancement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit360R"><div class="casContent"><span class="casTitleNuber">360</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors for cognitive enhancement</span></div><div class="casAuthors">Rose, Gregory M.; Hopper, Allen; De Vivo, Michael; Tehim, Ashok</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3329-3334</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  An effective treatment for age-related cognitive deficits remains an unmet medical need.  Currently available drugs for the symptomatic treatment of Alzheimer's disease or other dementias have limited efficacy.  This may be due to their action at only one of the many neurotransmitter systems involved in the complex mechanisms that underlie cognition.  An alternative approach would be to target second messenger systems that are utilized by multiple neurotransmitters.  CAMP is a second messenger that plays a key role in biochem. processes that regulate the cognitive process of memory consolidation.  Prolongation of cAMP signals can be accomplished by inhibiting phosphodiesterases (PDEs).  Eleven PDE families, comprised of more than 50 distinct members, are currently known.  This review summarizes the evidence demonstrating that rolipram, a selective inhibitor of cAMP-selective PDE4 enzymes, has pos. effects on learning and memory in animal models.  These data provide support for the general approach of second messenger modulation as a potential therapy for cognitive dysfunction, and specifically suggest that PDE4 inhibitors may have utility for improving the symptoms of cognitive decline assocd. with neurodegenerative and psychiatric diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrUM-8WbDbU7Vg90H21EOLACvtfcHk0ligAJs2ZEpLtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7vN&md5=1748930c164783595c858f9f05229a59</span></div><a href="/servlet/linkout?suffix=cit360&amp;dbid=16384&amp;doi=10.2174%2F138161205774370799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161205774370799%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DG.%2BM.%26aulast%3DHopper%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DTehim%26aufirst%3DA.%26atitle%3DPhosphodiesterase%2520inhibitors%2520for%2520cognitive%2520enhancement%26jtitle%3DCurr.%2520Pharm.%2520Des%26date%3D2005%26volume%3D11%26spage%3D3329%26epage%3D3334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref361"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref361'); return false;" data-citation="" class="refNumLink">361</a></strong><div class="NLM_citation" id="cit361"><span><span class="NLM_contrib-group">Kanes, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarczyk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, M. P.</span><span> </span><span class="NLM_article-title">Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2007&pages=239-246&author=S.+J.+Kanesauthor=J.+Tokarczykauthor=S.+J.+Siegelauthor=W.+Bilkerauthor=T.+Abelauthor=M.+P.+Kelly&title=Rolipram%3A+a+specific+phosphodiesterase+4+inhibitor+with+potential+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit361&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKanes%26aufirst%3DS.%2BJ.%26aulast%3DTokarczyk%26aufirst%3DJ.%26aulast%3DSiegel%26aufirst%3DS.%2BJ.%26aulast%3DBilker%26aufirst%3DW.%26aulast%3DAbel%26aufirst%3DT.%26aulast%3DKelly%26aufirst%3DM.%2BP.%26atitle%3DRolipram%253A%2520a%2520specific%2520phosphodiesterase%25204%2520inhibitor%2520with%2520potential%2520antipsychotic%2520activity%26jtitle%3DNeuroscience%26date%3D2007%26volume%3D144%26spage%3D239%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref362"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref362'); return false;" data-citation="" class="refNumLink">362</a></strong><div class="NLM_citation" id="cit362"><span><span class="NLM_contrib-group">Dyke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montana, J. G.</span><span> </span><span class="NLM_article-title">Update on the therapeutic potential of PDE4 inhibitors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref362/cit362&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1517%2F13543784.11.1.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref362/cit362&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11772317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref362/cit362&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=1-13&author=H.+J.+Dykeauthor=J.+G.+Montana&title=Update+on+the+therapeutic+potential+of+PDE4+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit362R"><div class="casContent"><span class="casTitleNuber">362</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the therapeutic potential of PDE4 inhibitors</span></div><div class="casAuthors">Dyke, Hazel J.; Montana, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase (PDE) enzymes are responsible for the inactivation of cAMP and cGMP.  Phosphodiesterase 4 (PDE4) is a cAMP specific phosphodiesterase expressed in inflammatory cells such as eosinophils.  Inhibition of PDE4 results in an elevation of cAMP in these cells, which in turn downregulates the inflammatory response.  The anti-inflammatory effects of PDE4 inhibitors have been well documented both in vitro and in vivo in a range of animal models.  The potential use of PDE4 inhibitors as anti-inflammatory agents for the treatment of diseases such as asthma, chronic obstructive pulmonary disease (COPD) and multiple sclerosis (MS), has received considerable attention from the pharmaceutical industry but to date, there are no selective PDE4 inhibitors on the market.  Early PDE4 inhibitors, such as rolipram suffered from dose limiting side effects, including nausea and emesis, which severely restricted their therapeutic utility.  Second generation compds. such as cilomilast have been identified with reduced side effect liability.  Indeed, cilomilast is showing good therapeutic effects in clin. trials for asthma and COPD and represents the most advanced selective PDE4 inhibitor for any indication.  The utility of this class of inhibitor in other inflammatory diseases is less well advanced.  However, data in animal models of rheumatoid arthritis (RA) and MS suggests that there is also significant potential for PDE4 inhibitors as treatments for these diseases and the results of clin. trials in these disease areas are eagerly awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcfUhqvSag17Vg90H21EOLACvtfcHk0ligAJs2ZEpLtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGgsQ%253D%253D&md5=f16a217b52d79f2ac4725b1ffa432c3e</span></div><a href="/servlet/linkout?suffix=cit362&amp;dbid=16384&amp;doi=10.1517%2F13543784.11.1.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.11.1.1%26sid%3Dliteratum%253Aachs%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DMontana%26aufirst%3DJ.%2BG.%26atitle%3DUpdate%2520on%2520the%2520therapeutic%2520potential%2520of%2520PDE4%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D11%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref363"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref363'); return false;" data-citation="" class="refNumLink">363</a></strong><div class="NLM_citation" id="cit363"><span><span class="NLM_contrib-group">Kehler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritzen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greve, D. R.</span><span> </span><span class="NLM_article-title">The potential therapeutic use of phosphodiesterase 10 inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref363/cit363&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1517%2F13543776.17.2.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref363/cit363&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=147-158&author=J.+Kehlerauthor=A.+Ritzenauthor=D.+R.+Greve&title=The+potential+therapeutic+use+of+phosphodiesterase+10+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit363R"><div class="casContent"><span class="casTitleNuber">363</span><div class="casTitle"><span class="NLM_cas:atitle">The potential therapeutic use of phosphodiesterase 10 inhibitors</span></div><div class="casAuthors">Kehler, Jan; Ritzen, Andreas; Greve, Daniel Rodriguez</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-158</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The discovery of the enzyme phosphodiesterase 10A (PDE10A) was reported simultaneously in 1999 by three independent groups.  PDE10A has been shown by localization studies to have the most restricted distribution of all the 11 known PDE families, with the PDE10A mRNA highly expressed only in the brain and testes.  In the brain, mRNA and protein are highly enriched in the striatum and, together with increased pharmacol. characterization, this unique distribution of PDE10A in the brain indicates a potential use of PDE10A inhibitors for treating neurol. and psychiatric disorders, in particular, psychotic disorders like schizophrenia.  However, PDE10A inhibitors have also been claimed to be useful as treatment for cancer, diabetes and esp. obesity.  Two years after the reported discovery of PDE10A, Bayer filed the first patent application claiming PDE10A inhibitors, followed shortly thereafter by Pfizer.  Since then, a no. of scientific publications and filed patents testify to an increasing pharmaceutical interest in this target.  This article highlights and reviews research advances published in the patent literature between the first patent publication in June 2002 and Nov. 2006.  The article is supplemented with selected publications from the scientific literature, emphasizing the possible involvement of PDE10A inhibitors in the treatment of schizophrenia and referring to studies aimed at understanding their mechanism and pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuxKfPnmDF7Vg90H21EOLACvtfcHk0ligAJs2ZEpLtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyhs7g%253D&md5=12a5d53fbc2c93039ded1952b56f0e12</span></div><a href="/servlet/linkout?suffix=cit363&amp;dbid=16384&amp;doi=10.1517%2F13543776.17.2.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.17.2.147%26sid%3Dliteratum%253Aachs%26aulast%3DKehler%26aufirst%3DJ.%26aulast%3DRitzen%26aufirst%3DA.%26aulast%3DGreve%26aufirst%3DD.%2BR.%26atitle%3DThe%2520potential%2520therapeutic%2520use%2520of%2520phosphodiesterase%252010%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2007%26volume%3D17%26spage%3D147%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref364"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref364'); return false;" data-citation="" class="refNumLink">364</a></strong><div class="NLM_citation" id="cit364"><span><span class="NLM_contrib-group">Siuciak, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeish, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strick, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref364/cit364&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.neuropharm.2006.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref364/cit364&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16769090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref364/cit364&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2006&pages=374-385&author=J.+A.+Siuciakauthor=S.+A.+McCarthyauthor=D.+S.+Chapinauthor=R.+A.+Fujiwaraauthor=L.+C.+Jamesauthor=R.+D.+Williamsauthor=J.+L.+Stockauthor=J.+D.+McNeishauthor=C.+A.+Strickauthor=F.+S.+Mennitiauthor=C.+J.+Schmidt&title=Genetic+deletion+of+the+striatum-enriched+phosphodiesterase+PDE10A%3A+evidence+for+altered+striatal+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit364R"><div class="casContent"><span class="casTitleNuber">364</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function</span></div><div class="casAuthors">Siuciak, Judith A.; McCarthy, Sheryl A.; Chapin, Douglas S.; Fujiwara, Remie A.; James, Larry C.; Williams, Robert D.; Stock, Jeffrey L.; McNeish, John D.; Strick, Christine A.; Menniti, Frank S.; Schmidt, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374-385</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PDE10A is a newly identified phosphodiesterase that is highly expressed by the medium spiny projection neurons of the striatum.  To investigate the physiol. role of PDE10A in the central nervous system, PDE10A knockout mice (PDE10A-/-) were characterized both behaviorally and neurochem.  PDE10A-/- mice showed decreased exploratory activity and a significant delay in the acquisition of conditioned avoidance behavior when compared to wild-type (PDE10A+/+) mice.  However, in a variety of other well-characterized behavioral tasks, including the elevated plus maze (anxiety), forced swim test (depression), hot plate (nociception) and two memory models (passive avoidance and Morris water maze), PDE10A-/- mice performed similarly to wild-type mice.  When challenged with PCP or MK-801, PDE10A-/- mice showed a blunted locomotor response in comparison to PDE10A+/+ mice.  In contrast, PDE10A-/- and PDE10A+/+ mice responded similarly to the locomotor stimulating effects of amphetamine and methamphetamine.  The authors' findings suggest that PDE10A is involved in regulating striatal output, possibly by reducing the sensitivity of medium spiny neurons to glutamatergic excitation.  These results are discussed in relationship to the hypothesis that PDE10A inhibition presents a novel treatment for psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxED8sUex3PbVg90H21EOLACvtfcHk0ljoZ7rFkMt7vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSnurk%253D&md5=0d5cef60a6c5bfb02df908b95a8debd6</span></div><a href="/servlet/linkout?suffix=cit364&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2006.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2006.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26aulast%3DMcCarthy%26aufirst%3DS.%2BA.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DFujiwara%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DL.%2BC.%26aulast%3DWilliams%26aufirst%3DR.%2BD.%26aulast%3DStock%26aufirst%3DJ.%2BL.%26aulast%3DMcNeish%26aufirst%3DJ.%2BD.%26aulast%3DStrick%26aufirst%3DC.%2BA.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DGenetic%2520deletion%2520of%2520the%2520striatum-enriched%2520phosphodiesterase%2520PDE10A%253A%2520evidence%2520for%2520altered%2520striatal%2520function%26jtitle%3DNeuropharmacology%26date%3D2006%26volume%3D51%26spage%3D374%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref365"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref365'); return false;" data-citation="" class="refNumLink">365</a></strong><div class="NLM_citation" id="cit365"><span><span class="NLM_contrib-group">Schmidt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harms, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikhande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siuciak, J. A.</span><span> </span><span class="NLM_article-title">The neurochemical and behavioral effects of papaverine in vivo suggest PDE10 inhibition is “antipsychotic”</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref365/cit365&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0920-9964%2803%2980867-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2003&pages=114&author=C.+J.+Schmidtauthor=D.+S.+Chapinauthor=S.+A.+McCarthyauthor=R.+A.+Fujiwaraauthor=J.+F.+Harmsauthor=A.+Shrikhandeauthor=L.+Chambersauthor=S.+Wongauthor=J.+A.+Siuciak&title=The+neurochemical+and+behavioral+effects+of+papaverine+in+vivo+suggest+PDE10+inhibition+is+%E2%80%9Cantipsychotic%E2%80%9D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit365&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2803%2980867-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252803%252980867-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DMcCarthy%26aufirst%3DS.%2BA.%26aulast%3DFujiwara%26aufirst%3DR.%2BA.%26aulast%3DHarms%26aufirst%3DJ.%2BF.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520neurochemical%2520and%2520behavioral%2520effects%2520of%2520papaverine%2520in%2520vivo%2520suggest%2520PDE10%2520inhibition%2520is%2520%25E2%2580%259Cantipsychotic%25E2%2580%259D%26jtitle%3DSchizophr.%2520Res.%26date%3D2003%26volume%3D60%26spage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref366"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref366'); return false;" data-citation="" class="refNumLink">366</a></strong><div class="NLM_citation" id="cit366"><span><span class="NLM_contrib-group">Siuciak, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harms, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chappie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphrey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Novel potent and selective phosphodiesterase 10A (PDE10A) inhibitors show activity in animal models of psychosis</span> <span class="citation_source-journal">Soc. Neurosci. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2006&pages=94-19&author=J.+A.+Siuciakauthor=D.+S.+Chapinauthor=S.+A.+McCarthyauthor=J.+F.+Harmsauthor=C.+B.+Foxauthor=T.+A.+Chappieauthor=J.+M.+Humphreyauthor=C.+Proulxauthor=P.+R.+Verhoestauthor=C.+J.+Schmidt&title=Novel+potent+and+selective+phosphodiesterase+10A+%28PDE10A%29+inhibitors+show+activity+in+animal+models+of+psychosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit366&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DMcCarthy%26aufirst%3DS.%2BA.%26aulast%3DHarms%26aufirst%3DJ.%2BF.%26aulast%3DFox%26aufirst%3DC.%2BB.%26aulast%3DChappie%26aufirst%3DT.%2BA.%26aulast%3DHumphrey%26aufirst%3DJ.%2BM.%26aulast%3DProulx%26aufirst%3DC.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DNovel%2520potent%2520and%2520selective%2520phosphodiesterase%252010A%2520%2528PDE10A%2529%2520inhibitors%2520show%2520activity%2520in%2520animal%2520models%2520of%2520psychosis%26jtitle%3DSoc.%2520Neurosci.%2520Abstr.%26date%3D2006%26volume%3D36%26spage%3D94%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref367"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref367'); return false;" data-citation="" class="refNumLink">367</a></strong><div class="NLM_citation" id="cit367"><span><span class="NLM_contrib-group">Meltzer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prus, A.</span><span> </span><span class="NLM_article-title">NK<sub>3</sub> receptor antagonists for the treatment of schizophrenia</span> <span class="citation_source-journal">Drug Discovery Today: Ther. Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">–</span> <span class="NLM_lpage">560</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref367/cit367&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ddstr.2006.11.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=555-560&author=H.+Meltzerauthor=A.+Prus&title=NK3+receptor+antagonists+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit367&amp;dbid=16384&amp;doi=10.1016%2Fj.ddstr.2006.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddstr.2006.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%26aulast%3DPrus%26aufirst%3DA.%26atitle%3DNK3%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Ther.%2520Strategies%26date%3D2006%26volume%3D3%26spage%3D555%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref368"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref368'); return false;" data-citation="" class="refNumLink">368</a></strong><div class="NLM_citation" id="cit368"><span><span class="NLM_contrib-group">Smesny, S.; Rosburg, T.; Baur, K.; Rudolph, N.; Sauer, H.</span><span> </span><span class="NLM_article-title">Cannabinoids influence lipid−arachidonic acid pathways in schizophrenia</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Smesny%2C+S.%3B+Rosburg%2C+T.%3B+Baur%2C+K.%3B+Rudolph%2C+N.%3B+Sauer%2C+H.+Cannabinoids+influence+lipid%E2%88%92arachidonic+acid+pathways+in+schizophrenia.+Neuropsychopharmacology%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit368&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmesny%26aufirst%3DS.%26atitle%3DCannabinoids%2520influence%2520lipid%25E2%2588%2592arachidonic%2520acid%2520pathways%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref369"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref369'); return false;" data-citation="" class="refNumLink">369</a></strong><div class="NLM_citation" id="cit369"><span><span class="NLM_contrib-group">Koethe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llenos, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulay, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrey, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leweke, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, S.</span><span> </span><span class="NLM_article-title">Expression of CB<sub>1</sub> cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression</span> <span class="citation_source-journal">J. Neural Transm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1055</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=1055-1063&author=D.+Koetheauthor=I.+C.+Llenosauthor=J.+R.+Dulayauthor=C.+Hoyerauthor=E.+F.+Torreyauthor=F.+M.+Lewekeauthor=S.+Weis&title=Expression+of+CB1+cannabinoid+receptor+in+the+anterior+cingulate+cortex+in+schizophrenia%2C+bipolar+disorder%2C+and+major+depression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit369&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoethe%26aufirst%3DD.%26aulast%3DLlenos%26aufirst%3DI.%2BC.%26aulast%3DDulay%26aufirst%3DJ.%2BR.%26aulast%3DHoyer%26aufirst%3DC.%26aulast%3DTorrey%26aufirst%3DE.%2BF.%26aulast%3DLeweke%26aufirst%3DF.%2BM.%26aulast%3DWeis%26aufirst%3DS.%26atitle%3DExpression%2520of%2520CB1%2520cannabinoid%2520receptor%2520in%2520the%2520anterior%2520cingulate%2520cortex%2520in%2520schizophrenia%252C%2520bipolar%2520disorder%252C%2520and%2520major%2520depression%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2007%26volume%3D114%26spage%3D1055%26epage%3D1063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref370"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref370'); return false;" data-citation="" class="refNumLink">370</a></strong><div class="NLM_citation" id="cit370"><span><span class="NLM_contrib-group">Zavitsanou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrick, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. F.</span><span> </span><span class="NLM_article-title">Selective antagonist [3H]SR141716A binding to cannabinoid CB<sub>1</sub> receptors is increased in the anterior cingulate cortex in schizophrenia</span> <span class="citation_source-journal">Prog. Neuropsychopharmacol. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref370/cit370&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pnpbp.2003.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref370/cit370&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14751433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref370/cit370&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=355-360&author=K.+Zavitsanouauthor=T.+Garrickauthor=X.+F.+Huang&title=Selective+antagonist+%5B3H%5DSR141716A+binding+to+cannabinoid+CB1+receptors+is+increased+in+the+anterior+cingulate+cortex+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit370R"><div class="casContent"><span class="casTitleNuber">370</span><div class="casTitle"><span class="NLM_cas:atitle">Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia</span></div><div class="casAuthors">Zavitsanou, Katerina; Garrick, Therese; Huang, Xu Feng</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-360</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Previous studies suggest that long-term cannabis use causes cognitive impairment, including lack of motivation and impaired attention, conditions that also resemble core neg. symptoms of schizophrenia.  The anterior cingulate cortex (ACC) plays an important role in normal cognition, particularly in relation to motivation and attention.  This could suggest that changes in the cannabinoid (CB) system might be present in the ACC of patients suffering schizophrenia.  The present study examd. the distribution and d. of CB1 cannabinoid receptors in the left ACC taken postmortem from patients with schizophrenia (n=10) and matched control subjects (n=9).  Radioligand binding of [3H]SR141716A, an antagonist that specifically targets CB1 receptors of the endogenous cannabinoid system, was examd. on ACC sections using quant. autoradiog.  CB1 receptors had a homogenous distribution among the layers of ACC.  A significant 64% increase in [3H]SR141716A specific binding to CB1 receptors was found in the schizophrenia group as compared to the control group (mean±S.E.M.: 46.15±6.22 vs. 28.02±4.20 fmol/mg estd. tissue equiv.; p=0.03).  The present results support the suggestion that changes in the endogenous cannabinoid system in the ACC may be involved in the pathol. of schizophrenia particularly in relation to neg. symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqENwOcrxFNPLVg90H21EOLACvtfcHk0ljoZ7rFkMt7vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVOnsQ%253D%253D&md5=936788a6fce33a361e80f8cfd6d88daf</span></div><a href="/servlet/linkout?suffix=cit370&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2003.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2003.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DZavitsanou%26aufirst%3DK.%26aulast%3DGarrick%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DX.%2BF.%26atitle%3DSelective%2520antagonist%2520%255B3H%255DSR141716A%2520binding%2520to%2520cannabinoid%2520CB1%2520receptors%2520is%2520increased%2520in%2520the%2520anterior%2520cingulate%2520cortex%2520in%2520schizophrenia%26jtitle%3DProg.%2520Neuropsychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2004%26volume%3D28%26spage%3D355%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref371"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref371'); return false;" data-citation="" class="refNumLink">371</a></strong><div class="NLM_citation" id="cit371"><span><span class="NLM_contrib-group">Emrich, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leweke, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, U.</span><span> </span><span class="NLM_article-title">Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">803</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref371/cit371&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0091-3057%2896%2900426-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref371/cit371&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9130308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref371/cit371&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2sXislaqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1997&pages=803-807&author=H.+M.+Emrichauthor=F.+M.+Lewekeauthor=U.+Schneider&title=Towards+a+cannabinoid+hypothesis+of+schizophrenia%3A+cognitive+impairments+due+to+dysregulation+of+the+endogenous+cannabinoid+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit371R"><div class="casContent"><span class="casTitleNuber">371</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system</span></div><div class="casAuthors">Emrich, Hinderk M.; Leweke, Markus; Schneider, Udo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">803-807</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The perceptual abnormalities induced by psychotogenic agents play a major role as tools for the understanding of model psychoses.  The recently discovered cannabinoid receptor system with its endogenous ligand anandamide can be regarded as an extremely relevant regulatory system, a dysfunctionality of which may explain at least one subtype of endogenous psychoses.  Neuropsychol. results (3-dimensional inversion illusion) in Δ9-tetrahydrocannabinol-intoxicated normal volunteers exhibited strong similarities with data acquired from patients with productive schizophrenic psychoses, regarding disturbances in internal regulation of perceptual processes.  The relevance of this finding to a general cognitive dysfunction concept of schizophrenic psychosis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8OGytYytNBLVg90H21EOLACvtfcHk0lilw1qPe9JLAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislaqs7w%253D&md5=816eee41796ad4445e6189dd4697f53a</span></div><a href="/servlet/linkout?suffix=cit371&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2896%2900426-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252896%252900426-1%26sid%3Dliteratum%253Aachs%26aulast%3DEmrich%26aufirst%3DH.%2BM.%26aulast%3DLeweke%26aufirst%3DF.%2BM.%26aulast%3DSchneider%26aufirst%3DU.%26atitle%3DTowards%2520a%2520cannabinoid%2520hypothesis%2520of%2520schizophrenia%253A%2520cognitive%2520impairments%2520due%2520to%2520dysregulation%2520of%2520the%2520endogenous%2520cannabinoid%2520system%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D1997%26volume%3D56%26spage%3D803%26epage%3D807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref372"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref372'); return false;" data-citation="" class="refNumLink">372</a></strong><div class="NLM_citation" id="cit372"><span><span class="NLM_contrib-group">Poncelet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnouin, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breliere, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrie, P.</span><span> </span><span class="NLM_article-title">Blockade of cannabinoid (CB<sub>1</sub>) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref372/cit372&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs002130050987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref372/cit372&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10394995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref372/cit372&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1MXjvValurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=1999&pages=144-150&author=M.+Ponceletauthor=M.+C.+Barnouinauthor=J.+C.+Breliereauthor=G.+Le+Furauthor=P.+Soubrie&title=Blockade+of+cannabinoid+%28CB1%29+receptors+by+141716+selectively+antagonizes+drug-induced+reinstatement+of+exploratory+behaviour+in+gerbils"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit372R"><div class="casContent"><span class="casTitleNuber">372</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behavior in gerbils</span></div><div class="casAuthors">Poncelet, Martine; Barnouin, Marie-Christine; Breliere, Jean-Claude; Le Fur, Gerard; Soubrie, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A cannabinoid hypothesis of schizophrenia has been proposed according to which cognitive dysfunction could be assocd. with dysregulation of an endogenous cannabinoid system.  The present study investigated whether SR 141716, a selective CB1 receptor antagonist, was able to reduce the hyperactivity induced in gerbils by various stimulant drugs known to produce or exacerbate schizophrenic symptoms.  Cocaine, d-amphetamine, morphine, and Win 55212-2 were administered i.p. (IP) either immediately before placing the animals in the test app. (non-habituated gerbils) or after a 2- to 3-h habituation period in the actimeter (habituated gerbils).  SR 141716 was given IP 30 min before the injection of stimulant drugs.  Horizontal activity was recorded every 10 min for 1 h in Digiscan activity monitor.  SR 141716 (0.3-3 mg/kg) dose-dependently suppressed the enhanced locomotor activity induced by each stimulant drug in habituated gerbils, but not in non-habituated animals.  Clozapine, an atypical antipsychotic compd., but not haloperidol, shared with SR 141716, the ability to differentially affect drug-induced hyperactivity in habituated vs. non-habituated gerbils.  The activation of cannabinoid systems is a required, permissive element in the ability of cocaine, d-amphetamine, morphine, and Win 55212-2 to reinstate behavior, i.e., to override stimulus satiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKsAvtIBBNq7Vg90H21EOLACvtfcHk0lilw1qPe9JLAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvValurc%253D&md5=c309610bdd6113555777358b19fa701b</span></div><a href="/servlet/linkout?suffix=cit372&amp;dbid=16384&amp;doi=10.1007%2Fs002130050987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002130050987%26sid%3Dliteratum%253Aachs%26aulast%3DPoncelet%26aufirst%3DM.%26aulast%3DBarnouin%26aufirst%3DM.%2BC.%26aulast%3DBreliere%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BFur%26aufirst%3DG.%26aulast%3DSoubrie%26aufirst%3DP.%26atitle%3DBlockade%2520of%2520cannabinoid%2520%2528CB1%2529%2520receptors%2520by%2520141716%2520selectively%2520antagonizes%2520drug-induced%2520reinstatement%2520of%2520exploratory%2520behaviour%2520in%2520gerbils%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D1999%26volume%3D144%26spage%3D144%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref373"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref373'); return false;" data-citation="" class="refNumLink">373</a></strong><div class="NLM_citation" id="cit373"><span><span> </span><span class="NLM_article-title">RxTrials instititute drug pipeline alert. FDA accepts iloperidone NDA</span>.  <span class="citation_source-journal">FDA News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">232</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=RxTrials+instititute+drug+pipeline+alert.+FDA+accepts+iloperidone+NDA.+FDA+News+2007%2C+5+%28232%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit373&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DRxTrials%2520instititute%2520drug%2520pipeline%2520alert.%2520FDA%2520accepts%2520iloperidone%2520NDA%26jtitle%3DFDA%2520News%26date%3D2007%26volume%3D5%26issue%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref374"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref374'); return false;" data-citation="" class="refNumLink">374</a></strong><div class="NLM_citation" id="cit374"><span><span class="NLM_contrib-group">Spedding, M.;</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa e Silva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perret, L.</span><span> </span><span class="NLM_article-title">A pathophysiological paradigm for the therapy of psychiatric disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=467-476&author=M.%3B+Speddingauthor=T.+Jayauthor=J.+Costa+e+Silvaauthor=L.+Perret&title=A+pathophysiological+paradigm+for+the+therapy+of+psychiatric+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit374&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpedding%26aufirst%3DM.%253B%26aulast%3DJay%26aufirst%3DT.%26aulast%3DCosta%2Be%2BSilva%26aufirst%3DJ.%26aulast%3DPerret%26aufirst%3DL.%26atitle%3DA%2520pathophysiological%2520paradigm%2520for%2520the%2520therapy%2520of%2520psychiatric%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D467%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref375"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref375'); return false;" data-citation="" class="refNumLink">375</a></strong><div class="NLM_citation" id="cit375"><span><span class="NLM_contrib-group">Horrobin, D. F.</span><span> </span><span class="NLM_article-title">Modern biomedical research: an internally self-consistent universe with little contact with medical reality</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=151-154&author=D.+F.+Horrobin&title=Modern+biomedical+research%3A+an+internally+self-consistent+universe+with+little+contact+with+medical+reality"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit375&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorrobin%26aufirst%3DD.%2BF.%26atitle%3DModern%2520biomedical%2520research%253A%2520an%2520internally%2520self-consistent%2520universe%2520with%2520little%2520contact%2520with%2520medical%2520reality%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D151%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref376"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref376'); return false;" data-citation="" class="refNumLink">376</a></strong><div class="NLM_citation" id="cit376"><span><span class="NLM_contrib-group">Holmes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leweke, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koethe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerth, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolden, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahn, S.</span><span> </span><span class="NLM_article-title">Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">e327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=e327&author=E.+Holmesauthor=T.+M.+Tsangauthor=J.+T.+Huangauthor=F.+M.+Lewekeauthor=D.+Koetheauthor=C.+W.+Gerthauthor=B.+M.+Noldenauthor=S.+Grossauthor=D.+Schreiberauthor=J.+K.+Nicholsonauthor=S.+Bahn&title=Metabolic+profiling+of+CSF%3A+evidence+that+early+intervention+may+impact+on+disease+progression+and+outcome+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit376&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DE.%26aulast%3DTsang%26aufirst%3DT.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%2BT.%26aulast%3DLeweke%26aufirst%3DF.%2BM.%26aulast%3DKoethe%26aufirst%3DD.%26aulast%3DGerth%26aufirst%3DC.%2BW.%26aulast%3DNolden%26aufirst%3DB.%2BM.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DD.%26aulast%3DNicholson%26aufirst%3DJ.%2BK.%26aulast%3DBahn%26aufirst%3DS.%26atitle%3DMetabolic%2520profiling%2520of%2520CSF%253A%2520evidence%2520that%2520early%2520intervention%2520may%2520impact%2520on%2520disease%2520progression%2520and%2520outcome%2520in%2520schizophrenia%26jtitle%3DPLoS%2520Med.%26date%3D2006%26volume%3D3%26spage%3De327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref377"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref377'); return false;" data-citation="" class="refNumLink">377</a></strong><div class="NLM_citation" id="cit377"><span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span> </span><span class="NLM_article-title">Catching up on schizophrenia: natural history and neurobiology</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=325-334&author=D.+A.+Lewisauthor=J.+A.+Lieberman&title=Catching+up+on+schizophrenia%3A+natural+history+and+neurobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit377&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DCatching%2520up%2520on%2520schizophrenia%253A%2520natural%2520history%2520and%2520neurobiology%26jtitle%3DNeuron%26date%3D2000%26volume%3D28%26spage%3D325%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref378"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref378'); return false;" data-citation="" class="refNumLink">378</a></strong><div class="NLM_citation" id="cit378"><span><span class="NLM_contrib-group">Glantz, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarskog, L. F.</span><span> </span><span class="NLM_article-title">Apoptotic mechanisms and the synaptic pathology of schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref378/cit378&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2005.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref378/cit378&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16226876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref378/cit378&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MnovF2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2006&pages=47-63&author=L.+A.+Glantzauthor=J.+H.+Gilmoreauthor=J.+A.+Liebermanauthor=L.+F.+Jarskog&title=Apoptotic+mechanisms+and+the+synaptic+pathology+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit378R"><div class="casContent"><span class="casTitleNuber">378</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptotic mechanisms and the synaptic pathology of schizophrenia</span></div><div class="casAuthors">Glantz Leisa A; Gilmore John H; Lieberman Jeffrey A; Jarskog L Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-63</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The cortical neuropathology of schizophrenia includes neuronal atrophy, decreased neuropil, and alterations in neuronal density.  Taken together with evidence of decreased synaptic markers and dendritic spines, the data suggest that synaptic circuitry is altered.  Recent neuroimaging studies also indicate that a progressive loss of cortical gray matter occurs early in the course of schizophrenia.  Although the mechanisms underlying these deficits are largely unknown, recent postmortem data implicate a role for altered neuronal apoptosis.  Apoptosis, a form of programmed cell death, is regulated by a complex cascade of pro- and anti-apoptotic proteins.  Apoptotic activation can lead to rapid neuronal death.  However, emerging data also indicate that sub-lethal apoptotic activity can lead to a limited form of apoptosis in terminal neurites and individual synapses to cause synaptic elimination without cell death.  For example, in Alzheimer's disease, a localized apoptotic mechanism is thought to contribute to early neurite and synapse loss leading to the initial cognitive decline.  Recent studies indicate that apoptotic regulatory proteins and DNA fragmentation patterns are altered in several cortical regions in schizophrenia.  This paper will review converging lines of data that implicate synaptic deficits in the pathophysiology of schizophrenia and propose an underlying role for apoptotic dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTH-6l-CmE2uaqcneEtCi92fW6udTcc2eaescrDtx4ZU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnovF2nug%253D%253D&md5=73d5d75bd379f7f0a77f36e6e7a0f20f</span></div><a href="/servlet/linkout?suffix=cit378&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2005.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2005.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DGlantz%26aufirst%3DL.%2BA.%26aulast%3DGilmore%26aufirst%3DJ.%2BH.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DJarskog%26aufirst%3DL.%2BF.%26atitle%3DApoptotic%2520mechanisms%2520and%2520the%2520synaptic%2520pathology%2520of%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D81%26spage%3D47%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref379"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref379'); return false;" data-citation="" class="refNumLink">379</a></strong><div class="NLM_citation" id="cit379"><span><span class="NLM_contrib-group">Insel, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolnick, E. M.</span><span> </span><span class="NLM_article-title">Cure therapeutics and strategic prevention: raising the bar for mental health research</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref379/cit379&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref379/cit379&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16355250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref379/cit379&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MnmslChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=11-17&author=T.+R.+Inselauthor=E.+M.+Scolnick&title=Cure+therapeutics+and+strategic+prevention%3A+raising+the+bar+for+mental+health+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit379R"><div class="casContent"><span class="casTitleNuber">379</span><div class="casTitle"><span class="NLM_cas:atitle">Cure therapeutics and strategic prevention: raising the bar for mental health research</span></div><div class="casAuthors">Insel T R; Scolnick E M</div><div class="citationInfo"><span class="NLM_cas:title">Molecular psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-7</span>
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    </div><div class="casAbstract">Mental disorders cause more disability than any other class of medical illness in Americans between ages 15 and 44 years.  The suicide rate is higher than the annual mortality from homicide, AIDS, and most forms of cancer.  In contrast to nearly all communicable and most non-communicable diseases, there is little evidence that the morbidity and mortality from mental disorders have changed in the past several decades.  Mental health advocates, including psychiatric researchers, have pointed to stigma as one of the reasons for the lack of progress with mental illnesses relative to other medical illnesses.  This review considers how the expectations and goals of the research community have contributed to this relative lack of progress.  In contrast to researchers in cancer and heart disease who have sought cures and preventions, biological psychiatrists in both academia and industry have set their sights on incremental and marketable advances, such as drugs with fewer adverse effects.  This essay argues for approaches that can lead to cures and strategies for prevention of schizophrenia and mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6mia5Y8_SJcve_zCu79I8fW6udTcc2eaescrDtx4ZU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnmslChsQ%253D%253D&md5=f17e613c44174495a6b3598150beb26f</span></div><a href="/servlet/linkout?suffix=cit379&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001777%26sid%3Dliteratum%253Aachs%26aulast%3DInsel%26aufirst%3DT.%2BR.%26aulast%3DScolnick%26aufirst%3DE.%2BM.%26atitle%3DCure%2520therapeutics%2520and%2520strategic%2520prevention%253A%2520raising%2520the%2520bar%2520for%2520mental%2520health%2520research%26jtitle%3DMol.%2520Psychiatry%26date%3D2006%26volume%3D11%26spage%3D11%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref380"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref380'); return false;" data-citation="" class="refNumLink">380</a></strong><div class="NLM_citation" id="cit380"><span><span class="NLM_contrib-group">Santarelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surget, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisstaub, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arancio, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belzung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hen, R.</span><span> </span><span class="NLM_article-title">Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">809</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref380/cit380&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1126%2Fscience.1083328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref380/cit380&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12907793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref380/cit380&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtVGqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2003&pages=805-809&author=L.+Santarelliauthor=M.+Saxeauthor=C.+Grossauthor=A.+Surgetauthor=F.+Battagliaauthor=S.+Dulawaauthor=N.+Weisstaubauthor=J.+Leeauthor=R.+Dumanauthor=O.+Arancioauthor=C.+Belzungauthor=R.+Hen&title=Requirement+of+hippocampal+neurogenesis+for+the+behavioral+effects+of+antidepressants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit380R"><div class="casContent"><span class="casTitleNuber">380</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants</span></div><div class="casAuthors">Santarelli, Luca; Saxe, Michael; Gross, Cornelius; Surget, Alexandre; Battaglia, Fortunato; Dulawa, Stephanie; Weisstaub, Noelia; Lee, James; Duman, Ronald; Arancio, Ottavio; Belzung, Catherine; Hen, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">5634</span>),
    <span class="NLM_cas:pages">805-809</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Various chronic antidepressant treatments increase adult hippocampal neurogenesis, but the functional importance of this phenomenon remains unclear.  Here, using genetic and radiol. methods, we show that disrupting antidepressant-induced neurogenesis blocks behavioral responses to antidepressants.  Serotonin 1A receptor null mice were insensitive to the neurogenic and behavioral effects of fluoxetine, a serotonin selective reuptake inhibitor.  X-irradn. of a restricted region of mouse brain contg. the hippocampus prevented the neurogenic and behavioral effects of two classes of antidepressants.  These findings suggest that the behavioral effects of chronic antidepressants may be mediated by the stimulation of neurogenesis in the hippocampus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF_g9pJxKj77Vg90H21EOLACvtfcHk0liokW-RT7E0JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtVGqsrY%253D&md5=35dcba65dfd5a695faa6d6702fc385f9</span></div><a href="/servlet/linkout?suffix=cit380&amp;dbid=16384&amp;doi=10.1126%2Fscience.1083328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1083328%26sid%3Dliteratum%253Aachs%26aulast%3DSantarelli%26aufirst%3DL.%26aulast%3DSaxe%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DSurget%26aufirst%3DA.%26aulast%3DBattaglia%26aufirst%3DF.%26aulast%3DDulawa%26aufirst%3DS.%26aulast%3DWeisstaub%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DDuman%26aufirst%3DR.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DBelzung%26aufirst%3DC.%26aulast%3DHen%26aufirst%3DR.%26atitle%3DRequirement%2520of%2520hippocampal%2520neurogenesis%2520for%2520the%2520behavioral%2520effects%2520of%2520antidepressants%26jtitle%3DScience%26date%3D2003%26volume%3D301%26spage%3D805%26epage%3D809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref381"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref381'); return false;" data-citation="" class="refNumLink">381</a></strong><div class="NLM_citation" id="cit381"><span><span class="NLM_contrib-group">Kippin, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der, K. D.</span><span> </span><span class="NLM_article-title">Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5815</span><span class="NLM_x">–</span> <span class="NLM_lpage">5823</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref381/cit381&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1523%2FJNEUROSCI.1120-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref381/cit381&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15958748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref381/cit381&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=5815-5823&author=T.+E.+Kippinauthor=S.+Kapurauthor=K.+D.+Van+Der&title=Dopamine+specifically+inhibits+forebrain+neural+stem+cell+proliferation%2C+suggesting+a+novel+effect+of+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit381R"><div class="casContent"><span class="casTitleNuber">381</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs</span></div><div class="casAuthors">Kippin, Tod E.; Kapur, Shitij; van der Kooy, Derek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5815-5823</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Neurogenesis has been implicated in antidepressant drug action and animal models of depression, suggesting that proliferating cells play a role in psychiatric disorders.  Similar studies using antipsychotic drugs have yielded conflicting results, perhaps because of the lack of focus on specific cell types.  We examine the effect of haloperidol on neural stem cells (NSCs), the ultimate precursors for adult cell genesis.  We show that haloperidol increases NSC nos., resulting in more progenitors and more new neurons and glia in the adult rat brain.  The increase in NSCs by haloperidol is dependent on central dopamine D2 receptors, and these receptors are expressed by NSCs.  D2 receptor stimulation in vitro inhibits NSC proliferation, which is reversed by haloperidol.  Thus, haloperidol increases adult mammalian brain proliferation by antagonizing dopamine at D2 receptors on NSCs.  These findings demonstrate a direct link between neural activity and NSC proliferation and implicate cell genesis in antipsychotic drug effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWBlzvHGSpVrVg90H21EOLACvtfcHk0lhWQ03rWmDpog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFent7c%253D&md5=c27628c088afc63758970b8bf87f46c6</span></div><a href="/servlet/linkout?suffix=cit381&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1120-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1120-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DKippin%26aufirst%3DT.%2BE.%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DVan%2BDer%26aufirst%3DK.%2BD.%26atitle%3DDopamine%2520specifically%2520inhibits%2520forebrain%2520neural%2520stem%2520cell%2520proliferation%252C%2520suggesting%2520a%2520novel%2520effect%2520of%2520antipsychotic%2520drugs%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D5815%26epage%3D5823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275'],'ref276':['cit276'],'ref277':['cit277'],'ref278':['cit278'],'ref279':['cit279'],'ref280':['cit280'],'ref281':['cit281'],'ref282':['cit282'],'ref283':['cit283'],'ref284':['cit284'],'ref285':['cit285'],'ref286':['cit286'],'ref287':['cit287'],'ref288':['cit288'],'ref289':['cit289'],'ref290':['cit290'],'ref291':['cit291'],'ref292':['cit292'],'ref293':['cit293'],'ref294':['cit294'],'ref295':['cit295'],'ref296':['cit296'],'ref297':['cit297'],'ref298':['cit298'],'ref299':['cit299'],'ref300':['cit300'],'ref301':['cit301'],'ref302':['cit302'],'ref303':['cit303'],'ref304':['cit304'],'ref305':['cit305'],'ref306':['cit306'],'ref307':['cit307'],'ref308':['cit308'],'ref309':['cit309'],'ref310':['cit310'],'ref311':['cit311'],'ref312':['cit312'],'ref313':['cit313'],'ref314':['cit314'],'ref315':['cit315'],'ref316':['cit316'],'ref317':['cit317'],'ref318':['cit318'],'ref319':['cit319'],'ref320':['cit320'],'ref321':['cit321'],'ref322':['cit322'],'ref323':['cit323'],'ref324':['cit324'],'ref325':['cit325'],'ref326':['cit326'],'ref327':['cit327'],'ref328':['cit328'],'ref329':['cit329'],'ref330':['cit330'],'ref331':['cit331'],'ref332':['cit332'],'ref333':['cit333'],'ref334':['cit334'],'ref335':['cit335'],'ref336':['cit336'],'ref337':['cit337'],'ref338':['cit338'],'ref339':['cit339'],'ref340':['cit340'],'ref341':['cit341'],'ref342':['cit342'],'ref343':['cit343'],'ref344':['cit344'],'ref345':['cit345'],'ref346':['cit346'],'ref347':['cit347'],'ref348':['cit348'],'ref349':['cit349'],'ref350':['cit350'],'ref351':['cit351'],'ref352':['cit352'],'ref353':['cit353'],'ref354':['cit354'],'ref355':['cit355'],'ref356':['cit356'],'ref357':['cit357'],'ref358':['cit358'],'ref359':['cit359'],'ref360':['cit360'],'ref361':['cit361'],'ref362':['cit362'],'ref363':['cit363'],'ref364':['cit364'],'ref365':['cit365'],'ref366':['cit366'],'ref367':['cit367'],'ref368':['cit368'],'ref369':['cit369'],'ref370':['cit370'],'ref371':['cit371'],'ref372':['cit372'],'ref373':['cit373'],'ref374':['cit374'],'ref375':['cit375'],'ref376':['cit376'],'ref377':['cit377'],'ref378':['cit378'],'ref379':['cit379'],'ref380':['cit380'],'ref381':['cit381']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 43 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. S. Prasadarao  Lingam</span>, <span class="hlFld-ContribAuthor ">Dnyaneshwar H.  Dahale</span>, <span class="hlFld-ContribAuthor ">Vijay E.  Rathi</span>, <span class="hlFld-ContribAuthor ">Yogesh B.  Shingote</span>, <span class="hlFld-ContribAuthor ">Rajni R.  Thakur</span>, <span class="hlFld-ContribAuthor ">Ajit S.  Mindhe</span>, <span class="hlFld-ContribAuthor ">Srinivas  Kummari</span>, <span class="hlFld-ContribAuthor ">Neelima  Khairatkar-Joshi</span>, <span class="hlFld-ContribAuthor ">Malini  Bajpai</span>, <span class="hlFld-ContribAuthor ">Daisy M.  Shah</span>, <span class="hlFld-ContribAuthor ">Ratika S.  Sapalya</span>, <span class="hlFld-ContribAuthor ">Srinivas  Gullapalli</span>, <span class="hlFld-ContribAuthor ">Praveen K.  Gupta</span>, <span class="hlFld-ContribAuthor ">Girish S.  Gudi</span>, <span class="hlFld-ContribAuthor ">Satyawan B.  Jadhav</span>, <span class="hlFld-ContribAuthor ">Rambabu  Pattem</span>, and <span class="hlFld-ContribAuthor ">Abraham  Thomas</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (20)
                                     , 8292-8308. <a href="https://doi.org/10.1021/acs.jmedchem.5b01240" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01240%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BPharmacological%252BEvaluation%252Bof%252B5%25252C6-Disubstituted%252BPyridin-2%2525281H%252529-one%252BDerivatives%252Bas%252BPhosphodiesterase%252B10A%252B%252528PDE10A%252529%252BAntagonists%26aulast%3DLingam%26aufirst%3DV.%2BS.%2BPrasadarao%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D06082015%26date%3D07102015%26date%3D22102015%26date%3D30092015%26volume%3D58%26issue%3D20%26spage%3D8292%26epage%3D8308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Albert J.  Robichaud</span>, <span class="hlFld-ContribAuthor ">Taekyu  Lee</span>, <span class="hlFld-ContribAuthor ">John  Tomesch</span>, <span class="hlFld-ContribAuthor ">Wei  Yao</span>, <span class="hlFld-ContribAuthor ">J. David  Beard</span>, <span class="hlFld-ContribAuthor ">Gretchen L.  Snyder</span>, <span class="hlFld-ContribAuthor ">Hongwen  Zhu</span>, <span class="hlFld-ContribAuthor ">Youyi  Peng</span>, <span class="hlFld-ContribAuthor ">Joseph P.  Hendrick</span>, <span class="hlFld-ContribAuthor ">Kimberly E.  Vanover</span>, <span class="hlFld-ContribAuthor ">Robert E.  Davis</span>, <span class="hlFld-ContribAuthor ">Sharon  Mates</span>, and <span class="hlFld-ContribAuthor ">Lawrence P.  Wennogle</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (6)
                                     , 2670-2682. <a href="https://doi.org/10.1021/jm401958n" title="DOI URL">https://doi.org/10.1021/jm401958n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401958n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401958n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BTetracyclic%252BQuinoxaline%252BDerivative%252Bas%252Ba%252BPotent%252Band%252BOrally%252BActive%252BMultifunctional%252BDrug%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNeuropsychiatric%252Band%252BNeurological%252BDisorders%26aulast%3DLi%26aufirst%3DPeng%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D20122013%26date%3D05032014%26date%3D27032014%26date%3D21022014%26volume%3D57%26issue%3D6%26spage%3D2670%26epage%3D2682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-François  Liégeois</span>, <span class="hlFld-ContribAuthor ">Marine  Deville</span>, <span class="hlFld-ContribAuthor ">Sébastien  Dilly</span>, <span class="hlFld-ContribAuthor ">Cédric  Lamy</span>, <span class="hlFld-ContribAuthor ">Floriane  Mangin</span>, <span class="hlFld-ContribAuthor ">Mélissa  Résimont</span>, and <span class="hlFld-ContribAuthor ">Frank I.  Tarazi</span>  . </span><span class="cited-content_cbyCitation_article-title">New Pyridobenzoxazepine Derivatives Derived from 5-(4-Methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): Chemical Synthesis and Pharmacological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (4)
                                     , 1572-1582. <a href="https://doi.org/10.1021/jm2013419" title="DOI URL">https://doi.org/10.1021/jm2013419</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm2013419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm2013419%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252BPyridobenzoxazepine%252BDerivatives%252BDerived%252Bfrom%252B5-%2525284-Methylpiperazin-1-yl%252529-8-chloro-pyrido%25255B2%25252C3-b%25255D%25255B1%25252C5%25255Dbenzoxazepine%252B%252528JL13%252529%25253A%252BChemical%252BSynthesis%252Band%252BPharmacological%252BEvaluation%26aulast%3DLi%25C3%25A9geois%26aufirst%3DJean-Fran%25C3%25A7ois%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D07102011%26date%3D13022012%26date%3D23022012%26date%3D23012012%26volume%3D55%26issue%3D4%26spage%3D1572%26epage%3D1582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reyes  Aranda</span>, <span class="hlFld-ContribAuthor ">Karen  Villalba</span>, <span class="hlFld-ContribAuthor ">Enrique  Raviña</span>, <span class="hlFld-ContribAuthor ">Christian F.  Masaguer</span>, <span class="hlFld-ContribAuthor ">José  Brea</span>, <span class="hlFld-ContribAuthor ">Filipe  Areias</span>, <span class="hlFld-ContribAuthor ">Eduardo  Domínguez</span>, <span class="hlFld-ContribAuthor ">Jana  Selent</span>, <span class="hlFld-ContribAuthor ">Laura  López</span>, <span class="hlFld-ContribAuthor ">Ferran  Sanz</span>, <span class="hlFld-ContribAuthor ">Manuel  Pastor</span> and <span class="hlFld-ContribAuthor ">María I.  Loza</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Binding Affinity, and Molecular Docking Analysis of New Benzofuranone Derivatives as Potential Antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2008,</strong> <em>51 </em>
                                    (19)
                                     , 6085-6094. <a href="https://doi.org/10.1021/jm800602w" title="DOI URL">https://doi.org/10.1021/jm800602w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm800602w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm800602w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252BBinding%252BAffinity%25252C%252Band%252BMolecular%252BDocking%252BAnalysis%252Bof%252BNew%252BBenzofuranone%252BDerivatives%252Bas%252BPotential%252BAntipsychotics%26aulast%3DAranda%26aufirst%3DReyes%26date%3D2008%26date%3D2008%26date%3D2008%26date%3D09%252010%25202008%26date%3D11%252009%25202008%26date%3D21%252005%25202008%26volume%3D51%26issue%3D19%26spage%3D6085%26epage%3D6094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Martínez</span>, <span class="hlFld-ContribAuthor ">Ponciano  García-Gutiérrez</span>, <span class="hlFld-ContribAuthor ">Rafael A.  Zubillaga</span>, <span class="hlFld-ContribAuthor ">Jorge  Garza</span>, <span class="hlFld-ContribAuthor ">Rubicelia  Vargas</span>. </span><span class="cited-content_cbyCitation_article-title">Main interactions of dopamine and risperidone with the dopamine D2 receptor. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2021,</strong> <em>23 </em>
                                    (26)
                                     , 14224-14230. <a href="https://doi.org/10.1039/D1CP01637G" title="DOI URL">https://doi.org/10.1039/D1CP01637G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CP01637G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CP01637G%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DMain%252Binteractions%252Bof%252Bdopamine%252Band%252Brisperidone%252Bwith%252Bthe%252Bdopamine%252BD2%252Breceptor%26aulast%3DMart%25C3%25ADnez%26aufirst%3DAna%26date%3D2021%26date%3D2021%26volume%3D23%26issue%3D26%26spage%3D14224%26epage%3D14230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roxana M.  Castillo</span>, <span class="hlFld-ContribAuthor ">Estrella  Ramos</span>, <span class="hlFld-ContribAuthor ">Ana  Martínez</span>. </span><span class="cited-content_cbyCitation_article-title">Interaction of graphene with antipsychotic drugs: Is there any charge transfer process?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computational Chemistry</span><span> <strong>2021,</strong> <em>42 </em>
                                    (1)
                                     , 60-65. <a href="https://doi.org/10.1002/jcc.26433" title="DOI URL">https://doi.org/10.1002/jcc.26433</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcc.26433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcc.26433%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computational%2520Chemistry%26atitle%3DInteraction%252Bof%252Bgraphene%252Bwith%252Bantipsychotic%252Bdrugs%25253A%252BIs%252Bthere%252Bany%252Bcharge%252Btransfer%252Bprocess%25253F%26aulast%3DCastillo%26aufirst%3DRoxana%2BM.%26date%3D2021%26date%3D2020%26volume%3D42%26issue%3D1%26spage%3D60%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillermo  Goode-Romero</span>, <span class="hlFld-ContribAuthor ">Ulrika  Winnberg</span>, <span class="hlFld-ContribAuthor ">Laura  Domínguez</span>, <span class="hlFld-ContribAuthor ">Ilich A.  Ibarra</span>, <span class="hlFld-ContribAuthor ">Rubicelia  Vargas</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Winnberg</span>, <span class="hlFld-ContribAuthor ">Ana  Martínez</span>. </span><span class="cited-content_cbyCitation_article-title">New information of dopaminergic agents based on quantum chemistry calculations. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-78446-4" title="DOI URL">https://doi.org/10.1038/s41598-020-78446-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-78446-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-78446-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DNew%252Binformation%252Bof%252Bdopaminergic%252Bagents%252Bbased%252Bon%252Bquantum%252Bchemistry%252Bcalculations%26aulast%3DGoode-Romero%26aufirst%3DGuillermo%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Martínez</span>, <span class="hlFld-ContribAuthor ">Ilich A.  Ibarra</span>, <span class="hlFld-ContribAuthor ">Rubicelia  Vargas</span>, . </span><span class="cited-content_cbyCitation_article-title">A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2019,</strong> <em>14 </em>
                                    (12)
                                     , e0224691. <a href="https://doi.org/10.1371/journal.pone.0224691" title="DOI URL">https://doi.org/10.1371/journal.pone.0224691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0224691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0224691%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DA%252Bquantum%252Bchemical%252Bapproach%252Brepresenting%252Ba%252Bnew%252Bperspective%252Bconcerning%252Bagonist%252Band%252Bantagonist%252Bdrugs%252Bin%252Bthe%252Bcontext%252Bof%252Bschizophrenia%252Band%252BParkinson%2525E2%252580%252599s%252Bdisease%26aulast%3DMart%25C3%25ADnez%26aufirst%3DAna%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D12%26spage%3De0224691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Bo  Shen</span>, <span class="hlFld-ContribAuthor ">Xiang-Ting  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in catalytic asymmetric intermolecular oxidation of alkynes. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (30)
                                     , 7106-7113. <a href="https://doi.org/10.1039/C9OB01096C" title="DOI URL">https://doi.org/10.1039/C9OB01096C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB01096C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB01096C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bcatalytic%252Basymmetric%252Bintermolecular%252Boxidation%252Bof%252Balkynes%26aulast%3DShen%26aufirst%3DWen-Bo%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D30%26spage%3D7106%26epage%3D7113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antipsychotics (Neuroleptics, N05A). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 1-17. <a href="https://doi.org/10.1002/14356007.a22_341.pub3" title="DOI URL">https://doi.org/10.1002/14356007.a22_341.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.a22_341.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.a22_341.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DAntipsychotics%252B%252528Neuroleptics%25252C%252BN05A%252529%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2019%26date%3D2019%26spage%3D1%26epage%3D17%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.  Butini</span>, <span class="hlFld-ContribAuthor ">K.  Nikolic</span>, <span class="hlFld-ContribAuthor ">S.  Kassel</span>, <span class="hlFld-ContribAuthor ">H.  Brückmann</span>, <span class="hlFld-ContribAuthor ">S.  Filipic</span>, <span class="hlFld-ContribAuthor ">D.  Agbaba</span>, <span class="hlFld-ContribAuthor ">S.  Gemma</span>, <span class="hlFld-ContribAuthor ">S.  Brogi</span>, <span class="hlFld-ContribAuthor ">M.  Brindisi</span>, <span class="hlFld-ContribAuthor ">G.  Campiani</span>, <span class="hlFld-ContribAuthor ">H.  Stark</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacology of dopamine receptor ligands. </span><span class="cited-content_cbyCitation_journal-name">Progress in Neurobiology</span><span> <strong>2016,</strong> <em>142 </em>, 68-103. <a href="https://doi.org/10.1016/j.pneurobio.2016.03.011" title="DOI URL">https://doi.org/10.1016/j.pneurobio.2016.03.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pneurobio.2016.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pneurobio.2016.03.011%26sid%3Dliteratum%253Aachs%26jtitle%3DProgress%2520in%2520Neurobiology%26atitle%3DPolypharmacology%252Bof%252Bdopamine%252Breceptor%252Bligands%26aulast%3DButini%26aufirst%3DS.%26date%3D2016%26volume%3D142%26spage%3D68%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Lin  Guo</span>, <span class="hlFld-ContribAuthor ">Hongliang  Duan</span>, <span class="hlFld-ContribAuthor ">Liming  Zhang</span>, <span class="hlFld-ContribAuthor ">Neng  Jiang</span>, <span class="hlFld-ContribAuthor ">Xuechu  Zhen</span>, <span class="hlFld-ContribAuthor ">Jianhua  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2015,</strong> <em>5 </em>
                                    (51)
                                     , 40964-40977. <a href="https://doi.org/10.1039/C5RA04714E" title="DOI URL">https://doi.org/10.1039/C5RA04714E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5RA04714E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5RA04714E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDiscovery%252Bof%252B4-benzoylpiperidine%252Band%252B3-%252528piperidin-4-yl%252529benzo%25255Bd%25255Disoxazole%252Bderivatives%252Bas%252Bpotential%252Band%252Bselective%252BGlyT1%252Binhibitors%26aulast%3DLiu%26aufirst%3DYang%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D51%26spage%3D40964%26epage%3D40977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deyun  Qian</span>, <span class="hlFld-ContribAuthor ">Haoxiang  Hu</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Bin  Tang</span>, <span class="hlFld-ContribAuthor ">Weimin  Ye</span>, <span class="hlFld-ContribAuthor ">Yidong  Wang</span>, <span class="hlFld-ContribAuthor ">Junliang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Gold(I)-Catalyzed Highly Diastereo- and Enantioselective Alkyne Oxidation/Cyclopropanation of 1,6-Enynes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2014,</strong> <em>126 </em>
                                    (50)
                                     , 13971-13975. <a href="https://doi.org/10.1002/ange.201407717" title="DOI URL">https://doi.org/10.1002/ange.201407717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201407717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201407717%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DGold%252528I%252529-Catalyzed%252BHighly%252BDiastereo-%252Band%252BEnantioselective%252BAlkyne%252BOxidation%25252FCyclopropanation%252Bof%252B1%25252C6-Enynes%26aulast%3DQian%26aufirst%3DDeyun%26date%3D2014%26date%3D2014%26volume%3D126%26issue%3D50%26spage%3D13971%26epage%3D13975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deyun  Qian</span>, <span class="hlFld-ContribAuthor ">Haoxiang  Hu</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Bin  Tang</span>, <span class="hlFld-ContribAuthor ">Weimin  Ye</span>, <span class="hlFld-ContribAuthor ">Yidong  Wang</span>, <span class="hlFld-ContribAuthor ">Junliang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Gold(I)-Catalyzed Highly Diastereo- and Enantioselective Alkyne Oxidation/Cyclopropanation of 1,6-Enynes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2014,</strong> <em>53 </em>
                                    (50)
                                     , 13751-13755. <a href="https://doi.org/10.1002/anie.201407717" title="DOI URL">https://doi.org/10.1002/anie.201407717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201407717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201407717%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DGold%252528I%252529-Catalyzed%252BHighly%252BDiastereo-%252Band%252BEnantioselective%252BAlkyne%252BOxidation%25252FCyclopropanation%252Bof%252B1%25252C6-Enynes%26aulast%3DQian%26aufirst%3DDeyun%26date%3D2014%26date%3D2014%26volume%3D53%26issue%3D50%26spage%3D13751%26epage%3D13755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert J.  Harvey</span>, <span class="hlFld-ContribAuthor ">Benjamin K.  Yee</span>. </span><span class="cited-content_cbyCitation_article-title">Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2013,</strong> <em>12 </em>
                                    (11)
                                     , 866-885. <a href="https://doi.org/10.1038/nrd3893" title="DOI URL">https://doi.org/10.1038/nrd3893</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd3893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd3893%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DGlycine%252Btransporters%252Bas%252Bnovel%252Btherapeutic%252Btargets%252Bin%252Bschizophrenia%25252C%252Balcohol%252Bdependence%252Band%252Bpain%26aulast%3DHarvey%26aufirst%3DRobert%2BJ.%26date%3D2013%26date%3D2013%26volume%3D12%26issue%3D11%26spage%3D866%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Phenothiazines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 301-309. <a href="https://doi.org/10.1002/9783527645640.ch49" title="DOI URL">https://doi.org/10.1002/9783527645640.ch49</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527645640.ch49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527645640.ch49%26sid%3Dliteratum%253Aachs%26atitle%3DPhenothiazines%26date%3D2013%26date%3D2013%26spage%3D301%26epage%3D309%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DLead%252BOptimization%252Bfor%252BMedicinal%252BChemists%26aulast%3DZaragoza%2BD%25C3%25B6rwald%26aufirst%3DFlorencio%26date%3D2012%26volume%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L.I.  Belen’kii</span>, <span class="hlFld-ContribAuthor ">Yu. B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XI, 2008–2009. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 195-290. <a href="https://doi.org/10.1016/B978-0-12-404598-9.00003-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-404598-9.00003-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-404598-9.00003-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-404598-9.00003-1%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXI%25252C%252B2008%2525E2%252580%2525932009%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DL.I.%26date%3D2013%26spage%3D195%26epage%3D290%26pub%3DElsevier%26date%3D2013%26volume%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neil S.  Cutshall</span>, <span class="hlFld-ContribAuthor ">Rene  Onrust</span>, <span class="hlFld-ContribAuthor ">Alex  Rohde</span>, <span class="hlFld-ContribAuthor ">Sasha  Gragerov</span>, <span class="hlFld-ContribAuthor ">Lauren  Hamilton</span>, <span class="hlFld-ContribAuthor ">Kevin  Harbol</span>, <span class="hlFld-ContribAuthor ">Hui-Rong  Shen</span>, <span class="hlFld-ContribAuthor ">Shawn  McKee</span>, <span class="hlFld-ContribAuthor ">Charles  Zuta</span>, <span class="hlFld-ContribAuthor ">Galina  Gragerova</span>, <span class="hlFld-ContribAuthor ">Vince  Florio</span>, <span class="hlFld-ContribAuthor ">Thomas N.  Wheeler</span>, <span class="hlFld-ContribAuthor ">Jennifer L.  Gage</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (17)
                                     , 5595-5599. <a href="https://doi.org/10.1016/j.bmcl.2012.07.007" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.07.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.07.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252B2-methoxyacylhydrazones%252Bas%252Bpotent%25252C%252Bselective%252BPDE10A%252Binhibitors%252Bwith%252Bactivity%252Bin%252Banimal%252Bmodels%252Bof%252Bschizophrenia%26aulast%3DCutshall%26aufirst%3DNeil%2BS.%26date%3D2012%26volume%3D22%26issue%3D17%26spage%3D5595%26epage%3D5599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajiv  Tandon</span>. </span><span class="cited-content_cbyCitation_article-title">Future directions in the treatment of schizophrenia. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 66-79. <a href="https://doi.org/10.2217/ebo.11.319" title="DOI URL">https://doi.org/10.2217/ebo.11.319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/ebo.11.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Febo.11.319%26sid%3Dliteratum%253Aachs%26atitle%3DFuture%252Bdirections%252Bin%252Bthe%252Btreatment%252Bof%252Bschizophrenia%26aulast%3DTandon%26aufirst%3DRajiv%26date%3D2012%26date%3D2012%26spage%3D66%26epage%3D79%26pub%3DFuture%2520Medicine%2520Ltd%26atitle%3DPharmacological%252BTreatments%252Bin%252BSchizophrenia%26aulast%3DKeshavan%26aufirst%3DMatcheri%2BS%26date%3D2012%26date%3D2012%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antipsychotics. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,<a href="https://doi.org/10.1002/14356007.a22_341.pub2" title="DOI URL">https://doi.org/10.1002/14356007.a22_341.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.a22_341.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.a22_341.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DAntipsychotics%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2012%26date%3D2012%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wesley K.  Kroeze</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacological Drugs: “Magic Shotguns” for Psychiatric Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 133-148. <a href="https://doi.org/10.1002/9781118098141.ch7" title="DOI URL">https://doi.org/10.1002/9781118098141.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118098141.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118098141.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DPolypharmacological%252BDrugs%25253A%252B%2525E2%252580%25259CMagic%252BShotguns%2525E2%252580%25259D%252Bfor%252BPsychiatric%252BDiseases%26aulast%3DKroeze%26aufirst%3DWesley%2BK.%26date%3D2012%26date%3D2012%26spage%3D133%26epage%3D148%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPolypharmacology%252Bin%252BDrug%252BDiscovery%26aulast%3DPeters%26aufirst%3DJens-Uwe%26date%3D2012%26volume%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William T.  McElroy</span>, <span class="hlFld-ContribAuthor ">Zheng  Tan</span>, <span class="hlFld-ContribAuthor ">Kallol  Basu</span>, <span class="hlFld-ContribAuthor ">Shu-Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Jennifer  Smotryski</span>, <span class="hlFld-ContribAuthor ">Ginny D.  Ho</span>, <span class="hlFld-ContribAuthor ">Deen  Tulshian</span>, <span class="hlFld-ContribAuthor ">William J.  Greenlee</span>, <span class="hlFld-ContribAuthor ">Deborra  Mullins</span>, <span class="hlFld-ContribAuthor ">Mario  Guzzi</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Zhang</span>, <span class="hlFld-ContribAuthor ">Carina  Bleickardt</span>, <span class="hlFld-ContribAuthor ">Robert  Hodgson</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazoloquinolines as PDE10A inhibitors: Discovery of a tool compound. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (3)
                                     , 1335-1339. <a href="https://doi.org/10.1016/j.bmcl.2011.12.080" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.12.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.12.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.12.080%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPyrazoloquinolines%252Bas%252BPDE10A%252Binhibitors%25253A%252BDiscovery%252Bof%252Ba%252Btool%252Bcompound%26aulast%3DMcElroy%26aufirst%3DWilliam%2BT.%26date%3D2012%26volume%3D22%26issue%3D3%26spage%3D1335%26epage%3D1339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Popiolek</span>, <span class="hlFld-ContribAuthor ">John F.  Ross</span>, <span class="hlFld-ContribAuthor ">Erik  Charych</span>, <span class="hlFld-ContribAuthor ">Pranab  Chanda</span>, <span class="hlFld-ContribAuthor ">Eckart D.  Gundelfinger</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Moss</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Brandon</span>, <span class="hlFld-ContribAuthor ">Mark H.  Pausch</span>. </span><span class="cited-content_cbyCitation_article-title">d-Amino Acid Oxidase Activity Is Inhibited by an Interaction with Bassoon Protein at the Presynaptic Active Zone. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2011,</strong> <em>286 </em>
                                    (33)
                                     , 28867-28875. <a href="https://doi.org/10.1074/jbc.M111.262063" title="DOI URL">https://doi.org/10.1074/jbc.M111.262063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.M111.262063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.M111.262063%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3Dd-Amino%252BAcid%252BOxidase%252BActivity%252BIs%252BInhibited%252Bby%252Ban%252BInteraction%252Bwith%252BBassoon%252BProtein%252Bat%252Bthe%252BPresynaptic%252BActive%252BZone%26aulast%3DPopiolek%26aufirst%3DMichael%26date%3D2011%26volume%3D286%26issue%3D33%26spage%3D28867%26epage%3D28875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorothy G.  Flood</span>, <span class="hlFld-ContribAuthor ">Gerard J.  Marek</span>, <span class="hlFld-ContribAuthor ">Michael  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Developing predictive CSF biomarkers—A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2011,</strong> <em>81 </em>
                                    (12)
                                     , 1422-1434. <a href="https://doi.org/10.1016/j.bcp.2011.01.021" title="DOI URL">https://doi.org/10.1016/j.bcp.2011.01.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2011.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2011.01.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDeveloping%252Bpredictive%252BCSF%252Bbiomarkers%2525E2%252580%252594A%252Bchallenge%252Bcritical%252Bto%252Bsuccess%252Bin%252BAlzheimer%252527s%252Bdisease%252Band%252Bneuropsychiatric%252Btranslational%252Bmedicine%26aulast%3DFlood%26aufirst%3DDorothy%2BG.%26date%3D2011%26volume%3D81%26issue%3D12%26spage%3D1422%26epage%3D1434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gary  Tresadern</span>, <span class="hlFld-ContribAuthor ">Jose Manuel  Bartolome</span>, <span class="hlFld-ContribAuthor ">Gregor J.  Macdonald</span>, <span class="hlFld-ContribAuthor ">Xavier  Langlois</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular properties affecting fast dissociation from the D2 receptor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2011,</strong> <em>19 </em>
                                    (7)
                                     , 2231-2241. <a href="https://doi.org/10.1016/j.bmc.2011.02.033" title="DOI URL">https://doi.org/10.1016/j.bmc.2011.02.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2011.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2011.02.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DMolecular%252Bproperties%252Baffecting%252Bfast%252Bdissociation%252Bfrom%252Bthe%252BD2%252Breceptor%26aulast%3DTresadern%26aufirst%3DGary%26date%3D2011%26volume%3D19%26issue%3D7%26spage%3D2231%26epage%3D2241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ann M.  Mortimer</span>. </span><span class="cited-content_cbyCitation_article-title">The Magic Shotgun: Does It Fit the Clinician and Will It Point at Schizophrenia?. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2011,</strong>,, 23-49. <a href="https://doi.org/10.1007/978-94-007-0834-1_2" title="DOI URL">https://doi.org/10.1007/978-94-007-0834-1_2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-94-007-0834-1_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-94-007-0834-1_2%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BMagic%252BShotgun%25253A%252BDoes%252BIt%252BFit%252Bthe%252BClinician%252Band%252BWill%252BIt%252BPoint%252Bat%252BSchizophrenia%25253F%26aulast%3DMortimer%26aufirst%3DAnn%2BM.%26date%3D2011%26date%3D2011%26spage%3D23%26epage%3D49%26pub%3DSpringer%2520Netherlands%26atitle%3DHandbook%252Bof%252BSchizophrenia%252BSpectrum%252BDisorders%25252C%252BVolume%252BIII%26aulast%3DRitsner%26aufirst%3DMichael%2BS.%26date%3D2011%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?: TABLE 1. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2011,</strong> <em>336 </em>
                                    (1)
                                     , 3-8. <a href="https://doi.org/10.1124/jpet.110.171751" title="DOI URL">https://doi.org/10.1124/jpet.110.171751</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.110.171751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.110.171751%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DProductivity%252BShortfalls%252Bin%252BDrug%252BDiscovery%25253A%252BContributions%252Bfrom%252Bthe%252BPreclinical%252BSciences%25253F%25253A%252BTABLE%252B1%26aulast%3DWilliams%26aufirst%3DMichael%26date%3D2011%26date%3D2010%26volume%3D336%26issue%3D1%26spage%3D3%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emir  Duzic</span>, <span class="hlFld-ContribAuthor ">Michael J.  Marino</span>, <span class="hlFld-ContribAuthor ">Michael  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Receptor Targets in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2010,</strong>,<a href="https://doi.org/10.1002/0471266949.bmc029.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc029.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc029.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc029.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DReceptor%252BTargets%252Bin%252BDrug%252BDiscovery%26aulast%3DDuzic%26aufirst%3DEmir%26date%3D2010%26date%3D2010%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mélissa  Résimont</span>, <span class="hlFld-ContribAuthor ">Jean-François  Liégeois</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and in vitro binding studies of piperazine-alkyl-naphthamides: Impact of homology and sulphonamide/carboxamide bioisosteric replacement on the affinity for 5-HT1A, α2A, D4.2, D3 and D2L receptors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (17)
                                     , 5199-5202. <a href="https://doi.org/10.1016/j.bmcl.2010.07.002" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.07.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.07.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bin%252Bvitro%252Bbinding%252Bstudies%252Bof%252Bpiperazine-alkyl-naphthamides%25253A%252BImpact%252Bof%252Bhomology%252Band%252Bsulphonamide%25252Fcarboxamide%252Bbioisosteric%252Breplacement%252Bon%252Bthe%252Baffinity%252Bfor%252B5-HT1A%25252C%252B%2525CE%2525B12A%25252C%252BD4.2%25252C%252BD3%252Band%252BD2L%252Breceptors%26aulast%3DR%25C3%25A9simont%26aufirst%3DM%25C3%25A9lissa%26date%3D2010%26volume%3D20%26issue%3D17%26spage%3D5199%26epage%3D5202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajiv  Tandon</span>, <span class="hlFld-ContribAuthor ">Henry A.  Nasrallah</span>, <span class="hlFld-ContribAuthor ">Matcheri S.  Keshavan</span>. </span><span class="cited-content_cbyCitation_article-title">Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. </span><span class="cited-content_cbyCitation_journal-name">Schizophrenia Research</span><span> <strong>2010,</strong> <em>122 </em>
                                    (1-3)
                                     , 1-23. <a href="https://doi.org/10.1016/j.schres.2010.05.025" title="DOI URL">https://doi.org/10.1016/j.schres.2010.05.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.schres.2010.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.schres.2010.05.025%26sid%3Dliteratum%253Aachs%26jtitle%3DSchizophrenia%2520Research%26atitle%3DSchizophrenia%25252C%252B%2525E2%252580%25259CJust%252Bthe%252BFacts%2525E2%252580%25259D%252B5.%252BTreatment%252Band%252Bprevention%252BPast%25252C%252Bpresent%25252C%252Band%252Bfuture%26aulast%3DTandon%26aufirst%3DRajiv%26date%3D2010%26volume%3D122%26issue%3D1-3%26spage%3D1%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert L.  Hudkins</span>, <span class="hlFld-ContribAuthor ">Michael J.  Marino</span>, <span class="hlFld-ContribAuthor ">Michael  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Cognition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2010,</strong>,, 15-60. <a href="https://doi.org/10.1002/0471266949.bmc242" title="DOI URL">https://doi.org/10.1002/0471266949.bmc242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc242%26sid%3Dliteratum%253Aachs%26atitle%3DCognition%26aulast%3DHudkins%26aufirst%3DRobert%2BL.%26date%3D2010%26date%3D2010%26spage%3D15%26epage%3D60%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeffrey M.  Brown</span>, <span class="hlFld-ContribAuthor ">Jie Jack  Li</span>, <span class="hlFld-ContribAuthor ">Michael W.  Sinz</span>. </span><span class="cited-content_cbyCitation_article-title">Antipsychotic Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2010,</strong>,, 161-218. <a href="https://doi.org/10.1002/0471266949.bmc103.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc103.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc103.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc103.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DAntipsychotic%252BAgents%26aulast%3DBrown%26aufirst%3DJeffrey%2BM.%26date%3D2010%26date%3D2010%26spage%3D161%26epage%3D218%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher L.  Cioffi</span>, <span class="hlFld-ContribAuthor ">Shuang  Liu</span>, <span class="hlFld-ContribAuthor ">Mark A.  Wolf</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Developments in Glycine Transporter-1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2010,</strong>,, 19-35. <a href="https://doi.org/10.1016/S0065-7743(10)45002-2" title="DOI URL">https://doi.org/10.1016/S0065-7743(10)45002-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S0065-7743(10)45002-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS0065-7743%2810%2945002-2%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252BDevelopments%252Bin%252BGlycine%252BTransporter-1%252BInhibitors%26aulast%3DCioffi%26aufirst%3DChristopher%2BL.%26date%3D2010%26spage%3D19%26epage%3D35%26pub%3DElsevier%26date%3D2010%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amaury  Graulich</span>, <span class="hlFld-ContribAuthor ">Marc  Léonard</span>, <span class="hlFld-ContribAuthor ">Mélissa  Résimont</span>, <span class="hlFld-ContribAuthor ">Xi-Ping  Huang</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>, <span class="hlFld-ContribAuthor ">Jean-François  Liégeois</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical Modifications on 4-Arylpiperazine-Ethyl Carboxamide Derivatives Differentially Modulate Affinity for 5-HT1A, D4.2, and α2A Receptors: Synthesis and In Vitro Radioligand Binding Studies. </span><span class="cited-content_cbyCitation_journal-name">Australian Journal of Chemistry</span><span> <strong>2010,</strong> <em>63 </em>
                                    (1)
                                     , 56. <a href="https://doi.org/10.1071/CH09353" title="DOI URL">https://doi.org/10.1071/CH09353</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1071/CH09353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1071%2FCH09353%26sid%3Dliteratum%253Aachs%26jtitle%3DAustralian%2520Journal%2520of%2520Chemistry%26atitle%3DChemical%252BModifications%252Bon%252B4-Arylpiperazine-Ethyl%252BCarboxamide%252BDerivatives%252BDifferentially%252BModulate%252BAffinity%252Bfor%252B5-HT1A%25252C%252BD4.2%25252C%252Band%252B%2525CE%2525B12A%252BReceptors%25253A%252BSynthesis%252Band%252BIn%252BVitro%252BRadioligand%252BBinding%252BStudies%26aulast%3DGraulich%26aufirst%3DAmaury%26date%3D2010%26volume%3D63%26issue%3D1%26spage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Commentary: Genome-based CNS drug discovery: d-Amino acid oxidase (DAAO) as a novel target for antipsychotic medications: Progress and challenges. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2009,</strong> <em>78 </em>
                                    (11)
                                     , 1360-1365. <a href="https://doi.org/10.1016/j.bcp.2009.06.108" title="DOI URL">https://doi.org/10.1016/j.bcp.2009.06.108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2009.06.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2009.06.108%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DCommentary%25253A%252BGenome-based%252BCNS%252Bdrug%252Bdiscovery%25253A%252Bd-Amino%252Bacid%252Boxidase%252B%252528DAAO%252529%252Bas%252Ba%252Bnovel%252Btarget%252Bfor%252Bantipsychotic%252Bmedications%25253A%252BProgress%252Band%252Bchallenges%26aulast%3DWilliams%26aufirst%3DMichael%26date%3D2009%26volume%3D78%26issue%3D11%26spage%3D1360%26epage%3D1365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T.A.  Hauser</span>, <span class="hlFld-ContribAuthor ">A.  Kucinski</span>, <span class="hlFld-ContribAuthor ">K.G.  Jordan</span>, <span class="hlFld-ContribAuthor ">G.J.  Gatto</span>, <span class="hlFld-ContribAuthor ">S.R.  Wersinger</span>, <span class="hlFld-ContribAuthor ">R.A.  Hesse</span>, <span class="hlFld-ContribAuthor ">E.K.  Stachowiak</span>, <span class="hlFld-ContribAuthor ">M.K.  Stachowiak</span>, <span class="hlFld-ContribAuthor ">R.L.  Papke</span>, <span class="hlFld-ContribAuthor ">P.M.  Lippiello</span>, <span class="hlFld-ContribAuthor ">M.  Bencherif</span>. </span><span class="cited-content_cbyCitation_article-title">TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2009,</strong> <em>78 </em>
                                    (7)
                                     , 803-812. <a href="https://doi.org/10.1016/j.bcp.2009.05.030" title="DOI URL">https://doi.org/10.1016/j.bcp.2009.05.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2009.05.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2009.05.030%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DTC-5619%25253A%252BAn%252Balpha7%252Bneuronal%252Bnicotinic%252Breceptor-selective%252Bagonist%252Bthat%252Bdemonstrates%252Befficacy%252Bin%252Banimal%252Bmodels%252Bof%252Bthe%252Bpositive%252Band%252Bnegative%252Bsymptoms%252Band%252Bcognitive%252Bdysfunction%252Bof%252Bschizophrenia%26aulast%3DHauser%26aufirst%3DT.A.%26date%3D2009%26volume%3D78%26issue%3D7%26spage%3D803%26epage%3D812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. J.  Enna</span>, <span class="hlFld-ContribAuthor ">M.  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges in the Search for Drugs to Treat Central Nervous System Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2009,</strong> <em>329 </em>
                                    (2)
                                     , 404-411. <a href="https://doi.org/10.1124/jpet.108.143420" title="DOI URL">https://doi.org/10.1124/jpet.108.143420</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.108.143420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.108.143420%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DChallenges%252Bin%252Bthe%252BSearch%252Bfor%252BDrugs%252Bto%252BTreat%252BCentral%252BNervous%252BSystem%252BDisorders%26aulast%3DEnna%26aufirst%3DS.%2BJ.%26date%3D2009%26date%3D2009%26volume%3D329%26issue%3D2%26spage%3D404%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.J.  Enna</span>, <span class="hlFld-ContribAuthor ">M.  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Defining the Role of Pharmacology in the Emerging World of Translational Research. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2009,</strong>,, 1-30. <a href="https://doi.org/10.1016/S1054-3589(08)57001-3" title="DOI URL">https://doi.org/10.1016/S1054-3589(08)57001-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S1054-3589(08)57001-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS1054-3589%2808%2957001-3%26sid%3Dliteratum%253Aachs%26atitle%3DDefining%252Bthe%252BRole%252Bof%252BPharmacology%252Bin%252Bthe%252BEmerging%252BWorld%252Bof%252BTranslational%252BResearch%26aulast%3DEnna%26aufirst%3DS.J.%26date%3D2009%26spage%3D1%26epage%3D30%26pub%3DElsevier%26atitle%3DContemporary%252BAspects%252Bof%252BBiomedical%252BResearch%252B-%252BDrug%252BDiscovery%26date%3D2009%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vincent  Castagné</span>, <span class="hlFld-ContribAuthor ">Paul C.  Moser</span>, <span class="hlFld-ContribAuthor ">Roger D.  Porsolt</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Behavioral Models for Predicting Antipsychotic Activity. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2009,</strong>,, 381-418. <a href="https://doi.org/10.1016/S1054-3589(08)57010-4" title="DOI URL">https://doi.org/10.1016/S1054-3589(08)57010-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S1054-3589(08)57010-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS1054-3589%2808%2957010-4%26sid%3Dliteratum%253Aachs%26atitle%3DPreclinical%252BBehavioral%252BModels%252Bfor%252BPredicting%252BAntipsychotic%252BActivity%26aulast%3DCastagn%25C3%25A9%26aufirst%3DVincent%26date%3D2009%26spage%3D381%26epage%3D418%26pub%3DElsevier%26atitle%3DContemporary%252BAspects%252Bof%252BBiomedical%252BResearch%252B-%252BDrug%252BDiscovery%26date%3D2009%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Y.  von Coburg</span>, <span class="hlFld-ContribAuthor ">T.  Kottke</span>, <span class="hlFld-ContribAuthor ">L.  Weizel</span>, <span class="hlFld-ContribAuthor ">X.  Ligneau</span>, <span class="hlFld-ContribAuthor ">H.  Stark</span>. </span><span class="cited-content_cbyCitation_article-title">Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2009,</strong> <em>19 </em>
                                    (2)
                                     , 538-542. <a href="https://doi.org/10.1016/j.bmcl.2008.09.012" title="DOI URL">https://doi.org/10.1016/j.bmcl.2008.09.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2008.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2008.09.012%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPotential%252Butility%252Bof%252Bhistamine%252BH3%252Breceptor%252Bantagonist%252Bpharmacophore%252Bin%252Bantipsychotics%26aulast%3Dvon%2BCoburg%26aufirst%3DY.%26date%3D2009%26volume%3D19%26issue%3D2%26spage%3D538%26epage%3D542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.J.  Enna</span>, <span class="hlFld-ContribAuthor ">G.Z.  Feuerstein</span>, <span class="hlFld-ContribAuthor ">J.  Piette</span>, <span class="hlFld-ContribAuthor ">M.  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Fifty years of Biochemical Pharmacology: The discipline and the journal. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2008,</strong> <em>76 </em>
                                    (1)
                                     , 1-10. <a href="https://doi.org/10.1016/j.bcp.2008.03.024" title="DOI URL">https://doi.org/10.1016/j.bcp.2008.03.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2008.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2008.03.024%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DFifty%252Byears%252Bof%252BBiochemical%252BPharmacology%25253A%252BThe%252Bdiscipline%252Band%252Bthe%252Bjournal%26aulast%3DEnna%26aufirst%3DS.J.%26date%3D2008%26volume%3D76%26issue%3D1%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael J.  Marino</span>, <span class="hlFld-ContribAuthor ">Lars J. S.  Knutsen</span>, <span class="hlFld-ContribAuthor ">Michael  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">ChemInform Abstract: Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era. </span><span class="cited-content_cbyCitation_journal-name">ChemInform</span><span> <strong>2008,</strong> <em>39 </em>
                                    (24)
                                     <a href="https://doi.org/10.1002/chin.200824249" title="DOI URL">https://doi.org/10.1002/chin.200824249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chin.200824249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchin.200824249%26sid%3Dliteratum%253Aachs%26jtitle%3DChemInform%26atitle%3DChemInform%252BAbstract%25253A%252BEmerging%252BOpportunities%252Bfor%252BAntipsychotic%252BDrug%252BDiscovery%252Bin%252Bthe%252BPostgenomic%252BEra%26aulast%3DMarino%26aufirst%3DMichael%2BJ.%26date%3D2008%26volume%3D39%26issue%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark J.  Millan</span>, <span class="hlFld-ContribAuthor ">Mauricette  Brocco</span>. </span><span class="cited-content_cbyCitation_article-title">Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138. </span><span class="cited-content_cbyCitation_journal-name">Therapies</span><span> <strong>2008,</strong> <em>63 </em>
                                    (3)
                                     , 187-229. <a href="https://doi.org/10.2515/therapie:2008041" title="DOI URL">https://doi.org/10.2515/therapie:2008041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2515/therapie:2008041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2515%2Ftherapie%3A2008041%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapies%26atitle%3DCognitive%252BImpairment%252Bin%252BSchizophrenia%25253A%252Ba%252BReview%252Bof%252BDevelopmental%252Band%252BGenetic%252BModels%25252C%252Band%252BPro-cognitive%252BProfile%252Bof%252Bthe%252BOptimised%252BD3%252B%25253E%252BD2%252BAntagonist%25252C%252BS33138%26aulast%3DMillan%26aufirst%3DMark%2BJ.%26date%3D2008%26volume%3D63%26issue%3D3%26spage%3D187%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="chart1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0002.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0003.jpeg" id="rightTab-_i23" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0004.jpeg" id="rightTab-_i37" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0005.jpeg" id="rightTab-_i40" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0006.jpeg" id="rightTab-_i45" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0007.jpeg" id="rightTab-_i46" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Chart 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0008.jpeg" id="rightTab-_i50" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0009.jpeg" id="rightTab-_i54" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Chart 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0010.jpeg" id="rightTab-_i59" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0011.jpeg" id="rightTab-_i60" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Chart 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0012.jpeg" id="rightTab-_i62" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="chart13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Chart 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/medium/jm-2007-01094q_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0013.jpeg" id="rightTab-_i64" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm701094q/production/images/large/jm-2007-01094q_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701094q&amp;id=chart13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 381 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Falkai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wobrock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenthoj, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattaz, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, H. J.</span><span> </span><span class="NLM_article-title">World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: acute treatment of schizophrenia</span> <span class="citation_source-journal">World J. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1080%2F15622970510030090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16173147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MrgtFaiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=132-191&author=P.+Falkaiauthor=T.+Wobrockauthor=J.+Liebermanauthor=B.+Glenthojauthor=W.+F.+Gattazauthor=H.+J.+Moller&title=World+Federation+of+Societies+of+Biological+Psychiatry+%28WFSBP%29+guidelines+for+biological+treatment+of+schizophrenia.+Part+1%3A+acute+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia</span></div><div class="casAuthors">Falkai Peter; Wobrock Thomas; Lieberman Jeffrey; Glenthoj Birte; Gattaz Wagner F; Moller Hans-Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">132-91</span>
        ISSN:<span class="NLM_cas:issn">1562-2975</span>.
    </div><div class="casAbstract">These guide lines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBO).  The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence.  These guidelines are intended for use by all physicians seeing and treating people with schizophrenia.  The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library.  The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D).  This first part of the guidelines covers disease definition, classification, epidemiology and course of schizophrenia, as well as the management of the acute phase treatment.  These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5l8JKjExhwW52AMpI4GK2fW6udTcc2eZjUEZsePgh4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrgtFaiuw%253D%253D&md5=d47b1cbd5e6979a085a179cf1e5e2bba</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1080%2F15622970510030090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15622970510030090%26sid%3Dliteratum%253Aachs%26aulast%3DFalkai%26aufirst%3DP.%26aulast%3DWobrock%26aufirst%3DT.%26aulast%3DLieberman%26aufirst%3DJ.%26aulast%3DGlenthoj%26aufirst%3DB.%26aulast%3DGattaz%26aufirst%3DW.%2BF.%26aulast%3DMoller%26aufirst%3DH.%2BJ.%26atitle%3DWorld%2520Federation%2520of%2520Societies%2520of%2520Biological%2520Psychiatry%2520%2528WFSBP%2529%2520guidelines%2520for%2520biological%2520treatment%2520of%2520schizophrenia.%2520Part%25201%253A%2520acute%2520treatment%2520of%2520schizophrenia%26jtitle%3DWorld%2520J.%2520Biol.%2520Psychiatry%26date%3D2005%26volume%3D6%26spage%3D132%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Saha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, J.</span><span> </span><span class="NLM_article-title">A systematic review of the prevalence of schizophrenia</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e141</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e141&author=S.+Sahaauthor=D.+Chantauthor=J.+Welhamauthor=J.+McGrath&title=A+systematic+review+of+the+prevalence+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DChant%26aufirst%3DD.%26aulast%3DWelham%26aufirst%3DJ.%26aulast%3DMcGrath%26aufirst%3DJ.%26atitle%3DA%2520systematic%2520review%2520of%2520the%2520prevalence%2520of%2520schizophrenia%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Carpenter, W. T.,  Jr.; Conley, R. R.; Buchanan, R. W.</span><span> </span><span class="NLM_article-title">Schizophrenia</span>. In  <span class="citation_source-book">Pharmacological Management of Neurological and Psychiatric Disorders</span>; <span class="NLM_contrib-group">Enna, S. J.; Coyle, J. T.</span>, Eds.; <span class="NLM_publisher-name">McGraw-Hill</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1998</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=27-51&author=W.+T.+Carpenter&author=R.+R.+Conley&author=R.+W.+Buchananauthor=S.+J.+Enna&author=J.+T.+Coyle&title=Pharmacological+Management+of+Neurological+and+Psychiatric+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DW.%2BT.%26atitle%3DSchizophrenia%26btitle%3DPharmacological%2520Management%2520of%2520Neurological%2520and%2520Psychiatric%2520Disorders%26aulast%3DEnna%26aufirst%3DS.%2BJ.%26pub%3DMcGraw-Hill%26date%3D1998%26spage%3D27%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Auquier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouillon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lader, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, C.</span><span> </span><span class="NLM_article-title">Mortality in schizophrenia</span> <span class="citation_source-journal">Pharmacoepidemiol. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2Fpds.1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17058327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28npvVCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=873-879&author=P.+Auquierauthor=C.+Lanconauthor=F.+Rouillonauthor=M.+Laderauthor=C.+Holmes&title=Mortality+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mortality in schizophrenia</span></div><div class="casAuthors">Auquier Pascal; Lancon Christophe; Rouillon Frederic; Lader Malcolm; Holmes Catriona</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and drug safety</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">873-9</span>
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    </div><div class="casAbstract">PURPOSE:  The purpose of this article is to describe the current status of knowledge on excess mortality in schizophrenia and its causative factors, and to expand upon previous work evaluating approaches that may reduce mortality rates.  METHODS:  Literature available since 1995 was identified in a computerized search of the bibliographical databases Medline and Embase, using the topics 'mortality' and 'schizophrenia', and in a cross-reference search for articles that were particularly relevant.  RESULTS:  Schizophrenia is associated with mortality rates that are two to three times higher than those expected or observed in the general population.  This excess of mortality is accounted for by a combination of an increased risk of suicide, in particular in young male patients soon after diagnosis, and more importantly, a higher number of natural deaths.  In order to diminish the level of suicide among people with schizophrenia, the majority of research has focused on the identification of risk factors that predispose patients to attempt or commit suicide, while unhealthy styles, polypharmacy and inadequate healthcare have been shown to contribute to the high natural mortality.  The link between the use of antipychotics and mortality has not been yet clarified.  CONCLUSION:  Dramatically increased mortality of schizophrenia patients is well established.  It is time to move beyond this topic, and work towards interventions that aim at reducing the mortality risk in such patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRikot9EnR3I7YtC3U5jeOifW6udTcc2eaEeDA59zXcirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28npvVCgtg%253D%253D&md5=0cba5ddf026bd80e8468247f6dcb7e42</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fpds.1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1325%26sid%3Dliteratum%253Aachs%26aulast%3DAuquier%26aufirst%3DP.%26aulast%3DLancon%26aufirst%3DC.%26aulast%3DRouillon%26aufirst%3DF.%26aulast%3DLader%26aufirst%3DM.%26aulast%3DHolmes%26aufirst%3DC.%26atitle%3DMortality%2520in%2520schizophrenia%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2006%26volume%3D15%26spage%3D873%26epage%3D879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Crow, T. J.</span><span> </span><span class="NLM_article-title">Molecular pathology of schizophrenia: more than one disease process</span> <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1136%2Fbmj.280.6207.66" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=6101544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL3cXhs1Wmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=1980&pages=66-68&author=T.+J.+Crow&title=Molecular+pathology+of+schizophrenia%3A+more+than+one+disease+process"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pathology of schizophrenia: more than one disease process?</span></div><div class="casAuthors">Crow, T. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Medical Journal</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">6207</span>),
    <span class="NLM_cas:pages">66-8</span>CODEN:
                <span class="NLM_cas:coden">BMJOAE</span>;
        ISSN:<span class="NLM_cas:issn">0007-1447</span>.
    </div><div class="casAbstract">A review with 40 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXd8uOWmWptrVg90H21EOLACvtfcHk0lgWBQLC7eK1aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhs1Wmu7g%253D&md5=2afcd7dff055669622339a82f49e56da</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1136%2Fbmj.280.6207.66&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.280.6207.66%26sid%3Dliteratum%253Aachs%26aulast%3DCrow%26aufirst%3DT.%2BJ.%26atitle%3DMolecular%2520pathology%2520of%2520schizophrenia%253A%2520more%2520than%2520one%2520disease%2520process%26jtitle%3DBr.%2520Med.%2520J.%26date%3D1980%26volume%3D280%26spage%3D66%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Sawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Schizophrenia: diverse approaches to a complex disease</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">692</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1126%2Fscience.1070532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11976442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtlOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=692-695&author=A.+Sawaauthor=S.+H.+Snyder&title=Schizophrenia%3A+diverse+approaches+to+a+complex+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Review: Schizophrenia: diverse approaches to a complex disease</span></div><div class="casAuthors">Sawa, Akira; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5568</span>),
    <span class="NLM_cas:pages">692-695</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is a debilitating mental illness that affects 1% of the. population.  Despite intensive study, its mol. etiol. remains enigmatic.  Like many common diseases, schizophrenia is multifactorial in origin, with both genetic and environmental contributions likely playing an important role in the manifestation of symptoms.  Recent advances based on pharmacol. studies, brain imaging analyses, and genetic research are now converging on tantalizing leads that point to a central role for several neurotransmitters, including dopamine, glutamate, and serotonin, that may interface with neurodevelopmental defects reflecting disease-related genetic aberrations.  Here, we provide a brief overview of the parallel approaches being used to identify the mol. causes of schizophrenia and discuss possible directions for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHr6I_om8RjLVg90H21EOLACvtfcHk0lgWBQLC7eK1aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtlOhtbs%253D&md5=49ca9e400ba12ac906f7284ae72d9e9f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070532%26sid%3Dliteratum%253Aachs%26aulast%3DSawa%26aufirst%3DA.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DSchizophrenia%253A%2520diverse%2520approaches%2520to%2520a%2520complex%2520disease%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D692%26epage%3D695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Tamminga, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span> </span><span class="NLM_article-title">The neuropharmacology of psychosis</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbm063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17562697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2szoslylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=937-946&author=C.+A.+Tammingaauthor=J.+M.+Davis&title=The+neuropharmacology+of+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The neuropharmacology of psychosis</span></div><div class="casAuthors">Tamminga Carol A; Davis John M</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">937-46</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">Antipsychotic drugs (APDs) are therapeutic in psychotic disorders.  They are not specific treatments for schizophrenia (SZ) but useful in bipolar disorder (BD), psychotic depression, Alzheimers disease, and other psychotic diagnoses.  In this perspective, we discuss the actions of APDs for the treatment of both SZ and bipolar-1 disorder (BD-1) with a specific focus on the implications of these data for the whole group of psychotic diagnoses.  Both schizophrenic and BD-1 are characterized by several symptom dimensions, some overlapping and some distinctive.  We discuss a dimensional approach to the diagnosis of BD and SZ and suggest that psychosis is an important dimension of each.  In order to define the dimension of psychosis more carefully would require additional research to fill in the gaps in our knowledge.  We propose that psychosis is a dimension that cuts through many psychiatric disorders, and the use of this dimension may be useful for clinical and research progress.  We discuss the kinds of data necessary to further support the dimensional aspects of psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHzG4u3UWGajAyhZbj3lKdfW6udTcc2eaEeDA59zXcirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szoslylsg%253D%253D&md5=da092e5611c6067de61b8777b41ee19e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbm063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbm063%26sid%3Dliteratum%253Aachs%26aulast%3DTamminga%26aufirst%3DC.%2BA.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520neuropharmacology%2520of%2520psychosis%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D937%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Walker, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kestler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochman, K. M.</span><span> </span><span class="NLM_article-title">Schizophrenia: etiology and course</span> <span class="citation_source-journal">Annu. Rev. Psychol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1146%2Fannurev.psych.55.090902.141950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14744221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FktlOmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=401-430&author=E.+Walkerauthor=L.+Kestlerauthor=A.+Bolliniauthor=K.+M.+Hochman&title=Schizophrenia%3A+etiology+and+course"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia: etiology and course</span></div><div class="casAuthors">Walker Elaine; Kestler Lisa; Bollini Annie; Hochman Karen M</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of psychology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">401-30</span>
        ISSN:<span class="NLM_cas:issn">0066-4308</span>.
    </div><div class="casAbstract">Decades of research on schizophrenia have not produced major breakthroughs, but gradual progress has been made in identifying risk factors and clarifying the nature of the etiologic process.  This article provides an overview of trends in research findings as well as current assumptions about the interplay between environmental and genetic factors in the etiology of schizophrenia.  Based on the cumulative findings, it appears that both genetic and prenatal factors can give rise to constitutional vulnerability.  Subsequent neuromaturational processes, especially those that occur during adolescence, and exposure to stressful events can trigger the behavioral expression of this vulnerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-6gep1jH3Hxgd2Wuil24tfW6udTcc2eaLzju8cYSAIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FktlOmsQ%253D%253D&md5=02d0f2cbb26628636dd659d1a74c93ac</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.psych.55.090902.141950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.psych.55.090902.141950%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%26aulast%3DKestler%26aufirst%3DL.%26aulast%3DBollini%26aufirst%3DA.%26aulast%3DHochman%26aufirst%3DK.%2BM.%26atitle%3DSchizophrenia%253A%2520etiology%2520and%2520course%26jtitle%3DAnnu.%2520Rev.%2520Psychol.%26date%3D2004%26volume%3D55%26spage%3D401%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">First, M. B.; Tasman, A. Ct.</span> In  <span class="citation_source-book">DSM-IV-TR Mental Disorders: Diagnosis, Etiology and Treatment</span>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Chichester, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=639-701&author=M.+B.+First&author=A.+Ct.+Tasman&title=DSM-IV-TR+Mental+Disorders%3A+Diagnosis%2C+Etiology+and+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFirst%26aufirst%3DM.%2BB.%26btitle%3DDSM-IV-TR%2520Mental%2520Disorders%253A%2520Diagnosis%252C%2520Etiology%2520and%2520Treatment%26pub%3DWiley%26date%3D2004%26spage%3D639%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Dickerson, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehman, A. F.</span><span> </span><span class="NLM_article-title">Evidence-based psychotherapy for schizophrenia</span> <span class="citation_source-journal">J. Nerv. Ment. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F01.nmd.0000195316.86036.8a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16462548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28%252Fns1arsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2006&pages=3-9&author=F.+B.+Dickersonauthor=A.+F.+Lehman&title=Evidence-based+psychotherapy+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence-based psychotherapy for schizophrenia</span></div><div class="casAuthors">Dickerson Faith B; Lehman Anthony F</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of nervous and mental disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-9</span>
        ISSN:<span class="NLM_cas:issn">0022-3018</span>.
    </div><div class="casAbstract">Many patients with schizophrenia have psychological distress and receive some form of psychotherapy.  Several different psychotherapeutic approaches for schizophrenia have been developed and studied.  Of these approaches, cognitive behavior therapy has the strongest evidence base and has shown benefit for symptom reduction in outpatients with residual symptoms.  In addition to cognitive behavior therapy, other approaches include compliance therapy, personal therapy, acceptance and commitment therapy, and supportive therapy.  Although usually studied as distinct approaches, the therapies overlap with each other in their therapeutic elements.  As psychotherapy for schizophrenia further evolves, it will likely be informed by other psychosocial interventions used with this clinical population.  In particular, techniques of remediating cognitive deficits, teaching behavioral skills, and educating about schizophrenia may be incorporated with psychotherapy.  Future research may also consider three different goals of psychotherapy with this population: to provide emotional support, to enhance skills for functional recovery, and to alter the underlying illness process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbzkHLtnHpO0cLvDNbOD4DfW6udTcc2eaLzju8cYSAIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252Fns1arsg%253D%253D&md5=3b2fd0fde526cd65466b037ebb07a263</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1097%2F01.nmd.0000195316.86036.8a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.nmd.0000195316.86036.8a%26sid%3Dliteratum%253Aachs%26aulast%3DDickerson%26aufirst%3DF.%2BB.%26aulast%3DLehman%26aufirst%3DA.%2BF.%26atitle%3DEvidence-based%2520psychotherapy%2520for%2520schizophrenia%26jtitle%3DJ.%2520Nerv.%2520Ment.%2520Dis.%26date%3D2006%26volume%3D194%26spage%3D3%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span> </span><span class="NLM_article-title">Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15289815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=79-104&author=S.+Miyamotoauthor=G.+E.+Duncanauthor=C.+E.+Marxauthor=J.+A.+Lieberman&title=Treatments+for+schizophrenia%3A+a+critical+review+of+pharmacology+and+mechanisms+of+action+of+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs</span></div><div class="casAuthors">Miyamoto, S.; Duncan, G. E.; Marx, C. E.; Lieberman, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-104</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development.  Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems.  Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia.  However, the pharmacol. properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life.  Moreover, the efficacy of antipsychotic drugs is limited prompting the clin. use of adjunctive pharmacy to augment the effects of treatment.  In addn., the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiol. hypotheses.  This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5K7PMOCd2ubVg90H21EOLACvtfcHk0ljSckT8ePAdbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3M&md5=f81c985a28797f02b7a1213c604433e4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001556%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DDuncan%26aufirst%3DG.%2BE.%26aulast%3DMarx%26aufirst%3DC.%2BE.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DTreatments%2520for%2520schizophrenia%253A%2520a%2520critical%2520review%2520of%2520pharmacology%2520and%2520mechanisms%2520of%2520action%2520of%2520antipsychotic%2520drugs%26jtitle%3DMol.%2520Psychiatry%26date%3D2005%26volume%3D10%26spage%3D79%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Klosterkotter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmeyer, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze-Lutter, F.</span><span> </span><span class="NLM_article-title">Diagnosing schizophrenia in the initial prodromal phase</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.58.2.158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11177117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3M7kvFGntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2001&pages=158-164&author=J.+Klosterkotterauthor=M.+Hellmichauthor=E.+M.+Steinmeyerauthor=F.+Schultze-Lutter&title=Diagnosing+schizophrenia+in+the+initial+prodromal+phase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing schizophrenia in the initial prodromal phase</span></div><div class="casAuthors">Klosterkotter J; Hellmich M; Steinmeyer E M; Schultze-Lutter F</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-64</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">BACKGROUND:  In schizophrenia research, early detection in the initial prodrome before first psychotic episodes is a major topic.  Therefore, the prognostic accuracy of initial prodromal symptoms was examined prospectively.  METHODS:  The study sample was composed of patients referred to outpatient departments of German psychiatric university departments, because of diagnostic problems, between 1987 and 1991.  They were examined with the Bonn Scale for the Assessment of Basic Symptoms and the Ninth Version of the Present State Examination to detect an incipient schizophrenic disorder.  Of 385 patients showing no schizophrenia-characteristic symptoms, between 1995 and 1998, 110 with and 50 without initial prodromal symptoms were followed up and reexamined with the same instruments for a transition to schizophrenia.  RESULTS:  During a mean follow-up period of 9.6 years, 79 (49.4%) of the 160 patients had transited to schizophrenia.  The absence of prodromal symptoms excluded a subsequent schizophrenia with a probability of 96% (sensitivity: 0.98; false-negative predictions: 1.3%), whereas their presence predicted schizophrenia with a probability of 70% (specificity: 0.59; false-positive predictions: 20%).  Certain disturbances, such as thought interference, disturbances of receptive language, or visual distortions, predicted schizophrenia, even with a probability up to 91% (specificity: 0.85-0.91; false-positive predictions: 1.9%-7.5%).  CONCLUSIONS:  The Bonn Scale for the Assessment of Basic Symptoms operationalization of prodromal symptoms performed well in the early detection of schizophrenia.  It therefore might be useful for the prediction of the disorder, especially if it is further refined to select those items with particularly high prognostic accuracy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVN8ekeLthwsK3uFsUIZtkfW6udTcc2ea8QeYgw65hILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7kvFGntQ%253D%253D&md5=1c3953ebd1eabbadb51c75e2067b29ae</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.58.2.158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.58.2.158%26sid%3Dliteratum%253Aachs%26aulast%3DKlosterkotter%26aufirst%3DJ.%26aulast%3DHellmich%26aufirst%3DM.%26aulast%3DSteinmeyer%26aufirst%3DE.%2BM.%26aulast%3DSchultze-Lutter%26aufirst%3DF.%26atitle%3DDiagnosing%2520schizophrenia%2520in%2520the%2520initial%2520prodromal%2520phase%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2001%26volume%3D58%26spage%3D158%26epage%3D164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Schmidt, C.</span><span> </span><span class="NLM_article-title">Psychiatric research. Putting the brakes on psychosis</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">976</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=976-977&author=C.+Schmidt&title=Psychiatric+research.+Putting+the+brakes+on+psychosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%26atitle%3DPsychiatric%2520research.%2520Putting%2520the%2520brakes%2520on%2520psychosis%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D976%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Cancro, R.</span><span> </span><span class="NLM_article-title">Schizophrenia</span>. In  <span class="citation_source-book">Treatments of Psychiatric Disorders: A Task Force Report of the American Psychiatric Association</span>; <span class="NLM_publisher-name">American Psychiatric Association</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">1989</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1485</span><span class="NLM_x">–</span> <span class="NLM_lpage">1606</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&pages=1485-1606&author=R.+Cancro&title=Treatments+of+Psychiatric+Disorders%3A+A+Task+Force+Report+of+the+American+Psychiatric+Association"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCancro%26aufirst%3DR.%26atitle%3DSchizophrenia%26btitle%3DTreatments%2520of%2520Psychiatric%2520Disorders%253A%2520A%2520Task%2520Force%2520Report%2520of%2520the%2520American%2520Psychiatric%2520Association%26pub%3DAmerican%2520Psychiatric%2520Association%26date%3D1989%26spage%3D1485%26epage%3D1606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, P. H.</span><span> </span><span class="NLM_article-title">Current and novel approaches to the drug treatment of schizophrenia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0002432" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=477-501&author=M.+Rowleyauthor=L.+J.+Bristowauthor=P.+H.+Hutson&title=Current+and+novel+approaches+to+the+drug+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Current and novel approaches to the drug treatment of schizophrenia</span></div><div class="casAuthors">Rowley, Michael; Bristow, Linda J.; Hutson, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 283 refs. on neurochem. hypotheses of schizophrenia, animal models developed for novel antipsychotic detection, and novel approaches to the drug treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh5OOZYcroI7Vg90H21EOLACvtfcHk0liWNKmnn6IQEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFKiug%253D%253D&md5=b30ff1715d5499955938fdbf236291f9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm0002432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0002432%26sid%3Dliteratum%253Aachs%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DHutson%26aufirst%3DP.%2BH.%26atitle%3DCurrent%2520and%2520novel%2520approaches%2520to%2520the%2520drug%2520treatment%2520of%2520schizophrenia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D477%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Harrison, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15263907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=40-68&author=P.+J.+Harrisonauthor=D.+R.+Weinberger&title=Schizophrenia+genes%2C+gene+expression%2C+and+neuropathology%3A+on+the+matter+of+their+convergence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence</span></div><div class="casAuthors">Harrison, P. J.; Weinberger, D. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-68</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This review critically summarizes the neuropathol. and genetics of schizophrenia, the relationship between them, and speculates on their functional convergence.  The morphol. correlates of schizophrenia are subtle, and range from a slight redn. in brain size to localized alterations in the morphol. and mol. compn. of specific neuronal, synaptic, and glial populations in the hippocampus, dorsolateral prefrontal cortex, and dorsal thalamus.  These findings have fostered the view of schizophrenia as a disorder of connectivity and of the synapse.  Although attractive, such concepts are vague, and differentiating primary events from epiphenomena has been difficult.  A way forward is provided by the recent identification of several putative susceptibility genes (including neuregulin, dysbindin, COMT, DISC1, RGS4, GRM3, and G72).  We discuss the evidence for these and other genes, along with what is known of their expression profiles and biol. roles in brain and how these may be altered in schizophrenia.  The evidence for several of the genes is now strong.  However, for none, with the likely exception of COMT, has a causative allele or the mechanism by which it predisposes to schizophrenia been identified.  Nevertheless, we speculate that the genes may all converge functionally upon schizophrenia risk via an influence upon synaptic plasticity and the development and stabilization of cortical microcircuitry.  NMDA receptor-mediated glutamate transmission may be esp. implicated, though there are also direct and indirect links to dopamine and GABA signaling.  Hence, there is a correspondence between the putative roles of the genes at the mol. and synaptic levels and the existing understanding of the disorder at the neural systems level.  Characterization of a core mol. pathway and a genetic cytoarchitecture' would be a profound advance in understanding schizophrenia, and may have equally significant therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEeG0dw3pqdbVg90H21EOLACvtfcHk0liWNKmnn6IQEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3N&md5=6e69aab6f45644278ca29a89ea03724a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001558%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DP.%2BJ.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DSchizophrenia%2520genes%252C%2520gene%2520expression%252C%2520and%2520neuropathology%253A%2520on%2520the%2520matter%2520of%2520their%2520convergence%26jtitle%3DMol.%2520Psychiatry%26date%3D2005%26volume%3D10%26spage%3D40%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Petronis, A.</span><span> </span><span class="NLM_article-title">The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">965</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2004.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15121478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Gisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=965-970&author=A.+Petronis&title=The+origin+of+schizophrenia%3A+genetic+thesis%2C+epigenetic+antithesis%2C+and+resolving+synthesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis</span></div><div class="casAuthors">Petronis, Arturas</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">965-970</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Traditionally, it has been thought that schizophrenia results from the interaction of predisposing genes and hazardous environmental factors.  In this article, the paradigm of "genes plus environment" is challenged, and a new interpretation is presented, in which the emphasis on DNA sequence variation is shared with epigenetic misregulation as a crit. etiopathogenic factor.  Partial epigenetic stability (metastability) of gene regulation is consistent with various nonmendelian irregularities of schizophrenia, such as the presence of clin. indistinguishable sporadic and familial cases, discordance of monozygotic twins, coincidence of peaks of susceptibility with major endocrine rearrangements, and fluctuating course of disease severity, among others.  It is also suggested that stochastic epigenetic events might account for a substantial portion of phenotypic variance, which traditionally has been ascribed to environmental effects.  This theoretic essay is constructed according to the principle of Hegelian dialectic reasoning (thesis-antithesis-synthesis), which serves the goal of showing that the best outcome of mol. genetic studies in schizophrenia (and perhaps other complex diseases) can be expected when components that effect chromatin structure and gene regulation are taken into account and investigated comprehensively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGLbFTxl9rV7Vg90H21EOLACvtfcHk0liWNKmnn6IQEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Gisr0%253D&md5=6c85564a1a2cd5be8451412ae8aa7263</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2004.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2004.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DPetronis%26aufirst%3DA.%26atitle%3DThe%2520origin%2520of%2520schizophrenia%253A%2520genetic%2520thesis%252C%2520epigenetic%2520antithesis%252C%2520and%2520resolving%2520synthesis%26jtitle%3DBiol.%2520Psychiatry%26date%3D2004%26volume%3D55%26spage%3D965%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sullivan, P. F.</span><span> </span><span class="NLM_article-title">The genetics of schizophrenia</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=614-618&author=P.+F.+Sullivan&title=The+genetics+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DP.%2BF.%26atitle%3DThe%2520genetics%2520of%2520schizophrenia%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D614%26epage%3D618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=31-36&author=M.+Williams&title=Genome-based+drug+discovery%3A+prioritizing+disease-susceptibility%2Fdisease-associated+genes+as+novel+drug+targets+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DGenome-based%2520drug%2520discovery%253A%2520prioritizing%2520disease-susceptibility%252Fdisease-associated%2520genes%2520as%2520novel%2520drug%2520targets%2520for%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2003%26volume%3D4%26spage%3D31%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Coyle, J. T.</span><span> </span><span class="NLM_article-title">Glutamate and schizophrenia: beyond the dopamine hypothesis</span> <span class="citation_source-journal">Cell. Mol. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs10571-006-9062-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16773445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtleksb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=365-384&author=J.+T.+Coyle&title=Glutamate+and+schizophrenia%3A+beyond+the+dopamine+hypothesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis</span></div><div class="casAuthors">Coyle, Joseph T.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4-6</span>),
    <span class="NLM_cas:pages">365-384</span>CODEN:
                <span class="NLM_cas:coden">CMNEDI</span>;
        ISSN:<span class="NLM_cas:issn">0272-4340</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals.  2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the neg. symptoms, cognitive impairments and physiol. disturbances obsd. in schizophrenia.  3. Furthermore, a no. of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission.  4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown redn. in neg. symptoms, improvement in cognition and in some cases redn. in pos. symptoms in schizophrenic patients receiving concurrent antipsychotic medications.  5. Thus, hypofunction of the NMDA receptor, possibly on crit. GABAergic inter-neurons, may contribute to the pathophysiol. of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7x2DRLp7eO7Vg90H21EOLACvtfcHk0liWNKmnn6IQEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtleksb3O&md5=f8410001e05e630ff19333692790857e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs10571-006-9062-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10571-006-9062-8%26sid%3Dliteratum%253Aachs%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3DGlutamate%2520and%2520schizophrenia%253A%2520beyond%2520the%2520dopamine%2520hypothesis%26jtitle%3DCell.%2520Mol.%2520Neurobiol.%26date%3D2006%26volume%3D26%26spage%3D365%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Taylor, D. M.</span><span> </span><span class="NLM_article-title">Antipsychotics and QT prolongation</span> <span class="citation_source-journal">Acta Psychiatr. Scand.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1034%2Fj.1600-0447.2003.02078.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12534433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1Wrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2003&pages=85-95&author=D.+M.+Taylor&title=Antipsychotics+and+QT+prolongation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotics and QT prolongation</span></div><div class="casAuthors">Taylor, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Psychiatrica Scandinavica</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-95</span>CODEN:
                <span class="NLM_cas:coden">APYSA9</span>;
        ISSN:<span class="NLM_cas:issn">0001-690X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Munksgaard</span>)
        </div><div class="casAbstract">A review.  The aim of this study was to evaluate literature relating to cardiac QT prolongation and the use of antipsychotic drugs.  Literature searches of EMBASE, Medline, PsychLIT were performed in Dec. 2001 and ref. sections of retrieved papers scrutinized for further relevant reports.  The Cardiac QTc interval is difficult to measure precisely or accurately but appears to be a useful predictor of risk of dysrhythmia (specifically torsade de pointes) and sudden death.  It is less clear that drug-induced QTc prolongation gives rise to similar risks but data are emerging, linking antipsychotic use to increased cardiac mortality.  Many antipsychotics have been clearly assocd. with QTc prolongation.  Methodol. considerations arguably preclude assuming that any antipsychotic is free of the risk of QTc prolongation and dysrhythmia.  Available data do not allow assessment of relative or abs. risk of dysrhythmia or sudden death engendered by antipsychotics but caution is advised.  Risk of dysrhythmia can very probably be reduced by careful prescribing of antipsychotics in low doses in simple drug regimens which avoid metabolic interactions.  Electrocardiog. monitoring may also help to reduce risk but review by specialist cardiologist may be necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolhHdJSE2ivrVg90H21EOLACvtfcHk0ljwhn9ZhfeJMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1Wrt70%253D&md5=2cfd6ebd65ac7d059841c834fdfe4901</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-0447.2003.02078.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-0447.2003.02078.x%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DD.%2BM.%26atitle%3DAntipsychotics%2520and%2520QT%2520prolongation%26jtitle%3DActa%2520Psychiatr.%2520Scand.%26date%3D2003%26volume%3D107%26spage%3D85%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Casey, D. E.</span><span> </span><span class="NLM_article-title">Metabolic issues and cardiovascular disease in patients with psychiatric disorders</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">15S</span><span class="NLM_x">–</span> <span class="NLM_lpage">22S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=15S-22S&issue=Suppl.+2&author=D.+E.+Casey&title=Metabolic+issues+and+cardiovascular+disease+in+patients+with+psychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasey%26aufirst%3DD.%2BE.%26atitle%3DMetabolic%2520issues%2520and%2520cardiovascular%2520disease%2520in%2520patients%2520with%2520psychiatric%2520disorders%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2005%26volume%3D118%26issue%3DSuppl.%25202%26spage%3D15S%26epage%3D22S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Newcomer, J. W.</span><span> </span><span class="NLM_article-title">Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1-93&issue=Suppl.+1&author=J.+W.+Newcomer&title=Second-generation+%28atypical%29+antipsychotics+and+metabolic+effects%3A+a+comprehensive+literature+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewcomer%26aufirst%3DJ.%2BW.%26atitle%3DSecond-generation%2520%2528atypical%2529%2520antipsychotics%2520and%2520metabolic%2520effects%253A%2520a%2520comprehensive%2520literature%2520review%26jtitle%3DCNS%2520Drugs%26date%3D2005%26volume%3D19%26issue%3DSuppl.%25201%26spage%3D1%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Dettling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anghelescu, I. G.</span><span> </span><span class="NLM_article-title">Antipsychotic drugs and schizophrenia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">354</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1056%2FNEJMc052822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16421374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xls1Krtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=298-300&author=M.+Dettlingauthor=I.+G.+Anghelescu&title=Antipsychotic+drugs+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drugs and schizophrenia</span></div><div class="casAuthors">Dettling, Michael; Anghelescu, Ion-George</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">298</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW-YdH_-MBorVg90H21EOLACvtfcHk0ljwhn9ZhfeJMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xls1Krtg%253D%253D&md5=de51e94af1a375e2760ba734f4eadffe</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1056%2FNEJMc052822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc052822%26sid%3Dliteratum%253Aachs%26aulast%3DDettling%26aufirst%3DM.%26aulast%3DAnghelescu%26aufirst%3DI.%2BG.%26atitle%3DAntipsychotic%2520drugs%2520and%2520schizophrenia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D298%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Leucht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauml, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span> </span><span class="NLM_article-title">Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbl025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16905632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28jksVyqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=183-191&author=S.+Leuchtauthor=R.+R.+Engelauthor=J.+Baumlauthor=J.+M.+Davis&title=Is+the+superior+efficacy+of+new+generation+antipsychotics+an+artifact+of+LOCF%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</span></div><div class="casAuthors">Leucht Stefan; Engel Rolf R; Bauml Josef; Davis John M</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-91</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">It has been argued that the efficacy superiority found in meta-analyses for some of the atypical antipsychotics is an artifact of higher dropout rates due to side effects in the haloperidol group combined with last-observation-carried-forward (LOCF) analyses.  We therefore reanalyzed a number of pivotal studies comparing new generation antipsychotics (NGAs) and conventional antipsychotics (CAs).  A total of 5 studies (n = 1271) comparing amisulpride and 3 studies (n = 2454) comparing olanzapine with CAs were reanalyzed using original patient data.  We applied 4 different models: LOCF, completer analysis, LOCF but excluding dropouts due to adverse events, and LOCF but excluding all dropouts with the exception of dropouts related to efficacy.  Effect sizes expressed as standardized mean differences between NGAs and CAs based on the 4 different analysis models were compared.  The overall results were not different irrespective of the model used.  Single studies, however, showed higher effect sizes when LOCF instead of other models was used.  Overall, it does not seem that higher dropout rates due to side effects in the haloperidol groups together with LOCF analyses consistently biased the results in favor of amisulpride and olanzapine.  Because the results of the single studies, however, showed that this may occasionally be the case, future studies should look at the data from different angles applying sensitivity analyses, and they may use alternative statistics such as mixed models, which need to be developed further.  Ultimately, strategies to reduce dropout rates are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6rFzFzFcpL3T4ugvCDgnZfW6udTcc2eY2cWuX1QqxKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jksVyqtw%253D%253D&md5=9cfd2c40c460c429141467c419cee239</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbl025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbl025%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DR.%2BR.%26aulast%3DBauml%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DIs%2520the%2520superior%2520efficacy%2520of%2520new%2520generation%2520antipsychotics%2520an%2520artifact%2520of%2520LOCF%253F%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D183%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobo, W. V.</span><span> </span><span class="NLM_article-title">Interpreting the efficacy findings in the CATIE study: what clinicians should know</span> <span class="citation_source-journal">CNS Spectrums</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=14-24&author=H.+Y.+Meltzerauthor=W.+V.+Bobo&title=Interpreting+the+efficacy+findings+in+the+CATIE+study%3A+what+clinicians+should+know"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DBobo%26aufirst%3DW.%2BV.%26atitle%3DInterpreting%2520the%2520efficacy%2520findings%2520in%2520the%2520CATIE%2520study%253A%2520what%2520clinicians%2520should%2520know%26jtitle%3DCNS%2520Spectrums%26date%3D2006%26volume%3D11%26spage%3D14%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Jones, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayhurst, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markwick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, S. W.</span><span> </span><span class="NLM_article-title">Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.63.10.1079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17015810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKhtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=1079-1087&author=P.+B.+Jonesauthor=T.+R.+Barnesauthor=L.+Daviesauthor=G.+Dunnauthor=H.+Lloydauthor=K.+P.+Hayhurstauthor=R.+M.+Murrayauthor=A.+Markwickauthor=S.+W.+Lewis&title=Randomized+controlled+trial+of+the+effect+on+quality+of+life+of+second-+vs+first-generation+antipsychotic+drugs+in+schizophrenia%3A+Cost+Utility+of+the+Latest+Antipsychotic+Drugs+in+Schizophrenia+Study+%28CUtLASS+1%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)</span></div><div class="casAuthors">Jones, Peter B.; Barnes, Thomas R. E.; Davies, Linda; Dunn, Graham; Lloyd, Helen; Hayhurst, Karen P.; Murray, Robin M.; Markwick, Alison; Lewis, Shon W.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1079-1087</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Second-generation (atypical) antipsychotics (SGAs) are more expensive than first-generation (typical) antipsychotics (FGAs) but are perceived to be more effective, with fewer adverse effects, and preferable to patients.  Most evidence comes from short-term efficacy trials of symptoms.  Objective: To test the hypothesis that in people with schizophrenia requiring a change in treatment, SGAs other than clozapine are assocd. with improved quality of life across 1 yr compared with FGAs.  Design: A noncommercially funded, pragmatic, multisite, randomized controlled trial of antipsychotic drug classes, with blind assessments at 12, 26, and 56 wk using intention-to-treat anal.  Setting: Fourteen community psychiatric services in the English National Health Service.  Participants: Two hundred twenty-seven people aged 18 to 65 years with DSM-IV schizophrenia and related disorders assessed for medication review because of inadequate response or adverse effects.  Interventions: Randomized prescription of either FGAs or SGAs (other than clozapine), with the choice of individual drug made by the managing psychiatrist.  Main Outcome Measures: Quality of Life Scale scores, symptoms, adverse effects, participant satisfaction, and costs of care.  Results: The primary hypothesis of significant improvement in Quality of Life Scale scores during the year after commencement of SGAs vs FGAs was excluded.  Participants in the FGA arm showed a trend toward greater improvements in Quality of Life Scale and symptom scores.  Participants reported no clear preference for either drug group; costs were similar.  Conclusions: In people with schizophrenia whose medication is changed for clin. reasons, there is no disadvantage across 1 yr in terms of quality of life, symptoms, or assocd. costs of care in using FGAs rather than nonclozapine SGAs.  Neither inadequate power nor patterns of drug discontinuation accounted for the result.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnqG682dYJM7Vg90H21EOLACvtfcHk0liuAqA5PP6Q_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKhtrzP&md5=b5027b469da573212342107d56543b1e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.63.10.1079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.63.10.1079%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BB.%26aulast%3DBarnes%26aufirst%3DT.%2BR.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DDunn%26aufirst%3DG.%26aulast%3DLloyd%26aufirst%3DH.%26aulast%3DHayhurst%26aufirst%3DK.%2BP.%26aulast%3DMurray%26aufirst%3DR.%2BM.%26aulast%3DMarkwick%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DS.%2BW.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520the%2520effect%2520on%2520quality%2520of%2520life%2520of%2520second-%2520vs%2520first-generation%2520antipsychotic%2520drugs%2520in%2520schizophrenia%253A%2520Cost%2520Utility%2520of%2520the%2520Latest%2520Antipsychotic%2520Drugs%2520in%2520Schizophrenia%2520Study%2520%2528CUtLASS%25201%2529%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2006%26volume%3D63%26spage%3D1079%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Stroup, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvoy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swartz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenheck, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefe, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao, J. K.</span><span> </span><span class="NLM_article-title">Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.163.4.611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16585435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287os1Kgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2006&pages=611-622&author=T.+S.+Stroupauthor=J.+A.+Liebermanauthor=J.+P.+McEvoyauthor=M.+S.+Swartzauthor=S.+M.+Davisauthor=R.+A.+Rosenheckauthor=D.+O.+Perkinsauthor=R.+S.+Keefeauthor=C.+E.+Davisauthor=J.+Severeauthor=J.+K.+Hsiao&title=Effectiveness+of+olanzapine%2C+quetiapine%2C+risperidone%2C+and+ziprasidone+in+patients+with+chronic+schizophrenia+following+discontinuation+of+a+previous+atypical+antipsychotic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</span></div><div class="casAuthors">Stroup T Scott; Lieberman Jeffrey A; McEvoy Joseph P; Swartz Marvin S; Davis Sonia M; Rosenheck Robert A; Perkins Diana O; Keefe Richard S E; Davis Clarence E; Severe Joanne; Hsiao John K</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">611-22</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">BACKGROUND:  In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown.  This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic.  METHOD:  Subjects with schizophrenia (N=444) who had discontinued the atypical antipsychotic randomly assigned during phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigation were randomly reassigned to double-blind treatment with a different antipsychotic (olanzapine, 7.5-30 mg/day [N=66]; quetiapine, 200-800 mg/day [N=63]; risperidone, 1.5-6.0 mg/day [N=69]; or ziprasidone, 40-160 mg/day [N=135]).  The primary aim was to determine if there were differences between these four treatments in effectiveness measured by time until discontinuation for any reason.  RESULTS:  The time to treatment discontinuation was longer for patients treated with risperidone (median: 7.0 months) and olanzapine (6.3 months) than with quetiapine (4.0 months) and ziprasidone (2.8 months).  Among patients who discontinued their previous antipsychotic because of inefficacy (N=184), olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine.  There were no significant differences between antipsychotics among those who discontinued their previous treatment because of intolerability (N=168).  CONCLUSIONS:  Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyaiGBE8WJGu98rul4nhSdfW6udTcc2eYy6puStY8nKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287os1Kgug%253D%253D&md5=7b0efddd9623cf4122c1ee69e77ec94a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.163.4.611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.163.4.611%26sid%3Dliteratum%253Aachs%26aulast%3DStroup%26aufirst%3DT.%2BS.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DMcEvoy%26aufirst%3DJ.%2BP.%26aulast%3DSwartz%26aufirst%3DM.%2BS.%26aulast%3DDavis%26aufirst%3DS.%2BM.%26aulast%3DRosenheck%26aufirst%3DR.%2BA.%26aulast%3DPerkins%26aufirst%3DD.%2BO.%26aulast%3DKeefe%26aufirst%3DR.%2BS.%26aulast%3DDavis%26aufirst%3DC.%2BE.%26aulast%3DSevere%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DJ.%2BK.%26atitle%3DEffectiveness%2520of%2520olanzapine%252C%2520quetiapine%252C%2520risperidone%252C%2520and%2520ziprasidone%2520in%2520patients%2520with%2520chronic%2520schizophrenia%2520following%2520discontinuation%2520of%2520a%2520previous%2520atypical%2520antipsychotic%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D163%26spage%3D611%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">McEvoy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroup, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenheck, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swartz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefe, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao, J. K.</span><span> </span><span class="NLM_article-title">Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">610</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.163.4.600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16585434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287os1KgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2006&pages=600-610&author=J.+P.+McEvoyauthor=J.+A.+Liebermanauthor=T.+S.+Stroupauthor=S.+M.+Davisauthor=H.+Y.+Meltzerauthor=R.+A.+Rosenheckauthor=M.+S.+Swartzauthor=D.+O.+Perkinsauthor=R.+S.+Keefeauthor=C.+E.+Davisauthor=J.+Severeauthor=J.+K.+Hsiao&title=Effectiveness+of+clozapine+versus+olanzapine%2C+quetiapine%2C+and+risperidone+in+patients+with+chronic+schizophrenia+who+did+not+respond+to+prior+atypical+antipsychotic+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</span></div><div class="casAuthors">McEvoy Joseph P; Lieberman Jeffrey A; Stroup T Scott; Davis Sonia M; Meltzer Herbert Y; Rosenheck Robert A; Swartz Marvin S; Perkins Diana O; Keefe Richard S E; Davis Clarence E; Severe Joanne; Hsiao John K</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">600-10</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine.  In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation.  METHOD:  Ninety-nine patients who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily because of inadequate efficacy, were randomly assigned to open-label treatment with clozapine (N=49) or blinded treatment with another newer atypical antipsychotic not previously received in the trial (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16]).  RESULTS:  Time until treatment discontinuation for any reason was significantly longer for clozapine (median=10.5 months) than for quetiapine (median=3.3), or risperidone (median=2.8), but not for olanzapine (median=2.7).  Time to discontinuation because of inadequate therapeutic effect was significantly longer for clozapine than for olanzapine, quetiapine, or risperidone.  At 3-month assessments, Positive and Negative Syndrome Scale total scores had decreased more in patients treated with clozapine than in patients treated with quetiapine or risperidone but not olanzapine.  One patient treated with clozapine developed agranulocytosis, and another developed eosinophilia; both required treatment discontinuation.  CONCLUSIONS:  For these patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypical antipsychotic.  Safety monitoring is necessary to detect and manage clozapine's serious side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyaiGBE8WJGoJKJbLTgsvCfW6udTcc2eYy6puStY8nKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287os1KgtQ%253D%253D&md5=5a4fed46f9e5be5d2af7a90782b52523</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.163.4.600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.163.4.600%26sid%3Dliteratum%253Aachs%26aulast%3DMcEvoy%26aufirst%3DJ.%2BP.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DStroup%26aufirst%3DT.%2BS.%26aulast%3DDavis%26aufirst%3DS.%2BM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRosenheck%26aufirst%3DR.%2BA.%26aulast%3DSwartz%26aufirst%3DM.%2BS.%26aulast%3DPerkins%26aufirst%3DD.%2BO.%26aulast%3DKeefe%26aufirst%3DR.%2BS.%26aulast%3DDavis%26aufirst%3DC.%2BE.%26aulast%3DSevere%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DJ.%2BK.%26atitle%3DEffectiveness%2520of%2520clozapine%2520versus%2520olanzapine%252C%2520quetiapine%252C%2520and%2520risperidone%2520in%2520patients%2520with%2520chronic%2520schizophrenia%2520who%2520did%2520not%2520respond%2520to%2520prior%2520atypical%2520antipsychotic%2520treatment%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D163%26spage%3D600%26epage%3D610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Jeste, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Carmen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohr, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, R. J.</span><span> </span><span class="NLM_article-title">Did schizophrenia exist before the eighteenth century</span> <span class="citation_source-journal">Compr. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0010-440X%2885%2990016-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=3905241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaL28%252FlsVOhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1985&pages=493-503&author=D.+V.+Jesteauthor=R.+del+Carmenauthor=J.+B.+Lohrauthor=R.+J.+Wyatt&title=Did+schizophrenia+exist+before+the+eighteenth+century"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Did schizophrenia exist before the eighteenth century?</span></div><div class="casAuthors">Jeste D V; del Carmen R; Lohr J B; Wyatt R J</div><div class="citationInfo"><span class="NLM_cas:title">Comprehensive psychiatry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">493-503</span>
        ISSN:<span class="NLM_cas:issn">0010-440X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-3QKU6NoKce2mnZh2OgS0fW6udTcc2eYbBDegXJt4Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FlsVOhtA%253D%253D&md5=fb89750721575debe32e4e05ec10518c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0010-440X%2885%2990016-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0010-440X%252885%252990016-1%26sid%3Dliteratum%253Aachs%26aulast%3DJeste%26aufirst%3DD.%2BV.%26aulast%3Ddel%2BCarmen%26aufirst%3DR.%26aulast%3DLohr%26aufirst%3DJ.%2BB.%26aulast%3DWyatt%26aufirst%3DR.%2BJ.%26atitle%3DDid%2520schizophrenia%2520exist%2520before%2520the%2520eighteenth%2520century%26jtitle%3DCompr.%2520Psychiatry%26date%3D1985%26volume%3D26%26spage%3D493%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Green, M. F.</span><span> </span><span class="NLM_article-title">Stimulating the development of drug treatments to improve cognition in schizophrenia</span> <span class="citation_source-journal">Ann. Rev. Clin. Psychol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1146%2Fannurev.clinpsy.3.022806.091529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17716052" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=159-180&author=M.+F.+Green&title=Stimulating+the+development+of+drug+treatments+to+improve+cognition+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1146%2Fannurev.clinpsy.3.022806.091529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.clinpsy.3.022806.091529%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DM.%2BF.%26atitle%3DStimulating%2520the%2520development%2520of%2520drug%2520treatments%2520to%2520improve%2520cognition%2520in%2520schizophrenia%26jtitle%3DAnn.%2520Rev.%2520Clin.%2520Psychol.%26date%3D2007%26volume%3D3%26spage%3D159%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Nuechterlein, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barch, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, R. K.</span><span> </span><span class="NLM_article-title">Identification of separable cognitive factors in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15531405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crlvFKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2004&pages=29-39&author=K.+H.+Nuechterleinauthor=D.+M.+Barchauthor=J.+M.+Goldauthor=T.+E.+Goldbergauthor=M.+F.+Greenauthor=R.+K.+Heaton&title=Identification+of+separable+cognitive+factors+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of separable cognitive factors in schizophrenia</span></div><div class="casAuthors">Nuechterlein Keith H; Barch Deanna M; Gold James M; Goldberg Terry E; Green Michael F; Heaton Robert K</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">One of the primary goals in the NIMH initiative to encourage development of new interventions for cognitive deficits in schizophrenia, Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS), has been to develop a reliable and valid consensus cognitive battery for use in clinical trials.  Absence of such a battery has hampered standardized evaluation of new treatments and, in the case of pharmacological agents, has been an obstacle to FDA approval of medications targeting cognitive deficits in schizophrenia.  A fundamental step in developing such a battery was to identify the major separable cognitive impairments in schizophrenia.  As part of this effort, we evaluated the empirical evidence for cognitive performance dimensions in schizophrenia, emphasizing factor analytic studies.  We concluded that seven separable cognitive factors were replicable across studies and represent fundamental dimensions of cognitive deficit in schizophrenia: Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning and Memory, Visual Learning and Memory, Reasoning and Problem Solving, and Verbal Comprehension.  An eighth domain, Social Cognition, was added due to recent increased interest in this area and other evidence of its relevance for clinical trials aiming to evaluate the impact of potential cognitive enhancers on cognitive performance and functional outcome.  Verbal Comprehension was not considered appropriate for a cognitive battery intended to be sensitive to cognitive change, due to its resistance to change.  The remaining seven domains were recommended for inclusion in the MATRICS-NIMH consensus cognitive battery and will serve as the basic structure for that battery.  These separable cognitive dimensions also have broader relevance to future research aimed at understanding the nature and structure of core cognitive deficits in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjOcc4H71WSkEksK8CslK8fW6udTcc2eYbBDegXJt4Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crlvFKrsA%253D%253D&md5=bb3fcc504206b4d2936ee995694d8f59</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DNuechterlein%26aufirst%3DK.%2BH.%26aulast%3DBarch%26aufirst%3DD.%2BM.%26aulast%3DGold%26aufirst%3DJ.%2BM.%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DGreen%26aufirst%3DM.%2BF.%26aulast%3DHeaton%26aufirst%3DR.%2BK.%26atitle%3DIdentification%2520of%2520separable%2520cognitive%2520factors%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2004%26volume%3D72%26spage%3D29%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Marder, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenton, W.</span><span> </span><span class="NLM_article-title">Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15531402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crlvFKkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2004&pages=5-9&author=S.+R.+Marderauthor=W.+Fenton&title=Measurement+and+treatment+research+to+improve+cognition+in+schizophrenia%3A+NIMH+MATRICS+initiative+to+support+the+development+of+agents+for+improving+cognition+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia</span></div><div class="casAuthors">Marder Stephen R; Fenton Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-9</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The impairments in social and vocational outcome that are common in schizophrenia are strongly related to the severity of impaired neurocognition.  This observation led to the initiation of The NIMH's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, which supports the development of pharmacological agents to improve cognition in schizophrenia.  MATRICS addresses barriers to drug development through a number of activities, including the development of a consensus battery for measuring cognition in schizophrenia; the development of a consensus regarding the most promising molecular targets that should be the focus of drug development; the use of a joint meeting with representatives from the industry, academia, NIMH, and the U.S.  Food and Drug Administration (FDA) to clarify guidelines for the design of clinical trials for cognition enhancing agents; and finally, to assist NIMH in developing its research agenda in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjOcc4H71WSnT4ugvCDgnZfW6udTcc2eYbBDegXJt4Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crlvFKkuw%253D%253D&md5=f778dc43a12f8bd4526c411368b738d6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DMarder%26aufirst%3DS.%2BR.%26aulast%3DFenton%26aufirst%3DW.%26atitle%3DMeasurement%2520and%2520treatment%2520research%2520to%2520improve%2520cognition%2520in%2520schizophrenia%253A%2520NIMH%2520MATRICS%2520initiative%2520to%2520support%2520the%2520development%2520of%2520agents%2520for%2520improving%2520cognition%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2004%26volume%3D72%26spage%3D5%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitt, P.</span><span> </span><span class="NLM_article-title">Schizophrenia as a disorder of neurodevelopment</span> <span class="citation_source-journal">Annu. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1146%2Fannurev.neuro.25.112701.142754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12052915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtF2hsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2002&pages=409-432&author=D.+A.+Lewisauthor=P.+Levitt&title=Schizophrenia+as+a+disorder+of+neurodevelopment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia as a disorder of neurodevelopment</span></div><div class="casAuthors">Lewis, David A.; Levitt, Pat</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">409-432</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A combination of genetic susceptibility and environmental perturbations appear to be necessary for the expression of schizophrenia.  In addn., the pathogenesis of the disease is hypothesized to be neurodevelopmental in nature based on reports of an excess of adverse events during the pre- and perinatal periods, the presence of cognitive and behavioral signs during childhood and adolescence, and the lack of evidence of a neurodegenerative process in most individuals with schizophrenia.  Recent studies of neurodevelopmental mechanisms strongly suggest that no single gene or factor is responsible for driving a highly complex biol. process.  Together, these findings suggest that combinatorial genetic and environmental factors, which disturb a normal developmental course early in life, result in mol. and histogenic responses that cumulatively lead to different developmental trajectories and the clin. phenotype recognized as schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokBRthEqD1WbVg90H21EOLACvtfcHk0li1ZN8UbeTTJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtF2hsbw%253D&md5=bab0de349e55e799fc9bf15938d93958</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.25.112701.142754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.25.112701.142754%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DLevitt%26aufirst%3DP.%26atitle%3DSchizophrenia%2520as%2520a%2520disorder%2520of%2520neurodevelopment%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2002%26volume%3D25%26spage%3D409%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Raine, A.</span><span> </span><span class="NLM_article-title">Schizotypal personality: neurodevelopmental and psychosocial trajectories</span> <span class="citation_source-journal">Ann. Rev. Clin. Psychol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1146%2Fannurev.clinpsy.2.022305.095318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17716072" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=291-326&author=A.+Raine&title=Schizotypal+personality%3A+neurodevelopmental+and+psychosocial+trajectories"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1146%2Fannurev.clinpsy.2.022305.095318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.clinpsy.2.022305.095318%26sid%3Dliteratum%253Aachs%26aulast%3DRaine%26aufirst%3DA.%26atitle%3DSchizotypal%2520personality%253A%2520neurodevelopmental%2520and%2520psychosocial%2520trajectories%26jtitle%3DAnn.%2520Rev.%2520Clin.%2520Psychol.%26date%3D2006%26volume%3D2%26spage%3D291%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Crow, T. J.</span><span> </span><span class="NLM_article-title">How and why genetic linkage has not solved the problem of psychosis: review and hypothesis</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.164.1.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17202538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgs1WgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2007&pages=13-21&author=T.+J.+Crow&title=How+and+why+genetic+linkage+has+not+solved+the+problem+of+psychosis%3A+review+and+hypothesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">How and why genetic linkage has not solved the problem of psychosis: review and hypothesis</span></div><div class="casAuthors">Crow Timothy J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-21</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The author examined the chromosomal linkage method as an approach to the genetic basis of schizophrenia and bipolar disorder.  METHOD:  Comparisons were conducted of recent meta-analyses of genome scans of schizophrenia and bipolar disorder and of the three largest (N>300) sibling pair studies of schizophrenia and schizoaffective disorder and a comparable study of bipolar illness.  RESULTS:  Recent meta-analyses have not identified consistent sites of linkage.  The three largest studies of schizophrenia fail to agree on a single locus, no commonality with bipolar illness has been demonstrated, and there is no replicable support for any of the current candidate genes.  DISCUSSION:  An alternative to the concept that DNA sequence variation lies in "multiple genes of small effect" is the hypothesis that the variation is epigenetic but related to the genetic transition ("the speciation event") that separated Homo sapiens from a prior hominid species.  This hypothesis draws attention to the chromosomal rearrangement (the Xq21.3/Yp translocation) that occurred some 6 million years ago in the hominid lineage and subsequent rearrangements, including a paracentric inversion, that have taken place within the translocated segment.  Here it is argued that the most recent of these events is relevant to specifically human characteristics, including language.  The gene pair protocadherin X and Y within this region is under new selective pressure and is in a novel (epigenetic) situation with respect to X inactivation.  CONCLUSIONS:  Epigenetic variation associated with chromosomal rearrangements that occurred in the hominid lineage and that relates to the evolution of language could account for predisposition to schizophrenia and schizoaffective and bipolar disorder and failure to detect such variation by standard linkage approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-UbtLFI4-l5HZzFRCXxVKfW6udTcc2eZZW8bsjMy8u7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgs1WgtA%253D%253D&md5=957bc6018ec0c5a0a1134bb84ee2465b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.164.1.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.164.1.13%26sid%3Dliteratum%253Aachs%26aulast%3DCrow%26aufirst%3DT.%2BJ.%26atitle%3DHow%2520and%2520why%2520genetic%2520linkage%2520has%2520not%2520solved%2520the%2520problem%2520of%2520psychosis%253A%2520review%2520and%2520hypothesis%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D164%26spage%3D13%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Morgan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, H.</span><span> </span><span class="NLM_article-title">Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma—a critical review</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbl053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17105965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28jksV2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=3-10&author=C.+Morganauthor=H.+Fisher&title=Environment+and+schizophrenia%3A+environmental+factors+in+schizophrenia%3A+childhood+trauma%E2%80%94a+critical+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma--a critical review</span></div><div class="casAuthors">Morgan Craig; Fisher Helen</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">There is renewed interest in the relationship between early childhood trauma and risk of psychosis in adulthood.  There are a large number of studies of psychiatric inpatients, and of outpatients in which a majority have a psychotic disorder, that suggest the prevalence of childhood trauma in these populations is high.  However, these are generally small studies of diagnostically heterogeneous and chronic samples and, as such, can tell us very little about whether childhood trauma is of etiological importance in psychosis.  A small number of recent population-based studies provide more robust evidence of an association, and there are now plausible biological mechanisms linking childhood trauma and psychosis.  However, there remain a number of conceptual and methodological issues, which mean much more research is needed before firm conclusions can be drawn about whether childhood trauma is a cause of psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6rFzFzFcpL_tos8R3JUhXfW6udTcc2eZZW8bsjMy8u7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jksV2jtw%253D%253D&md5=b41b038e68957a173ec1a421400548ce</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbl053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbl053%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DFisher%26aufirst%3DH.%26atitle%3DEnvironment%2520and%2520schizophrenia%253A%2520environmental%2520factors%2520in%2520schizophrenia%253A%2520childhood%2520trauma%25E2%2580%2594a%2520critical%2520review%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D3%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Krabbendam, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van, O. J.</span><span> </span><span class="NLM_article-title">Schizophrenia and urbanicity: a major environmental influence—conditional on genetic risk</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">799</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbi060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16150958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2Mrjtlelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2005&pages=795-799&author=L.+Krabbendamauthor=O.+J.+Van&title=Schizophrenia+and+urbanicity%3A+a+major+environmental+influence%E2%80%94conditional+on+genetic+risk"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk</span></div><div class="casAuthors">Krabbendam Lydia; van Os Jim</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">795-9</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">More than 10 studies have consistently shown that around one-third of all schizophrenia incidence may be related to unknown but likely unconfounded environmental factors operating in the urban environment that have an impact on developing children and adolescents to increase, relatively specifically, the later expression of psychosis-like at-risk mental states and overt psychotic disorders.  The available evidence suggests that causation (urban environment causes psychosis) is more important than selection (high-risk individuals move into urban areas) and that the effect of the environmental factors in the urban environment is conditional on genetic risk (i.e., there may be gene-environment interaction).  The effect associated with urbanicity has grown in more recent birth cohorts, while studies focusing on within-city contrasts have found important within-city variation in the incidence of schizophrenia associated with neighborhood social characteristics.  Future approaches may focus on the complex interactions between neighborhood cognitive social capital and genetic risk as the substrate for the increased incidence of schizophrenia in the increasingly urbanized areas that children are growing up in.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHRmsFg_e25Eg6wdEZmT2rfW6udTcc2eaBCTcmkQjHzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mrjtlelsg%253D%253D&md5=b196e34e2bf2dd6237c1c9dd369b8419</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbi060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbi060%26sid%3Dliteratum%253Aachs%26aulast%3DKrabbendam%26aufirst%3DL.%26aulast%3DVan%26aufirst%3DO.%2BJ.%26atitle%3DSchizophrenia%2520and%2520urbanicity%253A%2520a%2520major%2520environmental%2520influence%25E2%2580%2594conditional%2520on%2520genetic%2520risk%26jtitle%3DSchizophr.%2520Bull.%26date%3D2005%26volume%3D31%26spage%3D795%26epage%3D799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Gershon, E. S.</span><span> </span><span class="NLM_article-title">Pregnancy, chromosomes and receptors</span>.  <span class="citation_source-journal">Scientist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span><span class="NLM_issue">December Suppl. (Schizophrenia)</span><span class="NLM_x">) </span> <span class="NLM_fpage">45</span>− <span class="NLM_lpage">47</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=45-47&issue=December+Suppl.+%28Schizophrenia%29&author=E.+S.+Gershon&title=Pregnancy%2C+chromosomes+and+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGershon%26aufirst%3DE.%2BS.%26atitle%3DPregnancy%252C%2520chromosomes%2520and%2520receptors%26jtitle%3DScientist%26date%3D2007%26issue%3DDecember%2520Suppl.%2520%2528Schizophrenia%2529%26spage%3D45%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Torrey, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartko, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lun, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yolken, R. H.</span><span> </span><span class="NLM_article-title">Antibodies to <i>Toxoplasma gondii</i> in patients with schizophrenia: a meta-analysis</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">736</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbl050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17085743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s3ps1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=729-736&author=E.+F.+Torreyauthor=J.+J.+Bartkoauthor=Z.+R.+Lunauthor=R.+H.+Yolken&title=Antibodies+to+Toxoplasma+gondii+in+patients+with+schizophrenia%3A+a+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis</span></div><div class="casAuthors">Torrey E Fuller; Bartko John J; Lun Zhao-Rong; Yolken Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">729-36</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">Recent studies have linked infectious agents to schizophrenia.  The largest number of studies has involved the analysis of Toxoplasma gondii; these studies were subjected to a meta-analysis.  Published articles and abstracts were identified by searches of MEDLINE, Ovid, and Google Scholar; by a search of Chinese publications; through letters to researchers; and by visiting China.  Published and unpublished controlled studies that used serological methods for measuring T. gondii antibodies to assess inpatients and/or outpatients diagnosed with schizophrenia were selected for analysis, and source documents were translated as needed.  Forty-two studies carried out in 17 countries over 5 decades were identified; 23 of these (6 unpublished) met selection criteria.  The combined odds ratio (OR) was 2.73 (95% confidence interval, 2.10 to 3.60; chi-square with 1 df 263; P < .000001).  Seven studies that included only patients with first-episode schizophrenia (OR 2.54) did not differ significantly from 16 studies that included patients in all clinical phases (OR 2.79).  The results suggest that individuals with schizophrenia have an increased prevalence of antibodies to T. gondii.  This association is consistent with other epidemiological studies as well as with animal studies.  Although the OR of 2.73 is modest, it exceeds that for genetic or other environmental factors identified to date and suggests that Toxoplasma is in some way associated with a large number of cases of schizophrenia.  If an etiological association can be proven, it would have implications for the design of measures for the prevention and treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5GCvKt2-s4nqj_yg7twvpfW6udTcc2eaBCTcmkQjHzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3ps1Kktg%253D%253D&md5=4bf9691aeb7a4c6f9066ea3ab32079c7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbl050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbl050%26sid%3Dliteratum%253Aachs%26aulast%3DTorrey%26aufirst%3DE.%2BF.%26aulast%3DBartko%26aufirst%3DJ.%2BJ.%26aulast%3DLun%26aufirst%3DZ.%2BR.%26aulast%3DYolken%26aufirst%3DR.%2BH.%26atitle%3DAntibodies%2520to%2520Toxoplasma%2520gondii%2520in%2520patients%2520with%2520schizophrenia%253A%2520a%2520meta-analysis%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D729%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Eaton, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mors, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agerbo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortensen, P. B.</span><span> </span><span class="NLM_article-title">Association of schizophrenia and autoimmune diseases: linkage of Danish national registers</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.163.3.521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16513876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287isFyrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2006&pages=521-528&author=W.+W.+Eatonauthor=M.+Byrneauthor=H.+Ewaldauthor=O.+Morsauthor=C.+Y.+Chenauthor=E.+Agerboauthor=P.+B.+Mortensen&title=Association+of+schizophrenia+and+autoimmune+diseases%3A+linkage+of+Danish+national+registers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Association of schizophrenia and autoimmune diseases: linkage of Danish national registers</span></div><div class="casAuthors">Eaton William W; Byrne Majella; Ewald Henrik; Mors Ole; Chen Chuan-Yu; Agerbo Esben; Mortensen Preben Bo</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-8</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Individuals with schizophrenia and their relatives tend to have either higher or lower than expected prevalences of autoimmune disorders, especially rheumatoid arthritis, celiac disease, autoimmune thyroid diseases, and type 1 diabetes.  The purpose of the study was to estimate the association of schizophrenia with these disorders as well as a range of other autoimmune diseases in a single large epidemiologic study.  METHOD:  The Danish Psychiatric Register, the National Patient Register, and a register with socioeconomic information were linked to form a data file that included all 7,704 persons in Denmark diagnosed with schizophrenia from 1981 to 1998 and their parents along with a sample of matched comparison subjects and their parents.  The data linkage required that the autoimmune disease occur before the diagnosis of schizophrenia.  RESULTS:  A history of any autoimmune disease was associated with a 45% increase in risk for schizophrenia.  Nine autoimmune disorders had higher prevalence rates among patients with schizophrenia than among comparison subjects (crude incidence rate ratios ranging from 1.9 to 12.5), and 12 autoimmune diseases had higher prevalence rates among parents of schizophrenia patients than among parents of comparison subjects (adjusted incidence rate ratios ranging from 1.3 to 3.8).  Thyrotoxicosis, celiac disease, acquired hemolytic anemia, interstitial cystitis, and Sjogren's syndrome had higher prevalence rates among patients with schizophrenia than among comparison subjects and also among family members of schizophrenia patients than among family members of comparison subjects.  CONCLUSIONS:  Schizophrenia is associated with a larger range of autoimmune diseases than heretofore suspected.  Future research on comorbidity has the potential to advance understanding of pathogenesis of both psychiatric and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl-ee7fCyRFjjk2McQZ6XmfW6udTcc2eZ2k0pzj0Vqwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287isFyrtA%253D%253D&md5=51e712a23f4b7af86f581eece98dfdb2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.163.3.521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.163.3.521%26sid%3Dliteratum%253Aachs%26aulast%3DEaton%26aufirst%3DW.%2BW.%26aulast%3DByrne%26aufirst%3DM.%26aulast%3DEwald%26aufirst%3DH.%26aulast%3DMors%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DAgerbo%26aufirst%3DE.%26aulast%3DMortensen%26aufirst%3DP.%2BB.%26atitle%3DAssociation%2520of%2520schizophrenia%2520and%2520autoimmune%2520diseases%253A%2520linkage%2520of%2520Danish%2520national%2520registers%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D163%26spage%3D521%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Moore, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingford-Hughes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, G.</span><span> </span><span class="NLM_article-title">Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=319-328&author=T.+H.+Mooreauthor=S.+Zammitauthor=A.+Lingford-Hughesauthor=T.+R.+Barnesauthor=P.+B.+Jonesauthor=M.+Burkeauthor=G.+Lewis&title=Cannabis+use+and+risk+of+psychotic+or+affective+mental+health+outcomes%3A+a+systematic+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DT.%2BH.%26aulast%3DZammit%26aufirst%3DS.%26aulast%3DLingford-Hughes%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DT.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BB.%26aulast%3DBurke%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DG.%26atitle%3DCannabis%2520use%2520and%2520risk%2520of%2520psychotic%2520or%2520affective%2520mental%2520health%2520outcomes%253A%2520a%2520systematic%2520review%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D319%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Huxley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffer, A.</span><span> </span><span class="NLM_article-title">Schizophrenia as a genetic morphism</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=1964&pages=220-221&author=J.+Huxleyauthor=E.+Mayreauthor=A.+Hoffer&title=Schizophrenia+as+a+genetic+morphism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuxley%26aufirst%3DJ.%26aulast%3DMayre%26aufirst%3DE.%26aulast%3DHoffer%26aufirst%3DA.%26atitle%3DSchizophrenia%2520as%2520a%2520genetic%2520morphism%26jtitle%3DNature%26date%3D1964%26volume%3D204%26spage%3D220%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Patsopoulos, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatsioni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, J. P.</span><span> </span><span class="NLM_article-title">Claims of sex differences: an empirical assessment in genetic associations</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">880</span><span class="NLM_x">–</span> <span class="NLM_lpage">893</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2007&pages=880-893&author=N.+A.+Patsopoulosauthor=A.+Tatsioniauthor=J.+P.+Ioannidis&title=Claims+of+sex+differences%3A+an+empirical+assessment+in+genetic+associations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatsopoulos%26aufirst%3DN.%2BA.%26aulast%3DTatsioni%26aufirst%3DA.%26aulast%3DIoannidis%26aufirst%3DJ.%2BP.%26atitle%3DClaims%2520of%2520sex%2520differences%253A%2520an%2520empirical%2520assessment%2520in%2520genetic%2520associations%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2007%26volume%3D298%26spage%3D880%26epage%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Newton, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duman, R. S.</span><span> </span><span class="NLM_article-title">Neurogenic actions of atypical antipsychotic drugs and therapeutic implications</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=715-725&author=S.+S.+Newtonauthor=R.+S.+Duman&title=Neurogenic+actions+of+atypical+antipsychotic+drugs+and+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewton%26aufirst%3DS.%2BS.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DNeurogenic%2520actions%2520of%2520atypical%2520antipsychotic%2520drugs%2520and%2520therapeutic%2520implications%26jtitle%3DCNS%2520Drugs%26date%3D2007%26volume%3D21%26spage%3D715%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Sullivan, P. F.</span><span> </span><span class="NLM_article-title">Spurious genetic associations</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1121</span><span class="NLM_x">–</span> <span class="NLM_lpage">1126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2006.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17346679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFOrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=1121-1126&author=P.+F.+Sullivan&title=Spurious+genetic+associations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Spurious Genetic Associations</span></div><div class="casAuthors">Sullivan, Patrick F.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1121-1126</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Genetic assocn. studies are widely used in biomedical research and yet only a minority of pos. findings stand the test of replication.  I explored the capacity of assocn. studies to produce false pos. findings and the impact of various definitions of replication.  Methods: Genetically realistic simulation data of a typical genotyping/analytic approach for 10 single nucleotide polymorphisms (SNPs) in COMT, a commonly studied candidate gene.  Results: Candidate gene studies like those simulated here are highly likely to produce one or more false pos. findings at α ≤ .05, the pattern of findings can often be "compelling" or "intriguing," and false pos. findings propagate and confuse the literature unless the definition of replication is precise.  Conclusions: Findings from single assocn. studies constitute "tentative knowledge" and must be interpreted with exceptional caution.  For the assocn. method to function as intended, every statistical comparison must be tracked and reported, and integrated replication is essential.  Precise replication (the same SNPs, phenotype, and direction of assocn.) is required in the interpretation of multiple assocn. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvZbUahrMbrVg90H21EOLACvtfcHk0liawZk-nqKfHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFOrur0%253D&md5=825ffc077fd4f45f4d2c83badb1dca69</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DP.%2BF.%26atitle%3DSpurious%2520genetic%2520associations%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D61%26spage%3D1121%26epage%3D1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Williams, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canter, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, J. L.</span><span> </span><span class="NLM_article-title">Problems with genome-wide association studies</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1840</span><span class="NLM_x">–</span> <span class="NLM_lpage">1842</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1840-1842&author=S.+M.+Williamsauthor=J.+A.+Canterauthor=D.+C.+Crawfordauthor=J.+H.+Mooreauthor=M.+D.+Ritchieauthor=J.+L.+Haines&title=Problems+with+genome-wide+association+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DS.%2BM.%26aulast%3DCanter%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DD.%2BC.%26aulast%3DMoore%26aufirst%3DJ.%2BH.%26aulast%3DRitchie%26aufirst%3DM.%2BD.%26aulast%3DHaines%26aufirst%3DJ.%2BL.%26atitle%3DProblems%2520with%2520genome-wide%2520association%2520studies%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1840%26epage%3D1842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">ENCODE Project Consortium</span><span> </span><span class="NLM_article-title">Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">447</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnature05874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17571346" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2007&pages=799-816&author=+ENCODE+Project+Consortium&title=Identification+and+analysis+of+functional+elements+in+1%25+of+the+human+genome+by+the+ENCODE+pilot+project"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature05874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05874%26sid%3Dliteratum%253Aachs%26aulast%3DENCODE%2BProject%2BConsortium%26atitle%3DIdentification%2520and%2520analysis%2520of%2520functional%2520elements%2520in%25201%2525%2520of%2520the%2520human%2520genome%2520by%2520the%2520ENCODE%2520pilot%2520project%26jtitle%3DNature%26date%3D2007%26volume%3D447%26spage%3D799%26epage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Kendler, K. S.</span><span> </span><span class="NLM_article-title">The genetics of schizophrenia: chromosomal deletions, attentional disturbances, and spectrum boundaries</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1549</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.160.9.1549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12944326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3svgsFWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2003&pages=1549-1553&author=K.+S.+Kendler&title=The+genetics+of+schizophrenia%3A+chromosomal+deletions%2C+attentional+disturbances%2C+and+spectrum+boundaries"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The genetics of schizophrenia: chromosomal deletions, attentional disturbances, and spectrum boundaries</span></div><div class="casAuthors">Kendler Kenneth S</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1549-53</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREF4-5Nt9cPkkUaC_kzhvyfW6udTcc2eYFPQ1QsLLNLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgsFWmsg%253D%253D&md5=cb468e86aaaaeb4a87ec99cf39d64af6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.160.9.1549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.160.9.1549%26sid%3Dliteratum%253Aachs%26aulast%3DKendler%26aufirst%3DK.%2BS.%26atitle%3DThe%2520genetics%2520of%2520schizophrenia%253A%2520chromosomal%2520deletions%252C%2520attentional%2520disturbances%252C%2520and%2520spectrum%2520boundaries%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2003%26volume%3D160%26spage%3D1549%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaikh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, M. W.</span><span> </span><span class="NLM_article-title">Same brain, new decade. Challenges in CNS drug discovery in the postgenomic, proteomic era</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2001&pages=1-10&author=M.+Williamsauthor=J.+T.+Coyleauthor=S.+Shaikhauthor=M.+W.+Decker&title=Same+brain%2C+new+decade.+Challenges+in+CNS+drug+discovery+in+the+postgenomic%2C+proteomic+era"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26aulast%3DShaikh%26aufirst%3DS.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26atitle%3DSame%2520brain%252C%2520new%2520decade.%2520Challenges%2520in%2520CNS%2520drug%2520discovery%2520in%2520the%2520postgenomic%252C%2520proteomic%2520era%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2001%26volume%3D36%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Carlsson, A.</span><span> </span><span class="NLM_article-title">The Suppression of Psychotic Behavior. Part 3. Antipsychotic Agents: Elucidation of Their Mechanism of Action</span>. In  <span class="citation_source-book">Psycho- and Neuro-Pharmacology</span>; <span class="NLM_contrib-group">Parnham, M. J.; Bruinvels, J.</span>, Eds.; <span class="NLM_series">Discoveries in Pharmacology</span>; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>,<span class="NLM_x"> </span><span class="NLM_year">1983</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1</span>, pp  <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1983&pages=197-206&author=A.+Carlsson&title=Psycho-+and+Neuro-Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DA.%26atitle%3DThe%2520Suppression%2520of%2520Psychotic%2520Behavior.%2520Part%25203.%2520Antipsychotic%2520Agents%253A%2520Elucidation%2520of%2520Their%2520Mechanism%2520of%2520Action%26btitle%3DPsycho-%2520and%2520Neuro-Pharmacology%26aulast%3DParnham%26aufirst%3DM.%2BJ.%26pub%3DElsevier%26date%3D1983%26volume%3D1%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Creese, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burt, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=1976&pages=481-483&author=I.+Creeseauthor=D.+R.+Burtauthor=S.+H.+Snyder&title=Dopamine+receptor+binding+predicts+clinical+and+pharmacological+potencies+of+antischizophrenic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCreese%26aufirst%3DI.%26aulast%3DBurt%26aufirst%3DD.%2BR.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DDopamine%2520receptor%2520binding%2520predicts%2520clinical%2520and%2520pharmacological%2520potencies%2520of%2520antischizophrenic%2520drugs%26jtitle%3DScience%26date%3D1976%26volume%3D192%26spage%3D481%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Seeman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau-Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span> </span><span class="NLM_article-title">Antipsychotic drug doses and neuroleptic/dopamine receptors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">261</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2F261717a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=945467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaE28XlsFCisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1976&pages=717-719&author=P.+Seemanauthor=T.+Leeauthor=M.+Chau-Wongauthor=K.+Wong&title=Antipsychotic+drug+doses+and+neuroleptic%2Fdopamine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drug doses and neuroleptic/dopamine receptors</span></div><div class="casAuthors">Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">5562</span>),
    <span class="NLM_cas:pages">717-19</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Clin. effective antipsychotic drugs, e.g., chlorpromazine [50-53-3], blocked the stereospecific binding of 3H-labeled haloperidol [52-86-8] at concns. which correlated directly with their clin. potencies.  In addn., the antipsychotics blocked binding of dopamine [51-61-6], the IC50 values (concns. producing 50% blockade) for this effect correlated quant. with the clin. antipsychotic potencies.  The neuroleptic receptor assay can thus be used to screen potentially useful antipsychotic drugs.  The IC50 values for blockade of haloperidol binding were almost identical to the concns. of drugs in the patients plasma; e.g., 29 and 30nM, resp., for chlorpromazine.  These IC50 values may therefore be of therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXIuatc5GaFrVg90H21EOLACvtfcHk0lg_S4tVGW2TYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XlsFCisbk%253D&md5=2800e926625d767c976dbf4181fc6ad2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2F261717a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F261717a0%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DChau-Wong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%26atitle%3DAntipsychotic%2520drug%2520doses%2520and%2520neuroleptic%252Fdopamine%2520receptors%26jtitle%3DNature%26date%3D1976%26volume%3D261%26spage%3D717%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Richtand, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logue, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keck, P. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strakowski, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, R. K.</span><span> </span><span class="NLM_article-title">Dopamine and serotonin receptor binding and antipsychotic efficacy</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1726</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1715-1726&author=N.+M.+Richtandauthor=J.+A.+Welgeauthor=A.+D.+Logueauthor=P.+E.+Keckauthor=S.+M.+Strakowskiauthor=R.+K.+McNamara&title=Dopamine+and+serotonin+receptor+binding+and+antipsychotic+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichtand%26aufirst%3DN.%2BM.%26aulast%3DWelge%26aufirst%3DJ.%2BA.%26aulast%3DLogue%26aufirst%3DA.%2BD.%26aulast%3DKeck%26aufirst%3DP.%2BE.%26aulast%3DStrakowski%26aufirst%3DS.%2BM.%26aulast%3DMcNamara%26aufirst%3DR.%2BK.%26atitle%3DDopamine%2520and%2520serotonin%2520receptor%2520binding%2520and%2520antipsychotic%2520efficacy%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D1715%26epage%3D1726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lgHcBjZ13TZRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">The dopamine hypothesis of schizophrenia: focus on the dopamine receptor</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1251927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaE28XhsF2gtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=1976&pages=197-202&author=S.+H.+Snyder&title=The+dopamine+hypothesis+of+schizophrenia%3A+focus+on+the+dopamine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The dopamine hypothesis of schizophrenia:  focus on the dopamine receptor</span></div><div class="casAuthors">Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Psychiatry</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-202</span>CODEN:
                <span class="NLM_cas:coden">AJPSAO</span>;
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">A review with 31 refs. on the role of dopamine (I) [51-61-6] in schizophrenia and on the pharmacol. of drugs wich affect I receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIUxX7v_hIOrVg90H21EOLACvtfcHk0lgHcBjZ13TZRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XhsF2gtbw%253D&md5=2222fa0ca087bd0655f3edfe06c5066b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DThe%2520dopamine%2520hypothesis%2520of%2520schizophrenia%253A%2520focus%2520on%2520the%2520dopamine%2520receptor%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1976%26volume%3D133%26spage%3D197%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Rogers, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. H.</span><span> </span><span class="NLM_article-title">Novel approaches for the treatment of schizophrenia</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2006&pages=1-21&author=B.+N.+Rogersauthor=C.+H.+Schmidt&title=Novel+approaches+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DSchmidt%26aufirst%3DC.%2BH.%26atitle%3DNovel%2520approaches%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2006%26volume%3D41%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span> </span><span class="NLM_article-title">Catching up on schizophrenia: natural history and neurobiology</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=325-334&author=D.+A.+Lewisauthor=J.+A.+Lieberman&title=Catching+up+on+schizophrenia%3A+natural+history+and+neurobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DCatching%2520up%2520on%2520schizophrenia%253A%2520natural%2520history%2520and%2520neurobiology%26jtitle%3DNeuron%26date%3D2000%26volume%3D28%26spage%3D325%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">The role of serotonin in antipsychotic drug action</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">106S</span><span class="NLM_x">–</span> <span class="NLM_lpage">115S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=106S-115S&author=H.+Y.+Meltzer&title=The+role+of+serotonin+in+antipsychotic+drug+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DThe%2520role%2520of%2520serotonin%2520in%2520antipsychotic%2520drug%2520action%26jtitle%3DNeuropsychopharmacology%26date%3D1999%26volume%3D21%26spage%3D106S%26epage%3D115S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Gaddum, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammeed, K. A.</span><span> </span><span class="NLM_article-title">Drugs which antagonize 5-hydroxytryptamine</span> <span class="citation_source-journal">Br. J. Pharmacol. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=13172437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaG2cXmsFGmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1954&pages=240-248&author=J.+H.+Gaddumauthor=K.+A.+Hammeed&title=Drugs+which+antagonize+5-hydroxytryptamine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs which antagonize 5-hydroxytryptamine</span></div><div class="casAuthors">Gaddum, J. H.; Hameed, Khan A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology and Chemotherapy</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">240-8</span>CODEN:
                <span class="NLM_cas:coden">BJPCAL</span>;
        ISSN:<span class="NLM_cas:issn">0366-0826</span>.
    </div><div class="casAbstract">With suitable concns. of mepyramine, piperoxan, and atropine it was possible to inhibit the effects of histamine, adrenaline, and acetylcholine without altering the effects of 5-hydroxytryptamine (I) on pharmacol. test prepns., supporting the view that I acts on a specific receptor.  One type of receptor to I was present in smooth muscle of the rat uterus and rabbit's perfused ear and was inhibited by low concns. of lysergic acid diethylamide (II).  The 2nd type, present in nervous tissue of guinea-pig ileum, was not inhibited by II.  The effect of I on ileum was inhibited by atropine or cocaine in the same way nicotine is inhibited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz0Fm5NQMiSrVg90H21EOLACvtfcHk0lj7mfbifWrJBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2cXmsFGmtQ%253D%253D&md5=ef08f60a262dfbeec028e743379f6de2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaddum%26aufirst%3DJ.%2BH.%26aulast%3DHammeed%26aufirst%3DK.%2BA.%26atitle%3DDrugs%2520which%2520antagonize%25205-hydroxytryptamine%26jtitle%3DBr.%2520J.%2520Pharmacol.%2520Chemother.%26date%3D1954%26volume%3D9%26spage%3D240%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Leysen, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemegeers, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tollenaere, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laduron, P. M.</span><span> </span><span class="NLM_article-title">Serotonergic component of neuroleptic receptors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1978&pages=168-171&author=J.+E.+Leysenauthor=C.+J.+Niemegeersauthor=J.+P.+Tollenaereauthor=P.+M.+Laduron&title=Serotonergic+component+of+neuroleptic+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeysen%26aufirst%3DJ.%2BE.%26aulast%3DNiemegeers%26aufirst%3DC.%2BJ.%26aulast%3DTollenaere%26aufirst%3DJ.%2BP.%26aulast%3DLaduron%26aufirst%3DP.%2BM.%26atitle%3DSerotonergic%2520component%2520of%2520neuroleptic%2520receptors%26jtitle%3DNature%26date%3D1978%26volume%3D272%26spage%3D168%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikich, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, J. E.</span><span> </span><span class="NLM_article-title">Serotonergic basis of antipsychotic drug effects in schizophrenia</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1099</span><span class="NLM_x">–</span> <span class="NLM_lpage">1117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0006-3223%2898%2900187-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9836014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFKqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1998&pages=1099-1117&author=J.+A.+Liebermanauthor=R.+B.+Mailmanauthor=G.+Duncanauthor=L.+Sikichauthor=M.+Chakosauthor=D.+E.+Nicholsauthor=J.+E.+Kraus&title=Serotonergic+basis+of+antipsychotic+drug+effects+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A decade of serotonin research: Role of serotonin in treatment of psychosis. Serotonergic basis of antipsychotic drug effects in schizophrenia</span></div><div class="casAuthors">Lieberman, Jeffrey A.; Mailman, Richard B.; Duncan, Gary; Sikich, Lin; Chakos, Miranda; Nichols, David E.; Kraus, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1099-1117</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review and discussion with many refs.  Recent attention has been focused on the involvement of serotonin (5-HT) in the pathophysiol. of schizophrenia and its role in mediating antipsychotic drug effects.  There are 2 reasons for the new emphasis: the tremendous success of the so-called atypical antipsychotic drugs (a common feature of which is their high affinity for specific 5-HT receptor subtypes); and the elucidation of a complex family of 5-HT receptors whose function and pharmacol. is only beginning to be understood.  This paper will review the evidence that pertains to the role of 5-HT in mediating antipsychotic drug effects.  The interaction of dopamine and 5-HT systems will be reviewed, and the mechanisms of action of atypical antipsychotic drugs will be evaluated in this context.  The impact of serotonin on neurodevelopment, and the involvement of serotonin in the psychotomimetic and psychotogenic properties of hallucinogens, is discussed.  Together, these facts are placed into the context of changes in serotonergic function in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNtFkClCY2_7Vg90H21EOLACvtfcHk0lj7mfbifWrJBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFKqurk%253D&md5=2f37716bd875d593d1593fd93d4db466</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2898%2900187-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252898%252900187-5%26sid%3Dliteratum%253Aachs%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26aulast%3DDuncan%26aufirst%3DG.%26aulast%3DSikich%26aufirst%3DL.%26aulast%3DChakos%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKraus%26aufirst%3DJ.%2BE.%26atitle%3DSerotonergic%2520basis%2520of%2520antipsychotic%2520drug%2520effects%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D1998%26volume%3D44%26spage%3D1099%26epage%3D1117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Alex, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pehek, E. A.</span><span> </span><span class="NLM_article-title">Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pharmthera.2006.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17049611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2007&pages=296-320&author=K.+D.+Alexauthor=E.+A.+Pehek&title=Pharmacologic+mechanisms+of+serotonergic+regulation+of+dopamine+neurotransmission"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission</span></div><div class="casAuthors">Alex, K. D.; Pehek, E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-320</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The neurotransmitter dopamine (DA) has a long assocn. with normal functions such as motor control, cognition, and reward, as well as a no. of syndromes including drug abuse, schizophrenia, and Parkinson's disease.  Studies show that serotonin (5-HT) acts through several 5-HT receptors in the brain to modulate DA neurons in all 3 major dopaminergic pathways.  There are at least fourteen 5-HT receptor subtypes, many of which have been shown to play some role in mediating 5-HT/DA interactions.  Several subtypes, including the 5-HT1A, 5-HT1B, 5-HT2A, 5-HT3 and 5-HT4 receptors, act to facilitate DA release, while the 5-HT2C receptor mediates an inhibitory effect of 5-HT on DA release.  Most 5-HT receptor subtypes only modulate DA release when 5-HT and/or DA neurons are stimulated, but the 5-HT2C receptor, characterized by high levels of constitutive activity, inhibits tonic as well as evoked DA release.  This review summarizes the anatomical evidence for the presence of each 5-HT receptor subtype in dopaminergic regions of the brain and the neuropharmacol. evidence demonstrating regulation of each DA pathway.  The relevance of 5-HT receptor modulation of DA systems to the development of therapeutics used to treat schizophrenia, depression, and drug abuse is discussed.  Lastly, areas are highlighted in which future research would be maximally beneficial to the treatment of these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodrXef3tT1c7Vg90H21EOLACvtfcHk0lj7mfbifWrJBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgt7Y%253D&md5=df3ad8cc3cad32d3a3f04e93d99ffc71</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2006.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2006.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DAlex%26aufirst%3DK.%2BD.%26aulast%3DPehek%26aufirst%3DE.%2BA.%26atitle%3DPharmacologic%2520mechanisms%2520of%2520serotonergic%2520regulation%2520of%2520dopamine%2520neurotransmission%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D113%26spage%3D296%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Millan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lejeune, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cussac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivet, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audinot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adhumeau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brocco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Despaux, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peglion, J. L.</span><span> </span><span class="NLM_article-title">S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10604930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslGntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2000&pages=38-53&author=M.+J.+Millanauthor=A.+Gobertauthor=A.+Newman-Tancrediauthor=F.+Lejeuneauthor=D.+Cussacauthor=J.+M.+Rivetauthor=V.+Audinotauthor=A.+Adhumeauauthor=M.+Broccoauthor=J.+P.+Nicolasauthor=J.+A.+Boutinauthor=N.+Despauxauthor=J.+L.+Peglion&title=S18327+%281-%5B2-%5B4-%286-fluoro-1%2C+2-benzisoxazol-3-yl%29piperid-1-yl%5Dethyl%5D3-phenyl+imidazolin-2-one%29%2C+a+novel%2C+potential+antipsychotic+displaying+marked+antagonist+properties+at+alpha%281%29-+and+alpha%282%29-adrenergic+receptors%3A+I.+Receptorial%2C+neurochemical%2C+and+electrophysiological+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at α1- and α2-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile</span></div><div class="casAuthors">Millan, Mark J.; Gobert, Alain; Newman-Tancredi, Adrian; Lejeune, Francoise; Cussac, Didier; Rivet, Jean-Michel; Audinot, Valerie; Adhumeau, Agnes; Brocco, Mauricette; Nicolas, Jean-Paul; Boutin, Jean A.; Despaux, Nicole; Peglion, Jean-Louis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-53</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">S18327 displayed modest affinity for human (h)D2 and hD3 receptors and high affinity for hD4 receptors.  At each, S18327 antagonized stimulation of [35S]guanosine-5'-O-(3-thio)triphosphate binding by dopamine (DA).  It also blocked activation of mitogen-activated protein kinase at hD3 receptors.  The affinity of S18327 at hD1 and hD5 sites was modest.  S18327 showed pronounced affinity for human serotonin (h5-HT)2A receptors and human α1A-adrenergic receptors (hARs), at which it antagonized increases in intracellular Ca2+ concn. levels elicited by 5-HT and norepinephrine (NE), resp.  S18327 presented significant affinity for hα2A-ARs and antagonized NE-induced[35S]guanosine-5'-O-(3-thio)triphosphate binding both at these sites and at α2-ARs in rat amygdala.  Reflecting blockade of α2-autoreceptors, S18327 enhanced firing of adrenergic neurons in locus ceruleus, accelerated hippocampal synthesis of NE, and increased dialyzate levels of NE in hippocampus, accumbens, and frontal cortex.  S18327 abolished inhibition of ventrotegmental area-localized dopaminergic neurons by apomorphine.  However, S18327 alone did not affect their activity and only modestly enhanced cerebral turnover of DA and dialyzate levels of DA in striatum and accumbens.  In contrast, S18327 markedly increased dialyzate levels of DA in frontal cortex, an action abolished by the selective α2-AR agonist, S18616.  Finally, S18327 reduced synthesis and dialyzate levels of 5-HT in striatum and suppressed firing of dorsal raphe-localized serotonergic neurons, an action attenuated by the α1-AR agonist cirazoline.  In conclusion, S18327 possesses marked antagonist activity at α1-ARs and D4 and 5-HT2A receptors and less potent antagonist activity at α2-ARs and D1 and D2 receptors.  Antagonism by S18327 of α2-ARs enhances adrenergic transmission and reinforces frontocortical dopaminergic transmission, whereas blockade of α1-ARs inhibits dorsal raphe-derived serotonergic pathways.  As further described in the accompanying paper, this profile of activity may contribute to the potential antipsychotic properties of S18327.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf_-9Df2xyXLVg90H21EOLACvtfcHk0lgAxch2Ol6xxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslGntg%253D%253D&md5=f80b12e01145760f2725e868fe8e634a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DLejeune%26aufirst%3DF.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DRivet%26aufirst%3DJ.%2BM.%26aulast%3DAudinot%26aufirst%3DV.%26aulast%3DAdhumeau%26aufirst%3DA.%26aulast%3DBrocco%26aufirst%3DM.%26aulast%3DNicolas%26aufirst%3DJ.%2BP.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26aulast%3DDespaux%26aufirst%3DN.%26aulast%3DPeglion%26aufirst%3DJ.%2BL.%26atitle%3DS18327%2520%25281-%255B2-%255B4-%25286-fluoro-1%252C%25202-benzisoxazol-3-yl%2529piperid-1-yl%255Dethyl%255D3-phenyl%2520imidazolin-2-one%2529%252C%2520a%2520novel%252C%2520potential%2520antipsychotic%2520displaying%2520marked%2520antagonist%2520properties%2520at%2520alpha%25281%2529-%2520and%2520alpha%25282%2529-adrenergic%2520receptors%253A%2520I.%2520Receptorial%252C%2520neurochemical%252C%2520and%2520electrophysiological%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D292%26spage%3D38%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Lange, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinders, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolboom, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coolen, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">5103</span><span class="NLM_x">–</span> <span class="NLM_lpage">5108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070516u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5103-5108&author=J.+H.+Langeauthor=J.+H.+Reindersauthor=J.+T.+Tolboomauthor=J.+C.+Glennonauthor=H.+K.+Coolenauthor=C.+G.+Kruse&title=Principal+component+analysis+differentiates+the+receptor+binding+profiles+of+three+antipsychotic+drug+candidates+from+current+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm070516u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070516u%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%26aulast%3DReinders%26aufirst%3DJ.%2BH.%26aulast%3DTolboom%26aufirst%3DJ.%2BT.%26aulast%3DGlennon%26aufirst%3DJ.%2BC.%26aulast%3DCoolen%26aufirst%3DH.%2BK.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DPrincipal%2520component%2520analysis%2520differentiates%2520the%2520receptor%2520binding%2520profiles%2520of%2520three%2520antipsychotic%2520drug%2520candidates%2520from%2520current%2520antipsychotic%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5103%26epage%3D5108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsubara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">The ratios of serotonin<sub>2</sub> and dopamine<sub>2</sub> affinities differentiate atypical and typical antipsychotic drugs</span> <span class="citation_source-journal">Psychopharmacol. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=2576319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFWmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1989&pages=390-392&author=H.+Y.+Meltzerauthor=S.+Matsubaraauthor=J.+C.+Lee&title=The+ratios+of+serotonin2+and+dopamine2+affinities+differentiate+atypical+and+typical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, Herbert Y.; Matsubara, Shigehiro; Lee, Jar Chi</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology Bulletin</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">390-2</span>CODEN:
                <span class="NLM_cas:coden">PSYBB9</span>;
        ISSN:<span class="NLM_cas:issn">0048-5764</span>.
    </div><div class="casAbstract">Atypical antipsychotic drugs such as clozapine, fluperlapine, and melperone produce weak catalepsy in rodents, and minimal extrapyramidal symptoms and serum prolactin elevations in humans, compared to typical antipsychotic drugs such as haloperidol.  The biol. basis for these differences has been attributed to relatively weak blockade at D2 dopamine (DA) receptors, various effects at D1 receptors, or potent serotonin2 (5-HT2) antagonism, although other possibilities exist.  To clarify the relative importance of actions of D1, D2, and 5-HT2 receptors for identification of candidate typical and atypical drugs, the authors detd. the neg. log of the Ki (pKi) value of 21 typical and 17 atypical antipsychotic drugs for the striatal D1 and D2 and frontal cortex 5-HT2 receptors of rodent brain.  Cluster anal. identified that the 5-HT2/D2 ratio was the most successful means of utilizing this data to classify typical and atypical antipsychotic drugs correctly.  A 92% accuracy was achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0Xqr2TSGcLVg90H21EOLACvtfcHk0lgAxch2Ol6xxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFWmu7Y%253D&md5=3f5c199f61ada18f6210532b086b0e13</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMatsubara%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520ratios%2520of%2520serotonin2%2520and%2520dopamine2%2520affinities%2520differentiate%2520atypical%2520and%2520typical%2520antipsychotic%2520drugs%26jtitle%3DPsychopharmacol.%2520Bull.%26date%3D1989%26volume%3D25%26spage%3D390%26epage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Hippius, H.</span><span> </span><span class="NLM_article-title">The history of clozapine</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">S5</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1989&pages=S3-S5&issue=Suppl.&author=H.+Hippius&title=The+history+of+clozapine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHippius%26aufirst%3DH.%26atitle%3DThe%2520history%2520of%2520clozapine%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D1989%26volume%3D99%26issue%3DSuppl%26spage%3DS3%26epage%3DS5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Wahlbeck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essali, M. A.</span><span> </span><span class="NLM_article-title">Clozapine versus typical neuroleptic medication for schizophrenia</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD000059</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=CD000059&author=K.+Wahlbeckauthor=M.+Cheineauthor=M.+A.+Essali&title=Clozapine+versus+typical+neuroleptic+medication+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWahlbeck%26aufirst%3DK.%26aulast%3DCheine%26aufirst%3DM.%26aulast%3DEssali%26aufirst%3DM.%2BA.%26atitle%3DClozapine%2520versus%2520typical%2520neuroleptic%2520medication%2520for%2520schizophrenia%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2000%26spage%3DCD000059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Bagnall, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginnelly, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glanville, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbody, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgerson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleijnen, J.</span><span> </span><span class="NLM_article-title">A systematic review of atypical antipsychotic drugs in schizophrenia</span> <span class="citation_source-journal">Health Technol. Assess.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12925268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3szovVCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=1-193&author=A.+M.+Bagnallauthor=L.+Jonesauthor=L.+Ginnellyauthor=R.+Lewisauthor=J.+Glanvilleauthor=S.+Gilbodyauthor=L.+Daviesauthor=D.+Torgersonauthor=J.+Kleijnen&title=A+systematic+review+of+atypical+antipsychotic+drugs+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic review of atypical antipsychotic drugs in schizophrenia</span></div><div class="casAuthors">Bagnall A-M; Jones L; Ginnelly L; Lewis R; Glanville J; Gilbody S; Davies L; Torgerson D; Kleijnen J</div><div class="citationInfo"><span class="NLM_cas:title">Health technology assessment (Winchester, England)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1-193</span>
        ISSN:<span class="NLM_cas:issn">1366-5278</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCnB-pOEKCvJQHPYJuLg8TfW6udTcc2eZ2RfJ1zuhn_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3szovVCmug%253D%253D&md5=e511ad4857d7459fafd895cf636ffddd</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBagnall%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DGinnelly%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DGlanville%26aufirst%3DJ.%26aulast%3DGilbody%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DTorgerson%26aufirst%3DD.%26aulast%3DKleijnen%26aufirst%3DJ.%26atitle%3DA%2520systematic%2520review%2520of%2520atypical%2520antipsychotic%2520drugs%2520in%2520schizophrenia%26jtitle%3DHealth%2520Technol.%2520Assess.%26date%3D2003%26volume%3D7%26spage%3D1%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Kane, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigfeld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H.</span><span> </span><span class="NLM_article-title">Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.1988.01800330013001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=3046553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaL1czisFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1988&pages=789-796&author=J.+Kaneauthor=G.+Honigfeldauthor=J.+Singerauthor=H.+Meltzer&title=Clozapine+for+the+treatment-resistant+schizophrenic.+A+double-blind+comparison+with+chlorpromazine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine</span></div><div class="casAuthors">Kane J; Honigfeld G; Singer J; Meltzer H</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">789-96</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">The treatment of schizophrenic patients who fail to respond to adequate trials of neuroleptics is a major challenge.  Clozapine, an atypical antipsychotic drug, has long been of scientific interest, but its clinical development has been delayed because of an associated risk of agranulocytosis.  This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refractory to neuroleptics.  DSM-III schizophrenics who had failed to respond to at least three different neuroleptics underwent a prospective, single-blind trial of haloperidol (mean dosage, 61 +/- 14 mg/d) for six weeks.  Patients whose condition remained unimproved were then randomly assigned, in a double-blind manner, to clozapine (up to 900 mg/d) or chlorpromazine (up to 1800 mg/d) for six weeks.  Two hundred sixty-eight patients were entered in the double-blind comparison.  When a priori criteria were used, 30% of the clozapine-treated patients were categorized as responders compared with 4% of chlorpromazine-treated patients.  Clozapine produced significantly greater improvement on the Brief Psychiatric Rating Scale, Clinical Global Impression Scale, and Nurses' Observation Scale for Inpatient Evaluation; this improvement included "negative" as well as positive symptom areas.  Although no cases of agranulocytosis occurred during this relatively brief study, in our view, the apparently increased comparative risk requires that the use of clozapine be limited to selected treatment-resistant patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl1_q6E__kp8KL0FlyGHDofW6udTcc2ebtUpBmW5wPR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1czisFyisQ%253D%253D&md5=f3cba6c60391f3f227e206ab985e4b8c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.1988.01800330013001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.1988.01800330013001%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DJ.%26aulast%3DHonigfeld%26aufirst%3DG.%26aulast%3DSinger%26aufirst%3DJ.%26aulast%3DMeltzer%26aufirst%3DH.%26atitle%3DClozapine%2520for%2520the%2520treatment-resistant%2520schizophrenic.%2520A%2520double-blind%2520comparison%2520with%2520chlorpromazine%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1988%26volume%3D45%26spage%3D789%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Barnes, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvedy, C. J.</span><span> </span><span class="NLM_article-title">Pharmacological treatment strategies in the non-responsive schizophrenic patient</span> <span class="citation_source-journal">Int. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F00004850-199605002-00011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8803663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK28zps1GnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1996&pages=67-71&issue=Suppl.+2&author=T.+R.+Barnesauthor=C.+J.+McEvedy&title=Pharmacological+treatment+strategies+in+the+non-responsive+schizophrenic+patient"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment strategies in the non-responsive schizophrenic patient</span></div><div class="casAuthors">Barnes T R; McEvedy C J</div><div class="citationInfo"><span class="NLM_cas:title">International clinical psychopharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">11 Suppl 2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-71</span>
        ISSN:<span class="NLM_cas:issn">0268-1315</span>.
    </div><div class="casAbstract">The care of people with schizophrenia that has failed to respond to conventional antipsychotic medication remains a formidable challenge.  However, the introduction of clozapine heralded a new optimism in this area, and prompted an increase in research interest in the pharmacotherapeutic options for such patients.  This brief review covers some of the more recent studies with clozapine that are relevant to the use of the drug in clinical practice, and also summarises the potential indications, benefits and limitations of various adjuncts to antipsychotic drug treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8rigev3TehtbHMBt0mMIXfW6udTcc2ebtUpBmW5wPR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zps1GnsQ%253D%253D&md5=3f206d5a797032a4e81080e9104f4ca0</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1097%2F00004850-199605002-00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004850-199605002-00011%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DT.%2BR.%26aulast%3DMcEvedy%26aufirst%3DC.%2BJ.%26atitle%3DPharmacological%2520treatment%2520strategies%2520in%2520the%2520non-responsive%2520schizophrenic%2520patient%26jtitle%3DInt.%2520Clin.%2520Psychopharmacol.%26date%3D1996%26volume%3D11%26issue%3DSuppl.%25202%26spage%3D67%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeman, P.</span><span> </span><span class="NLM_article-title">Does fast dissociation from the dopamine D<sub>2</sub> receptor explain the action of atypical antipsychotics? A new hypothesis</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.158.3.360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11229973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3M7pslSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=360-369&author=S.+Kapurauthor=P.+Seeman&title=Does+fast+dissociation+from+the+dopamine+D2+receptor+explain+the+action+of+atypical+antipsychotics%3F+A+new+hypothesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis</span></div><div class="casAuthors">Kapur S; Seeman P</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">360-9</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Although atypical antipsychotics are becoming the treatment of choice for schizophrenia, what makes an antipsychotic "atypical" is not clear.  This article provides a new hypothesis about the mechanism of action of atypical antipsychotics.  METHOD:  Published data regarding the molecular, animal model, neuroimaging, and clinical aspects of typical and atypical antipsychotics were reviewed to develop this hypothesis.  Particular attention was paid to data regarding the role of the serotonin 5-HT(2) and dopamine D(4) receptors in atypicality.  RESULTS:  Neuroimaging data show that optimal dopamine D(2) occupancy is sufficient to produce the atypical antipsychotic effect.  Freedom from motor side effects results from low D(2) occupancy, not from high 5-HT(2) occupancy.  If D(2) occupancy is excessive, atypicality is lost even in the presence of high 5-HT(2) occupancy.  Animal data show that a rapid dissociation from the D(2) receptor at a molecular level produces the atypical antipsychotic effect.  In vitro data show that the single most powerful predictor of atypicality for the current generation of atypical antipsychotics is fast dissociation from the D(2) receptor, not its high affinity at 5-HT(2), D(4), or another receptor.  CONCLUSIONS:  The authors propose that fast dissociation from the D(2) receptor makes an antipsychotic more accommodating of physiological dopamine transmission, permitting an antipsychotic effect without motor side effects, prolactin elevation, or secondary negative symptoms.  In contrast to the multireceptor hypotheses, the authors predict that the atypical antipsychotic effect can be produced by appropriate modulation of the D(2) receptor alone; the blockade of other receptors is neither necessary nor sufficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1OTyBcviHdd0Q2ypr7jHkfW6udTcc2ebtUpBmW5wPR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7pslSltg%253D%253D&md5=dae2a684b208e0fc09688835b0975c00</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.3.360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.3.360%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DDoes%2520fast%2520dissociation%2520from%2520the%2520dopamine%2520D2%2520receptor%2520explain%2520the%2520action%2520of%2520atypical%2520antipsychotics%253F%2520A%2520new%2520hypothesis%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D360%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Ichikawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Laughlin, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=325-339&author=J.+Ichikawaauthor=J.+Daiauthor=I.+A.+O%E2%80%99Laughlinauthor=W.+L.+Fowlerauthor=H.+Y.+Meltzer&title=Atypical%2C+but+not+typical%2C+antipsychotic+drugs+increase+cortical+acetylcholine+release+without+an+effect+in+the+nucleus+accumbens+or+striatum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIchikawa%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Laughlin%26aufirst%3DI.%2BA.%26aulast%3DFowler%26aufirst%3DW.%2BL.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DAtypical%252C%2520but%2520not%2520typical%252C%2520antipsychotic%2520drugs%2520increase%2520cortical%2520acetylcholine%2520release%2520without%2520an%2520effect%2520in%2520the%2520nucleus%2520accumbens%2520or%2520striatum%26jtitle%3DNeuropsychopharmacology%26date%3D2002%26volume%3D26%26spage%3D325%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Kuroki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, J.</span><span> </span><span class="NLM_article-title">Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">774</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9918588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1MXpvFOmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=1999&pages=774-781&author=T.+Kurokiauthor=H.+Y.+Meltzerauthor=J.+Ichikawa&title=Effects+of+antipsychotic+drugs+on+extracellular+dopamine+levels+in+rat+medial+prefrontal+cortex+and+nucleus+accumbens"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens</span></div><div class="casAuthors">Kuroki, Toshihide; Meltzer, Herbert Y.; Ichikawa, Junji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">774-781</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present study was designed to compare the effects of typical and atypical antipsychotic drugs on extracellular dopamine (DA) levels in the medial prefrontal cortex (mPFC) and the nucleus accumbens (NAC), using in vivo microdialysis with dual probe implantation in awake, freely moving rats.  Amperozide (2 and 10 mg/kg), clozapine (5 and 20 mg/kg), and olanzapine (10 mg/kg), all of which are atypical antipsychotics, produced greater increases in extracellular DA levels in the mPFC than in the NAC.  Olanzapine (1 mg/kg), risperidone (0.1 and 1 mg/kg), also an atypical antipsychotic, and S-(-)-sulpiride (25 mg/kg), a typical antipsychotic, produced comparable increases in extra-cellular DA levels in the mPFC and the NAC.  S-(-)-sulpiride (10 mg/kg) and haloperidol (0.1 and 1 mg/kg), another typical antipsychotic, significantly increased extracellular DA levels in the NAC but not in the mPFC.  The effects of the six antipsychotic drugs to increase extracellular DA levels in the mPFC relative to those in the NAC was pos. correlated with the difference between their pKi values for serotonin (5-hydroxytryptamine, 5-HT2A) and DA-D2 receptors and was inversely correlated to their pKi values for D2 or D3 receptors, but was not for 5-HT2A receptors alone.  These results are consistent with the hypothesis that the ability of antipsychotic drugs to produce a greater increase in prefrontal compared with NAC extracellular DA levels may be related, in part, to weak D2 and D3 receptor affinity relative to 5-HT2A receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAWlyAnjsaprVg90H21EOLACvtfcHk0liruzAESnlf-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXpvFOmuw%253D%253D&md5=aca5e902a20d6edeefaacf3419c3d07d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuroki%26aufirst%3DT.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DIchikawa%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520antipsychotic%2520drugs%2520on%2520extracellular%2520dopamine%2520levels%2520in%2520rat%2520medial%2520prefrontal%2520cortex%2520and%2520nucleus%2520accumbens%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D288%26spage%3D774%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Moghaddam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunney, B. S.</span><span> </span><span class="NLM_article-title">Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1755</span><span class="NLM_x">–</span> <span class="NLM_lpage">1760</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1111%2Fj.1471-4159.1990.tb01230.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1969939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK3cXktVSntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1990&pages=1755-1760&author=B.+Moghaddamauthor=B.+S.+Bunney&title=Acute+effects+of+typical+and+atypical+antipsychotic+drugs+on+the+release+of+dopamine+from+prefrontal+cortex%2C+nucleus+accumbens%2C+and+striatum+of+the+rat%3A+an+in+vivo+microdialysis+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat:  an in vivo microdialysis study</span></div><div class="casAuthors">Moghaddam, Bita; Bunney, Benjamin S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1755-60</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">In vivo microdialysis has been used to study the acute effects of antipsychotic drugs on the extracellular level of dopamine from the nucleus accumbens, striatum, and prefrontal cortex of the rat.  (-)-Sulpiride (20, 50, and 100 mg/kg i.v.) and haloperidol (0.1 and 0.5 mg/kg i.v.) enhanced the outflow of dopamine in the striatum and nucleus accumbens.  In the medial prefrontal cortex, (-)-sulpiride at all doses tested did not affect the extracellular level of dopamine.  The effect of haloperidol was also attenuated in the medial prefrontal cortex; 0.1 mg/kg did not increase the outflow of dopamine and the effect of 0.5 mg/kg haloperidol was of shorter duration in the prefrontal cortex than that obsd. in striatum and nucleus accumbens.  The atypical antipsychotic drug clozapine (5 and 10 mg/kg) increased the extracellular concn. of dopamine in all three regions.  In contrast to the effects of sulpiride and haloperidol, that of clozapine in the medial prefrontal cortex was profound.  These data suggest that different classes of antipsychotic drugs may have distinct effects on the release of dopamine from the nigrostriatal, mesolimbic, and mesocortical terminals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXh61lbtJPCrVg90H21EOLACvtfcHk0liruzAESnlf-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktVSntr0%253D&md5=d8485270d0b53822ab5aaa5fb960ee3b</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1990.tb01230.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1990.tb01230.x%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DB.%26aulast%3DBunney%26aufirst%3DB.%2BS.%26atitle%3DAcute%2520effects%2520of%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%2520on%2520the%2520release%2520of%2520dopamine%2520from%2520prefrontal%2520cortex%252C%2520nucleus%2520accumbens%252C%2520and%2520striatum%2520of%2520the%2520rat%253A%2520an%2520in%2520vivo%2520microdialysis%2520study%26jtitle%3DJ.%2520Neurochem.%26date%3D1990%26volume%3D54%26spage%3D1755%26epage%3D1760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeman, P.</span><span> </span><span class="NLM_article-title">Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action</span> <span class="citation_source-journal">J. Psychiatry Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10740989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3c3gsFWlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2000&pages=161-166&author=S.+Kapurauthor=P.+Seeman&title=Antipsychotic+agents+differ+in+how+fast+they+come+off+the+dopamine+D2+receptors.+Implications+for+atypical+antipsychotic+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action</span></div><div class="casAuthors">Kapur S; Seeman P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-6</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">RATIONALE AND OBJECTIVE:  While the blockade of dopamine D2 receptors are necessary for antipsychotic action, antipsychotic agents differ nearly a thousand-fold in their affinity for the D2 receptor.  This affinity is determined by the rate at which the antipsychotic agent binds to (kon) and the rate at which it dissociates from (koff) the D2 receptors.  The objective of this study was to determine the relationship between kon, koff and the affinity (Ki) of antipsychotic agents for the D2 receptors, with particular reference to typical and atypical antipsychotic agents.  DESIGN:  The koff of several typical as well as atypical antipsychotic agents (nemonapride, spiperone, haloperidol, chlorpromazine, raclopride, olanzapine, sertindole, clozapine and quetiapine) was measured in vitro using the 3H-radiolabelled analogues of these drugs.  The affinity of these drugs for the D2 receptor was determined by competition with 3H-raclopride in vitro.  The kon was derived from values of affinity and ++koff.  MAIN OUTCOME MEASURES:  kon, koff, and the Ki of antipsychotic drugs.  RESULTS:  The range of affinity values was similar to that conventionally accepted (0.025-155 nmol/L).  The koff values varied a thousand-fold from 0.002 to 3.013 min-1, with relatively little variation in kon.  The rate at which antipsychotic agents come off the receptor (koff) accounted for 99% of the variation in their affinity for the D2 receptor; differences in kon did not account for differences in affinity.  CONCLUSIONS:  The differences in the affinity of antipsychotic agents are entirely determined by how fast they come off the D2 receptor.  These differences in koff may lead to functionally different kinds of dopamine blockade.  Drugs with a higher koff will be faster in blocking receptors, and once blocked, will provide more access to surges in dopamine transmission.  Since atypical drugs show a lower affinity and a faster dissociation, a higher koff for the D2 receptor is proposed as a mechanism for "atypical" antipsychotic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiFVfZJOQ7_1UIs6wFK5xJfW6udTcc2ebEFTVgRo2uIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3gsFWlsA%253D%253D&md5=bde1272de3b90ba1fd77b61805c3a39d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DAntipsychotic%2520agents%2520differ%2520in%2520how%2520fast%2520they%2520come%2520off%2520the%2520dopamine%2520D2%2520receptors.%2520Implications%2520for%2520atypical%2520antipsychotic%2520action%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2000%26volume%3D25%26spage%3D161%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Kessler, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansari, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2283</span><span class="NLM_x">–</span> <span class="NLM_lpage">2289</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=2283-2289&author=R.+M.+Kesslerauthor=M.+S.+Ansariauthor=P.+Riccardiauthor=R.+Liauthor=K.+Jayathilakeauthor=B.+Dawantauthor=H.+Y.+Meltzer&title=Occupancy+of+striatal+and+extrastriatal+dopamine+D2%2FD3+receptors+by+olanzapine+and+haloperidol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DR.%2BM.%26aulast%3DAnsari%26aufirst%3DM.%2BS.%26aulast%3DRiccardi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DDawant%26aufirst%3DB.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DOccupancy%2520of%2520striatal%2520and%2520extrastriatal%2520dopamine%2520D2%252FD3%2520receptors%2520by%2520olanzapine%2520and%2520haloperidol%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D2283%26epage%3D2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Agid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginovart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitcu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zipursky, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, S.</span><span> </span><span class="NLM_article-title">Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response—a double-blind PET study in schizophrenia</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1209</span><span class="NLM_x">–</span> <span class="NLM_lpage">1215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1209-1215&author=O.+Agidauthor=D.+Mamoauthor=N.+Ginovartauthor=I.+Vitcuauthor=A.+A.+Wilsonauthor=R.+B.+Zipurskyauthor=S.+Kapur&title=Striatal+vs+extrastriatal+dopamine+D2+receptors+in+antipsychotic+response%E2%80%94a+double-blind+PET+study+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAgid%26aufirst%3DO.%26aulast%3DMamo%26aufirst%3DD.%26aulast%3DGinovart%26aufirst%3DN.%26aulast%3DVitcu%26aufirst%3DI.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DZipursky%26aufirst%3DR.%2BB.%26aulast%3DKapur%26aufirst%3DS.%26atitle%3DStriatal%2520vs%2520extrastriatal%2520dopamine%2520D2%2520receptors%2520in%2520antipsychotic%2520response%25E2%2580%2594a%2520double-blind%2520PET%2520study%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D1209%26epage%3D1215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Kessler, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansari, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1991</span><span class="NLM_x">–</span> <span class="NLM_lpage">2001</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=1991-2001&author=R.+M.+Kesslerauthor=M.+S.+Ansariauthor=P.+Riccardiauthor=R.+Liauthor=K.+Jayathilakeauthor=B.+Dawantauthor=H.+Y.+Meltzer&title=Occupancy+of+striatal+and+extrastriatal+dopamine+D2+receptors+by+clozapine+and+quetiapine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DR.%2BM.%26aulast%3DAnsari%26aufirst%3DM.%2BS.%26aulast%3DRiccardi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DDawant%26aufirst%3DB.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DOccupancy%2520of%2520striatal%2520and%2520extrastriatal%2520dopamine%2520D2%2520receptors%2520by%2520clozapine%2520and%2520quetiapine%26jtitle%3DNeuropsychopharmacology%26date%3D2006%26volume%3D31%26spage%3D1991%26epage%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Poyurovsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epshtein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneidman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizman, A.</span><span> </span><span class="NLM_article-title">Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F00004714-200306000-00011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12826992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltFKjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=305-308&author=M.+Poyurovskyauthor=S.+Epshteinauthor=C.+Fuchsauthor=M.+Schneidmanauthor=R.+Weizmanauthor=A.+Weizman&title=Efficacy+of+low-dose+mirtazapine+in+neuroleptic-induced+akathisia%3A+a+double-blind+randomized+placebo-controlled+pilot+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Low-Dose Mirtazapine in Neuroleptic-Induced Akathisia: A Double-Blind Randomized Placebo-Controlled Pilot Study</span></div><div class="casAuthors">Poyurovsky, Michael; Epshtein, Svetlana; Fuchs, Camil; Schneidman, Michael; Weizman, Ronit; Weizman, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-308</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The nonselective serotonin (5-HT)-2A antagonists ritanserin, mianserin, and cyproheptadine were found efficacious in neuroleptic-induced akathisia (NIA).  Mirtazapine is structurally and pharmacol. similar to mianserin, and the authors sought to det. its anti-NIA activity.  Twenty-six neuroleptic-treated schizophrenic patients with DSM-IV diagnosis of NIA received add-on mirtazapine (15 mg/day) or placebo for 5 days in a double-blind design.  Patients were assessed at baseline and days 3 and 5 with the Barnes Akathisia Scale (BAS), Pos. and Neg. Symptom Scale, Hamilton Rating Scale for Depression, and Simpson-Angus Scale for parkinsonism.  Anal. of covariance with repeated measurements revealed significant group × time effects in favor of the mirtazapine group in both completers (n = 10 in each group) and intent-to-treat anal. (n = 13 in each group) for the BAS global subscale (F [1, 17] = 14.87, p = 0.001, and F [1, 23] = 13.24, p = 0.01, resp.) and objective subscale (F [1, 17] = 8.25, p = 0.011, and F [1, 23] = 7.35, p = 0.012, resp.) and borderline significant superiority for the BAS subjective subscale (F [1, 17] = 4.39, p = 0.051, and F [1, 23] = 4.12, p = 0.054, resp.) and distress subscale (F [1, 17] = 4.21, p = 0.056, and F [1, 23] = 3.80, p = 0.064, resp.).  Significantly more mirtazapine-than placebo-treated patients (53.8% [7/13] vs. 7.7% [1/13], resp.; χ2=8.3, p = 0.004) met operational response criterion, a redn. of at least two points on the BAS global subscale.  Mirtazapine treatment was assocd. with modest improvement of psychotic and parkinsonian symptoms.  Mild sedation was the only side effect.  Our study demonstrated that mirtazapine (15 mg/day) is an efficacious and well-tolerated therapeutic option in NIA.  Marked 5HT2A/2C antagonistic activity of mirtazapine apparently accounts for its anti-NIA activity.  The role of mirtazapine in the treatment of akathisia induced by atypical antipsychotic agents merits further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpepcVf6AevgbVg90H21EOLACvtfcHk0liuMR5BP0AbKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltFKjtLk%253D&md5=ad345d3ee27e50384b179f1821fbf0a0</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1097%2F00004714-200306000-00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004714-200306000-00011%26sid%3Dliteratum%253Aachs%26aulast%3DPoyurovsky%26aufirst%3DM.%26aulast%3DEpshtein%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DC.%26aulast%3DSchneidman%26aufirst%3DM.%26aulast%3DWeizman%26aufirst%3DR.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DEfficacy%2520of%2520low-dose%2520mirtazapine%2520in%2520neuroleptic-induced%2520akathisia%253A%2520a%2520double-blind%2520randomized%2520placebo-controlled%2520pilot%2520study%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2003%26volume%3D23%26spage%3D305%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Sur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallorga, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascarella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandish, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolnick, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title"><i>N</i>-Desmethylclozapine, an allosteric agonist at muscarinic<sub>1</sub> receptor, potentiates <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">13674</span><span class="NLM_x">–</span> <span class="NLM_lpage">13679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=13674-13679&author=C.+Surauthor=P.+J.+Mallorgaauthor=M.+Wittmannauthor=M.+A.+Jacobsonauthor=D.+Pascarellaauthor=J.+B.+Williamsauthor=P.+E.+Brandishauthor=D.+J.+Pettiboneauthor=E.+M.+Scolnickauthor=P.+J.+Conn&title=N-Desmethylclozapine%2C+an+allosteric+agonist+at+muscarinic1+receptor%2C+potentiates+N-methyl-d-aspartate+receptor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMallorga%26aufirst%3DP.%2BJ.%26aulast%3DWittmann%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DPascarella%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BB.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DScolnick%26aufirst%3DE.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DN-Desmethylclozapine%252C%2520an%2520allosteric%2520agonist%2520at%2520muscarinic1%2520receptor%252C%2520potentiates%2520N-methyl-d-aspartate%2520receptor%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D13674%26epage%3D13679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Lameh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonhaus, D. W.</span><span> </span><span class="NLM_article-title">Pharmacology of <i>N</i>-desmethylclozapine</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pharmthera.2007.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17583355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXns1yrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2007&pages=223-231&author=J.+Lamehauthor=E.+S.+Bursteinauthor=E.+Taylorauthor=D.+M.+Weinerauthor=K.+E.+Vanoverauthor=D.+W.+Bonhaus&title=Pharmacology+of+N-desmethylclozapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of N-desmethylclozapine</span></div><div class="casAuthors">Lameh, Jelveh; Burstein, Ethan S.; Taylor, Eve; Weiner, David M.; Vanover, Kimberly E.; Bonhaus, Douglas W.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-231</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Currently available treatments for schizophrenia have limited efficacy and are generally poorly tolerated.  However, among these antipsychotic agents, clozapine stands apart in having generally superior motoric tolerability and efficacy.  One intriguing possibility, based on clin. correlations, receptor activity profiles and studies with animal models predictive of antipsychotic or cognitive action is that the activity of N-desmethylclozapine (NDMC), a major metabolite of clozapine, may, at least in part, underlie the unique efficacy of clozapine.  In this review we compare the pharmacol. properties of NDMC to those of clozapine and consider how they may contribute to the overall clin. properties of clozapine.  We also consider whether NDMC, in its own right, might be a superior antipsychotic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBphY-h1xi2LVg90H21EOLACvtfcHk0liuMR5BP0AbKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXns1yrsro%253D&md5=6606ac8c9da24c82e08700976934d79b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2007.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2007.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DLameh%26aufirst%3DJ.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DBonhaus%26aufirst%3DD.%2BW.%26atitle%3DPharmacology%2520of%2520N-desmethylclozapine%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D115%26spage%3D223%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Natesan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckless, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nobrega, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, S.</span><span> </span><span class="NLM_article-title">Evaluation of <i>N</i>-desmethylclozapine as a potential antipsychotic═preclinical studies</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1540</span><span class="NLM_x">–</span> <span class="NLM_lpage">1549</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1540-1549&author=S.+Natesanauthor=G.+E.+Recklessauthor=K.+B.+Barlowauthor=J.+N.+Nobregaauthor=S.+Kapur&title=Evaluation+of+N-desmethylclozapine+as+a+potential+antipsychotic%E2%95%90preclinical+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNatesan%26aufirst%3DS.%26aulast%3DReckless%26aufirst%3DG.%2BE.%26aulast%3DBarlow%26aufirst%3DK.%2BB.%26aulast%3DNobrega%26aufirst%3DJ.%2BN.%26aulast%3DKapur%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520N-desmethylclozapine%2520as%2520a%2520potential%2520antipsychotic%25E2%2595%2590preclinical%2520studies%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D1540%26epage%3D1549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Coyle, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D.</span><span> </span><span class="NLM_article-title">Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1003</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1196%2Fannals.1300.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14684455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlGqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1003&publication_year=2003&pages=318-327&author=J.+T.+Coyleauthor=G.+Tsaiauthor=D.+Goff&title=Converging+evidence+of+NMDA+receptor+hypofunction+in+the+pathophysiology+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia</span></div><div class="casAuthors">Coyle, Joseph T.; Tsai, Guochuan; Goff, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1003</span>
        (<span class="NLM_cas:issue">Glutamate and Disorders of Cognition and Motivation</span>),
    <span class="NLM_cas:pages">318-327</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Numerous clin. studies demonstrate that subanesthetic doses of dissociative anesthetics, which are noncompetitive antagonists at the NMDA receptor, replicate in normal subjects the cognitive impairments, neg. symptoms, and brain functional abnormalities of schizophrenia.  Postmortem and genetic studies have identified several abnormalities assocd. with schizophrenia that would interfere with the activation of the glycine modulatory site on the NMDA receptor.  Placebo-controlled clin. trials with agents that directly or indirectly activate the glycine modulatory site consistently reduce neg. symptoms and frequently improve cognition in patients with chronic schizophrenia who are receiving concurrent typical antipsychotics.  Thus, there is convincing evidence that hypofunction of a subset of NMDA receptors may contribute to the symptomatic features of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQixZ_xxPHLVg90H21EOLACvtfcHk0liaamABSP82gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlGqtQ%253D%253D&md5=0688464460facbf01a7b2ecd701bc87d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1196%2Fannals.1300.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1196%252Fannals.1300.020%26sid%3Dliteratum%253Aachs%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26aulast%3DTsai%26aufirst%3DG.%26aulast%3DGoff%26aufirst%3DD.%26atitle%3DConverging%2520evidence%2520of%2520NMDA%2520receptor%2520hypofunction%2520in%2520the%2520pathophysiology%2520of%2520schizophrenia%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2003%26volume%3D1003%26spage%3D318%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Collier, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span> </span><span class="NLM_article-title">The genetics of schizophrenia: glutamate not dopamine</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">480</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ejphar.2003.08.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14623361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGmsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2003&pages=177-184&author=D.+A.+Collierauthor=T.+Li&title=The+genetics+of+schizophrenia%3A+glutamate+not+dopamine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The genetics of schizophrenia: glutamate not dopamine?</span></div><div class="casAuthors">Collier, David A.; Li, Tao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">177-184</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The major targets of current drugs used in mental health, such as neurotransmitter receptors and transporters, are based on serendipitous findings from several decades ago, and there is currently a severe drought of new drug targets.  There is a pressing need for novel drugs, and much hope has been placed on the use of mol. genetics to help define them.  However, despite evidence for a genetic basis to schizophrenia stretching back for over a century, and a heritability of about 80%, the identification of susceptibility genes has been an uphill struggle.  Candidate gene studies, which have generally focussed on obvious candidates from the dopamine and serotonin systems, as well as genes involved in brain development, have not generally been successful, although meta-anal. indicates that the dopamine D3 receptor gene (DRD3) and the serotonin receptor gene type 2A (HTR2A) may have a very small influence on risk.  Linkage anal. has provided robust evidence of genetic loci, for example, on chromosomes 8p, 13q and 22q, and also implies shared genetic etiol. with bipolar disorder.  The identification of these loci together with advances in genetic technol., esp. the characterization of polymorphisms, the understanding of haplotypes and the development of statistical methods, has lead to the identification of several plausible susceptibility genes, including neuregulin 1, proline dehydrogenase and dysbindin.  Interestingly, these genes point more towards a role for the glutamate pathway rather than the dopamine pathway in schizophrenia.  We have attempted to replicate some of these findings in schizophrenic patients from SW China, and we find significant assocn. with a novel neuregulin 1 haplotype, with proline dehydrogenase polymorphisms, but not with catechol-O-methyltransferase (COMT).  The replication of neuregulin 1 assocn. on chromosome 8p by several investigators is the most convincing to date, and the presence of a syndrome similar to dementia praecox of 8p linked families, and the lack of linkage of bipolar disorder to this region is a testament to the ideas of Kraepelin more than 100 yr ago.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGtod_Hv_OrVg90H21EOLACvtfcHk0liaamABSP82gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGmsrs%253D&md5=8f544e0ddf190c4203ef54b0a54c6780</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2003.08.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2003.08.105%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DT.%26atitle%3DThe%2520genetics%2520of%2520schizophrenia%253A%2520glutamate%2520not%2520dopamine%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D480%26spage%3D177%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Millan, M. J.</span><span> </span><span class="NLM_article-title"><i>N</i>-Methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-005-2199-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15761697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtV2iur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2005&pages=30-53&author=M.+J.+Millan&title=N-Methyl-d-aspartate+receptors+as+a+target+for+improved+antipsychotic+agents%3A+novel+insights+and+clinical+perspectives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-53</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Activation of "co-agonist" N-methyl-d-aspartate (NMDA) and GlycineB sites is mandatory for the operation of NMDA receptors, which play an important role in the control of mood, cognition, and motor function.  This article outlines the complex regulation of activity at GlycineB/NMDA receptors by multiple classes of endogenous ligand.  It also summarizes the evidence that a hypoactivity of GlycineB/NMDA receptors contributes to the pathogenesis of psychotic states, and that drugs which enhance activity at these sites may possess antipsychotic properties.  Polymorphisms in several genes known to interact with NMDA receptors are related to an altered risk for schizophrenia, and psychotic patients display changes in levels of mRNA encoding NMDA receptors, including the NR1 subunit on which GlycineB sites are located.  Schizophrenia is also assocd. with an overall decrease in activity of endogenous agonists at GlycineB/NMDA sites, whereas levels of endogenous antagonists are elevated.  NMDA receptor "open channel blockers," such as phencyclidine, are psychotomimetic in man and in rodents, and antipsychotic agents attenuate certain of their effects.  Moreover, mice with genetically invalidated GlycineB/NMDA receptors reveal similar changes in behavior.  Finally, in initial clin. studies, GlycineB agonists and inhibitors of Gly reuptake were found to potentiate the ability of "conventional" antipsychotics to improve neg. and, albeit modestly, cognitive and pos. symptoms.  In contrast, therapeutic effects of clozapine are not reinforced, likely since clozapine itself enhances activity at NMDA receptors.  Reduced activity at NMDA receptors is implicated in the etiol. of schizophrenia.  Correspondingly, drugs that (directly or indirectly) increase activity at GlycineB sites may be of use as adjuncts to other classes of antipsychotic agent.  However, there is an urgent need for broader clin. evaluation of this possibility, and, to date, there is no evidence that stimulation of GlycineB sites alone improves psychotic states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrik4YrYY-zS7Vg90H21EOLACvtfcHk0liaamABSP82gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtV2iur0%253D&md5=08bfcddb54b062d8ec9c0f1294984608</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-2199-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-2199-1%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DN-Methyl-d-aspartate%2520receptors%2520as%2520a%2520target%2520for%2520improved%2520antipsychotic%2520agents%253A%2520novel%2520insights%2520and%2520clinical%2520perspectives%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2005%26volume%3D179%26spage%3D30%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Heresco-Levy, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitt, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vass, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catinari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ermilov, M.</span><span> </span><span class="NLM_article-title"><span class="smallcaps smallerCapital">d</span>-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2004.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15780844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVWqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=577-585&author=U.+Heresco-Levyauthor=D.+C.+Javittauthor=R.+Ebsteinauthor=A.+Vassauthor=P.+Lichtenbergauthor=G.+Barauthor=S.+Catinariauthor=M.+Ermilov&title=d-Serine+efficacy+as+add-on+pharmacotherapy+to+risperidone+and+olanzapine+for+treatment-refractory+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia</span></div><div class="casAuthors">Heresco-Levy, Uriel; Javitt, Daniel C.; Ebstein, Richard; Vass, Agnes; Lichtenberg, Pesach; Bar, Gali; Catinari, Sara; Ermilov, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">577-585</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: D-serine, a selective full agonist at the glycine site of N-methyl--aspartate glutamate receptor, might presently be the compd. of choice for counteracting the hypothesized dysfunction of this receptor class in schizophrenia.  Studies performed with Taiwanese patients indicate that D-serine significantly improves schizophrenia symptoms when used as adjuvant to conventional neuroleptics but not to clozapine.  We assessed the efficacy and safety of D-serine adjuvant treatment for Occidental schizophrenia patients treated with newer atypical antipsychotics.  Methods: Thirty-nine risperidone- or olanzapine-treated schizophrenia patients participated in a double-blind, placebo-controlled, 6-wk crossover trial with 30 mg/kg/day D-serine added to their antipsychotic medication.  Measures of clin. efficacy and side effects were detd. biweekly throughout the study.  Clin. lab. parameters and amino acid serum levels were monitored.  Results: D-serine administration induced increased serine serum levels (p < .001) and resulted in significant (p < .001) improvements in neg., pos., cognitive, and depression symptoms, as measured by the Pos. and Neg. Syndrome Scale.  For approx. one third of the sample, D-serine treatment resulted in significant (>20%) redns. in Brief Psychiatric Rating Scale total scores.  D-serine was well tolerated, and no detrimental changes in clin. lab. parameters were noted.  Conclusions: These findings (1) indicate that risperidone and olanzapine efficacy might be augmented with D-serine adjuvant treatment; (2) confirm D-serine efficacy against main schizophrenia symptom domains; and (3) warrant the assessment of D-serine antipsychotic monotherapy for this illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3antEVGoMtrVg90H21EOLACvtfcHk0lhOy-CxKJSDuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVWqs70%253D&md5=f713584af1ab98f77b66020d1fbbd638</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2004.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2004.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DHeresco-Levy%26aufirst%3DU.%26aulast%3DJavitt%26aufirst%3DD.%2BC.%26aulast%3DEbstein%26aufirst%3DR.%26aulast%3DVass%26aufirst%3DA.%26aulast%3DLichtenberg%26aufirst%3DP.%26aulast%3DBar%26aufirst%3DG.%26aulast%3DCatinari%26aufirst%3DS.%26aulast%3DErmilov%26aufirst%3DM.%26atitle%3Dd-Serine%2520efficacy%2520as%2520add-on%2520pharmacotherapy%2520to%2520risperidone%2520and%2520olanzapine%2520for%2520treatment-refractory%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D2005%26volume%3D57%26spage%3D577%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Lane, H. Y.; Liu, H.-C.; Huang, C.-L.; Chang, Y. C.; Liau, C.-H.; Perng, C.-H.; Tsai, G.</span><span> </span><span class="NLM_article-title">Sarcosine (<i>N</i>-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study</span>.  <span class="citation_source-journal">Biol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lane%2C+H.+Y.%3B+Liu%2C+H.-C.%3B+Huang%2C+C.-L.%3B+Chang%2C+Y.+C.%3B+Liau%2C+C.-H.%3B+Perng%2C+C.-H.%3B+Tsai%2C+G.+Sarcosine+%28N-methylglycine%29+treatment+for+acute+schizophrenia%3A+a+randomized%2C+double-blind+study.+Biol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DH.%2BY.%26atitle%3DSarcosine%2520%2528N-methylglycine%2529%2520treatment%2520for%2520acute%2520schizophrenia%253A%2520a%2520randomized%252C%2520double-blind%2520study%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Lane, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, G. E.</span><span> </span><span class="NLM_article-title">Sarcosine or <span class="smallcaps smallerCapital">d</span>-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1196</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.62.11.1196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16275807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1CgsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2005&pages=1196-1204&author=H.+Y.+Laneauthor=Y.+C.+Changauthor=Y.+C.+Liuauthor=C.+C.+Chiuauthor=G.+E.+Tsai&title=Sarcosine+or+d-serine+add-on+treatment+for+acute+exacerbation+of+schizophrenia%3A+a+randomized%2C+double-blind%2C+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study</span></div><div class="casAuthors">Lane, Hsien-Yuan; Chang, Yue-Cune; Liu, Yi-Ching; Chiu, Chih-Chiang; Tsai, Guochuan E.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1196-1204</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia.  To det. whether NMDA-glycine site agonists or glycine transporter-1 inhibitors have better efficacy and whether NMDA receptor-enhancing agents have beneficial effects for acute exacerbation of schizophrenia.  Randomized, double-blind, placebo-controlled trial.  Inpatient units of 2 major medical centers in Taiwan.  Sixty-five schizophrenic inpatients with acute exacerbation.  Six weeks of treatment with sarcosine (2 g/d), D-serine (2 g/d), or placebo and concomitant optimal risperidone therapy.  Pos. and Neg. Syndrome Scale (PANSS) and Scale for the Assessment of Neg. Symptoms (SANS) (20 and 17 items) total scores.  The sarcosine group revealed more redns. in PANSS total scores than the placebo (P = .04) and D-serine (P < .001) groups.  Sarcosine adjunctive treatment was also superior to placebo in reducing SANS-20 (P = .007) and SANS-17 (P = .003) scores and to D-serine in decreasing SANS-20 (P = .006) and SANS-17 (P = .002) scores.  The PANSS-general, PANSS-cognitive, and PANSS-depressive symptoms scores and SANS-alogia and SANS-blunted affect scores improved significantly more in sarcosine-cotreated patients than in risperidone monotherapy patients (P ≤ .02 for all).  Sarcosine adjunctive therapy also surpassed D-serine in terms of PANSS-general, PANSS-pos., PANSS-neg., and PANSS-depressive symptoms scores (P ≤ .04 for all).  D-Serine and risperidone cotreatment did not differ significantly from risperidone monotherapy in all efficacy domains.  This first short-term treatment study on NMDA receptor-enhancing agents suggests that sarcosine, superior to D-serine, can benefit not only patients with long-term stable disease but also acutely ill persons with schizophrenia.  This finding indicates that a glycine transporter 1 inhibitor may be more efficacious than NMDA-glycine site agonists for adjuvant treatment of schizophrenia, at least during the acute phase.  Further studies are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyLHlPPnkgV7Vg90H21EOLACvtfcHk0lhOy-CxKJSDuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1CgsLzK&md5=8d2aa013405ff2f7b4dc531b40497d3e</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.62.11.1196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.62.11.1196%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DH.%2BY.%26aulast%3DChang%26aufirst%3DY.%2BC.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DChiu%26aufirst%3DC.%2BC.%26aulast%3DTsai%26aufirst%3DG.%2BE.%26atitle%3DSarcosine%2520or%2520d-serine%2520add-on%2520treatment%2520for%2520acute%2520exacerbation%2520of%2520schizophrenia%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2005%26volume%3D62%26spage%3D1196%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Moghaddam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, D.</span><span> </span><span class="NLM_article-title">Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2921</span><span class="NLM_x">–</span> <span class="NLM_lpage">2927</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1523%2FJNEUROSCI.17-08-02921.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9092613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2sXisValurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=2921-2927&author=B.+Moghaddamauthor=B.+Adamsauthor=A.+Vermaauthor=D.+Daly&title=Activation+of+glutamatergic+neurotransmission+by+ketamine%3A+a+novel+step+in+the+pathway+from+NMDA+receptor+blockade+to+dopaminergic+and+cognitive+disruptions+associated+with+the+prefrontal+cortex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</span></div><div class="casAuthors">Moghaddam, Bita; Adams, Barbara; Verma, Anita; Daly, Darron</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2921-2927</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Subanesthetic doses of ketamine, a noncompetitive NMDA receptor antagonist, impair prefrontal cortex (PFC) function in the rat and produce symptoms in humans similar to those obsd. in schizophrenia and dissociative states, including impaired performance of frontal lobe-sensitive tests.  Several lines of evidence suggest that ketamine may impair PFC function in part by interacting with dopamine neurotransmission in this region.  This study sought to det. the mechanism by which ketamine may disrupt dopaminergic neurotransmission in, and cognitive functions assocd. with, the PFC.  A thorough dose-response study using microdialysis in conscious rats indicated that low doses of ketamine (10, 20, and 30 mg/kg) increase glutamate outflow in the PFC, suggesting that at these doses ketamine may increase glutamatergic neurotransmission in the PFC at non-NMDA glutamate receptors.  An anesthetic dose of ketamine (200 mg/kg) decreased, and an intermediate dose of 50 mg/kg did not affect, glutamate levels.  Ketamine, at 30 mg/kg, also increased the release of dopamine in the PFC.  This increase was blocked by intra-PFC application of the AMPA/kainate receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione CNQX.  Furthermore, ketamine-induced activation of dopamine release and impairment of spatial delayed alternation in the rodent, a PFC-sensitive cognitive task, was ameliorated by systemic pretreatment with AMPA/kainate receptor antagonist LY293558.  These findings suggest that ketamine may disrupt dopaminergic neurotransmission in the PFC as well as cognitive functions assocd. with this region, in part, by increasing the release of glutamate, thereby stimulating postsynaptic non-NMDA glutamate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKNWCBwx_sLVg90H21EOLACvtfcHk0lhOy-CxKJSDuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisValurk%253D&md5=74f7a1696b2c30f0a38e34963334eb0b</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.17-08-02921.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.17-08-02921.1997%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DB.%26aulast%3DAdams%26aufirst%3DB.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DDaly%26aufirst%3DD.%26atitle%3DActivation%2520of%2520glutamatergic%2520neurotransmission%2520by%2520ketamine%253A%2520a%2520novel%2520step%2520in%2520the%2520pathway%2520from%2520NMDA%2520receptor%2520blockade%2520to%2520dopaminergic%2520and%2520cognitive%2520disruptions%2520associated%2520with%2520the%2520prefrontal%2520cortex%26jtitle%3DJ.%2520Neurosci.%26date%3D1997%26volume%3D17%26spage%3D2921%26epage%3D2927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Lorrain, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varney, M. A.</span><span> </span><span class="NLM_article-title">Effects of ketamine and <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">–</span> <span class="NLM_lpage">706</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2003&pages=697-706&author=D.+S.+Lorrainauthor=C.+S.+Bacceiauthor=L.+J.+Bristowauthor=J.+J.+Andersonauthor=M.+A.+Varney&title=Effects+of+ketamine+and+N-methyl-d-aspartate+on+glutamate+and+dopamine+release+in+the+rat+prefrontal+cortex%3A+modulation+by+a+group+II+selective+metabotropic+glutamate+receptor+agonist+LY379268"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BJ.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26atitle%3DEffects%2520of%2520ketamine%2520and%2520N-methyl-d-aspartate%2520on%2520glutamate%2520and%2520dopamine%2520release%2520in%2520the%2520rat%2520prefrontal%2520cortex%253A%2520modulation%2520by%2520a%2520group%2520II%2520selective%2520metabotropic%2520glutamate%2520receptor%2520agonist%2520LY379268%26jtitle%3DNeuroscience%26date%3D2003%26volume%3D117%26spage%3D697%26epage%3D706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Adams, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, B.</span><span> </span><span class="NLM_article-title">Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5545</span><span class="NLM_x">–</span> <span class="NLM_lpage">5554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9651235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1cXksFartLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=5545-5554&author=B.+Adamsauthor=B.+Moghaddam&title=Corticolimbic+dopamine+neurotransmission+is+temporally+dissociated+from+the+cognitive+and+locomotor+effects+of+phencyclidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine</span></div><div class="casAuthors">Adams, Barbara; Moghaddam, Bita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5545-5554</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The behavioral syndrome produced by phencyclidine (PCP) and its analog ketamine represents a pharmacol. model for some aspects of schizophrenia.  Despite the multifaceted properties of these drugs, the main mechanism for their psychotomimetic and cognitive-impairing effects has been thought heretofore to involve the corticolimbic dopamine system.  The present study examd. the temporal relation between alterations in corticolimbic dopamine and glutamate neurotransmission and two dopamine-dependent behavioral effects of PCP in the rodent that have relevance to the clin. phenomenol., namely, impairment of working memory, which is used to model the frontal lobe deficits assocd. with schizophrenia, and hyperlocomotion, which is used as a predictor of the propensity of a drug to elicit or exacerbate psychosis.  PCP increased dopamine and glutamate efflux in the prefrontal cortex and nucleus accumbens, as measured by microdialysis.  The increase in dopamine in both regions remained elevated well above baseline 2.5 h after the injection, at which time the expt. was terminated.  However, locomotor activity returned to baseline in <2 h after injection.  Furthermore, impaired performance in a discrete trial delayed alternation task, a rodent working memory task, was only evident ≤60 min after PCP injection; animals tested 80 min after injection, when cortical dopamine release was elevated at 300% of baseline, did not exhibit impaired performance.  These findings indicate that activation of dopamine neurotransmission is not sufficient to sustain PCP-induced locomotion and impairment of working memory.  Thus, effects of PCP, including a glutamatergic hyperstimulation, may be necessary to account for the psychotomimetic and cognitive-impairing effects of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZhIAn_TccKLVg90H21EOLACvtfcHk0lgnlqsgQLtxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFartLY%253D&md5=238f891f884d0ba6ac9e98bef1dd1670</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DB.%26aulast%3DMoghaddam%26aufirst%3DB.%26atitle%3DCorticolimbic%2520dopamine%2520neurotransmission%2520is%2520temporally%2520dissociated%2520from%2520the%2520cognitive%2520and%2520locomotor%2520effects%2520of%2520phencyclidine%26jtitle%3DJ.%2520Neurosci.%26date%3D1998%26volume%3D18%26spage%3D5545%26epage%3D5554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Aghajanian, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span> </span><span class="NLM_article-title">Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">825</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0006-8993%2899%2901224-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10216183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1MXisV2hu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=825&publication_year=1999&pages=161-171&author=G.+K.+Aghajanianauthor=G.+J.+Marek&title=Serotonin%2C+via+5-HT2A+receptors%2C+increases+EPSCs+in+layer+V+pyramidal+cells+of+prefrontal+cortex+by+an+asynchronous+mode+of+glutamate+release"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release</span></div><div class="casAuthors">Aghajanian, George K.; Marek, Gerard J.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">825</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">161-171</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Previously, serotonin (5-HT) was found to induce a marked increase in glutamatergic spontaneous excitatory postsynaptic currents (EPSCs) in apical dendrites of layer V pyramidal cells of prefrontal cortex; this effect was mediated by 5-HT2A receptors, a proposed site of action of hallucinogenic and atypical antipsychotic drugs.  Unexpectedly, although the effect of 5-HT was Ca2+-dependent and tetrodotoxin-sensitive, it did not appear to involve the activation of excitatory afferent impulse flow.  This paradox prompted us to investigate (in rat brain slices) whether 5-HT was acting through an atypical mode of excitatory transmitter release.  We found that the frequency of 5-HT-induced spontaneous EPSCs was fully supported by Sr2+ in the absence of added Ca2+, implicating the mechanism of asynchronous transmitter release which has been linked to the high-affinity Ca2+-sensor synaptotagmin III.  Although the early, synchronous component of elec. evoked EPSCs was reduced while 5-HT was being applied, late, nonsynchronous components were enhanced during 5-HT washout and also by the 5-HT2 partial agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI); the effect of DOI was blocked by a selective 5-HT2A antagonist (MDL 100907).  This late, nonsynchronous component was distinct from conventional polysynaptic EPSCs evoked in the presence of the GABAA antagonist bicuculline, but resembled asynchronous glutamatergic excitatory postsynaptic potentials (EPSPs) evoked in the presence of Sr2+.  An enhancement of asynchronous EPSCs by a specific neurotransmitter receptor has not been reported previously.  The possible role of excessive asynchronous transmission in the cerebral cortex in mediating the hallucinogenic effects of 5-HT2A agonists such as DOI is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOcZBhsnFz7Vg90H21EOLACvtfcHk0lgnlqsgQLtxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisV2hu7c%253D&md5=1db5c5a4c5a80bc3ee08298229e4bdff</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2899%2901224-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252899%252901224-X%26sid%3Dliteratum%253Aachs%26aulast%3DAghajanian%26aufirst%3DG.%2BK.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26atitle%3DSerotonin%252C%2520via%25205-HT2A%2520receptors%252C%2520increases%2520EPSCs%2520in%2520layer%2520V%2520pyramidal%2520cells%2520of%2520prefrontal%2520cortex%2520by%2520an%2520asynchronous%2520mode%2520of%2520glutamate%2520release%26jtitle%3DBrain%2520Res.%26date%3D1999%26volume%3D825%26spage%3D161%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Van Kammen, D. P.</span><span> </span><span class="NLM_article-title">γ-Aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=835733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaE2sXoslWhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=1977&pages=138-143&author=D.+P.+Van+Kammen&title=%CE%B3-Aminobutyric+acid+%28GABA%29+and+the+dopamine+hypothesis+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">γ-Aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia</span></div><div class="casAuthors">Van Kammen, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Psychiatry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-43</span>CODEN:
                <span class="NLM_cas:coden">AJPSAO</span>;
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">A review with 47 refs. including pharmacol. interventions that may raise GABA-mediated function in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBO82PpQSc4LVg90H21EOLACvtfcHk0lgnlqsgQLtxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXoslWhtA%253D%253D&md5=c1a957f58055dc01f836822ee6c61c11</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BKammen%26aufirst%3DD.%2BP.%26atitle%3D%25CE%25B3-Aminobutyric%2520acid%2520%2528GABA%2529%2520and%2520the%2520dopamine%2520hypothesis%2520of%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1977%26volume%3D134%26spage%3D138%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Wassef, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kochan, L. D.</span><span> </span><span class="NLM_article-title">GABA and schizophrenia: a review of basic science and clinical studies</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F01.jcp.0000095349.32154.a5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14624191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVCntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=601-640&author=A.+Wassefauthor=J.+Bakerauthor=L.+D.+Kochan&title=GABA+and+schizophrenia%3A+a+review+of+basic+science+and+clinical+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">GABA and schizophrenia: A review of basic science and clinical studies</span></div><div class="casAuthors">Wassef, Adel; Baker, Jeffrey; Kochan, Lisa D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-640</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  A converging body of evidence implicates the γ-aminobutyric acid (GABA) neurotransmitter system in the pathogenesis of schizophrenia.  The authors review neuroscience literature and clin. studies investigating the role of the GABA system in the pathophysiol. of schizophrenia.  First, a background on the GABA system is provided, including GABA pharmacol. and neuroanatomy of GABAergic neurons.  Results from basic science schizophrenia animal models and human studies are reviewed.  The role of GABA in cognitive dysfunction in schizophrenia is then presented, followed by a discussion of GABAergic compds. used in monotherapy or adjunctively in clin. schizophrenia studies.  In basic studies, redns. in GABAergic neuronal d. and abnormalities in receptors and reuptake sites have been identified in several cortical and subcortical GABA systems.  A model has been developed suggesting GABA's role (including GABA-dopamine interactions) in schizophrenia.  In several clin. studies, the use of adjunctive GABA agonists was assocd. with greater improvement in core schizophrenia symptoms.  Conclusions: Alterations in the GABA neurotransmitter system are found in clin. and basic neuroscience schizophrenia studies as well as animal models and may be involved in the pathophysiol. of schizophrenia.  The interaction of GABA with other well-characterized neurotransmitter abnormalities remains to be understood.  Future studies should elucidate the potential therapeutic role for GABA ligands in schizophrenia treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUFAE0s-24rVg90H21EOLACvtfcHk0lgnlqsgQLtxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVCntbw%253D&md5=69cda8f117fda03030986ca0dc548a10</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1097%2F01.jcp.0000095349.32154.a5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.jcp.0000095349.32154.a5%26sid%3Dliteratum%253Aachs%26aulast%3DWassef%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DKochan%26aufirst%3DL.%2BD.%26atitle%3DGABA%2520and%2520schizophrenia%253A%2520a%2520review%2520of%2520basic%2520science%2520and%2520clinical%2520studies%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2003%26volume%3D23%26spage%3D601%26epage%3D640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Benes, F. M.</span><span> </span><span class="NLM_article-title">Emerging principles of altered neural circuitry in schizophrenia</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">269</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0165-0173%2899%2900041-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10719152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3c7osFCquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2000&pages=251-269&author=F.+M.+Benes&title=Emerging+principles+of+altered+neural+circuitry+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging principles of altered neural circuitry in schizophrenia</span></div><div class="casAuthors">Benes F M</div><div class="citationInfo"><span class="NLM_cas:title">Brain research. Brain research reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">251-69</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This paper presents an overview of recent microscopic studies that have sought to define how limbic circuitry may be altered in postmortem schizophrenic brain.  The discussion is organized around several basic questions regarding the manner in which interconnections within and between the anterior cingulate cortex and hippocampal formation and involving the glutamate, GABA and dopamine systems may contribute to the pathophysiology of this disorder.  The answers to these questions are used to derive several conclusions regarding circuitry changes in schizophrenia: 1) Schizophrenia is not a 'typical' degenerative disorder, but rather it is one in which excitotoxicity may contribute to neuronal pathology, whether or not cell death occurs; 2) Three or more neurotransmitter systems may be simultaneously altered within a single microcircuit; 3) Each transmitter system may show circuitry changes in more than one region, but such changes may vary on a region-by-region basis; 4) The pathophysiology of schizophrenia may involve 'mis-wirings' in intrinsic circuits (microcircuitry) within a given region, but significant changes are probably also present at the level of interconnections between two or more regions within a network (macrocircuitry); 5) While some microscopic findings appear to be selectively present in schizophrenia and be related to a susceptibility gene for this disorder, others may also be present in patients with bipolar disorder; 6) Although some of the circuitry changes seen in schizophrenia and bipolar disorder seem to be associated with neuroleptic exposure, most are not and may reflect the influence of non-specific environmental factors such as pre- and/or postnatal stress; 7) Normal postnatal changes at the level of both macro- and microcircuitry within the limbic system may serve as 'triggers' for the onset of schizophrenia during adolescence.  Taken together, these emerging principles can provide a framework for future postmortem studies of schizophrenic brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStXyTLo7wGZP6AExegM5LLfW6udTcc2eZAvjIN3_69dbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7osFCquw%253D%253D&md5=0979c3a0bea53bba782138c1fd934d21</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS0165-0173%2899%2900041-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-0173%252899%252900041-7%26sid%3Dliteratum%253Aachs%26aulast%3DBenes%26aufirst%3DF.%2BM.%26atitle%3DEmerging%2520principles%2520of%2520altered%2520neural%2520circuitry%2520in%2520schizophrenia%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2000%26volume%3D31%26spage%3D251%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Lingjaerde, O.</span><span> </span><span class="NLM_article-title">Benzodiazepines in the treatment of schizophrenia: an updated survey</span> <span class="citation_source-journal">Acta Psychiatr. Scand.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">459</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1111%2Fj.1600-0447.1991.tb03177.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1685616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK387jtlensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1991&pages=453-459&author=O.+Lingjaerde&title=Benzodiazepines+in+the+treatment+of+schizophrenia%3A+an+updated+survey"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Benzodiazepines in the treatment of schizophrenia: an updated survey</span></div><div class="casAuthors">Lingjaerde O</div><div class="citationInfo"><span class="NLM_cas:title">Acta psychiatrica Scandinavica</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">453-9</span>
        ISSN:<span class="NLM_cas:issn">0001-690X</span>.
    </div><div class="casAbstract">Reports on the effects of benzodiazepines in schizophrenia have appeared since the early 1960s.  Conclusions drawn from these studies, most of which have been uncontrolled, have ranged from worse than placebo to better than neuroleptics.  A critical appraisal of the literature seems to warrant the following main conclusions.  Benzodiazepines alone, in conventional doses, have no convincing antipsychotic effect in schizophrenia, although they may reduce anxiety, tension and insomnia.  However, very high doses of diazepam, and possibly other benzodiazepines, may have a symptomatic antipsychotic effect, especially in paranoid-hallucinatory schizophrenics, also when given alone.  Benzodiazepines, in conventional doses, can enhance the antipsychotic effect of neuroleptics in schizophrenics who have not responded satisfactorily to neuroleptics alone.  This effect may be most conspicuous against hallucinations, but improvement may also be obtained from delusions, thought disturbances, some negative symptoms, anxiety and tension.  Some benzodiazepines may be more effective than others in schizophrenia, but this has been insufficiently elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_Fv5sszlCB3thwrmtH4OBfW6udTcc2eZAvjIN3_69dbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387jtlensQ%253D%253D&md5=79e0096ea98b723d78b24808655a7ff1</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0447.1991.tb03177.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0447.1991.tb03177.x%26sid%3Dliteratum%253Aachs%26aulast%3DLingjaerde%26aufirst%3DO.%26atitle%3DBenzodiazepines%2520in%2520the%2520treatment%2520of%2520schizophrenia%253A%2520an%2520updated%2520survey%26jtitle%3DActa%2520Psychiatr.%2520Scand.%26date%3D1991%26volume%3D84%26spage%3D453%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Taylor, C. P.</span><span> </span><span class="NLM_article-title">GABA receptors and GABAergic synapses as targets for drug development</span> <span class="citation_source-journal">Drug Dev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1990&pages=151-160&author=C.+P.+Taylor&title=GABA+receptors+and+GABAergic+synapses+as+targets+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DC.%2BP.%26atitle%3DGABA%2520receptors%2520and%2520GABAergic%2520synapses%2520as%2520targets%2520for%2520drug%2520development%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D1990%26volume%3D21%26spage%3D151%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Hashimoto, T.; Arion, D.; Unger, T.; Maldonado-Aviles, J. G.; Morris, H. M.; Volk, D. W.; Mirnics, K.; Lewis, D. A.</span><span> </span><span class="NLM_article-title">Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia</span>.  <span class="citation_source-journal">Mol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hashimoto%2C+T.%3B+Arion%2C+D.%3B+Unger%2C+T.%3B+Maldonado-Aviles%2C+J.+G.%3B+Morris%2C+H.+M.%3B+Volk%2C+D.+W.%3B+Mirnics%2C+K.%3B+Lewis%2C+D.+A.+Alterations+in+GABA-related+transcriptome+in+the+dorsolateral+prefrontal+cortex+of+subjects+with+schizophrenia.+Mol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DT.%26atitle%3DAlterations%2520in%2520GABA-related%2520transcriptome%2520in%2520the%2520dorsolateral%2520prefrontal%2520cortex%2520of%2520subjects%2520with%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Akbarian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. S.</span><span> </span><span class="NLM_article-title">Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.brainresrev.2006.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16759710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFCitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2006&pages=293-304&author=S.+Akbarianauthor=H.+S.+Huang&title=Molecular+and+cellular+mechanisms+of+altered+GAD1%2FGAD67+expression+in+schizophrenia+and+related+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders</span></div><div class="casAuthors">Akbarian, Schahram; Huang, Hsien-Sung</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-304</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The 67 and 65 kDa isoforms of glutamic acid decarboxylase, the key enzymes for GABA biosynthesis, are expressed at altered levels in postmortem brain of subjects diagnosed with schizophrenia and related disorders, including autism and bipolar illness.  The predominant finding is a decrease in GAD67 mRNA levels, affecting multiple brain regions, including prefrontal and temporal cortex.  Postmortem studies, in conjunction with animal models, identified several mechanisms that contribute to the dysregulation of GAD67 in cerebral cortex.  These include disordered connectivity formation during development, abnormal expression of Reelin and neural cell adhesion mol. (NCAM) glycoproteins, defects in neurotrophin signaling and alterations in dopaminergic and glutamatergic neurotransmission.  These mechanisms are likely to operate in conjunction with genetic risk factors for psychosis, including sequence polymorphisms residing in the promoter of GAD1 (2q31), the gene encoding GAD67.  We propose an integrative model, with multiple mol. and cellular mechanisms contributing to transcriptional dysregulation of GAD67 and cortical dysfunction in psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohPNNWoo19rbVg90H21EOLACvtfcHk0ljOrJzgi5BilA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFCitL8%253D&md5=9c0a8a5e8e505d46c03ded47f99fd3d8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2006.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2006.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DAkbarian%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DH.%2BS.%26atitle%3DMolecular%2520and%2520cellular%2520mechanisms%2520of%2520altered%2520GAD1%252FGAD67%2520expression%2520in%2520schizophrenia%2520and%2520related%2520disorders%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2006%26volume%3D52%26spage%3D293%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Benes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzilevich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subburaju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minns, M.</span><span> </span><span class="NLM_article-title">Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">10164</span><span class="NLM_x">–</span> <span class="NLM_lpage">10169</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=10164-10169&author=F.+M.+Benesauthor=B.+Limauthor=D.+Matzilevichauthor=J.+P.+Walshauthor=S.+Subburajuauthor=M.+Minns&title=Regulation+of+the+GABA+cell+phenotype+in+hippocampus+of+schizophrenics+and+bipolars"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenes%26aufirst%3DF.%2BM.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DMatzilevich%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DJ.%2BP.%26aulast%3DSubburaju%26aufirst%3DS.%26aulast%3DMinns%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520the%2520GABA%2520cell%2520phenotype%2520in%2520hippocampus%2520of%2520schizophrenics%2520and%2520bipolars%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D10164%26epage%3D10169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span> </span><span class="NLM_article-title">Systematic study of association of four GABAergic genes: glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABA<sub>B</sub> receptor 1 gene and GABA<sub>A</sub> receptor subunit β2 gene, with schizophrenia using a universal DNA microarray</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2007.02.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17412563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2szivF2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2007&pages=374-384&author=X.+Zhaoauthor=S.+Qinauthor=Y.+Shiauthor=A.+Zhangauthor=J.+Zhangauthor=L.+Bianauthor=C.+Wanauthor=G.+Fengauthor=N.+Guauthor=G.+Zhangauthor=G.+Heauthor=L.+He&title=Systematic+study+of+association+of+four+GABAergic+genes%3A+glutamic+acid+decarboxylase+1+gene%2C+glutamic+acid+decarboxylase+2+gene%2C+GABAB+receptor+1+gene+and+GABAA+receptor+subunit+%CE%B22+gene%2C+with+schizophrenia+using+a+universal+DNA+microarray"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic study of association of four GABAergic genes: glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABA(B) receptor 1 gene and GABA(A) receptor subunit beta2 gene, with schizophrenia using a universal DNA microarray</span></div><div class="casAuthors">Zhao Xu; Qin Shengying; Shi Yongyong; Zhang Aiping; Zhang Jing; Bian Li; Wan Chunling; Feng Guoyin; Gu Niufan; Zhang Guangqi; He Guang; He Lin</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">374-84</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Several studies have suggested the dysfunction of the GABAergic system as a risk factor in the pathogenesis of schizophrenia.  In the present study, case-control association analysis was conducted in four GABAergic genes: two glutamic acid decarboxylase genes (GAD1 and GAD2), a GABA(A) receptor subunit beta2 gene (GABRB2) and a GABA(B) receptor 1 gene (GABBR1).  Using a universal DNA microarray procedure we genotyped a total of 20 SNPs on the above four genes in a study involving 292 patients and 286 controls of Chinese descent.  Statistically significant differences were observed in the allelic frequencies of the rs187269C/T polymorphism in the GABRB2 gene (P=0.0450, chi(2)=12.40, OR=1.65) and the -292A/C polymorphism in the GAD1 gene (P=0.0450, chi(2)=14.64 OR=1.77).  In addition, using an electrophoretic mobility shift assay (EMSA), we discovered differences in the U251 nuclear protein binding to oligonucleotides representing the -292 SNP on the GAD1 gene, which suggests that the -292C allele has reduced transcription factor binding efficiency compared with the 292A allele.  Using the multifactor-dimensionality reduction method (MDR), we found that the interactions among the rs187269C/T polymorphism in the GABRB2 gene, the -243A/G polymorphism in the GAD2 gene and the 27379C/T and 661C/T polymorphisms in the GAD1 gene revealed a significant association with schizophrenia (P<0.001).  These findings suggest that the GABRB2 and GAD1 genes alone and the combined effects of the polymorphisms in the four GABAergic system genes may confer susceptibility to the development of schizophrenia in the Chinese population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1CQap_ZwngOkdrW1FkXG-fW6udTcc2eYOb-a2V8vTb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szivF2nug%253D%253D&md5=73e87b75b3e702e565e05247e5584949</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2007.02.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2007.02.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBian%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DGu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DSystematic%2520study%2520of%2520association%2520of%2520four%2520GABAergic%2520genes%253A%2520glutamic%2520acid%2520decarboxylase%25201%2520gene%252C%2520glutamic%2520acid%2520decarboxylase%25202%2520gene%252C%2520GABAB%2520receptor%25201%2520gene%2520and%2520GABAA%2520receptor%2520subunit%2520%25CE%25B22%2520gene%252C%2520with%2520schizophrenia%2520using%2520a%2520universal%2520DNA%2520microarray%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D93%26spage%3D374%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Selemon, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman-Rakic, P. S.</span><span> </span><span class="NLM_article-title">The reduced neuropil hypothesis: a circuit based model of schizophrenia</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0006-3223%2898%2900281-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9894571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1M7htF2nsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1999&pages=17-25&author=L.+D.+Selemonauthor=P.+S.+Goldman-Rakic&title=The+reduced+neuropil+hypothesis%3A+a+circuit+based+model+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">The reduced neuropil hypothesis: a circuit based model of schizophrenia</span></div><div class="casAuthors">Selemon L D; Goldman-Rakic P S</div><div class="citationInfo"><span class="NLM_cas:title">Biological psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-25</span>
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    </div><div class="casAbstract">In recent years, quantitative studies of the neuropathology of schizophrenia have reignited interest in the cerebral cortex and focused attention on the cellular and subcellular constituents that may be altered in this disease.  Findings have ranged from compromised circuitry in prefrontal areas to outright neuronal loss in temporal and cingulate cortices.  Herein, we propose that a reduction in interneuronal neuropil in the prefrontal cortex is a prominent feature of cortical pathology in schizophrenia and review the growing evidence for this view from reports of altered neuronal density and immunohistochemical markers in various cortical regions.  The emerging picture of neuropathology in schizophrenia is one of subtle changes in cellular architecture and brain circuity that nonetheless have a devastating impact on cortical function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtejfReLEhZZWtyewyzkyLfW6udTcc2eYOb-a2V8vTb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7htF2nsA%253D%253D&md5=ef0b99beb1d632843d3b9ca2492cd636</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2898%2900281-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252898%252900281-9%26sid%3Dliteratum%253Aachs%26aulast%3DSelemon%26aufirst%3DL.%2BD.%26aulast%3DGoldman-Rakic%26aufirst%3DP.%2BS.%26atitle%3DThe%2520reduced%2520neuropil%2520hypothesis%253A%2520a%2520circuit%2520based%2520model%2520of%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D1999%26volume%3D45%26spage%3D17%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Dwork, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancevski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosoklija, G.</span><span> </span><span class="NLM_article-title">White matter and cognitive function in schizophrenia</span> <span class="citation_source-journal">Int. J. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS1461145707007638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17313699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=513-536&author=A.+J.+Dworkauthor=B.+Mancevskiauthor=G.+Rosoklija&title=White+matter+and+cognitive+function+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">White matter and cognitive function in schizophrenia</span></div><div class="casAuthors">Dwork, Andrew J.; Mancevski, Branislav; Rosoklija, Gorazd</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">513-536</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  Abnormalities of cerebral white matter, oligodendrocytes, and myelin have been obsd. in schizophrenia with in-vivo imaging and post-mortem biochem.  White-matter abnormalities are also frequently assocd. with cognitive impairment in both healthy and diseased individuals, and cognitive dysfunction is an important component of schizophrenia.  While many studies have documented these assocns., only a handful have examd. the role of white matter in cognitive function in schizophrenia.  In this paper, we explore what is known about white-matter deficits in relation to schizophrenia, cognitive deficits, or both together, in order to generate a theor. model for the role that compromise of white matter might play in producing cognitive impairment in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ5o5vWvkxVbVg90H21EOLACvtfcHk0lgae4Vcf9BuTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt7k%253D&md5=58a11b74de917da1f3271144db27e333</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1017%2FS1461145707007638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145707007638%26sid%3Dliteratum%253Aachs%26aulast%3DDwork%26aufirst%3DA.%2BJ.%26aulast%3DMancevski%26aufirst%3DB.%26aulast%3DRosoklija%26aufirst%3DG.%26atitle%3DWhite%2520matter%2520and%2520cognitive%2520function%2520in%2520schizophrenia%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D10%26spage%3D513%26epage%3D536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Hulshoff Pol, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnack, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertens, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Haren, N. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Tweel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baare, W. F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R. S.</span><span> </span><span class="NLM_article-title">Volume changes in gray matter in patients with schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.159.2.244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11823266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD387gs1yltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=244-250&author=H.+E.+Hulshoff+Polauthor=H.+G.+Schnackauthor=M.+G.+Bertensauthor=N.+E.+M.+van+Harenauthor=I.+van+der+Tweelauthor=W.+G.+Staalauthor=W.+F.+C.+Baareauthor=R.+S.+Kahn&title=Volume+changes+in+gray+matter+in+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Volume changes in gray matter in patients with schizophrenia</span></div><div class="casAuthors">Hulshoff Pol Hilleke E; Schnack Hugo G; Bertens Madelief G B C; van Haren Neeltje E M; van der Tweel Ingeborg; Staal Wouter G; Baare Wim F C; Kahn Rene S</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">244-50</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Schizophrenia is generally characterized by a progressive decline in functioning.  Although structural brain abnormalities, particularly decrements in gray matter volume, are considered important to the pathology of schizophrenia, it is not resolved whether the brain abnormalities become more prominent over time.  METHOD:  Magnetic resonance brain images from 159 patients with schizophrenia and 158 healthy comparison subjects between 16 and 70 years of age were compared.  Using linear regression analysis, the authors analyzed the relationship between the volumes of the total brain, gray and white matter, cerebellum, and lateral and third ventricles with patient age.  RESULTS:  Total brain (-2.2%), cerebral gray matter (-3.3%), prefrontal gray matter (-4.4%), and prefrontal white matter (-3.5%) volumes were smaller, and lateral (27%) and third (30%) ventricle and peripheral CSF (11%) volumes were larger in schizophrenia patients.  A significant group-by-age interaction for gray matter volume was found, as shown by a steeper regression slope between age and gray matter volume in patients (-3.43 ml/year) than in healthy comparison subjects (-2.74 ml/year).  CONCLUSIONS:  The smaller brains of the patients with schizophrenia can be explained by decreases in gray matter volume.  Moreover, the finding that the smaller gray matter volume was more pronounced in older patients with schizophrenia may suggest progressive loss of cerebral gray matter in schizophrenia patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEEl3bXaKI7rxanA7vODO6fW6udTcc2eaxU4th7C4gZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387gs1yltg%253D%253D&md5=e325c662a644ae22ff521ba15e0054fc</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.2.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.2.244%26sid%3Dliteratum%253Aachs%26aulast%3DHulshoff%2BPol%26aufirst%3DH.%2BE.%26aulast%3DSchnack%26aufirst%3DH.%2BG.%26aulast%3DBertens%26aufirst%3DM.%2BG.%26aulast%3Dvan%2BHaren%26aufirst%3DN.%2BE.%2BM.%26aulast%3Dvan%2Bder%2BTweel%26aufirst%3DI.%26aulast%3DStaal%26aufirst%3DW.%2BG.%26aulast%3DBaare%26aufirst%3DW.%2BF.%2BC.%26aulast%3DKahn%26aufirst%3DR.%2BS.%26atitle%3DVolume%2520changes%2520in%2520gray%2520matter%2520in%2520patients%2520with%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D244%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Buchsbaum, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peled, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudbjartsson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazlett, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downhill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fallon, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atlas, S. W.</span><span> </span><span class="NLM_article-title">MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia</span> <span class="citation_source-journal">NeuroReport</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1998&pages=425-430&author=M.+S.+Buchsbaumauthor=C.+Y.+Tangauthor=S.+Peledauthor=H.+Gudbjartssonauthor=D.+Luauthor=E.+A.+Hazlettauthor=J.+Downhillauthor=M.+Haznedarauthor=J.+H.+Fallonauthor=S.+W.+Atlas&title=MRI+white+matter+diffusion+anisotropy+and+PET+metabolic+rate+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuchsbaum%26aufirst%3DM.%2BS.%26aulast%3DTang%26aufirst%3DC.%2BY.%26aulast%3DPeled%26aufirst%3DS.%26aulast%3DGudbjartsson%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DHazlett%26aufirst%3DE.%2BA.%26aulast%3DDownhill%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DM.%26aulast%3DFallon%26aufirst%3DJ.%2BH.%26aulast%3DAtlas%26aufirst%3DS.%2BW.%26atitle%3DMRI%2520white%2520matter%2520diffusion%2520anisotropy%2520and%2520PET%2520metabolic%2520rate%2520in%2520schizophrenia%26jtitle%3DNeuroReport%26date%3D1998%26volume%3D9%26spage%3D425%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, K. L.</span><span> </span><span class="NLM_article-title">Introduction to the special section: myelin and oligodendrocyte abnormalities in schizophrenia</span> <span class="citation_source-journal">Int. J. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS1461145706007449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17583597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=499-502&author=V.+Haroutunianauthor=K.+L.+Davis&title=Introduction+to+the+special+section%3A+myelin+and+oligodendrocyte+abnormalities+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Introduction to the Special Section: Myelin and oligodendrocyte abnormalities in schizophrenia</span></div><div class="casAuthors">Haroutunian, Vahram; Davis, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">499-502</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  A central tenet of modern views of the neurobiol. of schizophrenia is that the symptoms of schizophrenia arise from a failure of adequate communication between different brain regions and disruption of the circuitry that underlies behavior and perception.  Historically this disconnectivity syndrome has been approached from a neurotransmitter-based perspective.  However, efficient communication between brain circuits is also contingent on saltatory signal propagation and salubrious myelination of axons.  The papers in this Special Section examine the neuroanatomical and mol. biol. evidence for abnormal myelination and oligodendroglial function in schizophrenia through studies of post-mortem brain tissue and animal model systems.  The picture that emerges from the studies described suggests that although schizophrenia is not characterized by gross abnormalities of white matter such as those evident in multiple sclerosis, it does involve a profound dysregulation of myelin-assocd. gene expression, redns. in oligodendrocyte nos., and marked abnormalities in the ultrastructure of myelin sheaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Rm-kShoCTrVg90H21EOLACvtfcHk0lia85QICa7mXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt7s%253D&md5=239f5456e309bde3aabb6f61e5d1566d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1017%2FS1461145706007449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145706007449%26sid%3Dliteratum%253Aachs%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DK.%2BL.%26atitle%3DIntroduction%2520to%2520the%2520special%2520section%253A%2520myelin%2520and%2520oligodendrocyte%2520abnormalities%2520in%2520schizophrenia%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D10%26spage%3D499%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Hakak, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxbaum, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fienberg, A. A.</span><span> </span><span class="NLM_article-title">Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">4746</span><span class="NLM_x">–</span> <span class="NLM_lpage">4751</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=4746-4751&author=Y.+Hakakauthor=J.+R.+Walkerauthor=C.+Liauthor=W.+H.+Wongauthor=K.+L.+Davisauthor=J.+D.+Buxbaumauthor=V.+Haroutunianauthor=A.+A.+Fienberg&title=Genome-wide+expression+analysis+reveals+dysregulation+of+myelination-related+genes+in+chronic+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHakak%26aufirst%3DY.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DW.%2BH.%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DBuxbaum%26aufirst%3DJ.%2BD.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DFienberg%26aufirst%3DA.%2BA.%26atitle%3DGenome-wide%2520expression%2520analysis%2520reveals%2520dysregulation%2520of%2520myelination-related%2520genes%2520in%2520chronic%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D4746%26epage%3D4751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Georgieva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskvina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peirce, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmans, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macgregor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxbaum, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. C.</span><span> </span><span class="NLM_article-title">Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">12469</span><span class="NLM_x">–</span> <span class="NLM_lpage">12474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=12469-12474&author=L.+Georgievaauthor=V.+Moskvinaauthor=T.+Peirceauthor=N.+Nortonauthor=N.+J.+Brayauthor=L.+Jonesauthor=P.+Holmansauthor=S.+Macgregorauthor=S.+Zammitauthor=J.+Wilkinsonauthor=H.+Williamsauthor=I.+Nikolovauthor=N.+Williamsauthor=D.+Ivanovauthor=K.+L.+Davisauthor=V.+Haroutunianauthor=J.+D.+Buxbaumauthor=N.+Craddockauthor=G.+Kirovauthor=M.+J.+Owenauthor=M.+C.+O%E2%80%99Donovan&title=Convergent+evidence+that+oligodendrocyte+lineage+transcription+factor+2+%28OLIG2%29+and+interacting+genes+influence+susceptibility+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgieva%26aufirst%3DL.%26aulast%3DMoskvina%26aufirst%3DV.%26aulast%3DPeirce%26aufirst%3DT.%26aulast%3DNorton%26aufirst%3DN.%26aulast%3DBray%26aufirst%3DN.%2BJ.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DHolmans%26aufirst%3DP.%26aulast%3DMacgregor%26aufirst%3DS.%26aulast%3DZammit%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DH.%26aulast%3DNikolov%26aufirst%3DI.%26aulast%3DWilliams%26aufirst%3DN.%26aulast%3DIvanov%26aufirst%3DD.%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DBuxbaum%26aufirst%3DJ.%2BD.%26aulast%3DCraddock%26aufirst%3DN.%26aulast%3DKirov%26aufirst%3DG.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26atitle%3DConvergent%2520evidence%2520that%2520oligodendrocyte%2520lineage%2520transcription%2520factor%25202%2520%2528OLIG2%2529%2520and%2520interacting%2520genes%2520influence%2520susceptibility%2520to%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D12469%26epage%3D12474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Roy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtie, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Khodor, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sardi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooks, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benoit-Marand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corfas, G.</span><span> </span><span class="NLM_article-title">Loss of <i>erbB</i> signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">8131</span><span class="NLM_x">–</span> <span class="NLM_lpage">8136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=8131-8136&author=K.+Royauthor=J.+C.+Murtieauthor=B.+F.+El+Khodorauthor=N.+Edgarauthor=S.+P.+Sardiauthor=B.+M.+Hooksauthor=M.+Benoit-Marandauthor=C.+Chenauthor=H.+Mooreauthor=P.+O%E2%80%99Donnellauthor=D.+Brunnerauthor=G.+Corfas&title=Loss+of+erbB+signaling+in+oligodendrocytes+alters+myelin+and+dopaminergic+function%2C+a+potential+mechanism+for+neuropsychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DK.%26aulast%3DMurtie%26aufirst%3DJ.%2BC.%26aulast%3DEl%2BKhodor%26aufirst%3DB.%2BF.%26aulast%3DEdgar%26aufirst%3DN.%26aulast%3DSardi%26aufirst%3DS.%2BP.%26aulast%3DHooks%26aufirst%3DB.%2BM.%26aulast%3DBenoit-Marand%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DCorfas%26aufirst%3DG.%26atitle%3DLoss%2520of%2520erbB%2520signaling%2520in%2520oligodendrocytes%2520alters%2520myelin%2520and%2520dopaminergic%2520function%252C%2520a%2520potential%2520mechanism%2520for%2520neuropsychiatric%2520disorders%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D8131%26epage%3D8136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Segal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koschnick, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slegers, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hof, P. R.</span><span> </span><span class="NLM_article-title">Oligodendrocyte pathophysiology: a new view of schizophrenia</span> <span class="citation_source-journal">Int. J. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS146114570600722X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17291369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=503-511&author=D.+Segalauthor=J.+R.+Koschnickauthor=L.+H.+Slegersauthor=P.+R.+Hof&title=Oligodendrocyte+pathophysiology%3A+a+new+view+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Oligodendrocyte pathophysiology: a new view of schizophrenia</span></div><div class="casAuthors">Segal, Devorah; Koschnick, Jessica R.; Slegers, Linda H. A.; Hof, Patrick R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">503-511</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  A recent focus of schizophrenia research is disruption of white-matter integrity as a key facet of this complex disorder.  This was spurred, partly, by new imaging modalities, magnetic transfer imaging and diffusion tensor imaging, which showed differences in white-matter integrity and tract coherence in persons with schizophrenia compared to controls.  Oligodendrocytes, in particular, have been the subject of increased study after gene microarray analyses revealed that six myelin-related genes specific to oligodendrocytes have decreased expression levels in schizophrenia.  Oligodendrocytes have also been shown to be decreased in no. in the superior frontal gyrus of subjects with schizophrenia.  The MAG knockout mouse, missing a myelin-related gene linked to schizophrenia, may prove to be a useful animal model for the dysmyelination obsd. in the human disease.  Studies currently ongoing on this model have found changes in dendritic branching patterns of pyramidal cells in layer III of the prefrontal cortex.  Further characterization of the pathol. in these mice is underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA8cDI-BEjQbVg90H21EOLACvtfcHk0lg_Rbd6Kzv4Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Kgt78%253D&md5=b580af644fe5d5e6802430e786c36bb2</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1017%2FS146114570600722X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS146114570600722X%26sid%3Dliteratum%253Aachs%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DKoschnick%26aufirst%3DJ.%2BR.%26aulast%3DSlegers%26aufirst%3DL.%2BH.%26aulast%3DHof%26aufirst%3DP.%2BR.%26atitle%3DOligodendrocyte%2520pathophysiology%253A%2520a%2520new%2520view%2520of%2520schizophrenia%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D10%26spage%3D503%26epage%3D511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Woo, T. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowell, A. L.</span><span> </span><span class="NLM_article-title">Targeting synapses and myelin in the prevention of schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15653262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FosleksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2005&pages=193-207&author=T.+U.+Wooauthor=A.+L.+Crowell&title=Targeting+synapses+and+myelin+in+the+prevention+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting synapses and myelin in the prevention of schizophrenia</span></div><div class="casAuthors">Woo T-U W; Crowell A L</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">193-207</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Many of the functions that are mediated by the prefrontal cortex (PFC) are severely impaired in schizophrenia.  The maturation of these functions takes place during late adolescence and early adulthood, which coincides with the period of time when overt symptomatology of schizophrenia most commonly emerges.  Two developmental processes occurring during the periadolescence period appear to mediate the functional maturation of the PFC: pruning of exuberant synapses and myelination of axons.  It has long been speculated in the literature that disturbances of these processes may result in dysfunction of the PFC and thereby trigger the emergence of symptoms and deficits of schizophrenia.  Alternatively, but not mutually exclusively, it has also been suggested that these late developmental processes may not be aberrant but they "unmask" preexisting deficits in the PFC, resulting in the onset of symptoms.  The important implication of both of these scenarios is that in either case the emergence of PFC functional disturbances and the onset of symptoms and deficits of schizophrenia would in theory be preventable by pharmacologic manipulation of the synaptic pruning and/or axonal myelination processes.  Thus, better understanding of the cellular and molecular mechanisms that mediate these processes will provide truly novel insight into the therapeutics and prevention of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREMCZWEFaJroJKJbLTgsvCfW6udTcc2eaRYWWFHGfys7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FosleksQ%253D%253D&md5=8a2d803364cd381723dd2774e269ac1a</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DT.%2BU.%26aulast%3DCrowell%26aufirst%3DA.%2BL.%26atitle%3DTargeting%2520synapses%2520and%2520myelin%2520in%2520the%2520prevention%2520of%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2005%26volume%3D73%26spage%3D193%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Lim, K. O.</span><span> </span><span class="NLM_article-title">Connections in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">998</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.164.7.995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17606646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2szovFakuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2007&pages=995-998&author=K.+O.+Lim&title=Connections+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Connections in schizophrenia</span></div><div class="casAuthors">Lim Kelvin O</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">995-8</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRadZisR7EXCsve_zCu79I8fW6udTcc2eaRYWWFHGfys7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szovFakuw%253D%253D&md5=615d297011490d095520eca6c47073c1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.164.7.995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.164.7.995%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DK.%2BO.%26atitle%3DConnections%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D164%26spage%3D995%26epage%3D998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Horrobin, D. F.</span><span> </span><span class="NLM_article-title">The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0920-9964%2897%2900151-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9589514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1c3ltFCiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1998&pages=193-208&author=D.+F.+Horrobin&title=The+membrane+phospholipid+hypothesis+as+a+biochemical+basis+for+the+neurodevelopmental+concept+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia</span></div><div class="casAuthors">Horrobin D F</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-208</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The neurodevelopmental hypothesis of schizophrenia is becoming an important feature of research in the field.  However, its major drawback is that it lacks any biochemical basis which might draw the diverse observations together.  It is suggested that the membrane phospholipid hypothesis can provide such a biochemical basis and that the neurodevelopmental phospholipid concept offers a powerful paradigm to guide future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0-oAsfqF7Xf6AExegM5LLfW6udTcc2eYtF1z9coEmkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3ltFCiuw%253D%253D&md5=8b0f1760bbd4043e9f23982bde9a242a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2897%2900151-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252897%252900151-5%26sid%3Dliteratum%253Aachs%26aulast%3DHorrobin%26aufirst%3DD.%2BF.%26atitle%3DThe%2520membrane%2520phospholipid%2520hypothesis%2520as%2520a%2520biochemical%2520basis%2520for%2520the%2520neurodevelopmental%2520concept%2520of%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D1998%26volume%3D30%26spage%3D193%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Emsley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myburgh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oosthuizen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Rensburg, S. J.</span><span> </span><span class="NLM_article-title">Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1596</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.159.9.1596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12202284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD38vktlOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=1596-1598&author=R.+Emsleyauthor=C.+Myburghauthor=P.+Oosthuizenauthor=S.+J.+van+Rensburg&title=Randomized%2C+placebo-controlled+study+of+ethyl-eicosapentaenoic+acid+as+supplemental+treatment+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia</span></div><div class="casAuthors">Emsley Robin; Myburgh Christo; Oosthuizen Pieter; van Rensburg Susan J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1596-8</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The study investigated the efficacy and tolerability of ethyl-eicosapentaenoic acid (E-EPA) as add-on treatment in chronic, severe schizophrenia.  METHOD:  A randomized, parallel-group, double-blind, placebo-controlled, fixed-dose, add-on study was conducted over 12 weeks.  Forty patients with persistent symptoms after at least 6 months of stable antipsychotic treatment received E-EPA or placebo, in addition to their existing treatment.  RESULTS:  At 12 weeks, the E-EPA group had significantly greater reduction of Positive and Negative Syndrome Scale total scores and of dyskinesia scores than the placebo group.  CONCLUSIONS:  EPA may be an effective and well-tolerated add-on treatment in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmduL8oJpJeRjv2lLSLOxFfW6udTcc2eYtF1z9coEmkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vktlOqtA%253D%253D&md5=a2c344322c0afdd5333115a654e639b6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.9.1596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.9.1596%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DR.%26aulast%3DMyburgh%26aufirst%3DC.%26aulast%3DOosthuizen%26aufirst%3DP.%26aulast%3Dvan%2BRensburg%26aufirst%3DS.%2BJ.%26atitle%3DRandomized%252C%2520placebo-controlled%2520study%2520of%2520ethyl-eicosapentaenoic%2520acid%2520as%2520supplemental%2520treatment%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D1596%26epage%3D1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Fenton, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boronow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hibbeln, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knable, M.</span><span> </span><span class="NLM_article-title">A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">–</span> <span class="NLM_lpage">2074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.158.12.2071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11729030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3Mnot1akug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=2071-2074&author=W.+S.+Fentonauthor=F.+Dickersonauthor=J.+Boronowauthor=J.+R.+Hibbelnauthor=M.+Knable&title=A+placebo-controlled+trial+of+omega-3+fatty+acid+%28ethyl+eicosapentaenoic+acid%29+supplementation+for+residual+symptoms+and+cognitive+impairment+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia</span></div><div class="casAuthors">Fenton W S; Dickerson F; Boronow J; Hibbeln J R; Knable M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2071-4</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder.  METHOD:  Eighty-seven patients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despite neuroleptic treatment were randomly assigned to receive either 3 g/day of ethyl EPA (N=43) or placebo (N=44) in a 16-week, double-blind supplementation trial.  Assessments were performed at baseline and at weeks 1, 2, 4, 8, 12, and 16; a cognitive battery was administered at baseline and at week 16.  RESULTS:  No differences were found between groups in positive or negative symptoms, mood, cognition, or global impression ratings.  Results were similar for the intention-to-treat (N=87) and completer (N=75) groups.  CONCLUSIONS:  For schizophrenia patients treated with 3 g/day of ethyl EPA, improvement in residual symptoms and cognitive impairment was no greater than for schizophrenia patients treated with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpjrX2QIQDJr9KldV63DuefW6udTcc2eYtF1z9coEmkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mnot1akug%253D%253D&md5=d42ff74cb752a7a1966294dbe196e843</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.12.2071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.12.2071%26sid%3Dliteratum%253Aachs%26aulast%3DFenton%26aufirst%3DW.%2BS.%26aulast%3DDickerson%26aufirst%3DF.%26aulast%3DBoronow%26aufirst%3DJ.%26aulast%3DHibbeln%26aufirst%3DJ.%2BR.%26aulast%3DKnable%26aufirst%3DM.%26atitle%3DA%2520placebo-controlled%2520trial%2520of%2520omega-3%2520fatty%2520acid%2520%2528ethyl%2520eicosapentaenoic%2520acid%2529%2520supplementation%2520for%2520residual%2520symptoms%2520and%2520cognitive%2520impairment%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D2071%26epage%3D2074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Horrobin, D. F.</span><span> </span><span class="NLM_article-title">Omega-3 fatty acid for schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.160.1.188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12505833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FhtVWhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2003&pages=188-189&author=D.+F.+Horrobin&title=Omega-3+fatty+acid+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">omega-3 Fatty acid for schizophrenia</span></div><div class="casAuthors">Horrobin David F</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">188-9; author reply 189</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsO5OOVwADCMvLc4ARHEmzfW6udTcc2eYtF1z9coEmkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FhtVWhtA%253D%253D&md5=703fdda4b3394cdc41095d658485b671</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.160.1.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.160.1.188%26sid%3Dliteratum%253Aachs%26aulast%3DHorrobin%26aufirst%3DD.%2BF.%26atitle%3DOmega-3%2520fatty%2520acid%2520for%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2003%26volume%3D160%26spage%3D188%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Bartzokis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuechterlein, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altshuler, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mintz, J.</span><span> </span><span class="NLM_article-title">Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2007.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17407804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2svgtFSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2007&pages=13-22&author=G.+Bartzokisauthor=P.+H.+Luauthor=K.+H.+Nuechterleinauthor=M.+Gitlinauthor=C.+Doiauthor=N.+Edwardsauthor=C.+Lieuauthor=L.+L.+Altshulerauthor=J.+Mintz&title=Differential+effects+of+typical+and+atypical+antipsychotics+on+brain+myelination+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia</span></div><div class="casAuthors">Bartzokis George; Lu Po H; Nuechterlein Keith H; Gitlin Michael; Doi Clarissa; Edwards Nancy; Lieu Christopher; Altshuler Lori L; Mintz Jim</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">13-22</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">CONTEXT:  Imaging and post-mortem studies provide converging evidence that patients with schizophrenia have a dysregulated developmental trajectory of frontal lobe myelination even in adulthood.  Atypical antipsychotics have been shown to have a wide spectrum of efficacy across multiple psychiatric diseases and to be particularly efficacious in treatment resistant cases of disorders such as schizophrenia.  OBJECTIVE:  To test the a priori hypothesis that antipsychotic medications may differentially impact frontal lobe myelination in patients with schizophrenia.  DESIGN, SETTING, AND PARTICIPANTS:  Participants ranged in age from 18-35 years, were all male, and were recruited by a single group of investigators using the same criteria.  Two cohorts of subjects with schizophrenia early in their disease who were treated either with oral risperidone (Ris) or fluphenazine decanoate (Fd) were imaged in conjunction with cohorts of healthy controls.  Each cohort was imaged using a different MRI instrument using identical imaging sequences.  MAIN OUTCOME MEASURE:  MRI measures of frontal lobe white matter volume.  RESULTS:  We estimated differences due to differences in the MRI instruments used in the two studies in the two healthy control groups matched to the patient samples, adjusting for age and other covariates.  We then statistically removed those differences (which we assumed were due to instrument effects) from the data in the schizophrenia samples by subtraction.  Relative to the differences seen in controls, the two groups of schizophrenic patients differed in their pattern of frontal lobe structure with the Ris-treated group having significantly larger white matter volume than the Fd group.  CONCLUSIONS:  The results suggest that the choice of antipsychotic treatment may differentially impact brain myelination in adults with schizophrenia.  Prospective studies are needed to confirm this finding.  MRI can be used to dissect subtle differences in brain tissue characteristics and thus could help clarify the effect of pharmacologic treatments on neurodevelopmental and pathologic processes in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZ4Oqj7RRORXO4gDb7JggCfW6udTcc2eaa-Yvtvvd7qLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svgtFSrsQ%253D%253D&md5=6cee317df9bd90db873f7d5603249ead</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2007.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2007.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DBartzokis%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DP.%2BH.%26aulast%3DNuechterlein%26aufirst%3DK.%2BH.%26aulast%3DGitlin%26aufirst%3DM.%26aulast%3DDoi%26aufirst%3DC.%26aulast%3DEdwards%26aufirst%3DN.%26aulast%3DLieu%26aufirst%3DC.%26aulast%3DAltshuler%26aufirst%3DL.%2BL.%26aulast%3DMintz%26aufirst%3DJ.%26atitle%3DDifferential%2520effects%2520of%2520typical%2520and%2520atypical%2520antipsychotics%2520on%2520brain%2520myelination%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D93%26spage%3D13%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Owen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. C.</span><span> </span><span class="NLM_article-title">Schizophrenia: genes at last</span> <span class="citation_source-journal">Trends Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">518</span><span class="NLM_x">–</span> <span class="NLM_lpage">525</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.tig.2005.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16009449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Squ7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2005&pages=518-525&author=M.+J.+Owenauthor=N.+Craddockauthor=M.+C.+O%E2%80%99Donovan&title=Schizophrenia%3A+genes+at+last"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia: genes at last?</span></div><div class="casAuthors">Owen, M. J.; Craddock, N.; O'Donovan, M. C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">518-525</span>CODEN:
                <span class="NLM_cas:coden">TRGEE2</span>;
        ISSN:<span class="NLM_cas:issn">0168-9525</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Genetic epidemiol. studies suggest that individual variation in susceptibility to schizophrenia is largely genetic, reflecting alleles of moderate to small effect in multiple genes.  Mol. genetic studies have identified several potential regions of linkage and two assocd. chromosomal abnormalities, and evidence is accumulating in favor of several positional candidate genes.  Currently, the positional candidate genes for which we consider the evidence to be strong are those encoding dysbindin (DTNBP1) and neuregulin 1 (NRG1).  For other genes, disrupted in schizophrenia 1 (DISC1), D-amino-acid oxidase (DAO), D-amino-acid oxidase activator (DAOA, formerly known as G72) and regulator of G-protein signaling 4 (RGS4), the data are promising but not yet compelling.  The identification of these, and other susceptibility genes, will open up new avenues for research aimed at understanding the pathogenesis of schizophrenia, and will catalyze a re-appraisal of the classification of psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgdd8Y2a-2H7Vg90H21EOLACvtfcHk0liqQePHzassOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Squ7o%253D&md5=19a3170e0a9a413f94d8f6d3fe6058cd</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.tig.2005.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tig.2005.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DCraddock%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26atitle%3DSchizophrenia%253A%2520genes%2520at%2520last%26jtitle%3DTrends%2520Genet.%26date%3D2005%26volume%3D21%26spage%3D518%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Harrison, P. J.</span><span> </span><span class="NLM_article-title">Schizophrenia susceptibility genes and neurodevelopment</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2007.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17481418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s3ntlShuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=1119-1120&author=P.+J.+Harrison&title=Schizophrenia+susceptibility+genes+and+neurodevelopment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia susceptibility genes and neurodevelopment</span></div><div class="casAuthors">Harrison Paul J</div><div class="citationInfo"><span class="NLM_cas:title">Biological psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-20</span>
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsatmfAEXXwFWTCLT8lX9SfW6udTcc2eaa-Yvtvvd7qLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3ntlShuw%253D%253D&md5=0298cb28512bf0631b7ce968b633c8bc</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2007.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2007.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DP.%2BJ.%26atitle%3DSchizophrenia%2520susceptibility%2520genes%2520and%2520neurodevelopment%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D61%26spage%3D1119%26epage%3D1120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Arranz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Leon, J.</span><span> </span><span class="NLM_article-title">Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4002009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17549063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1Crurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=707-747&author=M.+J.+Arranzauthor=J.+de+Leon&title=Pharmacogenetics+and+pharmacogenomics+of+schizophrenia%3A+a+review+of+last+decade+of+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research</span></div><div class="casAuthors">Arranz, M. J.; de Leon, J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">707-747</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The last decade of research into the pharmacogenetics of antipsychotics has seen the development of genetic tests to det. the patients' metabolic status and the first attempts at personalization of antipsychotic treatment.  The most significant results are the assocn. between drug metabolic polymorphisms, mainly in cytochrome P 450 genes, with variations in drug metabolic rates and side effects.  Patients with genetically detd. CYP2D6 poor metabolizer (PMs) status may require lower doses of antipsychotic.  Alternatively, CYP2D6 ultrarapid metabolizers (UMs) will need increased drug dosage to obtain therapeutic response.  Addnl., polymorphisms in dopamine and serotonin receptor genes are repeatedly found assocd. with response phenotypes, probably reflecting the strong affinities that most antipsychotics display for these receptors.  In particular, there is important evidence suggesting assocn. between dopamine 2 receptor (D2) polymorphisms (Taq I and -141-C Ins/Del) and a dopamine 3 receptor (D3) polymorphism (Ser9Gly) with antipsychotic response and drug-induced tardive dyskinesia.  Addnl., there is accumulating evidence indicating the influence of a 5-HT2C polymorphism (-759-T/C) in antipsychotic-induced wt. gain.  Application of this knowledge to clin. practice is slowly gathering pace, with pretreatment detn. of individual's drug metabolic rates, via CYP genotyping, leading the field.  Genetic detn. of patients' metabolic status is expected to bring clin. benefits by helping to adjust therapeutic doses and reduce adverse reactions.  Genetic tests for the pretreatment prediction of antipsychotic response, although still in its infancy, have obvious implications for the selection and improvement of antipsychotic treatment.  These developments can be considered as successes, but the objectives of bringing pharmacogenetic and pharmacogenomic research in psychiatric clin. practice are far from being realized.  Further development of genetic tests is required before the concept of tailored treatment can be applied to psychopharmatherapy.  This review aims to summarize the key findings from the last decade of research in the field.  Current knowledge on genetic prediction of drug metabolic status, general response and drug-induced side effects will be reviewed and future pharmacogenomic and epigenetic research will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMc1xH6xQVzbVg90H21EOLACvtfcHk0liGNr81F8DDFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1Crurc%253D&md5=abadb4851c30ba3856ec52dd5ee8bac3</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4002009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4002009%26sid%3Dliteratum%253Aachs%26aulast%3DArranz%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BLeon%26aufirst%3DJ.%26atitle%3DPharmacogenetics%2520and%2520pharmacogenomics%2520of%2520schizophrenia%253A%2520a%2520review%2520of%2520last%2520decade%2520of%2520research%26jtitle%3DMol.%2520Psychiatry%26date%3D2007%26volume%3D12%26spage%3D707%26epage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Ioannidis, J. P.</span><span> </span><span class="NLM_article-title">Commentary: grading the credibility of molecular evidence for complex diseases</span> <span class="citation_source-journal">Int. J. Epidemiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">572</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fije%2Fdyl003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16540537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28zjtVyitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2006&pages=572-578&author=J.+P.+Ioannidis&title=Commentary%3A+grading+the+credibility+of+molecular+evidence+for+complex+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Commentary: grading the credibility of molecular evidence for complex diseases</span></div><div class="casAuthors">Ioannidis John P A</div><div class="citationInfo"><span class="NLM_cas:title">International journal of epidemiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">572-8; discussion 593-6</span>
        ISSN:<span class="NLM_cas:issn">0300-5771</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyqotWrLt9_AvupmecNw_lfW6udTcc2eZFOqM5OcXZarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zjtVyitg%253D%253D&md5=6587a7ef2d542e8e87c05c352b437008</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1093%2Fije%2Fdyl003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fije%252Fdyl003%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DJ.%2BP.%26atitle%3DCommentary%253A%2520grading%2520the%2520credibility%2520of%2520molecular%2520evidence%2520for%2520complex%2520diseases%26jtitle%3DInt.%2520J.%2520Epidemiol.%26date%3D2006%26volume%3D35%26spage%3D572%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Tunbridge, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Catechol-<i>o</i>-methyltransferase, cognition, and psychosis: Val158Met and beyond</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2005.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16476412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmsl2jurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=141-151&author=E.+M.+Tunbridgeauthor=P.+J.+Harrisonauthor=D.+R.+Weinberger&title=Catechol-o-methyltransferase%2C+cognition%2C+and+psychosis%3A+Val158Met+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond</span></div><div class="casAuthors">Tunbridge, Elizabeth M.; Harrison, Paul J.; Weinberger, Daniel R.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">This review summarizes our current understanding of catechol-o-methyltransferase (COMT) and how it relates to brain function and schizophrenia.  We begin by considering the COMT gene, its transcripts and proteins, and its relevance for central catecholamine function.  We then describe how variation in COMT activity affects the function of the prefrontal cortex (PFC) and assocd. areas, reviewing evidence that COMT modulates executive function and working memory and highlighting recent data that also implicate it in emotional processing.  Finally, we discuss briefly the genetic assocn. between COMT and schizophrenia, focusing in particular on the complex interaction of functional loci within the gene that may underlie the mixed results of studies to date.  We conclude by outlining preliminary data indicating that COMT is a promising therapeutic target for ameliorating the cognitive deficits assocd. with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp242swF50Jc7Vg90H21EOLACvtfcHk0liGNr81F8DDFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmsl2jurw%253D&md5=18505f5bdbdaa84a38b47ca604e873fb</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DTunbridge%26aufirst%3DE.%2BM.%26aulast%3DHarrison%26aufirst%3DP.%2BJ.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DCatechol-o-methyltransferase%252C%2520cognition%252C%2520and%2520psychosis%253A%2520Val158Met%2520and%2520beyond%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D60%26spage%3D141%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Diatchenko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slade, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nackley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigurdsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabalina, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shagin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Max, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makarov, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maixner, W.</span><span> </span><span class="NLM_article-title">Genetic basis for individual variations in pain perception and the development of a chronic pain condition</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fhmg%2Fddi013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15537663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFGlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2005&pages=135-143&author=L.+Diatchenkoauthor=G.+D.+Sladeauthor=A.+G.+Nackleyauthor=K.+Bhalangauthor=A.+Sigurdssonauthor=I.+Belferauthor=D.+Goldmanauthor=K.+Xuauthor=S.+A.+Shabalinaauthor=D.+Shaginauthor=M.+B.+Maxauthor=S.+S.+Makarovauthor=W.+Maixner&title=Genetic+basis+for+individual+variations+in+pain+perception+and+the+development+of+a+chronic+pain+condition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic basis for individual variations in pain perception and the development of a chronic pain condition</span></div><div class="casAuthors">Diatchenko, Luda; Slade, Gary D.; Nackley, Andrea G.; Bhalang, Konakporn; Sigurdsson, Asgeir; Belfer, Inna; Goldman, David; Xu, Ke; Shabalina, Svetlana A.; Shagin, Dmitry; Max, Mitchell B.; Makarov, Sergei S.; Maixner, William</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-143</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Pain sensitivity varies substantially among humans.  A significant part of the human population develops chronic pain conditions that are characterized by heightened pain sensitivity.  We identified three genetic variants (haplotypes) of the gene encoding catecholamine-O-methyltransferase (COMT) that we designated as low pain sensitivity (LPS), av. pain sensitivity (APS) and high pain sensitivity (HPS).  We show that these haplotypes encompass 96% of the human population, and five combinations of these haplotypes are strongly assocd. (P=0.0004) with variation in the sensitivity to exptl. pain.  The presence of even a single LPS haplotype diminishes, by as much as 2.3 times, the risk of developing myogenous temporomandibular joint disorder (TMD), a common musculoskeletal pain condition.  The LPS haplotype produces much higher levels of COMT enzymic activity when compared with the APS or HPS haplotypes.  Inhibition of COMT in the rat results in a profound increase in pain sensitivity.  Thus, COMT activity substantially influences pain sensitivity, and the three major haplotypes det. COMT activity in humans that inversely correlates with pain sensitivity and the risk of developing TMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogws27k2gPu7Vg90H21EOLACvtfcHk0liGNr81F8DDFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFGlsA%253D%253D&md5=475889479a249d6ac898612693d97182</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddi013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddi013%26sid%3Dliteratum%253Aachs%26aulast%3DDiatchenko%26aufirst%3DL.%26aulast%3DSlade%26aufirst%3DG.%2BD.%26aulast%3DNackley%26aufirst%3DA.%2BG.%26aulast%3DBhalang%26aufirst%3DK.%26aulast%3DSigurdsson%26aufirst%3DA.%26aulast%3DBelfer%26aufirst%3DI.%26aulast%3DGoldman%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DShabalina%26aufirst%3DS.%2BA.%26aulast%3DShagin%26aufirst%3DD.%26aulast%3DMax%26aufirst%3DM.%2BB.%26aulast%3DMakarov%26aufirst%3DS.%2BS.%26aulast%3DMaixner%26aufirst%3DW.%26atitle%3DGenetic%2520basis%2520for%2520individual%2520variations%2520in%2520pain%2520perception%2520and%2520the%2520development%2520of%2520a%2520chronic%2520pain%2520condition%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2005%26volume%3D14%26spage%3D135%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Alsobrook, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zohar, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leboyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabane, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebstein, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, D. L.</span><span> </span><span class="NLM_article-title">Association between the COMT locus and obsessive-compulsive disorder in females but not males</span> <span class="citation_source-journal">Am. J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2Fajmg.10040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11840516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD387hvVahsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2002&pages=116-120&author=J.+P.+Alsobrookauthor=A.+H.+Zoharauthor=M.+Leboyerauthor=N.+Chabaneauthor=R.+P.+Ebsteinauthor=D.+L.+Pauls&title=Association+between+the+COMT+locus+and+obsessive-compulsive+disorder+in+females+but+not+males"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Association between the COMT locus and obsessive-compulsive disorder in females but not males</span></div><div class="casAuthors">Alsobrook John P 2nd; Zohar Ada H; Leboyer Marion; Chabane Nadia; Ebstein Richard P; Pauls David L</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-20</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">A polymorphism in the coding region of catechol-O-methyltransferase gene (COMT) was previously reported to be associated with obsessive-compulsive disorder (OCD), particularly in male probands.  We attempted to replicate the previous finding using a family-based genetic design in haplotype relative risk (HRR) and transmission disequilibrium (TDT) analyses.  Fifty-six OCD probands and their parents were genotyped for the COMT locus using established methods.  Analysis of allele and genotype frequencies between the proband genotypes and the control (parental nontransmitted) genotypes failed to replicate the previous finding of gender divergence, gave no evidence of overall association, nor was linkage detected by TDT.  However, further analysis of the COMT allele frequencies by proband gender gave evidence of a mildly significant association with the low-activity COMT allele in female probands (P=0.049), but not in male probands.  These findings indicate that COMT may be etiologically relevant to OCD in a gender-specific manner opposite to that shown in previous studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXMeBCgq3LydFxYDaSSP8XfW6udTcc2ebCNAeAdTyePLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387hvVahsg%253D%253D&md5=d1f9d8e2235629763465b7532c009151</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1002%2Fajmg.10040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajmg.10040%26sid%3Dliteratum%253Aachs%26aulast%3DAlsobrook%26aufirst%3DJ.%2BP.%26aulast%3DZohar%26aufirst%3DA.%2BH.%26aulast%3DLeboyer%26aufirst%3DM.%26aulast%3DChabane%26aufirst%3DN.%26aulast%3DEbstein%26aufirst%3DR.%2BP.%26aulast%3DPauls%26aufirst%3DD.%2BL.%26atitle%3DAssociation%2520between%2520the%2520COMT%2520locus%2520and%2520obsessive-compulsive%2520disorder%2520in%2520females%2520but%2520not%2520males%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%26date%3D2002%26volume%3D114%26spage%3D116%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Erdal, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herken, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlu, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayazit, Y. A.</span><span> </span><span class="NLM_article-title">Significance of catechol-<i>O</i>-methyltransferase gene polymorphism in myofacial pain syndrome</span> <span class="citation_source-journal">Pain Clinic</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1163%2F156856903767650844" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=309-313&author=M.+E.+Erdalauthor=H.+Herkenauthor=M.+N.+Mutluauthor=Y.+A.+Bayazit&title=Significance+of+catechol-O-methyltransferase+gene+polymorphism+in+myofacial+pain+syndrome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1163%2F156856903767650844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1163%252F156856903767650844%26sid%3Dliteratum%253Aachs%26aulast%3DErdal%26aufirst%3DM.%2BE.%26aulast%3DHerken%26aufirst%3DH.%26aulast%3DMutlu%26aufirst%3DM.%2BN.%26aulast%3DBayazit%26aufirst%3DY.%2BA.%26atitle%3DSignificance%2520of%2520catechol-O-methyltransferase%2520gene%2520polymorphism%2520in%2520myofacial%2520pain%2520syndrome%26jtitle%3DPain%2520Clinic%26date%3D2003%26volume%3D15%26spage%3D309%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Goodman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavigne, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helzlsouer, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selhub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yager, J. D.</span><span> </span><span class="NLM_article-title">COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1661</span><span class="NLM_x">–</span> <span class="NLM_lpage">1665</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=1661-1665&author=J.+E.+Goodmanauthor=J.+A.+Lavigneauthor=K.+Wuauthor=K.+J.+Helzlsouerauthor=P.+T.+Stricklandauthor=J.+Selhubauthor=J.+D.+Yager&title=COMT+genotype%2C+micronutrients+in+the+folate+metabolic+pathway+and+breast+cancer+risk"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DJ.%2BE.%26aulast%3DLavigne%26aufirst%3DJ.%2BA.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DHelzlsouer%26aufirst%3DK.%2BJ.%26aulast%3DStrickland%26aufirst%3DP.%2BT.%26aulast%3DSelhub%26aufirst%3DJ.%26aulast%3DYager%26aufirst%3DJ.%2BD.%26atitle%3DCOMT%2520genotype%252C%2520micronutrients%2520in%2520the%2520folate%2520metabolic%2520pathway%2520and%2520breast%2520cancer%2520risk%26jtitle%3DCarcinogenesis%26date%3D2001%26volume%3D22%26spage%3D1661%26epage%3D1665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Voutilainen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuomainen, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korhonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mursu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virtanen, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Happonen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfthan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlund, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">North, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosher, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauhanen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiihonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salonen, J. T.</span><span> </span><span class="NLM_article-title">Functional COMT Val158Met polymorphism, risk of acute coronary events and serum homocysteine: the kuopio ischaemic heart disease risk factor study</span> <span class="citation_source-journal">PLoS ONE</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e181</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=e181&author=S.+Voutilainenauthor=T.+P.+Tuomainenauthor=M.+Korhonenauthor=J.+Mursuauthor=J.+K.+Virtanenauthor=P.+Happonenauthor=G.+Alfthanauthor=I.+Erlundauthor=K.+E.+Northauthor=M.+J.+Mosherauthor=J.+Kauhanenauthor=J.+Tiihonenauthor=G.+A.+Kaplanauthor=J.+T.+Salonen&title=Functional+COMT+Val158Met+polymorphism%2C+risk+of+acute+coronary+events+and+serum+homocysteine%3A+the+kuopio+ischaemic+heart+disease+risk+factor+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVoutilainen%26aufirst%3DS.%26aulast%3DTuomainen%26aufirst%3DT.%2BP.%26aulast%3DKorhonen%26aufirst%3DM.%26aulast%3DMursu%26aufirst%3DJ.%26aulast%3DVirtanen%26aufirst%3DJ.%2BK.%26aulast%3DHapponen%26aufirst%3DP.%26aulast%3DAlfthan%26aufirst%3DG.%26aulast%3DErlund%26aufirst%3DI.%26aulast%3DNorth%26aufirst%3DK.%2BE.%26aulast%3DMosher%26aufirst%3DM.%2BJ.%26aulast%3DKauhanen%26aufirst%3DJ.%26aulast%3DTiihonen%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DG.%2BA.%26aulast%3DSalonen%26aufirst%3DJ.%2BT.%26atitle%3DFunctional%2520COMT%2520Val158Met%2520polymorphism%252C%2520risk%2520of%2520acute%2520coronary%2520events%2520and%2520serum%2520homocysteine%253A%2520the%2520kuopio%2520ischaemic%2520heart%2520disease%2520risk%2520factor%2520study%26jtitle%3DPLoS%2520ONE%26date%3D2007%26volume%3D2%26spage%3De181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Frisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danziger, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelovsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenig, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mimouni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizman, A.</span><span> </span><span class="NLM_article-title">Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4000830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11317231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFGlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=243-245&author=A.+Frischauthor=N.+Lauferauthor=Y.+Danzigerauthor=E.+Michaelovskyauthor=S.+Leorauthor=C.+Carelauthor=D.+Steinauthor=S.+Fenigauthor=M.+Mimouniauthor=A.+Apterauthor=A.+Weizman&title=Association+of+anorexia+nervosa+with+the+high+activity+allele+of+the+COMT+gene%3A+a+family-based+study+in+Israeli+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients</span></div><div class="casAuthors">Frisch, A.; Laufer, N.; Danziger, Y.; Michaelovsky, E.; Leor, S.; Carel, C.; Stein, D.; Fenig, S.; Mimouni, M.; Apter, A.; Weizman, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-245</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Anorexia nervosa (AN) is a common, severe and disabling psychiatric disorder, characterized by profound wt. loss and body image disturbance.  Family and twin studies indicate a significant genetic contribution and pharmacol. data suggest possible dysfunction of the serotonergic and dopaminergic pathways.  Catechol-O-methyltransferase (COMT) is a candidate gene for mediating susceptibility to AN since it is involved in the dopamine catabolism and because its functional polymorphism (Val/Met 158) dets. high (H) and low (L) enzymic activity alleles.  51 Israeli AN patients and their parents were genotyped with the COMT polymorphism.  Using the haplotype relative risk (HRR) method it was found that the frequency of the H allele among alleles transmitted to AN patients from their parents was significantly higher than in those not transmitted (68% vs 51% X2 = 5.20, df = 1, P = 0.023, odds ratio: 2.01).  Transmission disequil. test (TDT) revealed that out of 49 heterozygote parents the H allele was transmitted to AN patients 33 times while the L allele was transmitted only 16 (McNemar's X2 = 5.90, df = 1, P = 0.015).  The study suggests that the COMT gene is assocd. with genetic susceptibility to AN, and that individuals homozygous for the high activity allele (HH) have a 2-fold increased risk for development of the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfFok5w6jlcrVg90H21EOLACvtfcHk0lgR9Y58ps33ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFGlu7Y%253D&md5=2a2e9b029bf90be11a858602bf7a3039</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4000830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4000830%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DA.%26aulast%3DLaufer%26aufirst%3DN.%26aulast%3DDanziger%26aufirst%3DY.%26aulast%3DMichaelovsky%26aufirst%3DE.%26aulast%3DLeor%26aufirst%3DS.%26aulast%3DCarel%26aufirst%3DC.%26aulast%3DStein%26aufirst%3DD.%26aulast%3DFenig%26aufirst%3DS.%26aulast%3DMimouni%26aufirst%3DM.%26aulast%3DApter%26aufirst%3DA.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DAssociation%2520of%2520anorexia%2520nervosa%2520with%2520the%2520high%2520activity%2520allele%2520of%2520the%2520COMT%2520gene%253A%2520a%2520family-based%2520study%2520in%2520Israeli%2520patients%26jtitle%3DMol.%2520Psychiatry%26date%3D2001%26volume%3D6%26spage%3D243%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">McGrath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawachi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascherio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colditz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, I.</span><span> </span><span class="NLM_article-title">Association between catechol-<i>O</i>-methyltransferase and phobic anxiety</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">1703</span><span class="NLM_x">–</span> <span class="NLM_lpage">1705</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.161.9.1703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15337664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2cvjtVSitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2004&pages=1703-1705&author=M.+McGrathauthor=I.+Kawachiauthor=A.+Ascherioauthor=G.+A.+Colditzauthor=D.+J.+Hunterauthor=I.+De+Vivo&title=Association+between+catechol-O-methyltransferase+and+phobic+anxiety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Association between catechol-O-methyltransferase and phobic anxiety</span></div><div class="casAuthors">McGrath Monica; Kawachi Ichiro; Ascherio Alberto; Colditz Graham A; Hunter David J; De Vivo Immaculata</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1703-5</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The authors assessed the association between the catechol-O-methyltransferase (COMT) Val158Met polymorphism and scores on the phobic anxiety scale of the Crown-Crisp Experimental Index.  METHOD:  A total of 1,234 women completed the Crown-Crisp Experimental Index phobic anxiety scale and were genotyped for the COMT polymorphism.  The authors used unconditional logistic regression to compute odds ratios and 95% confidence intervals (CIs) to evaluate the association between the COMT genotype and phobic anxiety.  RESULTS:  The mean scores for the three genotypes were statistically significantly different.  Compared to the COMT Met/Met genotype, the age-adjusted odds ratio for scoring >/=6 compared to scoring 0 or 1 were 1.15 (95% CI=0.71-1.85) and 1.99 (95% CI=1.17-3.40) for the COMT Val/Met and COMT Val/Val genotypes, respectively; a significant gene dosage effect was observed.  CONCLUSIONS:  Our results suggest that the functional COMT polymorphism is associated with the development of phobic anxiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQADwu3Vrlx25dYoSR9eyvsfW6udTcc2ebJ6fowXNPbv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvjtVSitQ%253D%253D&md5=7d56b7ee71482410f9f43b343aad47e7</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.161.9.1703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.161.9.1703%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DM.%26aulast%3DKawachi%26aufirst%3DI.%26aulast%3DAscherio%26aufirst%3DA.%26aulast%3DColditz%26aufirst%3DG.%2BA.%26aulast%3DHunter%26aufirst%3DD.%2BJ.%26aulast%3DDe%2BVivo%26aufirst%3DI.%26atitle%3DAssociation%2520between%2520catechol-O-methyltransferase%2520and%2520phobic%2520anxiety%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2004%26volume%3D161%26spage%3D1703%26epage%3D1705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Woo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, B. H.</span><span> </span><span class="NLM_article-title">The association between panic disorder and the L/L genotype of catechol-<i>O</i>-methyltransferase</span> <span class="citation_source-journal">J. Psychiatr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.jpsychires.2004.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15203287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2czgtlemsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2004&pages=365-370&author=J.+M.+Wooauthor=K.+S.+Yoonauthor=Y.+H.+Choiauthor=K.+S.+Ohauthor=Y.+S.+Leeauthor=B.+H.+Yu&title=The+association+between+panic+disorder+and+the+L%2FL+genotype+of+catechol-O-methyltransferase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The association between panic disorder and the L/L genotype of catechol-O-methyltransferase</span></div><div class="casAuthors">Woo Jong-Min; Yoon Kyung-Sik; Choi Young-Hee; Oh Kang-Sub; Lee Young-Sik; Yu Bum-Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">365-70</span>
        ISSN:<span class="NLM_cas:issn">0022-3956</span>.
    </div><div class="casAbstract">To clarify the role of catechol-O-methyltransferase (COMT) polymorphism in panic disorder (PD), we investigated a large group of Korean PD patients (N = 178) and controls (N = 182) using a case-control study.  We also assessed the response to paroxetine treatment and other clinical variables in the PD patients.  The increase in the COMT(L) allele was not statistically significant in PD (p = 0.104).  However, compared with the sum of the other genotypes, the frequency of the L/L genotype was significantly higher in PD (p = 0.042).  The odd ratios (ORs) also indicated a significant effect of the homozygosity for the COMT(L) allele on an increased risk for PD (OR=2.38; 95% CI 1.03-5.51).  In addition, patients with L/L genotype had higher trait-anxiety levels (p = 0.030) and poorer treatment response to paroxetine than those with other genotypes (p = 0.002).  Our results suggest that the COMT L/L genotype is associated with PD and the genetic variant of the COMT enzyme may be related to the clinical severity and treatment response to paroxetine in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuwYbRV842iBe4jJGKT5N0fW6udTcc2ebJ6fowXNPbv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czgtlemsw%253D%253D&md5=1b37515d2059c988175fef918f5bcaa9</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2004.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2004.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DJ.%2BM.%26aulast%3DYoon%26aufirst%3DK.%2BS.%26aulast%3DChoi%26aufirst%3DY.%2BH.%26aulast%3DOh%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DYu%26aufirst%3DB.%2BH.%26atitle%3DThe%2520association%2520between%2520panic%2520disorder%2520and%2520the%2520L%252FL%2520genotype%2520of%2520catechol-O-methyltransferase%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2004%26volume%3D38%26spage%3D365%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Baune, B. T.; Hohoff, C.; Berger, K.; Neumann, A.; Mortensen, S.; Roehrs, T.; Deckert, J.; Arolt, V.; Domschke, K.</span><span> </span><span class="NLM_article-title">Association of the COMT val158met variant with antidepressant treatment response in major depression</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Baune%2C+B.+T.%3B+Hohoff%2C+C.%3B+Berger%2C+K.%3B+Neumann%2C+A.%3B+Mortensen%2C+S.%3B+Roehrs%2C+T.%3B+Deckert%2C+J.%3B+Arolt%2C+V.%3B+Domschke%2C+K.+Association+of+the+COMT+val158met+variant+with+antidepressant+treatment+response+in+major+depression.+Neuropsychopharmacology%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaune%26aufirst%3DB.%2BT.%26atitle%3DAssociation%2520of%2520the%2520COMT%2520val158met%2520variant%2520with%2520antidepressant%2520treatment%2520response%2520in%2520major%2520depression%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Borroni, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agosti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghianda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenzi, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caimi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Luca, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padovani, A.</span><span> </span><span class="NLM_article-title">Catechol-<i>O</i>-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer disease</span> <span class="citation_source-journal">Neurosci. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2004&pages=127-129&author=B.+Borroniauthor=C.+Agostiauthor=S.+Archettiauthor=C.+Costanziauthor=S.+Bonomiauthor=D.+Ghiandaauthor=G.+L.+Lenziauthor=L.+Caimiauthor=M.+Di+Lucaauthor=A.+Padovani&title=Catechol-O-methyltransferase+gene+polymorphism+is+associated+with+risk+of+psychosis+in+Alzheimer+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBorroni%26aufirst%3DB.%26aulast%3DAgosti%26aufirst%3DC.%26aulast%3DArchetti%26aufirst%3DS.%26aulast%3DCostanzi%26aufirst%3DC.%26aulast%3DBonomi%26aufirst%3DS.%26aulast%3DGhianda%26aufirst%3DD.%26aulast%3DLenzi%26aufirst%3DG.%2BL.%26aulast%3DCaimi%26aufirst%3DL.%26aulast%3DDi%2BLuca%26aufirst%3DM.%26aulast%3DPadovani%26aufirst%3DA.%26atitle%3DCatechol-O-methyltransferase%2520gene%2520polymorphism%2520is%2520associated%2520with%2520risk%2520of%2520psychosis%2520in%2520Alzheimer%2520disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D2004%26volume%3D370%26spage%3D127%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">The genome: five years on</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16425665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28%252Fjsl2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=14-17&author=M.+Williams&title=The+genome%3A+five+years+on"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The genome: five years on</span></div><div class="casAuthors">Williams Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in investigational drugs (London, England : 2000)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-7</span>
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3trd7SzcHM_6BottYdIAWfW6udTcc2eZ0HU9l9moAuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252Fjsl2qtw%253D%253D&md5=cb4a4715130c6633f904daed207f65a8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DThe%2520genome%253A%2520five%2520years%2520on%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2006%26volume%3D7%26spage%3D14%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Bassett, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">AbdelMalik, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheorghiu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husted, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weksberg, R.</span><span> </span><span class="NLM_article-title">The schizophrenia phenotype in 22q11 deletion syndrome</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1580</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.160.9.1580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12944331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3svgsFWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2003&pages=1580-1586&author=A.+S.+Bassettauthor=E.+W.+Chowauthor=P.+AbdelMalikauthor=M.+Gheorghiuauthor=J.+Hustedauthor=R.+Weksberg&title=The+schizophrenia+phenotype+in+22q11+deletion+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">The schizophrenia phenotype in 22q11 deletion syndrome</span></div><div class="casAuthors">Bassett Anne S; Chow Eva W C; AbdelMalik Philip; Gheorghiu Mirona; Husted Janice; Weksberg Rosanna</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1580-6</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  This study investigated the schizophrenia phenotype in 24 subjects with 22q11 deletion syndrome (22qDS) and schizophrenia (22qDS-schizophrenia), a rare but relatively homogenous genetic subtype of schizophrenia associated with a microdeletion on chromosome 22.  Individuals with 22qDS are at genetically high risk for schizophrenia.  METHOD:  Standard measures of signs, symptoms, and course of schizophrenia were assessed in 16 adults with 22qDS-schizophrenia who did not meet criteria for mental retardation and in 46 adults with schizophrenia without evidence of 22qDS from a community familial sample.  RESULTS:  There were no significant differences in age at onset, lifetime or cross-sectional core positive and negative schizophrenic symptoms, or global functioning between the two groups of patients with schizophrenia.  Patients with 22qDS-schizophrenia had higher excitement subscale scores and less lifetime substance use than the comparison patients with schizophrenia, but no significant differences in anxiety-depression symptom severity were found between the groups.  CONCLUSIONS:  These findings indicate that the core clinical schizophrenia phenotype would not distinguish individuals with a 22qDS subtype from those with schizophrenia who did not have the 22qDS subtype.  The results provide further support for the utility of 22qDS-schizophrenia as a neurodevelopmental model of schizophrenia as well as support for prospective studies of individuals with 22qDS to help identify precursors of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREF4-5Nt9cPuIHSmpohpd0fW6udTcc2eZ0HU9l9moAuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgsFWmtw%253D%253D&md5=23337cc52c5e8ca653c7a68958f0f52c</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.160.9.1580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.160.9.1580%26sid%3Dliteratum%253Aachs%26aulast%3DBassett%26aufirst%3DA.%2BS.%26aulast%3DChow%26aufirst%3DE.%2BW.%26aulast%3DAbdelMalik%26aufirst%3DP.%26aulast%3DGheorghiu%26aufirst%3DM.%26aulast%3DHusted%26aufirst%3DJ.%26aulast%3DWeksberg%26aufirst%3DR.%26atitle%3DThe%2520schizophrenia%2520phenotype%2520in%252022q11%2520deletion%2520syndrome%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2003%26volume%3D160%26spage%3D1580%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Bassett, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caluseriu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weksberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, E. W.</span><span> </span><span class="NLM_article-title">Catechol-<i>O</i>-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1135</span><span class="NLM_x">–</span> <span class="NLM_lpage">1140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2006.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17217925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFOrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=1135-1140&author=A.+S.+Bassettauthor=O.+Caluseriuauthor=R.+Weksbergauthor=D.+A.+Youngauthor=E.+W.+Chow&title=Catechol-O-methyl+transferase+and+expression+of+schizophrenia+in+73+adults+with+22q11+deletion+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Catechol-O-methyl Transferase and Expression of Schizophrenia in 73 Adults with 22q11 Deletion Syndrome</span></div><div class="casAuthors">Bassett, Anne S.; Caluseriu, Oana; Weksberg, Rosanna; Young, Donald A.; Chow, Eva W. C.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1135-1140</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Catechol-O-Me transferase (COMT) is a candidate gene for schizophrenia with a role in dopamine metab., particularly in frontal cortex.  COMT is within the region commonly deleted in 22q11 deletion syndrome (22q11DS), a syndrome with high prevalence of schizophrenia.  We examd. the role of COMT in schizophrenia-related expression in 22q11DS.  Methods: We genotyped the COMT functional Val158/108Met allele in 73 Caucasian adults with 22q11DS (36 men, 37 women; aged 33.8, SD 10.1 years; 37 Met, 36 Val hemizygosity) blind to clin. data and assessed effects on symptoms and frontal functioning.  Results: The lower activity Met allele was not significantly more prevalent than the Val allele in 33 subjects with schizophrenia.  Excitement symptoms were more severe, however, and three frontal cognitive tests (theory of mind, Trails B, and olfactory identification), communication, and social functioning measures showed significantly worse performance with Met allele hemizygosity, even after accounting for effects of schizophrenia.  Conclusions: The results suggest that hemizygosity of the COMT functional allele exerts an effect on some measures of frontal functioning in 22q11DS.  Elevated levels of tonic dopamine activation assocd. with the COMT Met allele may underlie these aspects of expression.  We must look elsewhere for causes of the high prevalence of schizophrenia in 22q11DS, however.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeokUayaUXdLVg90H21EOLACvtfcHk0lhtFhqlCqRuoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFOrurs%253D&md5=3a3493e6406da8bd13f819a34698e61d</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DBassett%26aufirst%3DA.%2BS.%26aulast%3DCaluseriu%26aufirst%3DO.%26aulast%3DWeksberg%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DD.%2BA.%26aulast%3DChow%26aufirst%3DE.%2BW.%26atitle%3DCatechol-O-methyl%2520transferase%2520and%2520expression%2520of%2520schizophrenia%2520in%252073%2520adults%2520with%252022q11%2520deletion%2520syndrome%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D61%26spage%3D1135%26epage%3D1140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Egan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolachana, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callicott, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzanti, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">6917</span><span class="NLM_x">–</span> <span class="NLM_lpage">6922</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=6917-6922&author=M.+F.+Eganauthor=T.+E.+Goldbergauthor=B.+S.+Kolachanaauthor=J.+H.+Callicottauthor=C.+M.+Mazzantiauthor=R.+E.+Straubauthor=D.+Goldmanauthor=D.+R.+Weinberger&title=Effect+of+COMT+Val108%2F158+Met+genotype+on+frontal+lobe+function+and+risk+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DKolachana%26aufirst%3DB.%2BS.%26aulast%3DCallicott%26aufirst%3DJ.%2BH.%26aulast%3DMazzanti%26aufirst%3DC.%2BM.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DGoldman%26aufirst%3DD.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DEffect%2520of%2520COMT%2520Val108%252F158%2520Met%2520genotype%2520on%2520frontal%2520lobe%2520function%2520and%2520risk%2520for%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D6917%26epage%3D6922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Boot, E.; Booij, J.; Zinkstok, J.; Abeling, N.; de Haan, L.; Baas, F.; Linszen, D.; van Amelsvoort, T.</span><span> </span><span class="NLM_article-title">Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Boot%2C+E.%3B+Booij%2C+J.%3B+Zinkstok%2C+J.%3B+Abeling%2C+N.%3B+de+Haan%2C+L.%3B+Baas%2C+F.%3B+Linszen%2C+D.%3B+van+Amelsvoort%2C+T.+Disrupted+dopaminergic+neurotransmission+in+22q11+deletion+syndrome.+Neuropsychopharmacology%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoot%26aufirst%3DE.%26atitle%3DDisrupted%2520dopaminergic%2520neurotransmission%2520in%252022q11%2520deletion%2520syndrome%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Lu, B. Y.; Martin, K. E.; Edgar, J. C.; Smith, A. K.; Lewis, S. F.; Escamilla, M. A.; Miller, G. A.; Canive, J. M.</span><span> </span><span class="NLM_article-title">Effect of catechol <i>O</i>-methyltransferase Val(158)Met polymorphism on the P50 gating endophenotype in schizophrenia</span>.  <span class="citation_source-journal">Biol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lu%2C+B.+Y.%3B+Martin%2C+K.+E.%3B+Edgar%2C+J.+C.%3B+Smith%2C+A.+K.%3B+Lewis%2C+S.+F.%3B+Escamilla%2C+M.+A.%3B+Miller%2C+G.+A.%3B+Canive%2C+J.+M.+Effect+of+catechol+O-methyltransferase+Val%28158%29Met+polymorphism+on+the+P50+gating+endophenotype+in+schizophrenia.+Biol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DB.%2BY.%26atitle%3DEffect%2520of%2520catechol%2520O-methyltransferase%2520Val%2528158%2529Met%2520polymorphism%2520on%2520the%2520P50%2520gating%2520endophenotype%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Funke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malhotra, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plocik, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lencz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRosse, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucherlapati, R.</span><span> </span><span class="NLM_article-title">COMT genetic variation confers risk for psychotic and affective disorders: a case control study</span> <span class="citation_source-journal">Behav. Brain Funct.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1186%2F1744-9081-1-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16232322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MngsVSjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=19&author=B.+Funkeauthor=A.+K.+Malhotraauthor=C.+T.+Finnauthor=A.+M.+Plocikauthor=S.+L.+Lakeauthor=T.+Lenczauthor=P.+DeRosseauthor=J.+M.+Kaneauthor=R.+Kucherlapati&title=COMT+genetic+variation+confers+risk+for+psychotic+and+affective+disorders%3A+a+case+control+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">COMT genetic variation confers risk for psychotic and affective disorders: a case control study</span></div><div class="casAuthors">Funke Birgit; Malhotra Anil K; Finn Christine T; Plocik Alex M; Lake Stephen L; Lencz Todd; DeRosse Pamela; Kane John M; Kucherlapati Raju</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral and brain functions : BBF</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Variation in the COMT gene has been implicated in a number of psychiatric disorders, including psychotic, affective and anxiety disorders.  The majority of these studies have focused on the functional Val108/158Met polymorphism and yielded conflicting results, with limited studies examining the relationship between other polymorphisms, or haplotypes, and psychiatric illness.  We hypothesized that COMT variation may confer a general risk for psychiatric disorders and have genotyped four COMT variants (Val158Met, rs737865, rs165599, and a SNP in the P2 promoter [-278A/G; rs2097603]) in 394 Caucasian cases and 467 controls.  Cases included patients with schizophrenia (n = 196), schizoaffective disorder (n = 62), bipolar disorder (n = 82), major depression (n = 30), and patients diagnosed with either psychotic disorder NOS or depressive disorder NOS (n = 24).  RESULTS:  SNP rs2097603, the Val/Met variant and SNP rs165599 were significantly associated (p = 0.004; p = 0.05; p = 0.035) with a broad "all affected" diagnosis.  Haplotype analysis revealed a potentially protective G-A-A-A haplotype haplotype (-278A/G; rs737865; Val108/158Met; rs165599), which was significantly underrepresented in this group (p = 0.0033) and contained the opposite alleles of the risk haplotype previously described by Shifman et al.  Analysis of diagnostic subgroups within the "all affecteds group" showed an association of COMT in patients with psychotic disorders as well as in cases with affective illness although the associated variants differed.  The protective haplotype remained significantly underrepresented in most of these subgroups.  CONCLUSION:  Our results support the view that COMT variation provides a weak general predisposition to neuropsychiatric disease including psychotic and affective disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSep6d9yAzxFoNpW7w2tapOfW6udTcc2eYuJWtGTwMMc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MngsVSjsg%253D%253D&md5=2c981c5931addff99ecb4e267b8bb157</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1186%2F1744-9081-1-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1744-9081-1-19%26sid%3Dliteratum%253Aachs%26aulast%3DFunke%26aufirst%3DB.%26aulast%3DMalhotra%26aufirst%3DA.%2BK.%26aulast%3DFinn%26aufirst%3DC.%2BT.%26aulast%3DPlocik%26aufirst%3DA.%2BM.%26aulast%3DLake%26aufirst%3DS.%2BL.%26aulast%3DLencz%26aufirst%3DT.%26aulast%3DDeRosse%26aufirst%3DP.%26aulast%3DKane%26aufirst%3DJ.%2BM.%26aulast%3DKucherlapati%26aufirst%3DR.%26atitle%3DCOMT%2520genetic%2520variation%2520confers%2520risk%2520for%2520psychotic%2520and%2520affective%2520disorders%253A%2520a%2520case%2520control%2520study%26jtitle%3DBehav.%2520Brain%2520Funct.%26date%3D2005%26volume%3D1%26spage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Apud, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-<i>o</i>-methyltransferase inhibitors</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2165%2F00023210-200721070-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17579498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFCis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=535-557&author=J.+A.+Apudauthor=D.+R.+Weinberger&title=Treatment+of+cognitive+deficits+associated+with+schizophrenia%3A+potential+role+of+catechol-o-methyltransferase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of cognitive deficits associated with schizophrenia. Potential role of catechol-O-methyltransferase inhibitors</span></div><div class="casAuthors">Apud, Jose A.; Weinberger, Daniel R.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">535-557</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  In the last two decades, understanding of the dynamics of dopamine function in the prefrontal cortex and its role in prefrontal cortex physiol. has opened up new avenues for therapeutic interventions in conditions in which prefrontal cortex function is compromised.  Neuropsychol. and imaging studies of prefrontal information processing have confirmed specific cognitive and neurophysiol. abnormalities in individuals with schizophrenia.  Because such findings are also obsd. in the healthy siblings of patients with schizophrenia, they may represent intermediate phenotypes related to schizophrenia susceptibility genes.  Catechol-O-methyltransferase (COMT) represents an important candidate as a susceptibility gene for cognitive dysfunction in schizophrenia because of the unique role this enzyme plays in regulating prefrontal dopaminergic function.  A functional COMT polymorphism (Val158Met) predicts performance in tasks of prefrontal executive function and the neurophysiol. response measured with electroencephalog. and functional magnetic resonance imaging in tasks assessing working memory.  In fact, individuals with the Val/Val genotype, which encodes for the high-activity enzyme resulting in lower dopamine concns. in the prefrontal cortex, perform less well and are less efficient physiol. than Met/Met individuals.  These findings raise the possibility of new pharmacol. interventions for the treatment of prefrontal cortex dysfunction and of predicting outcome based on COMT genotype.  One strategy consists of the use of CNS-penetrant COMT inhibitors such as tolcapone.  A second strategy is to increase extracellular dopamine concns. in the frontal cortex by blocking the noradrenaline (norepinephrine) reuptake system, a secondary mechanism responsible for the disposal of dopamine from synaptic clefts in the prefrontal cortex.  A third possibility involves the use of modafinil, a drug with an unclear mechanism of action but with pos. effects on working memory in rodents.  The potential of these drugs to improve executive cognitive function by selectively increasing dopamine load in the frontal cortex but not in subcortical territories, and the possibility that response to them may be modified by a COMT polymorphism, provides a novel genotype-based targeted pharmacol. approach without abuse potential for the treatment of cognitive disorder in schizophrenia and in other conditions involving prefrontal cortex dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZmnS6TUnyZ7Vg90H21EOLACvtfcHk0ljZj2WUGJKQ8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFCis7s%253D&md5=380a19dbe5725aee9c41c264bee848ac</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.2165%2F00023210-200721070-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00023210-200721070-00002%26sid%3Dliteratum%253Aachs%26aulast%3DApud%26aufirst%3DJ.%2BA.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DTreatment%2520of%2520cognitive%2520deficits%2520associated%2520with%2520schizophrenia%253A%2520potential%2520role%2520of%2520catechol-o-methyltransferase%2520inhibitors%26jtitle%3DCNS%2520Drugs%26date%3D2007%26volume%3D21%26spage%3D535%26epage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Stefansson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigurdsson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinthorsdottir, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjornsdottir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigmundsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brynjolfsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunnarsdottir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivarsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjaltason, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birgisdottir, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonsson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudnadottir, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudmundsdottir, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjornsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingvarsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingason, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigfusson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardardottir, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sainz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johannesson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andresson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudbjartsson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manolescu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frigge, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulcher, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petursson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, K.</span><span> </span><span class="NLM_article-title">Neuregulin 1 and susceptibility to schizophrenia</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">877</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F342734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12145742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD38vos1CjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=877-892&author=H.+Stefanssonauthor=E.+Sigurdssonauthor=V.+Steinthorsdottirauthor=S.+Bjornsdottirauthor=T.+Sigmundssonauthor=S.+Ghoshauthor=J.+Brynjolfssonauthor=S.+Gunnarsdottirauthor=O.+Ivarssonauthor=T.+T.+Chouauthor=O.+Hjaltasonauthor=B.+Birgisdottirauthor=H.+Jonssonauthor=V.+G.+Gudnadottirauthor=E.+Gudmundsdottirauthor=A.+Bjornssonauthor=B.+Ingvarssonauthor=A.+Ingasonauthor=S.+Sigfussonauthor=H.+Hardardottirauthor=R.+P.+Harveyauthor=D.+Laiauthor=M.+Zhouauthor=D.+Brunnerauthor=V.+Mutelauthor=A.+Gonzaloauthor=G.+Lemkeauthor=J.+Sainzauthor=G.+Johannessonauthor=T.+Andressonauthor=D.+Gudbjartssonauthor=A.+Manolescuauthor=M.+L.+Friggeauthor=M.+E.+Gurneyauthor=A.+Kongauthor=J.+R.+Gulcherauthor=H.+Peturssonauthor=K.+Stefansson&title=Neuregulin+1+and+susceptibility+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin 1 and susceptibility to schizophrenia</span></div><div class="casAuthors">Stefansson Hreinn; Sigurdsson Engilbert; Steinthorsdottir Valgerdur; Bjornsdottir Soley; Sigmundsson Thordur; Ghosh Shyamali; Brynjolfsson Jon; Gunnarsdottir Steinunn; Ivarsson Omar; Chou Thomas T; Hjaltason Omar; Birgisdottir Birgitta; Jonsson Helgi; Gudnadottir Vala G; Gudmundsdottir Elsa; Bjornsson Asgeir; Ingvarsson Brynjolfur; Ingason Andres; Sigfusson Sigmundur; Hardardottir Hronn; Harvey Richard P; Lai Donna; Zhou Mingdong; Brunner Daniela; Mutel Vincent; Gonzalo Acuna; Lemke Greg; Sainz Jesus; Johannesson Gardar; Andresson Thorkell; Gudbjartsson Daniel; Manolescu Andrei; Frigge Michael L; Gurney Mark E; Kong Augustine; Gulcher Jeffrey R; Petursson Hannes; Stefansson Kari</div><div class="citationInfo"><span class="NLM_cas:title">American journal of human genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">877-92</span>
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    </div><div class="casAbstract">The cause of schizophrenia is unknown, but it has a significant genetic component.  Pharmacologic studies, studies of gene expression in man, and studies of mouse mutants suggest involvement of glutamate and dopamine neurotransmitter systems.  However, so far, strong association has not been found between schizophrenia and variants of the genes encoding components of these systems.  Here, we report the results of a genomewide scan of schizophrenia families in Iceland; these results support previous work, done in five populations, showing that schizophrenia maps to chromosome 8p.  Extensive fine-mapping of the 8p locus and haplotype-association analysis, supplemented by a transmission/disequilibrium test, identifies neuregulin 1 (NRG1) as a candidate gene for schizophrenia.  NRG1 is expressed at central nervous system synapses and has a clear role in the expression and activation of neurotransmitter receptors, including glutamate receptors.  Mutant mice heterozygous for either NRG1 or its receptor, ErbB4, show a behavioral phenotype that overlaps with mouse models for schizophrenia.  Furthermore, NRG1 hypomorphs have fewer functional NMDA receptors than wild-type mice.  We also demonstrate that the behavioral phenotypes of the NRG1 hypomorphs are partially reversible with clozapine, an atypical antipsychotic drug used to treat schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNlYdlXyBdeWhHGZei4OW9fW6udTcc2eZ_wt5xf8eqXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vos1CjtA%253D%253D&md5=416dbb13b7bb87c296f1fcfbadcfb64a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1086%2F342734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F342734%26sid%3Dliteratum%253Aachs%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSigurdsson%26aufirst%3DE.%26aulast%3DSteinthorsdottir%26aufirst%3DV.%26aulast%3DBjornsdottir%26aufirst%3DS.%26aulast%3DSigmundsson%26aufirst%3DT.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DBrynjolfsson%26aufirst%3DJ.%26aulast%3DGunnarsdottir%26aufirst%3DS.%26aulast%3DIvarsson%26aufirst%3DO.%26aulast%3DChou%26aufirst%3DT.%2BT.%26aulast%3DHjaltason%26aufirst%3DO.%26aulast%3DBirgisdottir%26aufirst%3DB.%26aulast%3DJonsson%26aufirst%3DH.%26aulast%3DGudnadottir%26aufirst%3DV.%2BG.%26aulast%3DGudmundsdottir%26aufirst%3DE.%26aulast%3DBjornsson%26aufirst%3DA.%26aulast%3DIngvarsson%26aufirst%3DB.%26aulast%3DIngason%26aufirst%3DA.%26aulast%3DSigfusson%26aufirst%3DS.%26aulast%3DHardardottir%26aufirst%3DH.%26aulast%3DHarvey%26aufirst%3DR.%2BP.%26aulast%3DLai%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DMutel%26aufirst%3DV.%26aulast%3DGonzalo%26aufirst%3DA.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DSainz%26aufirst%3DJ.%26aulast%3DJohannesson%26aufirst%3DG.%26aulast%3DAndresson%26aufirst%3DT.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DManolescu%26aufirst%3DA.%26aulast%3DFrigge%26aufirst%3DM.%2BL.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DGulcher%26aufirst%3DJ.%2BR.%26aulast%3DPetursson%26aufirst%3DH.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DNeuregulin%25201%2520and%2520susceptibility%2520to%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2002%26volume%3D71%26spage%3D877%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Bjarnadottir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haverfield-Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helgason, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigmundsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firth, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansdottir, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novak, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andresson, T.</span><span> </span><span class="NLM_article-title">Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/− knock-outs compared with wild-type mice</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4519</span><span class="NLM_x">–</span> <span class="NLM_lpage">4529</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1523%2FJNEUROSCI.4314-06.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17460065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltF2jtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=4519-4529&author=M.+Bjarnadottirauthor=D.+L.+Misnerauthor=S.+Haverfield-Grossauthor=S.+Bruunauthor=V.+G.+Helgasonauthor=H.+Stefanssonauthor=A.+Sigmundssonauthor=D.+R.+Firthauthor=B.+Nielsenauthor=R.+Stefansdottirauthor=T.+J.+Novakauthor=K.+Stefanssonauthor=M.+E.+Gurneyauthor=T.+Andresson&title=Neuregulin1+%28NRG1%29+signaling+through+Fyn+modulates+NMDA+receptor+phosphorylation%3A+differential+synaptic+function+in+NRG1%2B%2F%E2%88%92+knock-outs+compared+with+wild-type+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice</span></div><div class="casAuthors">Bjarnadottir, Maria; Misner, Dinah L.; Haverfield-Gross, Sascha; Bruun, Silas; Helgason, Vignir G.; Stefansson, Hreinn; Sigmundsson, Arnar; Firth, David R.; Nielsen, Berit; Stefansdottir, Ragnheidur; Novak, Thomas J.; Stefansson, Kari; Gurney, Mark E.; Andresson, Thorkell</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4519-4529</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">We previously identified Neuregulin 1 (NRG1) as a gene contributing to the risk of developing schizophrenia.  Furthermore, we showed that NRG1+/- mutant mice display behavioral abnormalities that are reversed by clozapine, an atypical antipsychotic drug used for the treatment of schizophrenia.  We now present evidence that ErbB4 (v-erb-a erythroblastic leukemia viral oncogene homolog 4), the tyrosine kinase receptor for NRG1 in hippocampal neurons, interacts with two nonreceptor tyrosine kinases, Fyn and Pyk2 (proline-rich tyrosine kinase 2).  NRG1 stimulation of cells expressing ErbB4 and Fyn leads to the assocn. of Fyn with ErbB4 and consequent activation.  Furthermore, we show that NRG1 signaling, through activation of Fyn and Pyk2 kinases, stimulates phosphorylation of Y1472 on the NR2B subunit of the NMDA receptor (NMDAR), a key regulatory site that modulates channel properties.  NR2B Y1472 is hypophosphorylated in NRG1+/- mutant mice, and this defect can be reversed by clozapine at a dose that reverses their behavioral abnormalities.  We also demonstrate that short-term synaptic plasticity is altered and theta-burst long-term potentiation is impaired in NRG1+/- mutant mice, and incubation of hippocampal slices from these mice with NRG1 reversed those effects.  Attenuated NRG1 signaling through ErbB4 may contribute to the pathophysiol. of schizophrenia through dysfunction of NMDAR modulation.  Thus, our data support the glutamate hypothesis of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXxhBS-u92bbVg90H21EOLACvtfcHk0liI_Ik4fiJanQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltF2jtbs%253D&md5=687aca3a32f7a2fa0ccc69abd4557984</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4314-06.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4314-06.2007%26sid%3Dliteratum%253Aachs%26aulast%3DBjarnadottir%26aufirst%3DM.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DHaverfield-Gross%26aufirst%3DS.%26aulast%3DBruun%26aufirst%3DS.%26aulast%3DHelgason%26aufirst%3DV.%2BG.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSigmundsson%26aufirst%3DA.%26aulast%3DFirth%26aufirst%3DD.%2BR.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DStefansdottir%26aufirst%3DR.%26aulast%3DNovak%26aufirst%3DT.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DAndresson%26aufirst%3DT.%26atitle%3DNeuregulin1%2520%2528NRG1%2529%2520signaling%2520through%2520Fyn%2520modulates%2520NMDA%2520receptor%2520phosphorylation%253A%2520differential%2520synaptic%2520function%2520in%2520NRG1%252B%252F%25E2%2588%2592%2520knock-outs%2520compared%2520with%2520wild-type%2520mice%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D4519%26epage%3D4529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Kampman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anttila, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saarela, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rontu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattila, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leinonen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehtimaki, T.</span><span> </span><span class="NLM_article-title">Neuregulin genotype and medication response in Finnish patients with schizophrenia</span> <span class="citation_source-journal">NeuroReport</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2517</span><span class="NLM_x">–</span> <span class="NLM_lpage">2520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=2517-2520&author=O.+Kampmanauthor=S.+Anttilaauthor=A.+Illiauthor=M.+Saarelaauthor=R.+Rontuauthor=K.+M.+Mattilaauthor=E.+Leinonenauthor=T.+Lehtimaki&title=Neuregulin+genotype+and+medication+response+in+Finnish+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKampman%26aufirst%3DO.%26aulast%3DAnttila%26aufirst%3DS.%26aulast%3DIlli%26aufirst%3DA.%26aulast%3DSaarela%26aufirst%3DM.%26aulast%3DRontu%26aufirst%3DR.%26aulast%3DMattila%26aufirst%3DK.%2BM.%26aulast%3DLeinonen%26aufirst%3DE.%26aulast%3DLehtimaki%26aufirst%3DT.%26atitle%3DNeuregulin%2520genotype%2520and%2520medication%2520response%2520in%2520Finnish%2520patients%2520with%2520schizophrenia%26jtitle%3DNeuroReport%26date%3D2004%26volume%3D15%26spage%3D2517%26epage%3D2520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Harrison, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, A. J.</span><span> </span><span class="NLM_article-title">Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2005.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16442083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmsl2jur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=132-140&author=P.+J.+Harrisonauthor=A.+J.+Law&title=Neuregulin+1+and+schizophrenia%3A+genetics%2C+gene+expression%2C+and+neurobiology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology</span></div><div class="casAuthors">Harrison, Paul J.; Law, Amanda J.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">132-140</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Neuregulin 1 (NRG1) is a leading schizophrenia susceptibility gene.  The NRG1 locus on chromosome 8p shows linkage to the disorder, and genetic assocn. has been found between schizophrenia and various non-coding polymorphisms and haplotypes, esp. at the 5' end of the NRG1 gene, in many but not all case-control and family studies.  NRG1 is a pleiotropic growth factor, important in nervous system development and functioning; roles include the modulation of neuronal migration, synaptogenesis, gliogenesis, neuron-glia communication, myelination, and neurotransmission.  Understanding the neurobiol. of NRG1 and its involvement in schizophrenia is challenged by the complexity of the gene, which gives rise to multiple functionally distinct isoforms, including six "types" of NRG1 defined by 5' exon usage.  Type IV and type I NRG1 may be particularly relevant to schizophrenia, with initial data showing altered expression of these isoforms in the disorder or in assocn. with NRG1 risk alleles.  We review the structure and functions of NRG1, consider the evidence for and against it being a schizophrenia susceptibility gene, and discuss mechanisms that might underlie the contribution of NRG1 to disease pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouJG1lix4yCLVg90H21EOLACvtfcHk0lhn3EfifxJ1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmsl2jur8%253D&md5=139f04d4b824662e43d8daa96abd6c17</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DP.%2BJ.%26aulast%3DLaw%26aufirst%3DA.%2BJ.%26atitle%3DNeuregulin%25201%2520and%2520schizophrenia%253A%2520genetics%252C%2520gene%2520expression%252C%2520and%2520neurobiology%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D60%26spage%3D132%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Peirce, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskvina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preece, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxbaum, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. C.</span><span> </span><span class="NLM_article-title">Convergent evidence for 2′,3′-cyclic nucleotide 3′-phosphodiesterase as a possible susceptibility gene for schizophrenia</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.63.1.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16389193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1Cruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=18-24&author=T.+R.+Peirceauthor=N.+J.+Brayauthor=N.+M.+Williamsauthor=N.+Nortonauthor=V.+Moskvinaauthor=A.+Preeceauthor=V.+Haroutunianauthor=J.+D.+Buxbaumauthor=M.+J.+Owenauthor=M.+C.+O%E2%80%99Donovan&title=Convergent+evidence+for+2%E2%80%B2%2C3%E2%80%B2-cyclic+nucleotide+3%E2%80%B2-phosphodiesterase+as+a+possible+susceptibility+gene+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Convergent evidence for 2'3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia</span></div><div class="casAuthors">Peirce, Timothy R.; Bray, Nicholas J.; Williams, Nigel M.; Norton, Nadine; Moskvina, Valentina; Preece, Anna; Haroutunian, Vahram; Buxbaum, Joseph D.; Owen, Michael J.; O'Donovan, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-24</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Convergent data make 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) a candidate gene for schizophrenia.  Reduced expression has been reported in the schizophrenic brain.  The CNP gene maps to a region to which we have reported linkage to schizophrenia.  Mice in which the CNP gene has been knocked out display central nervous system pathol. characteristics reminiscent of some features obsd. in schizophrenia.  2',3'-Cyclic nucleotide 3'-phosphodiesterase is used as a marker of myelin-forming cells and is detectable in cells of oligodendrocyte lineage throughout life.  Because CNP is thought to be important for oligodendrocyte function, altered expression has been interpreted as supportive of the hypothesis that altered oligodendrocyte function may be an etiol. factor in schizophrenia.  However, it is unclear whether the obsd. changes in the schizophrenic brain are primary or secondary.  Objectives: To det. if CNP expression is influenced by DNA polymorphisms and to verify if these polymorphisms are assocd. with schizophrenia.  Design: Allele-specific mRNA expression assay and genetic assocn. studies.  Setting: Unrelated subjects were ascertained from secondary psychiatric inpatient and outpatient services.  Participants: We used brain tissue from 60 anonymous individuals with no known psychiatric disorder; a case-control sample of 708 white individuals from the United Kingdom meeting DSM-IV criteria for schizophrenia matched for age, sex, and ethnicity to 711 blood donor controls; and a pedigree with DNA from 6 affected siblings and 1 parent, showing evidence for linkage to CNP.  Main Outcome Measures: Assocn. between allele and gene expression.  Assocn. between allele and schizophrenia.  Results: The exonic single nucleotide polymorphism rs2070106 was assocd. with CNP expression (P<.001).  Compatible with underexpression of CNP mRNA in schizophrenia, the lower-expressing A allele was significantly assocd. with schizophrenia (P=.04) in die case-control sample.  All affected individuals in the linked pedigree were homozygous for the lower-expression allele, providing independent support for the assocn. (P=.03).  Conclusions: Our data support the hypothesis that reduced CNP expression in the schizophrenic brain is relevant to disease etiol. and therefore provide support for the general hypothesis that altered oligodendrocyte function is an etiol. factor in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovrELRdAwkxLVg90H21EOLACvtfcHk0lhn3EfifxJ1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1Cruw%253D%253D&md5=8c93e92b773ac0e48dbd837895ca0f57</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.63.1.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.63.1.18%26sid%3Dliteratum%253Aachs%26aulast%3DPeirce%26aufirst%3DT.%2BR.%26aulast%3DBray%26aufirst%3DN.%2BJ.%26aulast%3DWilliams%26aufirst%3DN.%2BM.%26aulast%3DNorton%26aufirst%3DN.%26aulast%3DMoskvina%26aufirst%3DV.%26aulast%3DPreece%26aufirst%3DA.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DBuxbaum%26aufirst%3DJ.%2BD.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26atitle%3DConvergent%2520evidence%2520for%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-cyclic%2520nucleotide%25203%25E2%2580%25B2-phosphodiesterase%2520as%2520a%2520possible%2520susceptibility%2520gene%2520for%2520schizophrenia%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2006%26volume%3D63%26spage%3D18%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Corfas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxbaum, J. D.</span><span> </span><span class="NLM_article-title">Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia</span> <span class="citation_source-journal">Nat. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnn1258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15162166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1GgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=575-580&author=G.+Corfasauthor=K.+Royauthor=J.+D.+Buxbaum&title=Neuregulin+1-erbB+signaling+and+the+molecular%2Fcellular+basis+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia</span></div><div class="casAuthors">Corfas, Gabriel; Roy, Kristine; Buxbaum, Joseph D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">575-580</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is a devastating psychiatric disease that affects 0.5-1% of the world's adult population.  The hypothesis that this disease is a developmental disorder of the nervous system with late onset of its characteristic symptoms has been gaining acceptance in past years.  However, the anatomical, cellular and mol. bases of schizophrenia remain unclear.  Numerous studies point to alterations in different aspects of brain development as possible causes of schizophrenia, including defects in neuronal migration, neurotransmitter receptor expression and myelination.  Recently, the gene that encodes neuregulin-1 (NRG1) has been identified as a potential susceptibility gene for schizophrenia, and defects in the expression of erbB3, one of the NRG1 receptors, have been shown to occur in the prefrontal cortex of schizophrenic patients, suggesting that NRG1-erbB signaling is involved in the pathogenesis of schizophrenia.  These findings open new approaches to defining the mol. and cellular basis of schizophrenia in more mechanistic terms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdq9uN8qygebVg90H21EOLACvtfcHk0liGYh3pF7_kwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1GgsLo%253D&md5=30a6191ac013370d8566f014b9440547</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnn1258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1258%26sid%3Dliteratum%253Aachs%26aulast%3DCorfas%26aufirst%3DG.%26aulast%3DRoy%26aufirst%3DK.%26aulast%3DBuxbaum%26aufirst%3DJ.%2BD.%26atitle%3DNeuregulin%25201-erbB%2520signaling%2520and%2520the%2520molecular%252Fcellular%2520basis%2520of%2520schizophrenia%26jtitle%3DNat.%2520Neurosci.%26date%3D2004%26volume%3D7%26spage%3D575%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Flynn, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goghari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vavasour, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittall, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwork, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falkai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honer, W. G.</span><span> </span><span class="NLM_article-title">Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">820</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12931208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsFWhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=811-820&author=S.+W.+Flynnauthor=D.+J.+Langauthor=A.+L.+Mackayauthor=V.+Goghariauthor=I.+M.+Vavasourauthor=K.+P.+Whittallauthor=G.+N.+Smithauthor=V.+Arangoauthor=J.+J.+Mannauthor=A.+J.+Dworkauthor=P.+Falkaiauthor=W.+G.+Honer&title=Abnormalities+of+myelination+in+schizophrenia+detected+in+vivo+with+MRI%2C+and+post-mortem+with+analysis+of+oligodendrocyte+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins</span></div><div class="casAuthors">Flynn, S. W.; Lang, D. J.; Mackay, A. L.; Goghari, V.; Vavasour, I. M.; Whittall, K. P.; Smith, G. N.; Arango, V.; Mann, J. J.; Dwork, A. J.; Falkai, P.; Honer, W. G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">811-820</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Schizophrenia unfolds during the late period of brain maturation, while myelination is still continuing.  In the present study, the authors used MRI and T2 relaxation anal. to measure the myelin water fraction in schizophrenia.  In schizophrenia (n=30) compared with healthy subjects (n=27), overall white matter showed 12% lower myelin water fraction (P=0.031), with the most prominent effects on the left genu of the corpus callosum (36% lower, P=0.002).  The left anterior genu was affected in both first-episode (P=0.035) and chronic patients (P=0.011).  In healthy subjects, myelin water fraction in total white matter and in frontal white matter increased with age, and with years of education, indicating ongoing maturation.  In patients with schizophrenia, neither relation was statistically significant.  Post-mortem studies of anterior frontal cortex demonstrated less immunoreactivity of 2 oligodendrocyte-assocd. proteins in schizophrenia (2',3'-cyclic nucleotide 3'-phosphodiesterase by 33%, P=0.05; myelin-assocd. glycoprotein by 27%, P=0.14).  Impaired myelination in schizophrenia could contribute to abnormalities of neural connectivity and persistent functional impairment in the illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtKIMDeH25E7Vg90H21EOLACvtfcHk0liGYh3pF7_kwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsFWhtrY%253D&md5=bcc7ced371935d122b5a174e3d0d2b9b</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001337%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DS.%2BW.%26aulast%3DLang%26aufirst%3DD.%2BJ.%26aulast%3DMackay%26aufirst%3DA.%2BL.%26aulast%3DGoghari%26aufirst%3DV.%26aulast%3DVavasour%26aufirst%3DI.%2BM.%26aulast%3DWhittall%26aufirst%3DK.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BN.%26aulast%3DArango%26aufirst%3DV.%26aulast%3DMann%26aufirst%3DJ.%2BJ.%26aulast%3DDwork%26aufirst%3DA.%2BJ.%26aulast%3DFalkai%26aufirst%3DP.%26aulast%3DHoner%26aufirst%3DW.%2BG.%26atitle%3DAbnormalities%2520of%2520myelination%2520in%2520schizophrenia%2520detected%2520in%2520vivo%2520with%2520MRI%252C%2520and%2520post-mortem%2520with%2520analysis%2520of%2520oligodendrocyte%2520proteins%26jtitle%3DMol.%2520Psychiatry%26date%3D2003%26volume%3D8%26spage%3D811%26epage%3D820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">McCullumsmith, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beneyto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haroutunian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meador-Woodruff, J. H.</span><span> </span><span class="NLM_article-title">Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17223013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FnsFOrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2007&pages=15-27&author=R.+E.+McCullumsmithauthor=D.+Guptaauthor=M.+Beneytoauthor=E.+Kregerauthor=V.+Haroutunianauthor=K.+L.+Davisauthor=J.+H.+Meador-Woodruff&title=Expression+of+transcripts+for+myelination-related+genes+in+the+anterior+cingulate+cortex+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia</span></div><div class="casAuthors">McCullumsmith Robert E; Gupta Daya; Beneyto Monica; Kreger Emily; Haroutunian Vahram; Davis Kenneth L; Meador-Woodruff James H</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">15-27</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Several recent studies have found changes in the expression of genes functionally related to myelination and oligodendrocyte homeostasis in schizophrenia.  These studies utilized microarrays and quantitative PCR (QPCR), methodologies which do not permit direct, unamplified examination of mRNA expression.  In addition, these studies generally only examined transcript expression in homogenates of gray matter.  In the present study, we examined the expression of myelination-related genes previously implicated in schizophrenia by microarray or QPCR.  Using in situ hybridization, we measured transcript expression of 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), myelin-associated glycoprotein (MAG), transferrin (TF), quaking (QKI), gelsolin, myelin oligodendrocyte glycoprotein, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3, erbb2 interacting protein, motility-related protein-1, SRY-box containing gene 10, oligodendrocyte transcription factor 2, peripheral myelin protein 22, and claudin-11 in both gray and white matter of the anterior cingulate cortex (ACC) in subjects with schizophrenia (n=41) and a comparison group (n=34).  We found decreased expression of MAG, QKI, TF, and CNP transcripts in white matter.  We did not find any differences in expression of these transcripts between medicated (n=31) and unmedicated (n=10) schizophrenics, suggesting that these changes are not secondary to treatment with antipsychotics.  Finally, we found significant positive correlations between QKI and MAG or CNP mRNA expression, suggesting that the transcription factor QKI regulates MAG and CNP expression.  Our results support the hypothesis that myelination and oligodendrocyte function are impaired in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKRlaq_gfxtJcXNb62YGmbfW6udTcc2eahTXuvGt8_Xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FnsFOrtA%253D%253D&md5=85b17364d13957f8bd0bf3c1af66d6f4</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DMcCullumsmith%26aufirst%3DR.%2BE.%26aulast%3DGupta%26aufirst%3DD.%26aulast%3DBeneyto%26aufirst%3DM.%26aulast%3DKreger%26aufirst%3DE.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DMeador-Woodruff%26aufirst%3DJ.%2BH.%26atitle%3DExpression%2520of%2520transcripts%2520for%2520myelination-related%2520genes%2520in%2520the%2520anterior%2520cingulate%2520cortex%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D90%26spage%3D15%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gejman, P. V.</span><span> </span><span class="NLM_article-title">Neuregulin 1 (NRG1 ) and schizophrenia: analysis of a U.S. family sample and the evidence in the balance</span> <span class="citation_source-journal">Psychol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1610</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS0033291705005428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16219118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MrksVWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2005&pages=1599-1610&author=J.+Duanauthor=M.+Martinezauthor=A.+R.+Sandersauthor=C.+Houauthor=A.+J.+Krasnerauthor=D.+B.+Schwartzauthor=P.+V.+Gejman&title=Neuregulin+1+%28NRG1+%29+and+schizophrenia%3A+analysis+of+a+U.S.+family+sample+and+the+evidence+in+the+balance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Neuregulin 1 (NRG1 ) and schizophrenia: analysis of a US family sample and the evidence in the balance</span></div><div class="casAuthors">Duan Jubao; Martinez Maria; Sanders Alan R; Hou Cuiping; Krasner Aaron J; Schwartz Daniel B; Gejman Pablo V</div><div class="citationInfo"><span class="NLM_cas:title">Psychological medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1599-610</span>
        ISSN:<span class="NLM_cas:issn">0033-2917</span>.
    </div><div class="casAbstract">BACKGROUND:  Individual genome-wide linkage scans and meta-analyses support that one or more susceptibility genes for schizophrenia are located in chromosome 8p.  A gene from this region, neuregulin 1 (NRG1 ), known to be involved with glutamatergic function, has been found to be associated in some studied samples.  METHOD:  We have examined a new combined schizophrenia sample with 136 schizophrenia families largely of European ancestry (EA) and 646 subjects with DNA.  We genotyped 14 single nucleotide polymorphisms (SNPs) in NRG1 including those reported to comprise schizophrenia-associated haplotypes in Icelandic, Scottish, Irish, and Chinese Han populations.  RESULTS:  We found no evidence of association at a single-marker or a haplotypic level.  We review methodological aspects of previous studies to enable us to put our findings into context.  CONCLUSIONS:  Our failure to find an association between NRG1 and schizophrenia might reflect different linkage disequilibrium (LD) patterns found in different populations, disease allelic heterogeneity, clinical heterogeneity of schizophrenia, or inadequate statistical power deriving from moderate sample size.  NRG1, if a true gene for schizophrenia, accounts for a small fraction of the disease in most populations.  The confirmation of NRG1 as a schizophrenia susceptibility gene will require studies with a comprehensive set of markers and in larger samples.  The possibility remains that reports of NRG1 association might reflect false positives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3Sr3EzPuVblHFYivNCdPRfW6udTcc2eYiLQ7FgpZ9X7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrksVWksA%253D%253D&md5=9e34bacf48b1de296b963b80a39203d5</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1017%2FS0033291705005428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033291705005428%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DM.%26aulast%3DSanders%26aufirst%3DA.%2BR.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DKrasner%26aufirst%3DA.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BB.%26aulast%3DGejman%26aufirst%3DP.%2BV.%26atitle%3DNeuregulin%25201%2520%2528NRG1%2520%2529%2520and%2520schizophrenia%253A%2520analysis%2520of%2520a%2520U.S.%2520family%2520sample%2520and%2520the%2520evidence%2520in%2520the%2520balance%26jtitle%3DPsychol.%2520Med.%26date%3D2005%26volume%3D35%26spage%3D1599%26epage%3D1610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Ingason, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soeby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakobsen, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink-Jensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmingsen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werge, T.</span><span> </span><span class="NLM_article-title">No significant association of the 5′ end of neuregulin 1 and schizophrenia in a large Danish sample</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2005.12.850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16483744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287otV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2006&pages=1-5&author=A.+Ingasonauthor=K.+Soebyauthor=S.+Timmauthor=A.+G.+Wangauthor=K.+D.+Jakobsenauthor=A.+Fink-Jensenauthor=R.+Hemmingsenauthor=R.+H.+Bergauthor=T.+Werge&title=No+significant+association+of+the+5%E2%80%B2+end+of+neuregulin+1+and+schizophrenia+in+a+large+Danish+sample"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">No significant association of the 5' end of neuregulin 1 and schizophrenia in a large Danish sample</span></div><div class="casAuthors">Ingason Andres; Soeby Karen; Timm Sally; Wang August G; Jakobsen Klaus D; Fink-Jensen Anders; Hemmingsen Ralf; Berg Rasmussen Henrik; Werge Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Neuregulin 1 has been implicated as a susceptibility gene in schizophrenia.  Several research groups have reported association with the 5' end of the gene although no causative variant has been reported.  We have investigated whether there is association with the 5' end of the gene in Danish schizophrenia patients.  We found that the at-risk haplotype initially reported in the Icelandic population was not found in significant excess (or = 1.4, p = 0.12).  The haplotype structure in the Danish sample was similar to that of other reported in other Caucasian populations and highly different from that of Chinese.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXmqk5iGCx74qdXsLcGTEUfW6udTcc2eYiLQ7FgpZ9X7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287otV2ktg%253D%253D&md5=398f7f29e668234271ba264059d3314d</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2005.12.850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2005.12.850%26sid%3Dliteratum%253Aachs%26aulast%3DIngason%26aufirst%3DA.%26aulast%3DSoeby%26aufirst%3DK.%26aulast%3DTimm%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.%2BG.%26aulast%3DJakobsen%26aufirst%3DK.%2BD.%26aulast%3DFink-Jensen%26aufirst%3DA.%26aulast%3DHemmingsen%26aufirst%3DR.%26aulast%3DBerg%26aufirst%3DR.%2BH.%26aulast%3DWerge%26aufirst%3DT.%26atitle%3DNo%2520significant%2520association%2520of%2520the%25205%25E2%2580%25B2%2520end%2520of%2520neuregulin%25201%2520and%2520schizophrenia%2520in%2520a%2520large%2520Danish%2520sample%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D83%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Egan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakub, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callicott, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hariri, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattay, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertolino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon-Weickert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakkalanka, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">12604</span><span class="NLM_x">–</span> <span class="NLM_lpage">12609</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=12604-12609&author=M.+F.+Eganauthor=R.+E.+Straubauthor=T.+E.+Goldbergauthor=I.+Yakubauthor=J.+H.+Callicottauthor=A.+R.+Haririauthor=V.+S.+Mattayauthor=A.+Bertolinoauthor=T.+M.+Hydeauthor=C.+Shannon-Weickertauthor=M.+Akilauthor=J.+Crookauthor=R.+K.+Vakkalankaauthor=R.+Balkissoonauthor=R.+A.+Gibbsauthor=J.+E.+Kleinmanauthor=D.+R.+Weinberger&title=Variation+in+GRM3+affects+cognition%2C+prefrontal+glutamate%2C+and+risk+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DYakub%26aufirst%3DI.%26aulast%3DCallicott%26aufirst%3DJ.%2BH.%26aulast%3DHariri%26aufirst%3DA.%2BR.%26aulast%3DMattay%26aufirst%3DV.%2BS.%26aulast%3DBertolino%26aufirst%3DA.%26aulast%3DHyde%26aufirst%3DT.%2BM.%26aulast%3DShannon-Weickert%26aufirst%3DC.%26aulast%3DAkil%26aufirst%3DM.%26aulast%3DCrook%26aufirst%3DJ.%26aulast%3DVakkalanka%26aufirst%3DR.%2BK.%26aulast%3DBalkissoon%26aufirst%3DR.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DKleinman%26aufirst%3DJ.%2BE.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DVariation%2520in%2520GRM3%2520affects%2520cognition%252C%2520prefrontal%2520glutamate%252C%2520and%2520risk%2520for%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D12604%26epage%3D12609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span> </span><span class="NLM_article-title">Significant association between the genetic variations in the 5′ end of the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor subunit gene GRIN1 and schizophrenia</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2005.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16476413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFaisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=747-753&author=X.+Zhaoauthor=H.+Liauthor=Y.+Shiauthor=R.+Tangauthor=W.+Chenauthor=J.+Liuauthor=G.+Fengauthor=J.+Shiauthor=L.+Yanauthor=H.+Liuauthor=L.+He&title=Significant+association+between+the+genetic+variations+in+the+5%E2%80%B2+end+of+the+N-methyl-d-aspartate+receptor+subunit+gene+GRIN1+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Significant Association Between the Genetic Variations in the 5' End of the N-Methyl-D-Aspartate Receptor Subunit Gene GRIN1 and Schizophrenia</span></div><div class="casAuthors">Zhao, Xinzhi; Li, Huafang; Shi, Yongyong; Tang, Ruqi; Chen, Wuyan; Liu, Jixia; Feng, Guoyin; Shi, Jianguo; Yan, Lijuan; Liu, Huijun; He, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">747-753</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: N-methyl-D-aspartate (NMDA) receptors play important roles in many neurophysiol. processes.  Evidence from previous studies indicate that NMDA receptors contribute to the pathophysiol. of schizophrenia.  Two NMDA receptor subunit genes, GRIN1 and GRIN2A, are both good candidate genes for schizophrenia.  Method: We genotyped five single nucleotide polymorphisms (SNPs) in GRIN1 and two in GRIN2A in 2455 Han Chinese subjects, including population- and family-based samples, and performed case-control and transmission disequil. test (TDT) analyses.  A microsatellite in GRIN2A was genotyped in population-based samples and a Mann-Whitney U test was performed.  Results: A highly significant assocn. was detected at the 5' end of GRIN1.  Analyses of single variants and multiple-locus haplotypes indicate that the assocn. is mainly generated by rs11146020 (case-control study: p = .0000013, odds ratio = .61, 95% confidence interval .50-.74; TDT: p = .0019, T/NT = 79/123).  No assocn. was found in the GRIN2A polymorphisms.  Conclusions: Our results provide support for the hypothesis that NMDA receptors are an important factor in schizophrenia.  Moreover, rs11146020 is located in 5' untranslated region where several functional elements have been found.  Hence, the SNP is a potential candidate in altering risk for schizophrenia and worthy of further replication and functional study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOsUTnWuF3_rVg90H21EOLACvtfcHk0lirwOUMoenUwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFaisr4%253D&md5=4c3e72e6f870e41591cc162e8789384b</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DSignificant%2520association%2520between%2520the%2520genetic%2520variations%2520in%2520the%25205%25E2%2580%25B2%2520end%2520of%2520the%2520N-methyl-d-aspartate%2520receptor%2520subunit%2520gene%2520GRIN1%2520and%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D747%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Hong, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. J.</span><span> </span><span class="NLM_article-title">Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia</span> <span class="citation_source-journal">Psychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1097%2F00041444-200112000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11807413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD387hs1aqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=219-222&author=C.+J.+Hongauthor=Y.+W.+Yuauthor=C.+H.+Linauthor=C.+Y.+Chengauthor=S.+J.+Tsai&title=Association+analysis+for+NMDA+receptor+subunit+2B+%28GRIN2B%29+genetic+variants+and+psychopathology+and+clozapine+response+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia</span></div><div class="casAuthors">Hong C J; Yu Y W; Lin C H; Cheng C Y; Tsai S J</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatric genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-22</span>
        ISSN:<span class="NLM_cas:issn">0955-8829</span>.
    </div><div class="casAbstract">It is known that a syndrome resembling schizophrenia is produced by the N-methyl-d-aspartate receptor antagonists.  It has also been demonstrated that the level of an ionotropic N-methyl-d-aspartate 2B subunit (GRIN2B) of the glutamate receptor tends to increase after subchronic administration of clozapine, suggesting that GRIN2B may play an active role in the pathogenesis of schizophrenia and the function of clozapine medication.  We studied 100 schizophrenic patients, investigating the associations for the GRIN2B genetic variants, and psychiatric symptoms and clozapine response.  No significant differences were demonstrated comparing these three groups in terms of the baseline Brief Psychiatric Rating Scale (BPRS) score (P = 0.441).  The percentage of patients scoring within 20% of baseline BPRS after clozapine treatment was similar for the three genotype groups (P = 0.132).  A marginally higher mean clozapine dosage was revealed, however, for patients bearing the 2664C/C genotype (P = 0.013).  Although replication of this research is required to confirm the results, an association for the GRIN2B C2664T polymorphism and clozapine treatment is suggested from our findings, which may assist in the prediction of optimal dosage for schizophrenic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7dU054vF8aXy-c-E1v-fmfW6udTcc2eZItWXU1Z_cTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387hs1aqsA%253D%253D&md5=73c5bc493612928ff8060bdfd00f248a</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1097%2F00041444-200112000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00041444-200112000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DC.%2BJ.%26aulast%3DYu%26aufirst%3DY.%2BW.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DCheng%26aufirst%3DC.%2BY.%26aulast%3DTsai%26aufirst%3DS.%2BJ.%26atitle%3DAssociation%2520analysis%2520for%2520NMDA%2520receptor%2520subunit%25202B%2520%2528GRIN2B%2529%2520genetic%2520variants%2520and%2520psychopathology%2520and%2520clozapine%2520response%2520in%2520schizophrenia%26jtitle%3DPsychiatr.%2520Genet.%26date%3D2001%26volume%3D11%26spage%3D219%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Mohn, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, B. H.</span><span> </span><span class="NLM_article-title">Mice with reduced NMDA receptor expression display behaviors related to schizophrenia</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1999&pages=427-436&author=A.+R.+Mohnauthor=R.+R.+Gainetdinovauthor=M.+G.+Caronauthor=B.+H.+Koller&title=Mice+with+reduced+NMDA+receptor+expression+display+behaviors+related+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMohn%26aufirst%3DA.%2BR.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DKoller%26aufirst%3DB.%2BH.%26atitle%3DMice%2520with%2520reduced%2520NMDA%2520receptor%2520expression%2520display%2520behaviors%2520related%2520to%2520schizophrenia%26jtitle%3DCell%26date%3D1999%26volume%3D98%26spage%3D427%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLean, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myakishev, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris-Kerr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wormley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadek, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadambi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesare, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibberman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendler, K. S.</span><span> </span><span class="NLM_article-title">Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F341750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12098102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvV2qtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=337-348&author=R.+E.+Straubauthor=Y.+Jiangauthor=C.+J.+MacLeanauthor=Y.+Maauthor=B.+T.+Webbauthor=M.+V.+Myakishevauthor=C.+Harris-Kerrauthor=B.+Wormleyauthor=H.+Sadekauthor=B.+Kadambiauthor=A.+J.+Cesareauthor=A.+Gibbermanauthor=X.+Wangauthor=F.+A.+O%E2%80%99Neillauthor=D.+Walshauthor=K.+S.+Kendler&title=Genetic+variation+in+the+6p22.3+gene+DTNBP1%2C+the+human+ortholog+of+the+mouse+dysbindin+gene%2C+is+associated+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia</span></div><div class="casAuthors">Straub, Richard E.; Jiang, Yuxin; MacLean, Charles J.; Ma, Yunlong; Webb, Bradley T.; Myakishev, Maxim V.; Harris-Kerr, Carole; Wormley, Brandon; Sadek, Hannah; Kadambi, Bharat; Cesare, Anthony J.; Gibberman, Avi; Wang, Xu; O'Neill, F. Anthony; Walsh, Dermot; Kendler, Kenneth S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-348</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Prior evidence has supported the existence of multiple susceptibility genes for schizophrenia.  Multipoint linkage anal. of the 270 Irish high-d. pedigrees that we have studied, as well as results from several other samples, suggest that at least one such gene is located in region 6p24-21.  In the present study, family-based assocn. anal. of 36 simple sequence-length-polymorphism markers and of 17 SNP markers implicated two regions, sepd. by ∼7 Mb.  The first region, and the focus of this report, is 6p22.3.  In this region, single-nucleotide polymorphisms within the 140-kb gene DTNBP1 (dystrobrevin-binding protein 1, or dysbindin) are strongly assocd. with schizophrenia.  Uncorrected, empirical P values produced by the program TRANSMIT were significant (P <.01) for a no. of individual SNP markers, and most remained significant when the data were restricted to include only one affected offspring per nuclear family per extended pedigree; multiple three-marker haplotypes were highly significant (P =.008-.0001) under the restricted conditions.  The pattern of linkage disequil. is consistent with the presence of more than one susceptibility allele, but this important issue is unresolved.  The no. of markers tested in the adjacent genes, all of which are neg., is not sufficient to rule out the possibility that the dysbindin gene is not the actual susceptibility gene, but this possibility appears to be very unlikely.  We conclude that further investigation of dysbindin is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3luPjEDmn0bVg90H21EOLACvtfcHk0ljCK6db23yRxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvV2qtb4%253D&md5=999f50788656c9d7995c2a1f5a887369</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1086%2F341750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F341750%26sid%3Dliteratum%253Aachs%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMacLean%26aufirst%3DC.%2BJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DWebb%26aufirst%3DB.%2BT.%26aulast%3DMyakishev%26aufirst%3DM.%2BV.%26aulast%3DHarris-Kerr%26aufirst%3DC.%26aulast%3DWormley%26aufirst%3DB.%26aulast%3DSadek%26aufirst%3DH.%26aulast%3DKadambi%26aufirst%3DB.%26aulast%3DCesare%26aufirst%3DA.%2BJ.%26aulast%3DGibberman%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DF.%2BA.%26aulast%3DWalsh%26aufirst%3DD.%26aulast%3DKendler%26aufirst%3DK.%2BS.%26atitle%3DGenetic%2520variation%2520in%2520the%25206p22.3%2520gene%2520DTNBP1%252C%2520the%2520human%2520ortholog%2520of%2520the%2520mouse%2520dysbindin%2520gene%252C%2520is%2520associated%2520with%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2002%26volume%3D71%26spage%3D337%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrell, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gejman, P. V.</span><span> </span><span class="NLM_article-title">DTNBP1 (dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3′ end of the gene</span> <span class="citation_source-journal">Hum. Hered.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1159%2F000101961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17476109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlaku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=97-106&author=J.+Duanauthor=M.+Martinezauthor=A.+R.+Sandersauthor=C.+Houauthor=G.+J.+Burrellauthor=A.+J.+Krasnerauthor=D.+B.+Schwartzauthor=P.+V.+Gejman&title=DTNBP1+%28dystrobrevin+binding+protein+1%29+and+schizophrenia%3A+association+evidence+in+the+3%E2%80%B2+end+of+the+gene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">DTNBP1 (dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3' end of the gene</span></div><div class="casAuthors">Duan, Jubao; Martinez, Maria; Sanders, Alan R.; Hou, Cuiping; Burrell, Gregory J.; Krasner, Aaron J.; Schwartz, Daniel B.; Gejman, Pablo V.</div><div class="citationInfo"><span class="NLM_cas:title">Human Heredity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-106</span>CODEN:
                <span class="NLM_cas:coden">HUHEAS</span>;
        ISSN:<span class="NLM_cas:issn">0001-5652</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">(DTNBP1) has been identified as a susceptibility gene for schizophrenia (SZ) through a positional approach.  However, a variety of single nucleotide polymorphisms (SNPs) and haplotypes, in different parts of the gene, have been reported to be assocd. in different samples, and a precise mol. mechanism of disease remains to be defined.  We have performed an assocn. study with two well-characterized family samples not previously investigated at the DTNBP1 locus.  We examd. 646 subjects in 136 families with SZ, largely of European ancestry (EA), genotyping 26 SNPs in DTNBP1.  Three correlated markers (rs875462, rs760666, and rs7758659) at the 3' region of DTNBP1showed evidence for assocn. to SZ (p = 0.004), obsd. in both the EA (p = 0.031) and the African American (AA) subset (p = 0.045) with the same over-transmitted allele.  The most significant haplotype in our study was rs7758659-rs3213207 (global p = 0.0015), with rs3213207 being the most frequently reported assocd. marker in previous studies.  A non-conservative missense variant (Pro272Ser) in the 3' region of DTNBP1 that may impair DTNBP1 function was more common in SZ probands (8.2%) than in founders (5%) and in dbSNP (2.1%), but did not reach statistical significance.  These results provide evidence for an assocn. of SZ with SNPs at the 3' end of DTNBP1 in the samples studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9nOu1FcvqorVg90H21EOLACvtfcHk0lhxVQnUgQe5Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlaku7c%253D&md5=3e54d2c424c6e0397367e060cc4f8acb</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1159%2F000101961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000101961%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DM.%26aulast%3DSanders%26aufirst%3DA.%2BR.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DBurrell%26aufirst%3DG.%2BJ.%26aulast%3DKrasner%26aufirst%3DA.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BB.%26aulast%3DGejman%26aufirst%3DP.%2BV.%26atitle%3DDTNBP1%2520%2528dystrobrevin%2520binding%2520protein%25201%2529%2520and%2520schizophrenia%253A%2520association%2520evidence%2520in%2520the%25203%25E2%2580%25B2%2520end%2520of%2520the%2520gene%26jtitle%3DHum.%2520Hered.%26date%3D2007%26volume%3D64%26spage%3D97%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Van Den, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlraun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovalenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freudenberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonsson, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattila-Evenden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedvall, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapelski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rietschel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Propping, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nothen, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichon, S.</span><span> </span><span class="NLM_article-title">The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1438</span><span class="NLM_x">–</span> <span class="NLM_lpage">1443</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F379928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14618545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitlWn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2003&pages=1438-1443&author=B.+A.+Van+Denauthor=J.+Schumacherauthor=T.+G.+Schulzeauthor=A.+C.+Otteauthor=S.+Ohlraunauthor=S.+Kovalenkoauthor=T.+Beckerauthor=J.+Freudenbergauthor=E.+G.+Jonssonauthor=M.+Mattila-Evendenauthor=G.+C.+Sedvallauthor=P.+M.+Czerskiauthor=P.+Kapelskiauthor=J.+Hauserauthor=W.+Maierauthor=M.+Rietschelauthor=P.+Proppingauthor=M.+M.+Nothenauthor=S.+Cichon&title=The+DTNBP1+%28dysbindin%29+gene+contributes+to+schizophrenia%2C+depending+on+family+history+of+the+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease</span></div><div class="casAuthors">Van Den Bogaert, Ann; Schumacher, Johannes; Schulze, Thomas G.; Otte, Andreas C.; Ohlraun, Stephanie; Kovalenko, Svetlana; Becker, Tim; Freudenberg, Jan; Joensson, Erik G.; Mattila-evenden, Marja; Sedvall, Goeran C.; Czerski, Piotr M.; Kapelski, Pawel; Hauser, Joanna; Maier, Wolfgang; Rietschel, Marcella; Propping, Peter; Noethen, Markus M.; Cichon, Sven</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1438-1443</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">The authors have investigated the gene for dystrobrevin-binding protein 1 (DTNBP1), or dysbindin, which has been strongly suggested as a positional candidate gene for schizophrenia, in three samples of subjects with schizophrenia and unaffected control subjects of German (418 cases, 285 controls), Polish (294 cases, 113 controls), and Swedish (142 cases, 272 controls) descent.  The authors analyzed five single-nucleotide polymorphisms (P1635, P1325, P1320, P1757, and P1578) and identified significant evidence of assocn. in the Swedish sample but not in those from Germany or Poland.  The results in the Swedish sample became even more significant after a sep. anal. of those cases with a pos. family history of schizophrenia, in whom the five-marker haplotype A-C-A-T-T showed a P value of .00009 (3.1% in controls, 17.8% in cases; OR 6.75; P = .00153 after Bonferroni correction).  These results suggest that genetic variation in the dysbindin gene is particularly involved in the development of schizophrenia in cases with a familial loading of the disease.  This would also explain the difficulty of replicating this assocn. in consecutively ascertained case-control samples, which usually comprise only a small proportion of subjects with a family history of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEh3jhy6kFbVg90H21EOLACvtfcHk0lhxVQnUgQe5Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitlWn&md5=0abbdf8979feefe4f90ae1bea3650914</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1086%2F379928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F379928%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDen%26aufirst%3DB.%2BA.%26aulast%3DSchumacher%26aufirst%3DJ.%26aulast%3DSchulze%26aufirst%3DT.%2BG.%26aulast%3DOtte%26aufirst%3DA.%2BC.%26aulast%3DOhlraun%26aufirst%3DS.%26aulast%3DKovalenko%26aufirst%3DS.%26aulast%3DBecker%26aufirst%3DT.%26aulast%3DFreudenberg%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DE.%2BG.%26aulast%3DMattila-Evenden%26aufirst%3DM.%26aulast%3DSedvall%26aufirst%3DG.%2BC.%26aulast%3DCzerski%26aufirst%3DP.%2BM.%26aulast%3DKapelski%26aufirst%3DP.%26aulast%3DHauser%26aufirst%3DJ.%26aulast%3DMaier%26aufirst%3DW.%26aulast%3DRietschel%26aufirst%3DM.%26aulast%3DPropping%26aufirst%3DP.%26aulast%3DNothen%26aufirst%3DM.%2BM.%26aulast%3DCichon%26aufirst%3DS.%26atitle%3DThe%2520DTNBP1%2520%2528dysbindin%2529%2520gene%2520contributes%2520to%2520schizophrenia%252C%2520depending%2520on%2520family%2520history%2520of%2520the%2520disease%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2003%26volume%3D73%26spage%3D1438%26epage%3D1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Talbot, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eidem, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinsley, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gur, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, S. E.</span><span> </span><span class="NLM_article-title">Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">1353</span><span class="NLM_x">–</span> <span class="NLM_lpage">1363</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=1353-1363&author=K.+Talbotauthor=W.+L.+Eidemauthor=C.+L.+Tinsleyauthor=M.+A.+Bensonauthor=E.+W.+Thompsonauthor=R.+J.+Smithauthor=C.+G.+Hahnauthor=S.+J.+Siegelauthor=J.+Q.+Trojanowskiauthor=R.+E.+Gurauthor=D.+J.+Blakeauthor=S.+E.+Arnold&title=Dysbindin-1+is+reduced+in+intrinsic%2C+glutamatergic+terminals+of+the+hippocampal+formation+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTalbot%26aufirst%3DK.%26aulast%3DEidem%26aufirst%3DW.%2BL.%26aulast%3DTinsley%26aufirst%3DC.%2BL.%26aulast%3DBenson%26aufirst%3DM.%2BA.%26aulast%3DThompson%26aufirst%3DE.%2BW.%26aulast%3DSmith%26aufirst%3DR.%2BJ.%26aulast%3DHahn%26aufirst%3DC.%2BG.%26aulast%3DSiegel%26aufirst%3DS.%2BJ.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DGur%26aufirst%3DR.%2BE.%26aulast%3DBlake%26aufirst%3DD.%2BJ.%26aulast%3DArnold%26aufirst%3DS.%2BE.%26atitle%3DDysbindin-1%2520is%2520reduced%2520in%2520intrinsic%252C%2520glutamatergic%2520terminals%2520of%2520the%2520hippocampal%2520formation%2520in%2520schizophrenia%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D113%26spage%3D1353%26epage%3D1363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Chowdari, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirnics, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semwal, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">B. K., T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devlin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimgaonkar, V. L.</span><span> </span><span class="NLM_article-title">Association and linkage analyses of RGS4 polymorphisms in schizophrenia</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1373</span><span class="NLM_x">–</span> <span class="NLM_lpage">1380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fhmg%2F11.12.1373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12023979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XksFWms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=1373-1380&author=K.+V.+Chowdariauthor=K.+Mirnicsauthor=P.+Semwalauthor=J.+Woodauthor=E.+Lawrenceauthor=T.+Bhatiaauthor=S.+N.+Deshpandeauthor=T.+B.+K.author=R.+E.+Ferrellauthor=F.+A.+Middletonauthor=B.+Devlinauthor=P.+Levittauthor=D.+A.+Lewisauthor=V.+L.+Nimgaonkar&title=Association+and+linkage+analyses+of+RGS4+polymorphisms+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Association and linkage analyses of RGS4 polymorphisms in schizophrenia</span></div><div class="casAuthors">Chowdari, Kodavali V.; Mirnics, Karoly; Semwal, Prachi; Wood, Joel; Lawrence, Elizabeth; Bhatia, Triptish; Deshpande, Smita N.; Thelma, B. K.; Ferrell, Robert E.; Middleton, Frank A.; Devlin, Bernie; Levitt, Pat; Lewis, David A.; Nimgaonkar, Vishwajit L.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1373-1380</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Gene expression analyses of postmortem cerebral cortex suggest that transcription of the regulator of G-protein signaling 4 (RGS4) is decreased in a diagnosis-specific manner in subjects with schizophrenia.  To evaluate the possible role of RGS4 in the pathogenesis of schizophrenia, we conducted genetic assocn. and linkage studies using samples ascertained independently in Pittsburgh and New Delhi and by the NIMH Collaborative Genetics Initiative.  Using the transmission disequil. test, significant transmission distortion was obsd. in the Pittsburgh and NIMH samples.  Among single-nucleotide polymorphisms (SNPs) spanning approx. 300 kb, significant assocns. involved four SNPs localized to a 10 kb region at RGS4, but the assocd. haplotypes differed.  A trend for transmission distortion was also present in the Indian sample for haplotypes incorporating the same SNPs.  Consistent with the linkage/assocn. obsd. from the family-based tests, samples with affected siblings (NIMH, India) showed higher levels of allele sharing, identical by descent, at RGS4.  When the US patients were contrasted to two population-based control samples, however, no significant differences were obsd.  To check the specificity of the transmission bias, we therefore examd. US families with bipolar I disorder (BD1) probands.  This sample also showed a trend for transmission distortion, and differed significantly from the population-based controls for the four-SNP haplotypes tested in the other samples.  The transmission distortion is unlikely to be due to chance, but its mechanism and specificity require further study.  Our results illustrate the potential power of combining gene expression profiling and genomic analyses to identify susceptibility genes for genetically complex disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg-xKE593UwrVg90H21EOLACvtfcHk0lhbb2aWAb-eNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksFWms7Y%253D&md5=76b28246787987d38909b96f08f32d90</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F11.12.1373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F11.12.1373%26sid%3Dliteratum%253Aachs%26aulast%3DChowdari%26aufirst%3DK.%2BV.%26aulast%3DMirnics%26aufirst%3DK.%26aulast%3DSemwal%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DE.%26aulast%3DBhatia%26aufirst%3DT.%26aulast%3DDeshpande%26aufirst%3DS.%2BN.%26aulast%3DB.%2BK.%26aufirst%3DT.%26aulast%3DFerrell%26aufirst%3DR.%2BE.%26aulast%3DMiddleton%26aufirst%3DF.%2BA.%26aulast%3DDevlin%26aufirst%3DB.%26aulast%3DLevitt%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26atitle%3DAssociation%2520and%2520linkage%2520analyses%2520of%2520RGS4%2520polymorphisms%2520in%2520schizophrenia%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2002%26volume%3D11%26spage%3D1373%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Talkowski, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdari, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimgaonkar, V. L.</span><span> </span><span class="NLM_article-title">Can RGS4 polymorphisms be viewed as credible risk factors for schizophrenia? A critical review of the evidence</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbj058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16469939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD283ktFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2006&pages=203-208&author=M.+E.+Talkowskiauthor=K.+Chowdariauthor=D.+A.+Lewisauthor=V.+L.+Nimgaonkar&title=Can+RGS4+polymorphisms+be+viewed+as+credible+risk+factors+for+schizophrenia%3F+A+critical+review+of+the+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Can RGS4 polymorphisms be viewed as credible risk factors for schizophrenia? A critical review of the evidence</span></div><div class="casAuthors">Talkowski Michael E; Chowdari Kv; Lewis David A; Nimgaonkar Vishwajit L</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-8</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">There has been a recent explosion in the list of putative susceptibility genes for schizophrenia (SZ).  These genes have been identified on the basis of presumed pathogenesis, linkage, and genetic association studies.  While several promising candidates have arisen, identification of a conclusive genetic risk factor has remained elusive.  The proof would be most compelling if it stemmed from all three of these domains.  In this review, we consider such evidence in relation to the regulator of G-protein signaling 4 (RGS4), a gene localized to chromosome 1q23.  Disorder-specific changes in RGS4 mRNA levels have been observed in post-mortem brain samples; linkage has been reported at chromosome 1q23; and several association studies have concluded that significant associations exist.  The latter are supported by a recently conducted meta-analysis.  Thus, there is suggestive evidence in each of these domains implicating a role for RGS4 in SZ susceptibility.  However, analogous to other promising susceptibility candidates, the nature of the genetic association, the precise polymorphism(s) conferring risk, and the functional implications of sequence variation at this gene are unclear.  We review the published data and place them in the context of suggested criteria for establishing a candidate gene as a credible susceptibility factor for disorders with non-Mendelian patterns of inheritance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHQtI9xFsUKpcXNb62YGmbfW6udTcc2ea9pztDZD-Drrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283ktFOgug%253D%253D&md5=4f5d81c025460dfd525aeac4da8e087f</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbj058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbj058%26sid%3Dliteratum%253Aachs%26aulast%3DTalkowski%26aufirst%3DM.%2BE.%26aulast%3DChowdari%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26atitle%3DCan%2520RGS4%2520polymorphisms%2520be%2520viewed%2520as%2520credible%2520risk%2520factors%2520for%2520schizophrenia%253F%2520A%2520critical%2520review%2520of%2520the%2520evidence%26jtitle%3DSchizophr.%2520Bull.%26date%3D2006%26volume%3D32%26spage%3D203%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Prasad, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdari, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimgaonkar, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talkowski, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshavan, M. S.</span><span> </span><span class="NLM_article-title">Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15381923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnt1Slsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=213-219&author=K.+M.+Prasadauthor=K.+V.+Chowdariauthor=V.+L.+Nimgaonkarauthor=M.+E.+Talkowskiauthor=D.+A.+Lewisauthor=M.+S.+Keshavan&title=Genetic+polymorphisms+of+the+RGS4+and+dorsolateral+prefrontal+cortex+morphometry+among+first+episode+schizophrenia+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients</span></div><div class="casAuthors">Prasad, K. M. R.; Chowdari, K. V.; Nimgaonkar, V. L.; Talkowski, M. E.; Lewis, D. A.; Keshavan, M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-219</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polymorphisms of the gene encoding the regulator of G-protein signaling subtype 4 (RGS4) may confer risk for schizophrenia.1.  DNA microarray studies of postmortem brain samples have shown RGS4 underexpression in the dorsolateral prefrontal cortex (DLPFC, area 9), motor and visual cortices in schizophrenia patients relative to control subjects.2.  Underexpression of RGS4 in DLPFC is pathophysiol. significant because DLPFC pathol. in schizophrenia has been supported by neurocognitive,3,4 structural5 and functional6,7 imaging, postmortem,8 cellular9,10 and mol.11 pathol. studies.  For these reasons, we examd. the assocn. of DLPFC gray matter vol. with RGS4 polymorphisms in a series of antipsychotic-naive first-episode schizophrenia patients and control subjects.  We hypothesized that volumetric alterations of the DLPFC would be assocd. with RGS4 polymorphisms and that these differences would be more pronounced in patients than in controls.  We obsd. robust volumetric differences across the genotypes in the pooled sample of patients and control subjects; when sep. analyzed, we obsd. differences within the patient group (n=30) but not in control subject (n=27) group.  The findings suggest that RGS4 polymorphisms may contribute to structural alterations in the DLPFC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIyqOWbAdkc7Vg90H21EOLACvtfcHk0lhbb2aWAb-eNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnt1Slsw%253D%253D&md5=5cdb32e9d00b00606bedec20ca903d8b</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001562%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad%26aufirst%3DK.%2BM.%26aulast%3DChowdari%26aufirst%3DK.%2BV.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26aulast%3DTalkowski%26aufirst%3DM.%2BE.%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DKeshavan%26aufirst%3DM.%2BS.%26atitle%3DGenetic%2520polymorphisms%2520of%2520the%2520RGS4%2520and%2520dorsolateral%2520prefrontal%2520cortex%2520morphometry%2520among%2520first%2520episode%2520schizophrenia%2520patients%26jtitle%3DMol.%2520Psychiatry%26date%3D2005%26volume%3D10%26spage%3D213%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Buckholtz, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer-Lindenberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honea, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezawas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakkalanka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolachana, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verchinski, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sust, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattay, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callicott, J. H.</span><span> </span><span class="NLM_article-title">Allelic variation in RGS4 impacts functional and structural connectivity in the human brain</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1593</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1523%2FJNEUROSCI.5112-06.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17301167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitl2gu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1584-1593&author=J.+W.+Buckholtzauthor=A.+Meyer-Lindenbergauthor=R.+A.+Honeaauthor=R.+E.+Straubauthor=L.+Pezawasauthor=M.+F.+Eganauthor=R.+Vakkalankaauthor=B.+Kolachanaauthor=B.+A.+Verchinskiauthor=S.+Sustauthor=V.+S.+Mattayauthor=D.+R.+Weinbergerauthor=J.+H.+Callicott&title=Allelic+variation+in+RGS4+impacts+functional+and+structural+connectivity+in+the+human+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Allelic variation in RGS4 impacts functional and structural connectivity in the human brain</span></div><div class="casAuthors">Buckholtz, Joshua W.; Meyer-Lindenberg, Andreas; Honea, Robyn A.; Straub, Richard E.; Pezawas, Lukas; Egan, Michael F.; Vakkalanka, Radhakrishna; Kolachana, Bhaskar; Verchinski, Beth A.; Sust, Steven; Mattay, Venkata S.; Weinberger, Daniel R.; Callicott, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1584-1593</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Regulator of G-protein signaling 4 (RGS4) modulates postsynaptic signal transduction by affecting the kinetics of Gα-GTP binding.  Linkage, assocn., and postmortem studies have implicated the gene encoding RGS4 (RGS4) as a schizophrenia susceptibility factor.  Using a multimodal neuroimaging approach, we demonstrate that genetic variation in RGS4 is assocd. with functional activation and connectivity during working memory in the absence of overt behavioral differences, with regional gray and white matter vol. and with gray matter structural connectivity in healthy human subjects.  Specifically, variation at one RGS4 single nucleotide polymorphism that has been assocd. previously with psychosis (rs951436) impacts frontoparietal and frontotemporal blood oxygenation level-dependent response and network coupling during working memory and results in regionally specific redns. in gray and white matter structural vol. in individuals carrying the A allele.  These findings suggest mechanisms in brain for the assocn. of RGS4 with risk for psychiatric illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosqVnUstnVZ7Vg90H21EOLACvtfcHk0lgFIXoQSuw4yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitl2gu7s%253D&md5=541c1912095ca35c530dbbdfbde1c5b9</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5112-06.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5112-06.2007%26sid%3Dliteratum%253Aachs%26aulast%3DBuckholtz%26aufirst%3DJ.%2BW.%26aulast%3DMeyer-Lindenberg%26aufirst%3DA.%26aulast%3DHonea%26aufirst%3DR.%2BA.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DPezawas%26aufirst%3DL.%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DVakkalanka%26aufirst%3DR.%26aulast%3DKolachana%26aufirst%3DB.%26aulast%3DVerchinski%26aufirst%3DB.%2BA.%26aulast%3DSust%26aufirst%3DS.%26aulast%3DMattay%26aufirst%3DV.%2BS.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26aulast%3DCallicott%26aufirst%3DJ.%2BH.%26atitle%3DAllelic%2520variation%2520in%2520RGS4%2520impacts%2520functional%2520and%2520structural%2520connectivity%2520in%2520the%2520human%2520brain%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D1584%26epage%3D1593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Bowden, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tooney, P. A.</span><span> </span><span class="NLM_article-title">Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17071056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FmtlKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2007&pages=165-168&author=N.+A.+Bowdenauthor=R.+J.+Scottauthor=P.+A.+Tooney&title=Altered+expression+of+regulator+of+G-protein+signalling+4+%28RGS4%29+mRNA+in+the+superior+temporal+gyrus+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia</span></div><div class="casAuthors">Bowden Nikola A; Scott Rodney J; Tooney Paul A</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">165-8</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">To identify altered mRNA expression of regulator of G-protein signalling 4 (RGS4) in the superior temporal gyrus (STG) in schizophrenia mRNA expression of RGS4 was measured from post-mortem STG tissue from 13 individuals with schizophrenia and 13 matched non-psychiatric controls using relative real-time PCR.  Significantly decreased expression of RGS4 mRNA in the STG in schizophrenia was identified in 10 of the 13 matched pairs.  Altered expression of RGS4 in cortical regions previously implicated in schizophrenia, such as the STG further supports the notion of RGS4 as a potential genetic and functional biological marker of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC8bASUGlThX6CEoQgWY10fW6udTcc2eZzHZxD9fO19bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FmtlKkug%253D%253D&md5=f057e40f301553b2064aa3f6b71fa5bb</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DBowden%26aufirst%3DN.%2BA.%26aulast%3DScott%26aufirst%3DR.%2BJ.%26aulast%3DTooney%26aufirst%3DP.%2BA.%26atitle%3DAltered%2520expression%2520of%2520regulator%2520of%2520G-protein%2520signalling%25204%2520%2528RGS4%2529%2520mRNA%2520in%2520the%2520superior%2520temporal%2520gyrus%2520in%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D89%26spage%3D165%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Campbell, D. B.; Ebert, P. J.; Skelly, T.; Stroup, T. S.; Lieberman, J.; Levitt, P.; Sullivan, P. F.</span><span> </span><span class="NLM_article-title">Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia</span>.  <span class="citation_source-journal">Biol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Campbell%2C+D.+B.%3B+Ebert%2C+P.+J.%3B+Skelly%2C+T.%3B+Stroup%2C+T.+S.%3B+Lieberman%2C+J.%3B+Levitt%2C+P.%3B+Sullivan%2C+P.+F.+Ethnic+stratification+of+the+association+of+RGS4+variants+with+antipsychotic+treatment+response+in+schizophrenia.+Biol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DD.%2BB.%26atitle%3DEthnic%2520stratification%2520of%2520the%2520association%2520of%2520RGS4%2520variants%2520with%2520antipsychotic%2520treatment%2520response%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Chumakov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenfeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerassimenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavarec, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palicio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abderrahim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bougueleret, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puech, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen-Akenine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabrosse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lissarrague, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essioux, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millasseau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debailleul, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caterina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufaure, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malekzadeh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouillot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambucy, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Primas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saumier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boubkiri, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Saumier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasroune, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peixoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaye, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinchot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastucci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevillon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sainz-Fuertes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meguenni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aurich-Costa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherif, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimalac, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Duijn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauvreau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellette, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raelson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherbatich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riazanskaia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogaev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeymaekers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aerssens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konings, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luyten, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macciardi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sham, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span> </span><span class="NLM_article-title">Genetic and physiological data implicating the new human gene G72 and the gene for <span class="smallcaps smallerCapital">d</span>-amino acid oxidase in schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">13675</span><span class="NLM_x">–</span> <span class="NLM_lpage">13680</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=13675-13680&author=I.+Chumakovauthor=M.+Blumenfeldauthor=O.+Guerassimenkoauthor=L.+Cavarecauthor=M.+Palicioauthor=H.+Abderrahimauthor=L.+Bougueleretauthor=C.+Barryauthor=H.+Tanakaauthor=P.+La+Rosaauthor=A.+Puechauthor=N.+Tahriauthor=A.+Cohen-Akenineauthor=S.+Delabrosseauthor=S.+Lissarragueauthor=F.+P.+Picardauthor=K.+Mauriceauthor=L.+Essiouxauthor=P.+Millasseauauthor=P.+Grelauthor=V.+Debailleulauthor=A.+M.+Simonauthor=D.+Caterinaauthor=I.+Dufaureauthor=K.+Malekzadehauthor=M.+Belovaauthor=J.+J.+Luanauthor=M.+Bouillotauthor=J.+L.+Sambucyauthor=G.+Primasauthor=M.+Saumierauthor=N.+Boubkiriauthor=S.+Martin-Saumierauthor=M.+Nasrouneauthor=H.+Peixotoauthor=A.+Delayeauthor=V.+Pinchotauthor=M.+Bastucciauthor=S.+Guillouauthor=M.+Chevillonauthor=R.+Sainz-Fuertesauthor=S.+Meguenniauthor=J.+Aurich-Costaauthor=D.+Cherifauthor=A.+Gimalacauthor=C.+Van+Duijnauthor=D.+Gauvreauauthor=G.+Ouelletteauthor=I.+Fortierauthor=J.+Raelsonauthor=T.+Sherbatichauthor=N.+Riazanskaiaauthor=E.+Rogaevauthor=P.+Raeymaekersauthor=J.+Aerssensauthor=F.+Koningsauthor=W.+Luytenauthor=F.+Macciardiauthor=P.+C.+Shamauthor=R.+E.+Straubauthor=D.+R.+Weinbergerauthor=N.+Cohenauthor=D.+Cohen&title=Genetic+and+physiological+data+implicating+the+new+human+gene+G72+and+the+gene+for+d-amino+acid+oxidase+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChumakov%26aufirst%3DI.%26aulast%3DBlumenfeld%26aufirst%3DM.%26aulast%3DGuerassimenko%26aufirst%3DO.%26aulast%3DCavarec%26aufirst%3DL.%26aulast%3DPalicio%26aufirst%3DM.%26aulast%3DAbderrahim%26aufirst%3DH.%26aulast%3DBougueleret%26aufirst%3DL.%26aulast%3DBarry%26aufirst%3DC.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DLa%2BRosa%26aufirst%3DP.%26aulast%3DPuech%26aufirst%3DA.%26aulast%3DTahri%26aufirst%3DN.%26aulast%3DCohen-Akenine%26aufirst%3DA.%26aulast%3DDelabrosse%26aufirst%3DS.%26aulast%3DLissarrague%26aufirst%3DS.%26aulast%3DPicard%26aufirst%3DF.%2BP.%26aulast%3DMaurice%26aufirst%3DK.%26aulast%3DEssioux%26aufirst%3DL.%26aulast%3DMillasseau%26aufirst%3DP.%26aulast%3DGrel%26aufirst%3DP.%26aulast%3DDebailleul%26aufirst%3DV.%26aulast%3DSimon%26aufirst%3DA.%2BM.%26aulast%3DCaterina%26aufirst%3DD.%26aulast%3DDufaure%26aufirst%3DI.%26aulast%3DMalekzadeh%26aufirst%3DK.%26aulast%3DBelova%26aufirst%3DM.%26aulast%3DLuan%26aufirst%3DJ.%2BJ.%26aulast%3DBouillot%26aufirst%3DM.%26aulast%3DSambucy%26aufirst%3DJ.%2BL.%26aulast%3DPrimas%26aufirst%3DG.%26aulast%3DSaumier%26aufirst%3DM.%26aulast%3DBoubkiri%26aufirst%3DN.%26aulast%3DMartin-Saumier%26aufirst%3DS.%26aulast%3DNasroune%26aufirst%3DM.%26aulast%3DPeixoto%26aufirst%3DH.%26aulast%3DDelaye%26aufirst%3DA.%26aulast%3DPinchot%26aufirst%3DV.%26aulast%3DBastucci%26aufirst%3DM.%26aulast%3DGuillou%26aufirst%3DS.%26aulast%3DChevillon%26aufirst%3DM.%26aulast%3DSainz-Fuertes%26aufirst%3DR.%26aulast%3DMeguenni%26aufirst%3DS.%26aulast%3DAurich-Costa%26aufirst%3DJ.%26aulast%3DCherif%26aufirst%3DD.%26aulast%3DGimalac%26aufirst%3DA.%26aulast%3DVan%2BDuijn%26aufirst%3DC.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DOuellette%26aufirst%3DG.%26aulast%3DFortier%26aufirst%3DI.%26aulast%3DRaelson%26aufirst%3DJ.%26aulast%3DSherbatich%26aufirst%3DT.%26aulast%3DRiazanskaia%26aufirst%3DN.%26aulast%3DRogaev%26aufirst%3DE.%26aulast%3DRaeymaekers%26aufirst%3DP.%26aulast%3DAerssens%26aufirst%3DJ.%26aulast%3DKonings%26aufirst%3DF.%26aulast%3DLuyten%26aufirst%3DW.%26aulast%3DMacciardi%26aufirst%3DF.%26aulast%3DSham%26aufirst%3DP.%2BC.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26aulast%3DCohen%26aufirst%3DN.%26aulast%3DCohen%26aufirst%3DD.%26atitle%3DGenetic%2520and%2520physiological%2520data%2520implicating%2520the%2520new%2520human%2520gene%2520G72%2520and%2520the%2520gene%2520for%2520d-amino%2520acid%2520oxidase%2520in%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26spage%3D13675%26epage%3D13680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Boks, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rietkerk, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Beek, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommer, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Koning, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R. S.</span><span> </span><span class="NLM_article-title">Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.euroneuro.2006.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17250995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVWktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=567-572&author=M.+P.+Boksauthor=T.+Rietkerkauthor=M.+H.+van+de+Beekauthor=I.+E.+Sommerauthor=T.+J.+de+Koningauthor=R.+S.+Kahn&title=Reviewing+the+role+of+the+genes+G72+and+DAAO+in+glutamate+neurotransmission+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia</span></div><div class="casAuthors">Boks, M. P. M.; Rietkerk, T.; van de Beek, M. H.; Sommer, I. E.; de Koning, T. J.; Kahn, R. S.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">567-572</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  We review the role of two susceptibility genes; G72 and DAAO in glutamate neurotransmission and the etiol. of schizophrenia.  The gene product of G72 is an activator of DAAO (D-amino acid oxidase), which is the only enzyme oxidising D-serine.  D-Serine is an important co-agonist for the NMDA glutamate receptor and plays a role in neuronal migration and cell death.  Studies of -serine revealed lower serum levels in schizophrenia patients as compared to healthy controls.  Furthermore, administration of -serine as add-on medication reduced the symptoms of schizophrenia.  The underlying mechanism of the involvement of G72 and DAAO in schizophrenia is probably based on decreased levels of -serine and decreased NMDA receptor functioning in patients.  The involvement of this gene is therefore indirect support for the glutamate dysfunction hypothesis in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsQd-NGf4uCrVg90H21EOLACvtfcHk0li_RypehTRzuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVWktL0%253D&md5=458daf1d2510c701029ed6aa97148744</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2006.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2006.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DBoks%26aufirst%3DM.%2BP.%26aulast%3DRietkerk%26aufirst%3DT.%26aulast%3Dvan%2Bde%2BBeek%26aufirst%3DM.%2BH.%26aulast%3DSommer%26aufirst%3DI.%2BE.%26aulast%3Dde%2BKoning%26aufirst%3DT.%2BJ.%26aulast%3DKahn%26aufirst%3DR.%2BS.%26atitle%3DReviewing%2520the%2520role%2520of%2520the%2520genes%2520G72%2520and%2520DAAO%2520in%2520glutamate%2520neurotransmission%2520in%2520schizophrenia%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D17%26spage%3D567%26epage%3D572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Hashimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, R.</span><span> </span><span class="NLM_article-title">Mice lacking <span class="smallcaps smallerCapital">d</span>-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1033</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.brainres.2004.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15694926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1033&publication_year=2005&pages=210-215&author=A.+Hashimotoauthor=M.+Yoshikawaauthor=A.+Niwaauthor=R.+Konno&title=Mice+lacking+d-amino+acid+oxidase+activity+display+marked+attenuation+of+stereotypy+and+ataxia+induced+by+MK-801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Mice lacking D-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801</span></div><div class="casAuthors">Hashimoto, Atsushi; Yoshikawa, Masanobu; Niwa, Akira; Konno, Ryuichi</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1033</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The behavioral effects produced by MK-801 (0.4 mg/kg) were compared in mutant DAO-/- mice lacking -amino acid oxidase activity and normal DAO+/+ mice.  Mutant mice display marked diminution of stereotypy and ataxia induced by MK-801 compared to normal mice.  Because the -serine level in the brain of mutant mice is significantly higher than that of normal mice, the elevated -serine in the brain of mutant mice could antagonize MK-801-induced stereotypy and ataxia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmWfbRNOZnM7Vg90H21EOLACvtfcHk0li_RypehTRzuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOru74%253D&md5=eccfcf188c174fb98bc9f02e7b5d89da</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2004.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2004.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DNiwa%26aufirst%3DA.%26aulast%3DKonno%26aufirst%3DR.%26atitle%3DMice%2520lacking%2520d-amino%2520acid%2520oxidase%2520activity%2520display%2520marked%2520attenuation%2520of%2520stereotypy%2520and%2520ataxia%2520induced%2520by%2520MK-801%26jtitle%3DBrain%2520Res.%26date%3D2005%26volume%3D1033%26spage%3D210%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Korostishevsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaganovich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cholostoy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashkenazi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratner, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bening-Abu-Shach, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben Asher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritsner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navon, R.</span><span> </span><span class="NLM_article-title">Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2004.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15271585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFyksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=169-176&author=M.+Korostishevskyauthor=M.+Kaganovichauthor=A.+Cholostoyauthor=M.+Ashkenaziauthor=Y.+Ratnerauthor=D.+Daharyauthor=J.+Bernsteinauthor=U.+Bening-Abu-Shachauthor=E.+Ben+Asherauthor=D.+Lancetauthor=M.+Ritsnerauthor=R.+Navon&title=Is+the+G72%2FG30+locus+associated+with+schizophrenia%3F+Single+nucleotide+polymorphisms%2C+haplotypes%2C+and+gene+expression+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis</span></div><div class="casAuthors">Korostishevsky, Michael; Kaganovich, Miryam; Cholostoy, Alina; Ashkenazi, Maya; Ratner, Yael; Dahary, Dvir; Bernstein, Jeanne; Bening-Abu-Shach, Ullrike; Ben-Asher, Edna; Lancet, Doron; Ritsner, Michael; Navon, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-176</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The genes G72/G30 were recently implicated in schizophrenia in both Canadian and Russian populations.  The authors hypothesized that 1) polymorphic changes in this gene region might be assocd. with schizophrenia in the Ashkenazi Jewish population and that 2) changes in G72/G30 gene expression might be expected in schizophrenic patients compared with control subjects.  Eleven single nucleotide polymorphisms (SNPs) encompassing the G72/G30 genes were typed in the genomic DNA from 60 schizophrenic patients and 130 matched control subjects of Ashkenazi ethnic origin.  Case-control comparisons were based on linkage disequil. (LD) and haplotype frequency estns.  Gene expression anal. of G72 and G30 was performed on 88 postmortem dorsolateral prefrontal cortex samples.  Linkage disequil. anal. revealed two main SNP blocks.  Haplotype anal. on block II, contg. three SNPs external to the genes, demonstrated an assocn. with schizophrenia.  Gene expression anal. exhibited correlations between expression levels of the G72 and G30 genes, as well as a tendency toward overexpression of the G72 gene in schizophrenic brain samples of 44 schizophrenic patients compared with 44 control subjects.  It is likely that the G72/G30 region is involved in susceptibility to schizophrenia in the Ashkenazi population.  The elevation in expression of the G72 gene coincides with the glutamatergic theory of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPaJ1RTu5n_rVg90H21EOLACvtfcHk0li_RypehTRzuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFyksLk%253D&md5=39867b825d0abe084b75d49fed4f69c6</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2004.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2004.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DKorostishevsky%26aufirst%3DM.%26aulast%3DKaganovich%26aufirst%3DM.%26aulast%3DCholostoy%26aufirst%3DA.%26aulast%3DAshkenazi%26aufirst%3DM.%26aulast%3DRatner%26aufirst%3DY.%26aulast%3DDahary%26aufirst%3DD.%26aulast%3DBernstein%26aufirst%3DJ.%26aulast%3DBening-Abu-Shach%26aufirst%3DU.%26aulast%3DBen%2BAsher%26aufirst%3DE.%26aulast%3DLancet%26aufirst%3DD.%26aulast%3DRitsner%26aufirst%3DM.%26aulast%3DNavon%26aufirst%3DR.%26atitle%3DIs%2520the%2520G72%252FG30%2520locus%2520associated%2520with%2520schizophrenia%253F%2520Single%2520nucleotide%2520polymorphisms%252C%2520haplotypes%252C%2520and%2520gene%2520expression%2520analysis%26jtitle%3DBiol.%2520Psychiatry%26date%3D2004%26volume%3D56%26spage%3D169%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Schumacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamra, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freudenberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlraun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tullius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovalenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogaert, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rietschel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Propping, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nothen, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichon, S.</span><span> </span><span class="NLM_article-title">Examination of G72 and <span class="smallcaps smallerCapital">d</span>-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14966479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXht1Sjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=203-207&author=J.+Schumacherauthor=R.+A.+Jamraauthor=J.+Freudenbergauthor=T.+Beckerauthor=S.+Ohlraunauthor=A.+C.+Otteauthor=M.+Tulliusauthor=S.+Kovalenkoauthor=A.+V.+Bogaertauthor=W.+Maierauthor=M.+Rietschelauthor=P.+Proppingauthor=M.+M.+Nothenauthor=S.+Cichon&title=Examination+of+G72+and+d-amino-acid+oxidase+as+genetic+risk+factors+for+schizophrenia+and+bipolar+affective+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder</span></div><div class="casAuthors">Schumacher, J.; Jamra, R. Abon; Freudenberg, J.; Becker, T.; Ohlraun, S.; Otte, A. C. J.; Tullius, M.; Kovalenko, S.; Van Den Bogaert, A.; Maier, W.; Rietschel, M.; Propping, P.; Noethen, M. M.; Cichon, S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-207</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A recent study has suggested that the brain-expressed genes for G72 and D-amino-acid oxidase (DAAO) exert an influence on susceptibility to schizophrenia.  Our aim was to replicate this finding in German schizophrenic patients and to assess whether G72 and DAAO might also contribute to the development of bipolar affective disorder.  We genotyped 7 single-nucleotide polymorphisms (SNPs) in the G72 gene and 3 in the DAAO gene in 599 patients (299 schizophrenic, 300 bipolar) and 300 controls.  At G72, individual SNPs and a 4-marker haplotype were assocd. with schizophrenia.  The most significant SNP as well as the haplotype were also assocd. with bipolar affective disorder (BPAD).  DAAO was assocd. with schizophrenia, but not with BPAD.  The assocn. of variation at G72 with schizophrenia as well as BPAD provides mol. support for the hypothesis that these 2 major psychiatric disorders share some of their etiol. background.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf7hdjcbTClbVg90H21EOLACvtfcHk0lj1ahCWeIBfzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXht1Sjtbs%253D&md5=dc0c63f88f3ca42247626902fbc32b61</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001421%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DJ.%26aulast%3DJamra%26aufirst%3DR.%2BA.%26aulast%3DFreudenberg%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DT.%26aulast%3DOhlraun%26aufirst%3DS.%26aulast%3DOtte%26aufirst%3DA.%2BC.%26aulast%3DTullius%26aufirst%3DM.%26aulast%3DKovalenko%26aufirst%3DS.%26aulast%3DBogaert%26aufirst%3DA.%2BV.%26aulast%3DMaier%26aufirst%3DW.%26aulast%3DRietschel%26aufirst%3DM.%26aulast%3DPropping%26aufirst%3DP.%26aulast%3DNothen%26aufirst%3DM.%2BM.%26aulast%3DCichon%26aufirst%3DS.%26atitle%3DExamination%2520of%2520G72%2520and%2520d-amino-acid%2520oxidase%2520as%2520genetic%2520risk%2520factors%2520for%2520schizophrenia%2520and%2520bipolar%2520affective%2520disorder%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D203%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callicott, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hariri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattay, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigelow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppola, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">The G72/G30 gene complex and cognitive abnormalities in schizophrenia</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=2022-2032&author=T.+E.+Goldbergauthor=R.+E.+Straubauthor=J.+H.+Callicottauthor=A.+Haririauthor=V.+S.+Mattayauthor=L.+Bigelowauthor=R.+Coppolaauthor=M.+F.+Eganauthor=D.+R.+Weinberger&title=The+G72%2FG30+gene+complex+and+cognitive+abnormalities+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DStraub%26aufirst%3DR.%2BE.%26aulast%3DCallicott%26aufirst%3DJ.%2BH.%26aulast%3DHariri%26aufirst%3DA.%26aulast%3DMattay%26aufirst%3DV.%2BS.%26aulast%3DBigelow%26aufirst%3DL.%26aulast%3DCoppola%26aufirst%3DR.%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DThe%2520G72%252FG30%2520gene%2520complex%2520and%2520cognitive%2520abnormalities%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D2006%26volume%3D31%26spage%3D2022%26epage%3D2032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Hattori, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christian, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheshwari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detera-Wadleigh, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershon, E. S.</span><span> </span><span class="NLM_article-title">Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1131</span><span class="NLM_x">–</span> <span class="NLM_lpage">1140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F374822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12647258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslagtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2003&pages=1131-1140&author=E.+Hattoriauthor=C.+Liuauthor=J.+A.+Badnerauthor=T.+I.+Bonnerauthor=S.+L.+Christianauthor=M.+Maheshwariauthor=S.+D.+Detera-Wadleighauthor=R.+A.+Gibbsauthor=E.+S.+Gershon&title=Polymorphisms+at+the+G72%2FG30+gene+locus%2C+on+13q33%2C+are+associated+with+bipolar+disorder+in+two+independent+pedigree+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series</span></div><div class="casAuthors">Hattori, Eiji; Liu, Chunyu; Badner, Judith A.; Bonner, Tom I.; Christian, Susan L.; Maheshwari, Manjula; Detera-Wadleigh, Sevilla D.; Gibbs, Richard A.; Gershon, Elliot S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1131-1140</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Linkage evidence suggests that chromosome 13 (13q32-33) contains susceptibility genes for both bipolar disorder and schizophrenia.  Recently, genes called "G72" and "G30" were identified, and polymorphisms of these overlapping genes were reported to be assocd. with schizophrenia.  We studied two series of pedigrees with bipolar disorder: the Clin. Neurogenetics (CNG) pedigrees (in which linkage to illness had been previously reported at 13q32-33), with 83 samples from 22 multiplex families, and the National Institute of Mental Health (NIMH) Genetics Initiative pedigrees, with 474 samples from 152 families.  Sixteen single-nucleotide polymorphisms (SNPs) were genotyped at and around the G72/G30 locus, which covered a 157-kb region encompassing the entire complementary DNA sequences of G72 and G30.  We performed transmission/disequil. testing (TDT) and haplotype anal., since a linkage-disequil. block was present at this gene locus.  In the CNG and NIMH data sets, the results of global TDT of the entire haplotype set were significant and consistent (P =.0004 and P =.008, resp.).  In the CNG series, the assocd. genotypes divided the families into those with linkage and those without linkage (partitioned by the linkage evidence).  Anal. of the decay of haplotype sharing gave a location est. that included G72/G30 in its 95% confidence interval.  Although statistically significant assocn. was not detected for individual SNPs in the NIMH data set, the same haplotype was consistently over-transmitted in both series.  These data suggest that a susceptibility variant for bipolar illness exists in the vicinity of the G72/G30 genes.  Taken together with the earlier report, this is the first demonstration of a novel gene(s), discovered through a positional approach, independently assocd. with both bipolar illness and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAaxhb-qcG77Vg90H21EOLACvtfcHk0lj1ahCWeIBfzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslagtbk%253D&md5=c02b757f9a22b1827260aa5700238586</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1086%2F374822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F374822%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DBadner%26aufirst%3DJ.%2BA.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DChristian%26aufirst%3DS.%2BL.%26aulast%3DMaheshwari%26aufirst%3DM.%26aulast%3DDetera-Wadleigh%26aufirst%3DS.%2BD.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DGershon%26aufirst%3DE.%2BS.%26atitle%3DPolymorphisms%2520at%2520the%2520G72%252FG30%2520gene%2520locus%252C%2520on%252013q33%252C%2520are%2520associated%2520with%2520bipolar%2520disorder%2520in%2520two%2520independent%2520pedigree%2520series%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2003%26volume%3D72%26spage%3D1131%26epage%3D1140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Chen, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akula, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detera-Wadleigh, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potash, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePaulo, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnis, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, F. J.</span><span> </span><span class="NLM_article-title">Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14699445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=87-92&author=Y.+S.+Chenauthor=N.+Akulaauthor=S.+D.+Detera-Wadleighauthor=T.+G.+Schulzeauthor=J.+Thomasauthor=J.+B.+Potashauthor=J.+R.+DePauloauthor=M.+G.+McInnisauthor=N.+J.+Coxauthor=F.+J.+McMahon&title=Findings+in+an+independent+sample+support+an+association+between+bipolar+affective+disorder+and+the+G72%2FG30+locus+on+chromosome+13q33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33</span></div><div class="casAuthors">Chen, Y-S.; Akula, N.; Detera-Wadleigh, S. D.; Schulze, T. G.; Thomas, J.; Potash, J. B.; DePaulo, J. R.; McInnis, M. G.; Cox, N. J.; McMahon, F. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Markers near the nested genes G72 and G30 on chromosome 13q33 have been implicated in the etiol. of schizophrenia and, recently, bipolar affective disorder (BPAD).  Hattori, E.; et al (2003) reported that single-nucleotide polymorphisms (SNPs) near the G72/G30 locus were assocd. with BPAD in a sample of 22 pedigrees, and that SNP haplotypes were assocd. in a second, larger sample of triads.  The present study attempts to replicate this finding in an independent case-control sample.  Six SNPs near the G72/G30 locus, including the most strongly assocd. markers in the previous study, were tested in 139 cases and 113 ethnically matched controls.  Significant assocn. was detected between BPAD and two adjacent SNPs (smallest P=0.007; global P=0.024).  Haplotype anal. produced addnl. support for assocn. (smallest P=0.004; global P=0.004).  Anal. of 31 unlinked microsatellite markers detected no population stratification in the cases or controls studied.  Although the assocd. alleles and haplotypes differ from those previously reported, these new results provide further evidence, in an independent sample, for an assocn. between BPAD and genetic variation in the vicinity of the genes G72 and G30.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGproFFRzgLhCLVg90H21EOLACvtfcHk0lijx3xD1Isxow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtr%252FM&md5=f3c8767bf3425afa51521b700ba4b904</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001453%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DAkula%26aufirst%3DN.%26aulast%3DDetera-Wadleigh%26aufirst%3DS.%2BD.%26aulast%3DSchulze%26aufirst%3DT.%2BG.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DPotash%26aufirst%3DJ.%2BB.%26aulast%3DDePaulo%26aufirst%3DJ.%2BR.%26aulast%3DMcInnis%26aufirst%3DM.%2BG.%26aulast%3DCox%26aufirst%3DN.%2BJ.%26aulast%3DMcMahon%26aufirst%3DF.%2BJ.%26atitle%3DFindings%2520in%2520an%2520independent%2520sample%2520support%2520an%2520association%2520between%2520bipolar%2520affective%2520disorder%2520and%2520the%2520G72%252FG30%2520locus%2520on%2520chromosome%252013q33%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D87%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Yoshikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, A.</span><span> </span><span class="NLM_article-title">Acute treatment with morphine augments the expression of serine racemase and <span class="smallcaps smallerCapital">d</span>-amino acid oxidase mRNAs in rat brain</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">525</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16256980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gnt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=525&publication_year=2005&pages=94-97&author=M.+Yoshikawaauthor=H.+Andohauthor=K.+Itoauthor=T.+Suzukiauthor=M.+Kawaguchiauthor=H.+Kobayashiauthor=T.+Okaauthor=A.+Hashimoto&title=Acute+treatment+with+morphine+augments+the+expression+of+serine+racemase+and+d-amino+acid+oxidase+mRNAs+in+rat+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Acute treatment with morphine augments the expression of serine racemase and D-amino acid oxidase mRNAs in rat brain</span></div><div class="casAuthors">Yoshikawa, Masanobu; Andoh, Hidehiro; Ito, Kenji; Suzuki, Toshiyasu; Kawaguchi, Mitsuru; Kobayashi, Hiroyuki; Oka, Tetsuo; Hashimoto, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">525</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">94-97</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To obtain further insight into the interactions between the N-methyl-D-aspartate receptor and opioid receptor systems, we have investigated the effects of the acute treatment of morphine on the expression of serine racemase and D-amino acid oxidase mRNAs in several brain areas of rats.  The morphine administration produced a dose-dependent and transient elevation in the levels of serine racemase and D-amino acid oxidase mRNAs in all the brain areas.  The present results are the first to suggest an interaction between the expression of the mRNAs for the D-serine-related enzymes and the opioid receptor activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcpgUcyMlLPrVg90H21EOLACvtfcHk0lijx3xD1Isxow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gnt7fK&md5=0f682f0343642ae8b04dab4e426588fb</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DAndoh%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DKawaguchi%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DA.%26atitle%3DAcute%2520treatment%2520with%2520morphine%2520augments%2520the%2520expression%2520of%2520serine%2520racemase%2520and%2520d-amino%2520acid%2520oxidase%2520mRNAs%2520in%2520rat%2520brain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D525%26spage%3D94%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Yue, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span> </span><span class="NLM_article-title">Association of G72/G30 polymorphisms with early-onset and male schizophrenia</span> <span class="citation_source-journal">NeuroReport</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1899</span><span class="NLM_x">–</span> <span class="NLM_lpage">1902</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=1899-1902&author=W.+Yueauthor=Z.+Liuauthor=G.+Kangauthor=J.+Yanauthor=F.+Tangauthor=Y.+Ruanauthor=J.+Zhangauthor=D.+Zhang&title=Association+of+G72%2FG30+polymorphisms+with+early-onset+and+male+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DKang%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DRuan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DAssociation%2520of%2520G72%252FG30%2520polymorphisms%2520with%2520early-onset%2520and%2520male%2520schizophrenia%26jtitle%3DNeuroReport%26date%3D2006%26volume%3D17%26spage%3D1899%26epage%3D1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Liu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, H. G.</span><span> </span><span class="NLM_article-title">No association of G72 and <span class="smallcaps smallerCapital">d</span>-amino acid oxidase genes with schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16842973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28rnvFalsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2006&pages=15-20&author=Y.+L.+Liuauthor=C.+S.+Fannauthor=C.+M.+Liuauthor=C.+C.+Changauthor=J.+Y.+Wuauthor=S.+I.+Hungauthor=S.+K.+Liuauthor=M.+H.+Hsiehauthor=T.+J.+Hwangauthor=H.+Y.+Chanauthor=J.+J.+Chenauthor=S.+V.+Faraoneauthor=M.+T.+Tsuangauthor=W.+J.+Chenauthor=H.+G.+Hwu&title=No+association+of+G72+and+d-amino+acid+oxidase+genes+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">No association of G72 and D-amino acid oxidase genes with schizophrenia</span></div><div class="casAuthors">Liu Yu-Li; Fann Cathy Shen-Jang; Liu Chih-Min; Chang Chien Ching; Wu Jer-Yuarn; Hung Shuen-Iu; Liu Shih-Kai; Hsieh Ming H; Hwang Tzung-Jeng; Chan Hung-Yu; Chen Jiahn-Jyh; Faraone Stephen V; Tsuang Ming T; Chen Wei J; Hwu Hai-Gwo</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">15-20</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The genes of D-amino acid oxidase (DAAO) activator (DAOA or G72; 13q34) and DAAO (12q24) have been suggested as candidate genes and involved in the N-methyl-D-aspartate receptor regulation pathway for schizophrenia.  In order to evaluate the potential association of these two genes with schizophrenia in a Taiwanese sample, three single nucleotide polymorphisms (SNPs) for DAAO (rs2111902, rs3918346, rs3741775) and eleven SNPs for G72 (rs3916965, rs3916966, rs3916967, rs2391191, rs3916968, rs947267, rs778294, rs3916970, rs3916971, rs778293, rs3918342) were genotyped by the MALDI-TOF mass spectrometry method in 218 families (864 individuals) containing at least two siblings affected with schizophrenia.  In SNP-based single locus association analyses, neither G72 nor DAAO showed significant association with schizophrenia.  Additionally, a three-SNP haplotype in DAAO, and a four-SNP as well as a two-SNP haplotype in G72, showed no significant associations with schizophrenia.  These results suggest that the DAAO and G72 genes are not susceptibility genes for schizophrenia in a Taiwanese sample.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2IzNCcYz_Vq91pGlMMoT5fW6udTcc2eYsp4znkS6A2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rnvFalsw%253D%253D&md5=fb14d4eda9f5ddd61ad4b712e5ce8e5e</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DFann%26aufirst%3DC.%2BS.%26aulast%3DLiu%26aufirst%3DC.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DWu%26aufirst%3DJ.%2BY.%26aulast%3DHung%26aufirst%3DS.%2BI.%26aulast%3DLiu%26aufirst%3DS.%2BK.%26aulast%3DHsieh%26aufirst%3DM.%2BH.%26aulast%3DHwang%26aufirst%3DT.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DTsuang%26aufirst%3DM.%2BT.%26aulast%3DChen%26aufirst%3DW.%2BJ.%26aulast%3DHwu%26aufirst%3DH.%2BG.%26atitle%3DNo%2520association%2520of%2520G72%2520and%2520d-amino%2520acid%2520oxidase%2520genes%2520with%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D87%26spage%3D15%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Williams, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macgregor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raybould, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grozeva, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamshere, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, N.</span><span> </span><span class="NLM_article-title">Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">366</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.63.4.366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16585465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xktlekt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=366-373&author=N.+M.+Williamsauthor=E.+K.+Greenauthor=S.+Macgregorauthor=S.+Dwyerauthor=N.+Nortonauthor=H.+Williamsauthor=R.+Raybouldauthor=D.+Grozevaauthor=M.+Hamshereauthor=S.+Zammitauthor=L.+Jonesauthor=A.+Cardnoauthor=G.+Kirovauthor=I.+Jonesauthor=M.+C.+O%E2%80%99Donovanauthor=M.+J.+Owenauthor=N.+Craddock&title=Variation+at+the+DAOA%2FG30+locus+influences+susceptibility+to+major+mood+episodes+but+not+psychosis+in+schizophrenia+and+bipolar+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Variation at the DAOA/G30 locus influences susceptibility to major mood episode but not psychosis in schizophrenia and bipolar disorder</span></div><div class="casAuthors">Williams, Nigel M.; Green, Elaine K.; Macgregor, Stuart; Dwyer, Sarah; Norton, Nadine; Williams, Hywel; Raybould, Rachel; Grozeva, Detelina; Hamshere, Marian; Zammit, Stanley; Jones, Lisa; Cardno, Alastair; Kirov, George; Jones, Ian; O'Donovan, Michael C.; Owen, Michael J.; Craddock, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">366-373</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Variation at the DAOA/G30 locus has been described to be assocd. with both schizophrenia and bipolar disorder, but there is little consistency between studies of the tested polymorphisms or variants showing assocn.  Objectives: To obtain a stringent replication of assocn. in large samples of both disorders using consistent clin. and lab. methods, and to test the hypothesis that assocn. at DAOA/G30 identifies an underlying domain of psychopathol. abnormalities that cuts across traditional diagnostic categories.  Design: A systematic study of polymorphisms at DAOA/G30 using genetic case-control assocn. anal.  Setting: Subjects were unrelated and ascertained from general psychiatric inpatient and outpatient services.  Participants: White persons from the United Kingdom meeting criteria for DSM-IV schizophrenia (n = 709) or bipolar I disorder (n = 706) and 1416 ethnically matched controls.  Methods: Nine polymorphisms that tag common genetic variations at DAOA/G30 were genotyped in all of the individuals, and comparisons were made between affected and unaffected individuals.  Results: We identified significant assocn. (P = .01-.047) between 3 single-nucleotide polymorphisms and bipolar disorder but failed to find assocn. with schizophrenia.  Analyses across the traditional diagnostic categories revealed significant evidence (P = .002-.02) for assocn. with 4 single-nucleotide polymorphisms in the subset of cases (n = 818) in which episodes of major mood disorder had occurred (gene-wide P = .009).  We found a similar pattern of assocn. in bipolar cases and in schizophrenia cases in which individuals had experienced major mood disorder.  In contrast, we found no evidence for assocn. in the subset of cases (n = 1153) in which psychotic features occurred (all P > .08).  Conclusions: Despite being originally described as a schizophrenia susceptibility locus, our data suggest that variation at the DAOA/G30 locus does not primarily increase susceptibility for prototypical schizophrenia or psychosis.  Instead, our results imply that variation at the DAOA/G30 locus influences susceptibility to episodes of mood disorder across the traditional bipolar and schizophrenia categories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0VRETMHHdgbVg90H21EOLACvtfcHk0ljzzMy8XS3GYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xktlekt7w%253D&md5=b984dd0e1bf6f7c7edd24fd25672f01a</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.63.4.366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.63.4.366%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BM.%26aulast%3DGreen%26aufirst%3DE.%2BK.%26aulast%3DMacgregor%26aufirst%3DS.%26aulast%3DDwyer%26aufirst%3DS.%26aulast%3DNorton%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DH.%26aulast%3DRaybould%26aufirst%3DR.%26aulast%3DGrozeva%26aufirst%3DD.%26aulast%3DHamshere%26aufirst%3DM.%26aulast%3DZammit%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DCardno%26aufirst%3DA.%26aulast%3DKirov%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DI.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DCraddock%26aufirst%3DN.%26atitle%3DVariation%2520at%2520the%2520DAOA%252FG30%2520locus%2520influences%2520susceptibility%2520to%2520major%2520mood%2520episodes%2520but%2520not%2520psychosis%2520in%2520schizophrenia%2520and%2520bipolar%2520disorder%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2006%26volume%3D63%26spage%3D366%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Detera-Wadleigh, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, F. J.</span><span> </span><span class="NLM_article-title">G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2006.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16581030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmsl2jtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=106-114&author=S.+D.+Detera-Wadleighauthor=F.+J.+McMahon&title=G72%2FG30+in+schizophrenia+and+bipolar+disorder%3A+review+and+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">G72/G30 in Schizophrenia and Bipolar Disorder: Review and Meta-analysis</span></div><div class="casAuthors">Detera-Wadleigh, Sevilla D.; McMahon, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106-114</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Assocn. of the G72/G30 locus with schizophrenia and bipolar disorder has now been reported in several studies.  The G72/G30 locus may be one of several that account for the evidence of linkage that spans a broad region of chromosome 13q.  However, the story of G72/G30 is complex.  Our meta-anal. of published assocn. studies shows highly significant evidence of assocn. between nucleotide variations in the G72/G30 region and schizophrenia, along with compelling evidence of assocn. with bipolar disorder.  But the assocd. alleles and haplotypes are not identical across studies, and some strongly assocd. variants are located ∼50 kb telomeric of G72.  Interestingly, G72 and G30 are transcribed in opposite directions; hence, their transcripts could cross-regulate translation.  A functional native protein and functional motifs for G72 or G30 remain to be demonstrated.  The interaction of G72 with D-amino acid oxidase, itself of interest as a modulator of N-methyl-D-aspartate receptors through regulation of D-serine levels, has been reported in one study and could be a key functional link that deserves further investigation.  The assocn. findings in the G72/G30 region, among the most compelling in psychiatry, may expose an important mol. pathway involved in susceptibility to schizophrenia and bipolar disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0GWVDNGt_FrVg90H21EOLACvtfcHk0ljzzMy8XS3GYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmsl2jtbY%253D&md5=2c61b1975d113bce05f691a2dc6964d5</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DDetera-Wadleigh%26aufirst%3DS.%2BD.%26aulast%3DMcMahon%26aufirst%3DF.%2BJ.%26atitle%3DG72%252FG30%2520in%2520schizophrenia%2520and%2520bipolar%2520disorder%253A%2520review%2520and%2520meta-analysis%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D60%26spage%3D106%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Abou, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmael, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rietschel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nothen, M. M.</span><span> </span><span class="NLM_article-title">The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbl028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16914640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28rjtV2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2006&pages=599-608&author=J.+R.+Abouauthor=C.+Schmaelauthor=S.+Cichonauthor=M.+Rietschelauthor=J.+Schumacherauthor=M.+M.+Nothen&title=The+G72%2FG30+gene+locus+in+psychiatric+disorders%3A+a+challenge+to+diagnostic+boundaries"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries?</span></div><div class="casAuthors">Abou Jamra Rami; Schmael Christine; Cichon Sven; Rietschel Marcella; Schumacher Johannes; Nothen Markus M</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">599-608</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">In follow-up from evidence obtained in linkage studies, systematic linkage disequilibrium mapping within chromosomal region 13q33 has led to the identification of a schizophrenia susceptibility locus which harbors the genes G72 and G30.  These association findings have been replicated in several independent schizophrenia samples.  Association has also been found between genetic variants at the G72/G30 locus and bipolar affective disorder (BPAD), with replication in independent studies.  Results from studies of more detailed psychiatric phenotypes show that association exists with symptom clusters that are common to several disorders as well as with specific psychiatric diagnoses.  These findings may indicate that the association lies not with the diagnostic categories per se but with more specific aspects of the phenotype, such as affective symptoms and cognitive effects, which cross traditional psychiatric diagnostic boundaries.  At the molecular level, the picture remains far from clear.  No putative functional variants have been identified in the coding regions of G72 or G30, and it is therefore likely that disease susceptibility is caused by as yet unidentified variants which alter gene expression or splicing.  A further complication is the fact that inconsistencies are evident in the risk alleles and haplotypes observed to be associated across different samples and studies, which may suggest the presence of multiple susceptibility variants at this locus.  Functional analyses indicate that the G72 gene product plays a role in the activation of N-methyl-D-aspartate receptors, a molecular pathway implicated in both schizophrenia and BPAD, making it the most plausible candidate gene at this locus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgkQuoRCrl6kbxh97K6Vt6fW6udTcc2ebaorMSQgaC-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rjtV2qtw%253D%253D&md5=8a50265ab8bf1f7b88ea67d568109533</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbl028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbl028%26sid%3Dliteratum%253Aachs%26aulast%3DAbou%26aufirst%3DJ.%2BR.%26aulast%3DSchmael%26aufirst%3DC.%26aulast%3DCichon%26aufirst%3DS.%26aulast%3DRietschel%26aufirst%3DM.%26aulast%3DSchumacher%26aufirst%3DJ.%26aulast%3DNothen%26aufirst%3DM.%2BM.%26atitle%3DThe%2520G72%252FG30%2520gene%2520locus%2520in%2520psychiatric%2520disorders%253A%2520a%2520challenge%2520to%2520diagnostic%2520boundaries%26jtitle%3DSchizophr.%2520Bull.%26date%3D2006%26volume%3D32%26spage%3D599%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span> </span><span class="NLM_article-title">G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies</span> <span class="citation_source-journal">Genetics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2007&pages=917-922&author=D.+Liauthor=L.+He&title=G72%2FG30+genes+and+schizophrenia%3A+a+systematic+meta-analysis+of+association+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DG72%252FG30%2520genes%2520and%2520schizophrenia%253A%2520a%2520systematic%2520meta-analysis%2520of%2520association%2520studies%26jtitle%3DGenetics%26date%3D2007%26volume%3D175%26spage%3D917%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Millar, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao-Wei, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devon, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arveiler, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, D. J.</span><span> </span><span class="NLM_article-title">Genomic structure and localisation within a linkage hotspot of disrupted in schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4000784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11317219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFGlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=173-178&author=J.+K.+Millarauthor=S.+Christieauthor=S.+Andersonauthor=D.+Lawsonauthor=L.+D.+Hsiao-Weiauthor=R.+S.+Devonauthor=B.+Arveilerauthor=W.+J.+Muirauthor=D.+H.+Blackwoodauthor=D.+J.+Porteous&title=Genomic+structure+and+localisation+within+a+linkage+hotspot+of+disrupted+in+schizophrenia+1%2C+a+gene+disrupted+by+a+translocation+segregating+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic structure and localization within a linkage hotspot of Disrupted in Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia</span></div><div class="casAuthors">Millar, J. K.; Christie, S.; Anderson, S.; Lawson, D.; Loh, D. Hsiao-Wei; Devon, R. S.; Arveiler, B.; Muir, W. J.; Blackwood, D. H. R.; Porteous, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Two overlapping and antiparallel genes on chromosome 1, Disrupted In Schizophrenia 1 and 2 (DISC1 and DISC2), are disrupted by a (1;11)(q42.1;q14.3) translocation which segregates with schizophrenia through at least four generations of a large Scottish family.  Consequently, these genes are worthy of further investigation as candidate genes potentially involved in the etiol. of major psychiatric illness.  We have constructed a contiguous clone map of PACs and cosmids extending across at least 400 kb of the chromosome 1 translocation breakpoint region and this has provided the basis for examn. of the genomic structure of DISC1.  The gene consists of thirteen exons, estd. to extend across at least 300 kb of DNA.  The antisense gene DISC2 overlaps with exon 9.  Exon 11 contains an alternative splice site that removes 66 nucleotides from the open reading frame.  The final intron of DISC1 belongs to the rare AT-AC class of introns.  We have also mapped marker DIS251 in close proximity to DISC1, localising the gene within a crit. region identified by several independent studies.  Information regarding the structure of the DISC1 gene will facilitate assessment of its involvement in the etiol. of major mental illness in psychotic individuals unrelated to carriers of the translocation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsuW3XVZfay7Vg90H21EOLACvtfcHk0lgrEIu2JmZ-Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFGlurg%253D&md5=1b2d0c548b3020064408f7c32d2e59c6</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4000784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4000784%26sid%3Dliteratum%253Aachs%26aulast%3DMillar%26aufirst%3DJ.%2BK.%26aulast%3DChristie%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DD.%26aulast%3DHsiao-Wei%26aufirst%3DL.%2BD.%26aulast%3DDevon%26aufirst%3DR.%2BS.%26aulast%3DArveiler%26aufirst%3DB.%26aulast%3DMuir%26aufirst%3DW.%2BJ.%26aulast%3DBlackwood%26aufirst%3DD.%2BH.%26aulast%3DPorteous%26aufirst%3DD.%2BJ.%26atitle%3DGenomic%2520structure%2520and%2520localisation%2520within%2520a%2520linkage%2520hotspot%2520of%2520disrupted%2520in%2520schizophrenia%25201%252C%2520a%2520gene%2520disrupted%2520by%2520a%2520translocation%2520segregating%2520with%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry%26date%3D2001%26volume%3D6%26spage%3D173%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarginson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crombie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Clair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span> </span><span class="NLM_article-title">Genetic association between schizophrenia and the DISC1 gene in the Scottish population</span> <span class="citation_source-journal">Am. J. Med. Genet. B: Neuropsychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1SrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2006&pages=155-159&author=F.+Zhangauthor=J.+Sarginsonauthor=C.+Crombieauthor=N.+Walkerauthor=D.+St+Clairauthor=D.+Shaw&title=Genetic+association+between+schizophrenia+and+the+DISC1+gene+in+the+Scottish+population"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic association between schizophrenia and the DISC1 gene in the Scottish population</span></div><div class="casAuthors">Zhang, Feng; Sarginson, Jane; Crombie, Caroline; Walker, Nick; St. Clair, David; Shaw, Duncan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">141B</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">AJMGC9</span>;
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Several lines of evidence support the involvement of the disrupted in schizophrenia 1 (DISC1) gene in schizophrenia susceptibility, including its original identification in a schizophrenia family with a chromosome translocation, several genetic assocn. studies, and functional characterization of the gene product.  In the present study, we have genotyped multiple SNP and microsatellite markers in a large Scottish case-control sample.  We identified two SNPs and one microsatellite that show significant assocn. with schizophrenia.  The strongest assocn. is with a haplotype of SNPs rs751229 and rs3738401, located at the 5' end of the gene; the C-A haplotype of these SNPs is assocd. with a relative risk of schizophrenia of 5 in our population.  We also observe assocn. with a microsatellite in intron 7, but no assocn. with markers toward the 3' end of the gene.  The results are in broad agreement with those of other genetic studies, but there are differences in terms of the precise patterns of assocn.  This anal. further strengthens the candidacy of DISC1 as a risk factor for schizophrenia in the general population, and suggests that more intensive searching for causative variants is justified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqD59QkGi9B7Vg90H21EOLACvtfcHk0lgrEIu2JmZ-Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1SrtLs%253D&md5=6806dbc61cb83863225f04514a7d4ba3</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DSarginson%26aufirst%3DJ.%26aulast%3DCrombie%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DSt%2BClair%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DD.%26atitle%3DGenetic%2520association%2520between%2520schizophrenia%2520and%2520the%2520DISC1%2520gene%2520in%2520the%2520Scottish%2520population%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%2520B%253A%2520Neuropsychiatr.%2520Genet.%26date%3D2006%26volume%3D141%26spage%3D155%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Ekelund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hovatta, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paunio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varilo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suhonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellonen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinsheimer, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juvonen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arajarvi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partonen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suvisaari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonnqvist, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltonen, L.</span><span> </span><span class="NLM_article-title">Chromosome 1 loci in Finnish schizophrenia families</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1611</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fhmg%2F10.15.1611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11468279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFOiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2001&pages=1611-1617&author=J.+Ekelundauthor=I.+Hovattaauthor=A.+Parkerauthor=T.+Paunioauthor=T.+Variloauthor=R.+Martinauthor=J.+Suhonenauthor=P.+Ellonenauthor=G.+Chanauthor=J.+S.+Sinsheimerauthor=E.+Sobelauthor=H.+Juvonenauthor=R.+Arajarviauthor=T.+Partonenauthor=J.+Suvisaariauthor=J.+Lonnqvistauthor=J.+Meyerauthor=L.+Peltonen&title=Chromosome+1+loci+in+Finnish+schizophrenia+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Chromosome 1 loci in Finnish schizophrenia families</span></div><div class="casAuthors">Ekelund, Jesper; Hovatta, Iiris; Parker, Alex; Paunio, Tiina; Varilo, Teppo; Martin, Rory; Suhonen, Johanna; Ellonen, Pekka; Chan, Gayun; Sinsheimer, Janet S.; Sobel, Eric; Juvonen, Hannu; Arajarvi, Ritva; Partonen, Timo; Suvisaari, Jaana; Lonnqvist, Jouko; Meyer, Joanne; Peltonen, Leena</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1611-1617</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">We have earlier reported evidence for linkage to two regions on chromosome 1q32-q42 in schizophrenia families collected for two sep. studies in Finland.  Here we report the results of a fine mapping effort aimed at further definition of the chromosomal region of interest using a large, population-based study sample (221 families, 557 affected individuals).  Most affecteds (78%) had a DSM-IV schizophrenia diagnosis and the remaining had schizophrenia spectrum disorders.  We genotyped a total of 147 microsatellite markers on a wide 45 cM region of chromosome 1q.  The results were analyzed sep. for families originating from an internal isolate of Finland and for families from the rest of Finland, as well as for all families jointly.  We used traditional two-point linkage anal., SimWalk2 multipoint anal. and a novel gamete-competition assocn./linkage method.  Evidence for linkage was obtained for one locus in the combined sample (Zmax = 2.71, D1S2709) and in the nuclear families from outside the internal isolate (Zmax = 3.21, D1S2709).  In the families from the internal isolate the strongest evidence for linkage was obtained with markers located 22 cM centromeric from this marker (Zmax = 2.30, D1S245).  Multipoint anal. also indicated these loci.  Some evidence for assocn. with several markers was obsd. using the gamete-competition method.  Interestingly, the strongest evidence for linkage in the combined study sample was obtained for marker D1S2709, which is an intragenic marker of the DISC1 gene, previously suggested as a susceptibility gene for schizophrenia.  These results are consistent with the presence of susceptibility gene(s) in this chromosomal region, a result also implied in other recent family studies of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmp9KYBQRL0rVg90H21EOLACvtfcHk0lhc7_GH7i8JVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFOiurw%253D&md5=72221ff2dddd22fbb1999459558c1b79</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F10.15.1611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F10.15.1611%26sid%3Dliteratum%253Aachs%26aulast%3DEkelund%26aufirst%3DJ.%26aulast%3DHovatta%26aufirst%3DI.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DPaunio%26aufirst%3DT.%26aulast%3DVarilo%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DSuhonen%26aufirst%3DJ.%26aulast%3DEllonen%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DSinsheimer%26aufirst%3DJ.%2BS.%26aulast%3DSobel%26aufirst%3DE.%26aulast%3DJuvonen%26aufirst%3DH.%26aulast%3DArajarvi%26aufirst%3DR.%26aulast%3DPartonen%26aufirst%3DT.%26aulast%3DSuvisaari%26aufirst%3DJ.%26aulast%3DLonnqvist%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DPeltonen%26aufirst%3DL.%26atitle%3DChromosome%25201%2520loci%2520in%2520Finnish%2520schizophrenia%2520families%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2001%26volume%3D10%26spage%3D1611%26epage%3D1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Ekelund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennah, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiekkalinna, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonnqvist, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltonen, L.</span><span> </span><span class="NLM_article-title">Replication of 1q42 linkage in Finnish schizophrenia pedigrees</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1037</span><span class="NLM_x">–</span> <span class="NLM_lpage">1041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15197400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVGit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=1037-1041&author=J.+Ekelundauthor=W.+Hennahauthor=T.+Hiekkalinnaauthor=A.+Parkerauthor=J.+Meyerauthor=J.+Lonnqvistauthor=L.+Peltonen&title=Replication+of+1q42+linkage+in+Finnish+schizophrenia+pedigrees"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of 1q42 linkage in Finnish schizophrenia pedigrees</span></div><div class="casAuthors">Ekelund, J.; Hennah, W.; Hiekkalinna, T.; Parker, A.; Meyer, J.; Loennqvist, J.; Peltonen, L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1037-1041</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chromosome 1q has been implicated in the etiol. of schizophrenia in several independent studies.  However, the peak linkage findings have been dispersed over a large chromosomal region, with neg. findings in this region also being reported.  The authors' group has previously obsd. linkage on chromosome 1q42, maximizing within the DISC1 gene, which has also been implied in the etiol. of schizophrenia based on functional studies.  In the study presented here, the authors genotyped 300 polymorphic markers on chromosome 1 using a study sample of 70 families with multiple individuals affected with schizophrenia or related conditions, independent of the study samples in our previous reports.  The authors again found evidence for linkage on 1q42 maximizing within the DISC1 gene (rs1000731, lod=2.70).  Further, a haplotype contg. the most strongly linked markers showed some evidence of assocn. with the disease.  This replicates the previous linkage finding in the same region and constitutes supportive evidence for a susceptibility gene in this region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqelJAmTHzFxbVg90H21EOLACvtfcHk0lhc7_GH7i8JVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVGit70%253D&md5=68c523f5c1c94ae6313e04d3cf5e8310</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001536%26sid%3Dliteratum%253Aachs%26aulast%3DEkelund%26aufirst%3DJ.%26aulast%3DHennah%26aufirst%3DW.%26aulast%3DHiekkalinna%26aufirst%3DT.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DLonnqvist%26aufirst%3DJ.%26aulast%3DPeltonen%26aufirst%3DL.%26atitle%3DReplication%2520of%25201q42%2520linkage%2520in%2520Finnish%2520schizophrenia%2520pedigrees%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D1037%26epage%3D1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Hwu, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou-Yang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. F.</span><span> </span><span class="NLM_article-title">Linkage of schizophrenia with chromosome 1q loci in Taiwanese families</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12740602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFOjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=445-452&author=H.+G.+Hwuauthor=C.+M.+Liuauthor=C.+S.+Fannauthor=W.+C.+Ou-Yangauthor=S.+F.+Lee&title=Linkage+of+schizophrenia+with+chromosome+1q+loci+in+Taiwanese+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Linkage of schizophrenia with chromosome 1q loci in Taiwanese families</span></div><div class="casAuthors">Hwu, H-G.; Liu, C-M.; Fann, C. S-J.; Ou-Yang, W-C.; Lee, S. F-C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">445-452</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A pos. linkage of schizophrenia with chromosome 1q loci has been reported in Caucasian patients.  This study was designed to evaluate the linkage of schizophrenia with markers of the 1q22-44 region in 52 Taiwanese families with at least two affected siblings.  In the region 1q22-31 (17.8 cM), marker D1S1679 had a maximal proportion (0.57, P=0.03) of shared identity by descent (IBD) under a narrow phenotype (DSM-IV schizophrenia only).  In the region 1q42-44 (26.8 cM), the marker D1S251, located near the breakpoint of a balanced translocation t (1;11) (q42.1;q14.3) segregated with schizophrenia, and also near the neurodevelopment-related Disrupted in Schizophrenia 1' gene, had a max. NPL score of 1.73 (P=0.03) under the narrow phenotype model and 2.18 (P=0.01) under the broad phenotype model comprised of schizophrenia, schizoaffective disorder, and other nonaffective psychotic disorders as defined by DSM-IV criteria.  The marker D1S2836 also had a maximal proportion (0.57, P=0.05) of shared IBD under the broad model.  These findings may provide guidance for positional cloning studies on candidate genes in the 1q22-31 and 1q41-44 regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkh7wFc9XDbbVg90H21EOLACvtfcHk0ljpBYZ18bPRHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFOjtbk%253D&md5=24320d16ddcf618d6a9797405457326e</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001235%26sid%3Dliteratum%253Aachs%26aulast%3DHwu%26aufirst%3DH.%2BG.%26aulast%3DLiu%26aufirst%3DC.%2BM.%26aulast%3DFann%26aufirst%3DC.%2BS.%26aulast%3DOu-Yang%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DS.%2BF.%26atitle%3DLinkage%2520of%2520schizophrenia%2520with%2520chromosome%25201q%2520loci%2520in%2520Taiwanese%2520families%26jtitle%3DMol.%2520Psychiatry%26date%3D2003%26volume%3D8%26spage%3D445%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Chen, Q. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindpaintner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span> </span><span class="NLM_article-title">Case-control association study of disrupted-in-schizophrenia-1 (DISC1) gene and schizophrenia in the Chinese population</span> <span class="citation_source-journal">J. Psychiatr Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.jpsychires.2006.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16524593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s7jslegtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2007&pages=428-434&author=Q.+Y.+Chenauthor=Q.+Chenauthor=G.+Y.+Fengauthor=K.+Lindpaintnerauthor=L.+J.+Wangauthor=Z.+X.+Chenauthor=Z.+S.+Gaoauthor=J.+S.+Tangauthor=G.+Huangauthor=L.+He&title=Case-control+association+study+of+disrupted-in-schizophrenia-1+%28DISC1%29+gene+and+schizophrenia+in+the+Chinese+population"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Case-control association study of Disrupted-in-Schizophrenia-1 (DISC1) gene and schizophrenia in the Chinese population</span></div><div class="casAuthors">Chen Qing-Ying; Chen Qi; Feng Guo-Yin; Lindpaintner Klaus; Wang Li-Jun; Chen Zheng-Xiong; Gao Zhen-Song; Tang Ji-Sheng; Huang Gang; He Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">428-34</span>
        ISSN:<span class="NLM_cas:issn">0022-3956</span>.
    </div><div class="casAbstract">Disrupted-in-Schizophrenia-1 (DISC1) has first been identified as a candidate gene for schizophrenia through study of a Scottish family with a balanced (1; 11) (q42.1; q14.3) translocation.  Lots of linkage and association studies supported DISC1 as a risk factor for schizophrenia.  In this study, we genotyped three SNPs in DISC1 using a set of Han Chinese samples of 560 schizophrenics and 576 controls.  No positive association was detected in the whole samples but analysis of allele frequencies in female samples showed weak association between SNP rs2295959 and the disease (chi(2)=6.188, P=0.0135, OR=0.728, 95% CI=0.567-0.935).  Our results provide further evidence for sex difference for the effect of the gene on the aetiology of schizophrenia.  Our findings also would encourage further studies, particularly family-based association studies with larger samples, to analyze the association between DISC1 and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSw-M-59aPeCUHdcurJClFcfW6udTcc2ea5LAu0t7xtz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7jslegtA%253D%253D&md5=80b36866cdc6db22cfd9b7c2acf8baad</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2006.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2006.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%2BY.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DG.%2BY.%26aulast%3DLindpaintner%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DZ.%2BX.%26aulast%3DGao%26aufirst%3DZ.%2BS.%26aulast%3DTang%26aufirst%3DJ.%2BS.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DCase-control%2520association%2520study%2520of%2520disrupted-in-schizophrenia-1%2520%2528DISC1%2529%2520gene%2520and%2520schizophrenia%2520in%2520the%2520Chinese%2520population%26jtitle%3DJ.%2520Psychiatr%2520Res.%26date%3D2007%26volume%3D41%26spage%3D428%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">Porteous, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millar, J. K.</span><span> </span><span class="NLM_article-title">Disrupted in schizophrenia 1: building brains and memories</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=255-261&author=D.+J.+Porteousauthor=J.+K.+Millar&title=Disrupted+in+schizophrenia+1%3A+building+brains+and+memories"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPorteous%26aufirst%3DD.%2BJ.%26aulast%3DMillar%26aufirst%3DJ.%2BK.%26atitle%3DDisrupted%2520in%2520schizophrenia%25201%253A%2520building%2520brains%2520and%2520memories%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D255%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Koike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arguello, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kvajo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karayiorgou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogos, J. A.</span><span> </span><span class="NLM_article-title">Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3693</span><span class="NLM_x">–</span> <span class="NLM_lpage">3697</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=3693-3697&author=H.+Koikeauthor=P.+A.+Arguelloauthor=M.+Kvajoauthor=M.+Karayiorgouauthor=J.+A.+Gogos&title=Disc1+is+mutated+in+the+129S6%2FSvEv+strain+and+modulates+working+memory+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoike%26aufirst%3DH.%26aulast%3DArguello%26aufirst%3DP.%2BA.%26aulast%3DKvajo%26aufirst%3DM.%26aulast%3DKarayiorgou%26aufirst%3DM.%26aulast%3DGogos%26aufirst%3DJ.%2BA.%26atitle%3DDisc1%2520is%2520mutated%2520in%2520the%2520129S6%252FSvEv%2520strain%2520and%2520modulates%2520working%2520memory%2520in%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D3693%26epage%3D3697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Kamiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomoda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatten, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawa, A.</span><span> </span><span class="NLM_article-title">A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1067</span><span class="NLM_x">–</span> <span class="NLM_lpage">1078</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fncb1328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Kntr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=1067-1078&author=A.+Kamiyaauthor=K.+Kuboauthor=T.+Tomodaauthor=M.+Takakiauthor=R.+Younauthor=Y.+Ozekiauthor=N.+Sawamuraauthor=U.+Parkauthor=C.+Kudoauthor=M.+Okawaauthor=C.+A.+Rossauthor=M.+E.+Hattenauthor=K.+Nakajimaauthor=A.+Sawa&title=A+schizophrenia-associated+mutation+of+DISC1+perturbs+cerebral+cortex+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development</span></div><div class="casAuthors">Kamiya, Atsushi; Kubo, Ken-ichiro; Tomoda, Toshifumi; Takaki, Manabu; Youn, Richard; Ozeki, Yuji; Sawamura, Naoya; Park, Una; Kudo, Chikako; Okawa, Masako; Ross, Christopher A.; Hatten, Mary E.; Nakajima, Kazunori; Sawa, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1067-1078</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Disrupted-In-Schizophrenia-1 (DISC1), originally identified at the breakpoint of a chromosomal translocation that is linked to a rare familial schizophrenia, has been genetically implicated in schizophrenia in other populations.  Schizophrenia involves subtle cyto-architectural abnormalities that arise during neuro-development, but the underlying mol. mechanisms are unclear.  Here, we demonstrate that DISC1 is a component of the microtubule-assocd. dynein motor complex and is essential for maintaining the complex at the centrosome, hence contributing to normal microtubular dynamics.  Carboxy-terminal-truncated mutant DISC1 (mutDISC1), which results from a chromosomal translocation, functions in a dominant-neg. manner by redistributing wild-type DISC1 through self-assocn. and by dissocg. the DISC1-dynein complex from the centrosome.  Consequently, either depletion of endogenous DISC1 or expression of mutDISC1 impairs neurite outgrowth in vitro and proper development of the cerebral cortex in vivo.  These results indicate that DISC1 is involved in cerebral cortex development, and suggest that loss of DISC1 function may underlie neurodevelopmental dysfunction in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkrUfkjhqs8rVg90H21EOLACvtfcHk0ljpBYZ18bPRHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Kntr%252FL&md5=e8c1589b520226705e5651d464aa1247</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fncb1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1328%26sid%3Dliteratum%253Aachs%26aulast%3DKamiya%26aufirst%3DA.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DTomoda%26aufirst%3DT.%26aulast%3DTakaki%26aufirst%3DM.%26aulast%3DYoun%26aufirst%3DR.%26aulast%3DOzeki%26aufirst%3DY.%26aulast%3DSawamura%26aufirst%3DN.%26aulast%3DPark%26aufirst%3DU.%26aulast%3DKudo%26aufirst%3DC.%26aulast%3DOkawa%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DC.%2BA.%26aulast%3DHatten%26aufirst%3DM.%2BE.%26aulast%3DNakajima%26aufirst%3DK.%26aulast%3DSawa%26aufirst%3DA.%26atitle%3DA%2520schizophrenia-associated%2520mutation%2520of%2520DISC1%2520perturbs%2520cerebral%2520cortex%2520development%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2005%26volume%3D7%26spage%3D1067%26epage%3D1078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Hikida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaaro-Peled, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshadri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hookway, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tankou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pletnikov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawa, A.</span><span> </span><span class="NLM_article-title">Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">14501</span><span class="NLM_x">–</span> <span class="NLM_lpage">14506</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=14501-14506&author=T.+Hikidaauthor=H.+Jaaro-Peledauthor=S.+Seshadriauthor=K.+Oishiauthor=C.+Hookwayauthor=S.+Kongauthor=D.+Wuauthor=R.+Xueauthor=M.+Andradeauthor=S.+Tankouauthor=S.+Moriauthor=M.+Gallagherauthor=K.+Ishizukaauthor=M.+Pletnikovauthor=S.+Kidaauthor=A.+Sawa&title=Dominant-negative+DISC1+transgenic+mice+display+schizophrenia-associated+phenotypes+detected+by+measures+translatable+to+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHikida%26aufirst%3DT.%26aulast%3DJaaro-Peled%26aufirst%3DH.%26aulast%3DSeshadri%26aufirst%3DS.%26aulast%3DOishi%26aufirst%3DK.%26aulast%3DHookway%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DXue%26aufirst%3DR.%26aulast%3DAndrade%26aufirst%3DM.%26aulast%3DTankou%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DGallagher%26aufirst%3DM.%26aulast%3DIshizuka%26aufirst%3DK.%26aulast%3DPletnikov%26aufirst%3DM.%26aulast%3DKida%26aufirst%3DS.%26aulast%3DSawa%26aufirst%3DA.%26atitle%3DDominant-negative%2520DISC1%2520transgenic%2520mice%2520display%2520schizophrenia-associated%2520phenotypes%2520detected%2520by%2520measures%2520translatable%2520to%2520humans%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D14501%26epage%3D14506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group">Millar, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malloy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chubb, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huston, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandon, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camargo, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiting, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, D. J.</span><span> </span><span class="NLM_article-title">DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">310</span><span class="NLM_x">, </span> <span class="NLM_fpage">1187</span><span class="NLM_x">–</span> <span class="NLM_lpage">1191</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2005&pages=1187-1191&author=J.+K.+Millarauthor=B.+S.+Pickardauthor=S.+Mackieauthor=R.+Jamesauthor=S.+Christieauthor=S.+R.+Buchananauthor=M.+P.+Malloyauthor=J.+E.+Chubbauthor=E.+Hustonauthor=G.+S.+Baillieauthor=P.+A.+Thomsonauthor=E.+V.+Hillauthor=N.+J.+Brandonauthor=J.+C.+Rainauthor=L.+M.+Camargoauthor=P.+J.+Whitingauthor=M.+D.+Houslayauthor=D.+H.+Blackwoodauthor=W.+J.+Muirauthor=D.+J.+Porteous&title=DISC1+and+PDE4B+are+interacting+genetic+factors+in+schizophrenia+that+regulate+cAMP+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillar%26aufirst%3DJ.%2BK.%26aulast%3DPickard%26aufirst%3DB.%2BS.%26aulast%3DMackie%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DS.%2BR.%26aulast%3DMalloy%26aufirst%3DM.%2BP.%26aulast%3DChubb%26aufirst%3DJ.%2BE.%26aulast%3DHuston%26aufirst%3DE.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DThomson%26aufirst%3DP.%2BA.%26aulast%3DHill%26aufirst%3DE.%2BV.%26aulast%3DBrandon%26aufirst%3DN.%2BJ.%26aulast%3DRain%26aufirst%3DJ.%2BC.%26aulast%3DCamargo%26aufirst%3DL.%2BM.%26aulast%3DWhiting%26aufirst%3DP.%2BJ.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DBlackwood%26aufirst%3DD.%2BH.%26aulast%3DMuir%26aufirst%3DW.%2BJ.%26aulast%3DPorteous%26aufirst%3DD.%2BJ.%26atitle%3DDISC1%2520and%2520PDE4B%2520are%2520interacting%2520genetic%2520factors%2520in%2520schizophrenia%2520that%2520regulate%2520cAMP%2520signaling%26jtitle%3DScience%26date%3D2005%26volume%3D310%26spage%3D1187%26epage%3D1191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group">Crow, T. J.</span><span> </span><span class="NLM_article-title">Is DISC1 really a gene predisposing to psychosis</span> <span class="citation_source-journal">Br. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">190</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1192%2Fbjp.190.3.270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17329752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s7ivFykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2007&pages=270-271&author=T.+J.+Crow&title=Is+DISC1+really+a+gene+predisposing+to+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Is DISC1 really a gene predisposing to psychosis?</span></div><div class="casAuthors">Crow T J</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270; author reply 270-1</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnlSZlU-r1f5PlX7E30qdzfW6udTcc2ebxi0bAIoAWGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7ivFykuw%253D%253D&md5=f7b11ab919b2ed599e63429bd5e022c2</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1192%2Fbjp.190.3.270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.190.3.270%26sid%3Dliteratum%253Aachs%26aulast%3DCrow%26aufirst%3DT.%2BJ.%26atitle%3DIs%2520DISC1%2520really%2520a%2520gene%2520predisposing%2520to%2520psychosis%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D190%26spage%3D270%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group">Lo, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luan, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, H.</span><span> </span><span class="NLM_article-title">Association of SNPs and haplotypes in GABAA receptor beta2 gene with schizophrenia</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14699426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Gnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=603-608&author=W.+S.+Loauthor=C.+F.+Lauauthor=Z.+Xuanauthor=C.+F.+Chanauthor=G.+Y.+Fengauthor=L.+Heauthor=Z.+C.+Caoauthor=H.+Liuauthor=Q.+M.+Luanauthor=H.+Xue&title=Association+of+SNPs+and+haplotypes+in+GABAA+receptor+beta2+gene+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Association of SNPs and haplotypes in GABAA receptor β2 gene with schizophrenia</span></div><div class="casAuthors">Lo, W-S.; Lau, C-F.; Xuan, Z.; Chan, C-F.; Feng, G-Y.; He, L.; Cao, Z-C.; Liu, H.; Luan, Q-M.; Xue, H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-608</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Disturbances in GABAergic system have been obsd. in schizophrenics.  In the present study, population assocn. anal. was performed on 19 SNPs in the α1, β2, γ2, ε and π subunit genes of GABAA receptor.  Five SNPs in GABRB2, namely B2I7G1584T, rs1816071, rs194072, rs252944 and rs187269, were found to be significantly assocd., and their haplotypes in linkage disequil., with schizophrenia.  This represents the first report on any disease assocn. of SNPs in the human GABAA receptor genes, and focuses attention on the GABAergic hypothesis of schizophrenia etiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj9FZnnGG_GrVg90H21EOLACvtfcHk0ljIUieTzzi48A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Gnt74%253D&md5=b59b14a4570fa123bfd70e950724a576</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001461%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DW.%2BS.%26aulast%3DLau%26aufirst%3DC.%2BF.%26aulast%3DXuan%26aufirst%3DZ.%26aulast%3DChan%26aufirst%3DC.%2BF.%26aulast%3DFeng%26aufirst%3DG.%2BY.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DZ.%2BC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DQ.%2BM.%26aulast%3DXue%26aufirst%3DH.%26atitle%3DAssociation%2520of%2520SNPs%2520and%2520haplotypes%2520in%2520GABAA%2520receptor%2520beta2%2520gene%2520with%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D603%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group">Zai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, J. L.</span><span> </span><span class="NLM_article-title">Possible association between the γ-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophrenia</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.euroneuro.2004.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15820424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFKksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=347-352&author=G.+Zaiauthor=N.+Kingauthor=G.+W.+Wongauthor=C.+L.+Barrauthor=J.+L.+Kennedy&title=Possible+association+between+the+%CE%B3-aminobutyric+acid+type+B+receptor+1+%28GABBR1%29+gene+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Possible association between the gamma-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophrenia</span></div><div class="casAuthors">Zai, Gwyneth; King, Nicole; Wong, Gregory W. H.; Barr, Cathy L.; Kennedy, James L.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-352</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Schizophrenia (SCZ) is a severe neuropsychiatric disorder with a genetic component.  The major inhibitory GABA-(gamma-aminobutyric acid) ergic system may be involved.  The GABA type B receptor 1 (GABBR1) gene was localized to 6p21.3, a region linked to SCZ.  The authors therefore investigated 5 polymorphisms (A-7265G, C10497G, Ser-491-Ser-T1473C, Phe-659-Phe-T1977C, and 3'-UTR A33795G substitutions) in the GABBR1 gene in a sample of 101 DSM-IV SCZ probands and their families, 150 unrelated affected individuals matched with 150 healthy controls, using the transmission disequil. test (TDT) and case-control anal.  The authors did not observe biased transmission of alleles in any of the polymorphisms individually and haplotypes within the gene to SCZ probands.  However, a weak significant difference was obsd. in the A-7265G polymorphism between the allelic frequency (χ2 = 4.310, P = 0.038) and a trend was obsd. between the genotype frequency (χ2 = 4.970, 2 df, P = 0.083) of SCZ individuals and controls.  Further investigations of the role of GABBR1 in SCZ are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpnikTSakLgrVg90H21EOLACvtfcHk0lilOxWxjb0Gjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFKksL0%253D&md5=e6abff2d5a56349992aa5d5b83b38252</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2004.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2004.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DZai%26aufirst%3DG.%26aulast%3DKing%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DG.%2BW.%26aulast%3DBarr%26aufirst%3DC.%2BL.%26aulast%3DKennedy%26aufirst%3DJ.%2BL.%26atitle%3DPossible%2520association%2520between%2520the%2520%25CE%25B3-aminobutyric%2520acid%2520type%2520B%2520receptor%25201%2520%2528GABBR1%2529%2520gene%2520and%2520schizophrenia%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2005%26volume%3D15%26spage%3D347%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group">Adler, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffer, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, R.</span><span> </span><span class="NLM_article-title">Normalization of auditory physiology by cigarette smoking in schizophrenic patients</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">1856</span><span class="NLM_x">–</span> <span class="NLM_lpage">1861</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8238642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK2c%252FlslWitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=1993&pages=1856-1861&author=L.+E.+Adlerauthor=L.+D.+Hofferauthor=A.+Wiserauthor=R.+Freedman&title=Normalization+of+auditory+physiology+by+cigarette+smoking+in+schizophrenic+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Normalization of auditory physiology by cigarette smoking in schizophrenic patients</span></div><div class="casAuthors">Adler L E; Hoffer L D; Wiser A; Freedman R</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1856-61</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Because many schizophrenic patients are heavy smokers, it has been suggested that nicotine normalizes some neuronal deficit involved in their illness.  Schizophrenic subjects have various difficulties with maintenance of attention and selective processing of sensory information.  One defect in sensory gating in schizophrenia has been characterized by recording auditory evoked potentials.  Most normal subjects have a decrease in the evoked response to the second of two closely paired stimuli, whereas most schizophrenic subjects do not.  The aim of this study was to determine whether smoking normalizes this deficit in auditory sensory gating in schizophrenia.  METHOD:  Changes in auditory sensory gating in response to smoking cigarettes were studied in 10 smokers without psychiatric illness and 10 schizophrenic smokers.  Both groups were asked to abstain from smoking from 11:00 p.m. until 8:00 a.m. the next morning, when their auditory evoked responses to pairs of clicks were recorded.  The ability to gate sensory information is reflected in a decrease in the P50 wave amplitude in response to the second of the two stimuli.  After baseline recordings, the subjects smoked as much as they wished, and then two postsmoking recordings were performed.  RESULTS:  The schizophrenic patients had a marked but brief improvement in P50 auditory gating immediately after smoking, whereas P50 gating for the normal smokers was slightly impaired.  CONCLUSIONS:  This study suggests that cigarette smoking can transiently normalize the impairment of auditory sensory gating in schizophrenic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5QavxFsthtekdrW1FkXG-fW6udTcc2eaW9-cLUabJi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252FlslWitA%253D%253D&md5=5a095d3f2e6a46a68f9f9383919f1606</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdler%26aufirst%3DL.%2BE.%26aulast%3DHoffer%26aufirst%3DL.%2BD.%26aulast%3DWiser%26aufirst%3DA.%26aulast%3DFreedman%26aufirst%3DR.%26atitle%3DNormalization%2520of%2520auditory%2520physiology%2520by%2520cigarette%2520smoking%2520in%2520schizophrenic%2520patients%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1993%26volume%3D150%26spage%3D1856%26epage%3D1861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group">Kelly, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreadie, R.</span><span> </span><span class="NLM_article-title">Cigarette smoking and schizophrenia</span> <span class="citation_source-journal">Adv. Psychiatr. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">331</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1192%2Fapt.6.5.327" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=327-331&author=C.+Kellyauthor=R.+McCreadie&title=Cigarette+smoking+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1192%2Fapt.6.5.327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fapt.6.5.327%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DC.%26aulast%3DMcCreadie%26aufirst%3DR.%26atitle%3DCigarette%2520smoking%2520and%2520schizophrenia%26jtitle%3DAdv.%2520Psychiatr.%2520Treat.%26date%3D2000%26volume%3D6%26spage%3D327%26epage%3D331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group">Sacco, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seyal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudas, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vessicchio, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan-Sarin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jatlow, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, T. P.</span><span> </span><span class="NLM_article-title">Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.62.6.649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15939842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ptlWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2005&pages=649-659&author=K.+A.+Saccoauthor=A.+Termineauthor=A.+Seyalauthor=M.+M.+Dudasauthor=J.+C.+Vessicchioauthor=S.+Krishnan-Sarinauthor=P.+I.+Jatlowauthor=B.+E.+Wexlerauthor=T.+P.+George&title=Effects+of+cigarette+smoking+on+spatial+working+memory+and+attentional+deficits+in+schizophrenia%3A+involvement+of+nicotinic+receptor+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms</span></div><div class="casAuthors">Sacco Kristi A; Termine Angelo; Seyal Aisha; Dudas Melissa M; Vessicchio Jennifer C; Krishnan-Sarin Suchitra; Jatlow Peter I; Wexler Bruce E; George Tony P</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">649-59</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">BACKGROUND:  Cigarette smoking rates in schizophrenia are higher than in the general population.  OBJECTIVES:  To determine whether cigarette smoking modifies cognitive deficits in schizophrenia and to establish the role of nicotinic acetylcholine receptors (nAChRs) in mediating cigarette smoking-related cognitive enhancement.  DESIGN:  Neuropsychological assessments were performed at smoking baseline, after overnight abstinence, and after smoking reinstatement across 3 separate test weeks during which subjects were pretreated in a counterbalanced manner with the nonselective nAChR antagonist mecamylamine hydrochloride (0, 5, or 10 mg/d).  PARTICIPANTS:  Twenty-five smokers with schizophrenia and 25 control smokers.  SETTING:  Outpatient mental health center.  MAIN OUTCOME MEASURES:  Visuospatial working memory (VSWM) and Continuous Performance Test (CPT) scores.  RESULTS:  In smokers with schizophrenia and control smokers, overnight abstinence led to undetectable plasma nicotine levels and an increase in tobacco craving.  While abstinence reduced CPT hit rate in both groups, VSWM was only impaired in smokers with schizophrenia.  Smoking reinstatement reversed abstinence-induced cognitive impairment.  Enhancement of VSWM and CPT performance by smoking reinstatement in smokers with schizophrenia, but not the subjective effects of smoking, was blocked by mecamylamine treatment.  CONCLUSIONS:  Cigarette smoking may selectively enhance VSWM and attentional deficits in smokers with schizophrenia, which may depend on nAChR stimulation.  These findings may have implications for understanding the high rates of smoking in schizophrenia and for developing pharmacotherapies for cognitive deficits and nicotine dependence in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG4lFrjFq_mWBAiYWy6n3SfW6udTcc2eaW9-cLUabJi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ptlWjsg%253D%253D&md5=29fbb9d5a50174b7db25eaba77cbc35c</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.62.6.649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.62.6.649%26sid%3Dliteratum%253Aachs%26aulast%3DSacco%26aufirst%3DK.%2BA.%26aulast%3DTermine%26aufirst%3DA.%26aulast%3DSeyal%26aufirst%3DA.%26aulast%3DDudas%26aufirst%3DM.%2BM.%26aulast%3DVessicchio%26aufirst%3DJ.%2BC.%26aulast%3DKrishnan-Sarin%26aufirst%3DS.%26aulast%3DJatlow%26aufirst%3DP.%2BI.%26aulast%3DWexler%26aufirst%3DB.%2BE.%26aulast%3DGeorge%26aufirst%3DT.%2BP.%26atitle%3DEffects%2520of%2520cigarette%2520smoking%2520on%2520spatial%2520working%2520memory%2520and%2520attentional%2520deficits%2520in%2520schizophrenia%253A%2520involvement%2520of%2520nicotinic%2520receptor%2520mechanisms%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2005%26volume%3D62%26spage%3D649%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group">deHaan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavalaye, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linszen, D.</span><span> </span><span class="NLM_article-title">Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">505</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-005-0218-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2006&pages=500-505&author=L.+deHaanauthor=J.+Booijauthor=J.+Lavalayeauthor=A.+T.+vanauthor=D.+Linszen&title=Occupancy+of+dopamine+D2+receptors+by+antipsychotic+drugs+is+related+to+nicotine+addiction+in+young+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-0218-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-0218-x%26sid%3Dliteratum%253Aachs%26aulast%3DdeHaan%26aufirst%3DL.%26aulast%3DBooij%26aufirst%3DJ.%26aulast%3DLavalaye%26aufirst%3DJ.%26aulast%3Dvan%26aufirst%3DA.%2BT.%26aulast%3DLinszen%26aufirst%3DD.%26atitle%3DOccupancy%2520of%2520dopamine%2520D2%2520receptors%2520by%2520antipsychotic%2520drugs%2520is%2520related%2520to%2520nicotine%2520addiction%2520in%2520young%2520patients%2520with%2520schizophrenia%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2006%26volume%3D183%26spage%3D500%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group">Freedman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myles-Worsley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr-Urtreger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olincy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polymeropoulos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimherr, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wender, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruglyak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byerley, W.</span><span> </span><span class="NLM_article-title">Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=587-592&author=R.+Freedmanauthor=H.+Coonauthor=M.+Myles-Worsleyauthor=A.+Orr-Urtregerauthor=A.+Olincyauthor=A.+Davisauthor=M.+Polymeropoulosauthor=J.+Holikauthor=J.+Hopkinsauthor=M.+Hoffauthor=J.+Rosenthalauthor=M.+C.+Waldoauthor=F.+Reimherrauthor=P.+Wenderauthor=J.+Yawauthor=D.+A.+Youngauthor=C.+R.+Breeseauthor=C.+Adamsauthor=D.+Pattersonauthor=L.+E.+Adlerauthor=L.+Kruglyakauthor=S.+Leonardauthor=W.+Byerley&title=Linkage+of+a+neurophysiological+deficit+in+schizophrenia+to+a+chromosome+15+locus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFreedman%26aufirst%3DR.%26aulast%3DCoon%26aufirst%3DH.%26aulast%3DMyles-Worsley%26aufirst%3DM.%26aulast%3DOrr-Urtreger%26aufirst%3DA.%26aulast%3DOlincy%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DPolymeropoulos%26aufirst%3DM.%26aulast%3DHolik%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DJ.%26aulast%3DHoff%26aufirst%3DM.%26aulast%3DRosenthal%26aufirst%3DJ.%26aulast%3DWaldo%26aufirst%3DM.%2BC.%26aulast%3DReimherr%26aufirst%3DF.%26aulast%3DWender%26aufirst%3DP.%26aulast%3DYaw%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DD.%2BA.%26aulast%3DBreese%26aufirst%3DC.%2BR.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DPatterson%26aufirst%3DD.%26aulast%3DAdler%26aufirst%3DL.%2BE.%26aulast%3DKruglyak%26aufirst%3DL.%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DByerley%26aufirst%3DW.%26atitle%3DLinkage%2520of%2520a%2520neurophysiological%2520deficit%2520in%2520schizophrenia%2520to%2520a%2520chromosome%252015%2520locus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D587%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group">Leonard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olincy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloninger, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malaspina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svrakic, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, R.</span><span> </span><span class="NLM_article-title">Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative</span> <span class="citation_source-journal">Am. J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">312</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2F%28SICI%291096-8628%2819980710%2981%3A4%3C308%3A%3AAID-AJMG6%3E3.0.CO%3B2-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9674976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1czjslOgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1998&pages=308-312&author=S.+Leonardauthor=J.+Gaultauthor=T.+Mooreauthor=J.+Hopkinsauthor=M.+Robinsonauthor=A.+Olincyauthor=L.+E.+Adlerauthor=C.+R.+Cloningerauthor=C.+A.+Kaufmannauthor=M.+T.+Tsuangauthor=S.+V.+Faraoneauthor=D.+Malaspinaauthor=D.+M.+Svrakicauthor=R.+Freedman&title=Further+investigation+of+a+chromosome+15+locus+in+schizophrenia%3A+analysis+of+affected+sibpairs+from+the+NIMH+Genetics+Initiative"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative</span></div><div class="casAuthors">Leonard S; Gault J; Moore T; Hopkins J; Robinson M; Olincy A; Adler L E; Cloninger C R; Kaufmann C A; Tsuang M T; Faraone S V; Malaspina D; Svrakic D M; Freedman R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-12</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">Linkage of a neurophysiological deficit associated with schizophrenia, i.e., the failure to inhibit the auditory P50 response, was previously reported at chromosome 15q14.  The marker with the highest pairwise lod score, D15S1360, was isolated from a yeast artificial chromosome containing a candidate gene, the alpha7-nicotinic acetylcholine receptor gene.  In the present study, this linkage was further investigated in a subset of the NIMH Genetics Initiative schizophrenia families.  These families have not been studied neurophysiologically, as were the families in the original report.  Therefore, the DSMIII-R diagnosis of schizophrenia was used as the affected phenotype.  Twenty families fulfilled the criteria of at least one sibpair concordant for schizophrenia, along with their two parents or another affected relative outside the nuclear family, available for genotyping.  Sibpair analysis showed a significant proportion of D15S1360 alleles shared identical-by-descent (0.58; P < 0.0024).  The results further support the involvement of this chromosomal locus in the genetic transmission of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRn60l4znupf1w2ofyr07jXfW6udTcc2eZk_r5uCPPTTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1czjslOgsQ%253D%253D&md5=c35bd47bbb0f78641152c4034bb0cd6a</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-8628%2819980710%2981%3A4%3C308%3A%3AAID-AJMG6%3E3.0.CO%3B2-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-8628%252819980710%252981%253A4%253C308%253A%253AAID-AJMG6%253E3.0.CO%253B2-P%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DGault%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DT.%26aulast%3DHopkins%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DM.%26aulast%3DOlincy%26aufirst%3DA.%26aulast%3DAdler%26aufirst%3DL.%2BE.%26aulast%3DCloninger%26aufirst%3DC.%2BR.%26aulast%3DKaufmann%26aufirst%3DC.%2BA.%26aulast%3DTsuang%26aufirst%3DM.%2BT.%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DMalaspina%26aufirst%3DD.%26aulast%3DSvrakic%26aufirst%3DD.%2BM.%26aulast%3DFreedman%26aufirst%3DR.%26atitle%3DFurther%2520investigation%2520of%2520a%2520chromosome%252015%2520locus%2520in%2520schizophrenia%253A%2520analysis%2520of%2520affected%2520sibpairs%2520from%2520the%2520NIMH%2520Genetics%2520Initiative%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%26date%3D1998%26volume%3D81%26spage%3D308%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Eerdewegh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T.</span><span> </span><span class="NLM_article-title">A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families</span> <span class="citation_source-journal">Hum. Hered.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1159%2F000077543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15192278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksl2gurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2004&pages=59-68&author=S.+V.+Faraoneauthor=J.+Suauthor=L.+Taylorauthor=M.+Wilcoxauthor=P.+Van+Eerdeweghauthor=M.+T.+Tsuang&title=A+novel+permutation+testing+method+implicates+sixteen+nicotinic+acetylcholine+receptor+genes+as+risk+factors+for+smoking+in+schizophrenia+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Permutation Testing Method Implicates Sixteen Nicotinic Acetylcholine Receptor Genes as Risk Factors for Smoking in Schizophrenia Families</span></div><div class="casAuthors">Faraone, Stephen V.; Su, Jessica; Taylor, Levi; Wilcox, Marsha; Van Eerdewegh, Paul; Tsuang, Ming T.</div><div class="citationInfo"><span class="NLM_cas:title">Human Heredity</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">HUHEAS</span>;
        ISSN:<span class="NLM_cas:issn">0001-5652</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Smoking is a common correlate of schizophrenia, which leads to medical morbidity.  Although twin and adoption studies have consistently implicated genes in the etiol. of both smoking and schizophrenia, finding genes has been difficult.  Several authors have suggested that clin. or neurobiol. features assocd. with schizophrenia, such as smoking, might improve the ability to detect schizophrenia susceptibility genes by identifying genes related to the etiol. of that feature.  The objective of this study is to assess evidence for linkage of sixteen nicotinic acetylcholine receptor genes and smoking in schizophrenia families, using data from the NIMH Genetics Initiative for schizophrenia.  Sixteen nicotinic acetylcholine receptor genes were selected prior to anal.  We used a multipoint sibling pair linkage anal. program, SIBPAL2, with a smoking trait in schizophrenia families.  The significance of the group of candidate genes, in addn. to each individual candidate gene, was assessed using permutation testing, which adjusted for multiple comparisons.  The group of genes showed significant linkage to the smoking trait after adjusting for multiple comparisons through permutation testing (p = 0.039).  In addn., two of the individual candidate genes were significant (CHRNA2, p = 0.044) and (CHRNB2, p = 0.015) and two genes were marginally significant (CHRNA7, p = 0.095; CHRNA1, p = 0.076).  The significance of the complex hypothesis, involving sixteen genes, implicates the nicotinic system in smoking for schizophrenic families.  Individual gene anal. suggests that CHRNA2 and CHRNB2 may play a particular role in this involvement.  Such findings help prioritize genes for future case control studies.  In addn., we provide a novel permutation method that is useful in future analyses involving a single hypothesis, with multiple candidate genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEqVFPSQTvyLVg90H21EOLACvtfcHk0liTZzERqOg7mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksl2gurY%253D&md5=9b9dc0d6562250c3295440a8b2201402</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1159%2F000077543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000077543%26sid%3Dliteratum%253Aachs%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DWilcox%26aufirst%3DM.%26aulast%3DVan%2BEerdewegh%26aufirst%3DP.%26aulast%3DTsuang%26aufirst%3DM.%2BT.%26atitle%3DA%2520novel%2520permutation%2520testing%2520method%2520implicates%2520sixteen%2520nicotinic%2520acetylcholine%2520receptor%2520genes%2520as%2520risk%2520factors%2520for%2520smoking%2520in%2520schizophrenia%2520families%26jtitle%3DHum.%2520Hered.%26date%3D2004%26volume%3D57%26spage%3D59%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group">Leonard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianzon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drebing, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirota, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olincy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, R.</span><span> </span><span class="NLM_article-title">Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">–</span> <span class="NLM_lpage">1096</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchpsyc.59.12.1085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12470124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslejsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2002&pages=1085-1096&author=S.+Leonardauthor=J.+Gaultauthor=J.+Hopkinsauthor=J.+Logelauthor=R.+Vianzonauthor=M.+Shortauthor=C.+Drebingauthor=R.+Bergerauthor=D.+Vennauthor=P.+Sirotaauthor=G.+Zerbeauthor=A.+Olincyauthor=R.+G.+Rossauthor=L.+E.+Adlerauthor=R.+Freedman&title=Association+of+promoter+variants+in+the+%CE%B17+nicotinic+acetylcholine+receptor+subunit+gene+with+an+inhibitory+deficit+found+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia</span></div><div class="casAuthors">Leonard, Sherry; Gault, Judith; Hopkins, Jan; Logel, Judith; Vianzon, Ruby; Short, Margaret; Drebing, Carla; Berger, Ralph; Venn, Diana; Sirota, Pinkhas; Zerbe, Gary; Olincy, Ann; Ross, Randal G.; Adler, Lawrence E.; Freedman, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1085-1096</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Background: The α7 neuronal nicotinic acetylcholine receptor subunit gene (CHRNA7) was implicated as a candidate gene for schizophrenia, and for an auditory sensory processing deficit found in the disease, by both genetic linkage at 15q14 and biochem. data.  The expression of CHRNA7 is reduced in several brain regions in schizophrenic subjects compared with control subjects.  This study presents DNA sequence anal. of the core promoter region for CHRNA7 in schizophrenic and control subjects.  Methods: Single-strand conformation polymorphism anal. and DNA sequencing were used for mutation screening of the core promoter in the CHRNA7 gene.  The sample included subjects from 166 schizophrenic families and 165 controls.  Controls had no evidence of current or past psychosis and had auditory evoked potentials recorded.  Results: Multiple polymorphic patterns were identified in the CHRNA7 core promoter in both schizophrenic and control subjects.  Functional anal. of polymorphisms indicated that transcription was reduced.  The prevalence of functional promoter variants was statistically greater in schizophrenic subjects than in the controls.  Presence of an α7 promoter polymorphism in controls was assocd. with failure to inhibit the P50 auditory evoked potential response.  Conclusions: Although linkage disequil. with other genetic alterations cannot be excluded, the CHRNA7 core promoter variants, found in this study, may contribute to a common pathophysiol. feature of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA0UwLDMqkjLVg90H21EOLACvtfcHk0liTZzERqOg7mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslejsL4%253D&md5=2b0174e9ab18427a2d0fa215300c4c77</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.59.12.1085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.59.12.1085%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DGault%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DJ.%26aulast%3DLogel%26aufirst%3DJ.%26aulast%3DVianzon%26aufirst%3DR.%26aulast%3DShort%26aufirst%3DM.%26aulast%3DDrebing%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DVenn%26aufirst%3DD.%26aulast%3DSirota%26aufirst%3DP.%26aulast%3DZerbe%26aufirst%3DG.%26aulast%3DOlincy%26aufirst%3DA.%26aulast%3DRoss%26aufirst%3DR.%2BG.%26aulast%3DAdler%26aufirst%3DL.%2BE.%26aulast%3DFreedman%26aufirst%3DR.%26atitle%3DAssociation%2520of%2520promoter%2520variants%2520in%2520the%2520%25CE%25B17%2520nicotinic%2520acetylcholine%2520receptor%2520subunit%2520gene%2520with%2520an%2520inhibitory%2520deficit%2520found%2520in%2520schizophrenia%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2002%26volume%3D59%26spage%3D1085%26epage%3D1096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group">Curtis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blouin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radhakrishna, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehrig, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasseter, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolyniec, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestadt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombroski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazazian, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulver, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Housman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonarakis, S. E.</span><span> </span><span class="NLM_article-title">No evidence for linkage between schizophrenia and markers at chromosome 15q13-14</span> <span class="citation_source-journal">Am. J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2F%28SICI%291096-8628%2819990416%2988%3A2%3C109%3A%3AAID-AJMG1%3E3.0.CO%3B2-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10206225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1M3itFSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1999&pages=109-112&author=L.+Curtisauthor=J.+L.+Blouinauthor=U.+Radhakrishnaauthor=C.+Gehrigauthor=V.+K.+Lasseterauthor=P.+Wolyniecauthor=G.+Nestadtauthor=B.+Dombroskiauthor=H.+H.+Kazazianauthor=A.+E.+Pulverauthor=D.+Housmanauthor=D.+Bertrandauthor=S.+E.+Antonarakis&title=No+evidence+for+linkage+between+schizophrenia+and+markers+at+chromosome+15q13-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">No evidence for linkage between schizophrenia and markers at chromosome 15q13-14</span></div><div class="casAuthors">Curtis L; Blouin J L; Radhakrishna U; Gehrig C; Lasseter V K; Wolyniec P; Nestadt G; Dombroski B; Kazazian H H; Pulver A E; Housman D; Bertrand D; Antonarakis S E</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-12</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">Freedman et al. [1997: Proc Natl Acad Sci USA 94:587-592] reported linkage in nine multiplex schizophrenia families to markers on chromosome 15, using impaired neuronal inhibition to repeated auditory stimuli (P50), a neurophysiological deficit associated with schizophrenia, as the phenotype.  The highest LOD score obtained (5.3 at theta = 0) was for marker D15S1360 mapped to chromosome 15q13-14, less than 120 kb from the alpha7-nicotinic receptor (CHRNA7) gene.  The study also reported a small positive LOD score for D15S1360 when examined for linkage to the schizophrenia phenotype.  Following these findings, we examined three polymorphic markers (D15S1360, L76630, and ACTC) on chromosome 15q13-14 near the CHRNA7 gene for linkage to schizophrenia, using 54 pedigrees from an independent study.  Alleles for these three markers were genotyped and analyzed using parametric and nonparametric methods.  No LOD score above 1.00 was obtained for any marker, and affected sib-pair analysis likewise showed no evidence for linkage.  We conclude that in our families the region around the CHRNA7 locus does not contain a major locus for susceptibility to schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk3N8ZO0OrzEmhnSqMnvzDfW6udTcc2eY9dFy8wf5aZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3itFSltA%253D%253D&md5=49ff25dc0bce7919544a81aa618a309e</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-8628%2819990416%2988%3A2%3C109%3A%3AAID-AJMG1%3E3.0.CO%3B2-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-8628%252819990416%252988%253A2%253C109%253A%253AAID-AJMG1%253E3.0.CO%253B2-3%26sid%3Dliteratum%253Aachs%26aulast%3DCurtis%26aufirst%3DL.%26aulast%3DBlouin%26aufirst%3DJ.%2BL.%26aulast%3DRadhakrishna%26aufirst%3DU.%26aulast%3DGehrig%26aufirst%3DC.%26aulast%3DLasseter%26aufirst%3DV.%2BK.%26aulast%3DWolyniec%26aufirst%3DP.%26aulast%3DNestadt%26aufirst%3DG.%26aulast%3DDombroski%26aufirst%3DB.%26aulast%3DKazazian%26aufirst%3DH.%2BH.%26aulast%3DPulver%26aufirst%3DA.%2BE.%26aulast%3DHousman%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DAntonarakis%26aufirst%3DS.%2BE.%26atitle%3DNo%2520evidence%2520for%2520linkage%2520between%2520schizophrenia%2520and%2520markers%2520at%2520chromosome%252015q13-14%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%26date%3D1999%26volume%3D88%26spage%3D109%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group">Talkowski, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimgaonkar, V. L.</span><span> </span><span class="NLM_article-title">Dopamine genes and schizophrenia: case closed or evidence pending</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">–</span> <span class="NLM_lpage">1081</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1093%2Fschbul%2Fsbm076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17630406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2srgvFyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=1071-1081&author=M.+E.+Talkowskiauthor=M.+Bamneauthor=H.+Mansourauthor=V.+L.+Nimgaonkar&title=Dopamine+genes+and+schizophrenia%3A+case+closed+or+evidence+pending"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine genes and schizophrenia: case closed or evidence pending?</span></div><div class="casAuthors">Talkowski Michael E; Bamne Mikhil; Mansour Hader; Nimgaonkar Vishwajit L</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1071-81</span>
        ISSN:<span class="NLM_cas:issn">0586-7614</span>.
    </div><div class="casAbstract">The dopamine hypothesis of schizophrenia (SZ) has motivated a large number of genetic association studies but few if any dopaminergic (DA) polymorphisms are accepted as credible risk factors at present.  To evaluate whether dopamine-related genes have been investigated adequately, we surveyed public genetic databases and published SZ association studies with regard to 14 conventional DA genes and 7 selected dopamine-interacting proteins.  We estimate that 325 polymorphisms would be required to evaluate the impact of common variation on SZ risk among Caucasian samples.  To date, 98 polymorphisms have been analyzed in published association studies.  We estimate that only 19 of these variations have been evaluated in samples with at least 50% power to detect an association of the effect size commonly found in genetically complex disorders.  While it is possible that DA genes do not harbor genetic risk factors for SZ, our review suggests that satisfactory conclusions for most genes cannot be drawn at present.  Whole-genome association studies have begun to fill this void, but additional analyses are likely to be needed.  Recommendations for future association studies include analysis of adequately powered samples, judiciously selected polymorphisms, multiple ethnic groups, and concurrent evaluation of function at associated single-nucleotide polymorphisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnh99bDRxYg8RAV4D_Ins_fW6udTcc2eYQA5maVkYQxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srgvFyrtg%253D%253D&md5=8e8a7a7f5218fed20ab7f173fa474cac</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbm076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbm076%26sid%3Dliteratum%253Aachs%26aulast%3DTalkowski%26aufirst%3DM.%2BE.%26aulast%3DBamne%26aufirst%3DM.%26aulast%3DMansour%26aufirst%3DH.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26atitle%3DDopamine%2520genes%2520and%2520schizophrenia%253A%2520case%2520closed%2520or%2520evidence%2520pending%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D1071%26epage%3D1081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group">Fallin, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasseter, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avramopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicodemus, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolyniec, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestadt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huganir, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulver, A. E.</span><span> </span><span class="NLM_article-title">Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios</span> <span class="citation_source-journal">Am. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1086%2F497703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16380905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ygtLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=918-936&author=M.+D.+Fallinauthor=V.+K.+Lasseterauthor=D.+Avramopoulosauthor=K.+K.+Nicodemusauthor=P.+S.+Wolyniecauthor=J.+A.+McGrathauthor=G.+Steelauthor=G.+Nestadtauthor=K.+Y.+Liangauthor=R.+L.+Huganirauthor=D.+Valleauthor=A.+E.+Pulver&title=Bipolar+I+disorder+and+schizophrenia%3A+a+440-single-nucleotide+polymorphism+screen+of+64+candidate+genes+among+Ashkenazi+Jewish+case-parent+trios"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Bipolar I disorder and schizophrenia: A 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios</span></div><div class="casAuthors">Fallin, M. Daniele; Lasseter, Virginia K.; Avramopoulos, Dimitrios; Nicodemus, Kristin K.; Wolyniec, Paula S.; McGrath, John A.; Steel, Gary; Nestadt, Gerald; Liang, Kung-Yee; Huganir, Richard L.; Valle, David; Pulver, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">918-936</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Bipolar, schizophrenia, and schizoaffective disorders are common, highly heritable psychiatric disorders, for which familial coaggregation, as well as epidemiol. and genetic evidence, suggests overlapping etiologies.  No definitive susceptibility genes have yet been identified for any of these disorders.  Genetic heterogeneity, combined with phenotypic imprecision and poor marker coverage, has contributed to the difficulty in defining risk variants.  We focused on families of Ashkenazi Jewish descent, to reduce genetic heterogeneity, and, as a precursor to genomewide assocn. studies, we undertook a single-nucleotide polymorphism (SNP) genotyping screen of 64 candidate genes (440 SNPs) chosen on the basis of previous linkage or of assocn. and/or biol. relevance.  We genotyped an av. of 6.9 SNPs per gene, with an av. d. of 1 SNP per 11.9 kb in 323 bipolar I disorder and 274 schizophrenia or schizoaffective Ashkenazi case-parent trios.  Using single-SNP and haplotype-based transmission/disequil. tests, we ranked genes on the basis of strength of assocn.  Six genes (DAO, GRM3, GRM4, GRIN2B, IL2RB, and TUBA8) met this criterion for bipolar I disorder; only DAO has been previously assocd. with bipolar disorder.  Six genes (RGS4, SCA1, GRM4, DPYSL2, NOS1, and GRID1) met this criterion for schizophrenia or schizoaffective disorder; five replicate previous assocns., and one, GRID1, shows a novel assocn. with schizophrenia.  In addn., six genes (DPYSL2, DTNBP1, G30/G72, GRID1, GRM4, and NOS1) showed overlapping suggestive evidence of assocn. in both disorders.  These results may help to prioritize candidate genes for future study from among the many suspected/proposed for schizophrenia and bipolar disorders.  They provide further support for shared genetic susceptibility between these two disorders that involve glutamate-signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzKkGnZnTIObVg90H21EOLACvtfcHk0liMHMbeye-SMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ygtLbL&md5=6608559e392030ac38c84d4efc9393a6</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1086%2F497703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F497703%26sid%3Dliteratum%253Aachs%26aulast%3DFallin%26aufirst%3DM.%2BD.%26aulast%3DLasseter%26aufirst%3DV.%2BK.%26aulast%3DAvramopoulos%26aufirst%3DD.%26aulast%3DNicodemus%26aufirst%3DK.%2BK.%26aulast%3DWolyniec%26aufirst%3DP.%2BS.%26aulast%3DMcGrath%26aufirst%3DJ.%2BA.%26aulast%3DSteel%26aufirst%3DG.%26aulast%3DNestadt%26aufirst%3DG.%26aulast%3DLiang%26aufirst%3DK.%2BY.%26aulast%3DHuganir%26aufirst%3DR.%2BL.%26aulast%3DValle%26aufirst%3DD.%26aulast%3DPulver%26aufirst%3DA.%2BE.%26atitle%3DBipolar%2520I%2520disorder%2520and%2520schizophrenia%253A%2520a%2520440-single-nucleotide%2520polymorphism%2520screen%2520of%252064%2520candidate%2520genes%2520among%2520Ashkenazi%2520Jewish%2520case-parent%2520trios%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2005%26volume%3D77%26spage%3D918%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group">Staddon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arranz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancama, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Nievas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrizabalaga, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckland, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mata, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, R. W.</span><span> </span><span class="NLM_article-title">Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population</span> <span class="citation_source-journal">Schizophr. Res</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15567076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crpsVCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2005&pages=49-54&author=S.+Staddonauthor=M.+J.+Arranzauthor=D.+Mancamaauthor=F.+Perez-Nievasauthor=I.+Arrizabalagaauthor=R.+Anneyauthor=P.+Bucklandauthor=A.+Elkinauthor=S.+Osborneauthor=J.+Munroauthor=I.+Mataauthor=R.+W.+Kerwin&title=Association+between+dopamine+D3+receptor+gene+polymorphisms+and+schizophrenia+in+an+isolate+population"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population</span></div><div class="casAuthors">Staddon Susan; Arranz Maria J; Mancama Dalu; Perez-Nievas Fernando; Arrizabalaga Inaki; Anney Richard; Buckland Paul; Elkin Amanda; Osborne Sarah; Munro Janet; Mata Ignacio; Kerwin Robert W</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-54</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">There are several lines of evidence implicating the dopamine D3 receptor in the pathophysiology of schizophrenia.  The Ser9Gly polymorphism of the dopamine D3 receptor gene (DRD3) has been the most extensively investigated DRD3 variant in connection with the disease but results have been inconclusive.  Recent reports indicate that the Ser9Gly polymorphism is in linkage disequilibrium with other markers, but association studies between DRD3 haplotypes and schizophrenia have had mixed results.  Genetic heterogeneity may be one of the causes of contradicting results.  In order to clarify the role of DRD3 alterations in the aetiology of disease, we have investigated three D3 genetic variants (Ser9Gly, -205-G/A, -7685-G/C) in a sample of patients with schizophrenia or schizoaffective disorder (N=118) and controls (N=162) recruited from a human isolate from Navarra (Northern Spain) of Basque origin.  Although no association was found between the Ser9Gly or the -205-A/G polymorphisms and disease, an excess of allele -7685-C was observed in patients (p=0.002 after correction for multiple analyses).  Haplotype analysis shows the three markers to be in strong linkage disequilibrium (p<0.0001) and strongly associated with disease (p<1x 10(-5)).  These results may suggest that these polymorphisms exert a combined or synergistic effect on susceptibility to schizophrenia, or are in linkage with an unknown causative factor.  However, further replication in independent samples is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSF_qcmKJg1blQKX3ooHxWjfW6udTcc2eYQA5maVkYQxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpsVCmtQ%253D%253D&md5=ef591a077cfba433b49594bcc0459476</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DStaddon%26aufirst%3DS.%26aulast%3DArranz%26aufirst%3DM.%2BJ.%26aulast%3DMancama%26aufirst%3DD.%26aulast%3DPerez-Nievas%26aufirst%3DF.%26aulast%3DArrizabalaga%26aufirst%3DI.%26aulast%3DAnney%26aufirst%3DR.%26aulast%3DBuckland%26aufirst%3DP.%26aulast%3DElkin%26aufirst%3DA.%26aulast%3DOsborne%26aufirst%3DS.%26aulast%3DMunro%26aufirst%3DJ.%26aulast%3DMata%26aufirst%3DI.%26aulast%3DKerwin%26aufirst%3DR.%2BW.%26atitle%3DAssociation%2520between%2520dopamine%2520D3%2520receptor%2520gene%2520polymorphisms%2520and%2520schizophrenia%2520in%2520an%2520isolate%2520population%26jtitle%3DSchizophr.%2520Res%26date%3D2005%26volume%3D73%26spage%3D49%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group">Mitsuyasu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ninomiya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinukawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahira, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, V. P.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springett, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashiro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanba, S.</span><span> </span><span class="NLM_article-title">Genetic structure of the dopamine receptor D4 gene (DRD4) and lack of association with schizophrenia in Japanese patients</span> <span class="citation_source-journal">J. Psychiatr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.jpsychires.2006.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16887146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s3mtFyktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2007&pages=763-775&author=H.+Mitsuyasuauthor=H.+Kawasakiauthor=H.+Ninomiyaauthor=N.+Kinukawaauthor=T.+Yamanakaauthor=T.+Tahiraauthor=V.+P.+Stantonauthor=G.+M.+Springettauthor=K.+Hayashiauthor=N.+Tashiroauthor=S.+Kanba&title=Genetic+structure+of+the+dopamine+receptor+D4+gene+%28DRD4%29+and+lack+of+association+with+schizophrenia+in+Japanese+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic structure of the dopamine receptor D4 gene (DRD4) and lack of association with schizophrenia in Japanese patients</span></div><div class="casAuthors">Mitsuyasu Hiroshi; Kawasaki Hiroaki; Ninomiya Hideaki; Kinukawa Naoko; Yamanaka Takeharu; Tahira Tomoko; Stanton Vincent P Jr; Springett Gregory M; Hayashi Kenshi; Tashiro Nobutada; Kanba Shigenobu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">763-75</span>
        ISSN:<span class="NLM_cas:issn">0022-3956</span>.
    </div><div class="casAbstract">In order to investigate the contribution of genetic variation in the human dopamine receptor D4 gene (DRD4) to the risk of developing schizophrenia, we carried out a genetic analysis of 27 polymorphisms in 216 schizophrenic patients and 243 healthy controls from the Kyushu region of Japan.  Twenty-two single nucleotide polymorphisms (SNPs) and five insertion/deletion polymorphisms were analyzed in this study, including four novel SNPs and a novel mononucleotide repeat.  Linkage disequilibrium (LD) and haplotype analyses reveal weak LD across the DRD4 gene.  In univariate analysis female individuals with allele -521C had a higher risk for schizophrenia.  However, this finding was not significant after correction for multiple hypothesis testing.  No other polymorphisms or haplotypes differed between schizophrenic patients and controls.  Likewise, multivariate analyses did not reveal any statistically significant associations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLiZw_gc8v50bxh97K6Vt6fW6udTcc2ebqjWi8Pn-grLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3mtFyktw%253D%253D&md5=d28f2ed06d54ca3b0dd549c7c302a7c9</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2006.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2006.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuyasu%26aufirst%3DH.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DNinomiya%26aufirst%3DH.%26aulast%3DKinukawa%26aufirst%3DN.%26aulast%3DYamanaka%26aufirst%3DT.%26aulast%3DTahira%26aufirst%3DT.%26aulast%3DStanton%26aufirst%3DV.%2BP.%26aulast%3DSpringett%26aufirst%3DG.%2BM.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DTashiro%26aufirst%3DN.%26aulast%3DKanba%26aufirst%3DS.%26atitle%3DGenetic%2520structure%2520of%2520the%2520dopamine%2520receptor%2520D4%2520gene%2520%2528DRD4%2529%2520and%2520lack%2520of%2520association%2520with%2520schizophrenia%2520in%2520Japanese%2520patients%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2007%26volume%3D41%26spage%3D763%26epage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group">Khodayari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garshasbi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahimi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafizi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebrahimi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najmabadi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohadi, M.</span><span> </span><span class="NLM_article-title">Association of the dopamine transporter gene (DAT1) core promoter polymorphism-67T variant with schizophrenia</span> <span class="citation_source-journal">Am. J. Med. Genet. B: Neuropsychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2Fajmg.b.30067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2czntVahtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2004&pages=10-12&author=N.+Khodayariauthor=M.+Garshasbiauthor=F.+Fadaiauthor=A.+Rahimiauthor=L.+Hafiziauthor=A.+Ebrahimiauthor=H.+Najmabadiauthor=M.+Ohadi&title=Association+of+the+dopamine+transporter+gene+%28DAT1%29+core+promoter+polymorphism-67T+variant+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Association of the dopamine transporter gene (DAT1) core promoter polymorphism -67T variant with schizophrenia</span></div><div class="casAuthors">Khodayari N; Garshasbi M; Fadai F; Rahimi A; Hafizi L; Ebrahimi A; Najmabadi H; Ohadi Mina</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">129B</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-2</span>
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    </div><div class="casAbstract">Dysfunction of the central dopaminergic neurotransmission has been suggested to play an important role in the etiology of schizophrenia.  The dopamine transporter (DAT1) mediates the active reuptake of dopamine from the synapses and thereby plays a key role in the regulation of the dopaminergic neurotransmission.  In this study, we sought to determine the possible association of the DAT1 gene core promoter polymorphism -67A/T with schizophrenia in a case/control study.  The allele and genotype frequencies of the polymorphism were studied in 100 patients and 100 controls, which were matched on the basis of sex, age, and ethnicity.  The genotype frequencies in the patients group were as follows: AA 29%; AT 59%; TT 12% versus the genotype frequencies in the control group: AA 57%; AT 38%; TT 5% [chi2 = 16.54, df = 2, OR = 2.25 (95% CI 1.46-3.45, P < or = 0.0003].  For the first time, these findings provide tentative evidence for the contribution of the DAT1 gene core promoter polymorphism to the etiopathophysiology of schizophrenia at least in the Iranian male population that we studied.  Replication studies of independent samples and family-based association studies are necessary to further evaluate the significance of our findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWuOT5Fj1SKWPgL4LrC-0VfW6udTcc2ebqjWi8Pn-grLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czntVahtQ%253D%253D&md5=70c70e057762c690813985dde7af9656</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1002%2Fajmg.b.30067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajmg.b.30067%26sid%3Dliteratum%253Aachs%26aulast%3DKhodayari%26aufirst%3DN.%26aulast%3DGarshasbi%26aufirst%3DM.%26aulast%3DFadai%26aufirst%3DF.%26aulast%3DRahimi%26aufirst%3DA.%26aulast%3DHafizi%26aufirst%3DL.%26aulast%3DEbrahimi%26aufirst%3DA.%26aulast%3DNajmabadi%26aufirst%3DH.%26aulast%3DOhadi%26aufirst%3DM.%26atitle%3DAssociation%2520of%2520the%2520dopamine%2520transporter%2520gene%2520%2528DAT1%2529%2520core%2520promoter%2520polymorphism-67T%2520variant%2520with%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%2520B%253A%2520Neuropsychiatr.%2520Genet.%26date%3D2004%26volume%3D129%26spage%3D10%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group">Gamma, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glatt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T.</span><span> </span><span class="NLM_article-title">Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.09.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15567077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crpsVCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2005&pages=55-58&author=F.+Gammaauthor=S.+V.+Faraoneauthor=S.+J.+Glattauthor=Y.+C.+Yehauthor=M.+T.+Tsuang&title=Meta-analysis+shows+schizophrenia+is+not+associated+with+the+40-base-pair+repeat+polymorphism+of+the+dopamine+transporter+gene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene</span></div><div class="casAuthors">Gamma F; Faraone Stephen V; Glatt Stephen J; Yeh Yu-Chi; Tsuang Ming T</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-8</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">OBJECTIVE:  Several case-control studies examined an association between schizophrenia and the 40-bp variable number tandem repeat (VTNR) polymorphism in the 3'-UTR of the dopamine transporter gene (SLC6A3).  The results of these studies have been equivocal due to small sample size and low power.  This meta-analysis has the aim to evaluate the collective evidence for an association between the VTNR polymorphism and schizophrenia.  METHOD:  Different meta-analyses were performed, sequentially considering the 9- and 10-repeat alleles and different genotypes (genotypes 9/9, 9/10, 10/10) as risk factors for schizophrenia.  Analyses of the alleles included 659 cases and 563 controls from six case-control studies.  RESULTS:  The pooled OR from each analysis approximated 1.0, and none were significant.  Lack of significance attributable to the negative effects of single large studies or to heterogeneity between the studies was excluded.  CONCLUSION:  Despite over 90% power to detect a significant odds ratio as small as 1.3, no association was observed.  Considering the cumulative evidence from six case-control studies and results from additional family-based studies, it seems unlikely that the 40-base-pair VTNR polymorphism of the SLC6A3 gene influences risk for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSF_qcmKJg1bl1C8OJBvdfbfW6udTcc2ebqjWi8Pn-grLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpsVCmug%253D%253D&md5=bcadfcd81802e7661ec3edecd11169d2</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DGamma%26aufirst%3DF.%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DGlatt%26aufirst%3DS.%2BJ.%26aulast%3DYeh%26aufirst%3DY.%2BC.%26aulast%3DTsuang%26aufirst%3DM.%2BT.%26atitle%3DMeta-analysis%2520shows%2520schizophrenia%2520is%2520not%2520associated%2520with%2520the%252040-base-pair%2520repeat%2520polymorphism%2520of%2520the%2520dopamine%2520transporter%2520gene%26jtitle%3DSchizophr.%2520Res.%26date%3D2005%26volume%3D73%26spage%3D55%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group">Miyakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotnikova, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonegawa, S.</span><span> </span><span class="NLM_article-title">Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">8987</span><span class="NLM_x">–</span> <span class="NLM_lpage">8992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=8987-8992&author=T.+Miyakawaauthor=L.+M.+Leiterauthor=D.+J.+Gerberauthor=R.+R.+Gainetdinovauthor=T.+D.+Sotnikovaauthor=H.+Zengauthor=M.+G.+Caronauthor=S.+Tonegawa&title=Conditional+calcineurin+knockout+mice+exhibit+multiple+abnormal+behaviors+related+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyakawa%26aufirst%3DT.%26aulast%3DLeiter%26aufirst%3DL.%2BM.%26aulast%3DGerber%26aufirst%3DD.%2BJ.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DSotnikova%26aufirst%3DT.%2BD.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DTonegawa%26aufirst%3DS.%26atitle%3DConditional%2520calcineurin%2520knockout%2520mice%2520exhibit%2520multiple%2520abnormal%2520behaviors%2520related%2520to%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D8987%26epage%3D8992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group">Impagnatiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guidotti, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwivedi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruncho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisu, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzunov, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalheiser, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappas, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tueting, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, E.</span><span> </span><span class="NLM_article-title">A decrease of reelin expression as a putative vulnerability factor in schizophrenia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">15718</span><span class="NLM_x">–</span> <span class="NLM_lpage">15723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=15718-15723&author=F.+Impagnatielloauthor=A.+R.+Guidottiauthor=C.+Pesoldauthor=Y.+Dwivediauthor=H.+Carunchoauthor=M.+G.+Pisuauthor=D.+P.+Uzunovauthor=N.+R.+Smalheiserauthor=J.+M.+Davisauthor=G.+N.+Pandeyauthor=G.+D.+Pappasauthor=P.+Tuetingauthor=R.+P.+Sharmaauthor=E.+Costa&title=A+decrease+of+reelin+expression+as+a+putative+vulnerability+factor+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DGuidotti%26aufirst%3DA.%2BR.%26aulast%3DPesold%26aufirst%3DC.%26aulast%3DDwivedi%26aufirst%3DY.%26aulast%3DCaruncho%26aufirst%3DH.%26aulast%3DPisu%26aufirst%3DM.%2BG.%26aulast%3DUzunov%26aufirst%3DD.%2BP.%26aulast%3DSmalheiser%26aufirst%3DN.%2BR.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26aulast%3DPandey%26aufirst%3DG.%2BN.%26aulast%3DPappas%26aufirst%3DG.%2BD.%26aulast%3DTueting%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DR.%2BP.%26aulast%3DCosta%26aufirst%3DE.%26atitle%3DA%2520decrease%2520of%2520reelin%2520expression%2520as%2520a%2520putative%2520vulnerability%2520factor%2520in%2520schizophrenia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D15718%26epage%3D15723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group">Roffman, J. L.; Weiss, A. P.; Purcell, S.; Caffalette, C. A.; Freudenreich, O.; Henderson, D. C.; Bottiglieri, T.; Wong, D. H.; Halsted, C. H.; Goff, D. C.</span><span> </span><span class="NLM_article-title">Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia</span>.  <span class="citation_source-journal">Biol. Psychiatry</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Roffman%2C+J.+L.%3B+Weiss%2C+A.+P.%3B+Purcell%2C+S.%3B+Caffalette%2C+C.+A.%3B+Freudenreich%2C+O.%3B+Henderson%2C+D.+C.%3B+Bottiglieri%2C+T.%3B+Wong%2C+D.+H.%3B+Halsted%2C+C.+H.%3B+Goff%2C+D.+C.+Contribution+of+methylenetetrahydrofolate+reductase+%28MTHFR%29+polymorphisms+to+negative+symptoms+in+schizophrenia.+Biol.+Psychiatry%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoffman%26aufirst%3DJ.%2BL.%26atitle%3DContribution%2520of%2520methylenetetrahydrofolate%2520reductase%2520%2528MTHFR%2529%2520polymorphisms%2520to%2520negative%2520symptoms%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group">Proitsi, P.; Li, T.; Hamilton, G.; Di Forti, M.; Collier, D.; Killick, R.; Chen, R.; Sham, P.; Murray, R.; Powell, J.; Lovestone, S.</span><span> </span><span class="NLM_article-title">Positional pathway screen of wnt signaling genes in schizophrenia: association with DKK4</span>.  <span class="citation_source-journal">Biol. Psychiatry</span><div class="note"><p class="first last"><b>2007,</b><i>62,</i> 275–278.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Proitsi%2C+P.%3B+Li%2C+T.%3B+Hamilton%2C+G.%3B+Di+Forti%2C+M.%3B+Collier%2C+D.%3B+Killick%2C+R.%3B+Chen%2C+R.%3B+Sham%2C+P.%3B+Murray%2C+R.%3B+Powell%2C+J.%3B+Lovestone%2C+S.+Positional+pathway+screen+of+wnt+signaling+genes+in+schizophrenia%3A+association+with+DKK4.+Biol.+Psychiatry2007%2C62%2C+275%E2%80%93278."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DProitsi%26aufirst%3DP.%26atitle%3DPositional%2520pathway%2520screen%2520of%2520wnt%2520signaling%2520genes%2520in%2520schizophrenia%253A%2520association%2520with%2520DKK4%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group">Numata, S.; Ueno, S. I.; Iga, J. I.; Yamauchi, K.; Hongwei, S.; Hashimoto, R.; Takeda, M.; Kunugi, H.; Itakura, M.; Ohmori, T.</span><span> </span><span class="NLM_article-title">TGFBR2 gene expression and genetic association with schizophrenia</span>.  <span class="citation_source-journal">J. Psychiatr. Res.</span>, in press.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Numata%2C+S.%3B+Ueno%2C+S.+I.%3B+Iga%2C+J.+I.%3B+Yamauchi%2C+K.%3B+Hongwei%2C+S.%3B+Hashimoto%2C+R.%3B+Takeda%2C+M.%3B+Kunugi%2C+H.%3B+Itakura%2C+M.%3B+Ohmori%2C+T.+TGFBR2+gene+expression+and+genetic+association+with+schizophrenia.+J.+Psychiatr.+Res.%2C+in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNumata%26aufirst%3DS.%26atitle%3DTGFBR2%2520gene%2520expression%2520and%2520genetic%2520association%2520with%2520schizophrenia%26jtitle%3DJ.%2520Psychiatr.%2520Res." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group">Eastwood, S. L.; Harrison, P. J.</span><span> </span><span class="NLM_article-title">Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Eastwood%2C+S.+L.%3B+Harrison%2C+P.+J.+Decreased+mRNA+expression+of+netrin-G1+and+netrin-G2+in+the+temporal+lobe+in+schizophrenia+and+bipolar+disorder.+Neuropsychopharmacology%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEastwood%26aufirst%3DS.%2BL.%26atitle%3DDecreased%2520mRNA%2520expression%2520of%2520netrin-G1%2520and%2520netrin-G2%2520in%2520the%2520temporal%2520lobe%2520in%2520schizophrenia%2520and%2520bipolar%2520disorder%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group">Chahl, L. A.</span><span> </span><span class="NLM_article-title">TRP’s: links to schizophrenia?</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><div class="note"><p class="first last"><b>2007,</b><i>1772,</i> 968–977.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chahl%2C+L.+A.+TRP%E2%80%99s%3A+links+to+schizophrenia%3FBiochim.+Biophys.+Acta2007%2C1772%2C+968%E2%80%93977."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChahl%26aufirst%3DL.%2BA.%26atitle%3DTRP%25E2%2580%2599s%253A%2520links%2520to%2520schizophrenia%253F%26jtitle%3DBiochim.%2520Biophys.%2520Acta" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group">Ishiguro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toru, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itokawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumaji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okubo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwawaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arinami, T.</span><span> </span><span class="NLM_article-title">Association between polymorphisms in the type 1 σ receptor gene and schizophrenia</span> <span class="citation_source-journal">Neurosci. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1998&pages=45-48&author=H.+Ishiguroauthor=T.+Ohtsukiauthor=M.+Toruauthor=M.+Itokawaauthor=J.+Aokiauthor=H.+Shibuyaauthor=A.+Kurumajiauthor=Y.+Okuboauthor=A.+Iwawakiauthor=K.+Otaauthor=H.+Shimizuauthor=H.+Hamaguchiauthor=T.+Arinami&title=Association+between+polymorphisms+in+the+type+1+%CF%83+receptor+gene+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshiguro%26aufirst%3DH.%26aulast%3DOhtsuki%26aufirst%3DT.%26aulast%3DToru%26aufirst%3DM.%26aulast%3DItokawa%26aufirst%3DM.%26aulast%3DAoki%26aufirst%3DJ.%26aulast%3DShibuya%26aufirst%3DH.%26aulast%3DKurumaji%26aufirst%3DA.%26aulast%3DOkubo%26aufirst%3DY.%26aulast%3DIwawaki%26aufirst%3DA.%26aulast%3DOta%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DH.%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DArinami%26aufirst%3DT.%26atitle%3DAssociation%2520between%2520polymorphisms%2520in%2520the%2520type%25201%2520%25CF%2583%2520receptor%2520gene%2520and%2520schizophrenia%26jtitle%3DNeurosci.%2520Lett.%26date%3D1998%26volume%3D257%26spage%3D45%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group">Ohmori, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinkai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span> </span><span class="NLM_article-title">Polymorphisms of the σ<sub>1</sub> receptor gene in schizophrenia: an association study</span> <span class="citation_source-journal">Am. J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1002%2F%28SICI%291096-8628%2820000207%2996%3A1%3C118%3A%3AAID-AJMG23%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10686564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3cvitlyitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=118-122&author=O.+Ohmoriauthor=T.+Shinkaiauthor=T.+Suzukiauthor=C.+Okanoauthor=H.+Kojimaauthor=T.+Teraoauthor=J.+Nakamura&title=Polymorphisms+of+the+%CF%831+receptor+gene+in+schizophrenia%3A+an+association+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Polymorphisms of the sigma(1) receptor gene in schizophrenia: An association study</span></div><div class="casAuthors">Ohmori O; Shinkai T; Suzuki T; Okano C; Kojima H; Terao T; Nakamura J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-22</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">Possible involvement of sigma receptors in the pathogenesis of schizophrenia has been suggested.  In this study we searched systematically for polymorphisms in the 5'-franking region of the sigma(1) receptor.  Genetic variation in this region could reduce the expression of the gene, and this suggestion is compatible with findings of reduced sigma binding sites in several cortical regions of schizophrenia.  We confirmed G-241T and G-240T polymorphisms; these two consecutive polymorphisms were resolved to be in complete linkage disequilibrium with each other by single-strand conformation polymorphism (SSCP) analysis.  We also identified the A61C (Gln2Pro) polymorphism, which was in almost complete linkage disequilibrium with G-241T/G-240T.  There was no significant difference in the distribution of alleles or overall genotypes of the polymorphisms between schizophrenic patients (n = 129) and controls (n = 140).  We found slight increased homozygosity for T-241/T-240 and C61 in patients compared with controls using multiple comparison (p = 0. 045).  However, the significance did not remain when a Bonferroni correction was made (p = 0.135).  These results do not support that the sigma(1) receptor gene plays a major role in the pathogenesis of schizophrenia.  Am.  J.  Med.  Genet. (Neuropsychiatr.  Genet.) 96:118-122, 2000.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPXt4iirRsYmhHGZei4OW9fW6udTcc2eY9iG6HiAL4dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvitlyitg%253D%253D&md5=73d2a0faa1d580cf3b7c4cccf4485801</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-8628%2820000207%2996%3A1%3C118%3A%3AAID-AJMG23%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-8628%252820000207%252996%253A1%253C118%253A%253AAID-AJMG23%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DShinkai%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DOkano%26aufirst%3DC.%26aulast%3DKojima%26aufirst%3DH.%26aulast%3DTerao%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DJ.%26atitle%3DPolymorphisms%2520of%2520the%2520%25CF%25831%2520receptor%2520gene%2520in%2520schizophrenia%253A%2520an%2520association%2520study%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%26date%3D2000%26volume%3D96%26spage%3D118%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group">Uchida, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ujike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, S.</span><span> </span><span class="NLM_article-title">No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies</span> <span class="citation_source-journal">BMC Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=13&author=N.+Uchidaauthor=H.+Ujikeauthor=K.+Nakataauthor=M.+Takakiauthor=A.+Nomuraauthor=T.+Katsuauthor=Y.+Tanakaauthor=T.+Imamuraauthor=A.+Sakaiauthor=S.+Kuroda&title=No+association+between+the+sigma+receptor+type+1+gene+and+schizophrenia%3A+results+of+analysis+and+meta-analysis+of+case-control+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DN.%26aulast%3DUjike%26aufirst%3DH.%26aulast%3DNakata%26aufirst%3DK.%26aulast%3DTakaki%26aufirst%3DM.%26aulast%3DNomura%26aufirst%3DA.%26aulast%3DKatsu%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DA.%26aulast%3DKuroda%26aufirst%3DS.%26atitle%3DNo%2520association%2520between%2520the%2520sigma%2520receptor%2520type%25201%2520gene%2520and%2520schizophrenia%253A%2520results%2520of%2520analysis%2520and%2520meta-analysis%2520of%2520case-control%2520studies%26jtitle%3DBMC%2520Psychiatry%26date%3D2003%26volume%3D3%26spage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group">Puri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuillin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thirumalai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasucki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quested, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pimm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorey, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandasami, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badacsonyi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punukollu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadeem, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurling, H. M.</span><span> </span><span class="NLM_article-title">Failure to confirm allelic association between markers at the CAPON gene locus and schizophrenia in a British sample</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.biopsych.2005.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16202394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=195-197&author=V.+Puriauthor=A.+McQuillinauthor=S.+Thirumalaiauthor=J.+Lawrenceauthor=R.+Krasuckiauthor=K.+Choudhuryauthor=S.+Dattaauthor=S.+Kerwinauthor=D.+Questedauthor=N.+Bassauthor=J.+Pimmauthor=G.+Lambauthor=H.+Mooreyauthor=G.+Kandasamiauthor=A.+Badacsonyiauthor=K.+Kellyauthor=J.+Morganauthor=B.+Punukolluauthor=H.+Nadeemauthor=D.+Curtisauthor=H.+M.+Gurling&title=Failure+to+confirm+allelic+association+between+markers+at+the+CAPON+gene+locus+and+schizophrenia+in+a+British+sample"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Failure to Confirm Allelic Association Between Markers at the CAPON Gene Locus and Schizophrenia in a British Sample</span></div><div class="casAuthors">Puri, Vinay; McQuillin, Andrew; Thirumalai, Srinivasa; Lawrence, Jacob; Krasucki, Robert; Choudhury, Khalid; Datta, Susmita; Kerwin, Simon; Quested, Digby; Bass, Nicholas; Pimm, Jonathan; Lamb, Graham; Moorey, Helen; Kandasami, Gomathinayagam; Badacsonyi, Allison; Kelly, Katie; Morgan, Jenny; Punukollu, Bhaskar; Nadeem, Haitham; Curtis, David; Gurling, Hugh M. D.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-197</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Linkage studies have confirmed that chromosome 1q23.3 is a susceptibility locus for schizophrenia.  It was then claimed that markers at the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase (CAPON) gene showed allelic assocn. with schizophrenia in Canadian families.  A second Chinese study found a base pair polymorphism at the CAPON gene also assocd. with schizophrenia.  Methods: We attempted replication using eight markers from the Canadian study in a UK based sample of 450 cases and 450 supernormal controls.  Results: We found no evidence for allelic or haplotypic assocn. with schizophrenia for any of the markers found to be assocd. in the Canadian sample.  Conclusions: The neg. results might reflect genetic heterogeneity between the Canadian, Chinese and UK samples or be due to methodol. problems.  The present finding weakens the evidence that mutations or variation in the CAPON gene are causing genetic susceptibility to schizophrenia in European populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrki7QPC6Zsb7Vg90H21EOLACvtfcHk0lhn6Uzll5ziJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVGkug%253D%253D&md5=650a99e7c442b2d6e4e6123007827cfc</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DV.%26aulast%3DMcQuillin%26aufirst%3DA.%26aulast%3DThirumalai%26aufirst%3DS.%26aulast%3DLawrence%26aufirst%3DJ.%26aulast%3DKrasucki%26aufirst%3DR.%26aulast%3DChoudhury%26aufirst%3DK.%26aulast%3DDatta%26aufirst%3DS.%26aulast%3DKerwin%26aufirst%3DS.%26aulast%3DQuested%26aufirst%3DD.%26aulast%3DBass%26aufirst%3DN.%26aulast%3DPimm%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DG.%26aulast%3DMoorey%26aufirst%3DH.%26aulast%3DKandasami%26aufirst%3DG.%26aulast%3DBadacsonyi%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DMorgan%26aufirst%3DJ.%26aulast%3DPunukollu%26aufirst%3DB.%26aulast%3DNadeem%26aufirst%3DH.%26aulast%3DCurtis%26aufirst%3DD.%26aulast%3DGurling%26aufirst%3DH.%2BM.%26atitle%3DFailure%2520to%2520confirm%2520allelic%2520association%2520between%2520markers%2520at%2520the%2520CAPON%2520gene%2520locus%2520and%2520schizophrenia%2520in%2520a%2520British%2520sample%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D195%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group">Clark, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mata, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arranz, M. J.</span><span> </span><span class="NLM_article-title">No association between ADRA2A polymorphisms and schizophrenia</span> <span class="citation_source-journal">Am. J. Med. Genet. B: Neuropsychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFalu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2007&pages=341-343&author=D.+A.+Clarkauthor=I.+Mataauthor=R.+W.+Kerwinauthor=J.+Munroauthor=M.+J.+Arranz&title=No+association+between+ADRA2A+polymorphisms+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">No association between ADRA2A polymorphisms and schizophrenia</span></div><div class="casAuthors">Clark, D. A.; Mata, I.; Kerwin, R. W.; Munro, J.; Arranz, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">144B</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-343</span>CODEN:
                <span class="NLM_cas:coden">AJMGC9</span>;
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">There is evidence to suggest that the α2A-adrenergic receptor may be involved in schizophrenia.  With attention directed at the upstream regulatory region of the gene which codes for this receptor (ADRA2A), we proposed that single nucleotide polymorphisms (SNPs) within this region influences susceptibility to schizophrenia by altering the expression of this receptor.  We opted to test for an influence on susceptibility by assocn. study using 112 schizophrenic/schizoaffective disorder patients and 159 controls.  The region of interest was screened for SNPs using a combination of bioinformatic searches and sequencing.  A total of nine SNPs were discovered, of which four (-5972-G/A, -2211-A/T, -1291-C/G and -261-G/A) were genotyped in the entire clin. sample.  No assocns. were evident, suggesting no influence for these SNPs in susceptibility to schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgn0fy6z3yybVg90H21EOLACvtfcHk0lhn6Uzll5ziJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFalu74%253D&md5=72538fb0b206f382360d871153043b62</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DD.%2BA.%26aulast%3DMata%26aufirst%3DI.%26aulast%3DKerwin%26aufirst%3DR.%2BW.%26aulast%3DMunro%26aufirst%3DJ.%26aulast%3DArranz%26aufirst%3DM.%2BJ.%26atitle%3DNo%2520association%2520between%2520ADRA2A%2520polymorphisms%2520and%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%2520B%253A%2520Neuropsychiatr.%2520Genet.%26date%3D2007%26volume%3D144%26spage%3D341%26epage%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group">Le Niculescu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balaraman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidhu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerome, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edenberg, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuczenski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurnberger, J. I.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuang, M. T</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu, A. B.</span><span> </span><span class="NLM_article-title">Towards understanding the schizophrenia code: an expanded convergent functional genomics approach</span> <span class="citation_source-journal">Am. J. Med. Genet. B: Neuropsychiatr. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Sru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2007&pages=129-158&author=H.+Le+Niculescuauthor=Y.+Balaramanauthor=S.+Patelauthor=J.+Tanauthor=K.+Sidhuauthor=R.+E.+Jeromeauthor=H.+J.+Edenbergauthor=R.+Kuczenskiauthor=M.+A.+Geyerauthor=J.+I.+Nurnbergerauthor=S.+V.+Faraoneauthor=M.+T+Tsuangauthor=A.+B.+Niculescu&title=Towards+understanding+the+schizophrenia+code%3A+an+expanded+convergent+functional+genomics+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Towards understanding the schizophrenia code: an expanded convergent functional genomics approach</span></div><div class="casAuthors">Le-Niculescu, H.; Balaraman, Y.; Patel, S.; Tan, J.; Sidhu, K.; Jerome, R. E.; Edenberg, H. J.; Kuczenski, R.; Geyer, M. A.; Nurnberger, J. I., Jr.; Faraone, S. V.; Tsuang, M. T.; Niculescu, A. B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">144B</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-158</span>CODEN:
                <span class="NLM_cas:coden">AJMGC9</span>;
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Identifying genes for schizophrenia through classical genetic approaches has proven arduous.  Here, we present a comprehensive convergent anal. that translationally integrates brain gene expression data from a relevant pharmacogenomic mouse model (involving treatments with a psychomimetic agent-phencyclidine (PCP), and an anti-psychotic-clozapine), with human genetic linkage data and human postmortem brain data, as a Bayesian strategy of cross validating findings.  Topping the list of candidate genes, we have three genes involved in GABA neurotransmission (GABRA1, GABBR1, and GAD2), one gene involved in glutamate neurotransmission (GRIA2), one gene involved in neuropeptide signaling (TAC1), two genes involved in synaptic function (SYN2 and KCNJ4), six genes involved in myelin/glial function (CNP, MAL, MBP, PLP1, MOBP and GFAP), and one gene involved in lipid metab. (LPL).  These data suggest that schizophrenia is primarily a disorder of brain functional and structural connectivity, with GABA neurotransmission playing a prominent role.  These findings may explain the EEG gamma band abnormalities detected in schizophrenia.  The anal. also revealed other high probability candidates genes (neurotransmitter signaling, other structural proteins, ion channels, signal transduction, regulatory enzymes, neuronal migration/neurite outgrowth, clock genes, transcription factors, RNA regulatory genes), pathways and mechanisms of likely importance in pathophysiol.  Some of the pathways identified suggest possible avenues for augmentation pharmacotherapy of schizophrenia with other existing agents, such as benzodiazepines, anticonvulsants and lipid modulating agents.  Other pathways are new potential targets for drug development.  Lastly, a comparison with our earlier work on bipolar disorder illuminates the significant mol. overlap between schizophrenia and bipolar disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAlLjMQxkpnLVg90H21EOLACvtfcHk0ljNDMOQ4Jp8Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Sru7s%253D&md5=3ccb7736f7fb1969d8bdd39060354d0b</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BNiculescu%26aufirst%3DH.%26aulast%3DBalaraman%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DSidhu%26aufirst%3DK.%26aulast%3DJerome%26aufirst%3DR.%2BE.%26aulast%3DEdenberg%26aufirst%3DH.%2BJ.%26aulast%3DKuczenski%26aufirst%3DR.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DNurnberger%26aufirst%3DJ.%2BI.%26aulast%3DFaraone%26aufirst%3DS.%2BV.%26aulast%3DTsuang%26aufirst%3DM.%2BT%26aulast%3DNiculescu%26aufirst%3DA.%2BB.%26atitle%3DTowards%2520understanding%2520the%2520schizophrenia%2520code%253A%2520an%2520expanded%2520convergent%2520functional%2520genomics%2520approach%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%2520B%253A%2520Neuropsychiatr.%2520Genet.%26date%3D2007%26volume%3D144%26spage%3D129%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group">McClellan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Susser, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M. C.</span><span> </span><span class="NLM_article-title">Schizophrenia: a common disease caused by multiple rare alleles</span> <span class="citation_source-journal">Br. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">190</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1192%2Fbjp.bp.106.025585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17329737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2s7ivFyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2007&pages=194-199&author=J.+M.+McClellanauthor=E.+Susserauthor=M.+C.+King&title=Schizophrenia%3A+a+common+disease+caused+by+multiple+rare+alleles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia: a common disease caused by multiple rare alleles</span></div><div class="casAuthors">McClellan Jon M; Susser Ezra; King Mary-Claire</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">194-9</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">Schizophrenia is widely held to stem from the combined effects of multiple common polymorphisms, each with a small impact on disease risk.  We suggest an alternative view: that schizophrenia is highly heterogeneous genetically and that many predisposing mutations are highly penetrant and individually rare, even specific to single cases or families.  This "common disease--rare alleles" hypothesis is supported by recent findings in human genomics and by allelic and locus heterogeneity for other complex traits.  We review the implications of this model for gene discovery research in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnlSZlU-r1f90Q2ypr7jHkfW6udTcc2eY1ASS6Do3T-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7ivFyltg%253D%253D&md5=dab7809d16aadb88add52ef7d937e1ef</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1192%2Fbjp.bp.106.025585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.bp.106.025585%26sid%3Dliteratum%253Aachs%26aulast%3DMcClellan%26aufirst%3DJ.%2BM.%26aulast%3DSusser%26aufirst%3DE.%26aulast%3DKing%26aufirst%3DM.%2BC.%26atitle%3DSchizophrenia%253A%2520a%2520common%2520disease%2520caused%2520by%2520multiple%2520rare%2520alleles%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D190%26spage%3D194%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group">Patil, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martenyi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreev, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avedisova, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardenstein, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurovich, I. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morozova, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosolov, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neznanov, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reznik, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smulevich, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tochilov, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1102</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnm1632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17767166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSgtrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1102-1107&author=S.+T.+Patilauthor=L.+Zhangauthor=F.+Martenyiauthor=S.+L.+Loweauthor=K.+A.+Jacksonauthor=B.+V.+Andreevauthor=A.+S.+Avedisovaauthor=L.+M.+Bardensteinauthor=I.+Y.+Gurovichauthor=M.+A.+Morozovaauthor=S.+N.+Mosolovauthor=N.+G.+Neznanovauthor=A.+M.+Reznikauthor=A.+B.+Smulevichauthor=V.+A.+Tochilovauthor=B.+G.+Johnsonauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=Activation+of+mGlu2%2F3+receptors+as+a+new+approach+to+treat+schizophrenia%3A+a+randomized+phase+2+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial</span></div><div class="casAuthors">Patil, Sandeep T.; Zhang, Lu; Martenyi, Ferenc; Lowe, Stephen L.; Jackson, Kimberley A.; Andreev, Boris V.; Avedisova, Alla S.; Bardenstein, Leonid M.; Gurovich, Issak Y.; Morozova, Margarita A.; Mosolov, Sergey N.; Neznanov, Nikolai G.; Reznik, Alexander M.; Smulevich, Anatoly B.; Tochilov, Vladimir A.; Johnson, Bryan G.; Monn, James A.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1102-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathol. features of disrupted neuronal excitability and plasticity within limbic structures of the brain.  These pathol. features manifest behaviorally as pos. symptoms (including hallucinations, delusions and thought disorder), neg. symptoms (such as social withdrawal, apathy and emotional blunting) and other psychopathol. symptoms (such as psychomotor retardation, lack of insight, poor attention and impulse control).  Altered glutamate neurotransmission has for decades been linked to schizophrenia, but all commonly prescribed antipsychotics act on dopamine receptors.  LY404039 is a selective agonist for metabotropic glutamate 2/3 (mGlu2/3) receptors and has shown antipsychotic potential in animal studies.  With data from rodents, we provide new evidence that mGlu2/3 receptor agonists work by a distinct mechanism different from that of olanzapine.  To clin. test this mechanism, an oral prodrug of LY404039 (LY2140023) was evaluated in schizophrenic patients with olanzapine as an active control in a randomized, three-armed, double-blind, placebo-controlled study.  Treatment with LY2140023, like treatment with olanzapine, was safe and well-tolerated; treated patients showed statistically significant improvements in both pos. and neg. symptoms of schizophrenia compared to placebo (P < 0.001 at week 4).  Notably, patients treated with LY2140023 did not differ from placebo-treated patients with respect to prolactin elevation, extrapyramidal symptoms or wt. gain.  These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtB0jdSzAQrVg90H21EOLACvtfcHk0ljNDMOQ4Jp8Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSgtrvF&md5=afab88e888cba7e72e14c4e949f894d7</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1038%2Fnm1632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1632%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DS.%2BT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DJackson%26aufirst%3DK.%2BA.%26aulast%3DAndreev%26aufirst%3DB.%2BV.%26aulast%3DAvedisova%26aufirst%3DA.%2BS.%26aulast%3DBardenstein%26aufirst%3DL.%2BM.%26aulast%3DGurovich%26aufirst%3DI.%2BY.%26aulast%3DMorozova%26aufirst%3DM.%2BA.%26aulast%3DMosolov%26aufirst%3DS.%2BN.%26aulast%3DNeznanov%26aufirst%3DN.%2BG.%26aulast%3DReznik%26aufirst%3DA.%2BM.%26aulast%3DSmulevich%26aufirst%3DA.%2BB.%26aulast%3DTochilov%26aufirst%3DV.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DActivation%2520of%2520mGlu2%252F3%2520receptors%2520as%2520a%2520new%2520approach%2520to%2520treat%2520schizophrenia%253A%2520a%2520randomized%2520phase%25202%2520clinical%2520trial%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D1102%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group">Dunayevich, E.; Erickson, J.; Levine, L.; Landbloom, R.; Schoepp, D. D.; Tollefson, G. D.</span><span> </span><span class="NLM_article-title">Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, in press.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Dunayevich%2C+E.%3B+Erickson%2C+J.%3B+Levine%2C+L.%3B+Landbloom%2C+R.%3B+Schoepp%2C+D.+D.%3B+Tollefson%2C+G.+D.+Efficacy+and+tolerability+of+an+mGlu2%2F3+agonist+in+the+treatment+of+generalized+anxiety+disorder.+Neuropsychopharmacology%2C+in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunayevich%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520an%2520mGlu2%252F3%2520agonist%2520in%2520the%2520treatment%2520of%2520generalized%2520anxiety%2520disorder%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">A return to the fundamentals of drug discovery</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14983970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FpsVejsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=29-33&author=M.+Williams&title=A+return+to+the+fundamentals+of+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">A return to the fundamentals of drug discovery?</span></div><div class="casAuthors">Williams Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in investigational drugs (London, England : 2000)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-33</span>
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFI00P36ra3KqcneEtCi92fW6udTcc2ebkPmxzZzv9trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FpsVejsg%253D%253D&md5=90a01e280254d52e31ba8df7c619ac9b</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DA%2520return%2520to%2520the%2520fundamentals%2520of%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2004%26volume%3D5%26spage%3D29%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group">Marcotte, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, L. K.</span><span> </span><span class="NLM_article-title">Animal models of schizophrenia: a critical review</span> <span class="citation_source-journal">J. Psychiatry Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11762207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD38%252Fjs1Sjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2001&pages=395-410&author=E.+R.+Marcotteauthor=D.+M.+Pearsonauthor=L.+K.+Srivastava&title=Animal+models+of+schizophrenia%3A+a+critical+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of schizophrenia: a critical review</span></div><div class="casAuthors">Marcotte E R; Pearson D M; Srivastava L K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">395-410</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">Current research into schizophrenia has remained highly fragmented, much like the clinical presentation of the disease itself.  Differing theories as to the cause and progression of schizophrenia, as well as the heterogeneity of clinical symptoms, have made it difficult to develop a coherent framework suitable for animal modelling.  However, a number of limited animal models have been developed to explore various causative theories and to test specific mechanistic hypotheses.  Historically, these models have been based on the manipulation of neurotransmitter systems believed to be involved in schizophrenia.  In recent years, the emphasis has shifted to targeting relevant brain regions in an attempt to explore potential etiologic hypotheses.  The specific animal models developed within these frameworks are described in this review.  Emphasis is placed on the critical evaluation of currently available models because these models help to shape the direction of future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKcAfzhfkiXzdblLE_E9PWfW6udTcc2ebkPmxzZzv9trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252Fjs1Sjuw%253D%253D&md5=c90ea93a6490d940ece1a2eeb0339bb6</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DE.%2BR.%26aulast%3DPearson%26aufirst%3DD.%2BM.%26aulast%3DSrivastava%26aufirst%3DL.%2BK.%26atitle%3DAnimal%2520models%2520of%2520schizophrenia%253A%2520a%2520critical%2520review%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2001%26volume%3D26%26spage%3D395%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group">Sams-Dodd, F.</span><span> </span><span class="NLM_article-title">A test of the predictive validity of animal models of schizophrenia based on phencyclidine and <span class="smallcaps smallerCapital">d</span>-amphetamine</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=293-304&author=F.+Sams-Dodd&title=A+test+of+the+predictive+validity+of+animal+models+of+schizophrenia+based+on+phencyclidine+and+d-amphetamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSams-Dodd%26aufirst%3DF.%26atitle%3DA%2520test%2520of%2520the%2520predictive%2520validity%2520of%2520animal%2520models%2520of%2520schizophrenia%2520based%2520on%2520phencyclidine%2520and%2520d-amphetamine%26jtitle%3DNeuropsychopharmacology%26date%3D1998%26volume%3D18%26spage%3D293%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group">Weiner, I.</span><span> </span><span class="NLM_article-title">The “two-headed” latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-002-1313-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12601500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVCgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2003&pages=257-297&author=I.+Weiner&title=The+%E2%80%9Ctwo-headed%E2%80%9D+latent+inhibition+model+of+schizophrenia%3A+modeling+positive+and+negative+symptoms+and+their+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment</span></div><div class="casAuthors">Weiner, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">257-297</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Rationale. Latent inhibition (LI), namely, poorer performance on a learning task involving a previously pre-exposed non-reinforced stimulus, is disrupted in the rat by the dopamine (DA) releaser amphetamine which produces and exacerbates psychotic (pos.) symptoms, and this is reversed by treatment with typical and atypical antipsychotic drugs (APDs) which on their own potentiate LI.  These phenomena are paralleled by disrupted LI in normal amphetamine-treated humans, in high schizotypal humans, and in schizophrenia patients in the acute stages of the disorder, as well as by potentiated LI in normal humans treated with APDs.  Consequently, disrupted LI is considered to provide an animal model of pos. symptoms of schizophrenia with face, construct and predictive validity.  Objectives.  To review most of the rodent data on the neural substrates of LI as well as on the effects of APDs on this phenomenon with an attempt to interpret and integrate these data within the framework of the switching model of LI; to show that there are two distinct LI models, disrupted and abnormally persistent LI; to relate these findings to the clin. condition.  The nucleus accumbens (NAC) and its DA innervation form a crucial component of the neural circuitry of LI, and are involved at the conditioning stage.  There is a clear functional differentiation between the NAC shell and core subregions whereby damage to the shell disrupts LI and damage to the core renders LI abnormally persistent under conditions that disrupt LI in normal rats.  The effects of shell and core lesions parallel those produced by lesions to the major sources of input to the NAC: entorhinal cortex lesion, like shell lesion, disrupts LI, whereas hippocampal lesion, like core lesion, produces persistent LI with changes in context, and basolateral amygdala (BLA) lesion, like core lesion, produces persistent LI with extended conditioning.  Systemically induced blockade of glutamatergic as well as DA transmission produce persistent LI via effects exerted at the conditioning stage, whereas enhancement of DA transmission disrupts LI via effects at the conditioning stage.  Serotonergic manipulations can disrupt or potentiate LI via effects at the pre-exposure stage.  Both typical and atypical APDs potentiate LI via effects at conditioning whereas atypical APDs in addn. disrupt LI via effects at pre-exposure.  Schizophrenia patients can exhibit disrupted or normal LI as a function of the state of the disorder (acute vs. chronic), as well as persistent LI.  Conclusions.  Different drug and lesion manipulations produce two poles of abnormality in LI, namely, disrupted LI under conditions which lead to LI in normal rats, and abnormally persistent LI under conditions which disrupt it in normal rats.  Disrupted and persistent LI are differentially responsive to APDs, with the former reversed by both typical and atypical APDs and the latter selectively reversed by atypical APDs.  It is suggested that this "two-headed LI model" mimics two extremes of deficient cognitive switching seen in schizophrenia, excessive and retarded switching between assocns., mediated by dysfunction of different brain circuitries, and can serve to model pos. symptoms of schizophrenia and typical antipsychotic action, as well as neg. symptoms of schizophrenia and atypical antipsychotic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCPGkGeIm5lLVg90H21EOLACvtfcHk0lg83So_37IfoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVCgsbk%253D&md5=bd3898d17b46c9fdf8a1172f2b6f3728</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1007%2Fs00213-002-1313-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-002-1313-x%26sid%3Dliteratum%253Aachs%26aulast%3DWeiner%26aufirst%3DI.%26atitle%3DThe%2520%25E2%2580%259Ctwo-headed%25E2%2580%259D%2520latent%2520inhibition%2520model%2520of%2520schizophrenia%253A%2520modeling%2520positive%2520and%2520negative%2520symptoms%2520and%2520their%2520treatment%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2003%26volume%3D169%26spage%3D257%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group">Ford, J. M.</span><span> </span><span class="NLM_article-title">Schizophrenia: the broken P300 and beyond</span> <span class="citation_source-journal">Psychophysiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">682</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1999&pages=667-682&author=J.+M.+Ford&title=Schizophrenia%3A+the+broken+P300+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFord%26aufirst%3DJ.%2BM.%26atitle%3DSchizophrenia%253A%2520the%2520broken%2520P300%2520and%2520beyond%26jtitle%3DPsychophysiology%26date%3D1999%26volume%3D36%26spage%3D667%26epage%3D682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group">Louchart-de la Chapelle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levillain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Elst, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haouzir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dollfus, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campion, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibaut, F.</span><span> </span><span class="NLM_article-title">P50 inhibitory gating deficit is correlated with the negative symptomatology of schizophrenia</span> <span class="citation_source-journal">Psychiatry Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.psychres.2003.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16014313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MzptlGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2005&pages=27-34&author=S.+Louchart-de+la+Chapelleauthor=D.+Levillainauthor=J.+F.+Menardauthor=A.+Van+der+Elstauthor=G.+Allioauthor=S.+Haouzirauthor=S.+Dollfusauthor=D.+Campionauthor=F.+Thibaut&title=P50+inhibitory+gating+deficit+is+correlated+with+the+negative+symptomatology+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">P50 inhibitory gating deficit is correlated with the negative symptomatology of schizophrenia</span></div><div class="casAuthors">Louchart-de la Chapelle Sandrine; Levillain Daniel; Menard Jean-Francois; Van der Elst Alexis; Allio Gabrielle; Haouzir Sadeq; Dollfus Sonia; Campion Dominique; Thibaut Florence</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-34</span>
        ISSN:<span class="NLM_cas:issn">0165-1781</span>.
    </div><div class="casAbstract">Abnormal sensory gating in schizophrenia has frequently been reported.  The strength of central inhibitory pathways was measured using the P50 component of the auditory evoked potential in a conditioning-testing paradigm.  The relationships between a relative decrease in P50 amplitude to repeated auditory stimuli and clinical symptoms remain controversial.  Using the Positive and Negative Syndrome Scale, we studied the P50 auditory conditioning-testing paradigm in 81 schizophrenic subjects, categorized into subgroups with and without prominent negative symptoms, in comparison with 88 control subjects.  We found increased ratios of testing stimuli to conditioning stimuli in both schizophrenic subgroups relative to findings in the control group.  In addition, we found significantly increased mean latencies of the P50 responses to conditioning (C) and testing (T) stimuli and significantly increased T/C ratios in the subgroup with negative symptoms compared with the subgroup with non-negative symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgBYDANNTKUpagfuraLLzSfW6udTcc2eaWpnH_TqgOCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzptlGntw%253D%253D&md5=62d86441942fbbf49fc1f12a468ba70a</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.psychres.2003.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psychres.2003.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DLouchart-de%2Bla%2BChapelle%26aufirst%3DS.%26aulast%3DLevillain%26aufirst%3DD.%26aulast%3DMenard%26aufirst%3DJ.%2BF.%26aulast%3DVan%2Bder%2BElst%26aufirst%3DA.%26aulast%3DAllio%26aufirst%3DG.%26aulast%3DHaouzir%26aufirst%3DS.%26aulast%3DDollfus%26aufirst%3DS.%26aulast%3DCampion%26aufirst%3DD.%26aulast%3DThibaut%26aufirst%3DF.%26atitle%3DP50%2520inhibitory%2520gating%2520deficit%2520is%2520correlated%2520with%2520the%2520negative%2520symptomatology%2520of%2520schizophrenia%26jtitle%3DPsychiatry%2520Res.%26date%3D2005%26volume%3D136%26spage%3D27%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group">Braff, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span> </span><span class="NLM_article-title">Gating and habituation of the startle reflex in schizophrenic patients</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1567275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK383jtFKktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1992&pages=206-215&author=D.+L.+Braffauthor=C.+Grillonauthor=M.+A.+Geyer&title=Gating+and+habituation+of+the+startle+reflex+in+schizophrenic+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Gating and habituation of the startle reflex in schizophrenic patients</span></div><div class="casAuthors">Braff D L; Grillon C; Geyer M A</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-15</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">Schizophrenic patients exhibit impairments in both sensorimotor gating and habituation in a number of paradigms.  Through human and animal model research, these fundamental cognitive deficits have well-described neurobiologic bases and offer insights into the neuroanatomic and neurotransmitter abnormalities that characterize patients with schizophrenic spectrum disorders.  In this context, the startle response is particularly interesting, because it is a cross-species response to strong stimuli that is plastic or alterable using experimental and neurobiologic manipulations.  Thirty-nine medicated schizophrenic patients and 37 normal control subjects were studied in a new electromyography based startle response paradigm in which both prepulse inhibition (an operational measure of sensorimotor gating) and habituation (the normal decrease in response magnitude to repeated stimuli over time) can be separated and assessed in one test session.  The results indicate that schizophrenic patients have extensive deficits in both intramodal and cross-modal sensorimotor gating and a trend to show acoustic startle habituation deficits.  The deficit in prepulse inhibition of startle amplitude exhibited by schizophrenic patients was evident when an acoustic prepulse stimulus preceded either an acoustic or a tactile startle stimulus.  No deficit was observed in the prepulse-induced facilitation of startle latencies, indicating that the failure of gating was not due to a failure of stimulus detection.  These findings suggest centrally mediated deficits in sensorimotor gating in schizophrenic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmgyi6ciJduI2y4bB4mnvYfW6udTcc2eaWpnH_TqgOCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK383jtFKktA%253D%253D&md5=5d17032b7a6addae27cc31e198ac4675</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBraff%26aufirst%3DD.%2BL.%26aulast%3DGrillon%26aufirst%3DC.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26atitle%3DGating%2520and%2520habituation%2520of%2520the%2520startle%2520reflex%2520in%2520schizophrenic%2520patients%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1992%26volume%3D49%26spage%3D206%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group">Grillon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ameli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charney, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braff, D.</span><span> </span><span class="NLM_article-title">Startle gating deficits occur across prepulse intensities in schizophrenic patients</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0006-3223%2892%2990183-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1467378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK3s7gsVehtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1992&pages=939-943&author=C.+Grillonauthor=R.+Ameliauthor=D.+S.+Charneyauthor=J.+Krystalauthor=D.+Braff&title=Startle+gating+deficits+occur+across+prepulse+intensities+in+schizophrenic+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Startle gating deficits occur across prepulse intensities in schizophrenic patients</span></div><div class="casAuthors">Grillon C; Ameli R; Charney D S; Krystal J; Braff D</div><div class="citationInfo"><span class="NLM_cas:title">Biological psychiatry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">939-43</span>
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    </div><div class="casAbstract">The effects of prepulse stimuli of different intensities in inhibiting the startle reflex was assessed in 14 age-matched and gender-matched schizophrenic patients and 14 normal controls.  The subjects were presented with startling stimuli consisting of bursts of white noise (106 dBA) with or without prepulse stimuli.  Four intensities of prepulse stimuli were utilized: 75, 80, 85, and 90 dBA.  Throughout the testing, the background noise was maintained at 70 dBA.  The prepulse stimuli more effectively inhibited the startle reflex in the control group compared to the schizophrenic patients who showed deficient prepulse inhibition (gating) of the startle reflex.  These results suggest that schizophrenics have impaired central inhibitory mechanisms over a fairly broad range of background noise to prepulse ratios.  Further studies are needed to clarify exactly which ratios are optimal in eliciting prepulse inhibition (PPI) and in differentiating between schizophrenic and control groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAyGtpcdk70Kx48Rj5GnGofW6udTcc2eaWpnH_TqgOCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s7gsVehtQ%253D%253D&md5=3fa2fcdc1daaa605af185753a9646c39</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1016%2F0006-3223%2892%2990183-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-3223%252892%252990183-Z%26sid%3Dliteratum%253Aachs%26aulast%3DGrillon%26aufirst%3DC.%26aulast%3DAmeli%26aufirst%3DR.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DKrystal%26aufirst%3DJ.%26aulast%3DBraff%26aufirst%3DD.%26atitle%3DStartle%2520gating%2520deficits%2520occur%2520across%2520prepulse%2520intensities%2520in%2520schizophrenic%2520patients%26jtitle%3DBiol.%2520Psychiatry%26date%3D1992%26volume%3D32%26spage%3D939%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs-Thomson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braff, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swerdlow, N. R.</span><span> </span><span class="NLM_article-title">Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs002130100811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11549216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtlCqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2001&pages=117-154&author=M.+A.+Geyerauthor=K.+Krebs-Thomsonauthor=D.+L.+Braffauthor=N.+R.+Swerdlow&title=Pharmacological+studies+of+prepulse+inhibition+models+of+sensorimotor+gating+deficits+in+schizophrenia%3A+a+decade+in+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review</span></div><div class="casAuthors">Geyer, Mark A.; Krebs-Thomson, Kirsten; Braff, David L.; Swerdlow, Neal R.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">117-154</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with refs. is given.  Patients with schizophrenia exhibit deficits in an operational measure of sensorimotor gating: prepulse inhibition (PPI) of startle.  Similar deficits in PPI are produced in rats by pharmacol. or developmental manipulations.  These exptl. induced PPI deficits in rats are clearly not animal models of schizophrenia per se, but appear to provide models of sensorimotor gating deficits in schizophrenia patients that have face, predictive, and construct validity.  In rodents, disruptions in PPI of startle are produced by: stimulation of D2 dopamine (DA) receptors, produced by amphetamine or apomorphine; activation of serotonergic systems, produced by serotonin (5-HT) releasers or direct agonists at multiple serotonin receptors; and blockade of N-methyl-D-aspartate (NMDA) receptors, produced by drugs such as phencyclidine (PCP).  Accordingly, dopaminergic, serotonergic, and glutamatergic models of disrupted PPI have evolved and were applied to the identification of potential antipsychotic treatments.  In addn., some developmental manipulations, such as isolation rearing, have provided non-pharmacol. animal models of the PPI deficits seen in schizophrenia.  This review summarizes and evaluates studies assessing the effects of systemic drug administrations on PPI in rats.  Studies examg. systemic drug effects on PPI in rats prior to Jan. 15, 2001 were compiled and organized into 6 annotated appendices.  Based on this catalog of studies, the specific advantages and disadvantages of each of the 4 main PPI models used in the study of antipsychotic drugs were critically evaluated.  Despite some notable inconsistencies, the literature provides strong support for disruptions in PPI in rats produced by DA agonists, 5-HT2 agonists, NMDA antagonists, and isolation rearing.  Each of these models exhibits sensitivity to at least some antipsychotic medications.  While the PPI model based on the effects of direct DA agonists is the most well-validated for the identification of known antipsychotics, the isolation rearing model also appears to be sensitive to both typical and atypical antipsychotics.  The 5-HT PPI model is less generally sensitive to antipsychotic medications, but can provide insight into the contribution of serotonergic systems to the actions of newer antipsychotics that act upon multiple receptors.  The deficits in PPI produced by NMDA antagonists appear to be more sensitive to clozapine-like atypical antipsychotics than to typical antipsychotics.  Hence, despite some exceptions to this generalization, the NMDA PPI model might aid in the identification of novel or atypical antipsychotic medications.  Studies of drug effects on PPI in rats have generated 4 distinctive models that have utility in the identification of antipsychotic medications.  Because each of these models has specific advantages and disadvantages, the choice of model to be used depends upon the question being addressed.  This review should help to guide such decisions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMUgR_yJM15bVg90H21EOLACvtfcHk0lglcB7d4MfM3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtlCqtLY%253D&md5=dcf9c549a4a0063d55478351c784be31</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1007%2Fs002130100811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002130100811%26sid%3Dliteratum%253Aachs%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DKrebs-Thomson%26aufirst%3DK.%26aulast%3DBraff%26aufirst%3DD.%2BL.%26aulast%3DSwerdlow%26aufirst%3DN.%2BR.%26atitle%3DPharmacological%2520studies%2520of%2520prepulse%2520inhibition%2520models%2520of%2520sensorimotor%2520gating%2520deficits%2520in%2520schizophrenia%253A%2520a%2520decade%2520in%2520review%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2001%26volume%3D156%26spage%3D117%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group">Boksa, P.</span><span> </span><span class="NLM_article-title">Animal models of obstetric complications in relation to schizophrenia</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.brainresrev.2004.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15063096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2c7mvVGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=1-17&author=P.+Boksa&title=Animal+models+of+obstetric+complications+in+relation+to+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of obstetric complications in relation to schizophrenia</span></div><div class="casAuthors">Boksa Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Brain research. Brain research reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidemiological studies have provided strong evidence that exposure to obstetric complications is associated with an increased risk for later development of schizophrenia.  These human studies have now begun to tease out which specific pregnancy, labor/delivery or neonatal complications might confer greatest risk for schizophrenia.  Animal modeling can be a useful tool to directly ask if a particular obstetric complication can actually cause changes in brain function or behavior resembling changes in schizophrenia.  This review describes currently available animal models for some of the obstetric complications with greatest effect size for schizophrenia, including maternal diabetes, preeclampsia, infection and stress during pregnancy, intrauterine growth retardation and fetal/neonatal hypoxia.  Where available, evidence that these types of obstetric complications in animals produce alterations in CNS function or behavior, related to features of schizophrenic pathology, is presented.  Animal models might provide insights into the mechanisms by which specific obstetric complications have long-term influence on brain development leading to increased risk for schizophrenia.  Factors common to several obstetric complications associated with schizophrenia may also be discerned.  In this way, animal modeling may provide the framework for human studies to ask further more refined questions concerning the role of specific obstetric factors contributing to schizophrenia, and may provide clues to prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0XbAlyVeJhTToTC3aBaesfW6udTcc2ebCPOjCH3mQMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7mvVGmtA%253D%253D&md5=9ccac532a2767c31b679f736ecd31634</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2004.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2004.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DBoksa%26aufirst%3DP.%26atitle%3DAnimal%2520models%2520of%2520obstetric%2520complications%2520in%2520relation%2520to%2520schizophrenia%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2004%26volume%3D45%26spage%3D1%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group">Lipska, B. K.</span><span> </span><span class="NLM_article-title">Using animal models to test a neurodevelopmental hypothesis of schizophrenia</span> <span class="citation_source-journal">J. Psychiatry Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15309044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2cvgsV2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=282-286&author=B.+K.+Lipska&title=Using+animal+models+to+test+a+neurodevelopmental+hypothesis+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Using animal models to test a neurodevelopmental hypothesis of schizophrenia</span></div><div class="casAuthors">Lipska Barbara K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">282-6</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">A series of studies has shown that neonatal excitotoxic disconnection of the rat ventral hippocampus may serve as a heuristic model of schizophrenia.  The model mimics a spectrum of neurobiologic and behavioural features of schizophrenia.  It produces functional pathology in critical brain regions implicated in schizophrenia and connected with the hippocampal formation, namely, the striatum, nucleus accumbens and the prefrontal cortex.  These brain regions are also targeted by antipsychotic drugs.  Neonatal insult leads in young adulthood to the emergence of abnormalities in a number of dopamine-related behaviours.  It also models some of the negative aspects of schizophrenia, such as social impairments and working memory deficits.  Moreover, our data show that even transient inactivation of the ventral hippocampus during a critical period of development that produces subtle anatomical changes in the hippocampus may be sufficient to trigger behavioural changes similar to those observed in animals with the permanent excitotoxic lesion.  The results of bromodeoxyuridine (BrdU) incorporation studies show that this transient disconnection in the CA1 and CA2 area of the hippocampus may have long-lasting consequences for neurogenesis in the dentate gyrus.  Our data suggest that neonatal disconnection of the ventral hippocampus alters development and plasticity of prefrontal cortical circuitry and produces a constellation of behavioural and cellular changes that mimic many aspects of schizophrenia.  The neonatal hippocampal disconnection model represents a potential new model of schizophrenia without a gross anatomical lesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZfG1UEEH_MmmbXvSEQle5fW6udTcc2ebCPOjCH3mQMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvgsV2jtw%253D%253D&md5=e76bb25fc2e87911ff27b338ef3f5719</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipska%26aufirst%3DB.%2BK.%26atitle%3DUsing%2520animal%2520models%2520to%2520test%2520a%2520neurodevelopmental%2520hypothesis%2520of%2520schizophrenia%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2004%26volume%3D29%26spage%3D282%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group">Lipska, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaskiw, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D. R.</span><span> </span><span class="NLM_article-title">Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1993&pages=67-75&author=B.+K.+Lipskaauthor=G.+E.+Jaskiwauthor=D.+R.+Weinberger&title=Postpubertal+emergence+of+hyperresponsiveness+to+stress+and+to+amphetamine+after+neonatal+excitotoxic+hippocampal+damage%3A+a+potential+animal+model+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipska%26aufirst%3DB.%2BK.%26aulast%3DJaskiw%26aufirst%3DG.%2BE.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DPostpubertal%2520emergence%2520of%2520hyperresponsiveness%2520to%2520stress%2520and%2520to%2520amphetamine%2520after%2520neonatal%2520excitotoxic%2520hippocampal%2520damage%253A%2520a%2520potential%2520animal%2520model%2520of%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D1993%26volume%3D9%26spage%3D67%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group">Daenen, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolterink, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerrits, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Ree, J. M.</span><span> </span><span class="NLM_article-title">Amygdala or ventral hippocampal lesions at two early stages of life differentially affect open field behaviour later in life; an animal model of neurodevelopmental psychopathological disorders</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0166-4328%2801%2900350-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11844573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD387ht1CmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2002&pages=67-78&author=E.+W.+Daenenauthor=G.+Wolterinkauthor=M.+A.+Gerritsauthor=J.+M.+van+Ree&title=Amygdala+or+ventral+hippocampal+lesions+at+two+early+stages+of+life+differentially+affect+open+field+behaviour+later+in+life%3B+an+animal+model+of+neurodevelopmental+psychopathological+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Amygdala or ventral hippocampal lesions at two early stages of life differentially affect open field behaviour later in life; an animal model of neurodevelopmental psychopathological disorders</span></div><div class="casAuthors">Daenen Elisabeth W P M; Wolterink Gerrit; Gerrits Mirjam A F M; Van Ree Jan M</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural brain research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">67-78</span>
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    </div><div class="casAbstract">Psychiatric disorders like schizophrenia or autism are thought to result from disruption of the normal pattern of brain development.  Abnormalities in the amygdaloid complex and hippocampus have been reported in these disorders.  In the present study rats were lesioned in the amygdala or ventral hippocampus on day 7 of life (immature brain) or day 21 of life (almost mature brain) and open field behaviour was determined later in life before and after puberty.  Lesioning on day 7 resulted in behavioural changes, interpreted as locomotor stereotypy and decreased anxiety in case of amygdala or hippocampus, respectively.  These effects were more profoundly present after puberty.  Lesioning on day 21 did not result in these behavioural changes, which subscribes to the importance of the stage of brain maturation on functional development.  The results suggest that the behavioural changes in rats lesioned on day 7 may due to a malfunctioning of structures connected to the amygdala or ventral hippocampus.  Brain lesions made on day 7 of life may serve as a potential model of psychopathological neurodevelopmental disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSV2jl0mqc5tO3MPKNEWB5RfW6udTcc2eYIUA4bUvui6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387ht1CmtQ%253D%253D&md5=ed5b0663464c51490e1e5a6032b2abfc</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1016%2FS0166-4328%2801%2900350-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-4328%252801%252900350-3%26sid%3Dliteratum%253Aachs%26aulast%3DDaenen%26aufirst%3DE.%2BW.%26aulast%3DWolterink%26aufirst%3DG.%26aulast%3DGerrits%26aufirst%3DM.%2BA.%26aulast%3Dvan%2BRee%26aufirst%3DJ.%2BM.%26atitle%3DAmygdala%2520or%2520ventral%2520hippocampal%2520lesions%2520at%2520two%2520early%2520stages%2520of%2520life%2520differentially%2520affect%2520open%2520field%2520behaviour%2520later%2520in%2520life%253B%2520an%2520animal%2520model%2520of%2520neurodevelopmental%2520psychopathological%2520disorders%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2002%26volume%3D131%26spage%3D67%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group">Joober, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boksa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benkelfat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouleau, G.</span><span> </span><span class="NLM_article-title">Genetics of schizophrenia: from animal models to clinical studies</span> <span class="citation_source-journal">J. Psychiatry Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">336</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12271789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD38vosFOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=336-347&author=R.+Jooberauthor=P.+Boksaauthor=C.+Benkelfatauthor=G.+Rouleau&title=Genetics+of+schizophrenia%3A+from+animal+models+to+clinical+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics of schizophrenia: from animal models to clinical studies</span></div><div class="casAuthors">Joober Ridha; Boksa Patricia; Benkelfat Chawki; Rouleau Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">336-47</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">Genetic epidemiological studies strongly suggest that additive and interactive genes, each with small effects, mediate the genetic vulnerability for schizophrenia.  With the human genome working draft at hand, candidate gene (and ultimately large-scale genome-wide) association studies are gaining renewed interest in the effort to unravel the complex genetics of schizophrenia.  In the absence of an unequivocally established biological theory for schizophrenia, identifying candidate genes to be tested in an association paradigm remains a challenging task.  We maintain that it is possible to use animal models to map genes or loci involved in behavioural traits that are relevant to schizophrenia.  The human genes (or syntenic loci) homologous to those identified in mice can subsequently be tested in patients with schizophrenia who have been carefully phenotyped for traits "isomorphic" to the ones modelled in mice.  If confirmed in humans, these genes may be further analyzed in the animal model to identify their role and the biological network they are involved in.  To tackle the complex and intimidating problem of the genetics of schizophrenia, it may be necessary to go from animal models to human studies and vice versa; this strategy has been proven to be efficient in less complicated, though complex, human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWW2loxrEJSZVVjGoY74BafW6udTcc2eYIUA4bUvui6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vosFOqtA%253D%253D&md5=e4f057d81ed404a0f541250761b86d95</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJoober%26aufirst%3DR.%26aulast%3DBoksa%26aufirst%3DP.%26aulast%3DBenkelfat%26aufirst%3DC.%26aulast%3DRouleau%26aufirst%3DG.%26atitle%3DGenetics%2520of%2520schizophrenia%253A%2520from%2520animal%2520models%2520to%2520clinical%2520studies%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2002%26volume%3D27%26spage%3D336%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group">Kellendonk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polan, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malleret, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vronskaya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winiger, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandel, E. R.</span><span> </span><span class="NLM_article-title">Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.neuron.2006.01.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16476668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFyjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=603-615&author=C.+Kellendonkauthor=E.+H.+Simpsonauthor=H.+J.+Polanauthor=G.+Malleretauthor=S.+Vronskayaauthor=V.+Winigerauthor=H.+Mooreauthor=E.+R.+Kandel&title=Transient+and+selective+overexpression+of+dopamine+D2+receptors+in+the+striatum+causes+persistent+abnormalities+in+prefrontal+cortex+functioning"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning</span></div><div class="casAuthors">Kellendonk, Christoph; Simpson, Eleanor H.; Polan, H. Jonathan; Malleret, Gael; Vronskaya, Svetlana; Winiger, Vanessa; Moore, Holly; Kandel, Eric R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">603-615</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Increased activity of D2 receptors (D2Rs) in the striatum has been linked to the pathophysiol. of schizophrenia.  To det. directly the behavioral and physiol. consequences of increased D2R function in the striatum, we generated mice with reversibly increased levels of D2Rs restricted to the striatum.  D2 transgenic mice exhibit selective cognitive impairments in working memory tasks and behavioral flexibility without more general cognitive deficits.  The deficit in the working memory task persists even after the transgene has been switched off, indicating that it results not from continued overexpression of D2Rs but from excess expression during development.  To det. the effects that may mediate the obsd. cognitive deficits, we analyzed the prefrontal cortex, the brain structure mainly assocd. with working memory.  We found that D2R overexpression in the striatum impacts dopamine levels, rates of dopamine turnover, and activation of D1 receptors in the prefrontal cortex, measures that are crit. for working memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBx2c7jWNhS7Vg90H21EOLACvtfcHk0lgj1GqRE4x8Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFyjtr0%253D&md5=1f974c993ee1b8f3b3fc126aad4ce721</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2006.01.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2006.01.023%26sid%3Dliteratum%253Aachs%26aulast%3DKellendonk%26aufirst%3DC.%26aulast%3DSimpson%26aufirst%3DE.%2BH.%26aulast%3DPolan%26aufirst%3DH.%2BJ.%26aulast%3DMalleret%26aufirst%3DG.%26aulast%3DVronskaya%26aufirst%3DS.%26aulast%3DWiniger%26aufirst%3DV.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DKandel%26aufirst%3DE.%2BR.%26atitle%3DTransient%2520and%2520selective%2520overexpression%2520of%2520dopamine%2520D2%2520receptors%2520in%2520the%2520striatum%2520causes%2520persistent%2520abnormalities%2520in%2520prefrontal%2520cortex%2520functioning%26jtitle%3DNeuron%26date%3D2006%26volume%3D49%26spage%3D603%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group">Almond, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fradley, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutter, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandon, N. J.</span><span> </span><span class="NLM_article-title">Behavioral and biochemical characterization of a mutant mouse strain lacking <span class="smallcaps smallerCapital">d</span>-amino acid oxidase activity and its implications for schizophrenia</span> <span class="citation_source-journal">Mol. Cell. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">324</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.mcn.2006.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16843004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2006&pages=324-334&author=S.+L.+Almondauthor=R.+L.+Fradleyauthor=E.+J.+Armstrongauthor=R.+B.+Heavensauthor=A.+R.+Rutterauthor=R.+J.+Newmanauthor=C.+S.+Chiuauthor=R.+Konnoauthor=P.+H.+Hutsonauthor=N.+J.+Brandon&title=Behavioral+and+biochemical+characterization+of+a+mutant+mouse+strain+lacking+d-amino+acid+oxidase+activity+and+its+implications+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia</span></div><div class="casAuthors">Almond, S. L.; Fradley, R. L.; Armstrong, E. J.; Heavens, R. B.; Rutter, A. R.; Newman, R. J.; Chiu, C. S.; Konno, R.; Hutson, P. H.; Brandon, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">324-334</span>CODEN:
                <span class="NLM_cas:coden">MOCNED</span>;
        ISSN:<span class="NLM_cas:issn">1044-7431</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Amino acid oxidase (DAO) degrades -serine, a co-agonist at the NMDA receptor (NMDAR).  Hypofunction of the NMDAR has been suggested to contribute to the pathophysiol. of schizophrenia.  Intriguingly, DAO has been recently identified as a risk factor for schizophrenia through genetic assocn. studies.  A naturally occurring mouse strain (ddY/DAO-) has been identified which lacks DAO activity.  We have characterized this strain both behaviorally and biochem. to evaluate DAO as a target for schizophrenia.  We have confirmed that this strain lacks DAO activity and shown for the first time it has increased occupancy of the NMDAR glycine site due to elevated extracellular D-serine levels and has enhanced NMDAR function in vivo.  Furthermore, the ddY/DAO- strain displays behaviors which suggest that it will be a useful tool for evaluation of the clin. benefit of DAO inhibition in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe3jOi1kOw0rVg90H21EOLACvtfcHk0lgj1GqRE4x8Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWrsr4%253D&md5=2b4ba43b50f49d5b035ba22042518c3e</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2Fj.mcn.2006.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mcn.2006.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DAlmond%26aufirst%3DS.%2BL.%26aulast%3DFradley%26aufirst%3DR.%2BL.%26aulast%3DArmstrong%26aufirst%3DE.%2BJ.%26aulast%3DHeavens%26aufirst%3DR.%2BB.%26aulast%3DRutter%26aufirst%3DA.%2BR.%26aulast%3DNewman%26aufirst%3DR.%2BJ.%26aulast%3DChiu%26aufirst%3DC.%2BS.%26aulast%3DKonno%26aufirst%3DR.%26aulast%3DHutson%26aufirst%3DP.%2BH.%26aulast%3DBrandon%26aufirst%3DN.%2BJ.%26atitle%3DBehavioral%2520and%2520biochemical%2520characterization%2520of%2520a%2520mutant%2520mouse%2520strain%2520lacking%2520d-amino%2520acid%2520oxidase%2520activity%2520and%2520its%2520implications%2520for%2520schizophrenia%26jtitle%3DMol.%2520Cell.%2520Neurosci.%26date%3D2006%26volume%3D32%26spage%3D324%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group">O’Tuathaigh, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babovic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Sullivan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clifford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tighe, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croke, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waddington, J. L.</span><span> </span><span class="NLM_article-title">Phenotypic characterization of spatial cognition and social behavior in mice with “knockout” of the schizophrenia risk gene neuregulin 1</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2007&pages=18-27&author=C.+M.+O%E2%80%99Tuathaighauthor=D.+Babovicauthor=G.+J.+O%E2%80%99Sullivanauthor=J.+J.+Cliffordauthor=O.+Tigheauthor=D.+T.+Crokeauthor=R.+Harveyauthor=J.+L.+Waddington&title=Phenotypic+characterization+of+spatial+cognition+and+social+behavior+in+mice+with+%E2%80%9Cknockout%E2%80%9D+of+the+schizophrenia+risk+gene+neuregulin+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Tuathaigh%26aufirst%3DC.%2BM.%26aulast%3DBabovic%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DG.%2BJ.%26aulast%3DClifford%26aufirst%3DJ.%2BJ.%26aulast%3DTighe%26aufirst%3DO.%26aulast%3DCroke%26aufirst%3DD.%2BT.%26aulast%3DHarvey%26aufirst%3DR.%26aulast%3DWaddington%26aufirst%3DJ.%2BL.%26atitle%3DPhenotypic%2520characterization%2520of%2520spatial%2520cognition%2520and%2520social%2520behavior%2520in%2520mice%2520with%2520%25E2%2580%259Cknockout%25E2%2580%259D%2520of%2520the%2520schizophrenia%2520risk%2520gene%2520neuregulin%25201%26jtitle%3DNeuroscience%26date%3D2007%26volume%3D147%26spage%3D18%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group">Clapcote, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipina, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millar, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerch, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trimble, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuraba, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiroishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkelman, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sled, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gondo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roder, J. C.</span><span> </span><span class="NLM_article-title">Behavioral phenotypes of Disc1 missense mutations in mice</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2007&pages=387-402&author=S.+J.+Clapcoteauthor=T.+V.+Lipinaauthor=J.+K.+Millarauthor=S.+Mackieauthor=S.+Christieauthor=F.+Ogawaauthor=J.+P.+Lerchauthor=K.+Trimbleauthor=M.+Uchiyamaauthor=Y.+Sakurabaauthor=H.+Kanedaauthor=T.+Shiroishiauthor=M.+D.+Houslayauthor=R.+M.+Henkelmanauthor=J.+G.+Sledauthor=Y.+Gondoauthor=D.+J.+Porteousauthor=J.+C.+Roder&title=Behavioral+phenotypes+of+Disc1+missense+mutations+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClapcote%26aufirst%3DS.%2BJ.%26aulast%3DLipina%26aufirst%3DT.%2BV.%26aulast%3DMillar%26aufirst%3DJ.%2BK.%26aulast%3DMackie%26aufirst%3DS.%26aulast%3DChristie%26aufirst%3DS.%26aulast%3DOgawa%26aufirst%3DF.%26aulast%3DLerch%26aufirst%3DJ.%2BP.%26aulast%3DTrimble%26aufirst%3DK.%26aulast%3DUchiyama%26aufirst%3DM.%26aulast%3DSakuraba%26aufirst%3DY.%26aulast%3DKaneda%26aufirst%3DH.%26aulast%3DShiroishi%26aufirst%3DT.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DHenkelman%26aufirst%3DR.%2BM.%26aulast%3DSled%26aufirst%3DJ.%2BG.%26aulast%3DGondo%26aufirst%3DY.%26aulast%3DPorteous%26aufirst%3DD.%2BJ.%26aulast%3DRoder%26aufirst%3DJ.%2BC.%26atitle%3DBehavioral%2520phenotypes%2520of%2520Disc1%2520missense%2520mutations%2520in%2520mice%26jtitle%3DNeuron%26date%3D2007%26volume%3D54%26spage%3D387%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group">Low, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, J.</span><span> </span><span class="NLM_article-title">What is a schizophrenic mouse?</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">348</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2007&pages=348-349&author=N.+C.+Lowauthor=J.+Hardy&title=What+is+a+schizophrenic+mouse%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DN.%2BC.%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DWhat%2520is%2520a%2520schizophrenic%2520mouse%253F%26jtitle%3DNeuron%26date%3D2007%26volume%3D54%26spage%3D348%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group">Sivagnanasundaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubank, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illingworth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skuse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scambler, P.</span><span> </span><span class="NLM_article-title">Differential gene expression in the hippocampus of the Df1/+ mice: a model for 22q11.2 deletion syndrome and schizophrenia</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1139</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.brainres.2007.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17292336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVWgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1139&publication_year=2007&pages=48-59&author=S.+Sivagnanasundaramauthor=D.+Fletcherauthor=M.+Hubankauthor=E.+Illingworthauthor=D.+Skuseauthor=P.+Scambler&title=Differential+gene+expression+in+the+hippocampus+of+the+Df1%2F%2B+mice%3A+a+model+for+22q11.2+deletion+syndrome+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Differential gene expression in the hippocampus of the Df1/+ mice: A model for 22q11.2 deletion syndrome and schizophrenia</span></div><div class="casAuthors">Sivagnanasundaram, Sinthuja; Fletcher, Danielle; Hubank, Mike; Illingworth, Elizabeth; Skuse, David; Scambler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-59</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Genes and a 3-Mb deletion mapping to human chromosome 22q11.2 have been implicated in 22q11.2 deletion syndrome (22q11.2DS) and schizophrenia.  The Df1 heterozygous (Df1/+) mice, a model for 22q11.2DS, display specific deficits in hippocampus-dependent learning and memory and impaired sensorimotor gating, abnormalities obsd. in patients with schizophrenia and 22q11.2DS.  In light of the analogous behavioral abnormalities obsd. between the Df1/+ mice and 22q11.2DS and schizophrenia resp., particularly in assocn. with the 22q11.2 deletion, the Df1/+ mice are suitable for investigating the mol. changes that may underlie the cognitive deficits and behavioral abnormalities arising as a result of this deletion.  Hence we applied microarray technol. to identify such mol. changes in the hippocampus at the transcript level.  Twelve genes mapping to the deleted region were reliably identified as expressed in the hippocampus by microarray anal. 159 other differentially expressed genes/ESTs were also identified.  Thus far differential expression of fifteen of these genes involved in signal transduction, synaptic plasticity, neuronal differentiation, microtubule assembly and ubiquitin pathway relevant to hippocampus mediated function have been confirmed by real-time PCR.  Of particular interest is the decreased expression (32%) of calmodulin 1, encoding a calcium-dependent protein involved in the calmodulin-calcineurin regulated pathway implicated in learning and memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqVsuRJ6JzF7Vg90H21EOLACvtfcHk0ljWPNpJ4344jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVWgsr4%253D&md5=4a0d2977527dd0c840ce4e1050192359</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2007.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2007.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DSivagnanasundaram%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DD.%26aulast%3DHubank%26aufirst%3DM.%26aulast%3DIllingworth%26aufirst%3DE.%26aulast%3DSkuse%26aufirst%3DD.%26aulast%3DScambler%26aufirst%3DP.%26atitle%3DDifferential%2520gene%2520expression%2520in%2520the%2520hippocampus%2520of%2520the%2520Df1%252F%252B%2520mice%253A%2520a%2520model%2520for%252022q11.2%2520deletion%2520syndrome%2520and%2520schizophrenia%26jtitle%3DBrain%2520Res.%26date%3D2007%26volume%3D1139%26spage%3D48%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group">Van den Buuse, M.</span><span> </span><span class="NLM_article-title">Prepulse inhibition of acoustic startle in spontaneously hypertensive rats</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.bbr.2004.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15313020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2cvgslyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2004&pages=331-337&author=M.+Van+den+Buuse&title=Prepulse+inhibition+of+acoustic+startle+in+spontaneously+hypertensive+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Prepulse inhibition of acoustic startle in spontaneously hypertensive rats</span></div><div class="casAuthors">van den Buuse Maarten</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural brain research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-7</span>
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    </div><div class="casAbstract">Prepulse inhibition is modulated by dopaminergic drugs and is disrupted in attention-deficit hyperactivity disorder, as well as mental illnesses such as schizophrenia.  Spontaneously hypertensive rats (SHR) have been proposed as an animal model of attention-deficit hyperactivity disorder and show marked alterations of dopaminergic regulation of behaviour.  SHR showed significantly lower startle amplitude than Wistar-Kyoto (WKY) rats and Sprague-Dawley (SD) rats, but no difference in startle habituation.  Baseline percentage prepulse inhibition was higher in SHR and WKY rats than in SD rats.  Treatment with amphetamine caused significant disruption of prepulse inhibition in SHR and WKY rats, but not SD rats.  In contrast, treatment with apomorphine caused prepulse-dependent disruption of prepulse inhibition in SD rats only.  Both MK-801 and 8-OH-DPAT treatment caused disruption of prepulse inhibition in all three rat strains.  This study shows differential changes in startle level and prepulse inhibition in SHR, however these rats are not uniformly different from either WKY rats or SD rats and WKY rats differ in a number of respects from SD rats.  In conclusion, these data further reveal altered dopaminergic regulation of behaviour in SHR, but also shows that caution is needed about the control strain used to compare these animals with.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZ6QQNnkMStJotVjB3IRIyfW6udTcc2eZUBFrhmcUC07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvgslyltQ%253D%253D&md5=15fc9f1552478284ac1923689eec67fb</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2004.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2004.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BBuuse%26aufirst%3DM.%26atitle%3DPrepulse%2520inhibition%2520of%2520acoustic%2520startle%2520in%2520spontaneously%2520hypertensive%2520rats%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2004%26volume%3D154%26spage%3D331%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group">Feifel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melendez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shilling, P. D.</span><span> </span><span class="NLM_article-title">Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=731-738&author=D.+Feifelauthor=G.+Melendezauthor=P.+D.+Shilling&title=Reversal+of+sensorimotor+gating+deficits+in+Brattleboro+rats+by+acute+administration+of+clozapine+and+a+neurotensin+agonist%2C+but+not+haloperidol%3A+a+potential+predictive+model+for+novel+antipsychotic+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeifel%26aufirst%3DD.%26aulast%3DMelendez%26aufirst%3DG.%26aulast%3DShilling%26aufirst%3DP.%2BD.%26atitle%3DReversal%2520of%2520sensorimotor%2520gating%2520deficits%2520in%2520Brattleboro%2520rats%2520by%2520acute%2520administration%2520of%2520clozapine%2520and%2520a%2520neurotensin%2520agonist%252C%2520but%2520not%2520haloperidol%253A%2520a%2520potential%2520predictive%2520model%2520for%2520novel%2520antipsychotic%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2004%26volume%3D29%26spage%3D731%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group">Feifel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melendez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shilling, P. D.</span><span> </span><span class="NLM_article-title">The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.bbr.2007.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17559953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2007&pages=278-286&author=D.+Feifelauthor=G.+Melendezauthor=K.+Priebeauthor=P.+D.+Shilling&title=The+effects+of+chronic+administration+of+established+and+putative+antipsychotics+on+natural+prepulse+inhibition+deficits+in+Brattleboro+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats</span></div><div class="casAuthors">Feifel, David; Melendez, Gilia; Priebe, Kristianne; Shilling, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-286</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We previously reported that vasopressin deficient Brattleboro (BRAT) rats exhibit deficits in prepulse inhibition (PPI) of the startle reflex that are consistent with PPI deficits exhibited by patients with schizophrenia and other neuropsychiatric disorders.  Preliminary evidence indicates that this may be the basis of a predictive model for antipsychotic drug efficacy.  Here we report the effects of acute and chronic administration of established and putative antipsychotics on these PPI deficits.  BRAT rats, compared to their deriv. strain, Long Evans rats, exhibited significantly decreased PPI and startle habituation consistent with patients with schizophrenia and other neuropsychiatric disorders.  The second generation antipsychotics, risperidone and clozapine as well as a neurotensin agonist (PD149163) increased BRAT rat PPI, whereas saline, the typical antipsychotic, haloperidol, and a vasopressin analog (1-desamino--arginine vasopressin) did not.  Similar to their effects in humans, chronic administration of antipsychotic drugs produced stronger effects than acute administration.  These results further support the BRAT rat as a model of sensorimotor gating deficits with predictive validity for antipsychotics.  The model appears to be able to differentiate first generation from second generation antipsychotics, identify putative antipsychotics with novel mechanisms (i.e., peptides) and reasonably model the therapeutic time course of antipsychotic drugs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzIur8GgxCSLVg90H21EOLACvtfcHk0ljUVgCFCY2qgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFygtL8%253D&md5=4b6c630b4b4e3d4ed1bff491837c680f</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2007.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2007.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DFeifel%26aufirst%3DD.%26aulast%3DMelendez%26aufirst%3DG.%26aulast%3DPriebe%26aufirst%3DK.%26aulast%3DShilling%26aufirst%3DP.%2BD.%26atitle%3DThe%2520effects%2520of%2520chronic%2520administration%2520of%2520established%2520and%2520putative%2520antipsychotics%2520on%2520natural%2520prepulse%2520inhibition%2520deficits%2520in%2520Brattleboro%2520rats%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2007%26volume%3D181%26spage%3D278%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group">Olivier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groppi, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarnyai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span> </span><span class="NLM_article-title">The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs002130100828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11549230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtlCqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2001&pages=284-290&author=B.+Olivierauthor=C.+Leahyauthor=T.+Mullenauthor=R.+Paylorauthor=V.+E.+Groppiauthor=Z.+Sarnyaiauthor=D.+Brunner&title=The+DBA%2F2J+strain+and+prepulse+inhibition+of+startle%3A+a+model+system+to+test+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?</span></div><div class="casAuthors">Olivier, Berend; Leahy, Christina; Mullen, Tanner; Paylor, Richard; Groppi, Vincent E.; Sarnyai, Zoltan; Brunner, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">284-290</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Prepulse inhibition (PPI) of the startle response in mice is increasingly used as a paradigm of sensory gating with potential predictive and construct validity towards schizophrenia.  Establishment of a mouse PPI paradigm in which typical and atypical antipsychotic drugs directly improve a low performance PPI.  Three strains of mice - C57Bl/6J, 129S6/SvEvTac and DBA/2J - were tested in a startle paradigm with 3 prepulse intensities, 2, 4, and 8 dB above background.  Under these conditions, risperidone (0, 0.25, 0.5, and 1 mg/kg i.p.) and clozapine (0, 1, 3, and 9 mg/kg i.p.) improved PPI in all 3 strains, with order of effect in DBA/2J > 129S6/SvEvTac > C57Bl/6J.  The DBA/2J strain showed larger PPI-enhancing effects, without disturbing the basal startle response.  Two α7 nicotinic receptor agonists, GTS-21 (1-10 mg/kg i.p.) and AR-R17779 (1-10 mg/kg i.p.) were inactive in the PPI procedure in DBA/2J mice.  DBA/2J mice were very sensitive to the antipsychotic-like effects of atypical (clozapine) and typical (risperidone) antipsychotics, and this strain is proposed as a model to directly measure sensory gating properties of drugs.  α7 Nicotinergic receptor agonists were ineffective in this PPI paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYrWulmkGVrVg90H21EOLACvtfcHk0ljUVgCFCY2qgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtlCqurw%253D&md5=30db2d3ab455931c1dee97379da6b802</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1007%2Fs002130100828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002130100828%26sid%3Dliteratum%253Aachs%26aulast%3DOlivier%26aufirst%3DB.%26aulast%3DLeahy%26aufirst%3DC.%26aulast%3DMullen%26aufirst%3DT.%26aulast%3DPaylor%26aufirst%3DR.%26aulast%3DGroppi%26aufirst%3DV.%2BE.%26aulast%3DSarnyai%26aufirst%3DZ.%26aulast%3DBrunner%26aufirst%3DD.%26atitle%3DThe%2520DBA%252F2J%2520strain%2520and%2520prepulse%2520inhibition%2520of%2520startle%253A%2520a%2520model%2520system%2520to%2520test%2520antipsychotics%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2001%26volume%3D156%26spage%3D284%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group">Flood, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasior, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, M. J.</span><span> </span><span class="NLM_article-title">Variables affecting prepulse inhibition of the startle reflex and the response to antipsychotics in DBA/2NCrl mice</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-007-0894-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17668187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CltbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2007&pages=203-211&author=D.+G.+Floodauthor=M.+Gasiorauthor=M.+J.+Marino&title=Variables+affecting+prepulse+inhibition+of+the+startle+reflex+and+the+response+to+antipsychotics+in+DBA%2F2NCrl+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Variables affecting prepulse inhibition of the startle reflex and the response to antipsychotics in DBA/2NCrl mice</span></div><div class="casAuthors">Flood, Dorothy G.; Gasior, Maciej; Marino, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-211</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">DBA/2 mice demonstrate poor prepulse inhibition (PPI) as is also obsd. in schizophrenic patients, and their PPI is improved by antipsychotics.  Thus, the DBA/2 mouse is increasingly used for testing of novel antipsychotics in PPI; however, the strain has not been fully characterized for relevant variables affecting compd. testing.  The objectives of this study were to compare four DBA/2 substrains, evaluate light- and dark-phase testing on startle, PPI, and drug-induced improvement in PPI in DBA/2NCrl mice, test chamber lighting on startle and PPI in DBA/2NCrl mice and to evaluate vehicles on baseline PPI in DBA/2NCrl mice.  DBA/2NCrl and DBA/2J mice were acceptable for PPI testing, while DBA/2NHsd mice had diminished startle reflexes.  Startle responses to the prepulses alone were obsd. in 46% of the DBA/2NTac mice.  PPI and startle did not show diurnal variations or variations due to chamber lighting.  Olanzapine and aripiprazole showed better drug-induced improvements in PPI during the light phase.  The vehicle 25% (2-hydroxypropyl)-β-cyclodextrin variably improved PPI, an effect not obsd. with other vehicles.  DBA/2NHsd and DBA/2NTac mice were unacceptable for PPI expts.  The finding of responses to the prepulses alone by DBA/2NTac mice further indicates the advisability of routinely monitoring responses to prepulses alone.  Unlike rats, DBA/2NCrl mice did not have greater startle amplitudes during the dark phase.  Compd. efficacy was better during the light phase because of poorer PPI in the vehicle group.  Some vehicles may have unacceptable effects on PPI in DBA/2NCrl mice and may not be appropriate for studies evaluating novel compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwFwaoCxXHRrVg90H21EOLACvtfcHk0ljUVgCFCY2qgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CltbrN&md5=00ab647340a969ede579d8ed2feddb92</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1007%2Fs00213-007-0894-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-007-0894-9%26sid%3Dliteratum%253Aachs%26aulast%3DFlood%26aufirst%3DD.%2BG.%26aulast%3DGasior%26aufirst%3DM.%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26atitle%3DVariables%2520affecting%2520prepulse%2520inhibition%2520of%2520the%2520startle%2520reflex%2520and%2520the%2520response%2520to%2520antipsychotics%2520in%2520DBA%252F2NCrl%2520mice%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2007%26volume%3D195%26spage%3D203%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group">D’Hooge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Deyn, P. P.</span><span> </span><span class="NLM_article-title">Applications of the Morris water maze in the study of learning and memory</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0165-0173%2801%2900067-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11516773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3MvntFyitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2001&pages=60-90&author=R.+D%E2%80%99Hoogeauthor=P.+P.+De+Deyn&title=Applications+of+the+Morris+water+maze+in+the+study+of+learning+and+memory"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of the Morris water maze in the study of learning and memory</span></div><div class="casAuthors">D'Hooge R; De Deyn P P</div><div class="citationInfo"><span class="NLM_cas:title">Brain research. Brain research reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Morris water maze (MWM) was described 20 years ago as a device to investigate spatial learning and memory in laboratory rats.  In the meanwhile, it has become one of the most frequently used laboratory tools in behavioral neuroscience.  Many methodological variations of the MWM task have been and are being used by research groups in many different applications.  However, researchers have become increasingly aware that MWM performance is influenced by factors such as apparatus or training procedure as well as by the characteristics of the experimental animals (sex, species/strain, age, nutritional state, exposure to stress or infection).  Lesions in distinct brain regions like hippocampus, striatum, basal forebrain, cerebellum and cerebral cortex were shown to impair MWM performance, but disconnecting rather than destroying brain regions relevant for spatial learning may impair MWM performance as well.  Spatial learning in general and MWM performance in particular appear to depend upon the coordinated action of different brain regions and neurotransmitter systems constituting a functionally integrated neural network.  Finally, the MWM task has often been used in the validation of rodent models for neurocognitive disorders and the evaluation of possible neurocognitive treatments.  Through its many applications, MWM testing gained a position at the very core of contemporary neuroscience research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRf7R5RmXH7hRKDYG3bNImrfW6udTcc2eYM75wR_pF9nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvntFyitw%253D%253D&md5=dcf5c0168a705aae724bb4d7e0abccc4</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2FS0165-0173%2801%2900067-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-0173%252801%252900067-4%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DR.%26aulast%3DDe%2BDeyn%26aufirst%3DP.%2BP.%26atitle%3DApplications%2520of%2520the%2520Morris%2520water%2520maze%2520in%2520the%2520study%2520of%2520learning%2520and%2520memory%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2001%26volume%3D36%26spage%3D60%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group">Wilson, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. A.</span><span> </span><span class="NLM_article-title">Cholinergic manipulations and passive avoidance in the rat: effects on acquisition and recall</span> <span class="citation_source-journal">Acta Neurobiol. Exp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=7887188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK2M7ptlGntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=377-391&author=W.+J.+Wilsonauthor=J.+A.+Cook&title=Cholinergic+manipulations+and+passive+avoidance+in+the+rat%3A+effects+on+acquisition+and+recall"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinergic manipulations and passive avoidance in the rat: effects on acquisition and recall</span></div><div class="casAuthors">Wilson W J; Cook J A</div><div class="citationInfo"><span class="NLM_cas:title">Acta neurobiologiae experimentalis</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">377-91</span>
        ISSN:<span class="NLM_cas:issn">0065-1400</span>.
    </div><div class="casAbstract">A review of the literature concerning cholinergic manipulations and passive avoidance reveals that state-dependency is usually not controlled adequately, nor is acquisition of the passive avoidance task ascertained before retention is tested.  These problems make interpretation of results difficult.  We report three experiments on 129 rats, controlling both of these factors, in which scopolamine and pilocarpine impaired both acquisition and retention of a passive avoidance response.  Lesions of the nucleus basalis magnocellularis had no effect on this task.  The results suggest that an optimal level of central cholinergic activity exists for learning and memory, and that deviations from this optimal level impair acquisition and retention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNsan4zefecpcXNb62YGmbfW6udTcc2eYM75wR_pF9nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7ptlGntA%253D%253D&md5=d0823a052bc71795f34e1090604db0f7</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DW.%2BJ.%26aulast%3DCook%26aufirst%3DJ.%2BA.%26atitle%3DCholinergic%2520manipulations%2520and%2520passive%2520avoidance%2520in%2520the%2520rat%253A%2520effects%2520on%2520acquisition%2520and%2520recall%26jtitle%3DActa%2520Neurobiol.%2520Exp.%26date%3D1994%26volume%3D54%26spage%3D377%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubert, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenegre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milinkevitch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porsolt, R. D.</span><span> </span><span class="NLM_article-title">Effects of piracetam on indices of cognitive function in a delayed alternation task in young and aged rats</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">688</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0091-3057%2894%2990088-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=7862724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFaltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1994&pages=683-688&author=S.+Rouxauthor=I.+Hubertauthor=A.+Lenegreauthor=D.+Milinkevitchauthor=R.+D.+Porsolt&title=Effects+of+piracetam+on+indices+of+cognitive+function+in+a+delayed+alternation+task+in+young+and+aged+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of piracetam on indices of cognitive function in a delayed alteration task in young and aged rats</span></div><div class="casAuthors">Roux, Sylvain; Hubert, Isabelle; Lenegre, Antoine; Milinkevitch, Daniel; Porsolt, Roger D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">683-8</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The effects of piracetam (64, 128, and 256 mg/kg PO) on the performance of a delayed alternation in a Skinner Box were investigated.  Test sessions consisted of 36 trials during which animals were first presented with a single lever (left or right) followed 5, 10, or 20 s later by two levers.  A press on the lever opposite to that presented previously (nonmatching to sample) was rewarded.  The no. of correct responses and the reaction times to the one- and two-lever presentations were recorded.  All animals received all treatments in a balanced order.  Aged animals showed clear deficits on all three parameters.  Piracetam was without effect on the performance of young animals but dose-dependently decreased the choice reaction times (two levers) in aged animals without affecting the other two parameters.  These results suggest that piracetam does not affect short-term memory but may facilitate choice behavior in aged animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYYWvMpV-5GLVg90H21EOLACvtfcHk0ljE7mFyBtTVFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFaltL8%253D&md5=5c2d497417d9026afac2c44b17878935</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1016%2F0091-3057%2894%2990088-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-3057%252894%252990088-4%26sid%3Dliteratum%253Aachs%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DHubert%26aufirst%3DI.%26aulast%3DLenegre%26aufirst%3DA.%26aulast%3DMilinkevitch%26aufirst%3DD.%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26atitle%3DEffects%2520of%2520piracetam%2520on%2520indices%2520of%2520cognitive%2520function%2520in%2520a%2520delayed%2520alternation%2520task%2520in%2520young%2520and%2520aged%2520rats%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D1994%26volume%3D49%26spage%3D683%26epage%3D688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group">Murphy, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGorry, P. D.</span><span> </span><span class="NLM_article-title">Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16930948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD28nmsVeitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2006&pages=5-25&author=B.+P.+Murphyauthor=Y.+C.+Chungauthor=T.+W.+Parkauthor=P.+D.+McGorry&title=Pharmacological+treatment+of+primary+negative+symptoms+in+schizophrenia%3A+a+systematic+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review</span></div><div class="casAuthors">Murphy Brendan P; Chung Young-Chul; Park Tae-Won; McGorry Patrick D</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">5-25</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">BACKGROUND:  Optimal treatment of primary negative symptoms is important because their presence is associated with poor outcome.  AIMS:  To systematically review all studies dealing with the efficacy of pharmacological agents on primary negative symptoms.  METHOD:  A comprehensive search of the relevant literature was undertaken using electronic database, reference lists and personal contact.  RESULTS:  There is a lack of standardized research designs.  Amisulpride is the most extensively studied drug with respect to efficacy against primary negative symptoms.  At low doses it demonstrates a consistent, modest effect compared to placebo, though not to conventional antipsychotics and has yet to be tested against other atypicals.  Evidence from multiple studies that used simple statistical analyses and inclusion criteria for patients with primary negative symptoms does not support a direct effect for clozapine.  Path-analysis studies support the direct effects of risperidone, olanzapine, sertindole and aripiprazole, however, different statistical analyses of the same risperidone study produced conflicting results and the direct effects of olanzapine were not confirmed in selected patients with primary negative symptoms.  There are no studies supporting the use of ziprasidone or quetiapine.  The effects of typical antipsychotics on primary negative symptoms are inconclusive and likely to depend on drug dosages.  Selective serotonin reuptake inhibitors (SSRIs), mirtazepine and NMDA agonists show early promise but require further study.  Novel agents such as selegiline, naltrexone, dehydroepiandrosterone, galantamine, Ginkgo, nitric oxide, L-deprenyl and pergolide show positive effects on general negative symptoms but remain untested against primary negative symptoms.  CONCLUSIONS:  Further studies using standardized selective inclusion criteria and controlling for chronicity are needed.  Research guidelines are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4q2ys7r2A8sRAV4D_Ins_fW6udTcc2eZQMEGh9Ac9vbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nmsVeitA%253D%253D&md5=446745a0581fea16f62f08d48b0676ac</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DB.%2BP.%26aulast%3DChung%26aufirst%3DY.%2BC.%26aulast%3DPark%26aufirst%3DT.%2BW.%26aulast%3DMcGorry%26aufirst%3DP.%2BD.%26atitle%3DPharmacological%2520treatment%2520of%2520primary%2520negative%2520symptoms%2520in%2520schizophrenia%253A%2520a%2520systematic%2520review%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D88%26spage%3D5%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group">Orthen-Gambill, N.</span><span> </span><span class="NLM_article-title">Sucrose intake unaffected by fenfluramine but suppressed by amphetamine administration</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2FBF00431772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=2997826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL2MXlsFeqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1985&pages=25-29&author=N.+Orthen-Gambill&title=Sucrose+intake+unaffected+by+fenfluramine+but+suppressed+by+amphetamine+administration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Sucrose intake unaffected by fenfluramine but suppressed by amphetamine administration</span></div><div class="casAuthors">Orthen-Gambill, Nilla</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-9</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">The acute effects of the anorectic agents, fenfluramine  [458-24-2] and amphetamine  [300-62-9], on nutrient selection were studied in male rats.  One group of animals received continuous access to both granulated sucrose  [57-50-1] and Purina chow (presented in sep. cups), while the other group received only Purina chow.  Four doses of fenfluramine (0, 1.5, 3.0, 6.0 mg/kg) and 4 doses of amphetamine (0, 0.5, 1.0, 2.0 mg/kg) were tested.  Injections were given at the beginning of the feeding period, and nutrient intakes were measured at 2, 4, and 8 h postinjection.  While both fenfluramine and amphetamine resulted in similar overall decreases in caloric intakes, the 2 drugs produced different effects on nutrient selection.  Following fenfluramine administration, sucrose intakes remained relatively unaffected, while Purina chow intakes showed pronounced suppression.  In contrast, amphetamine administration resulted in a more equal suppression of both sucrose and Purina chow intakes.  While the overall decreases in food intake seen with fenfluramine and amphetamine may be linked to changes in central neurotransmitter levels, the sparing of sucrose consumption obsd. with fenfluramine may also involve drug-induced changes in peripheral metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTms7_YGeEnbVg90H21EOLACvtfcHk0lgJRGeoSaHMCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlsFeqsb0%253D&md5=f50bfd08304b105f964ff82cd880e477</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1007%2FBF00431772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00431772%26sid%3Dliteratum%253Aachs%26aulast%3DOrthen-Gambill%26aufirst%3DN.%26atitle%3DSucrose%2520intake%2520unaffected%2520by%2520fenfluramine%2520but%2520suppressed%2520by%2520amphetamine%2520administration%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D1985%26volume%3D87%26spage%3D25%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group">Wauquier, A.</span><span> </span><span class="NLM_article-title">Neuroleptics and brain self-stimulation behavior</span> <span class="citation_source-journal">Int. Rev. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0074-7742%2808%2960643-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=43847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL3cXhslCjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1979&pages=335-403&author=A.+Wauquier&title=Neuroleptics+and+brain+self-stimulation+behavior"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroleptics and brain self-stimulation behavior</span></div><div class="casAuthors">Wauquier, Albert</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">335-403</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    </div><div class="casAbstract">A review with 172 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWyPEeSbx6xbVg90H21EOLACvtfcHk0lgJRGeoSaHMCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhslCjs70%253D&md5=8244e538245d15ffdd10f979d973b6a5</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1016%2FS0074-7742%2808%2960643-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0074-7742%252808%252960643-1%26sid%3Dliteratum%253Aachs%26aulast%3DWauquier%26aufirst%3DA.%26atitle%3DNeuroleptics%2520and%2520brain%2520self-stimulation%2520behavior%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D1979%26volume%3D21%26spage%3D335%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group">Turgeon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoge, S. G.</span><span> </span><span class="NLM_article-title">Prior exposure to phencyclidine decreases voluntary sucrose consumption and operant performance for food reward</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pbb.2003.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14643837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Cjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2003&pages=393-400&author=S.+M.+Turgeonauthor=S.+G.+Hoge&title=Prior+exposure+to+phencyclidine+decreases+voluntary+sucrose+consumption+and+operant+performance+for+food+reward"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Prior exposure to phencyclidine decreases voluntary sucrose consumption and operant performance for food reward</span></div><div class="casAuthors">Turgeon, Sarah M.; Hoge, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">393-400</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Prior exposure to the psychotomimetic drug phencyclidine (PCP) produces a no. of schizophrenia-like behaviors in animals.  The goal of the present study was to det. whether prior exposure to PCP produces decreased reward function, thereby modeling one aspect of neg. schizophrenic symptomatol.  To this aim, the consequences of prior exposure to PCP were assessed on two types of appetitive consumptive behavior.  In the first set of expts., the effects of PCP (15 mg/kg, 20 h before testing) on sucrose consumption were tested for three consecutive days under conditions of deprivation and nondeprivation.  In the deprivation condition, animals were water deprived for 4 h prior to injection of PCP or saline (SAL).  Twenty hours following the injection (24 h after the onset of water deprivation), animals were allowed access to either 5% sucrose or water for 30 min.  In the nondeprivation condition, 5% sucrose consumption was measured for 30 min, 20 h after PCP or SAL injection and water consumption was measured during the 23.5 h preceding sucrose consumption.  PCP decreased both sucrose and water consumption under deprivation conditions on the second and third day of testing but selectively decreased sucrose consumption under nondeprivation conditions on all three testing days.  LiCl (50 mg/kg, 20 h before testing) did not significantly reduce sucrose consumption in the nondeprivation paradigm, indicating that the effect of PCP was not due to conditioned taste aversion.  In the second expt., PCP (15 mg/kg, 20 h before testing) decreased operant performance when animals were switched from a continuous reinforcement schedule of food delivery to a fixed ratio (FR4) schedule.  Apomorphine (APO, 30 μg/kg, 30 min before testing), a pos. control, induced a similar performance deficit.  However, the PCP-induced deficit was not apparent until the third day of FR4 testing while the APO deficit was apparent on the first day.  The effects of PCP on sucrose consumption demonstrate PCP-induced decreases in reward function.  However, the delayed appearance of the PCP-induced decrease in operant performance suggests that these results may be better explained by a PCP-induced attentional deficit, also characteristic of schizophrenic psychopathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq38J7BfwyAsrVg90H21EOLACvtfcHk0lgJRGeoSaHMCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Cjs7Y%253D&md5=371b9fe6b3afd4ff835bb175e7a547b8</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2003.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2003.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DTurgeon%26aufirst%3DS.%2BM.%26aulast%3DHoge%26aufirst%3DS.%2BG.%26atitle%3DPrior%2520exposure%2520to%2520phencyclidine%2520decreases%2520voluntary%2520sucrose%2520consumption%2520and%2520operant%2520performance%2520for%2520food%2520reward%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D2003%26volume%3D76%26spage%3D393%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group">Turgeon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulick, V. C.</span><span> </span><span class="NLM_article-title">Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">524</span><span class="NLM_x">–</span> <span class="NLM_lpage">530</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pbb.2007.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17320157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Ojsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2007&pages=524-530&author=S.+M.+Turgeonauthor=V.+C.+Hulick&title=Differential+effects+of+acute+and+subchronic+clozapine+and+haloperidol+on+phencyclidine-induced+decreases+in+voluntary+sucrose+consumption+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats</span></div><div class="casAuthors">Turgeon, Sarah M.; Hulick, Virginia C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">524-530</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prior exposure to the psychotomimetic drug phencyclidine (PCP) decreases voluntary sucrose consumption in rats.  This may be indicative of reduced reward function, a phenomenon assocd. with neg. schizophrenic symptomatol.  Given that atypical antipsychotics have been shown to ameliorate neg. symptoms of schizophrenia more effectively than typical neuroleptics, this effect should be reversed by clozapine but not haloperidol.  PCP (15 mg/kg) or saline was administered 20 h prior to testing for voluntary sucrose consumption in non-deprived rats.  In the acute expts., rats were treated with clozapine (5 mg/kg), haloperidol (0.2 mg/kg), or vehicle 45 min prior to testing.  In the subchronic expts., rats were treated with clozapine (3 mg/kg, bid), haloperidol (0.5 mg/kg, bid), or vehicle for 10 days prior to PCP administration.  Acute clozapine exacerbated the PCP-induced decrease in sucrose consumption without altering water consumption.  Acute haloperidol produced an overall decrease in sucrose consumption in both PCP-pretreated and control groups.  Subchronic treatment with clozapine, but not haloperidol, reversed PCP-induced decreases in sucrose consumption.  The synergistic effect of acute clozapine and PCP may reflect a PCP-induced increase in the reward-reducing properties of CLZ, normally seen only at higher doses.  The observation that subchronic clozapine, but not haloperidol, reversed PCP-induced decreases in sucrose consumption supports the hypothesis that this effect of PCP represents a plausible animal model for neg. schizophrenic symptomatol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVG1qRQG2wBrVg90H21EOLACvtfcHk0ljVFqQpIX9uuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Ojsr0%253D&md5=820be135d6ec92fd70fb09f7c4430f07</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2007.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2007.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DTurgeon%26aufirst%3DS.%2BM.%26aulast%3DHulick%26aufirst%3DV.%2BC.%26atitle%3DDifferential%2520effects%2520of%2520acute%2520and%2520subchronic%2520clozapine%2520and%2520haloperidol%2520on%2520phencyclidine-induced%2520decreases%2520in%2520voluntary%2520sucrose%2520consumption%2520in%2520rats%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D2007%26volume%3D86%26spage%3D524%26epage%3D530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group">Gambill, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornetsky, C.</span><span> </span><span class="NLM_article-title">Effects of chronic d-amphetamine on social behavior of the rat: implications for an animal model of paranoid schizophrenia</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2FBF00426835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=826965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaE2sXjslKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1976&pages=215-223&author=J.+D.+Gambillauthor=C.+Kornetsky&title=Effects+of+chronic+d-amphetamine+on+social+behavior+of+the+rat%3A+implications+for+an+animal+model+of+paranoid+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of chronic d-amphetamine on social behavior of the rat:  implications for an animal model of paranoid schizophrenia</span></div><div class="casAuthors">Gambill, John D.; Kornetsky, Conan</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-23</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">Rats in a social colony were given increasing daily i.p. doses of d-amphetamine [51-64-9] ≤8 mg/kg.  Subordinant rats receiving d-amphetamine actively withdrew from social interactions by retreating to strategically defensible locations in the environment.  They remained hypervigilant of other rats and overreacted to their approaches by either fleeing or by defensively rearing and boxing.  On the other hand, when the dominant rat received the max. dose, it seemed totally oblivious to the other rats.  The responses to drug treatment in subordinant rats may provide a model for the social behavior of frightened paranoid schizophrenics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq70_O5gjA96rVg90H21EOLACvtfcHk0ljVFqQpIX9uuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXjslKmuw%253D%253D&md5=ab97ed498c7f33dfe724d5da8c84ebb5</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1007%2FBF00426835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00426835%26sid%3Dliteratum%253Aachs%26aulast%3DGambill%26aufirst%3DJ.%2BD.%26aulast%3DKornetsky%26aufirst%3DC.%26atitle%3DEffects%2520of%2520chronic%2520d-amphetamine%2520on%2520social%2520behavior%2520of%2520the%2520rat%253A%2520implications%2520for%2520an%2520animal%2520model%2520of%2520paranoid%2520schizophrenia%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D1976%26volume%3D50%26spage%3D215%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group">Knobbout, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellenbroek, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, A. R.</span><span> </span><span class="NLM_article-title">The influence of social structure on social isolation in amphetamine-treated Java monkeys (<i>Macaca fascicularis</i>)</span> <span class="citation_source-journal">Behav. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=417-429&author=D.+A.+Knobboutauthor=B.+A.+Ellenbroekauthor=A.+R.+Cools&title=The+influence+of+social+structure+on+social+isolation+in+amphetamine-treated+Java+monkeys+%28Macaca+fascicularis%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnobbout%26aufirst%3DD.%2BA.%26aulast%3DEllenbroek%26aufirst%3DB.%2BA.%26aulast%3DCools%26aufirst%3DA.%2BR.%26atitle%3DThe%2520influence%2520of%2520social%2520structure%2520on%2520social%2520isolation%2520in%2520amphetamine-treated%2520Java%2520monkeys%2520%2528Macaca%2520fascicularis%2529%26jtitle%3DBehav.%2520Pharmacol.%26date%3D1996%26volume%3D7%26spage%3D417%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group">Steinpreis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sokolowski, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papanikolaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salamone, J. D.</span><span> </span><span class="NLM_article-title">The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0091-3057%2894%2990162-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8208777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2cXitVyms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1994&pages=579-585&author=R.+E.+Steinpreisauthor=J.+D.+Sokolowskiauthor=A.+Papanikolaouauthor=J.+D.+Salamone&title=The+effects+of+haloperidol+and+clozapine+on+PCP-+and+amphetamine-induced+suppression+of+social+behavior+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of haloperidol and clozapine on PCP - and amphetamine-induced suppression of social behavior in the rat</span></div><div class="casAuthors">Steinpreis, Rhea E.; Sokolowski, Jonathan D.; Papanikolaou, Alex; Salamone, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">579-85</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    </div><div class="casAbstract">Previous work has shown that phencyclidine (PCP) and amphetamine decrease social behavior in rats.  The purpose of the present study was to det. the effects of the dopamine antagonists clozapine and haloperidol on PCP- and amphetamine-induced changes in rat social behavior.  An intruder paradigm was used, in which rats were injected with drug and placed into a stable home colony of three other rats.  Social behaviors were recorded for 30 min.  Both amphetamine (4.0 mg/kg) and PCP (4.0 mg/kg) substantially reduced social behavior.  Haloperidol and clozapine did not produce a general reversal of the effects of amphetamine or PCP on the total no. of social behaviors.  Nevertheless, 0.025 mg/kg haloperidol did reverse the effects of PCP and amphetamine on some of the specific social behaviors obsd. (side threats, mounting, crawling under).  Clozapine had no effect on reversing the actions of amphetamine on social behavior, but 2.0 mg/kg clozapine did reverse the effect of PCP on side threats and mounting.  These results indicate that DA antagonists do not restore normal social behavior in animals treated with PCP or amphetamine, but can reverse some of the effects of PCP or amphetamine on specific social behaviors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXb7eVBx_btLVg90H21EOLACvtfcHk0ljVFqQpIX9uuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitVyms7s%253D&md5=737454ca7d32fa30cbfdfc85eafc144c</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1016%2F0091-3057%2894%2990162-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-3057%252894%252990162-7%26sid%3Dliteratum%253Aachs%26aulast%3DSteinpreis%26aufirst%3DR.%2BE.%26aulast%3DSokolowski%26aufirst%3DJ.%2BD.%26aulast%3DPapanikolaou%26aufirst%3DA.%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520effects%2520of%2520haloperidol%2520and%2520clozapine%2520on%2520PCP-%2520and%2520amphetamine-induced%2520suppression%2520of%2520social%2520behavior%2520in%2520the%2520rat%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D1994%26volume%3D47%26spage%3D579%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group">Schlemmer, R. F.,  Jr.; Davis, J. M.</span><span> </span><span class="NLM_article-title">A Comparison of Three Psychotomimetic-Induced Models of Psychosis in Nonhuman Primate Social Colonies</span>. In  <span class="citation_source-book">Ethopharmacology: Primate Models of Neuropsychiatric Disorders</span>; <span class="NLM_contrib-group">Miczek, K. A.</span>, Ed.; <span class="NLM_publisher-name">Alan R. Liss</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1983</span><span class="NLM_x">; </span> <span class="NLM_fpage">33</span>− <span class="NLM_lpage">78</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1983&pages=33-78&author=R.+F.+Schlemmer&author=J.+M.+Davisauthor=K.+A.+Miczek&title=Ethopharmacology%3A+Primate+Models+of+Neuropsychiatric+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSchlemmer%26aufirst%3DR.%2BF.%26atitle%3DA%2520Comparison%2520of%2520Three%2520Psychotomimetic-Induced%2520Models%2520of%2520Psychosis%2520in%2520Nonhuman%2520Primate%2520Social%2520Colonies%26btitle%3DEthopharmacology%253A%2520Primate%2520Models%2520of%2520Neuropsychiatric%2520Disorders%26aulast%3DMiczek%26aufirst%3DK.%2BA.%26pub%3DAlan%2520R.%2520Liss%26date%3D1983%26spage%3D33%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span><span class="NLM_contrib-group">Goudie, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumnall, H. R.</span><span> </span><span class="NLM_article-title">Cyproheptadine resembles clozapine <i>in vivo</i> following both acute and chronic administration in rats</span> <span class="citation_source-journal">J. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1177%2F0269881107067076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17329298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Wksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=179-190&author=A.+J.+Goudieauthor=G.+D.+Cooperauthor=J.+C.+Coleauthor=H.+R.+Sumnall&title=Cyproheptadine+resembles+clozapine+in+vivo+following+both+acute+and+chronic+administration+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats</span></div><div class="casAuthors">Goudie, Andrew J.; Cooper, Gillian D.; Cole, Jon C.; Sumnall, Harry R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-190</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Cyproheptadine is a cheap, widely available anti-allergy drug with a broad receptor binding profile which resembles that of clozapine.  In rats discriminating clozapine from vehicle cyproheptadine mimicked clozapine very closely.  Acutely it induced full generalization in the absence of response suppression, as obsd. with clozapine.  Chronic administration of clozapine and cyproheptadine induced tolerance and cross-tolerance resp. to the clozapine stimulus.  This was characterized by circa 3.5-fold parallel shifts to the right in the clozapine generalization curves.  Such tolerance and cross-tolerance was spontaneously reversible, suggesting that it was pharmacodynamic, and that clozapine and cyproheptadine induce similar neuroadaptations when administered chronically.  Administration of chlordiazepoxide at a very high dose induced no cross-tolerance to the clozapine stimulus showing the pharmacol. specificity of tolerance.  The clozapine stimulus is a compd. cue involving actions at various receptors, and various clozapine-like antipsychotic (APD) drugs generalize fully to it.  These data demonstrate that in vivo cyproheptadine resembles clozapine both acutely and chronically.  The findings, in conjunction with other actions of cyproheptadine - induction of wt. gain, alleviation of clozapine withdrawal, anxiolytic actions, alleviation of 'typical' APD-induced motoric side effects, and some preliminary clin. findings - suggest that further study of cyproheptadine in conjunction with a 'typical' APD for the possible treatment of schizophrenia is merited at both pre-clin. and clin. levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokDPn1ZPQtELVg90H21EOLACvtfcHk0lgWAfZoZzjoag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Wksbw%253D&md5=f20cfb940640814b477f55a3f6d84345</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1177%2F0269881107067076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881107067076%26sid%3Dliteratum%253Aachs%26aulast%3DGoudie%26aufirst%3DA.%2BJ.%26aulast%3DCooper%26aufirst%3DG.%2BD.%26aulast%3DCole%26aufirst%3DJ.%2BC.%26aulast%3DSumnall%26aufirst%3DH.%2BR.%26atitle%3DCyproheptadine%2520resembles%2520clozapine%2520in%2520vivo%2520following%2520both%2520acute%2520and%2520chronic%2520administration%2520in%2520rats%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2007%26volume%3D21%26spage%3D179%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span><span class="NLM_contrib-group">Kikuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uwahodo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirose, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oshiro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, S.</span><span> </span><span class="NLM_article-title">7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1<i>H</i>)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=7616416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2MXntVWlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1995&pages=329-336&author=T.+Kikuchiauthor=K.+Tottoriauthor=Y.+Uwahodoauthor=T.+Hiroseauthor=T.+Miwaauthor=Y.+Oshiroauthor=S.+Morita&title=7-%284-%5B4-%282%2C3-Dichlorophenyl%29-1-piperazinyl%5Dbutyloxy%29-3%2C4-dihydro-2%281H%29-quinolinone+%28OPC-14597%29%2C+a+new+putative+antipsychotic+drug+with+both+presynaptic+dopamine+autoreceptor+agonistic+activity+and+postsynaptic+D2+receptor+antagonistic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">7-{4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity</span></div><div class="casAuthors">Kikuchi, Tetsuro; Tottori, Katsura; Uwahodo, Yasufumi; Hirose, Tsuyoshi; Miwa, Takashi; Oshiro, Yasuo; Morita, Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">329-36</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The effects of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a deriv. of the dopamine (DA) autoreceptor agonist 7-{3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy}-2(1H)-quinolinone (OPC-4392), on DA receptors were biochem. and behaviorally studied and compared with those of OPC-4392.  Both OPC-14597 and OPC-4392 inhibited reserpine- and gamma-butyrolactone (GBL)-induced increase in tyrosine hydroxylase activity in the mouse and rat brain.  The effects of OPC-14597 were comparable to those of OPC04392 and were completely antagonized by haloperidol.  OPC-14597, unlike apomorphine, did not evoke postsynaptic DA receptor-stimulating behavioral signs such as hyperlocomotion in the reserpinized mice and contralateral rotation in rats with unilateral striatal 6-hydroxydopamine lesions.  Both OPC-14597 and OPC-4392 inhibited such apomorphine-induced postsynaptic behavioral changes as stereotypy and hyperlocomotion in mice and rats and rotation in rats with unilateral striatal kainic acid lesions.  The anti-apomorphine effects of OPC-14597 were about 30 to 140 times greater than those of OPC-4392 and were obsd. at doses that inhibit the increases in tyrosine hydroxylase activity.  The affinities of OPC-14597 for 3H-spiperone-labeled D2 receptors in the rat frontal cortex, limbic forebrain and striatum were higher than those of OPC-4392.  These results suggest that OPC-14597 is a unique antipsychotic drug candidate, being a DA autoreceptor agonist that has a stronger postsynaptic D2 receptor antagonistic activity than that of OPC-4392.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9cUwebqVxn7Vg90H21EOLACvtfcHk0lgWAfZoZzjoag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntVWlt7c%253D&md5=37354f14ec4e30898ffe78848252bebc</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKikuchi%26aufirst%3DT.%26aulast%3DTottori%26aufirst%3DK.%26aulast%3DUwahodo%26aufirst%3DY.%26aulast%3DHirose%26aufirst%3DT.%26aulast%3DMiwa%26aufirst%3DT.%26aulast%3DOshiro%26aufirst%3DY.%26aulast%3DMorita%26aufirst%3DS.%26atitle%3D7-%25284-%255B4-%25282%252C3-Dichlorophenyl%2529-1-piperazinyl%255Dbutyloxy%2529-3%252C4-dihydro-2%25281H%2529-quinolinone%2520%2528OPC-14597%2529%252C%2520a%2520new%2520putative%2520antipsychotic%2520drug%2520with%2520both%2520presynaptic%2520dopamine%2520autoreceptor%2520agonistic%2520activity%2520and%2520postsynaptic%2520D2%2520receptor%2520antagonistic%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D274%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group">Hoyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boddeke, H. W.</span><span> </span><span class="NLM_article-title">Partial agonists, full agonists, antagonists: dilemmas of definition</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1993&pages=270-275&author=D.+Hoyerauthor=H.+W.+Boddeke&title=Partial+agonists%2C+full+agonists%2C+antagonists%3A+dilemmas+of+definition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoyer%26aufirst%3DD.%26aulast%3DBoddeke%26aufirst%3DH.%2BW.%26atitle%3DPartial%2520agonists%252C%2520full%2520agonists%252C%2520antagonists%253A%2520dilemmas%2520of%2520definition%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1993%26volume%3D14%26spage%3D270%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group">Meller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, M.</span><span> </span><span class="NLM_article-title">Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0014-2999%2888%2990413-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=2907486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL1cXmt1ehs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1988&pages=151-154&author=E.+Mellerauthor=A.+Enzauthor=M.+Goldstein&title=Absence+of+receptor+reserve+at+striatal+dopamine+receptors+regulating+cholinergic+neuronal+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity</span></div><div class="casAuthors">Meller, Emanuel; Enz, Albert; Goldstein, Menek</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">151-4</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">N-Propylnorapomorphine (NPA) dose dependently increased rat striatal acetylcholine levels [50% ED (ED50) = 18 μg/kg].  After irreversible dopamine (DA) receptor inactivation with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, neither the ED50 nor the slope of the dose-response curve for NPA was altered, whereas the maximal response was reduced to 56% of control.  Anal. of the results yielded a linear relationship between receptor occupancy and response (i.e. no receptor reserve).  In contrast, DA autoreceptors display a large receptor reserve for NPA.  Evidently, a differential receptor reserve at pre- vs. postsynaptic DA receptors in rat striatum accounts for the autoreceptor selectivity of DA agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQEoUNjhfV-rVg90H21EOLACvtfcHk0lgWAfZoZzjoag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmt1ehs78%253D&md5=22322b968d9eb9e86a4f2c96c699402e</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2888%2990413-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252888%252990413-X%26sid%3Dliteratum%253Aachs%26aulast%3DMeller%26aufirst%3DE.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DGoldstein%26aufirst%3DM.%26atitle%3DAbsence%2520of%2520receptor%2520reserve%2520at%2520striatal%2520dopamine%2520receptors%2520regulating%2520cholinergic%2520neuronal%2520activity%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1988%26volume%3D155%26spage%3D151%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group">Tamminga, C. A.</span><span> </span><span class="NLM_article-title">Partial dopamine agonists in the treatment of psychosis</span> <span class="citation_source-journal">J. Neural Transm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=411-420&author=C.+A.+Tamminga&title=Partial+dopamine+agonists+in+the+treatment+of+psychosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamminga%26aufirst%3DC.%2BA.%26atitle%3DPartial%2520dopamine%2520agonists%2520in%2520the%2520treatment%2520of%2520psychosis%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2002%26volume%3D109%26spage%3D411%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group">Benkert, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Siecheneder, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, H.</span><span> </span><span class="NLM_article-title">Dopamine agonists in schizophrenia: a review</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2F0924-977X%2895%2900022-H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8775758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2MXptlCms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=43-53&issue=Suppl.&author=O.+Benkertauthor=F.+Muller-Siechenederauthor=H.+Wetzel&title=Dopamine+agonists+in+schizophrenia%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonists in schizophrenia: a review</span></div><div class="casAuthors">Benkert, O.; Mueller-Siecheneder, F.; Wetzel, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">Suppl.</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with many refs.  Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochem. abnormality alone, indirect pharmacol. evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. pos. symptomatol.  Synthesis and release of dopamine as well as firing rates of dopaminergic neurons are controlled by stimulation of autoreceptors via a neg. feedback regulation.  Investigations on therapeutic effects of autoreceptor-nonselective dopamine agonists in schizophrenia have yielded inconsistent results.  Dopamine autoreceptor agonists like pramipexole, roxindole, talipexole and OPC-4392 as well as partial agonists like terguride and SDZ HDC 912 have been tested in pos. schizophrenic symptomatol. to reduce the postulated excess of central dopaminergic activity.  However, administration of autoreceptor-'selective' agonists did not result in a significant improvement of pos. symptoms.  In predominantly neg. schizophrenic symptomatol., a dopamine deficit rather than an excess has been hypothesized.  Consequently, a nonselective dopamine agonistic action could be effective in some neg. symptoms.  Current evidence from several open and one placebo-controlled clin. trial suggests that some dopamine autoreceptor agonists like pramipexole, roxindole and talipexole may produce a mild improvement of symptoms like affective flattening, depressed mood, alogia and avolition.  Nevertheless, these findings do not yet allow a reliable judgement and remain to be clarified by further double-blind placebo-controlled studies over a sufficient treatment duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpZegHtiVmUrVg90H21EOLACvtfcHk0ljNRjJ_Ql32vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptlCms7g%253D&md5=7049529e49afc3344ef8c826d222b0c6</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=10.1016%2F0924-977X%2895%2900022-H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0924-977X%252895%252900022-H%26sid%3Dliteratum%253Aachs%26aulast%3DBenkert%26aufirst%3DO.%26aulast%3DMuller-Siecheneder%26aufirst%3DF.%26aulast%3DWetzel%26aufirst%3DH.%26atitle%3DDopamine%2520agonists%2520in%2520schizophrenia%253A%2520a%2520review%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D1995%26volume%3D5%26issue%3DSuppl%26spage%3D43%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group">Hirose, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span> </span><span class="NLM_article-title">Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist</span> <span class="citation_source-journal">J. Med. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=284-290&issue=Suppl.&author=T.+Hiroseauthor=T.+Kikuchi&title=Aripiprazole%2C+a+novel+antipsychotic+agent%3A+dopamine+D2+receptor+partial+agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirose%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DT.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520antipsychotic%2520agent%253A%2520dopamine%2520D2%2520receptor%2520partial%2520agonist%26jtitle%3DJ.%2520Med.%2520Invest.%26date%3D2005%26volume%3D52%26issue%3DSuppl%26spage%3D284%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group">Shapiro, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiodo, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R.</span><span> </span><span class="NLM_article-title">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1400</span><span class="NLM_x">–</span> <span class="NLM_lpage">1411</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1400-1411&author=D.+A.+Shapiroauthor=S.+Renockauthor=E.+Arringtonauthor=L.+A.+Chiodoauthor=L.+X.+Liuauthor=D.+R.+Sibleyauthor=B.+L.+Rothauthor=R.+Mailman&title=Aripiprazole%2C+a+novel+atypical+antipsychotic+drug+with+a+unique+and+robust+pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DD.%2BA.%26aulast%3DRenock%26aufirst%3DS.%26aulast%3DArrington%26aufirst%3DE.%26aulast%3DChiodo%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DL.%2BX.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMailman%26aufirst%3DR.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520atypical%2520antipsychotic%2520drug%2520with%2520a%2520unique%2520and%2520robust%2520pharmacology%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1400%26epage%3D1411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reavill, C.</span><span> </span><span class="NLM_article-title">Aripiprazole acts as a selective dopamine D2 receptor partial agonist</span> <span class="citation_source-journal">Expert. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1517%2F13543784.16.6.771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17501690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=771-775&author=M.+Woodauthor=C.+Reavill&title=Aripiprazole+acts+as+a+selective+dopamine+D2+receptor+partial+agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole acts as a selective dopamine D2 receptor partial agonist</span></div><div class="casAuthors">Wood, Martyn; Reavill, Charlie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">771-775</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacol. profile.  It has been claimed that partial agonism of the dopamine D2 and 5-HT1A receptors and antagonism of the 5-HT2 receptor contribute to the clin. profile of aripiprazole, a so-called dopamine- and 5-HT stabilizer.  However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole.  This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D2 receptor and does not affect 5-HT receptors at therapeutic doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWgIj2R8RUsLVg90H21EOLACvtfcHk0ljNRjJ_Ql32vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOisrw%253D&md5=3fb0254fb1e67e4669e397ad3cbbc977</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.6.771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.6.771%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%26aulast%3DReavill%26aufirst%3DC.%26atitle%3DAripiprazole%2520acts%2520as%2520a%2520selective%2520dopamine%2520D2%2520receptor%2520partial%2520agonist%26jtitle%3DExpert.%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D771%26epage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group">Keck, P. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, S. L.</span><span> </span><span class="NLM_article-title">Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic</span> <span class="citation_source-journal">Expert. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=655-662&author=P.+E.+Keckauthor=S.+L.+McElroy&title=Aripiprazole%3A+a+partial+dopamine+D2+receptor+agonist+antipsychotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DP.%2BE.%26aulast%3DMcElroy%26aufirst%3DS.%2BL.%26atitle%3DAripiprazole%253A%2520a%2520partial%2520dopamine%2520D2%2520receptor%2520agonist%2520antipsychotic%26jtitle%3DExpert.%2520Opin.%2520Invest.%2520Drugs%26date%3D2003%26volume%3D12%26spage%3D655%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group">McCreary, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashby, C. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinders, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselink, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herremans, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Stuivenberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feenstra, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT<sub>1A</sub> receptor agonist potential antipsychotic drug</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=78-94&author=A.+C.+McCrearyauthor=J.+C.+Glennonauthor=C.+R.+Ashbyauthor=H.+Y.+Meltzerauthor=Z.+Liauthor=J.+H.+Reindersauthor=M.+B.+Hesselinkauthor=S.+K.+Longauthor=A.+H.+Herremansauthor=H.+van+Stuivenbergauthor=R.+W.+Feenstraauthor=C.+G.+Kruse&title=SLV313+%281-%282%2C3-dihydro-benzo%5B1%2C4%5Ddioxin-5-yl%29-4-+%5B5-%284-fluoro-phenyl%29-pyridin-3-ylmethyl%5D-piperazine+monohydrochloride%29%3A+a+novel+dopamine+D2+receptor+antagonist+and+5-HT1A+receptor+agonist+potential+antipsychotic+drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DGlennon%26aufirst%3DJ.%2BC.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DReinders%26aufirst%3DJ.%2BH.%26aulast%3DHesselink%26aufirst%3DM.%2BB.%26aulast%3DLong%26aufirst%3DS.%2BK.%26aulast%3DHerremans%26aufirst%3DA.%2BH.%26aulast%3Dvan%2BStuivenberg%26aufirst%3DH.%26aulast%3DFeenstra%26aufirst%3DR.%2BW.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DSLV313%2520%25281-%25282%252C3-dihydro-benzo%255B1%252C4%255Ddioxin-5-yl%2529-4-%2520%255B5-%25284-fluoro-phenyl%2529-pyridin-3-ylmethyl%255D-piperazine%2520monohydrochloride%2529%253A%2520a%2520novel%2520dopamine%2520D2%2520receptor%2520antagonist%2520and%25205-HT1A%2520receptor%2520agonist%2520potential%2520antipsychotic%2520drug%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D78%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbato, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heisternerg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira, N. A.</span><span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia</span> <span class="citation_source-journal">Schizophr. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=446&author=H.+Y.+Meltzerauthor=L.+M.+Barbatoauthor=J.+Heisternergauthor=P.+P.+Yeungauthor=N.+A.+Shapira&title=A+randomized%2C+double-blind%2C+placebo-controlled+efficacy+and+safety+study+of+bifeprunox+as+treatment+for+patients+with+acutely+exacerbated+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DBarbato%26aufirst%3DL.%2BM.%26aulast%3DHeisternerg%26aufirst%3DJ.%26aulast%3DYeung%26aufirst%3DP.%2BP.%26aulast%3DShapira%26aufirst%3DN.%2BA.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520efficacy%2520and%2520safety%2520study%2520of%2520bifeprunox%2520as%2520treatment%2520for%2520patients%2520with%2520acutely%2520exacerbated%2520schizophrenia%26jtitle%3DSchizophr.%2520Bull.%26date%3D2007%26volume%3D33%26spage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cussac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depoortere, R.</span><span> </span><span class="NLM_article-title">Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17659474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1Knsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=539-554&author=A.+Newman-Tancrediauthor=D.+Cussacauthor=R.+Depoortere&title=Neuropharmacological+profile+of+bifeprunox%3A+merits+and+limitations+in+comparison+with+other+third-generation+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics</span></div><div class="casAuthors">Newman-Tancredi, Adrian; Cussac, Didier; Depoortere, Ronan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (Thomson Scientific)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">539-554</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is characterized by a range of pos. and neg. symptoms, and cognitive deficits.  While pos. symptoms respond to current antipsychotic agents, neg. symptoms and cognitive deficits are often resistant to pharmacopea.  Thus research is now focused on developing third-generation antipsychotics that combine antagonism or partial agonism at dopamine D2-like receptors with agonism at serotonin 5-HT1A receptors.  Such an assocn. is anticipated to provide therapeutic benefits against a broader range of schizophrenia symptoms.  Bifeprunox is one such third-generation antipsychotic agent which acts as a partial agonist at D2-like receptors and is an efficacious agonist at 5-HT1A receptors, with little interaction at 5-HT2A/2C, muscarinic or histaminergic H1 receptors.  This review summarizes the pharmacol. profiles of the current antipsychotic agents and describes the rationale behind the development of third-generation antipsychotics.  It also evaluates current data concerning bifeprunox in comparison with currently available antipsychotics, as well as those that are still under clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojeH0wGFNm5bVg90H21EOLACvtfcHk0lhl5JnJIT74CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1Knsrc%253D&md5=95f4f0b129c6127aa70477de9132db3a</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DDepoortere%26aufirst%3DR.%26atitle%3DNeuropharmacological%2520profile%2520of%2520bifeprunox%253A%2520merits%2520and%2520limitations%2520in%2520comparison%2520with%2520other%2520third-generation%2520antipsychotics%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D8%26spage%3D539%26epage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref276"><div class="reference"><strong class="refLabel"><a href="#ref276" class="rightTabRefNumLink">276</a></strong><div class="NLM_citation" id="rightTab-cit276"><span><span class="NLM_contrib-group">Wadenberg, M.-L. G.</span><span> </span><span class="NLM_article-title">Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT<sub>1A</sub> receptors</span> <span class="citation_source-journal">Future Neurol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2217%2F14796708.2.2.153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2itrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=153-165&author=M.-L.+G.+Wadenberg&title=Bifeprunox%3A+a+novel+antipsychotic+agent+with+partial+agonist+properties+at+dopamine+D2+and+serotonin+5-HT1A+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors</span></div><div class="casAuthors">Wadenberg, Marie-Louise G.</div><div class="citationInfo"><span class="NLM_cas:title">Future Neurology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-165</span>CODEN:
                <span class="NLM_cas:coden">FNUEAM</span>;
        ISSN:<span class="NLM_cas:issn">1479-6708</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Most second-generation, atypical, dopamine (DA) D2/5-HT2 blocking antipsychotics still induce extrapyramidal side effects (EPS) in higher doses.  Wt. gain and metabolic disturbances are also a problem, and neg. and cognitive symptoms have not been sufficiently addressed.  The current brain DA mesolimbic hyperactive/mesocortical hypoactive hypothesis of schizophrenia suggests that DA D2/5-HT1A receptor partial agonist properties may be more efficacious with less side effects.  DA D2 receptor partial agonists may stabilize a hyperactive/hypoactive DA condition.  Addnl. 5-HT1A stimulation may enhance therapeutic efficacy and also improve EPS liability profile.  In clin. trials in schizophrenic patients, the novel DA D2/5-HT1A partial agonist bifeprunox indeed demonstrates therapeutic efficacy, a safe EPS profile and appears beneficial regarding wt. gain, prolactin, blood lipid and glucose levels and cardiac rhythm.  The data on bifeprunox are promising and suggest that combined DA D2/5-HT1A partial agonism may well be important properties for future-generation antipsychotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr-UMb2Am2ErVg90H21EOLACvtfcHk0lhl5JnJIT74CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2itrw%253D&md5=4b9df0c72aeeb3cdc4a7e7b17ba55410</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.2217%2F14796708.2.2.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F14796708.2.2.153%26sid%3Dliteratum%253Aachs%26aulast%3DWadenberg%26aufirst%3DM.-L.%2BG.%26atitle%3DBifeprunox%253A%2520a%2520novel%2520antipsychotic%2520agent%2520with%2520partial%2520agonist%2520properties%2520at%2520dopamine%2520D2%2520and%2520serotonin%25205-HT1A%2520receptors%26jtitle%3DFuture%2520Neurol%26date%3D2007%26volume%3D2%26spage%3D153%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref277"><div class="reference"><strong class="refLabel"><a href="#ref277" class="rightTabRefNumLink">277</a></strong><div class="NLM_citation" id="rightTab-cit277"><span><span class="NLM_contrib-group">Assie, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravailhe, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucillon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">Contrasting contribution of 5-hydroxytryptamine<sub>1A</sub> receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.105.087163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15987834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=265-272&author=M.+B.+Assieauthor=V.+Ravailheauthor=V.+Faucillonauthor=A.+Newman-Tancredi&title=Contrasting+contribution+of+5-hydroxytryptamine1A+receptor+activation+to+neurochemical+profile+of+novel+antipsychotics%3A+frontocortical+dopamine+and+hippocampal+serotonin+release+in+rat+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: Frontocortical dopamine and hippocampal serotonin release in rat brain</span></div><div class="casAuthors">Assie, Marie-Bernadette; Ravailhe, Veronique; Faucillon, Valerie; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-272</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several novel antipsychotics, such as aripiprazole, bifeprunox, SSR181507 [(3-exo)-8-benzoyl-N-(((2S)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl)methyl)-8-azabicyclo(3.2.1)octane-3-methanamine], and SLV313 [1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-piperazine], activate serotonin 5-hydroxytryptamine (5-HT)1A receptors.  Such activity is assocd. with enhanced treatment of neg. symptoms and cognitive deficits, which may be mediated by modulation of cerebral dopamine and serotonin levels.  We employed microdialysis coupled to high pressure liq. chromatog. with electrochem. detection to examine 5-HT1A receptor activation in the modulation of extracellular dopamine in medial prefrontal cortex and serotonin in hippocampus of freely moving rats.  The above compds. were compared with drugs that have less interaction with 5-HT1A receptors (clozapine, nemonapride, ziprasidone, olanzapine, risperidone, and haloperidol).  Hippocampal 5-HT was decreased by bifeprunox, SSR181507, SLV313, sarizotan, and nemonapride, effects similar to those seen with the 5-HT1A agonist, (+)-8-hydroxy-2-(di-n-propylamino)tetralin [(+)8-OH-DPAT], consistent with activation of 5-HT1A autoreceptors.  These decreases were reversed by the selective 5-HT1A antagonist, WAY100635 [N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide].  In contrast, haloperidol, risperidone, clozapine, olanzapine, ziprasidone, and aripiprazole did not significantly modify hippocampal serotonin levels.  In medial prefrontal cortex, dopamine levels were increased by SSR181507, SLV313, sarizotan, and (+)8-OH-DPAT.  These effects were reversed by WAY100635, indicating mediation by 5-HT1A receptors.  In contrast, the increases in dopamine levels induced by clozapine, risperidone, olanzapine, and ziprasidone were not blocked by WAY100635, consistent with predominant influence of other mechanisms in the actions of these drugs.  Haloperidol, nemonapride, and the D2 partial agonists, aripiprazole and bifeprunox, did not significantly alter dopamine release.  Taken together, these data demonstrate the diverse contribution of 5-HT1A receptor activation to the profile of antipsychotics and suggest that novel drugs selectively targeting D2 and 5-HT1A receptors may present distinctive therapeutic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBt7wOWcBBz7Vg90H21EOLACvtfcHk0lhl5JnJIT74CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7rN&md5=02dd395718229c99a82c4e3db88dcb82</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.087163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.087163%26sid%3Dliteratum%253Aachs%26aulast%3DAssie%26aufirst%3DM.%2BB.%26aulast%3DRavailhe%26aufirst%3DV.%26aulast%3DFaucillon%26aufirst%3DV.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DContrasting%2520contribution%2520of%25205-hydroxytryptamine1A%2520receptor%2520activation%2520to%2520neurochemical%2520profile%2520of%2520novel%2520antipsychotics%253A%2520frontocortical%2520dopamine%2520and%2520hippocampal%2520serotonin%2520release%2520in%2520rat%2520brain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D265%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref278"><div class="reference"><strong class="refLabel"><a href="#ref278" class="rightTabRefNumLink">278</a></strong><div class="NLM_citation" id="rightTab-cit278"><span><span class="NLM_contrib-group">Cosi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carilla-Durand, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assie, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ormiere, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maraval, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leduc, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">535</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ejphar.2006.01.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16554049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFGmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2006&pages=135-144&author=C.+Cosiauthor=E.+Carilla-Durandauthor=M.+B.+Assieauthor=A.+M.+Ormiereauthor=M.+Maravalauthor=N.+Leducauthor=A.+Newman-Tancredi&title=Partial+agonist+properties+of+the+antipsychotics+SSR181507%2C+aripiprazole+and+bifeprunox+at+dopamine+D2+receptors%3A+G+protein+activation+and+prolactin+release"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release</span></div><div class="casAuthors">Cosi, Cristina; Carilla-Durand, Elisabeth; Assie, Marie Bernadette; Ormiere, Anne Marie; Maraval, Mireille; Leduc, Nathalie; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">135-144</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dopamine D2 receptor antagonists induce hyperprolactinemia depending on the extent of D2 receptor blockade.  We compared the effects of the new antipsychotic agents SSR181507, bifeprunox, and SLV313 with those of aripiprazole, clozapine, and haloperidol, on functional measures of dopamine D2 receptor activity in vitro and in vivo: [35S]-GTPγS binding to membranes from Sf9 insect cells expressing human dopamine D2 Long (hD2 L) receptors, and serum prolactin levels in the rat.  All compds. antagonized apomorphine-induced G protein activation at dopamine hD2 L receptors.  Antagonist potencies of aripiprazole, bifeprunox and SLV313 were similar to haloperidol (pK b = 9.12), whereas SSR181507 (8.16) and clozapine (7.35) were less potent.  Haloperidol, SLV313 and clozapine were silent antagonists but SSR181507, bifeprunox and aripiprazole stimulated [35S]-GTPγS binding by 17.5%, 26.3% and 25.6%, resp., relative to 100 μM apomorphine (Emax = 100%). pEC50s were: SSR181507, 8.08; bifeprunox, 8.97; aripiprazole, 8.56.  These effects were antagonized by raclopride.  Following oral administration in vivo, the drugs increased prolactin release to different extents.  SLV313 and haloperidol potently (ED50 0.12 and 0.22 mg/kg p.o., resp.) stimulated prolactin release up to 86 and 83 ng/mL.  Aripiprazole potently (ED50 0.66 mg/kg p.o.) but partially (32 ng/mL) induced prolactin release.  SSR181507 (ED50 4.9 mg/kg p.o.) also partially (23 ng/mL) enhanced prolactin release.  Bifeprunox only weakly increased prolactin at high doses (13 ng/mL at 40 mg/kg) and clozapine only affected prolactin at the highest dose tested (41 ng/mL at 40 mg/kg).  Prolactin levels of the corresponding vehicle-treated animals were < 4.3 ng/mL.  These data show that (1) SSR181507, aripiprazole and bifeprunox, but not SLV313, are partial agonists at dopamine hD2 L receptors in vitro; (2) SSR181507, bifeprunox and aripiprazole exhibit reduced prolactin release in vivo compared with drugs that are neutral antagonists at dopamine D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrtKly85ekeLVg90H21EOLACvtfcHk0ljq5gZxqSURJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFGmu74%253D&md5=f3d0bc9e55df9cfd8b48338824545c22</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.01.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.01.051%26sid%3Dliteratum%253Aachs%26aulast%3DCosi%26aufirst%3DC.%26aulast%3DCarilla-Durand%26aufirst%3DE.%26aulast%3DAssie%26aufirst%3DM.%2BB.%26aulast%3DOrmiere%26aufirst%3DA.%2BM.%26aulast%3DMaraval%26aufirst%3DM.%26aulast%3DLeduc%26aufirst%3DN.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DPartial%2520agonist%2520properties%2520of%2520the%2520antipsychotics%2520SSR181507%252C%2520aripiprazole%2520and%2520bifeprunox%2520at%2520dopamine%2520D2%2520receptors%253A%2520G%2520protein%2520activation%2520and%2520prolactin%2520release%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D535%26spage%3D135%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref279"><div class="reference"><strong class="refLabel"><a href="#ref279" class="rightTabRefNumLink">279</a></strong><div class="NLM_citation" id="rightTab-cit279"><span><span class="NLM_contrib-group">Depoortere, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrault, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergis, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decobert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simiand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scatton, B.</span><span> </span><span class="NLM_article-title">SSR181507, a dopamine D2 receptor antagonist and 5-HT<sub>1A</sub> receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">–</span> <span class="NLM_lpage">1902</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1889-1902&author=R.+Depoortereauthor=D.+Boulayauthor=G.+Perraultauthor=O.+Bergisauthor=M.+Decobertauthor=D.+Franconauthor=M.+Jungauthor=J.+Simiandauthor=P.+Soubrieauthor=B.+Scatton&title=SSR181507%2C+a+dopamine+D2+receptor+antagonist+and+5-HT1A+receptor+agonist.+II%3A+Behavioral+profile+predictive+of+an+atypical+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDepoortere%26aufirst%3DR.%26aulast%3DBoulay%26aufirst%3DD.%26aulast%3DPerrault%26aufirst%3DG.%26aulast%3DBergis%26aufirst%3DO.%26aulast%3DDecobert%26aufirst%3DM.%26aulast%3DFrancon%26aufirst%3DD.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DSimiand%26aufirst%3DJ.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DScatton%26aufirst%3DB.%26atitle%3DSSR181507%252C%2520a%2520dopamine%2520D2%2520receptor%2520antagonist%2520and%25205-HT1A%2520receptor%2520agonist.%2520II%253A%2520Behavioral%2520profile%2520predictive%2520of%2520an%2520atypical%2520antipsychotic%2520activity%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1889%26epage%3D1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref280"><div class="reference"><strong class="refLabel"><a href="#ref280" class="rightTabRefNumLink">280</a></strong><div class="NLM_citation" id="rightTab-cit280"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popadak, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">H<sub>1</sub>-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=519-526&author=W.+K.+Kroezeauthor=S.+J.+Hufeisenauthor=B.+A.+Popadakauthor=S.+M.+Renockauthor=S.+Steinbergauthor=P.+Ernsbergerauthor=K.+Jayathilakeauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=H1-histamine+receptor+affinity+predicts+short-term+weight+gain+for+typical+and+atypical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DPopadak%26aufirst%3DB.%2BA.%26aulast%3DRenock%26aufirst%3DS.%2BM.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DH1-histamine%2520receptor%2520affinity%2520predicts%2520short-term%2520weight%2520gain%2520for%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D519%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref281"><div class="reference"><strong class="refLabel"><a href="#ref281" class="rightTabRefNumLink">281</a></strong><div class="NLM_citation" id="rightTab-cit281"><span><span class="NLM_contrib-group">Glassman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigger, J. T.,  Jr</span><span> </span><span class="NLM_article-title">Antipsychotic drugs: prolonged QTc interval, <i>torsade de pointes</i>, and sudden death</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">1774</span><span class="NLM_x">–</span> <span class="NLM_lpage">1782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1176%2Fappi.ajp.158.11.1774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11691681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3MnktVentQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=1774-1782&author=A.+H.+Glassmanauthor=J.+T.+Bigger&title=Antipsychotic+drugs%3A+prolonged+QTc+interval%2C+torsade+de+pointes%2C+and+sudden+death"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death</span></div><div class="casAuthors">Glassman A H; Bigger J T Jr</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1774-82</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The authors review the mechanisms and establish the risk of torsade de pointes and sudden death with antipsychotic drugs.  METHOD:  They present a review of original concepts, the distinction between familial and drug-induced cases of torsade de pointes, and the recognition of the role of noncardiac drugs in torsade de pointes and sudden death.  They review the evidence linking QTc interval prolongation, potassium channels, and torsade de pointes from both the long QT syndrome and drugs.  They examine the risk for torsade de pointes from antipsychotic drugs and estimate the frequency of sudden death on the basis of epidemiological data in normal and schizophrenic populations.  RESULTS:  All drugs that cause torsade de pointes prolong the QTc interval and bind to the potassium rectifier channel, but the relationships are not precise.  Prediction of torsade de pointes and sudden death can be improved by examining dose dependency, the percent of QTc intervals higher than 500 msec, and the risk of drug-drug interactions.  Although sudden unexpected death occurs almost twice as often in populations treated with antipsychotics as in normal populations, there are still only 10-15 such events in 10,000 person-years of observation.  CONCLUSIONS:  Although pimozide, sertindole, droperidol, and haloperidol have been documented to cause torsade de pointes and sudden death, the most marked risk is with thioridazine.  There is no association with olanzapine, quetiapine, or risperidone.  Ziprasidone does prolong the QT interval, but there is no evidence to suggest that this leads to torsade de pointes or sudden death.  Only widespread use will prove if ziprasidone is entirely safe.  To date, all antipsychotic drugs have the potential for serious adverse events.  Balancing these risks with the positive effects of treatment poses a challenge for psychiatry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSchHdwJKkRrP6AExegM5LLfW6udTcc2eaWt-KiUyRyZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnktVentQ%253D%253D&md5=e7ad13b4d164c94efaa27ac2052e9c3d</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.11.1774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.11.1774%26sid%3Dliteratum%253Aachs%26aulast%3DGlassman%26aufirst%3DA.%2BH.%26aulast%3DBigger%26aufirst%3DJ.%2BT.%26atitle%3DAntipsychotic%2520drugs%253A%2520prolonged%2520QTc%2520interval%252C%2520torsade%2520de%2520pointes%252C%2520and%2520sudden%2520death%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D1774%26epage%3D1782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref282"><div class="reference"><strong class="refLabel"><a href="#ref282" class="rightTabRefNumLink">282</a></strong><div class="NLM_citation" id="rightTab-cit282"><span><span class="NLM_contrib-group">Straus, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleumink, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieleman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">’t Jong, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingma, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturkenboom, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stricker, B. H.</span><span> </span><span class="NLM_article-title">Antipsychotics and the risk of sudden cardiac death</span> <span class="citation_source-journal">Arch. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">1293</span><span class="NLM_x">–</span> <span class="NLM_lpage">1297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2004&pages=1293-1297&author=S.+M.+Strausauthor=G.+S.+Bleuminkauthor=J.+P.+Dielemanauthor=L.+J.+van+derauthor=G.+W.+%E2%80%99t+Jongauthor=J.+H.+Kingmaauthor=M.+C.+Sturkenboomauthor=B.+H.+Stricker&title=Antipsychotics+and+the+risk+of+sudden+cardiac+death"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStraus%26aufirst%3DS.%2BM.%26aulast%3DBleumink%26aufirst%3DG.%2BS.%26aulast%3DDieleman%26aufirst%3DJ.%2BP.%26aulast%3Dvan%2Bder%26aufirst%3DL.%2BJ.%26aulast%3D%25E2%2580%2599t%2BJong%26aufirst%3DG.%2BW.%26aulast%3DKingma%26aufirst%3DJ.%2BH.%26aulast%3DSturkenboom%26aufirst%3DM.%2BC.%26aulast%3DStricker%26aufirst%3DB.%2BH.%26atitle%3DAntipsychotics%2520and%2520the%2520risk%2520of%2520sudden%2520cardiac%2520death%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D2004%26volume%3D164%26spage%3D1293%26epage%3D1297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref283"><div class="reference"><strong class="refLabel"><a href="#ref283" class="rightTabRefNumLink">283</a></strong><div class="NLM_citation" id="rightTab-cit283"><span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koro, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">L’Italien, G. J.</span><span> </span><span class="NLM_article-title">The metabolic syndrome and schizophrenia: a review</span> <span class="citation_source-journal">Int. Rev. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1080%2F09540260500071798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16194788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MritFCjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=173-180&author=J.+Meyerauthor=C.+E.+Koroauthor=G.+J.+L%E2%80%99Italien&title=The+metabolic+syndrome+and+schizophrenia%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic syndrome and schizophrenia: a review</span></div><div class="casAuthors">Meyer Jonathan; Koro Carol E; L'Italien Gilbert J</div><div class="citationInfo"><span class="NLM_cas:title">International review of psychiatry (Abingdon, England)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-80</span>
        ISSN:<span class="NLM_cas:issn">0954-0261</span>.
    </div><div class="casAbstract">The clinical phenomenon described as the metabolic syndrome has received considerable attention both in the recent medical literature and popular press.  Many of the sequelae of events attributable to newer atypical antipsychotics are consistent with the metabolic syndrome definition.  This article describes and summarizes the information available on metabolic syndrome in the mental illness disease area and the proposed mechanisms for the increased prevalence of the metabolic syndrome in this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_XZQ_6ygeS4IRAdBLKY41fW6udTcc2eYerOYD1-mnwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MritFCjuw%253D%253D&md5=2d7f9b4d4a591f33cc4d4afb782f2eb7</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1080%2F09540260500071798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09540260500071798%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DKoro%26aufirst%3DC.%2BE.%26aulast%3DL%25E2%2580%2599Italien%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520metabolic%2520syndrome%2520and%2520schizophrenia%253A%2520a%2520review%26jtitle%3DInt.%2520Rev.%2520Psychiatry%26date%3D2005%26volume%3D17%26spage%3D173%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref284"><div class="reference"><strong class="refLabel"><a href="#ref284" class="rightTabRefNumLink">284</a></strong><div class="NLM_citation" id="rightTab-cit284"><span><span class="NLM_contrib-group">Goudie, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halford, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dovey, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neill, J. C.</span><span> </span><span class="NLM_article-title">H<sub>1</sub>-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2209</span><span class="NLM_x">–</span> <span class="NLM_lpage">2211</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=2209-2211&author=A.+J.+Goudieauthor=J.+C.+Halfordauthor=T.+M.+Doveyauthor=G.+D.+Cooperauthor=J.+C.+Neill&title=H1-histamine+receptor+affinity+predicts+short-term+weight+gain+for+typical+and+atypical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoudie%26aufirst%3DA.%2BJ.%26aulast%3DHalford%26aufirst%3DJ.%2BC.%26aulast%3DDovey%26aufirst%3DT.%2BM.%26aulast%3DCooper%26aufirst%3DG.%2BD.%26aulast%3DNeill%26aufirst%3DJ.%2BC.%26atitle%3DH1-histamine%2520receptor%2520affinity%2520predicts%2520short-term%2520weight%2520gain%2520for%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D2209%26epage%3D2211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref285"><div class="reference"><strong class="refLabel"><a href="#ref285" class="rightTabRefNumLink">285</a></strong><div class="NLM_citation" id="rightTab-cit285"><span><span class="NLM_contrib-group">Kim, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snowman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teuscher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">3456</span><span class="NLM_x">–</span> <span class="NLM_lpage">3459</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3456-3459&author=S.+F.+Kimauthor=A.+S.+Huangauthor=A.+M.+Snowmanauthor=C.+Teuscherauthor=S.+H.+Snyder&title=Antipsychotic+drug-induced+weight+gain+mediated+by+histamine+H1+receptor-linked+activation+of+hypothalamic+AMP-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BF.%26aulast%3DHuang%26aufirst%3DA.%2BS.%26aulast%3DSnowman%26aufirst%3DA.%2BM.%26aulast%3DTeuscher%26aufirst%3DC.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DAntipsychotic%2520drug-induced%2520weight%2520gain%2520mediated%2520by%2520histamine%2520H1%2520receptor-linked%2520activation%2520of%2520hypothalamic%2520AMP-kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D3456%26epage%3D3459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref286"><div class="reference"><strong class="refLabel"><a href="#ref286" class="rightTabRefNumLink">286</a></strong><div class="NLM_citation" id="rightTab-cit286"><span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenga, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calligaro, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemrick-Luecke, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisenbaum, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaus, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundquist, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tupper, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiernicki, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. L.</span><span> </span><span class="NLM_article-title">Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4<i>H</i>-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H<sub>1</sub> receptor affinity than olanzapine</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">1265</span><span class="NLM_x">–</span> <span class="NLM_lpage">1277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.105.089326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16141369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlalurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=1265-1277&author=K.+Rasmussenauthor=M.+J.+Benvengaauthor=F.+P.+Bymasterauthor=D.+O.+Calligaroauthor=I.+R.+Cohenauthor=J.+F.+Falconeauthor=S.+K.+Hemrick-Lueckeauthor=F.+M.+Martinauthor=N.+A.+Mooreauthor=L.+K.+Nisenbaumauthor=J.+M.+Schausauthor=S.+J.+Sundquistauthor=D.+E.+Tupperauthor=T.+R.+Wiernickiauthor=D.+L.+Nelson&title=Preclinical+pharmacology+of+FMPD+%5B6-fluoro-10-%5B3-%282-methoxyethyl%29-4-methyl-piperazin-1-yl%5D-2-methyl-4H-3-thia-4%2C9-diaza-benzo%5Bf%5Dazulene%5D%3A+a+potential+novel+antipsychotic+with+lower+histamine+H1+receptor+affinity+than+olanzapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]:A potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine</span></div><div class="casAuthors">Rasmussen, Kurt; Benvenga, Mark J.; Bymaster, Frank P.; Calligaro, David O.; Cohen, Ilene R.; Falcone, Julie F.; Hemrick-Luecke, Susan K.; Martin, Fionna M.; Moore, Nicholas A.; Nisenbaum, Laura K.; Schaus, John M.; Sundquist, Sarah J.; Tupper, David E.; Wiernicki, Todd R.; Nelson, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1265-1277</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene] is a potential novel antipsychotic with high affinity for dopamine D2 (Ki = 6.3 nM), 5-HT2A (Ki = 7.3 nM), and 5-HT6 (Ki = 8.0 nM) human recombinant receptors and lower affinity for histamine H1 (Ki = 30 nM) and 5-HT2C (Ki = 102 nM) human recombinant receptors than olanzapine.  Oral administration of FMPD increased rat nucleus accumbens 3,4-dihyroxyphenylacetic acid concns. (ED200 = 6 mg/kg), blocked 5-HT2A agonist-induced increases in rat serum corticosterone levels (ED50 = 1.8 mg/kg), and inhibited the ex vivo binding of [125I]SB-258585 [4-iodo-N-[4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]- benzenesulfonamide] to striatal 5-HT6 receptors (ED50 = 10 mg/kg) but failed to inhibit ex vivo binding of [3H]pyrilamine to hypothalamic histamine H1 receptors at doses of up to 30 mg/kg.  In electrophysiol. studies, acute administration of FMPD selectively elevated the no. of spontaneously active A10 (vs. A9) dopamine neurons and chronic administration selectively decreased the no. of spontaneously active A10 (vs. A9) dopamine neurons.  FMPD did not produce catalepsy at doses lower than 25 mg/kg p.o.  In Fos-induction studies, FMPD had an atypical antipsychotic profile in the striatum and nucleus accumbens and increased Fos expression in orexin-contg. neurons of the hypothalamus.  FMPD produced only a transient elevation of prolactin levels.  These data indicate that FMPD is an orally available potent antagonist of dopamine D2, 5-HT2A, and 5-HT6 receptors and a weak antagonist of H1 and 5-HT2C receptors.  FMPD has the potential to have efficacy in treating schizophrenia and bipolar mania with a low risk of treatment-emergent extrapyramidal symptoms, prolactin elevation, and wt. gain.  Clin. trials are needed to test these hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrphTNFAvhZjLVg90H21EOLACvtfcHk0lhwyWVzpsmH-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlalurnK&md5=11bb1fabd4cc6f820041ce4f0fd4e725</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.089326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.089326%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DBenvenga%26aufirst%3DM.%2BJ.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DCohen%26aufirst%3DI.%2BR.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DHemrick-Luecke%26aufirst%3DS.%2BK.%26aulast%3DMartin%26aufirst%3DF.%2BM.%26aulast%3DMoore%26aufirst%3DN.%2BA.%26aulast%3DNisenbaum%26aufirst%3DL.%2BK.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DSundquist%26aufirst%3DS.%2BJ.%26aulast%3DTupper%26aufirst%3DD.%2BE.%26aulast%3DWiernicki%26aufirst%3DT.%2BR.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26atitle%3DPreclinical%2520pharmacology%2520of%2520FMPD%2520%255B6-fluoro-10-%255B3-%25282-methoxyethyl%2529-4-methyl-piperazin-1-yl%255D-2-methyl-4H-3-thia-4%252C9-diaza-benzo%255Bf%255Dazulene%255D%253A%2520a%2520potential%2520novel%2520antipsychotic%2520with%2520lower%2520histamine%2520H1%2520receptor%2520affinity%2520than%2520olanzapine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D1265%26epage%3D1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref287"><div class="reference"><strong class="refLabel"><a href="#ref287" class="rightTabRefNumLink">287</a></strong><div class="NLM_citation" id="rightTab-cit287"><span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroup, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvoy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swartz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenheck, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefe, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao, J. K.</span><span> </span><span class="NLM_article-title">Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">1209</span><span class="NLM_x">–</span> <span class="NLM_lpage">1223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1056%2FNEJMoa051688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16172203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=1209-1223&author=J.+A.+Liebermanauthor=T.+S.+Stroupauthor=J.+P.+McEvoyauthor=M.+S.+Swartzauthor=R.+A.+Rosenheckauthor=D.+O.+Perkinsauthor=R.+S.+Keefeauthor=S.+M.+Davisauthor=C.+E.+Davisauthor=B.+D.+Lebowitzauthor=J.+Severeauthor=J.+K.+Hsiao&title=Effectiveness+of+antipsychotic+drugs+in+patients+with+chronic+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</span></div><div class="casAuthors">Lieberman, Jeffrey A.; Stroup, T. Scott; McEvoy, Joseph P.; Swartz, Marvin S.; Rosenheck, Robert A.; Perkins, Diana O.; Keefe, Richard S. E.; Davis, Sonia M.; Davis, Clarence E.; Lebowitz, Barry D.; Severe, Joanne; Hsiao, John K.; Adler, L.; Bari, M.; Belz, I.; Bland, R.; Blocher, T.; Bolyard, B.; Buffenstein, A.; Burruss, J.; Byerly, M.; Canive, J.; Caroff, S.; Casat, C.; Chavez-Rice, E.; Csernansky, J.; Delgado, P.; Douyon, R.; D'Souza, C.; Glick, I.; Goff, D.; Gratz, S.; Grossberg, G. T.; Hale, M.; Hamner, M.; Jaffe, R.; Jeste, D.; Kablinger, A.; Khan, A.; Lamberti, S.; Levy, M. T.; Lieberman, J. A.; Maguire, G.; Manschreck, T.; McEvoy, J.; McGee, M.; Meltzer, H.; Miller, A.; Miller, D. D.; Nastrallah, H.; Nemeroff, C.; Olson, S.; Oxenkrug, G. F.; Patel, J.; Reimherr, F.; Riggio, S.; Risch, S.; Saltz, B.; Simpatico, T.; Simpson, G.; Smith, M.; Sommi, R.; Steinbook, R. M.; Stevens, M.; Tapp, A.; Torres, R.; Weiden, P.; Wolberg, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1209-1223</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly.  We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study.  A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 mo.  Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration.  The primary aim was to delineate differences in the overall effectiveness of these five treatments.  Overall, 74% of patients discontinued the study medication before 18 mo (1061 of the 1432 patients who received at least one dose): 64% of those assigned to olanzapine, 75% of those assigned to perphenazine, 82% of those assigned to quetiapine, 74% of those assigned to risperidone, and 79% of those assigned to ziprasidone.  The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P < 0.001) or risperidone (P = 0.002) group, but not in the perphenazine (P = 0.021) or ziprasidone (P = 0.028) group.  The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P = 0.04); olanzapine was assocd. with more discontinuation for wt. gain or metabolic effects, and perphenazine was assocd. with more discontinuation for extrapyramidal effects.  The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons.  Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional anti-psychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.  Olanzapine was assocd. with greater wt. gain and increases in measures of glucose and lipid metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod3gBNEmBl1LVg90H21EOLACvtfcHk0lgdDn7GRuDGrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeltL%252FN&md5=d7fee36157ec0240ebef0813791335ec</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051688%26sid%3Dliteratum%253Aachs%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DStroup%26aufirst%3DT.%2BS.%26aulast%3DMcEvoy%26aufirst%3DJ.%2BP.%26aulast%3DSwartz%26aufirst%3DM.%2BS.%26aulast%3DRosenheck%26aufirst%3DR.%2BA.%26aulast%3DPerkins%26aufirst%3DD.%2BO.%26aulast%3DKeefe%26aufirst%3DR.%2BS.%26aulast%3DDavis%26aufirst%3DS.%2BM.%26aulast%3DDavis%26aufirst%3DC.%2BE.%26aulast%3DLebowitz%26aufirst%3DB.%2BD.%26aulast%3DSevere%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DJ.%2BK.%26atitle%3DEffectiveness%2520of%2520antipsychotic%2520drugs%2520in%2520patients%2520with%2520chronic%2520schizophrenia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D1209%26epage%3D1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref288"><div class="reference"><strong class="refLabel"><a href="#ref288" class="rightTabRefNumLink">288</a></strong><div class="NLM_citation" id="rightTab-cit288"><span><a href="http://www.clinicaltrials.gov/ct/search?term=schiophrenia" class="extLink">www.clinicaltrials.gov/ct/search?term=schiophrenia</a>. <div class="note"><p class="first last">Accessed Aug 4, 2007.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=www.clinicaltrials.gov%2Fct%2Fsearch%3Fterm%3Dschiophrenia.+Accessed+Aug+4%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref289"><div class="reference"><strong class="refLabel"><a href="#ref289" class="rightTabRefNumLink">289</a></strong><div class="NLM_citation" id="rightTab-cit289"><span><span class="NLM_contrib-group">Simard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Reekum, R.</span><span> </span><span class="NLM_article-title">The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies</span> <span class="citation_source-journal">J. Neuropsychiatry Clin. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15616167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVWmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=409-425&author=M.+Simardauthor=R.+van+Reekum&title=The+acetylcholinesterase+inhibitors+for+treatment+of+cognitive+and+behavioral+symptoms+in+dementia+with+Lewy+bodies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies</span></div><div class="casAuthors">Simard, Martine; van Reekum, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuropsychiatry and Clinical Neurosciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">409-425</span>CODEN:
                <span class="NLM_cas:coden">JNCNE7</span>;
        ISSN:<span class="NLM_cas:issn">0895-0172</span>.
    
            (<span class="NLM_cas:orgname">American Psychiatric Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Dementia with Lewy bodies (DLB) is a common cause of dementia with effects on cognition, mood, behavior, and function.  Changes in the acetylcholine system have been reported in brains of patients with DLB, which provides a rationale for trials of acetylcholinesterase inhibitors in DLB.  This review includes all English-language publications found via Medline and related to the efficacy and/or safety of these compds. in DLB.  Preliminary data suggest that these compds. may be efficacious in DLB and that future randomized clin. trials are strongly needed.  Methodol. limitations of the existing data include small sample sizes, and the paucity of standardized psychometric measures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwQRigQlcg1rVg90H21EOLACvtfcHk0lgdDn7GRuDGrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVWmtg%253D%253D&md5=3416ccfe7e2bacba9b3b6d2483b2df23</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DM.%26aulast%3Dvan%2BReekum%26aufirst%3DR.%26atitle%3DThe%2520acetylcholinesterase%2520inhibitors%2520for%2520treatment%2520of%2520cognitive%2520and%2520behavioral%2520symptoms%2520in%2520dementia%2520with%2520Lewy%2520bodies%26jtitle%3DJ.%2520Neuropsychiatry%2520Clin.%2520Neurosci.%26date%3D2004%26volume%3D16%26spage%3D409%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref290"><div class="reference"><strong class="refLabel"><a href="#ref290" class="rightTabRefNumLink">290</a></strong><div class="NLM_citation" id="rightTab-cit290"><span><span class="NLM_contrib-group">McKeith, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Ser, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesnes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cicin-Sain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiegel, R.</span><span> </span><span class="NLM_article-title">Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">2031</span><span class="NLM_x">–</span> <span class="NLM_lpage">2036</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2000&pages=2031-2036&author=I.+McKeithauthor=T.+Del+Serauthor=P.+Spanoauthor=M.+Emreauthor=K.+Wesnesauthor=R.+Anandauthor=A.+Cicin-Sainauthor=R.+Ferraraauthor=R.+Spiegel&title=Efficacy+of+rivastigmine+in+dementia+with+Lewy+bodies%3A+a+randomised%2C+double-blind%2C+placebo-controlled+international+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeith%26aufirst%3DI.%26aulast%3DDel%2BSer%26aufirst%3DT.%26aulast%3DSpano%26aufirst%3DP.%26aulast%3DEmre%26aufirst%3DM.%26aulast%3DWesnes%26aufirst%3DK.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DCicin-Sain%26aufirst%3DA.%26aulast%3DFerrara%26aufirst%3DR.%26aulast%3DSpiegel%26aufirst%3DR.%26atitle%3DEfficacy%2520of%2520rivastigmine%2520in%2520dementia%2520with%2520Lewy%2520bodies%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520international%2520study%26jtitle%3DLancet%26date%3D2000%26volume%3D356%26spage%3D2031%26epage%3D2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref291"><div class="reference"><strong class="refLabel"><a href="#ref291" class="rightTabRefNumLink">291</a></strong><div class="NLM_citation" id="rightTab-cit291"><span><span class="NLM_contrib-group">Shea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKnight, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockwood, K.</span><span> </span><span class="NLM_article-title">Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients</span> <span class="citation_source-journal">Int. Psychogeriatr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1017%2FS1041610298005341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9785144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK1M%252FgtFehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=229-238&author=C.+Sheaauthor=C.+MacKnightauthor=K.+Rockwood&title=Donepezil+for+treatment+of+dementia+with+Lewy+bodies%3A+a+case+series+of+nine+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit291R"><div class="casContent"><span class="casTitleNuber">291</span><div class="casTitle"><span class="NLM_cas:atitle">Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients</span></div><div class="casAuthors">Shea C; MacKnight C; Rockwood K</div><div class="citationInfo"><span class="NLM_cas:title">International psychogeriatrics / IPA</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-38</span>
        ISSN:<span class="NLM_cas:issn">1041-6102</span>.
    </div><div class="casAbstract">Dementia with Lewy bodies (DLB) is common.  Symptomatic treatment can be difficult.  We reviewed nine consecutive patients with DLB (mean age 77.5 [range 67 to 84] years; seven men and two women; mean duration of disease 3.7 [range 1.5 to 8.0] years) who had been treated with donepezil.  Each initially received 2.5 to 5 mg per day of donepezil, and was stabilized on 5 mg per day.  Donepezil was increased to 10 mg per day in five patients.  The mean observation period was 12 (range 8 to 24) weeks.  Target symptoms included cognition, hallucinations, parkinsonism, and functional abilities.  By both cognitive testing and family reports, cognition improved in seven of nine patients, remained the same in one of nine, and fluctuated in one of nine (mean Mini-Mental State Examination change 4.4 +/- 6.3 points).  Function was improved or maintained in six of nine patients and fluctuated in two of nine.  Hallucinations initially worsened, then fluctuated in one patient, but improvement in frequency, duration, and content was reported in eight of nine cases.  In three of nine patients, treatment with donepezil resulted in worsening of parkinsonism, which in each case responded to levodopa/carbidopa.  Treatment of DLB patients with donepezil for 12 weeks most commonly improved hallucinations, and sometimes improved cognition and overall function.  Treatment with donepezil was sometimes associated with worse parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWpYaQZZjmxf6BottYdIAWfW6udTcc2eaWfgQyG9R9obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FgtFehsQ%253D%253D&md5=e7a6bceae64edaf3c2b5ee84f3857e35</span></div><a href="/servlet/linkout?suffix=cit291&amp;dbid=16384&amp;doi=10.1017%2FS1041610298005341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1041610298005341%26sid%3Dliteratum%253Aachs%26aulast%3DShea%26aufirst%3DC.%26aulast%3DMacKnight%26aufirst%3DC.%26aulast%3DRockwood%26aufirst%3DK.%26atitle%3DDonepezil%2520for%2520treatment%2520of%2520dementia%2520with%2520Lewy%2520bodies%253A%2520a%2520case%2520series%2520of%2520nine%2520patients%26jtitle%3DInt.%2520Psychogeriatr.%26date%3D1998%26volume%3D10%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref292"><div class="reference"><strong class="refLabel"><a href="#ref292" class="rightTabRefNumLink">292</a></strong><div class="NLM_citation" id="rightTab-cit292"><span><span class="NLM_contrib-group">Shannon, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swedberg, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeppesen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheardown, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauerberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink-Jensen, A.</span><span> </span><span class="NLM_article-title">Xanomeline, an M<sub>1</sub>/M<sub>4</sub> preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0920-9964%2899%2900138-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10785583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3c3kvFShug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2000&pages=249-259&author=H.+E.+Shannonauthor=K.+Rasmussenauthor=F.+P.+Bymasterauthor=J.+C.+Hartauthor=S.+C.+Petersauthor=M.+D.+Swedbergauthor=L.+Jeppesenauthor=M.+J.+Sheardownauthor=P.+Sauerbergauthor=A.+Fink-Jensen&title=Xanomeline%2C+an+M1%2FM4+preferring+muscarinic+cholinergic+receptor+agonist%2C+produces+antipsychotic-like+activity+in+rats+and+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit292R"><div class="casContent"><span class="casTitleNuber">292</span><div class="casTitle"><span class="NLM_cas:atitle">Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice</span></div><div class="casAuthors">Shannon H E; Rasmussen K; Bymaster F P; Hart J C; Peters S C; Swedberg M D; Jeppesen L; Sheardown M J; Sauerberg P; Fink-Jensen A</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-59</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Xanomeline is an M(1)/M(4) preferring muscarinic receptor agonist which decreased psychotic behaviors in patients with Alzheimer's disease, suggesting that xanomeline might be useful in the treatment of psychotic symptoms in patients with schizophrenia.  The purpose of the present studies was, therefore, to compare the pharmacologic profile of xanomeline with that of known antipsychotic drugs.  Electrophysiologically, xanomeline, after both acute and chronic administration in rats, inhibited A10 but not A9 dopamine cells in a manner which was blocked by the muscarinic receptor antagonist scopolamine.  Behaviorally, xanomeline, like haloperidol, clozapine and olanzapine, blocked dopamine agonist-induced turning in unilateral 6-hydroxydopamine-lesioned rats, as well as apomorphine-induced climbing in mice.  However, unlike the dopamine antagonist antipsychotic haloperidol, xanomeline did not produce catalepsy in rats.  Moreover, xanomeline, like haloperidol, clozapine and olanzapine, inhibited conditioned avoidance responding in rats, an effect which also was blocked by scopolamine.  The present results thus demonstrate that xanomeline has a pharmacologic profile which is similar to that of the atypical antipsychotics clozapine and olanzapine, thus indicating that xanomeline has the potential to be a novel approach in the treatment of psychotic symptoms in patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTihsHSLfSgZ3y-c-E1v-fmfW6udTcc2ebawJ70q8yrgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3kvFShug%253D%253D&md5=34ff0cecc296de723491b20f0d6f864c</span></div><a href="/servlet/linkout?suffix=cit292&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2899%2900138-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252899%252900138-3%26sid%3Dliteratum%253Aachs%26aulast%3DShannon%26aufirst%3DH.%2BE.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DHart%26aufirst%3DJ.%2BC.%26aulast%3DPeters%26aufirst%3DS.%2BC.%26aulast%3DSwedberg%26aufirst%3DM.%2BD.%26aulast%3DJeppesen%26aufirst%3DL.%26aulast%3DSheardown%26aufirst%3DM.%2BJ.%26aulast%3DSauerberg%26aufirst%3DP.%26aulast%3DFink-Jensen%26aufirst%3DA.%26atitle%3DXanomeline%252C%2520an%2520M1%252FM4%2520preferring%2520muscarinic%2520cholinergic%2520receptor%2520agonist%252C%2520produces%2520antipsychotic-like%2520activity%2520in%2520rats%2520and%2520mice%26jtitle%3DSchizophr.%2520Res.%26date%3D2000%26volume%3D42%26spage%3D249%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref293"><div class="reference"><strong class="refLabel"><a href="#ref293" class="rightTabRefNumLink">293</a></strong><div class="NLM_citation" id="rightTab-cit293"><span><span class="NLM_contrib-group">Bodick, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offen, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levey, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutler, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tollefson, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, S. M.</span><span> </span><span class="NLM_article-title">Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease</span> <span class="citation_source-journal">Arch. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1001%2Farchneur.1997.00550160091022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9109749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK2s3mtlyktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1997&pages=465-473&author=N.+C.+Bodickauthor=W.+W.+Offenauthor=A.+I.+Leveyauthor=N.+R.+Cutlerauthor=S.+G.+Gauthierauthor=A.+Satlinauthor=H.+E.+Shannonauthor=G.+D.+Tollefsonauthor=K.+Rasmussenauthor=F.+P.+Bymasterauthor=D.+J.+Hurleyauthor=W.+Z.+Potterauthor=S.+M.+Paul&title=Effects+of+xanomeline%2C+a+selective+muscarinic+receptor+agonist%2C+on+cognitive+function+and+behavioral+symptoms+in+Alzheimer+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit293R"><div class="casContent"><span class="casTitleNuber">293</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease</span></div><div class="casAuthors">Bodick N C; Offen W W; Levey A I; Cutler N R; Gauthier S G; Satlin A; Shannon H E; Tollefson G D; Rasmussen K; Bymaster F P; Hurley D J; Potter W Z; Paul S M</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">465-73</span>
        ISSN:<span class="NLM_cas:issn">0003-9942</span>.
    </div><div class="casAbstract">OBJECTIVE:  To evaluate the therapeutic effects of selective cholinergic replacement with xanomeline tartrate, an m1 and m4 selective muscarinic receptor (mAChR) agonist in patients with probable Alzheimer disease (AD).  DESIGN:  A 6-month, randomized, double-blind, placebo-controlled, parallel-group trial followed by a 1-month, single-blind, placebo washout.  SETTING:  Outpatients at 17 centers in the United States and Canada.  PARTICIPANTS:  A total of 343 men and women at least 60 years of age with mild to moderate AD.  INTERVENTIONS:  Patients received 75, 150, or 225 mg (low, medium, and high doses) of xanomeline per day or placebo for 6 months.  OUTCOME MEASURES:  Scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog), the Clinician's Interview-Based Impression of Change (CIBIC+), the Alzheimer's Disease Symptomatology Scale (ADSS), and the Nurses' Observational Scale for Geriatric Patients (NOSGER).  RESULTS:  A significant treatment effect existed for ADAS-Cog (high dose vs placebo; P < or = .05), and CIBIC+ (high dose vs placebo; P < or = .02).  Treatment Emergent Signs and Symptoms analysis of the ADSS, which assesses behavioral symptoms in patients with AD, disclosed significant (P < or = .002) dose-dependent reductions in vocal outbursts, suspiciousness, delusions, agitation, and hallucinations.  On end-point analysis, NOSGER, which assesses memory, instrumental activities of daily living, self-care, mood, social behavior, and disturbing behavior in the elderly, also showed a significant dose-response relationship (P < or = .02).  In the high-dose arm, 52% of patients discontinued treatment because of adverse events; dose-dependent adverse events were predominantly gastrointestinal in nature.  Syncope, defined as loss of consciousness and muscle tone, occurred in 12.6% of patients in the high-dose group.  CONCLUSIONS:  The observed improvements in ADAS-Cog and CIBIC+ following treatment with xanomeline provide the first evidence, from a large-scale, placebo-controlled clinical trial, that a direct-acting muscarinic receptor agonist can improve cognitive function in patients with AD.  Furthermore, the dramatic and favorable effects on disturbing behaviors in AD suggest a novel approach for treatment of noncognitive symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5beLwC0CkxUGy1nwu7K2mfW6udTcc2ebawJ70q8yrgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3mtlyktQ%253D%253D&md5=a1d8d3b2b495133fb37078d387136243</span></div><a href="/servlet/linkout?suffix=cit293&amp;dbid=16384&amp;doi=10.1001%2Farchneur.1997.00550160091022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneur.1997.00550160091022%26sid%3Dliteratum%253Aachs%26aulast%3DBodick%26aufirst%3DN.%2BC.%26aulast%3DOffen%26aufirst%3DW.%2BW.%26aulast%3DLevey%26aufirst%3DA.%2BI.%26aulast%3DCutler%26aufirst%3DN.%2BR.%26aulast%3DGauthier%26aufirst%3DS.%2BG.%26aulast%3DSatlin%26aufirst%3DA.%26aulast%3DShannon%26aufirst%3DH.%2BE.%26aulast%3DTollefson%26aufirst%3DG.%2BD.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DHurley%26aufirst%3DD.%2BJ.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DPaul%26aufirst%3DS.%2BM.%26atitle%3DEffects%2520of%2520xanomeline%252C%2520a%2520selective%2520muscarinic%2520receptor%2520agonist%252C%2520on%2520cognitive%2520function%2520and%2520behavioral%2520symptoms%2520in%2520Alzheimer%2520disease%26jtitle%3DArch.%2520Neurol.%26date%3D1997%26volume%3D54%26spage%3D465%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref294"><div class="reference"><strong class="refLabel"><a href="#ref294" class="rightTabRefNumLink">294</a></strong><div class="NLM_citation" id="rightTab-cit294"><span><span class="NLM_contrib-group">Xiang, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Q. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C. Y.</span><span> </span><span class="NLM_article-title">Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2006.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16524698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD287ovVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2006&pages=201-210&author=Y.+Q.+Xiangauthor=Z.+J.+Zhangauthor=Y.+Z.+Wengauthor=Y.+M.+Zhaiauthor=W.+B.+Liauthor=Z.+J.+Caiauthor=Q.+R.+Tanauthor=C.+Y.+Wang&title=Serum+concentrations+of+clozapine+and+norclozapine+in+the+prediction+of+relapse+of+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit294R"><div class="casContent"><span class="casTitleNuber">294</span><div class="casTitle"><span class="NLM_cas:atitle">Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia</span></div><div class="casAuthors">Xiang Ying-Qiang; Zhang Zhang-Jin; Weng Yong-Zhen; Zhai Yi-Min; Li Wen-Biao; Cai Zhuo-Ji; Tan Qing-Rong; Wang Chuan-Yue</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">201-10</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Schizophrenic outpatients (n=102) whose condition had stabilized with clozapine (CLZ) therapy and were being maintained on CLZ were followed for 1 year.  Clinical status and concentrations of serum clozapine (CLZ) and its metabolite norclozapine (NCLZ) were evaluated periodically or when relapse occurred.  Relapse was defined as a significant exacerbation of psychotic symptoms or hospitalization.  Thirty-three patients relapsed and 69 did not.  Relapse patients displayed significantly lower serum concentrations of CLZ and a sum of CLZ and NCLZ at endpoint than non-relapses (CLZ: 162 ng/ml vs. 237 ng/ml, p<0.001; CLZ+NCLZ: 225 ng/ml vs. 301 ng/ml, p<0.001).  When all subjects were pooled together, a significant inverse correlation was observed between percent increase in the total score on the Brief Psychiatric Rating Scale (BPRS) from baseline and serum levels of CLZ alone (r=0.404, p<0.001) and the sum of CLZ and NCLZ (r=0.364, p<0.001).  Relapses and non-relapses were well separated by a threshold CLZ serum concentration of 200 ng/ml with a sensitivity of 73% and a specificity of 80%.  The threshold value represented about a 40% lower serum CLZ level than concentration achieved in acute treatment.  Survival analysis showed a similarity of the relapse risk over time defined by the CLZ serum threshold and by symptomatic criteria.  These results suggest that effective relapse prevention may require maintenance of patients at CLZ serum concentrations above 200 ng/ml and above 60% of the acute-phase level during long-term maintenance treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRumTWZBORPmgRQsDqrjW_fW6udTcc2ebawJ70q8yrgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287ovVCisQ%253D%253D&md5=14e10ca9f6728468a99d7b67f3b9dc1b</span></div><a href="/servlet/linkout?suffix=cit294&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DY.%2BQ.%26aulast%3DZhang%26aufirst%3DZ.%2BJ.%26aulast%3DWeng%26aufirst%3DY.%2BZ.%26aulast%3DZhai%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DW.%2BB.%26aulast%3DCai%26aufirst%3DZ.%2BJ.%26aulast%3DTan%26aufirst%3DQ.%2BR.%26aulast%3DWang%26aufirst%3DC.%2BY.%26atitle%3DSerum%2520concentrations%2520of%2520clozapine%2520and%2520norclozapine%2520in%2520the%2520prediction%2520of%2520relapse%2520of%2520patients%2520with%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D83%26spage%3D201%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref295"><div class="reference"><strong class="refLabel"><a href="#ref295" class="rightTabRefNumLink">295</a></strong><div class="NLM_citation" id="rightTab-cit295"><span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veinbergs, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalding, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lameh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levey, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacksell, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span> </span><span class="NLM_article-title">The role of M<sub>1</sub> muscarinic receptor agonism of <i>N</i>-desmethylclozapine in the unique clinical effects of clozapine</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-004-1940-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15258717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVehtLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2004&pages=207-216&author=D.+M.+Weinerauthor=H.+Y.+Meltzerauthor=I.+Veinbergsauthor=E.+M.+Donohueauthor=T.+A.+Spaldingauthor=T.+T.+Smithauthor=N.+Mohellauthor=S.+C.+Harveyauthor=J.+Lamehauthor=N.+Nashauthor=K.+E.+Vanoverauthor=R.+Olssonauthor=K.+Jayathilakeauthor=M.+Leeauthor=A.+I.+Leveyauthor=U.+Hacksellauthor=E.+S.+Bursteinauthor=R.+E.+Davisauthor=M.+R.+Brann&title=The+role+of+M1+muscarinic+receptor+agonism+of+N-desmethylclozapine+in+the+unique+clinical+effects+of+clozapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit295R"><div class="casContent"><span class="casTitleNuber">295</span><div class="casTitle"><span class="NLM_cas:atitle">The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine</span></div><div class="casAuthors">Weiner, D. M.; Meltzer, H. Y.; Veinbergs, I.; Donohue, E. M.; Spalding, T. A.; Smith, T. T.; Mohell, N.; Harvey, S. C.; Lameh, J.; Nash, N.; Vanover, K. E.; Olsson, R.; Jayathilake, K.; Lee, M.; Levey, A. I.; Hacksell, U.; Burstein, E. S.; Davis, R. E.; Brann, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Clozapine is a unique antipsychotic, with efficacy against pos. symptoms in treatment-resistant schizophrenic patients, and the ability to improve cognition and treat the neg. symptoms characteristic of this disease.  Despite its unique clin. actions, no specific mol. mechanism responsible for these actions has yet been described.  To comprehensively profile a large library of neuropsychiatric drugs, including most antipsychotics, at human monoamine receptors using R-SAT, an in vitro functional assay.  Profiling revealed that N-desmethylclozapine (NDMC), the principal metabolite of clozapine, but not clozapine itself, is a potent and efficacious muscarinic receptor agonist, a mol. property not shared by any other antipsychotic.  To further explore the role of NDMC muscarinic receptor agonist properties in mediating the physiol. actions of clozapine, systemically administered NDMC was found to stimulate the phosphorylation of mitogen-activated protein kinase (MAP kinase) in mouse CA1 hippocampal neurons, an effect that was blocked by scopolamine, confirming central M1 muscarinic receptor agonist activity in vivo.  Lastly, an anal. of clozapine and NDMC serum levels in schizophrenic patients indicated that high NDMC/clozapine ratios better predicted improvement in cognitive functioning and quality of life than the levels of either compd. alone.  The muscarinic receptor agonist activities of NDMC are unique among antipsychotics, and provide a possible mol. basis for the superior clin. effects of clozapine pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTt5orAqq3dLVg90H21EOLACvtfcHk0lhIGK_r-qVrfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVehtLvJ&md5=565a237b914964552581b11a09853f58</span></div><a href="/servlet/linkout?suffix=cit295&amp;dbid=16384&amp;doi=10.1007%2Fs00213-004-1940-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-004-1940-5%26sid%3Dliteratum%253Aachs%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DVeinbergs%26aufirst%3DI.%26aulast%3DDonohue%26aufirst%3DE.%2BM.%26aulast%3DSpalding%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DT.%2BT.%26aulast%3DMohell%26aufirst%3DN.%26aulast%3DHarvey%26aufirst%3DS.%2BC.%26aulast%3DLameh%26aufirst%3DJ.%26aulast%3DNash%26aufirst%3DN.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DOlsson%26aufirst%3DR.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DLevey%26aufirst%3DA.%2BI.%26aulast%3DHacksell%26aufirst%3DU.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26atitle%3DThe%2520role%2520of%2520M1%2520muscarinic%2520receptor%2520agonism%2520of%2520N-desmethylclozapine%2520in%2520the%2520unique%2520clinical%2520effects%2520of%2520clozapine%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2004%26volume%3D177%26spage%3D207%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref296"><div class="reference"><strong class="refLabel"><a href="#ref296" class="rightTabRefNumLink">296</a></strong><div class="NLM_citation" id="rightTab-cit296"><span><span class="NLM_contrib-group">Singhal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oz, M.</span><span> </span><span class="NLM_article-title">Antipsychotic clozapine inhibits the function of α7-nicotinic acetylcholine receptors</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2007&pages=387-394&author=S.+K.+Singhalauthor=L.+Zhangauthor=M.+Moralesauthor=M.+Oz&title=Antipsychotic+clozapine+inhibits+the+function+of+%CE%B17-nicotinic+acetylcholine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit296&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSinghal%26aufirst%3DS.%2BK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMorales%26aufirst%3DM.%26aulast%3DOz%26aufirst%3DM.%26atitle%3DAntipsychotic%2520clozapine%2520inhibits%2520the%2520function%2520of%2520%25CE%25B17-nicotinic%2520acetylcholine%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2007%26volume%3D52%26spage%3D387%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref297"><div class="reference"><strong class="refLabel"><a href="#ref297" class="rightTabRefNumLink">297</a></strong><div class="NLM_citation" id="rightTab-cit297"><span><span class="NLM_contrib-group">Olincy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. E.</span><span> </span><span class="NLM_article-title">Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1192</span><span class="NLM_x">–</span> <span class="NLM_lpage">1201</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2007&pages=1192-1201&author=A.+Olincyauthor=K.+E.+Stevens&title=Treating+schizophrenia+symptoms+with+an+%CE%B17+nicotinic+agonist%2C+from+mice+to+men"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit297&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOlincy%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DK.%2BE.%26atitle%3DTreating%2520schizophrenia%2520symptoms%2520with%2520an%2520%25CE%25B17%2520nicotinic%2520agonist%252C%2520from%2520mice%2520to%2520men%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D74%26spage%3D1192%26epage%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref298"><div class="reference"><strong class="refLabel"><a href="#ref298" class="rightTabRefNumLink">298</a></strong><div class="NLM_citation" id="rightTab-cit298"><span><span class="NLM_contrib-group">Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M.</span><span> </span><span class="NLM_article-title">Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711</span>.  <span class="citation_source-journal">Biol. Psychiatry</span><div class="note"><p class="first last"><b>2007,</b><i>63,</i> 92–97.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hashimoto%2C+K.%3B+Ishima%2C+T.%3B+Fujita%2C+Y.%3B+Matsuo%2C+M.%3B+Kobashi%2C+T.%3B+Takahagi%2C+M.%3B+Tsukada%2C+H.%3B+Iyo%2C+M.+Phencyclidine-induced+cognitive+deficits+in+mice+are+improved+by+subsequent+subchronic+administration+of+the+novel+selective+%CE%B17+nicotinic+receptor+agonist+SSR180711.+Biol.+Psychiatry2007%2C63%2C+92%E2%80%9397."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit298&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DPhencyclidine-induced%2520cognitive%2520deficits%2520in%2520mice%2520are%2520improved%2520by%2520subsequent%2520subchronic%2520administration%2520of%2520the%2520novel%2520selective%2520%25CE%25B17%2520nicotinic%2520receptor%2520agonist%2520SSR180711%26jtitle%3DBiol.%2520Psychiatry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref299"><div class="reference"><strong class="refLabel"><a href="#ref299" class="rightTabRefNumLink">299</a></strong><div class="NLM_citation" id="rightTab-cit299"><span><span class="NLM_contrib-group">Mihalak, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetje, C. W.</span><span> </span><span class="NLM_article-title">Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=801-805&author=K.+B.+Mihalakauthor=F.+I.+Carrollauthor=C.+W.+Luetje&title=Varenicline+is+a+partial+agonist+at+%CE%B14%CE%B22+and+a+full+agonist+at+%CE%B17+neuronal+nicotinic+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit299&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMihalak%26aufirst%3DK.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DLuetje%26aufirst%3DC.%2BW.%26atitle%3DVarenicline%2520is%2520a%2520partial%2520agonist%2520at%2520%25CE%25B14%25CE%25B22%2520and%2520a%2520full%2520agonist%2520at%2520%25CE%25B17%2520neuronal%2520nicotinic%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D801%26epage%3D805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref300"><div class="reference"><strong class="refLabel"><a href="#ref300" class="rightTabRefNumLink">300</a></strong><div class="NLM_citation" id="rightTab-cit300"><span><span class="NLM_contrib-group">Dunbar, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchibhatla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wamsley, J.</span><span> </span><span class="NLM_article-title">Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)</span> <span class="citation_source-journal">J. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1177%2F0269881107066855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17329297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Wksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=171-178&author=G.+C.+Dunbarauthor=F.+Inglisauthor=R.+Kuchibhatlaauthor=T.+Sharmaauthor=M.+Tomlinsonauthor=J.+Wamsley&title=Effect+of+ispronicline%2C+a+neuronal+nicotinic+acetylcholine+receptor+partial+agonist%2C+in+subjects+with+age+associated+memory+impairment+%28AAMI%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit300R"><div class="casContent"><span class="casTitleNuber">300</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)</span></div><div class="casAuthors">Dunbar, Geoffrey C.; Inglis, Fraser; Kuchibhatla, Ramana; Sharma, Tonmoy; Tomlinson, Mark; Wamsley, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-178</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Cognitive decline seen in the normal elderly is assocd. with selective loss of neuronal nicotinic acetylcholine receptors (nAChRs).  Nicotine given either by inhalation or transdermally helps cognition, but unacceptable side effects limit its utility.  The present study assessed the safety, tolerability and effect on cognition of ispronicline, a highly selective partial agonist at the α4β2 nAChR, in elderly subjects (n = 76) with age assocd. memory impairment (AAMI).  This double-blind, placebo-controlled cross-over study explored ascending oral doses of ispronicline in the range 50-150 mg given as a single morning dose for a period of 3 wk.  Pharmacokinetics (PK) were assessed, as well as cognitive function measured by means of the Cognitive Drug Research (CDR) computerized test battery.  Ispronicline had a favorable safety profile and was well tolerated at doses below 150 mg.  No effect of clin. importance was seen on biochem., haematol., urine anal., vital signs, ECG (ECG) or Holter monitoring.  The most frequent drug induced adverse event was light-headedness (dizziness).  A beneficial effect was seen on cognition across the dose range.  This was most marked at 50 mg on factors measuring attention and episodic memory.  PK anal. indicated a plasma Cmax range of 5-25/35 ng/mL ispronicline was assocd. with the most beneficial effect.  These early results demonstrate ispronicline was well tolerated and did not display the side effects typical of nicotine.  Ispronicline also had a beneficial effect on cognition in subjects with AAMI.  This was seen most strongly in a Cmax range that had been predicted from pre-clin. animal studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrktOwlNLoEtLVg90H21EOLACvtfcHk0lhIGK_r-qVrfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Wksb8%253D&md5=e73a6f0ec5a75698571e10505a3ca9da</span></div><a href="/servlet/linkout?suffix=cit300&amp;dbid=16384&amp;doi=10.1177%2F0269881107066855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881107066855%26sid%3Dliteratum%253Aachs%26aulast%3DDunbar%26aufirst%3DG.%2BC.%26aulast%3DInglis%26aufirst%3DF.%26aulast%3DKuchibhatla%26aufirst%3DR.%26aulast%3DSharma%26aufirst%3DT.%26aulast%3DTomlinson%26aufirst%3DM.%26aulast%3DWamsley%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520ispronicline%252C%2520a%2520neuronal%2520nicotinic%2520acetylcholine%2520receptor%2520partial%2520agonist%252C%2520in%2520subjects%2520with%2520age%2520associated%2520memory%2520impairment%2520%2528AAMI%2529%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2007%26volume%3D21%26spage%3D171%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref301"><div class="reference"><strong class="refLabel"><a href="#ref301" class="rightTabRefNumLink">301</a></strong><div class="NLM_citation" id="rightTab-cit301"><span><span class="NLM_contrib-group">Arneric, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holladay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">Neuronal nicotinic receptors: a perspective on two decades of drug discovery research</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1092</span><span class="NLM_x">–</span> <span class="NLM_lpage">1101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2007&pages=1092-1101&author=S.+P.+Arnericauthor=M.+Holladayauthor=M.+Williams&title=Neuronal+nicotinic+receptors%3A+a+perspective+on+two+decades+of+drug+discovery+research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit301&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArneric%26aufirst%3DS.%2BP.%26aulast%3DHolladay%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DNeuronal%2520nicotinic%2520receptors%253A%2520a%2520perspective%2520on%2520two%2520decades%2520of%2520drug%2520discovery%2520research%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D74%26spage%3D1092%26epage%3D1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref302"><div class="reference"><strong class="refLabel"><a href="#ref302" class="rightTabRefNumLink">302</a></strong><div class="NLM_citation" id="rightTab-cit302"><span><span class="NLM_contrib-group">Hoffer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, S.</span><span> </span><span class="NLM_article-title">Histamine therapy for schizophrenia: a follow-up study</span> <span class="citation_source-journal">Can. Med Assoc. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1955</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">352</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14352097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaG2M%252FltlKrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1955&pages=352-355&author=A.+Hofferauthor=S.+Parsons&title=Histamine+therapy+for+schizophrenia%3A+a+follow-up+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit302R"><div class="casContent"><span class="casTitleNuber">302</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine therapy for schizophrenia: a follow-up study</span></div><div class="casAuthors">HOFFER A; PARSONS S</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Medical Association journal</span>
        (<span class="NLM_cas:date">1955</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">352-5</span>
        ISSN:<span class="NLM_cas:issn">0008-4409</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqxF1ZPkosme2qxNLjzXe8fW6udTcc2eaXh18yp7zNLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG2M%252FltlKrtw%253D%253D&md5=4c785567b2b44192ca24b5e963804bf4</span></div><a href="/servlet/linkout?suffix=cit302&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffer%26aufirst%3DA.%26aulast%3DParsons%26aufirst%3DS.%26atitle%3DHistamine%2520therapy%2520for%2520schizophrenia%253A%2520a%2520follow-up%2520study%26jtitle%3DCan.%2520Med%2520Assoc.%2520J.%26date%3D1955%26volume%3D72%26spage%3D352%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref303"><div class="reference"><strong class="refLabel"><a href="#ref303" class="rightTabRefNumLink">303</a></strong><div class="NLM_citation" id="rightTab-cit303"><span><span class="NLM_contrib-group">Arrang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbarg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, J. C.</span><span> </span><span class="NLM_article-title">Auto-inhibition of brain histamine release mediated by a novel class (H<sub>3</sub>) of histamine receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2F302832a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=6188956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaL3sXitFSmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=1983&pages=832-837&author=J.+M.+Arrangauthor=M.+Garbargauthor=J.+C.+Schwartz&title=Auto-inhibition+of+brain+histamine+release+mediated+by+a+novel+class+%28H3%29+of+histamine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit303R"><div class="casContent"><span class="casTitleNuber">303</span><div class="casTitle"><span class="NLM_cas:atitle">Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor</span></div><div class="casAuthors">Arrang, Jean Michel; Garbarg, Monique; Schwartz, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5911</span>),
    <span class="NLM_cas:pages">832-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The K+-induced release of 3H-labeled histamine (I)  [51-45-6] from rat cerebral cortex slices was inhibited by exogenous I, suggesting the presence of histaminic receptors by which this compd. can control its own release.  Although Nα-methylhistamine  [673-50-7] and Nα,Nα-dimethylhistamine  [673-46-1] also inhibited [3H]-I release, a no. of compds. known to exhibit agonist activities of H1 or H2 receptors had no significant effect.  Consequently, autoinhibition of I release by the brain is apparently mediated by a type of receptor (histaminic H3) that is clearly different from H1 and H2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpu3HYACgLprVg90H21EOLACvtfcHk0lgBnbuY-aldSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXitFSmsbc%253D&md5=891b1e95467aa9213317c930f12bf3b7</span></div><a href="/servlet/linkout?suffix=cit303&amp;dbid=16384&amp;doi=10.1038%2F302832a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F302832a0%26sid%3Dliteratum%253Aachs%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DGarbarg%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26atitle%3DAuto-inhibition%2520of%2520brain%2520histamine%2520release%2520mediated%2520by%2520a%2520novel%2520class%2520%2528H3%2529%2520of%2520histamine%2520receptor%26jtitle%3DNature%26date%3D1983%26volume%3D302%26spage%3D832%26epage%3D837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref304"><div class="reference"><strong class="refLabel"><a href="#ref304" class="rightTabRefNumLink">304</a></strong><div class="NLM_citation" id="rightTab-cit304"><span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmerman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J.</span><span> </span><span class="NLM_article-title">The histamine H3 receptor: from gene cloning to H<sub>3</sub> receptor drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnrd1631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15665857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1Wlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=107-120&author=R.+Leursauthor=R.+A.+Bakkerauthor=H.+Timmermanauthor=I.+J.+de+Esch&title=The+histamine+H3+receptor%3A+from+gene+cloning+to+H3+receptor+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit304R"><div class="casContent"><span class="casTitleNuber">304</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: from gene cloning to H3 receptor drugs</span></div><div class="casAuthors">Leurs, Rob; Bakker, Remko A.; Timmerman, Henk; de Esch, Iwan J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-120</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the cloning of the histamine H3 receptor cDNA in 1999 by Lovenberg and coworkers, this histamine receptor has gained the interest of many pharmaceutical companies as a potential drug target for the treatment of various important disorders, including obesity, attention-deficit hyperactivity disorder, Alzheimer's disease, schizophrenia, as well as for myocardial ischemia, migraine and inflammatory diseases.  Here, the authors discuss relevant information on this target protein and describe the development of various H3 receptor agonists and antagonists, and their effects in preclin. animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS284dYZ2NqrVg90H21EOLACvtfcHk0lgBnbuY-aldSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1Wlsw%253D%253D&md5=78f1127c7e8fb9abd416dae666f5bcfe</span></div><a href="/servlet/linkout?suffix=cit304&amp;dbid=16384&amp;doi=10.1038%2Fnrd1631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1631%26sid%3Dliteratum%253Aachs%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DBakker%26aufirst%3DR.%2BA.%26aulast%3DTimmerman%26aufirst%3DH.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%26atitle%3DThe%2520histamine%2520H3%2520receptor%253A%2520from%2520gene%2520cloning%2520to%2520H3%2520receptor%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D107%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref305"><div class="reference"><strong class="refLabel"><a href="#ref305" class="rightTabRefNumLink">305</a></strong><div class="NLM_citation" id="rightTab-cit305"><span><span class="NLM_contrib-group">Esbenshade, T. A.; Fox, G. B.; Cowart, M. D.</span><span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> receptor antagonists: preclinical promise for treating obesity and cognitive disorders</span>.  <span class="citation_source-journal">Mol. Interventions</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span>− <span class="NLM_lpage">88</span>,  <span class="NLM_fpage">59</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=77+59-88&author=T.+A.+Esbenshade&author=G.+B.+Fox&author=M.+D.+Cowart&title=Histamine+H3+receptor+antagonists%3A+preclinical+promise+for+treating+obesity+and+cognitive+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit305&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26atitle%3DHistamine%2520H3%2520receptor%2520antagonists%253A%2520preclinical%2520promise%2520for%2520treating%2520obesity%2520and%2520cognitive%2520disorders%26jtitle%3DMol.%2520Interventions%26date%3D2006%26volume%3D6%26spage%3D77%26epage%3D88%26spage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref306"><div class="reference"><strong class="refLabel"><a href="#ref306" class="rightTabRefNumLink">306</a></strong><div class="NLM_citation" id="rightTab-cit306"><span><span class="NLM_contrib-group">Hudkins, R. H.; Raddatz, R.</span><span> </span><span class="NLM_article-title">Recent advances in drug discovery of histamine H<sub>3</sub> antagonists</span>.  <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><div class="note"><p class="first last"><b>2007,</b><i>42,</i> 49–62.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hudkins%2C+R.+H.%3B+Raddatz%2C+R.+Recent+advances+in+drug+discovery+of+histamine+H3+antagonists.+Annu.+Rep.+Med.+Chem.2007%2C42%2C+49%E2%80%9362."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit306&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BH.%26atitle%3DRecent%2520advances%2520in%2520drug%2520discovery%2520of%2520histamine%2520H3%2520antagonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref307"><div class="reference"><strong class="refLabel"><a href="#ref307" class="rightTabRefNumLink">307</a></strong><div class="NLM_citation" id="rightTab-cit307"><span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pudiak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamme, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T.</span><span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> receptor antagonists: from target identification to drug leads</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1084</span><span class="NLM_x">–</span> <span class="NLM_lpage">1096</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1084-1096&author=P.+Bonaventureauthor=M.+Letavicauthor=C.+Dugovicauthor=S.+Wilsonauthor=L.+Aluisioauthor=C.+Pudiakauthor=B.+Lordauthor=C.+Mazurauthor=F.+Kammeauthor=S.+Nishinoauthor=N.+Carruthersauthor=T.+Lovenberg&title=Histamine+H3+receptor+antagonists%3A+from+target+identification+to+drug+leads"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit307&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DLetavic%26aufirst%3DM.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DPudiak%26aufirst%3DC.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DMazur%26aufirst%3DC.%26aulast%3DKamme%26aufirst%3DF.%26aulast%3DNishino%26aufirst%3DS.%26aulast%3DCarruthers%26aufirst%3DN.%26aulast%3DLovenberg%26aufirst%3DT.%26atitle%3DHistamine%2520H3%2520receptor%2520antagonists%253A%2520from%2520target%2520identification%2520to%2520drug%2520leads%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D1084%26epage%3D1096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref308"><div class="reference"><strong class="refLabel"><a href="#ref308" class="rightTabRefNumLink">308</a></strong><div class="NLM_citation" id="rightTab-cit308"><span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresford, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brackenborough, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briggs, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calver, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluderay, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crook, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gartlon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heslop, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martyn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ociepka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schogger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stean, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wald, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolley, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worby, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">GSK189254, a novel H<sub>3</sub> receptor antagonist that binds to histamine H<sub>3</sub> receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">1032</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref308/cit308&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.107.120311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref308/cit308&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17327487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref308/cit308&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFeqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=1032-1045&author=A.+D.+Medhurstauthor=A.+R.+Atkinsauthor=I.+J.+Beresfordauthor=K.+Brackenboroughauthor=M.+A.+Briggsauthor=A.+R.+Calverauthor=J.+Ciliaauthor=J.+E.+Cluderayauthor=B.+Crookauthor=J.+B.+Davisauthor=R.+K.+Davisauthor=R.+P.+Davisauthor=L.+A.+Dawsonauthor=A.+G.+Foleyauthor=J.+Gartlonauthor=M.+I.+Gonzalezauthor=T.+Heslopauthor=W.+D.+Hirstauthor=C.+Jenningsauthor=D.+N.+Jonesauthor=L.+P.+Lacroixauthor=A.+Martynauthor=S.+Ociepkaauthor=A.+Rayauthor=C.+M.+Reganauthor=J.+C.+Robertsauthor=J.+Schoggerauthor=E.+Southamauthor=T.+O.+Steanauthor=B.+K.+Trailauthor=N.+Uptonauthor=G.+Wadsworthauthor=J.+A.+Waldauthor=T.+Whiteauthor=J.+Witheringtonauthor=M.+L.+Woolleyauthor=A.+Worbyauthor=D.+M.+Wilson&title=GSK189254%2C+a+novel+H3+receptor+antagonist+that+binds+to+histamine+H3+receptors+in+Alzheimer%E2%80%99s+disease+brain+and+improves+cognitive+performance+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit308R"><div class="casContent"><span class="casTitleNuber">308</span><div class="casTitle"><span class="NLM_cas:atitle">GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models</span></div><div class="casAuthors">Medhurst, Andrew D.; Atkins, Alan R.; Beresford, Isabel J.; Brackenborough, Kim; Briggs, Michael A.; Calver, Andrew R.; Cilia, Jackie; Cluderay, Jane E.; Crook, Barry; Davis, John B.; Davis, Rebecca K.; Davis, Robert P.; Dawson, Lee A.; Foley, Andrew G.; Gartlon, Jane; Gonzalez, M. Isabel; Heslop, Teresa; Hirst, Warren D.; Jennings, Carol; Jones, Declan N. C.; Lacroix, Laurent P.; Martyn, Abbe; Ociepka, Sandrine; Ray, Alison; Regan, Ciaran M.; Roberts, Jennifer C.; Schogger, Joanne; Southam, Eric; Stean, Tania O.; Trail, Brenda K.; Upton, Neil; Wadsworth, Graham; Wald, Jeffrey A.; White, Trevor; Witherington, Jason; Woolley, Marie L.; Worby, Angela; Wilson, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1032-1045</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">6[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) is a novel histamine H3 receptor antagonist with high affinity for human (pKi = 9.59-9.90) and rat (pKi = 8.51-9.17) H3 receptors.  GSK189254 is >10,000-fold selective for human H3 receptors vs. other targets tested, and it exhibited potent functional antagonism (pA2 = 9.06 vs. agonist-induced changes in cAMP) and inverse agonism [pIC50 = 8.20 vs. basal guanosine 5'-O-(3-[35S]thio)triphosphate binding] at the human recombinant H3 receptor.  In vitro autoradiog. demonstrated specific [3H]GSK189254 binding in rat and human brain areas, including cortex and hippocampus.  In addn., dense H3 binding was detected in medial temporal cortex samples from severe cases of Alzheimer's disease, suggesting for the first time that H3 receptors are preserved in late-stage disease.  After oral administration, GSK189254 inhibited cortical ex vivo R-(-)-α-methyl[imidazole-2,5(n)-3H]histamine dihydrochloride ([3H]R-α-methylhistamine) binding (ED50 = 0.17 mg/kg) and increased c-Fos immunoreactivity in prefrontal and somatosensory cortex (3 mg/kg).  Microdialysis studies demonstrated that GSK189254 (0.3-3 mg/kg p.o.) increased the release of acetylcholine, noradrenaline, and dopamine in the anterior cingulate cortex and acetylcholine in the dorsal hippocampus.  Functional antagonism of central H3 receptors was demonstrated by blockade of R-α-methylhistamine-induced dipsogenia in rats (ID50 = 0.03 mg/kg p.o.).  GSK189254 significantly improved performance of rats in diverse cognition paradigms, including passive avoidance (1 and 3 mg/kg p.o.), water maze (1 and 3 mg/kg p.o.), object recognition (0.3 and 1 mg/kg p.o.), and attentional set shift (1 mg/kg p.o.).  These data suggest that GSK189254 may have therapeutic potential for the symptomatic treatment of dementia in Alzheimer's disease and other cognitive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1RSEKGEQaDbVg90H21EOLACvtfcHk0ljuZyiZczaUgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFeqs74%253D&md5=c72dfbcb1db4f56cda723eff6b0f0e85</span></div><a href="/servlet/linkout?suffix=cit308&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.120311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.120311%26sid%3Dliteratum%253Aachs%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DAtkins%26aufirst%3DA.%2BR.%26aulast%3DBeresford%26aufirst%3DI.%2BJ.%26aulast%3DBrackenborough%26aufirst%3DK.%26aulast%3DBriggs%26aufirst%3DM.%2BA.%26aulast%3DCalver%26aufirst%3DA.%2BR.%26aulast%3DCilia%26aufirst%3DJ.%26aulast%3DCluderay%26aufirst%3DJ.%2BE.%26aulast%3DCrook%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DDavis%26aufirst%3DR.%2BK.%26aulast%3DDavis%26aufirst%3DR.%2BP.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DFoley%26aufirst%3DA.%2BG.%26aulast%3DGartlon%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DM.%2BI.%26aulast%3DHeslop%26aufirst%3DT.%26aulast%3DHirst%26aufirst%3DW.%2BD.%26aulast%3DJennings%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DD.%2BN.%26aulast%3DLacroix%26aufirst%3DL.%2BP.%26aulast%3DMartyn%26aufirst%3DA.%26aulast%3DOciepka%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DRegan%26aufirst%3DC.%2BM.%26aulast%3DRoberts%26aufirst%3DJ.%2BC.%26aulast%3DSchogger%26aufirst%3DJ.%26aulast%3DSoutham%26aufirst%3DE.%26aulast%3DStean%26aufirst%3DT.%2BO.%26aulast%3DTrail%26aufirst%3DB.%2BK.%26aulast%3DUpton%26aufirst%3DN.%26aulast%3DWadsworth%26aufirst%3DG.%26aulast%3DWald%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DT.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DWoolley%26aufirst%3DM.%2BL.%26aulast%3DWorby%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DGSK189254%252C%2520a%2520novel%2520H3%2520receptor%2520antagonist%2520that%2520binds%2520to%2520histamine%2520H3%2520receptors%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brain%2520and%2520improves%2520cognitive%2520performance%2520in%2520preclinical%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D1032%26epage%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref309"><div class="reference"><strong class="refLabel"><a href="#ref309" class="rightTabRefNumLink">309</a></strong><div class="NLM_citation" id="rightTab-cit309"><span><span class="NLM_contrib-group">Ligneau, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landais, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piriou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uguen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmentier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anaclet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, J. C.</span><span> </span><span class="NLM_article-title">Brain histamine and schizophrenia: potential therapeutic applications of H<sub>3</sub>-receptor inverse agonists studied with BF2.649</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1215</span><span class="NLM_x">–</span> <span class="NLM_lpage">1224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1215-1224&author=X.+Ligneauauthor=L.+Landaisauthor=D.+Perrinauthor=J.+Piriouauthor=M.+Uguenauthor=E.+Denisauthor=P.+Robertauthor=R.+Parmentierauthor=C.+Anacletauthor=J.+S.+Linauthor=A.+Burbanauthor=J.+M.+Arrangauthor=J.+C.+Schwartz&title=Brain+histamine+and+schizophrenia%3A+potential+therapeutic+applications+of+H3-receptor+inverse+agonists+studied+with+BF2.649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit309&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DLandais%26aufirst%3DL.%26aulast%3DPerrin%26aufirst%3DD.%26aulast%3DPiriou%26aufirst%3DJ.%26aulast%3DUguen%26aufirst%3DM.%26aulast%3DDenis%26aufirst%3DE.%26aulast%3DRobert%26aufirst%3DP.%26aulast%3DParmentier%26aufirst%3DR.%26aulast%3DAnaclet%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%2BS.%26aulast%3DBurban%26aufirst%3DA.%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26atitle%3DBrain%2520histamine%2520and%2520schizophrenia%253A%2520potential%2520therapeutic%2520applications%2520of%2520H3-receptor%2520inverse%2520agonists%2520studied%2520with%2520BF2.649%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D1215%26epage%3D1224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref310"><div class="reference"><strong class="refLabel"><a href="#ref310" class="rightTabRefNumLink">310</a></strong><div class="NLM_citation" id="rightTab-cit310"><span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radek, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komater, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faghih, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueter, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">Pharmacological properties of ABT-239 [4-(2-{2-[(2<i>R</i>)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H<sub>3</sub> receptor antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.104.078402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15608077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=176-190&author=G.+B.+Foxauthor=T.+A.+Esbenshadeauthor=J.+B.+Panauthor=R.+J.+Radekauthor=K.+M.+Kruegerauthor=B.+B.+Yaoauthor=K.+E.+Browmanauthor=M.+J.+Buckleyauthor=M.+E.+Ballardauthor=V.+A.+Komaterauthor=H.+Minerauthor=M.+Zhangauthor=R.+Faghihauthor=L.+E.+Rueterauthor=R.+S.+Bitnerauthor=K.+U.+Drescherauthor=J.+Wetterauthor=K.+Marshauthor=M.+Lemaireauthor=R.+D.+Porsoltauthor=Y.+L.+Bennaniauthor=J.+P.+Sullivanauthor=M.+D.+Cowartauthor=M.+W.+Deckerauthor=A.+A.+Hancock&title=Pharmacological+properties+of+ABT-239+%5B4-%282-%7B2-%5B%282R%29-2-methylpyrrolidinyl%5Dethyl%7D-benzofuran-5-yl%29benzonitrile%5D%3A+II.+Neurophysiological+characterization+and+broad+preclinical+efficacy+in+cognition+and+schizophrenia+of+a+potent+and+selective+histamine+H3+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit310R"><div class="casContent"><span class="casTitleNuber">310</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist</span></div><div class="casAuthors">Fox, Gerard B.; Esbenshade, Timothy A.; Pan, Jia Bao; Radek, Richard J.; Krueger, Kathleen M.; Yao, Betty B.; Browman, Kaitlin E.; Buckley, Michael J.; Ballard, Michael E.; Komater, Victoria A.; Miner, Holly; Zhang, Min; Faghih, Ramin; Rueter, Lynne E.; Bitner, R. Scott; Drescher, Karla U.; Wetter, Jill; Marsh, Kennan; Lemaire, Martine; Porsolt, Roger D.; Bennani, Youssef L.; Sullivan, James P.; Cowart, Marlon D.; Decker, Michael W.; Hancock, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-190</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acute pharmacol. blockade of central histamine H3 receptors (H3Rs) enhances arousal/attention in rodents.  However, there is little information available for other behavioral domains or for repeated administration using selective compds.  ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] exemplifies such a selective, nonimidazole H3R antagonist with high affinity for rat (pKi = 8.9) and human (pKi = 9.5) H3Rs.  Acute functional blockade of central H3Rs was demonstrated by blocking the dipsogenia response to the selective H3R agonist (R)-α-methylhistamine in mice.  In cognition studies, acquisition of a five-trial, inhibitory avoidance test in rat pups was improved with ABT-239 (0.1-1.0 mg/kg), a 10- to 150-fold gain in potency, with similar efficacy, over previous antagonists such as thioperamide, ciproxifan, A-304121 [(4-(3-(4-((2R)-2-aminopropanoyl)-1-piperazinyl)propoxy)phenyl)(cyclopropyl) methanone], A-317920 [N-((1R)-2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide], and A-349821 [(4'-(3-((R,R)2,5-dimethyl-pyrrolidin-1-yl)-propoxy)-biphenyl-4-yl)- morpholin-4-yl-methanone].  Efficacy in this model was maintained for 3 to 6 h and following repeated dosing with ABT-239.  Social memory was also improved in adult (0.01-0.3 mg/kg) and aged (0.3-1.0 mg/kg) rats.  In schizophrenia models, ABT-239 improved gating deficits in DBA/2 mice using prepulse inhibition of startle (1.0-3.0 mg/kg) and N40 (1.0-10.0 mg/kg).  Furthermore, ABT-239 (1.0 mg/kg) attenuated methamphetamine-induced hyperactivity in mice.  In freely moving rat microdialysis studies, ABT-239 enhanced acetylcholine release (0.1-3.0 mg/kg) in adult rat frontal cortex and hippocampus and enhanced dopamine release in frontal cortex (3.0 mg/kg), but not striatum.  In summary, broad efficacy was obsd. with ABT-239 across animal models such that potential clin. efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5hD1Q0ydnubVg90H21EOLACvtfcHk0ljuZyiZczaUgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLo%253D&md5=437e154a172071e4c5d31e44134ab1b5</span></div><a href="/servlet/linkout?suffix=cit310&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.078402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.078402%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DPan%26aufirst%3DJ.%2BB.%26aulast%3DRadek%26aufirst%3DR.%2BJ.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DBuckley%26aufirst%3DM.%2BJ.%26aulast%3DBallard%26aufirst%3DM.%2BE.%26aulast%3DKomater%26aufirst%3DV.%2BA.%26aulast%3DMiner%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DFaghih%26aufirst%3DR.%26aulast%3DRueter%26aufirst%3DL.%2BE.%26aulast%3DBitner%26aufirst%3DR.%2BS.%26aulast%3DDrescher%26aufirst%3DK.%2BU.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DPharmacological%2520properties%2520of%2520ABT-239%2520%255B4-%25282-%257B2-%255B%25282R%2529-2-methylpyrrolidinyl%255Dethyl%257D-benzofuran-5-yl%2529benzonitrile%255D%253A%2520II.%2520Neurophysiological%2520characterization%2520and%2520broad%2520preclinical%2520efficacy%2520in%2520cognition%2520and%2520schizophrenia%2520of%2520a%2520potent%2520and%2520selective%2520histamine%2520H3%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D176%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref311"><div class="reference"><strong class="refLabel"><a href="#ref311" class="rightTabRefNumLink">311</a></strong><div class="NLM_citation" id="rightTab-cit311"><span><span class="NLM_contrib-group">Cowart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gfesser, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faghih, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milicic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baranowski, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molesky, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komater, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagne, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">Novel heterocyclic-substituted benzofuran histamine H<sub>3</sub> receptor antagonists: in vitro properties, drug-likeness, and behavioral activity</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1243</span><span class="NLM_x">–</span> <span class="NLM_lpage">1255</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1243-1255&author=M.+Cowartauthor=G.+A.+Gfesserauthor=K.+E.+Browmanauthor=R.+Faghihauthor=T.+R.+Millerauthor=I.+Milicicauthor=J.+L.+Baranowskiauthor=K.+M.+Kruegerauthor=D.+G.+Witteauthor=A.+L.+Moleskyauthor=V.+A.+Komaterauthor=M.+J.+Buckleyauthor=G.+J.+Diazauthor=G.+D.+Gagneauthor=D.+Zhouauthor=X.+Dengauthor=L.+Panauthor=E.+M.+Robertsauthor=M.+S.+Diehlauthor=J.+M.+Wetterauthor=K.+C.+Marshauthor=G.+B.+Foxauthor=J.+D.+Brioniauthor=T.+A.+Esbenshadeauthor=A.+A.+Hancock&title=Novel+heterocyclic-substituted+benzofuran+histamine+H3+receptor+antagonists%3A+in+vitro+properties%2C+drug-likeness%2C+and+behavioral+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit311&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCowart%26aufirst%3DM.%26aulast%3DGfesser%26aufirst%3DG.%2BA.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DFaghih%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DT.%2BR.%26aulast%3DMilicic%26aufirst%3DI.%26aulast%3DBaranowski%26aufirst%3DJ.%2BL.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DWitte%26aufirst%3DD.%2BG.%26aulast%3DMolesky%26aufirst%3DA.%2BL.%26aulast%3DKomater%26aufirst%3DV.%2BA.%26aulast%3DBuckley%26aufirst%3DM.%2BJ.%26aulast%3DDiaz%26aufirst%3DG.%2BJ.%26aulast%3DGagne%26aufirst%3DG.%2BD.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DE.%2BM.%26aulast%3DDiehl%26aufirst%3DM.%2BS.%26aulast%3DWetter%26aufirst%3DJ.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DNovel%2520heterocyclic-substituted%2520benzofuran%2520histamine%2520H3%2520receptor%2520antagonists%253A%2520in%2520vitro%2520properties%252C%2520drug-likeness%252C%2520and%2520behavioral%2520activity%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D1243%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref312"><div class="reference"><strong class="refLabel"><a href="#ref312" class="rightTabRefNumLink">312</a></strong><div class="NLM_citation" id="rightTab-cit312"><span><span class="NLM_contrib-group">Javitt, D. C.</span><span> </span><span class="NLM_article-title">Glycine modulators in schizophrenia</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1067</span><span class="NLM_x">–</span> <span class="NLM_lpage">1072</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12186269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFOnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=1067-1072&author=D.+C.+Javitt&title=Glycine+modulators+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit312R"><div class="casContent"><span class="casTitleNuber">312</span><div class="casTitle"><span class="NLM_cas:atitle">Glycine modulators in schizophrenia</span></div><div class="casAuthors">Javitt, Daniel C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (PharmaPress Ltd.)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1067-1072</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    
            (<span class="NLM_cas:orgname">PharmaPress Ltd.</span>)
        </div><div class="casAbstract">A review.  N-methyl-D-aspartate (NMDA) receptor dysfunction may play a key role in the pathophysiol. of schizophrenia.  Recent studies have investigated the ability of NMDA/glycine-site modulators to ameliorate persistent neg. and cognitive symptoms.  Several full or partial glycine-site agonists, including glycine, D-serine and D-cycloserine, have shown effectiveness in small-scale clin. trials.  Glycine levels in brain are regulated by GLYT1-type glycine transporters.  Recently developed glycine transport inhibitors (GTI) have preclin. behavioral effects similar to those of glycine or D-serine, and may represent a 'next generation' approach to the treatment of the persistent neg. and cognitive symptoms of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHJn9BGdsbZ7Vg90H21EOLACvtfcHk0ljV07bPpfmz-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFOnsL4%253D&md5=96d9eed6c77e9019c84556710b6196e6</span></div><a href="/servlet/linkout?suffix=cit312&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJavitt%26aufirst%3DD.%2BC.%26atitle%3DGlycine%2520modulators%2520in%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D3%26spage%3D1067%26epage%3D1072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref313"><div class="reference"><strong class="refLabel"><a href="#ref313" class="rightTabRefNumLink">313</a></strong><div class="NLM_citation" id="rightTab-cit313"><span><span class="NLM_contrib-group">Atkinson, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ognyanov, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tham, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klitenick, M. A.</span><span> </span><span class="NLM_article-title">ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1414</span><span class="NLM_x">–</span> <span class="NLM_lpage">1420</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=1414-1420&author=B.+N.+Atkinsonauthor=S.+C.+Bellauthor=M.+De+Vivoauthor=L.+R.+Kowalskiauthor=S.+M.+Lechnerauthor=V.+I.+Ognyanovauthor=C.+S.+Thamauthor=C.+Tsaiauthor=J.+Jiaauthor=D.+Ashtonauthor=M.+A.+Klitenick&title=ALX+5407%3A+a+potent%2C+selective+inhibitor+of+the+hGlyT1+glycine+transporter"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit313&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DB.%2BN.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DKowalski%26aufirst%3DL.%2BR.%26aulast%3DLechner%26aufirst%3DS.%2BM.%26aulast%3DOgnyanov%26aufirst%3DV.%2BI.%26aulast%3DTham%26aufirst%3DC.%2BS.%26aulast%3DTsai%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DAshton%26aufirst%3DD.%26aulast%3DKlitenick%26aufirst%3DM.%2BA.%26atitle%3DALX%25205407%253A%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520the%2520hGlyT1%2520glycine%2520transporter%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D1414%26epage%3D1420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref314"><div class="reference"><strong class="refLabel"><a href="#ref314" class="rightTabRefNumLink">314</a></strong><div class="NLM_citation" id="rightTab-cit314"><span><span class="NLM_contrib-group">Depoortere, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dargazanli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estenne-Bouhtou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coste, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanneau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desvignes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncelet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaulme, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decobert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cudennec, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voltz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terranova, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemmelin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marabout, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sevrin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vige, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avenet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oury-Donat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrault, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griebel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scatton, B.</span><span> </span><span class="NLM_article-title">Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1963</span><span class="NLM_x">–</span> <span class="NLM_lpage">1985</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=1963-1985&author=R.+Depoortereauthor=G.+Dargazanliauthor=G.+Estenne-Bouhtouauthor=A.+Costeauthor=C.+Lanneauauthor=C.+Desvignesauthor=M.+Ponceletauthor=M.+Heaulmeauthor=V.+Santucciauthor=M.+Decobertauthor=A.+Cudennecauthor=C.+Voltzauthor=D.+Boulayauthor=J.+P.+Terranovaauthor=J.+Stemmelinauthor=P.+Rogerauthor=B.+Maraboutauthor=M.+Sevrinauthor=X.+Vigeauthor=B.+Bitonauthor=R.+Steinbergauthor=D.+Franconauthor=R.+Alonsoauthor=P.+Avenetauthor=F.+Oury-Donatauthor=G.+Perraultauthor=G.+Griebelauthor=P.+Georgeauthor=P.+Soubrieauthor=B.+Scatton&title=Neurochemical%2C+electrophysiological+and+pharmacological+profiles+of+the+selective+inhibitor+of+the+glycine+transporter-1+SSR504734%2C+a+potential+new+type+of+antipsychotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit314&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDepoortere%26aufirst%3DR.%26aulast%3DDargazanli%26aufirst%3DG.%26aulast%3DEstenne-Bouhtou%26aufirst%3DG.%26aulast%3DCoste%26aufirst%3DA.%26aulast%3DLanneau%26aufirst%3DC.%26aulast%3DDesvignes%26aufirst%3DC.%26aulast%3DPoncelet%26aufirst%3DM.%26aulast%3DHeaulme%26aufirst%3DM.%26aulast%3DSantucci%26aufirst%3DV.%26aulast%3DDecobert%26aufirst%3DM.%26aulast%3DCudennec%26aufirst%3DA.%26aulast%3DVoltz%26aufirst%3DC.%26aulast%3DBoulay%26aufirst%3DD.%26aulast%3DTerranova%26aufirst%3DJ.%2BP.%26aulast%3DStemmelin%26aufirst%3DJ.%26aulast%3DRoger%26aufirst%3DP.%26aulast%3DMarabout%26aufirst%3DB.%26aulast%3DSevrin%26aufirst%3DM.%26aulast%3DVige%26aufirst%3DX.%26aulast%3DBiton%26aufirst%3DB.%26aulast%3DSteinberg%26aufirst%3DR.%26aulast%3DFrancon%26aufirst%3DD.%26aulast%3DAlonso%26aufirst%3DR.%26aulast%3DAvenet%26aufirst%3DP.%26aulast%3DOury-Donat%26aufirst%3DF.%26aulast%3DPerrault%26aufirst%3DG.%26aulast%3DGriebel%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DScatton%26aufirst%3DB.%26atitle%3DNeurochemical%252C%2520electrophysiological%2520and%2520pharmacological%2520profiles%2520of%2520the%2520selective%2520inhibitor%2520of%2520the%2520glycine%2520transporter-1%2520SSR504734%252C%2520a%2520potential%2520new%2520type%2520of%2520antipsychotic%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D1963%26epage%3D1985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref315"><div class="reference"><strong class="refLabel"><a href="#ref315" class="rightTabRefNumLink">315</a></strong><div class="NLM_citation" id="rightTab-cit315"><span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span> </span><span class="NLM_article-title">Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">807</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=807-811&author=C.+W.+Lindsleyauthor=Z.+Zhaoauthor=W.+H.+Leisterauthor=J.+O%E2%80%99Brienauthor=W.+Lemaireauthor=D.+L.+Williamsauthor=T.+B.+Chenauthor=R.+S.+Changauthor=M.+Burnoauthor=M.+A.+Jacobsonauthor=C.+Surauthor=G.+G.+Kinneyauthor=D.+J.+Pettiboneauthor=P.+R.+Tillerauthor=S.+Smithauthor=N.+N.+Tsouauthor=M.+E.+Dugganauthor=P.+J.+Connauthor=G.+D.+Hartman&title=Design%2C+synthesis%2C+and+in+vivo+efficacy+of+glycine+transporter-1+%28GlyT1%29+inhibitors+derived+from+a+series+of+%5B4-phenyl-1-%28propylsulfonyl%29piperidin-4-yl%5Dmethyl+benzamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit315&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DTiller%26aufirst%3DP.%2BR.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520glycine%2520transporter-1%2520%2528GlyT1%2529%2520inhibitors%2520derived%2520from%2520a%2520series%2520of%2520%255B4-phenyl-1-%2528propylsulfonyl%2529piperidin-4-yl%255Dmethyl%2520benzamides%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D807%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref316"><div class="reference"><strong class="refLabel"><a href="#ref316" class="rightTabRefNumLink">316</a></strong><div class="NLM_citation" id="rightTab-cit316"><span><span class="NLM_contrib-group">Tsai, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. T.</span><span> </span><span class="NLM_article-title"><span class="smallcaps smallerCapital">d</span>-Serine added to clozapine for the treatment of schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">1822</span><span class="NLM_x">–</span> <span class="NLM_lpage">1825</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref316/cit316&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10553752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref316/cit316&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FhvFWrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1999&pages=1822-1825&author=G.+E.+Tsaiauthor=P.+Yangauthor=L.+C.+Chungauthor=I.+C.+Tsaiauthor=C.+W.+Tsaiauthor=J.+T.+Coyle&title=d-Serine+added+to+clozapine+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit316R"><div class="casContent"><span class="casTitleNuber">316</span><div class="casTitle"><span class="NLM_cas:atitle">D-serine added to clozapine for the treatment of schizophrenia</span></div><div class="casAuthors">Tsai G E; Yang P; Chung L C; Tsai I C; Tsai C W; Coyle J T</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1822-5</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  D-Serine is a full agonist at the glycine site on the N-methyl-D-aspartate (NMDA) receptor.  Previous administration of D-serine to schizophrenic patients taking nonclozapine antipsychotics improved positive, negative, and cognitive symptoms, whereas the partial agonist D-cycloserine improved negative symptoms of patients taking conventional antipsychotics but worsened symptoms in clozapine-treated patients.  To study the difference between full and partial agonists at the NMDA receptor glycine site, the clinical effects of adding D-serine to clozapine were assessed.  METHOD:  In a 6-week double-blind trial, 20 schizophrenic patients received placebo or D-serine (30 mg/kg per day) in addition to clozapine.  Clinical efficacy, side effects, and serum levels of D-serine were determined every other week.  RESULTS:  The patients exhibited no improvement with D-serine, nor did their symptoms worsen, as previously reported with D-cycloserine.  CONCLUSIONS:  The results suggest either that clozapine may have an agonistic effect on the NMDA system or that clozapine-treated patients do not respond to D-serine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSg_EqLFISEu1HFYivNCdPRfW6udTcc2eaclEnBUYkDD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FhvFWrsg%253D%253D&md5=c751c699c41f5056935a8d85c88e9c75</span></div><a href="/servlet/linkout?suffix=cit316&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DG.%2BE.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DChung%26aufirst%3DL.%2BC.%26aulast%3DTsai%26aufirst%3DI.%2BC.%26aulast%3DTsai%26aufirst%3DC.%2BW.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3Dd-Serine%2520added%2520to%2520clozapine%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1999%26volume%3D156%26spage%3D1822%26epage%3D1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref317"><div class="reference"><strong class="refLabel"><a href="#ref317" class="rightTabRefNumLink">317</a></strong><div class="NLM_citation" id="rightTab-cit317"><span><span class="NLM_contrib-group">Tuominen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiihonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlbeck, K.</span><span> </span><span class="NLM_article-title">Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref317/cit317&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2004.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref317/cit317&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15560967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref317/cit317&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2crovVyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2005&pages=225-234&author=H.+J.+Tuominenauthor=J.+Tiihonenauthor=K.+Wahlbeck&title=Glutamatergic+drugs+for+schizophrenia%3A+a+systematic+review+and+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit317R"><div class="casContent"><span class="casTitleNuber">317</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis</span></div><div class="casAuthors">Tuominen Harri J; Tiihonen Jari; Wahlbeck Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">225-34</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">OBJECTIVE:  To evaluate the efficacy of glutamatergic drugs, acting agonistically on the N-methyl-D-aspartate (NMDA) or the non-NMDA receptors, in schizophrenia.  METHOD:  All relevant randomized controlled trials of glutamatergic drugs for schizophrenia were obtained from the Cochrane Schizophrenia Group's Register of Trials without any language or year limitations.  Trials were classified according to their methodological quality.  For binary and continuous data, relative risks and weighted (WMD) or standardized mean differences (SMD) were calculated, respectively.  RESULTS:  Eighteen short-term trials with 343 randomized patients were included in the meta-analysis.  In all of these trials, glycine, D-serine, D-cycloserine or ampakine CX516 was used to augment antipsychotics.  NMDA receptor co-agonists glycine and D-serine are effective in reducing negative symptoms (N = 132, fixed effect model SMD = -0.66, 95% CI -1.02 to -0.29, p = 0.0004) of schizophrenia, the magnitude of the effect is moderate.  D-Cycloserine, a partial agonist of NMDA receptors, is less effective towards negative symptoms (N = 119, fixed effect model SMD = -0.11, 95% CI -0.48 to 0.25, p = 0.6).  Positive symptoms fail to respond to glutamatergic medication.  Available derived data on cognitive functioning do not indicate a significant effect of glycine or D-serine (N = 80, random effect model WMD = -2.79, 95% CI -6.17 to 0.60, p = 0.11).  CONCLUSIONS:  In the current limited data set, a moderate amelioration of negative symptoms of schizophrenia was found, but no other statistically significant beneficial effects on symptoms of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWMnnE49ze_fxQvRxYU81tfW6udTcc2eaclEnBUYkDD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crovVyntw%253D%253D&md5=2aacaaa0e6fba75cf152ef85a668ba77</span></div><a href="/servlet/linkout?suffix=cit317&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2004.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2004.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DTuominen%26aufirst%3DH.%2BJ.%26aulast%3DTiihonen%26aufirst%3DJ.%26aulast%3DWahlbeck%26aufirst%3DK.%26atitle%3DGlutamatergic%2520drugs%2520for%2520schizophrenia%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DSchizophr.%2520Res.%26date%3D2005%26volume%3D72%26spage%3D225%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref318"><div class="reference"><strong class="refLabel"><a href="#ref318" class="rightTabRefNumLink">318</a></strong><div class="NLM_citation" id="rightTab-cit318"><span>Sepracor Inc. <span> </span><span class="NLM_article-title">Pyrrole and Pyrazole DAAO Inhibitors</span>. WO/2005/066135,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sepracor+Inc.+Pyrrole+and+Pyrazole+DAAO+Inhibitors.+WO%2F2005%2F066135%2C+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit318&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DPyrrole%2520and%2520Pyrazole%2520DAAO%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref319"><div class="reference"><strong class="refLabel"><a href="#ref319" class="rightTabRefNumLink">319</a></strong><div class="NLM_citation" id="rightTab-cit319"><span>Sepracor Inc. <span> </span><span class="NLM_article-title">Benzo[<span class="smallcaps smallerCapital">d</span>]isoxazol-3-ol DAAO Inhibitors</span>. U.S. 7,166,725 B2,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sepracor+Inc.+Benzo%5Bd%5Disoxazol-3-ol+DAAO+Inhibitors.+U.S.+7%2C166%2C725+B2%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit319&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DBenzo%255Bd%255Disoxazol-3-ol%2520DAAO%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref320"><div class="reference"><strong class="refLabel"><a href="#ref320" class="rightTabRefNumLink">320</a></strong><div class="NLM_citation" id="rightTab-cit320"><span><span class="NLM_contrib-group">Chavez-Noriega, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaffhauser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia</span> <span class="citation_source-journal">Curr. Drug Targets: CNS Neurol. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">281</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref320/cit320&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2174%2F1568007023339337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref320/cit320&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12769619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref320/cit320&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFKgtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=261-281&author=L.+E.+Chavez-Noriegaauthor=H.+Schaffhauserauthor=U.+C.+Campbell&title=Metabotropic+glutamate+receptors%3A+potential+drug+targets+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit320R"><div class="casContent"><span class="casTitleNuber">320</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors: Potential drug targets for the treatment of schizophrenia</span></div><div class="casAuthors">Chavez-Noriega, Laura E.; Schaffhauser, Herve; Campbell, Una C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: CNS & Neurological Disorders</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-281</span>CODEN:
                <span class="NLM_cas:coden">CDTCCC</span>;
        ISSN:<span class="NLM_cas:issn">1568-007X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is a debilitating chronic psychiatric illness affecting 1% of the population.  The cardinal features of schizophrenia are pos. symptoms (thought disorder, hallucinations, catatonic behavior), neg. symptoms (social withdrawal, anhedonia, apathy) and cognitive impairment.  Although progress in elucidating the etiol. of schizophrenia has been slow, new insights on the neurochem. and neurophysiol. mechanisms underlying the pathophysiol. of this illness are beginning to emerge.  The glutamate/N-methyl-D-aspartate (NMDA) hypofunction hypothesis of schizophrenia is supported by observations that administration of NMDA glutamate receptor antagonists such as phencyclidine (PCP) or ketamine induces psychosis in humans; moreover, decreased levels of glutamate and changes in several markers of glutamatergic function occur in schizophrenic brain.  Administration of PCP or ketamine to rodents elicits an increase in locomotion and stereotypy accompanied by an increase in glutamate efflux in several brain regions.  Systemic administration of group II metabotropic glutamate (mGlu) receptor agonists suppresses PCP-induced behavioral effects and the increase in glutamate efflux.  Activation of group II mGlu receptors (mGlu2 and mGlu3) decreases glutamate release from presynaptic nerve terminals, suggesting that group II mGlu receptor agonists may be beneficial in the treatment of schizophrenia.  In addn., pharmacol. manipulations that enhance NMDA function may be efficacious antipsychotics.  Selective activation of mGlu5 receptors significantly potentiates NMDA-induced responses, supporting this novel approach for the treatment of schizophrenia.  The glutamate hypothesis of schizophrenia predicts that agents that restore the balance in glutamatergic neurotransmission will ameliorate the symptomatol. assocd. with this illness.  Development of potent, efficacious, systemically active drugs will help to address the antipsychotic potential of these novel therapeutics.  This review will discuss recent progress in elucidating the pharmacol. and function of group II mGlu and mGlu5 receptors in the context of current hypotheses on the pathophysiol. of schizophrenia and the need for new and better antipsychotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNJSTzsZh9hbVg90H21EOLACvtfcHk0ljwDG7rLfSiBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFKgtrk%253D&md5=c58d098adfa3964101deb45511c46af2</span></div><a href="/servlet/linkout?suffix=cit320&amp;dbid=16384&amp;doi=10.2174%2F1568007023339337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568007023339337%26sid%3Dliteratum%253Aachs%26aulast%3DChavez-Noriega%26aufirst%3DL.%2BE.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26atitle%3DMetabotropic%2520glutamate%2520receptors%253A%2520potential%2520drug%2520targets%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520CNS%2520Neurol.%2520Disord.%26date%3D2002%26volume%3D1%26spage%3D261%26epage%3D281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref321"><div class="reference"><strong class="refLabel"><a href="#ref321" class="rightTabRefNumLink">321</a></strong><div class="NLM_citation" id="rightTab-cit321"><span><span class="NLM_contrib-group">Cartmell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref321/cit321&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10490900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref321/cit321&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlaks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1999&pages=161-170&author=J.+Cartmellauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=The+metabotropic+glutamate+2%2F3+receptor+agonists+LY354740+and+LY379268+selectively+attenuate+phencyclidine+versus+d-amphetamine+motor+behaviors+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit321R"><div class="casContent"><span class="casTitleNuber">321</span><div class="casTitle"><span class="NLM_cas:atitle">The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats</span></div><div class="casAuthors">Cartmell, Jayne; Monn, James A.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Previous animal studies have indicated that drugs targeted at metabotropic glutamate (mGlu) receptors may be useful for treatment of psychosis.  In this article, the effects of the novel, potent, and selective mGlu2/3 receptor agonists LY354740 and LY379268, and the clin. effective agents clozapine and haloperidol, were investigated using phencyclidine (PCP; 5 mg/kg)- vs. d-amphetamine (AMP; 3 mg/kg)-evoked motor activities.  LY354740 (1-10 mg/kg s.c.), LY379268 (0.3-3 mg/kg s.c.), clozapine (1-10 mg/kg s.c.), and haloperidol (0.03-1 mg/kg s.c.) reversed the increases in ambulations, fine motor (nonambulatory) movements, and decreased time at rest evoked by PCP.  Furthermore, the inhibitions of the PCP response by the mGlu2/3 agonist LY379268, but not by clozapine, were completely reversed by the selective mGlu2/3 receptor antagonist LY341495.  Doses of LY354740 and LY379268 that blocked the effects on PCP had no effects on rotorod performance, and (with the exception of rearing behavior) had minimal effects on AMP-evoked motor activities.  Clozapine blocked AMP-induced rearing but enhanced AMP-induced ambulations and fine movements at the lower doses (1 and 3 mg/kg).  Unlike the mGlu2/3 agonists, the highest dose of clozapine tested (10 mg/kg) impaired animals on the rotorod.  Haloperidol potently blocked all PCP and AMP effects, but only at doses assocd. with motor impairment.  These data demonstrate that mGlu2/3 receptor agonists act via a unique mechanism to selectively block PCP-induced behaviors.  Moreover, the marked mGlu2/3 receptor-mediated inhibitions of PCP-evoked behaviors by LY354740 and LY379268, with minimal effects on AMP, may indicate potential antipsychotic effects in humans in the absence of dopamine mediated extrapyramidal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6C09T4kWFLVg90H21EOLACvtfcHk0ljwDG7rLfSiBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlaks7g%253D&md5=93425a0c85f8dfbea2a7cd5323e645c2</span></div><a href="/servlet/linkout?suffix=cit321&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCartmell%26aufirst%3DJ.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DThe%2520metabotropic%2520glutamate%25202%252F3%2520receptor%2520agonists%2520LY354740%2520and%2520LY379268%2520selectively%2520attenuate%2520phencyclidine%2520versus%2520d-amphetamine%2520motor%2520behaviors%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D291%26spage%3D161%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref322"><div class="reference"><strong class="refLabel"><a href="#ref322" class="rightTabRefNumLink">322</a></strong><div class="NLM_citation" id="rightTab-cit322"><span><span class="NLM_contrib-group">Rorick-Kehn, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knitowski, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salhoff, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffey, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tizzano, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinzie, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref322/cit322&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-007-0758-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref322/cit322&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17384937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref322/cit322&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtlGktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2007&pages=121-136&author=L.+M.+Rorick-Kehnauthor=B.+G.+Johnsonauthor=K.+M.+Knitowskiauthor=C.+R.+Salhoffauthor=J.+M.+Witkinauthor=K.+W.+Perryauthor=K.+I.+Griffeyauthor=J.+P.+Tizzanoauthor=J.+A.+Monnauthor=D.+L.+McKinzieauthor=D.+D.+Schoepp&title=In+vivo+pharmacological+characterization+of+the+structurally+novel%2C+potent%2C+selective+mGlu2%2F3+receptor+agonist+LY404039+in+animal+models+of+psychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit322R"><div class="casContent"><span class="casTitleNuber">322</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders</span></div><div class="casAuthors">Rorick-Kehn, Linda M.; Johnson, Bryan G.; Knitowski, Karen M.; Salhoff, Craig R.; Witkin, Jeffrey M.; Perry, Kenneth W.; Griffey, Kelly I.; Tizzano, Joseph P.; Monn, James A.; McKinzie, David L.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Data from both preclin. and clin. studies have provided proof of concept that modulation of limbic and forebrain glutamate, via mGlu2/3 receptor agonists, might provide therapeutic benefits in many psychiatric disorders including schizophrenia and anxiety.  The aim of this study was to assess the efficacy of a structurally novel, potent, selective mGlu2/3 receptor agonist with improved bioavailability (LY404039) in animal models predictive of antipsychotic and anxiolytic efficacy.  LY404039 was assessed in amphetamine- and phencyclidine-induced hyperlocomotion, conditioned avoidance responding, fear-potentiated startle, marble burying, and rotarod behavioral tests.  Monoamine release and turnover were assessed using microdialysis and ex vivo tissue levels.  LY404039 attenuated amphetamine- and phencyclidine-induced hyperlocomotion (3-30 and 10 mg/kg, resp.).  LY404039 (3-10 mg/kg) inhibited conditioned avoidance responding.  LY404039 also reduced fear-potentiated startle in rats (3-30 μg/kg) and marble burying in mice (3-10 mg/kg), indicating anxiolytic-like effects.  Importantly, LY404039 did not produce sedative effects or motor impairment as measured by rotarod performance and lack of escape failures in the conditioned avoidance task (at doses up to 30 and 10 mg/kg, resp.).  LY404039 (10 mg/kg) also increased dopamine and serotonin release/turnover in the prefrontal cortex.  These results demonstrate the broad preclin. efficacy of LY404039 across multiple animal models of antipsychotic and anxiolytic efficacy.  Addnl., this compd. modulates mesocortical neurotransmission and provides a novel mechanism for the treatment of psychiatric disorders that may be assocd. with improved efficacy and reduced incidence of undesirable side effects.  As glutamatergic dysfunction has been linked to the etiol. of schizophrenia, clin. studies with more potent mGlu2/3 agonists, such as LY404039, may be useful to explore the validity of this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYlJEGsofLAbVg90H21EOLACvtfcHk0ljwDG7rLfSiBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtlGktr8%253D&md5=b829e3e415cd9bdaf44ac26ee8863edb</span></div><a href="/servlet/linkout?suffix=cit322&amp;dbid=16384&amp;doi=10.1007%2Fs00213-007-0758-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-007-0758-3%26sid%3Dliteratum%253Aachs%26aulast%3DRorick-Kehn%26aufirst%3DL.%2BM.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DKnitowski%26aufirst%3DK.%2BM.%26aulast%3DSalhoff%26aufirst%3DC.%2BR.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DPerry%26aufirst%3DK.%2BW.%26aulast%3DGriffey%26aufirst%3DK.%2BI.%26aulast%3DTizzano%26aufirst%3DJ.%2BP.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DMcKinzie%26aufirst%3DD.%2BL.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DIn%2520vivo%2520pharmacological%2520characterization%2520of%2520the%2520structurally%2520novel%252C%2520potent%252C%2520selective%2520mGlu2%252F3%2520receptor%2520agonist%2520LY404039%2520in%2520animal%2520models%2520of%2520psychiatric%2520disorders%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2007%26volume%3D193%26spage%3D121%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref323"><div class="reference"><strong class="refLabel"><a href="#ref323" class="rightTabRefNumLink">323</a></strong><div class="NLM_citation" id="rightTab-cit323"><span><span class="NLM_contrib-group">Pinkerton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cube, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaffhauser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daggett, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J. M.</span><span> </span><span class="NLM_article-title">Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1565</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1565-1571&author=A.+B.+Pinkertonauthor=R.+V.+Cubeauthor=J.+H.+Hutchinsonauthor=J.+K.+Jamesauthor=M.+F.+Gardnerauthor=B.+A.+Roweauthor=H.+Schaffhauserauthor=D.+E.+Rodriguezauthor=U.+C.+Campbellauthor=L.+P.+Daggettauthor=J.+M.+Vernier&title=Allosteric+potentiators+of+the+metabotropic+glutamate+receptor+2+%28mGlu2%29.+Part+3%3A+Identification+and+biological+activity+of+indanone+containing+mGlu2+receptor+potentiators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit323&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DCube%26aufirst%3DR.%2BV.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DJames%26aufirst%3DJ.%2BK.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DRowe%26aufirst%3DB.%2BA.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DRodriguez%26aufirst%3DD.%2BE.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DDaggett%26aufirst%3DL.%2BP.%26aulast%3DVernier%26aufirst%3DJ.%2BM.%26atitle%3DAllosteric%2520potentiators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25202%2520%2528mGlu2%2529.%2520Part%25203%253A%2520Identification%2520and%2520biological%2520activity%2520of%2520indanone%2520containing%2520mGlu2%2520receptor%2520potentiators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1565%26epage%3D1571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref324"><div class="reference"><strong class="refLabel"><a href="#ref324" class="rightTabRefNumLink">324</a></strong><div class="NLM_citation" id="rightTab-cit324"><span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberle, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, H. E.</span><span> </span><span class="NLM_article-title">Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=206-218&issue=Suppl.+1&author=C.+K.+Jonesauthor=E.+L.+Eberleauthor=S.+C.+Petersauthor=J.+A.+Monnauthor=H.+E.+Shannon&title=Analgesic+effects+of+the+selective+group+II+%28mGlu2%2F3%29+metabotropic+glutamate+receptor+agonists+LY379268+and+LY389795+in+persistent+and+inflammatory+pain+models+after+acute+and+repeated+dosing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit324&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DEberle%26aufirst%3DE.%2BL.%26aulast%3DPeters%26aufirst%3DS.%2BC.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DShannon%26aufirst%3DH.%2BE.%26atitle%3DAnalgesic%2520effects%2520of%2520the%2520selective%2520group%2520II%2520%2528mGlu2%252F3%2529%2520metabotropic%2520glutamate%2520receptor%2520agonists%2520LY379268%2520and%2520LY389795%2520in%2520persistent%2520and%2520inflammatory%2520pain%2520models%2520after%2520acute%2520and%2520repeated%2520dosing%26jtitle%3DNeuropharmacology%26date%3D2005%26volume%3D49%26issue%3DSuppl.%25201%26spage%3D206%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref325"><div class="reference"><strong class="refLabel"><a href="#ref325" class="rightTabRefNumLink">325</a></strong><div class="NLM_citation" id="rightTab-cit325"><span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref325/cit325&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.103.048702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref325/cit325&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12660307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref325/cit325&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvF2lur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=116-123&author=G.+G.+Kinneyauthor=M.+Burnoauthor=U.+C.+Campbellauthor=L.+M.+Hernandezauthor=D.+Rodriguezauthor=L.+J.+Bristowauthor=P.+J.+Conn&title=Metabotropic+glutamate+subtype+5+receptors+modulate+locomotor+activity+and+sensorimotor+gating+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit325R"><div class="casContent"><span class="casTitleNuber">325</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents</span></div><div class="casAuthors">Kinney, Gene G.; Burno, Maryann; Campbell, Una C.; Hernandez, Lisa M.; Rodriguez, Dana; Bristow, Linda J.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-123</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Use-dependent N-methyl-D-asparate receptor (NMDAR) antagonists produce behaviors in human volunteers that resemble schizophrenia and exacerbate those behaviors in schizophrenic patients, suggesting that hypofunction of NMDAR-mediated neuronal circuitry may be involved in the etiol. of clin. schizophrenia.  Activation of the metabotropic glutamate receptor subtype 5 (mGluR5) enhances NMDAR-mediated currents in vitro.  Thus, activation of mGluR5 could potentiate hypofunctional NMDARs in neuronal circuitry relevant to schizophrenia.  To further elucidate the role of mGluR5, the present study examd. the effects of mGluR5 antagonist administration, with and without coadministration of the use-dependent NMDAR antagonist phencyclidine (PCP), on locomotor activity and prepulse inhibition (PPI) of the acoustic startle response in rodents.  We further examd. PPI in mGluR5 knockout mice.  Finally, we examd. PPI after administration of the mGluR5 agonist 2-chloro-5-hydroxyphenylglycine (CHPG) alone and in combination with amphetamine.  The data indicate that the mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine has no effect on locomotor activity or PPI by itself but does potentiate both PCP-induced locomotor activity and disruption of PPI.  We further found that mGluR5 knockout mice display consistent deficits in PPI relative to their wild-type controls.  Finally, the data indicate that CHPG has no effect on PPI by itself, but ameliorates amphetamine-induced disruption of PPI.  Collectively, these data suggest that mGluR5 receptors play a modulatory role on rodent PPI and locomotor behaviors and are consistent with the hypothesis that mGluR5 agonist/potentiator may represent a novel approach for antipsychotic drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf6hlEX7jl2LVg90H21EOLACvtfcHk0lgHSoinOzpTxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvF2lur8%253D&md5=10d6738c19a05e1bbb2a63c04c86432f</span></div><a href="/servlet/linkout?suffix=cit325&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.048702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.048702%26sid%3Dliteratum%253Aachs%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DHernandez%26aufirst%3DL.%2BM.%26aulast%3DRodriguez%26aufirst%3DD.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DMetabotropic%2520glutamate%2520subtype%25205%2520receptors%2520modulate%2520locomotor%2520activity%2520and%2520sensorimotor%2520gating%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D116%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref326"><div class="reference"><strong class="refLabel"><a href="#ref326" class="rightTabRefNumLink">326</a></strong><div class="NLM_citation" id="rightTab-cit326"><span><span class="NLM_contrib-group">Henry, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Masten, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markou, A.</span><span> </span><span class="NLM_article-title">The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1199</span><span class="NLM_x">–</span> <span class="NLM_lpage">1209</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=1199-1209&author=S.+A.+Henryauthor=V.+Lehmann-Mastenauthor=F.+Gaspariniauthor=M.+A.+Geyerauthor=A.+Markou&title=The+mGluR5+antagonist+MPEP%2C+but+not+the+mGluR2%2F3+agonist+LY314582%2C+augments+PCP+effects+on+prepulse+inhibition+and+locomotor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit326&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DS.%2BA.%26aulast%3DLehmann-Masten%26aufirst%3DV.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DMarkou%26aufirst%3DA.%26atitle%3DThe%2520mGluR5%2520antagonist%2520MPEP%252C%2520but%2520not%2520the%2520mGluR2%252F3%2520agonist%2520LY314582%252C%2520augments%2520PCP%2520effects%2520on%2520prepulse%2520inhibition%2520and%2520locomotor%2520activity%26jtitle%3DNeuropharmacology%26date%3D2002%26volume%3D43%26spage%3D1199%26epage%3D1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref327"><div class="reference"><strong class="refLabel"><a href="#ref327" class="rightTabRefNumLink">327</a></strong><div class="NLM_citation" id="rightTab-cit327"><span><span class="NLM_contrib-group">Brody, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulawa, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conquet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span> </span><span class="NLM_article-title">Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref327/cit327&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref327/cit327&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14699440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref327/cit327&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=35-41&author=S.+A.+Brodyauthor=S.+C.+Dulawaauthor=F.+Conquetauthor=M.+A.+Geyer&title=Assessment+of+a+prepulse+inhibition+deficit+in+a+mutant+mouse+lacking+mGlu5+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit327R"><div class="casContent"><span class="casTitleNuber">327</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors</span></div><div class="casAuthors">Brody, S. A.; Dulawa, S. C.; Conquet, F.; Geyer, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-41</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The glutamate hypothesis of schizophrenia derived from evidence that phencyclidine, a noncompetitive N-methyl-D-aspartate (NMDA) antagonist, produces schizophrenia-like symptoms in healthy humans.  Sensorimotor gating, measured by prepulse inhibition (PPI), is a fundamental form of information processing that is deficient in schizophrenia patients and rodents treated with NMDA antagonists.  Hence, PPI is widely used to study the neurobiol. of schizophrenia.  As the use of PPI as a model of gating deficits in schizophrenia has become more widespread, it has become increasingly important to assess such deficits accurately.  Here we identify a possible role of mGluR5 in PPI by using wild type (WT) and mGluR5 knockout (KO) mice of two different background strains, 129SvPasIco and C57BL/6.  In both strains, PPI was disrupted dramatically in the mGluR5 KO mice throughout a range of interstimulus intervals and sensory modalities.  The present findings further support the glutamate hypothesis of schizophrenia and identify a functional role for mGluR5 in sensorimotor gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjaGWdVbLdtbVg90H21EOLACvtfcHk0lgHSoinOzpTxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtr7P&md5=595be94962ebb72a7a60f93b5ad24f64</span></div><a href="/servlet/linkout?suffix=cit327&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001404%26sid%3Dliteratum%253Aachs%26aulast%3DBrody%26aufirst%3DS.%2BA.%26aulast%3DDulawa%26aufirst%3DS.%2BC.%26aulast%3DConquet%26aufirst%3DF.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26atitle%3DAssessment%2520of%2520a%2520prepulse%2520inhibition%2520deficit%2520in%2520a%2520mutant%2520mouse%2520lacking%2520mGlu5%2520receptors%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D35%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref328"><div class="reference"><strong class="refLabel"><a href="#ref328" class="rightTabRefNumLink">328</a></strong><div class="NLM_citation" id="rightTab-cit328"><span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickel, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clements, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisnoski, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. L.,  Jr</span><span> </span><span class="NLM_article-title">A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref328/cit328&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.104.079244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref328/cit328&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15608073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref328/cit328&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=199-206&author=G.+G.+Kinneyauthor=J.+A.+O%E2%80%99Brienauthor=W.+Lemaireauthor=M.+Burnoauthor=D.+J.+Bickelauthor=M.+K.+Clementsauthor=T.+B.+Chenauthor=D.+D.+Wisnoskiauthor=C.+W.+Lindsleyauthor=P.+R.+Tillerauthor=S.+Smithauthor=M.+A.+Jacobsonauthor=C.+Surauthor=M.+E.+Dugganauthor=D.+J.+Pettiboneauthor=P.+J.+Connauthor=D.+L.+Williams&title=A+novel+selective+positive+allosteric+modulator+of+metabotropic+glutamate+receptor+subtype+5+has+in+vivo+activity+and+antipsychotic-like+effects+in+rat+behavioral+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit328R"><div class="casContent"><span class="casTitleNuber">328</span><div class="casTitle"><span class="NLM_cas:atitle">A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models</span></div><div class="casAuthors">Kinney, Gene G.; O'Brien, Julie A.; Lemaire, Wei; Burno, Maryann; Bickel, Denise J.; Clements, Michelle K.; Chen, Tsing-Bau; Wisnoski, David D.; Lindsley, Craig W.; Tiller, Philip R.; Smith, Sheri; Jacobson, Marlene A.; Sur, Cyrille; Duggan, Mark E.; Pettibone, Douglas J.; Conn, P. Jeffrey; Williams, David L., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">199-206</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We found that 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) is a potent and selective pos. allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5).  In Chinese hamster ovary cells expressing human mGluR5, CDPPB potentiated threshold responses to glutamate in fluorometric Ca2+ assays more than 7-fold with an EC50 value of approx. 27 nM.  At 1 μM, CDPPB shifted mGluR5 agonist concn. response curves to glutamate, quisqualate, and (R,S)-3,5-dihydroxyphenylglycine 3- to 9-fold to the left.  At higher concns., CDPPB exhibited agonist-like activity on cells expressing mGluR5.  No other activity was obsd. on any other mGluR or cell type at concns. up to 10 μM.  CDPPB had no effect on [3H]quisqualate binding to mGluR5 but did compete for binding of [3H]methoxyPEPy, an analog of the selective mGluR5 neg. allosteric modulator MPEP.  CDPPB was found to be brain penetrant and reversed amphetamine-induced locomotor activity and amphetamine-induced deficits in prepulse inhibition in rats, two models sensitive to antipsychotic drug treatment.  These results demonstrate that pos. allosteric modulation of mGluR5 produces behavioral effects, suggesting that such modulation serves as a viable approach to increasing mGluR5 activity in vivo.  These effects are consistent with the hypothesis that allosteric potentiation of mGluR5 may provide a novel approach for development of antipsychotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5MND_DZkDL7Vg90H21EOLACvtfcHk0libicbNNmF-WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLg%253D&md5=371bb91ca8ac48cdf8b38c95634385da</span></div><a href="/servlet/linkout?suffix=cit328&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.079244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.079244%26sid%3Dliteratum%253Aachs%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DBickel%26aufirst%3DD.%2BJ.%26aulast%3DClements%26aufirst%3DM.%2BK.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DWisnoski%26aufirst%3DD.%2BD.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DTiller%26aufirst%3DP.%2BR.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26atitle%3DA%2520novel%2520selective%2520positive%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptor%2520subtype%25205%2520has%2520in%2520vivo%2520activity%2520and%2520antipsychotic-like%2520effects%2520in%2520rat%2520behavioral%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D199%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref329"><div class="reference"><strong class="refLabel"><a href="#ref329" class="rightTabRefNumLink">329</a></strong><div class="NLM_citation" id="rightTab-cit329"><span><span class="NLM_contrib-group">Arai, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, M.</span><span> </span><span class="NLM_article-title">Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref329/cit329&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2174%2F138945007780618490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref329/cit329&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17504103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref329/cit329&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVWmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=583-602&author=A.+C.+Araiauthor=M.+Kessler&title=Pharmacology+of+ampakine+modulators%3A+from+AMPA+receptors+to+synapses+and+behavior"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit329R"><div class="casContent"><span class="casTitleNuber">329</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior</span></div><div class="casAuthors">Arai, A. C.; Kessler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">583-602</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Ampakines are drugs structurally derived from aniracetam that potentiate currents mediated by AMPA type glutamate receptors.  These drugs slow deactivation and attenuate desensitization of AMPA receptor currents, increase synaptic responses and enhance long-term potentiation.  This review focuses mainly on recent physiol. studies and on evidence for two distinct subfamilies.  Type I compds. like CX546 are very effective in prolonging synaptic responses while type II compds. like CX516 mainly increase response amplitude.  Type I and II drugs do not compete in binding assays and thus presumably act through sep. sites.  Their differences are likely to have consequences also for synaptic plasticity and behavior.  Thus, while all ampakines facilitated long-term potentiation, only CX546 enhanced long-term depression.  Further discussed are studies showing that ampakine effects vary substantially between neurons, with increases in EPSCs being larger in CA1 pyramidal cells than in thalamus and in hippocampal interneurons.  In behavioral tests, ampakines facilitate learning in many paradigms including odor discrimination, spatial mazes, and conditioning, and they improved short-term memory in a non-matching-to-sample task.  Pos. results were also obtained in various psychol. tests with human subjects.  The drugs were effective in correcting behaviors in various animal models of schizophrenia and depression.  Lastly, evidence is discussed that ampakines have few adverse effects at therapeutically relevant concns. and that they protect neurons against neurotoxic insults, in part by mobilizing growth factors like BDNF.  Type II drugs like CX516 in particular appear to be inherently safe since their ability to prolong responses is kinetically limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoUgfoEMXCALVg90H21EOLACvtfcHk0libicbNNmF-WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVWmurk%253D&md5=77ecd4442f0c551eaec7a9d52c218efc</span></div><a href="/servlet/linkout?suffix=cit329&amp;dbid=16384&amp;doi=10.2174%2F138945007780618490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007780618490%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DA.%2BC.%26aulast%3DKessler%26aufirst%3DM.%26atitle%3DPharmacology%2520of%2520ampakine%2520modulators%253A%2520from%2520AMPA%2520receptors%2520to%2520synapses%2520and%2520behavior%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26spage%3D583%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref330"><div class="reference"><strong class="refLabel"><a href="#ref330" class="rightTabRefNumLink">330</a></strong><div class="NLM_citation" id="rightTab-cit330"><span><span class="NLM_contrib-group">Dunlop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, K.</span><span> </span><span class="NLM_article-title">Glutamate transport inhibitors as targets for treating psychosis</span> <span class="citation_source-journal">Drug Discovery Today: Ther. Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref330/cit330&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ddstr.2006.10.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=533-537&author=J.+Dunlopauthor=K.+Marquis&title=Glutamate+transport+inhibitors+as+targets+for+treating+psychosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit330&amp;dbid=16384&amp;doi=10.1016%2Fj.ddstr.2006.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddstr.2006.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DMarquis%26aufirst%3DK.%26atitle%3DGlutamate%2520transport%2520inhibitors%2520as%2520targets%2520for%2520treating%2520psychosis%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Ther.%2520Strategies%26date%3D2006%26volume%3D3%26spage%3D533%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref331"><div class="reference"><strong class="refLabel"><a href="#ref331" class="rightTabRefNumLink">331</a></strong><div class="NLM_citation" id="rightTab-cit331"><span><span class="NLM_contrib-group">McCullumsmith, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meador-Woodruff, J. H.</span><span> </span><span class="NLM_article-title">Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">368</span><span class="NLM_x">–</span> <span class="NLM_lpage">375</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=368-375&author=R.+E.+McCullumsmithauthor=J.+H.+Meador-Woodruff&title=Striatal+excitatory+amino+acid+transporter+transcript+expression+in+schizophrenia%2C+bipolar+disorder%2C+and+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit331&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCullumsmith%26aufirst%3DR.%2BE.%26aulast%3DMeador-Woodruff%26aufirst%3DJ.%2BH.%26atitle%3DStriatal%2520excitatory%2520amino%2520acid%2520transporter%2520transcript%2520expression%2520in%2520schizophrenia%252C%2520bipolar%2520disorder%252C%2520and%2520major%2520depressive%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2002%26volume%3D26%26spage%3D368%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref332"><div class="reference"><strong class="refLabel"><a href="#ref332" class="rightTabRefNumLink">332</a></strong><div class="NLM_citation" id="rightTab-cit332"><span><span class="NLM_contrib-group">Crino, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shumate, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulter, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks-Kayal, A. R.</span><span> </span><span class="NLM_article-title">Increased expression of the neuronal glutamate transporter (EAAT3/EAAC1) in hippocampal and neocortical epilepsy</span> <span class="citation_source-journal">Epilepsia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=211-218&author=P.+B.+Crinoauthor=H.+Jinauthor=M.+D.+Shumateauthor=M.+B.+Robinsonauthor=D.+A.+Coulterauthor=A.+R.+Brooks-Kayal&title=Increased+expression+of+the+neuronal+glutamate+transporter+%28EAAT3%2FEAAC1%29+in+hippocampal+and+neocortical+epilepsy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit332&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrino%26aufirst%3DP.%2BB.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DShumate%26aufirst%3DM.%2BD.%26aulast%3DRobinson%26aufirst%3DM.%2BB.%26aulast%3DCoulter%26aufirst%3DD.%2BA.%26aulast%3DBrooks-Kayal%26aufirst%3DA.%2BR.%26atitle%3DIncreased%2520expression%2520of%2520the%2520neuronal%2520glutamate%2520transporter%2520%2528EAAT3%252FEAAC1%2529%2520in%2520hippocampal%2520and%2520neocortical%2520epilepsy%26jtitle%3DEpilepsia%26date%3D2002%26volume%3D43%26spage%3D211%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref333"><div class="reference"><strong class="refLabel"><a href="#ref333" class="rightTabRefNumLink">333</a></strong><div class="NLM_citation" id="rightTab-cit333"><span><span class="NLM_contrib-group">Wroblewska, B.</span><span> </span><span class="NLM_article-title">NAAG as a neurotransmitter</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">576</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref333/cit333&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2F0-387-30172-0_23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref333/cit333&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16802723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref333/cit333&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFygtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=576&publication_year=2006&pages=317-325&author=B.+Wroblewska&title=NAAG+as+a+neurotransmitter"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit333R"><div class="casContent"><span class="casTitleNuber">333</span><div class="casTitle"><span class="NLM_cas:atitle">NAAG as a neurotransmitter</span></div><div class="casAuthors">Wroblewska, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">576</span>
        (<span class="NLM_cas:issue">N-Acetylaspartate</span>),
    <span class="NLM_cas:pages">317-325</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  A review on the role of N-acetylaspartylglutamate (NAAG) as a neurotransmitter.  It discusses NAAG in the context of pain models and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRSgVqaVFABLVg90H21EOLACvtfcHk0ljBv6x000RkqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFygtrs%253D&md5=19e8133bd82cc9e117e85bcded7f9b2d</span></div><a href="/servlet/linkout?suffix=cit333&amp;dbid=16384&amp;doi=10.1007%2F0-387-30172-0_23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F0-387-30172-0_23%26sid%3Dliteratum%253Aachs%26aulast%3DWroblewska%26aufirst%3DB.%26atitle%3DNAAG%2520as%2520a%2520neurotransmitter%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2006%26volume%3D576%26spage%3D317%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref334"><div class="reference"><strong class="refLabel"><a href="#ref334" class="rightTabRefNumLink">334</a></strong><div class="NLM_citation" id="rightTab-cit334"><span><span class="NLM_contrib-group">Wroblewska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pshenichkin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neale, J. H.</span><span> </span><span class="NLM_article-title"><i>N</i>-Acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref334/cit334&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1046%2Fj.1471-4159.1997.69010174.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref334/cit334&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9202308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref334/cit334&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2sXktV2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=174-181&author=B.+Wroblewskaauthor=J.+T.+Wroblewskiauthor=S.+Pshenichkinauthor=A.+Surinauthor=S.+E.+Sullivanauthor=J.+H.+Neale&title=N-Acetylaspartylglutamate+selectively+activates+mGluR3+receptors+in+transfected+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit334R"><div class="casContent"><span class="casTitleNuber">334</span><div class="casTitle"><span class="NLM_cas:atitle">N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells</span></div><div class="casAuthors">Wroblewska, Barbara; Wroblewski, Jarda T.; Pshenichkin, Sergei; Surin, Alexander; Sullivan, Suzanne E.; Neale, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-181</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">In previous studies, we demonstrated that the neuropeptide, N-acetylaspartylglutamate (NAAG), meets the traditional criteria for a neurotransmitter and selectively activates metabotropic glutamate receptor mGluR2 or mGluR3 in cultured cerebellar granule cells and glia.  Sequence homol. and pharmacol. data suggest that these two receptors are highly related structurally and functionally.  To define more rigorously the receptor specificity of NAAG, cloned rat cDNAs for mGluR1-6 were transiently or stably transfected into Chinese hamster ovary cells and human embryonic kidney cells and assayed for their second messenger responses to the two endogenous neurotransmitters, glutamate and NAAG, as well as to metabotropic receptor agonists, trans-1-aminocyclopentane-1,3-dicarboxylate (trans-ACPD) and L-2-amino-4-phosphonobutyrate (L-AP4).  Despite the high degree of relatedness of mGluR2 and mGluR3, NAAG selectively activated the mGluR3 receptor.  NAAG activated neither mGluR2 nor mGluR1, mGluR4, mGluR5, or mGluR6.  The mGluR agonist, trans-ACPD, activated each of the transfected receptors, whereas L-AP4 activated mGluR4 and mGluR6, consistent with the published selectivity of these agonists.  Hybrid cDNA constructs of the extracellular domains of mGluR2 and mGluR3 were independently fused with the transmembrane and cytoplasmic domain of mGluR1a.  This latter receptor domain is coupled to phosphoinositol turnover, and its activation increases intracellular calcium.  The cells transfected with these chimeric receptors responded to activation by glutamate and trans-ACPD with increases in intracellular calcium.  NAAG activated the chimeric receptor that contained the extracellular domain of mGluR3 and did not activate the mGluR2 chimera.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGOi2H5RX3W7Vg90H21EOLACvtfcHk0ljBv6x000RkqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktV2msrk%253D&md5=ebcceed22e3f04dfe9701804e47cb4b0</span></div><a href="/servlet/linkout?suffix=cit334&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1997.69010174.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1997.69010174.x%26sid%3Dliteratum%253Aachs%26aulast%3DWroblewska%26aufirst%3DB.%26aulast%3DWroblewski%26aufirst%3DJ.%2BT.%26aulast%3DPshenichkin%26aufirst%3DS.%26aulast%3DSurin%26aufirst%3DA.%26aulast%3DSullivan%26aufirst%3DS.%2BE.%26aulast%3DNeale%26aufirst%3DJ.%2BH.%26atitle%3DN-Acetylaspartylglutamate%2520selectively%2520activates%2520mGluR3%2520receptors%2520in%2520transfected%2520cells%26jtitle%3DJ.%2520Neurochem.%26date%3D1997%26volume%3D69%26spage%3D174%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref335"><div class="reference"><strong class="refLabel"><a href="#ref335" class="rightTabRefNumLink">335</a></strong><div class="NLM_citation" id="rightTab-cit335"><span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neale, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomper, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">NAAG peptidase inhibitors and their potential for diagnosis and therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1026</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref335/cit335&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fnrd1903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref335/cit335&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16341066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref335/cit335&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1015-1026&author=J.+Zhouauthor=J.+H.+Nealeauthor=M.+G.+Pomperauthor=A.+P.+Kozikowski&title=NAAG+peptidase+inhibitors+and+their+potential+for+diagnosis+and+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit335R"><div class="casContent"><span class="casTitleNuber">335</span><div class="casTitle"><span class="NLM_cas:atitle">NAAG peptidase inhibitors and their potential for diagnosis and therapy</span></div><div class="casAuthors">Zhou, Jia; Neale, Joseph H.; Pomper, Martin G.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1015-1026</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Modulation of N-acetyl-L-aspartyl-L-glutamate peptidase activity with small-mol. inhibitors holds promise for a wide variety of diseases that involve glutamatergic transmission, and has implications for the diagnosis and therapy of cancer.  This new class of compds., of which at least one has entered clin. trials and proven to be well tolerated, has demonstrated efficacy in exptl. models of pain, schizophrenia, amyotrophic lateral sclerosis, traumatic brain injury and, when appropriately functionalized, can image prostate cancer.  Further investigation of these promising drug candidates will be needed to bring them to the marketplace.  The recent publication of the x-ray crystal structure for the enzymic target of these compds. should facilitate the development of other new agents with enhanced activity that could improve both the diagnosis and treatment of neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5SLEevwkG37Vg90H21EOLACvtfcHk0ljBv6x000RkqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjJ&md5=0b869a52270f951f4e03c458672e373f</span></div><a href="/servlet/linkout?suffix=cit335&amp;dbid=16384&amp;doi=10.1038%2Fnrd1903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1903%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DNeale%26aufirst%3DJ.%2BH.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DNAAG%2520peptidase%2520inhibitors%2520and%2520their%2520potential%2520for%2520diagnosis%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D1015%26epage%3D1026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref336"><div class="reference"><strong class="refLabel"><a href="#ref336" class="rightTabRefNumLink">336</a></strong><div class="NLM_citation" id="rightTab-cit336"><span><span class="NLM_contrib-group">Salmi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, B.</span><span> </span><span class="NLM_article-title">Dihydrexidine. The First Full Dopamine D1 Receptor Agonist</span> <span class="citation_source-journal">CNS Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">230</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=230-242&author=P.+Salmiauthor=R.+Isacsonauthor=B.+Kull&title=Dihydrexidine.+The+First+Full+Dopamine+D1+Receptor+Agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit336&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalmi%26aufirst%3DP.%26aulast%3DIsacson%26aufirst%3DR.%26aulast%3DKull%26aufirst%3DB.%26atitle%3DDihydrexidine.%2520The%2520First%2520Full%2520Dopamine%2520D1%2520Receptor%2520Agonist%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2004%26volume%3D10%26spage%3D230%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref337"><div class="reference"><strong class="refLabel"><a href="#ref337" class="rightTabRefNumLink">337</a></strong><div class="NLM_citation" id="rightTab-cit337"><span><span class="NLM_contrib-group">Castner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman-Rakic, P. S.</span><span> </span><span class="NLM_article-title">Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">2020</span><span class="NLM_x">–</span> <span class="NLM_lpage">2022</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=2020-2022&author=S.+A.+Castnerauthor=G.+V.+Williamsauthor=P.+S.+Goldman-Rakic&title=Reversal+of+antipsychotic-induced+working+memory+deficits+by+short-term+dopamine+D1+receptor+stimulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit337&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCastner%26aufirst%3DS.%2BA.%26aulast%3DWilliams%26aufirst%3DG.%2BV.%26aulast%3DGoldman-Rakic%26aufirst%3DP.%2BS.%26atitle%3DReversal%2520of%2520antipsychotic-induced%2520working%2520memory%2520deficits%2520by%2520short-term%2520dopamine%2520D1%2520receptor%2520stimulation%26jtitle%3DScience%26date%3D2000%26volume%3D287%26spage%3D2020%26epage%3D2022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref338"><div class="reference"><strong class="refLabel"><a href="#ref338" class="rightTabRefNumLink">338</a></strong><div class="NLM_citation" id="rightTab-cit338"><span><span class="NLM_contrib-group">Goldman-Rakic, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siever, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G. V.</span><span> </span><span class="NLM_article-title">Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref338/cit338&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs00213-004-1793-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref338/cit338&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15118803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref338/cit338&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVahtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2004&pages=3-16&author=P.+S.+Goldman-Rakicauthor=S.+A.+Castnerauthor=T.+H.+Svenssonauthor=L.+J.+Sieverauthor=G.+V.+Williams&title=Targeting+the+dopamine+D1+receptor+in+schizophrenia%3A+insights+for+cognitive+dysfunction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit338R"><div class="casContent"><span class="casTitleNuber">338</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D1 receptor in schizophrenia: Insights for cognitive dysfunction</span></div><div class="casAuthors">Goldman-Rakic, Patricia S.; Castner, Stacy A.; Svensson, Torgny H.; Siever, Larry J.; Williams, Graham V.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review with refs.  Background and rationale: Reinstatement of the function of working memory, the cardinal cognitive process essential for human reasoning and judgment, is potentially the most intractable problem for the treatment of schizophrenia.  Since deficits in working memory are assocd. with dopamine dysregulation and altered D1 receptor signaling within prefrontal cortex, we present the case for targeting novel drug therapies towards enhancing prefrontal D1 stimulation for the amelioration of the debilitating cognitive deficits in schizophrenia.  Objectives: This review examines the role of dopamine in regulating cellular and circuit function within prefrontal cortex in order to understand the significance of the dopamine dysregulation found in schizophrenia and related non-human primate models.  By revealing the assocns. among prefrontal neuronal function, dopamine and D1 signaling, and cognition, we seek to pinpoint the mechanisms by which dopamine modulates working memory processes and how these mechanisms may be exploited to improve cognitive function.  Results and conclusions: Dopamine deficiency within dorsolateral prefrontal cortex leads to abnormal recruitment of this region by cognitive tasks.  Both preclin. and clin. studies have demonstrated a direct relationship between prefrontal dopamine function and the integrity of working memory, suggesting that insufficient D1 receptor signaling in this region results in cognitive deficits.  Moreover, working memory deficits can be ameliorated by treatments that augment D1 receptor stimulation, indicating that this target presents a unique opportunity for the restoration of cognitive function in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp539YARYKsU7Vg90H21EOLACvtfcHk0linNiQNmtFktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVahtL0%253D&md5=814e05ee453cf0aaf6ae9b7b0fe0ef59</span></div><a href="/servlet/linkout?suffix=cit338&amp;dbid=16384&amp;doi=10.1007%2Fs00213-004-1793-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-004-1793-y%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman-Rakic%26aufirst%3DP.%2BS.%26aulast%3DCastner%26aufirst%3DS.%2BA.%26aulast%3DSvensson%26aufirst%3DT.%2BH.%26aulast%3DSiever%26aufirst%3DL.%2BJ.%26aulast%3DWilliams%26aufirst%3DG.%2BV.%26atitle%3DTargeting%2520the%2520dopamine%2520D1%2520receptor%2520in%2520schizophrenia%253A%2520insights%2520for%2520cognitive%2520dysfunction%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D2004%26volume%3D174%26spage%3D3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref339"><div class="reference"><strong class="refLabel"><a href="#ref339" class="rightTabRefNumLink">339</a></strong><div class="NLM_citation" id="rightTab-cit339"><span><span class="NLM_contrib-group">Millan, M. J.; Mannoury, I. C.; Novi, F.; Maggio, R.; Audinot, V.; Newman-Tancredi, A.; Cussac, D.; Pasteau, V.; Boutin, J. A.; Dubuffet, T.; Lavielle, G.</span><span> </span><span class="NLM_article-title">S33138, a preferential dopamine D<sub>3</sub> versus D<sub>2</sub> receptor antagonist and potential antipsychotic agent. I. Receptor-binding profile and functional actions at G-protein coupled receptors</span>.  <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Millan%2C+M.+J.%3B+Mannoury%2C+I.+C.%3B+Novi%2C+F.%3B+Maggio%2C+R.%3B+Audinot%2C+V.%3B+Newman-Tancredi%2C+A.%3B+Cussac%2C+D.%3B+Pasteau%2C+V.%3B+Boutin%2C+J.+A.%3B+Dubuffet%2C+T.%3B+Lavielle%2C+G.+S33138%2C+a+preferential+dopamine+D3+versus+D2+receptor+antagonist+and+potential+antipsychotic+agent.+I.+Receptor-binding+profile+and+functional+actions+at+G-protein+coupled+receptors.+J.+Pharmacol.+Exp.+Ther.%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit339&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DS33138%252C%2520a%2520preferential%2520dopamine%2520D3%2520versus%2520D2%2520receptor%2520antagonist%2520and%2520potential%2520antipsychotic%2520agent.%2520I.%2520Receptor-binding%2520profile%2520and%2520functional%2520actions%2520at%2520G-protein%2520coupled%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref340"><div class="reference"><strong class="refLabel"><a href="#ref340" class="rightTabRefNumLink">340</a></strong><div class="NLM_citation" id="rightTab-cit340"><span><span class="NLM_contrib-group">Van Tol, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunzow, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niznik, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, O.</span><span> </span><span class="NLM_article-title">Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">–</span> <span class="NLM_lpage">614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref340/cit340&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2F350610a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref340/cit340&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=1840645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref340/cit340&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK38XhsV2n" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1991&pages=610-614&author=H.+H.+Van+Tolauthor=J.+R.+Bunzowauthor=H.+C.+Guanauthor=R.+K.+Sunaharaauthor=P.+Seemanauthor=H.+B.+Niznikauthor=O.+Civelli&title=Cloning+of+the+gene+for+a+human+dopamine+D4+receptor+with+high+affinity+for+the+antipsychotic+clozapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit340R"><div class="casContent"><span class="casTitleNuber">340</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine</span></div><div class="casAuthors">Van Tol, Hubert H. M.; Bunzow, James R.; Guan, Hong Chang; Sunahara, Roger K.; Seeman, Philip; Niznik, Hyman B.; Civelli, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">6319</span>),
    <span class="NLM_cas:pages">610-14</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The cloning of a gene that encodes a clozapine-sensitive dopamine receptor, D4 is reported.  The D4 receptor gene has high homol. to the human dopamine D2 and D3 receptor genes.  The pharmacol. characteristics of this receptor resemble those of the D2 and D3 receptors, but its affinity for clozapine is one order of magnitude higher.  Recognition and characterization of this clozapine neuroleptic site may prove useful in the design of new types of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpneU9aH4jnoLVg90H21EOLACvtfcHk0linNiQNmtFktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsV2n&md5=de5f7ade54d85f54181c53d15d6af169</span></div><a href="/servlet/linkout?suffix=cit340&amp;dbid=16384&amp;doi=10.1038%2F350610a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F350610a0%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BTol%26aufirst%3DH.%2BH.%26aulast%3DBunzow%26aufirst%3DJ.%2BR.%26aulast%3DGuan%26aufirst%3DH.%2BC.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DNiznik%26aufirst%3DH.%2BB.%26aulast%3DCivelli%26aufirst%3DO.%26atitle%3DCloning%2520of%2520the%2520gene%2520for%2520a%2520human%2520dopamine%2520D4%2520receptor%2520with%2520high%2520affinity%2520for%2520the%2520antipsychotic%2520clozapine%26jtitle%3DNature%26date%3D1991%26volume%3D350%26spage%3D610%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref341"><div class="reference"><strong class="refLabel"><a href="#ref341" class="rightTabRefNumLink">341</a></strong><div class="NLM_citation" id="rightTab-cit341"><span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grady, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsapakis, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarazi, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldessarini, R. J.</span><span> </span><span class="NLM_article-title">Regulation of working memory by dopamine D4 receptor in rats</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1648</span><span class="NLM_x">–</span> <span class="NLM_lpage">1655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=1648-1655&author=K.+Zhangauthor=C.+J.+Gradyauthor=E.+M.+Tsapakisauthor=S.+L.+Andersenauthor=F.+I.+Taraziauthor=R.+J.+Baldessarini&title=Regulation+of+working+memory+by+dopamine+D4+receptor+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit341&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DGrady%26aufirst%3DC.%2BJ.%26aulast%3DTsapakis%26aufirst%3DE.%2BM.%26aulast%3DAndersen%26aufirst%3DS.%2BL.%26aulast%3DTarazi%26aufirst%3DF.%2BI.%26aulast%3DBaldessarini%26aufirst%3DR.%2BJ.%26atitle%3DRegulation%2520of%2520working%2520memory%2520by%2520dopamine%2520D4%2520receptor%2520in%2520rats%26jtitle%3DNeuropsychopharmacology%26date%3D2004%26volume%3D29%26spage%3D1648%26epage%3D1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref342"><div class="reference"><strong class="refLabel"><a href="#ref342" class="rightTabRefNumLink">342</a></strong><div class="NLM_citation" id="rightTab-cit342"><span><span class="NLM_contrib-group">Arnsten, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, K.</span><span> </span><span class="NLM_article-title">The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2000&pages=405-410&author=A.+F.+Arnstenauthor=B.+Murphyauthor=K.+Merchant&title=The+selective+dopamine+D4+receptor+antagonist%2C+PNU-101387G%2C+prevents+stress-induced+cognitive+deficits+in+monkeys"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit342&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArnsten%26aufirst%3DA.%2BF.%26aulast%3DMurphy%26aufirst%3DB.%26aulast%3DMerchant%26aufirst%3DK.%26atitle%3DThe%2520selective%2520dopamine%2520D4%2520receptor%2520antagonist%252C%2520PNU-101387G%252C%2520prevents%2520stress-induced%2520cognitive%2520deficits%2520in%2520monkeys%26jtitle%3DNeuropsychopharmacology%26date%3D2000%26volume%3D23%26spage%3D405%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref343"><div class="reference"><strong class="refLabel"><a href="#ref343" class="rightTabRefNumLink">343</a></strong><div class="NLM_citation" id="rightTab-cit343"><span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collinson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragan, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridgill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saywell, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tricklebank, M. D.</span><span> </span><span class="NLM_article-title">L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">1256</span><span class="NLM_x">–</span> <span class="NLM_lpage">1263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref343/cit343&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9400001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref343/cit343&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1cXis1Cqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=1256-1263&author=L.+J.+Bristowauthor=N.+Collinsonauthor=G.+P.+Cookauthor=N.+Curtisauthor=S.+B.+Freedmanauthor=J.+J.+Kulagowskiauthor=P.+D.+Leesonauthor=S.+Patelauthor=C.+I.+Raganauthor=M.+Ridgillauthor=K.+L.+Saywellauthor=M.+D.+Tricklebank&title=L-745%2C870%2C+a+subtype+selective+dopamine+D4+receptor+antagonist%2C+does+not+exhibit+a+neuroleptic-like+profile+in+rodent+behavioral+tests"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit343R"><div class="casContent"><span class="casTitleNuber">343</span><div class="casTitle"><span class="NLM_cas:atitle">L-745870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests</span></div><div class="casAuthors">Bristow, Linda J.; Collinson, Neil; Cook, Gina P.; Curtis, Neil; Freedman, Stephen B.; Kulagowski, Janusz J.; Leeson, Paul D.; Patel, Smita; Ragan, C. Ian; Ridgill, Mark; Saywell, Kay L.; Tricklebank, Mark D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1256-1263</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">This study examd. the high-affinity, selective dopamine D4 receptor antagonist, L-745870 (3-{[4-(4-chlorophenyl)piperazin-1-yl]methyl}-1H-pyrrolo[2,3-b]pyridine) in rodent behavioral models used to predict antipsychotic potential and side-effect liabilities in humans.  In contrast to the classical neuroleptic, haloperidol, and the atypical neuroleptic, clozapine, L-745870 failed to antagonize amphetamine-induced hyperactivity in mice or impair conditioned avoidance responding in the rat at doses selectively blocking D4 receptors.  Furthermore, L-745870 failed to reverse the deficit in prepulse inhibition of acoustic startle responding induced by the nonselective dopamine D2/3/4 receptor agonist apomorphine, an effect which was abolished in rats pretreated with the D2/3 receptor antagonist, raclopride (0.2 mg/kg s.c.).  L-745870 had no effect on apomorphine-induced stereotypy in the rat but did induce catalepsy in the mouse, albeit at a high dose of 100 mg/kg, which is likely to occupy dopamine D2 receptors in vivo.  High doses also impaired motor performance; in rats L-745870 significantly reduced spontaneous locomotor activity (min. ED = 30 mg/kg) and in mice, L-745870 reduced the time spent on a rotarod revolving at 15 rpm (min. ED = 100 mg/kg).  Altogether these results suggest that dopamine D4 receptor antagonism is not responsible for the ability of clozapine to attenuate amphetamine-induced hyperactivity and conditioned avoidance responding in rodents.  Furthermore, the lack of effect of L-745870 in these behavioral tests is consistent with the inability of the compd. to alleviate psychotic symptoms in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-i7KBCKHpxrVg90H21EOLACvtfcHk0linNiQNmtFktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1Cqtg%253D%253D&md5=6fa87b67fd755980d2c41851e444de1b</span></div><a href="/servlet/linkout?suffix=cit343&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DCollinson%26aufirst%3DN.%26aulast%3DCook%26aufirst%3DG.%2BP.%26aulast%3DCurtis%26aufirst%3DN.%26aulast%3DFreedman%26aufirst%3DS.%2BB.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DRagan%26aufirst%3DC.%2BI.%26aulast%3DRidgill%26aufirst%3DM.%26aulast%3DSaywell%26aufirst%3DK.%2BL.%26aulast%3DTricklebank%26aufirst%3DM.%2BD.%26atitle%3DL-745%252C870%252C%2520a%2520subtype%2520selective%2520dopamine%2520D4%2520receptor%2520antagonist%252C%2520does%2520not%2520exhibit%2520a%2520neuroleptic-like%2520profile%2520in%2520rodent%2520behavioral%2520tests%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D1256%26epage%3D1263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref344"><div class="reference"><strong class="refLabel"><a href="#ref344" class="rightTabRefNumLink">344</a></strong><div class="NLM_citation" id="rightTab-cit344"><span><span class="NLM_contrib-group">Bristow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragan, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seabrook, G. R.</span><span> </span><span class="NLM_article-title">Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1997&pages=186-188&author=L.+J.+Bristowauthor=M.+S.+Kramerauthor=J.+Kulagowskiauthor=S.+Patelauthor=C.+I.+Raganauthor=G.+R.+Seabrook&title=Schizophrenia+and+L-745%2C870%2C+a+novel+dopamine+D4+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit344&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26aulast%3DKramer%26aufirst%3DM.%2BS.%26aulast%3DKulagowski%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DRagan%26aufirst%3DC.%2BI.%26aulast%3DSeabrook%26aufirst%3DG.%2BR.%26atitle%3DSchizophrenia%2520and%2520L-745%252C870%252C%2520a%2520novel%2520dopamine%2520D4%2520receptor%2520antagonist%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1997%26volume%3D18%26spage%3D186%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref345"><div class="reference"><strong class="refLabel"><a href="#ref345" class="rightTabRefNumLink">345</a></strong><div class="NLM_citation" id="rightTab-cit345"><span><span class="NLM_contrib-group">Gazi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nozulak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoeffter, P.</span><span> </span><span class="NLM_article-title">NGD 94-1 as an agonist at human recombinant dopamine D4.4 receptors expressed in HEK293 cells</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">R9</span><span class="NLM_x">–</span> <span class="NLM_lpage">R10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1999&pages=R9-R10&author=L.+Gaziauthor=B.+Sommerauthor=J.+Nozulakauthor=P.+Schoeffter&title=NGD+94-1+as+an+agonist+at+human+recombinant+dopamine+D4.4+receptors+expressed+in+HEK293+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit345&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGazi%26aufirst%3DL.%26aulast%3DSommer%26aufirst%3DB.%26aulast%3DNozulak%26aufirst%3DJ.%26aulast%3DSchoeffter%26aufirst%3DP.%26atitle%3DNGD%252094-1%2520as%2520an%2520agonist%2520at%2520human%2520recombinant%2520dopamine%2520D4.4%2520receptors%2520expressed%2520in%2520HEK293%2520cells%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D372%26spage%3DR9%26epage%3DR10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref346"><div class="reference"><strong class="refLabel"><a href="#ref346" class="rightTabRefNumLink">346</a></strong><div class="NLM_citation" id="rightTab-cit346"><span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croston, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currier, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalding, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs-Thomson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacksell, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span> </span><span class="NLM_article-title">5-Hydroxytryptamine<sub>2a</sub> receptor inverse agonists as antipsychotics</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref346/cit346&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11561089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref346/cit346&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFWltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=268-276&author=D.+M.+Weinerauthor=E.+S.+Bursteinauthor=N.+Nashauthor=G.+E.+Crostonauthor=E.+A.+Currierauthor=K.+E.+Vanoverauthor=S.+C.+Harveyauthor=E.+Donohueauthor=H.+C.+Hansenauthor=C.+M.+Anderssonauthor=T.+A.+Spaldingauthor=D.+F.+Gibsonauthor=K.+Krebs-Thomsonauthor=S.+B.+Powellauthor=M.+A.+Geyerauthor=U.+Hacksellauthor=M.+R.+Brann&title=5-Hydroxytryptamine2a+receptor+inverse+agonists+as+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit346R"><div class="casContent"><span class="casTitleNuber">346</span><div class="casTitle"><span class="NLM_cas:atitle">5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics</span></div><div class="casAuthors">Weiner, D. M.; Burstein, E. S.; Nash, N.; Croston, G. E.; Currier, E. A.; Vanover, K. E.; Harvey, S. C.; Donohue, E.; Hansen, H. C.; Andersson, C. M.; Spalding, T. A.; Gibson, D. F. C.; Krebs-Thomson, K.; Powell, S. B.; Geyer, M. A.; Hacksell, U.; Brann, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">268-276</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have used a cell-based functional assay to define the pharmacol. profiles of a wide range of central nervous system active compds. as agonists, competitive antagonists, and inverse agonists at almost all known monoaminergic G-protein-coupled receptor (GPCR) subtypes.  Detailed profiling of 40 antipsychotics confirmed that as expected, most of these agents are potent competitive antagonists of the dopamine D2 receptor.  Surprisingly, this anal. also revealed that most are potent and fully efficacious 5-hydroxytryptamine (5-HT)2A receptor inverse agonists.  No other mol. property was shared as universally by this class of compds.  Furthermore, comparisons of receptor potencies revealed that antipsychotics with the highest extrapyramidal side effects (EPS) liability are significantly more potent at D2 receptors, the EPS-sparing atypical agents had relatively higher potencies at 5-HT2A receptors, while three were significantly more potent at 5-HT2A receptors.  Functional high-throughput screening of a diverse chem. library identified 530 ligands with inverse agonist activity at 5-HT2A receptors, including several series of compds. related to known antipsychotics, as well as a no. of novel chemistries.  An analog of one of the novel chem. series, AC-90179, was pharmacol. profiled against the remaining monoaminergic GPCRs and a highly selective 5-HT2A receptor inverse agonist.  The behavioral pharmacol. of AC-90179 is characteristic of an atypical antipsychotic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz5gySB-lx-LVg90H21EOLACvtfcHk0li4Ao8wa_uLUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFWltb8%253D&md5=0dfb323ac371f6c494236e32eb2ce032</span></div><a href="/servlet/linkout?suffix=cit346&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26aulast%3DNash%26aufirst%3DN.%26aulast%3DCroston%26aufirst%3DG.%2BE.%26aulast%3DCurrier%26aufirst%3DE.%2BA.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DHarvey%26aufirst%3DS.%2BC.%26aulast%3DDonohue%26aufirst%3DE.%26aulast%3DHansen%26aufirst%3DH.%2BC.%26aulast%3DAndersson%26aufirst%3DC.%2BM.%26aulast%3DSpalding%26aufirst%3DT.%2BA.%26aulast%3DGibson%26aufirst%3DD.%2BF.%26aulast%3DKrebs-Thomson%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DS.%2BB.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DHacksell%26aufirst%3DU.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26atitle%3D5-Hydroxytryptamine2a%2520receptor%2520inverse%2520agonists%2520as%2520antipsychotics%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D299%26spage%3D268%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref347"><div class="reference"><strong class="refLabel"><a href="#ref347" class="rightTabRefNumLink">347</a></strong><div class="NLM_citation" id="rightTab-cit347"><span><span class="NLM_contrib-group">Navailles, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spampinato, U.</span><span> </span><span class="NLM_article-title">Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin<sub>2C</sub> receptors</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1311</span><span class="NLM_x">–</span> <span class="NLM_lpage">1319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref347/cit347&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1111%2Fj.1471-4159.2006.04188.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref347/cit347&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17018023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref347/cit347&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yks7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=1311-1319&author=S.+Navaillesauthor=D.+Moisonauthor=D.+Ryczkoauthor=U.+Spampinato&title=Region-dependent+regulation+of+mesoaccumbens+dopamine+neurons+in+vivo+by+the+constitutive+activity+of+central+serotonin2C+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit347R"><div class="casContent"><span class="casTitleNuber">347</span><div class="casTitle"><span class="NLM_cas:atitle">Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin 2C receptors</span></div><div class="casAuthors">Navailles, Sylvia; Moison, Delphine; Ryczko, Dimitri; Spampinato, Umberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1311-1319</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Central serotonin 2C receptors (5-HT2CRs) control the mesoaccumbens dopamine (DA) pathway.  This control involves the constitutive activity (CA) of 5-HT2CRs, and is thought to engage regionally distinct populations of 5-HT2CRs, leading to opposite functional effects.  Here, using in vivo microdialysis in halothane-anesthetized rats, we investigated the relative contribution of ventral tegmental area (VTA) and nucleus accumbens shell (NAc) 5-HT2CRs in the phasic/tonic control of accumbal DA release, to specifically identify the nature (inhibition/excitation) of the control, and the role of the 5-HT2CR CA.  Intra-VTA injections of the selective 5-HT2CR antagonists SB 242084 and/or SB 243213 (0.1-0.5 μg/0.2 μL) prevented the decrease in accumbal DA outflow induced by the 5-HT2CR agonist Ro 60-0175 (3 mg/kg, i.p), but did not affect the increase in DA outflow induced by the 5-HT2CR inverse agonist SB 206553 (5 mg/kg, i.p).  Intra-NAc infusions of SB 242084 (0.1-1 μM) blocked Ro 60-0175- and SB 206553-induced changes of DA outflow.  Intra-NAc, but not intra-VTA administration of SB 206553 increased basal DA outflow.  These findings demonstrate that both VTA and NAc 5-HT2CRs participate in the inhibitory control exerted by 5-HT2CRs on accumbal DA release, and that the NAc shell may represent a primary action site for the CA of 5-HT2CRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPNwO4upWLArVg90H21EOLACvtfcHk0li4Ao8wa_uLUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yks7nN&md5=8e67ee3560b9e43c3b2f7add6f0cc388</span></div><a href="/servlet/linkout?suffix=cit347&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04188.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04188.x%26sid%3Dliteratum%253Aachs%26aulast%3DNavailles%26aufirst%3DS.%26aulast%3DMoison%26aufirst%3DD.%26aulast%3DRyczko%26aufirst%3DD.%26aulast%3DSpampinato%26aufirst%3DU.%26atitle%3DRegion-dependent%2520regulation%2520of%2520mesoaccumbens%2520dopamine%2520neurons%2520in%2520vivo%2520by%2520the%2520constitutive%2520activity%2520of%2520central%2520serotonin2C%2520receptors%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D99%26spage%3D1311%26epage%3D1319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref348"><div class="reference"><strong class="refLabel"><a href="#ref348" class="rightTabRefNumLink">348</a></strong><div class="NLM_citation" id="rightTab-cit348"><span><span class="NLM_contrib-group">Glatt, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snowman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Clozapine: selective labeling of sites resembling 5HT<sub>6</sub> serotonin receptors may reflect psychoactive profile</span> <span class="citation_source-journal">Mol. Med</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref348/cit348&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8521297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref348/cit348&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2MXmsVGgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=398-406&author=C.+E.+Glattauthor=A.+M.+Snowmanauthor=D.+R.+Sibleyauthor=S.+H.+Snyder&title=Clozapine%3A+selective+labeling+of+sites+resembling+5HT6+serotonin+receptors+may+reflect+psychoactive+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit348R"><div class="casContent"><span class="casTitleNuber">348</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine: selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile</span></div><div class="casAuthors">Glatt, Charles E.; Snowman, Adele M.; Sibley, David R.; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Baltimore, MD, United States)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-406</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    </div><div class="casAbstract">Clozapine, the classic atypical neuroleptic, exerts therapeutic actions in schizophrenic patients unresponsive to most neuroleptics.  Clozapine interacts with numerous neurotransmitter receptors, and selective actions at novel subtypes of dopamine and serotonin receptors have been proposed to explain clozapine's unique psychotropic effects.  To identify sites with which clozapine preferentially interacts in a therapeutic setting, we have characterized clozapine binding to brain membranes.  [3H]Clozapine binding was examd. in rat brain membranes as well as cloned-expressed 5-HT6 serotonin receptors.  [3H]Clozapine binds with low nanomolar affinity to two distinct sites.  One reflects muscarinic receptors consistent with the drug's anticholinergic actions.  The drug competition profile of the second site most closely resembles 5HT6 serotonin receptors, though serotonin itself displays low affinity.  [3H]Clozapine binding levels are similar in all brain regions examd. with no concn. in the corpus striatum.  Besides muscarinic receptors, clozapine primarily labels sites with properties resembling 5HT6 serotonin receptors.  If this is also the site with which clozapine principally interacts in intact human brain, it may account for the unique beneficial actions of clozapine and other atypical neuroleptics, and provide a mol. target for developing new, safer, and more effective agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSPrW-DMBTRbVg90H21EOLACvtfcHk0lj9qZtdpJFRwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsVGgtbc%253D&md5=1b08638cfcf1f7262c25647425b98f5a</span></div><a href="/servlet/linkout?suffix=cit348&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlatt%26aufirst%3DC.%2BE.%26aulast%3DSnowman%26aufirst%3DA.%2BM.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DClozapine%253A%2520selective%2520labeling%2520of%2520sites%2520resembling%25205HT6%2520serotonin%2520receptors%2520may%2520reflect%2520psychoactive%2520profile%26jtitle%3DMol.%2520Med%26date%3D1995%26volume%3D1%26spage%3D398%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref349"><div class="reference"><strong class="refLabel"><a href="#ref349" class="rightTabRefNumLink">349</a></strong><div class="NLM_citation" id="rightTab-cit349"><span><span class="NLM_contrib-group">Mitchell, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumaier, J. F.</span><span> </span><span class="NLM_article-title">5-HT<sub>6</sub> receptors: a novel target for cognitive enhancement</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref349/cit349&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pharmthera.2005.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref349/cit349&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16005519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref349/cit349&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Olsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2005&pages=320-333&author=E.+S.+Mitchellauthor=J.+F.+Neumaier&title=5-HT6+receptors%3A+a+novel+target+for+cognitive+enhancement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit349R"><div class="casContent"><span class="casTitleNuber">349</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT6 receptors: a novel target for cognitive enhancement</span></div><div class="casAuthors">Mitchell, Ellen S.; Neumaier, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">320-333</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Over the past decade, there has been increasing interest in the role of serotonin 6 (5-HT6) receptors in higher cognitive processes such as memory.  Polymorphisms of the 5-HT6 receptor have been implicated in syndromes that affect cognition, such as schizophrenia and dementia.  Manipulation of 5-HT6 receptor activity alters the transmission of several neurotransmitters important in memory: acetylcholine and glutamate, as well as dopamine, gamma -aminobutyric acid (GABA), epinephrine (E), and norepinephrine (NE).  Several 5-HT6 antagonists have been developed, advancing the understanding of the relationship between 5-HT6 blockade and memory consolidation in diverse learning paradigms.  There is also evidence that 5-HT6 receptor activity affects anxiety behaviors and may be involved in the pathophysiol. of schizophrenia.  Several clin. useful atypical antipsychotics and antidepressants have 5-HT6 affinity, but recently developed selective 5-HT6 receptor antagonists may present attractive, new therapeutic options for several types of disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVJqq1oagMarVg90H21EOLACvtfcHk0lj9qZtdpJFRwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Olsr%252FO&md5=a3b24549c7ffbee5d9ae0f119ea258b7</span></div><a href="/servlet/linkout?suffix=cit349&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DE.%2BS.%26aulast%3DNeumaier%26aufirst%3DJ.%2BF.%26atitle%3D5-HT6%2520receptors%253A%2520a%2520novel%2520target%2520for%2520cognitive%2520enhancement%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D108%26spage%3D320%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref350"><div class="reference"><strong class="refLabel"><a href="#ref350" class="rightTabRefNumLink">350</a></strong><div class="NLM_citation" id="rightTab-cit350"><span><span class="NLM_contrib-group">Holenz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merce, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codony, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buschmann, H.</span><span> </span><span class="NLM_article-title">Medicinal chemistry strategies to 5-HT<sub>6</sub> receptor ligands as potential cognitive enhancers and antiobesity agents</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=283-299&author=J.+Holenzauthor=P.+J.+Pauwelsauthor=J.+L.+Diazauthor=R.+Merceauthor=X.+Codonyauthor=H.+Buschmann&title=Medicinal+chemistry+strategies+to+5-HT6+receptor+ligands+as+potential+cognitive+enhancers+and+antiobesity+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit350&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DPauwels%26aufirst%3DP.%2BJ.%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DMerce%26aufirst%3DR.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DBuschmann%26aufirst%3DH.%26atitle%3DMedicinal%2520chemistry%2520strategies%2520to%25205-HT6%2520receptor%2520ligands%2520as%2520potential%2520cognitive%2520enhancers%2520and%2520antiobesity%2520agents%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2006%26volume%3D11%26spage%3D283%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref351"><div class="reference"><strong class="refLabel"><a href="#ref351" class="rightTabRefNumLink">351</a></strong><div class="NLM_citation" id="rightTab-cit351"><span><span class="NLM_contrib-group">King, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleight, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolley, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsden, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fone, K. C.</span><span> </span><span class="NLM_article-title">5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=195-204&author=M.+V.+Kingauthor=A.+J.+Sleightauthor=M.+L.+Woolleyauthor=I.+A.+Tophamauthor=C.+A.+Marsdenauthor=K.+C.+Fone&title=5-HT6+receptor+antagonists+reverse+delay-dependent+deficits+in+novel+object+discrimination+by+enhancing+consolidation%E2%80%94an+effect+sensitive+to+NMDA+receptor+antagonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit351&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DM.%2BV.%26aulast%3DSleight%26aufirst%3DA.%2BJ.%26aulast%3DWoolley%26aufirst%3DM.%2BL.%26aulast%3DTopham%26aufirst%3DI.%2BA.%26aulast%3DMarsden%26aufirst%3DC.%2BA.%26aulast%3DFone%26aufirst%3DK.%2BC.%26atitle%3D5-HT6%2520receptor%2520antagonists%2520reverse%2520delay-dependent%2520deficits%2520in%2520novel%2520object%2520discrimination%2520by%2520enhancing%2520consolidation%25E2%2580%2594an%2520effect%2520sensitive%2520to%2520NMDA%2520receptor%2520antagonism%26jtitle%3DNeuropharmacology%26date%3D2004%26volume%3D47%26spage%3D195%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref352"><div class="reference"><strong class="refLabel"><a href="#ref352" class="rightTabRefNumLink">352</a></strong><div class="NLM_citation" id="rightTab-cit352"><span><span class="NLM_contrib-group">Lindner, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodges, D. B.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orie, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsa, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barten, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guss, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillman, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starrett, J. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribkoff, V. K.</span><span> </span><span class="NLM_article-title">An assessment of the effects of serotonin 6 (5-HT<sub>6</sub>) receptor antagonists in rodent models of learning</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref352/cit352&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1124%2Fjpet.103.056002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref352/cit352&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12975483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref352/cit352&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Shsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=682-691&author=M.+D.+Lindnerauthor=D.+B.+Hodgesauthor=J.+B.+Hoganauthor=A.+F.+Orieauthor=J.+A.+Corsaauthor=D.+M.+Bartenauthor=C.+Polsonauthor=B.+J.+Robertsonauthor=V.+L.+Gussauthor=K.+W.+Gillmanauthor=J.+E.+Starrettauthor=V.+K.+Gribkoff&title=An+assessment+of+the+effects+of+serotonin+6+%285-HT6%29+receptor+antagonists+in+rodent+models+of+learning"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit352R"><div class="casContent"><span class="casTitleNuber">352</span><div class="casTitle"><span class="NLM_cas:atitle">An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning</span></div><div class="casAuthors">Lindner, Mark D.; Hodges, Donald B., Jr.; Hogan, John B.; Orie, Anitra F.; Corsa, Jason A.; Barten, Donna M.; Polson, Craig; Robertson, Barbara J.; Guss, Valerie L.; Gillman, Kevin W.; Starrett, John E., Jr.; Gribkoff, Valentin K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">682-691</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Antagonists of serotonin 6 (5-HT6) receptors have been reported to enhance cognition in animal models of learning, although this finding has not been universal.  We have assessed the therapeutic potential of the specific 5-HT6 receptor antagonists 4-amino-N-(2,6-bis-methylamino-pyrimidin-4-yl)-benzenesulfonamide (Ro 04-6790) and 5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2- benzothiophenesulfonamide (SB-271046) in rodent models of cognitive function.  Although mice express the 5-HT6 receptor and the function of this receptor has been investigated in mice, all reports of activity with 5-HT6 receptor antagonists have used rat models.  In the present study, receptor binding revealed that the pharmacol. properties of the mouse receptor are different from the rat and human receptor: Ro 04-6790 does not bind to the mouse 5-HT6 receptor, so all in vivo testing included in the present report was conducted in rats.  We replicated previous reports that 5-HT6 receptor antagonists produce a stretching syndrome previously shown to be mediated through cholinergic mechanisms, but Ro 04-6790 and SB-271046 failed to attenuate scopolamine-induced deficits in a test of contextual fear conditioning.  We also failed to replicate the significant effects reported previously in both an autoshaping task and in a version of the Morris water maze.  The results of our expts. are not consistent with previous reports that suggested that 5-HT6 antagonists might have therapeutic potential for cognitive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1aBFn1xz7d7Vg90H21EOLACvtfcHk0lj9qZtdpJFRwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Shsrg%253D&md5=43eec6e55d870801aca53ebdcf11e987</span></div><a href="/servlet/linkout?suffix=cit352&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.056002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.056002%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DM.%2BD.%26aulast%3DHodges%26aufirst%3DD.%2BB.%26aulast%3DHogan%26aufirst%3DJ.%2BB.%26aulast%3DOrie%26aufirst%3DA.%2BF.%26aulast%3DCorsa%26aufirst%3DJ.%2BA.%26aulast%3DBarten%26aufirst%3DD.%2BM.%26aulast%3DPolson%26aufirst%3DC.%26aulast%3DRobertson%26aufirst%3DB.%2BJ.%26aulast%3DGuss%26aufirst%3DV.%2BL.%26aulast%3DGillman%26aufirst%3DK.%2BW.%26aulast%3DStarrett%26aufirst%3DJ.%2BE.%26aulast%3DGribkoff%26aufirst%3DV.%2BK.%26atitle%3DAn%2520assessment%2520of%2520the%2520effects%2520of%2520serotonin%25206%2520%25285-HT6%2529%2520receptor%2520antagonists%2520in%2520rodent%2520models%2520of%2520learning%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D307%26spage%3D682%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref353"><div class="reference"><strong class="refLabel"><a href="#ref353" class="rightTabRefNumLink">353</a></strong><div class="NLM_citation" id="rightTab-cit353"><span><span class="NLM_contrib-group">Pouzet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didriksen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnt, J.</span><span> </span><span class="NLM_article-title">Effects of the 5-HT<sub>6</sub> receptor antagonist, SB-271046, in animal models for schizophrenia</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref353/cit353&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0091-3057%2801%2900743-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref353/cit353&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11888555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref353/cit353&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVChur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=635-643&author=B.+Pouzetauthor=M.+Didriksenauthor=J.+Arnt&title=Effects+of+the+5-HT6+receptor+antagonist%2C+SB-271046%2C+in+animal+models+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit353R"><div class="casContent"><span class="casTitleNuber">353</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the 5-HT6 receptor antagonist, SB-271046, in animal models for schizophrenia</span></div><div class="casAuthors">Pouzet, B.; Didriksen, M.; Arnt, J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">635-643</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The 5-HT6 receptor is targeted by several new antipsychotics such as clozapine, olanzapine, and sertindole.  We studied the effect of SB-271046 [5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide], a specific 5-HT6 receptor antagonist, in three models for the pos. symptoms of schizophrenia-d-amphetamine-induced hyperactivity, and d-amphetamine- or phencyclidine (PCP)-disrupted prepulse inhibition (PPI).  We also tested this compd. in a model for the neg. symptoms of schizophrenia, PCP-disrupted social interaction (SIT) in rats.  Induction of side effects by this compd. was evaluated by testing its potency to reduce spontaneous motility, and to induce catalepsy in rats.  The effect of SB-271046 was compared to clozapine in all models tested.  This study showed that SB-271046 had no beneficial effect in PCP-disrupted SIT.  However, SB-271046 dose-dependently normalized d-amphetamine-disrupted PPI, but did not reverse PCP-disrupted PPI.  In addn., SB-271046 did not antagonize d-amphetamine-induced hyperactivity.  Thus, this specific 5-HT6 receptor antagonist was assocd. with a clear pos. outcome in only one model for the pos. symptoms of schizophrenia, and had no beneficial effect in the model for neg. symptoms.  Consequently, it is clear that SB-271046 is not expected to have an antipsychotic efficacy, at least when given as monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ4ROm5ZpVPLVg90H21EOLACvtfcHk0lhHGPbdP5oTpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVChur4%253D&md5=32c4a1f8b85b72e5e54af4f05dad3f67</span></div><a href="/servlet/linkout?suffix=cit353&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2801%2900743-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252801%252900743-2%26sid%3Dliteratum%253Aachs%26aulast%3DPouzet%26aufirst%3DB.%26aulast%3DDidriksen%26aufirst%3DM.%26aulast%3DArnt%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520the%25205-HT6%2520receptor%2520antagonist%252C%2520SB-271046%252C%2520in%2520animal%2520models%2520for%2520schizophrenia%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D2002%26volume%3D71%26spage%3D635%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref354"><div class="reference"><strong class="refLabel"><a href="#ref354" class="rightTabRefNumLink">354</a></strong><div class="NLM_citation" id="rightTab-cit354"><span><span class="NLM_contrib-group">Siuciak, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strick, C. A.</span><span> </span><span class="NLM_article-title">Treating neuropsychiatric disorders with PDE10A inhibitors</span> <span class="citation_source-journal">Drug Discovery Today: Ther. Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref354/cit354&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ddstr.2006.10.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=527-532&author=J.+A.+Siuciakauthor=C.+A.+Strick&title=Treating+neuropsychiatric+disorders+with+PDE10A+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit354&amp;dbid=16384&amp;doi=10.1016%2Fj.ddstr.2006.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddstr.2006.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26aulast%3DStrick%26aufirst%3DC.%2BA.%26atitle%3DTreating%2520neuropsychiatric%2520disorders%2520with%2520PDE10A%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Ther.%2520Strategies%26date%3D2006%26volume%3D3%26spage%3D527%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref355"><div class="reference"><strong class="refLabel"><a href="#ref355" class="rightTabRefNumLink">355</a></strong><div class="NLM_citation" id="rightTab-cit355"><span><span class="NLM_contrib-group">Halene, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, S. J.</span><span> </span><span class="NLM_article-title">PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">870</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=870-878&author=T.+B.+Haleneauthor=S.+J.+Siegel&title=PDE+inhibitors+in+psychiatry-future+options+for+dementia%2C+depression+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit355&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalene%26aufirst%3DT.%2BB.%26aulast%3DSiegel%26aufirst%3DS.%2BJ.%26atitle%3DPDE%2520inhibitors%2520in%2520psychiatry-future%2520options%2520for%2520dementia%252C%2520depression%2520and%2520schizophrenia%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D870%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref356"><div class="reference"><strong class="refLabel"><a href="#ref356" class="rightTabRefNumLink">356</a></strong><div class="NLM_citation" id="rightTab-cit356"><span><span class="NLM_contrib-group">Hebb, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, H. A.</span><span> </span><span class="NLM_article-title">Role of phosphodiesterases in neurological and psychiatric disease</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref356/cit356&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.coph.2006.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref356/cit356&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=17113826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref356/cit356&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntlGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=86-92&author=A.+L.+Hebbauthor=H.+A.+Robertson&title=Role+of+phosphodiesterases+in+neurological+and+psychiatric+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit356R"><div class="casContent"><span class="casTitleNuber">356</span><div class="casTitle"><span class="NLM_cas:atitle">Role of phosphodiesterases in neurological and psychiatric disease</span></div><div class="casAuthors">Hebb, Andrea L. O.; Robertson, Harold A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-92</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotides such as cAMP and cGMP play a central role in neuronal cell function and are regulated by changes in synthesis and/or degrdn.  Degrdn. is regulated by phosphodiesterases (PDEs), a group of enzymes consisting of at least 11 families, several of which have multiple isoforms.  As inhibition of PDEs can have profound effects on cell function, there is considerable interest in selective antagonists of these enzymes.  Recent work has also revealed that PDEs are heterogeneously distributed, thus making them interesting targets for drug development.  In particular, PDE10A may play a role in disorders that involve striatal neurons, such as Huntington's disease and psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot53Y0Vz3VFbVg90H21EOLACvtfcHk0lhHGPbdP5oTpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntlGhtg%253D%253D&md5=364fce31458b6e8ff62ea473da63621e</span></div><a href="/servlet/linkout?suffix=cit356&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2006.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2006.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DHebb%26aufirst%3DA.%2BL.%26aulast%3DRobertson%26aufirst%3DH.%2BA.%26atitle%3DRole%2520of%2520phosphodiesterases%2520in%2520neurological%2520and%2520psychiatric%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2007%26volume%3D7%26spage%3D86%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref357"><div class="reference"><strong class="refLabel"><a href="#ref357" class="rightTabRefNumLink">357</a></strong><div class="NLM_citation" id="rightTab-cit357"><span><span class="NLM_contrib-group">Boolell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gepi-Attee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muirhead, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterloh, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, C.</span><span> </span><span class="NLM_article-title">Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction</span> <span class="citation_source-journal">Int. J. Impotence Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref357/cit357&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=8858389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref357/cit357&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADyaK2s%252FhtFekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1996&pages=47-52&author=M.+Boolellauthor=M.+J.+Allenauthor=S.+A.+Ballardauthor=S.+Gepi-Atteeauthor=G.+J.+Muirheadauthor=A.+M.+Naylorauthor=I.+H.+Osterlohauthor=C.+Gingell&title=Sildenafil%3A+an+orally+active+type+5+cyclic+GMP-specific+phosphodiesterase+inhibitor+for+the+treatment+of+penile+erectile+dysfunction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit357R"><div class="casContent"><span class="casTitleNuber">357</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction</span></div><div class="casAuthors">Boolell M; Allen M J; Ballard S A; Gepi-Attee S; Muirhead G J; Naylor A M; Osterloh I H; Gingell C</div><div class="citationInfo"><span class="NLM_cas:title">International journal of impotence research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">47-52</span>
        ISSN:<span class="NLM_cas:issn">0955-9930</span>.
    </div><div class="casAbstract">Sildenafil (Viagra, UK-92,480) is a novel oral agent under development for the treatment of penile erectile dysfunction.  Erection is dependent on nitric oxide and its second messenger, cyclic guanosine monophosphate (cGMP).  However, the relative importance of phosphodiesterase (PDE) isozymes is not clear.  We have identified both cGMP- and cyclic adenosine monophosphate-specific phosphodiesterases (PDEs) in human corpora cavernosa in vitro.  The main PDE activity in this tissue was due to PDE5, with PDE2 and 3 also identified.  Sildenafil is a selective inhibitor of PDE5 with a mean IC50 of 0.0039 microM.  In human volunteers, we have shown sildenafil to have suitable pharmacokinetic and pharmacodynamic properties (rapid absorption, relatively short half-life, no significant effect on heart rate and blood pressure) for an oral agent to be taken, as required, prior to sexual activity.  Moreover, in a clinical study of 12 patients with erectile dysfunction without an established organic cause, we have shown sildenafil to enhance the erectile response (duration and rigidity of erection) to visual sexual stimulation, thus highlighting the important role of PDE5 in human penile erection.  Sildenafil holds promise as a new effective oral treatment for penile erectile dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHiUn0Ryiem0bxh97K6Vt6fW6udTcc2eaTt2qnA5EKobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FhtFekuw%253D%253D&md5=35783bf8f6ff593b0a67e7e302392cd5</span></div><a href="/servlet/linkout?suffix=cit357&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoolell%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DM.%2BJ.%26aulast%3DBallard%26aufirst%3DS.%2BA.%26aulast%3DGepi-Attee%26aufirst%3DS.%26aulast%3DMuirhead%26aufirst%3DG.%2BJ.%26aulast%3DNaylor%26aufirst%3DA.%2BM.%26aulast%3DOsterloh%26aufirst%3DI.%2BH.%26aulast%3DGingell%26aufirst%3DC.%26atitle%3DSildenafil%253A%2520an%2520orally%2520active%2520type%25205%2520cyclic%2520GMP-specific%2520phosphodiesterase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520penile%2520erectile%2520dysfunction%26jtitle%3DInt.%2520J.%2520Impotence%2520Res.%26date%3D1996%26volume%3D8%26spage%3D47%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref358"><div class="reference"><strong class="refLabel"><a href="#ref358" class="rightTabRefNumLink">358</a></strong><div class="NLM_citation" id="rightTab-cit358"><span><span class="NLM_contrib-group">Siuciak, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorhees, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repaske, D. R.</span><span> </span><span class="NLM_article-title">Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2007&pages=113-124&author=J.+A.+Siuciakauthor=S.+A.+McCarthyauthor=D.+S.+Chapinauthor=T.+M.+Reedauthor=C.+V.+Vorheesauthor=D.+R.+Repaske&title=Behavioral+and+neurochemical+characterization+of+mice+deficient+in+the+phosphodiesterase-1B+%28PDE1B%29+enzyme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit358&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26aulast%3DMcCarthy%26aufirst%3DS.%2BA.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DReed%26aufirst%3DT.%2BM.%26aulast%3DVorhees%26aufirst%3DC.%2BV.%26aulast%3DRepaske%26aufirst%3DD.%2BR.%26atitle%3DBehavioral%2520and%2520neurochemical%2520characterization%2520of%2520mice%2520deficient%2520in%2520the%2520phosphodiesterase-1B%2520%2528PDE1B%2529%2520enzyme%26jtitle%3DNeuropharmacology%26date%3D2007%26volume%3D53%26spage%3D113%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref359"><div class="reference"><strong class="refLabel"><a href="#ref359" class="rightTabRefNumLink">359</a></strong><div class="NLM_citation" id="rightTab-cit359"><span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mix, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winblad, B.</span><span> </span><span class="NLM_article-title">The antidepressant and antiinflammatory effects of rolipram in the central nervous system</span> <span class="citation_source-journal">CNS Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">398</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=387-398&author=J.+Zhuauthor=E.+Mixauthor=B.+Winblad&title=The+antidepressant+and+antiinflammatory+effects+of+rolipram+in+the+central+nervous+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit359&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMix%26aufirst%3DE.%26aulast%3DWinblad%26aufirst%3DB.%26atitle%3DThe%2520antidepressant%2520and%2520antiinflammatory%2520effects%2520of%2520rolipram%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2001%26volume%3D7%26spage%3D387%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref360"><div class="reference"><strong class="refLabel"><a href="#ref360" class="rightTabRefNumLink">360</a></strong><div class="NLM_citation" id="rightTab-cit360"><span><span class="NLM_contrib-group">Rose, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tehim, A.</span><span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors for cognitive enhancement</span> <span class="citation_source-journal">Curr. Pharm. Des</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3329</span><span class="NLM_x">–</span> <span class="NLM_lpage">3334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref360/cit360&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.2174%2F138161205774370799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref360/cit360&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16250839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref360/cit360&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3329-3334&author=G.+M.+Roseauthor=A.+Hopperauthor=M.+De+Vivoauthor=A.+Tehim&title=Phosphodiesterase+inhibitors+for+cognitive+enhancement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit360R"><div class="casContent"><span class="casTitleNuber">360</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors for cognitive enhancement</span></div><div class="casAuthors">Rose, Gregory M.; Hopper, Allen; De Vivo, Michael; Tehim, Ashok</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3329-3334</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  An effective treatment for age-related cognitive deficits remains an unmet medical need.  Currently available drugs for the symptomatic treatment of Alzheimer's disease or other dementias have limited efficacy.  This may be due to their action at only one of the many neurotransmitter systems involved in the complex mechanisms that underlie cognition.  An alternative approach would be to target second messenger systems that are utilized by multiple neurotransmitters.  CAMP is a second messenger that plays a key role in biochem. processes that regulate the cognitive process of memory consolidation.  Prolongation of cAMP signals can be accomplished by inhibiting phosphodiesterases (PDEs).  Eleven PDE families, comprised of more than 50 distinct members, are currently known.  This review summarizes the evidence demonstrating that rolipram, a selective inhibitor of cAMP-selective PDE4 enzymes, has pos. effects on learning and memory in animal models.  These data provide support for the general approach of second messenger modulation as a potential therapy for cognitive dysfunction, and specifically suggest that PDE4 inhibitors may have utility for improving the symptoms of cognitive decline assocd. with neurodegenerative and psychiatric diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrUM-8WbDbU7Vg90H21EOLACvtfcHk0liB1Gc0WZWsNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7vN&md5=1748930c164783595c858f9f05229a59</span></div><a href="/servlet/linkout?suffix=cit360&amp;dbid=16384&amp;doi=10.2174%2F138161205774370799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161205774370799%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DG.%2BM.%26aulast%3DHopper%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DTehim%26aufirst%3DA.%26atitle%3DPhosphodiesterase%2520inhibitors%2520for%2520cognitive%2520enhancement%26jtitle%3DCurr.%2520Pharm.%2520Des%26date%3D2005%26volume%3D11%26spage%3D3329%26epage%3D3334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref361"><div class="reference"><strong class="refLabel"><a href="#ref361" class="rightTabRefNumLink">361</a></strong><div class="NLM_citation" id="rightTab-cit361"><span><span class="NLM_contrib-group">Kanes, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarczyk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, M. P.</span><span> </span><span class="NLM_article-title">Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2007&pages=239-246&author=S.+J.+Kanesauthor=J.+Tokarczykauthor=S.+J.+Siegelauthor=W.+Bilkerauthor=T.+Abelauthor=M.+P.+Kelly&title=Rolipram%3A+a+specific+phosphodiesterase+4+inhibitor+with+potential+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit361&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKanes%26aufirst%3DS.%2BJ.%26aulast%3DTokarczyk%26aufirst%3DJ.%26aulast%3DSiegel%26aufirst%3DS.%2BJ.%26aulast%3DBilker%26aufirst%3DW.%26aulast%3DAbel%26aufirst%3DT.%26aulast%3DKelly%26aufirst%3DM.%2BP.%26atitle%3DRolipram%253A%2520a%2520specific%2520phosphodiesterase%25204%2520inhibitor%2520with%2520potential%2520antipsychotic%2520activity%26jtitle%3DNeuroscience%26date%3D2007%26volume%3D144%26spage%3D239%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref362"><div class="reference"><strong class="refLabel"><a href="#ref362" class="rightTabRefNumLink">362</a></strong><div class="NLM_citation" id="rightTab-cit362"><span><span class="NLM_contrib-group">Dyke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montana, J. G.</span><span> </span><span class="NLM_article-title">Update on the therapeutic potential of PDE4 inhibitors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref362/cit362&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1517%2F13543784.11.1.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref362/cit362&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=11772317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref362/cit362&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=1-13&author=H.+J.+Dykeauthor=J.+G.+Montana&title=Update+on+the+therapeutic+potential+of+PDE4+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit362R"><div class="casContent"><span class="casTitleNuber">362</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the therapeutic potential of PDE4 inhibitors</span></div><div class="casAuthors">Dyke, Hazel J.; Montana, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase (PDE) enzymes are responsible for the inactivation of cAMP and cGMP.  Phosphodiesterase 4 (PDE4) is a cAMP specific phosphodiesterase expressed in inflammatory cells such as eosinophils.  Inhibition of PDE4 results in an elevation of cAMP in these cells, which in turn downregulates the inflammatory response.  The anti-inflammatory effects of PDE4 inhibitors have been well documented both in vitro and in vivo in a range of animal models.  The potential use of PDE4 inhibitors as anti-inflammatory agents for the treatment of diseases such as asthma, chronic obstructive pulmonary disease (COPD) and multiple sclerosis (MS), has received considerable attention from the pharmaceutical industry but to date, there are no selective PDE4 inhibitors on the market.  Early PDE4 inhibitors, such as rolipram suffered from dose limiting side effects, including nausea and emesis, which severely restricted their therapeutic utility.  Second generation compds. such as cilomilast have been identified with reduced side effect liability.  Indeed, cilomilast is showing good therapeutic effects in clin. trials for asthma and COPD and represents the most advanced selective PDE4 inhibitor for any indication.  The utility of this class of inhibitor in other inflammatory diseases is less well advanced.  However, data in animal models of rheumatoid arthritis (RA) and MS suggests that there is also significant potential for PDE4 inhibitors as treatments for these diseases and the results of clin. trials in these disease areas are eagerly awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcfUhqvSag17Vg90H21EOLACvtfcHk0liB1Gc0WZWsNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGgsQ%253D%253D&md5=f16a217b52d79f2ac4725b1ffa432c3e</span></div><a href="/servlet/linkout?suffix=cit362&amp;dbid=16384&amp;doi=10.1517%2F13543784.11.1.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.11.1.1%26sid%3Dliteratum%253Aachs%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DMontana%26aufirst%3DJ.%2BG.%26atitle%3DUpdate%2520on%2520the%2520therapeutic%2520potential%2520of%2520PDE4%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D11%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref363"><div class="reference"><strong class="refLabel"><a href="#ref363" class="rightTabRefNumLink">363</a></strong><div class="NLM_citation" id="rightTab-cit363"><span><span class="NLM_contrib-group">Kehler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritzen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greve, D. R.</span><span> </span><span class="NLM_article-title">The potential therapeutic use of phosphodiesterase 10 inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref363/cit363&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1517%2F13543776.17.2.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref363/cit363&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=147-158&author=J.+Kehlerauthor=A.+Ritzenauthor=D.+R.+Greve&title=The+potential+therapeutic+use+of+phosphodiesterase+10+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit363R"><div class="casContent"><span class="casTitleNuber">363</span><div class="casTitle"><span class="NLM_cas:atitle">The potential therapeutic use of phosphodiesterase 10 inhibitors</span></div><div class="casAuthors">Kehler, Jan; Ritzen, Andreas; Greve, Daniel Rodriguez</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-158</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The discovery of the enzyme phosphodiesterase 10A (PDE10A) was reported simultaneously in 1999 by three independent groups.  PDE10A has been shown by localization studies to have the most restricted distribution of all the 11 known PDE families, with the PDE10A mRNA highly expressed only in the brain and testes.  In the brain, mRNA and protein are highly enriched in the striatum and, together with increased pharmacol. characterization, this unique distribution of PDE10A in the brain indicates a potential use of PDE10A inhibitors for treating neurol. and psychiatric disorders, in particular, psychotic disorders like schizophrenia.  However, PDE10A inhibitors have also been claimed to be useful as treatment for cancer, diabetes and esp. obesity.  Two years after the reported discovery of PDE10A, Bayer filed the first patent application claiming PDE10A inhibitors, followed shortly thereafter by Pfizer.  Since then, a no. of scientific publications and filed patents testify to an increasing pharmaceutical interest in this target.  This article highlights and reviews research advances published in the patent literature between the first patent publication in June 2002 and Nov. 2006.  The article is supplemented with selected publications from the scientific literature, emphasizing the possible involvement of PDE10A inhibitors in the treatment of schizophrenia and referring to studies aimed at understanding their mechanism and pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuxKfPnmDF7Vg90H21EOLACvtfcHk0lg-wuQ-PIeMaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyhs7g%253D&md5=12a5d53fbc2c93039ded1952b56f0e12</span></div><a href="/servlet/linkout?suffix=cit363&amp;dbid=16384&amp;doi=10.1517%2F13543776.17.2.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.17.2.147%26sid%3Dliteratum%253Aachs%26aulast%3DKehler%26aufirst%3DJ.%26aulast%3DRitzen%26aufirst%3DA.%26aulast%3DGreve%26aufirst%3DD.%2BR.%26atitle%3DThe%2520potential%2520therapeutic%2520use%2520of%2520phosphodiesterase%252010%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2007%26volume%3D17%26spage%3D147%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref364"><div class="reference"><strong class="refLabel"><a href="#ref364" class="rightTabRefNumLink">364</a></strong><div class="NLM_citation" id="rightTab-cit364"><span><span class="NLM_contrib-group">Siuciak, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeish, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strick, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref364/cit364&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.neuropharm.2006.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref364/cit364&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16769090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref364/cit364&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2006&pages=374-385&author=J.+A.+Siuciakauthor=S.+A.+McCarthyauthor=D.+S.+Chapinauthor=R.+A.+Fujiwaraauthor=L.+C.+Jamesauthor=R.+D.+Williamsauthor=J.+L.+Stockauthor=J.+D.+McNeishauthor=C.+A.+Strickauthor=F.+S.+Mennitiauthor=C.+J.+Schmidt&title=Genetic+deletion+of+the+striatum-enriched+phosphodiesterase+PDE10A%3A+evidence+for+altered+striatal+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit364R"><div class="casContent"><span class="casTitleNuber">364</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function</span></div><div class="casAuthors">Siuciak, Judith A.; McCarthy, Sheryl A.; Chapin, Douglas S.; Fujiwara, Remie A.; James, Larry C.; Williams, Robert D.; Stock, Jeffrey L.; McNeish, John D.; Strick, Christine A.; Menniti, Frank S.; Schmidt, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374-385</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PDE10A is a newly identified phosphodiesterase that is highly expressed by the medium spiny projection neurons of the striatum.  To investigate the physiol. role of PDE10A in the central nervous system, PDE10A knockout mice (PDE10A-/-) were characterized both behaviorally and neurochem.  PDE10A-/- mice showed decreased exploratory activity and a significant delay in the acquisition of conditioned avoidance behavior when compared to wild-type (PDE10A+/+) mice.  However, in a variety of other well-characterized behavioral tasks, including the elevated plus maze (anxiety), forced swim test (depression), hot plate (nociception) and two memory models (passive avoidance and Morris water maze), PDE10A-/- mice performed similarly to wild-type mice.  When challenged with PCP or MK-801, PDE10A-/- mice showed a blunted locomotor response in comparison to PDE10A+/+ mice.  In contrast, PDE10A-/- and PDE10A+/+ mice responded similarly to the locomotor stimulating effects of amphetamine and methamphetamine.  The authors' findings suggest that PDE10A is involved in regulating striatal output, possibly by reducing the sensitivity of medium spiny neurons to glutamatergic excitation.  These results are discussed in relationship to the hypothesis that PDE10A inhibition presents a novel treatment for psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxED8sUex3PbVg90H21EOLACvtfcHk0lg-wuQ-PIeMaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSnurk%253D&md5=0d5cef60a6c5bfb02df908b95a8debd6</span></div><a href="/servlet/linkout?suffix=cit364&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2006.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2006.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26aulast%3DMcCarthy%26aufirst%3DS.%2BA.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DFujiwara%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DL.%2BC.%26aulast%3DWilliams%26aufirst%3DR.%2BD.%26aulast%3DStock%26aufirst%3DJ.%2BL.%26aulast%3DMcNeish%26aufirst%3DJ.%2BD.%26aulast%3DStrick%26aufirst%3DC.%2BA.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DGenetic%2520deletion%2520of%2520the%2520striatum-enriched%2520phosphodiesterase%2520PDE10A%253A%2520evidence%2520for%2520altered%2520striatal%2520function%26jtitle%3DNeuropharmacology%26date%3D2006%26volume%3D51%26spage%3D374%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref365"><div class="reference"><strong class="refLabel"><a href="#ref365" class="rightTabRefNumLink">365</a></strong><div class="NLM_citation" id="rightTab-cit365"><span><span class="NLM_contrib-group">Schmidt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harms, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikhande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siuciak, J. A.</span><span> </span><span class="NLM_article-title">The neurochemical and behavioral effects of papaverine in vivo suggest PDE10 inhibition is “antipsychotic”</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref365/cit365&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0920-9964%2803%2980867-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2003&pages=114&author=C.+J.+Schmidtauthor=D.+S.+Chapinauthor=S.+A.+McCarthyauthor=R.+A.+Fujiwaraauthor=J.+F.+Harmsauthor=A.+Shrikhandeauthor=L.+Chambersauthor=S.+Wongauthor=J.+A.+Siuciak&title=The+neurochemical+and+behavioral+effects+of+papaverine+in+vivo+suggest+PDE10+inhibition+is+%E2%80%9Cantipsychotic%E2%80%9D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit365&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2803%2980867-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252803%252980867-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DMcCarthy%26aufirst%3DS.%2BA.%26aulast%3DFujiwara%26aufirst%3DR.%2BA.%26aulast%3DHarms%26aufirst%3DJ.%2BF.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520neurochemical%2520and%2520behavioral%2520effects%2520of%2520papaverine%2520in%2520vivo%2520suggest%2520PDE10%2520inhibition%2520is%2520%25E2%2580%259Cantipsychotic%25E2%2580%259D%26jtitle%3DSchizophr.%2520Res.%26date%3D2003%26volume%3D60%26spage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref366"><div class="reference"><strong class="refLabel"><a href="#ref366" class="rightTabRefNumLink">366</a></strong><div class="NLM_citation" id="rightTab-cit366"><span><span class="NLM_contrib-group">Siuciak, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harms, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chappie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphrey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Novel potent and selective phosphodiesterase 10A (PDE10A) inhibitors show activity in animal models of psychosis</span> <span class="citation_source-journal">Soc. Neurosci. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2006&pages=94-19&author=J.+A.+Siuciakauthor=D.+S.+Chapinauthor=S.+A.+McCarthyauthor=J.+F.+Harmsauthor=C.+B.+Foxauthor=T.+A.+Chappieauthor=J.+M.+Humphreyauthor=C.+Proulxauthor=P.+R.+Verhoestauthor=C.+J.+Schmidt&title=Novel+potent+and+selective+phosphodiesterase+10A+%28PDE10A%29+inhibitors+show+activity+in+animal+models+of+psychosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit366&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiuciak%26aufirst%3DJ.%2BA.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DMcCarthy%26aufirst%3DS.%2BA.%26aulast%3DHarms%26aufirst%3DJ.%2BF.%26aulast%3DFox%26aufirst%3DC.%2BB.%26aulast%3DChappie%26aufirst%3DT.%2BA.%26aulast%3DHumphrey%26aufirst%3DJ.%2BM.%26aulast%3DProulx%26aufirst%3DC.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DNovel%2520potent%2520and%2520selective%2520phosphodiesterase%252010A%2520%2528PDE10A%2529%2520inhibitors%2520show%2520activity%2520in%2520animal%2520models%2520of%2520psychosis%26jtitle%3DSoc.%2520Neurosci.%2520Abstr.%26date%3D2006%26volume%3D36%26spage%3D94%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref367"><div class="reference"><strong class="refLabel"><a href="#ref367" class="rightTabRefNumLink">367</a></strong><div class="NLM_citation" id="rightTab-cit367"><span><span class="NLM_contrib-group">Meltzer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prus, A.</span><span> </span><span class="NLM_article-title">NK<sub>3</sub> receptor antagonists for the treatment of schizophrenia</span> <span class="citation_source-journal">Drug Discovery Today: Ther. Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">–</span> <span class="NLM_lpage">560</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref367/cit367&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.ddstr.2006.11.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=555-560&author=H.+Meltzerauthor=A.+Prus&title=NK3+receptor+antagonists+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit367&amp;dbid=16384&amp;doi=10.1016%2Fj.ddstr.2006.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddstr.2006.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%26aulast%3DPrus%26aufirst%3DA.%26atitle%3DNK3%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Ther.%2520Strategies%26date%3D2006%26volume%3D3%26spage%3D555%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref368"><div class="reference"><strong class="refLabel"><a href="#ref368" class="rightTabRefNumLink">368</a></strong><div class="NLM_citation" id="rightTab-cit368"><span><span class="NLM_contrib-group">Smesny, S.; Rosburg, T.; Baur, K.; Rudolph, N.; Sauer, H.</span><span> </span><span class="NLM_article-title">Cannabinoids influence lipid−arachidonic acid pathways in schizophrenia</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span>, <div class="note"><p class="first last"> in press.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Smesny%2C+S.%3B+Rosburg%2C+T.%3B+Baur%2C+K.%3B+Rudolph%2C+N.%3B+Sauer%2C+H.+Cannabinoids+influence+lipid%E2%88%92arachidonic+acid+pathways+in+schizophrenia.+Neuropsychopharmacology%2C+%E2%80%89in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit368&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmesny%26aufirst%3DS.%26atitle%3DCannabinoids%2520influence%2520lipid%25E2%2588%2592arachidonic%2520acid%2520pathways%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref369"><div class="reference"><strong class="refLabel"><a href="#ref369" class="rightTabRefNumLink">369</a></strong><div class="NLM_citation" id="rightTab-cit369"><span><span class="NLM_contrib-group">Koethe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llenos, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulay, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrey, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leweke, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, S.</span><span> </span><span class="NLM_article-title">Expression of CB<sub>1</sub> cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression</span> <span class="citation_source-journal">J. Neural Transm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1055</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=1055-1063&author=D.+Koetheauthor=I.+C.+Llenosauthor=J.+R.+Dulayauthor=C.+Hoyerauthor=E.+F.+Torreyauthor=F.+M.+Lewekeauthor=S.+Weis&title=Expression+of+CB1+cannabinoid+receptor+in+the+anterior+cingulate+cortex+in+schizophrenia%2C+bipolar+disorder%2C+and+major+depression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit369&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoethe%26aufirst%3DD.%26aulast%3DLlenos%26aufirst%3DI.%2BC.%26aulast%3DDulay%26aufirst%3DJ.%2BR.%26aulast%3DHoyer%26aufirst%3DC.%26aulast%3DTorrey%26aufirst%3DE.%2BF.%26aulast%3DLeweke%26aufirst%3DF.%2BM.%26aulast%3DWeis%26aufirst%3DS.%26atitle%3DExpression%2520of%2520CB1%2520cannabinoid%2520receptor%2520in%2520the%2520anterior%2520cingulate%2520cortex%2520in%2520schizophrenia%252C%2520bipolar%2520disorder%252C%2520and%2520major%2520depression%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2007%26volume%3D114%26spage%3D1055%26epage%3D1063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref370"><div class="reference"><strong class="refLabel"><a href="#ref370" class="rightTabRefNumLink">370</a></strong><div class="NLM_citation" id="rightTab-cit370"><span><span class="NLM_contrib-group">Zavitsanou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrick, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. F.</span><span> </span><span class="NLM_article-title">Selective antagonist [3H]SR141716A binding to cannabinoid CB<sub>1</sub> receptors is increased in the anterior cingulate cortex in schizophrenia</span> <span class="citation_source-journal">Prog. Neuropsychopharmacol. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref370/cit370&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.pnpbp.2003.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref370/cit370&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=14751433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref370/cit370&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=355-360&author=K.+Zavitsanouauthor=T.+Garrickauthor=X.+F.+Huang&title=Selective+antagonist+%5B3H%5DSR141716A+binding+to+cannabinoid+CB1+receptors+is+increased+in+the+anterior+cingulate+cortex+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit370R"><div class="casContent"><span class="casTitleNuber">370</span><div class="casTitle"><span class="NLM_cas:atitle">Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia</span></div><div class="casAuthors">Zavitsanou, Katerina; Garrick, Therese; Huang, Xu Feng</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-360</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Previous studies suggest that long-term cannabis use causes cognitive impairment, including lack of motivation and impaired attention, conditions that also resemble core neg. symptoms of schizophrenia.  The anterior cingulate cortex (ACC) plays an important role in normal cognition, particularly in relation to motivation and attention.  This could suggest that changes in the cannabinoid (CB) system might be present in the ACC of patients suffering schizophrenia.  The present study examd. the distribution and d. of CB1 cannabinoid receptors in the left ACC taken postmortem from patients with schizophrenia (n=10) and matched control subjects (n=9).  Radioligand binding of [3H]SR141716A, an antagonist that specifically targets CB1 receptors of the endogenous cannabinoid system, was examd. on ACC sections using quant. autoradiog.  CB1 receptors had a homogenous distribution among the layers of ACC.  A significant 64% increase in [3H]SR141716A specific binding to CB1 receptors was found in the schizophrenia group as compared to the control group (mean±S.E.M.: 46.15±6.22 vs. 28.02±4.20 fmol/mg estd. tissue equiv.; p=0.03).  The present results support the suggestion that changes in the endogenous cannabinoid system in the ACC may be involved in the pathol. of schizophrenia particularly in relation to neg. symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqENwOcrxFNPLVg90H21EOLACvtfcHk0lhKZ0CNqPWw8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVOnsQ%253D%253D&md5=936788a6fce33a361e80f8cfd6d88daf</span></div><a href="/servlet/linkout?suffix=cit370&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2003.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2003.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DZavitsanou%26aufirst%3DK.%26aulast%3DGarrick%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DX.%2BF.%26atitle%3DSelective%2520antagonist%2520%255B3H%255DSR141716A%2520binding%2520to%2520cannabinoid%2520CB1%2520receptors%2520is%2520increased%2520in%2520the%2520anterior%2520cingulate%2520cortex%2520in%2520schizophrenia%26jtitle%3DProg.%2520Neuropsychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2004%26volume%3D28%26spage%3D355%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref371"><div class="reference"><strong class="refLabel"><a href="#ref371" class="rightTabRefNumLink">371</a></strong><div class="NLM_citation" id="rightTab-cit371"><span><span class="NLM_contrib-group">Emrich, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leweke, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, U.</span><span> </span><span class="NLM_article-title">Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system</span> <span class="citation_source-journal">Pharmacol. Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">803</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref371/cit371&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2FS0091-3057%2896%2900426-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref371/cit371&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=9130308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref371/cit371&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK2sXislaqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1997&pages=803-807&author=H.+M.+Emrichauthor=F.+M.+Lewekeauthor=U.+Schneider&title=Towards+a+cannabinoid+hypothesis+of+schizophrenia%3A+cognitive+impairments+due+to+dysregulation+of+the+endogenous+cannabinoid+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit371R"><div class="casContent"><span class="casTitleNuber">371</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system</span></div><div class="casAuthors">Emrich, Hinderk M.; Leweke, Markus; Schneider, Udo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">803-807</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The perceptual abnormalities induced by psychotogenic agents play a major role as tools for the understanding of model psychoses.  The recently discovered cannabinoid receptor system with its endogenous ligand anandamide can be regarded as an extremely relevant regulatory system, a dysfunctionality of which may explain at least one subtype of endogenous psychoses.  Neuropsychol. results (3-dimensional inversion illusion) in Δ9-tetrahydrocannabinol-intoxicated normal volunteers exhibited strong similarities with data acquired from patients with productive schizophrenic psychoses, regarding disturbances in internal regulation of perceptual processes.  The relevance of this finding to a general cognitive dysfunction concept of schizophrenic psychosis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8OGytYytNBLVg90H21EOLACvtfcHk0lhKZ0CNqPWw8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislaqs7w%253D&md5=816eee41796ad4445e6189dd4697f53a</span></div><a href="/servlet/linkout?suffix=cit371&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2896%2900426-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252896%252900426-1%26sid%3Dliteratum%253Aachs%26aulast%3DEmrich%26aufirst%3DH.%2BM.%26aulast%3DLeweke%26aufirst%3DF.%2BM.%26aulast%3DSchneider%26aufirst%3DU.%26atitle%3DTowards%2520a%2520cannabinoid%2520hypothesis%2520of%2520schizophrenia%253A%2520cognitive%2520impairments%2520due%2520to%2520dysregulation%2520of%2520the%2520endogenous%2520cannabinoid%2520system%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D1997%26volume%3D56%26spage%3D803%26epage%3D807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref372"><div class="reference"><strong class="refLabel"><a href="#ref372" class="rightTabRefNumLink">372</a></strong><div class="NLM_citation" id="rightTab-cit372"><span><span class="NLM_contrib-group">Poncelet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnouin, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breliere, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrie, P.</span><span> </span><span class="NLM_article-title">Blockade of cannabinoid (CB<sub>1</sub>) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils</span> <span class="citation_source-journal">Psychopharmacology (Berlin)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref372/cit372&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1007%2Fs002130050987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref372/cit372&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=10394995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref372/cit372&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADyaK1MXjvValurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=1999&pages=144-150&author=M.+Ponceletauthor=M.+C.+Barnouinauthor=J.+C.+Breliereauthor=G.+Le+Furauthor=P.+Soubrie&title=Blockade+of+cannabinoid+%28CB1%29+receptors+by+141716+selectively+antagonizes+drug-induced+reinstatement+of+exploratory+behaviour+in+gerbils"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit372R"><div class="casContent"><span class="casTitleNuber">372</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behavior in gerbils</span></div><div class="casAuthors">Poncelet, Martine; Barnouin, Marie-Christine; Breliere, Jean-Claude; Le Fur, Gerard; Soubrie, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A cannabinoid hypothesis of schizophrenia has been proposed according to which cognitive dysfunction could be assocd. with dysregulation of an endogenous cannabinoid system.  The present study investigated whether SR 141716, a selective CB1 receptor antagonist, was able to reduce the hyperactivity induced in gerbils by various stimulant drugs known to produce or exacerbate schizophrenic symptoms.  Cocaine, d-amphetamine, morphine, and Win 55212-2 were administered i.p. (IP) either immediately before placing the animals in the test app. (non-habituated gerbils) or after a 2- to 3-h habituation period in the actimeter (habituated gerbils).  SR 141716 was given IP 30 min before the injection of stimulant drugs.  Horizontal activity was recorded every 10 min for 1 h in Digiscan activity monitor.  SR 141716 (0.3-3 mg/kg) dose-dependently suppressed the enhanced locomotor activity induced by each stimulant drug in habituated gerbils, but not in non-habituated animals.  Clozapine, an atypical antipsychotic compd., but not haloperidol, shared with SR 141716, the ability to differentially affect drug-induced hyperactivity in habituated vs. non-habituated gerbils.  The activation of cannabinoid systems is a required, permissive element in the ability of cocaine, d-amphetamine, morphine, and Win 55212-2 to reinstate behavior, i.e., to override stimulus satiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKsAvtIBBNq7Vg90H21EOLACvtfcHk0lhKZ0CNqPWw8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvValurc%253D&md5=c309610bdd6113555777358b19fa701b</span></div><a href="/servlet/linkout?suffix=cit372&amp;dbid=16384&amp;doi=10.1007%2Fs002130050987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002130050987%26sid%3Dliteratum%253Aachs%26aulast%3DPoncelet%26aufirst%3DM.%26aulast%3DBarnouin%26aufirst%3DM.%2BC.%26aulast%3DBreliere%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BFur%26aufirst%3DG.%26aulast%3DSoubrie%26aufirst%3DP.%26atitle%3DBlockade%2520of%2520cannabinoid%2520%2528CB1%2529%2520receptors%2520by%2520141716%2520selectively%2520antagonizes%2520drug-induced%2520reinstatement%2520of%2520exploratory%2520behaviour%2520in%2520gerbils%26jtitle%3DPsychopharmacology%2520%2528Berlin%2529%26date%3D1999%26volume%3D144%26spage%3D144%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref373"><div class="reference"><strong class="refLabel"><a href="#ref373" class="rightTabRefNumLink">373</a></strong><div class="NLM_citation" id="rightTab-cit373"><span><span> </span><span class="NLM_article-title">RxTrials instititute drug pipeline alert. FDA accepts iloperidone NDA</span>.  <span class="citation_source-journal">FDA News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">232</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=RxTrials+instititute+drug+pipeline+alert.+FDA+accepts+iloperidone+NDA.+FDA+News+2007%2C+5+%28232%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit373&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DRxTrials%2520instititute%2520drug%2520pipeline%2520alert.%2520FDA%2520accepts%2520iloperidone%2520NDA%26jtitle%3DFDA%2520News%26date%3D2007%26volume%3D5%26issue%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref374"><div class="reference"><strong class="refLabel"><a href="#ref374" class="rightTabRefNumLink">374</a></strong><div class="NLM_citation" id="rightTab-cit374"><span><span class="NLM_contrib-group">Spedding, M.;</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa e Silva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perret, L.</span><span> </span><span class="NLM_article-title">A pathophysiological paradigm for the therapy of psychiatric disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=467-476&author=M.%3B+Speddingauthor=T.+Jayauthor=J.+Costa+e+Silvaauthor=L.+Perret&title=A+pathophysiological+paradigm+for+the+therapy+of+psychiatric+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit374&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpedding%26aufirst%3DM.%253B%26aulast%3DJay%26aufirst%3DT.%26aulast%3DCosta%2Be%2BSilva%26aufirst%3DJ.%26aulast%3DPerret%26aufirst%3DL.%26atitle%3DA%2520pathophysiological%2520paradigm%2520for%2520the%2520therapy%2520of%2520psychiatric%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D467%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref375"><div class="reference"><strong class="refLabel"><a href="#ref375" class="rightTabRefNumLink">375</a></strong><div class="NLM_citation" id="rightTab-cit375"><span><span class="NLM_contrib-group">Horrobin, D. F.</span><span> </span><span class="NLM_article-title">Modern biomedical research: an internally self-consistent universe with little contact with medical reality</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=151-154&author=D.+F.+Horrobin&title=Modern+biomedical+research%3A+an+internally+self-consistent+universe+with+little+contact+with+medical+reality"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit375&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorrobin%26aufirst%3DD.%2BF.%26atitle%3DModern%2520biomedical%2520research%253A%2520an%2520internally%2520self-consistent%2520universe%2520with%2520little%2520contact%2520with%2520medical%2520reality%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D151%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref376"><div class="reference"><strong class="refLabel"><a href="#ref376" class="rightTabRefNumLink">376</a></strong><div class="NLM_citation" id="rightTab-cit376"><span><span class="NLM_contrib-group">Holmes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leweke, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koethe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerth, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolden, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahn, S.</span><span> </span><span class="NLM_article-title">Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">e327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=e327&author=E.+Holmesauthor=T.+M.+Tsangauthor=J.+T.+Huangauthor=F.+M.+Lewekeauthor=D.+Koetheauthor=C.+W.+Gerthauthor=B.+M.+Noldenauthor=S.+Grossauthor=D.+Schreiberauthor=J.+K.+Nicholsonauthor=S.+Bahn&title=Metabolic+profiling+of+CSF%3A+evidence+that+early+intervention+may+impact+on+disease+progression+and+outcome+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit376&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DE.%26aulast%3DTsang%26aufirst%3DT.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%2BT.%26aulast%3DLeweke%26aufirst%3DF.%2BM.%26aulast%3DKoethe%26aufirst%3DD.%26aulast%3DGerth%26aufirst%3DC.%2BW.%26aulast%3DNolden%26aufirst%3DB.%2BM.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DD.%26aulast%3DNicholson%26aufirst%3DJ.%2BK.%26aulast%3DBahn%26aufirst%3DS.%26atitle%3DMetabolic%2520profiling%2520of%2520CSF%253A%2520evidence%2520that%2520early%2520intervention%2520may%2520impact%2520on%2520disease%2520progression%2520and%2520outcome%2520in%2520schizophrenia%26jtitle%3DPLoS%2520Med.%26date%3D2006%26volume%3D3%26spage%3De327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref377"><div class="reference"><strong class="refLabel"><a href="#ref377" class="rightTabRefNumLink">377</a></strong><div class="NLM_citation" id="rightTab-cit377"><span><span class="NLM_contrib-group">Lewis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span> </span><span class="NLM_article-title">Catching up on schizophrenia: natural history and neurobiology</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=325-334&author=D.+A.+Lewisauthor=J.+A.+Lieberman&title=Catching+up+on+schizophrenia%3A+natural+history+and+neurobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit377&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BA.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DCatching%2520up%2520on%2520schizophrenia%253A%2520natural%2520history%2520and%2520neurobiology%26jtitle%3DNeuron%26date%3D2000%26volume%3D28%26spage%3D325%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref378"><div class="reference"><strong class="refLabel"><a href="#ref378" class="rightTabRefNumLink">378</a></strong><div class="NLM_citation" id="rightTab-cit378"><span><span class="NLM_contrib-group">Glantz, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarskog, L. F.</span><span> </span><span class="NLM_article-title">Apoptotic mechanisms and the synaptic pathology of schizophrenia</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref378/cit378&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1016%2Fj.schres.2005.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref378/cit378&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16226876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref378/cit378&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MnovF2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2006&pages=47-63&author=L.+A.+Glantzauthor=J.+H.+Gilmoreauthor=J.+A.+Liebermanauthor=L.+F.+Jarskog&title=Apoptotic+mechanisms+and+the+synaptic+pathology+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit378R"><div class="casContent"><span class="casTitleNuber">378</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptotic mechanisms and the synaptic pathology of schizophrenia</span></div><div class="casAuthors">Glantz Leisa A; Gilmore John H; Lieberman Jeffrey A; Jarskog L Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-63</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The cortical neuropathology of schizophrenia includes neuronal atrophy, decreased neuropil, and alterations in neuronal density.  Taken together with evidence of decreased synaptic markers and dendritic spines, the data suggest that synaptic circuitry is altered.  Recent neuroimaging studies also indicate that a progressive loss of cortical gray matter occurs early in the course of schizophrenia.  Although the mechanisms underlying these deficits are largely unknown, recent postmortem data implicate a role for altered neuronal apoptosis.  Apoptosis, a form of programmed cell death, is regulated by a complex cascade of pro- and anti-apoptotic proteins.  Apoptotic activation can lead to rapid neuronal death.  However, emerging data also indicate that sub-lethal apoptotic activity can lead to a limited form of apoptosis in terminal neurites and individual synapses to cause synaptic elimination without cell death.  For example, in Alzheimer's disease, a localized apoptotic mechanism is thought to contribute to early neurite and synapse loss leading to the initial cognitive decline.  Recent studies indicate that apoptotic regulatory proteins and DNA fragmentation patterns are altered in several cortical regions in schizophrenia.  This paper will review converging lines of data that implicate synaptic deficits in the pathophysiology of schizophrenia and propose an underlying role for apoptotic dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTH-6l-CmE2uaqcneEtCi92fW6udTcc2eYLRvqDWtUi77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnovF2nug%253D%253D&md5=73d5d75bd379f7f0a77f36e6e7a0f20f</span></div><a href="/servlet/linkout?suffix=cit378&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2005.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2005.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DGlantz%26aufirst%3DL.%2BA.%26aulast%3DGilmore%26aufirst%3DJ.%2BH.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DJarskog%26aufirst%3DL.%2BF.%26atitle%3DApoptotic%2520mechanisms%2520and%2520the%2520synaptic%2520pathology%2520of%2520schizophrenia%26jtitle%3DSchizophr.%2520Res.%26date%3D2006%26volume%3D81%26spage%3D47%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref379"><div class="reference"><strong class="refLabel"><a href="#ref379" class="rightTabRefNumLink">379</a></strong><div class="NLM_citation" id="rightTab-cit379"><span><span class="NLM_contrib-group">Insel, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolnick, E. M.</span><span> </span><span class="NLM_article-title">Cure therapeutics and strategic prevention: raising the bar for mental health research</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref379/cit379&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1038%2Fsj.mp.4001777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref379/cit379&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=16355250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref379/cit379&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A280%3ADC%252BD2MnmslChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=11-17&author=T.+R.+Inselauthor=E.+M.+Scolnick&title=Cure+therapeutics+and+strategic+prevention%3A+raising+the+bar+for+mental+health+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit379R"><div class="casContent"><span class="casTitleNuber">379</span><div class="casTitle"><span class="NLM_cas:atitle">Cure therapeutics and strategic prevention: raising the bar for mental health research</span></div><div class="casAuthors">Insel T R; Scolnick E M</div><div class="citationInfo"><span class="NLM_cas:title">Molecular psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-7</span>
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    </div><div class="casAbstract">Mental disorders cause more disability than any other class of medical illness in Americans between ages 15 and 44 years.  The suicide rate is higher than the annual mortality from homicide, AIDS, and most forms of cancer.  In contrast to nearly all communicable and most non-communicable diseases, there is little evidence that the morbidity and mortality from mental disorders have changed in the past several decades.  Mental health advocates, including psychiatric researchers, have pointed to stigma as one of the reasons for the lack of progress with mental illnesses relative to other medical illnesses.  This review considers how the expectations and goals of the research community have contributed to this relative lack of progress.  In contrast to researchers in cancer and heart disease who have sought cures and preventions, biological psychiatrists in both academia and industry have set their sights on incremental and marketable advances, such as drugs with fewer adverse effects.  This essay argues for approaches that can lead to cures and strategies for prevention of schizophrenia and mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6mia5Y8_SJcve_zCu79I8fW6udTcc2eYLRvqDWtUi77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnmslChsQ%253D%253D&md5=f17e613c44174495a6b3598150beb26f</span></div><a href="/servlet/linkout?suffix=cit379&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001777%26sid%3Dliteratum%253Aachs%26aulast%3DInsel%26aufirst%3DT.%2BR.%26aulast%3DScolnick%26aufirst%3DE.%2BM.%26atitle%3DCure%2520therapeutics%2520and%2520strategic%2520prevention%253A%2520raising%2520the%2520bar%2520for%2520mental%2520health%2520research%26jtitle%3DMol.%2520Psychiatry%26date%3D2006%26volume%3D11%26spage%3D11%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref380"><div class="reference"><strong class="refLabel"><a href="#ref380" class="rightTabRefNumLink">380</a></strong><div class="NLM_citation" id="rightTab-cit380"><span><span class="NLM_contrib-group">Santarelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surget, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisstaub, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arancio, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belzung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hen, R.</span><span> </span><span class="NLM_article-title">Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">809</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref380/cit380&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1126%2Fscience.1083328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref380/cit380&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=12907793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref380/cit380&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtVGqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2003&pages=805-809&author=L.+Santarelliauthor=M.+Saxeauthor=C.+Grossauthor=A.+Surgetauthor=F.+Battagliaauthor=S.+Dulawaauthor=N.+Weisstaubauthor=J.+Leeauthor=R.+Dumanauthor=O.+Arancioauthor=C.+Belzungauthor=R.+Hen&title=Requirement+of+hippocampal+neurogenesis+for+the+behavioral+effects+of+antidepressants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit380R"><div class="casContent"><span class="casTitleNuber">380</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants</span></div><div class="casAuthors">Santarelli, Luca; Saxe, Michael; Gross, Cornelius; Surget, Alexandre; Battaglia, Fortunato; Dulawa, Stephanie; Weisstaub, Noelia; Lee, James; Duman, Ronald; Arancio, Ottavio; Belzung, Catherine; Hen, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">5634</span>),
    <span class="NLM_cas:pages">805-809</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Various chronic antidepressant treatments increase adult hippocampal neurogenesis, but the functional importance of this phenomenon remains unclear.  Here, using genetic and radiol. methods, we show that disrupting antidepressant-induced neurogenesis blocks behavioral responses to antidepressants.  Serotonin 1A receptor null mice were insensitive to the neurogenic and behavioral effects of fluoxetine, a serotonin selective reuptake inhibitor.  X-irradn. of a restricted region of mouse brain contg. the hippocampus prevented the neurogenic and behavioral effects of two classes of antidepressants.  These findings suggest that the behavioral effects of chronic antidepressants may be mediated by the stimulation of neurogenesis in the hippocampus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF_g9pJxKj77Vg90H21EOLACvtfcHk0lhhjusKxu72sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtVGqsrY%253D&md5=35dcba65dfd5a695faa6d6702fc385f9</span></div><a href="/servlet/linkout?suffix=cit380&amp;dbid=16384&amp;doi=10.1126%2Fscience.1083328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1083328%26sid%3Dliteratum%253Aachs%26aulast%3DSantarelli%26aufirst%3DL.%26aulast%3DSaxe%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DSurget%26aufirst%3DA.%26aulast%3DBattaglia%26aufirst%3DF.%26aulast%3DDulawa%26aufirst%3DS.%26aulast%3DWeisstaub%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DDuman%26aufirst%3DR.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DBelzung%26aufirst%3DC.%26aulast%3DHen%26aufirst%3DR.%26atitle%3DRequirement%2520of%2520hippocampal%2520neurogenesis%2520for%2520the%2520behavioral%2520effects%2520of%2520antidepressants%26jtitle%3DScience%26date%3D2003%26volume%3D301%26spage%3D805%26epage%3D809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref381"><div class="reference"><strong class="refLabel"><a href="#ref381" class="rightTabRefNumLink">381</a></strong><div class="NLM_citation" id="rightTab-cit381"><span><span class="NLM_contrib-group">Kippin, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der, K. D.</span><span> </span><span class="NLM_article-title">Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5815</span><span class="NLM_x">–</span> <span class="NLM_lpage">5823</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref381/cit381&amp;dbid=16&amp;doi=10.1021%2Fjm701094q&amp;key=10.1523%2FJNEUROSCI.1120-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref381/cit381&amp;dbid=8&amp;doi=10.1021%2Fjm701094q&amp;key=15958748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref381/cit381&amp;dbid=32&amp;doi=10.1021%2Fjm701094q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=5815-5823&author=T.+E.+Kippinauthor=S.+Kapurauthor=K.+D.+Van+Der&title=Dopamine+specifically+inhibits+forebrain+neural+stem+cell+proliferation%2C+suggesting+a+novel+effect+of+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit381R"><div class="casContent"><span class="casTitleNuber">381</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs</span></div><div class="casAuthors">Kippin, Tod E.; Kapur, Shitij; van der Kooy, Derek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5815-5823</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Neurogenesis has been implicated in antidepressant drug action and animal models of depression, suggesting that proliferating cells play a role in psychiatric disorders.  Similar studies using antipsychotic drugs have yielded conflicting results, perhaps because of the lack of focus on specific cell types.  We examine the effect of haloperidol on neural stem cells (NSCs), the ultimate precursors for adult cell genesis.  We show that haloperidol increases NSC nos., resulting in more progenitors and more new neurons and glia in the adult rat brain.  The increase in NSCs by haloperidol is dependent on central dopamine D2 receptors, and these receptors are expressed by NSCs.  D2 receptor stimulation in vitro inhibits NSC proliferation, which is reversed by haloperidol.  Thus, haloperidol increases adult mammalian brain proliferation by antagonizing dopamine at D2 receptors on NSCs.  These findings demonstrate a direct link between neural activity and NSC proliferation and implicate cell genesis in antipsychotic drug effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWBlzvHGSpVrVg90H21EOLACvtfcHk0lhhjusKxu72sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFent7c%253D&md5=c27628c088afc63758970b8bf87f46c6</span></div><a href="/servlet/linkout?suffix=cit381&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1120-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1120-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DKippin%26aufirst%3DT.%2BE.%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DVan%2BDer%26aufirst%3DK.%2BD.%26atitle%3DDopamine%2520specifically%2520inhibits%2520forebrain%2520neural%2520stem%2520cell%2520proliferation%252C%2520suggesting%2520a%2520novel%2520effect%2520of%2520antipsychotic%2520drugs%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D5815%26epage%3D5823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm701094q&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2008.51.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm701094q%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm701094q" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                562KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679971271acf3c94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
